At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
hour NN N
of IN N
infusion NN N
, , N
compared VBN N
with IN N
saline NN i
, , i
L-arginine JJ i
infusion NN N
increased VBD N
basal JJ o
forearm NN o
blood NN o
flow NN o
, , o
nitrite JJ o
and CC o
nitrate JJ o
( ( o
NOx NNP o
) ) o
, , o
and CC o
forearm NN o
cGMP NN o
release NN o
and CC o
decreased VBD o
endothelin-1 NN o
. . o

Group NNP N
A NNP N
was VBD N
restored VBN N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
Artglass NNP i
polymer NN i
core NN i
; : i
group NN N
B NNP N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
Charisma NNP i
composite JJ i
resin NN i
core NN i
; : i
and CC N
group NN N
C NNP N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
AB NNP i
composite JJ i
resin NN i
core NN i
. . i

No DT N
significant JJ N
intergroup NN N
differences NNS N
in IN N
the DT N
trend NN N
of IN N
the DT N
two CD N
plasma NN o
proteins NNS o
( ( o
albumin NN o
, , o
transferrin NN o
) ) o
, , o
lymphocytes VBZ o
, , o
weight NN o
, , o
IL-6 NNP o
, , o
CPR NNP o
and CC o
TNFalpha NNP o
were VBD o
detected VBN o
. . o

RESULTS VB N
The DT N
decreased JJ N
levels NNS o
of IN o
serum NN o
trace NN o
elements NNS o
, , o
glutathione NN o
peroxidase NN o
activity NN o
and CC o
total JJ o
antioxidant JJ o
capacity NN o
, , o
and CC o
increased VBD o
malondialdehyde NN o
, , o
glutathion NN o
reductase NN o
was VBD N
observed VBN N
in IN N
cervical JJ p
cancer NN p
patients NNS p
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
changes NNS N
in IN N
RBC NNP o
EPA NNP o
content NN o
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
changes NNS N
in IN N
SBP NNP o
and CC o
DBP NNP o
and CC N
directly RB N
correlated VBN N
with IN N
the DT N
increases NNS N
in IN N
HDL NNP o
cholesterol NN o
and CC o
non-HDL JJ o
cholesterol NN o
concentrations NNS o
. . o

BACKGROUND IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
asymmetric JJ N
dimethylarginine NN i
( ( i
ADMA NNP i
) ) i
levels NNS N
could MD N
be VB N
elevated VBN N
and CC N
influence VB N
endothelin-1 JJ N
and CC N
nitric JJ N
oxide NN N
release NN N
and CC N
action NN N
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome NN p
X NNP p
( ( p
CSX NNP p
) ) p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
slit-lamp JJ o
characteristics NNS o
of IN o
the DT o
corneal NN o
ulceration NN o
, , o
corrected VBN o
distance NN o
visual JJ o
acuity NN o
, , o
duration NN o
until IN o
healing VBG o
, , o
and CC o
complications NNS o
were VBD N
documented VBN N
in IN N
each DT N
group NN N
. . N

RG-CMH JJ i
intervention NN i
was VBD N
also RB N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
levels NNS o
of IN o
T NNP o
cells NNS o
, , o
helper JJR o
T NNP o
cells NNS o
, , o
cytotoxic NN o
T NNP o
cells NNS o
and CC o
natural JJ o
killer NN o
cells NNS o
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

GD NNP i
caused VBD N
greater JJR N
fatigue NN o
, , o
hepatotoxicity NN o
, , o
neutropenia NN o
, , o
and CC o
thrombocytopenia NNS o
but CC o
not RB o
febrile JJ o
neutropenia NN o
; : o
CD NN o
caused VBD o
more JJR o
hand-foot JJ o
syndrome NN o
, , o
gastrointestinal JJ o
toxicity NN o
, , o
and CC o
mucositis NN o
. . o

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
onset NN o
and CC o
average JJ o
root NN o
mean JJ o
square JJ o
amplitude NN o
of IN o
EMG NNP o
activity NN o
in IN o
the DT o
peroneal NN o
muscles NNS o
was VBD N
calculated VBN N
following VBG N
the DT N
release NN N
of IN N
a DT N
trap NN N
door NN N
mechanism NN N
causing VBG N
inversion NN N
. . N

Cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
collected VBN N
during IN N
surgical JJ N
plane NN N
anesthesia NN N
and CC N
the DT N
collected JJ N
CSF NNP N
samples NNS N
were VBD N
used VBN N
to TO N
assay VB N
for IN N
human JJ N
IL-10 NNP N
, , N
rat VBZ N
IL-1 NNP N
, , N
rat VBZ N
IL-6 NNP N
, , N
and CC N
rat VB N
TNF- JJ N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Intra-operative JJ o
blood NN o
loss NN o
, , o
post-operative JJ o
blood NN o
loss NN o
, , o
blood NN o
transfusion NN o
rates NNS o
, , o
operative JJ o
morbidity NN o
, , o
uterine JJ o
blood NN o
flow NN o
and CC o
ovarian JJ o
function NN o
. . o

RESULTS NNP N
Both NNP N
nitric JJ N
oxide NN N
or CC N
iloprost NN N
attenuated JJ N
cardiopulmonary JJ o
bypass-induced JJ o
thrombocytopenia NN o
, , o
reduction NN o
of IN o
glycoprotein NN o
Ib NNP o
and CC o
glycoprotein VB o
IIb NNP o
levels NNS o
, , o
translocation NN o
of IN o
P-selectin NNP o
, , o
microparticle NN o
formation NN o
, , o
Mac-1 NNP o
upregulation NN o
, , o
and CC o
suppression NN o
of IN o
collagen-induced JJ o
aggregation NN o
. . o

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
oral JJ i
dimercapto NN i
succinic JJ i
acid NN i
( ( i
DMSA NNP i
) ) i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
ages VBZ p
3-8 CD p
years NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
A NNP N
reduction NN N
in IN N
the DT N
median JJ o
pain NN o
score NN o
, , o
ulcer JJ o
size NN o
, , o
number NN o
of IN o
ulcers NNS o
, , o
or CC o
total JJ o
number NN o
of IN o
ulcer JJ o
episodes NNS o
. . o

CONCLUSION NNP N
Both NNP N
agents NNS N
, , N
enalapril NN i
and CC i
amlodipine NN i
, , N
reduced VBD N
blood NN o
pressure NN o
, , N
but CC N
only RB N
amlodipine VB i
reduced VBN N
platelet JJ o
aggregation NN o
and CC o
platelet NN o
production NN o
of IN o
malondialdehyde NN o
, , N
indicating VBG N
its PRP$ N
action NN N
on IN N
the DT N
arachidonic JJ N
acid NN N
metabolic JJ N
pathway NN N
. . N

Whether NNP N
n3 NN i
fatty RB i
acid JJ i
ethyl NN i
ester NN i
( ( i
FAEE NNP i
) ) i
supplementation NN i
improves VBZ N
arterial JJ N
stiffness NN N
in IN N
obese JJ p
participants NNS p
on IN N
a DT N
weight JJ N
loss NN N
diet NN N
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( o
S NNP o
) ) o
Quality NN o
of IN o
the DT o
visualization NN o
of IN o
the DT o
uterine JJ o
cavity NN o
, , o
procedure NN o
time NN o
, , o
complications NNS o
, , o
patient JJ o
discomfort NN o
, , o
and CC o
satisfaction NN o
rate NN o
. . o

Renal JJ o
plasma NN o
flow NN o
and CC o
MSA NNP o
increased VBD N
significantly RB N
during IN N
the DT N
insulin NN N
clamp NN N
, , N
whereas JJ N
renal JJ N
NE NNP N
and CC N
total JJ N
body NN N
NE NNP N
spillover NN N
remained VBD N
unchanged JJ N
, , N
suggesting VBG N
nonuniform JJ N
regional JJ N
sympathetic JJ N
nerve NN N
responses NNS N
to TO N
acute VB N
hyperinsulinemia NN N
. . N

Worn NNP N
contact NN N
lenses NNS N
were VBD N
analyzed VBN N
for IN N
lipid JJ N
uptake JJ N
using VBG N
high-performance NN N
liquid NN N
chromatography NN N
by IN N
two CD N
laboratories NNS N
: : N
Alcon NNP N
Laboratories NNPS N
( ( N
right JJ N
lens NNS N
total JJ N
uptake NN N
) ) N
and CC N
OTG NNP N
Research NNP N
& CC N
Consultancy NNP N
( ( N
left VBN N
lens VBZ N
total JJ N
uptake NN N
and CC N
individual JJ N
lipid JJ N
classes NNS N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
releasing VBG N
factor NN N
combined VBD N
test NN N
with IN N
arginine JJ i
vasopressin NN i
were VBD N
compared VBN N
in IN N
the DT N
same JJ N
subjects NNS N
with IN N
a DT N
conventional JJ N
combined JJ N
test NN N
using VBG N
insulin NN N
together RB N
with IN N
thyrotrophin JJ i
releasing VBG i
hormone NN i
and CC i
luteinising VBG i
hormone NN i
releasing VBG i
hormone NN i
. . i

Effluent JJ o
carcinogen NN o
antigen-125 JJ o
levels NNS o
were VBD N
inversely RB N
correlated VBN N
with IN N
peritoneal JJ N
glucose JJ N
exposure NN N
during IN N
lactate NN N
but CC N
not RB N
bicarbonate VB N
APD NNP N
, , N
indicating VBG N
improved VBN N
in IN N
vivo JJ N
mesothelial NN N
cell NN N
tolerance NN N
of IN N
high-dose JJ N
glucose NN N
with IN N
the DT N
neutral-pH JJ N
PD NNP N
fluid NN N
with IN N
reduced VBN N
glucose JJ N
degradation NN N
product NN N
content NN N
. . N

BACKGROUND NNP N
Diltiazem NNP i
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
in IN p
atrial JJ p
fibrillation NN p
and/or IN p
atrial JJ p
flutter NN p
. . p

The DT N
antihypertensive JJ N
treatment NN N
decreased VBD N
serum JJ o
MDA NNP o
levels NNS o
but CC N
increased VBD N
SOD NNP N
content NN N
, , N
and CC N
probucol NN N
treatment NN N
exaggerated VBD N
these DT N
effects NNS N
, , N
with IN N
greater JJR N
reduction NN N
of IN N
serum NN o
MDA NNP o
levels NNS o
and CC o
greater JJR o
increase NN o
of IN o
SOD NNP o
content NN o
. . o

Secondary JJ N
end NN N
points NNS N
evaluated VBD N
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

Eleven JJ p
patients NNS p
with IN p
well-documented JJ p
hepatorenal JJ p
syndrome NN p
were VBD N
studied VBN N
by IN N
measurement NN N
of IN N
blood NN o
volume NN o
, , o
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
plasma VBP o
aldosterone JJ o
concentration NN o
, , o
renin JJ o
substrate NN o
concentration NN o
, , o
and CC o
plasma JJ o
renin NN o
activity NN o
. . o

Concerning VBG N
parameters NNS N
of IN N
bone NN o
turnover NN o
, , o
first RB o
ICTP NNP o
as IN o
marker NN o
of IN o
bone NN o
resorption NN o
showed VBD N
a DT N
significant JJ N
increase NN N
, , N
later RB N
on IN N
the DT N
marker NN o
of IN o
bone NN o
formation NN o
increased VBD N
as RB N
well RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( o
S NNP o
) ) o
Rate NNP o
of IN o
development NN o
of IN o
expanded JJ o
blastocysts NNS o
suitable JJ o
for IN o
transfer NN o
or CC o
vitrification NN o
( ( o
primary JJ o
outcome NN o
) ) o
, , o
fertilization NN o
, , o
aneuploidy NN o
, , o
and CC o
sustained VBD o
implantation NN o
. . o

The DT N
cumulative JJ N
dose NN N
response NN N
effect NN N
of IN N
eicosapentaenoic NN i
and CC i
docosahexaenoic JJ i
acid NN i
on IN N
blood NN o
pressure NN o
, , o
plasma NN o
lipid JJ o
profile NN o
and CC o
diet JJ o
pattern NN o
in IN N
mild NN p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
. . p

CONCLUSION NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
When WRB N
methadone NN i
was VBD N
administered VBN N
by IN N
the DT N
SC NNP N
route NN N
, , N
the DT N
half-life NN N
was VBD N
longer RBR N
, , N
but CC N
the DT N
individual JJ N
variation NN N
in IN N
plasma JJ o
concentrations NNS o
was VBD N
greater JJR N
compared VBN N
with IN N
IV NNP N
administration NN N
. . N

CONCLUSIONS NNP N
Sublingual NNP i
micronized VBD i
HRT NNP i
favorably RB N
decreases VBZ N
serum NN o
and CC o
urine JJ o
markers NNS o
of IN o
bone NN o
metabolism NN o
, , N
prevents VBZ N
bone JJ N
loss NN N
, , N
and CC N
results NNS N
in IN N
a DT N
slight JJ N
increase NN N
in IN N
spine NN N
and CC N
hip NN N
bone NN N
mineral JJ N
density NN N
. . N

RESULTS VB N
A DT N
single JJ N
vaccination NN N
with IN N
either DT N
dose NN N
induced VBD N
substantial JJ N
increases NNS N
in IN N
H1N1 NNP o
A/California/07/2009 NNP o
hemagglutination NN o
inhibition NN o
( ( o
HI NNP o
) ) o
and CC o
neutralizing VBG o
( ( o
MN NNP o
) ) o
antibody NN o
titers NNS o
in IN N
both DT N
adult NN p
and CC p
elderly JJ p
subjects NNS p
. . p

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
; : o
secondary JJ o
endpoints NNS o
were VBD o
time NN o
from IN o
first JJ o
progression NN o
to TO o
death NN o
( ( o
TFPTD NNP o
) ) o
and CC o
tolerability NN o
. . o

CONCLUSIONS NNP N
Vilazodone NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
cardiac JJ o
repolarization NN o
, , o
heart NN o
rate NN o
, , o
PR NNP o
or CC o
QRS NNP o
interval JJ o
duration NN o
, , o
or CC o
ECG NNP o
morphology NN o
in IN N
healthy JJ p
adult NN p
participants NNS p
. . p

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Registration NNP N
included VBD N
hemodynamic JJ N
data NNS N
from IN N
the DT N
peripheral JJ N
artery NN N
and CC N
the DT N
pulmonary JJ N
artery NN N
, , N
and CC N
the DT N
measurement NN N
of IN N
cardiac JJ o
troponin NN o
I PRP o
( ( o
CTnI NNP o
) ) o
and CC o
creatine JJ o
kinase NN o
isoenzyme NN o
MB NNP o
( ( o
CK-MB NNP o
) ) o
values NNS o
. . o

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
effect NN N
of IN N
increased JJ N
carbohydrate NN i
and CC i
fiber NN i
intakes NNS i
on IN i
serum JJ i
short-chain JJ i
fatty JJ i
acids NNS i
( ( i
SCFAs NNP i
) ) i
and CC N
the DT N
relation NN N
between IN N
changes NNS N
in IN N
serum NN N
acetate NN N
and CC N
changes NNS N
in IN N
blood NN N
lipids NNS N
. . N

The DT N
oligonucleotide JJ N
primer NN N
pairs NNS N
for IN N
the DT N
microsatellite JJ N
DNA NN N
markers NNS N
were VBD N
D8S133 NNP N
, , N
D8S136 NNP N
, , N
D8S137 NNP N
, , N
ANK1 NNP N
on IN N
chromosome NN N
8p12-21 CD N
, , N
LPLTET NNP i
on IN N
chromosome NN N
8p22 CD N
, , N
and CC N
D17S855 NNP N
( ( N
intragenic JJ N
to TO N
the DT N
BRCA1 NNP N
gene NN N
) ) N
on IN N
chromosome NN N
17q21 CD N
. . N

GH NNP i
treatment NN N
did VBD N
not RB N
induce VB N
a DT N
further JJ N
increase NN N
in IN N
insulin JJ o
levels NNS o
during IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
but CC N
significantly RB N
decreased VBD N
free JJ o
fatty JJ o
acid NN o
( ( o
FFA NNP o
) ) o
levels NNS o
during IN N
OGTT NNP N
. . N

The DT N
acid NN N
challenge NN N
after IN N
in IN N
situ JJ N
remineralization NN N
for IN N
both DT N
control NN N
and CC N
CPP-ACP-treated JJ N
lesions NNS N
resulted VBD N
in IN N
demineralization NN o
underneath IN N
the DT N
remineralized JJ N
zone NN N
, , N
indicating VBG N
that IN N
the DT N
remineralized JJ N
mineral NN N
was VBD N
more RBR N
resistant JJ N
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ o
results NNS o
of IN o
the DT o
cervix NN o
and CC o
the DT o
mRNA JJ o
expression NN o
of IN o
hTERT NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
epidural JJ N
administration NN N
of IN N
lidocaine JJ i
plus CC i
ketamine JJ i
resulted VBN N
in IN N
longer JJR N
caudal NN N
analgesia NN N
in IN N
standing VBG N
conscious JJ N
dromedary JJ N
camels NNS N
compared VBN N
with IN N
the DT N
effect NN N
of IN N
administering VBG N
lidocaine JJ i
alone RB N
. . N

Changes NNS N
in IN N
total JJ o
cholesterol NN o
and CC o
LDL NNP o
cholesterol NN o
were VBD N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
factor NN o
VIIc NNP o
in IN N
the DT N
DYDR NNP N
group NN N
and CC N
negatively RB N
with IN N
changes NNS N
in IN N
factor NN o
VIIc NNP o
in IN N
the DT N
T-group NNP N
. . N

We PRP N
tested VBD N
the DT N
extent NN N
to TO N
which WDT N
systemic JJ N
nitric JJ i
oxide IN i
synthase JJ i
inhibition NN i
[ NNP i
N NNP i
( ( i
G NNP i
) ) i
-monomethyl-L-arginine NN i
( ( i
L-NMMA NNP i
) ) i
] NN i
can MD N
reverse VB N
the DT N
drop NN N
in IN N
blood NN N
pressure NN N
that WDT N
occurs VBZ N
after IN N
exercise NN N
in IN N
humans NNS N
. . N

Sixty CD p
7x3 CD p
mm NNS p
pressed VBN p
ceramic JJ p
discs NN p
of IN p
IPS NNP p
e.max NN p
were VBD N
fabricated VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
six CD N
groups NNS N
of IN N
different JJ i
dentin NN i
surface NN i
treatments NNS i
( ( i
control NN i
, , i
desensitizer NN i
, , i
disinfectant NN i
, , i
saliva NN i
, , i
blood NN i
, , i
and CC i
hydrogen VB i
peroxide NN i
) ) i
. . i

Secondary JJ N
outcomes NNS N
included VBD N
blood NN o
lipid NN o
, , o
fasting VBG o
glucose NN o
, , o
and CC o
insulin NN o
levels NNS o
and CC o
side NN o
effects NNS o
related VBN o
to TO o
elevated VBN o
blood NN o
pressure NN o
and CC o
increased VBD o
dietary JJ o
fiber NN o
intake NN o
. . o

The DT N
complete JJ o
inhibition NN o
rate NN o
of IN o
vomiting VBG o
was VBD N
as RB N
high JJ N
as IN N
71.4 CD N
% NN N
and CC N
92.3 CD N
% NN N
in IN N
the DT N
single JJ N
and CC N
combination NN N
groups NNS N
, , N
respectively RB N
, , N
showing VBG N
no DT N
significant JJ N
difference NN N
. . N

During IN N
the DT N
one CD N
year NN N
therapy IN N
the DT N
levels NNS o
of IN o
serum NN o
bilirubin NN o
, , o
uric JJ o
acid NN o
and CC o
triglycerides NNS o
were VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
but CC N
the DT N
group NN N
treated VBD N
with IN N
metoprolol NN i
and CC i
hydralazine NN i
. . i

Secondary JJ N
endpoints NNS N
included VBD N
PFS NNP o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
the DT o
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
and CC o
tolerability NN o
. . o

At IN N
T12 NNP N
, , N
before IN N
the DT N
allergen NN N
challenge NN N
, , N
serum NN o
ECP NNP o
levels NNS o
increased VBN N
in IN N
the DT N
placebo NN N
group NN N
and CC N
blood NN o
eosinophils NNS o
showed VBD N
a DT N
trend NN N
towards NNS N
lower JJR N
numbers NNS N
in IN N
the DT N
active JJ N
one NN N
. . N

Fibrinogen NN o
and CC o
plasminogen NN o
concentrations NNS o
in IN o
plasma NN o
, , o
plasminogen NN o
activator NN o
inhibitor NN o
activity NN o
in IN o
plasma NN o
and CC o
fibrinolytic JJ o
activity NN o
in IN o
concentrated JJ o
euglobulins NNS o
were VBD N
determined VBN N
before IN N
surgery NN N
and CC N
on IN N
the DT N
first JJ N
, , N
third JJ N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

RESULTS NNP N
FMA NNP o
total JJ o
scores NNS o
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ N
shoulder NN N
abduction NN N
during IN N
reach NN N
was VBD N
less RBR N
in IN N
the DT N
MT NNP N
+ NNP N
MG NNP N
and CC N
MT NNP N
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP N
group NN N
. . N

BACKGROUND NNP N
Characterization NNP N
of IN N
fatal JJ o
and CC o
non-fatal JJ o
reactions NNS o
to TO N
food NN N
indicates NNS N
that IN N
the DT N
majority NN N
of IN N
reactions NNS N
are VBP N
due JJ N
to TO N
the DT N
ingestion NN N
of IN N
prepared JJ N
foods NNS N
rather RB N
than IN N
the DT N
non-processed JJ N
allergen NN N
. . N

For IN N
all DT N
patients NNS N
, , N
synthesis NN N
of IN N
IL-1 NNP N
beta NN N
increased VBD N
constitutively RB N
and CC N
in IN N
response NN N
to TO N
immune-mediated JJ N
stimulants NNS N
( ( N
PHA NNP N
, , N
IL-2 NNP N
, , N
and CC N
mitochondrial JJ N
antigen NN N
) ) N
but CC N
not RB N
the DT N
bacterial JJ o
stimulants NNS o
LPS NNP o
or CC o
S NNP o
epidermidis NN o
. . o

BACKGROUND NNP N
Total NNP i
parenteral JJ i
nutrition NN i
( ( i
TPN NNP i
) ) i
supplemented VBD i
with IN i
glutamine NN i
( ( i
GLN NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
for IN N
patients NNS p
with IN p
bone NN p
marrow NN p
transplantation NN p
( ( p
BMT NNP p
) ) p
. . p

The DT N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
plasma NN o
TGs NNP o
, , o
C1 NNP o
, , o
and CC o
C2 NNP o
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
WL+FAEE NNP N
group NN N
than IN N
in IN N
the DT N
WL NNP N
group NN N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
of IN N
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
HDL NNP o
, , o
LDL NNP o
and CC o
TGs NNP o
in IN N
OG NNP N
subjects NNS N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP o
levels NNS o
. . o

By IN N
blocking VBG N
ileal NN N
bile NN N
acid NN N
transporter NN N
in IN N
the DT N
terminal NN N
ileum NN N
, , N
it PRP N
highly RB N
efficiently RB N
interrupts VBZ N
the DT N
enterohepatic JJ N
circulation NN N
of IN N
BAs NNP N
, , N
and CC N
should MD N
be VB N
of IN N
benefit NN N
to TO N
patients NNS p
with IN p
cholestatic JJ p
liver NN p
diseases NNS p
. . p

Biopsies NNS N
were VBD N
taken VBN N
from IN N
the DT N
gastric JJ N
antrum NN N
and CC N
corpus NN N
for IN N
determination NN N
of IN N
prostaglandin NN N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
by IN N
ELISA NNP N
and CC N
cyclooxygenase NN N
( ( N
COX-1 JJ N
and CC N
COX-2 NNP N
) ) N
and CC N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS JJ N
and CC N
iNOS NN N
) ) N
by IN N
western JJ N
blot NN N
. . N

Venous JJ N
blood NN N
samples NNS N
were VBD N
obtained VBN N
for IN N
determination NN N
of IN N
serum JJ o
cytokines NNS o
including VBG o
interleukin-1beta JJ o
( ( o
IL-1beta NNP o
) ) o
, , o
tumor JJ o
necrosis NN o
factor-alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , o
RANKL NNP o
, , o
osteoprotegerin NN o
, , o
and CC o
markers NNS o
of IN o
bone NN o
formation NN o
and CC o
resorption NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
change NN N
in IN N
oxygen NN o
saturation NN o
, , o
respiratory NN o
rate NN o
, , o
and CC o
RDAI NNP o
score NN o
at IN N
any DT N
assessment JJ N
period NN N
. . N

Changes NNS N
in IN N
arterial JJ o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
or CC o
plasma VB o
beta-endorphin JJ o
, , o
cortisol NN o
, , o
and CC o
glucose JJ o
concentration NN o
did VBD N
not RB N
show VB N
any DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Blood NNP o
glucose NN o
and CC o
plasma JJ o
insulin NN o
and CC o
glucagon NN o
concentrations NNS o
rose VBD o
post-operatively RB o
whether IN N
or CC N
not RB N
insulin NN N
was VBD N
given VBN N
, , N
but CC N
the DT N
increment NN N
in IN N
insulin NN o
concentration NN o
was VBD N
significantly RB N
greater JJR N
when WRB N
insulin NN N
was VBD N
given VBN N
. . N

RESULTS VB N
The DT N
significantly RB N
raised VBN o
levels NNS o
of IN o
MDA NNP o
and CC o
SOD NNP o
, , o
and CC o
decreased JJ o
levels NNS o
of IN o
reduced VBN o
glutathione NN o
( ( o
GSH NNP o
) ) o
during IN N
uncontrolled JJ N
stage NN N
of IN N
diabetes NNS N
indicated VBD N
free JJ N
radical JJ N
stress NN N
induced VBD N
lipid JJ N
peroxidation NN N
. . N

Statistically RB N
significantly RB N
greater JJR N
improvement NN N
in IN N
ABC NNP o
Stereotypic NNP o
Behavior NNP o
and CC o
Hyperactivity NNP o
total JJ o
subscale NN o
scores NNS o
was VBD N
also RB N
consistent JJ N
across IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
. . N

Recent JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
the DT N
calcium NN i
channel NN i
blocking VBG i
agents NNS i
can MD N
inhibit VB N
experimentally RB N
induced JJ N
bronchoconstriction NN N
in IN N
asthmatics NNS N
, , N
but CC N
their PRP$ N
protective JJ N
action NN N
has VBZ N
been VBN N
variable JJ N
. . N

The DT N
tPA JJ o
mass NN o
concentrations NNS o
also RB N
dropped VBD N
, , N
both DT N
before IN N
and CC N
after IN N
VO NNP N
, , N
but CC N
tPA JJ o
activities NNS o
were VBD N
unchanged JJ N
, , N
as IN N
were VBD N
von JJ o
Willebrand NNP o
factor NN o
( ( o
vWF NN o
) ) o
levels NNS o
. . o

There EX N
were VBD N
significant JJ N
effects NNS N
for IN N
erosion NN o
( ( N
orange JJ N
juice NN N
produced VBD N
significantly RB N
more JJR N
erosion NN o
than IN N
water NN N
) ) N
and CC N
for IN N
abrasion NN N
( ( N
paste NN N
A DT N
was VBD N
significantly RB N
more RBR N
abrasive JJ N
to TO N
dentine VB N
than IN N
paste NN N
B NNP N
) ) N
. . N

As IN N
to TO N
the DT N
neuroendocrinological JJ N
effect NN N
, , N
cyproheptadine JJ N
augmentation NN N
did VBD N
not RB N
reduce VB N
the DT N
plasma NN o
prolactin NN o
level NN o
but CC N
did VBD N
induce VB N
a DT N
decrease NN N
in IN N
the DT N
plasma NN o
cortisol NN o
level NN o
. . o

Margarines NNS i
fortified VBN i
with IN i
? . i
acid NN i
, , i
eicosapentaenoic JJ i
acid NN i
, , i
or CC i
docosahexaenoic JJ i
acid NN i
alter IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
but CC N
do VBP N
not RB N
affect VB N
the DT N
antioxidant JJ N
status NN N
of IN N
healthy JJ p
adults NNS p
. . p

In IN N
summary JJ N
, , N
E10A NNP i
plus CC i
chemotherapy NN i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
therapeutic JJ N
approach NN N
in IN N
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
or CC p
nasopharyngeal JJ p
carcinoma NN p
. . p

RESULTS VB N
The DT N
RV NNP N
pacing NN N
contributed VBD N
to TO N
significant JJ N
increase NN N
in IN N
left JJ o
atrial JJ o
volume NN o
, , o
left VBD o
ventricular JJ o
( ( o
LV NNP o
) ) o
end-systolic JJ o
volume NN o
, , o
and CC o
LV NNP o
mass NN o
compared VBN N
to TO N
BiV NNP N
pacing NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Peak-stimulated NNP o
LH NNP o
, , o
estradiol NN o
, , o
T NNP o
, , o
growth NN o
rate NN o
, , o
pubertal JJ o
progression NN o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

Serum NNP o
calcium NN o
levels NNS o
decreased VBN N
in IN N
most JJS N
patients NNS N
after IN N
surgery NN N
, , N
but CC N
recovered VBD N
earliest JJS N
in IN N
Group NNP N
A. NNP N
Hypercalcemia NNP N
and CC N
PTH NNP N
inhibition NN N
did VBD N
not RB N
occur VB N
in IN N
gs NN N
A NNP N
and CC N
B NNP N
. . N

CONCLUSIONS NNP N
Nitric NNP N
oxide IN N
plus CC N
iloprost VB N
reduced VBN N
the DT N
deleterious JJ N
effects NNS N
of IN N
cardiopulmonary JJ N
bypass NN N
, , N
such JJ N
as IN N
thrombocytopenia NN o
, , o
platelet NN o
activation NN o
, , o
platelet-leukocyte JJ o
aggregate NN o
formation NN o
, , o
and CC o
suppression NN o
of IN o
platelet NN o
aggregative JJ o
responses NNS o
. . o

Cytosine NNP i
arabinoside NN i
( ( i
CA NNP i
) ) i
was VBD N
utilized VBN N
in IN N
efforts NNS N
to TO N
synchronize VB N
leukemic JJ N
cells NNS N
in IN N
DNA NNP N
synthesis NN N
for IN N
treatment NN N
with IN N
vincristine NN i
, , i
prednisone NN i
, , i
and CC i
L-asparaginase NNP i
in IN N
children NNS p
with IN p
acute JJ p
leukemia NN p
in IN p
relapse NN p
. . p

CONCLUSIONS NNP N
The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
ferulic JJ N
acid NN N
from IN N
rye NN N
bran NN N
is VBZ N
bioavailable JJ N
and CC N
that IN N
the DT N
urinary JJ N
concentration NN N
of IN N
ferulic JJ N
acid NN N
reflects VBZ N
the DT N
dietary JJ N
intake NN N
of IN N
this DT N
hydroxycinnamic JJ N
acid NN N
. . N

Main NNP N
outcome NN N
measures NNS N
were VBD N
best-corrected JJ o
visual JJ o
acuity NN o
, , o
central JJ o
retinal JJ o
thickness NN o
, , o
nuclear JJ o
density NN o
units NNS o
' POS o
changes NNS o
, , o
and CC o
rate NN o
of IN o
complications NNS o
. . o

Combined JJ N
administration NN N
of IN N
amino JJ i
acids NNS i
and CC N
glucose VB N
decreased VBN N
endogenous JJ o
glucose JJ o
production NN o
( ( N
P=.001 NNP N
) ) N
and CC N
stimulated VBN o
insulin NN o
secretion NN o
( ( N
P=.001 NNP N
) ) N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
the DT N
administration NN N
of IN N
amino JJ N
acids NNS N
alone RB N
. . N

Treatment NN N
with IN N
simvastatin NN i
or CC i
gemfibrozil NN i
in IN N
hypertensive JJ p
patients NNS p
in IN p
hydrochlorothiazide JJ i
monotherapy NN N
can MD N
reduce VB N
total JJ o
cholesterol NN o
and CC o
LDL-cholesterol NNP o
plasma NN o
levels NNS o
, , N
while IN N
significantly RB N
increasing VBG N
HDL NNP o
plasma NN o
levels NNS o
compared VBN N
to TO N
placebo VB i
. . i

BACKGROUND NNP N
AND NNP N
AIM NNP N
An DT N
oral JJ N
glutamine NN N
load NN N
in IN N
cirrhotic JJ p
patients NNS p
awaiting VBG p
liver JJ p
transplantation NN p
was VBD N
shown VBN N
to TO N
cause VB N
a DT N
rise NN N
in IN N
blood NN o
ammonia NN o
and CC o
psychometric NN o
abnormalities NNS o
which WDT N
were VBD N
reversed VBN N
by IN N
hepatic JJ N
transplantation NN N
. . N

Postprandial NNP o
triglyceride NN o
levels NNS o
tended VBD N
to TO N
be VB N
higher JJR N
after IN N
all DT N
fibre-rich JJ N
meals NNS N
, , N
but CC N
only RB N
significant JJ N
for IN N
oat NN N
powder NN N
and CC N
the DT N
mixed JJ N
meal NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
. . N

The DT N
vaccine NN N
response NN N
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS N
in IN N
levels NNS o
of IN o
influenza JJ o
hemagglutination-inhibition NN o
( ( o
HAI NNP o
) ) o
antibodies NNS o
and CC o
of IN o
IgG NNP o
antibodies NNS o
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
combined JJ N
treatments NNS N
significantly RB N
promoted VBD N
healing NN o
of IN o
rat NN o
gastric JJ o
ulcers NNS o
whereas VBP N
each DT N
agent NN N
alone RB N
had VBD N
no DT N
significant JJ N
effect NN N
as IN N
compared VBN N
with IN N
control NN i
( ( i
saline NN i
) ) i
. . i

Safety NN o
and CC o
immunogenicity NN o
of IN N
a DT N
combined JJ i
pentavalent NN i
diphtheria NN i
, , i
tetanus NN i
, , i
acellular JJ i
pertussis NN i
, , i
inactivated VBN i
poliovirus NN i
and CC i
Haemophilus NNP i
influenzae VBP i
type JJ i
b-tetanus JJ i
conjugate NN i
vaccine NN i
in IN N
infants NNS N
, , N
compared VBN N
with IN N
a DT N
whole JJ i
cell NN i
pertussis NN i
pentavalent NN i
vaccine NN i
. . i

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
it PRP N
seems VBZ N
that IN N
ginger NN N
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB N
eicosanoid JJ N
levels NNS N
, , N
perhaps RB N
by IN N
inhibiting VBG N
their PRP$ N
synthesis NN N
from IN N
arachidonic JJ N
acid NN N
. . N

Importantly RB N
, , N
the DT N
number NN o
of IN o
deaths NNS o
related VBN o
to TO o
infections NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
low JJ N
versus NN N
high JJ N
CD19 NNP N
group NN N
( ( N
P NNP N
< NNP N
.0202 NNP N
) ) N
. . N

Compared VBN N
with IN N
placebo NN i
, , N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
of IN N
the DT N
change NN N
from IN N
baseline NN N
showed VBD N
that IN N
cilomilast NN N
did VBD N
not RB N
alter VB N
any DT N
sputum JJ o
endpoint NN o
or CC o
FEV1 NNP o
. . o

With IN N
the DT N
rHA NN N
fusion NN N
protein NN N
as IN N
antigen NN N
, , N
we PRP N
successfully RB N
prepared VBD N
and CC N
screened VBD N
specific JJ N
monoclonal JJ N
antibodys NN N
against IN N
the DT N
H5N1 NNP N
subtype NN N
AIV NNP N
, , N
which WDT N
indicated VBD N
that IN N
the DT N
rHA NN N
had VBD N
antigen VBN N
epitopes NNS N
and CC N
biofunctions NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Metformin NNP i
therapy NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
total JJ o
T NNP o
, , o
LH NNP o
level NN o
, , o
LH/FSH NNP o
ratio NN o
, , o
insulin NN o
resistance NN o
, , o
and CC o
mean JJ o
BMI NNP o
. . o

The DT N
number NN N
of IN N
patients NNS N
developing VBG N
abnormal JJ N
liver NN N
function NN N
tests NNS N
( ( N
including VBG N
clinically RB N
significant JJ N
elevation NN N
) ) N
, , N
hemoglobin UH o
, , o
and CC o
creatinine JJ o
clearance NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
oral JJ N
diclofenac NN i
group NN N
. . N

Total JJ o
cholesterol NN o
, , o
triglycerides NNS o
, , o
HDL NNP o
and CC o
LDL NNP o
cholesterol NN o
fractions NNS o
were VBD N
determined VBN N
twice RB N
during IN N
an DT N
initial JJ N
4-week JJ N
washout NN N
phase NN N
, , N
and CC N
after IN N
a DT N
1- JJ N
, , N
3- JJ N
and CC N
6-month JJ N
active JJ N
hypotensive JJ N
drug NN N
phase NN N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
hospital JJ o
mortality NN o
and CC o
morbidity NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
and CC o
length NN o
of IN o
sick JJ o
leave VBP o
from IN o
work NN o
. . o

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
hematologic JJ o
toxicity NN o
, , o
transfusion NN o
requirements NNS o
, , o
duration NN o
of IN o
fever NN o
, , o
and CC o
hepatic JJ o
toxicity NN o
between IN N
the DT N
treatment NN N
groups NNS N
. . N

METHODS NNP N
Using NNP N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN o
genes NNS o
and CC o
leptin NN o
receptor NN o
genes NNS o
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS p
with IN p
uterine JJ p
myomas NN p
, , p
untreated VBD p
or CC p
treated VBN p
with IN p
GnRH NNP p
analogue NN p
. . p

The DT N
rate NN o
of IN o
healing NN o
of IN o
gastric JJ o
lesions NNS o
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS N
free JJ N
of IN N
infection NN o
accumulated VBN o
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ o
lesions NNS o
. . o

Circadian JJ o
patterns NNS o
of IN o
plasma NN o
melatonin NN o
, , o
glucose NN o
, , o
lactic JJ o
acid NN o
, , o
and CC o
corticosterone NN o
were VBD N
maintained VBN N
in IN N
all DT N
rats NNS N
except IN N
those DT N
exposed VBN N
to TO N
constant VB N
bright JJ N
light NN N
or CC N
the DT N
highest JJS N
level NN N
of IN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

The DT N
effects NNS N
of IN N
chloroquine NN i
, , i
amodiaquine NN i
and CC i
chloroquine NN i
plus CC i
chlorpheniramine NN i
on IN N
the DT N
disposition NN p
kinetics NNS p
of IN p
the DT p
hepatomegaly NN p
associated VBN p
with IN p
acute NN p
, , p
uncomplicated JJ p
, , p
Plasmodium NNP p
falciparum NN p
malaria NN p
in IN p
children NNS p
. . p

Betamethasone NNP i
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN o
, , o
scaling VBG o
and CC o
pruritus NN o
, , o
faster JJR o
than IN o
pimecrolimus NN o
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Accordingly RB N
, , N
the DT N
cerebral JJ o
metabolic NN o
ratio NN o
decreased VBD N
equally RB N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
: : N
from IN N
5.8 CD N
at IN N
rest NN N
to TO N
1.7 CD N
and CC N
1.8 CD N
, , N
respectively RB N
. . N

At IN N
anaesthesia JJ N
induction NN N
, , N
serum JJ N
carnitine NN N
was VBD N
significantly RB N
increased VBN N
in IN N
treated JJ N
patients NNS N
, , N
but CC N
carnitine JJ o
concentrations NNS o
in IN o
the DT o
right JJ o
atrial JJ o
biopsy NN o
obtained VBN N
just RB N
before RB N
aortic JJ N
declamping NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Better NNP o
effects NNS o
on IN o
the DT o
pathological JJ o
results NNS o
of IN o
the DT o
cervix NN o
and CC o
the DT o
mRNA JJ o
expression NN o
of IN o
hTERT NN o
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Consumption NN N
of IN N
industrial JJ i
trans NNS i
fatty JJ i
acids NNS i
( ( i
iTFA NN i
) ) i
increases VBZ N
LDL NNP o
cholesterol NN o
, , o
decreases VBZ o
HDL NNP o
cholesterol NN o
, , N
and CC N
is VBZ N
strongly RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

Plasma NNP o
aldosterone NN o
levels NNS o
decreased VBN N
to TO N
a DT N
normal JJ N
range NN N
, , N
glomerular JJ o
filtration NN o
rate NN o
and CC o
renal JJ o
plasma NN o
flow NN o
both DT o
increased VBN o
, , o
and CC o
urinary JJ o
excretion NN o
of IN o
sodium NN o
and CC o
potassium NN o
both DT N
returned VBN N
toward IN N
normal JJ N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP i
of IN i
recombinant JJ i
blood NN i
coagulation NN i
factor NN i
VIII NNP i
( ( i
BDDrFVIII NNP i
) ) i
increases VBZ N
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

RESULTS JJ N
Meals NNS i
with IN i
rye NN i
bran NN i
gave VBD N
a DT N
lower JJR N
postprandial JJ o
glucose NN o
peak NN o
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
, , N
and CC N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
women NNS N
compared VBN N
to TO N
men NNS N
. . N

Papanicolaou NNP o
smear NN o
showed VBD o
reactive JJ o
or CC o
reparative JJ o
changes NNS o
and CC o
karyopyknotic JJ o
index NN o
exhibited VBD N
a DT N
significant JJ N
increase NN N
in IN N
superficial JJ o
cells NNS o
in IN N
both DT N
groups NNS N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
percentage NN o
of IN o
children NNS o
with IN o
detectable JJ o
antibodies NNS o
and CC o
the DT o
reciprocal JJ o
geometric JJ o
mean NN o
titers NNS o
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
at IN N
two CD N
months NNS N
of IN N
age NN N
for IN N
antibodies NNS N
to TO N
all DT N
three CD N
poliovirus NN N
types NNS N
. . N

Basal NNP o
nitric JJ o
oxide JJ o
synthesis NN o
of IN o
the DT o
renal JJ o
vasculature NN o
was VBD N
assessed VBN N
by IN N
the DT N
decrease NN N
in IN N
RPF NNP N
after IN N
inhibition NN N
of IN N
nitric JJ N
oxide JJ N
synthase NN N
with IN N
NG-monomethyl-L-arginine NNP N
( ( N
L-NMMA NNP N
; : N
4.25 CD N
mg/kg NN N
) ) N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
use NN N
of IN N
leukocyte JJ N
reduction NN N
filters NNS N
on IN N
the DT N
activity NN N
of IN N
polymorphonuclear NN N
neutrophils NNS N
( ( N
PMN NNP N
) ) N
in IN N
patients NNS p
undergoing VBG p
surgical JJ p
myocardial JJ p
revascularisation NN p
. . p

It PRP N
is VBZ N
an DT N
inhibitor NN N
of IN N
the DT N
enzyme NN N
that WDT N
converts VBZ N
angiotensin NN N
I PRP N
( ( N
Angiotensin NNP N
Converting NNP N
Enzyme NNP N
, , N
ACE NNP N
) ) N
into IN N
angiotensin NN N
II NNP N
as RB N
well RB N
as IN N
causing VBG N
the DT N
degradation NN N
of IN N
the DT N
vasodilator NN N
bradykinin NN N
into IN N
an DT N
inactive JJ i
heptapeptide NN i
. . i

In IN N
both DT N
groups NNS N
plasma VBP o
levels NNS o
of IN o
fibrinogen NN o
and CC o
factor NN o
VII NNP o
increased VBD N
while IN N
the DT N
capacity NN N
of IN N
coagulation NN N
inhibition NN N
was VBD N
affected VBN N
by IN N
increased JJ N
protein NN N
C NNP N
and CC N
decreased VBN N
protein NN N
S NNP N
levels NNS N
. . N

CONCLUSIONS NNP N
Enflurane NNP i
causes VBZ N
a DT N
decrease NN N
in IN N
ShvO2 NNP N
, , N
which WDT N
indicates VBZ N
an DT N
impairment NN N
of IN N
splanchnic JJ N
perfusion NN N
corresponding VBG N
to TO N
the DT N
reduction NN N
in IN N
CO NNP o
and CC o
MAP NNP o
in IN N
a DT N
dose-dependent JJ N
manner NN N
. . N

Cyclosporine-A NNP i
( ( i
CsA NNP i
) ) i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
opening NN N
of IN N
the DT N
mitochondrial JJ N
permeability NN N
transition NN N
pore NN N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
key JJ N
role NN N
in IN N
myocardial JJ N
reperfusion NN N
injury NN N
. . N

Animal NNP N
studies NNS N
have VBP N
suggested VBN N
interspecies NNS N
differences NNS N
in IN N
brain NN N
norepinephrine NN N
( ( N
NE NNP N
) ) N
metabolism NN N
, , N
especially RB N
with IN N
regard NN N
to TO N
the DT N
relative JJ N
proportions NNS N
of IN N
3,4-dihydroxyphenylethyleneglycol JJ N
( ( N
DOPEG NNP N
) ) N
compared VBN N
to TO N
3-methoxy-4-hydroxyphenylethyleneglycol CD N
( ( N
MOPEG NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ N
percentage NN N
decrease NN N
of IN N
AMH NNP o
levels NNS o
in IN N
the DT N
BC NNP i
group NN N
and CC N
LS NNP N
group NN N
at IN N
3- JJ N
, , N
6- JJ N
, , N
and CC N
12-month JJ N
follow-up NN N
. . N

Nausea NN o
was VBD N
noted VBN N
in IN N
71.4 CD N
% NN N
and CC N
46.2 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
inhibitory JJ o
effect NN o
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

RESULTS NNP N
DMSA NNP N
greatly RB N
increased VBD N
the DT N
excretion NN o
of IN o
lead NN o
, , o
substantially RB o
increased VBN o
excretion NN o
of IN o
tin NN o
and CC o
bismuth NN o
, , o
and CC o
somewhat RB o
increased VBD o
the DT o
excretion NN o
of IN o
thallium NN o
, , o
mercury NN o
, , o
antimony NN o
, , o
and CC o
tungsten NNS o
. . o

Both DT o
cortisol NN o
and CC o
growth NN o
hormone NN o
responses VBZ o
to TO N
the DT N
releasing VBG N
factors NNS N
with IN N
arginine JJ i
vasopressin NN i
were VBD N
much RB N
greater JJR N
than IN N
those DT N
seen VBN N
with IN N
insulin NN N
induced VBN N
hypoglycaemia NN N
or CC N
the DT N
combined JJ N
releasing NN N
factors NNS N
without IN N
arginine JJ i
vasopressin NN i
. . i

UNLABELLED NN N
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
cytarabine NN N
, , N
acting VBG N
by IN N
at IN N
least JJS N
two CD N
different JJ N
mechanisms NNS N
, , N
enhances VBZ N
the DT N
cytotoxic JJ o
effect NN o
of IN N
cisplatin NN i
in IN N
in IN N
vitro JJ N
systems NNS N
. . N

Administration NN N
of IN N
PU NNP N
significantly RB N
increased VBD N
urinary JJ o
flow NN o
rate NN o
though IN N
in IN N
the DT N
controls NNS N
urinary JJ o
flow NN o
rate NN o
decreased VBN N
, , N
size NN N
of IN N
the DT N
prostate NN N
diminished VBD N
and CC N
increased VBD N
, , N
respectively RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Balloon NNP o
insertion NN o
to TO o
delivery NN o
interval NN o
, , o
successful JJ o
ripening VBG o
rate NN o
, , o
cesarean JJ o
delivery NN o
rate NN o
, , o
maternal JJ o
adverse JJ o
events NNS o
and CC o
maternal JJ o
satisfaction NN o
. . o

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
ECMO NNP N
circuit NN N
and CC N
samples NNS N
of IN N
blood NN N
were VBD N
evaluated VBN N
hourly RB N
for IN N
phase NN o
separation NN o
, , o
layering VBG o
out IN o
of IN o
the DT o
emulsion NN o
from IN o
blood NN o
, , o
agglutination NN o
, , o
and CC o
blood NN o
clots NNS o
. . o

We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
heme JJ i
oxygenase-1 JJ i
( ( i
HO-1 NNP i
) ) i
on IN N
this DT N
HBO NNP N
inhibition NN N
of IN N
iNOS JJ N
induction NN N
and CC N
acute NN p
lung NN p
injury NN p
in IN p
septic JJ p
rat NN p
lungs NNS p
. . p

Furthermore RB N
, , N
the DT N
negative JJ N
mean NN N
change NN N
in IN N
lag NN o
time NN o
to TO o
oxidation NN o
found VBN N
in IN N
the DT N
PUFA-diet JJ N
group NN N
differed VBD N
significantly RB N
from IN N
the DT N
slightly RB N
positive JJ N
mean NN N
change NN N
found VBD N
in IN N
the DT N
MUFA-diet JJ N
group NN N
. . N

The DT N
primary JJ N
contributor NN N
to TO N
the DT N
plasma NN o
alkalosis NN o
was VBD N
an DT N
increased VBN N
[ NN N
SID NNP N
] NNP N
, , N
as IN N
a DT N
result NN N
of IN N
increased VBN N
plasma NN N
[ NN N
Na+ NNP N
] NNP N
and CC N
decreased VBD N
plasma NNS N
[ JJ N
Cl- NNP N
] NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
changes NNS N
in IN N
markers NNS o
of IN o
bone NN o
resorption NN o
( ( N
urine JJ N
N-telopeptide NNP N
cross-linked JJ N
collagen NN N
type NN N
I PRP N
) ) N
and CC N
formation NN N
( ( N
osteocalcin JJ N
, , N
N-terminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
, , N
and CC N
bone-specific JJ N
alkaline NN N
phosphatase NN N
) ) N
. . N

Behavioral JJ o
response NN o
variables NNS o
, , o
salivary JJ o
cortisol NN o
concentration NN o
, , o
WBC NNP o
count NN o
, , o
and CC o
serum JJ o
concentrations NNS o
of IN o
glucose NN o
, , o
prolactin NN o
, , o
haptoglobin NN o
, , o
and CC o
C-reactive JJ o
protein NN o
were VBD N
analyzed VBN N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
anastrozole NN i
and CC i
clomiphene NN i
citrate NN i
( ( i
CC NNP i
) ) i
on IN N
follicular NN N
development NN N
and CC N
ovulation NN N
in IN N
infertile JJ p
women NNS p
with IN p
ovulatory JJ p
dysfunction NN p
. . p

Cardiac NNP o
index NN o
and CC o
heart NN o
rate NN o
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ o
peripheral JJ o
resistance NN o
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN N
( ( N
2-10 CD N
% NN N
) ) N
. . N

INCLUSION NNP p
CRITERIA NNP p
severe JJ p
coronary JJ p
stenosis NN p
of IN p
anterior JJ p
descending VBG p
coronary JJ p
artery NN p
; : p
no DT p
collateral NN p
flow NN p
on IN p
angiography NN p
; : p
at IN p
least JJS p
two CD p
normokinetic JJ p
segments NNS p
in IN p
the DT p
myocardial JJ p
region NN p
supplied VBN p
by IN p
the DT p
vessel NN p
being VBG p
bypassed VBN p
. . p

There EX N
was VBD N
a DT N
greater JJR N
increase NN N
of IN N
prolactin NN o
in IN N
the DT N
risperidone NN i
group NN N
, , N
while IN N
alanine JJ o
amino NN o
transferase NN o
( ( o
ALT NNP o
) ) o
had VBD N
further RBR N
increased VBN N
in IN N
the DT N
haloperidol NN i
group NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ o
data NNS o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
heart NN o
rate NN o
or CC o
oxygen NN o
saturation NN o
between IN N
groups NNS N
. . N

The DT N
arginine-supplemented JJ N
group NN N
showed VBD N
a DT N
mean JJ o
natural JJ o
killer NN o
cell NN o
cytotoxicity NN o
increase NN N
of IN N
18.9 CD N
lytic JJ N
units NNS N
, , N
whereas IN N
the DT N
placebo NN N
group NN N
showed VBD N
an DT N
increase NN N
of IN N
0.3 CD N
lytic JJ N
units NNS N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN N
in IN N
systemic JJ o
clearance NN o
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

After IN N
treatment NN N
, , N
MPO NNP o
activity NN o
and CC o
MDA NNP o
levels NNS o
were VBD N
significantly RB N
reduced VBN N
; : N
SOD NNP o
activity NN o
and CC o
NOx NNP o
levels NNS o
were VBD N
significantly RB N
increased VBN N
with IN N
nebivolol NN N
but CC N
remained VBD N
unchanged JJ N
with IN N
metoprolol NN N
. . N

BACKGROUND NNP N
Imiquimod NNP i
is VBZ N
an DT N
immune JJ N
response NN N
modifier NN N
that IN N
up-regulates JJ N
cytokines NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
in IN N
clinical JJ N
studies NNS N
to TO N
reduce VB N
or CC N
clear VB N
basal NN N
cell NN N
carcinoma NN N
tumors NNS N
when WRB N
applied VBN N
topically RB N
. . N

Shocks NNS N
were VBD N
delivered VBN N
between IN N
the DT N
right JJ i
ventricular NN i
coil NN i
and CC i
either DT i
an DT i
active JJ i
can MD i
alone RB i
( ( i
single JJ i
coil NN i
) ) i
or CC i
an DT i
active JJ i
can MD i
with IN i
the DT i
proximal JJ i
atrial JJ i
coil NN i
( ( i
dual JJ i
coil NN i
) ) i
. . i

Impact NN N
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
clindamycin JJ i
phosphate JJ i
1.2 CD i
% NN i
-benzoyl NNP i
peroxide RB i
2.5 CD i
% NN i
aqueous JJ i
gel NN i
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
moderate JJ p
to TO p
severe VB p
acne JJ p
vulgaris NN p
. . p

Both DT N
the DT N
absolute NN N
and CC N
percentage NN N
decreases NNS N
in IN N
mean JJ o
blood NN o
pressure NN o
induced VBN N
by IN N
nifedipine NN i
and CC N
the DT N
combination NN N
compared VBN N
with IN N
placebo NN i
were VBD N
similar JJ N
and CC N
significantly RB N
greater JJR N
than IN N
those DT N
induced VBN N
by IN N
chlorthalidone NN N
. . N

Outcomes NNS o
included VBD o
incidence NN o
of IN o
clinically RB o
significant JJ o
postoperative JJ o
pulmonary JJ o
complications NNS o
, , o
fever RB o
, , o
length NN o
of IN o
stay NN o
, , o
and CC o
restoration NN o
of IN o
mobility NN o
. . o

RESULTS NNP N
Expression NNP o
of IN o
leptin NN o
genes NNS o
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

An DT N
increased VBN N
[ NN N
Atot NNP N
] NNP N
, , N
due JJ N
to TO N
increased VBN N
[ NNP N
PP NNP N
] NNP N
and CC N
a DT N
sustained JJ N
increase NN N
in IN N
plasma JJ N
[ JJ N
acetate NN N
] NN N
, , N
contributed VBD N
a DT N
minor JJ N
acidifying NN N
effect NN N
. . N

A DT N
decrease NN N
in IN N
leg NN o
blood NN o
flow NN o
volume NN o
and CC N
a DT N
corresponding JJ N
increase NN N
in IN N
leg JJ o
peripheral JJ o
vascular JJ o
resistance NN o
were VBD N
noted VBN N
in IN N
the DT N
misoprostol NN i
group NN N
. . N

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
10- JJ N
to TO N
20-fold JJ N
increase NN N
in IN N
urinary JJ o
levels NNS o
of IN o
cobalt NN o
and CC o
chromium NN o
was VBD N
observed VBN N
throughout IN N
the DT N
entire JJ N
follow-up NN N
in IN N
the DT N
MOM NNP i
group NN N
. . N

Despite IN N
a DT N
dose-dependent JJ N
suppression NN o
of IN o
sACE NN o
, , N
there EX N
were VBD N
no DT N
observed VBN N
statistically RB N
significant JJ N
differences NNS N
in IN N
ALDO NNP o
and CC o
A-II NNP o
suppression NN o
or CC o
escape NN o
with IN N
escalating VBG N
doses NNS N
of IN N
enalapril NN i
within IN N
each DT N
subgroup NN N
. . N

PegFeG-CSF NNP i
provided VBD N
the DT N
most RBS N
therapeutic JJ N
and CC N
sustainable JJ o
neutrophil JJ o
production NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
FIV-uninfected JJ N
and CC N
FIV-infected JJ N
cats NNS N
, , N
without IN N
the DT N
development NN N
of IN N
neutralizing VBG N
antibodies NNS N
. . N

We PRP N
examined VBD N
the DT N
prognostic JJ N
value NN N
of IN N
inflammatory JJ N
markers NNS N
( ( N
albumin NN N
, , N
white-cell JJ N
count NN N
and CC N
its PRP$ N
components NNS N
, , N
and CC N
platelets NNS N
) ) N
in IN N
pre-treated JJ p
patients NNS p
with IN p
advanced JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Overall NNP o
survival NN o
, , o
time NN o
to TO o
first JJ o
recurrence NN o
, , o
complication NN o
rates NNS o
, , o
and CC o
surgical JJ o
outcomes NNS o
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
were VBD N
the DT N
combined JJ o
incidence NN o
of IN o
death NN o
, , o
target NN o
lesion NN o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
repeat NN o
angioplasty NN o
, , o
and CC o
coronary JJ o
artery NN o
bypass NN o
graft NN o
surgery NN o
. . o

Bone NNP o
turnover NN o
was VBD N
determined VBN N
by IN N
ICTP NNP N
( ( N
type NN N
I PRP N
collagen VBP N
carboxyterminal JJ N
cross-linked JJ N
telopeptide NN N
) ) N
as IN N
parameter NN N
of IN N
bone NN N
resorption NN N
and CC N
PICP NNP N
( ( N
carboxyterminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
) ) N
as IN N
marker NN N
of IN N
bone NN N
formation NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
frequency NN o
of IN o
allelic JJ o
imbalance NN o
between IN o
primary JJ o
and CC o
metastatic JJ o
tumors NNS o
at IN N
any DT N
marker NN N
analyzed VBN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

METHODS NNP N
Forty NNP p
cases NNS p
with IN p
respiration NN p
and CC p
cardiac JJ p
arrest NN p
in IN p
the DT p
department NN p
of IN p
critical JJ p
care NN p
medicine NN p
were VBD N
randomly RB N
divided VBN N
into IN N
low JJ i
VT NNP i
ventilation NN i
group NN i
and CC i
conventional JJ i
VT NNP i
group NN i
. . i

Decreases NNS N
in IN N
serum NN o
prolactin NN o
concentrations NNS o
in IN N
response NN N
to TO N
perioperative JJ N
stress NN N
were VBD N
significantly RB N
smaller JJR N
in IN N
dogs NNS N
exposed VBN N
to TO N
sDAP VB N
, , N
compared VBN N
with IN N
findings NNS N
in IN N
dogs NNS N
exposed VBN N
to TO N
the DT N
sham NN N
treatment NN N
. . N

We PRP N
conclude VBP N
that DT N
cyclo-oxygenase NN N
is VBZ N
rapidly RB N
synthesised VBN N
in IN N
bradykinin-responsive JJ N
tissues NNS N
in IN N
vivo NN N
and CC N
that IN N
this DT N
reflects VBZ N
similarly RB N
rapid JJ N
enzyme JJ N
biosynthesis NN N
in IN N
tissues NNS N
that WDT N
produce VBP N
PGI2 NNP N
under IN N
basal NN N
conditions NNS N
. . N

CONCLUSION NN N
This DT N
study NN N
demonstrates VBZ N
an DT N
immunostimulatory JJ N
effect NN N
of IN N
the DT N
histamine-2-receptor JJ i
antagonist NN i
, , i
ranitidine NN i
, , N
both DT N
at IN N
the DT N
cellular JJ N
and CC N
mediator NN N
levels NNS N
in IN N
patients NNS p
after IN p
head JJ p
injury NN p
. . p

The DT N
absolute JJ o
number NN o
of IN o
blood NN o
and CC o
sputum NN o
eosinophils NNS o
did VBD N
not RB N
change VB N
significantly RB N
after IN N
allergen NN N
or CC N
placebo NN N
challenge NN N
( ( N
P NNP N
> NNP N
0.07 CD N
, , N
both DT N
comparisons NNS N
) ) N
. . N

METHODS NNP N
In IN N
ten NN N
paired JJ N
biopsies NNS N
, , N
crystallinity NN o
, , o
apparent JJ o
length NN o
and CC o
width/thickness NN o
of IN o
crystals NNS o
, , o
interplanar NN o
distances NNS o
, , o
and CC o
lattice JJ o
parameters NNS o
of IN o
unit NN o
cells NNS o
were VBD N
assessed VBN N
by IN N
X-ray JJ N
diffraction NN N
and CC N
selected VBN N
area NN N
electron NN N
diffraction NN N
. . N

Moreover RB N
, , N
in IN N
vitro JJ N
studies NNS N
have VBP N
suggested VBN N
the DT N
presence NN N
of IN N
anticoagulant JJ N
effects NNS N
of IN N
3-hydroxy-3-methylglutaryl JJ i
coenzyme NN i
A NNP i
reductase NN i
inhibitors NNS i
, , i
as IN i
lipopolysaccharide NN i
( ( i
LPS NNP i
) ) i
-induced VBD i
monocyte JJ i
tissue NN i
factor NN i
( ( i
TF NNP i
) ) i
was VBD N
suppressed VBN N
. . N

We PRP N
predicted VBD N
that IN N
, , N
under IN N
these DT N
circumstances NNS N
, , N
insulin-stimulated JJ i
endothelin-1 JJ i
( ( i
ET-1 NNP i
) ) i
action NN i
( ( N
assessed VBN N
with IN N
the DT N
type NN N
A NNP N
endothelin NN N
receptor NN N
antagonist IN N
BQ-123 NNP N
) ) N
would MD N
be VB N
augmented VBN N
in IN N
proportion NN N
to TO N
hyperinsulinemia NN N
. . N

Polysomnography NNP N
demonstrated VBD N
that IN N
the DT N
percentage NN o
of IN o
SWS NNP o
was VBD N
not RB N
different JJ N
when WRB N
saline NN N
and CC N
GHRH NNP N
antagonist VBP N
nights NNS N
were VBD N
compared VBN N
( ( N
P=0.607 NNP N
) ) N
; : N
other JJ N
quantifiable JJ N
sleep JJ o
parameters NNS o
were VBD N
also RB N
unchanged JJ N
. . N

No DT N
intergroup NN N
differences NNS N
were VBD N
found VBN N
with IN N
respect NN N
to TO N
the DT N
number NN N
of IN N
punctures NNS N
( ( N
mean JJ N
value NN N
1.6 CD N
+/- JJ N
0.83 CD N
) ) N
and CC N
the DT N
incidence NN o
of IN o
complications NNS o
. . o

In IN N
the DT N
chemokinesis NN N
assay NN N
, , N
the DT N
maximum JJ o
distance NN o
moved VBN o
by IN o
neutrophils NNS o
in IN o
the DT o
presence NN o
of IN o
C18:0 NNP o
PAF NNP o
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
seen VBN N
with IN N
the DT N
C16:0 NNP N
compound NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ o
outcome NN o
measure NN o
was VBD o
the DT o
change NN o
from IN o
baseline NN o
in IN o
serum NN o
[ NN o
Na NNP o
( ( o
+ NNP o
) ) o
] VBP o
area NN o
under IN o
the DT o
curve NN o
. . o

Sporadic JJ o
increases NNS o
in IN o
transaminase NN o
levels NNS o
, , o
increases NNS o
in IN o
cholesterol NN o
and CC o
serum JJ o
creatinine NN o
levels NNS o
, , o
and CC o
decreases NNS o
in IN o
neutrophil NN o
and CC o
hemoglobin NN o
levels NNS o
were VBD N
observed VBN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-matched JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
QT NNP o
interval NN o
corrected VBD o
for IN o
heart NN o
rate NN o
( ( o
QTc NNP o
) ) o
using VBG N
an DT N
individual JJ N
correction NN N
method NN N
( ( N
QTcI NNP N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN i
in IN N
Lipiodol NNP N
exerts VBZ N
a DT N
more RBR N
favorable JJ N
focal JJ o
therapeutic JJ o
effect NN o
than IN N
does VBZ N
epirubicin VB N
in IN N
Lipiodol NNP N
in IN N
the DT N
initial JJ N
treatment NN N
of IN N
hepatocellular JJ N
carcinoma NN N
. . N

METHODS NNP N
Variations NNP N
in IN N
SkBF NNP N
and CC N
Tsk NNP N
in IN N
adult NN p
volunteers NNS p
were VBD N
simultaneously RB i
recorded VBN i
with IN i
a DT i
thermostatic JJ i
laser NN i
Doppler NNP i
system NN i
during IN i
a DT i
20-minute JJ i
radiofrequency NN i
exposure NN i
session NN i
and CC i
a DT i
20-minute JJ i
sham NN i
session NN i
. . i

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
vitamin JJ i
A-fortified JJ i
cooking NN i
oil NN i
ration NN i
; : i
to TO i
Control-1 NNP i
group NN i
with IN i
unfortified JJ i
cooking NN i
oil NN i
ration NN i
; : i
and CC i
to TO i
Control-2 NNP i
group NN i
without IN i
cooking VBG i
oil NN i
ration NN i
. . i

A DT N
pharmacologic JJ N
effect NN N
was VBD N
apparent JJ N
from IN N
a DT N
dose-dependent JJ N
statistically RB N
significant JJ N
decrease NN N
in IN N
the DT N
mean JJ o
prothrombin NN o
time NN o
in IN N
all DT N
N7-GP JJ N
groups NNS N
as IN N
compared VBN N
with IN N
placebo NN i
. . i

The DT N
ID NNP N
Group NNP N
, , N
following VBG N
OK-432 JJ N
injection NN N
, , N
had VBD N
a DT N
4.8 CD N
% NN N
incidence NN o
of IN o
fever NN o
and CC N
a DT N
52.4 CD N
% NN N
incidence NN N
of IN N
local JJ o
abscess NN o
formation NN o
at IN N
the DT N
injection NN N
site NN N
. . N

The DT N
down-regulation NN N
of IN N
co-transporter NN N
KCC2 NNP N
after IN N
spinal JJ N
cord NN N
transection NN N
in IN N
animals NNS N
leads NNS N
to TO N
the DT N
depolarising NN N
( ( N
excitatory NN N
) ) N
action NN N
of IN N
GABA NNP N
and CC N
glycine NN N
and CC N
thus RB N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
inhibitory JJ N
synaptic JJ N
efficiency NN N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
the DT N
decrease NN N
in IN N
serum NN o
TC NNP o
, , o
LDL-C NNP o
and CC o
triglyceride NN o
levels NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
second JJ N
group NN N
than IN N
the DT N
first JJ N
group NN N
. . N

The DT N
authors NNS N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
oral JJ i
temazepam NN i
, , i
a DT i
medium NN i
half-life JJ i
benzodiazepine NN i
vs IN i
oral JJ i
zolpidem NN i
, , i
a DT i
short JJ i
half-life JJ i
non-benzodiazepine JJ i
drug NN i
, , i
vs NN i
placebo NN i
. . i

In IN N
a DT N
tamoxifen NN N
randomised VBN N
patient JJ N
material NN N
, , N
absent JJ N
YAP1 NNP N
protein NN N
expression NN N
was VBD N
associated VBN N
with IN N
impaired JJ N
tamoxifen NN N
response NN N
which WDT N
was VBD N
significant JJ N
upon IN N
interaction NN N
analysis NN N
( ( N
p JJ N
= NNP N
0.042 CD N
) ) N
. . N

We PRP N
also RB N
sought VBD N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
BMD NNP o
loss NN o
, , N
including VBG N
markers NNS N
of IN N
systemic JJ N
inflammation NN N
[ NNP N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptors NNS N
( ( N
sTNFR NN N
I PRP N
and CC N
II NNP N
) ) N
] NN N
. . N

No DT N
significant JJ N
difference NN N
in IN N
eradication NN o
rates NNS o
was VBD N
observed VBN N
among IN N
the DT N
three CD N
groups NNS N
both DT N
in IN N
intention NN N
to TO N
treat VB N
analysis NN N
and CC N
in IN N
per IN N
protocol NN N
analysis NN N
. . N

The DT N
subjects NNS N
lost VBD N
2.1 CD N
% NN N
of IN N
body NN o
weight NN o
during IN N
active JJ N
drug NN N
phase NN N
, , N
but CC N
there RB N
was VBD N
a DT N
rebound NN o
weight NN o
gain NN o
during IN N
the DT N
subsequent JJ N
placebo NN N
phase NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
logarithm NN N
of IN N
the DT N
heart NN o
rate NN o
, , o
recovery NN o
time NN o
or CC o
quality NN o
of IN o
recovery NN o
between IN N
the DT N
three CD N
induction NN N
groups NNS N
. . N

BACKGROUND NNP N
New NNP N
antibacterial JJ N
agents NNS N
with IN N
activity NN N
against IN N
pathogenic JJ N
strains NNS N
resistant VBP N
to TO N
established VBN N
antibiotics NNS N
are VBP N
needed VBN N
to TO N
treat VB N
patients NNS p
with IN p
secondarily RB p
infected VBN p
dermatitis NN p
( ( p
SID NNP p
) ) p
. . p

Five CD N
days NNS N
later RB N
, , N
we PRP N
only RB N
found VBD N
single-labelled JJ o
motor NN o
and CC o
sensory JJ o
neurons NNS o
in IN N
the DT N
normal JJ N
and CC N
end-to-end JJ N
coaptation NN N
groups NNS N
, , N
while IN N
some DT N
dual-labelled JJ N
neurons NNS N
can MD N
be VB N
identified VBN N
in IN N
end-to-side JJ N
coaptation NN N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Two CD N
samples NNS o
( ( o
pretest JJS o
, , o
posttest JJS o
) ) o
of IN o
salivary JJ o
cortisol NNS o
were VBD N
analyzed VBN N
using VBG N
an DT N
enzyme JJ N
immunoassay JJ N
kit NN N
; : N
the DT N
average NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Impact NN N
of IN N
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
therapy NN i
( ( i
olmesartan JJ i
or CC i
valsartan NN i
) ) i
on IN N
coronary JJ N
atherosclerotic JJ N
plaque NN N
volume NN N
measured VBN N
by IN N
intravascular JJ N
ultrasound NN N
in IN N
patients NNS p
with IN p
stable JJ p
angina JJ p
pectoris NN p
. . p

The DT N
change NN N
in IN N
heart NN o
rate NN o
and CC o
oxygen NN o
saturation NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
EBM NNP i
group NN N
and CC N
returned VBN N
to TO N
baseline VB N
values NNS N
sooner JJR N
than IN N
in IN N
the DT N
DW NNP N
group NN N
. . N

CONCLUSIONS NNP N
Moderately RB N
accelerated JJ N
fractionation NN N
is VBZ N
superior JJ N
to TO N
conventional JJ N
treatment NN N
in IN N
HNSCC NNP N
but CC N
the DT N
response NN N
is VBZ N
heterogeneous JJ N
and CC N
may MD N
be VB N
predicted VBN N
by IN N
high JJ N
expression NN N
of IN N
EGFr NNP N
and CC N
well/moderate JJ N
tumor NN N
differentiation NN N
. . N

SECONDARY NNP N
OUTCOMES NNP N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
evaluation NN o
of IN o
ECG NNP o
for IN o
ischaemia NN o
and CC o
QT NNP o
interval NN o
, , o
hypoglycaemic JJ o
and CC o
anti-hypertensive JJ o
medication NN o
and CC o
cardiovascular JJ o
events NNS o
. . o

BACKGROUND NNP N
XS0601 NNP N
, , N
consisting VBG N
of IN N
active JJ i
ingredients NNS i
( ( i
Chuangxiongol NNP i
and CC i
paeoniflorin NN i
) ) i
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
inhibit VB N
arterial JJ N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
in IN N
preliminary JJ N
human JJ N
studies NNS N
. . N

The DT N
presence NN N
of IN N
leishmanial JJ i
antigen NN i
( ( i
with IN i
BCG NNP i
) ) i
in IN N
the DT N
inoculum NN N
suppressed VBD N
the DT N
IgG NNP N
response NN N
to TO N
Mycobacterium NNP N
tuberculosis/Mycobacterium NN N
bovis-related JJ N
( ( N
PPD NNP N
and CC N
BCG NNP N
) ) N
, , N
but CC N
not RB N
M. NNP N
leprae-related JJ N
( ( N
MLSA NNP N
) ) N
-related VBD N
, , N
antigens NNS N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
overall JJ o
survival NN o
, , o
tumor NN o
response NN o
rate NN o
( ( o
Response NNP o
Evaluation NNP o
Criteria NNP o
in IN o
Solid NNP o
Tumors NNP o
) ) o
, , o
and CC o
safety NN o
. . o

Warfarin NNP i
was VBD N
started VBN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
the DT N
dosage NN N
was VBD N
adjusted VBN N
to TO N
maintain VB N
the DT N
thromboplastin JJ N
international JJ N
normalised VBN N
ratio NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
2.5 CD N
. . N

MAIN NNP N
RESULTS NNP N
Rapid NNP N
injection NN N
was VBD N
less RBR N
painful JJ N
than IN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ i
0.5 CD N
mg/kg NN N
, , N
but CC N
was VBD N
similar JJ N
to TO N
slow VB N
injection NN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ i
1.0 CD N
mg/kg NN N
. . N

Folic NNP N
acid NN N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN N
in IN N
blood NN o
folate JJ o
concentrations NNS o
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
and CC N
the DT N
area NN N
under IN N
plasma JJ N
concentration NN N
vs. FW N
time NN N
curves NNS N
( ( N
AUCs NNP N
) ) N
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

Norfloxacin NNP i
, , i
trimethoprim/sulfamethoxazole NN i
, , N
cytokines NNS N
, , N
nitric JJ N
oxide NN N
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP o
( ( o
IkB-alpha NNP o
) ) o
, , o
neutrophil JJ o
oxidative JJ o
burst NN o
, , o
and CC o
rate NN o
of IN o
apoptotic JJ o
events NNS o
were VBD N
determined VBN N
. . N

CONCLUSION NNP N
The DT N
combination NN N
of IN N
fluoxetine JJ i
plus CC i
local JJ i
application NN i
of IN i
lidocaine JJ i
ointment NN i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
fluoxetine VB i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
premature JJ N
ejaculation NN N
. . N

CONCLUSION NNP N
Zoledronic NNP i
acid NN i
significantly RB N
reduced VBD N
skeletal JJ N
complications NNS N
compared VBN N
with IN N
placebo NN i
across IN N
multiple JJ N
end NN N
points NNS N
in IN N
Japanese JJ p
women NNS p
with IN p
bone NN p
metastases NNS p
from IN p
breast NN p
cancer NN p
. . p

HYPOTHESIS NNP N
Dermal NNP N
iontophoretic JJ N
administration NN N
of IN N
dexamethasone NN i
sodium NN i
phosphate NN i
will MD N
be VB N
significantly RB N
more RBR N
effective JJ N
in IN N
controlling VBG N
pain NN N
than IN N
a DT N
placebo NN i
in IN N
patients NNS p
with IN p
medial JJ p
or CC p
lateral JJ p
elbow NN p
epicondylitis NN p
. . p

CONCLUSION NNP N
Laparoscopic NNP i
stripping NN i
of IN i
ovarian JJ i
endometriotic JJ i
cyst NN i
significantly RB N
decreases VBZ N
serum JJ o
AMH NNP o
levels NNS o
and CC o
increases VBZ o
basal JJ o
FSH NNP o
levels NNS o
independent JJ N
from IN N
the DT N
method NN N
used VBN N
to TO N
obtain VB N
hemostasis NN N
on IN N
the DT N
ovarian JJ N
tissue NN N
. . N

RESULTS VB N
The DT N
mean JJ o
approach NN o
withdrawal NN o
problem NN o
composite JJ o
score NN o
was VBD N
significantly RB N
higher JJR N
before IN N
supplementation NN N
than IN N
after IN N
, , N
both DT N
in IN N
the DT N
placebo NN i
and CC N
in IN N
the DT N
gluten-casein JJ N
group NN N
. . N

Attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
remove VB N
endotoxin NN N
, , N
the DT N
main JJ N
cause NN N
of IN N
sepsis NN N
, , N
from IN N
the DT N
circulation NN N
using VBG N
polymyxin NN i
B NNP i
immobilized VBD i
fiber NN i
, , i
charcoal NN i
hemoperfusion NN i
, , N
and CC N
plasma NN N
or CC N
whole JJ N
blood NN N
exchange NN N
. . N

Outcome NN N
measures NNS N
were VBD N
the DT N
incidence NN o
of IN o
macular JJ o
edema NN o
, , o
retinal JJ o
thickness NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
and CC o
presence NN o
of IN o
persistent JJ o
subretinal JJ o
fluid NN o
. . o

OBJECTIVE NN N
To TO N
compare VB N
efficacy NN N
of IN N
ultrasonography-guided JJ i
BRSB NNP i
and CC i
local JJ i
anesthetic JJ i
infiltration NN i
( ( i
LAI NNP i
) ) i
in IN N
providing VBG N
postoperative JJ p
analgesia NN p
after IN p
pediatric JJ p
umbilical JJ p
hernia NN p
repair NN p
. . p

The DT N
effect NN N
of IN N
3- JJ i
( ( i
2-benzylmethylaminoethyl JJ i
) ) i
benzoic NN i
acid JJ i
methyl NN i
ester NN i
hydrochloride NN i
( ( i
PRL-8-53 NNP i
) ) i
on IN N
learning NN N
and CC N
on IN N
retention NN N
of IN N
verbal JJ N
information NN N
in IN N
human JJ p
subjects NNS p
was VBD N
investigated VBN N
. . N

CONCLUSIONS NNP N
Clopidogrel NNP i
plus CC i
acetylsalicylic JJ i
acid NN i
showed VBD N
significantly RB N
superior JJ N
antithrombotic JJ o
efficacy NN o
compared VBN N
with IN N
extended-release JJ i
dipyridamole JJ i
plus CC i
acetylsalicylic JJ i
acid NN i
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
humans NNS p
. . p

No DT N
significant JJ N
dose NN N
related VBN N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
renal JJ o
clearance NN o
of IN o
3-MX JJ o
, , o
1-MU JJ o
and CC o
DMU NNP o
, , N
indicating VBG N
linear JJ N
urinary JJ N
excretion NN N
kinetics NNS N
of IN N
the DT N
metabolites NNS N
. . N

Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ o
blood NN o
neutrophil NN o
count NN o
, , N
but CC N
no DT N
other JJ N
clinically RB N
relevant JJ N
changes NNS N
in IN N
hematology NN o
or CC o
clinical JJ o
chemistry NN o
were VBD N
observed VBN N
. . N

High-tone CD i
audiometry NN i
was VBD N
performed VBN N
when WRB N
possible JJ N
; : N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
hearing VBG o
loss NN o
( ( N
3/12 CD N
and CC N
3/11 CD N
) ) N
or CC N
prodromal JJ o
signs NNS o
of IN o
ototoxicity NN o
( ( N
5/12 CD N
and CC N
4/11 CD N
) ) N
. . N

Thrombin-antithrombin JJ o
III NNP o
complex NN o
, , o
fibrinogen NN o
degradation NN o
product NN o
and CC o
tissue NN o
plasminogen NN o
activator NN o
levels NNS o
, , o
reflecting VBG o
activation NN o
of IN o
the DT o
coagulation NN o
and CC o
fibrinolytic JJ o
systems NNS o
, , N
respectively RB N
, , N
decreased VBD N
uniformly RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
a DT N
small JJ N
( ( N
1.1 CD N
? . N
5.6 CD N
s NN N
) ) N
but CC N
possibly RB N
beneficial JJ N
additional JJ N
effect NN N
when WRB N
combining VBG N
chronic JJ N
beta-alanine JJ N
supplementation NN N
with IN N
acute JJ N
sodium NN N
bicarbonate NN N
supplementation NN N
compared VBN N
with IN N
chronic JJ N
beta-alanine JJ N
supplementation NN N
alone RB N
. . N

Duration NN o
on IN o
treadmill NN o
and CC o
right JJ o
ventricular NN o
ejection NN o
fraction NN o
post NN o
exercise NN o
increased VBD o
, , o
while IN o
diastolic JJ o
and CC o
systolic JJ o
artery NN o
pressure NN o
decreased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Dan NNP i
Shao NNP i
Tang NNP i
( ( i
DST NNP i
) ) i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

The DT N
great JJ N
dispersion NN N
of IN N
the DT N
results NNS N
of IN N
plasminogen NN o
activator NN o
inhibitor NN o
activity NN o
was VBD N
the DT N
plausible JJ N
cause NN N
of IN N
the DT N
lack NN N
of IN N
any DT N
significant JJ N
difference NN N
in IN N
this DT N
variable NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
Raynaud NNP p
's POS p
syndrome NN p
have VBP p
abnormal JJ p
digital JJ p
vasoconstriction NN p
, , N
which WDT N
may MD N
be VB N
secondary JJ N
to TO N
impaired JJ N
synthesis NN N
of IN N
, , N
or CC N
impaired JJ N
sensitivity NN N
to TO N
, , N
nitric JJ N
oxide NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Significantly NNP N
lower JJR N
abdominal NN o
and CC o
shoulder NN o
tip NN o
pain NN o
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
vasovagal JJ o
reactions NNS o
were VBD N
observed VBN N
in IN N
group NN N
B NNP N
in IN N
comparison NN N
with IN N
group NN N
A NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
change NN N
from IN N
baseline NN N
for IN N
peroneal JJ o
reaction NN o
time NN o
or CC o
average JJ o
peroneal JJ o
muscle NN o
activity NN o
at IN o
any DT o
post NN o
treatment NN o
time NN o
. . o

RESULTS NNP N
Histological NNP N
analysis NN N
, , N
PMNs/alveoli NNP N
ratio NN N
, , N
and CC N
wet/dry JJ N
weight NN N
ratio NN N
measurements NNS N
demonstrated VBD N
that IN N
LPS NNP N
caused VBD N
significant JJ N
lung JJ N
injury NN N
and CC N
HBO NNP N
and/or VBP N
hemin NN N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
lung NN N
injury NN N
. . N

RESULTS VB N
The DT N
biochemical JJ N
parameters NNS N
were VBD N
examined VBN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
differences NNS N
in IN N
the DT N
levels NNS o
of IN o
hemoglobin NN o
and CC o
hemotocrit NN o
before IN N
delivery NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
changes NNS o
in IN o
plasma NN o
lipids NNS o
, , o
A1C NNP o
, , o
fasting VBG o
glucose NN o
, , o
insulin NN o
sensitivity NN o
, , o
and CC o
anthropometric JJ o
measures NNS o
. . o

However RB N
, , N
neither CC N
the DT N
primary JJ N
end NN N
point NN N
( ( N
P NNP N
=.25 NNP N
) ) N
nor CC N
most JJS N
of IN N
the DT N
secondary JJ N
end NN N
points NNS N
demonstrated VBD N
a DT N
significant JJ o
benefit NN o
of IN o
rhNGF NN o
. . o

Superior JJ N
efficacy NN N
of IN N
clopidogrel NN i
plus CC i
acetylsalicylic JJ i
acid NNS i
compared VBN N
with IN N
extended-release JJ i
dipyridamole JJ i
plus CC i
acetylsalicylic JJ i
acid NN i
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND IN N
The DT N
effect NN N
of IN N
L-arginine NNP i
and CC i
L-citrulline NNP i
on IN N
blood NN o
pressure NN o
and CC o
right JJ o
ventricular NN o
function NN o
in IN N
heart NN p
failure NN p
patients NNS p
with IN p
preserved JJ p
ejection NN p
fraction NN p
( ( p
HFpEF NNP p
) ) p
is VBZ N
unknown JJ N
. . N

RESULTS NNP N
Baseline NNP N
clinical JJ N
characteristics NNS N
of IN N
the DT N
allopurinol NN i
and CC N
placebo NN i
groups NNS N
demonstrated VBD N
no DT N
differences NNS N
in IN N
terms NNS N
of IN N
clinical JJ o
characteristics NNS o
, , o
endothelial JJ o
function NN o
and CC o
inflammatory JJ o
markers NNS o
. . o

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
the DT N
average JJ o
time NN o
spent VBN o
in IN o
the DT o
operating NN o
room NN o
or CC o
in IN o
the DT o
total JJ o
irrigation NN o
fluid NN o
used VBN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
observed VBN N
. . N

As IN N
demonstrated VBN N
by IN N
in IN N
vitro NN N
studies NNS N
, , N
cisplatin NN i
( ( i
CDDP NNP i
) ) i
is VBZ N
able JJ N
to TO N
down-regulate VB N
the DT N
AGAT NNP N
activity NN N
, , N
suggesting VBG N
that IN N
CDDP NNP i
could MD N
enhance VB N
the DT N
antitumor NN o
activity NN o
of IN o
TMZ NNP o
. . o

If IN N
so RB N
administered VBN N
it PRP N
would MD N
not RB N
increase VB N
bodily RB N
sodium JJ N
load NN N
and CC N
unlike IN N
isotonic JJ N
crystalloid NN N
solution NN N
it PRP N
dose VBD N
not RB N
cause JJ N
accumulation NN N
of IN N
water NN N
in IN N
the DT N
body NN N
on IN N
equipollent JJ N
basis NN N
. . N

Elevated VBN N
neutrophil JJ o
counts NNS o
, , o
elevated VBD o
platelet NN o
counts NNS o
, , N
and CC N
a DT N
high JJ N
neutrophil-lymphocyte JJ N
ratio NN N
were VBD N
significant JJ N
independent JJ N
predictors NNS N
for IN N
shorter JJR N
OS NNP N
in IN N
a DT N
model NN N
with IN N
established VBN N
prognostic JJ N
factors NNS N
. . N

Rapid JJ N
injection NN N
facilitated VBD N
LMA NNP N
insertion NN N
, , N
unlike IN N
slow JJ N
injection NN N
with IN N
lidocaine JJ i
0.5 CD N
mg/kg NN N
pretreatment NN N
, , N
and CC N
was VBD N
similarly RB N
successful JJ N
to TO N
slow VB N
injection NN N
after IN N
pretreatment NN N
with IN N
lidocaine JJ i
1.0 CD N
mg/kg NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
administration NN N
of IN N
tromethamine NN i
( ( i
THAM NNP i
) ) i
, , N
a DT N
buffer NN N
which WDT N
does VBZ N
not RB N
increase VB N
carbon NN o
dioxide NN o
production NN o
, , N
would MD N
modify VB N
these DT N
changes NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
healing VBG o
rate NN o
of IN o
the DT o
duodenal JJ o
ulcer NN o
after IN N
four CD N
weeks NNS N
, , N
86.7 CD N
% NN N
being VBG N
achieved VBN N
for IN N
both DT N
groups NNS N
. . N

Blood NNP o
pressure NN o
and CC o
total JJ o
peripheral JJ o
resistance NN o
responses NNS o
were VBD N
dependent JJ N
on IN N
pre- NN N
( ( N
antagonist/agonist NN N
) ) N
setting NN N
, , N
but CC N
heart NN o
rate NN o
and CC o
cardiac JJ o
output NN o
were VBD N
not RB N
influenced VBN N
by IN N
this DT N
factor NN N
. . N

Placental JJ o
growth NN o
factor NN o
( ( o
PlGF NNP o
) ) o
, , o
a DT o
member NN o
of IN o
the DT o
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
( ( o
VEGF NNP o
) ) o
family NN o
, , N
acts VBZ N
via IN N
the DT N
flt-1 JJ N
receptor NN N
and CC N
promotes VBZ N
endothelial JJ N
activation NN N
and CC N
macrophage NN N
recruitment NN N
into IN N
atherosclerotic JJ N
lesions NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP o
DNA NNP o
copy NN o
numbers NNS o
in IN o
the DT o
tears NNS o
or CC o
saliva NN o
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ o
blood NN o
count NN o
( ( o
leucocytes NNS o
, , o
granulocytes NNS o
, , o
lymphocytes NNS o
, , o
monocytes NNS o
, , o
thrombocytes NNS o
, , o
hemoglobin NN o
, , o
hematocrit NN o
) ) o
and CC o
the DT o
incidence NN o
of IN o
infections NNS o
. . o

RESULTS NNP N
Only RB N
the DT N
sarpogrelate NN N
group NN N
showed VBD N
increases NNS N
in IN N
plasma NN o
adiponectin NN o
and CC N
decreases NNS N
in IN N
both DT N
plasma NN o
and CC o
urinary JJ o
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
and CC o
albumin-to-creatinine JJ o
ratio NN o
levels NNS o
. . o

Hypotensive JJ N
effects NNS N
and CC N
influence NN N
on IN N
serum NN o
lipids NNS o
of IN N
SQ29,852 NNP i
, , i
a DT i
new JJ i
angiotensin NN i
converting VBG i
enzyme JJ i
inhibitor NN i
, , N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
: : p
a DT N
comparison NN N
with IN N
atenolol NN i
. . i

We PRP N
hypothesized VBD N
that IN N
there EX N
would MD N
be VB N
improved VBN N
fixation NN N
of IN N
high-porosity NN i
trabecular JJ i
metal NN i
( ( i
TM NNP i
) ) i
tibial JJ i
components NNS i
compared VBN i
to TO i
low-porosity JJ i
titanium NN i
pegged VBD i
porous JJ i
fiber-metal JJ i
( ( i
Ti NNP i
) ) i
polyethylene NN i
metal JJ i
backings NNS i
. . i

Two CD N
fluorescent JJ i
tracers NNS i
( ( N
true JJ N
blue NN N
and CC N
diamidino NN N
yellow NN N
) ) N
were VBD N
applied VBN N
to TO N
the DT N
proximal JJ N
ends NNS N
of IN N
tibial JJ N
and CC N
common JJ N
peroneal NN N
nerves NNS N
, , N
respectively RB N
after IN N
four CD N
or CC N
six CD N
months NNS N
of IN N
nerve DT N
coaptation NN N
. . N

Satisfaction NN o
rate NN o
, , o
operative JJ o
time NN o
, , o
discharge NN o
time NN o
, , o
complication NN o
rate NN o
, , o
reintervention NN o
rate NN o
, , o
and CC o
resumption NN o
of IN o
normal JJ o
activity NN o
were VBD N
evaluated VBN N
in IN N
each DT N
group NN N
. . N

AIMS NNP N
Adenosine NNP N
monophosphate NN N
( ( N
AMP NNP N
) ) N
acts VBZ N
indirectly RB N
via IN N
primed VBN N
airway RB N
mast JJ N
cells NNS N
to TO N
induce VB N
bronchial JJ N
hyper-responsiveness NN N
, , N
which WDT N
in IN N
turn NN N
correlates NNS N
with IN N
eosinophilic JJ N
asthmatic JJ N
inflammation NN N
and CC N
atopic JJ N
disease NN N
expression NN N
. . N

Importantly RB N
, , N
2D-STE JJ N
analysis NN N
demonstrated VBD N
the DT N
presence NN N
of IN N
subclinical JJ o
LV NNP o
systolic NN o
and CC o
diastolic JJ o
dysfunction NN o
with IN o
impaired JJ o
circumferential NN o
and CC o
longitudinal JJ o
strain NN o
and CC o
strain NN o
rate NN o
at IN o
the DT o
isovolumic JJ o
relaxation NN o
time NN o
. . o

Plasma NNP o
and CC o
urine JJ o
concentrations NNS o
of IN o
tyrosine NN o
and CC o
phenylalanine NN o
were VBD N
far RB N
higher JJR N
in IN N
the DT N
infants NNS N
fed VBP N
F1 NNP N
to TO N
F4 NNP N
, , N
especially RB N
F2 NNP N
and CC N
F4 NNP N
, , N
than IN N
in IN N
the DT N
infants NNS N
fed VBN N
BM NNP N
. . N

No DT N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ o
levels NNS o
, , o
insulin NN o
sensitivity NN o
index NN o
and CC o
lipid JJ o
profile NN o
as RB o
well RB o
as IN o
in IN o
biochemical JJ o
and CC o
cell NN o
count NN o
parameters NNS o
in IN N
any DT N
groups NNS N
. . N

Mexiletine NNP i
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
tendon NN o
reflexes NNS o
, , o
vibration NN o
threshold NN o
levels NNS o
, , o
beat-to-beat JJ o
variation NN o
in IN o
heart NN o
rate NN o
during IN o
deep JJ o
breathing NN o
, , o
and CC o
postural JJ o
blood NN o
pressure NN o
response NN o
. . o

About IN N
platelet NN N
5-HT JJ N
, , N
there EX N
is VBZ N
neither DT N
order NN N
x NNP N
treatment NN N
interaction NN N
, , N
nor CC N
treatment NN N
effect NN N
but CC N
a DT N
significant JJ N
order NN N
effect NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Significantly RB N
more JJR N
patients NNS N
in IN N
the DT N
AMX-CL NNP i
group NN N
than IN N
in IN N
the DT N
CAE NNP i
or CC i
CEC NNP i
group NN N
had VBD N
a DT N
side NN o
effect NN o
, , o
primarily RB o
diarrhea NN o
, , o
vomiting VBG o
, , o
or CC o
diaper JJ o
rash NN o
. . o

Nicotine NNP i
caused VBD N
a DT N
small JJ N
overall JJ N
reduction NN N
in IN N
global JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
but CC N
, , N
when WRB N
the DT N
data NNS N
were VBD N
normalized VBN N
, , N
several JJ N
brain NN N
regions NNS N
showed VBD N
relative JJ N
increases NNS N
in IN N
activity NN o
. . o

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
morning NN o
stiffness NN o
, , o
walking VBG o
time NN o
, , o
erythrocyte JJ o
sedimentation NN o
rate NN o
, , o
C-reactive JJ o
protein NN o
, , o
or CC o
rheumatoid VB o
factor NN o
between IN o
the DT o
groups NNS o
. . o

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
diminished JJ N
variability NN N
in IN N
performance NN N
in IN N
the DT N
tested JJ N
frequency NN N
bands NNS N
with IN N
Hydergine NNP i
, , N
the DT N
opposite JJ N
tendency NN N
being VBG N
obtained VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
efficacy NN N
of IN N
Rioprostil NNP i
( ( N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
) ) N
is VBZ N
compared VBN N
with IN N
that DT N
of IN N
ranitidine NN i
in IN N
the DT N
recurrence NN N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
( ( N
s NN N
) ) N
. . N

BACKGROUND NNP N
Ischemic NNP i
preconditioning NN i
( ( i
IPC NNP i
) ) i
and CC i
anesthetic JJ i
preconditioning NN i
( ( i
APC NNP i
) ) i
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

Thus RB N
, , N
no DT N
dose JJ N
adjustment NN N
for IN N
either DT N
risperidone NN i
orgalantamine NN i
is VBZ N
necessary JJ N
when WRB N
these DT N
two CD N
drugs NNS N
are VBP N
administered VBN N
together RB N
in IN N
the DT N
dose JJ N
range NN N
evaluated VBD N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Positive NNP o
response NN o
was VBD o
defined VBN o
by IN o
a DT o
score NN o
of IN o
much JJ o
improved VBN o
or CC o
very RB o
much JJ o
improved VBN o
on IN o
the DT o
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Improvement NNP o
subscale NN o
. . o

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival NN o
, , o
tumor NN o
response NN o
, , o
duration NN o
of IN o
response NN o
, , o
and CC o
time NN o
to TO o
response NN o
. . o

There EX N
was VBD N
no DT N
observed JJ N
effect NN N
on IN N
newborn JJ o
serum NN o
electrolyte NN o
levels NNS o
with IN N
amnioinfusion NN N
, , N
nor CC N
was VBD N
there EX N
any DT N
apparent JJ N
benefit NN N
of IN N
infusion NN N
of IN N
warmed JJ N
saline NN N
compared VBN N
with IN N
room-temperature JJ N
saline NN N
. . N

Icosapent NNP i
Ethyl NNP i
( ( i
Eicosapentaenoic NNP i
Acid NNP i
Ethyl NNP i
Ester NNP i
) ) i
: : i
Effects NNS N
Upon IN N
High-Sensitivity NNP N
C-Reactive JJ N
Protein NNP N
and CC N
Lipid NNP N
Parameters NNP N
in IN N
Patients NNP p
With IN p
Metabolic NNP p
Syndrome NNP p
. . p

RESULTS NN N
Before IN N
application NN N
of IN N
saline JJ N
solutions NNS N
, , N
mucociliary JJ o
clearance NN o
times NNS o
in IN N
the DT N
three CD N
patient NN N
treatment NN N
groups NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
delayed VBN N
, , N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

The DT N
incidence NN o
of IN o
shivering NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN i
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN N
group NN N
. . N

Daily JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ i
( ( i
Cladribine NNP i
, , i
CDA NNP i
) ) i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
hairy NN p
cell NN p
leukemia NN p
, , N
but CC N
may MD N
cause VB N
severe JJ N
neutropenia NN o
and CC o
neutropenic JJ o
fever NN o
. . o

Experimentally RB N
, , N
two CD N
slotted VBD i
nails NNS i
, , i
the DT i
Grosse-Kempf NNP i
nail NN i
and CC i
the DT i
AO/ASIF NNP i
universal JJ i
femoral JJ i
nail NN i
, , N
were VBD N
compared VBN N
to TO N
the DT N
non-slotted JJ i
Grosse-Kempf NNP i
nail NN i
and CC N
control NN N
bone NN N
using VBG N
a DT N
cadaver JJ N
femoral JJ N
osteotomy NN N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS o
of IN o
peak JJ o
expiratory NN o
flow NN o
, , o
FEV1 NNP o
, , o
and CC o
FVC NNP o
at IN o
baseline NN o
and CC o
at IN o
the DT o
end NN o
of IN o
treatment NN o
. . o

BALF NNP o
levels NNS o
of IN o
total JJ o
protein NN o
, , o
neutrophils NNS o
, , o
and CC o
leukotriene JJ o
B4 NNP o
tended VBD N
to TO N
decrease VB N
in IN N
EPA+GLA NNP N
patients NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
as IN N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
maximum JJ N
force NN N
measurements NNS N
and CC N
stimulation NN N
order NN N
, , N
which WDT N
was VBD N
not RB N
apparent JJ N
in IN N
the DT N
fatigue JJ o
time NN o
or CC o
FTI NNP o
measurements NNS o
. . o

Skeletal JJ N
muscle NN N
STARS NNP N
, , N
myocardian-related JJ N
transcription NN N
factor-A NN N
( ( N
MRTF-A NNP N
) ) N
and CC N
serum JJ N
response NN N
factor NN N
( ( N
SRF NNP N
) ) N
mRNA NN N
and CC N
protein NN N
, , N
as RB N
well RB N
as IN N
muscle NN N
cross-sectional JJ N
area NN N
and CC N
maximal JJ N
voluntary JJ N
contraction NN N
, , N
were VBD N
measured VBN N
. . N

RESULTS NNP N
Oral NNP N
NAA NNP N
resulted VBD N
in IN N
a DT N
profound NN N
plasma NN N
alkalosis NN N
marked VBN N
by IN N
decreased JJ N
plasma NN N
[ NNP N
H+ NNP N
] NNP N
and CC N
increased VBD N
plasma NN N
[ NN N
TCO2 NNP N
] NNP N
and CC N
[ NNP N
HCO3- NNP N
] NNP N
compared VBN N
to TO N
Control NNP N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD o
fluid JJ o
retention NN o
, , o
nausea NN o
, , o
fatigue NN o
, , o
skin JJ o
rash NN o
, , o
gastrointestinal JJ o
complaints NNS o
, , o
and CC o
myalgia NN o
. . o

BACKGROUND NNP N
Although IN N
moderate JJ N
caffeine NN N
ingestion NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
arrhythmogenic JJ N
, , N
caffeine JJ N
toxicity NN N
can MD N
cause VB N
severe JJ o
cardiac JJ o
arrhythmias NN o
, , o
including VBG o
atrial JJ o
fibrillation NN o
and CC o
ventricular JJ o
tachycardia NN o
. . o

Uterine JJ o
volume NN o
, , o
mean VB o
operating NN o
time NN o
, , o
uterine JJ o
weight NN o
, , o
drop NN o
in IN o
hemoglobin NN o
, , o
intraoperative JJ o
complications NNS o
, , o
conversions NNS o
to TO o
laparotomy VB o
, , o
and CC o
hospital NN o
stay NN o
were VBD N
recorded VBN N
. . N

Zoledronic JJ i
acid NN i
is VBZ N
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN N
in IN N
increasing VBG N
lumbar NN o
spine NN o
( ( o
LS NNP o
) ) o
bone NN o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
both DT N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Similarly RB N
, , N
no DT N
effects NNS N
were VBD N
seen VBN N
on IN N
secondary JJ N
vascular JJ N
end NN N
points NNS N
, , N
except IN N
for IN N
a DT N
suggestion NN N
of IN N
protection NN N
versus NN N
strokes NNS N
and CC N
transient JJ N
ischemic JJ N
attacks NNS N
. . N

Urinary JJ o
aldosterone NN o
was VBD N
decreased VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
fashion NN N
and CC N
its PRP$ N
changes NNS N
were VBD N
largely RB N
independent JJ N
of IN N
plasma JJ N
renin NN N
activity NN N
. . N

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
sumatriptan JJ i
differ NN N
from IN N
those DT N
of IN N
previously RB N
described VBN N
5-HT-receptor JJ N
agonists NNS N
, , N
and CC N
may MD N
be VB N
a DT N
consequence NN N
of IN N
selective JJ N
activation NN N
of IN N
5-HT1D JJ N
or CC N
5-HT1B JJ N
receptors NNS N
. . N

The DT N
effects NNS N
of IN N
low- JJ i
, , i
medium- JJ i
, , i
and CC i
high-oil NN i
distillers NNS i
dried VBD i
grains NNS i
with IN i
solubles NNS i
on IN N
growth NN o
performance NN o
, , o
nutrient JJ o
digestibility NN o
, , o
and CC o
fat JJ o
quality NN o
in IN N
finishing VBG p
pigs NNS p
. . p

The DT N
mean JJ o
extraction NN o
recovery NN o
for IN N
rilpivirine NN i
( ( N
94.9 CD N
% NN N
) ) N
and CC N
IS NNP N
( ( N
99.9 CD N
% NN N
) ) N
from IN N
spiked VBN N
plasma NN N
samples NNS N
was VBD N
consistent JJ N
and CC N
reproducible JJ N
. . N

Measurements NNS o
of IN o
American NNP o
Urological NNP o
Association NNP o
symptom VBD o
score RB o
, , o
peak JJ o
urine JJ o
flow NN o
rate NN o
and CC o
prostate NN o
specific JJ o
antigen NN o
( ( o
PSA NNP o
) ) o
are VBP N
often RB N
followed VBN N
over RP N
time NN N
in IN N
urological JJ N
management NN N
. . N

Post NNP N
hoc NN N
analysis NN N
of IN N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ i
acid NNS i
versus VBP i
daily JJ i
oral JJ i
risedronate NN i
on IN N
lumbar NN o
spine NN o
bone NN o
mineral JJ o
density NN o
in IN N
different JJ p
subgroups NNS p
with IN p
glucocorticoid-induced JJ p
osteoporosis NN p
. . p

BACKGROUND NNP N
Experimental NNP N
data NNS N
in IN N
humans NNS N
on IN N
the DT N
contribution NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
and CC N
angiotensin NN N
II NNP N
type NN N
1 CD N
receptor NN N
blockers NNS N
to TO N
the DT N
nitric JJ N
oxide NN N
system NN N
of IN N
the DT N
renal JJ N
vasculature NN N
are VBP N
inconsistent JJ N
. . N

Overall JJ N
pTBA NN i
resulted VBD N
in IN N
an DT N
absolute NN o
risk NN o
reduction NN o
of IN N
5.9 CD N
% NN N
and CC N
a DT N
relative JJ N
risk NN N
reduction NN N
of IN N
10.4 CD N
% NN N
unfavorable JJ N
outcome NN N
( ( N
P=0.54 NNP N
) ) N
. . N

All DT N
patients NNS N
receiving VBG N
BMAC NNP N
experienced VBD N
improvements NNS N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
, , N
but CC N
only RB N
those DT N
with IN N
NIHF NNP N
showed VBD N
improvements NNS N
in IN N
left JJ o
ventricular JJ o
end-systolic JJ o
diameter NN o
and CC o
B-type NNP o
natriuretic JJ o
peptide NN o
. . o

Heart NNP o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
mixed JJ o
venous JJ o
oxygen NN o
saturation NN o
increased VBD N
significantly RB N
during IN N
dopexamine JJ i
infusion NN N
, , N
whereas JJ N
systemic JJ o
vascular NN o
resistance NN o
was VBD N
reduced VBN N
. . N

Similarly RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
urinary JJ o
calcium NN o
and CC o
phosphorus JJ o
excretion NN o
or CC o
deterioration NN o
in IN o
kidney NN o
function NN o
were VBD N
detected VBN N
in IN N
patients NNS N
administered VBN N
paricalcitol NNS N
compared VBN N
with IN N
placebo NN i
. . i

The DT N
difference NN N
between IN N
the DT N
two CD N
treatments NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
and CC N
the DT N
between-subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
4.17 CD N
, , N
d.f NN N
. . N

The DT N
immediate JJ N
response NN N
and CC N
the DT N
changes NNS N
in IN N
Mth-DRS NNP o
values NNS o
, , o
sputum NN o
eosinophils NNS o
and CC o
serum VB o
ECP NNP o
levels NNS o
following VBG N
the DT N
allergen NN N
challenge NN N
were VBD N
attenuated VBN N
in IN N
the DT N
active JJ N
group NN N
. . N

Serum NNP o
G-CSF NNP o
levels NNS o
during IN N
the DT N
rhG-CSF JJ i
therapy NN i
greatly RB N
exceeded VBD N
endogenous JJ o
G-CSF NNP o
levels NNS o
and CC N
were VBD N
mainly RB N
due JJ N
to TO N
the DT N
presence NN N
of IN N
exogenous JJ N
rhG-CSF NN N
rather RB N
than IN N
increased VBN N
levels NNS N
of IN N
endogenous JJ N
G-CSF NNP N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
immunotherapy NN N
with IN N
HPV6 NNP i
L1 NNP i
virus NN N
like IN N
particles NNS N
( ( N
VLPs NNP N
) ) N
without IN N
adjuvant NN N
( ( N
VLP NNP N
immunotherapy NN N
) ) N
reduces VBZ N
recurrence NN o
of IN o
genital JJ o
warts NNS o
following VBG N
destructive JJ N
therapy NN N
. . N

Circadian JJ o
rhythms NN o
in IN N
dietary JJ N
and CC N
water NN N
intake NN N
and CC N
levels NNS N
of IN N
plasma NN N
total JJ N
fatty JJ N
acids NNS N
and CC N
lipid JJ N
fractions NNS N
remained VBD N
entrained JJ N
during IN N
exposure NN N
to TO N
either DT N
control NN i
conditions NNS i
or CC i
low-intensity NN i
light NN i
during IN N
the DT N
dark JJ N
phase NN N
. . N

It PRP N
does VBZ N
not RB N
increase VB N
the DT N
mortality NN o
rate NN o
, , o
and CC o
the DT o
morbidity NN o
rate NN o
seems VBZ N
to TO N
be VB N
even RB N
lower JJR N
than IN N
that DT N
in IN N
OC NNP N
. . N

BACKGROUND NNP N
In IN N
the DT N
treatment NN N
of IN N
reflux NN N
oesophagitis NN N
, , N
H2-receptor NNP N
antagonists NNS N
are VBP N
still RB N
widely RB N
used VBN N
in IN N
spite NN N
of IN N
the DT N
apparent JJ N
higher JJR N
efficacy NN N
of IN N
proton NN N
pump NN N
inhibitors NNS N
. . N

Twelve NNP N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
complained VBD N
of IN N
diminished JJ N
dark NN o
adaptability NN o
, , N
and CC N
nine CD N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus IN N
one CD N
control NN N
subject NN N
had VBD N
mild JJ o
dermatological JJ o
alterations NNS o
. . o

As IN N
a DT N
secondary JJ N
objective NN N
, , N
changes NNS o
in IN o
injected JJ o
joint NN o
tenderness NN o
and CC o
swelling VBG o
scores NNS o
, , o
each DT o
measured VBN o
on IN o
a DT o
four-point JJ o
scale NN o
, , N
were VBD N
evaluated VBN N
. . N

Toxicity NN o
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
arms NNS N
for IN N
anemia NN o
, , o
leukopenia NN o
, , o
neutropenia NN o
, , o
thrombocytopenia NN o
, , o
fatigue NN o
, , o
constipation NN o
and CC o
arthralgias/myalgias NN o
. . o

RESULTS VB N
The DT N
authors NNS N
demonstrated VBD N
that IN N
total JJ o
and CC o
conjugated VBD o
bilirubin NN o
, , o
alkaline JJ o
phosphatase NN o
, , o
alanine JJ o
aminotransferase NN o
, , o
aspartate VBP o
amino JJ o
transferase NN o
and CC o
cholinesterase NN o
did VBD N
not RB N
change VB N
significantly RB N
during IN N
the DT N
5-days JJ N
observation NN N
period NN N
. . N

Similar JJ N
observations NNS N
were VBD N
found VBN N
when WRB N
the DT N
drug NN N
was VBD N
injected VBN N
in IN N
the DT N
diseased JJ N
coronary JJ N
arteries NNS N
in IN N
a DT N
small JJ N
dose NN N
( ( N
0.075 CD N
mg/kg NN N
) ) N
so IN N
that DT N
peripheral JJ N
effects NNS N
were VBD N
not RB N
present JJ N
. . N

In IN N
each DT N
patient NN N
, , N
an DT N
in IN N
vivo NN N
kinetic JJ N
study NN N
of IN N
apolipoprotein NN N
B NNP N
( ( N
ApoB NNP N
) ) N
-containing VBG N
lipoproteins NNS N
with IN N
[ JJ N
13C CD N
] JJ N
leucine NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

In IN N
contrast NN N
, , N
a DT N
significant JJ N
difference NN N
for IN N
better JJR N
EFS NNP N
( ( N
p=0.0015 NN N
) ) N
in IN N
the DT N
BCL2 NNP N
positive JJ N
group NN N
of IN N
the DT N
ABC NNP N
subgroups NNS N
subtypes NNS N
treated VBN N
with IN N
rituximab NN N
containing VBG N
chemotherapy NN N
. . N

The DT N
spontaneous JJ o
bone NN o
loss NN o
was VBD N
similar JJ N
at IN N
all PDT N
the DT N
skeletal JJ N
sites NNS N
measured VBD N
, , N
with IN N
a DT N
mean JJ N
spontaneous JJ N
loss NN N
in IN N
calcanean JJ N
BMD NNP N
of IN N
1.6 CD N
% NN N
over IN N
one CD N
year NN N
. . N

However RB N
, , N
urinary JJ o
calcium NN o
excretion NN o
was VBD o
markedly RB o
higher JJR o
and CC o
urinary JJ o
pH NN o
and CC o
bicarbonate NN o
excretion NN o
significantly RB N
lower JJR N
in IN N
cows NNS N
fed VBP N
the DT N
anion NN N
diet NN N
than IN N
in IN N
cows NNS N
fed VBP N
the DT N
cation NN N
diet NN N
. . N

After IN N
intravenous JJ N
adrenaline NN i
there EX N
was VBD N
a DT N
good JJ N
clinical JJ N
and CC N
biochemical JJ N
response NN N
, , N
but CC N
after IN N
endotracheal JJ N
adrenaline NN N
there EX N
was VBD N
no DT N
change NN N
in IN N
serum JJ o
adrenaline NN o
and CC o
no DT o
measurable JJ o
clinical JJ o
response NN o
. . o

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
advanced JJ p
heart NN p
failure NN p
, , p
vasopressin NN p
receptor NN p
antagonism NN p
with IN p
conivaptan NN i
resulted VBN N
in IN N
favorable JJ N
changes NNS N
in IN N
hemodynamics NNS o
and CC o
urine JJ o
output NN o
without IN o
affecting VBG o
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
. . o

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN i
and CC i
ciprofloxacin NN i
hydrochloride NN i
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS p
with IN p
filtering VBG p
blebs NN p
. . p

Induction NNP i
treatment NN i
with IN i
ATG NNP i
has VBZ N
the DT N
advantage NN N
of IN N
a DT N
lower JJR N
incidence NN N
of IN N
acute JJ N
rejection NN N
, , N
but CC N
it PRP N
significantly RB N
increases VBZ N
adverse JJ o
events NNS o
, , o
particularly RB o
CMV NNP o
infection NN o
. . o

The DT N
AF NNP o
frequency NN o
decreased VBD N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
meloxicam NN i
and CC N
a DT N
glucosamine-chondroitin JJ i
( ( i
Glu-Ch NNP i
) ) i
supplement NN i
in IN N
the DT N
management NN N
of IN N
feline NN p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Subcutaneously NNP N
injected VBD N
rapid-acting JJ N
insulin NN N
analogs NNS N
do VBP N
not RB N
replicate VB N
physiologic JJ N
insulin NN N
action NN N
due JJ N
to TO N
delays NNS N
in IN N
their PRP$ N
onset NN N
and CC N
peak JJ N
action NN N
resulting VBG N
in IN N
postprandial JJ N
glucose JJ N
excursions NNS N
. . N

Bile NNP o
lipid JJ o
composition NN o
was VBD N
determined VBN N
and CC N
the DT N
saturation NN o
index NN o
calculated VBD N
before IN N
and CC N
after IN N
treatment NN N
, , N
on IN N
samples NNS N
collected VBN N
by IN N
duodenal JJ N
siphonage NN N
after IN N
caerulein JJ N
stimulation NN N
, , N
in IN N
both DT N
groups NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
eradication NN N
of IN N
Helicobacter NNP N
pylori FW N
( ( N
H.pylori NNP N
) ) N
in IN N
the DT N
patients NNS p
with IN p
duodenal JJ p
ulcer NN p
( ( p
Du NNP p
) ) p
upon IN p
the DT p
DU NNP p
recurrence NN p
. . p

Micronucleus NNP o
levels NNS o
in IN o
peripheral JJ o
lymphocytes NNS o
and CC N
changes NNS N
seen VBN N
after IN N
intervention NN N
were VBD N
studied VBN N
in IN N
relation NN N
to TO N
the DT N
MTHFR NNP N
C677T NNP N
genotype NN N
, , N
basal JJ o
homocysteine NN o
and CC o
plasma JJ o
folate NN o
levels NNS o
. . o

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
a DT N
multiallergic JJ N
condition NN N
and CC N
the DT N
combination NN N
and/or JJ N
purification NN N
of IN N
allergen NN N
extracts NNS N
administered VBN N
during IN N
hyposensitization NN N
may MD N
influence VB N
the DT N
production NN N
of IN N
IgG NNP N
anti- JJ N
IgG NNP N
antibodies NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Serum NNP o
and CC o
urine JJ o
cotinine NN o
, , o
lung NN o
function NN o
, , o
and CC o
cytokines NNS o
IL-4 NNP o
, , o
IL-5 NNP o
, , o
IL-6 NNP o
, , o
tumor NN o
necrosis NN o
factor NN o
( ( o
TNF NNP o
) ) o
-alpha NN o
, , o
and CC o
IFN-gamma NNP o
. . o

Mean NNP o
cumulative JJ o
change NN o
in IN o
milk NN o
yield NN o
and CC o
interval JJ o
change NN o
in IN o
milk NN o
yield NN o
were VBD N
greater JJR N
in IN N
cows NNS N
treated VBN N
with IN N
isotonic JJ i
saline NN i
solution NN i
than IN N
in IN N
cows NNS N
treated VBN N
with IN N
hypertonic JJ i
saline JJ i
solution NN i
. . i

BACKGROUND NNP N
Photodynamic NNP i
therapy NN i
( ( i
PDT NNP i
) ) i
with IN i
topical JJ i
5-aminolaevulinic JJ i
acid NN i
( ( i
ALA NNP i
) ) i
followed VBN i
by IN i
irradiation NN i
with IN i
incoherent JJ i
light NN i
( ( i
ALA-PDT NNP i
) ) i
for IN N
recalcitrant NN N
warts NNS N
have VBP N
had VBN N
beneficial JJ N
results NNS N
. . N

Serum NNP o
hormone-binding JJ o
globulin NN o
levels NNS o
increased VBN N
in IN N
41.4 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

After IN N
intake NN N
of IN N
amantadine NN N
, , N
a DT N
significant JJ N
dose-dependent JJ N
decrease NN N
of IN N
ICF NNP o
was VBD N
noticed VBN N
as RB N
well RB N
as IN N
a DT N
significant JJ N
increase NN N
of IN N
L-ICI NNP o
as IN N
compared VBN N
to TO N
placebo VB i
. . i

In IN N
the DT N
montelukast/levocetirizine NN N
arm NN N
, , N
montelukast NN N
decreased VBD N
nasal JJ o
eosinophilia RB o
more RBR N
significantly RB N
than IN N
levocetirizine NN i
, , N
whereas NNS N
in IN N
reduction NN N
of IN N
sICAM-1 JJ N
all DT N
active JJ N
treatment NN N
options NNS N
were VBD N
equally RB N
effective JJ N
. . N

OBJECTIVE NN N
To TO N
compare VB N
levels NNS N
of IN N
serum NN o
LH NNP o
during IN N
continued VBN N
use NN N
of IN N
leuprolide JJ i
acetate NN i
( ( i
LA NNP i
) ) i
with IN N
levels NNS N
during IN N
the DT N
first JJ N
week NN N
after IN N
discontinuing VBG N
LA NNP N
. . N

Expression NN o
of IN o
OPN NNP o
protein NN o
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( N
IHC NNP N
) ) N
and CC N
in IN N
BM NNP N
serum NN N
( ( N
ELISA NNP N
) ) N
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Overall JJ N
, , N
these DT N
findings NNS N
indicate VBP N
that IN N
there EX N
are VBP N
no DT N
apparent JJ N
advantages NNS N
in IN N
toxicity NN o
and CC o
efficacy NN o
by IN N
giving VBG N
CDA NNP N
weekly RB N
rather RB N
than IN N
daily RB N
. . N

CONCLUSIONS NNP N
Trimegestone NNP i
was VBD N
associated VBN N
with IN N
less RBR N
procoagulant JJ o
changes NNS o
in IN o
factor NN o
VIIa NNP o
and CC o
factor NN o
VIIc NNP o
activity NN o
and CC N
larger JJR N
decrease NN N
in IN N
PAI-1 NNP o
activity NN o
compared VBN N
with IN N
the DT N
dydrogesterone NN N
preparation NN N
. . N

Side-effects NNS N
such JJ N
as IN N
hypotension NN o
, , o
nausea NN o
, , o
pruritus NN o
, , o
shivering NN o
, , o
and CC o
headache NN o
were VBD N
recorded VBN N
RESULTS NNP N
Demographic NNP N
data NNS N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
higher JJR N
PR NNP o
and CC o
catD JJ o
concentrations NNS o
in IN N
diffuse NN N
adenocarcinomas NN N
, , N
and CC N
the DT N
overexpression NN N
of IN N
TAG-72 NNP N
in IN N
the DT N
intestinal JJ N
type NN N
, , N
support VB N
the DT N
existence NN N
of IN N
two CD N
modes NNS N
of IN N
gastric JJ N
carcinogenesis NN N
. . N

In IN N
one CD N
other JJ N
case NN N
an DT N
urticarial JJ o
rash NN o
appeared VBD N
, , N
but CC N
disappeared VBD N
spontaneously RB N
when WRB N
the DT N
drug NN N
was VBD N
temporarily RB N
stopped VBN N
and CC N
did VBD N
not RB N
reappear VB N
when WRB N
it PRP N
was VBD N
administered VBN N
again RB N
. . N

GLP-1 NNP o
did VBD o
not RB o
change VB o
perception NN o
of IN o
isobaric JJ o
distension NN o
but CC N
reduced VBD N
the DT N
perception NN o
score RB o
related VBN o
to TO o
corresponding VBG o
bag NN o
volume NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

RESULTS VB N
A DT N
significant JJ N
difference NN N
in IN N
improvement NN N
of IN N
overall JJ o
subjective JJ o
symptoms NNS o
in IN N
an DT N
intent-to-treat JJ N
analysis NN N
between IN N
groups NNS N
T NNP N
and CC N
C NNP N
was VBD N
found VBN N
at IN N
the DT N
follow-ups NNS N
. . N

Blood NNP o
chemistry NN o
monitoring NN o
indicated VBD N
that DT N
reduction NN N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
strongly RB N
correlated VBN N
with IN N
an DT N
increase NN N
in IN N
baseline JJ N
levels NNS N
of IN N
some DT N
enzymes NNS N
for IN N
niacin-treated JJ N
subjects NNS N
. . N

OBJECTIVES NNP N
So NNP N
far RB N
it PRP N
has VBZ N
not RB N
clearly RB N
been VBN N
demonstrated VBN N
that IN N
systematic JJ N
mediastinal JJ N
lymphadenectomy NN i
improves VBZ N
survival JJ N
in IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
. . p

QRHT NN i
can MD N
appropriately RB N
increase VB N
the DT N
levels NNS o
of IN o
glucose NN o
, , o
lactic JJ o
acid NN o
, , o
citric JJ o
acid NN o
, , o
high-density NN o
lipoprotein NN o
, , o
phosphatidylcholine NN o
, , o
glycerophosphate JJ o
choline NN o
, , o
hydroxybutyrate NN o
, , o
alanine NN o
, , o
and CC o
glutamate NN o
. . o

Dofequidar NNP i
fumarate NN i
( ( i
MS-209 NNP i
) ) i
in IN N
combination NN N
with IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil NN i
for IN N
patients NNS p
with IN p
advanced JJ p
or CC p
recurrent JJ p
breast NN p
cancer NN p
. . p

Effects NNS N
of IN N
conjugated JJ i
linoleic JJ i
acid NN i
supplementation NN i
and CC i
exercise NN i
on IN N
post-heparin JJ o
lipoprotein NN o
lipase NN o
, , o
butyrylcholinesterase NN o
, , o
blood NN o
lipid JJ o
profile NN o
and CC o
glucose JJ o
metabolism NN o
in IN N
young JJ p
men NNS p
. . p

Peak-to-peak JJ o
and CC o
mean JJ o
systolic JJ o
pressure NN o
differences NNS o
across IN N
the DT N
valves NNS N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
B-S NNP N
than IN N
in IN N
the DT N
L-K NNP N
valves NNS N
, , N
particularly RB N
when WRB N
the DT N
small JJ N
valve NN N
sizes NNS N
were VBD N
compared VBN N
. . N

Taken VBN N
together RB N
, , N
these DT N
data NNS N
show VBP N
that IN N
the DT N
combination NN N
of IN N
nifedipine JJ i
+ FW i
chlorthalidone NN i
does VBZ N
not RB N
exert VB N
any DT N
additive JJ o
antihypertensive JJ o
effect NN o
compared VBN N
with IN N
nifedipine JJ i
alone NN N
. . N

Enteral JJ i
nutrition NN i
with IN i
eicosapentaenoic JJ i
acid NN i
, , i
gamma-linolenic JJ i
acid NN i
, , i
and CC i
antioxidants NNS i
reduces NNS N
alveolar JJ N
inflammatory JJ N
mediators NNS N
and CC N
protein NN N
influx NN N
in IN N
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

Non-invasive JJ N
electrophysiological JJ N
techniques NNS N
were VBD N
used VBN N
to TO N
assess VB N
presynaptic JJ N
inhibition NN N
, , N
postsynaptic JJ N
inhibition NN N
and CC N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
in IN N
the DT N
spinal JJ N
cord NN N
. . N

Controlling VBG N
the DT N
dose NN N
of IN N
heparin NN i
with IN N
coagulation NN N
tests NNS N
resulted VBD N
in IN N
the DT N
administration NN N
of IN N
significantly RB N
larger JJR N
daily JJ N
doses NNS N
of IN N
heparin NN i
with IN N
intermittent JJ N
injections NNS N
than IN N
with IN N
continuous JJ N
infusion NN N
. . N

CONCLUSION NNP N
Plasma NNP o
endotoxin NN o
and CC o
cytokines NNS o
( ( o
TNF-alpha NNP o
, , o
IL-1 NNP o
beta NN o
, , o
IL-6 NNP o
and CC o
IL-8 NNP o
) ) o
can MD N
be VB N
removed VBN N
effectively RB N
with IN N
CRRT NNP N
in IN N
severely RB p
burned VBN p
patients NNS p
with IN p
sepsis NN p
. . p

Strength NN o
of IN o
hand NN o
grip NN o
was VBD N
the DT N
best JJS N
predictor NN N
of IN N
volume NN N
delivered VBN N
and CC N
was VBD N
more RBR N
strongly RB N
correlated VBN N
with IN N
volumes NNS N
delivered VBN N
by IN N
one CD N
rather RB N
than IN N
two CD N
hands NNS N
. . N

Correspondingly RB N
the DT N
decrease NN N
of IN N
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
and CC o
urinary JJ o
prostaglandin NN o
excretion NN o
( ( N
PGE2 NNP N
) ) N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
treated VBD N
initially RB N
with IN N
indomethacin NN i
. . i

Mean NNP o
prolactin NN o
of IN N
adult NN p
females NNS p
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
. . N

The DT N
achieved JJ N
rates NNS o
of IN o
remission NN o
and CC o
survival JJ o
time NN o
showed VBD N
an DT N
obvious JJ N
dependence NN N
on IN N
the DT N
histological JJ N
type NN N
of IN N
tumor NN N
and CC N
on IN N
the DT N
degree NN N
of IN N
differentiation NN N
. . N

We PRP N
conclude VBP N
that IN N
neither CC N
0.05 CD N
percent NN N
desonide NN i
ointment NN i
nor CC N
2.5 CD N
percent NN N
hydrocortisone NN i
ointment NN i
compromised VBD N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS p
with IN p
atopic NN p
dermatitis NN p
treated VBD N
topically RB N
for IN N
four CD N
weeks NNS N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
amino JJ i
acids NNS i
L-arginine JJ i
and CC i
citrulline NN i
on IN N
endothelial JJ N
function NN N
in IN N
patients NNS p
in IN p
stable JJ p
diastolic NN p
and CC p
right JJ p
heart NN p
failure NN p
using VBG p
photoplethysmography NN p
. . p

Primary JJ N
hemostasis NN N
was VBD N
assessed VBN N
with IN N
a DT N
platelet NN o
function NN o
analyser NN o
( ( o
PFA-100 NNP o
) ) o
, , o
which WDT o
measures VBZ o
the DT o
closure NN o
time NN o
( ( o
CT NNP o
) ) o
of IN o
a DT o
collagen- JJ o
and CC o
epinephrine-coated JJ o
pore NN o
by IN o
aggregating VBG o
platelets NNS o
in IN o
flowing VBG o
blood NN o
. . o

Middle NNP o
cerebral JJ o
arterial JJ o
blood NN o
flow NN o
velocities NNS o
decreased VBN N
significantly RB N
after IN N
administration NN N
of IN N
isoflurane NN i
and CC i
propofol NN i
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

Also RB N
here RB N
, , N
this DT N
was VBD N
contrasted VBN N
by IN N
better JJR N
EFS NNP N
( ( N
p=0.039 NN N
) ) N
in IN N
the DT N
LMO2 NNP N
positive JJ N
group NN N
of IN N
ABC NNP N
subtypes NNS N
when WRB N
treated VBN N
with IN N
the DT N
rituximab NN N
containing VBG N
regimen NNS N
. . N

Recombinant JJ i
murine NN i
GM-CSF NNP i
administration NN N
to TO N
neonatal JJ p
rats NNS p
has VBZ N
resulted VBN N
in IN N
neutrophilia JJ N
, , N
increased JJ N
neutrophil NN o
production NN o
, , N
and CC N
increased VBD N
survival NN N
of IN N
pups NNS N
during IN N
experimental JJ N
Staphylococcus NNP N
aureus NN N
sepsis NN N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
on IN N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
scores NNS o
and CC o
Clinical NNP o
Global NNP o
Impression-Severity NNP o
( ( o
CGI-S NNP o
) ) o
scores VBZ o
. . o

A DT N
fenbendazole JJ N
oral JJ N
drench NN N
in IN N
addition NN N
to TO N
an DT N
ivermectin JJ i
pour-on JJ i
reduces NNS N
parasite JJ o
burden NN o
and CC N
improves VBZ N
feedlot NN o
and CC o
carcass NN o
performance NN o
of IN N
finishing VBG p
heifers NNS p
compared VBN N
with IN N
endectocides NNS N
alone RB N
. . N

CONCLUSION NNP N
Ixabepilone NNP i
, , N
with IN N
or CC N
without IN N
estramustine JJ i
phosphate NN i
, , N
is VBZ N
well RB N
tolerated VBN N
and CC N
has VBZ N
antitumor VBN o
activity NN o
in IN N
patients NNS p
with IN p
castrate JJ p
metastatic JJ p
prostate NN p
cancer NN p
. . p

In IN N
a DT N
previous JJ N
study NN N
it PRP N
was VBD N
demonstrated VBN N
that IN N
patients NNS N
with IN N
multiallergy JJ i
hyposensitized VBN i
with IN i
combined JJ i
allergen NN i
extracts NNS i
showed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
IgG NNP o
anti-IgG JJ o
titres NNS o
during IN N
treatment NN N
. . N

BACKGROUND NNP N
An DT N
oral JJ N
formulation NN N
of IN N
ganciclovir NN i
( ( i
GCV NNP i
) ) i
was VBD N
recently RB N
approved VBN N
for IN N
the DT N
prevention NN N
of IN N
cytomegalovirus NN N
disease NN N
in IN N
solid JJ p
organ NN p
transplant JJ p
recipients NNS p
. . p

Consecutive JJ N
procedural JJ N
angiograms NNS N
of IN N
patients NNS p
randomly RB p
assigned VBN p
to TO p
EES NNP p
( ( p
n=669 NN p
) ) p
or CC p
PES NNP p
( ( p
n=333 RB p
) ) p
were VBD p
analysed VBN p
by IN p
an DT p
independent JJ p
angiographic JJ p
core NN p
laboratory NN p
. . p

B-TG NNP o
and CC o
PF4 NNP o
plasma NN o
levels NNS o
and CC o
ADP-induced NNP o
platelet NN o
aggregation NN o
were VBD N
determined VBN N
in IN N
basal NN N
conditions NNS N
, , N
and CC N
two CD N
hours NNS N
, , N
and CC N
seven CD N
and CC N
fourteen JJ N
days NNS N
after IN N
starting VBG N
with IN N
ASA NNP i
or CC i
placebo NN i
. . i

Initial JJ N
segmentation NN N
at IN N
baseline NN N
was VBD N
evaluated VBN N
to TO N
be VB N
satisfactory JJ N
in IN N
93.9 CD N
% NN N
of IN N
nodules NNS N
for IN N
P1 NNP N
, , N
84.4 CD N
% NN N
for IN N
P2 NNP N
, , N
and CC N
88.4 CD N
% NN N
for IN N
P3 NNP o
. . o

No DT N
other JJ N
plasma NN o
free JJ o
essential JJ o
fatty NN o
acid RB o
changed VBD N
during IN N
the DT N
trial NN N
, , N
although IN N
the DT N
HDL NNP o
: : o
cholesterol NN o
increased VBD N
slightly RB N
but CC N
non-significantly RB N
with IN N
an DT N
increase NN N
in IN N
EPA NNP N
and CC N
DHA NNP N
. . N

For IN N
both DT N
systolic JJ o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DBP NNP o
) ) o
blood NN o
pressure NN o
, , o
change NN o
in IN o
polyunsaturated JJ o
fatty JJ o
acid NNS o
intake NN o
was VBD N
the DT N
strongest JJS N
dietary JJ N
predictor NN N
of IN N
BP NNP o
change NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
time NN N
between IN N
loading VBG N
dose NN N
and CC N
stent JJ N
deployment NN N
( ( N
35.2 CD N
in IN N
ticagrelor NN N
and CC N
42.7 CD N
min NN N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

Overall JJ o
tolerability NN o
of IN N
both DT N
treatments NNS N
was VBD N
similar JJ N
to TO N
placebo VB i
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS N
on IN N
cardiac JJ N
repolarisation NN N
with IN N
either DT N
mizolastine NN i
or CC i
loratadine NN i
. . i

Comparative JJ N
effects NNS N
of IN N
valsartan JJ i
versus NN i
amlodipine NN i
on IN N
left JJ N
ventricular JJ N
mass NN N
and CC N
reactive JJ N
oxygen NN N
species NNS N
formation NN N
by IN N
monocytes NNS N
in IN N
hypertensive JJ p
patients NNS p
with IN p
left JJ p
ventricular JJ p
hypertrophy NN p
. . p

Changes NNS o
in IN o
biliary JJ o
ursodeoxycholic JJ o
acid NN o
correlated VBN N
significantly RB N
but CC N
weakly RB N
with IN N
the DT N
changes NNS N
in IN N
serum NN o
alkaline NN o
phosphatase NN o
, , o
AST NNP o
, , o
bilirubin NN o
, , o
and CC o
in IN o
Mayo NNP o
risk NN o
score NN o
. . o

BACKGROUND IN N
The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
recombinant JJ i
human JJ i
antithrombin NN i
( ( i
rhAT NN i
) ) i
for IN N
restoring VBG N
heparin NN N
responsiveness NN N
in IN N
heparin NN p
resistant JJ p
patients NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
. . p

BACKGROUND NNP N
A NNP N
new JJ N
aqueous JJ N
gel JJ N
formulation NN N
of IN N
dapsone NN i
has VBZ N
been VBN N
developed VBN N
that IN N
allows VBZ N
clinically-effective JJ N
doses NNS N
of IN N
dapsone NN N
to TO N
be VB N
administered VBN N
topically RB N
with IN N
minimal JJ N
systemic JJ N
absorption NN N
. . N

Acute JJ N
drug NN N
effects NNS N
were VBD N
recorded VBN N
, , N
focusing VBG N
on IN N
electrocardiography NN o
, , o
respiratory NN o
movements NNS o
, , o
arterial JJ o
blood NN o
oxygen NN o
saturation NN o
, , o
and CC o
electroencephalography NN o
( ( o
EEG NNP o
) ) o
. . o

Preclinical NNP N
and CC N
emerging VBG N
clinical JJ N
evidence NN N
show NN N
that IN N
the DT N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
bone NN N
marrow NN N
mononuclear JJ N
cells NNS N
( ( N
BMCs NNP N
) ) N
following VBG N
AMI NNP N
leads VBZ N
to TO N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
function NN N
( ( N
LVEF NNP N
) ) N
. . N

All DT N
three CD N
studied VBD N
drugs NNS N
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
reactance NN o
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
decrease NN N
in IN N
resonant JJ o
frequency NN o
. . o

The DT N
significant JJ N
fall NN o
of IN o
MDA NNP o
and CC o
SOD NNP o
and CC o
increased VBD o
levels NNS o
of IN o
GSH NNP o
in IN N
blood NN N
in IN N
both DT N
groups NNS N
after IN N
control NN N
revealed VBD N
beneficial JJ N
effects NNS N
of IN N
glycemic JJ N
control NN N
on IN N
oxidative JJ N
stress NN N
. . N

Therefore RB N
, , N
the DT N
potentiating VBG N
effect NN N
of IN N
sevoflurane NN i
seems VBZ N
to TO N
be VB N
mainly RB N
of IN N
PD NNP N
origin NN N
, , N
probably RB N
due JJ N
to TO N
an DT N
increased VBN N
sensitivity NN N
of IN N
the DT N
neuromuscular JJ N
junction NN N
. . N

Overall JJ o
, , o
acetate NN o
, , o
butyrate NN o
, , o
and CC o
total JJ o
SCFA NNP o
concentrations NNS o
were VBD N
higher JJR N
when WRB N
participants NNS N
consumed VBD N
RS NNP N
compared VBN N
with IN N
entry NN N
and CC N
NSP NNP N
diets NNS N
, , N
but CC N
individual JJ N
responses NNS N
varied VBD N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

Statistically RB N
significant JJ N
changes NNS N
in IN N
fatigue NN o
, , o
pain NN o
, , o
appetite NN o
, , o
diarrhea NN o
, , o
and CC o
global JJ o
QOL NNP o
scores NNS o
were VBD N
detected VBN N
during IN N
RT NNP N
. . N

RESULTS NNP N
Effectiveness NNP o
of IN o
the DT o
GHRH NNP o
antagonist NN o
was VBD N
validated VBN N
in IN N
all DT N
subjects NNS N
by IN N
demonstrating VBG N
93+/-1.8 CD N
% NN N
( ( N
P=0.012 NNP N
) ) N
suppression NN o
of IN o
GH NNP o
response NN o
to TO N
a DT N
GHRH NNP N
bolus NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ o
events NNS o
, , o
development NN o
of IN o
persistent JJ o
AF NNP o
, , o
left VBD o
atrial JJ o
dimension NN o
, , o
and CC o
quality-of-life NN o
( ( o
QOL NNP o
) ) o
. . o

It PRP N
causes VBZ N
membrane JJ N
depolarisation NN N
of IN N
sensory JJ N
neurons NNS N
, , N
which WDT N
release VBP N
CGRP NNP N
, , N
SP NNP N
and CC N
other JJ N
pain NN N
peptides NNS N
; : N
excitation NN N
is VBZ N
followed VBN N
by IN N
a DT N
refractory NN N
state NN N
, , N
causing VBG N
inactivation NN N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

The DT N
main JJ N
adverse JJ N
events NNS N
were VBD N
gastrointestinal JJ N
disorders NNS N
( ( N
2.5 CD N
% NN N
) ) N
and CC N
pruritus NN o
( ( N
2.5 CD N
% NN N
) ) N
; : N
safety NN o
profiles NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
safety NN o
evaluation NN o
was VBD N
performed VBN N
during IN N
the DT N
28-day JJ N
follow-up NN N
and CC N
serum NN N
samples NNS N
for IN N
anti-rabies NNS N
antibody JJ N
titration NN N
were VBD N
collected VBN N
on IN N
D0 NNP N
( ( N
before IN N
injection NN N
) ) N
D3 NNP N
, , N
D7 NNP N
, , N
D14 NNP N
and CC N
D28 NNP N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
meloxicam NN i
resulted VBN N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
mobility NN o
and CC o
activity NN o
levels NNS o
of IN N
cats NNS N
with IN N
OA NNP N
until IN N
the DT N
placebo NN i
was VBD N
introduced VBN N
. . N

CONCLUSIONS NNP N
Left NNP N
ventricular JJ N
thrombosis NN N
is VBZ N
not RB N
reduced VBN N
, , N
and CC N
may MD N
even RB N
be VB N
increased VBN N
, , N
by IN N
early JJ N
moderate NN N
to TO N
severe VB N
mitral JJ N
regurgitation NN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

Thus RB N
metformin JJ i
treatment NN N
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
insulin NN o
sensitivity NN o
, , o
blood NN o
pressure NN o
or CC o
sympathetic JJ o
activity NN o
in IN N
this DT N
small JJ N
group NN N
of IN N
patients NNS N
. . N

The DT N
total JJ o
effectiveness NN o
rate NN o
was VBD N
77.69 CD N
% NN N
( ( N
94/121 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
, , N
71.56 CD N
% NN N
( ( N
78/109 CD N
) ) N
in IN N
those DT N
with IN N
complications NNS N
. . N

Hydrocortisone CD i
infusion NN i
induced VBD N
an DT N
increase NN N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
systemic JJ o
vascular NN o
resistance NN o
, , N
and CC N
a DT N
decline NN N
of IN N
heart NN o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
norepinephrine JJ o
requirement NN o
. . o

It PRP N
has VBZ N
been VBN N
confirmed VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
ACEIs NNP N
) ) N
and CC N
angiotensin $ N
II NNP N
receptor NN N
blockers NNS N
( ( N
ARBs NNP N
) ) N
reduce VB N
urinary JJ N
protein NN N
excretion NN N
and CC N
attenuate VB N
the DT N
development NN N
of IN N
renal JJ N
injury NN N
. . N

Mecamylamine NNP i
increased VBD N
several JJ N
measures NNS N
of IN N
cigarette NN o
smoking NN o
, , o
including VBG o
number NN o
of IN o
cigarettes NNS o
, , o
number NN o
of IN o
puffs NNS o
per IN o
cigarette NN o
, , o
and CC o
expired VBD o
air NN o
carbon NN o
monoxide NN o
level NN o
. . o

Median JJ o
remedication NN o
times NNS o
with IN N
both DT N
doses NNS N
of IN N
ibuprofen JJ i
arginate NN i
were VBD N
similar JJ N
to TO N
those DT N
with IN N
both DT N
doses NNS N
of IN N
ibuprofen NN i
, , N
ranging VBG N
from IN N
4.0 CD N
to TO N
5.2 CD N
hours NNS N
. . N

Secondary JJ N
outcomes NNS N
include VBP N
the DT N
effect NN N
of IN N
amlodipine NN i
therapy NN i
on IN N
systolic JJ o
and CC o
diastolic JJ o
function NN o
, , o
strain NN o
and CC o
strain NN o
rate NN o
and CC o
liver NN o
iron NN o
content NN o
. . o

Neither DT N
budesonide NN N
nor CC N
fluticasone NN i
produced VBD N
significant JJ N
suppression NN N
of IN N
plasma NN o
osteocalcin NN o
, , N
although IN N
the DT N
higher JJR N
doses NNS N
of IN N
both DT N
drugs NNS N
significantly RB N
reduced VBD N
fasting JJ o
urinary JJ o
calcium NN o
levels NNS o
. . o

Only RB N
two CD N
groups NNS N
( ( N
Optibond NNP N
FL NNP N
and CC N
G NNP N
Bond NNP N
) ) N
presented VBD N
equal JJ N
percentages NNS N
of IN N
marginal JJ N
adaptation NN N
on IN N
enamel NN N
and CC N
dentin NN N
; : N
in IN N
the DT N
other JJ N
groups NNS N
, , N
the DT N
rate NN N
of IN N
degradation NN N
was VBD N
product NN N
dependent NN N
. . N

Significant JJ N
differences NNS N
in IN N
complications NNS N
occurring VBG N
more RBR N
in IN N
phlebectomy NN N
than IN N
in IN N
compression NN i
sclerotherapy NN i
therapy NN N
were VBD N
blisters NNS o
, , o
teleangiectatic JJ o
matting NN o
, , o
scar NN o
formation NN o
, , o
and CC o
bruising VBG o
from IN o
bandaging VBG o
. . o

Histological JJ N
examination NN N
of IN N
biopsies NNS N
taken VBN N
from IN N
the DT N
abrasions NNS N
of IN N
two CD N
volunteers NNS N
showed VBD N
the DT N
dermis NN N
remained VBD N
intact JJ N
, , N
making VBG N
the DT N
model NN N
highly RB N
suitable JJ N
for IN N
the DT N
study NN N
of IN N
superficial JJ N
wounds NNS N
. . N

Patients NNS N
treated VBN N
with IN N
allopurinol NN i
showed VBD N
less RBR N
myocardial JJ o
production NN o
of IN o
free JJ o
radicals NNS o
, , N
indicating VBG N
that IN N
its PRP$ N
protective JJ N
effect NN N
may MD N
be VB N
due JJ N
to TO N
its PRP$ N
antioxidative JJ N
properties NNS N
. . N

Survival NNP o
curve NN o
analyses NNS o
revealed VBD N
little JJ N
difference NN N
between IN N
these DT N
groups NNS N
for IN N
major JJ N
vascular JJ N
end NN N
points NNS N
, , N
total JJ o
mortality NN o
, , o
all DT o
amputations NNS o
, , o
or CC o
myocardial JJ o
infarctions NNS o
. . o

Our PRP$ N
goal NN N
was VBD N
to TO N
evaluate VB N
retrograde VB N
bone NN N
marrow NN N
cell NN N
delivery NN N
in IN N
patients NNS p
with IN p
either DT p
ischemic JJ p
heart NN p
failure NN p
( ( p
IHF NNP p
) ) p
or CC p
nonischemic JJ p
heart NN p
failure NN p
( ( p
NIHF NNP p
) ) p
. . p

The DT N
effects NNS N
of IN N
eprosartan NN i
on IN N
RPF NNP N
are VBP N
mediated VBN N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
by IN N
an DT N
increased JJ N
bioavailability NN N
of IN N
nitric JJ N
oxide NN N
in IN N
the DT N
renal JJ N
vasculature NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
noninferiority NN o
of IN o
9-month JJ o
target NN o
vessel JJ o
failure NN o
defined VBD o
as IN o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
target VB o
vessel JJ o
revascularization NN o
. . o

For IN N
hypnosis NN N
, , N
synergistic JJ N
interaction NN N
was VBD N
found VBN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
the DT N
combination NN N
having VBG N
1.44 CD N
times NNS N
the DT N
potency NN N
of IN N
the DT N
individual JJ N
agents NNS N
. . N

In IN N
contrast NN N
to TO N
alkaline VB o
phosphatase NN o
, , N
a DT N
fall NN N
in IN N
inflammatory JJ N
activity NN N
stimulated VBN N
and CC N
impairment NN N
of IN N
functional JJ N
capacity NN N
significantly RB N
decreased VBD N
osteocalcin JJ N
levels NNS N
in IN N
patients NNS p
with IN p
RA NNP p
. . p

Blood NNP o
loss NN o
during IN o
parenchymal JJ o
transection NN o
and CC o
speed NN o
of IN o
transection NN o
were VBD N
the DT N
primary JJ N
endpoints NNS N
, , N
whereas IN N
the DT N
degree NN o
of IN o
postoperative JJ o
liver JJ o
injury NN o
and CC o
morbidity NN o
were VBD N
secondary JJ N
endpoints NNS N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
Naproxen NNP i
, , i
Novafen NNP i
and CC i
Tramadol NNP i
taken VBN N
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
RA NNP N
with IN N
IL-1Ra NNP N
resulted VBD N
in IN N
reduced JJ N
mononuclear NN N
cell NN N
infiltration NN N
of IN N
synovial JJ N
membrane NN N
, , N
which WDT N
may MD N
represent VB N
the DT N
in IN N
vivo JJ N
inhibition NN N
of IN N
biologically RB N
relevant JJ N
IL-1ss-mediated JJ N
pathogenic JJ N
effects NNS N
. . N

CONCLUSIONS NNP N
The DT N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
enzyme JJ i
preparation NN i
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
to TO N
administer VB N
and CC N
effective JJ N
for IN N
removal NN N
of IN N
the DT N
accumulated JJ N
metabolite NN N
porphobilinogen NN N
from IN N
plasma NN N
and CC N
urine NN N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
patients NNS p
with IN p
Chagas NNP p
heart NN p
disease NN p
have VBP p
lower JJR p
Se NNP p
levels NNS p
than IN p
healthy JJ p
individuals NNS p
and CC p
patients NNS p
with IN p
T. NNP p
cruzi NN p
infection NN p
without IN p
of IN p
cardiac JJ p
disease NN p
. . p

The DT N
incidence NN N
of IN N
postoperative JJ N
dreaming NN N
following VBG N
the DT N
use NN N
of IN N
morphine NN i
and CC i
pentazocine NN i
as IN N
premedicants NNS N
in IN N
an DT N
otherwise RB N
standard JJ N
anaesthetic JJ N
sequence NN N
is VBZ N
compared VBN N
in IN N
healthy JJ p
volunteers NNS p
. . p

However RB N
, , N
the DT N
present JJ N
data NNS N
can MD N
not RB N
exclude VB N
the DT N
possibility NN N
that IN N
the DT N
neuroendocrine JJ N
changes NNS N
reflect VBP N
nonspecific JJ N
stress NN N
responses NNS N
or CC N
changes NNS N
in IN N
pituitary JJ N
blood NN N
flow NN N
. . N

Results NNS N
favored VBD N
a DT N
muscle NN N
protein-sparing JJ N
effect NN N
of IN N
exercise NN i
, , N
as IN N
a DT N
significant JJ N
decrease NN N
in IN N
creatinine JJ o
excretion NN o
in IN N
controls NNS N
only RB N
suggested VBD N
muscle NN N
protein NN N
loss NN N
associated VBN N
with IN N
inactivity NN N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
studied JJ N
parameters NNS N
between IN N
the DT N
test NN N
and CC N
the DT N
control NN N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Following VBG N
drug NN N
administration NN N
the DT N
decrease NN N
in IN N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
and CC N
the DT N
increase NN N
in IN N
heart NN o
rate NN o
were VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Irradiation NNP N
within IN N
16-20 JJ N
h NN N
before IN N
operation NN N
and CC N
use NN N
of IN N
NSAID NNP i
( ( i
Voltaren NNP i
resinat NN i
) ) i
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
relevant JJ N
heterotopic NN N
ossification NN N
after IN N
total JJ N
hip NN N
replacement NN N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ o
level NN o
and CC o
mean JJ o
blood NN o
loss NN o
. . o

INTERVENTIONS NNP N
PDT NNP i
with IN i
the DT i
Ciaglia NNP i
technique NN i
using VBG i
the DT i
Ciaglia NNP i
PDT NNP i
introducer NN i
set NN i
and CC i
the DT i
Griggs NNP i
technique NN i
using VBG i
a DT i
Griggs NNP i
PDT NNP i
kit NN i
and CC i
guidewire NN i
dilating NN i
forceps NNS i
. . i

DISCUSSION NNP N
Combined NNP N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN o
of IN o
falls NNS o
and CC o
improving VBG o
muscle NN o
function NN o
in IN N
community-dwelling JJ p
older NN p
individuals NNS p
. . p

The DT N
study NN N
described VBD N
here RB N
investigates VBZ N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
glycerol NN i
lidocaine NN i
eardrops VBZ i
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
abacterial JJ p
otitis NN p
externa NN p
( ( p
CAS NNP p
No NNP p
. . p

From IN N
ECG NNP N
no DT N
significant JJ N
ST NNP N
deviations NNS N
were VBD N
found VBN N
and CC N
no DT N
significant JJ N
changes NNS N
regarding VBG N
B-Hb NNP o
, , o
blood NN o
pressure NN o
or CC o
pulse NN o
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Lanthanum NNP i
carbonate NN i
( ( i
Fosrenol NNP i
) ) i
is VBZ N
a DT N
new JJ N
non-aluminum JJ N
, , N
non-calcium JJ i
phosphate NN i
binder NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN i
in IN N
patients NNS p
with IN p
end-stage JJ p
renal JJ p
disease NN p
( ( p
ESRD NNP p
) ) p
. . p

Prolonged JJ N
infusion NN N
of IN N
low-dose JJ N
gemcitabine NN i
and CC i
cisplatin NN i
( ( i
GC NNP i
) ) i
proved VBD N
to TO N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
patients NNS p
with IN p
advanced JJ p
bladder NN p
cancer NN p
. . p

RESULTS VB N
A NNP N
significative JJ N
reduction NN N
of IN N
angina NN o
crisis NN o
number NN o
, , o
duration NN o
, , o
intensity NN o
and CC o
the DT o
number NN o
of IN o
sublingual JJ o
nitrates NNS o
doses NNS o
were VBD N
observed VBN N
equally RB N
in IN N
both DT N
groups NNS N
. . N

The DT N
relative JJ N
increase NN N
in IN N
glucose JJ o
turnover NN o
during IN N
ATP NNP N
infusion NN N
compared VBN N
with IN N
baseline NN N
showed VBD N
a DT N
significant JJ N
correlation NN N
with IN N
the DT N
ATP NNP N
dose NN N
( ( N
r=0.58 NN N
, , N
P=0.02 NNP N
) ) N
. . N

MEASUREMENTS NNP N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN o
of IN o
deep JJ o
venous JJ o
thrombosis NN o
in IN N
patients NNS p
with IN p
adequate JJ p
bilateral JJ p
venograms NNS p
; : p
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN o
. . o

A DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
active JJ N
drugs NNS N
and CC N
placebo NN i
, , N
while IN N
no DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
among IN N
the DT N
three CD N
drugs NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
overall JJ o
survival NN o
, , N
with IN N
a DT N
median NN N
of IN N
19.4 CD N
and CC N
21.5 CD N
months NNS N
for IN N
CP NNP i
and CC i
cisplatin NN i
, , N
respectively RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP i
on IN N
gastrointestinal JJ o
mucosa NN o
and CC o
platelet NN o
functions NNS o
in IN N
healthy JJ p
human JJ p
volunteers NNS p
. . p

These DT N
results NNS N
were VBD N
accomplished VBN N
by IN N
two CD N
applications NNS N
per IN N
day NN N
as IN N
compared VBN N
to TO N
the DT N
four CD N
necessary JJ N
applications NNS N
of IN N
Plc NNP i
, , N
on IN N
a DT N
half JJ N
daily JJ N
pilocarpine NN i
dose NN N
with IN N
Polym NNP N
. . N

The DT N
functional JJ N
role NN N
of IN N
the DT N
jejunum NN N
and CC N
ileum NN N
with IN N
regard NN N
to TO N
peripheral JJ N
plasma NN N
levels NNS N
of IN N
intact JJ N
neurotensin JJ N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
of IN N
neurotensin NN N
was VBD N
studied VBN N
by IN N
using VBG N
jejunoileal JJ i
bypass NN i
as IN N
a DT N
model NN N
. . N

[ VB N
The DT N
effect NN N
of IN N
losartan JJ i
versus NN N
atenolol NN i
on IN N
cardiovascular JJ o
morbidity NN o
and CC o
mortality NN o
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
in IN p
the DT p
LIFE-study NNP p
] NNP p
. . p

The DT N
effect NN N
of IN N
metformin NN i
and CC i
insulin NN i
on IN N
sympathetic JJ o
nerve NN o
activity NN o
, , o
norepinephrine JJ o
spillover NN o
and CC o
blood NN o
pressure NN o
in IN N
obese JJ p
, , p
insulin JJ p
resistant NN p
, , p
normoglycemic JJ p
, , p
hypertensive JJ p
men NNS p
. . p

A DT N
dose-dependent JJ N
reduction NN N
in IN N
plasma NN o
Abeta NNP o
was VBD N
demonstrated VBN N
, , N
and CC N
changes NNS N
in IN N
plasma NN o
Abeta NNP o
concentrations NNS o
were VBD N
temporally RB N
related VBN N
to TO N
the DT N
pharmacokinetic JJ N
characteristics NNS N
of IN N
LY450139 NNP N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
simultaneously RB i
administered VBN i
didanosine NN i
( ( i
ddI NN i
) ) i
on IN N
the DT N
absorption NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
itraconazole NN i
. . i

On IN N
the DT N
first JJ N
postoperative JJ N
day NN N
, , N
the DT N
increase NN N
in IN N
the DT N
mean JJ o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
IP NNP N
patients NNS N
. . N

Topical JJ i
PUVA NNP i
, , i
etretinate NN i
, , i
and CC i
combined VBN i
PUVA NNP i
and CC i
etretinate VB i
for IN i
palmoplantar JJ i
pustulosis NN i
: : i
comparison NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
the DT N
influences NNS N
of IN N
tonsillar JJ N
and CC N
dental JJ N
focal JJ N
infections NNS N
. . N

Thus RB N
, , N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
treated VBN p
with IN p
emergency NN i
angioplasty NN i
had VBD N
significantly RB N
less RBR N
severe JJ o
residual JJ o
coronary JJ o
stenosis NN o
and CC o
exercise-induced JJ o
periinfarct NN o
ischemia NN o
than IN N
did VBD N
those DT N
treated VBN N
with IN N
intracoronary JJ i
streptokinase NN i
. . i

Biofeedback NNP N
reduced VBD N
the DT N
duration NN o
of IN o
headaches NNS o
by IN N
1.9 CD N
days NNS N
, , N
and CC N
the DT N
frequency NN o
of IN o
days NNS o
when WRB o
headache NN o
intensity NN o
was VBD N
? . N
by IN N
2.4 CD N
times NNS N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
analgesic JJ N
effect NN N
of IN N
lidocaine NN i
and CC N
a DT N
combination NN N
of IN N
lidocaine NN i
and CC i
ketamine NN i
following VBG N
epidural JJ N
administration NN N
in IN N
dromedary JJ N
camels NNS N
. . N

Immune NNP i
globulin NN i
therapy NN i
had VBD N
no DT N
effect NN N
on IN N
respiratory NN o
distress NN o
syndrome NN o
, , o
bronchopulmonary JJ o
dysplasia NN o
, , o
intracranial JJ o
hemorrhage NN o
, , o
the DT o
duration NN o
of IN o
hospitalization NN o
, , o
or CC o
mortality NN o
. . o

Treatment NN N
with IN N
palifermin NN i
showed VBD N
beneficial JJ N
effects NNS N
on IN N
mucositis NN N
, , N
but CC N
no DT N
significant JJ N
effect NN N
on IN N
engraftment NN o
, , o
acute JJ o
graft-versus-host JJ o
disease NN o
( ( o
GVHD NNP o
) ) o
, , o
or CC o
early JJ o
survival NN o
. . o

However RB N
, , N
the DT N
influence NN N
of IN N
pH NN N
on IN N
cerebral JJ o
lactate JJ o
uptake NN o
and CC N
, , N
in IN N
turn NN N
, , N
on IN N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
exercise NN N
is VBZ N
not RB N
known VBN N
. . N

The DT N
formation NN o
of IN o
perindoprilat NN o
was VBD N
slightly RB N
reduced VBN N
in IN N
the DT N
group NN N
also RB N
receiving VBG N
hydrochlorothiazide NN i
and CC N
there EX N
was VBD N
a DT N
very RB N
small JJ N
reduction NN N
in IN N
ACE NNP o
inhibition NN o
in IN N
this DT N
group NN N
. . N

Metformin NNP i
, , i
naltrexone NN i
, , i
or CC i
the DT i
combination NN i
of IN i
prednisolone NN i
and CC i
antiandrogenic JJ i
oral JJ i
contraceptives NNS i
as IN N
first-line JJ N
therapy NN N
in IN N
hyperinsulinemic JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

Secondary JJ N
efficacy NN N
endpoints NNS N
included VBD N
pain NN o
intensity NN o
difference NN o
( ( o
PID NNP o
) ) o
and CC o
pain NN o
relief NN o
( ( o
PR NNP o
) ) o
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

CONCLUSION NNP N
Loss NNP o
of IN o
LH NNP o
after IN N
stopping VBG N
LA NNP i
is VBZ N
likely JJ N
to TO N
be VB N
clinically RB N
important JJ N
in IN N
ovarian JJ N
stimulation NN N
regimens NNS N
that WDT N
use VBP N
pure JJ N
FSH NNP N
with IN N
LA NNP i
in IN N
ultrashort JJ N
protocols NNS N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
long-term JJ N
effects NNS N
of IN N
finasteride NN i
on IN N
pressure-flow JJ N
parameters NNS N
in IN N
men NNS p
with IN p
urodynamically RB p
documented VBN p
bladder NN p
outflow JJ p
obstruction NN p
( ( p
BOO NNP p
) ) p
. . p

CONCLUSION NNP N
Combination NNP N
treatment NN N
with IN N
minoxidil NN i
and CC N
lignocaine NN i
helps VBZ N
in IN N
faster RBR N
healing NN N
of IN N
anal JJ N
fissures NNS N
and CC N
provides VBZ N
better RBR N
symptomatic JJ o
relief NN o
than IN N
either DT N
drug NN N
alone RB N
. . N

In IN N
contrast NN N
, , N
serum JJ o
insulin NN o
levels NNS o
, , o
C-peptide NNP o
levels NNS o
, , o
and CC o
serum JJ o
glibenclamide NN o
profiles NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
enalapril NN i
and CC i
placebo NN i
. . i

CONCLUSION NNP N
An DT N
increase NN N
in IN N
mammographic JJ o
density NN o
was VBD N
demonstrated VBN N
in IN N
most JJS N
subjects NNS N
undergoing VBG N
continuous JJ N
combined VBN N
HRT NNP N
and CC N
was VBD N
most RBS N
pronounced JJ N
in IN N
subjects NNS N
with IN N
a DT N
lower JJR N
baseline NN N
density NN N
percentage NN N
. . N

Main NNP N
outcome NN N
measures NNS N
were VBD N
incidence NN o
of IN o
clomiphene NN o
resistance NN o
, , o
monofollicular JJ o
response NN o
, , o
fasting VBG o
insulin/glucose JJ o
ratio NN o
, , o
serum NN o
testosterone NN o
, , o
and CC o
pregnancy NN o
rates NNS o
. . o

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Subnormal NNP o
bone NN o
mineral NN o
density NN o
( ( o
BMD NNP o
) ) o
and CC o
increased JJ o
fracture NN o
risk NN o
are VBP N
described VBN N
in IN N
patients NNS p
with IN p
growth NN p
hormone NN p
deficiency NN p
( ( p
GHD NNP p
) ) p
. . p

Two CD N
subjects NNS N
receiving VBG N
VPA NNP i
developed VBD N
increased VBN N
serum NN o
ammonia NN o
levels NNS o
, , N
one CD N
with IN N
an DT N
associated JJ N
parent NN N
report NN N
of IN N
slurred JJ o
speech NN o
and CC o
mild JJ o
cognitive JJ o
slowing NN o
. . o

The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
the DT N
between IN N
subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
5.85 CD N
, , N
d.f NN N
. . N

Simultaneously RB N
, , N
this DT N
intervention NN N
increased VBD N
interferon- JJ o
( ( o
IFN- NNP o
) ) o
level NN o
and CC o
unchanged JJ o
interleukin-4 JJ o
level NN o
, , o
as RB o
well RB o
as IN o
, , o
decreased VBD o
myeloperoxidase NN o
( ( o
MPO NNP o
) ) o
and CC o
interleukin-6 JJ o
levels NNS o
in IN o
plasma NN o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
artificial JJ o
recurrent NN o
caries NNS o
can MD N
be VB N
reduced VBN N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
a DT N
glass-ionomer JJ N
liner NN N
under IN N
amalgam JJ N
restorations NNS N
. . N

The DT N
potential JJ N
antioxidative JJ N
effect NN N
of IN N
the DT N
rye NN i
bran NN i
intervention NN i
was VBD N
investigated VBN N
by IN N
measuring VBG N
low-density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
susceptibility NN o
to TO o
copper VB o
oxidation NN o
ex FW o
vivo NN o
. . o

DISCUSSION NNP N
Data NNP N
suggest NN N
that IN N
PDS NNP i
suture NN i
can MD N
protect VB N
against IN N
development NN N
of IN N
aseptic JJ N
sternal JJ N
complications NNS N
following VBG N
median JJ N
sternotomy NN N
in IN N
high-risk JJ p
patients NNS p
with IN p
little JJ p
body NN p
mass NN p
. . p

This DT N
procedure NN N
is VBZ N
associated VBN N
with IN N
significantly RB N
less JJR N
blood JJ o
loss NN o
and CC o
shorter JJR o
hospitalization NN o
; : o
however RB N
, , N
it PRP N
is VBZ N
associated VBN N
with IN N
significantly RB N
longer RBR N
operating VBG N
time NN N
. . N

Ischaemia NNP o
reduction NN o
with IN o
iCSO NN o
was VBD N
greatest VBN N
at IN N
a DT N
CFI NNP N
of IN N
0.05-0.20 NNP N
, , N
whereas NN N
in IN N
the DT N
low JJ N
and CC N
high JJ N
CFI NNP N
range VBP N
the DT N
effect NN N
of IN N
iCSO NN N
was VBD N
absent JJ N
. . N

RESULTS NNP N
Clozapine NNP i
tended VBD N
to TO N
reduce VB N
chorea NN N
in IN N
neuroleptic JJ N
naive JJ N
patients NNS N
only RB N
( ( N
AIMS NNP N
) ) N
; : N
improvement NN N
seemed VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
higher JJR N
doses NNS N
of IN N
clozapine NN i
. . i

CONCLUSION NNP N
Lumbar NNP i
interlaminar JJ i
epidural JJ i
injections NNS i
of IN i
local JJ i
anesthetic JJ i
with IN i
or CC i
without IN i
steroids NNS i
provide VBP N
relief NN N
in IN N
a DT N
significant JJ N
proportion NN N
of IN N
patients NNS p
with IN p
lumbar JJ p
central JJ p
spinal JJ p
stenosis NN p
. . p

We PRP N
used VBD N
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
TMS NNP i
) ) i
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
single JJ N
doses NNS N
of IN N
amantadine NN i
on IN N
human JJ p
motor NN p
cortex NN p
excitability NN p
in IN p
normal JJ p
subjects NNS p
. . p

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
placebo NN i
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
6.5 CD N
, , N
29.7 CD N
and CC N
7.9 CD N
% NN N
. . N

OBJECTIVE NN N
To TO N
observe VB N
the DT N
effect NN N
of IN N
Fuzheng NNP i
Yiliu NNP i
Granule NNP i
( ( i
FZYLG NNP i
) ) i
on IN N
cell NN N
cycle NN N
and CC N
nuclear JJ N
transcription NN N
factor-kappa NN N
B NNP N
( ( N
NF-kappa NNP N
B NNP N
) ) N
in IN N
tissue NN N
of IN N
esophageal-gastric JJ N
carcinoma NN N
. . N

When WRB N
compared VBN N
against IN N
the DT N
control NN N
, , N
this DT N
regimen NNS N
produced VBD N
reduction NN N
of IN N
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
, , N
whereas IN N
the DT N
IOPO NNP N
regimen NNS N
did VBD N
not RB N
. . N

BACKGROUND NNP N
Azimilide NNP i
dihydrochloride NN i
( ( i
azimilide IN i
) ) i
is VBZ N
an DT N
investigational JJ N
antiarrhythmic JJ N
drug NN N
that WDT N
has VBZ N
been VBN N
tested VBN N
in IN N
patients NNS N
with IN N
a DT N
variety NN N
of IN N
arrhythmias NN N
. . N

Our PRP$ N
observations NNS N
suggest VBP N
that IN N
a DT N
fat JJ N
high NN N
in IN N
stearic JJ N
acid NN N
might MD N
affect VB N
Lp NNP N
[ VB N
a DT N
] NN N
in IN N
a DT N
different JJ N
way NN N
than IN N
fats NNS N
high JJ N
in IN N
palmitic JJ N
and CC N
myristic+lauric JJ N
acid NN N
. . N

There EX N
were VBD N
no DT N
associations NNS N
between IN N
the DT N
risk NN o
of IN o
venous JJ o
thrombosis NN o
and CC o
total JJ o
cholesterol NN o
, , o
low JJ o
density NN o
lipoprotein-cholesterol NN o
, , o
high JJ o
density NN o
lipoprotein-cholesterol NN o
, , o
triglycerides NNS o
, , o
glucose NN o
or CC o
smoking NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
increases NNS N
in IN N
any DT N
other JJ o
reactogenicity NN o
events NNS o
or CC o
adverse JJ o
events NNS o
in IN N
the DT N
vaccine NN N
recipients NNS N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
. . N

An DT N
open JJ N
, , N
parallel JJ N
group NN N
comparison NN N
of IN N
quinapril NN i
and CC i
captopril NN i
, , N
when WRB N
added VBN N
to TO N
diuretic JJ N
therapy NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
elderly JJ p
patients NNS p
with IN p
heart NN p
failure NN p
. . p

ACE NNP N
inhibitors NNS N
may MD N
cause VB N
a DT N
temporary JJ o
increase NN o
of IN o
the DT o
insulin NN o
sensitivity NN o
, , N
which WDT N
leads VBZ N
to TO N
an DT N
increased VBN N
risk NN o
of IN o
hypoglycemia NN o
under IN N
these DT N
conditions NNS N
. . N

However RB N
, , N
the DT N
time NN o
of IN o
recovery NN o
showed VBD N
a DT N
significant JJ N
decrease NN N
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
clonidine NN i
produces VBZ N
a DT N
dose-dependent JJ N
increase NN N
in IN N
the DT N
sweating NN o
threshold NN o
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN N
of IN N
sweating NN N
. . N

A DT N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
azithromycin NN i
for IN N
the DT N
treatment NN N
of IN N
chlamydia NN p
( ( p
Chlamydophila NNP p
felis RB p
) ) p
infection NN p
in IN p
cats NNS p
. . p

Additional JJ N
significant JJ N
toxic NN N
effects NNS N
included VBD N
nausea NN o
and CC o
vomiting NN o
, , o
hypotension NN o
, , o
leukopenia NN o
, , o
thrombocytopenia NN o
, , o
and CC o
evidence NN o
of IN o
hepatic JJ o
toxicity NN o
. . o

The DT N
prevalence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
in IN N
the DT N
pharynx NN N
, , N
however RB N
, , N
was VBD N
increased VBN N
after IN N
treatment NN N
with IN N
penicillin NN i
, , N
whereas IN N
no DT N
change NN N
was VBD N
noted VBN N
following VBG N
treatment NN N
with IN N
cefaclor NN N
. . N

AIM NNP N
To TO N
compare VB N
Desflurane NNP i
( ( i
D NNP i
) ) i
versus NN i
Sevoflurane NNP i
( ( i
S NNP i
) ) i
on IN N
hepatic JJ N
, , N
renal JJ N
functions NNS N
, , N
haemodynamics NNS N
and CC N
perioperative JJ N
course NN N
for IN N
cirrhotic JJ p
patients NNS p
undergoing VBG p
major JJ p
liver NN p
resection NN p
. . p

The DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples VBZ N
form VB N
middle-and-late JJ N
stage NN N
tumor NN N
patients NNS N
receiving VBG N
chemotherapy NN N
was VBD N
detected VBN N
before IN N
and CC N
after IN N
treatment NN N
using VBG N
nested JJ N
methylation-specific JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
MSP NNP N
) ) N
. . N

Aspirin NNP i
and CC i
nonsteroidal JJ i
antiinflammatory NN i
drugs NNS i
( ( i
NSAIDs NNP i
) ) i
damage VBP N
the DT N
gastroduodenal JJ N
epithelium NN N
by IN N
two CD N
mechanisms NNS N
: : N
direct JJ N
toxic NN N
effects NNS N
and CC N
effects NNS N
related VBN N
to TO N
the DT N
depletion NN N
of IN N
endogenous JJ N
prostaglandins NNS N
. . N

Four CD N
parameters NNS N
were VBD N
followed VBN N
: : N
serum-specific JJ N
IgE NNP N
against IN N
antigen NN N
E NNP N
, , N
total JJ N
blocking VBG N
antibody NN N
against IN N
antigen NN N
E NNP N
, , N
local JJ N
and CC N
systemic JJ N
reactions NNS N
to TO N
injection NN N
therapy NN N
, , N
and CC N
symptom NN N
score NN N
indices NNS N
. . N

A DT N
small JJ N
but CC N
significant JJ N
increase NN N
( ( N
relative JJ N
to TO N
prevaccination VB N
level NN N
) ) N
in IN N
response NN N
to TO N
MLSA NNP N
, , N
but CC N
not RB N
to TO N
BCG NNP o
or CC o
PPD NNP o
was VBD N
observed VBN N
in IN N
the DT N
non-BCG-vaccinated JJ N
groups NNS N
. . N

However RB N
, , N
whereas JJ N
pain NN o
scores NNS o
increased VBD N
during IN N
the DT N
day NN N
on IN N
twice-daily JJ N
CR NNP i
morphine NN i
( ( N
P=0.0108 NNP N
) ) N
, , N
they PRP N
remained VBD N
stable JJ N
on IN N
OAD NNP N
morphine NN N
. . N

OBJECTIVE NNP N
Previous NNP N
studies NNS N
have VBP N
suggested VBN N
that IN N
post-irradiation NN N
GH NNP N
insufficiency NN N
results NNS N
from IN N
a DT N
loss NN N
of IN N
GHRH NNP N
secretion NN N
, , N
since IN N
many JJ N
patients NNS N
were VBD N
able JJ N
to TO N
release VB N
GH NNP N
following VBG N
exogenous JJ N
GHRH NNP N
stimulation NN N
. . N

RESULTS NNP N
Regarding NNP N
chemical NN o
and CC o
clinical JJ o
pregnancy NN o
rates NNS o
, , o
the DT o
number NN o
of IN o
retrieved JJ o
oocytes NNS o
was VBD o
significantly RB o
higher JJR o
and CC o
OHSS NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
antagonist NN N
group NN N
. . N

INTERPRETATION NNP N
Prophylactic NNP i
VT NNP i
ablation NN i
before IN i
defibrillator NN i
implantation NN i
seemed VBD N
to TO N
prolong VB N
time NN N
to TO N
recurrence NN N
of IN N
VT NNP N
in IN N
patients NNS p
with IN p
stable JJ p
VT NNP p
, , p
previous JJ p
myocardial JJ p
infarction NN p
, , p
and CC p
reduced VBD p
LVEF NNP p
. . p

Analgesic JJ o
efficacy NN o
, , o
maternal JJ o
side NN o
effects NNS o
, , o
changes NNS o
in IN o
the DT o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
and CC o
duration NN o
of IN o
labor NN o
were VBD N
assessed VBN N
. . N

BACKGROUND NNP N
Omeprazole NNP i
and CC i
famotidine VB i
both DT N
reduce VB N
severity NN o
of IN o
exercise-induced JJ o
gastritis NN o
, , N
but CC N
administering VBG N
famotidine NN i
is VBZ N
easier JJR N
than IN N
administering VBG N
omeprazole JJ i
during IN N
racing VBG N
competition NN N
. . N

RATIONALE NNP N
Continuous NNP i
positive JJ i
airway NN i
pressure NN i
( ( i
CPAP NNP i
) ) i
use NN N
is VBZ N
associated VBN N
with IN N
reduced JJ N
motor NN N
vehicle NN N
accidents NNS N
in IN N
patients NNS p
with IN p
obstructive JJ p
sleep NN p
apnea NN p
( ( p
OSA NNP p
) ) p
. . p

The DT N
P-ESDM NNP i
group NN N
reported VBD N
no DT N
increase NN N
in IN N
parenting VBG o
stress NN o
, , N
whereas IN N
the DT N
Community NNP N
group NN N
experienced VBD N
an DT N
increase NN N
over IN N
the DT N
same JJ N
3-month JJ N
period NN N
. . N

Atrial JJ o
flutter NN o
cycle NN o
length NN o
and CC o
atrial JJ o
monophasic JJ o
action NN o
potential JJ o
duration NN o
recorded VBN N
from IN N
the DT N
right JJ N
atrium NN N
during IN N
atrial JJ N
flutter NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
following VBG N
infusion NN N
of IN N
ibutilide NN i
, , i
procainamide NN i
, , i
or CC i
placebo NN i
. . i

The DT N
pulsatility NN o
index NN o
and CC o
resistivity NN o
index NN o
increased VBD N
significantly RB N
only RB N
after IN N
the DT N
propofol NN N
infusion NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
YDJ NNP i
played VBD N
a DT N
role NN N
in IN N
clearing VBG o
HR-HPV NNP o
infection NN o
and CC N
reversing VBG N
the DT N
cervical JJ N
precancerous JJ N
changes NNS N
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

Results NNS N
of IN N
a DT N
phase NN N
I/II NNP N
trial NN N
of IN N
recombinant JJ i
human JJ i
granulocyte-macrophage NN i
colony-stimulating NN i
factor NN i
in IN N
very RB N
low JJ N
birthweight NN p
neonates NNS p
: : p
significant JJ N
induction NN N
of IN N
circulatory NN o
neutrophils NNS o
, , o
monocytes NNS o
, , o
platelets NNS o
, , o
and CC o
bone NN o
marrow NN o
neutrophils NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
alveolar JJ N
macrophages NNS N
from IN N
BAL NNP N
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
ability NN N
to TO N
phagocytose VB N
unopsonized JJ N
Candida NNP N
albicans NNS N
and CC N
a DT N
decrease NN N
in IN N
superoxide JJ o
production NN o
. . o

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN i
and CC i
vitamin NN i
D NNP i
on IN N
falls NNS o
and CC o
parameters NNS o
of IN o
muscle NN o
function NN o
in IN N
community-dwelling JJ p
elderly JJ p
women NNS p
and CC p
men NNS p
. . p

However RB N
, , N
inadequate JJ N
intake NN N
of IN N
vegetable JJ N
and CC N
fruit NN N
is VBZ N
a DT N
concern NN N
in IN N
Japan.We NNP N
therefore RB N
produced VBD N
a DT N
juice NN N
mixture NN N
of IN N
fresh JJ N
fruit NN N
and CC N
komatsuna NN N
( ( N
Brassica NNP N
rapa VBZ N
L. NNP N
var NN N
. . N

Relation NN N
of IN N
improvement NN N
in IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
with IN N
atorvastatin NN i
to TO N
reductions NNS N
in IN N
hospitalizations NNS p
for IN p
heart NN p
failure NN p
( ( p
from IN p
the DT p
Treating NNP p
to TO p
New NNP p
Targets NNP p
[ NNP p
TNT NNP p
] NNP p
study NN N
) ) N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanism NN N
of IN N
Feiyangqin NNP i
Rectum NNP i
Condensed VBD i
Liquid NNP i
( ( i
FRCL NNP i
) ) i
in IN N
treating VBG N
children NNS p
syncytial JJ p
viral JJ p
pneumonia NN p
. . p

BACKGROUND NNP N
Consumption NNP N
of IN N
soluble JJ i
dietary JJ i
fibre NN i
is VBZ N
correlated VBN N
with IN N
decreased JJ N
postprandial JJ o
glucose NN o
and CC o
insulin NN o
responses NNS o
and CC N
hence NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

Acute NNP N
intravenous JJ N
L-arginine JJ i
infusion NN N
decreases VBZ N
endothelin-1 JJ N
levels NNS N
and CC N
improves VBZ N
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
angina JJ p
pectoris NN p
and CC p
normal JJ p
coronary JJ p
arteriograms NNS p
: : p
correlation NN N
with IN N
asymmetric JJ N
dimethylarginine NN N
levels NNS N
. . N

PURPOSE NNP N
The DT N
role NN N
of IN N
antiviral JJ i
prophylaxis NN i
in IN N
preventing VBG N
hepatitis NN o
B NNP o
virus NN o
( ( o
HBV NNP o
) ) o
reactivation NN o
before IN N
rituximab-based JJ i
chemotherapy NN i
in IN N
patients NNS p
with IN p
lymphoma NN p
and CC p
resolved VBD p
hepatitis NN p
B NNP p
is VBZ N
unclear JJ N
. . N

The DT N
absolute JJ N
risks NNS N
of IN N
retinopathy NN N
and CC N
nephropathy JJ N
were VBD N
proportional JJ N
to TO N
the DT N
mean NN o
glycosylated VBD o
hemoglobin NN o
( ( o
HbA NNP o
( ( o
1c CD o
) ) o
) ) o
level NN o
over IN N
the DT N
follow-up JJ N
period NN N
preceding VBG N
each DT N
event NN N
. . N

The DT N
plasma NN o
PLP NNP o
concentrations NNS o
in IN o
maternal JJ o
and CC o
cord JJ o
blood NN o
were VBD N
highly RB N
correlated VBN N
and CC N
indicated VBD N
a DT N
dependence NN N
of IN N
fetal JJ N
vitamin NN N
B6 NNP N
nutrition NN N
on IN N
maternal JJ N
circulating NN N
PLP NNP N
. . N

CONCLUSIONS NNP N
This DT N
Phase NNP N
I PRP N
study VBP N
demonstrated VBD N
that IN N
CS NNP i
vaginal JJ i
gel NN i
was VBD N
safe JJ N
, , N
well RB N
tolerated VBN N
and CC N
acceptable JJ N
by IN N
HIV-infected JJ p
women NNS p
and CC p
their PRP$ p
male JJ p
partners NNS p
. . p

We PRP N
previously RB N
described VBD N
significant JJ N
reductions NNS N
in IN N
resting VBG o
energy NN o
expenditure NN o
( ( o
REE NNP o
) ) o
, , N
as IN N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
, , N
over IN N
the DT N
course NN N
of IN N
HSCT NNP i
. . i

RESULTS VB N
The DT N
oral JJ N
formulation NN N
of IN N
cetirizine/PSE NN i
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
superior NN N
to TO N
placebo VB i
in IN N
improving VBG N
nasal JJ o
obstruction NN o
during IN N
both DT N
challenges NNS N
. . N

Overexpression NN N
of IN N
vascular JJ i
endothelial JJ i
growth NN i
factor NN i
( ( i
VEGF NNP i
) ) i
and CC N
its PRP$ N
cellular JJ N
receptor NN N
KDR NNP i
( ( i
VEGFR-2 NNP i
) ) i
in IN N
the DT N
bone NN N
marrow NN N
of IN N
patients NNS p
with IN p
acute JJ p
myeloid NN p
leukemia NN p
. . p

The DT N
pain NN o
threshold NN o
and CC o
the DT o
summation NN o
threshold NN o
to TO o
electrical JJ o
stimuli NNS o
and CC o
the DT o
summation NN o
threshold NN o
to TO o
heat VB o
stimuli NNS o
increased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine JJ i
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
flap NN N
designs NNS N
in IN N
operation NN o
time NN o
, , o
maximum JJ o
interincisal NN o
opening NN o
, , o
and CC o
the DT o
number NN o
of IN o
analgesics NNS o
taken VBN o
. . o

In IN N
this DT N
study NN N
, , N
the DT N
hypothesis NN N
tested VBD N
was VBD N
that IN N
low JJ N
doses NNS N
of IN N
propranolol NN i
could MD N
alter VB N
bone NN o
properties NNS o
and CC o
enhance NN o
orthotopic RB o
endochondral JJ o
bone NN o
formation NN o
. . o

CONCLUSIONS NNP N
The DT N
interobserver JJ N
agreement NN N
of IN N
PB NNP N
delineation NN N
was VBD N
moderate JJ N
but CC N
was VBD N
improved VBN N
by IN N
the DT N
DR. NNP N
Major NNP N
deviations NNS N
could MD N
be VB N
identified VBN N
for IN N
the DT N
majority NN N
of IN N
centers NNS N
. . N

However RB N
, , N
predose JJ o
and CC o
postdose JJ o
ALDO NNP o
and CC o
A-II NNP o
levels NNS o
did VBD N
not RB N
differ VB N
between IN N
each DT N
genotype NN N
subgroup NN N
at IN N
baseline NN N
or CC N
by IN N
enalapril JJ N
dose NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

RESULTS VB N
The DT N
mean JJ o
average JJ o
difference NN o
in IN o
femoral JJ o
neck NN o
resection NN o
height NN o
was VBD N
0.84 CD N
mm NN N
when WRB N
using VBG N
the DT N
osteotomy NN N
guide NN N
and CC N
1.69 CD N
mm NN N
without IN N
the DT N
guide NN N
. . N

The DT N
increase NN N
in IN N
the DT N
number NN o
of IN o
decayed JJ o
and CC o
filled JJ o
root NN o
surfaces NNS o
after IN N
one CD N
year NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
halothane NN i
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
mean JJ o
cortisol NN o
and CC o
glucose NN o
levels NNS o
after IN N
the DT N
start NN N
of IN N
surgery NN N
. . N

BACKGROUND NNP N
Combinations NNP N
of IN N
infero-temporal JJ N
and CC N
either DT N
supero-nasal JJ i
( ( i
'inferior-superior JJ i
' '' i
) ) i
or CC i
medial JJ i
percaruncular NN i
( ( i
'inferior-medial JJ i
' '' i
) ) i
injections NNS i
are VBP N
popular JJ N
double-injection NN N
techniques NNS N
for IN N
establishing VBG N
peribulbar NN N
block NN N
analgesia NN N
. . N

Except IN N
for IN N
neutropenia NN o
and CC o
leukopenia NN o
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
excess NN N
of IN N
grade NN o
3/4 CD o
adverse JJ o
events NNS o
compared VBN N
with IN N
CAF NNP i
. . i

The DT N
most RBS N
common JJ N
treatment NN N
emergent JJ N
adverse JJ o
event NN o
was VBD N
( ( N
mostly RB N
mild VBN N
) ) N
retrograde NN o
ejaculation NN o
( ( N
silodosin JJ N
28.1 CD N
% NN N
of IN N
patients NNS N
, , N
placebo RB N
0.9 CD N
% NN N
) ) N
. . N

BACKGROUND NNP N
Talc NNP N
has VBZ N
been VBN N
generally RB N
accepted VBN N
to TO N
be VB N
the DT N
most RBS N
effective JJ N
sclerosant NN N
for IN N
chemical NN N
pleurodesis NN N
, , N
although IN N
the DT N
optimal JJ N
route NN N
of IN N
administration NN N
remains VBZ N
unclear JJ N
. . N

CONCLUSION NNP N
Pazopanib NNP i
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
PFS NNP o
and CC o
tumor NN o
response NN o
compared VBN N
with IN N
placebo NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ p
patients NNS p
with IN p
advanced JJ p
and/or NNS p
metastatic JJ p
RCC NNP p
. . p

Importantly RB N
, , N
no DT N
seizures NNS o
occurred VBD N
in IN N
these DT N
ill JJ N
neonates NNS N
who WP N
may MD N
potentially RB N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
tramadol JJ o
toxicity NN o
compared VBN N
with IN N
adults NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
, , N
in IN N
the DT N
light NN N
of IN N
previous JJ N
findings NNS N
, , N
that IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
ANF NNP i
represents VBZ N
a DT N
non-selective JJ N
action NN N
of IN N
ANF NNP i
on IN N
aldosterone NN N
release NN N
. . N

Long-term JJ N
effects NNS N
of IN N
ezetimibe-plus-statin JJ i
therapy NN i
on IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
levels NNS o
as IN N
compared VBN N
with IN N
double-dose JJ i
statin NN i
therapy NN i
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

CONCLUSIONS NNP N
Topical NNP N
administration NN N
of IN N
diclofenac NN i
was VBD N
effective JJ N
in IN N
maintaining VBG N
mydriasis NN N
during IN N
vitrectomy NN N
and CC N
in IN N
reducing VBG N
postoperative JJ N
pain NN N
and CC N
anterior JJ N
chamber NN N
flare NN N
as IN N
determined VBN N
by IN N
slit-lamp JJ N
evaluations NNS N
. . N

Secondary JJ N
assessments NNS N
examined VBD N
the DT N
effects NNS N
of IN N
the DT N
PGE1 NNP N
infusion NN N
on IN N
plasma NN N
mediated VBN N
suppression NN N
of IN N
PMN NNP N
superoxide JJ N
production NN N
and CC N
loss NN N
of IN N
PMN NNP N
granule NN N
enzyme NN N
content NN N
. . N

CONCLUSION NNP N
Pretreatment NNP N
with IN N
minidose JJ i
succinylcholine JJ i
causes VBZ N
no DT N
greater JJR N
incidence NN N
of IN N
fasciculations NNS N
than IN N
pancuronium NN i
in IN N
rapid-sequence JJ p
intubation NN p
of IN p
head NN p
trauma NN p
patients NNS p
in IN N
an DT N
ED NNP N
setting NN N
. . N

Skull-base JJ N
invasion NN N
was VBD N
classified VBN N
according VBG N
to TO N
the DT N
incidence NN N
of IN N
each DT N
site NN N
( ( N
type JJ N
I PRP N
sites NNS N
inside IN N
pharyngobasilar JJ N
fascia NN N
and CC N
clivus NN N
vs. FW N
type NN N
II NNP N
sites VBZ N
outside IN N
pharyngobasilar JJ N
fascia NN N
) ) N
. . N

The DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
decreased VBN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

A DT N
significant JJ N
increase NN N
in IN N
endometritis NN N
and CC N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
neonatal JJ o
infections NNS o
and CC o
cesarean JJ o
section NN o
rates NNS o
were VBD N
noted VBN N
with IN N
treatment NN N
. . N

Prevention NN N
of IN N
postoperative JJ N
hypocalcemia NN N
with IN N
routine JJ N
oral JJ N
calcium NN i
and CC i
vitamin NN i
D NNP i
supplements NNS i
in IN N
patients NNS p
with IN p
differentiated JJ p
papillary JJ p
thyroid NN p
carcinoma NN p
undergoing JJ p
total JJ p
thyroidectomy NN p
plus CC p
central JJ p
neck NN p
dissection NN p
. . p

Dose NNP N
distribution NN N
curves NNS N
in IN N
cross-section NN N
and CC N
midsagittal JJ N
planes NNS N
are VBP N
shown VBN N
and CC N
calculations NNS N
or CC N
equivalent JJ N
doses NNS N
at IN N
various JJ N
selected VBN N
points NNS N
using VBG N
Ellis NNP N
's POS N
nominal JJ N
single-dose JJ N
formula NN N
are VBP N
tabulated VBN N
. . N

Safety NN N
analysis NN N
demonstrated VBD N
no DT N
dose-dependent JJ N
increase NN N
in IN N
adverse JJ o
events NNS o
, , o
and CC o
no DT o
drug-related JJ o
increase NN o
in IN o
daytime JJ o
somnolence NN o
was VBD N
observed VBN N
. . N

OBJECTIVE NNP N
Preliminary NNP N
evidence NN N
suggests VBZ N
that IN N
omega-3 JJ i
fatty JJ i
acids NNS i
may MD N
reduce VB N
hyperactivity NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

AIM IN N
The DT N
aim NN N
of IN N
study NN N
was VBD N
test JJ N
efficacy NN N
of IN N
accelerated JJ i
postoperative JJ i
radiotherapy NN i
-- : i
concomitant JJ i
boost NN i
in IN N
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
. . p

BACKGROUND NNP N
Intravenous NNP N
cangrelor NN N
, , N
a DT N
rapid-acting NN N
, , N
reversible JJ N
adenosine NN N
diphosphate NN N
( ( N
ADP NNP N
) ) N
receptor NN N
antagonist NN N
, , N
might MD N
reduce VB N
ischemic JJ N
events NNS N
during IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

The DT N
fee NN N
for IN N
the DT N
As NNP N
test NN N
was VBD N
US NNP N
$ $ N
0.28 CD N
, , N
higher JJR N
than IN N
the DT N
cost NN N
of IN N
the DT N
test NN N
( ( N
US NNP N
$ $ N
0.16 CD N
) ) N
. . N

OBJECTIVE NN N
To TO N
compare VB N
the DT N
fracture NN o
resistances NNS o
of IN N
pulpless NN N
teeth NNS N
restored VBD N
with IN N
FRC NNP i
( ( i
Fiber NNP i
Reinforced NNP i
Composite NNP i
) ) i
posts NNS i
and CC i
three CD i
kinds NNS i
of IN i
resin NN i
core NN i
material NN i
. . i

HBV NNP o
DNA NNP o
, , o
HBeAg NNP o
and CC o
liver JJ o
functions NNS o
were VBD N
detected VBN N
at IN N
different JJ N
time NN N
points NNS N
, , N
and CC N
the DT N
number NN o
of IN o
cells NNS o
that WDT o
secrete VBP o
IFN-gamma NNP o
were VBD N
detected VBN N
by IN N
ELISPOT NNP N
. . N

In IN N
the DT N
normal JJ N
men NNS N
, , N
insulin NN N
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN o
plasma NN o
glucagon NN o
and CC o
C-peptide JJ o
levels NNS o
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN N
in IN N
the DT N
arginine-induced JJ o
glucagon NN o
response NN o
. . o

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Acute NNP N
intermittent NN N
porphyria NN N
is VBZ N
an DT N
autosomal JJ N
dominant JJ N
disorder NN N
caused VBN N
by IN N
deficient JJ N
activity NN N
of IN N
the DT N
third JJ N
enzyme NN N
in IN N
the DT N
haem NN N
biosynthetic JJ N
pathway NN N
, , N
porphobilinogen NN N
deaminase NN N
. . N

Hormone CD N
replacement NN N
therapy NN N
producing VBG N
an DT N
effect NN N
equivalent NN N
to TO N
higher JJR N
oestradiol JJ N
concentrations NNS N
is VBZ N
likely JJ N
to TO N
increase VB N
the DT N
risk NN o
of IN o
side NN o
effects NNS o
without IN N
conferring VBG N
any DT N
additional JJ N
benefit NN N
. . N

The DT N
effect NN N
of IN N
modified VBN i
eggs NNS i
and CC i
an DT i
egg-yolk NN i
based VBN i
beverage NN i
on IN N
serum NN o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

Alpha NNP i
interferon NN i
has VBZ N
shown VBN N
initial JJ N
promise NN N
in IN N
the DT N
treatment NN N
of IN N
low-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
( ( N
NHL NNP N
) ) N
, , N
especially RB N
with IN N
the DT N
nodular JJ N
form NN N
of IN N
the DT N
disease NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
myocardial JJ N
protection NN N
during IN N
ischemia NN N
was VBD N
sufficient JJ N
to TO N
prevent VB N
significant JJ N
reductions NNS N
of IN N
myocardial JJ o
ATP NNP o
and CC o
creatine VB o
phosphate JJ o
irrespective NN N
of IN N
supplementation NN N
with IN N
CP NNP N
. . N

Standard-dose JJ i
lansoprazole NN i
is VBZ N
more RBR N
effective JJ N
than IN N
high-dose JJ N
ranitidine NN i
in IN N
achieving VBG N
endoscopic NN o
healing NN o
and CC o
symptom JJ o
relief NN o
in IN N
patients NNS p
with IN p
moderately RB p
severe JJ p
reflux NN p
oesophagitis NN p
. . p

This DT N
inhibition NN N
was VBD N
incomplete JJ N
because IN N
AII NNP N
levels NNS N
increased VBD N
markedly RB N
when WRB N
captopril NN i
was VBD N
given VBN N
( ( N
no DT N
treatment NN N
effect NN N
: : N
p NN N
< VBZ N
0.37 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
incidence NN o
of IN o
fever NN o
, , o
physiotherapist JJ o
time NN o
, , o
or CC o
the DT o
number NN o
of IN o
treatments NNS o
. . o

BACKGROUND NNP N
Catheter NNP i
ablation NN i
( ( i
CA NNP i
) ) i
and CC i
minimally RB i
invasive JJ i
surgical JJ i
ablation NN i
( ( i
SA NNP i
) ) i
have VBP N
become VBN N
accepted JJ N
therapy NN N
for IN N
antiarrhythmic JJ N
drug-refractory JJ N
atrial JJ N
fibrillation NN N
. . N

RESULTS VB N
The DT N
infiltrating JJ N
growth NN N
pattern NN N
was VBD N
significantly RB N
associated VBN N
with IN N
histological JJ N
subtype NN N
and CC N
lymphovascular JJ N
invasion NN N
, , N
while IN N
high-grade JJ N
budding NN N
was VBD N
significantly RB N
associated VBN N
with IN N
tumor NN N
grade NN N
and CC N
lymphovascular JJ N
invasion NN N
. . N

Supplementation NN N
with IN N
n3 JJ i
fatty JJ i
acid NN i
ethyl NN i
esters NNS i
increases VBZ N
large JJ N
and CC N
small JJ N
artery NN N
elasticity NN N
in IN N
obese JJ p
adults NNS p
on IN p
a DT p
weight JJ p
loss NN p
diet NN p
. . p

BACKGROUND NNP N
6-mercaptopurine NN i
has VBZ N
been VBN N
a DT N
standard JJ N
component NN N
of IN N
long-term JJ N
continuing VBG N
treatment NN N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
, , N
whereas JJ N
6-thioguanine NN i
has VBZ N
been VBN N
mainly RB N
used VBN N
for IN N
intensification NN N
courses NNS N
. . N

BACKGROUND NNP N
B-type NNP N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
levels NNS N
are VBP N
reliably RB N
elevated VBN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
and CC N
therefore RB N
helpful JJ N
in IN N
its PRP$ N
diagnosis NN N
. . N

Although IN N
the DT N
incidence NN o
of IN o
myelosuppression NN o
and CC o
alopecia NN o
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
B NNP N
, , N
neuropathy NN o
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
group NN N
A NNP N
. . N

The DT N
combination NN N
of IN N
dietary JJ N
sodium NN N
restriction NN N
with IN N
blockade NN N
of IN N
the DT N
renin NN N
system NN N
by IN N
an DT N
ACE NNP N
inhibitor NN N
is VBZ N
a DT N
particularly RB N
effective JJ N
way NN N
to TO N
improve VB N
blood NN o
pressure NN o
control NN o
. . o

BACKGROUND NNP N
& CC N
AIMS NNP N
Helicobacter NNP N
pylori-infected JJ N
gastric JJ N
mucosa NN N
evolves VBZ N
through IN N
stages NNS N
of IN N
chronic JJ N
gastritis NN N
, , N
intestinal JJ N
metaplasia NN N
( ( N
IM NNP N
) ) N
, , N
glandular JJ N
atrophy NN N
( ( N
GA NNP N
) ) N
, , N
and CC N
dysplasia NN N
before IN N
carcinoma NN N
develops NNS N
. . N

Both DT N
types NNS N
of IN N
radiation NN N
techniques NNS N
lowered VBD N
the DT N
incidence NN o
of IN o
loco-regional JJ o
recurrences NNS o
significantly RB N
, , N
but CC N
had VBD N
no DT N
significant JJ N
influence NN N
on IN N
the DT N
overall JJ o
survival NN o
. . o

PATIENTS NNP N
Two CD p
hundred VBD p
and CC p
one CD p
functional JJ p
class NN p
I PRP p
and CC p
II NNP p
patients NNS p
with IN p
definite JJ p
or CC p
classic JJ p
rheumatoid NN p
arthritis NN p
, , p
previously RB p
untreated VBN p
with IN p
disease NN p
modifying VBG p
antirheumatic JJ p
drugs NNS p
. . p

No DT N
marked JJ N
differences NNS N
in IN N
follow-up JJ N
new JJ o
and CC o
recurrent JJ o
caries NNS o
were VBD N
found VBN N
between IN N
the DT N
stannous JJ N
fluoride JJ N
gel NN N
control NN N
and CC N
IFRS NNP N
groups NNS N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN i
, , i
imidacloprid JJ i
, , i
and CC i
fipronil- NN i
( ( i
S NNP i
) ) i
-methoprene NN i
against IN N
Ctenocephalides NNP N
felis JJ N
infestations NNS N
on IN N
cats NNS p
for IN p
one CD p
month NN p
following VBG p
a DT p
single JJ p
treatment NN p
was VBD p
evaluated VBN p
. . p

The DT N
small JJ N
red JJ N
berry NN N
, , N
wolfberry NN N
( ( N
Fructus NNP N
barbarum VBZ N
L. NNP N
; : N
Gou NNP N
Qi NNP N
Zi NNP N
and CC N
Kei NNP N
Tze NNP N
) ) N
, , N
is VBZ N
one CD N
of IN N
the DT N
richest JJS N
natural JJ N
sources NNS N
of IN N
zeaxanthin NN i
. . i

Of IN N
the DT N
four CD N
in IN N
active JJ N
treatment NN N
that WDT N
sustained VBD N
improvement NN N
, , N
three CD N
had VBD N
a DT N
maximum JJ N
dose NN N
of IN N
0.13-0.15 JJ N
mg/kg/day NN N
, , N
while IN N
those DT N
who WP N
regressed VBD N
had VBD N
doses NNS N
? . N
mg/kg/day NN N
. . N

GHBP NNP i
was VBD N
measured VBN N
by IN N
ligand-mediated JJ N
immunofunctional JJ N
assay NN N
, , N
and CC N
serum JJ N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
was VBD N
determined VBN N
by IN N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
, , N
using VBG N
a DT N
truncated JJ N
IGF-I JJ N
analog NN N
as IN N
the DT N
radioligand NN N
. . N

Appetite NNP o
loss NN o
developed VBD N
in IN N
92.9 CD N
% NN N
and CC N
41.7 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
prevention NN N
effect NN N
was VBD N
clearly RB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

We PRP N
also RB N
documented VBD N
a DT N
decline NN N
in IN N
mid-arm JJ o
muscle NN o
area NN o
, , o
suggesting VBG o
depletion NN o
of IN o
muscle NN o
mass NN o
, , N
while IN N
triceps NNS N
skinfold RB N
, , N
a DT N
marker NN N
of IN N
fat JJ N
stores NNS N
, , N
was VBD N
unchanged JJ N
. . N

Conversely RB N
, , N
all DT N
HuG-CSF-treated JJ N
cats NNS N
developed VBD N
neutralizing VBG o
antibodies NNS o
, , N
suggesting VBG N
cross-reactive JJ N
antibodies NNS N
to TO N
endogenous JJ N
G-CSF NNP N
in IN N
a DT N
majority NN N
of IN N
the DT N
cases NNS N
with IN N
severe JJ N
neutropenia NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
diarrhea RB o
, , o
hypertension NN o
, , o
hair NN o
color NN o
changes NNS o
, , o
nausea NN o
, , o
anorexia NN o
, , o
and CC o
vomiting NN o
. . o

CONCLUSIONS NNP N
Bonding NNP N
resin NN N
or CC N
liquid JJ N
polish JJ N
coatings NNS N
significantly RB N
reduce VB N
early JJ o
biofilm NN o
formation NN o
, , N
which WDT N
in IN N
turn NN N
might MD N
affect VB N
the DT N
overall JJ N
plaque NN N
accumulation NN N
on IN N
provisional JJ N
restorations NNS N
. . N

Gastroesophageal NNP N
reflux NN N
and CC N
tracheal JJ N
aspiration NN N
in IN N
the DT N
thoracotomy JJ N
position NN N
: : N
should MD N
ranitidine VB N
premedication NN N
be VB N
routine JJ N
? . N
UNLABELLED JJ N
Aspiration NN N
of IN N
gastric JJ N
contents NNS N
may MD N
contribute VB N
to TO N
pulmonary JJ N
complications NNS N
after IN N
thoracotomy NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
antacid NN N
dose NN N
should MD N
be VB N
so RB N
great JJ N
that IN N
it PRP N
binds VBZ N
secreted JJ N
acid NN N
before IN N
the DT N
dose NN N
leaves VBZ N
the DT N
stomach NN N
. . N

The DT N
cure NN o
rate NN o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
obviously RB N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
increased VBD N
ADMA NNP N
levels NNS N
play VBP N
a DT N
role NN N
in IN N
the DT N
abnormal JJ N
vascular JJ N
reactivity NN N
that WDT N
is VBZ N
observed VBN N
in IN N
patients NNS p
with IN p
CSX NNP p
. . p

The DT N
mechanism NN N
of IN N
action NN N
of IN N
vortioxetine NN i
is VBZ N
thought VBN N
to TO N
be VB N
related VBN N
to TO N
direct JJ N
modulation NN N
of IN N
serotonin NN N
( ( N
5-HT JJ N
) ) N
receptor NN N
activity NN N
and CC N
inhibition NN N
of IN N
the DT N
serotonin NN N
transporter NN N
. . N

Mitral JJ N
surgery NN N
allows VBZ N
an DT N
immediate JJ N
surgical JJ N
auricular NN N
remodeling NN N
and CC N
besides NNS N
in IN N
those DT N
cases NNS N
in IN N
which WDT N
sinus NN N
rhythm NN N
is VBZ N
reached VBN N
, , N
it PRP N
is VBZ N
followed VBN N
by IN N
a DT N
late JJ N
remodeling NN N
. . N

Significant JJ N
preservation NN N
of IN N
platelet NN o
numbers NNS o
and CC o
function NN o
were VBD N
shown VBN N
without IN N
significant JJ N
haemodynamic JJ N
problems NNS N
, , N
but CC N
no DT N
effect NN N
on IN N
cerebral JJ o
deficits NNS o
could MD N
be VB N
found VBN N
. . N

Corrected VBN o
TIMI NNP o
frame NN o
count NN o
was VBD N
furthermore RB N
lower JJR N
in IN N
the DT N
nicorandil NN i
group NN N
( ( N
21.0+/-9.1 JJ N
versus NN N
25.1+/-14.1 CD N
; : N
P=0.0009 NNP N
) ) N
. . N

Clinical JJ N
benefits NNS N
of IN N
concurrent JJ i
capecitabine NN i
and CC i
cisplatin NN i
versus NN i
concurrent NN i
cisplatin NN i
and CC i
5-flurouracil JJ i
in IN N
locally RB p
advanced JJ p
squamous JJ p
cell NN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

Intradermal JJ N
injection NN N
of IN N
the DT N
C16:0 NNP i
and CC i
C18:0 NNP i
PAF NNP i
homologues NNS i
induced VBD N
dose-dependent JJ N
increases NNS N
in IN N
weal JJ o
volume NN o
and CC o
flare JJ o
area NN o
responses NNS o
which WDT N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

End NN N
points NNS N
were VBD N
patient JJ o
and CC o
graft NN o
survival NN o
, , o
acute NN o
and CC o
chronic JJ o
rejection NN o
, , o
and CC o
incidence NN o
of IN o
steroid JJ o
side NN o
effects NNS o
during IN N
the DT N
first JJ N
year NN N
after IN N
LT NNP N
. . N

Labetalol NNP i
exerted VBD N
a DT N
net JJ N
inhibitory NN N
effect NN N
on IN N
plasma NN o
renin NN o
activity NN o
, , N
which WDT N
was VBD N
related VBN N
to TO N
basal VB N
renin NN N
values NNS N
and CC N
was VBD N
already RB N
maximal JJ N
at IN N
the DT N
lowest JJS N
doses NNS N
. . N

In IN N
enalapril JJ i
group NN N
, , N
the DT N
reduced JJ N
values NNS N
of IN N
systolic JJ o
blood NN o
pressure NN o
and CC o
pulse JJ o
pressure NN o
in IN o
central JJ o
aorta NNS o
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
. . N

Low-dose JJ i
growth NN i
hormone NN i
treatment NN i
with IN i
diet JJ i
restriction NN i
accelerates VBZ o
body JJ o
fat JJ o
loss NN o
, , o
exerts VBZ o
anabolic JJ o
effect NN o
and CC o
improves VBZ o
growth NN o
hormone NN o
secretory NN o
dysfunction NN o
in IN N
obese JJ p
adults NNS p
. . p

PURPOSE NN N
To TO N
compare VB N
the DT N
Eppendorf NNP i
PO2 NNP i
histograph NN i
and CC i
the DT i
alkaline NN i
comet NN i
assay VBP i
as IN N
methods NNS N
of IN N
measuring VBG N
tumor NN o
hypoxia NN o
in IN N
patients NNS p
with IN p
head-and-neck JJ p
squamous JJ p
cell NN p
carcinomas NN p
. . p

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
overall JJ o
response NN o
rate NN o
[ NNP o
complete JJ o
clinical JJ o
response NN o
( ( o
CCR NNP o
) ) o
plus CC o
partial JJ o
response NN o
( ( o
PR NNP o
) ) o
] NN o
. . o

Mean NNP o
arterial JJ o
pressure NN o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
induction NN N
, , N
immediately RB N
after IN N
intubation NN N
and CC N
every DT N
minute NN N
for IN N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

The DT N
mean JJ o
volumes NNS o
of IN o
contrast NN o
agent NN o
used VBN o
and CC o
prehydration NN o
given VBN N
for IN N
each DT N
of IN N
the DT N
three CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.83 CD N
) ) N
. . N

Because IN N
DHA NNP i
is VBZ N
a DT N
highly RB N
unsaturated JJ N
fatty JJ N
acid NN N
, , N
it PRP N
could MD N
serve VB N
as IN N
a DT N
target NN N
for IN N
free-radical JJ N
induced JJ N
oxidation NN N
, , N
resulting VBG N
in IN N
increased VBN N
oxidative JJ o
stress NN o
. . o

Erythrocyte NNP o
deformability NN o
, , o
endothelin NN o
levels NNS o
, , o
and CC o
renal JJ o
function NN o
in IN N
cyclosporin-treated JJ p
renal JJ p
transplant NN p
recipients NNS p
: : p
effects NNS N
of IN N
intervention NN i
with IN i
fish JJ i
oil NN i
and CC i
corn NN i
oil NN i
. . i

There EX N
was VBD N
no DT N
difference NN N
in IN N
microcystic JJ o
or CC o
tarsal JJ o
conjunctiva JJ o
response NN o
, , o
lens VBZ o
comfort NN o
, , o
refractive JJ o
change NN o
, , o
or CC o
visual JJ o
acuity NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
L-arginine NNP i
and CC N
citrulline NN N
to TO N
patients NNS N
with IN N
HFpEF NNP o
improved VBD o
right JJ o
ventricular NN o
function NN o
by IN o
increasing VBG o
right JJ o
ventricular NN o
ejection NN o
fraction NN o
, , N
and CC N
probably RB N
decreasing VBG N
systolic JJ o
pulmonary JJ o
artery NN o
pressure NN o
. . o

Safety NN o
, , o
pharmacokinetics NNS o
and CC o
pharmocodynamics NNS o
of IN N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
in IN N
healthy JJ p
subjects NNS p
and CC p
asymptomatic JJ p
carriers NNS p
of IN p
the DT p
acute JJ p
intermittent NN p
porphyria NNS p
gene NN p
who WP p
have VBP p
increased VBN p
porphyrin NN p
precursor NN p
excretion NN p
. . p

RESULTS NNP N
PROP NNP o
taste NN o
phenotype NN o
and CC o
taste NN o
receptor NN o
genotype NN o
were VBD o
not RB o
associated VBN o
with IN o
NRT NNP o
usage NN o
or CC o
sensory JJ o
response NN o
to TO o
NRT NNP o
, , N
after IN N
adjusting VBG N
for IN N
other JJ N
factors NNS N
. . N

Nasal NNP i
versus NN i
oronasal RB i
continuous JJ i
positive JJ i
airway NN i
pressure NN i
masks NNS i
for IN N
obstructive JJ p
sleep JJ p
apnea NN p
: : p
a DT N
pilot NN N
investigation NN N
of IN N
pressure NN N
requirement NN N
, , N
residual JJ N
disease NN N
, , N
and CC N
leak NN N
. . N

Because IN N
these DT N
cells NNS N
may MD N
survive VB N
in IN N
transplant JJ N
recipients NNS N
for IN N
a DT N
long JJ N
time NN N
, , N
recipients NNS N
of IN N
blood NN N
stem NN N
cells NNS N
may MD N
be VB N
less JJR N
immunocompromised JJ N
than IN N
recipients NNS N
of IN N
marrow NN N
. . N

RESULTS NNP N
In IN N
response NN N
to TO N
insulin VB N
compared VBN N
with IN N
placebo NN i
, , N
we PRP N
found VBD N
a DT N
significant JJ N
CBF NNP o
decrease NN o
in IN N
the DT N
hypothalamus NN N
in IN N
both DT N
lean JJ N
and CC N
overweight/obese JJ N
participants NNS N
. . N

RESULTS VB N
The DT N
level NN o
of IN o
ACTH NNP o
and CC o
CORT NNP o
in IN o
plasma NN o
decreased VBN o
and CC o
lymphocyte JJ o
proliferative JJ o
reaction NN o
reduced VBN N
in IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
Across NNP N
studies NNS N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS N
receiving VBG N
LAIV NNP N
had VBD N
a DT N
? . N
2-fold JJ N
increase NN N
in IN N
strain-specific JJ o
IgA NNP o
ratio NN o
compared VBN N
with IN N
placebo NN i
recipients NNS N
. . N

Neither DT N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN o
of IN o
urinary JJ o
leakage NN o
. . o

Similar JJ N
challenge NN N
vehicle NN N
recipes NNS N
were VBD N
used VBN N
, , N
the DT N
only JJ N
difference NN N
being VBG N
the DT N
lower JJR o
fat JJ o
content NN o
( ( N
22.9 CD N
% NN N
compared VBN N
with IN N
31.5 CD N
% NN N
) ) N
. . N

Postoperative JJ o
respiratory NN o
mechanics NNS o
, , N
however RB N
, , N
were VBD N
not RB N
significantly RB N
improved VBN N
and CC N
delayed VBN o
respiratory NN o
depression NN o
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
. . N

Primary JJ N
endpoints NNS N
are VBP N
modelled VBN o
cardiovascular JJ o
risk NN o
at IN o
one CD o
year NN o
, , o
and CC o
cardiovascular JJ o
mortality NN o
and CC o
morbidity NN o
at IN N
five CD N
years NNS N
after IN N
diagnosis NN N
of IN N
diabetes NNS N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN N
muscarinic JJ N
transmission NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
maternal JJ o
vital JJ o
parameters NNS o
, , o
fetal JJ o
heart NN o
rate NN o
( ( o
FHR NNP o
) ) o
or CC o
Apgar NNP o
scores NNS o
between IN N
the DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Delivery NNP o
success NN o
rate NN o
, , o
maternal JJ o
perineal NN o
and CC o
vaginal JJ o
injuries NNS o
, , o
maternal JJ o
anaesthetic JJ o
requirements NNS o
, , o
neonatal JJ o
scalp NN o
and CC o
facial JJ o
injuries NNS o
. . o

Physiological JJ N
responses NNS N
, , N
such JJ N
as IN N
water NN N
turnover NN N
, , N
surface NN N
temperature NN N
, , N
and CC N
rectal JJ N
temperature NN N
, , N
as RB N
well RB N
as IN N
drinking VBG o
behavior NN o
of IN o
sheep NN o
were VBD N
also RB N
evaluated VBN N
. . N

CONCLUSIONS NNP N
The DT N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NNP i
laser NN i
system NN i
is VBZ N
effective JJ N
for IN N
preparation NN N
of IN N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
and CC N
resin NN N
restorations NNS N
are VBP N
retained VBN N
by IN N
lased JJ N
tooth NN N
surfaces NNS N
. . N

Functional JJ N
studies NNS N
between IN N
the DT N
cross-over NN N
periods NNS N
showed VBD N
flow-rate JJ N
values NNS N
close RB N
to TO N
normal JJ N
, , N
with IN N
an DT N
increase NN N
in IN N
residual JJ o
volume NN o
and CC o
functional JJ o
residual JJ o
capacity NN o
. . o

INTERPRETATION NNP N
AND CC N
CONCLUSIONS NNP N
Both NNP N
schemes NNS N
of IN N
chemotherapy NN N
followed VBN N
by IN N
radiotherapy NN N
produce VBP N
high JJ N
percentages NNS N
of IN N
CR NNP o
, , o
low JJ o
risk NN o
of IN o
relapse NN o
and CC o
an DT o
acceptable JJ o
toxicity NN o
. . o

BACKGROUND NNP N
2-Chloroprocaine JJ i
( ( i
2-CP JJ i
) ) i
used VBN N
for IN N
lumbar JJ N
epidural JJ N
anesthesia NN N
( ( N
LEA NNP N
) ) N
reportedly RB N
decreases VBZ N
the DT N
efficacy NN N
of IN N
epidural JJ i
morphine NN i
( ( i
EM NNP i
) ) i
administered VBD N
for IN N
post-cesarean JJ N
section NN N
( ( N
CS NNP N
) ) N
analgesia NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
no DT N
difference NN N
in IN N
the DT N
total JJ o
time NN o
for IN N
catheter NN N
placement NN N
, , N
because IN N
puncture NN N
was VBD N
performed VBN N
faster RB N
when WRB N
aided VBN N
by IN N
sonography NN N
. . N

Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN o
in IN o
height JJ o
standard NN o
deviation NN o
score VBD o
H-SDSCA NNP o
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
. . N

Increased VBN o
fibrinolytic JJ o
capacity NN o
was VBD N
indicated VBN N
by IN N
elevated JJ N
activity NN N
and CC N
reduced JJ N
antigen NN o
levels NNS o
of IN o
tissue NN o
plasminogen NN o
activator NN o
and CC o
reduced JJ o
activity NN o
and CC o
concentration NN o
of IN o
tissue NN o
plasminogen NN o
activator NN o
inhibitor NN o
. . o

Effects NNS N
of IN N
reducing VBG N
dietary JJ i
[ NN i
( ( i
Na+ NNP i
+ NNP i
K+ NNP i
) ) i
- : i
( ( i
Cl- JJ i
+ NNP i
SO4= NNP i
) ) i
] NN i
on IN N
the DT N
rate NN N
of IN N
calcium NN i
mobilisation NN i
by IN N
dairy NN p
cows NNS p
at IN p
parturition NN p
. . p

Both DT N
group NN N
A NNP N
and CC N
group NN N
GA NNP N
demonstrated VBD N
a DT N
preservation NN o
of IN o
circulating VBG o
AT-III NNP o
when WRB N
compared VBN N
to TO N
group NN N
C NNP N
; : N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
GA NNP N
. . N

Evaluations NNS N
included VBD N
Clinician NNP o
's POS o
Erythema NNP o
Assessment NNP o
( ( o
CEA NNP o
) ) o
, , o
Patient NNP o
's POS o
Self-Assessment JJ o
( ( o
PSA NNP o
) ) o
, , o
Chroma NNP o
Meter NNP o
measurements NNS o
and CC o
adverse JJ o
events NNS o
. . o

However RB N
, , N
DAS28 NNP o
remission NN o
rates NNS o
were VBD N
higher JJR N
( ( N
even RB N
when WRB N
using VBG N
the DT N
lower JJR N
cut NN N
point NN N
) ) N
than IN N
the DT N
SDAI NNP o
and CC o
CDAI NNP o
remission NN o
rates NNS o
. . o

The DT N
rate NN o
of IN o
surgical JJ o
reattachment NN o
of IN o
the DT o
retina NN o
was VBD N
found VBN N
to TO N
be VB N
similar JJ N
with IN N
either DT N
technique NN N
over IN N
a DT N
minimum JJ N
follow-up JJ N
period NN N
of IN N
one CD N
year NN N
. . N

CONCLUSIONS NNP N
Prophylactic NNP i
cranial JJ i
irradiation NN i
given VBN N
to TO N
patients NNS N
with IN N
small-cell JJ N
lung NN N
cancer NN N
in IN N
complete JJ N
remission NN N
decreases VBZ N
the DT N
risk NN N
of IN N
brain NN N
metastasis NN N
threefold VBD N
without IN N
a DT N
significant JJ N
increase NN N
in IN N
complications NNS o
. . o

On IN N
the DT N
ATEC NNP o
, , o
sensory/cognitive JJ o
awareness NN o
significantly RB N
improved VBN N
( ( N
p JJ N
= NNP N
0.0367 CD N
) ) N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Indomethacin NNP i
did VBD N
not RB N
reduce VB N
the DT N
frequency NN o
of IN o
dose JJ o
reductions NNS o
for IN o
toxic JJ o
side-effects NNS o
and CC N
did VBD N
not RB N
permit VB N
the DT N
administration NN N
of IN N
higher JJR N
interferon NN N
doses NNS N
. . N

Immunogenicity NN o
was VBD N
measured VBN N
by IN N
specific JJ o
IgG NNP o
( ( o
Mite NNP o
) ) o
and CC o
IgG4 NNP o
( ( o
Mite NNP o
) ) o
, , N
by IN N
antibody-blocking JJ N
properties NNS N
on IN N
basophil NN N
activation NN N
, , N
and CC N
by IN N
the DT N
T NNP N
cell NN N
subset NN N
transcription NN N
factors NNS N
Foxp3 NNP N
, , N
T-bet NNP N
, , N
and CC N
GATA-3 NNP N
. . N

DISCUSSION NNP N
Greater NNP N
vital JJ N
bone NN N
fill NN N
in IN N
the DT N
PUT NNP N
group NN N
may MD N
be VB N
attributable JJ N
to TO N
earlier RBR N
and CC N
greater JJR N
vascular JJ N
invasion NN N
of IN N
the DT N
carrier NN N
material NN N
. . N

Some DT N
case NN N
reports NNS N
mention NN N
that IN N
Spironolactone NNP i
, , N
a DT N
mineral JJ i
corticoid NN i
antagonist NN i
and CC i
aldosterone NN i
antagonist NN i
, , N
reduces NNS N
binging VBG o
in IN N
patients NNS p
with IN p
bulimia JJ p
nervosa NN p
. . p

The DT N
mean JJ o
satisfaction NN o
grading NN o
was VBD N
9.2 CD N
on IN N
a DT N
visual JJ o
analogue NN o
scale NN o
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
8.1 CD N
in IN N
controls NNS N
( ( N
p=0.004 NN N
) ) N
. . N

Although IN N
the DT N
sedative JJ N
with IN N
IV NNP N
form NN N
might MD N
appear VB N
sooner NN N
, , N
IM NNP N
form NN N
of IN N
midazolam NN i
can MD N
be VB N
effectively RB N
used VBN N
in IN N
patient NN N
with IN N
limited JJ N
IV NNP N
access NN N
. . N

CONCLUSIONS NNP i
Unrecognized NNP i
overnight VBD i
hypoglycaemia NN i
in IN N
children NNS p
and CC p
adolescents NNS p
on IN p
pituitary JJ p
hormone NN p
replacement NN p
is VBZ N
uncommon JJ N
but CC N
BG NNP N
levels NNS N
quickly RB N
become VBP N
abnormal JJ N
when WRB N
treatment NN N
and CC N
meals NNS N
are VBP N
omitted VBN N
. . N

Although IN N
biopsy JJ N
fragmentation NN N
was VBD N
commoner NN N
with IN N
the DT N
suction NN N
needle NN N
, , N
the DT N
length NN N
and CC N
volume NN N
of IN N
the DT N
largest JJS N
core NN N
obtained VBN N
was VBD N
similar JJ N
to TO N
results NNS N
with IN N
the DT N
sheathed JJ N
needle NN N
. . N

OUTCOMES NNP N
MEASURED NNP N
Primary NNP N
study NN N
outcomes NNS N
were VBD N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
. . o

There EX N
were VBD N
no DT N
instances NNS N
of IN N
tissue NN o
orientation NN o
loss NN o
in IN N
the DT N
scalpel NN N
or CC N
marker NN N
arms NNS N
, , N
nor CC N
were VBD N
there EX N
any DT N
visible JJ o
score NN o
mark NN o
scars NNS o
at IN N
follow-up NN N
. . N

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
In IN N
the DT N
placebo NN i
condition NN N
, , N
sleep JJ o
inertia NN o
was VBD N
manifested VBN N
as IN N
significantly RB N
impaired JJ N
psychomotor NN o
vigilance NN o
upon IN N
awakening VBG N
from IN N
the DT N
naps NNS N
. . N

Statistically RB N
significant JJ N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
were VBD N
not RB N
considered VBN N
clinically RB N
significant JJ N
. . N

The DT N
PRL NNP o
response NN o
to TO o
TRH NNP o
was VBD N
lower JJR N
in IN N
both DT N
group NN N
I PRP N
and CC N
group NN p
II NNP p
obese VBZ p
men NNS p
than IN p
in IN p
normal JJ p
controls NNS p
and CC p
was VBD p
similar JJ p
between IN p
group NN p
I PRP p
and CC p
group NN p
II NNP p
. . p

CONCLUSIONS NNP N
Postprandial NNP o
glucose NN o
, , o
insulin NN o
and CC o
triglyceride JJ o
concentrations NNS o
are VBP N
influenced VBN N
by IN N
dietary JJ N
fibre-rich JJ N
meals NNS N
, , N
depending VBG N
on IN N
fibre NN N
source NN N
, , N
dose NN N
of IN N
soluble JJ N
and CC N
total JJ N
fibre NN N
and CC N
possibly RB N
gender NN N
. . N

Energy NNP o
intake NN o
and CC o
amount NN o
of IN o
carbohydrate NN o
ingested VBN o
by IN N
both DT N
groups NNS N
diminished VBD N
over IN N
the DT N
trial NN N
, , N
whereas IN N
the DT N
consumption NN o
of IN o
protein NN o
and CC o
fibre NN o
increased VBD o
and CC o
lipid JJ o
ingestion NN o
remained VBD N
unchanged JJ N
. . N

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
ATRA NNP N
reduced VBD N
relapse NN N
in IN N
patients NNS N
with IN N
lower JJR N
MN1 NNP N
levels NNS N
, , N
but CC N
no DT N
significant JJ N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

Split-course JJ i
therapy NN i
resulted VBD N
in IN N
a DT N
significantly RB N
better JJR N
survival NN o
rate NN o
in IN N
cases NNS N
of IN N
large JJ N
cell NN N
carcinoma NN N
but CC N
the DT N
number NN N
of IN N
cases NNS N
was VBD N
small JJ N
. . N

We PRP N
conclude VBP N
that DT N
desmopressin NN i
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN o
loss NN o
or CC o
blood NN o
product NN o
requirements NNS o
in IN N
patients NNS p
with IN p
excessive JJ p
immediate JJ p
postoperative JJ p
bleeding NN p
. . p

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
antishivering VBG N
effect NN N
of IN N
clonidine NN i
results NNS N
from IN N
central JJ N
thermoregulatory JJ N
inhibition NN N
rather RB N
than IN N
a DT N
specific JJ N
peripheral JJ N
action NN N
on IN N
thermogenic JJ N
muscular JJ N
activity NN N
. . N

CONCLUSION NNP N
Sequential NNP N
erlotinib NN i
and CC i
docetaxel NN i
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
docetaxel RB i
alone JJ i
as IN N
second-line JJ N
treatment NN N
for IN N
advanced JJ N
NSCLC NNP N
with IN N
wild-type JJ N
or CC N
unknown JJ N
EGFR NNP N
status NN N
. . N

Control NNP N
and CC N
experimental JJ N
tests NNS N
were VBD N
also RB N
performed VBN N
in IN N
seven CD p
male JJ p
patients NNS p
with IN p
subclinical JJ p
hypothyroidism NN p
and CC p
were VBD p
repeated VBN p
in IN p
the DT p
same JJ p
obese JJ p
subjects NNS p
after IN p
substantial JJ p
weight JJ p
loss NN p
. . p

Reduction NN N
in IN N
sympathetic JJ o
tone NN o
by IN N
CLO NNP i
resulted VBD N
in IN N
a DT N
decreased JJ N
tolerance NN N
to TO N
tilt VB N
in IN N
three CD N
out IN N
of IN N
eight CD N
controls NNS N
and CC N
in IN N
all PDT N
the DT N
NMS NNP N
patients NNS N
. . N

When WRB N
administered VBN N
intravenously RB N
, , N
antazoline JJ i
exerts VBZ N
a DT N
strong JJ N
antiarrhythmic JJ N
effect NN N
on IN N
supraventricular JJ o
arrhythmia NN o
, , N
especially RB N
on IN N
AF NNP N
, , N
facilitating VBG N
rapid JJ N
conversion NN N
to TO N
sinus VB N
rhythm NN N
. . N

Atenolol NNP i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

ATP NNP i
infusion NN N
has VBZ N
been VBN N
found VBN N
to TO N
significantly RB N
inhibit VB N
loss NN N
of IN N
body NN N
weight NN N
, , N
fat JJ N
mass NN N
and CC N
fat-free JJ N
mass NN N
in IN N
patients NNS p
with IN p
advanced JJ p
lung NN p
cancer NN p
. . p

However RB N
, , N
the DT N
change NN N
in IN N
cortisol JJ o
level NN o
was VBD N
uncorrelated VBN N
with IN N
the DT N
change NN N
in IN N
report NN N
of IN N
acute JJ N
stress NN N
; : N
females NNS N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ibuprofen NN i
on IN N
gastric JJ N
mucosa NN N
and CC N
enzymes NNS N
involved VBN N
in IN N
gastroprotection NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

Besides IN N
, , N
adverse JJ o
reactions NNS o
occurred VBD N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP N
has VBZ N
similar JJ N
clinical JJ o
safety NN o
and CC o
efficacy NN o
compared VBN N
with IN N
PES NNP i
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

Rye NNP i
bran NN i
bread NN i
intake VB N
elevates NNS N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NN o
in IN N
humans NNS N
, , N
but CC N
does VBZ N
not RB N
affect VB N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
oxidation VB N
ex FW N
vivo FW N
. . N

CONCLUSIONS NNP N
Amiprilose NNP N
HCl NNP N
has VBZ N
significant JJ N
anti-inflammatory JJ N
activity NN N
and CC N
a DT N
favorable JJ N
safety NN N
profile NN N
when WRB N
used VBN N
as IN N
the DT N
sole JJ N
antirheumatic JJ N
therapy NN N
in IN N
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
. . p

We PRP N
previously RB N
demonstrated VBD N
that IN N
granulocyte-macrophage JJ o
colony-stimulating JJ o
factor NN o
( ( o
GM-CSF NNP o
) ) o
production NN o
and CC o
mRNA JJ o
expression NN o
from IN o
stimulated VBN o
neonatal JJ o
mononuclear JJ o
cells NNS o
are VBP N
significantly RB N
less JJR N
than IN N
that DT N
from IN N
adult NN N
cells NNS N
. . N

PURPOSE NN N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN i
alone RB i
and CC N
with IN N
aspirin NN i
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS p
and CC p
saliva NN p
of IN p
healthy JJ p
individuals NNS p
. . p

Skillful NNP N
laser NN N
ablation NN N
can MD N
remove VB N
any DT N
volume NN N
of IN N
human JJ N
papillomavirus-associated JJ N
vulvar NN N
disease NN N
but CC N
can MD N
not RB N
prevent VB N
reactivation NN N
of IN N
the DT N
surrounding VBG N
latent JJ N
viral JJ N
reservoir NN N
during IN N
postoperative JJ N
healing NN N
. . N

BACKGROUND NNP N
Rapid NNP N
conversion NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
to TO N
sinus VB N
rhythm NN N
may MD N
be VB N
achieved VBN N
by IN N
the DT N
administration NN N
of IN N
class NN i
IA NNP i
, , i
IC NNP i
and CC i
III NNP i
antiarrhythmic JJ i
drugs NNS i
or CC i
vernakalant JJ i
hydrochloride NN i
. . i

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
intravenous JJ i
human JJ i
secretin NN i
is VBZ N
not RB N
effective JJ N
in IN N
changing VBG N
behaviour NN N
and CC N
communication NN N
in IN N
children NNS p
with IN p
ASD NNP p
when WRB N
compared VBN N
to TO N
placebo VB i
. . i

The DT N
degree NN o
of IN o
ventilatory NN o
limitation NN o
, , N
as IN N
expressed VBN N
by IN N
the DT N
Ve/maximum NNP o
voluntary JJ o
ventilation NN o
ratio NN o
, , N
was VBD N
similar JJ N
in IN N
both DT N
conditions NNS N
in IN N
patients NNS p
with IN p
COPD NNP p
. . p

The DT N
mean JJ o
serum NN o
potassium NN o
was VBD N
elevated VBN N
by IN N
0.3 CD N
mmol/l NNS N
after IN N
addition NN N
of IN N
enalapril NN i
to TO N
the DT N
diuretic JJ N
treatment NN N
, , N
but CC N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
hyperkalaemia NN N
. . N

CONCLUSIONS VB N
A NNP N
dose NN N
of IN N
2,500 CD N
IU NNP N
enoxaparin/day NN N
does VBZ N
not RB N
cause VB N
more RBR N
bleeding JJ o
complications NNS o
than IN N
SH NNP i
5,000 CD N
IU NNP N
three CD N
times NNS N
daily RB N
when WRB N
used VBN N
to TO N
prevent VB N
thrombosis NN N
. . N

Loratadine NNP i
, , N
which WDT N
served VBD N
as IN N
a DT N
positive JJ N
control NN N
, , N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN i
for IN N
most JJS N
endpoints NNS N
, , N
validating VBG N
the DT N
study NN N
results NNS N
. . N

Propofol NNP i
decreased VBD N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
and CC o
systemic JJ o
vascular JJ o
resistance NN o
immediately RB N
after IN N
IoA NNP N
but CC N
did VBD N
not RB N
change VB o
heart NN o
rate NN o
, , o
cardiac JJ o
output NN o
, , o
or CC o
oxygen NN o
delivery NN o
. . o

We PRP N
have VBP N
monitored VBN N
the DT N
effect NN N
of IN N
cyclosporin NN i
administered VBN N
during IN N
a DT N
planned JJ N
programme NN N
of IN N
third-party JJ N
blood NN N
transfusions NNS N
on IN N
the DT N
development NN N
of IN N
both DT N
cytotoxic JJ o
and CC o
anti-idiotypic JJ o
antibodies NNS o
. . o

PURPOSE NN N
To TO N
evaluate VB N
the DT N
additional JJ N
therapeutic JJ N
effect NN N
of IN N
single JJ i
intravitreal NN i
bevacizumab NN i
injection NN N
on IN N
standard JJ i
laser NN i
treatment NN i
in IN N
the DT N
management NN N
of IN N
proliferative JJ p
diabetic JJ p
retinopathy NN p
. . p

Clomiphene NNP i
citrate NN i
induction NN N
resulted VBD N
in IN N
higher JJR N
ovulation NN o
rates NNS o
and CC o
thicker NN o
endometrium NN o
in IN N
the DT N
metformin NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Some DT N
side-effects NNS N
, , N
such JJ N
as IN N
posttransplant JJ o
diabetes NNS o
mellitus NNS o
and CC N
probably RB N
some DT N
lipid JJ o
abnormalities NNS o
, , N
could MD N
rather RB N
be VB N
traced VBN N
to TO N
a DT N
higher JJR N
dose NN N
of IN N
steroids NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
No NNP N
medical JJ N
treatment NN N
is VBZ N
available JJ N
for IN N
polycystic JJ N
liver NN N
disease NN N
, , N
a DT N
frequent JJ N
manifestation NN N
of IN N
autosomal-dominant JJ p
polycystic JJ p
kidney NN p
disease NN p
( ( p
ADPKD NNP p
) ) p
. . p

Thus RB N
, , N
endurance JJ o
physical JJ o
activity NN o
improves VBZ N
the DT N
fibrinolytic JJ N
risk NN N
factor NN N
profile NN N
by IN N
reducing VBG N
PAI-1 NNP N
while IN N
leaving VBG N
tPA JJ N
activity NN N
unaffected VBD N
, , N
independently RB N
of IN N
food NN N
composition NN N
. . N

The DT N
study NN N
showed VBD N
a DT N
relatively RB N
small JJ o
weight NN o
gain NN o
an DT N
average NN N
of IN N
0.9 CD N
kg NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.3 CD N
kg NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Intra-luminal NNP N
nicotine NN N
significantly RB N
reduces VBZ N
both DT N
smooth JJ o
muscle NN o
tone NN o
and CC o
contractile NN o
activity NN o
in IN N
the DT N
recto-sigmoid JJ N
colon NN N
in IN N
both DT N
normal JJ p
subjects NNS p
and CC p
patients NNS p
with IN p
UC NNP p
. . p

CONCLUSIONS NNP N
No NNP N
clear JJ N
benefit NN N
in IN N
terms NNS N
of IN N
response NN o
rates NNS o
, , o
median JJ o
TTP NNP o
or CC o
OS NNP o
was VBD N
shown VBN N
with IN N
the DT N
combination NN N
of IN N
TMZ NNP i
+ NNP i
CDDP NNP i
. . i

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
SH NNP i
can MD N
alter VB N
autonomic JJ o
modulation NN o
of IN o
heart NN o
rate NN o
and CC N
cause NN N
increased VBD N
inhomogeneity NN N
of IN N
ventricular JJ N
recovery NN N
times NNS N
. . N

We PRP N
conclude VBP N
that DT N
Interceed NNP N
( ( N
TC7 NNP N
) ) N
effectively RB N
reduced VBD N
the DT N
incidence NN o
and CC o
extent NN o
of IN o
postoperative JJ o
adhesions NNS o
, , N
even RB N
in IN N
patients NNS p
with IN p
severe JJ p
endometriosis NN p
. . p

CONCLUSION NNP N
FNB NNP i
with IN i
0.5 CD i
% NN i
bupivacaine NN i
provided VBN N
longer JJR N
time NN N
to TO N
first JJ N
analgesic JJ N
and CC N
lower RBR N
narcotic JJ N
requirements NNS N
after IN N
patellar JJ N
tendon NN N
graft NN N
ACL NNP N
reconstruction NN N
when WRB N
compared VBN N
to TO N
0.25 CD N
% NN N
bupivacaine NN i
. . i

DEBR NNP i
alone RB N
showed VBD N
reductions NNS N
in IN N
tooth DT o
mobility NN o
and CC o
PPD NNP o
and CC N
a DT N
significantly RB N
smaller JJR N
gain NN N
in IN N
CPAL NNP N
than IN N
in IN N
presplint NN N
teeth NNS N
treated VBN N
with IN N
BRG NNP N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
changes NNS N
in IN N
VE NNP N
were VBD N
accompanied VBN N
by IN N
decreases NNS N
in IN N
mean NN o
and CC o
peak JJ o
inspiratory NN o
and CC o
expiratory NN o
flow NN o
rates NNS o
. . o

CONCLUSIONS NNP N
This DT N
study NN N
demonstrated VBD N
that IN N
this DT N
remifentanil JJ N
regimen NNS N
provided VBD N
significantly RB N
more RBR N
rapid JJ o
recovery NN o
and CC N
used VBD N
significantly RB N
less JJR N
propofol JJ i
compared VBN N
with IN N
the DT N
fentanyl JJ N
regimen NNS N
. . N

Effects NNS N
of IN N
supplementation NN N
of IN N
whole JJ N
corn NN N
germ NN N
on IN N
reproductive JJ o
performance NN o
, , o
calf JJ o
performance NN o
, , o
and CC o
leptin JJS o
concentration NN o
in IN N
primiparous JJ p
and CC p
mature JJ p
beef NN p
cows NNS p
. . p

CONCLUSIONS NNP o
Weight NNP o
gain NN o
was VBD N
more RBR N
pronounced JJ N
in IN N
AN NNP N
subjects NNS N
and CC N
more RBR N
likely JJ N
to TO N
occur VB N
in IN N
younger JJR N
subjects NNS N
with IN N
a DT N
higher JJR N
baseline NN N
weight VBD o
z-score NN o
. . o

METHODS NNP N
Seventy-six JJ p
patients NNS p
with IN p
esophageal JJ p
gastric JJ p
carcinoma NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
FZYLG NNP i
group NN i
and CC i
the DT i
control NN i
group NN i
. . i

We PRP N
conclude VBP N
that DT N
fenretinide NN N
showed VBD N
a DT N
lack NN N
of IN N
effect NN N
on IN N
the DT N
DNA NNP o
content NN o
distribution NN o
and CC o
the DT o
morphology NN o
of IN o
urothelial JJ o
cells NNS o
obtained VBN N
in IN N
serial JJ N
bladder NN N
washings NNS N
. . N

The DT N
effects NNS N
on IN N
platelet NN o
and CC o
endothelial JJ o
function NN o
, , N
either RB N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
or CC N
angiotensin NN N
receptor NN N
antagonists NNS N
, , N
are VBP N
still RB N
not RB N
well RB N
understood RB N
. . N

Ventilation NNP o
( ( o
Ve NNP o
) ) o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
blood NN o
pressure NN o
, , o
and CC o
muscle NN o
sympathetic JJ o
nervous JJ o
activity NN o
( ( o
MSNA NNP o
) ) o
data NNS o
were VBD N
continuously RB N
obtained VBN N
. . N

Long-term JJ N
use NN N
of IN N
Viozan NNP i
( ( i
sibenadet JJ i
HCl NNP i
) ) i
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
results NNS N
of IN N
a DT N
1-year JJ N
study NN N
. . N

Recombinant JJ i
human JJ i
TSH NNP i
has VBZ N
been VBN N
developed VBN N
to TO N
facilitate VB N
monitoring NN N
for IN N
thyroid JJ N
carcinoma NN N
recurrence NN N
or CC N
persistence NN N
without IN N
the DT N
attendant JJ N
morbidity NN N
of IN N
hypothyroidism NN N
seen VBN N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
. . N

This DT N
beneficial JJ N
effect NN N
of IN N
HBO NNP N
involves VBZ N
inhibition NN N
of IN N
inducible JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
iNOS NN N
) ) N
expression NN N
and CC N
subsequent JJ N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
biosynthesis NN N
. . N

The DT N
immunological JJ N
trends NNS N
observed VBN N
in IN N
vitro JJ N
support NN N
an DT N
important JJ N
role NN N
for IN N
histamine NN N
in IN N
the DT N
induction NN N
of IN N
immunosuppression NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
response NN N
to TO N
the DT N
mitogen NN N
phytohemagglutinin NN N
. . N

Serum NNP o
concentrations NNS o
of IN o
hemoglobin NN o
levels NNS o
, , o
follicle-stimulating JJ o
hormone NN o
, , o
and CC o
liver RB o
enzymes NNS o
were VBD N
obtained VBN N
, , N
and CC N
endometrial JJ N
samples NNS N
, , N
symptoms NNS N
, , N
and CC N
menstrual JJ N
bleeding NN N
were VBD N
also RB N
assessed VBN N
. . N

NFV NNP o
pharmacokinetic JJ o
measurements NNS o
were VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
treatment NN N
groups NNS N
, , N
yet RB N
exposure NN N
to TO N
the DT N
NFV NNP N
metabolite NN N
, , N
M8 NNP N
, , N
was VBD N
significantly RB N
higher JJR N
in IN N
subjects NNS N
receiving VBG N
RTV NNP i
. . i

Intravitreal NNP i
bevacizumab NN i
injection NN N
was VBD N
well RB N
tolerated VBN N
and CC N
could MD N
be VB N
used VBN N
as IN N
primary JJ N
treatment NN N
in IN N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
perfused VBN N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

BACKGROUND NNP N
Mirror NNP N
therapy NN N
( ( N
MT NNP N
) ) N
and CC N
mesh JJ N
glove NN N
( ( N
MG NNP N
) ) N
afferent NN N
stimulation NN N
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN o
impairment NN o
after IN N
stroke NN N
. . N

Yet RB N
, , N
the DT N
effects NNS N
of IN N
MECC NNP N
on IN N
the DT N
intraoperative JJ N
microvascular JJ N
perfusion NN N
in IN N
comparison NN N
with IN N
conventional JJ i
extracorporeal JJ i
circulation NN i
( ( i
CECC NNP i
) ) i
have VBP N
not RB N
been VBN N
studied VBN N
so RB N
far RB N
. . N

In IN N
a DT N
prespecified JJ N
analysis NN N
of IN N
the DT N
LIFE-study NNP N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
losartan NN i
and CC i
atenolol NN i
on IN N
cardiovascular JJ o
morbidity NN o
and CC o
mortality NN o
in IN N
diabetic JJ p
patients NNS p
. . p

Group NNP N
I PRP N
initially RB N
received VBD N
professional JJ i
mechanical JJ i
tooth-cleaning NN i
, , i
tongue-scraping NN i
, , i
chlorhexidine NN i
treatment NN i
, , i
and CC i
oral JJ i
hygiene NN i
instructions NNS i
concentrated VBD i
on IN N
the DT N
approximal JJ N
surfaces NNS N
most RBS N
colonized VBN N
by IN N
S. NNP N
mutans NNS N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
blood NN N
samples NNS N
were VBD N
collected VBN N
and CC N
the DT N
flow-mediated JJ N
dilation NN N
( ( N
FMD NNP N
) ) N
and CC N
isosorbide JJ i
dinitrate NN i
( ( i
ISDN NNP i
) ) i
-mediated VBD N
dilation NN N
of IN N
the DT N
brachial JJ N
artery NN N
were VBD N
performed VBN N
. . N

[ JJ N
Effects NNS N
of IN N
shuxuening VBG i
injection NN i
on IN N
the DT N
levels NNS N
of IN N
serum NN N
matrix RBS N
metalloproteinase-9 JJ N
and CC N
tissue JJ N
inhibitor NN N
of IN N
metalloproteinase-1 NN N
in IN N
acute NN p
exacerbated VBD p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
patients NNS p
] VBP p
. . N

PURPOSE NN N
To TO N
evaluate VB N
the DT N
treatment NN N
outcomes RB N
after IN N
guided VBN i
tissue NN i
regeneration NN i
( ( i
GTR NNP i
) ) i
with IN N
a DT N
bioabsorbable JJ i
membrane NN i
in IN N
Class NNP p
II NNP p
furcation NN p
defects NNS p
in IN p
mandibular JJ p
molars NNS p
. . p

Comparative NNP N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
eprinomectin JJ i
versus NN i
ivermectin NN i
, , N
and CC N
field NN N
efficacy NN N
of IN N
eprinomectin NN i
only RB N
, , N
for IN N
the DT N
treatment NN N
of IN N
chorioptic JJ p
mange NN p
in IN p
alpacas NN p
. . p

CONCLUSIONS NNP N
Both NNP N
IBMC NNP i
and CC i
PMMC NNP i
are VBP N
successful JJ N
means NNS N
of IN N
providing VBG N
relief NN N
from IN N
severe JJ N
mitral JJ N
stenosis NN N
with IN N
a DT N
gain NN N
in IN N
valve JJ N
area NN N
and CC N
reduction NN N
in IN N
transmitral JJ N
gradient NN N
. . N

Although IN N
amantadine NN N
has VBZ N
several JJ N
mechanisms NNS N
of IN N
action NN N
, , N
the DT N
NMDA-receptor NNP N
antagonism NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
relevant JJ N
effect NN N
on IN N
cortical JJ N
excitability NN N
. . N

This DT N
might MD N
result VB N
from IN N
potentiation NN N
of IN N
arterial JJ N
baroreflexes NNS N
, , N
but CC N
whether IN N
or CC N
not RB N
PUFA NNP i
enhance NN N
baroreflex NN N
function NN N
has VBZ N
never RB N
been VBN N
studied VBN N
in IN N
humans NNS p
. . p

BACKGROUND NNP N
Femoral NNP i
nerve NN i
block NN i
( ( i
FNB NNP i
) ) i
with IN N
varying VBG N
concentrations NNS N
of IN N
bupivacaine NN i
is VBZ N
often RB N
used VBN N
for IN N
postoperative JJ p
analgesia NN p
after IN p
anterior JJ p
cruciate NN p
ligament NN p
( ( p
ACL NNP p
) ) p
reconstruction NN p
. . p

CONCLUSIONS NNP N
Gemcitabine NNP i
plus CC i
erlotinib NN i
is VBZ N
more RBR N
effective JJ N
than IN N
gemcitabine VB i
alone JJ i
for IN N
treating VBG N
metastatic JJ p
pancreatic JJ p
cancer NN p
patients NNS p
, , p
especially RB p
those DT p
with IN p
EGFR NNP p
mutations NNS p
. . p

The DT N
numbers NNS o
of IN o
supplemental JJ o
injections NNS o
required VBN N
at IN N
each DT N
observation NN N
period NN N
and CC N
the DT N
total JJ N
volume NN N
of IN N
injectate NN N
required VBN N
to TO N
produce VB N
ocular JJ N
and CC N
lid JJ N
akinesia NN N
were VBD N
compared VBN N
. . N

MEASUREMENTS NNP N
Main NNP N
outcomes NNS N
were VBD N
12-month JJ N
changes NNS N
from IN N
baseline NN N
in IN N
bone NN o
formation NN o
and CC o
resorption NN o
markers NNS o
and CC o
bone NN o
mass NN o
measured VBD N
according VBG N
to TO N
quantitative JJ N
ultrasound JJ N
scanning NN N
. . N

There EX N
was VBD N
a DT N
poor JJ N
correlation NN N
between IN N
microscopy NN N
and CC N
culture NN N
of IN N
the DT N
bile NN N
for IN N
bacteria NNS N
and CC N
there EX N
was VBD N
no DT N
increase NN N
in IN N
sepsis NN N
when WRB N
bacteria NNS N
were VBD N
observed VBN N
on IN N
microscopy NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
impaired JJ N
metabolism NN N
of IN N
BK NNP N
induced VBN N
by IN N
ACE NNP N
inhibitors NNS N
may MD N
relate VB N
to TO N
the DT N
manifestation NN N
of IN N
cough NN N
in IN N
hypertensive JJ p
patients NNS p
receiving VBG p
ACE NNP p
inhibitors NNS p
. . p

The DT N
inhibitors NNS N
of IN N
cAMP-dependent JJ N
protein NN N
kinase NN N
( ( N
PKA NNP N
) ) N
and CC N
AMP-activated JJ N
protein NN N
kinase NN N
( ( N
AMPK NNP N
) ) N
blocked VBD N
acetate-induced JJ N
eNOS JJ N
phosphorylation NN N
in IN N
the DT N
early JJ N
and CC N
the DT N
late JJ N
phase NN N
respectively RB N
. . N

Bone NNP o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
of IN o
lumbar NN o
spine NN o
( ( o
L1-L4 NNP o
) ) o
and CC o
proximal JJ o
femur NN o
were VBD N
determined VBN N
using VBG N
dual JJ N
X-ray JJ N
absorptiometry NN N
at IN N
baseline NN N
and CC N
after IN N
one CD N
year NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
of IN N
CS NNP i
as IN N
a DT N
function NN o
of IN o
HOA NNP o
increase NN o
for IN N
the DT N
Planoscan NNP N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
four CD N
cases NNS N
( ( N
12.9 CD N
% NN N
) ) N
the DT N
sentinel NN N
lymph NN N
node NN N
was VBD N
the DT N
only JJ N
site NN N
of IN N
metastasis NN N
, , N
all DT N
of IN N
them PRP N
being VBG N
detected VBN N
by IN N
association NN N
of IN N
hematoxylin NN N
and CC N
eosin NN N
and CC N
immunohistochemical JJ N
examination NN N
. . N

CONCLUSIONS VB N
A DT N
decreased JJ N
incidence NN N
of IN N
nephrotoxicity NN N
provides VBZ N
evidence NN N
of IN N
a DT N
real JJ N
clinical JJ N
benefit NN N
to TO N
patient VB N
management NN N
in IN N
patients NNS p
with IN p
hematologic JJ p
malignancies NNS p
. . p

Short-term JJ N
effects NNS N
of IN N
prednisolone NN i
and CC i
dexamethasone NN i
on IN N
circulating VBG N
concentrations NNS N
of IN N
leptin NN N
and CC N
sex NN N
hormone-binding JJ N
globulin NN N
in IN N
children NNS p
being VBG p
treated VBN p
for IN p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
. . p

Adverse JJ o
events NNS o
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
previously RB N
with IN N
sumatriptan NNS i
and CC N
were VBD N
mostly RB N
mild JJ N
to TO N
moderate VB N
in IN N
intensity NN N
, , N
short-lived JJ N
, , N
and CC N
resolved VBD N
spontaneously RB N
. . N

However RB N
, , N
ER NNP N
status NN N
had VBD N
no DT N
effect NN N
on IN N
overall JJ o
survival NN o
( ( N
30.0 CD N
months NNS N
for IN N
CAF NNP N
v FW N
29.3 CD N
months NNS N
for IN N
CAFTH NNP N
) ) N
. . N

The DT N
degree NN o
of IN o
protection NN o
by IN N
heparin NN N
against IN N
adenosine-induced JJ N
bronchoconstriction NN N
was VBD N
not RB N
correlated VBN N
with IN N
that DT N
against IN N
methacholine-induced JJ N
bronchoconstriction NN N
( ( N
r JJ N
= NN N
0.60 CD N
, , N
NS NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
We PRP N
recorded VBD N
the DT N
number NN o
of IN o
transfusions NNS o
, , o
the DT o
number NN o
of IN o
donor JJ o
exposures NNS o
, , o
and CC o
various JJ o
clinical JJ o
and CC o
physiologic JJ o
outcomes NNS o
. . o

In IN N
experimental JJ N
studies NNS N
, , N
activation NN N
of IN N
the DT N
inflammatory JJ N
regulator NN N
, , N
nuclear JJ N
factor NN N
kappa NN N
B NNP N
( ( N
NFlB NNP N
) ) N
, , N
contributes VBZ N
to TO N
endothelial JJ N
activation NN N
and CC N
reduced JJ N
nitric JJ N
oxide NN N
production NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN i
and CC i
sodium NN i
ascorbate NN i
on IN N
resin-dentin JJ N
microtensile NN N
bond NN N
strength NN N
( ( N
? . N
) ) N
. . N

Amphotericin NNP i
B NNP N
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
: : p
a DT N
comparison NN N
of IN N
the DT N
toxicities NNS o
and CC o
pharmacokinetics NNS o
of IN N
amphotericin NN i
B NNP i
administered VBN i
in IN i
dextrose JJ i
versus NN i
lipid JJ i
emulsion NN i
. . i

In IN N
contrast NN N
, , N
YHO NNP i
not RB N
only RB N
increased VBD N
basal NN o
plasma NN o
NorEpi NNP o
levels NNS o
and CC o
MSNA NNP o
, , N
but CC N
also RB N
prevented VBD N
syncope NN N
in IN N
seven CD N
out IN N
of IN N
eight CD N
patients NNS N
. . N

Effects NNS N
of IN N
intravenous JJ i
iron NN i
combined VBN i
with IN i
low-dose JJ i
recombinant JJ i
human JJ i
erythropoietin NN i
on IN N
transfusion NN N
requirements NNS N
in IN N
iron-deficient JJ p
patients NNS p
undergoing VBG p
bilateral JJ p
total JJ p
knee NN p
replacement NN p
arthroplasty NN p
. . p

The DT N
study NN N
was VBD N
undertaken VBN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prednisone- NN N
and CC N
triple-treatment JJ N
upon IN N
bone JJ o
mineral NN o
content NN o
( ( o
BMC NNP o
) ) o
and CC o
vitamin $ o
D NNP o
metabolism NN o
. . o

Nine NNP N
cases NNS N
not RB N
excluded VBN N
by IN N
central JJ N
pathology NN N
review NN N
were VBD N
PML-RAR NNP N
alpha JJ N
negative JJ N
, , N
and CC N
notably RB N
, , N
none NN N
of IN N
five CD N
of IN N
these DT N
cases NNS N
treated VBD N
with IN N
ATRA NNP i
achieved VBD N
complete JJ o
remission NN o
( ( o
CR NNP o
) ) o
. . o

The DT N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
could MD N
provide VB N
a DT N
higher JJR N
degree NN N
of IN N
blockade NN N
of IN N
the DT N
renin-angiotensin NN N
system NN N
than IN N
either DT N
agent JJ N
alone RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
efficacy NN N
endpoints NNS N
were VBD N
intra-individual JJ o
differences NNS o
( ( o
test-reference NN o
) ) o
in IN o
mean JJ o
Hb NNP o
levels NNS o
and CC o
mean JJ o
weekly JJ o
dose/kg NN o
of IN o
body NN o
weight NN o
. . o

Fever NNP o
( ( o
> CD o
or CC o
=38.5 VB o
degrees NNS o
C NNP o
) ) o
and CC o
other JJ o
complications NNS o
( ( o
including VBG o
infections NNS o
) ) o
occurring VBG o
between IN o
admission NN o
and CC o
discharge NN o
( ( o
or CC o
death NN o
) ) o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Handgrip NNP o
and CC o
quadriceps JJ o
strength NN o
decreased VBD N
following VBG N
surgery NN N
, , N
but CC N
not RB N
to TO N
a DT N
significantly RB N
different JJ N
extent NN N
in IN N
the DT N
placebo NN N
and CC N
supplemented VBD N
groups NNS N
. . N

The DT N
difference NN N
in IN N
CR NNP o
rates NNS o
among IN N
both DT N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
even RB N
when WRB N
calculated VBN N
according VBG N
to TO N
the DT N
stage NN o
or CC o
histologic JJ o
grouping NN o
. . o

BACKGROUND IN N
The DT N
short-term JJ N
effects NNS N
of IN N
denopamine NN i
, , N
an DT N
orally RB N
available JJ N
beta-stimulant JJ N
, , N
on IN N
exercise NN N
capacity NN N
were VBD N
studied VBN N
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Sitaxsentan NNP i
is VBZ N
a DT N
highly RB N
selective JJ N
endothelin-A JJ N
receptor NN N
antagonist NN N
that WDT N
was VBD N
recently RB N
withdrawn VBN N
by IN N
the DT N
manufacturer NN N
because IN N
of IN N
a DT N
pattern NN N
of IN N
idiosyncratic JJ N
liver JJ N
injury NN N
. . N

BACKGROUND NNP N
Long-chain NNP N
n-3 JJ N
polyunsaturated VBD N
fatty JJ N
acids NNS N
have VBP N
variable JJ N
effects NNS N
on IN N
LDL NNP N
cholesterol NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
docosahexaenoic NN i
acid NN i
( ( i
DHA NNP i
) ) i
are VBP N
uncertain JJ N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
the DT N
profile NN o
of IN o
serum JJ o
phosphorus NN o
during IN N
titration NN N
and CC N
parathyroid NN N
hormone NN N
, , N
calcium NN N
, , N
and CC N
calcium NN N
x NN N
phosphorus NN N
( ( N
Ca NNP N
x NNP N
P NNP N
) ) N
product NN N
levels NNS N
. . N

FINDINGS NNP N
Weal NNP o
size NN o
, , o
and CC o
thus RB o
envenomisation NN o
, , N
increased VBD N
as IN N
the DT N
time NN o
from IN o
stinging VBG o
to TO o
removal NN o
of IN o
the DT o
sting NN o
increased VBD N
, , N
even RB N
within IN N
a DT N
few JJ N
seconds NNS N
. . N

Significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
duration NN o
of IN o
convalescence NN o
too RB o
( ( N
group NN N
A DT N
9.3+/-7.2 JJ N
days NNS N
; : N
group NN N
B NNP N
12.1+/-7 CD N
. . N

Furthermore RB N
, , N
there EX N
were VBD N
identical JJ N
shortening NN N
of IN N
inspiratory JJ N
time NN N
and CC N
prolongation NN N
of IN N
duty NN N
ratio NN N
( ( N
inspiratory JJ N
time/duration NN N
of IN N
a DT N
breath NN N
) ) N
in IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
alpha-Linolenic JJ o
acid JJ o
concentrations NNS o
in IN N
the DT N
plasma NN o
phospholipid JJ o
fraction NN o
increased VBD N
significantly RB N
in IN N
both DT N
groups NNS N
during IN N
the DT N
experimental JJ N
phase NN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

Blood NNP o
pressure NN o
reduction NN o
was VBD N
significant JJ N
in IN N
these DT N
all DT N
groups NNS N
and CC N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
blood NN o
pressure NN o
reduction NN o
among IN N
the DT N
groups NNS N
. . N

Similarly RB N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
digoxin NN o
pharmacokinetics NNS o
were VBD N
observed VBN N
when WRB N
digoxin NN i
was VBD N
administered VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
donepezil NN i
. . i

Pretreatment NN N
with IN N
ranitidine NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
disposition NN o
of IN o
intravenously RB o
administered VBN o
triazolam NN o
but CC o
significantly RB o
increased VBD o
the DT o
area NN o
under IN o
the DT o
serum JJ o
drug NN o
concentration-time JJ o
curve NN o
of IN o
oral JJ o
triazolam NN o
. . o

Unopposed VBN N
estrogen NN N
increases NNS N
total JJ o
plasma JJ o
factor NN o
VII NNP o
, , N
but CC N
not RB N
active JJ N
factor NN N
VII NNP N
-- : N
a DT N
short-term JJ N
placebo-controlled JJ N
study NN N
in IN N
healthy JJ p
postmenopausal NN p
women NNS p
. . p

CONCLUSION NNP N
The DT N
potential JJ N
role NN N
of IN N
finasteride NN i
on IN N
hematuria NNS N
related VBN N
to TO N
BPH NNP N
may MD N
be VB N
the DT N
suppressive JJ N
effect NN N
on IN N
MVD NNP N
in IN N
the DT N
suburethral JJ N
tissue NN N
of IN N
prostate NN N
. . N

We PRP N
compared VBN N
the DT N
periods NNS N
with IN N
and CC N
without IN N
Na+ NNP N
modeling NN N
: : N
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
weight NN o
gained VBN o
interdialysis NN o
, , o
mean JJ o
blood NN o
pressure NN o
predialysis NN o
and CC o
postdialysis NN o
, , o
and CC o
hemoconcentration NN o
. . o

Both DT N
products NNS N
were VBD N
safe JJ N
, , N
with IN N
no DT N
serious JJ o
adverse JJ o
events NNS o
, , N
and CC N
in IN N
particular JJ N
, , N
no DT N
anaphylactic JJ o
reactions NNS o
or CC o
serum NN o
sickness NN o
was VBD N
reported VBN N
. . N

The DT N
InsuPatch NNP N
( ( N
IP NNP N
) ) N
is VBZ N
a DT N
novel JJ N
insulin NN N
infusion NN N
site NN N
warming VBG N
device NN N
developed VBD N
to TO N
accelerate VB N
insulin NN N
action NN N
by IN N
increasing VBG N
blood NN N
flow NN N
to TO N
the DT N
area NN N
of IN N
insulin NN N
absorption NN N
. . N

Furthermore RB N
, , N
temperature NN o
elevation NN o
is VBZ N
dependent JJ N
on IN N
both DT N
the DT N
duration NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
activity NN N
, , N
which WDT N
may MD N
eventually RB N
affect VB N
1RM CD N
performance NN N
. . N

Similarly RB N
, , N
the DT N
rate NN o
of IN o
change NN o
in IN o
aortic JJ o
PWV NNP o
was VBD N
significantly RB N
decreased VBN N
with IN N
the DT N
use NN N
of IN N
the DT N
high-flux JJ N
polyamide NN N
membrane NN N
. . N

CONCLUSIONS NNP N
Neridronate NNP i
is VBZ N
an DT N
effective JJ N
treatment NN N
in IN N
preventing VBG N
bone NN o
loss NN o
in IN N
the DT N
hip NN N
and CC N
lumbar NN N
spine NN N
in IN N
men NNS p
receiving VBG p
ADT NNP p
for IN p
prostate NN p
cancer NN p
. . p

After IN N
acute JJ N
salt NN N
loading NN N
, , N
borderline JJ N
subjects NNS N
with IN N
high JJ N
intralymphocytic JJ N
sodium NN N
showed VBD N
a DT N
significant JJ N
greater JJR N
natriuresis NN o
whereas RBR o
intralymphocytic JJ o
sodium NN o
increased VBD N
only RB N
in IN N
those DT N
subjects NNS N
in IN N
whom WP N
it PRP N
was VBD N
initially RB N
normal JJ N
. . N

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
imidapril NN i
on IN N
plasma NN o
plasminogen NN o
activator NN o
inhibitor NN o
activity NN o
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

Overall JJ N
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN N
CRP NNP o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
sTNF-R2 NNS o
were VBD N
observed VBN N
after IN N
the DT N
vitamin NN N
D NNP N
supplementation NN N
period NN N
. . N

Mean JJ o
blood NN o
flow NN o
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
DIND NNP o
was VBD N
lower RBR N
in IN N
the DT N
pTBA NN i
group NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
fewer JJR N
patients NNS N
required VBN N
therapeutic JJ N
angioplasty NN N
to TO N
treat VB N
DIND NNP N
( ( N
P=0.03 NNP N
) ) N
. . N

The DT N
poor JJ N
metabolizer NN N
demonstrated VBN N
in IN N
both DT N
oral JJ N
formulations NNS N
high JJ N
plasma NN N
concentrations NNS N
, , N
increased VBD N
AUCs NNP o
and CC o
prolonged VBD o
terminal JJ o
half-lives NNS o
as RB N
well RB N
as IN N
increased VBN N
renal JJ o
excretion NN o
of IN o
prajmalium NN o
bitartrate NN o
. . o

However RB N
, , N
median JJ o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
were VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
treated VBN N
with IN N
concomitant JJ N
chemoradiotherapy NN N
. . N

Mean NNP o
bactericidal NN o
activity NN o
in IN o
CSF NNP o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
ceftriaxone NN i
than IN N
in IN N
the DT N
conventional JJ N
treatment NN N
group NN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
therapy NN N
. . N

Both DT N
angiotensin JJ i
receptor NN i
blockers NNS i
( ( i
ARB NNP i
) ) i
and CC i
the DT i
DASH NNP i
( ( i
Dietary NNP i
Approaches NNP i
to TO i
Stop NNP i
Hypertension NNP i
) ) i
diet VBP i
effectively RB N
lower JJR N
blood NN N
pressure NN N
in IN N
hypertensive JJ p
patients NNS p
. . p

Lp NNP i
[ VBZ N
a DT N
] JJ N
concentrations NNS N
were VBD N
not RB N
associate JJ N
with IN N
changes NNS N
in IN N
tissue-plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
activity NN o
, , o
factor NN o
VII NNP o
coagualant NN o
activity NN o
, , o
or CC o
plasma NN o
LDL NNP o
cholesterol NN o
. . o

Median JJ o
response NN o
duration NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
, , o
and CC o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

CONCLUSION NNP N
Electro-acupuncture NN i
may MD N
reduce VB N
immunologic JJ o
damage NN o
caused VBN N
by IN N
chemotherapy NN N
, , N
thus RB N
it PRP N
can MD N
be VB N
used VBN N
as IN N
the DT N
auxiliary JJ i
therapy NN i
for IN N
patients NNS p
undergoing JJ p
chemotherapy NN p
. . p

Infrared NNP N
LED NNP N
irradiation NN N
applied VBD N
during IN N
high-intensity NN i
treadmill NN i
training VBG i
improves NNS N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ p
women NNS p
: : p
a DT N
6-month JJ N
longitudinal JJ N
study NN N
. . N

In IN N
vivo JJ N
skin JJ N
penetration NN N
studies NNS N
showed VBD N
that IN N
epidermal JJ N
exposure NN N
to TO N
bioelastic JJ N
thromboxane NN N
synthetase NN N
inhibitor NN N
( ( N
TSI NNP N
) ) N
matrix NN N
resulted VBD N
in IN N
local JJ o
tissue NN o
concentrations NNS o
of IN o
TSI NNP o
sufficient NN o
for IN o
thromboxane NN o
synthetase NN o
inhibition NN o
. . o

Levamisole RB i
appeared VBD N
to TO N
adversely RB N
affect VB N
CR NNP o
rates NNS o
in IN N
nodular JJ N
mixed JJ N
and CC N
nodular JJ N
large-cell NN N
lymphoma NN N
and CC N
CR NNP N
duration NN N
in IN N
patients NNS p
with IN p
unfavorable JJ p
histology NN p
ML NNP p
. . p

CONCLUSION NNP N
GnRH NNP i
antagonists NNS i
are VBP N
more RBR N
effective JJ N
, , N
safe JJ N
and CC N
a DT N
well RB N
tolerated JJ N
alternative NN N
to TO N
agonists NNS N
for IN N
assisted JJ N
reproduction NN N
cycles NNS N
in IN N
PCOS NNP p
patients NNS p
. . p

BMC NNP o
fell VBD N
rapidly RB N
and CC N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
demonstrating VBG N
that IN N
the DT N
triple-treatment NN N
has VBZ N
no DT N
preventive JJ N
effect NN N
on IN N
corticosteroid NN N
induced VBN N
osteopenia NN N
. . N

Compared VBN N
with IN N
the DT N
intake NN N
of IN N
commercial JJ N
vegetable JJ N
juice NN N
, , N
the DT N
intake NN N
of IN N
fresh JJ N
fruit NN N
and CC N
B. NNP N
rapa NN N
juice NN N
is VBZ N
highly RB N
effective JJ N
in IN N
reducing VBG N
serum NN o
cholesterol NN o
. . o

No DT o
episodes NNS o
of IN o
apnoea NN o
were VBD N
recorded VBN N
in IN N
the DT N
remifentanil NN N
groups NNS N
, , N
while IN N
administration NN N
of IN N
fentanyl NN N
resulted VBN N
in IN N
apnoea NN N
in IN N
three CD N
animals NNS N
( ( N
one CD N
at IN N
each DT N
dose JJ N
level NN N
) ) N
. . N

Vaginal JJ o
tolerance NN o
tests NNS o
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ i
vaginal JJ i
gel NN i
( ( i
Acidform NNP i
) ) i
without IN i
or CC i
with IN i
nonoxynol-9 JJ i
( ( i
N-9 NNP i
) ) i
. . i

BACKGROUND IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
dietary JJ i
intervention NN i
can MD N
inhibit VB N
the DT N
development NN N
of IN N
recurrent NN N
colorectal NN N
adenomas NN N
, , N
which WDT N
are VBP N
precursors NNS N
of IN N
most JJS N
large-bowel JJ N
cancers NNS N
. . N

In IN N
addition NN N
, , N
blood NN N
cardioplegic JJ N
solution NN N
samples NNS N
were VBD N
collected VBN N
in IN N
Group NNP N
I PRP N
from IN N
the DT N
lines NNS N
proximal NN N
and CC N
distal NN N
to TO N
the DT N
filter NN N
during IN N
first JJ N
and CC N
last JJ N
administration NN N
. . N

Free JJ o
estradiol NN o
decreased VBN N
in IN N
53.85 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

Results NNS N
also RB N
indicated VBD N
that IN N
children NNS N
reported VBD N
more RBR N
anxiety NN o
and CC N
exhibited VBD N
more RBR N
behavioral JJ o
distress NN o
in IN N
the DT N
CB NNP N
group NN N
than IN N
in IN N
the DT N
hypnosis NN N
group NN N
. . N

Previous JJ N
investigators NNS N
have VBP N
demonstrated VBN N
enhanced JJ N
detection NN N
of IN N
atrial JJ N
defects NNS N
by IN N
the DT N
dye-dilution NN N
technique NN N
after IN N
delivery NN N
of IN N
contrast NN N
medium NN N
into IN N
the DT N
inferior NN N
rather RB N
than IN N
the DT N
superior JJ N
vena NN N
cava NN N
. . N

Mollosil NNP i
Plus NNP N
showed VBD N
a DT N
performance NN N
comparable JJ N
to TO N
that DT N
of IN N
Molloplast NNP N
B NNP N
, , N
and CC N
the DT N
other JJ N
materials NNS N
had VBD N
slightly RB N
lower JJR N
performance NN N
especially RB N
in IN N
terms NNS N
of IN N
fungal JJ N
colonization NN N
. . N

Medium NN i
chain NN i
triglyceride JJ i
oil NN i
consumption NN i
as IN N
part NN N
of IN N
a DT N
weight JJ N
loss NN N
diet NN N
does VBZ N
not RB N
lead VB N
to TO N
an DT N
adverse JJ N
metabolic NN N
profile NN N
when WRB N
compared VBN N
to TO N
olive JJ i
oil NN i
. . i

The DT N
secondary JJ N
variables NNS N
showed VBD N
no DT N
notable JJ N
differences NNS N
with IN N
respect NN N
to TO N
lung NN o
function NN o
, , o
exacerbations NNS o
or CC o
health-related JJ o
quality NN o
of IN o
life NN o
. . o

The DT N
levels NNS o
of IN o
the DT o
systolic NN o
and CC o
diastolic JJ o
pressures NNS o
at IN N
entry NN N
were VBD N
not RB N
predictive JJ N
of IN N
the DT N
dose NN N
of IN N
nifedipine NN i
required VBN N
for IN N
effective JJ o
blood NN o
pressure NN o
control NN o
. . o

After IN N
ovarian JJ N
stimulation NN N
with IN N
clomiphene NN i
and CC i
human JJ i
menopausal NN i
gonadotrophin NN i
( ( i
HMG NNP i
) ) i
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal NN N
phase NN N
has VBZ N
never RB N
been VBN N
scientifically RB N
demonstrated VBN N
. . N

RESULTS VB N
The DT N
plasma JJ o
levels NNS o
of IN o
ADA NNP o
in IN N
patients NNS p
with IN p
chronic JJ p
schizophrenia NN p
who WP p
received VBD p
clozapine NN i
were VBD N
significantly RB N
higher JJR N
than IN N
patients NNS N
who WP N
received VBD N
haloperidol NN i
. . i

Inhibition NN N
of IN N
increased JJ N
central JJ N
sympathetic JJ N
vasoconstrictor NN N
outflow NN N
is VBZ N
one CD N
mechanism NN N
by IN N
which WDT N
nocturnal JJ i
CPAP NNP i
reduces NNS N
awake VBP N
BP NNP N
in IN N
HF NNP p
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
OSA NNP p
. . p

The DT N
HA NNP N
gene NN N
of IN N
the DT N
H5N1 NNP N
subtype NN N
of IN N
avian JJ N
influenza NN N
virus NN N
( ( N
AIV NNP N
) ) N
was VBD N
inserted VBN N
into IN N
the DT N
pBCX NN N
vector NN N
and CC N
expressed VBD N
efficiently RB N
in IN N
Escherichia NNP N
coli NN N
BL21 NNP N
( ( N
DE3 NNP N
) ) N
. . N

Our PRP$ N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
a DT N
small JJ N
dose NN N
of IN N
subconjunctival JJ i
5-FU JJ i
provides VBZ N
significantly RB N
lower JJR N
postoperative JJ o
intraocular JJ o
pressure NN o
than IN N
does VBZ N
no DT N
antimetabolite JJ N
treatment NN N
. . N

Therefore RB N
, , N
we PRP N
hypothesized VBD N
that IN N
enhanced VBD N
mTOR NNS N
signaling VBG N
might MD N
be VB N
responsible JJ N
for IN N
the DT N
greater JJR N
muscle NN N
protein NN N
synthesis NN N
when WRB N
leucine-enriched JJ N
EAA+CHOs NNP N
are VBP N
ingested VBN N
during IN N
postexercise JJ N
recovery NN N
. . N

These DT N
tests NNS N
showed VBD N
a DT N
total JJ N
failure NN N
of IN N
the DT N
benzimidazole NN i
, , i
imidothiazole NN i
, , N
macrocyclic JJ N
lactone NN N
and CC N
salicylanilide JJ N
groups NNS N
of IN N
anthelmintics NNS N
to TO N
control VB N
H. NNP N
contortus JJ N
infections NNS N
of IN N
sheep NN N
and CC N
goats NNS N
on IN N
all DT N
farms NNS N
. . N

PARTICIPANTS NNP N
Consecutive NNP p
postmenopausal NN p
women NNS p
( ( p
N=130 NNP p
; : p
mean JJ p
age NN p
? . p
SD NNP p
, , p
65.44 CD p
) ) p
with IN p
mild JJ p
CVI NNP p
. . p

OBJECTIVE NN N
To TO N
determine VB N
if IN N
any DT N
differences NNS N
exist VBP N
in IN N
healing NN N
and CC N
complications NNS N
between IN N
reamed VBN i
and CC i
unreamed JJ i
nailing NN i
in IN N
patients NNS p
with IN p
tibial JJ p
shaft NN p
fractures NNS p
. . p

The DT N
Ultracision NNP N
dissector NN N
has VBZ N
been VBN N
widely RB N
used VBN N
in IN N
laparoscopic NN N
surgery NN N
and CC N
is VBZ N
documented VBN N
to TO N
be VB N
safe JJ N
and CC N
fast JJ N
for IN N
cutting VBG N
and CC N
coagulating VBG N
tissue NN N
. . N

Use NNP N
of IN N
high-dose JJ i
cytarabine NN i
to TO N
enhance VB N
cisplatin JJ i
cytotoxicity-effects NNS i
on IN N
the DT N
response NN o
and CC o
overall JJ o
survival NN o
rates NNS o
of IN N
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

PURPOSE NNP N
Sulindac NNP N
is VBZ N
a DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
effective JJ N
in IN N
regressing VBG N
adenomas NN N
in IN N
patients NNS p
with IN p
familial JJ p
adenomatous JJ p
polyposis NN p
( ( p
FAP NNP p
) ) p
. . p

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN o
of IN o
nausea NN o
, , o
headache NN o
, , o
diarrhea NN o
and CC o
pyrexia NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

BACKGROUND NNP N
Studies NNPS N
all DT N
over IN N
the DT N
world NN N
reported VBD N
that IN N
smoking VBG o
relapses NNS o
occur VBP N
during IN N
the DT N
first JJ N
two CD N
weeks NNS N
after IN N
a DT N
quit NN N
date NN N
. . N

Treatment NN N
of IN N
vaginal JJ N
adenosis NN N
with IN N
the DT N
carbon NN i
dioxide NN i
laser NN i
did VBD N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN o
of IN o
development NN o
of IN o
new JJ o
dysplasia NN o
in IN N
the DT N
DES-exposed JJ p
offspring NN p
. . p

AIM NNP N
To TO N
evaluate VB N
the DT N
shear JJ N
bond NN N
strength NN N
of IN N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ i
glass-ionomer JJ i
cement NN i
( ( i
RMGIC NNP i
) ) i
using VBG N
various JJ N
methods NNS N
of IN N
enamel JJ N
conditioning NN N
. . N

The DT N
effects NNS N
and CC N
changes NNS N
of IN N
the DT N
indexes NNS o
including VBG o
renal JJ o
function NN o
, , o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
before IN N
and CC N
after IN N
treatment NN N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Single NNP N
and CC N
short-term JJ N
dosing NN N
with IN N
levocetirizine NN i
conferred VBN N
similar JJ N
improvements NNS N
in IN N
bronchial JJ N
hyper-responsiveness NN N
to TO N
AMP NNP N
challenge NN N
, , N
which WDT N
was VBD N
unrelated JJ N
to TO N
prechallenge VB N
airway RB N
calibre NN N
. . N

A DT N
prothrombin JJ o
time NN o
( ( o
PT NNP o
) ) o
ratio NN o
( ( N
patient JJ N
PT NNP N
divided VBN N
by IN N
control NN N
PT NNP N
) ) N
between IN N
1.3 CD N
and CC N
2.5 CD N
was VBD N
considered VBN N
to TO N
be VB N
in IN N
the DT N
therapeutic JJ N
range NN N
. . N

Before IN N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
procedure NN N
, , N
infant JJ N
stress NN N
was VBD N
evaluated VBN N
by IN N
heart NN o
rate NN o
, , o
respiration NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
transcutaneous JJ o
oxygen NN o
saturation NN o
. . o

The DT N
changes NNS N
between IN N
pre-treatment NN N
and CC N
the DT N
eight-week JJ N
follow-up NN N
also RB N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.03 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
detection NN o
of IN o
lymph NN o
nodes NNS o
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.56 CD N
) ) N
. . N

A DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
increases NNS N
induced VBD N
sputum JJ o
inflammatory JJ o
markers NNS o
in IN N
non-asthmatic JJ p
subjects NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
: : p
correlation NN N
with IN N
plasma JJ N
interleukin-5 NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
enflurane NN i
and CC i
isoflurane NN i
on IN N
hepatic JJ o
venous JJ o
oxygen NN o
saturation NN o
( ( o
ShvO2 NNP o
) ) o
and CC o
splanchnic JJ o
oxygen NN o
( ( o
O2 NNP o
) ) o
extraction NN o
. . o

CONCLUSIONS NNP N
Trocar-guided NNP i
transvaginal JJ i
synthetic JJ i
mesh NN i
for IN N
advanced JJ N
anterior JJ N
POP NNP N
repair NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
anatomical JJ N
success NN N
rate NN N
for IN N
the DT N
anterior JJ N
compartment NN N
compared VBN N
with IN N
traditional JJ N
colporrhaphy NN N
. . N

Suggestive JJ N
but CC N
non-significant JJ N
results NNS N
were VBD N
found VBN N
in IN N
Vineland NNP o
Adaptive NNP o
Behaviour NNP o
Scales NNP o
( ( o
Communication NNP o
Sub-domain NNP o
) ) o
and CC o
ADOS NNP o
stereotyped VBD o
and CC o
restricted VBD o
behaviour NN o
domain NN o
. . o

BACKGROUND NNP N
Nicotine NNP N
may MD N
be VB N
of IN N
therapeutic JJ N
value NN N
in IN N
ulcerative JJ p
colitis NN p
( ( p
UC NNP p
) ) p
, , N
although IN N
its PRP$ N
mechanism NN N
of IN N
action NN N
has VBZ N
not RB N
been VBN N
established VBN N
. . N

Upregulation NN N
of IN N
endogenous JJ N
synthesis NN N
of IN N
the DT N
major JJ N
protein NN N
on IN N
HDL NNP N
particles NNS N
, , N
apolipoprotein RB N
A-I NNP N
( ( N
apoA-I NN N
) ) N
, , N
represents VBZ N
a DT N
novel JJ N
approach NN N
to TO N
generation NN N
of IN N
new JJ N
HDL NNP N
particles NNS N
. . N

UNLABELLED NNP N
Breast NNP N
lymphoscintigraphy NN N
using VBG N
( ( N
99m CD N
) ) N
Tc-sulfur CD N
colloid NN N
( ( N
( ( N
99m CD N
) ) N
Tc-SC NN N
) ) N
is VBZ N
well RB N
established VBN N
in IN N
clinical JJ N
practice NN N
for IN N
staging VBG p
patients NNS p
with IN p
breast JJ p
carcinoma NN p
. . p

CONTEXT NNP N
Nerve NNP N
growth NN N
factor NN N
is VBZ N
a DT N
neurotrophic JJ N
factor NN N
that WDT N
promotes VBZ N
the DT N
survival NN N
of IN N
small JJ N
fiber NNP N
sensory JJ N
neurons NNS N
and CC N
sympathetic JJ N
neurons NNS N
in IN N
the DT N
peripheral JJ N
nervous JJ N
system NN N
. . N

Plasma NN o
AT NNP o
, , o
lipid-standardized JJ o
AT NNP o
, , o
and CC o
LDL NNP o
AT NNP o
levels NNS o
rose VBD o
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
both DT N
the DT N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
groups NNS N
compared VBN N
with IN N
baseline NN N
. . N

The DT N
plasma NN o
triglyceride IN o
level NN o
and CC o
the DT o
triglyceride JJ o
distribution NN o
within IN N
the DT N
individual JJ N
lipoprotein NN N
fractions NNS N
were VBD N
not RB N
altered VBN N
in IN N
any DT N
consistent JJ N
manner NN N
by IN N
the DT N
addition NN N
of IN N
guar NN i
. . i

An DT N
experimental JJ N
model NN N
of IN N
HPAT NNP N
axis NN N
inhibited VBN N
by IN N
corticosterone NN N
( ( N
CORT NNP N
) ) N
was VBD N
established VBN N
to TO N
observe VB N
the DT N
effect NN N
of IN N
EB NNP N
on IN N
relevant JJ N
indices NNS N
of IN N
HPAT NNP N
axis NN N
. . N

The DT N
slight JJ N
increase NN N
in IN N
local JJ o
recurrence NN o
rate NN o
in IN N
transfused JJ N
patients NNS N
appears VBZ N
to TO N
be VB N
related VBN N
to TO N
complicated VBN N
, , N
in IN N
particular JJ N
rectal NN N
, , N
surgery NN N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
exogenous JJ i
bile NN i
acid NN i
therapy NN i
in IN N
patients NNS p
with IN p
poor JJ p
pouch JJ p
function NN p
after IN p
restorative JJ p
proctocolectomy NN p
for IN p
ulcerative JJ p
colitis NN p
. . p

In IN N
the DT N
placebo NN i
control NN i
group NN N
an DT N
increase NN N
in IN N
micronuclei NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
detected VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
period NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
rate NN N
of IN N
in IN N
vivo JJ N
platelet NN N
accumulation NN N
on IN N
Dacron NNP N
grafts NNS N
can MD N
be VB N
quantitated VBN N
and CC N
that IN N
ASA NNP N
+ NNP N
DPM NNP N
reduced VBD N
this DT N
rate NN N
in IN N
man NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN o
of IN o
drained JJ o
blood NN o
, , o
transfusion NN o
requirements NNS o
, , o
knee JJ o
motion NN o
or CC o
wound NN o
status NN o
. . o

Moreover RB N
, , N
the DT N
increased VBN N
level NN o
of IN o
HMGB1 NNP o
exhibited VBD o
in IN o
a DT o
late JJ o
stage NN o
of IN o
CCI NNP o
was VBD N
inhibited VBN N
by IN N
exogenous JJ N
overexpression NN N
of IN N
hIL-10 NN N
in IN N
the DT N
CCI NNP N
model NN N
. . N

The DT N
relapse-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
by IN N
60Co CD N
radiation NN N
in IN N
Stage NNP N
II NNP N
patients NNS N
, , N
but CC N
was VBD N
unaffected VBN N
by IN N
radiation NN N
in IN N
the DT N
other JJ N
subgroups NNS N
. . N

The DT N
intervention NN N
group NN N
showed VBD N
less JJR N
decline NN N
in IN N
function NN N
, , N
as IN N
measured VBN N
by IN N
disability NN o
days NNS o
and CC o
lower JJR o
scores NNS o
on IN o
the DT o
Health NNP o
Assessment NNP o
Questionnaire NNP o
. . o

Furthermore RB N
, , N
when WRB N
analyzed VBN N
by IN N
Ki67 NNP N
immunohistochemistry NN N
, , N
letrozole NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
tamoxifen NN N
in IN N
reducing VBG N
tumor NN N
proliferation NN N
( ( N
P=0.0009 NNP N
) ) N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
provide VBP N
evidence NN N
for IN N
increased JJ N
expression NN o
of IN o
VEGF/VEGFR-2 NNP o
of IN o
leukemic JJ o
blasts NNS o
and CC N
correlation NN N
with IN N
angiogenesis NN N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
AML NNP N
patients NNS N
. . N

As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN o
velocity NN o
in IN N
these DT N
patients NNS N
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases NNS N
. . N

Recombinant JJ i
human JJ i
granulocyte NN i
and CC i
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
and CC i
GM-CSF NNP i
) ) i
administered VBD N
following VBG N
cytotoxic NN N
chemotherapy NNS N
have VBP N
a DT N
similar JJ N
ability NN N
to TO N
mobilize VB N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
trimetazidine NN i
and CC i
propranolol NN i
at IN N
the DT N
doses NNS N
studied VBN N
have VBP N
similar JJ N
efficacy NN N
in IN N
patients NNS p
with IN p
stable JJ p
angina JJ p
pectoris NN p
. . p

BACKGROUND NNP N
Although IN N
indomethacin NN i
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
, , N
side NN N
effects NNS N
are VBP N
frequently RB N
observed VBN N
. . N

CONCLUSION NNP N
Further NNP N
evaluation NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
validity NN N
of IN N
the DT N
observed JJ N
reduction NN N
in IN N
infection-related JJ o
deaths NNS o
in IN N
patients NNS p
treated VBN p
with IN p
interferon NN p
gamma NN p
. . p

A DT N
low JJ N
mean JJ o
8-oxo-dG JJ o
concentration NN o
is VBZ N
seen VBN N
in IN N
DNA NNP N
of IN N
women NNS N
from IN N
all DT N
five CD N
countries NNS N
, , N
and CC N
of IN N
men NNS N
from IN N
France NNP N
and CC N
Spain NNP N
. . N

In IN N
peripheral JJ o
blood NN o
monocytes NNS o
, , o
human JJ o
leukocyte VBD o
antigen-DR JJ o
expression NN o
was VBD N
only RB N
slightly RB N
depressed VBN N
, , N
whereas NNS N
in IN N
vitro JJ N
phagocytosis NN N
and CC N
the DT N
monocyte-activating JJ N
cytokine JJ N
interleukin-12 NN N
increased VBD N
. . N

The DT N
incidence NN o
of IN o
degeneration NN o
and CC o
necrosis NN o
in IN o
the DT o
squamous JJ o
epithelium NN o
adjacent NN o
to TO o
carcinoma VB o
was VBD N
higher RBR N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

RESULTS JJ N
Complication NNP o
rate NN o
was VBD N
5.26 CD N
% NN N
for IN N
group NN N
A NNP N
( ( N
none NN N
needed VBN N
conversion NN N
) ) N
and CC N
4.68 CD N
% NN N
for IN N
group NN N
B NNP N
. . N

BACKGROUND NNP N
Unsedated VBD i
transnasal JJ i
endoscopy NN i
( ( i
TNE NNP i
) ) i
may MD N
be VB N
safer JJR N
and CC N
less RBR N
expensive JJ N
than IN N
standard JJ i
endoscopy NN i
( ( i
SE NNP i
) ) i
for IN N
detecting VBG N
Barrett NNP N
's POS N
esophagus NN N
( ( N
BE NNP N
) ) N
. . N

Polyunsaturated VBN i
fatty JJ i
acids NNS i
arachidonic JJ i
acid NN i
( ( N
ARA NNP N
) ) N
and CC N
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP i
) ) i
may MD N
have VB N
key JJ N
role NN N
in IN N
brain NN N
network NN N
maturation NN N
. . N

Renal JJ o
function NN o
was VBD N
assessed VBN N
by IN N
measurement NN N
of IN N
the DT N
glomerular JJ o
filtration NN o
rate NN o
( ( N
single JJ N
bolus IN N
51Cr-EDTA JJ N
technique NN N
) ) N
and CC N
by IN N
the DT N
urinary JJ o
albumin JJ o
excretion NN o
rate NN o
( ( o
radioimmunoassay NN o
) ) o
. . o

The DT N
pattern NN N
of IN N
ipilimumab-induced JJ o
antibody NN o
titers NNS o
to TO o
microbial JJ o
flora NN o
and CC o
the DT o
histologic NN o
features NNS o
and CC o
location NN o
of IN o
the DT o
inflammation NN o
were VBD N
distinct JJ N
from IN N
classic JJ N
IBD NNP N
. . N

A DT N
similar JJ N
pattern NN N
of IN N
increased VBN N
skin NN o
reaction NN o
toxicity NN o
occurred VBD N
with IN N
both DT N
study NN N
creams NNS N
compared VBN N
with IN N
the DT N
dry JJ N
powder NN N
regimen NNS N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN i
, , N
the DT N
diode NN i
laser NN i
was VBD N
more RBR N
convenient JJ N
, , N
technically RB N
easier JJR N
to TO N
administer VB N
, , N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

Effects NNS N
of IN N
a DT N
low-salt JJ i
diet NN i
and CC N
of IN N
acute JJ N
salt NN N
loading VBG N
on IN N
blood NN o
pressure NN o
and CC o
intralymphocytic JJ o
sodium NN o
concentration NN o
in IN N
young JJ p
subjects NNS p
with IN p
borderline JJ p
hypertension NN p
. . p

RESULTS JJ N
Freedom-from-treatment-failure NNP o
( ( o
FFTF NNP o
) ) o
and CC o
survival NN o
( ( o
SV NNP o
) ) o
curves VBZ o
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
20- JJ N
, , N
30- JJ N
, , N
and CC N
40-Gy JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
ropinirole NN i
is VBZ N
more RBR N
effective JJ N
than IN N
levodopa JJS N
SR NNP N
in IN N
the DT N
treatment NN N
of IN N
RLS NNP N
in IN N
patients NNS p
on IN p
chronic JJ p
hemodialysis NN p
. . p

Under IN o
OT NNP o
activation NN o
differences NNS o
between IN N
genotypes NNS N
were VBD N
more RBR N
evident JJ N
( ( N
though IN N
not RB N
statistically RB N
significantly RB N
increased VBN N
) ) N
and CC N
RT NNP N
were VBD N
accelerated VBN N
in IN N
homozygotic JJ N
risk NN N
allele NN N
carriers NNS N
. . N

CONCLUSION NN N
In IN N
this DT N
population NN N
, , N
the DT N
efficacy NN o
and CC o
tolerability NN o
observed VBN N
with IN N
amlodipine JJ i
maleate NN i
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
with IN N
amlodipine JJ i
besylate NN i
. . i

Fulvestrant NNP N
continued VBD N
to TO N
be VB N
well RB N
tolerated VBN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
joint JJ N
disorders NNS N
compared VBN N
with IN N
anastrozole NN i
( ( N
P NNP N
= NNP N
0.0234 CD N
) ) N
. . N

Increases NNS N
in IN N
serum NN o
PSA NNP o
in IN N
men NNS N
receiving VBG N
dutasteride NN N
should MD N
be VB N
considered VBN N
suspicious JJ N
and CC N
serial JJ N
PSA NNP N
measurements NNS N
should MD N
be VB N
used VBN N
to TO N
evaluate VB N
changes NNS N
from IN N
nadir NN N
. . N

OBJECTIVES NNP N
To TO N
present VB N
clinical JJ N
evidence NN N
with IN N
botulinum NN i
toxin NN i
A NNP i
( ( i
BTX-A NNP i
) ) i
suggesting VBG N
an DT N
antinociceptive JJ N
role NN N
in IN N
patients NNS p
with IN p
interstitial JJ p
cystitis NN p
( ( p
IC NNP p
) ) p
. . p

[ JJ N
Biological NNP N
and CC N
clinical JJ N
effects NNS N
of IN N
oral JJ i
magnesium NN i
and CC N
associated VBN N
magnesium-vitamin JJ i
B6 NNP i
administration NN N
on IN N
certain JJ N
disorders NNS N
observed VBN N
in IN N
infantile JJ p
autism NN p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

However RB N
, , N
a DT N
slight JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
GOT NNP o
, , o
GPT NNP o
and CC o
LDH NNP o
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Effect NN N
of IN N
finasteride NN i
on IN N
serum NN N
androstenedione NN N
and CC N
risk NN N
of IN N
prostate NN N
cancer NN N
within IN N
the DT N
prostate NN N
cancer NN N
prevention NN N
trial NN N
: : N
differential JJ N
effect NN N
on IN N
high- NN N
and CC N
low-grade JJ N
disease NN N
. . N

The DT N
apparent JJ N
arrest NN N
of IN N
progressive JJ o
joint JJ o
damage NN o
seen VBN N
in IN N
four CD N
patients NNS N
after IN N
treatment NN N
with IN N
IL-1Ra NNP N
was VBD N
associated VBN N
with IN N
reduced JJ N
intimal JJ N
layer NN N
macrophage NN N
accumulation NN N
in IN N
all DT N
patients NNS N
. . N

Our PRP$ N
study NN N
demonstrates VBZ N
a DT N
reversible JJ o
depression NN o
of IN o
myocardial JJ o
contractility NN o
and CC o
hemodynamic JJ o
alterations NNS o
during IN N
rapid JJ N
permissive JJ N
hypercapnia NN N
which WDT N
were VBD N
attenuated VBN N
by IN N
buffering VBG N
with IN N
THAM NNP i
. . i

CONCLUSION NNP N
The DT N
combination NN N
of IN N
resistive JJ i
underwater NN i
exercises NNS i
and CC i
interferential JJ i
current JJ i
therapy NN i
is VBZ N
a DT N
potentially RB N
valuable JJ N
treatment NN N
for IN N
patients NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
. . p

In IN N
terms NNS N
of IN N
percentage NN N
the DT N
greatest JJS N
change NN N
was VBD N
found VBN N
in IN N
reactance NN N
, , N
in IN N
relation NN N
to TO N
the DT N
initial JJ N
value NN N
, , N
followed VBN N
by IN N
Raw NNP N
and CC N
FEV1 NNP N
. . N

The DT N
incidence NN o
rate NN o
of IN o
serious JJ o
adverse JJ o
events NNS o
, , o
viral JJ o
infections NNS o
and CC o
fungal JJ o
infections NNS o
was VBD N
similar JJ N
across IN N
groups NNS N
during IN N
the DT N
LTE NNP N
. . N

BACKGROUND NNP N
Contrary NNP N
to TO N
aerobic VB i
exercise NN i
, , i
strength NN i
training NN i
( ( i
ST NNP i
) ) i
is VBZ N
associated VBN N
with IN N
decreased JJ N
central JJ N
arterial JJ N
compliance NN N
in IN N
young JJ p
men NNS p
. . p

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS p
recovering VBG p
from IN p
mild JJ p
acute JJ p
pancreatitis NN p
typically RB p
receive VBP N
a DT N
clear JJ i
liquid NN i
diet NN i
( ( i
CLD NNP i
) ) i
when WRB N
ready JJ N
to TO N
initiate VB N
oral JJ N
nutrition NN N
. . N

Bradykinin NNP N
B2 NNP N
receptor NN N
antagonism NN N
decreased VBD N
intraoperative JJ o
fibrinolytic JJ o
capacity NN o
as RB N
much RB N
as IN N
EACA NNP N
, , N
but CC N
only RB N
EACA NNP N
decreased VBD N
D-dimer NNP N
formation NN N
and CC N
tended VBD N
to TO N
decrease VB N
postoperative JJ N
bleeding NN N
. . N

Blood NNP o
flow NN o
velocity NN o
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
MECC NNP N
group NN N
, , N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
after IN N
aortic JJ N
crossclamping NN N
( ( N
T2 NNP N
) ) N
. . N

The DT N
increase NN N
in IN N
insulin JJ o
sensitivity NN o
induced VBN N
by IN N
fasting VBG N
was VBD N
comparable JJ N
to TO N
the DT N
increase NN N
in IN N
insulin JJ N
sensitivity NN N
induced VBN N
by IN N
fasting VBG N
combined VBN N
with IN N
pegvisomant NN i
. . i

From IN N
the DT N
pantoprazole NN N
plasma NN N
concentration NN N
vs. FW N
time NN N
curves NNS N
, , N
the DT N
pharmacokinetic JJ N
parameters NNS N
AUC NNP N
( ( N
last JJ N
) ) N
and CC N
C NNP N
( ( N
max NN N
) ) N
were VBD N
obtained VBN N
, , N
with IN N
and CC N
without IN N
food NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
the DT N
changes NNS N
of IN N
endogenous JJ N
estrogen NN N
and CC N
the DT N
concentration NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
in IN N
the DT N
serum NN N
of IN N
Chinese JJ N
women NNS N
was VBD N
investigated VBN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
torasemide NN i
is VBZ N
suitable JJ N
for IN N
the DT N
treatment NN N
of IN N
sodium NN N
retention NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
ascites NNS p
. . p

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
FNB NNP i
using VBG i
0.25 CD i
% NN i
or CC i
0.5 CD i
% NN i
bupivacaine NN i
provided VBN N
better RBR N
analgesia NN N
with IN N
less JJR N
effect NN N
on IN N
quadriceps NNS N
strengths NNS N
after IN N
ACL NNP N
reconstruction NN N
. . N

However RB N
, , N
the DT N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
further JJ N
studies NNS N
with IN N
a DT N
placebo NN i
group NN N
to TO N
rule VB N
out IN N
the DT N
placebo NN N
effect NN N
. . N

Permissive NNP N
hypercapnia NN N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN N
systemic JJ o
vascular JJ o
resistance NN o
( ( o
SVR NNP o
) ) o
and CC N
increases VBZ N
in IN N
cardiac JJ o
output NN o
( ( o
Q NNP o
) ) o
. . o

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
ophthalmic JJ i
timolol NN i
and CC N
time NN N
of IN N
administration NN N
on IN N
cardiovascular JJ o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
young JJ p
male NN p
volunteers NNS p
. . p

In IN N
comparison NN N
to TO N
the DT N
Ca NNP N
( ( N
++ NNP N
) ) N
-blocker NN N
Gallopamil NNP N
the DT N
antiischemic JJ N
effects NNS N
of IN N
Enoximone NNP i
were VBD N
more RBR N
pronounced JJ N
, , N
a DT N
synergistic JJ N
action NN N
was VBD N
, , N
however RB N
, , N
observed VBD N
. . N

RESULTS VB N
The DT N
facial JJ o
swelling NN o
measurements NNS o
and CC o
VAS NNP o
scores NNS o
were VBD N
lower JJR N
in IN N
the DT N
envelope NN N
flap NN N
group NN N
compared VBN N
to TO N
the DT N
triangular JJ N
flap NN N
group NN N
. . N

A DT N
gradual JJ N
increase NN N
of IN N
AP-1 NNP o
activation NN o
was VBD N
found VBN N
in IN N
non-progressive JJ N
and CC N
progressive JJ N
phases NNS N
of IN N
atherosclerosis NN N
respectively RB N
( ( N
P NNP N
< NNP N
0.044 CD N
) ) N
. . N

The DT N
percentage NN o
of IN o
ST NNP o
resolution NN o
did VBD N
not RB N
show VB N
any DT N
differences NNS N
between IN N
groups NNS N
( ( N
84.8 CD N
in IN N
ticagrelor NN N
vs. FW N
70.8 CD N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

However RB N
, , N
a DT N
significant JJ N
interaction NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
was VBD N
found VBN N
between IN N
the DT N
treatment NN N
and CC N
the DT N
number NN o
of IN o
invaded JJ o
lymph NN o
nodes NNS o
. . o

The DT N
itching NN o
and CC o
burning NN o
symptoms NNS o
were VBD N
not RB N
severe JJ N
and CC N
can MD N
be VB N
explained VBN N
by IN N
the DT N
preservative JJ N
benzyl NN N
alcohol NN N
present NN N
in IN N
the DT N
CS NNP N
gel NN N
. . N

The DT N
effect NN N
of IN N
a DT N
single JJ N
oral JJ N
dose NN N
on IN N
the DT N
responses NNS N
of IN N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
to TO N
isoprenaline VB i
infusion NN i
has VBZ N
been VBN N
studied VBN N
in IN N
healthy JJ p
volunteers NNS p
. . p

Plasma NNP o
level NN o
of IN o
ISDN NNP o
and CC o
the DT o
mononitrates NNS o
, , N
measured VBD N
one CD N
and CC N
four CD N
hours NNS N
after IN N
drug NN N
intake NN N
, , N
rose VBD N
almost RB N
linearly JJ N
in IN N
relation NN N
to TO N
dose VB N
. . N

However RB N
, , N
the DT N
inherent JJ N
heterogeneity NN N
in IN N
nasal JJ N
antibody NN N
levels NNS N
and CC N
variability NN N
in IN N
nasal JJ N
specimen NNS N
collection NN N
hinders VBZ N
the DT N
precise JJ N
evaluation NN N
of IN N
mucosal NN N
antibody NN N
responses NNS N
. . N

[ JJ i
Whole NNP i
gut NN i
irrigation NN i
with IN i
isotonic JJ i
mannitol NN i
solution NN i
in IN N
the DT N
treatment NN N
of IN N
gastrointestinal JJ p
bleeding NN p
due JJ p
to TO p
cirrhosis NN p
: : p
a DT N
controlled VBN N
study NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

These DT N
data NNS N
support NN N
the DT N
concept NN N
that IN N
P-selectin NNP i
on IN N
the DT N
microvascular JJ N
endothelium NN N
is VBZ N
critical JJ N
to TO N
both DT N
acute JJ N
vascular NN N
occlusion NN N
and CC N
chronically RB N
impaired JJ N
microvascular JJ N
blood NN N
flow NN N
in IN N
SCD NNP N
. . N

Duration NN o
of IN o
granulocytopenia NN o
was VBD N
reduced VBN N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
but CC N
thrombocytopenia NN o
was VBD N
prolonged VBN N
, , N
and CC N
the DT N
number NN o
of IN o
platelet NN o
transfusions NNS o
was VBD N
increased VBN N
. . N

It PRP N
became VBD N
evident JJ N
that IN N
the DT N
recurrence NN o
rate NN o
in IN N
the DT N
doxorubicin NN i
or CC N
epirubicin JJ N
instillation NN N
arm NN N
was VBD N
lower JJR N
that IN N
in IN N
the DT N
no DT N
instillation NN N
arm NN N
. . N

Glucocorticoid NNP o
receptor NN o
( ( o
GR NNP o
) ) o
binding NN o
and CC o
neurotransmitter JJ o
concentrations NNS o
were VBD N
measured VBN N
in IN N
stress-related JJ N
brain NN N
regions NNS N
, , N
and CC N
histological JJ N
analyses NNS N
of IN N
the DT N
adrenal JJ N
were VBD N
performed VBN N
. . N

The DT N
sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( N
implemented VBN N
the DT N
intervention NN i
) ) i
or CC i
the DT i
control NN i
group NN i
( ( i
continued VBN i
usual JJ i
training NN i
) ) i
. . i

Importantly RB N
, , N
administration NN N
of IN N
propranolol NN i
attenuated VBN N
this DT N
impairment NN N
, , N
with IN N
the DT N
ASD NNP N
group NN N
performing VBG N
significantly RB N
better RBR N
in IN N
the DT N
propranolol NN i
condition NN N
than IN N
the DT N
placebo JJ N
condition NN N
. . N

The DT N
relapse NN o
rates NNS o
were VBD N
62.5 CD N
% NN N
for IN N
gradual JJ N
placebo NN N
substitution NN N
and CC N
12.5 CD N
% NN N
for IN N
continued JJ N
risperidone NN N
; : N
this DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

The DT N
two CD N
groups NNS N
had VBD N
a DT N
similar JJ N
3-year JJ o
disease-free JJ o
survival NN o
, , o
progression NN o
free JJ o
survival NN o
, , o
and CC o
overall JJ o
survival NN o
, , o
i.e NN o
. . o

The DT N
primary JJ N
( ( N
efficacy NN N
) ) N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN o
of IN o
unnecessary JJ o
angiography NN o
as IN N
defined VBN N
by IN N
a DT N
normal JJ N
( ( N
> JJ N
0.8 CD N
) ) N
invasive JJ N
fractional JJ N
flow NN N
reserve NN N
. . N

Terbinafine NN i
levels NNS N
were VBD N
determined VBN N
by IN N
high JJ N
pressure NN N
liquid NN N
chromatography NN N
with IN N
tandem JJ N
mass NN N
detection NN N
( ( N
HPLC-MS/MS NNP N
) ) N
and CC N
the DT N
lower JJR N
limit NN N
of IN N
quantification NN N
was VBD N
set VBN N
at IN N
9.99 CD N
ng/mL NNS N
. . N

ECG NNP o
, , o
MAP NNP o
, , o
HR NNP o
, , o
CVP NNP o
, , o
continuous JJ o
cardiac NN o
output NN o
( ( o
CCO NNP o
) ) o
index NN o
and CC o
BIS NNP o
were VBD N
continuously RB N
monitored VBN N
during IN N
anesthesia NN N
. . N

Second JJ N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

During IN N
the DT N
break NN N
between IN N
sets NNS N
, , N
the DT N
participants NNS N
either CC N
rested VBN i
( ( i
control VB i
[ NNP i
CON NNP i
] NNP i
) ) i
or CC N
completed VBN N
a DT N
static JJ i
stretching NN i
protocol NN i
( ( i
static JJ i
stretch NN i
[ NNP i
SS NNP i
] NNP i
) ) i
. . i

However RB N
, , N
retention NN o
of IN o
calcium NN o
, , o
phosphorus NN o
( ( o
both DT o
formulas NN o
) ) o
, , o
and CC o
zinc NN o
( ( o
Similac NNP o
With IN o
Whey NNP o
+ NNP o
Iron NNP o
) ) o
was VBD N
inadequate JJ N
to TO N
meet VB N
estimated JJ N
fetal JJ N
requirements NNS N
. . N

Serum NNP o
and CC o
ascitic JJ o
levels NNS o
of IN o
tumor NN o
necrosis NN o
factor-alpha JJ o
, , o
interferon-gamma JJ o
, , o
interleukin-12 JJ o
, , o
and CC o
nitric JJ o
oxide NN o
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
. . N

BACKGROUND NNP N
Angiotensin-converting NNP i
enzyme NN i
inhibitors NNS i
provide VBP N
hemodynamic JJ N
and CC N
symptomatic JJ N
benefit NN N
and CC N
are VBP N
associated VBN N
with IN N
improved JJ N
survival NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

Differential JJ N
effects NNS N
of IN N
vitamin NN i
K1 NNP i
on IN N
AFP NNP N
and CC N
DCP NNP N
levels NNS N
in IN N
patients NNS p
with IN p
unresectable JJ p
HCC NNP p
and CC p
in IN p
HCC NNP p
cell NN p
lines NNS p
. . p

Number NNP o
of IN o
negative JJ o
life NN o
events NNS o
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
parenting VBG o
stress NN o
and CC o
sense NN o
of IN o
competence NN o
across IN N
both DT N
groups NNS N
. . N

The DT N
difference NN N
in IN N
proportions NNS N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
minus CC N
TISSEEL NNP N
VH NNP N
, , N
was VBD N
1.4 CD N
% NN N
with IN N
a DT N
standard JJ N
error NN N
of IN N
3.70 CD N
% NN N
. . N

RESULTS NNP N
All PDT N
the DT N
approaches NNS N
were VBD N
able JJ N
to TO N
markedly RB N
reduce VB N
the DT N
PD NNP N
values NNS N
from IN N
the DT N
baseline NN N
to TO N
the DT N
other JJ N
evaluation NN N
periods NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Risperidone NN i
and CC N
donepezil NN i
are VBP N
both DT N
metabolized VBN N
through IN N
cytochrome NN N
P450 NNP N
2D6 CD N
and CC N
3A4 CD N
, , N
raising VBG N
the DT N
possibility NN N
of IN N
drug NN N
interactions NNS N
with IN N
combination NN N
therapy NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
isoniazid NN i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN p
in IN p
tuberculin JJ p
skin JJ p
test-positive JJ p
and CC p
negative JJ p
individuals NNS p
with IN p
HIV NNP p
infection NN p
. . p

Additionally RB N
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
found VBN N
in IN N
terms NNS N
of IN N
uroporphyrin NN o
I PRP o
, , o
heptacarboxyporphyrin NN o
I PRP o
, , o
hexacarboxyporphyrin NN o
and CC o
pentacarboxyporphyrin NN o
I PRP o
. . o

CONCLUSION NNP N
Recurrence NNP o
rate NN o
is VBZ N
reduced VBN N
to TO N
one-third JJ N
after IN N
tension-free JJ N
herniotomies NNS N
as IN N
compared VBN N
with IN N
the DT N
conventionel NN N
herniotomies NNS N
without IN N
increase NN N
in IN N
complication NN o
rate NN o
. . o

Low-dose JJ i
, , i
prolonged JJ i
infusion NN i
gemcitabine NN i
in IN i
combination NN i
with IN i
cisplatin NN i
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
standard JJ N
GC NNP N
regimen NNS N
with IN N
favorable JJ N
toxicity NN o
profile NN o
and CC o
less RBR o
financial JJ o
costs NNS o
. . o

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
trends NNS N
within IN N
or CC N
between IN N
treatment NN N
groups NNS N
on IN N
the DT N
C-SSRS NNP o
, , o
laboratory NN o
values NNS o
, , o
electrocardiogram NN o
, , o
or CC o
vital JJ o
sign NN o
parameters NNS o
. . o

RESULTS NNP N
Baseline NNP o
spontaneous JJ o
activity NN o
in IN N
all DT N
subjects NNS N
showed VBD N
both DT N
high- JJ N
and CC N
low-frequency JJ N
components NNS N
; : N
in IN N
three CD N
patients NNS N
with IN N
UC NNP N
, , N
the DT N
low-frequency NN N
activity NN N
was VBD N
of IN N
high JJ N
amplitude NN N
. . N

The DT N
requirements NNS o
for IN o
respiratory JJ o
support NN o
and CC o
adverse JJ o
effects NNS o
were VBD N
also RB N
significantly RB N
lower JJR N
when WRB N
using VBG N
the DT N
bispectral JJ N
index NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
microbiologic JJ o
yields NNS o
and CC o
complication NN o
rates NNS o
associated VBN N
with IN N
vitreous JJ N
needle JJ N
tap NN N
and CC N
vitreous JJ N
biopsy NN N
in IN N
the DT N
Endophthalmitis NNP N
Vitrectomy NNP N
Study NNP N
( ( N
EVS NNP N
) ) N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
basal NN o
and CC o
peak JJ o
concentrations NNS o
of IN o
luteinising VBG o
hormone NN o
, , o
follicle NN o
stimulating VBG o
hormone NN o
, , o
thyroid JJ o
stimulating VBG o
hormone NN o
, , o
and CC o
prolactin NN o
. . o

CONCLUSIONS NNP N
Pravastatin NNP i
led VBD N
to TO N
significant JJ N
early JJ N
reduction NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
cardiovascular JJ N
events NNS N
in IN N
post-MI JJ p
women NNS p
with IN p
average JJ p
cholesterol NN p
levels NNS p
. . p

AX-CPT JJ o
performance NN o
was VBD N
assessed VBN N
following VBG N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
propranolol NN i
( ( N
a DT N
beta NN N
adrenergic JJ N
antagonist NN N
) ) N
and CC N
following VBG N
placebo NN N
( ( N
sugar NN N
pill NN N
) ) N
administration NN N
. . N

While IN N
not RB N
all DT N
results NNS N
were VBD N
statistically RB N
significant JJ N
at IN N
conventional JJ N
levels NNS N
, , N
intervention NN N
effects NNS N
were VBD N
positive JJ N
in IN N
virtually RB N
all DT N
cases NNS N
and CC N
effect NN N
magnitudes NNS N
frequently RB N
were VBD N
large JJ N
. . N

BACKGROUND IN N
The DT N
present JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
the DT N
role NN N
warm JJ N
saline NN i
rinse NN i
in IN N
the DT N
prevention NN N
of IN N
alveolar JJ N
osteitis NN N
following VBG N
dental JJ N
extractions NNS N
. . N

Pre-treatment JJ o
disease NN o
scores NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
meloxicam NN i
group NN N
for IN N
owner NN N
mobility NN N
( ( N
p=0.01 NN N
) ) N
and CC N
veterinary JJ N
lameness NN N
( ( N
p=0.02 NN N
) ) N
. . N

CONCLUSIONS NNP N
Epoetin NNP i
zeta NN i
is VBZ N
therapeutically RB N
equivalent JJ N
to TO N
epoetin VB N
alfa NN N
in IN N
the DT N
maintenance NN N
of IN N
target NN N
Hb NNP N
levels NNS N
in IN N
patients NNS p
with IN p
renal JJ p
anaemia NN p
. . p

Peripheral JJ o
natural JJ o
killer NN o
( ( o
NK NNP o
) ) o
and CC o
LAK NNP o
activities NNS o
were VBD N
augmented VBN N
in IN N
all DT N
patients NNS N
and CC N
total JJ o
white JJ o
blood NN o
cell NN o
counts NNS o
were VBD N
increased VBN N
during IN N
IS-IL-2 NNP N
therapy NN N
. . N

Immunization NN o
triggered VBD o
significant JJ o
increases NNS o
in IN o
anti-tetanus JJ o
and CC o
anti-diphtheria JJ o
IgG NNP o
levels NNS o
over IN N
each DT N
group NN N
's POS N
pre-Td JJ N
baseline NN N
levels NNS N
and CC N
those DT N
of IN N
an DT N
unvaccinated JJ N
control NN N
group NN N
. . N

YAP1 NNP i
downregulation NN N
resulted VBD N
in IN N
increased JJ N
progesterone NN o
receptor NN o
( ( o
PgR NNP o
) ) o
expression NN o
and CC N
a DT N
delayed NN N
and CC N
weaker JJR N
tamoxifen NN N
in IN N
support NN N
of IN N
the DT N
clinical JJ N
data NNS N
. . N

This DT N
study NN N
summarizes VBZ N
the DT N
treatment NN N
effect NN N
of IN N
zoledronic JJ i
acid JJ i
infusion NN i
on IN N
lumbar NN o
spine NN o
bone NN o
mineral JJ o
density NN o
in IN N
different JJ p
subgroups NNS p
with IN p
glucocorticoid-induced JJ p
osteoporosis NN p
. . p

Diastolic NNP o
duration NN o
was VBD o
calculated VBN o
by IN o
subtracting VBG o
the DT o
electromechanical JJ o
systole NN o
from IN o
the DT o
R-R NNP o
interval NN o
and CC o
expressed VBD o
as IN o
a DT o
percentage NN o
of IN o
the DT o
cardiac JJ o
cycle NN o
( ( o
% NN o
D NNP o
) ) o
. . o

Efficacy NNP o
outcome JJ o
measures NNS o
included VBD o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
subscale NN o
and CC o
the DT o
Clinical JJ o
Global NNP o
Impression-Improvement NN o
score NN o
( ( o
CGI-I NNP o
) ) o
. . o

OBJECTIVE NN N
To TO N
investigate VB N
long-term JJ N
safety NN N
and CC N
efficacy NN N
after IN N
intracoronary JJ i
injection NN i
of IN i
autologous JJ i
mononuclear JJ i
bone NN i
marrow NN i
cells NNS i
( ( i
mBMCs NN i
) ) i
in IN N
acute JJ p
myocardial JJ p
infarction NN p
( ( p
AMI NNP p
) ) p
. . p

This DT N
increased VBN N
morbidity NN N
mainly RB N
seemed VBD N
to TO N
be VB N
caused VBN N
by IN N
symptoms NNS N
usually RB N
associated VBN N
with IN N
respiratory JJ o
tract JJ o
infection NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

METHODS JJ N
Participants NNS p
were VBD p
pregnant JJ p
women NNS p
( ( p
N=56 NNP p
) ) p
, , p
with IN p
past JJ p
histories NNS p
of IN p
MDD/PPMD NNP p
but CC p
not RB p
depressed VBN p
in IN p
their PRP$ p
current JJ p
pregnancy NN p
. . p

In IN N
the DT N
oat NN N
cereal NN N
group NN N
, , N
a DT N
trend NN N
was VBD N
observed VBN N
for IN N
a DT N
lower JJR N
total JJ o
insulin NN o
response NN o
to TO N
a DT N
glucose JJ N
load NN N
, , N
suggesting VBG N
improved VBN N
insulin JJ N
sensitivity NN N
. . N

CONCLUSION NNP N
VIP NNP i
combination NN i
chemotherapy NN i
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
time NN o
to TO o
progression NN o
and CC o
overall JJ o
survival NN o
over IN N
VP NNP N
therapy NN N
in IN N
patients NNS p
with IN p
extensive JJ p
SCLC NNP p
. . p

We PRP N
conclude VBP N
that DT N
ofloxacin NN N
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

The DT N
incidence NN o
of IN o
mucosal NN o
trauma NN o
, , o
sore RB o
throat NN o
, , o
and CC o
hemodynamic JJ o
responses NNS o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

Mean JJ o
time NN o
intervals NNS o
to TO o
delivery NN o
, , o
need NN o
for IN o
oxytocin JJ o
augmentation NN o
, , o
and CC o
routes NNS o
of IN o
delivery NN o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

PoCT NNP p
device NN p
operators NNS p
were VBD N
provided VBN N
with IN N
a DT N
colour-coded JJ i
QC NNP i
Result NNP i
Sheet NNP i
and CC i
QC NNP i
Action NNP i
Sheet NNP i
for IN i
on-site JJ i
recording NN i
and CC i
interpreting NN i
of IN i
their PRP$ i
results NNS i
. . i

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
vertical JJ o
migration NN o
of IN N
the DT N
device NN N
into IN N
the DT N
femoral JJ N
head NN N
between IN N
the DT N
implants NNS N
used VBN N
( ( N
p JJ N
= NNP N
0.3 CD N
) ) N
. . N

We PRP N
hypothesized VBD N
that IN N
higher JJR N
amounts NNS N
of IN N
wear NN N
particles NNS N
result VBP N
in IN N
increased JJ N
release NN N
of IN N
metal NN N
ions NNS N
and CC N
ultimately RB N
lead JJ N
to TO N
an DT N
increased VBN N
incidence NN N
of IN N
metal NN N
allergy NN N
. . N

The DT N
peroxisome JJ i
proliferator-activated JJ i
receptor-gamma JJ i
agonist NN i
pioglitazone NN i
increases VBZ N
number NN o
and CC o
function NN o
of IN o
endothelial JJ o
progenitor NN o
cells NNS o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

BACKGROUND NNP N
Quick NNP N
change NN N
( ( N
QC NNP N
) ) N
and CC N
double JJ N
pumping NN N
( ( N
DP NNP N
) ) N
are VBP N
common JJ N
methods NNS N
of IN N
substituting VBG N
the DT N
infusion NN N
of IN N
inotropes NNS N
given VBN N
through IN N
intravenous JJ N
pump NN N
. . N

In IN N
the DT N
clonidine NN i
plus CC i
naltrexone NN i
protocol NN N
, , N
clonidine NN i
was VBD N
administered VBN N
and CC N
naltrexone NN i
was VBD N
administered VBN N
in IN N
increasing VBG N
doses NNS N
over IN N
five CD N
days NNS N
. . N

Subjects NNS p
underwent JJ p
pre- JJ p
and CC p
post-treatment JJ p
lab NN p
testing VBG p
to TO p
evaluate VB p
plasma NN o
reduced VBN o
glutathione NN o
, , o
oxidized VBD o
glutathione NN o
, , o
cysteine NN o
, , o
taurine NN o
, , o
free JJ o
and CC o
total JJ o
sulfate NN o
, , o
and CC o
whole-blood JJ o
glutathione NN o
levels NNS o
. . o

Active JJ N
treatments NNS N
and CC N
placebo NNS i
were VBD N
comparable JJ N
as RB N
far RB N
as IN N
concerns NNS N
occurrence IN N
of IN N
side-effects NNS N
( ( N
12-20 CD N
% NN N
) ) N
including VBG N
galactorrhoea NN o
, , o
breast NN o
tenderness NN o
and CC o
menstrual JJ o
changes NNS o
. . o

RESULTS NN N
At IN N
posttest NN N
, , N
a DT N
significant JJ N
increase NN N
in IN N
cardiovascular JJ o
fitness NN o
and CC o
decrease NN o
in IN o
BMI NNP o
were VBD N
found VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
evidence NN N
is VBZ N
provided VBN N
for IN N
the DT N
efficacy NN N
of IN N
repeated JJ N
doses NNS N
of IN N
porcine NN i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autism NN p
. . p

[ JJ N
Long-term JJ N
effects NNS N
of IN N
7-year JJ N
growth NN i
hormone CD i
substitution NN i
on IN N
bone NN o
metabolism NN o
, , o
bone NN o
density NN o
, , o
and CC o
bone NN o
quality NN o
in IN N
growth NN p
hormone-deficient JJ p
adults NNS p
] POS p
. . N

CONCLUSIONS NNP N
Ranolazine NNP i
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP o
and CC o
A1C NNP o
in IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
and CC p
poorly RB p
controlled VBN p
diabetes NNS p
. . p

Although IN N
fibric JJ N
acid NN N
derivatives NNS N
increase VBP N
serum JJ o
HDL-C NNP o
levels NNS o
and CC o
decrease VB o
triglyceride NN o
levels NNS o
, , N
their PRP$ N
effects NNS N
on IN N
renal JJ N
function NN N
are VBP N
largely RB N
unknown JJ N
. . N

Comparative JJ N
evaluation NN N
of IN N
calcium NN i
hydroxide NN i
and CC i
zinc NN i
oxide RB i
eugenol RB i
as IN N
root JJ p
canal JJ p
filling NN p
materials NNS p
for IN p
primary JJ p
molars NNS p
: : p
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
. . N

Use NNP N
of IN N
ampicillin/sulbactam JJ N
results NNS N
in IN N
a DT N
significantly RB N
lower JJR N
SWI NNP o
rate NN o
than IN N
use NN N
of IN N
cefoxitin NN i
, , N
which WDT N
may MD N
be VB N
a DT N
result NN N
of IN N
improved JJ N
enterococcal JJ N
and CC N
Bacteroides NNP N
coverage NN N
. . N

However RB N
, , N
the DT N
pharmacodynamic NN N
( ( N
PD NNP N
) ) N
effects NNS N
of IN N
the DT N
PDE NNP i
inhibitor NN i
pentoxifylline NN i
on IN N
platelet NN o
function NN o
profiles NNS o
in IN N
DM NNP N
patients NNS N
receiving VBG N
DAPT NNP N
are VBP N
unknown JJ N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
number NN o
of IN o
attempts NNS o
at IN o
esophageal JJ o
intubation NN o
, , o
the DT o
amount NN o
of IN o
sedation NN o
used VBN o
, , o
and CC o
the DT o
examination NN o
time NN o
. . o

Renal JJ o
function NN o
was VBD N
assessed VBN N
by IN N
serially RB N
measuring VBG N
the DT N
serum NN o
creatinine NN o
, , o
glomerular JJ o
filtration NN o
rate NN o
( ( o
using VBG o
Cr51-EDTA NNP o
) ) o
, , o
and CC o
24-h JJ o
urinary JJ o
protein NN o
excretion NN o
. . o

Skeletal-related JJ o
events NNS o
( ( o
SREs NNP o
) ) o
were VBD N
defined VBN N
as IN N
pathologic JJ N
bone NN N
fractures NNS N
, , N
spinal JJ N
cord NN N
compression NN N
, , N
surgery NN N
to TO N
bone VB N
, , N
radiation NN N
therapy NN N
to TO N
bone VB N
, , N
and CC N
hypercalcemia NN N
of IN N
malignancy NN N
. . N

Triptorelin NNP o
decreased VBD o
uterine JJ o
volume NN o
, , N
calculated VBN N
by IN N
ultrasonography NN N
, , N
by IN N
26.5 CD N
% NN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
the DT N
volume NN N
remained VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
. . N

AIM NNP N
This DT N
study NN N
compares VBZ N
the DT N
effects NNS N
of IN N
laparoscopic JJ i
lymphadenectomy JJ i
versus IN N
those DT N
of IN N
abdominal JJ i
lymphadenectomy NN i
in IN N
patients NNS p
with IN p
endometrial JJ p
cancer NN p
. . p

BACKGROUND NNP N
Because IN N
of IN N
the DT N
widespread JJ N
existence NN N
of IN N
Neisseria NNP N
gonorrhoeae NN N
resistant NN N
to TO N
penicillin VB N
or CC N
tetracycline VB N
, , N
ceftriaxone NN N
is VBZ N
now RB N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
gonorrhea NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
pharmacokinetics NNS N
of IN N
corifollitropin NN N
alfa NN N
and CC N
rFSH NN N
are VBP N
quite RB N
different JJ N
but CC N
their PRP$ N
induced JJ N
pharmacodynamic JJ o
effects NNS o
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

Onset NNP o
of IN o
complete JJ o
motor NN o
blockade NN o
was VBD o
fastest JJS o
and CC o
the DT o
degree NN o
of IN o
motor NN o
blockade NN o
was VBD N
most RBS N
profound JJ N
with IN N
the DT N
mixture NN N
containing VBG N
equal JJ N
proportions NNS N
of IN N
lidocaine NN i
and CC i
bupivacaine NN i
. . i

Although IN N
the DT N
incidence NN N
of IN N
angiographic JJ o
restenosis NN o
tended VBD N
to TO N
be VB N
lower JJR N
with IN N
warfarin NN N
, , N
none NN N
of IN N
these DT N
differences NNS N
was VBD N
significant JJ N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN i
( ( i
Dostinex NNP i
, , i
a DT i
dopamine JJ i
agonist NN i
) ) i
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP i
( ( i
a DT i
gonadotropin-releasing NN i
hormone NN i
agonist NN i
) ) i
. . i

This DT N
is VBZ N
a DT N
prospective JJ N
study NN N
that WDT N
compares VBZ N
the DT N
effects NNS N
of IN N
calcium NN i
acetate NN i
and CC i
sevelamer NN i
on IN N
coronary JJ o
calcification NN o
( ( o
CAC NNP o
) ) o
and CC o
bone $ o
histology NN o
. . o

Platelet NNP o
membrane NN o
glycoprotein NN o
Ib NNP o
and CC o
glycoprotein NN o
IIb/IIIa NNP o
, , o
P-selectin NNP o
, , o
platelet-derived JJ o
microparticles NNS o
, , o
leukocyte JJ o
CD11b/CD18 NNP o
( ( o
Mac-1 NNP o
) ) o
, , o
and CC o
platelet-leukocyte JJ o
aggregate NN o
were VBD N
quantified VBN N
by IN N
means NNS N
of IN N
flow JJ N
cytometry NN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
use NN N
of IN N
maintenance NN N
therapy NN N
in IN N
maximally RB N
tolerated VBN N
doses NNS N
may MD N
be VB N
associated VBN N
with IN N
an DT N
increased VBN N
survival NN N
in IN N
childhood NN N
ALL NNP N
. . N

No DT o
serious JJ o
clinical JJ o
or CC o
laboratory JJ o
adverse JJ o
events NNS o
occurred VBD N
, , N
and CC N
no DT N
anti-evolocumab JJ o
antibody NN o
development NN o
was VBD N
detected VBN N
during IN N
the DT N
study NN N
. . N

A DT N
high JJ N
dose NN N
of IN N
either DT N
eprosartan NN i
or CC i
enalapril VB i
significantly RB N
decreased VBN N
the DT N
indices NNS N
of IN N
platelet NN o
activation NN o
and CC o
endothelial JJ o
dysfunction NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

Tolfenamic NNP i
acid NN i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin JJ N
biosynthesis NN N
, , N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
migraine NN N
attacks NNS N
. . N

RESULTS NNP N
Ecstasy NNP N
users NNS N
showed VBD N
a DT N
broad JJ N
pattern NN N
of IN N
statistically RB N
significant JJ N
, , N
but CC N
clinically RB o
small JJ o
, , o
impairment NN o
of IN o
memory NN o
and CC o
prolonged JJ o
reaction NN o
times NNS o
. . o

CONCLUSIONS NNP N
PI NNP N
was VBD N
an DT N
earlier JJR N
, , N
clearer JJR N
and CC N
more RBR N
sensitive JJ N
indicator NN N
of IN N
the DT N
development NN N
of IN N
epidural-induced JJ N
sympathectomy NN N
than IN N
either DT N
skin JJ o
temperature NN o
or CC o
MAP NNP o
. . o

CONCLUSION VB N
The DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
was VBD N
more RBR N
successful JJ N
for IN N
the DT N
internal JJ N
cardioversion NN N
of IN N
both DT N
persistent JJ N
and CC N
induced JJ N
AF NNP N
in IN N
patients NNS N
( ( N
in IN N
terms NNS N
of IN N
leading VBG N
edge NN N
voltage NN N
) ) N
. . N

Vascular JJ i
endothelial JJ i
growth NN i
factor NN i
( ( i
VEGF NNP i
) ) i
and CC N
its PRP$ N
cellular JJ N
receptor NN N
VEGFR-2 NNP N
have VBP N
been VBN N
implicated VBN N
as IN N
the DT N
main JJ N
endothelial JJ N
pathway NN N
required VBN N
for IN N
tumor NN N
neovascularization NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
transdermal JJ i
estradiol NNS i
combined VBN i
with IN i
long-cycle NN i
progestins NNS i
was VBD N
associated VBN N
with IN N
no DT N
net JJ N
activation NN N
of IN N
coagulation NN N
despite IN N
reduced JJ N
levels NNS N
of IN N
coagulation NN N
inhibitors NNS N
. . N

Autologous JJ i
platelets NNS i
were VBD i
labelled VBN i
and CC i
re-injected JJ i
seven CD i
days NNS i
following VBG i
surgery NN i
and CC i
the DT i
graft NN i
thrombogenicity NN i
index NN i
calculated VBD N
as IN N
the DT N
daily JJ N
rise NN N
in IN N
the DT N
ratio NN N
of IN N
emissions NNS N
from IN N
the DT N
graft NN N
over IN N
a DT N
reference NN N
site NN N
. . N

However RB N
, , N
this DT N
could MD N
not RB N
be VB N
confirmed VBN N
using VBG N
estimates NNS N
from IN N
the DT N
Bergman NNP N
Minimal NNP N
Model NNP N
, , N
perhaps RB N
because IN N
of IN N
our PRP$ N
small JJ N
sample NN N
size NN N
. . N

Predicting VBG o
Overall JJ o
Survival NNP o
After IN N
Stereotactic NNP i
Ablative NNP i
Radiation NNP i
Therapy NNP i
in IN N
Early-Stage NNP p
Lung NNP p
Cancer NNP p
: : p
Development NNP N
and CC N
External NNP N
Validation NNP N
of IN N
the DT N
Amsterdam NNP N
Prognostic NNP N
Model NNP N
. . N

Two-week JJ N
indwelling NN N
did VBD N
not RB N
increase VB N
the DT N
risk NN o
of IN o
infection NN o
compared VBN o
with IN o
1-week JJ o
indwelling NN o
at IN N
any DT N
of IN N
the DT N
sites NNS N
in IN N
critically RB p
ill JJ p
patients NNS p
. . p

CONCLUSION NN N
Improvements NNS N
to TO N
whole VB N
body NN N
insulin JJ N
sensitivity NN N
after IN N
short-term JJ N
aerobic JJ i
exercise NN i
training NN i
are VBP N
due JJ N
to TO N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
heptic JJ N
insulin NN N
sensitivity NN N
. . N

OBJECTIVE NN N
To TO N
observe VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
probucol NN i
on IN N
serum NN o
malondialdehyde NN o
( ( o
MDA NNP o
) ) o
and CC o
superoxide JJ o
dismutase NN o
( ( o
SOD NNP o
) ) o
in IN N
patients NNS p
with IN p
primary JJ p
hypertension NN p
. . p

On IN N
stepwise NN N
logistic JJ N
regression NN N
analysis NN N
, , N
hepatitis NN N
B NNP N
virus NN N
DNA NNP N
, , N
AST NNP N
and CC N
a DT N
history NN N
of IN N
acute JJ N
hepatitis NN N
predicted VBD N
response NN N
independently RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

To TO N
obtain VB N
the DT N
bioactive JJ N
antigen NN N
proteins NNS N
in IN N
large JJ N
quantities NNS N
, , N
a DT N
new JJ N
protein NN N
expression NN N
vector NN N
pBCX NN N
was VBD N
constructed VBN N
, , N
which WDT N
is VBZ N
based VBN N
on IN N
the DT N
pET32a NN N
vector NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
cutaneous JJ N
vasodilation NN N
in IN N
response NN N
to TO N
acupuncture VB N
stimulation NN N
may MD N
not RB N
occur VB N
through IN N
an DT N
axon JJ N
reflex NN N
as IN N
previously RB N
reported VBN N
. . N

AIM NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
acetazolamide NN i
on IN N
cystoid NN N
macular NN N
oedema NN N
( ( N
CMO NNP N
) ) N
in IN N
patients NNS p
with IN p
Behcet NNP p
's POS p
disease NN p
. . p

For IN N
the DT N
first JJ N
time NN N
, , N
this DT N
study NN N
has VBZ N
revealed VBN N
that IN N
acute JJ N
smoking NN N
speeds VBZ N
the DT N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ p
habitual JJ p
smokers NNS p
. . p

RESULTS NNP N
We PRP N
observed VBD N
an DT N
advantage NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
compared VBN N
with IN N
placebo NN i
for IN N
hyperactivity NN N
and CC N
stereotypy NN N
, , N
each DT N
with IN N
a DT N
large JJ N
effect NN N
size NN N
. . N

It PRP N
is VBZ N
essential JJ N
to TO N
provide VB N
an DT N
adequate JJ N
amount NN N
of IN N
rumen-degradable JJ N
nitrogen NN N
( ( N
RDN NNP N
) ) N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
in IN N
the DT N
rumen NNS N
on IN N
straw-based JJ N
diets NNS N
. . N

Time NN o
to TO o
extubation NN o
, , o
morphine NN o
and CC o
midazolam NN o
amounts NNS o
, , o
hourly RB o
pain NN o
scores NNS o
, , o
and CC o
seizure NN o
activity NN o
were VBD N
compared VBN N
using VBG N
an DT N
intention-to-treat JJ N
and CC N
per-protocol JJ N
analysis NN N
. . N

The DT N
suppressive JJ N
activity NN N
of IN N
the DT N
patient NN N
plasma NN N
was VBD N
assayed VBN N
by IN N
measurement NN N
of IN N
normal JJ N
PMN NNP N
superoxide NN N
production NN N
relative JJ N
to TO N
normal JJ N
control NN N
plasma NN N
( ( N
ratio JJ N
P NNP N
: : N
C NNP N
) ) N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
for IN N
mean JJ o
change NN o
in IN o
Fridericia NNP o
's POS o
correction NN o
of IN o
QT NNP o
during IN N
the DT N
trial NN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
document VB N
the DT N
clinical JJ N
consequences NNS N
of IN N
this DT N
finding NN N
, , N
for IN N
example NN N
in IN N
severe JJ p
asthmatic JJ p
patients NNS p
. . p

In IN N
the DT N
subgroup NN N
of IN N
Avastin-treated JJ N
eyes NNS N
, , N
multivariate NN N
analysis NN N
identified VBN N
hemoglobin JJ N
A1c NNP N
as IN N
the DT N
strongest JJS N
predictor NN N
of IN N
proliferative JJ o
diabetic JJ o
retinopathy NN o
recurrence NN o
( ( N
p=0.033 NN N
) ) N
. . N

BACKGROUND NNP N
An DT N
imbalance NN N
in IN N
the DT N
excitatory/inhibitory JJ N
systems NNS N
with IN N
abnormalities NNS N
in IN N
the DT N
glutamatergic NN N
pathways VBZ N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
. . N

RATIONALE NNP N
( ( N
+/- JJ N
) ) N
3,4-Methylenedioxymethamphetamine CD i
( ( i
MDMA NNP i
or CC i
ecstasy NN i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
cause VB N
long JJ N
term NN N
damage NN N
to TO N
serotonergic VB N
cerebral JJ N
neurons NNS N
in IN N
animals NNS N
. . N

Bradykinin NNP N
increases VBZ N
during IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
and CC N
stimulates VBZ N
the DT N
release NN o
of IN o
nitric JJ o
oxide NN o
, , o
inflammatory JJ o
cytokines NNS o
, , o
and CC o
tissue-type JJ o
plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
, , N
acting VBG N
through IN N
its PRP$ N
B2 NNP N
receptor NN N
. . N

Previous JJ N
reports NNS N
suggested VBD N
that IN N
CD19+ NNP N
B NNP N
cells NNS N
are VBP N
markedly RB N
increased VBN N
in IN N
myeloma NN N
patients NNS N
and CC N
that IN N
this DT N
population NN N
shares NNS N
clonotypic VBD N
rearrangements NNS N
with IN N
the DT N
malignant JJ N
plasma NN N
cell NN N
. . N

CONCLUSIONS NNP N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
, , N
which WDT N
is VBZ N
available JJ N
over-the-counter JJ N
, , N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
neck NN N
pain NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Rating VBG o
Scale NNP o
( ( o
total JJ o
score NN o
) ) o
. . o

RESULTS NN N
After IN N
treatments NNS N
, , N
statistically RB N
significant JJ N
improvements NNS N
in IN N
the DT N
baseline NN N
KP NNP N
were VBD N
observed VBN N
in IN N
erythema NN o
and CC o
melanin NN o
index NN o
of IN N
mexameter NN N
on IN N
treated JJ N
upper JJ N
arms NNS N
. . N

We PRP N
have VBP N
recently RB N
shown VBN N
that IN N
total JJ o
TFPI NNP o
activity NN o
, , o
plasma VBP o
free JJ o
TFPI NNP o
antigen NN o
, , o
and CC o
heparin NN o
releasable JJ o
TFPI NNP o
were VBD N
partially RB N
depleted VBN N
during IN N
repeated VBN N
and CC N
continuous JJ N
i.v NN N
. . N

However RB N
, , N
severe JJ o
anemia NN o
and CC o
febrile JJ o
neutropenia NN o
are VBP N
statistically RB N
more RBR N
frequent JJ N
in IN N
the DT N
VNR/CDDP NNP N
arm NN N
than IN N
in IN N
the DT N
DCT/CDDP NNP N
one NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
rate NN o
of IN o
thrombolytic JJ o
use NN o
, , o
90-day JJ o
functional JJ o
outcomes NNS o
, , o
incidence NN o
of IN o
intracerebral JJ o
hemorrhages NNS o
, , o
and CC o
technical JJ o
observations NNS o
. . o

Vancomycin NNP i
was VBD N
added VBN N
in IN N
all DT N
cases NNS N
of IN N
persistent JJ N
fever NN N
in IN N
the DT N
ceftazidime NN N
arm NN N
, , N
but CC N
only RB N
when WRB N
there EX N
was VBD N
microbiologically RB N
documented VBN N
resistance NN N
in IN N
the DT N
piperacillin/tazobactam NN N
arm NN N
. . N

However RB N
, , N
DPP-4 NNP N
inhibitors NNS N
also RB N
reduce VB N
fasting VBG o
blood NN o
glucose NN o
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

There EX N
was VBD N
a DT N
mean JJ N
increase NN N
in IN N
serum JJ o
creatinine NN o
concentration NN o
associated VBN N
with IN N
CSA NNP N
; : N
no DT N
persons NNS N
were VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
for IN N
this DT N
reason NN N
. . N

Especially RB N
for IN N
patients NNS p
with IN p
pulmonary JJ p
tuberculosis NN p
or CC p
aged VBN p
patients NNS p
with IN p
primary JJ p
bladder NN p
tumors NNS p
, , p
mitoxantrone NN i
and CC i
doxorubicin NN i
may MD N
be VB N
the DT N
tolerable JJ N
and CC N
effective JJ N
intravesical JJ N
agents NNS N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
mortality NN o
, , o
morbidity NN o
or CC o
incapacity NN o
for IN o
work NN o
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

With IN N
the DT N
low JJ N
infusion NN N
rate NN N
, , N
arterial JJ N
pressure NN N
increased VBD N
to TO N
its PRP$ N
control NN N
value NN N
during IN N
operation NN N
; : N
it PRP N
remained VBD N
at IN N
the DT N
postinduction NN N
value NN N
with IN N
high JJ N
infusion NN N
rates NNS N
. . N

Fecal JJ o
SCFA NNP o
levels NNS o
varied VBD N
widely RB N
among IN N
participants NNS N
at IN N
entry NN N
( ( N
butyrate JJ N
concentrations NNS N
: : N
3.5-32.6 JJ N
mmol/kg NN N
; : N
butyrate JJ N
excretions NNS N
: : N
0.3-18.2 JJ N
mmol/48 NN N
h NN N
) ) N
. . N

Two CD N
patients NNS N
who WP N
received VBD N
phenoxymethylpenicillin NN i
and CC N
two CD N
given VBN N
doxycycline VBP i
subsequently RB N
developed VBN N
major JJ o
manifestations NNS o
of IN o
Lyme NNP o
borreliosis NN o
; : o
these DT N
did VBD N
not RB N
occur VB N
in IN N
patients NNS N
receiving VBG N
azithromycin NN i
. . i

Studies NNS N
performed VBN N
on IN N
airway NN N
smooth JJ N
muscle NN N
in IN N
vitro NNS N
have VBP N
indicated VBN N
that IN N
salmeterol NN i
is VBZ N
a DT N
partial JJ N
agonist NN N
on IN N
the DT N
beta2-receptor NN N
in IN N
comparison NN N
to TO N
formoterol VB N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
for IN N
evaluations NNS N
of IN N
overall JJ o
pain NN o
intensity NN o
, , o
analgesic JJ o
efficacy NN o
, , o
or CC o
adverse JJ o
events NNS o
. . o

The DT N
incidence NN N
of IN N
hot JJ o
flashes NNS o
increased VBD N
significantly RB N
over IN N
baseline NN N
in IN N
the DT N
10-mg JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
5-mg JJ N
group NN N
. . N

Topical JJ i
tetracaine NN i
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN o
score NN o
, , N
although IN N
it PRP N
did VBD N
lead VB N
to TO N
faster VB N
recovery NN N
times NNS N
. . N

No DT N
trends NNS N
in IN N
heart NN o
rate NN o
or CC o
ECG NNP o
parameters NNS o
, , N
including VBG N
the DT N
QTc NNP o
interval NN o
and CC o
T-wave NNP o
morphology NN o
, , N
were VBD N
observed VBN N
. . N

CONCLUSION NN N
At IN N
mean JJ N
5-year JJ N
angiography NN N
in IN N
largely RB N
asymptomatic JJ N
patients NNS N
, , N
the DT N
selection NN N
of IN N
arterial JJ N
or CC N
venous JJ N
conduit NN N
for IN N
the DT N
second JJ N
graft NN N
has VBZ N
not RB N
significantly RB N
affected JJ N
patency NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
central JJ N
effects NNS N
of IN N
captopril NN i
and CC N
enalapril NN i
were VBD N
minor JJ N
and CC N
not RB N
constant JJ N
in IN N
young JJ p
healthy JJ p
men NNS p
. . p

CONCLUSION NN N
There EX N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
any DT N
difference NN N
in IN N
discomfort NN o
scores NNS o
between IN N
the DT N
ocular JJ N
irrigation NN N
fluids NNS N
when WRB N
used VBN N
without IN N
the DT N
MTL NNP N
. . N

BACKGROUND IN N
The DT N
sources NNS N
and CC N
the DT N
impact NN N
of IN N
maternal JJ N
bacteria NNS N
on IN N
the DT N
initial JJ N
inoculum NN N
of IN N
the DT N
intestinal JJ N
microflora NN N
of IN N
newborn JJ N
infants NNS N
remain VBP N
elusive JJ N
. . N

Rapid JJ o
absorption NN o
, , N
with IN N
most JJS N
Cmax NNP N
values NNS N
from IN N
50-60 JJ N
micrograms/ml NN N
reached VBD N
within IN N
1.5-3 JJ N
h NN N
, , N
was VBD N
found VBN N
for IN N
both DT N
tablet JJ N
formulations NNS N
. . N

CONCLUSIONS NNP N
Lesser NNP N
concentrations NNS N
of IN N
ropivacaine NN i
and CC i
fentanyl JJ i
provide NN N
comparable JJ N
analgesia NN N
with IN N
less JJR N
motor NN o
block NN o
despite IN N
the DT N
use NN N
of IN N
similar JJ N
amounts NNS N
of IN N
ropivacaine NN i
and CC N
fentanyl NN N
. . N

In IN N
conclusion NN N
, , N
1-yr JJ N
treatment NN N
with IN N
melatonin NN N
increased VBN N
BMD NNP o
at IN o
femoral JJ o
neck NN o
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
while IN N
high-dose JJ N
melatonin NN N
increased VBD N
vBMD NN N
in IN N
the DT N
spine NN N
. . N

Using VBG N
analysis NN N
of IN N
variance NN N
and CC N
chi-square NN N
tests NNS N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
any DT N
of IN N
these DT N
parameters NNS N
between IN N
the DT N
two CD N
patients NNS N
groups NNS N
. . N

These DT N
results NNS N
are VBP N
in IN N
accordance NN N
with IN N
the DT N
hypothesis NN N
that IN N
the DT N
nephrotoxic JJ N
effect NN N
of IN N
cyclosporin NN i
A NNP N
results NNS N
from IN N
a DT N
preferential JJ N
constriction NN N
of IN N
afferent JJ N
glomerular JJ N
vessels NNS N
. . N

Similar JJ N
trends NNS N
were VBD N
noted VBN N
for IN N
changes NNS N
in IN N
the DT N
% NN N
of IN N
sites NNS N
with IN N
bleeding VBG o
on IN o
probing VBG o
in IN N
the DT N
0.01 CD N
% NN N
P-113 NNP N
group NN N
. . N

RESULTS VB N
The DT N
demographic JJ N
and CC N
other JJ N
baseline NN N
parameters NNS N
such JJ N
as IN N
indications NNS N
for IN N
extractions NNS N
were VBD N
comparable JJ N
among IN N
the DT N
study NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Nasotracheal NNP i
intubation NN i
under IN i
CTSC NNP i
guidance NN i
increases VBZ N
the DT N
success NN N
rate NN N
of IN N
airway NN N
instrumentation NN N
, , N
and CC N
also RB N
reduces VBZ N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
epistaxis NN o
. . o

[ JJ N
Comparison NNP N
of IN N
three CD N
analgesic JJ N
methods NNS N
for IN N
postoperative JJ N
pain NN N
relief NN N
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ o
interleukin-6 JJ o
concentration NN o
following VBG N
radical JJ N
surgery NN N
for IN N
gastric JJ p
carcinoma NN p
] NN p
. . p

RESULTS NNP N
Both NNP N
MDD NNP N
patients NNS N
and CC N
age-matched JJ N
controls NNS N
demonstrated VBD N
a DT N
significant JJ N
reaction NN o
time NN o
( ( o
RT NNP o
) ) o
and CC o
P3b NNP o
latency NN o
differences NNS o
between IN N
predicted VBN N
and CC N
random JJ N
targets NNS N
. . N

CONCLUSIONS NNP N
Although IN N
probably RB N
not RB N
arrhythmogenic JJ N
in IN N
normal JJ N
subjects NNS N
, , N
moderate JJ N
caffeine NN N
ingestion NN N
does VBZ N
produce VB N
a DT N
small JJ N
but CC N
statistically RB N
significant JJ N
prolongation NN N
of IN N
signal-averaged JJ o
QRS NNP o
complexes NNS o
. . o

Estrogen NNP i
replacement NN i
therapy NN i
is VBZ N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
hot JJ o
flashes NNS o
, , N
but CC N
its PRP$ N
use NN N
is VBZ N
controversial JJ N
in IN N
breast NN p
cancer NN p
survivors NNS p
. . p

The DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
Version NNP o
( ( o
ABC-CV NNP o
) ) o
and CC o
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
scale NN o
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

Gastrointestinal JJ o
side NN o
effects NNS o
and CC o
hand-foot JJ o
syndrome NN o
were VBD N
more JJR N
common JJ N
with IN N
combination NN N
therapy NN N
, , N
whereas JJ N
myalgia NN o
, , o
arthralgia NN o
, , o
and CC o
neutropenic JJ o
fever/sepsis NN o
were VBD N
more JJR N
common JJ N
with IN N
single-agent JJ i
docetaxel NN i
. . i

CONCLUSION NNP N
Topical NNP N
bupivacaine NN i
decreases VBZ N
postoperative JJ o
pain NN o
scores NNS o
significantly RB N
compared VBN N
with IN N
placebo NN i
in IN N
women NNS p
undergoing VBG p
laparoscopic NN p
tubal JJ p
sterilization NN p
with IN p
silastic JJ p
bands NNS p
. . p

LIMITATIONS NNP N
Carryover NNP N
effects NNS N
limited VBD N
the DT N
power NN N
to TO N
detect VB N
significant JJ N
changes NNS N
in IN N
endothelial-derived JJ N
vasoregulators NNS N
, , N
and CC N
future JJ N
studies NNS N
will MD N
require VB N
parallel JJ N
trial NN N
designs NNS N
. . N

The DT N
primary NN N
study VBD N
end JJ N
point NN N
was VBD N
the DT N
grading NN o
of IN o
acute NN o
and CC o
late JJ o
nonhematologic NN o
toxicities NNS o
( ( o
mucositis NN o
, , o
dysphagia NN o
, , o
xerostomia NN o
) ) o
induced VBN N
by IN N
radiochemotherapy NN N
. . N

AIMS NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
synthetic JJ i
GLP-1 NNP i
on IN N
fundus NN o
tone NN o
and CC o
volume NN o
waves NNS o
, , o
gastric JJ o
compliance NN o
, , N
and CC N
perception NN N
of IN N
gastric JJ N
distension NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
of IN N
hirsute JJ N
women NNS N
with IN N
third JJ N
generation NN N
OCs NNP N
containing VBG N
desogestrel NN N
results NNS N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
sex NN o
hormone-binding JJ o
globulin NN o
and CC o
decrease NN o
in IN o
free JJ o
testosterone NN o
and CC o
3alpha-androstanediol JJ o
glucuronide NN o
. . o

Furthermore RB N
, , N
we PRP N
investigated VBD N
the DT N
perfusate NN N
of IN N
the DT N
graft NN N
liver NN N
in IN N
both DT N
groups NNS N
and CC N
detected JJ N
signs NNS N
of IN N
a DT N
decreased JJ N
t-PA JJ o
release NN o
in IN N
the DT N
infusion NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
intake NN N
of IN N
lean JJ N
fish NN N
at IN N
least JJS N
four CD N
times NNS N
per IN N
week NN N
could MD N
reduce VB N
blood NN o
pressure NN o
levels NNS o
in IN N
CHD NNP N
patients NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
heart NN o
rate NN o
throughout IN N
maintenance NN N
therapy NN N
with IN N
propranolol NN i
, , N
which WDT N
continued VBD N
through IN N
the DT N
tenth JJ N
hospital NN N
day NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Statistically NNP N
significant JJ N
correlations NNS N
between IN N
smoking NN o
and CC o
nutrient JJ o
intake NN o
, , o
HbA1c NNP o
, , o
and CC o
serum VB o
lipid JJ o
levels NNS o
. . o

Fibula NNP o
, , o
scapula NN o
, , o
iliac JJ o
crest NN o
, , o
rib NN o
, , o
and CC o
metatarsal NN o
as RB N
well RB N
as IN N
the DT N
radial JJ N
forearm NN N
osseocutaneous JJ N
flaps NNS N
have VBP N
all DT N
been VBN N
utilized VBN N
for IN N
this DT N
purpose NN N
. . N

Individuals NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
anti-Helicobacter JJ i
pylori NN i
triple JJ i
therapy NN i
and/or NN i
dietary JJ i
supplementation NN i
with IN i
ascorbic JJ i
acid NN i
, , i
beta-carotene JJ i
, , i
or CC i
their PRP$ i
corresponding JJ i
placebos NNS i
. . i

We PRP N
also RB N
compared VBN N
changes NNS N
in IN N
other JJ N
ABC-C JJ o
subscale NN o
scores NNS o
and CC o
Clinical NNP o
Global NNP o
Impressions-Improvement NNP o
( ( o
CGI-I NNP o
) ) o
scale NN o
scores NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

Furthermore RB N
, , N
significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP o
score NN o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
raw JJ N
CM NNP N
group NN N
only RB N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN o
with IN o
which WDT o
gallium NN o
interfered VBD o
with IN o
readings NNS o
or CC o
time NN o
to TO o
complete VB o
the DT o
study NN o
. . o

Patients NNS p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
or CC p
anaplastic JJ p
lymphoma NN p
kinase NN p
genomic JJ p
tumor NN p
aberrations NNS p
should MD N
have VB N
disease NN N
progression NN N
on IN N
FDA-approved NNP N
therapy NN N
for IN N
these DT N
aberrations NNS N
prior VBP N
to TO N
receiving VBG N
ramucirumab NN N
. . N

YDJ NNP i
external JJ i
lotion NN i
and CC i
YDJ NNP i
cream NN i
were VBD N
applied VBN N
to TO N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ i
saline NN i
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
rates NNS o
of IN o
definite JJ o
infections NNS o
was VBD N
greatest JJS N
for IN N
fungal JJ N
infections NNS N
, , N
intermediate NN N
for IN N
bacterial JJ N
infections NNS N
, , N
and CC N
lowest JJS N
for IN N
viral JJ N
infections NNS N
. . N

Basal NNP o
sex NN o
steroid NN o
suppression NN o
, , o
growth NN o
rates NNS o
, , o
pubertal JJ o
progression NN o
, , o
bone NN o
age NN o
advancement NN o
, , o
and CC o
adverse JJ o
events NNS o
were VBD N
similar JJ N
with IN N
either DT N
dose NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Attention NNP N
deficits NNS N
are VBP N
often RB N
among IN N
the DT N
most RBS N
persistent JJ N
and CC N
debilitating VBG N
impairments NNS N
resulting VBG N
from IN N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
in IN N
obese JJ p
subjects NNS p
given VBN N
a DT N
hypocaloric JJ i
diet NN i
, , i
GH NNP i
accelerates VBZ o
body NN o
fat JJ o
loss NN o
, , o
exerts VBZ o
anabolic JJ o
effects NNS o
and CC o
improves NNS o
GH NNP o
secretion NN o
. . o

Homogenous JJ o
enhancement NN o
of IN o
deep JJ o
veins NNS o
was VBD N
more RBR N
assuredly RB N
achieved VBN N
with IN N
protocol NN N
C. NNP N
CONCLUSION NNP N
With IN N
protocol NN N
C NNP N
, , N
qualitatively RB N
acceptable JJ N
enhancement NN N
can MD N
be VB N
obtained VBN N
in IN N
whole-body JJ i
CT NNP i
. . i

The DT N
study NN N
shows VBZ N
that IN N
in IN N
infants NNS p
with IN p
atopic NN p
dermatitis NN p
, , N
raised VBD N
serum JJ N
total NN N
IgE NNP N
has VBZ N
significantly RB N
different JJ N
determinants NNS N
from IN N
that IN N
a DT N
specific JJ N
allergen NN N
sensitization NN N
. . N

A DT N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
local JJ i
estrogen NN i
with IN i
or CC i
without IN i
local JJ i
testosterone NN i
on IN N
vulvovaginal JJ o
and CC o
sexual JJ o
dysfunction NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

Blood NNP o
pressure NN o
, , o
FG NNP o
, , o
and CC o
lipid JJ o
profiles NNS o
were VBD N
significantly RB N
correlated VBN N
with IN N
antioxidant JJ o
enzymes NNS o
activities NNS o
after IN N
supplementation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Effect NN N
of IN N
entacapone NN i
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN N
response NN N
to TO N
acute VB N
treatment NN N
with IN N
levodopa NN N
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
. . p

CONCLUSIONS NNP N
Pulsed VBD i
low-intensity NN i
direct JJ i
current JJ i
represents VBZ N
a DT N
useful JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN N
stage NN N
II NNP N
and CC N
stage NN N
III NNP N
chronic JJ N
decubitus NN N
ulcers NNS N
by IN N
increasing VBG N
the DT N
healing NN N
rate NN N
. . N

Interobserver NNP o
reliability NN o
between IN N
the DT N
radiologists NNS N
was VBD N
considered VBN N
excellent NN N
for IN N
both DT N
CT NNP N
and CC N
MRI NNP N
( ( N
ICC NNP N
= NNP N
0.777 CD N
and CC N
0.843 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NN N
With IN N
the DT N
use NN N
of IN N
leukocyte JJ o
reduction NN o
filters NNS o
, , N
we PRP N
found VBD N
significantly RB N
lower JJR N
beta-glucuronidase NN o
levels NNS o
in IN o
arterial JJ o
and CC o
coronary JJ o
sinus NN o
blood NN o
samples NNS o
. . o

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
immunological JJ N
and CC N
functional JJ N
effects NNS N
of IN N
a DT N
liposome-entrapped JJ i
D. NNP i
pteronyssinus NN i
vaccine NN i
on IN N
mite JJ p
monosensitive NN p
, , p
mild JJ p
asthma NN p
patients NNS p
. . p

No DT N
dose-response JJ o
effect NN o
was VBD N
observed VBN N
with IN N
either DT N
drug NN N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
treatment NN N
with IN N
fluticasone NN i
or CC N
budesonide NN i
. . i

The DT N
mean JJ o
exercise NN o
time NN o
was VBD N
219.9 CD N
seconds NNS N
in IN N
the DT N
air NN N
control NN N
period NN N
and CC N
221.3 CD N
seconds NNS N
after IN N
purified VBN N
air NN N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
Effects NNPS N
of IN N
Naltrexone NNP i
on IN N
Subjective NNP N
Response NNP N
to TO N
Methamphetamine NNP i
in IN N
a DT N
Clinical JJ N
Sample NN N
: : N
a DT N
Double-Blind NNP N
, , N
Placebo-Controlled NNP N
Laboratory NNP N
Study NNP N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN N
technique NN N
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ N
positioning NN N
than IN N
the DT N
holder NN N
technique NN N
. . N

Effect NN N
of IN N
L-arginine NNP i
or CC i
L-citrulline JJ i
oral JJ i
supplementation NN i
on IN N
blood NN o
pressure NN o
and CC o
right JJ o
ventricular NN o
function NN o
in IN N
heart NN p
failure NN p
patients NNS p
with IN p
preserved JJ p
ejection NN p
fraction NN p
. . p

Participants NNS N
in IN N
both DT N
groups NNS N
also RB N
reduced VBD N
their PRP$ N
time NN o
spent VBN o
in IN o
prolonged JJ o
sitting NN o
bouts NNS o
( ( o
? . o
) ) o
and CC o
increased JJ o
time NN o
spent VBN o
standing NN o
and CC o
stepping NN o
. . o

Women NNS p
not RB p
using VBG p
HRT NNP i
had VBD N
faster JJR N
propagation NN o
rates NNS o
and CC o
higher JJR o
maximum NN o
production NN o
than IN N
women NNS N
using VBG N
HRT NNP i
; : i
after IN i
supplementation NN i
with IN i
fish JJ i
oil NN i
and CC i
alpha-tocopheryl JJ i
acetate NN i
these DT N
differences NNS N
prevailed VBD N
. . N

Higher JJR N
allergen NN N
doses NNS N
were VBD N
associated VBN N
with IN N
drug-related JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
, , o
predominantly RB o
manifested VBN o
by IN o
pruritus NN o
, , o
erythema NN o
, , o
wheal NN o
, , o
or CC o
eczema NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
extent NN o
of IN o
sensory JJ o
block NN o
, , o
percentage NN o
of IN o
patients NNS o
with IN o
motor NN o
block NN o
or CC o
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

However RB N
, , N
this DT N
study NN N
did VBD N
not RB N
find VB N
significant JJ N
differences NNS N
in IN N
scaling VBG N
time NN N
between IN N
product NN N
and CC N
placebo NN i
when WRB N
using VBG N
a DT N
2-minute JJ N
gel NN N
contact NN N
time NN N
. . N

BACKGROUND NNP N
To TO N
investigate VB N
if IN N
coadministration NN N
of IN N
enalapril NN i
alters NNS N
the DT N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN i
by IN N
employing VBG N
an DT N
euglycemic JJ N
glucose-clamp NN N
technique NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

Both DT N
multiplane NN i
and CC i
biplane NN i
probes NNS i
provided VBD N
excellent JJ N
visualization NN o
of IN o
cardiac JJ o
structures NNS o
and CC o
Doppler NNP o
signals NNS o
, , N
but CC N
the DT N
multiplane NN i
probe NN i
was VBD N
significantly RB N
superior JJ N
to TO N
the DT N
biplane NN N
probe NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Duration NNP o
of IN o
anesthesia NN o
, , o
invasiveness NN o
of IN o
surgery NN o
, , o
and CC o
baseline NN o
core NN o
temperature NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Dietary NNP i
sodium NN i
restriction NN i
alone RB i
is VBZ N
effective JJ N
in IN N
lowering VBG o
blood NN o
pressure NN o
in IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Efficacy NN o
and CC o
safety NN o
of IN N
zidovudine NN i
and CC i
zalcitabine NN i
combined VBN N
with IN N
a DT N
combination NN N
of IN N
herbs NN N
in IN N
the DT N
treatment NN N
of IN N
HIV-infected NNP p
Thai NNP p
patients NNS p
. . p

RESULTS RB N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
operative JJ o
duration NN o
, , o
resection NN o
weight NN o
, , o
resection NN o
speed NN o
or CC o
radicality NN o
of IN o
resection NN o
. . o

The DT N
response NN o
rates NNS o
for IN o
control NN o
of IN o
pleural JJ o
effusion NN o
were VBD N
73.4 CD N
% NN N
in IN N
the DT N
N-CWS NNP N
group NN N
and CC N
46.1 CD N
% NN N
in IN N
the DT N
N-CWS NNP N
group NN N
. . N

Therefore IN N
we PRP N
evaluated VBD N
the DT N
profile NN N
of IN N
AP-1 NNP N
activation NN N
through IN N
histological JJ N
analysis NN N
and CC N
tested VBD N
the DT N
potential JJ N
benefit NN N
of IN N
AP-1 NNP N
inhibition NN N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ N
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

Association NNP N
of IN N
PML-RAR NNP N
alpha JJ N
fusion NN N
mRNA NN N
type NN N
with IN N
pretreatment JJ N
hematologic JJ N
characteristics NNS N
but CC N
not RB N
treatment NN N
outcome NN N
in IN N
acute JJ p
promyelocytic JJ p
leukemia NN p
: : p
an DT N
intergroup NN N
molecular NN N
study NN N
. . N

However RB N
, , N
when WRB N
subjects NNS N
were VBD N
examined VBN N
individually RB N
both DT N
the DT N
GHRH- NNP N
and CC N
the DT N
TRH-induced NNP o
hormonal JJ o
peaks NNS o
and CC N
the DT N
subsequent JJ N
fall NN N
were VBD N
not RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

Most JJS N
adverse JJ N
events NNS N
reported VBN N
were VBD N
mild JJ N
or CC N
moderate JJ N
and CC N
the DT N
incidence NN N
is VBZ N
as RB N
would MD N
be VB N
expected VBN N
in IN N
this DT N
patient JJ N
population NN N
. . N

From IN N
these DT N
results NNS N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
in IN N
the DT N
patients NNS N
tested VBN N
, , N
intradermal JJ N
injection NN N
of IN N
OK-432 NNP N
appears VBZ N
to TO N
be VB N
clinically RB N
superior JJ N
to TO N
intramuscular JJ N
injection NN N
. . N

BACKGROUND NNP N
Heightened VBD N
central JJ N
sympathetic JJ N
nervous JJ N
outflow NN N
is VBZ N
common JJ N
in IN N
essential JJ N
hypertension NN N
, , N
contributing VBG N
to TO N
hypertension NN N
development NN N
and CC N
perhaps RB N
also RB N
to TO N
complications NNS N
. . N

Because IN N
implant JJ N
ruptures NNS N
often RB N
occur VBP N
asymptomatically RB N
, , N
any DT N
woman NN N
with IN N
silicone NN N
implants NNS N
, , N
regardless RB N
of IN N
rupture NN N
status NN N
, , N
should MD N
be VB N
evaluated VBN N
at IN N
regular JJ N
intervals NNS N
. . N

We PRP N
have VBP N
developed VBN N
novel JJ N
molecular JJ N
methods NNS N
using VBG N
a DT N
stool NN N
sample NN N
, , N
which WDT N
contains VBZ N
intact JJ N
sloughed VBN N
colon NN N
cells NNS N
, , N
to TO N
quantify VB N
colonic JJ N
gene NN N
expression NN N
profiles NNS N
. . N

aureus NN N
was VBD N
0.31 CD N
and CC N
0.28 CD N
for IN N
heifers NNS N
in IN N
the DT N
prepartum NN N
and CC N
postpartum NN N
groups NNS N
, , N
respectively RB N
, , N
compared VBN N
with IN N
that DT N
for IN N
heifers NNS N
in IN N
the DT N
control NN N
group NN N
. . N

[ IN N
The DT N
effects NNS N
of IN N
early JJ i
enteral JJ i
nutrition NN i
with IN i
addition NN i
of IN i
probiotics NNS i
on IN N
the DT N
prognosis NN N
of IN N
patients NNS p
suffering VBG p
from IN p
severe JJ p
acute NN p
pancreatitis NN p
] NN p
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ o
parameters NNS o
for IN o
motor NN o
control NN o
and CC o
the DT o
Motor NNP o
Activity NNP o
Log NNP o
and CC o
ABILHAND NNP o
Questionnaire NNP o
for IN o
daily JJ o
function NN o
. . o

In IN N
patients NNS N
with IN N
AS NNP N
, , N
pancuronium NN N
increased VBD N
heart NN o
rate NN o
more JJR o
than IN o
vecuronium NN o
or CC o
atracurium NN o
; : o
heart NN o
rates NNS o
were VBD N
also RB N
higher JJR N
with IN N
the DT N
pancuronium-metocurine JJ i
mixture NN i
than IN i
with IN i
vecuronium NN i
. . i

CONCLUSIONS VB N
It PRP N
was VBD N
determined VBN N
that IN N
the DT N
use NN N
of IN N
oxytocin NN i
after IN N
shoulder NN N
delivery NN N
has VBZ N
more JJR N
effects NNS N
on IN N
decreasing VBG N
the DT N
amount NN o
of IN o
postpartum NN o
hemorrhage NN o
. . o

Besides IN N
the DT N
established VBN N
cytokines NNS N
, , N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
is VBZ N
demonstrated VBN N
as IN N
an DT N
important JJ N
factor NN N
in IN N
enhancing VBG N
vascular JJ N
leakage NN N
in IN N
sepsis NN N
. . N

The DT N
effects NNS N
of IN N
clonidine NN i
and CC i
hydrochlorothiazide NN i
on IN N
cognitive JJ N
function NN N
were VBD N
studied VBN N
in IN N
hypertensive JJ p
adolescents NNS p
requiring VBG p
pharmacologic JJ p
therapy NN p
for IN p
blood NN p
pressure NN p
control NN p
. . p

However RB N
, , N
to TO N
date NN N
, , N
no DT N
studies NNS N
have VBP N
compared VBN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
amlodipine JJ i
camsylate NN i
and CC i
amlodipine JJ i
besylate NN i
in IN N
treating VBG N
hypertension NN N
. . N

RESULTS NN N
In IN N
both DT N
groups NNS N
, , N
HV NNP o
and CC o
HV NNP o
standard JJ o
deviation NN o
score VBD o
HV-SDSCA NNP o
increased VBD N
during IN N
treatment NN N
and CC N
decreased VBD N
during IN N
observation NN N
periods NNS N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
zoledronic JJ i
acid NN i
for IN N
the DT N
treatment NN N
of IN N
bone NN p
metastases NNS p
from IN p
breast NN p
cancer NN p
. . p

Changes NNS o
in IN o
cardiac JJ o
index NN o
, , o
systemic JJ o
and CC o
pulmonary JJ o
vascular NN o
resistance NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
placebo NN i
. . i

Plasma NNP o
levels NNS o
, , o
areas NNS o
under IN o
24-hour JJ o
plasma NN o
concentration NN o
curves NNS o
and CC o
urinary JJ o
excretion NN o
were VBD N
similar JJ N
by IN N
both DT N
formulations NNS N
in IN N
steady JJ N
state NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
lipid JJ o
profiles NNS o
, , o
inflammatory JJ o
markers NNS o
, , o
24-h JJ o
ambulatory NN o
blood NN o
pressure NN o
, , o
and CC o
carotid JJ o
artery NN o
intimamedia NN o
thickness NN o
. . o

BACKGROUND NNP N
Osteoporosis NNP N
is VBZ N
associated VBN N
with IN N
cirrhosis NN N
of IN N
the DT N
liver NN N
, , N
but CC N
the DT N
effects NNS N
of IN N
therapy NN N
for IN N
osteoporosis NN N
associated VBN N
with IN N
cirrhosis NN N
are VBP N
still RB N
controversial JJ N
. . N

In IN N
summary JJ N
, , N
the DT N
irritative JJ N
and CC N
obstructive JJ N
symptoms NNS N
caused VBN N
by IN N
benign JJ o
prostatic JJ o
hypertrophy NN o
were VBD N
decreased VBN N
and CC N
urodynamic JJ N
studies NNS N
were VBD N
markedly RB N
improved VBN N
by IN N
the DT N
alpha JJ N
1-blocker NN N
, , N
YM617 NNP N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
with IN N
secondary JJ N
endpoints NNS N
of IN N
time NN o
to TO o
disease VB o
progression NN o
and CC o
quality NN o
of IN o
life NN o
. . o

In IN N
multivariable JJ N
analysis NN N
, , N
only RB N
lower JJR N
baseline NN N
CD4 NNP o
cell NN o
count NN o
and CC o
higher JJR o
HIV-1 NNP o
RNA NNP o
were VBD o
associated VBN o
with IN o
greater JJR o
increase NN o
in IN o
weight NN o
, , o
BMI NNP o
, , o
or CC o
LBM NNP o
. . o

IP NNP i
assessed VBN i
by IN i
lactulose NN i
: : i
mannitol NN i
( ( i
L/M NNP i
) ) i
sugar NN i
permeability NN i
test NN i
and CC i
behavior NN i
assessed VBN N
by IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
and CC o
Conners NNP o
Parent NNP o
Rating NNP o
were VBD N
measured VBN N
. . N

The DT N
less RBR N
favourable JJ N
improvement NN N
in IN N
periodontal JJ o
function NN o
of IN o
postsplint NN o
or CC o
nonsplint NN o
teeth NNS o
seemed VBD N
to TO N
be VB N
due JJ N
to TO N
the DT N
loss NN N
of IN N
BRG NNP N
material NN N
caused VBN N
by IN N
tooth DT N
mobility NN N
. . N

Plasma NNP o
total JJ o
factor NN o
VII NNP o
was VBD N
measured VBN N
by IN N
use NN N
of IN N
a DT N
chromogenic JJ N
assay NN N
; : N
plasma CC N
active JJ N
FVII NNP N
by IN N
a DT N
recently RB N
developed VBN N
method NN N
using VBG N
truncated JJ N
tissue NN N
factor NN N
. . N

CONCLUSIONS VB N
The DT N
rates NNS o
of IN o
MACEs NNP o
, , o
TVR NNP o
, , o
and CC o
stent JJ o
thrombosis NN o
during IN N
the DT N
three-year JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
the DT N
SES NNP N
and CC N
PES NNP N
Groups NNP N
. . N

Changes NNS N
in IN N
body NN o
weight NN o
, , o
total JJ o
fat JJ o
intake NN o
, , o
urinary JJ o
sodium NN o
and CC o
potassium NN o
did VBD N
not RB N
have VB N
significant JJ N
predictive JJ N
power NN N
in IN N
any DT N
of IN N
the DT N
analyses NNS N
. . N

PARTICIPANTS NNS N
Participants NNS p
( ( p
N=106 NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
WB NNP i
exercise NN i
, , i
NWB NNP i
exercise NN i
, , i
or CC i
a DT i
control NN i
group NN i
( ( i
no DT i
exercise NN i
) ) i
. . i

Effective JJ o
response NN o
rates NNS o
for IN N
the DT N
above NN N
mentioned VBD N
three CD N
groups NNS N
were VBD N
69.2 CD N
% NN N
, , N
69.2 CD N
% NN N
and CC N
55.8 CD N
% NN N
, , N
respectively RB N
. . N

Significant JJ N
differences NNS N
were VBD N
also RB N
found VBN N
for IN N
some DT N
breast NN o
cancer-specific JJ o
symptoms NNS o
[ MD o
swelling VBG o
, , o
mobility NN o
and CC o
pain NN o
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
] NN N
. . N

We PRP N
conclude VBP N
that IN N
periarticularly RB i
administered VBN i
morphine NN i
in IN N
arthroscopic JJ N
subacromial JJ N
decompression NN N
in IN N
the DT N
dosage NN N
applied VBN N
in IN N
this DT N
study NN N
does VBZ N
exert VB N
no DT N
relevant JJ N
analgesic JJ N
effect NN N
. . N

Perindopril NNP i
, , N
whether IN N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
hydrochlorothiazide NN i
, , N
was VBD N
well RB N
tolerated VBN o
and CC o
produced VBN o
no DT o
clinically RB o
significant JJ o
change NN o
in IN o
routine JJ o
haematology NN o
or CC o
serum JJ o
biochemistry NN o
. . o

INTRODUCTION NNP N
Estimating VBG N
the DT N
cost NN N
utility NN N
of IN N
hemiarthroplasty NN N
compared VBN N
to TO N
internal JJ N
fixation NN N
in IN N
the DT N
treatment NN N
of IN N
displaced JJ p
femoral JJ p
neck NN p
fractures NNS p
in IN p
the DT p
elderly JJ p
. . p

Interleukin-1 JJ i
beta NN i
( ( i
IL-1 NNP i
beta NN i
) ) i
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
PBC NNP N
by IN N
contributing VBG N
to TO N
altered VBN N
immune JJ N
function NN N
and CC N
fibrosis NN N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN N
followed VBN N
by IN N
autotransplantation NN i
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ p
relapsed JJ p
patients NNS p
with IN p
aggressive JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

Samples NNS N
from IN N
saliva NN N
, , N
dental JJ N
plaque NN N
and CC N
faeces NNS N
and CC N
biopsies NNS N
from IN N
antrum NN N
and CC N
corpus NN N
were VBD N
analysed VBN N
in IN N
order NN N
to TO N
determine VB N
the DT N
ecological JJ N
changes NNS N
in IN N
the DT N
normal JJ N
microflora NN N
. . N

In IN N
contrast NN N
, , N
SDZ NNP N
ENS-163 NNP N
with IN N
saline NN N
had VBD N
no DT N
effect NN N
on IN N
CNTB NNP o
scores NNS o
, , o
increased VBN o
salivation NN o
, , o
and CC o
increased VBD o
heart NN o
rate NN o
. . o

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
reported VBN N
were VBD N
worsening VBG o
of IN o
UC NNP o
and CC o
headache NN o
; : o
both DT N
were VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
placebo NN N
group NN N
. . N

TNF NNP i
therapy NN i
is VBZ N
effective JJ N
for IN N
all DT N
aspects NNS N
of IN N
psoriatic JJ N
disease NN N
, , N
but CC N
these DT N
drugs NNS N
are VBP N
costly JJ N
and CC N
the DT N
long-term JJ N
effects NNS N
are VBP N
unknown JJ N
. . N

Upon IN N
removal NN N
of IN N
each DT N
patch NN N
, , N
skin NN N
sites NNS N
were VBD N
evaluated VBN N
for IN N
signs NNS N
of IN N
irritation NN N
, , N
and CC N
subjective JJ N
complaints NNS N
such JJ N
as IN N
itching NN o
or CC o
burning NN o
were VBD N
recorded VBN N
. . N

Change NN N
in IN N
functional JJ o
ability NN o
remained VBD N
significantly RB N
better RBR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
out IN N
to TO N
8-week JJ N
follow-up NN N
. . N

The DT N
24-gauge JJ N
Gertie NNP N
Marx NNP N
needle RB N
resulted VBD N
in IN N
more RBR N
successful JJ o
location NN o
of IN o
the DT o
spinal JJ o
space NN o
on IN N
the DT N
second JJ N
attempt NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
some DT N
effects NNS N
of IN N
low JJ N
protein NN N
provision NN N
in IN N
utero NN N
can MD N
be VB N
alleviated VBN N
by IN N
an DT N
adequate JJ N
nutrient JJ N
supply NN N
post-partum NN N
. . N

The DT N
in IN N
vivo JJ N
effects NNS N
of IN N
oral JJ N
clarithromycin JJ i
administration NN N
on IN N
the DT N
in IN N
vivo JJ N
activity NN N
of IN N
cytochrome NN N
P450 NNP N
1A2 CD N
, , N
2C9 CD N
, , N
and CC N
2D6 CD N
were VBD N
determined VBN N
. . N

Cyproheptadine NNP i
augmentation NN N
, , N
compared VBN N
to TO N
administration NN N
of IN N
haloperidol NN i
with IN N
placebo NN i
, , N
did VBD N
not RB N
produce VB N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
psychotic JJ o
symptoms NNS o
. . o

The DT N
results NNS N
showed VBD N
that IN N
a DT N
trend NN N
in IN N
favour NN N
of IN N
the DT N
buflomedil NN N
group NN N
in IN N
three CD N
of IN N
the DT N
tests NNS N
became VBD N
statistically RB N
significant JJ N
in IN N
the DT N
fourth JJ N
. . N

Mean JJ o
scores NNS o
favored VBD N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
, , N
but CC N
no DT N
significant JJ N
differences NNS N
between IN N
these DT N
groups NNS N
and CC N
the DT N
ROC NNP N
group NN N
were VBD N
obtained VBN N
. . N

Biofilms NNS N
are VBP N
sessile JJ N
communities NNS N
of IN N
bacteria NNS N
embedded VBN N
in IN N
self-produced JJ N
extracellular JJ N
polysaccharide NN N
matrix NN N
and CC N
are VBP N
considered VBN N
to TO N
be VB N
responsible JJ N
for IN N
bacterial JJ N
infections NNS N
in IN N
humans NNS N
. . N

BACKGROUND NNP N
Prophylactic NNP i
cranial JJ i
irradiation NN i
in IN N
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
decreases VBZ N
the DT N
overall JJ N
rate NN N
of IN N
brain NN N
metastases NNS N
without IN N
an DT N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

In IN N
the DT N
jejunum NN N
, , N
villus JJ N
height NN N
, , N
crypt NN N
depth NN N
, , N
and CC N
the DT N
number NN N
of IN N
goblet NN N
cells NNS N
producing VBG N
neutral JJ N
, , N
acidic JJ N
, , N
sulfated VBN N
, , N
and CC N
sialylated VBD N
mucins NNS N
were VBD N
measured VBN N
. . N

BACKGROUND NNP N
Allopurinol NNP i
has VBZ N
been VBN N
widely RB N
used VBN N
for IN N
treatment NN N
of IN N
hyperuricemia NN N
, , N
however RB N
, , N
it PRP N
may MD N
be VB N
associated VBN N
with IN N
various JJ N
adverse JJ N
effects NNS N
. . N

Studies NNS N
on IN N
the DT N
platelet NN N
functioning NN N
showed VBD N
an DT N
obvious JJ N
decrease NN N
in IN N
platelet NN o
aggregation NN o
in IN N
those DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
. . N

Accuracy NNP o
( ( o
correction NN o
rate NN o
) ) o
, , o
recognition NN o
accuracy NN o
( ( o
correction NN o
rate-commission NN o
error NN o
rate NN o
) ) o
, , o
and CC o
response NN o
time NN o
were VBD N
measured VBN N
during IN N
each DT N
experiment NN N
. . N

BACKGROUND NNP N
Tibial NNP i
tubercle-trochlear JJ i
groove NN i
distance NN i
( ( i
TT-TG NNP i
) ) i
is VBZ N
a DT N
commonly RB N
used VBN N
measurement NN N
for IN N
surgical JJ N
decision NN N
making NN N
in IN N
patients NNS p
with IN p
patellofemoral JJ p
malalignment NN p
and CC p
instability NN p
. . p

1H CD N
nuclear JJ N
magnetic JJ i
resonance-based JJ i
metabolomic NN i
study NN N
on IN N
efficacy NN N
of IN N
Qingrehuatan NNP i
decoction NN i
against IN N
abundant JJ N
phlegm-heat JJ N
syndrome NN N
in IN N
young JJ p
adults NNS p
with IN p
essential JJ p
hypertension NN p
. . p

OBJECTIVE NN N
To TO N
compare VB N
elastic JJ i
stable JJ i
intramedullary JJ i
nailing NN i
( ( i
ESIN NNP i
) ) i
with IN N
nonoperative JJ N
treatment NN N
of IN N
fully RB p
displaced VBN p
midshaft NN p
clavicular NN p
fractures NNS p
in IN p
adults NNS p
. . p

The DT N
present JJ N
study NN N
demonstrates VBZ N
that IN N
DEX NNP i
is VBZ N
less RBR N
inhibitory JJ N
for IN N
phytohemagglutinin NN N
( ( N
PHA NNP N
) ) N
-induced VBD N
T NNP N
cell NN N
proliferation NN N
in IN N
AD NNP N
patients NNS N
as IN N
compared VBN N
to TO N
age-matched JJ N
controls NNS N
. . N

The DT N
arousal NN o
index NN o
was VBD N
significantly RB N
higher JJR N
during IN N
leak JJR N
periods NNS N
, , N
and CC N
its PRP$ N
changes NNS N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
mouth NN N
leak NN N
. . N

However RB N
, , N
the DT N
timing NN N
of IN N
such JJ N
form NN N
processing NN N
aberrations NNS N
is VBZ N
much RB N
later RBR N
than IN N
the DT N
timing NN N
of IN N
abnormal JJ N
magnocellular JJ N
visual JJ N
processing NN N
measured VBN N
directly RB N
here RB N
. . N

BACKGROUND NNP N
In IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
a DT N
defective JJ N
nitric JJ N
oxide IN N
signaling VBG N
is VBZ N
involved VBN N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
diastolic NN N
abnormalities NNS N
and CC N
remodeling VBG N
. . N

CONCLUSION NNP N
RFA NNP N
took VBD N
longer JJR N
to TO N
perform VB N
but CC N
resulted VBD N
in IN N
a DT N
significantly RB N
better RBR N
early RB N
outcome NN N
than IN N
conventional JJ N
surgery NN N
in IN N
suitable JJ N
patients NNS N
with IN N
great JJ N
saphenous JJ N
varicose NN N
veins NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
the DT N
1-min JJ N
protocol NN N
, , N
the DT N
maximum JJ o
negative JJ o
pressure NN o
tolerated VBD o
did VBD N
not RB N
vary JJ N
regardless NN N
of IN N
the DT N
protocol NN N
used VBN N
. . N

The DT N
MVPF NNP i
group NN N
demonstrated VBD N
a DT N
39.0 CD N
per IN N
cent NN N
greater JJR N
reduction NN N
in IN N
pain NN o
after IN N
application NN N
of IN N
the DT N
dressing NN N
over IN N
the DT N
silver JJ i
sulphadiazine NN i
group NN N
. . N

BACKGROUND NNP N
Laparoscopic NNP i
appendectomy NN i
( ( i
LA NNP i
) ) i
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

Oral JJ i
sodium NN i
phosphate NN i
is VBZ N
a DT N
cost-effective JJ N
colonoscopy NN N
preparation NN N
that WDT N
is VBZ N
better RBR N
tolerated VBN N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
polyethylene JJ i
glycol-electrolyte JJ i
lavage NN i
solution NN i
or CC i
castor NN i
oil NN i
. . i

RESULTS JJ N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Postoperative JJ o
response NN o
to TO o
treatment NN o
, , o
liver JJ o
function NN o
change NN o
( ( o
ALT NNP o
) ) o
, , o
AFP NNP o
, , o
imaging VBG o
examination NN o
of IN o
the DT o
tumor NN o
, , o
patient NN o
's POS o
survival NN o
were VBD N
evaluated VBN N
. . N

Our PRP$ N
results NNS N
provide VBP N
indirect JJ N
evidence NN N
that IN N
reversible JJ N
changes NNS N
in IN N
the DT N
cation-chloride JJ N
transport NN N
system NN N
induce JJ N
modulations NNS N
of IN N
inhibitory JJ N
neuronal JJ N
activity NN N
at IN N
spinal JJ N
cord NN N
level NN N
in IN N
humans NNS N
. . N

Ranitidine NNP i
pretreatment NN N
had VBD N
no DT N
effect NN N
on IN N
triazolam NN o
's POS o
terminal JJ o
elimination NN o
rate NN o
constant JJ o
or CC o
on IN o
the DT o
time NN o
to TO o
reach VB o
maximum JJ o
serum JJ o
triazolam NN o
concentration NN o
. . o

There EX N
was VBD N
a DT N
dose JJ N
related JJ N
reduction NN N
in IN N
symptoms NNS o
, , o
plasma JJ o
follicle NN o
stimulating VBG o
hormone NN o
concentration NN o
, , o
and CC o
urinary JJ o
calcium NN o
and CC o
hydroxyproline JJ o
excretion NN o
. . o

With IN N
the DT N
comparable JJ N
relaxivities NNS N
of IN N
gadodiamide JJ i
injection NN i
and CC i
gadopentetate NN i
dimeglumine NN i
, , N
similarities NNS N
in IN N
results NNS N
have VBP N
to TO N
be VB N
expected VBN N
when WRB N
using VBG N
these DT N
media NNS N
for IN N
MR NNP p
image NN p
enhancement NN p
. . p

The DT N
treatment NN N
effect NN N
of IN N
eptifibatide NN i
is VBZ N
realized VBN N
regardless RB N
of IN N
renal JJ N
function NN N
and CC N
trends VBZ N
toward IN N
being VBG N
greater JJR N
in IN N
patients NNS p
with IN p
mild JJ p
renal JJ p
impairment NN p
. . p

Avian JJ N
influenza NN N
is VBZ N
a DT N
severe JJ N
disease NN N
among IN N
farmed JJ p
poultry NN p
and CC p
free-living JJ p
birds NNS p
and CC p
a DT p
constant JJ p
threat NN p
to TO p
the DT p
commercial JJ p
chicken NN p
industry NN p
around IN p
the DT p
world NN p
. . p

These DT N
results NNS N
suggest VBP N
that IN N
continuous JJ N
infusion NN N
of IN N
morphine NN i
may MD N
be VB N
an DT N
inferior JJ N
regimen NNS N
to TO N
intermittent VB N
bolus JJ N
administration NN N
in IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
. . N

Peripheral NNP N
opioid NN N
receptors NNS N
have VBP N
been VBN N
found VBN N
in IN N
inflamed JJ N
synovia NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
intra-articularly JJ i
administered JJ i
morphine NN i
after IN N
arthroscopic NN N
knee NN N
surgery NN N
has VBZ N
been VBN N
proven VBN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
beta NN o
, , o
t NN o
( ( o
1/2 CD o
) ) o
, , o
and CC o
t NN o
( ( o
max NN o
) ) o
between IN N
the DT N
two CD N
occasions NNS N
. . N

Levels NNS o
of IN o
fibrinogen NN o
, , o
activated VBD o
factor NN o
VII NNP o
, , o
and CC o
factor NN o
VII NNP o
antigen NN o
were VBD N
not RB N
significantly RB N
influenced VBN N
by IN N
hormone NN N
replacement NN N
therapy NN N
treatment NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
WP NNP i
+ NNP i
NCHT NNP i
, , i
PO NNP i
+ NNP i
NCHT NNP i
, , i
WP NNP i
+ NNP i
AHT NNP i
, , i
or CC i
PO NNP i
+ NNP i
AHT NNP i
. . i

Pain NNP o
detection NN o
and CC o
tolerance NN o
thresholds NNS o
for IN o
pressure NN o
and CC o
electric JJ o
stimuli NNS o
were VBD N
measured VBN N
in IN N
six CD N
selected VBN N
dermatomes NNS N
( ( N
C5 NNP N
, , N
T4 NNP N
, , N
T10 NNP N
, , N
L1 NNP N
, , N
L4 NNP N
and CC N
T10BACK NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
effectiveness NN N
of IN N
the DT N
medications NNS N
on IN N
pain NN o
relief NN o
, , o
or CC o
in IN o
stinging VBG o
on IN o
instillation NN o
. . o

The DT N
role NN N
of IN N
IgA NNP N
in IN N
providing VBG N
protection NN N
against IN N
influenza NN N
in IN N
children NNS N
vaccinated VBN N
with IN N
live JJ N
attenuated VBN N
influenza JJ N
vaccine NN N
( ( N
LAIV NNP N
) ) N
has VBZ N
not RB N
been VBN N
well RB N
described VBN N
. . N

Most JJS N
frequent JJ N
treatment-emergent JJ N
adverse JJ N
events NNS N
were VBD N
dizziness RB o
, , o
somnolence NN o
, , o
irritability NN o
, , o
headache NN o
, , o
fall NN o
, , o
and CC o
ataxia NN o
. . o

Because IN N
of IN N
slow JJ N
accrual NN N
, , N
the DT N
two CD N
chemotherapy NN N
groups NNS N
were VBD N
combined VBN N
and CC N
compared VBN N
with IN N
ASC NNP N
alone RB N
for IN N
the DT N
primary JJ N
outcome NN N
of IN N
overall JJ o
survival NN o
. . o

A DT N
potent JJ N
oral JJ N
P-selectin NNP i
blocking NN i
agent NN i
improves VBZ N
microcirculatory JJ N
blood NN N
flow NN N
and CC N
a DT N
marker NN N
of IN N
endothelial JJ N
cell NN N
injury NN N
in IN N
patients NNS p
with IN p
sickle JJ p
cell NN p
disease NN p
. . p

Eight CD N
weeks NNS N
of IN N
assisted JJ i
range-of-motion NN i
exercise NN i
attenuates VBZ N
the DT N
decrease NN N
in IN N
bone NN o
strength NN o
and CC N
may MD N
decrease VB N
the DT N
risk NN N
of IN N
osteopenia NN N
in IN N
premature JJ p
infants NNS p
. . p

The DT N
combined JJ N
administration NN N
of IN N
MMC NNP i
and CC i
HCFU NNP i
was VBD N
suggested VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ i
adjuvant NN i
chemotherapy NN i
for IN N
noncuratively RB p
resected VBN p
cases NNS p
of IN p
colorectal JJ p
carcinoma NN p
. . p

Furthermore RB N
, , N
the DT N
dentition NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
experimental JJ N
groups NNS N
was VBD N
treated VBN N
, , N
at IN N
three-month JJ N
intervals NNS N
, , N
with IN N
chlorhexidine NN N
and CC N
fluoride JJ N
varnish NN N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Moderate-intensity NNP i
step NN i
aerobics NNS i
training VBG i
significantly RB N
increases VBZ N
peak JJ o
oxygen NN o
uptake NN o
and CC o
peak JJ o
workloads NNS o
in IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
heart NN p
failure NN p
. . p

The DT N
TT-specific NNP o
immunoglobulin NN o
G NNP o
( ( o
IgG NNP o
) ) o
boost VBD o
efficiency NN o
was VBD N
marginal JJ N
higher JJR N
in IN N
the DT N
vitamin NN N
D NNP N
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
was VBD N
evidence NN N
of IN N
variation NN N
in IN N
sensitivity NN N
between IN N
endoscopists NNS N
, , N
but CC N
significant JJ N
miss JJ o
rates NNS o
for IN o
small JJ o
adenomas NNS o
were VBD N
found VBN N
among IN N
essentially RB N
all DT N
endoscopists NNS N
. . N

The DT N
AUC NNP o
and CC o
Cmax NNP o
after IN o
fasting VBG o
were VBD N
closely RB N
similar JJ N
to TO N
those DT N
after IN N
a DT N
meal NN N
, , N
showing VBG N
that IN N
bioavailability NN o
was VBD N
not RB N
affected VBN N
by IN N
food NN N
intake NN N
. . N

INTRODUCTION NNP N
Few NNP N
combinations NNS N
of IN N
highly RB N
active JJ N
antiretrovirals NNS N
have VBP N
been VBN N
studied VBN N
in IN N
nucleoside JJ N
reverse NN N
transcription NN N
inhibitor NN N
( ( N
NRTI NNP N
) ) N
-experienced VBD N
, , N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
-infected VBD N
children NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
CVC NNP N
use/type NN N
or CC N
duration NN N
or CC N
in IN N
positive/negative JJ N
BC NNP i
with/without NN i
associated VBN N
C NNP N
reactive JJ N
protein NN N
rise NN N
in IN N
SCAMP NNP N
versus NN N
control NN N
groups NNS N
. . N

At IN N
TI2 NNP N
, , N
previous JJ N
to TO N
the DT N
allergen NN N
challenge NN N
, , N
the DT N
active JJ N
group NN N
showed VBD N
higher JJR N
values NNS N
of IN N
both DT N
FEV1 NNP o
and CC o
Mth-PD20 NNP o
and CC o
lower JJR o
values NNS o
of IN o
Mth-DRS NNP o
. . o

Cortisol NNP o
levels NNS o
in IN N
patients NNS p
with IN p
Alzheimer NNP p
's POS p
disease NN p
( ( p
AD NNP p
) ) p
are VBP N
relatively RB N
unaffected JJ N
by IN N
a DT N
challenge NN N
with IN N
dexamethasone NN i
( ( i
DEX NNP i
) ) i
in IN N
vivo NN N
. . N

There EX N
is VBZ N
much JJ N
evidence NN N
suggesting VBG N
that IN N
the DT N
decline NN N
in IN N
ovarian JJ N
function NN N
after IN N
menopause NN N
is VBZ N
associated VBN N
with IN N
spontaneous JJ N
increases NNS N
in IN N
proinflammatory JJ N
cytokines NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
mean JJ o
age NN o
, , o
anaesthetic JJ o
time NN o
, , o
perioperative JJ o
morbidity NN o
, , o
or CC o
postoperative JJ o
mobility NN o
. . o

Fenoterol NNP i
treatment NN i
increased VBD N
both DT N
superimposed VBN o
Pdi NNP o
twitch NN o
and CC o
Pdi NNP o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
and CC N
decreased VBD N
the DT N
value NN N
of IN N
( ( N
1-superimposed JJ N
Pdi NNP N
twitch/Pdi NN N
twitch NN N
of IN N
relaxed JJ N
diaphragm NN N
) ) N
. . N

rHu NN N
EPO NNP N
treatment NN N
affects VBZ N
the DT N
T NNP N
lymphocyte NN N
subsets NNS N
inducing VBG N
a DT N
deep JJ N
decrease NN N
of IN N
CD8 NNP N
and CC N
CD16 NNP N
cell NN N
percentage NN N
leading VBG N
to TO N
normalisation NN N
of IN N
the DT N
CD4/CD8 NNP N
ratio NN N
. . N

CONCLUSION NNP N
TISSEEL NNP i
VH NNP i
S/D NNP i
is VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
use NN N
as IN N
an DT N
adjunct NN N
to TO N
hemostasis VB N
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
. . p

Similarly RB N
, , N
there EX N
were VBD N
no DT N
clinically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
cardiac JJ N
variables NNS N
, , N
or CC N
in IN N
vital JJ N
signs NNS N
. . N

PURPOSE NNP N
Iron-containing JJ N
products NNS N
are VBP N
atypical JJ N
in IN N
terms NNS N
of IN N
their PRP$ N
pharmacokinetic JJ N
properties NNS N
because IN N
iron NN N
is VBZ N
only RB N
removed VBN N
by IN N
plasma NN N
sampling NN N
and CC N
is VBZ N
non-linear JJ N
. . N

CONCLUSIONS NNP N
Fructose-1,6-diphosphate NNP i
produces VBZ N
a DT N
modest JJ N
but CC N
significant JJ N
increase NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
heart NN p
failure NN p
. . p

No DT N
difference NN N
in IN N
marginal JJ o
conjunctival NN o
sensitivity NN o
was VBD N
found VBN N
between IN N
upper JJ N
and CC N
lower JJR N
eyelids NNS N
( ( N
all DT N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
an DT N
advantage NN N
to TO N
administering VBG N
xylitol NN i
and CC i
fructose JJ i
with IN N
regard NN N
to TO N
the DT N
intestinal JJ o
absorption NN o
and CC o
concomitant NN o
symptoms NNS o
as IN N
compared VBN N
with IN N
sorbitol NN i
. . i

However RB N
, , N
while IN N
there EX N
is VBZ N
much JJ N
anecdotal JJ N
evidence NN N
to TO N
that DT N
effect NN N
, , N
the DT N
empirical JJ N
literature NN N
is VBZ N
very RB N
inconsistent JJ N
. . N

Changes NNS N
in IN N
functional JJ o
capillary JJ o
density NN o
( ( o
FCD NNP o
) ) o
, , o
blood NN o
flow NN o
velocity NN o
, , o
and CC o
vessel RB o
diameter NN o
were VBD N
analyzed VBN N
by IN N
a DT N
blinded JJ N
investigator NN N
. . N

In IN N
addition NN N
, , N
ORR NNP o
was VBD N
significantly RB N
higher JJR N
with IN N
letrozole JJR i
than IN i
tamoxifen NN i
in IN N
the DT N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
HER1/HER2+ NNP N
subgroup NN N
( ( N
P=0.0004 NNP N
) ) N
. . N

Aspiration NN N
documented VBN N
by IN N
modified JJ i
videofluoroscopic NN i
barium NN i
swallow NN i
technique NN i
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
risk NN o
of IN o
pneumonia NN o
and CC o
death NN o
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
. . N

BACKGROUND NNP N
Low NNP N
heart NN N
rate NN N
ischemia NN N
, , N
as IN N
detected VBN N
by IN N
Holter NNP N
ambulatory JJ N
electrocardiographic JJ N
monitoring NN N
, , N
suggests VBZ N
that IN N
reduced VBD N
coronary JJ N
flow NN N
is VBZ N
the DT N
major JJ N
factor NN N
leading VBG N
to TO N
ischemia VB N
. . N

Removal JJ o
rates NNS o
for IN o
thrombosis NN o
that WDT N
could MD N
not RB N
be VB N
resolved VBN N
with IN N
thrombolysis NN N
were VBD N
0.53 CD N
and CC N
0.43/1,000 CD N
catheter-days NNS N
for IN N
Palindrome NNP N
and CC N
HemoStar NNP N
, , N
respectively RB N
( ( N
P=0.7 NNP N
) ) N
. . N

[ JJ N
Physical NNP N
performance NN N
and CC N
sedation NN N
: : N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
a DT N
benzodiazepine NN i
( ( i
temazepam NN i
) ) i
and CC N
of IN N
a DT N
non-benzodiazepine JJ i
hypnotic NN i
( ( i
zolpidem NN i
) ) i
] NN i
. . N

[ RB N
Prophylactic NNP N
use NN N
of IN N
low JJ N
molecular JJ N
weight NN N
heparin NN i
in IN N
combination NN N
with IN N
graduated JJ i
compression NN i
stockings NNS i
in IN N
post-operative JJ p
patients NNS p
with IN p
gynecologic JJ p
cancer NN p
] NN p
. . p

The DT N
overall JJ o
incidence NN o
of IN o
adverse JJ o
drug NN o
reaction NN o
was VBD N
11.79 CD N
% NN N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

Visual JJ N
Assessment NNP N
of IN N
Relative NNP N
Apical NNP N
Sparing NNP N
Pattern NNP N
Is VBZ N
More RBR N
Useful JJ N
Than NNP N
Quantitative NNP N
Assessment NNP N
for IN N
Diagnosing NNP N
Cardiac NNP N
Amyloidosis NNP N
in IN N
Borderline NNP N
or CC N
Mildly RB N
Increased VBD N
Left NNP o
Ventricular NNP o
Wall NNP o
Thickness NNP o
. . o

Persons NNS N
with IN N
one CD N
or CC N
two CD N
l JJ N
alleles NNS N
or CC N
higher JJR N
CSF NNP N
5HIAA CD N
levels NNS N
also RB N
exhibited VBD N
greater JJR N
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
responses NNS o
to TO N
a DT N
mental JJ N
stress NN N
protocol NN N
. . N

Effects NNS N
of IN N
perioperative JJ i
indomethacin NN i
on IN N
intracranial JJ p
pressure NN p
, , p
cerebral JJ p
blood NN p
flow NN p
, , p
and CC p
cerebral JJ p
metabolism NN p
in IN p
patients NNS p
subjected VBN p
to TO p
craniotomy VB p
for IN p
cerebral JJ p
tumors NNS p
. . p

CONCLUSIONS NNP N
Opioid NNP N
doses VBZ N
commonly RB N
prescribed VBN N
in IN N
IV NNP N
opioid FW N
treatment NN N
induce NN N
marked VBD N
respiratory NN o
and CC o
circulatory NN o
depression NN o
, , N
as RB N
well RB N
as IN N
occasionally RB N
irregular JJ o
paroxysmal JJ o
EEG NNP o
activity NN o
. . o

The DT N
primary JJ N
outcome NN N
event NN N
( ( N
POE NNP N
) ) N
was VBD N
a DT N
composite NN o
of IN o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
nonfatal JJ o
stroke NN o
, , o
resuscitated VBD o
cardiac JJ o
arrest NN o
or CC o
cardiovascular JJ o
death NN o
. . o

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
; : o
secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

A DT N
pilot NN N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ i
arginine NN i
to TO N
enhance VB N
immune JJ N
function NN N
in IN N
persons NNS p
with IN p
HIV/AIDS NNP p
. . p

Hypertension NN N
after IN N
treatment NN N
with IN N
vascular JJ i
endothelial JJ i
growth NN i
factor NN i
( ( i
VEGF NNP i
) ) i
receptor NN i
inhibitors NNS i
is VBZ N
associated VBN N
with IN N
superior JJ N
treatment NN N
outcomes NNS N
for IN N
advanced JJ p
cancer NN p
patients NNS p
. . p

Elevated JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor NN N
alpha NN N
( ( N
TNF-alpha NNP N
) ) N
have VBP N
been VBN N
reported VBN N
to TO N
correlate VB N
with IN N
the DT N
development NN N
of IN N
transplant-related JJ N
complications NNS N
after IN N
bone NN N
marrow NN N
transplantation NN N
( ( N
BMT NNP N
) ) N
. . N

OBJECTIVE NN N
To TO N
prospectively RB N
compare VB N
two CD N
commonly RB N
used VBD N
methods NNS N
for IN N
percutaneous JJ i
dilational JJ i
tracheostomy NN i
( ( i
PDT NNP i
) ) i
in IN N
critically RB p
ill JJ p
patients NNS p
. . p

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
median JJ o
duration NN o
of IN o
response NN o
and CC o
median JJ o
survival NN o
for IN N
the DT N
two CD N
regimens NNS N
. . N

More JJR N
than IN N
two CD N
adenomas NNS N
at IN N
first JJ N
examination NN N
was VBD N
the DT N
only JJ N
factor NN N
found VBD N
to TO N
be VB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN o
of IN o
new JJ o
significant JJ o
neoplasia NN o
. . o

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
on IN N
arterial JJ o
blood NN o
pressure NN o
and CC o
sodium NN o
metabolism NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
] NN p
. . p

Effect NN N
of IN N
nitric-oxide-generating JJ i
system NN i
on IN N
microcirculatory NN p
blood NN p
flow NN p
in IN p
skin NN p
of IN p
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

High JJ N
doses NNS N
of IN N
atorvastatin NN i
reduce VB N
blood NN o
lipid NN o
levels NNS o
more RBR N
than IN N
conventional JJ N
doses NNS N
, , N
however RB N
, , N
the DT N
change NN N
in IN N
compliance NN N
is VBZ N
not RB N
dose-dependent JJ N
. . N

) ) i
lipid JJ i
emulsion NN i
( ( i
LCT NNP i
, , i
MCT NNP i
, , i
Olive-oil NNP i
and CC i
Fish-oil NNP i
) ) i
in IN N
patients NNS p
undergoing VBG p
elective JJ p
gastrointestial JJ p
surgery NN p
during IN p
the DT p
early JJ p
postoperative JJ p
period NN p
. . p

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
the DT N
rate NN o
of IN o
biopsy-confirmed JJ o
acute JJ o
rejection NN o
( ( o
BCAR NNP o
) ) o
and CC o
renal JJ o
function NN o
, , o
as IN o
measured VBN o
by IN o
serum JJ o
creatinine NN o
. . o

Prophylactic JJ i
Transluminal NNP i
Balloon NNP i
Angioplasty NNP i
( ( i
pTBA NN i
) ) i
appeared VBD N
to TO N
prevent VB N
delayed JJ o
ischemic JJ o
neurological JJ o
deficit NN o
in IN N
a DT N
pilot NN N
study NN N
. . N

Radial JJ N
artery NN N
was VBD N
cannulated VBN N
for IN N
arterial JJ N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
monitoring NN N
and CC N
blood NN N
sampling NN N
and CC N
Swan-Ganz NNP N
catheter NN N
was VBD N
position NN N
in IN N
the DT N
pulmonary JJ N
artery NN N
via IN N
right JJ N
internal JJ N
jugular NN N
vein NN N
under IN N
local JJ N
anesthesia NN N
. . N

Cerebral JJ o
blood NN o
flow NN o
( ( o
CBF NNP o
) ) o
and CC o
cerebral JJ o
metabolic NN o
rate NN o
for IN o
oxygen NN o
( ( o
CMRO2 NNP o
) ) o
were VBD N
measured VBN N
by IN N
a DT N
modification NN N
of IN N
the DT N
Kety-Schmidt NNP N
technique NN N
using VBG N
i.v NN N
. . N

OUTCOMES NNP N
Composite NNP N
CV NNP N
events NNS N
, , N
that DT N
is VBZ N
, , N
ischaemic JJ o
coronary NN o
and CC o
cerebrovascular JJ o
events NNS o
, , o
components NNS o
of IN o
the DT o
composite JJ o
CV NNP o
outcome NN o
, , o
and CC o
death NN o
. . o

Furthermore RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
magnitude NN N
of IN N
the DT N
positive JJ N
nor CC N
the DT N
negative JJ N
priming NN N
effects NNS N
of IN N
the DT N
groups NNS N
. . N

The DT N
response NN o
rate NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
, , o
and CC o
median JJ o
survival NN o
time NN o
were VBD N
superior JJ N
in IN N
the DT N
premenopausal JJ p
women NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
ranitidine NN i
or CC i
omeprazole JJ i
administration NN N
on IN N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
cephalexin NN N
. . N

Nucleotides NNP i
added VBD N
to TO N
milk-based JJ N
formula NN N
benefit NN N
infant NN N
immune NN N
status NN N
, , N
but CC N
reports NNS N
of IN N
the DT N
immunologic JJ N
effects NNS N
of IN N
adding VBG N
nucleotides NNS i
to TO i
soy-based JJ i
formula NN i
are VBP N
not RB N
available JJ N
. . N

CONCLUSION NNP N
The DT N
bias NN N
of IN N
measuring VBG N
haemoglobin JJ N
concentration NN N
by IN N
pulse JJ N
oximetry NN N
is VBZ N
dependent JJ N
on IN N
whether IN N
a DT N
crystalloid NN N
or CC N
a DT N
colloid JJ N
fluid NN N
is VBZ N
infused VBN N
. . N

The DT N
necessity NN N
of IN N
additional JJ N
ketoprofen NN N
therapy NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
( ( N
25.0 CD N
% NN N
vs JJ N
50.0 CD N
% NN N
, , N
P=.074 NNP N
) ) N
. . N

Central NNP o
nervous JJ o
system NN o
function NN o
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP o
Steady NNP o
State NNP o
Response NNP o
( ( o
ASSR NNP o
) ) o
and CC o
Bispectral NNP o
Index NNP o
( ( o
BIS NNP o
) ) o
analysis NN o
of IN o
electrooculogram NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
adjuvant NN N
AT NNP N
improved VBD N
disease-free JJ o
survival NN o
compared VBN N
with IN N
AC NNP N
in IN N
operable JJ N
breast NN N
cancer NN N
. . N

Predefined VBN N
study NN N
endpoints NNS N
are VBP N
gastric JJ o
cancer NN o
, , o
precancerous JJ o
lesions NNS o
( ( o
dysplasia NN o
, , o
adenoma NN o
) ) o
, , o
other JJ o
cancers NNS o
, , o
and CC o
death NN o
. . o

It PRP N
may MD N
be VB N
therefore RB N
concluded VBD N
that IN N
the DT N
evaluated JJ N
formulations NNS N
are VBP N
bioequivalent JJ N
in IN N
terms NNS N
of IN N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
. . N

Up IN N
to TO N
five CD N
independent JJ N
adjudicators NNS N
independently RB N
determined VBD N
two CD N
primary JJ N
outcomes NNS N
: : N
tumor NN N
status NN N
at IN N
death NN N
or CC N
at IN N
final JJ N
follow-up NN N
and CC N
the DT N
cause NN N
of IN N
death NN N
. . N

Comparative JJ N
evaluation NN N
of IN N
olopatadine JJ i
ophthalmic JJ i
solution NN i
( ( N
0.1 CD N
% NN N
) ) N
versus NN N
ketorolac NN i
ophthalmic JJ i
solution NN i
( ( N
0.5 CD N
% NN N
) ) N
using VBG N
the DT N
provocative JJ N
antigen NN N
challenge NN N
model NN N
. . N

RESULTS NN N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
systolic JJ o
and CC o
diastolic JJ o
pressure NN o
, , o
rate-pressure JJ o
product NN o
, , o
in IN o
glucose NN o
or CC o
catecholamine NN o
levels NNS o
. . o

BACKGROUND NN N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
pure-cut JJ N
electrosurgical JJ N
current JJ N
for IN N
endoscopic JJ N
sphincterotomy NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
post-ERCP JJ N
pancreatitis NN N
. . N

Baseline NNP N
renal JJ N
function NN N
is VBZ N
the DT N
major JJ N
determinant NN N
of IN N
the DT N
rate NN N
of IN N
rise NN N
, , N
height NN N
, , N
and CC N
duration NN N
of IN N
Cr NNP N
trajectory NN N
after IN N
contrast NN N
exposure NN N
. . N

Therefore RB N
, , N
blockade NN N
of IN N
HGF-MET NNP N
signalling NN N
might MD N
be VB N
a DT N
valid JJ N
therapeutic JJ N
strategy NN N
, , N
in IN N
combination NN N
with IN N
BRAF NNP N
inhibition NN N
, , N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
specific JJ N
cellular JJ N
immunoresponse NN N
of IN N
peripheral JJ N
blood NN N
lymphocytes NNS N
in IN N
the DT N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
treated VBD p
with IN p
different JJ p
doses NNS p
of IN p
recombinant JJ i
hepatitis NN i
B NNP i
vaccine NN i
. . i

Retinal JJ N
vessels NNS N
showed VBD N
a DT N
small JJ N
diameter NN N
increase NN N
, , N
whereas RB N
red JJ o
blood NN o
cell NN o
speed NN o
decreased VBN N
, , N
resulting VBG N
in IN N
an DT N
unchanged JJ o
total JJ o
retinal JJ o
blood NN o
flow NN o
. . o

Among IN N
subjects NNS N
with IN N
recurrent NN N
adenomas NN N
, , N
the DT N
mean NN N
( ( N
+/-SE JJ N
) ) N
number NN N
of IN N
such JJ N
lesions NNS N
was VBD N
1.85+/-0.08 JJ N
in IN N
the DT N
intervention NN N
group NN N
and CC N
1.84+/-0.07 NNS N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
rate NN o
of IN o
reporting NN o
of IN o
adverse JJ o
events NNS o
considered VBN o
to TO o
be VB o
drug-related JJ o
and CC o
the DT o
rate NN o
of IN o
withdrawals NNS o
were VBD N
similar JJ N
for IN N
both DT N
treatments NNS N
. . N

Discrepancies NNS o
in IN o
postoperative JJ o
leg NN o
length NN o
were VBD N
5.45 CD N
mm NNS N
and CC N
13.37 CD N
mm NN N
in IN N
the DT N
groups NNS N
with IN N
and CC N
without IN N
the DT N
guide NN N
, , N
respectively RB N
. . N

The DT N
post-ischaemic JJ o
functional JJ o
recovery NN o
of IN N
the DT N
heart NN N
was VBD N
assessed VBN N
by IN N
clinical JJ N
parameters NNS N
, , N
as RB N
well RB N
as IN N
by IN N
biochemical JJ N
and CC N
ultrastructure JJ N
evaluations NNS N
on IN N
biopsy NN N
specimens NNS N
. . N

Statistically RB N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
was VBD N
the DT N
difference NN N
in IN N
postoperative JJ o
bleeding NN o
evaluated VBN N
with IN N
particular JJ N
attention NN N
in IN N
patients NNS p
of IN p
advanced JJ p
age NN p
. . p

There EX N
was VBD N
a DT N
fall NN N
in IN N
urinary JJ o
dopamine NN o
( ( o
DA NNP o
) ) o
and CC o
noradrenaline JJ o
( ( o
NA NNP o
) ) o
levels NNS o
and CC o
increased JJ o
excretion NN o
of IN o
homovanillic JJ o
acid NN o
( ( o
HVA NNP o
) ) o
. . o

Experimental JJ N
studies NNS N
suggest VBP N
that IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
EPO NNP i
) ) i
independent JJ N
of IN N
its PRP$ N
erythropoietic JJ N
effect NN N
may MD N
be VB N
used VBN N
clinically RB N
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
. . N

Ciprodex NN i
treatment NN N
also RB N
decreased VBD N
the DT N
rate NN o
of IN o
clinically RB o
diagnosed VBN o
otitis NN o
media NNS o
( ( o
OM NNP o
) ) o
and CC o
effusion NN o
following VBG o
TT NNP o
placement NN o
( ( N
p JJ N
< NN N
or CC N
=0.0006 NN N
) ) N
. . N

The DT N
low JJ N
solubility NN N
of IN N
desflurane NN i
has VBZ N
been VBN N
shown VBN N
to TO N
contribute VB N
to TO N
faster VB N
awakening VBG N
from IN N
anesthesia NN N
when WRB N
compared VBN N
with IN N
other JJ N
anesthetics NNS N
in IN N
common JJ N
use NN N
. . N

Noradrenaline NNP o
concentrations NNS o
decreased VBD N
to TO N
less JJR N
than IN N
baseline NN N
values NNS N
in IN N
the DT N
extradural JJ N
group NN N
and CC N
were VBD N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
opioid JJ N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Women NNP p
( ( p
8,800 CD p
) ) p
, , p
aged VBD p
30-62 CD p
, , p
were VBD p
randomly RB p
selected VBN p
among IN p
women NNS p
without IN p
a DT p
registered JJ p
Pap NNP p
smear NN p
in IN p
the DT p
two CD p
latest JJS p
screening VBG p
rounds NNS p
. . p

A DT N
reduction NN N
of IN N
the DT N
increase NN o
of IN o
scar NN o
width NN o
was VBD N
seen VBN N
in IN N
the DT N
Contractubex-treated JJ N
group NN N
as IN N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
. . N

CONCLUSION VB N
The DT N
27-gauge JJ i
NVS NNP i
is VBZ N
an DT N
effective JJ N
surgical JJ N
procedure NN N
in IN N
eyes NNS N
with IN N
epiretinal JJ N
membrane NN N
and CC N
it PRP N
induces VBZ N
less JJR N
progression NN N
of IN N
nuclear JJ N
sclerosis NN N
than IN N
25-gauge JJ N
vitrectomy NN N
. . N

No DT N
adverse JJ o
side NN o
effects NNS o
attributable JJ N
to TO N
captopril VB i
were VBD N
noted VBN N
, , N
except IN N
in IN N
one CD N
patient NN N
in IN N
whom WP N
proteinuria NN N
developed VBD N
after IN N
seven CD N
weeks NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
change NN o
of IN o
global JJ o
LV NNP o
systolic JJ o
function NN o
by IN N
echocardiography NN N
or CC N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
during IN N
the DT N
follow-up NN N
. . N

Additionally RB N
subjects VBZ p
with IN p
autism NN p
spectrum NN p
disorders NNS p
showed VBD N
a DT N
significantly RB N
increased VBN N
prolactin NN o
response NN o
to TO o
m-CPP NN o
compared VBN N
to TO N
normal JJ N
controls NNS N
, , N
with IN N
neither DT N
group NN N
responding VBG N
to TO N
placebo VB i
. . i

CONCLUSIONS NNP N
Allograft NNP N
mixed VBD N
with IN N
an DT N
experimental JJ N
putty NN N
carrier NN N
produced VBD N
significantly RB N
more RBR N
vital JJ N
bone NN N
fill NN N
than IN N
did VBD N
the DT N
use NN N
of IN N
a DT N
xenograft NN N
with IN N
no DT N
carrier NN N
material NN N
. . N

These DT N
data NNS N
suggest VBP N
the DT N
effectiveness NN N
of IN N
interferon NN i
given VBN N
as IN N
induction NN N
and CC N
as IN N
maintenance NN N
treatment NN N
in IN N
the DT N
therapy NN N
of IN N
II NNP p
type NN p
mixed JJ p
essential JJ p
cryoglobulinemia NN p
. . p

Many JJ N
different JJ N
formulations NNS N
were VBD N
prepared VBN N
, , N
among IN N
which WDT N
F3-coded NNP N
formulation NN N
was VBD N
only RB N
selected VBN N
due JJ N
to TO N
releasing VBG N
of IN N
98.03 CD N
% NN N
active JJ N
substance NN N
at IN N
45th CD N
minute NN N
. . N

There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
side NN o
effects NNS o
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

NMES NNP i
robot-assisted JJ i
training NN i
showed VBD N
better JJR N
performance NN o
in IN o
releasing VBG o
muscle NN o
co-contraction NN o
than IN N
the DT N
robot-assisted JJ N
across IN N
the DT N
training NN N
sessions NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
regard NN N
to TO N
AUC NNP N
( ( N
0-18 CD N
) ) N
or CC N
evolution NN N
of IN N
BASDAI NNP o
scores NNS o
and CC o
biomarkers NNS o
of IN o
inflammation NN o
. . o

Angiotensin NNP N
II NNP N
infusion NN N
increased VBD N
filtration NN N
fraction NN N
, , N
but CC N
decreased VBD N
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
and CC o
urine JJ o
flow NN o
sharply RB o
. . o

Comparison NNP N
of IN N
the DT N
efficacy NN N
of IN N
fluoxetine NN i
alone RB i
vs. FW i
fluoxetine JJ i
plus CC i
local JJ i
lidocaine NN i
ointment NN i
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

These DT N
observed VBD N
changes NNS N
in IN N
insulin NN o
sensitivity NN o
are VBP N
likely JJ N
to TO N
be VB N
clinically RB N
relevant JJ N
, , N
especially RB N
in IN N
individuals NNS N
predisposed VBN N
to TO N
develop VB N
glucose JJ N
intolerance NN N
. . N

CONCLUSIONS VB N
A DT N
doubling JJ N
factor NN N
is VBZ N
effective JJ N
for IN N
maintaining VBG N
the DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
detection NN N
in IN N
men NNS N
on IN N
dutasteride NN N
. . N

Modulation NN N
of IN N
the DT N
intestinal JJ N
environment NN N
, , N
innate VB N
immune JJ N
response NN N
, , N
and CC N
barrier JJR N
function NN N
by IN N
dietary JJ i
threonine NN i
and CC i
purified JJ i
fiber NN i
during IN N
a DT N
coccidiosis NN N
challenge NN N
in IN N
broiler NN p
chicks NNS p
. . p

Thirty-six JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD i
of IN i
two CD i
treatment NN i
conditions NNS i
, , i
one CD i
of IN i
which WDT i
was VBD i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
. . i

In IN N
particular JJ N
, , N
the DT N
incidence NN o
and CC o
magnitude NN o
of IN o
febrile JJ o
temperatures NNS o
were VBD N
significantly RB N
lower JJR N
between IN N
the DT N
4th CD N
and CC N
8th CD N
days NNS N
of IN N
treatment NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
safety NN o
and CC o
Immunogenicity NNP o
of IN N
the DT N
Poliomyelitis NNP i
vaccine NN i
( ( i
Human NNP i
Diploid NNP i
Cell NNP i
) ) i
in IN N
> NN N
or CC N
=2 VB p
month-old JJ p
children NNS p
. . p

No DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
effect NN N
variables NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
before IN N
, , N
during IN N
or CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
intraoperative JJ N
mitomycin NN N
C NNP N
during IN N
deep JJ N
sclerectomy NN N
significantly RB N
reduced VBD N
the DT N
postoperative JJ o
IOP NNP o
and CC o
increased VBD o
the DT o
success NN o
rate NN o
of IN o
the DT o
procedure NN o
. . o

When WRB N
dazmegrel NN N
was VBD N
orally RB N
administered VBN N
to TO N
greyhound VB i
dogs NNS i
wearing VBG i
leg NN i
casts NNS i
, , N
it PRP N
resulted VBD N
in IN N
a DT N
sparring JJ N
effect NN N
on IN N
the DT N
skin JJ N
areas NNS N
of IN N
potential JJ N
pressure NN N
ulcer NN N
development NN N
. . N

Brief JJ N
Report NNP N
: : N
Randomized JJ N
test NN N
of IN N
the DT N
efficacy NN N
of IN N
picture NN i
exchange NN i
communication NN i
system NN i
on IN N
highly RB N
generalized JJ N
picture NN N
exchanges NNS N
in IN N
children NNS p
with IN p
ASD NNP p
. . p

This DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
when WRB N
first RB N
study VB N
episodes NNS N
were VBD N
considered VBN N
separately RB N
( ( N
six CD N
flu NN N
versus NN N
nil JJ N
itra NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
10-year JJ o
OS NNP o
rate NN o
was VBD N
13.8 CD N
% NN N
in IN N
the DT N
surgery NN N
arm NN N
and CC N
13.1 CD N
% NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
diltiazem NN i
, , N
a DT N
moderate JJ N
inhibitor NN N
of IN N
CYP3A4 NNP N
, , N
on IN N
the DT N
single-dose JJ N
pharmacokinetics NNS N
of IN N
ACT-178882 NNP N
in IN N
healthy JJ p
subjects NNS p
. . p

A DT N
slight JJ N
elevation NN o
of IN o
heart NN o
rate NN o
was VBD N
observed VBN N
more RBR N
often RB N
in IN N
the DT N
adrenaline NN N
group NN N
( ( N
P NNP N
= NNP N
0.043 CD N
) ) N
. . N

Inclusion NN N
of IN N
anti-phospholipase JJ N
A2 NNP N
antibody NN N
to TO N
backgrounding VBG N
diets NNS N
on IN N
performance NN N
, , N
feed NN N
efficiency NN N
, , N
in IN N
vitro JJ N
fermentation NN N
, , N
and CC N
the DT N
acute-phase JJ N
response NN N
of IN N
growing VBG p
beef NN p
calves NNS p
. . p

Plasma NNP o
prothrombin NN o
and CC o
serum JJ o
alkaline JJ o
phosphatase NN o
levels NNS o
of IN o
the DT o
zinc NNP o
group NN o
increased VBD o
and CC o
serum JJ o
bilirubin NN o
and CC o
serum JJ o
carotene NN o
decreased VBN N
significantly RB N
. . N

Baseline JJ o
mean NN o
scores NNS o
and CC o
rates NNS o
at IN o
which WDT o
pts NNS o
failed VBD o
to TO o
complete VB o
QoL NNP o
assessment NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
arms NNS N
. . N

Guthrie NNP N
cards NNS N
can MD N
be VB N
used VBN N
to TO N
accurately RB N
genotype VB N
CYP21 NNP N
and CC N
other JJ N
relevant JJ N
markers NNS N
, , N
potentially RB N
enhancing VBG N
the DT N
specificity NN N
and CC N
sensitivity NN N
of IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
screening NN N
. . N

Our PRP$ N
hypothesis NN N
is VBZ N
that IN N
coinduction NN N
with IN N
clonidine NN i
reduces VBZ N
the DT N
incidence NN N
of IN N
PONV NNP o
in IN N
adult NN p
patients NNS p
undergoing VBG p
breast NN p
cancer NN p
surgery NN p
. . p

We PRP N
used VBD N
this DT N
situation NN N
to TO N
determine VB N
the DT N
antiplatelet NN o
efficacy NN o
of IN N
L-arginine NNP i
and CC i
S-nitrosoglutathione NNP i
( ( i
GSNO NNP i
) ) i
, , N
a DT N
physiological JJ N
nitric JJ N
oxide IN N
donor NN N
with IN N
possible JJ N
platelet NN N
specificity NN N
. . N

Effects NNS N
of IN N
strontium NN i
on IN N
the DT N
quality NN o
of IN o
bone NN o
apatite JJ o
crystals NNS o
: : o
a DT N
paired JJ N
biopsy NN N
study NN N
in IN N
postmenopausal JJ p
osteoporotic JJ p
women NNS p
. . p

Denopamine NNP i
increased VBD N
heart NN o
rate NN o
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
but CC N
had VBD N
little JJ N
effect NN N
on IN N
heart NN o
rate NN o
in IN N
patients NNS p
with IN p
sinus JJ p
rhythm NN p
. . p

A DT N
significant JJ N
decrease NN N
in IN N
number NN o
of IN o
tender NN o
sites NNS o
on IN o
the DT o
masticatory NN o
muscles NNS o
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

The DT N
new JJ o
infection NN o
rates NNS o
for IN N
quarters NNS N
that WDT N
received VBD N
intramammary JJ i
tilmicosin NNS i
compared VBN N
with IN N
the DT N
intramammary JJ i
placebo NN i
were VBD N
14.4 CD N
and CC N
19.4 CD N
% NN N
, , N
respectively RB N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
birth NN o
weight NN o
, , o
treatment NN o
with IN o
antibiotics NNS o
, , o
and CC o
the DT o
starting JJ o
time NN o
of IN o
breast-feeding NN o
among IN N
the DT N
three CD N
groups NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN N
proteins NNS N
and CC N
leptin JJ N
receptor NN N
proteins NNS N
in IN N
studied JJ N
tissues NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
end-to-side JJ N
neurorrhaphy NN N
can MD N
induce VB N
the DT N
functional JJ N
collateral NN N
sprouting NN N
of IN N
both DT N
motor NN N
and CC N
sensory JJ N
axons NNS N
in IN N
the DT N
peripheral JJ N
nerve NN N
. . N

CONCLUSION NNP N
Procalcitonin NNP i
is VBZ N
a DT N
helpful JJ N
and CC N
safe JJ N
tool NN N
for IN N
guiding VBG N
duration NN N
of IN N
antibiotic JJ N
treatment NN N
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
. . p

The DT N
proportions NNS N
of IN N
eicosapentaenoic NN N
and CC N
docosahexaenoic JJ i
acids NNS i
in IN N
serum JJ o
lipids NNS o
increased VBD N
in IN N
the DT N
fatty JJ N
fish NN N
group NN N
only RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
triple JJ i
drug NN i
therapy NN i
was VBD N
more RBR N
efficacious JJ N
than IN N
any DT N
double JJ N
drug NN N
regimen NNS N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ o
histological JJ o
changes NNS o
in IN o
renal JJ o
allografts NNS o
. . o

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

The DT N
effect NN N
of IN N
valaciclovir NN i
on IN N
cytomegalovirus NN N
viremia NN N
and CC N
viruria NN N
detected VBN N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
patients NNS p
with IN p
advanced JJ p
human JJ p
immunodeficiency NN p
virus NN p
disease NN p
. . p

AIM NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
local JJ i
estrogen NN i
with IN i
or CC i
without IN i
local JJ i
testosterone NN i
on IN N
urogenital JJ o
and CC o
sexual JJ o
health NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

Formoterol NNP i
caused VBD N
a DT N
significantly RB N
higher JJR N
tremor NN o
score NN o
and CC N
a DT N
larger JJR N
drop NN N
in IN N
S-potassium NNP N
than IN N
salmeterol NN i
at IN N
the DT N
highest JJS N
doses NNS N
. . N

Linezolid NNP N
was VBD N
well RB N
tolerated VBN o
and CC o
the DT o
frequency NN o
of IN o
drug-related JJ o
adverse JJ o
events NNS o
was VBD N
similar JJ N
between IN N
the DT N
linezolid JJ N
and CC N
placebo JJ i
groups NNS N
. . N

PERSPECTIVE NN N
This DT N
study NN N
showed VBD N
that IN N
KC NNP i
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ o
pain NN o
responses NNS o
in IN N
preterm JJ p
infants NNS p
. . p

Secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
safety NN o
. . o

There EX N
are VBP N
multiple JJ N
design NN N
possibilities NNS N
for IN N
VPs NNP N
, , N
however RB N
there EX N
is VBZ N
little JJ N
formal JJ N
evidence NN N
to TO N
support VB N
individual JJ N
design NN N
features NNS N
. . N

Only RB N
one CD N
case NN N
of IN N
secondary JJ o
post-tonsillectomy JJ o
haemorrhage NN o
was VBD N
recorded VBN N
, , N
in IN N
the DT N
potassium NN i
titanyl NN i
phosphate VBP i
laser NN i
group NN N
( ( N
2.5 CD N
per IN N
cent NN N
) ) N
, , N
managed VBD N
conservatively RB N
. . N

RESULTS NN N
After IN N
PE NNP N
treatment NN N
, , N
nerve NN o
function NN o
defect NN o
appeared VBD N
to TO N
improve VB N
better JJR N
than IN N
the DT N
IVIg NNP N
group NN N
and CC N
clinical JJ N
effect NN N
was VBD N
better JJR N
than IN N
the DT N
IVIg NNP N
group NN N
. . N

Second JJ N
, , N
the DT N
application NN N
of IN N
principal JJ N
component JJ N
analysis NN N
indicated VBD N
that IN N
the DT N
positive JJ o
waveform NN o
elicited VBN N
by IN N
the DT N
words NNS N
in IN N
the DT N
test NN N
list NN N
was VBD N
a DT N
P300 NNP N
. . N

Mean NNP o
free JJ o
testosterone NN o
and CC o
3alpha-androstanediol JJ o
glucuronide NN o
decreased VBD N
significantly RB N
in IN N
the DT N
group NN N
receiving VBG N
ethinyl JJ i
estradiol/desogestrel NN i
but CC N
not RB N
in IN N
the DT N
ethinyl NN N
estradiol/levonorgestrel NN N
group NN N
. . N

UNLABELLED JJ N
Reports NNS N
of IN N
transient JJ N
neurological JJ N
symptoms NNS N
with IN N
the DT N
use NN N
of IN N
subarachnoid JJ i
lidocaine NN i
has VBZ N
generated VBN N
interest NN N
in IN N
alternate JJ N
local JJ N
anesthetics NNS N
of IN N
intermediate JJ N
duration NN N
, , N
such JJ N
as IN N
mepivacaine NN N
. . N

Furosemide NNP i
, , N
a DT N
loop NN N
diuretic NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
selectively RB N
and CC N
reversibly RB N
block VB N
inhibitory NN N
postsynaptic JJ N
potentials NNS N
without IN N
affecting VBG N
excitatory JJ N
postsynaptic JJ N
potentials NNS N
in IN N
animal JJ N
spinal JJ N
neurons NNS N
. . N

RESULT VB N
The DT N
incidences NNS N
of IN N
nausea NN o
, , o
retching VBG o
or CC o
vomiting VBG o
during IN N
the DT N
first JJ N
and CC N
second JJ N
24-h JJ N
periods NNS N
after IN N
surgery NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Sixty NNP p
adult NN p
participants NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
listen-and-repeat JJ i
learning VBG i
conditions NNS i
: : i
speaking NN i
, , i
rhythmic JJ i
speaking NN i
, , i
or CC i
singing NN i
. . i

Secondary JJ N
endpoints NNS N
were VBD N
cTFC JJ o
prior RB o
to TO o
PCI NNP o
, , o
TIMI NNP o
flow NN o
grade NN o
, , o
MBG NNP o
and CC o
the DT o
percentage NN o
of IN o
ST NNP o
resolution NN o
. . o

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN i
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN p
predisposed VBN p
patients NNS p
with IN p
myasthenia JJ p
gravis NN p
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN N
. . N

CONCLUSION NNP N
Fluvoxamine NNP i
and CC i
clomipramine NN i
are VBP N
equally RB N
effective JJ N
in IN N
severe JJ N
depression NN N
, , N
but CC N
fluvoxamine NN i
has VBZ N
a DT N
better JJR N
safety NN N
and CC N
tolerability NN N
profile NN N
. . N

CONCLUSION NN N
It PRP N
is VBZ N
concluded VBN N
that IN N
oral JJ N
NaAcetate NNP N
could MD N
be VB N
used VBN N
as IN N
both DT N
an DT N
alkalinizing NN N
agent NN N
and CC N
an DT N
alternative JJ N
energy NN N
source NN N
in IN N
the DT N
horse NN N
. . N

However RB N
, , N
the DT N
level NN o
of IN o
emergent JJ o
over-selectivity NN o
was VBD N
significantly RB N
reduced VBN N
by IN N
a DT N
mindfulness NN N
induction NN N
when WRB N
compared VBN N
to TO N
a DT N
no- JJ N
intervention NN N
control NN N
group NN N
. . N

A DT N
comparative JJ N
study NN N
of IN N
a DT N
new JJ i
food NN i
supplement NN i
, , i
ViviScal NNP i
, , i
with IN i
fish JJ i
extract NN i
for IN N
the DT N
treatment NN N
of IN N
hereditary JJ N
androgenic JJ N
alopecia NN N
in IN N
young JJ p
males NNS p
. . p

CONCLUSION NNP N
Diltiazem NNP i
reduced VBD N
the DT N
clinical JJ N
and CC N
electrocardiographical JJ N
aspects NNS N
and CC N
raises VBZ N
the DT N
effort NN N
tolerance NN N
during IN N
the DT N
ergometric JJ N
test NN N
in IN N
patients NNS p
with IN p
stable JJ p
angina NN p
. . p

It PRP N
is VBZ N
suggested VBN N
that IN N
addition NN N
of IN N
clofibrate NN N
may MD N
be VB N
useful JJ N
in IN N
maturity-onset JJ p
diabetics NNS p
not RB p
adequately RB p
controlled VBN p
by IN p
diet NN p
combined VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
phrenic JJ N
nerve NN N
palsy NN N
causes VBZ N
a DT N
significant JJ N
impairment NN N
of IN N
dynamic JJ o
lung NN o
volumes NNS o
during IN N
the DT N
early JJ N
postoperative JJ N
period NN N
after IN N
pneumonectomy NN N
. . N

Effect NN N
of IN N
pravastatin NN i
on IN N
cardiovascular JJ N
events NNS N
in IN N
women NNS p
after IN p
myocardial JJ p
infarction NN p
: : p
the DT N
cholesterol NN N
and CC N
recurrent JJ N
events NNS N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

OBJECTIVE NN N
To TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
solution NN N
of IN N
nicotine NN N
on IN N
sustained JJ N
resting NN N
pressure NN N
( ( N
tone NN N
) ) N
and CC N
contractile JJ N
activity NN N
in IN N
the DT N
human JJ N
colon NN N
. . N

OBJECTIVES NNP N
Certain NNP N
GI NNP N
prokinetic JJ N
agents NNS N
have VBP N
been VBN N
shown VBN N
to TO N
affect VB N
cardiac JJ N
repolarization NN N
, , N
which WDT N
may MD N
be VB N
associated VBN N
with IN N
life-threatening JJ N
arrhythmias NNS N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
fitted VBN N
with IN N
two CD N
IFRS NNP i
retainers NNS i
and CC N
also RB N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
1100-ppm JJ i
fluoride JJ i
conventional JJ i
sodium NN i
fluoride NN i
dentifrice NN i
twice RB i
daily RB i
. . i

PURPOSE NN N
This DT N
study NN N
evaluated VBD N
the DT N
bond NN N
strength NN N
of IN N
two CD N
etch-and-rinse JJ i
adhesive JJ i
systems NNS i
( ( i
two- JJ i
and CC i
three-step NN i
) ) i
and CC i
a DT i
self-etching JJ i
system NN i
to TO i
coronal VB i
and CC i
root VB i
canal JJ i
dentin NN i
. . i

For IN N
their PRP$ N
second JJ N
and CC N
third JJ N
infusions NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Z NNP N
then RB N
P NNP N
or CC N
P NNP N
then RB N
Z NNP N
, , N
and CC N
questioned VBD N
on IN N
their PRP$ N
preferences NNS N
. . N

The DT N
clinical JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
propofol JJ i
infusion NN i
with IN i
and CC i
without IN i
EDTA NNP i
for IN N
maintenance NN N
anesthesia NN N
in IN N
healthy JJ p
children NNS p
undergoing VBG p
ambulatory NN p
surgery NN p
. . p

However RB N
, , N
the DT N
lower JJR N
risk NN N
recorded VBN N
with IN N
fondaparinux NN i
than IN i
enoxaparin NN i
was VBD N
clinically RB N
important JJ N
, , N
with IN N
no DT N
increase NN N
in IN N
clinically RB o
relevant JJ o
bleeding NN o
. . o

Olopatadine NNP i
is VBZ N
a DT N
dual JJ N
acting NN N
H1 NNP N
histamine NN N
receptor NN N
antagonist NN N
and CC N
a DT N
mast NN N
cell NN N
stabilizer NN N
, , N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG N
allergic JJ N
conjunctivitis NN N
. . N

RESULTS VB N
The DT N
participants NNS N
' POS N
mean JJ N
age NN N
was VBD N
27.56 CD N
in IN N
the DT N
aloe NN N
vera NN N
group NN N
and CC N
26.62 CD N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
addition NN N
, , N
this DT N
analysis NN N
strongly RB N
suggests VBZ N
that IN N
low JJ N
peripheral JJ N
blood NN N
levels NNS N
of IN N
CD19+ NNP N
cells NNS N
are VBP N
an DT N
adverse JJ N
prognostic JJ N
sign NN N
in IN N
myeloma NN N
. . N

The DT N
usefulness NN N
of IN N
intravenous JJ N
dexmedetomidine NN i
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
was VBD N
studied VBN N
in IN N
patients NNS p
anesthetized VBN p
with IN p
thiopental JJ i
, , i
fentanyl JJ i
, , i
nitrous JJ i
oxide NN i
, , i
and CC i
oxygen NN i
. . i

A DT N
significant JJ N
redistribution NN N
of IN N
tidal JJ N
variation NN N
to TO N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lung NN N
was VBD N
observed VBN N
on IN N
electrical JJ N
impedance NN N
tomography NN N
measurements NNS N
when WRB N
increasing VBG N
mean VB o
airway JJ o
pressure NN o
. . o

The DT N
fall NN N
in IN N
MSNA NNP i
was VBD N
unrelated JJ N
to TO N
the DT N
decrease NN N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
( ( N
r=0.41 NN N
, , N
p=0.14 NN N
) ) N
. . N

Radiotherapy NNP i
increased VBD N
postoperative JJ o
mortality NN o
and CC o
complications NNS o
and CC o
reduced JJ o
local JJ o
and CC o
distant JJ o
recurrence NN o
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

CONCLUSIONS JJ N
Low-intensity NNP i
back-strengthening NN i
exercise NN i
was VBD N
effective JJ N
in IN N
improving VBG N
the DT N
quality NN o
of IN o
life NN o
and CC o
back RB o
extensor JJ o
strength NN o
in IN N
patients NNS p
with IN p
osteoporosis NN p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
neuropsychological JJ o
function NN o
or CC o
abnormalities NNS o
indicated VBN N
by IN N
computed JJ N
tomography NN N
brain NN N
scans NNS N
. . N

We PRP N
also RB N
report VBP N
an DT N
analysis NN N
comparing VBG N
the DT N
proportion NN N
of IN N
eyes NNS N
that WDT N
developed VBD N
one CD N
or CC N
more JJR N
key JJ N
events NNS N
to TO N
the DT N
cumulative JJ N
number NN N
of IN N
injections NNS N
. . N

However RB N
, , N
the DT N
mean JJ o
duration NN o
of IN o
therapeutic JJ o
response NN o
is VBZ N
significantly RB N
higher RBR N
in IN N
the DT N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0,01 CD N
) ) N
. . N

Effects NNS N
of IN N
water NN i
extracts NNS i
of IN i
Graptopetalum NNP i
paraguayense NN i
on IN N
blood NN o
pressure NN o
, , o
fasting VBG o
glucose NN o
, , o
and CC o
lipid JJ o
profiles NNS o
of IN N
subjects NNS p
with IN p
metabolic JJ p
syndrome NN p
. . p

Plasma NNP o
levels NNS o
of IN N
lysozyme NN N
, , N
a DT N
characteristic JJ N
product NN N
of IN N
PMN NNP N
degranulation NN N
, , N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
. . N

Primary JJ o
surgery NN o
, , o
good JJ o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
, , N
only RB N
one CD N
metastatic JJ N
site NN N
, , N
and CC N
oxaliplatin-based JJ N
second-line JJ N
treatment NN N
independently RB N
predicted VBD N
a DT N
longer RBR N
OS NNP o
. . o

CONCLUSION NN N
AT NNP N
did VBD N
not RB N
improve VB N
DFS NNP o
or CC o
overall JJ o
survival NN o
in IN N
this DT N
population NN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
more JJR N
toxicity NN o
. . o

The DT N
contribution NN N
of IN N
salvage NN N
surgery NN N
to TO N
overall JJ o
survival NN o
was VBD N
similar JJ N
for IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
as IN N
was VBD N
the DT N
surgical JJ N
complication NN N
rate NN N
. . N

It PRP N
is VBZ N
more RBR N
convenient JJ N
than IN N
the DT N
8-site JJ N
method NN N
, , N
and CC N
can MD N
be VB N
used VBN N
economically RB N
with IN N
vaccines NNS N
formulated VBN N
in IN N
1.0 CD N
or CC N
0.5 CD N
ml NN N
ampoules NNS N
. . N

Eighteen NNP p
sedentary JJ p
male NN p
volunteers NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
CLA NNP i
and CC i
Placebo NNP i
( ( i
PLC NNP i
) ) i
supplementation NN N
groups NNS N
. . N

Serum NNP o
cholesterols NNS o
, , o
LDL/HDL NNP o
ratios NNS o
, , o
LDL NNP o
cholesterols VBZ o
, , o
and CC o
triglyceride JJ o
determinations NNS o
in IN N
male JJ p
tobacco NN p
users NNS p
significantly RB p
exceeded VBD p
those DT p
in IN p
nonsmoking JJ p
males NNS p
. . p

UNLABELLED JJ N
Growth NNP i
hormone NN i
( ( i
GH NNP i
) ) i
treatment NN N
in IN N
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
GH NNP p
deficiency NN p
has VBZ N
beneficial JJ N
effects NNS N
on IN N
bone NN N
mass NN N
. . N

In IN N
an DT N
attempt NN N
to TO N
compensate VB N
for IN N
the DT N
lower JJR N
efficacy NN N
, , N
H2-receptor NNP N
antagonists NNS N
are VBP N
now RB N
increasingly RB N
being VBG N
used VBN N
at IN N
a DT N
higher JJR N
dose NN N
. . N

Accordingly RB N
, , N
demonstration NN N
that IN N
a DT N
specific JJ N
molecular JJ N
subtype NN N
accounts NNS N
for IN N
superior JJ N
outcome NN N
, , N
when WRB N
using VBG N
these DT N
regimens NNS N
, , N
is VBZ N
needed VBN N
. . N

BACKGROUND NNP N
Paliperidone NNP i
ER NNP i
monotherapy NN i
was VBD N
efficacious JJ N
in IN N
treating VBG N
acute NN N
mania NN N
in IN N
two CD N
3-week JJ N
studies NNS N
in IN N
patients NNS p
with IN p
bipolar JJ p
I PRP p
disorder VBP p
. . p

In IN N
the DT N
favorable JJ N
subgroup NN N
, , N
85.8 CD N
% NN N
had VBD N
a DT N
negative JJ N
early JJ N
PET JJ N
scan JJ N
( ( N
standard JJ N
arm NN N
, , N
one CD N
event NN N
v NN N
experimental JJ N
arm NN N
, , N
nine CD N
events NNS N
) ) N
. . N

In IN N
the DT N
rat NN N
surgical JJ N
model NN N
used VBN N
, , N
right JJ N
femora NNS N
were VBD N
fixed VBN N
to TO N
a DT N
polyethylene NN N
plate NN N
and CC N
then RB N
defects NNS N
were VBD N
created VBN N
mid-diaphysis NN N
and CC N
subsequently RB N
filled VBN N
with IN N
demineralized JJ N
bone NN N
matrix NN N
. . N

CONCLUSION NNP N
Argatroban NNP N
dose-dependently JJ N
increases NNS N
coagulation NN N
parameters NNS N
and CC N
, , N
compared VBN N
to TO N
UFH NNP N
, , N
demonstrates VBZ N
a DT N
superior JJ N
predictable JJ N
anticoagulant JJ N
effect NN N
in IN N
patients NNS p
undergoing VBG p
elective JJ p
PCI NNP p
. . p

Because IN N
the DT N
mechanism NN N
of IN N
action NN N
for IN N
ipilimumab NN N
is VBZ N
thought VBN N
to TO N
be VB N
HLA NNP N
independent JJ N
, , N
most JJS N
trials NNS N
enrolled VBD N
patients NNS N
without IN N
regard NN N
to TO N
HLA NNP N
subtype NN N
. . N

OBJECTIVE NN N
In IN N
the DT N
past JJ N
years NNS N
the DT N
interaction NN N
of IN N
GH NNP N
and CC N
11beta CD N
hydroxysteroid JJ N
dehydrogenase NN N
( ( N
11betaHSD CD N
) ) N
in IN N
the DT N
pathogenesis NN N
of IN N
central JJ N
obesity NN N
has VBZ N
been VBN N
suggested VBN N
. . N

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
nonexercising JJ i
control NN i
group NN i
, , i
a DT i
cycle NN i
training NN i
group NN i
( ( i
cycle NN i
) ) i
, , i
or CC i
one CD i
of IN i
the DT i
two CD i
HCT NNP i
groups NNS i
. . i

We PRP N
conclude VBP N
that IN N
amifostine NN N
can MD N
be VB N
safely RB N
administered VBN N
prior RB N
to TO N
high-dose JJ N
melphalan NN N
and CC N
significantly RB N
reduces VBZ N
the DT N
frequency NN o
and CC o
severity NN o
of IN o
therapy-induced JJ o
oral JJ o
mucositis NN o
. . o

PATIENTS NNP N
Endocrinologically NNP p
normal JJ p
women NNS p
with IN p
a DT p
medical JJ p
indication NN p
for IN p
IVF NNP p
or CC p
intracytoplasmic JJ p
sperm JJ p
injection NN p
, , p
or CC p
healthy JJ p
volunteers NNS p
. . p

The DT N
CTRS-R JJ N
: : N
S NNP N
Hyperactivity NNP N
subscore NN N
also RB N
improved VBN N
significantly RB N
for IN N
atomoxetine NN i
compared VBN N
with IN N
placebo NN i
, , N
but CC N
not RB N
the DT N
other JJ N
CTRS-R JJ N
: : N
S JJ N
subscores NNS N
. . N

The DT N
pharmacokinetic JJ N
profile NN N
of IN N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
showed VBD N
dose JJ N
proportionality NN N
, , N
and CC N
the DT N
elimination NN N
half-life NN N
was VBD N
about IN N
2.0 CD N
hours NNS N
for IN N
the DT N
two CD N
highest JJS N
doses NNS N
. . N

[ RB N
Clinical NNP N
study NN N
of IN N
treating VBG N
knee NN p
osteoarthritis NN p
( ( p
Bi NNP p
syndrome NN p
of IN p
knee NN p
) ) p
by IN N
massage NN i
combined VBN i
Chinese JJ i
materia NNS i
medica VBP i
footbath JJ i
fumigation NN i
and CC i
washing VBG i
] NN i
. . N

Furthermore RB N
, , N
beta-lactamase NN N
produced VBN N
by IN N
other JJ N
bacteria NNS N
in IN N
the DT N
pharynx NN N
could MD N
potentially RB N
inactivate VB N
the DT N
penicillin NN N
, , N
resulting VBG N
in IN N
increased VBN N
treatment NN N
failures NNS o
or CC o
infection NN o
relapses NNS o
. . o

The DT N
primary JJ N
diagnoses NNS N
; : N
clinical JJ N
characteristics NNS N
; : N
and CC N
IL-6 NNP o
, , o
sTNF-R55 NN o
, , o
and CC o
sTNF-R75 JJ o
levels NNS o
were VBD N
similar JJ N
among IN N
the DT N
five CD N
age NN N
groups NNS N
. . N

SAS NNP i
is VBZ N
recommended VBN N
over RP N
DAS NNP N
as IN N
a DT N
stretching VBG i
protocol NN N
in IN N
terms NNS N
of IN N
strength NN o
, , o
hamstring VBG o
range NN o
of IN o
motion NN o
, , o
and CC o
damage NN o
markers NNS o
. . o

BACKGROUND NNP N
Few NNP N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
once-weekly JJ i
oral JJ i
bisphosphonate NN i
therapy NN i
in IN N
breast NN p
cancer NN p
survivors NNS p
. . p

Concentric NNP o
( ( o
maximal JJ o
EMG NNP o
activity NN o
during IN o
extension NN o
) ) o
and CC o
eccentric JJ o
( ( o
maximal JJ o
EMG NNP o
activity NN o
during IN o
flexion NN o
) ) o
ratios NNS o
were VBD N
also RB N
used VBN N
in IN N
the DT N
analyses NNS N
. . N

With IN N
the DT N
addition NN N
of IN N
transoperative JJ i
lympho-scintigraphy NN i
five CD N
extra JJ N
sentinel NN N
nodes NNS N
, , N
not RB N
identified VBN N
by IN N
the DT N
blue JJ N
dye NN N
alone RB N
, , N
were VBD N
identified VBN N
and CC N
considered VBN N
for IN N
histopathology NN N
study NN N
. . N

[ JJ N
Effects NNS N
of IN N
dujieqing VBG i
oral JJ i
liquid NN i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
] NN p
. . p

Clinical JJ N
and CC N
prognostic JJ N
significance NN N
of IN N
serum NN N
magnesium NN N
concentration NN N
in IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
congestive JJ p
heart NN p
failure NN p
: : p
the DT N
PROMISE NNP N
Study NNP N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
prognostic JJ N
significance NN N
of IN N
SLN NNP N
metastatic JJ N
deposits NNS N
< VBP N
or CC N
= VBP N
0.2 CD N
mm NNS N
in IN N
patients NNS p
treated VBN p
in IN p
a DT p
referral JJ p
cancer NN p
center NN p
in IN p
Brazil NNP p
. . p

The DT N
overall JJ N
difference NN N
in IN N
the DT N
number NN o
of IN o
complications NNS o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
92.86 CD N
% NN N
) ) N
maintained VBD N
sinus JJ o
rhythm NN o
without IN o
cardioversion NN o
or CC N
defibrillation NN N
after IN N
release NN N
of IN N
aortic JJ N
cross NN N
clamp NN N
( ( N
P=0.002 NNP N
) ) N
. . N

There EX N
was VBD N
also RB N
some DT N
evidence NN N
that IN N
cumulative JJ o
time NN o
to TO o
perform VB o
the DT o
three CD o
100-m JJ o
swims NNS o
was VBD N
decreased VBN N
in IN N
the DT N
Cr NNP N
group NN N
. . N

However RB N
, , N
in IN N
the DT N
desloratadine/montelukast NN N
arm NN N
, , N
the DT N
resulting VBG N
improvement NN N
of IN N
combination NN N
therapy NN N
of IN N
sICAM-1 NN o
and CC o
the DT o
influx NN o
of IN o
eosinophils NNS o
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

We PRP N
conclude VBP N
that IN N
all DT N
three CD N
Hib NNP i
conjugate NN i
vaccines NNS i
( ( i
PRP-T NNP i
, , i
HbOC NNP i
, , i
and CC i
PRP-OMP NNP i
) ) i
were VBD N
immunogenic JJ o
after IN N
three CD N
primary JJ N
doses NNS N
among IN N
Philippine JJ p
infants NNS p
. . p

BACKGROUND NNP N
Phosphorus NNP N
is VBZ N
associated VBN N
with IN N
mortality NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
not RB p
on IN p
dialysis NN p
, , p
possibly RB p
through IN p
phosphorus-dependent JJ p
vascular JJ p
calcification NN p
. . p

To TO N
determine VB N
if IN N
a DT N
relationship NN N
exists VBZ N
between IN N
changes NNS N
in IN N
torque NN o
production NN o
and CC o
Hoffmann NNP o
reflex NN o
( ( o
H-reflex NNP o
) ) o
following VBG N
ankle JJ N
joint JJ N
cryotherapy NN N
treatment NN N
. . N

While IN N
cooling VBG N
muscle NN N
may MD N
have VB N
a DT N
deleterious JJ N
effect NN N
on IN N
motor NN N
function NN N
, , N
cooling VBG N
the DT N
joint JJ N
may MD N
enhance VB N
motor NN N
function NN N
around IN N
the DT N
joint NN N
. . N

BACKGROUND NNP N
Blood NNP i
transfusions NNS i
prevent VBP N
recurrent JJ N
stroke NN N
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
, , N
but CC N
the DT N
value NN N
of IN N
transfusions NNS N
in IN N
preventing VBG N
a DT N
first JJ N
stroke NN N
is VBZ N
unknown JJ N
. . N

The DT N
synergy NN N
effect NN N
could MD N
not RB N
be VB N
examined VBN N
for IN N
dentine NN N
due JJ N
to TO N
the DT N
truncation NN N
effect NN N
as IN N
the DT N
set NN N
limit NN N
of IN N
the DT N
profilometer NN N
was VBD N
exceeded VBN N
. . N

Although IN N
the DT N
operative JJ N
time NN N
for IN N
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
is VBZ N
significantly RB N
longer RBR N
, , N
the DT N
success NN o
rate NN o
remains VBZ N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

INTERPRETATION NNP N
Addition NNP N
of IN N
ganitumab NN N
to TO N
endocrine VB N
treatment NN N
in IN N
women NNS p
with IN p
previously RB p
treated VBN p
hormone-receptor-positive JJ p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
did VBD N
not RB N
improve VB N
outcomes NNS N
. . N

Metformin NNP i
therapy NN i
improves VBZ N
ovulatory JJ o
rates NNS o
, , o
cervical JJ o
scores NNS o
, , o
and CC o
pregnancy NN o
rates NNS o
in IN N
clomiphene JJ p
citrate-resistant JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

Two CD p
hundred CD p
and CC p
thirty-seven JJ p
students NNS p
, , p
drawn NN p
from IN p
six CD p
homeroom NN p
grade NN p
eight CD p
classes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB i
and CC i
control VB i
( ( i
no DT i
intervention NN i
) ) i
conditions NNS i
. . i

PURPOSE NN N
To TO N
evaluate VB N
the DT N
risk NN o
of IN o
developing VBG o
radiation NN o
myelitis NN o
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP N
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
. . N

Mean JJ N
changes NNS N
tended VBD N
toward IN N
faster RBR N
transit NN o
times NNS o
in IN N
the DT N
left NN N
colon NN N
and CC N
the DT N
rectum NN N
, , N
although IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Throughout IN N
the DT N
infusion NN N
, , N
changes NNS N
in IN N
transcutaneous JJ o
PCO2 NNP o
( ( o
tcPCO2 NN o
) ) o
, , o
subjective JJ o
anxiety NN o
, , o
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
recorded VBN N
continuously RB N
. . N

In IN N
this DT N
study NN N
seven CD p
patients NNS p
with IN p
infantile JJ p
autism NN p
, , p
three CD p
before IN p
puberty NN p
and CC p
four CD p
after IN p
puberty NN p
, , N
were VBD N
given VBN N
a DT N
gluten-free JJ i
diet NN i
. . i

A DT N
significant JJ N
reduction NN N
in IN N
the DT N
incidence NN o
of IN o
chemotherapy-related JJ o
oral JJ o
mucositis NN o
occurred VBD N
across IN N
multiple JJ N
cycles NNS N
of IN N
treatment NN N
in IN N
patients NNS N
treated VBN N
with IN N
filgrastim NN i
. . i

The DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
was VBD N
measured VBN N
by IN N
challenging VBG N
LDL NNP N
with IN N
hemin NN N
and CC N
H2O2 NNP N
and CC N
measuring VBG N
the DT N
time NN N
for IN N
the DT N
reaction NN N
to TO N
reach VB N
maximum JJ N
velocity NN N
. . N

Although IN N
both DT N
therapies NNS N
worsened VBD N
the DT N
lipid JJ o
profile NN o
, , N
the DT N
oral JJ N
pill NN N
administration NN N
was VBD N
associated VBN N
with IN N
a DT N
more RBR N
evident JJ N
increase NN N
of IN N
circulating VBG o
triglycerides NNS o
. . o

Sodium NNP i
dodecyl VBZ i
sulfate-PAGE NN i
combined VBN i
with IN i
scanning VBG i
analysis NN i
demonstrated VBD N
that IN N
the DT N
msyB-HA JJ N
fusion NN N
protein NN N
accounted VBD N
for IN N
29.5 CD N
% NN N
of IN N
the DT N
total JJ N
bacterial JJ N
protein NN N
, , N
90.5 CD N
% NN N
being VBG N
soluble JJ N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
in IN N
a DT N
similar JJ N
way NN N
to TO N
compare VB N
capsular JJ N
contracture NN N
around IN N
smooth JJ N
and CC N
textured VBD N
saline-filled JJ i
prostheses NNS i
with IN N
pores NNS N
of IN N
small JJ N
size NN N
. . N

High JJ N
dietary JJ N
Zn NNP N
treatment NN N
led VBD N
to TO N
a DT N
reduced JJ o
abundance NN o
of IN o
CD8 NNP o
( ( o
+ NN o
) ) o
? . o
T-cells NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
little JJ N
difference NN N
could MD N
be VB N
found VBN N
in IN N
the DT N
patient JJ N
outcome NN N
variables NNS N
of IN N
the DT N
different JJ N
treatment NN N
groups NNS N
. . N

There EX N
was VBD N
some DT N
evidence NN N
of IN N
therapeutic JJ N
carry-over JJ N
effects NNS N
in IN N
both DT N
clinical JJ N
and CC N
biochemical JJ N
measures NNS N
in IN N
those DT N
children NNS N
who WP N
received VBD N
NTX NNP i
before IN i
PLC NNP i
. . i

INTRODUCTION NNP N
A NNP N
significant JJ N
number NN N
of IN N
postmenopausal JJ p
women NNS p
suffer VBP N
from IN N
distressing VBG N
problems NNS N
because IN N
of IN N
urogenital JJ N
atrophy NN N
secondary JJ N
to TO N
the DT N
decline NN N
in IN N
circulating VBG N
estrogen NN N
levels NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
pulse JJ N
oximeter NN N
PI NNP N
provides VBZ N
an DT N
earlier JJR N
and CC N
clearer JJR N
indication NN N
of IN N
sympathectomy NN N
following VBG N
epidural JJ N
anesthesia NNS N
than IN N
skin JJ N
temperature NN N
and CC N
arterial JJ N
pressure NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
of IN N
caudal JJ N
block NN N
with IN N
diclofenac JJ i
suppository NN i
and CC i
local JJ i
anesthetic JJ i
infiltration NN i
in IN N
children NNS p
undergoing VBG p
laparoscopy NN p
. . p

The DT N
results NNS N
show VBP N
that IN N
an DT N
improvement NN N
in IN N
masticatory JJ N
performance NN N
does VBZ N
not RB N
imply VB N
the DT N
same JJ N
improvement NN N
in IN N
chewing VBG N
experience NN N
and CC N
vice NN N
versa NN N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

We PRP N
enrolled VBD N
postmenopausal JJ p
women NNS p
with IN p
hormone-receptor-positive JJ p
, , p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
previously RB p
treated VBN p
with IN p
endocrine JJ p
treatment NN p
. . p

The DT N
current JJ N
study NN N
has VBZ N
been VBN N
designed VBN N
to TO N
compare VB N
the DT N
classical JJ i
mono NN i
chemotherapy NN i
docetaxel NN i
with IN N
a DT N
docetaxel NN i
cisplatin NN i
doublet NN i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN o
relief NN o
, , o
or CC o
stinging VBG o
on IN o
instillation NN o
( ( N
P NNP N
= NNP N
.29 NNP N
) ) N
. . N

Increased VBN o
frequency NN o
of IN o
whining VBG o
occurred VBN N
after IN N
administration NN N
of IN N
methadone NN i
and CC N
may MD N
be VB N
a DT N
drug NN N
effect NN N
and CC N
not RB N
a DT N
sign NN o
of IN o
pain NN o
. . o

After IN N
the DT N
conclusion NN N
of IN N
surgery NN N
but CC N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
, , N
the DT N
anesthesiologist NN N
administered VBD N
either CC N
nicotine JJ i
nasal NN i
spray NN i
or CC i
a DT i
placebo NN i
. . i

INTERPRETATION NNP N
Pembrolizumab NNP i
prolongs NNS N
overall JJ N
survival NN N
and CC N
has VBZ N
a DT N
favourable JJ N
benefit-to-risk JJ N
profile NN N
in IN N
patients NNS p
with IN p
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

This DT N
RPA NNP N
had VBD N
moderate JJ N
discrimination NN N
in IN N
SABR NNP N
datasets NNS N
( ( N
c-index NN N
range NN N
: : N
0.52-0.60 JJ N
) ) N
but CC N
was VBD N
of IN N
limited JJ N
value NN N
in IN N
the DT N
surgical JJ N
validation NN N
cohort NN N
. . N

The DT N
results NNS N
indicate VBP N
a DT N
significantly RB N
higher JJR N
morbidity NN N
among IN N
patients NNS N
treated VBN N
with IN N
preoperative JJ N
irradiation NN N
compared VBN N
with IN N
those DT N
irradiated JJ N
postoperative JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Efficacy NN o
of IN o
treatment NN o
, , o
Chinese JJ o
medicine JJ o
syndrome NN o
scores NNS o
, , o
end-point JJ o
events NNS o
occurrence NN o
as RB o
well RB o
as IN o
changes NNS o
of IN o
related JJ o
laboratory NN o
indices NNS o
were VBD N
observed VBN N
. . N

Untoward IN o
side-effect JJ o
incidence NN o
was VBD N
much JJ N
higher JJR N
in IN N
the DT N
diethylstilbestrol NN N
group NN N
( ( N
30.4 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
tamoxifen NN i
( ( N
3.5 CD N
% NN N
) ) N
. . N

The DT N
GM-CSF NNP i
group NN N
had VBD N
lower JJR N
haemoglobin NN o
concentrations NNS o
and CC o
platelets NNS o
counts NNS o
, , o
and CC o
higher JJR o
plasma NN o
urea JJ o
creatinine NN o
and CC o
bilirubin NN o
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Vaginal NNP N
hormonal JJ N
contraception NN N
appears VBZ N
to TO N
be VB N
preferable JJ N
to TO N
oral JJ N
ethinylestradiol NN N
+ NNP N
drospirenone NN N
administration NN N
in IN N
hyperinsulinemic JJ p
patients NNS p
with IN p
PCOS NNP p
. . p

In IN N
a DT N
competing-risks JJ N
analysis NN N
, , N
those DT N
factors NNS N
that WDT N
increased VBD N
the DT N
risk NN o
of IN o
arrhythmic JJ o
death NN o
also RB N
increased VBD N
the DT N
risk NN o
of IN o
nonarrhythmic JJ o
deaths NNS o
. . o

All DT N
methods NNS N
of IN N
the DT N
treatment NN N
of IN N
severe JJ N
sepsis NN N
are VBP N
discussed VBN N
with IN N
reference NN N
to TO N
treatment NN N
indications NNS N
, , N
efficacy NN N
, , N
and CC N
outcome JJ N
parameters NNS N
. . N

Statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
TIMP NNP i
and CC N
TOT NNP i
when WRB N
measuring VBG N
their PRP$ N
effects NNS N
on IN N
perceived JJ o
exertion NN o
and CC o
perceived VBD o
fatigue NN o
. . o

RESULTS NNP N
Obtaining NNP N
opioids NNS N
from IN N
doctors NNS N
was VBD N
associated VBN N
with IN N
lower JJR N
pre-treatment JJ N
drug NN N
spending NN N
, , N
while IN N
obtaining VBG N
opioids NNS N
from IN N
dealers/patients NNS N
was VBD N
associated VBN N
with IN N
greater JJR N
spending NN N
. . N

It PRP N
is VBZ N
therefore RB N
essential JJ N
to TO N
evaluate VB N
current JJ N
drugs NNS N
, , N
one CD N
of IN N
which WDT N
is VBZ N
the DT N
water NN N
extract NN N
of IN N
the DT N
bark NN N
of IN N
the DT N
tree NN N
Choerospondias NNP N
axillaris NN N
. . N

Influence NN N
of IN N
exercise NN i
training NN i
on IN N
leptin NN o
levels NNS o
in IN N
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
: : p
A DT N
pilot NN N
study NN N
. . N

This DT N
earlier JJR N
work NN N
suggested VBD N
that IN N
cefotaxime NN i
might MD N
be VB N
more RBR N
effective JJ N
than IN N
cephamandole NN i
in IN N
preventing VBG N
wound JJ N
sepsis NN N
in IN N
emergency NN N
abdominal JJ N
surgery NN N
. . N

) ) i
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
for IN N
the DT N
control NN N
of IN N
hot JJ o
flashes NNS o
in IN N
postmenopausal NN p
patients NNS p
with IN p
a DT p
history NN p
of IN p
breast NN p
cancer NN p
. . p

Hemagglutinin NNP N
( ( N
HA NNP N
) ) N
is VBZ N
the DT N
major JJ N
immunogen NN N
on IN N
the DT N
envelope NN N
of IN N
influenza NN N
A NNP N
virus NN N
and CC N
is VBZ N
the DT N
predominant JJ N
inducer NN N
of IN N
neutralizing VBG N
antibody NN N
. . N

Including VBG N
results NNS N
obtained VBN N
by IN N
second-look JJ N
laparotomy NN N
, , N
we PRP N
did VBD N
not RB N
observe VB N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN o
rates NNS o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Release NN o
of IN o
cortisol NN o
but CC N
not RB N
of IN N
prolactin NN o
after IN N
dexfenfluramine JJ i
administration NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
of IN N
ecstasy JJ N
users NNS N
compared VBN N
with IN N
the DT N
controls NNS N
. . N

36-month JJ N
treatment NN N
experience NN N
of IN N
two CD N
doses NNS N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
for IN N
children NNS p
with IN p
central JJ p
precocious JJ p
puberty NN p
. . p

The DT N
effect NN N
of IN N
RVX-208 NNP i
on IN N
other JJ o
lipid JJ o
and CC o
inflammatory JJ o
markers NNS o
, , o
safety NN o
and CC o
tolerability NN o
will MD N
also RB N
be VB N
assessed VBN N
in IN N
both DT N
studies NNS N
. . N

Additionally RB N
, , N
the DT N
joint JJ N
attention NN N
group NN N
improved VBD N
in IN N
the DT N
proportion NN o
of IN o
time NN o
spent VBN o
sharing VBG o
coordinated VBN o
joint JJ o
looks NNS o
between IN N
intervener NN N
and CC N
probe NN N
. . N

Main NNP N
outcome NN N
measures NNS N
were VBD N
body JJ o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
serum JJ o
leptin NN o
and CC o
sex NN o
hormone NN o
binding VBG o
globulin NN o
( ( o
SHBG NNP o
) ) o
. . o

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
extrapyramidal NN o
symptoms NNS o
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
nitrous JJ i
oxide NN i
does VBZ N
not RB N
contribute VB N
to TO N
the DT N
occurrence NN N
of IN N
nausea NN o
or CC o
vomiting NN o
after IN p
isoflurane NN p
anesthesia NN p
for IN p
gynecologic JJ p
laparotomies NNS p
. . p

The DT N
treatment NN N
is VBZ N
usually RB N
with IN N
either DT N
phenobarbital NN N
or CC N
phenytoin NN i
, , N
but CC N
the DT N
efficacy NN N
of IN N
the DT N
two CD N
drugs NNS N
has VBZ N
not RB N
been VBN N
compared VBN N
directly RB N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
platelet NN o
activation NN o
and CC o
fibrinolyis NN o
in IN N
acute JJ p
atherosclerotic JJ p
ischemic JJ p
stroke NN p
patients NNS p
to TO N
clarify VB N
the DT N
relationship NN N
between IN N
them PRP N
. . N

These DT N
observations NNS N
suggest VBP N
that IN N
the DT N
cardiovascular JJ o
events NNS o
associated VBN N
with IN N
both DT N
agents NNS N
result VBP N
from IN N
hypogonadism NN N
rather RB N
than IN N
a DT N
direct JJ N
drug NN N
effect NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Both NNP N
larger JJR N
molecule NN N
removal NN N
and CC N
dialyzer NN N
biocompatibility NN N
have VBP N
been VBN N
implicated VBN N
in IN N
the DT N
high-flux JJ p
hemodialysis NN p
( ( p
HD NNP p
) ) p
-associated VBD p
favorable JJ p
outcome NN p
. . p

Effects NNS N
of IN N
maternal JJ i
and CC i
dietary JJ i
selenium NN i
( ( i
Se-enriched NNP i
yeast NN i
) ) i
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN p
in IN p
goats NNS p
. . p

The DT N
results NNS N
of IN N
this DT N
study NN N
have VBP N
shown VBN N
that IN N
interactions NNS N
among IN N
homocysteine JJ N
metabolism NN N
gene NN N
polymorphisms JJ N
lead NN N
to TO N
dramatic JJ N
elevations NNS N
in IN N
the DT N
folate NN N
deficiency NN N
risk NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

Twenty CD N
teeth NNS N
from IN N
each DT N
group NN N
were VBD N
used VBN N
for IN N
the DT N
apical JJ i
leakage NN i
test NN i
and CC i
the DT i
remaining VBG i
five CD i
teeth NNS i
from IN i
each DT i
group NN i
were VBD i
used VBN i
for IN i
examination NN i
under IN i
the DT i
scanning NN i
electron NN i
microscope NN i
( ( i
SEM NNP i
) ) i
. . i

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
number NN o
of IN o
patients NNS o
who WP o
died VBD o
or CC o
in IN o
the DT o
number NN o
who WP o
had VBD o
clinically RB o
relevant JJ o
bleeding NN o
. . o

The DT N
authors NNS N
' POS N
study NN N
compared VBN N
suture NN i
with IN i
a DT i
new JJ i
coaptive JJ i
film NN i
device NN i
, , i
3M CD i
Steri-Strip JJ i
S NNP i
Surgical NNP i
Skin NNP i
Closure NNP i
, , i
on IN i
linear JJ i
incisions NNS i
. . i

There EX N
were VBD N
more JJR N
renal JJ o
toxicity NN o
, , o
leucopenia NN o
, , o
and CC o
anaemia NN o
in IN N
the DT N
cisplatin NN N
group NN N
, , N
and CC N
more JJR N
thrombocytopenia NN o
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
protein NN N
: : N
carbohydrate JJ N
ratios NNS N
in IN N
the DT N
diet NN N
of IN N
pregnant JJ p
gilts NNS p
on IN N
maternal JJ o
cortisol NN o
concentrations NNS o
and CC N
the DT N
adrenocortical JJ o
and CC o
sympathoadrenal JJ o
reactivity NN o
in IN p
their PRP$ p
offspring NN p
. . p

Unique NNP N
attributes VBZ N
render VBP N
it PRP N
a DT N
promising JJ N
candidate NN N
for IN N
prophylactic JJ N
mass NN N
immunization NN N
, , N
even RB N
in IN N
subjects NNS N
for IN N
whom WP N
conventional JJ N
smallpox NN N
vaccines NNS N
are VBP N
contraindicated VBN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
number NN o
of IN o
verbal JJ o
attempts NNS o
or CC o
number NN o
of IN o
correct JJ o
words NNS o
were VBD N
noted VBN N
between IN N
groups NNS N
following VBG N
treatment NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
increases NNS N
were VBD N
observed VBN N
in IN N
the DT N
anthropometric JJ o
indices NNS o
of IN N
the DT N
subjects NNS N
receiving VBG N
the DT N
high-calcium NN i
fortified VBD i
milk NN i
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
decreased JJ N
pain NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
morphine JJ o
utilization NN o
and CC o
the DT o
analgesic JJ o
effect NN o
of IN o
nicotine NN o
was VBD N
not RB N
associated VBN N
with IN N
hypertension NN o
or CC o
tachycardia NN o
. . o

ADMA NN o
levels NNS o
were VBD N
positively RB N
correlated VBN N
with IN N
basal JJ o
endothelin-1 JJ o
levels NNS o
and CC N
negatively RB N
correlated VBN N
with IN N
insulin-induced JJ N
incremental JJ N
levels NNS N
of IN N
NOx NNP o
and CC o
forearm NN o
cGMP NN o
release NN o
. . o

There EX N
was VBD N
no DT N
significant JJ N
between-group JJ N
difference NN N
in IN N
mean JJ o
heart NN o
rate NN o
or CC o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

MEASUREMENTS NNP N
Urine NNP o
benzoylecgonine NN o
( ( o
BE NNP o
) ) o
concentrations NNS o
, , o
self-report NN o
of IN o
cocaine NN o
use NN o
and CC o
global JJ o
impression NN o
scores NNS o
served VBD N
as IN N
primary JJ N
outcome NN N
measures NNS N
. . N

Sublingual JJ i
administration NN i
of IN i
micronized JJ i
estradiol NN i
and CC i
progesterone NN i
, , N
with IN N
and CC N
without IN N
micronized VBN i
testosterone NN i
: : i
effect NN N
on IN N
biochemical JJ o
markers NNS o
of IN o
bone NN o
metabolism NN o
and CC o
bone JJ o
mineral JJ o
density NN o
. . o

This DT N
may MD N
suggest VB N
reductions NNS N
in IN N
mortality NN N
associated VBN N
with IN N
azithromycin JJ i
MDA NNP N
are VBP N
due JJ N
to TO N
a DT N
mechanism NN N
other JJ N
than IN N
improved JJ N
nutritional JJ N
status NN N
. . N

Isometric JJ o
contractions NNS o
reduce VB o
plantar NN o
flexor NN o
moment NN o
, , o
Achilles NNP o
tendon VBZ o
stiffness NN o
, , o
and CC o
neuromuscular JJ o
activity NN o
but CC o
remove VB o
the DT o
subsequent JJ o
effects NNS o
of IN o
stretch NN o
. . o

Safety NN N
endpoints NNS N
included VBD N
occurrence NN o
of IN o
neutralizing VBG o
anti-erythro JJ o
poietin NN o
antibodies NNS o
, , o
tolerability NN o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

Safety NN o
and CC o
efficacy NN o
of IN N
oral JJ i
DMSA NNP i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
Part VB N
A DT N
-- : N
medical JJ N
results NNS N
. . N

A DT N
Phase NNP N
I PRP N
clinical VBP N
study NN N
demonstrated VBD N
that IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
PPS NNP i
increased VBD N
microvascular JJ o
blood NN o
flow NN o
in IN N
patients NNS p
with IN p
SCD NNP p
. . p

Rioprostil NNP i
, , N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
, , N
in IN N
the DT N
once-daily JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ p
ulcer JJ p
recurrence NN p
: : p
a DT N
comparison NN N
with IN N
ranitidine NN i
. . i

Measurement NN N
of IN N
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic JJ N
acid NN N
, , N
( ( N
PGE-M NNP N
) ) N
, , N
the DT N
major JJ N
urinary JJ N
metabolite NN N
of IN N
prostaglandin NN N
E1 NNP N
and CC N
E2 NNP N
in IN N
man NN N
provides VBZ N
a DT N
useful JJ N
indicator NN N
to TO N
monitor VB N
prostaglandin JJ N
biosynthesis NN N
. . N

RESULTS VB N
The DT N
average JJ o
time NN o
to TO o
fracture VB o
healing NN o
was VBD N
16.7 CD N
weeks NNS N
in IN N
the DT N
reamed VBN i
group NN N
and CC N
25.7 CD N
weeks NNS N
in IN N
the DT N
unreamed JJ N
group NN N
. . N

RESULTS VB N
The DT N
detachment NN o
of IN o
the DT o
neurosensory JJ o
retina NN o
and CC o
retinal JJ o
pigment NN o
epithelium NN o
improved VBN N
in IN N
all DT N
eyes NNS N
, , N
but CC N
all DT N
neovascular JJ o
lesions NNS o
increased VBD o
in IN o
size NN o
. . o

Baseline NNP o
subjective NN o
and CC o
blinded VBD o
physician JJ o
dyschromia NN o
and CC o
rhytid NN o
scores NNS o
revealed VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
IPL NNP N
and CC N
Er NNP N
: : N
YAG NNP N
randomly RB N
assigned VBD N
sides NNS N
. . N

BACKGROUND NNP N
Autism NNP p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
is VBZ N
associated VBN N
with IN N
altered JJ N
face NN N
processing NN N
and CC N
decreased JJ N
activity NN N
in IN N
brain NN N
regions NNS N
involved VBN N
in IN N
face NN N
processing NN N
. . N

The DT N
low JJ N
rate NN N
of IN N
recorded VBN N
complications NNS N
showed VBD N
that IN N
both DT N
techniques NNS N
cause VBP N
little JJ N
damage NN N
to TO N
the DT N
tonsillar JJ N
bed NN N
during IN N
dissection NN N
, , N
thus RB N
minimising VBG N
complications NNS N
. . N

Isolates NNS N
at IN N
diagnosis NN N
and CC N
from IN N
positive JJ N
cultures NNS N
after IN N
treatment NN N
completion NN N
underwent NN N
genotyping VBG N
using VBG N
IS6110 NNP N
( ( N
with IN N
secondary JJ N
genotyping NN N
for IN N
isolates NNS N
with IN N
less JJR N
than IN N
six CD N
copies NNS N
of IN N
IS6110 NNP N
) ) N
. . N

The DT N
opening NN N
of IN N
the DT N
female JJ N
urethra NN N
is VBZ N
located VBN N
within IN N
the DT N
vulvar NN N
vestibule NN N
, , N
making VBG N
insertion NN N
of IN N
urinary JJ N
catheters NNS N
into IN N
females NNS N
a DT N
greater JJR N
technical JJ N
challenge NN N
than IN N
in IN N
males NNS N
. . N

CONCLUSION NNP N
The DT N
Silicone NNP N
Study NNP N
showed VBD N
that IN N
silicone NN N
oil NN N
and CC N
perfluoropropane NN N
gas NN N
were VBD N
equal JJ N
in IN N
most JJS N
respects NNS N
for IN N
the DT N
management NN N
of IN N
retinal JJ N
detachments NNS N
with IN N
PVR NNP N
. . N

Moreover RB N
, , N
the DT N
treatment NN N
efficacy NN N
of IN N
carboplatin NN i
arm NN N
is VBZ N
not RB N
different JJ N
from IN N
the DT N
standard JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
locoregional JJ N
advanced JJ N
stage NN N
NPC NNP N
. . N

MEASURES NNP N
systolic JJ o
and CC o
early JJ o
diastolic JJ o
velocities NNS o
were VBD N
registered VBN N
by IN N
Tissue NNP N
Doppler NNP N
from IN N
a DT N
long-axis JJ N
view NN N
of IN N
the DT N
interventricular JJ N
septum NN N
or CC N
the DT N
anterior JJ N
wall NN N
of IN N
the DT N
left JJ N
ventricle NN N
. . N

A DT N
single JJ N
prophylactic JJ N
intraoperative NN N
dose NN N
of IN N
intravenous JJ N
amiodarone NN i
decreased VBD N
post NN o
bypass NN o
arrhythmia NN o
in IN N
this DT N
study NN N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
anaerobic JJ o
bacteria NNS o
in IN N
the DT N
feces NNS N
and CC N
colon NN N
contents NNS N
of IN N
patients NNS N
receiving VBG N
metronidazole NN i
. . i

Median JJ o
home NN o
lighting NN o
was VBD N
4.3 CD N
times NNS N
and CC N
2.8 CD N
times NNS N
lower JJR N
than IN N
clinic JJ N
lighting NN N
in IN N
areas NNS N
tested VBN N
for IN N
DVA NNP N
and CC N
NVA NNP N
, , N
respectively RB N
. . N

CYP21 NNP i
genotyping VBG i
indicated VBD N
a DT N
heterozygote NN N
rate NN N
of IN N
2.8 CD N
% NN N
for IN N
classic JJ N
mutations NNS N
( ( N
excluding VBG N
CYP21 NNP N
deletions NNS N
) ) N
, , N
and CC N
2.0 CD N
% NN N
for IN N
nonclassic JJ N
mutations NNS N
in IN N
New NNP p
Zealanders NNP p
. . p

BACKGROUND NNP N
Cardiac NNP i
resynchronization NN i
therapy NN i
( ( i
CRT NNP i
) ) i
improves VBZ N
clinical JJ N
outcome NN N
in IN N
selected VBN p
patients NNS p
with IN p
advanced JJ p
congestive JJ p
heart NN p
failure NN p
. . p

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ i
iliohypogastric JJ i
block NN i
( ( i
group NN i
C NNP i
given VBN i
saline NN i
and CC i
group NN i
P NNP i
and CC i
DB NNP i
given VBN i
levobupivacaine NN i
) ) i
. . i

A DT N
significant JJ N
increase NN N
in IN N
aortic JJ o
PWV NNP o
, , o
a DT o
marker NN o
of IN o
aortic JJ o
stiffness NN o
, , N
was VBD N
noted VBN N
after IN N
patients NNS p
switched VBD p
from IN p
high-flux NN p
to TO p
low-flux JJ p
polyamide NN p
membranes NNS p
. . p

Although IN N
EMDA NNP i
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
patients NNS N
with IN N
various JJ N
diseases NNS N
, , N
controlled VBN N
studies NNS N
are VBP N
lacking VBG N
in IN N
patients NNS p
with IN p
rheumatic JJ p
disease NN p
. . p

CONCLUSIONS NNP N
Vitamin NNP N
E NNP N
did VBD N
not RB N
appear VB N
to TO N
reduce VB N
the DT N
incidence NN o
of IN o
sensory JJ o
neuropathy NN o
in IN N
the DT N
studied JJ N
group NN N
of IN N
patients NNS p
receiving VBG p
neurotoxic JJ p
chemotherapy NN p
. . p

BACKGROUND NNP N
Genital NNP N
infection NN N
with IN N
human JJ N
papillomavirus NN N
, , N
the DT N
cause NN N
of IN N
genital JJ N
warts NNS N
, , N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
sexually RB N
transmitted JJ N
diseases NNS N
. . N

The DT N
excretion NN N
rate NN N
of IN N
uric JJ N
acid NN N
in IN N
urine NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
new JJ N
index NN N
for IN N
pharmacological JJ N
effects NNS N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

Testosterone CD i
administered JJ N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
. . N

Studies NNS N
of IN N
vector-parasite JJ N
relations NNS N
of IN N
Wuchereria NNP N
bancrofti NN N
suggest VBP N
that IN N
a DT N
reduction NN N
in IN N
the DT N
microfilarial JJ N
reservoir NN N
by IN N
mass NN N
chemotherapy NN N
may MD N
interrupt VB N
transmission NN N
and CC N
thereby RB N
eliminate VB N
infection NN N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
frequency NN o
and CC o
intensity NN o
of IN o
myofascial JJ o
pain NN o
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

Dietary NNP N
potential JJ N
renal JJ N
acid NN N
load NN N
( ( N
PRAL NNP N
) ) N
and CC N
daily JJ N
net NN N
endogenous JJ N
acid NN N
production NN N
( ( N
NEAP NNP N
) ) N
at IN N
baseline NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Local JJ i
therapy NN i
with IN i
glycerol NN i
lidocaine NN i
eardrops VBZ i
is VBZ N
a DT N
safe JJ N
, , N
and CC N
cost-effective JJ N
treatment NN N
for IN N
the DT N
widely RB N
spread JJ N
clinical JJ N
picture NN N
of IN N
acute JJ p
abacterial JJ p
otitis NN p
externa NN p
. . p

The DT N
low JJ N
pressure NN N
suction NN N
drain NN N
removed VBD N
an DT N
intraperitoneal NN N
marker NN N
, , N
gentamicin NN N
, , N
more RBR N
effectively RB N
than IN N
the DT N
high JJ N
pressure NN N
suction NN N
drain NN N
, , N
but CC N
not RB N
more RBR N
effectively RB N
than IN N
the DT N
passive JJ N
drain NN N
. . N

RESULTS NNP N
Intraoperative NNP N
administration NN N
of IN N
ketorolac NN i
resulted VBD N
in IN N
better JJR N
quality NN o
of IN o
pain NN o
control NN o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
regardless NN N
of IN N
route NN N
of IN N
administration NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
quality NN o
of IN o
life NN o
score NN o
between IN N
the DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
. . N

The DT N
clinical JJ o
efficacy NN o
was VBD N
the DT N
same JJ N
although IN N
the DT N
alleviation NN N
of IN N
vasomotor NN o
symptoms NNS o
was VBD N
somewhat RB N
slower JJR N
in IN N
those DT N
women NNS N
receiving VBG N
preparation NN N
A DT N
. . N

This DT N
tendency NN N
was VBD N
also RB N
supported VBN N
by IN N
moderate JJ N
effect NN N
sizes NNS N
and CC N
qualitative JJ N
indications NNS N
of IN N
likely JJ N
harmful NN N
or CC N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
RSA-SS NNP i
. . i

Significantly RB N
more RBR N
deaths NNS o
of IN o
presumed JJ o
fungal JJ o
origin NN o
occurred VBD N
in IN N
flu NN N
than IN N
itra JJ N
( ( N
seven CD N
versus NN N
nil NN N
, , N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

While IN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
in IN N
the DT N
number NN o
of IN o
lymph JJ o
node JJ o
dissection NN o
, , o
operative JJ o
time NN o
and CC o
postoperative JJ o
chest NN o
tube NN o
drainage NN o
time NN o
. . o

Blinded VBN N
operators NNS N
calculated VBD N
angiographic JJ o
corrected VBN o
TIMI NNP o
Frame NNP o
count NN o
( ( o
cTFC NN o
) ) o
and CC o
myocardial JJ o
blush NN o
grade NN o
( ( o
MBG NNP o
) ) o
before IN N
and CC N
after IN N
stent JJ N
implantation NN N
. . N

Several JJ N
generic JJ N
formulations NNS N
have VBP N
been VBN N
approved VBN N
, , N
raising VBG N
concern NN N
over IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
these DT N
products NNS N
compared VBN N
with IN N
brand-name JJ N
Coumadin NNP N
. . N

GOALS NNP N
AND CC N
BACKGROUND NNP N
The DT N
role NN N
of IN N
preventive JJ N
lymphadenectomy NN N
has VBZ N
not RB N
yet RB N
been VBN N
determined VBN N
for IN N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
patients NNS p
. . p

CONCLUSION NNP N
ZJC1 NNP N
can MD N
enhance VB N
the DT N
density NN o
and CC o
motility NN o
of IN o
sperm NN o
and CC o
reduce VB o
the DT o
sperm JJ o
deformity NN o
rate NN o
in IN N
patients NNS p
with IN p
OSM NNP p
. . p

The DT N
median JJ o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
was VBD N
3.8 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
5.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
safety NN o
. . o

CONCLUSIONS NNP N
Video-assisted NNP i
thoracoscopic NN i
talc NN i
insufflation NN i
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
superior JJ N
approach NN N
compared VBN N
with IN N
talc NN N
slurry NN N
in IN N
our PRP$ N
study NN N
. . N

In IN N
conclusion NN N
, , N
a DT N
short-term JJ N
resistance NN N
training NN N
protocol NN N
improved VBD N
mucosal JJ o
immunity NN o
response NN o
as RB N
well RB N
as IN N
salivary JJ N
testosterone NN N
levels NNS N
in IN N
sedentary JJ p
adults NNS p
with IN p
DS NNP p
. . p

Paired VBN N
comparisons NNS N
revealed VBD N
a DT N
significant JJ N
difference NN N
in IN N
efficacy NN o
between IN N
CAE NNP i
and CC N
CEC NNP i
and CC N
a DT N
nearly RB N
significant JJ N
difference NN N
between IN N
AMX-CL NNP i
and CC i
CEC NNP i
. . i

Bupivacaine NNP i
produced VBD N
a DT N
significant JJ N
incidence NN N
of IN N
residual JJ o
motor NN o
block NN o
compared VBN N
with IN N
levobupivacaine NN i
or CC i
ropivacaine NN i
at IN N
wake-up NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
deliberate NN N
mild JJ N
hypothermia NN N
is VBZ N
easily RB N
achieved VBN N
intraoperatively RB N
, , N
complete JJ N
rewarming NN N
may MD N
be VB N
difficult JJ N
to TO N
attain VB N
during IN N
craniotomy NN N
with IN N
current JJ N
methods NNS N
. . N

In IN N
order NN N
to TO N
evaluate VB N
any DT N
beneficial JJ N
effect NN N
of IN N
such JJ N
an DT N
administration NN N
, , N
a DT N
group NN N
of IN N
patients NNS p
with IN p
recurrent JJ p
gastric JJ p
cancer NN p
was VBD N
studied VBN N
. . N

Blood NNP o
pressure NN o
, , o
heart NN o
rate NN o
, , o
oxygen NN o
saturation NN o
, , o
total JJ o
amount NN o
of IN o
analgesic JJ o
consumed VBN o
and CC o
adverse JJ o
effects NNS o
were VBD N
also RB N
recorded VBN N
. . N

Improvement NN N
in IN N
anxiety NN o
and CC o
sedation NN o
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
placebo NN i
. . i

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
these DT N
study NN N
measures NNS N
among IN N
the DT N
three CD N
treatment NN N
conditions NNS N
( ( N
P NNP N
> VBZ N
0.1 CD N
for IN N
all DT N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
whether IN N
these DT N
pharmacological JJ N
differences NNS N
between IN N
salmeterol NN i
and CC i
formoterol NN i
also RB N
are VBP N
applicable JJ N
to TO N
asthmatic JJ p
patients NNS p
. . p

Zolmitriptan NNP i
( ( N
Zomig NNP N
, , N
formerly RB N
311C90 CD N
) ) N
is VBZ N
a DT N
selective JJ N
5-hydroxytryptamine JJ N
( ( N
5-HT JJ N
) ) N
1B/1D-receptor JJ N
agonist NN N
with IN N
central JJ N
and CC N
peripheral JJ N
activity NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN N
. . N

Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
a DT N
model NN N
, , N
wherein VBP N
the DT N
5-HT4R JJ o
density NN o
adjusts VBZ N
to TO N
changes NNS N
in IN N
the DT N
extracellular JJ N
5-HT JJ N
tonus NN N
. . N

GM-CSF JJ i
appears VBZ N
to TO N
improve VB N
the DT N
response NN o
to TO o
influenza VB o
vaccination NN o
in IN N
some DT N
groups NNS N
of IN N
SCT NNP p
patients NNS p
, , N
but CC N
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

The DT N
relative JJ N
risks NNS N
of IN N
0.67 CD N
and CC N
0.74 CD N
were VBD N
clinically RB N
similar JJ N
and CC N
the DT N
difference NN N
between IN N
them PRP N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

This DT N
higher JJR N
intensity NN N
was VBD N
a DT N
result NN N
of IN N
shorter JJR N
post-R3 NN N
intervals NNS N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
whereas IN N
the DT N
post-COPADM JJ N
intervals NNS N
were VBD N
not RB N
statistically RB N
reduced VBN N
. . N

Efficacy NN o
and CC o
radiographic JJ o
progression NN o
were VBD o
assessed VBN o
using VBG o
American JJ o
College NNP o
of IN o
Rheumatology NNP o
response NN o
criteria NNS o
, , o
disease NN o
activity NN o
scores VBZ o
, , o
and CC o
Total NNP o
Sharp NNP o
Score NNP o
( ( o
TSS NNP o
) ) o
. . o

However RB N
, , N
the DT N
published VBN N
article NN N
concluded VBD N
that IN N
both DT N
drugs NNS N
were VBD N
efficacious JJ N
versus NN N
placebo NN i
for IN N
a DT N
post NN N
hoc NN N
subgroup NN N
of IN N
patients NNS N
. . N

RESULTS NNP N
Cigarette NNP o
, , o
cigar NN o
, , o
or CC o
pipe NN o
use NN o
at IN o
each DT o
time NN o
interval NN o
correlated VBD o
with IN o
significantly RB o
increased VBN o
caloric JJ o
intake NN o
in IN N
males NNS N
but CC N
not RB N
in IN N
females NNS N
. . N

Solid NNP N
core NN N
filling VBG N
material NN N
such JJ N
as IN N
gutta-percha NN N
has VBZ N
been VBN N
used VBN N
to TO N
fill VB N
the DT N
root NN N
canal NN N
in IN N
conjunction NN N
with IN N
a DT N
sealer NN N
to TO N
prevent VB N
apical JJ N
leakage NN N
. . N

One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
, , N
threshold JJ N
ROP NNP N
was VBD N
treated VBN N
with IN N
an DT N
814/815 CD N
nm JJ N
diode NN i
laser NN i
, , N
while IN N
the DT N
other JJ N
eye NN N
was VBD N
treated VBN N
with IN N
cryotherapy NN i
. . i

In IN N
the DT N
management NN N
of IN N
wounds NNS N
, , N
sometimes RB N
it PRP N
is VBZ N
recommended VBN N
to TO N
give VB N
an DT N
adult-type JJ i
tetanus-diphtheria NN i
( ( i
Td NNP i
) ) i
vaccine NN i
dose JJ i
plus CC i
tetanus JJ i
immune JJ i
globulin NN i
( ( i
TIG NNP i
) ) i
. . i

BACKGROUND NNP N
Previous NNP N
investigations NNS N
in IN N
pancreatic JJ N
cancer NN N
suggest VBP N
a DT N
prognostic JJ N
role NN N
for IN N
? . N
muscle NN N
actin NN N
( ( N
? . N
) ) N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
the DT N
peritumoural JJ N
stroma NN N
. . N

Blockade NN N
of IN N
cytotoxic JJ i
T-lymphocyte JJ i
antigen-4 NN i
( ( N
CTLA-4 NNP N
) ) N
by IN N
ipilimumab NN N
leads NNS N
to TO N
immune-mediated JJ N
tumor NN N
regression NN N
and CC N
immune-related JJ N
adverse JJ N
events NNS N
( ( N
irAEs NN N
) ) N
, , N
including VBG N
diarrhea NN o
and CC o
colitis NN o
. . o

The DT N
mean JJ o
NRS NNP o
pain NN o
score NN o
before IN N
the DT N
most RBS N
recent JJ N
dose NN N
of IN N
pain NN N
medication NN N
after IN N
ED NNP N
discharge NN N
was VBD N
7.6 CD N
NRS NNP N
units NNS N
for IN N
both DT N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
pharmacokinetics NNS N
and CC N
effects NNS N
of IN N
methadone NN i
on IN N
behaviour NN N
and CC N
plasma JJ N
concentrations NNS N
of IN N
cortisol NN N
and CC N
vasopressin NN N
in IN N
healthy JJ p
dogs NNS p
. . p

RESULTS NNP N
Among IN N
ABC-C NNP o
subscales NNS o
, , o
Hyperactivity NNP o
and CC o
Irritability NNP o
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN i
group NN N
. . N

HYPOTHESIS NNP N
Bovine NNP o
pericardium NN o
( ( o
BP NNP o
) ) o
demonstrates VBZ o
improved JJ o
intraoperative JJ o
hemostasis NN o
and CC o
equivalent JJ o
perioperative JJ o
morbidity NN o
compared VBN N
with IN N
Dacron NNP N
when WRB N
used VBN N
as IN N
patch JJ N
material NN N
for IN N
angioplasty NN N
following VBG N
carotid JJ N
endarterectomy NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
risperidone NN i
, , N
when WRB N
administered VBN N
with IN N
galantamine NN i
, , N
did VBD N
not RB N
change VB N
the DT N
bioavailability NN o
of IN o
galantamine NN o
at IN N
steady JJ N
state NN N
. . N

Plasma VB N
A DT N
increased VBN N
with IN N
dose NN N
, , N
and CC N
CSF NNP N
A NNP N
increased VBD N
at IN N
the DT N
highest JJS N
dose NN N
, , N
suggesting VBG N
that IN N
intravenous JJ N
ponezumab NN N
alters NNS N
central JJ N
A NNP N
levels NNS N
. . N

There EX N
was VBD N
a DT N
trend NN N
of IN N
a DT N
reduced JJ N
proportion NN o
of IN o
rapid JJ o
eye NN o
movement NN o
sleep JJ o
with IN o
increased JJ o
exercise NN o
intensity NN o
( ( N
P NNP N
= NNP N
0.067 CD N
) ) N
. . N

PATIENTS NN N
Patients NNS p
with IN p
ACS NNP p
on IN p
clopidogrel NN p
who WP p
were VBD p
scheduled VBN p
for IN p
PCI NNP p
found VBD p
to TO p
have VB p
a DT p
platelet NN p
reactivity NN p
? . p
AUC NNP p
with IN p
the DT p
Multiplate NNP p
Analyzer NNP p
, , p
i.e NN p
. . p

The DT N
groups NNS N
were VBD N
analysed VBN N
for IN N
intraoperative JJ o
blood NN o
loss NN o
, , o
drainage NN o
, , o
transfusion NN o
requirements NNS o
, , o
perioperative JJ o
haemoglobin NN o
decrease NN o
, , o
wound NN o
haematoma NN o
, , o
and CC o
clinical JJ o
deep NN o
venous JJ o
thrombosis NN o
. . o

Investigations NNS N
from IN N
the DT N
last JJ N
decade NN N
established VBD N
that IN N
extent NN N
of IN N
ICH-mediated NNP N
brain NN N
injury NN N
relates VBZ N
directly RB N
to TO N
blood VB N
clot NN N
volume NN N
and CC N
duration NN N
of IN N
blood NN N
exposure NN N
to TO N
brain NN N
tissue NN N
. . N

RESULTS NNP N
In IN N
nine CD N
control NN N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
severity NN o
of IN o
OSA NNP o
, , o
MSNA NNP o
, , o
systolic JJ o
BP NNP o
, , o
or CC o
HR NNP o
. . o

In IN N
normal JJ p
postpartum JJ p
women NNS p
, , N
the DT N
postdelivery NN N
fall NN N
in IN N
serum NN o
prolactin NN o
levels NNS o
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
treated JJ N
and CC N
control JJ N
subjects NNS N
. . N

RESULTS NNP N
High NNP N
? . N
expression NN N
in IN N
tumour JJ N
stroma NN N
was VBD N
associated VBN N
with IN N
worse JJ N
patient NN N
outcome NN N
( ( N
DFS NNP N
: : N
P=0.05 NNP N
, , N
OS NNP N
: : N
P=0.047 NN N
) ) N
. . N

BACKGROUND IN N
The DT N
consumption NN N
of IN N
non-ready-to-eat JJ i
cereal NN i
and CC i
ready-to-eat NN i
cereal NN i
( ( i
RTEC NNP i
) ) i
breakfasts NNS N
have VBP N
been VBN N
associated VBN N
with IN N
increased JJ N
nutrient NN N
intakes NNS N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
intraventricular JJ o
hemorrhage NN o
and CC o
intraparenchymal JJ o
hemorrhage NN o
were VBD N
independent JJ N
risk NN N
factors NNS N
for IN N
shunt NN N
dependency NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Complete NNP N
denudation NN N
of IN N
oocytes NNS N
before IN N
slush JJ N
nitrogen NN N
vitrification NN N
does VBZ N
not RB N
influence VB N
survival JJ o
rates NNS o
but CC N
positively RB N
affects VBZ N
oocyte JJ N
meiotic JJ o
spindle NN o
competence NN o
. . o

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
TACE NNP i
therapy NN i
alone RB i
, , N
the DT N
combination NN N
therapy NN N
improves VBZ N
the DT N
tumor NN o
necrosis NN o
rate NN o
and CC N
prolongs VBZ N
the DT N
patients NNS N
' POS N
survival JJ N
duration NN N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
treatment NN N
with IN N
pentoxifylline NN i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
platelet NN o
inhibitory NN o
effects NNS o
in IN N
DM NNP p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
receiving VBG p
DAPT NNP p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
influence NN N
of IN N
a DT N
co-administration NN N
of IN N
aspirin NN i
and CC i
NSAID NNP i
on IN N
platelet NN o
aggregation NN o
. . o

The DT N
difference NN N
in IN N
time NN o
to TO o
relapse VB o
between IN N
aripiprazole NN i
and CC i
placebo NN i
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.097 NNP N
) ) N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
survival JJ o
, , o
tumor JJ o
response NN o
, , o
safety NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

CONCLUSIONS NNP N
Transfusion NNP N
greatly RB N
reduces VBZ N
the DT N
risk NN N
of IN N
a DT N
first JJ N
stroke NN N
in IN N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
who WP p
have VBP p
abnormal JJ p
results NNS p
on IN p
transcranial JJ p
Doppler NNP p
ultrasonography NN p
. . p

Multivariate NNP N
analysis NN N
results NNS N
indicated VBD N
that IN N
the DT N
lower JJR N
the DT N
tissue NN N
density NN N
percentage NN N
before IN N
treatment NN N
, , N
the DT N
greater JJR N
the DT N
increase NN N
in IN N
density NN N
percentage NN N
after IN N
treatment NN N
. . N

One CD N
group NN N
of IN N
patients NNS N
was VBD N
treated VBN N
with IN N
implantation NN i
of IN i
a DT i
cardioverter-defibrillator NN i
; : i
the DT i
other JJ i
received JJ i
class NN i
III NNP i
antiarrhythmic JJ i
drugs NNS i
, , i
primarily RB i
amiodarone NN i
at IN N
empirically RB N
determined VBN N
doses NNS N
. . N

Rituximab NNP i
plus CC i
intravenous JJ i
bolus NN i
chemotherapy NN i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
immunocompetent JJ p
patients NNS p
with IN p
B-cell NNP p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
. . p

Because IN N
children NNS N
at IN N
each DT N
grade NN N
were VBD N
distributed VBN N
across IN N
two CD N
classrooms NNS N
( ( N
clusters NNS N
) ) N
and CC N
were VBD N
homogeneous JJ N
, , N
each DT N
grade NN N
was VBD N
considered VBN N
to TO N
consist VB N
of IN N
a DT N
matched JJ N
pair NN N
. . N

Effect NN N
of IN N
testosterone NN i
and CC i
a DT i
nutritional JJ i
supplement NN i
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
on IN N
hospital JJ N
admissions NNS N
in IN N
undernourished JJ p
older JJR p
men NNS p
and CC p
women NNS p
. . p

One CD p
hundred VBD p
thirty NN p
patients NNS p
will MD N
be VB N
randomly RB N
allocated VBN N
into IN N
either CC N
the DT N
intervention NN N
or CC N
placebo NN i
group NN N
at IN N
a DT N
ratio NN N
of IN N
1:1 CD N
. . N

Median JJ o
post-hospital JJ o
stay NN o
was VBD N
1.7 CD N
days NNS N
for IN N
group NN N
A NNP N
while IN N
it PRP N
was VBD N
longer RB N
( ( N
2.9 CD N
days NNS N
) ) N
for IN N
group NN N
B NNP N
. . N

This DT N
, , N
coupled VBN N
with IN N
the DT N
decreases NNS N
in IN N
VE NNP N
resulted VBD N
in IN N
decreases NNS N
in IN N
the DT N
ventilatory NN o
equivalents NNS o
to TO o
CO2 NNP o
and CC o
O2 NNP o
( ( o
VE/VCO2 NNP o
, , o
VE/VO2 NNP o
) ) o
. . o

However RB N
, , N
it PRP N
can MD N
not RB N
be VB N
concluded VBN N
that IN N
L-carnitine NNP i
provides VBZ N
an DT N
advantageous JJ N
support NN N
therapy NN N
for IN N
well-compensated JJ p
patients NNS p
requiring VBG p
cardiac JJ p
surgery NN p
. . p

Riluzole NNP i
is VBZ N
a DT N
glutamate-modulating JJ N
agent NN N
with IN N
neuroprotective JJ N
properties NNS N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
positive JJ N
effects NNS N
in IN N
many JJ N
neuropsychiatric JJ N
disorders NNS N
. . N

Effects NNS N
of IN N
interaction NN N
of IN N
RRR-alpha-tocopheryl NNP i
acetate NN i
and CC i
fish JJ i
oil NN i
on IN N
low-density-lipoprotein JJ N
oxidation NN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
and CC p
without IN p
hormone-replacement JJ p
therapy NN p
. . p

There EX N
was VBD N
only RB N
one CD N
death NN N
in IN N
JET NNP N
group NN N
( ( N
1.8 CD N
% NN N
) ) N
with IN N
no DT N
significant JJ N
difference NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Riluzole NNP i
was VBD N
fairly RB N
well RB N
tolerated VBN N
, , N
although IN N
it PRP N
was VBD N
associated VBN N
with IN N
one CD N
case NN N
of IN N
pancreatitis NN N
and CC N
five CD N
instances NNS N
of IN N
slight JJ N
increases NNS N
in IN N
transaminases NNS o
. . o

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
0.59-mg JJ i
and CC i
2.1-mg JJ i
fluocinolone NN i
acetonide NN i
( ( i
FA NNP i
) ) i
intravitreous JJ i
implants NNS i
in IN N
noninfectious JJ p
posterior JJ p
uveitis NN p
. . p

QRHT NN i
could MD N
also RB N
decrease VB N
the DT N
levels NNS N
of IN N
low-density JJ o
lipoprotein/very JJ o
low-density NN o
lipoprotein NN o
, , o
lipids NNS o
, , o
N-acetyl NNP o
glycoprotein NN o
, , o
and CC o
O-acetyl NNP o
glycoprotein NN o
. . o

Further RB N
, , N
pioglitazone NN i
significantly RB N
reduced VBN N
RA NNP o
disease NN o
activity NN o
( ( N
P=0.02 NNP N
) ) N
and CC N
CRP NNP o
levels NNS o
( ( N
P=0.001 NNP N
) ) N
, , N
while IN N
improving VBG N
lipid JJ o
profiles NNS o
. . o

These DT N
results NNS N
indicate VBP N
that IN N
an DT N
undisturbed JJ N
wound NN N
healing VBG N
process NN N
using VBG N
BRG NNP N
together RB N
with IN N
tooth DT N
stability NN N
is VBZ N
beneficial JJ N
to TO N
overall JJ N
clinical JJ N
success NN N
. . N

AIM NNP N
Pharmacodynamic NNP N
analysis NN N
of IN N
intravenous JJ N
recombinant JJ i
urate JJ i
oxidase NN i
produced VBN N
by IN N
Escherichia NNP N
coli NN N
was VBD N
performed VBN N
in IN N
healthy JJ p
subjects NNS p
using VBG p
a DT p
pharmacokinetic/pharmacodynamic JJ p
( ( p
PK/PD NNP p
) ) p
model NN p
. . p

There EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
survival JJ o
benefit NN o
with IN N
ASC NNP N
plus CC N
MVP NNP N
( ( N
HR NNP N
0.99 CD N
[ NNP N
0.78-1.27 JJ N
] NN N
; : N
p=0.95 NN N
) ) N
. . N

OBJECTIVES NN N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
ankle JJ i
cryotherapy NN i
on IN N
voluntary JJ o
and CC o
resting VBG o
motor NN o
function NN o
of IN o
the DT o
soleus NN o
over IN N
a DT N
60-minute JJ N
period NN N
. . N

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ o
changes NNS o
and CC o
surgical JJ o
stress NN o
response NN o
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

Ibuprofen NNP i
provided VBD N
greater JJR N
temperature NN o
decrement NN o
and CC o
longer JJR o
duration NN o
of IN o
antipyresis NN o
than IN N
acetaminophen NN i
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
administered VBN N
in IN N
approximately RB N
equal JJ N
doses NNS N
. . N

An DT N
equivalence NN N
trial NN N
of IN N
maintenance NN N
therapy NN N
was VBD N
carried VBN N
out RP N
in IN N
children NNS p
with IN p
B NNP p
non-Hodgkin JJ p
lymphoma NN p
, , p
and CC p
serves VBZ p
as IN p
an DT p
illustration NN p
. . p

RESULTS NN N
Patients NNS N
reported VBD N
similar JJ N
median JJ o
pain NN o
scores NNS o
and CC N
were VBD N
equally RB N
satisfied VBN o
with IN o
pain NN o
relief NN o
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
other JJ N
modulators NNS N
of IN N
its PRP$ N
activity NN N
could MD N
be VB N
of IN N
interest NN N
for IN N
further JJ N
studies NNS N
in IN N
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
short-term JJ i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
pretreatment NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
inhibits NNS N
prostaglandin VBP N
release NN N
. . N

CONCLUSION NNP N
The DT N
composite JJ N
restoration NN N
of IN N
FRC NNP i
posts NNS i
combined VBD i
with IN i
resin NN i
core NN i
and CC i
resin VB i
crown NN i
can MD N
improve VB N
the DT N
fracture NN o
resistance NN o
of IN N
the DT N
pulpless JJ N
roots NNS N
. . N

The DT N
subjective JJ N
improvement NN N
in IN N
various JJ N
degrees NNS N
and CC N
the DT N
shrinkage NN o
of IN o
tumor NN o
in IN o
the DT o
X-ray JJ o
films NNS o
were VBD N
present JJ N
in IN N
5/25 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
chemotherapy NN N
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP N
formulation NN N
is VBZ N
bioequivalent JJ N
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

CA NNP N
proved VBD N
superior JJ N
to TO N
placebo VB i
on IN N
the DT N
evolution NN N
of IN N
markers NNS N
of IN N
alcohol NN N
ingestion NN N
at IN N
three CD N
months NNS N
, , N
in IN N
this DT N
large-scale JJ N
multicenter NN N
study NN N
. . N

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
one CD N
vs NN N
two CD N
daily JJ N
bouts NNS N
of IN N
walking VBG N
on IN N
aerobic JJ N
fitness NN N
and CC N
body NN N
composition NN N
in IN N
postmenopausal JJ p
women NNS p
. . p

However RB N
, , N
the DT N
levels NNS o
of IN o
titres NNS o
of IN o
anti-PT JJ o
and CC o
anti-FHA JJ o
antibodies NNS o
in IN N
all PDT N
the DT N
three CD N
vaccines NNS N
that WDT N
confer VBP N
protection NN N
are VBP N
not RB N
known VBN N
. . N

The DT N
additional JJ N
NMES NNP N
application NN N
in IN N
the DT N
treatment NN N
could MD N
bring VB N
more JJR N
improvements NNS N
in IN N
the DT N
distal JJ o
motor NN o
functions NNS o
and CC N
faster JJR N
rehabilitation NN N
progress NN N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
= NNP N
.092 NNP N
chi-square JJ N
statistic NN N
) ) N
was VBD N
found VBN N
in IN N
implant JJ o
integration NN o
or CC o
the DT o
response NN o
of IN o
crestal JJ o
bone NN o
. . o

Primary JJ N
outcomes NNS N
were VBD N
change NN N
in IN N
total JJ o
scores NNS o
on IN o
the DT o
caregiver-completed JJ o
Social NNP o
Responsiveness NNP o
Scale NNP o
and CC o
clinician-ratings NNS o
on IN o
the DT o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
. . o

Renal JJ N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN o
and CC o
severity NN o
of IN o
the DT o
histologic JJ o
lesions NNS o
. . o

The DT N
clinical JJ N
improvement NN N
was VBD N
striking VBG N
, , N
although IN N
the DT N
number NN N
of IN N
patients NNS N
still RB N
incapacitated VBN N
was VBD N
relatively RB N
large JJ N
in IN N
patients NNS N
with IN N
the DT N
small JJ i
L-K JJ i
valves NNS i
( ( N
Nos NNP N
. . N

BACKGROUND NNP N
Suture NNP N
knots FW N
present JJ N
several JJ N
disadvantages NNS N
in IN N
wound NN N
closure NN N
, , N
because IN N
they PRP N
are VBP N
tedious JJ N
to TO N
tie VB N
and CC N
place VB N
ischemic JJ N
demands NNS N
on IN N
tissue NN N
. . N

Long-term JJ N
administration NN N
of IN N
a DT N
beta-carotene JJ i
preparation NN i
derived VBN i
from IN i
Dunaliella NNP i
bardawil NN i
, , i
a DT i
beta-carotene-rich JJ i
algae NN i
, , N
was VBD N
studied VBN N
in IN N
healthy JJ p
young JJ p
male NN p
volunteers NNS p
. . p

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
non-glycoprotein JJ N
IIb/IIIa NNP N
properties NNS N
of IN N
abciximab NNS N
do VBP N
not RB N
translate VB N
into IN N
a DT N
discernible JJ N
long-term JJ N
clinical JJ N
benefit NN N
among IN N
diabetic JJ p
patients NNS p
. . p

CONCLUSIONS NNP N
Clindamycin NNP i
vaginal JJ i
cream NN i
therapy NN i
was VBD N
associated VBN N
with IN N
significantly RB N
prolonged VBN N
gestation NN N
and CC N
reduced JJ N
cost NN N
of IN N
neonatal JJ N
care NN N
in IN N
women NNS p
with IN p
BV NNP p
. . p

Efficacy NN o
measures NNS o
, , o
overall JJ o
response NN o
rate NN o
, , o
time-to-progression NN o
and CC o
overall JJ o
survival NN o
were VBD N
equivalent JJ N
in IN N
both DT N
arms NNS N
. . N

Argon NNP i
laser NN i
trabeculoplasty NN i
is VBZ N
an DT N
effective JJ N
adjunct NN N
in IN N
managing VBG N
to TO N
control VB N
intraocular JJ N
pressure NN N
in IN N
black JJ p
Jamaican NNP p
glaucoma NN p
patients NNS p
. . p

Combined VBN N
use NN N
of IN N
cytostatics NNS N
and CC N
irradiation NN N
appeared VBD N
safe JJ o
, , o
tolerable JJ o
and CC N
significantly RB N
more RBR N
effective JJ N
than IN N
radiotherapy RB N
alone RB N
as IN N
assessed VBN N
by IN N
local JJ o
control NN o
of IN o
tumor NN o
and CC o
survival NN o
. . o

Adverse JJ o
effects NNS o
reported VBN N
by IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN N
included VBD N
erythema NN o
, , o
edema NN o
, , o
induration NN o
, , o
vesicles NNS o
, , o
erosion NN o
, , o
ulceration NN o
, , o
excoriation NN o
, , o
and CC o
scabbing NN o
. . o

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

A DT N
selection NN N
of IN N
resistant JJ N
enterobacteria NN N
and CC N
an DT N
increase NN N
in IN N
beta-lactamase JJ o
production NN o
was VBD N
observed VBN N
in IN N
the DT N
faecal JJ N
samples NNS N
during IN N
the DT N
omeprazole JJ N
plus CC N
amoxycillin JJ N
treatment NN N
. . N

[ JJ N
Opposing NNP N
effects NNS N
of IN N
propranolol NN i
and CC N
diltiazem NN i
on IN N
the DT N
angina NN o
threshold NN o
during IN N
an DT N
exercise NN N
test NN N
in IN N
patients NNS p
with IN p
syndrome JJ p
X NNP p
] NNP p
. . p

Weight NNP o
gain NN o
, , o
increased VBD o
appetite RB o
, , o
anxiety NN o
, , o
and CC o
fatigue NN o
were VBD N
the DT N
most RBS N
frequently RB N
reported VBN N
side NN o
effects NNS o
. . o

INTERVENTIONS NNP N
Introducer NNP N
PEG NNP i
was VBD N
performed VBN N
by IN N
using VBG N
the DT N
Freka NNP i
Pexact-15 NNP i
CH/FR NNP i
, , N
with IN N
the DT N
gastric NN N
wall NN N
nonsurgically RB N
sutured VBD N
to TO N
the DT N
anterior JJ N
abdominal JJ N
wall NN N
by IN N
use NN N
of IN N
an DT N
endoscope NN N
. . N

BACKGROUND NNP N
Oral NNP i
dipyridamole NN i
induces NNS N
accumulation NN N
of IN N
endogenous JJ N
adenosine NN N
, , N
which WDT N
in IN N
a DT N
hypoxic NN N
milieu NN N
exerts VBZ N
experimentally RB N
an DT N
angiogenic JJ N
effect NN N
on IN N
coronary JJ N
collateral NN N
circulation NN N
. . N

Headache NNP o
, , o
hypotension NN o
, , o
nausea NN o
, , o
constipation NN o
, , o
and CC o
postural JJ o
hypotension NN o
were VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
. . N

Relative JJ o
numbers NNS o
of IN o
CD16 NNP o
cells NNS o
were VBD N
significantly RB N
elevated VBN N
, , N
but CC N
NK NNP o
cell VBP o
cytotoxic JJ o
activity NN o
was VBD N
within IN N
a DT N
normal JJ N
range NN N
. . N

[ JJ N
Impact NNP N
of IN N
heparin NN i
on IN N
coagulation NN o
index NN o
during IN N
the DT N
therapy NN N
of IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
in IN N
patients NNS p
with IN p
liver JJ p
failure NN p
] NN p
. . N

[ IN N
The DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN i
and CC i
indapamide NN i
on IN N
the DT N
peripheral JJ N
blood NN N
pressure NN N
and CC N
central JJ N
blood NN N
pressure NN N
through IN N
pulse JJ N
wave NN N
analysis NN N
] NN N
. . N

We PRP N
will MD N
also RB N
be VB N
able JJ N
to TO N
confirm VB N
if IN N
the DT N
effects NNS N
of IN N
acupuncture NN N
are VBP N
equivalent JJ N
to TO N
those DT N
of IN N
the DT N
conventional JJ i
drug NN i
cetirizine NN i
hydrochloride NN i
. . i

RESULTS NNP N
Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
indicated VBD N
a DT N
significant JJ N
interaction NN N
effect NN N
of IN N
transcranial JJ N
direct JJ N
current JJ N
stimulation NN N
type NN N
and CC N
time NN N
on IN N
the DT N
recognition NN o
accuracy NN o
. . o

The DT N
ACTH-stimulated JJ o
mean NN o
cortisol NN o
values NNS o
after IN N
four CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
baseline NN N
values VBZ N
for IN N
either DT N
treatment NN N
group NN N
. . N

Recently RB N
a DT N
newer NN N
more RBR N
tolerated JJ N
schedule NN N
of IN N
the DT N
VNR/CDDP NNP N
regimen NN N
has VBZ N
been VBN N
published VBN N
and CC N
is VBZ N
widely RB N
employed VBN N
in IN N
medical JJ N
practice NN N
. . N

Use NNP N
of IN N
an DT N
inspiratory JJ N
impedance NN N
threshold JJ N
device NN N
on IN N
a DT N
facemask NN i
and CC i
endotracheal VB i
tube NN i
to TO N
reduce VB N
intrathoracic JJ o
pressures NNS o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
. . N

Also RB N
, , N
CD19 NNP N
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
addition NN N
to TO N
plasma VB N
cell NN N
labeling VBG N
indices NNS N
, , N
beta2-microglobulin NN N
, , N
hemoglobin NN N
, , N
and CC N
plasmablastic JJ N
morphology NN N
. . N

In IN N
those DT N
given VBN N
Taikong NNP i
Yangxin NNP i
, , N
the DT N
early JJ N
phase NN N
was VBD N
amplified VBN N
by IN N
2.5-fold JJ N
, , N
and CC N
the DT N
effects NNS N
of IN N
bed NN N
rest NN N
on IN N
the DT N
late JJ N
phase NN N
were VBD N
prevented VBN N
. . N

The DT N
effect NN N
of IN N
perindopril NN i
and CC i
hydrochlorothiazide VB i
alone RB N
and CC N
in IN N
combination NN N
on IN N
blood NN o
pressure NN o
and CC N
on IN N
the DT N
renin-angiotensin NN N
system NN N
in IN N
hypertensive JJ p
subjects NNS p
. . p

The DT N
effect NN N
of IN N
quality NN o
and CC o
amount NN o
of IN o
dietary JJ o
fat NN o
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
to TO N
oxidation NN N
in IN N
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
. . p

The DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ i
treatment NN i
of IN i
neurosurgical JJ i
operation NN i
and CC i
drug NN i
treatment NN i
( ( i
Mannitol NNP i
, , i
Citioline NNP i
Sodium NNP i
, , i
Cefeazidime NNP i
, , i
etc NN i
) ) i
. . i

Deslorelin NNP o
suppressed VBD o
ovarian JJ o
activity NN o
in IN N
pre-pubertal JJ N
bitches NNS N
, , N
and CC N
oestrous JJ N
induction NN N
was VBD N
not RB N
observed VBN N
despite IN N
the DT N
presence NN N
of IN N
the DT N
primary JJ N
stimulatory JJ N
effect NN N
of IN N
the DT N
drug NN N
. . N

Intradermal JJ N
delivery NN N
of IN N
insulin NN N
is VBZ N
a DT N
viable JJ N
delivery NN N
route NN N
alternative NN N
providing VBG N
reduced JJ N
time NN N
for IN N
insulin JJ N
absorption NN N
with IN N
less JJR N
intra-subject JJ N
variability NN N
and CC N
lower JJR N
glycemic JJ N
response NN N
. . N

However RB N
, , N
these DT N
regimens NNS N
are VBP N
still RB N
costly JJ N
, , N
duration NN N
is VBZ N
about IN N
one CD N
week NN N
or CC N
less JJR N
, , N
and CC N
side-effects NNS N
are VBP N
not RB N
negligible JJ N
. . N

With IN N
the DT N
exception NN N
of IN N
an DT N
increase NN N
in IN N
t NN N
( ( N
max NN N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
pharmacokinetic JJ o
interactions NNS o
between IN N
cephalexin NN i
and CC i
ranitidine NN i
or CC i
omeprazole NN i
. . i

Thus RB N
, , N
18HL CD N
reduced VBN N
force NN N
and CC N
strain NN N
on IN N
the DT N
AT NNP N
during IN N
running VBG N
via IN N
a DT N
reduction NN N
in IN N
dorsiflexion NN N
, , N
which WDT N
lengthened VBD N
the DT N
AT NNP N
moment NN N
arm NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
ANF NNP i
on IN N
the DT N
increase NN N
in IN N
plasma JJ o
aldosterone NN o
due JJ N
to TO N
metoclopramide VB i
in IN N
man NN p
. . p

In IN N
comparison NN N
with IN N
normal JJ N
controls NNS N
, , N
the DT N
myeloma NN N
patients NNS N
exhibited VBD N
a DT N
marked JJ N
heterogeneity NN N
in IN N
the DT N
number NN o
of IN o
circulating VBG o
CD19+ NNP o
B NNP o
cells NNS o
as IN N
detected VBN N
by IN N
flow JJ N
cytometry NN N
. . N

Non-steroidal JJ i
anti-inflammatory JJ i
drugs NNS i
( ( i
NSAIDs NNP i
) ) i
may MD N
be VB N
used VBN N
to TO N
reduce VB N
neck NN N
pain NN N
and CC N
associated VBN N
inflammation NN N
and CC N
facilitate NN N
earlier RBR N
recovery NN N
. . N

Comparison NNP N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
faropenem JJ i
daloxate NN i
and CC i
cefuroxime NN i
axetil NN i
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
bacterial JJ p
maxillary JJ p
sinusitis NN p
in IN p
adults NNS p
. . p

The DT N
addition NN N
of IN N
fentanyl NN N
to TO N
lidocaine VB i
for IN N
transvaginal JJ N
oocyte NN N
retrieval NN N
results NNS N
in IN N
a DT N
more RBR N
comfortable JJ N
patient NN N
in IN N
the DT N
OR NNP N
and CC N
PACU NNP N
. . N

Recent JJ N
studies NNS N
demonstrate VBP N
that IN N
not RB N
only RB N
estrogens VBZ N
but CC N
also RB N
androgens VBZ N
may MD N
serve VB N
as IN N
regulators NNS N
of IN N
estrogen-responsive JJ N
as RB N
well RB N
as IN N
estrogen-unresponsive JJ N
human JJ N
breast NN N
cancers NNS N
. . N

Confocal JJ i
microscopy NN i
was VBD N
used VBN N
for IN N
the DT N
6-week JJ N
treatment NN N
group NN N
to TO N
examine VB N
the DT N
target NN N
tumor NN N
area NN N
at IN N
each DT N
interval JJ N
visit NN N
and CC N
immediately RB N
before IN N
Mohs NNP i
micrographic JJ i
surgery NN i
. . i

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
BRAF NNP N
mutation NN N
on IN N
survival NN o
and CC o
treatment NN o
efficacy NN o
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
colon NN p
cancer NN p
. . p

CONCLUSIONS NNP N
Fadrozole NNP i
HCL NNP i
was VBD N
as RB N
efficacious JJ N
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN p
patients NNS p
with IN p
metastatic JJ p
breast NN p
carcinoma NN p
after IN p
one CD p
hormonal JJ p
therapy NN p
. . p

Higher JJR o
serum NN o
concentration NN o
and CC o
area NN o
under IN o
the DT o
plasma JJ o
concentration NN o
curve NN o
( ( o
AUC NNP o
) ) o
were VBD N
not RB N
associated VBN N
with IN N
an DT N
improved JJ N
EFS NNP N
. . N

The DT N
effect NN N
of IN N
vitamin JJ i
A-fortified NNP i
coconut NN i
cooking VBG i
oil NN i
on IN N
the DT N
serum NN N
retinol JJ N
concentration NN N
of IN N
Filipino NNP p
children NNS p
4-7 CD p
years NNS p
old JJ p
. . p

Conventional JJ i
in IN i
vitro JJ i
fertilization NN i
versus IN i
intracytoplasmic JJ i
sperm JJ i
injection NN i
in IN N
patients NNS p
with IN p
borderline JJ p
semen NNS p
: : p
a DT N
randomized JJ N
study NN N
using VBG N
sibling VBG N
oocytes NNS N
. . N

IMPLICATIONS NNP N
Gastroesophageal NNP o
reflux NN o
( ( o
GER NNP o
) ) o
and CC o
tracheal JJ o
aspiration NN o
of IN o
acid NN o
may MD o
increase VB o
morbidity NN o
and CC o
mortality NN o
in IN N
patients NNS p
undergoing VBG p
thoracotomy NN p
. . p

In IN N
addition NN N
, , N
polymorphisms NN N
in IN N
the DT N
E158K NNP N
or CC N
E308G NNP N
allele NNS N
were VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
mucosal NN o
prostanoid NN o
levels NNS o
in IN N
patients NNS N
treated VBN N
with IN N
sulindac NN N
. . N

CONCLUSIONS NNP N
Somatostatin NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
ranitidine NN i
in IN N
controlling VBG N
acute JJ N
non-variceal JJ N
gastrointestinal JJ N
bleeding NN N
in IN N
patients NNS p
with IN p
Forrest NNP p
IB NNP p
bleeding NN p
activity NN p
. . p

BACKGROUND NNP N
Some DT N
investigators NNS N
found VBD N
a DT N
greater JJR N
incidence NN N
of IN N
hypotension NN N
in IN N
patients NNS N
receiving VBG N
intrathecal JJ N
hyperbaric JJ N
solution NN N
than IN N
in IN N
patients NNS p
receiving VBG p
plain JJ p
solution NN p
for IN p
cesarean JJ p
section NN p
. . p

RESULTS NN N
After IN N
the DT N
CPB NNP N
, , N
OI NNP N
and CC N
Cstat NNP N
in IN N
all DT N
groups NNS N
decreased VBD N
significantly RB N
, , N
while IN N
Raw NNP o
and CC o
P NNP o
( ( o
A- NNP o
) ) o
O2 NNP o
increased VBD N
significantly RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP i
abdominis NN i
plane NN i
( ( i
TAP NNP i
) ) i
block NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

The DT N
sensitivity NN o
and CC o
specificity NN o
for IN N
detecting VBG N
intestinal JJ N
metaplasia NN N
by IN N
TNE NNP i
compared VBN N
with IN N
those DT N
by IN N
SE NNP N
was VBD N
0.91 CD N
and CC N
1.00 CD N
, , N
respectively RB N
. . N

BACKGROUND NNP N
Hypertonic NNP i
saline NN i
improves VBZ N
organ JJ o
perfusion NN o
and CC o
patient JJ o
survival NN o
during IN N
hemorrhagic NN N
shock NN N
because IN N
it PRP N
expands VBZ N
plasma JJ N
volume NN N
and CC N
increases VBZ N
tissue NN N
oxygenation NN N
. . N

UNLABELLED NNP N
Dramatic NNP N
effects NNS N
on IN N
autistic JJ N
behaviour NN N
after IN N
repeated VBN N
injections NNS N
of IN N
the DT N
gastrointestinal JJ N
hormone NN N
secretin NN N
have VBP N
been VBN N
referred VBN N
in IN N
a DT N
number NN N
of IN N
case NN N
reports NNS N
. . N

The DT N
ratio NN N
between IN N
thrombin-antithrombin-III-complexes NNS N
and CC N
fibrin JJ N
degradation NN N
products NNS N
were VBD N
unchanged JJ N
signifying VBG N
no DT N
effect NN N
of IN N
hormonal JJ N
intake NN N
on IN N
the DT N
balance NN N
between IN N
thrombin JJ N
formation NN N
and CC N
fibrin JJ N
resolution NN N
. . N

CONCLUSIONS NNP N
Diltiazem NNP i
reduces VBZ N
the DT N
frequency NN o
and CC o
severity NN o
of IN o
ischemic JJ o
type NN o
ST NNP o
depression NN o
in IN N
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

METHODS NNP N
Fifty-nine NNP p
children NNS p
, , p
aged VBN p
3-5 CD p
years NNS p
, , p
with IN p
no DT p
cerebral JJ p
palsy NN p
, , p
participated VBN p
in IN p
the DT p
study NN p
. . p

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ i
leukocyte JJ i
IFN-alpha NN i
on IN N
the DT N
immune JJ o
response NN o
to TO N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

CONCLUSION NNP N
The DT N
conventional JJ i
scaling NN i
and CC i
root NN i
planing NN i
and CC i
the DT i
calculus JJ i
deattachment NN i
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
probing VBG N
depth NN N
values NNS N
, , N
regardless RB N
of IN N
the DT N
instrumentation NN N
method NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
two CD N
products NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
pulse JJ o
rate NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
ECG NNP o
intervals NNS o
. . o

Neither DT N
torasemide JJ N
nor CC N
furosemide JJ i
induced VBD N
any DT N
significant JJ N
change NN N
in IN N
serum NN o
electrolyte NN o
or CC o
creatinine NN o
concentrations NNS o
, , o
or CC o
in IN o
ammonia JJ o
levels NNS o
. . o

This DT N
effect NN N
was VBD N
well RB N
maintained VBN N
in IN N
the DT N
supine JJ N
position NN N
, , N
although IN N
during IN N
standing VBG N
it PRP N
tended VBD N
to TO N
be VB N
less RBR N
evident JJ N
with IN N
increasing VBG N
doses NNS N
. . N

BACKGROUND NNP N
Neuropathic NNP N
pain NN N
is VBZ N
a DT N
complex JJ N
state NN N
of IN N
chronic JJ N
pain NN N
that WDT N
is VBZ N
usually RB N
accompanied VBN N
by IN N
peripheral JJ N
and CC N
central JJ N
nervous JJ N
system NN N
damage NN N
or CC N
dysfunction NN N
. . N

Outcomes NNS N
measured VBN N
were VBD N
airway RB o
leak JJ o
pressure NN o
, , o
ease NN o
and CC o
time NN o
for IN o
insertion NN o
, , o
fibreoptic JJ o
examination NN o
, , o
incidence NN o
of IN o
gastric JJ o
insufflation NN o
and CC o
complications NNS o
. . o

CONCLUSION NNP N
Sentinel NNP N
lymph NN N
node NN N
detection NN N
and CC N
analysis NN N
is VBZ N
feasible JJ N
, , N
technique NN N
is VBZ N
relatively RB N
simple JJ N
and CC N
is VBZ N
able JJ N
to TO N
produce VB N
upstage NN N
in IN N
colorectal JJ N
cancer NN N
. . N

CONCLUSION NNP N
Analgesic NNP N
efficacy NN N
of IN N
EM NNP i
is VBZ N
decreased VBN N
when WRB N
2-CP JJ N
is VBZ N
used VBN N
for IN N
LEA NNP N
compared VBN N
to TO N
when WRB N
Lido NNP N
+ NNP N
Epi NNP N
is VBZ N
used VBN N
. . N

The DT N
incidence NN o
of IN o
necrotizing VBG o
enterocolitis NN o
was VBD N
12.0 CD N
percent NN N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
9.5 CD N
percent NN N
in IN N
the DT N
control NN N
group NN N
. . N

Presented VBN N
is VBZ N
a DT N
prospective JJ N
study NN N
comparing VBG N
limited JJ i
SMAS NNP i
( ( i
lateral JJ i
SMASectomy NNP i
) ) i
, , i
conventional JJ i
SMAS NNP i
, , i
extended VBD i
SMAS NNP i
, , i
and CC i
composite JJ i
rhytidectomies NNS i
. . i

In IN N
this DT N
study NN N
, , N
an DT N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NNP i
laser NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
cavity NN N
preparation NN N
and CC N
restoration NN N
replacement NN N
. . N

No DT N
significant JJ N
genotype-dependent JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
V NNP o
( ( o
2peak CD o
) ) o
, , o
muscle NN o
strength NN o
, , o
muscle NN o
endurance NN o
or CC o
lactate NN o
threshold NN o
. . o

CONCLUSION NNP N
Unreamed NNP N
nailing NN N
in IN N
patients NNS p
with IN p
tibial JJ p
shaft NN p
fractures NNS p
may MD N
be VB N
associated VBN N
with IN N
higher JJR N
rates NNS N
of IN N
secondary JJ N
operations NNS N
and CC N
malunions NNS N
compared VBN N
with IN N
reamed JJ i
nailing NN i
. . i

At IN N
the DT N
highest JJS N
thermal JJ N
burden NN N
, , N
the DT N
effect NN N
of IN N
nifedipine NN i
was VBD N
inconsistent JJ N
and CC N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
placebo NN i
. . i

Median JJ o
survival NN o
was VBD N
7.6 CD N
months NNS N
in IN N
the DT N
ASC NNP N
alone RB N
group NN N
and CC N
8.5 CD N
months NNS N
in IN N
the DT N
ASC NNP N
plus CC N
chemotherapy JJ N
group NN N
. . N

Biventricular JJ i
pacing VBG i
improves NNS N
cardiac JJ o
function NN o
and CC N
prevents NNS N
further RBR N
left VBD N
atrial JJ N
remodeling NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
atrial JJ p
fibrillation NN p
after IN p
atrioventricular JJ p
node JJ p
ablation NN p
. . p

BACKGROUND NNP N
In IN N
T3 NNP p
rectal JJ p
cancer NN p
( ( p
RC NNP p
) ) p
, , p
preoperative JJ i
chemoradiotherapy NN i
[ JJ i
5-fluorouracil JJ i
( ( i
5-FU-RT JJ i
) ) i
] NN i
reduces VBZ N
local JJ N
recurrences NNS N
, , N
but CC N
does VBZ N
not RB N
affect VB N
overall JJ o
survival NN o
. . o

The DT N
effect NN N
of IN N
exercise NN i
in IN N
preventing VBG N
falls NNS N
varied VBN N
significantly RB N
by IN N
baseline JJ o
physical JJ o
function NN o
level NN o
( ( N
p JJ N
< NN N
or CC N
=.002 NN N
) ) N
. . N

A DT N
common JJ N
variation NN N
in IN N
this DT N
gene NN N
( ( N
rs3796863 NN N
) ) N
was VBD N
recently RB N
found VBN N
to TO N
be VB N
associated VBN N
with IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Low-dose JJ N
, , N
vaginally RB N
administered VBN N
estrogens NNS i
may MD N
enhance VB N
local JJ N
benefits NNS N
of IN N
systemic JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
urogenital JJ N
atrophy NN N
in IN N
postmenopausal JJ p
women NNS p
on IN p
hormone NN p
therapy NN p
. . p

Changes NNS N
in IN N
dietary JJ N
stage NN N
of IN N
change NN N
were VBD N
associated VBN N
with IN N
decreases NNS N
in IN N
fat JJ o
intake NN o
and CC o
increases NNS o
in IN o
fiber NN o
, , o
fruit NN o
and CC o
vegetable JJ o
intake NN o
. . o

Comparison NNP N
of IN N
neodymium-doped JJ i
yttrium NN i
aluminum NN i
garnet NN i
laser NN i
treatment NN i
with IN i
cold JJ i
knife NN i
endoscopic NN i
incision NN i
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ p
patients NNS p
. . p

Endometrial JJ N
cytology NN N
using VBG N
a DT N
softcyte NN N
or CC N
an DT N
endocyte NN N
achieved VBN N
high JJ N
correct JJ N
diagnosis NN N
rate NN N
for IN N
cancer NN N
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
. . N

Twenty-one CD p
attention NN p
deficit NN p
disorder NN p
with IN p
hyperactivity NN p
and CC p
seven CD p
autistic JJ p
children NNS p
were VBD p
randomly RB i
exposed VBN i
to TO i
negatively RB i
ionized JJ i
and CC i
ambient JJ i
atmospheres NNS i
under IN i
rigorously RB i
controlled VBN i
experimental JJ i
conditions NNS i
. . i

Based VBN N
on IN N
a DT N
definition NN N
of IN N
lactate NN N
steady JJ N
state NN N
( ( N
LSS NNP N
) ) N
as IN N
less JJR N
than IN N
a DT N
0.5 CD N
mmol.l-1 JJ N
increase NN N
, , N
this DT N
value NN N
signified VBD N
LSS NNP N
. . N

Switching VBG o
DBS NNP o
on IN o
improved JJ o
balance NN o
scores NNS o
, , N
and CC N
scores VBZ N
further RBR N
improved VBN N
with IN N
medication NN N
, , N
compared VBN N
to TO N
the DT N
off RP N
state NN N
. . N

These DT N
effects NNS N
seem VBP N
to TO N
be VB N
mediated VBN N
via IN N
mechanisms NNS N
that WDT N
are VBP N
different JJ N
from IN N
those DT N
of IN N
angiotensin JJ N
II NNP N
receptor NN N
blocker NN N
or CC N
thiazolidinedione NN i
. . i

For IN N
geometric JJ o
mean NN o
titers NNS o
( ( o
GMT NNP o
) ) o
, , o
antibody NN o
titers NNS o
below IN N
the DT N
cutoff NN N
of IN N
the DT N
assay NN N
were VBD N
given VBN N
, , N
arbitrarily RB N
, , N
0.05 CD N
IU/mL NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
relationships NNS N
between IN N
the DT N
serum NN o
of IN o
TARC NNP o
level NN o
and CC o
the DT o
CARS NNP o
score NN o
, , N
age NN N
, , N
or CC N
gender VB N
for IN N
any DT N
group NN N
. . N

The DT N
authors NNS N
have VBP N
studied VBN N
indices NNS N
of IN N
natriuretic JJ i
peptide NN i
and CC i
oxidative JJ i
stress NN i
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
. . p

Correlation NN N
of IN N
quantitative JJ N
measures NNS N
with IN N
the DT N
modified JJ N
Ashworth NNP N
scale NN N
in IN N
the DT N
assessment NN N
of IN N
plantar NN p
flexor NN p
spasticity NN p
in IN p
patients NNS p
with IN p
traumatic JJ p
brain NN p
injury NN p
. . p

BACKGROUND NNP N
Fungal NNP N
infection NN N
is VBZ N
a DT N
frequent JJ N
and CC N
often RB N
fatal JJ o
complication NN o
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN p
therapy NN p
for IN p
acute JJ p
leukemia NN p
. . p

Buspirone NN i
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
efficacious JJ o
, , o
without IN o
side JJ o
effects NNS o
, , o
for IN o
decreasing VBG o
hyperactivity NN o
and CC N
increasing VBG N
completed VBN N
performance NN N
tasks NNS N
. . N

CONCLUSION NNP N
Leucocyte NNP N
depletion NN N
is VBZ N
not RB N
associated VBN N
with IN N
better JJR N
long-term JJ o
survival NN o
and CC o
lower JJR o
recurrence NN o
rates NNS o
in IN N
patients NNS p
with IN p
gastrointestinal JJ p
cancer NN p
. . p

CONCLUSIONS NNP N
Dietary NNP i
PUFA NNP i
supplementation NN i
markedly RB N
potentiates VBZ N
baroreflex JJ N
function NN N
and CC N
enhances NNS N
heart NN o
rate NN o
variability NN o
in IN N
patients NNS p
with IN p
stable JJ p
congestive JJ p
heart NN p
failure NN p
. . p

CONCLUSION NNP N
Markers NNP N
of IN N
systemic JJ N
inflammation NN N
contribute NN N
significantly RB N
to TO N
prognostic JJ N
classification NN N
in IN N
addition NN N
to TO N
established VBN N
factors NNS N
for IN N
pre-treated JJ p
patients NNS p
with IN p
advanced JJ p
RCC NNP p
. . p

BACKGROUND IN N
It PRP N
is VBZ N
known VBN N
that IN N
the DT N
bifidobacteria NN N
flora VBP N
play NN N
important JJ N
roles NNS N
in IN N
mucosal NN N
host NN N
defense NN N
and CC N
can MD N
prevent VB N
infectious JJ N
diseases NNS N
. . N

The DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
suggesting VBG N
that IN N
the DT N
multi-media JJ N
tablet NN N
device NN N
was VBD N
more RBR N
effective JJ N
method NN N
. . N

AIMS NNP N
Preclinical NNP N
data NN N
suggest NN N
that IN N
signalling VBG N
through IN N
the DT N
HGF-MET NNP N
pathway NN N
may MD N
confer VB N
resistance NN N
to TO N
BRAF NNP N
inhibition NN N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

CONCLUSIONS NNP N
DJQ NNP N
showed VBD N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
effects NNS N
, , N
but CC N
with IN N
no DT N
effect NN N
on IN N
the DT N
hematopoietic JJ N
function NN N
of IN N
the DT N
bone NN N
marrow NN N
. . N

Lornoxicam NNP i
was VBD N
very RB N
well RB N
tolerated VBN o
at IN N
all DT N
three CD N
doses NNS N
studied VBN N
, , N
with IN N
no DT N
adverse JJ N
events NNS N
definitely RB N
attributable JJ N
to TO N
its PRP$ N
administration NN N
. . N

The DT N
renin-angiotensin NN N
system NN N
played VBD N
a DT N
part NN N
in IN N
maintenance NN N
of IN N
blood NN N
pressure NN N
only RB N
with IN N
severe JJ N
salt NN N
restriction NN N
and CC N
in IN N
a DT N
small JJ N
proportion NN N
of IN N
cases NNS N
. . N

Primary JJ N
end NN N
point NN N
will MD N
be VB N
the DT N
conversion NN o
of IN o
AF NNP o
to TO o
sinus VB o
rhythm NN o
confirmed VBN o
in IN o
an DT o
electrocardiogram NN o
( ( o
ECG NNP o
) ) o
during IN N
the DT N
observation NN N
period NN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

INTERPRETATION NNP N
The DT N
addition NN N
of IN N
chemotherapy NN N
to TO N
ASC NNP N
offers VBZ N
no DT N
significant JJ N
benefits NNS N
in IN N
terms NNS N
of IN N
overall JJ o
survival NN o
or CC o
quality NN o
of IN o
life NN o
. . o

Influence NN N
of IN N
glyceryl NN i
trinitrate NN i
on IN N
venous JJ N
and CC N
arterial JJ N
effects NNS N
of IN N
chronic NN N
, , N
asymmetric JJ N
isosorbide NN i
dinitrate NN i
treatment NN i
in IN N
patients NNS p
with IN p
ischemic JJ p
heart NN p
disease NN p
. . p

INTRODUCTION NNP N
Decreasing NNP N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR p
adults NNS p
. . p

Variation NN N
in IN N
BCG NNP N
efficacy NN N
was VBD N
marked VBN N
when WRB N
vaccine NN N
was VBD N
given VBN N
at IN N
school NN N
age NN N
but CC N
absent NN N
at IN N
birth NN N
, , N
which WDT N
points VBZ N
towards NNS N
blocking VBG N
as IN N
the DT N
dominant JJ N
mechanism NN N
. . N

Efficacy NN o
and CC o
safety NN o
relative VBP N
to TO N
placebo VB i
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN i
and CC N
sustained-release JJ N
pseudoephedrine NN i
in IN N
the DT N
management NN N
of IN N
nasal JJ o
congestion NN o
. . o

Therefore RB N
, , N
no DT N
significant JJ N
pharmacokinetic JJ o
differences NNS o
occurred VBD N
in IN N
either CC N
risperidone VB i
active JJ N
moiety NN N
or CC N
donepezil NN i
when WRB N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
. . N

Using VBG N
a DT N
PSA NNP o
increase NN o
from IN o
nadir NN o
of IN N
0.8 CD N
ng/ml IN N
the DT N
sensitivity NN N
of IN N
dutasteride NN N
was VBD N
0.548 CD N
and CC N
its PRP$ N
specificity NN N
was VBD N
0.795 CD N
. . N

Racemic NNP i
epinephrine NN i
has VBZ N
been VBN N
advocated VBN N
for IN N
the DT N
treatment NN N
of IN N
croup NN N
, , N
but CC N
controlled VBD N
studies NNS N
have VBP N
not RB N
proved VBN N
it PRP N
more RBR N
effective JJ N
than IN N
saline NN N
. . N

This DT N
finding NN N
supports VBZ N
the DT N
results NNS N
of IN N
previous JJ N
US NNP N
and CC N
European JJ N
studies NNS N
, , N
which WDT N
have VBP N
also RB N
shown VBN N
that IN N
lanthanum NN N
carbonate NN N
treatment NN N
effectively RB N
controls VBZ N
serum JJ N
phosphorus NN N
levels NNS N
. . N

The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN i
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
and CC N
a DT N
reduced JJ N
bleeding NN N
time NN N
. . N

No DT N
significant JJ N
change NN N
in IN N
the DT N
ratio NN o
of IN o
the DT o
FEV1 NNP o
and CC o
the DT o
FVC NNP o
was VBD N
demonstrated VBN N
in IN N
either CC N
the DT N
iopamidol NN N
or CC N
the DT N
sodium NN N
iothalamate NN N
groups NNS N
. . N

However RB N
, , N
a DT N
slight JJ N
decrease NN N
in IN N
early JJ o
insulin NN o
response NN o
to TO o
glucose VB o
was VBD N
observed VBN N
in IN N
the DT N
nifedipine NN i
and CC N
the DT N
nitrendipine JJ N
groups NNS N
. . N

The DT N
highest JJS N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
by IN N
the DT N
loop NN N
technique NN N
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

The DT N
anti-inflammatory JJ N
, , N
analgesic JJ N
and CC N
tranquillizing JJ N
activity NN N
of IN N
a DT N
synthetic JJ N
compound NN N
called VBD N
parsalmide NN N
was VBD N
investigated VBN N
in IN N
patients NNS p
suffering VBG p
from IN p
inflammatory NN p
and CC p
degenerative JJ p
rheumatic JJ p
arthropathies NNS p
. . p

Already RB N
after IN N
the DT N
first JJ N
week NN N
of IN N
the DT N
skiing VBG N
tour NN N
there EX N
were VBD N
significant JJ N
drops NNS N
in IN N
PAI-1 NNP o
activities NNS o
, , o
cholesterol NN o
and CC o
triglycerides NNS o
. . o

These DT N
results NNS N
seem VBP N
to TO N
confirm VB N
the DT N
value NN N
of IN N
parenteral JJ N
short-term JJ N
antibiotic JJ N
prophylaxis NN N
of IN N
postoperative JJ N
infection NN N
in IN N
such JJ N
kind NN N
of IN N
clean JJ N
operative JJ N
procedure NN N
. . N

Multiple JJ N
linear JJ N
regression NN N
analysis NN N
revealed VBD N
the DT N
change NN N
in IN N
HDL-C NNP N
to TO N
be VB N
an DT N
independent JJ N
variable JJ N
showing VBG N
a DT N
positive JJ N
correlation NN N
with IN N
the DT N
carotid NN N
IMT NNP N
reduction NN N
. . N

RESULTS NNP N
Heatwrap NNP N
therapy NN N
was VBD N
shown VBN N
to TO N
provide VB N
significant JJ N
therapeutic JJ N
benefits NNS N
when WRB N
compared VBN N
with IN N
placebo NN i
during IN N
both CC N
the DT N
treatment NN N
and CC N
follow-up JJ N
period NN N
. . N

RESULTS NNP N
Plasma NNP o
glutathione NN o
( ( o
GSH NNP o
) ) o
and CC o
alpha- JJ o
and CC o
gamma-tocopherol JJ o
concentrations NNS o
decreased VBN N
and CC N
the DT N
GSH NNP o
redox NN o
state NN o
became VBD N
more RBR N
oxidized JJ N
after IN N
conditioning VBG N
chemotherapy NN N
. . N

The DT N
WOMAC NNP o
score NN o
at IN N
three CD N
, , N
six CD N
, , N
and CC N
twelve JJ N
months NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
piriformis NN N
fossa NN N
and CC N
trochanteric JJ N
nailing NN N
groups NNS N
. . N

CONCLUSIONS NNP N
The DT N
presence NN N
of IN N
brain NN N
MRI NNP N
abnormalities NNS N
at IN N
the DT N
time NN N
of IN N
an DT N
optic JJ N
neuritis NN N
attack NN N
is VBZ N
a DT N
strong JJ N
predictor NN N
of IN N
the DT N
15-year JJ N
risk NN N
of IN N
MS NNP N
. . N

Consistent JJ N
with IN N
previous JJ N
reports NNS N
gadodiamide NN N
injection NN N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
contrast NN N
medium NN N
for IN N
MR NNP N
imaging NN N
of IN N
the DT N
pituitary JJ N
region NN N
. . N

A DT N
low JJ N
intention NN N
to TO N
be VB N
physically RB N
active JJ N
was VBD N
a DT N
strong JJ N
predictor NN N
for IN N
dropout NN o
within IN N
both DT N
delivery NN N
modes FW N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
The DT N
administration NN N
of IN N
L-arginine NNP i
and CC i
citrulline NN i
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
endothelial JJ N
function NN N
as IN N
shown VBN N
by IN N
the DT N
normalized JJ N
MAT/TT NNP N
index NN N
. . N

Clinical JJ N
usefulness NN N
of IN N
serum NN N
prostate NN N
specific JJ N
antigen NN N
for IN N
the DT N
detection NN N
of IN N
prostate NN N
cancer NN N
is VBZ N
preserved VBN N
in IN N
men NNS p
receiving VBG p
the DT p
dual JJ p
5alpha-reductase JJ p
inhibitor NN p
dutasteride NN p
. . p

OBJECTIVE NNP N
Captopril NNP i
and CC N
enalapril NNS i
have VBP N
been VBN N
reported VBN N
to TO N
influence VB N
cognitive JJ o
functions NNS o
and CC o
quality NN o
of IN o
life NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

Side-effects NNS o
in IN N
both DT N
groups NNS N
were VBD N
those DT N
commonly JJ N
seen VBN N
with IN N
non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
and CC N
, , N
as IN N
expected VBN N
, , N
gastro-intestinal JJ N
and CC N
CNS NNP N
disturbances NNS N
predominated VBD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
plasma NN o
, , o
lipid-standardized JJ o
, , o
and CC o
LDL NNP o
AT NNP o
levels NNS o
between IN o
RRR-AT NNP o
and CC o
all-rac-AT JJ o
supplementation NN o
at IN N
any DT N
dose JJ N
comparison NN N
. . N

The DT N
urea JJ N
end-product NN N
method NN N
suggested VBD N
that IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
whole-body NN o
protein NN o
turnover NN o
after IN N
surgery NN N
, , N
whether IN N
or CC N
not RB N
insulin NN N
was VBD N
given VBN N
. . N

CONCLUSIONS NNP N
Osteoporosis NNP N
was VBD N
prevalent VBN N
in IN N
low JJ N
ASM NNP N
groups NNS N
( ( N
SS NNP N
and CC N
SO NNP N
) ) N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
, , N
particularly RB N
in IN N
the DT N
SO NNP N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
response NN N
to TO N
test VB N
drug NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
. . N

Effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
gastric JJ N
emptying NN N
of IN N
solids NNS N
in IN N
Japanese JJ p
smokers NNS p
: : p
a DT N
crossover NN N
study NN N
using VBG N
the DT N
13C-octanoic JJ N
acid NN N
breath NN N
test NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
preprocedural JJ o
baseline NN o
pain NN o
from IN N
the DT N
control NN N
group NN N
, , N
compared VBN N
with IN N
the DT N
experimental JJ N
group NN N
. . N

OBJECTIVES IN N
We PRP N
postulated VBD N
that IN N
femoral JJ N
vein JJ N
delivery NN N
of IN N
contrast NN N
medium NN N
because IN N
of IN N
streaming NN N
, , N
might MD N
enhance VB N
precordial JJ N
echocardiographic JJ N
detection NN N
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
if IN N
sevoflurane JJ i
administration NN N
could MD N
exert VB N
myocardial JJ o
protection NN o
during IN N
following VBG N
coronary JJ N
occlusion NN N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

The DT N
higher JJR N
mortality NN o
rate NN o
among IN N
the DT N
patients NNS N
with IN N
hypermagnesemia NN N
is VBZ N
attributable JJ N
to TO N
older JJR N
age NN N
, , N
more RBR N
advanced JJ N
heart NN N
failure NN N
and CC N
renal JJ N
insufficiency NN N
. . N

The DT N
tyrosine NN N
kinase NN N
receptor NN N
EGFR NNP N
pathway NN N
is VBZ N
one CD N
of IN N
the DT N
oncogenic JJ N
signaling NN N
cascades NNS N
involved VBN N
in IN N
lung NN p
cancer NN p
, , p
mediating VBG p
the DT p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
gene NN p
EGFR NNP p
. . p

CONCLUSIONS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
CAC NNP o
progression NN o
or CC o
changes NNS o
in IN o
bone NN o
remodeling NN o
between IN N
the DT N
calcium NN N
and CC N
the DT N
sevelamer NN N
groups NNS N
. . N

Patients NNS o
' POS o
vital JJ o
signs NNS o
, , o
additional JJ o
analgesic NN o
requests NNS o
, , o
PONV NNP o
( ( o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
) ) o
and CC o
other JJ o
side NN o
effects NNS o
were VBD N
registered VBN N
. . N

METHODS NNP N
Sixty NNP p
ASA NNP p
class NN p
I PRP p
patients NNS p
scheduled VBN p
for IN p
herniorrhapy NN p
under IN p
spinal JJ p
anesthesia NN p
were VBD N
assigned VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ o
rates NNS o
of IN N
the DT N
rectal JJ p
carcinoma NN p
patients NNS p
receiving VBG p
radiotherapy NN i
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

CONCLUSION NNP N
Disease NNP N
activity NN N
in IN N
RA NNP N
is VBZ N
reduced VBN N
by IN N
tocilizumab NN N
treatment NN N
, , N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
composite JJ N
measure NN N
used VBN N
to TO N
evaluate VB N
disease NN o
activity NN o
. . o

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
interleukin-1 JJ i
receptor NN i
antagonist NN i
( ( i
IL-1Ra NNP i
) ) i
on IN N
synovial JJ N
tissue NN N
in IN N
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

Tonsillar JJ o
focal JJ o
infection NN o
( ( o
TFI NNP o
) ) o
and CC o
dental JJ o
focal JJ o
infection NN o
( ( o
DFI NNP o
) ) o
were VBD N
found VBN N
in IN N
6/20 CD p
and CC p
17/20 CD p
patients NNS p
, , p
respectively RB p
. . p

Bacteriologic NNP N
studies NNS N
of IN N
feces NNS N
and CC N
colon NN N
content NN N
revealed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN o
of IN o
aerobic JJ o
bacteria NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

UNLABELLED IN N
We PRP N
estimated VBD N
the DT N
cost-effectiveness NN N
of IN N
hemiarthroplasty NN i
compared VBN i
to TO i
internal JJ i
fixation NN i
for IN N
elderly JJ p
patients NNS p
with IN p
displaced JJ p
femoral JJ p
neck NN p
fractures NNS p
. . p

Children NNP o
's POS o
IQs NNP o
and CC o
language NN o
comprehension NN o
did VBD N
not RB N
increase VB N
, , N
but CC N
adaptive/social JJ o
behavior NN o
scores NNS o
and CC o
expressive JJ o
language NN o
quotients NNS o
decreased VBN o
. . o

The DT N
larval JJ o
negative JJ o
conversion NN o
rates NNS o
of IN o
Ancylostoma NNP o
duodenale NN o
and CC o
Necator NNP o
americanus VBP o
were VBD N
77.7 CD N
and CC N
83.2 CD N
% NN N
respectively RB N
. . N

CONCLUSIONS NNP N
EPL NNP N
and CC N
LPL NNP N
are VBP N
as IN N
feasible JJ N
and CC N
effective JJ N
as IN N
TPL NNP N
and CC N
can MD N
be VB N
adequately RB N
performed VBN N
with IN N
a DT N
reasonable JJ N
complication NN N
rate NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
repeated VBD N
sensory JJ N
inputs NNS N
could MD N
enhance VB N
brain NN N
plasticity NN N
and CC N
cortical JJ N
motor NN N
output NN N
. . N

BACKGROUND/AIMS NNP N
Retrospective NNP N
studies NNS N
suggest VBP N
that IN N
the DT N
prognosis NN N
of IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
variceal NN p
hemorrhage NN p
has VBZ N
improved VBN N
in IN N
more RBR N
recent JJ N
decades NNS N
. . N

Running VBG N
in IN N
parallel NN N
with IN N
the DT N
main JJ N
study NN N
is VBZ N
a DT N
prospective JJ N
economic JJ N
analysis NN N
, , N
the DT N
objectives NNS N
of IN N
which WDT N
are VBP N
( ( N
1 CD N
) ) N
to TO N
estimate VB N
the DT N
effectiveness NN N
of IN N
pravastatin NN i
compared VBN N
with IN N
placebo NN i
in IN N
terms NNS N
of IN N
survival NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
and CC o
quality-adjusted JJ o
life-years NNS o
( ( o
QALY NNP o
) ) o
; : o
( ( N
2 CD N
) ) N
to TO N
estimate VB N
the DT N
resource NN N
usage NN N
associated VBN N
with IN N
pravastatin NNS i
compared VBN N
with IN N
placebo-in JJ N
particular JJ N
, , N
to TO N
study VB N
whether IN N
it PRP N
alters VBZ N
resource JJ N
usage NN N
through IN N
prevention NN N
of IN N
disease NN N
progression NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
use VB N
this DT N
information NN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
with IN N
cost NN N
per IN N
quality-adjusted JJ N
life-year JJ N
as IN N
the DT N
unit NN N
of IN N
analysis NN N
. . N

The DT N
total JJ N
amount NN N
of IN N
protein NN N
deaminated VBN N
and CC N
the DT N
amino NN N
groups NNS N
incorporated VBD N
into IN N
urea NN N
was VBD N
calculated VBN N
to TO N
be VB N
approximately RB N
20-23 JJ N
g. VBP N
The DT N
net JJ N
amount NN N
of IN N
glucose NN N
estimated VBN N
to TO N
be VB N
produced VBN N
, , N
based VBN N
on IN N
the DT N
quantity NN o
of IN o
amino JJ o
acids NNS o
deaminated VBD o
, , N
was VBD N
approximately RB N
11-13 JJ N
g. NN N
However RB N
, , N
the DT N
amount NN o
of IN o
glucose JJ o
appearing VBG o
in IN N
the DT N
circulation NN N
was VBD N
only RB N
approximately RB N
2 CD N
g. VBD N
The DT N
peripheral JJ o
plasma NN o
glucose JJ o
concentration NN o
decreased VBN N
by IN N
approximately RB N
1 CD N
mM NNS N
after IN N
ingestion NN N
of IN N
either DT N
protein NN N
or CC N
water NN N
, , N
confirming VBG N
that IN N
ingested JJ N
protein NN N
does VBZ N
not RB N
result VB N
in IN N
a DT N
net JJ N
increase NN N
in IN N
glucose JJ N
concentration NN N
, , N
and CC N
results NNS N
in IN N
only RB N
a DT N
modest JJ N
increase NN N
in IN N
the DT N
rate NN o
of IN o
glucose JJ o
disappearance NN o
. . o

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
include VB N
PMO NNP p
patients NNS p
( ( p
postmenopausal JJ p
women NNS p
; : p
aged VBN p
between IN p
50 CD p
and CC p
70 CD p
years NNS p
; : p
have VBP p
been VBN p
postmenopausal VBN p
for IN p
at IN p
least JJS p
5 CD p
years NNS p
and CC p
diagnosed VBD p
with IN p
OP NNP p
using VBG p
proximal JJ p
femur JJ p
T-score NN p
) ) p
with IN p
concomitant JJ p
lumbar NN p
OA NNP p
( ( p
patients NNS p
with IN p
confounding VBG p
disorders NNS p
like IN p
diabetes NNS p
, , p
hypertension NN p
, , p
hyperlipidemia NN p
, , p
and CC p
previous JJ p
fracture NN p
history NN p
, , p
etcetera NN p
, , p
will MD p
be VB p
excluded VBN p
) ) p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
two CD N
arms NNS N
: : N
PEMFs NNP i
group NN i
and CC i
sham NN i
PEMFs NNP i
group NN N
. . N

PURPOSE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
1 CD N
) ) N
describe NN N
elements NNS N
of IN N
the DT N
financial JJ N
and CC N
quality-of-life JJ o
burden NN o
of IN o
dysfunctional JJ o
uterine JJ o
bleeding NN o
( ( p
DUB NNP p
) ) p
from IN p
the DT p
perspective NN p
of IN p
women NNS p
who WP p
agreed VBD p
to TO p
obtain VB p
surgical JJ p
treatment NN p
; : p
2 CD p
) ) p
explore NN N
associations NNS N
between IN N
DUB NNP N
symptom NN N
characteristics NNS N
and CC N
the DT N
financial JJ N
and CC N
quality-of-life JJ N
burden NN N
; : N
3 CD N
) ) N
estimate VBP N
the DT N
annual JJ N
dollar NN N
value NN N
of IN N
the DT N
financial JJ N
burden NN N
; : N
and CC N
4 CD N
) ) N
estimate VBP N
the DT N
most RBS N
that DT N
could MD N
be VB N
spent VBN N
on IN N
surgery NN N
to TO N
eliminate VB N
DUB NNP N
symptoms NNS N
for IN N
which WDT N
medical JJ N
treatment NN N
has VBZ N
been VBN N
unsuccessful JJ N
that WDT N
would MD N
result VB N
in IN N
a DT N
$ $ N
50,000/quality-adjusted JJ N
life-year JJ N
incremental JJ N
cost-effectiveness NN N
ratio NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
lipotoxicity NN i
on IN N
beta-cell NN N
function NN N
, , N
eight CD p
obese JJ p
African JJ p
Americans NNPS p
with IN p
KPDM NNP p
, , p
eight CD p
obese JJ p
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
with IN p
severe JJ p
hyperglycemia NN p
without IN p
ketosis NN p
( ( p
ketosis-resistant JJ p
type NN p
2 CD p
diabetes NNS p
) ) p
, , p
and CC p
nine CD p
nondiabetic JJ p
obese NNS p
control NN p
subjects VBZ p
underwent JJ p
intravenous JJ i
infusion NN i
of IN i
20 CD i
% NN i
intralipid NN i
at IN N
40 CD N
ml/h NN N
for IN N
48 CD N
h. JJ N
beta-Cell NN N
function NN N
was VBD N
assessed VBN N
by IN N
changes NNS N
in IN N
insulin NN N
and CC N
C-peptide JJ N
concentration NN N
during IN N
infusions NNS N
and CC N
by IN N
changes NNS N
in IN N
acute JJ o
insulin NN o
response NN o
to TO o
arginine VB o
stimulation NN o
( ( o
AIR NNP o
( ( o
arg NN o
) ) o
) ) o
before IN N
and CC N
after IN N
lipid JJ N
infusion NN N
. . N

Tissue NN p
samples NNS p
from IN p
93 CD p
de NNS p
novo FW p
diffuse RB p
large JJ p
B-cell NNP p
lymphoma NN p
patients NNS p
seen VBN p
between IN p
1995 CD p
and CC p
2009 CD p
randomly NN p
receiving VBG p
either CC p
standard JJ i
combination NN i
chemotherapy NN i
( ( i
CHOP NNP i
, , i
n=48 NN i
) ) i
or CC i
the DT i
identical JJ i
program NN i
with IN i
rituximab NN i
( ( N
n=45 JJ N
) ) N
were VBD N
subtyped VBN N
using VBG N
an DT N
investigational JJ N
immunohistochemical NN N
( ( N
IHC NNP N
) ) N
based VBN N
tissue NN N
microarray NN N
( ( N
TMA NNP N
) ) N
and CC N
contrasted VBN N
to TO N
the DT N
approximately RB N
corresponding JJ N
categories NNS N
as IN N
defined VBN N
either CC N
by IN N
Hans NNPS N
and CC N
associates NNS N
using VBG N
a DT N
three CD N
marker NN N
panel NN N
into IN N
germinal JJ N
or CC N
non-germinal JJ N
centre NN N
subtypes NNS N
or CC N
by IN N
Choi NNP N
and CC N
colleagues NNS N
with IN N
two CD N
additional JJ N
antibodies NNS N
into IN N
germinal JJ N
centre NN N
( ( N
GCB NNP N
) ) N
or CC N
activated VBN N
B-cells NNP N
( ( N
ABC NNP N
) ) N
. . N

In IN N
this DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aerosolized JJ i
albuterol NN i
with IN i
the DT i
dry JJ i
powder NN i
formulation NN N
, , N
231 CD p
patients NNS p
with IN p
chronic JJ p
reversible JJ p
obstructive JJ p
airway NN p
disease NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
placebo NN i
albuterol NN i
aerosol NN i
followed VBD i
immediately RB i
by IN i
active JJ i
albuterol NN i
powder NN i
( ( i
200 CD i
micrograms NNS i
) ) i
or CC i
active JJ i
albuterol NN i
aerosol NN i
( ( N
two CD N
puffs NNS N
, , N
180 CD N
micrograms NNS N
) ) N
followed VBD N
immediately RB N
by IN N
placebo NN i
lactose JJ i
powder NN i
four CD N
times NNS N
a DT N
day NN N
for IN N
a DT N
period NN N
of IN N
12 CD N
weeks NNS N
. . N

We PRP N
formulated VBD N
four CD N
specific JJ N
questions NNS N
: : N
( ( N
1 CD N
) ) N
can MD N
a DT N
concurrent JJ N
SAS NNP N
shorten VBD N
the DT N
onset NN N
of IN N
automatic JJ N
postural JJ N
responses NNS N
? . N
; : N
and CC N
if IN N
so RB N
( ( N
2 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
forward RB N
versus FW N
backward NN N
perturbations NNS N
? . N
; : N
( ( N
3 CD N
) ) N
does VBZ N
this DT N
effect NN N
depend NN N
on IN N
prior JJ N
knowledge NN N
of IN N
the DT N
perturbation NN N
direction NN N
? . N
; : N
and CC N
( ( N
4 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
low- JJ N
and CC N
high-magnitude JJ N
perturbations NNS N
? . N
Balance NNP N
was VBD N
perturbed VBN N
in IN N
11 CD p
healthy JJ p
participants NNS p
by IN p
a DT p
movable JJ p
platform NN p
that IN p
suddenly RB p
translated VBN p
forward RB p
or CC p
backward RB p
. . p

METHODS NNP N
This DT N
phase NN N
III NNP N
prospective NN N
, , N
randomized VBN N
, , N
and CC N
stratified VBD N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
four CD N
courses NNS N
of IN N
combined JJ i
fluorouracil NN i
( ( i
1000 CD i
mg NN i
per IN i
square JJ i
meter NN i
of IN i
body-surface JJ i
area NN i
daily RB i
for IN i
four CD i
days NNS i
) ) i
and CC i
cisplatin NN i
( ( i
75 CD i
mg NN i
per IN i
square JJ i
meter NN i
on IN i
the DT i
first JJ i
day NN i
) ) i
plus CC i
5000 CD i
cGy NN i
of IN i
radiation NN i
therapy NN i
, , i
as IN i
compared VBN i
with IN i
6400 CD i
cGy NN i
of IN i
radiation NN i
therapy NN i
alone RB i
, , N
in IN N
patients NNS p
with IN p
squamous-cell JJ p
carcinoma NN p
or CC p
adenocarcinoma NN p
of IN p
the DT p
thoracic NN p
esophagus NN p
. . p

METHODS NNP N
Between NNP p
1999 CD p
and CC p
2002 CD p
, , p
1397 CD p
antiretroviral-treatment-naive JJ p
patients NNS p
, , p
presenting VBG p
at IN p
18 CD p
clinical JJ p
trial NN p
units NNS p
with IN p
80 CD p
research NN p
sites NNS p
in IN p
the DT p
USA NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
1:1:1 CD N
to TO N
a DT N
protease NN i
inhibitor NN i
( ( i
PI NNP i
) ) i
strategy NN i
( ( i
PI NNP i
plus CC i
nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitor NN i
[ NNP i
NRTI NNP i
] NNP i
; : i
n=470 NN i
) ) i
, , i
a DT i
non-nucleoside JJ i
reverse NN i
transcriptase NN i
inhibitor NN i
( ( i
NNRTI NNP i
) ) i
strategy NN i
( ( i
NNRTI NNP i
plus CC i
NRTI NNP i
; : i
n=463 NN i
) ) i
, , i
or CC i
a DT i
three-class JJ i
strategy NN i
( ( i
PI NNP i
plus CC i
NNRTI NNP i
plus CC i
NRTI NNP i
; : i
n=464 NN N
) ) N
. . N

We PRP N
measured VBD N
the DT N
plasma JJ o
concentrations NNS o
of IN o
IL-6 NNP o
and CC o
IL-8 NNP o
at IN N
the DT N
start NN N
of IN N
every DT N
hemoperfusion NN N
treatment NN N
, , N
and CC N
the DT N
following JJ N
parameters NNS N
were VBD N
compared VBN N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
hemoperfusion NN N
group NN N
on IN N
days NNS N
3 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
: : N
hemodynamics NNS o
( ( o
cardiac JJ o
index NN o
, , o
systemic JJ o
vascular NN o
resistance NN o
index NN o
, , o
heart NN o
rate NN o
, , o
and CC o
mean JJ o
arterial JJ o
pressure NN o
) ) o
; : o
change NN o
of IN o
hematology NN o
and CC o
coagulation NN o
function NN o
; : o
organ JJ o
function NN o
; : o
and CC o
the DT o
sequential JJ o
organ JJ o
failure NN o
assessment NN o
( ( o
SOFA NNP o
) ) o
score NN o
. . o

In IN N
each DT N
case NN N
of IN N
acute JJ p
promyelocytic JJ p
leukemia NN p
( ( p
APL NNP p
) ) p
one CD N
of IN N
three CD N
PML-RAR JJ N
alpha NN N
mRNA NN N
types NNS N
is VBZ N
produced VBN N
, , N
depending VBG N
on IN N
the DT N
break/fusion NN N
site NN N
in IN N
the DT N
PML NNP N
gene NN N
that WDT N
is VBZ N
linked VBN N
to TO N
a DT N
common JJ N
RAR NNP N
alpha JJ N
gene NN N
segment NN N
: : N
a DT N
short JJ N
( ( N
S NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
3 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
a DT N
long JJ N
( ( N
L NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
6 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
or CC N
a DT N
variable JJ N
( ( N
V NNP N
) ) N
-form NN N
type NN N
, , N
variably RB N
deleted VBD N
PML NNP N
exon VBD N
6 CD N
RAR NNP N
alpha NN N
exon VBD N
3 CD N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1988 CD p
and CC p
December NNP p
1992 CD p
, , p
231 CD p
patients NNS p
with IN p
estrogen JJ p
receptor NN p
( ( p
ER NNP p
) ) p
-positive CD p
or CC p
ER-unknown JJ p
metastatic JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil VB i
? . i
) ) i
or CC i
chemohormonal JJ i
therapy NN i
( ( i
CAF NNP i
plus CC i
tamoxifen NN i
and CC i
Halotestin NNP i
? . i
; : i
Pharmacia-Upjohn NNP i
, , i
Kalamazoo NNP i
, , i
MI NNP i
? . i
) ) i
as IN i
front-line JJ i
therapy NN i
for IN N
metastatic JJ p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
Fifty NNP p
patients NNS p
with IN p
early JJ p
cervical JJ p
cancer NN p
( ( p
FIGO NNP p
stages VBZ p
IA2 NNP p
, , p
IB1 NNP p
, , p
IIA NNP p
< VBZ p
2 CD p
cm NN p
) ) p
or CC p
locally RB p
advanced JJ p
cervical JJ p
cancer NN p
( ( p
FIGO NNP p
stages VBZ p
IB2 NNP p
, , p
IIA NNP p
> NNP p
2cm CD p
, , p
IIB NNP p
) ) p
who WP p
received VBD p
neoadjuvant JJ i
treatment NN i
( ( i
chemotherapy NN i
or CC i
radiochemotherapy NN i
) ) i
and CC p
demonstrated VBD p
a DT p
complete JJ p
or CC p
partial JJ p
clinical JJ p
response NN p
and CC p
early JJ p
stage NN p
endometrioid JJ p
endometrial JJ p
cancer NN p
( ( p
FIGO NNP p
stages VBZ p
IB NNP p
, , p
II NNP p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO p
undergo VB p
TB NNP p
( ( p
arm IN p
A NNP p
) ) p
or CC p
SES NNP p
( ( p
arm NN p
B NNP p
) ) p
. . p

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS N
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT N
pictorial JJ N
flip NN N
chart NN N
to TO N
describe VB N
atrial JJ N
fibrillation NN N
; : N
the DT N
consequences NNS N
of IN N
a DT N
minor JJ N
stroke NN N
, , N
a DT N
major JJ N
stroke NN N
, , N
and CC N
a DT N
major JJ N
bleeding NN N
episode NN N
; : N
the DT N
chance NN N
of IN N
stroke NN N
if IN N
not RB N
taking VBG N
warfarin NN N
; : N
the DT N
chance NN N
of IN N
a DT N
major JJ N
bleeding NN N
episode NN N
if IN N
taking VBG N
warfarin NN N
; : N
examples NNS N
of IN N
the DT N
inconvenience NN N
, , N
minor JJ N
side NN N
effects NNS N
, , N
and CC N
costs NNS N
of IN N
warfarin JJ N
therapy NN N
; : N
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN N
methods NNS N
to TO N
determine VB N
their PRP$ N
MCIDs NNP N
( ( N
the DT N
smallest JJS N
reduction NN N
in IN N
stroke NN N
risk NN N
at IN N
which WDT N
the DT N
patients NNS N
were VBD N
willing JJ N
to TO N
take VB N
warfarin NN N
) ) N
. . N

METHODOLOGY NNP N
One CD p
hundred CD p
and CC p
ninety-three JJ p
( ( p
193 CD p
) ) p
H. NNP p
pylori-positive JJ p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
the DT p
following JJ p
7-day JJ p
treatments NNS p
: : p
Group NNP p
A NNP p
( ( p
N NNP p
= NNP p
64 CD p
) ) p
: : p
amoxicillin NN i
, , i
clarithromycin NN i
and CC i
rabeprazole NN i
; : i
Group NNP p
B NNP p
( ( p
N NNP p
= NNP p
64 CD p
) ) p
: : p
tinidazole NN i
, , i
clarithromycin NN i
and CC i
ranitidine NN i
bismuth NN i
citrate NN i
; : i
Group NNP N
C NNP N
( ( N
N NNP N
= NNP N
65 CD N
) ) N
: : N
tinidazole NN i
, , i
clarithromycin NN i
and CC i
rabeprazole JJ i
Eradication NNP i
was VBD N
assessed VBN N
by IN N
13C-Urea JJ N
Breath NNP N
Test NNP N
6-8 JJ N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
therapy NN N
. . N

Measures NNS o
of IN o
the DT o
relative JJ o
areas NNS o
under IN o
the DT o
power NN o
spectral JJ o
curve NN o
were VBD N
made VBN N
for IN N
each DT N
of IN N
the DT N
following JJ N
frequency NN N
bands NNS N
: : N
slow VB N
alpha NN N
( ( N
7.5 CD N
to TO N
10 CD N
Hz NNP N
) ) N
; : N
fast VBN N
alpha NN N
( ( N
10.5 CD N
to TO N
13.0 CD N
Hz NNP N
) ) N
; : N
slow JJ N
beta NN N
( ( N
13.5 CD N
to TO N
19.5 CD N
Hz NNP N
) ) N
; : N
and CC N
fast VB N
beta NN N
( ( N
20 CD N
to TO N
26 CD N
Hz NNP N
) ) N
at IN N
electrodes NNS N
F3 NNP N
, , N
F4 NNP N
, , N
C3 NNP N
, , N
C4 NNP N
, , N
P3 NNP o
, , o
P4 NNP o
, , o
O1 NNP o
, , o
and CC o
O2 NNP o
. . o

In IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
, , N
60 CD p
treatment-resistant JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
mean VB p
age=14.5 RB p
? . p
2.4 CD p
years NNS p
) ) p
, , p
with IN p
moderate JJ p
to TO p
severe VB p
OCD NNP p
( ( p
mean JJ p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive-Compulsive JJ p
Scale NNP p
( ( p
CY-BOCS NNP p
) ) p
=28.2 NN p
? . p
3.7 CD p
) ) p
, , p
17 CD p
of IN p
whom WP p
also RB p
had VBD p
concomitant JJ p
autism NN p
spectrum NN p
disorder NN p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
riluzole NN i
( ( i
final JJ i
dose NN i
of IN i
100 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
in IN i
addition NN i
to TO i
the DT i
existing VBG i
treatment NN i
regimen NNS i
. . i

A DT N
meta-analysis NN N
of IN N
the DT N
pooled JJ N
results NNS N
from IN N
six CD N
double-blind JJ N
trials NNS N
showed VBD N
that IN N
risperidone NN i
at IN N
doses NNS N
ranging VBG N
from IN N
4 CD N
to TO N
8 CD N
mg/day NN N
had VBD N
a DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
higher JJR N
negative JJ o
symptom JJ o
response NN o
rate NN o
, , N
defined VBN N
as IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
20 CD N
% NN N
or CC N
more JJR N
reduction NN o
in IN o
scores NNS o
on IN o
the DT o
negative JJ o
subscale NN o
of IN o
the DT o
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
, , N
than IN N
patients NNS N
receiving VBG N
active JJ N
controls NNS N
. . N

METHODS NNP N
Full-term NNP p
newborns NNS p
and CC p
children NNS p
( ( p
n JJ p
= NNP p
488 CD p
) ) p
through IN p
8 CD p
yr NN p
of IN p
age NN p
who WP p
required VBD p
general JJ p
anesthesia NN p
and CC p
tracheal JJ p
intubation NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either CC N
a DT N
cuffed NN i
tube NN i
sized VBN i
by IN i
a DT i
new JJ i
formula NN i
[ NN i
size NN i
( ( i
mm JJ i
internal JJ i
diameter NN i
) ) i
= NN i
( ( i
age/4 NN i
) ) i
+ VBZ i
3 CD i
] NN i
, , i
or CC i
an DT i
uncuffed JJ i
tube NN i
sized VBN i
by IN i
the DT i
modified JJ i
Cole NNP i
's POS i
formula NN i
[ NN i
size NN i
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
4 CD N
] NN N
. . N

World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
improved VBN o
in IN N
19 CD N
and CC N
was VBD N
unchanged JJ N
in IN N
10 CD N
; : N
exercise NN N
capacity NN N
significantly RB N
improved VBN N
with IN N
the DT N
6-minute JJ o
walk NN o
distance NN o
, , N
improving VBG N
on IN N
follow-up NN N
from IN N
455.7 CD N
? . N
71.5 CD N
to TO N
498 CD N
? . N
70 CD N
m NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
and CC N
peak JJ o
oxygen NN o
consumption NN o
increasing VBG N
from IN N
25.5 CD N
? . N
10.2 CD N
to TO N
27.4 CD N
? . N
10 CD N
( ( N
p NN N
= RB N
0.04 CD N
) ) N
. . N

Peak NNP o
levels NNS o
of IN o
total JJ o
TFPI NNP o
activity NN o
and CC o
free JJ o
TFPI NNP o
antigen NN o
were VBD N
detected VBN N
1 CD N
h NN N
after IN N
injection NN N
, , N
whereas IN N
maximal JJ o
prolongation NN o
of IN o
activated VBN o
partial JJ o
thromboplastin NN o
time NN o
( ( o
APTT NNP o
) ) o
and CC o
peak JJ o
levels NNS o
of IN o
anti-factor JJ o
Xa NNP o
activity NN o
and CC o
anti-factor NN o
IIa NNP o
activity NN o
were VBD N
detected VBN N
after IN N
4 CD N
h. NN N
On IN N
UFH NNP i
administered VBD N
twice RB N
daily RB N
, , N
free JJ o
TFPI NNP o
antigen NN o
decreased VBN N
by IN N
44 CD N
% NN N
from IN N
baseline JJ N
level NN N
before IN N
the DT N
first JJ N
injection NN N
on IN N
day NN N
1 CD N
to TO N
pre-injection NN N
level NN N
on IN N
day NN N
5 CD N
. . N

METHODS NNP N
Thirty NNP p
subjects NNS p
( ( p
8 CD p
men NNS p
and CC p
22 CD p
women NNS p
) ) p
who WP p
had VBD p
minor JJ p
RAS NNP p
at IN p
least JJS p
once RB p
a DT p
month NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
soybean JJ i
oil NN i
group NN i
or CC i
a DT i
perilla JJ i
oil NN i
group NN i
in IN i
a DT i
double-blind JJ i
manner NN i
( ( i
experimental JJ i
phase NN i
) ) i
after IN i
a DT i
run-in JJ i
phase NN i
of IN i
4 CD i
mo NN i
during IN i
which WDT i
subjects NNS i
used VBD i
a DT i
reference NN i
oil NN i
, , i
the DT i
most RBS i
popular JJ i
cooking NN i
oil NN i
in IN i
Japan NNP i
, , i
or CC i
a DT i
50/50 CD i
mixture NN i
of IN i
soybean JJ i
oil NN i
and CC i
rapeseed NN i
oil NN i
. . i

In IN N
an DT N
analysis NN N
of IN N
82 CD p
children NNS p
who WP N
received VBD N
a DT N
full JJ N
course NN N
of IN N
6 CD N
days NNS N
or CC N
more JJR N
of IN N
AmB NNP i
( ( N
117 CD N
courses NNS N
) ) N
, , N
it PRP N
was VBD N
shown VBN N
that IN N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
plasma JJ o
urea JJ o
and CC o
creatinine JJ o
concentrations NNS o
and CC o
in IN o
potassium NN o
requirement NN o
after IN N
6 CD N
days NNS N
of IN N
therapy NN N
with IN N
both DT N
AmB NNP N
infused VBN N
in IN N
dextrose NN N
and CC N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
of IN N
AmB NNP N
administration NN N
. . N

CONCLUSION NNP N
( ( N
1 CD N
) ) N
Serum NNP N
level NN N
of IN N
sCD44v6 NN N
could MD N
be VB N
taken VBN N
as IN N
the DT N
criterion NN N
for IN N
evaluating VBG N
the DT N
development NN N
and CC N
prognosis NN N
of IN N
gastric JJ N
cancer NN N
, , N
as RB N
well RB N
as IN N
the DT N
therapeutic JJ N
target NN N
for IN N
anti-metastasis JJ N
treatment NN N
; : N
( ( N
2 CD N
) ) N
Serum NNP N
level NN N
of IN N
sCD44v6 NN N
is VBZ N
related VBN N
to TO N
some DT N
extent NN N
with IN N
TCM NNP N
type NN N
of IN N
blood NN N
stasis NN N
and CC N
Pi-deficiency NN N
; : N
( ( N
3 CD N
) ) N
WTC NNP i
combined VBN i
with IN i
chemotherapy NN i
could MD N
further RB N
inhibit VB N
the DT N
expression NN N
of IN N
serum NN N
sCD44v6 NN N
in IN N
gastric JJ p
carcinoma NN p
patients NNS p
. . p

SPEM NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
double-blind NN N
study NN N
performed VBD N
to TO N
test VB N
the DT N
acute NN N
and CC N
chronic JJ N
electrophysiological JJ N
behavior NN N
of IN N
three CD N
different JJ N
ventricular JJ N
leads NNS N
: : N
( ( N
1 CD N
) ) N
an DT N
ion NN N
exchange NN N
membrane NN N
with IN N
30-microgram JJ i
dexamethasone NN i
elution NN i
in IN i
a DT i
contoured JJ i
activated JJ i
carbon NN i
tip NN i
lead NN i
( ( i
Membrane NNP i
1400T CD i
, , i
30 CD i
patients NNS i
) ) i
; : i
( ( i
2 CD i
) ) i
the DT i
same JJ i
lead NN i
design NN i
without IN i
steroid NN i
( ( i
Membrane NNP i
1401T CD i
, , i
24 CD i
patients NNS i
) ) i
; : i
and CC i
( ( i
3 CD i
) ) i
the DT i
same JJ i
lead NN i
design NN i
without IN i
steroid NN i
or CC i
membrane NN i
( ( i
control NN i
group NN N
, , N
27 CD N
patients NNS N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Eighty NNP p
patients NNS p
with IN p
CD20 NNP p
( ( p
+ NNP p
) ) p
lymphoma NN p
and CC p
resolved VBD p
hepatitis NN p
B NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
prophylactic JJ i
entecavir NN i
( ( i
ETV NNP i
) ) i
before IN i
chemotherapy NN i
to TO i
3 CD i
months NNS i
after IN i
completing VBG i
chemotherapy NN i
( ( i
ETV NNP i
prophylactic JJ i
group NN i
, , i
n RB i
= VBZ i
41 CD i
) ) i
or CC i
to TO i
receive VB i
therapeutic JJ i
ETV NNP i
at IN N
the DT N
time NN N
of IN N
HBV NNP i
reactivation NN i
and CC i
hepatitis NN i
B NNP i
surface NN i
antigen NN i
( ( i
HBsAg NNP i
) ) i
reverse NN i
seroconversion NN i
since IN i
chemotherapy NN i
( ( N
control NN N
group NN N
, , N
n RB N
= VBZ N
39 CD N
) ) N
. . N

The DT N
following NN N
are VBP N
the DT N
primary JJ N
outcomes NNS N
to TO N
be VB N
measured VBN N
: : N
( ( N
1 CD N
) ) N
the DT N
trajectories NNS N
of IN N
the DT N
left NN o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
the DT N
follow-up JJ N
period NN N
; : N
( ( N
2 CD N
) ) N
reduction NN N
of IN N
heart NN o
disease NN o
progression NN o
rates NNS o
, , N
with IN N
progression NN N
defined VBN N
as IN N
a DT N
10 CD N
% NN N
decrease NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
; : o
and CC o
( ( o
3 CD o
) ) o
rate NN o
of IN o
hospital NN o
admissions NNS o
attributable JJ o
to TO o
dysrhythmia VB o
, , o
heart NN o
failure NN o
or CC o
stroke NN o
due JJ N
to TO N
Chagas NNP N
disease NN N
. . N

The DT N
blood NN N
samples NNS N
were VBD N
collected VBN N
for IN N
e NN N
same JJ N
measurements NNS N
of IN N
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
and CC o
tumor JJ o
necrosis NN o
factor NN o
( ( o
TNF- NNP o
) ) o
by IN o
enzyme NN o
linked VBN o
immunosorbent JJ o
assay NN o
( ( o
ELISA NNP o
) ) o
, , o
and CC o
for IN o
the DT o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
lactic JJ o
acid NN o
dehydrogenase NN o
( ( o
LDH NNP o
) ) o
, , o
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
, , o
amylase NN o
and CC o
lipase NN o
by IN N
biochemistry NN N
assay VBP N
1 CD N
day NN N
before IN N
intervention NN N
of IN N
nutrition NN N
, , N
and CC N
7 CD N
days NNS N
and CC N
14 CD N
days NNS N
after IN N
intervention NN N
. . N

METHODS NNP N
Patients NNS p
aged VBD p
25 CD p
to TO p
74 CD p
years NNS p
attending VBG p
community NN p
pharmacies NNS p
with IN p
a DT p
prescription NN p
for IN p
at IN p
least JJS p
1 CD p
drug NN p
indicated VBN p
for IN p
CVD NNP p
or CC p
CV NNP p
risk NN p
factors NNS p
were VBD p
randomized VBN p
to TO p
2 CD p
groups NNS p
: : p
an DT p
intervention NN i
group NN i
that WDT i
received VBD i
pharmaceutical JJ i
care NN i
, , i
which WDT i
was VBD i
provided VBN i
by IN i
specially RB i
trained JJ i
pharmacists NNS i
working VBG i
in IN i
collaboration NN i
with IN i
physicians NNS i
, , i
and CC i
a DT i
control NN i
group NN i
that WDT i
received VBD i
usual JJ i
care NN i
( ( i
routine JJ i
dispensing VBG i
counseling NN i
) ) i
and CC i
verbal JJ i
and CC i
written VBN i
counseling VBG i
regarding VBG i
CVD NNP i
prevention NN i
. . i

METHOD NNP N
Two CD p
hundred VBD p
eighteen JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
6-17 CD p
years NNS p
) ) p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
, , p
and CC p
with IN p
behaviors NNS p
such JJ p
as IN p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
symptoms NNS p
, , N
were VBD N
randomized VBN N
1:1:1:1 CD N
to TO N
aripiprazole VB i
( ( N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
mg/day NN N
) ) N
or CC N
placebo NN i
in IN N
this DT N
8-week JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
parallel-group JJ N
study NN N
. . N

This DT N
study NN N
showed VBD N
that IN N
in IN N
symptomatic JJ p
patients NNS p
with IN p
moderate-to-severe JJ p
asthma NN p
, , p
Salm/FP NNP p
( ( p
50/250 CD p
microg RB p
bd NN p
) ) p
, , N
administered VBN N
in IN N
a DT N
single JJ N
convenient NN N
device NN N
( ( N
Diskus NNP N
) ) N
, , N
was VBD N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
an DT N
approximately RB N
three-fold JJ N
higher JJR N
microgram NN N
corticosteroid VBP N
dose NN N
of IN N
Bud NNP N
( ( N
800 CD N
microg RB N
bd NN N
) ) N
given VBN N
concurrently RB N
with IN N
Form NNP N
( ( N
12 CD N
microg RB N
bd NN N
) ) N
in IN N
terms NNS N
of IN N
improvement NN N
in IN N
PEFam NNP N
, , N
and CC N
superior JJ N
at IN N
reducing VBG N
exacerbations NNS N
and CC N
nights NNS N
with IN N
symptoms NNS N
or CC N
night-time JJ N
awakenings NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
, , N
477 CD p
women NNS p
with IN p
anemia NN p
, , p
iron NN p
deficiency NN p
, , p
and CC p
heavy JJ p
uterine JJ p
bleeding NN p
were VBD N
assigned VBN N
to TO N
receive VB N
either DT N
IV NNP i
ferric NN i
carboxymaltose NN i
( ( N
< JJ N
or=1000 NN N
mg NN N
over IN N
15 CD N
min NNS N
, , N
repeated VBD N
weekly JJ N
to TO N
achieve VB N
a DT N
total JJ i
calculated JJ i
replacement NN i
dose NN i
) ) i
or CC i
325 CD i
mg NN i
of IN i
ferrous JJ i
sulfate NN i
( ( i
65 CD i
mg NN i
elemental JJ i
iron NN i
) ) i
prescribed VBD i
orally RB i
thrice JJ i
daily RB i
for IN i
6 CD i
weeks NNS i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
6-week JJ N
pilot NN N
trial NN N
investigating VBG N
the DT N
effects NNS N
of IN N
1.5 CD N
g/d NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
( ( i
.84 JJ i
g/d NN i
eicosapentaenoic NN i
acid NN i
, , i
.7 NNP i
g/d NN i
docosahexaenoic NN i
acid NN i
) ) i
supplementation NN i
in IN N
13 CD p
children NNS p
( ( p
aged VBN p
5 CD p
to TO p
17 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorders NNS p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
. . p

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
multicenter NN N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
oral JJ i
contraceptives NNS i
( ( i
OC NNP i
) ) i
containing VBG i
100 CD i
micrograms NNS i
levonorgestrel NN i
( ( i
LNG NNP i
) ) i
/20 VBP i
micrograms NNS i
ethinyl VBP i
estradiol NN i
( ( i
EE NNP i
) ) i
( ( i
Aless/Loette NNP i
) ) i
and CC i
1000 CD i
micrograms NNS i
norethindrone JJ i
acetate NN i
( ( i
NETA NNP i
) ) i
/20 VBP i
micrograms NNS i
EE NNP i
( ( i
Loestrin NNP i
Fe NNP i
1/20 CD i
) ) i
on IN N
menstrual JJ N
cycle NN N
control NN N
over IN N
four CD N
cycles NNS N
of IN N
use NN N
. . N

To TO N
evaluate VB N
whether IN N
the DT N
inhibitory JJ o
control NN o
of IN o
TSH NNP o
and CC o
the DT o
stimulatory NN o
control NN o
of IN o
prolactin NN o
( ( o
PRL NNP o
) ) o
secretion NN o
exerted VBN N
by IN N
endogenous JJ N
serotonin NN N
was VBD N
altered VBN N
in IN N
obesity NN p
, , p
22 CD p
obese JJ p
men NNS p
and CC p
10 CD p
normal JJ p
controls NNS p
were VBD N
tested VBN N
with IN N
TRH NNP i
( ( i
200 CD i
micrograms NNS i
IV NNP i
bolus NN i
) ) i
in IN i
the DT i
presence NN i
( ( i
experimental JJ i
test NN i
) ) i
and CC i
absence NN i
( ( i
control VB i
test NN i
) ) i
of IN i
the DT i
serotonergic JJ i
agonist NN i
fenfluramine NN i
( ( i
60 CD i
mg NN i
PO NNP i
90 CD i
min NN i
before IN i
TRH NNP i
) ) i
. . i

MATERIAL NNP N
AND CC N
METHODS NNP N
Two CD p
hundred CD p
and CC p
two CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
surgical JJ i
approach NN i
( ( i
total JJ i
laryngectomy NN i
with IN i
partial JJ i
pharyngectomy NN i
and CC i
neck NN i
dissection NN i
, , i
followed VBN i
by IN i
irradiation NN i
) ) i
or CC i
to TO i
the DT i
chemotherapy NN i
arm NN i
up IN i
to TO i
three CD i
cycles NNS i
of IN i
induction NN i
chemotherapy NN i
( ( i
cisplatin JJ i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
day NN i
1 CD i
+ CD i
5-FU JJ i
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1-5 JJ N
) ) N
followed VBD N
for IN N
complete JJ N
responders NNS N
by IN N
irradiation NN N
and CC N
otherwise RB N
by IN N
conventional JJ N
treatment NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
two CD N
estroprogestins NNS i
( ( i
EPs NNP i
) ) i
, , i
ethinyl-estradiol JJ i
( ( i
EE NNP i
) ) i
30 CD i
mcg/drospirenone NN i
( ( i
DRSP NNP i
) ) i
3 CD N
mg NN N
, , N
and CC N
ethinyl-estradiol NN N
( ( N
EE NNP N
) ) N
30 CD N
mcg/chlormadinone NN N
acetate NN N
( ( N
CMA NNP N
) ) N
2 CD N
mg NN N
, , N
both DT N
on IN N
increased VBN N
serum NN o
androgen NN o
levels NNS o
and CC N
on IN N
several JJ N
skin NN N
parameters NNS N
in IN N
women NNS p
affected VBN p
by IN p
mild NN p
to TO p
severe VB p
acne NN p
and CC p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
polymyxin NN i
sulfate NN i
7500 CD i
IU/neomycin NNP i
sulfate NN i
3500 CD i
IU/dexamethasone NNP i
phosphate VB i
0.1 CD i
% NN i
( ( i
PN+Dx NNP i
) ) i
otic JJ i
solution NN i
with IN i
polymyxin NN i
sulfate NN i
7500 CD i
IU/neomycin NNP i
sulfate NN i
3500 CD i
IU NNP i
( ( i
PN-Dx NNP i
) ) i
in IN N
patients NNS p
with IN p
acute JJ p
bacterial JJ p
otitis NN p
externa NN p
( ( p
AOE NNP p
) ) p
, , N
in IN N
order NN N
to TO N
determine VB N
the DT N
possible JJ N
benefit NN N
of IN N
the DT N
addition NN N
of IN N
dexamethasone NN i
. . i

PURPOSE NN N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
sustained VBN N
virologic IN N
suppression NN N
) ) N
and CC N
safety/tolerability NN N
of IN N
a DT N
switch NN N
to TO N
lamivudine VB i
300 CD N
mg NNS N
once RB N
daily JJ N
( ( N
QD NNP N
) ) N
versus NN N
continued VBD N
lamivudine JJ i
150 CD N
mg JJ N
twice RB N
daily RB N
( ( N
BID NNP N
) ) N
in IN N
virologically RB p
suppressed VBN p
patients NNS p
( ( p
HIV-1 NNP p
RNA NNP p
< NNP p
400 CD p
copies/mL NN p
for IN p
> NN p
or CC p
=3 JJ p
months NNS p
) ) p
on IN p
stable JJ p
( ( p
> JJ p
or CC p
=6 JJ p
months NNS p
) ) p
therapy NN p
with IN p
lamivudine JJ i
150 CD i
mg NN i
BID NNP i
plus CC i
stavudine NN i
and CC N
either DT N
indinavir NN i
or CC i
nelfinavir NN i
. . i

METHODS NNP N
HIV NNP p
and CC p
HCV NNP p
genotype VBP p
1- JJ p
and CC p
4-coinfected JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
pegylated VBN i
interferon- JJ i
270 CD i
? . i
plus CC i
ribavirin JJ i
1,600 CD i
mg JJ i
daily JJ i
and CC i
epoetin- JJ i
for IN i
4 CD i
weeks NNS i
, , i
followed VBN i
by IN i
pegylated JJ i
interferon- NN i
at IN i
standard JJ i
dosages NNS i
plus CC i
weight-based JJ i
ribavirin NN i
( ( i
WBR NNP i
) ) i
dosage NN i
for IN i
8 CD i
weeks NNS i
( ( i
induction NN i
arm NN i
[ NNP i
IA NNP i
] NNP i
) ) i
, , i
or CC i
pegylated VBD i
interferon- JJ i
plus CC i
WBR NNP i
for IN i
12 CD i
weeks NNS i
( ( i
standard JJ i
therapy NN i
arm NN i
[ NNP i
SA NNP i
] NNP i
) ) N
. . N

There EX N
were VBD N
higher JJR o
POGO NNP o
scores NNS o
with IN o
the DT o
LFS NNP o
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

Compared VBN N
with IN N
the DT N
control NN N
period NN N
, , N
nicotinic JJ i
acid NN i
therapy NN i
reduced VBD N
the DT N
plasma NN o
total JJ o
cholesterol NN o
level NN o
by IN N
24 CD N
% NN N
, , N
plasma JJ o
triglyceride IN o
level NN o
by IN N
45 CD N
% NN N
, , N
very-low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
58 CD N
% NN N
, , N
and CC N
low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
15 CD N
% NN N
, , N
and CC N
it PRP N
increased VBD N
the DT N
high-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
34 CD N
% NN N
. . N

RESULTS NNP N
Nosocomial NNP o
infections NNS o
of IN o
the DT o
blood NN o
, , o
meninges NNS o
, , o
or CC o
urinary JJ o
tract NN o
occurred VBD N
in IN N
439 CD N
of IN N
the DT N
2416 CD N
infants NNS N
( ( N
18.2 CD N
percent NN N
) ) N
: : N
208 CD N
( ( N
17.3 CD N
percent NN N
) ) N
in IN N
the DT N
immune JJ N
globulin NN N
group NN N
and CC N
231 CD N
( ( N
19.1 CD N
percent NN N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
relative JJ N
risk NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.77 CD N
to TO N
1.08 CD N
) ) N
. . N

Time NN N
to TO N
regression VB N
to TO N
two CD N
segments NNS N
of IN N
partial JJ o
and CC o
complete JJ o
sensory NN o
blockade NN o
was VBD N
positively RB N
correlated VBN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
with IN N
increasing VBG N
dose NN N
of IN N
bupivacaine NN i
in IN N
the DT N
solutions NNS N
and CC N
ranged VBD N
from IN N
84 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
70 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
lidocaine NN i
, , N
to TO N
128 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
101 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
bupivacaine NN i
. . i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS o
of IN o
plasma NN o
plasminogen NN o
activator NN o
inhibitor NN o
( ( o
PAI NNP o
) ) o
activity NN o
and CC o
serum JJ o
ACE NNP o
activity NN o
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD p
patients NNS p
with IN p
AMI NNP p
within IN p
12 CD p
hours NNS p
after IN p
the DT p
onset NN p
of IN p
the DT p
symptom NN p
and CC N
who WP N
randomly VBP N
received VBN N
early JJ N
treatment NN N
with IN N
either CC N
the DT N
ACE NNP i
inhibitor NN i
imidapril NN i
or CC i
a DT i
placebo NN i
( ( N
20 CD N
patients NNS N
in IN N
the DT N
imidapril NN i
group NN N
and CC N
20 CD N
in IN N
the DT N
placebo NN i
group NN N
) ) N
. . N

There EX N
were VBD N
no DT N
deaths NNS o
or CC o
bile-duct NN o
lesions NNS o
in IN N
either DT N
group NN N
, , N
but CC N
the DT N
postoperative JJ o
complication NN o
rate NN o
was VBD N
significantly RB N
( ( N
p=0.0048 NN N
) ) N
higher JJR N
in IN N
the DT N
OC NNP N
than IN N
in IN N
the DT N
LC NNP N
group NN N
: : N
seven CD N
( ( N
23 CD N
% NN N
) ) N
patients NNS N
had VBD N
major JJ N
and CC N
six CD N
( ( N
19 CD N
% NN N
) ) N
minor NN N
complications NNS N
after IN N
OC NNP N
, , N
whereas IN N
only RB N
one CD N
( ( N
3 CD N
% NN N
) ) N
minor JJ N
complication NN N
occurred VBD N
after IN N
LC NNP N
. . N

METHOD NNP N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
randomized VBD N
124 CD p
children NNS p
( ( p
4 CD p
through IN p
13 CD p
years NNS p
of IN p
age NN p
) ) p
with IN p
PDDs NNP p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
to TO p
medication VB p
alone RB p
( ( p
MED NNP p
; : p
n CC p
= $ p
49 CD p
; : p
risperidone NN i
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
; : N
if IN N
ineffective JJ N
, , N
switch VB N
to TO N
aripiprazole VB i
was VBD i
permitted VBN i
) ) i
or CC i
a DT i
combination NN i
of IN i
medication NN i
plus CC i
parent NN i
training NN i
( ( i
PT NNP i
) ) i
( ( N
COMB NNP N
; : N
n CC N
= VB N
75 CD N
) ) N
. . N

They PRP N
were VBD N
subjected VBN N
to TO N
the DT N
following JJ p
assessments NNS p
: : p
1 CD p
) ) p
oropharyngeal NN p
class NN p
according VBG p
to TO p
the DT p
modified VBN p
Mallampati NNP p
criteria NNS p
; : p
2 CD p
) ) p
the DT p
new JJ p
, , p
upper JJ p
lip NN p
bite IN p
criteria-class NN p
I PRP p
= VBP p
lower JJR p
incisors NNS p
can MD p
bite VB p
the DT p
upper JJ p
lip NN p
above IN p
the DT p
vermilion NN p
line NN p
, , p
class NN p
II NNP p
= NNP p
lower JJR p
incisors NNS p
can MD p
bite VB p
the DT p
upper JJ p
lip NN p
below IN p
the DT p
vermilion NN p
line NN p
, , p
and CC p
class NN p
III NNP p
= NNP p
lower JJR p
incisors NNS p
can MD p
not RB p
bite VB p
the DT p
upper JJ p
lip NN p
; : p
and CC p
3 CD p
) ) p
laryngeal NN p
view NN p
grading VBG p
according VBG p
to TO p
Cormack NNP p
's POS p
criteria NNS p
. . p

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

There EX N
was VBD N
also RB N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
clinical JJ o
symptom NN o
score NN o
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
in IN N
the DT N
PN+Dx NNP N
group NN N
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
a DT N
moderately RB N
severe JJ o
symptom NN o
score NN o
with IN N
more JJR N
than IN N
seven CD N
points NNS N
at IN N
Visit NNP N
1 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
and CC N
in IN N
patients NNS N
suffering VBG N
from IN N
their PRP$ N
current JJ o
episode NN o
of IN o
otitis NN o
externa NN o
for IN N
more JJR N
than IN N
2 CD N
days NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

METHODS NNP N
STEMI NNP p
patients NNS p
undergoing VBG p
emergency NN p
PCI NNP p
in IN p
affiliated JJ p
hospital NN p
of IN p
Beihua NNP p
University NNP p
between IN p
October NNP p
2006 CD p
and CC p
January NNP p
2009 CD p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
control NN i
group NN i
( ( i
n JJ i
= NNP i
34 CD i
) ) i
without IN i
any DT i
intervention NN i
after IN i
PTCA NNP i
, , N
and CC N
the DT N
postconditioning NN N
group NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
with IN N
ischemia NN i
postconditioning VBG i
within IN i
first JJ i
minutes NNS i
of IN i
reflow NN i
by IN i
3 CD i
episodes NNS i
of IN i
30-second JJ i
inflation NN i
and CC i
30-second JJ i
deflation NN i
with IN i
the DT i
angioplasty JJ i
balloon NN i
. . i

Whilst IN N
the DT N
Triple NNP N
P NNP N
Positive NNP N
Parenting NNP N
Program NNP N
has VBZ N
a DT N
large JJ N
evidence NN N
base NN N
( ( N
Sanders NNP N
, , N
Clinical NNP N
Child NNP N
and CC N
Family NNP N
Psychology NNP N
Review NNP N
2:71-90 CD N
, , N
1999 CD N
; : N
Sanders NNP N
, , N
Journal NNP N
of IN N
Consulting NNP N
and CC N
Clinical NNP N
Psychology NNP N
68:624-640 CD N
, , N
2000 CD N
) ) N
and CC N
preliminary JJ N
evidence NN N
indicates VBZ N
that IN N
Stepping VBG N
Stones NNP N
Triple NNP N
P NNP N
is VBZ N
also RB N
efficacious JJ N
( ( N
Roberts NNP N
, , N
Journal NNP N
of IN N
Clinical NNP N
Child NNP N
and CC N
Adolescent NNP N
Psychology NNP N
, , N
35 CD N
( ( N
2 CD N
) ) N
:180-193 NN N
, , N
2006 CD N
) ) N
, , N
to TO N
date NN N
Stepping NNP N
Stones NNP N
has VBZ N
not RB N
been VBN N
evaluated VBN N
with IN N
the DT N
ASD NNP N
population NN N
. . N

METHODS NNP N
Males NNP p
and CC p
females NNS p
, , p
ages VBZ p
14 CD p
to TO p
25 CD p
years NNS p
, , p
with IN p
a DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
Text NNP p
Revision NNP p
diagnosis NN p
of IN p
an DT p
ASD NNP p
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
10-week JJ N
trial NN N
consisting NN N
of IN N
8 CD N
weeks NNS N
of IN N
active JJ i
drug NN i
with IN i
either DT i
weekly JJ i
or CC i
daily JJ i
administration NN i
of IN i
50 CD i
mg NN i
of IN i
DCS NNP i
followed VBN i
by IN i
a DT i
2-week JJ i
follow-up JJ i
visit NN i
. . i

Participants NNS p
in IN p
the DT p
Age-Related JJ p
Eye NNP p
Disease NNP p
Study NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ i
antioxidants NNS i
( ( i
vitamin JJ i
C NNP i
, , i
500 CD i
mg NN i
; : i
vitamin CC i
E NNP i
, , i
400 CD i
IU NNP i
; : i
beta NN i
carotene NN i
, , i
15 CD i
mg NN i
) ) i
, , i
zinc NN i
and CC i
copper NN i
( ( i
zinc NN i
, , i
80 CD i
mg NN i
; : i
cupric JJ i
oxide NN i
, , i
2 CD i
mg NN i
) ) i
, , i
antioxidants NNS i
plus CC i
zinc NN i
and CC i
copper NN i
, , i
or CC i
placebo NN i
. . i

METHOD NNP N
30 CD p
individuals NNS p
( ( p
BMI NNP p
? . p
28 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
were VBD p
randomized VBN p
to TO p
one CD p
of IN p
three CD p
conditions NNS p
: : p
i NN i
) ) i
The DT i
combination NN i
of IN i
a DT i
standardized JJ i
lifestyle NN i
modification NN i
( ( i
LM NNP i
) ) i
program NN i
for IN i
individuals NNS i
with IN i
SMI NNP i
and CC i
payment NN i
for IN i
group NN i
attendance NN i
( ( i
CM NNP i
( ( i
attendance NN i
) ) i
) ) i
, , i
ii NN i
) ) i
The DT i
combination NN i
of IN i
LM NNP i
and CC i
payment NN i
for IN i
weight JJ i
loss NN i
( ( i
CM NNP i
( ( i
weight NN i
) ) i
) ) i
, , i
and CC i
iii NN i
) ) i
waitlist NN i
control NN i
( ( i
CON NNP i
) ) i
. . i

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
safety NN o
and CC o
cost NN o
of IN N
Seretide NNP i
( ( i
salmeterol/fluticasone NN i
propionate NN i
( ( i
Salm/FP NNP i
) ) i
, , N
50/250 CD N
microg NN N
bd NN N
) ) N
via IN N
Diskus NNP N
with IN N
formoterol NN i
( ( N
Form NNP N
; : N
12 CD N
microg NN N
bd NN N
) ) N
and CC N
budesonide NN i
( ( N
Bud NNP N
; : N
800 CD N
microg NN N
bd NN N
) ) N
given VBN N
concurrently RB N
( ( N
Form+Bud NNP N
) ) N
via IN N
Turbuhaler NNP N
in IN N
patients NNS p
with IN p
moderate-to-severe JJ p
asthma NNS p
who WP p
were VBD p
uncontrolled VBN p
on IN p
existing VBG p
corticosteroid JJ p
therapy NN p
. . p

In IN N
this DT N
prospective JJ N
study NN N
, , N
14 CD p
patients NNS p
with IN p
colonic JJ p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
a DT N
6-hour JJ N
stable JJ i
isotope NN i
infusion NN i
study NN i
( ( i
3 CD i
hours NNS i
of IN i
fasting VBG i
followed VBN i
by IN i
3-hour JJ i
infusions NNS i
of IN i
amino NN i
acids NNS i
, , i
Travasol NNP i
[ NNP N
Baxter NNP N
, , N
Montreal NNP N
, , N
Canada NNP N
] VBD N
10 CD N
% NN N
at IN N
0.02 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
with IN N
or CC N
without IN N
glucose JJ N
at IN N
4 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
) ) N
on IN N
the DT N
second JJ N
day NN N
after IN N
colorectal JJ N
surgery NN N
. . N

Also RB N
, , N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
late JJ o
gastrointestinal NN o
and CC o
genitourinary JJ o
toxicity NN o
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
, , N
with IN N
a DT N
3-year JJ o
rate NN o
of IN o
Grade NNP o
2 CD o
or CC o
greater JJR o
toxicity NN o
of IN N
17 CD N
% NN N
and CC N
16 CD N
% NN N
for IN N
the DT N
hypofractionation NN N
arm NN N
and CC N
14 CD N
% NN N
and CC N
11 CD N
% NN N
for IN N
the DT N
conventional JJ N
fractionation NN N
arm NN N
, , N
respectively RB N
. . N

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ i
ofloxacin NN i
or CC i
topical JJ i
ciprofloxacin NN i
( ( i
instillation NN i
of IN i
0.3 CD i
% NN i
ophthalmic JJ i
solution NN i
every DT i
30 CD i
minutes NNS i
for IN i
4 CD i
hours NNS i
before IN i
surgery NN i
) ) i
, , i
or CC i
a DT i
combined JJ i
topical JJ i
plus CC i
oral JJ i
regimen NNS i
( ( i
ciprofloxacin JJ i
hydrochloride NN i
, , N
four CD N
100-mg JJ N
tablets NNS N
, , N
or CC N
ofloxacin RB i
, , N
one CD N
400-mg JJ N
tablet NN N
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN N
) ) N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
in IN N
10 CD p
healthy JJ p
females NNS p
( ( p
age NN p
range NN p
22-36 CD p
years NNS p
, , p
mean JJ p
29.1 CD p
+/- JJ p
5.4 CD p
) ) p
who WP p
were VBD p
hospitalized VBN p
and CC p
challenged VBN p
on IN p
two CD p
consecutive JJ p
days NNS p
with IN p
placebo NN i
( ( i
peppermint JJ i
tea NN i
) ) i
or CC i
75 CD i
mg NN i
of IN i
pure JJ i
histamine NN i
( ( i
equaling VBG i
124 CD i
mg JJ i
histamine NN i
dihydrochloride NN i
, , i
dissolved VBN i
in IN i
peppermint NN i
tea NN i
) ) i
. . i

METHOD NNP N
Twenty-four CD p
children NNS p
( ( p
aged VBN p
5-17 CD p
years NNS p
) ) p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
and CC p
co-morbid JJ p
disruptive JJ p
behavior NN p
who WP p
responded VBD p
favorably RB p
to TO p
open-label JJ p
treatment NN p
with IN p
risperidone NN i
as IN N
part NN N
of IN N
a DT N
previously RB N
described VBN N
controlled VBN N
discontinuation NN N
study NN N
completed VBD N
two CD N
different JJ N
computerized JJ N
attention NN N
tasks NNS N
at IN N
baseline NN N
, , N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
24 CD N
of IN N
open-label JJ N
treatment NN N
, , N
and CC N
, , N
at IN N
8 CD N
weeks NNS N
after IN N
random JJ N
assignment NN N
to TO N
either DT N
placebo NN i
or CC i
risperidone NN i
. . i

Ten CD N
monozygotic JJ N
twin NN N
pairs NNS N
of IN N
pregnant JJ N
cows NNS N
( ( N
five CD N
pairs NNS N
of IN N
parity NN N
1 CD N
or CC N
2 CD N
, , N
and CC N
five CD N
pairs NNS N
of IN N
parity NN N
3 CD N
or CC N
more JJR N
) ) N
were VBD N
allocated VBN N
to TO N
two CD N
diets NNS N
which WDT N
were VBD N
formulated VBN i
to TO i
provide VB i
either RB i
-4 JJ i
meq NN i
( ( i
anion NN i
diet NN i
) ) i
or CC i
+572.5 JJ i
meq NN i
( ( i
cation NN i
diet NN i
) ) i
of IN i
[ NN i
( ( i
Na+ NNP i
+ NNP i
K+ NNP i
) ) i
- : i
( ( i
Cl- JJ i
+ NNP i
SO4= NNP i
) ) i
] VBD i
kg-1 JJ i
dietary JJ i
dry JJ i
matter NN i
( ( i
DM NNP i
) ) i
. . i

Azithromycin NNP i
was VBD N
widely RB N
distributed VBN N
within IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
; : N
sustained VBN N
concentrations NNS N
of IN N
the DT N
drug NN N
were VBD N
detectable JJ N
at IN N
the DT N
last JJ N
sampling JJ N
time NN N
( ( N
204 CD N
h NN N
) ) N
in IN N
lung NN N
tissue NN N
and CC N
bronchial JJ N
washing NN N
, , N
with IN N
long JJ N
terminal JJ N
half-lives NNS N
of IN N
132.86 CD N
and CC N
74.32 CD N
h NN N
at IN N
500 CD N
mg JJ N
daily JJ N
and CC N
133.32 CD N
and CC N
70.5 CD N
h NN N
at IN N
1000 CD N
mg JJ N
daily RB N
, , N
respectively RB N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
cardiorespiratory JJ o
effects NNS o
of IN N
IV NNP N
administration NN N
of IN N
propofol NN i
( ( i
4 CD i
mg/kg NN i
) ) i
, , i
ketamine JJ i
hydrochloride NN i
and CC i
propofol NN i
( ( i
2 CD i
mg/kg RB i
each DT i
; : i
K-P NNP i
) ) i
, , i
or CC i
ketamine VB i
hydrochloride NN i
( ( N
5 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN i
( ( i
0.2 CD i
mg/kg NN i
; : i
K-D NNP i
) ) i
before IN N
and CC N
after IN N
induction NN N
of IN N
anesthesia NN N
( ( N
IoA NNP N
) ) N
in IN N
dogs NNS p
sedated VBN p
with IN p
acepromazine JJ i
maleate NN i
and CC i
oxymorphone NN i
hydrochloride NN i
. . i

Patients NNS p
were VBD p
selected VBN p
on IN p
the DT p
basis NN p
of IN p
: : p
a DT p
) ) p
occurrence NN p
in IN p
the DT p
last JJ p
4 CD p
weeks NNS p
of IN p
at IN p
least JJS p
5/10 CD p
selected VBN p
symptoms NNS o
( ( o
anorexia NN o
, , o
nausea NN o
, , o
vomiting VBG o
, , o
upper JJ o
abdominal JJ o
pain NN o
, , o
postprandial JJ o
bloating NN o
, , o
abdominal JJ o
fullness NN o
, , o
early JJ o
satiety NN o
, , o
belching NN o
, , o
heartburn NN o
, , o
regurgitation NN o
) ) o
, , o
severity NN o
of IN p
which WDT p
should MD p
reach/exceed VB p
a DT p
total JJ p
score NN p
of IN p
8 CD p
, , p
as IN p
assessed VBN p
by IN p
a DT p
specific JJ p
scale NN p
ranging VBG p
from IN p
0 CD p
( ( p
absent NN p
) ) p
to TO p
3 CD p
( ( p
severe JJ p
) ) p
; : p
b VBN p
) ) p
normal JJ p
results NNS p
of IN p
routine JJ p
biochemical NN p
, , p
ultrasound NN p
and CC p
endoscopic JJ p
examinations NNS p
. . p

CONCLUSION NNP N
Since IN N
the DT N
90 CD N
% NN N
CI NNP N
for IN N
AUC NNP o
( ( o
last JJ o
) ) o
and CC o
C NNP o
( ( o
max NN o
) ) o
ratios NNS o
were VBD N
within IN N
the DT N
80-125 JJ N
% NN N
interval NN N
proposed VBN N
by IN N
the DT N
US NNP N
FDA NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
pantoprazole JJ i
40 CD N
mg NN N
DR NNP N
tablet NN N
( ( N
test JJS N
formulation NN N
) ) N
with IN N
and CC N
without IN N
food NN N
was VBD N
bioequivalent NN N
to TO N
the DT N
reference NN N
40 CD N
mg NN N
DR NNP N
tablet NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
. . N

Coprimary JJ N
endpoints NNS N
were VBD N
MRI-assessed JJ o
indices NNS o
( ( o
total JJ o
vessel NN o
area NN o
, , o
wall JJ o
area NN o
, , o
wall NN o
thickness NN o
, , o
and CC o
normalised VBD o
wall NN o
index NN o
[ JJ o
average JJ o
carotid NN o
] NN o
) ) o
after IN N
24 CD N
months NNS N
and CC N
( ( N
18 CD N
) ) N
F-fluorodeoxyglucose NNP N
( ( N
( ( N
18 CD N
) ) N
F-FDG NN N
) ) N
PET/CT NNP N
assessment NN N
of IN N
arterial JJ N
inflammation NN N
within IN N
an DT N
index NN N
vessel NN N
( ( N
right JJ N
carotid NN N
, , N
left VBD N
carotid NN N
, , N
or CC N
ascending VBG N
thoracic JJ N
aorta NN N
) ) N
after IN N
6 CD N
months NNS N
, , N
with IN N
no-harm JJ N
boundaries NNS N
established VBN N
before IN N
unblinding NN N
of IN N
the DT N
trial NN N
. . N

During IN N
ad NN N
libitum NN N
food NN N
intake NN N
, , N
after IN N
4 CD N
days NNS N
of IN N
METH NNP i
( ( N
40 CD N
mg/day NN N
) ) N
or CC N
PLAC NNP i
oral JJ i
therapy NN i
, , N
both DT N
groups NNS N
increased VBD N
their PRP$ N
energy NN o
intake NN o
over IN o
weight JJ o
maintenance NN o
, , N
but CC N
the DT N
increase NN N
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
METH NNP N
group NN N
compared VBN N
with IN N
the DT N
PLAC NNP N
group NN N
( ( N
4,554 CD N
+/- JJ N
1,857 CD N
vs. FW N
2,867 CD N
+/- JJ N
846 CD N
kcal/day NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
treatments NNS N
consisted VBN N
of IN N
( ( N
1 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ i
triazolam NN i
tablet NN i
after IN i
treatment NN i
with IN i
ranitidine NN i
; : i
( ( i
2 CD i
) ) i
one CD i
orally RB i
administered VBN i
0.25-mg JJ i
triazolam NN i
tablet NN i
, , i
with IN i
no DT i
ranitidine JJ i
pretreatment NN i
; : i
( ( i
3 CD i
) ) i
a DT i
0.25-mg JJ i
intravenous JJ i
dose NN i
of IN i
triazolam NN i
after IN i
treatment NN i
with IN i
ranitidine NN i
; : i
and CC N
( ( N
4 CD N
) ) N
a DT N
0.25-mg JJ i
intravenous JJ i
dose NN i
of IN i
triazolam NN i
, , i
with IN i
no DT i
ranitidine NN i
pretreatment NN i
. . i

METHODS NNP N
A NNP N
prospectively RB N
planned VBD N
, , N
combined VBN N
, , N
overall JJ N
survival NN N
analysis NN N
was VBD N
performed VBN N
, , N
including VBG N
data NNS N
from IN N
two CD N
Phase NNP N
III NNP N
trials NNS N
that WDT N
compared VBN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
fulvestrant NN i
( ( N
250 CD N
mg NN N
monthly RB N
; : N
n CC N
= VB N
428 CD N
) ) N
with IN N
anastrozole NN i
( ( N
1 CD N
mg NNS N
daily RB N
; : N
n CC N
= VB N
423 CD N
) ) N
in IN N
the DT N
treatment NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
breast NN p
carcinoma NN p
who WP p
had VBD p
disease NN p
progression NN p
after IN p
receipt NN p
of IN p
previous JJ p
endocrine NN p
treatment NN p
. . p

METHODS NNP N
Of IN N
813 CD p
patients NNS p
with IN p
previously RB p
untreated VBN p
metastatic JJ p
colorectal NN p
cancer NN p
, , N
we PRP N
randomly VBP N
assigned VBD N
402 CD N
to TO N
receive VB N
irinotecan JJ i
, , i
bolus JJ i
fluorouracil NN i
, , i
and CC i
leucovorin NN i
( ( i
IFL NNP i
) ) i
plus CC i
bevacizumab NN i
( ( N
5 CD N
mg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight JJ N
every DT N
two CD N
weeks NNS N
) ) N
and CC N
411 CD N
to TO N
receive VB N
IFL NNP i
plus CC i
placebo NN i
. . i

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
combination NN N
of IN N
ZDV NNP i
200 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
ddC VB i
0.75 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
and CC i
SH NNP i
2.5 CD i
g NN i
three CD i
times NNS i
per IN i
day NN i
or CC i
a DT i
combination NN i
of IN i
ZDV NNP i
200 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
ddC VB i
0.75 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
and CC i
placebo VBZ i
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
for IN N
24 CD N
weeks NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ o
WSL-scores NNS o
was VBD N
found VBN N
over IN N
time NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
there RB N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
concerning VBG N
the DT N
number NN N
of IN N
sites NNS N
that WDT N
totally RB N
disappeared VBD N
after IN N
12 CD N
months NNS N
in IN N
favour NN N
of IN N
the DT N
CPP-ACP NNP N
regime NN N
, , N
63 CD N
% NN N
compared VBN N
with IN N
25 CD N
% NN N
respectively RB N
. . N

RESULTS JJ N
Thirty-seven JJ p
patients NNS p
consented VBN p
to TO p
participate VB p
in IN p
the DT p
study NN p
( ( p
54 CD p
% NN p
male NN p
; : p
mean JJ p
age NN p
58.7 CD p
? . p
9.5 CD p
years NNS p
; : p
median JJ p
body NN p
mass NN p
index NN p
26.8 CD p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
, , p
range VBP p
16.4-47.6 JJ p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
) ) p
; : p
33 CD p
patients NNS p
completed VBD p
the DT p
study NN p
and CC p
28 CD p
patients NNS p
returned VBD p
the DT p
questionnaire NN p
( ( p
response NN p
rate NN p
= VBD p
85 CD p
% NN p
) ) p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplemental JJ i
oral JJ i
vitamin NN i
D NNP i
( ( i
placebo NN i
, , N
1,000 CD N
, , N
2,000 CD N
, , N
or CC N
4,000 CD N
IU/day NN N
of IN N
vitamin NN N
D3 NNP N
orally RB N
for IN N
3 CD N
months NNS N
) ) N
in IN N
328 CD p
African JJ p
Americans NNPS p
( ( p
median JJ p
age NN p
, , p
51 CD p
years NNS p
) ) p
of IN p
public JJ p
housing NN p
communities NNS p
in IN p
Boston NNP p
, , p
MA NNP p
, , p
who WP p
were VBD p
enrolled VBN p
over RP p
three CD p
consecutive JJ p
winter NN p
periods NNS p
( ( p
2007-2010 JJ p
) ) p
. . p

A DT N
Japanese JJ N
version NN N
of IN N
the DT N
Autism NNP i
Spectrum NNP i
Quotient NNP i
( ( i
AQ NNP i
) ) i
, , i
AQ-J NNP i
was VBD N
administered VBN N
to TO N
25 CD p
normally RB p
intelligent JJ p
high-functioning JJ p
pervasive JJ p
developmental NN p
disorder NN p
( ( p
HPDD NNP p
) ) p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
24.2 CD p
years NNS p
; : p
24 CD p
male NN p
, , p
one CD p
female NN p
) ) p
and CC p
215 CD p
controls NNS p
( ( p
mean JJ p
age NN p
, , p
30.4 CD p
years NNS p
; : p
86 CD p
male NN p
, , p
129 CD p
female NN p
) ) p
randomly RB p
selected VBN p
from IN p
the DT p
general JJ p
population NN p
. . p

Sixty-eight JJ p
patients NNS p
( ( p
44 CD p
men NNS p
and CC p
24 CD p
women NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
44.3 CD p
( ( p
1.2 CD p
) ) p
yr NN p
and CC p
verified VBD p
GH NNP p
deficiency NN p
participated VBD p
in IN p
a DT p
2-phase JJ p
treatment NN p
trial NN p
with IN N
an DT N
initial JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
, , N
6-month JJ N
period NN N
, , N
followed VBN N
by IN N
an DT N
open JJ N
treatment NN N
period NN N
, , N
thereby RB N
ensuring VBG N
all DT N
patients NNS N
12 CD N
months NNS N
of IN N
GH NNP i
treatment NN i
. . i

Between JJ p
1977 CD p
and CC p
1983 CD p
the DT p
Southwest NNP p
Oncology NNP p
Group NNP p
( ( p
SWOG NNP p
) ) p
evaluated VBD p
chemotherapy NN i
alone RB i
( ( i
cyclophosphamide JJ i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
prednisone NN i
; : i
CHOP NNP i
) ) i
or CC i
chemoimmunotherapy NN i
( ( i
CHOP-levamisole JJ i
or CC i
CHOP-levamisole-BCG JJ i
) ) i
in IN N
a DT N
randomized JJ N
prospective JJ N
clinical JJ N
trial NN N
involving VBG N
715 CD p
eligible JJ p
patients NNS p
with IN p
all DT p
types NNS p
of IN p
malignant JJ p
lymphoma NN p
( ( p
ML NNP p
) ) p
. . p

The DT N
cumulative JJ N
proportions NNS N
of IN N
the DT N
children NNS N
with IN N
complete JJ N
resolution NN N
of IN N
their PRP$ N
enlarged JJ N
livers NNS N
at IN N
48 CD N
, , N
96 CD N
, , N
168 CD N
or CC N
336 CD N
and CC N
504 CD N
h NN N
after IN N
commencement NN N
of IN N
treatment NN N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
treated VBN N
with IN N
CQ NNP i
plus CC i
chlorpheniramine NN i
( ( i
CQCP NNP i
) ) i
than IN N
in IN N
the DT N
other JJ N
two CD N
treatment NN N
groups NNS N
( ( N
with IN N
P-values NNP N
of IN N
0.02 CD N
, , N
0.001 CD N
, , N
0.00000 CD N
and CC N
0.00002 CD N
, , N
respectively RB N
) ) N
. . N

METHODS NNP N
Patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
, , p
mild-to-moderate JJ p
hypertension NN p
( ( p
diastolic JJ p
blood NN p
pressure NN p
85-105 JJ p
mmHg NN p
, , p
systolic JJ p
blood NN p
pressure NN p
< VBZ p
160 CD p
mmHg NN p
, , p
and CC p
24-hour JJ p
mean JJ p
systolic JJ p
blood NN p
pressure NN p
> VBZ p
130 CD p
mmHg NN p
) ) p
, , p
and CC p
microalbuminuria NNS p
were VBD p
randomized VBN p
to TO p
1 CD p
year NN p
of IN p
doubleblind NN i
treatment NN i
with IN i
fixed-dose JJ i
manidipine/delapril NN i
( ( N
n=54 JJ N
) ) N
or CC N
losartan/hydrochlorothiazide JJ i
( ( i
HCTZ NNP i
) ) i
( ( N
n=56 JJ N
) ) N
. . N

RESULTS NNP N
Among IN N
patients NNS N
not RB N
taking VBG N
vitamin RP N
A DT N
prior JJ N
to TO N
entry NN N
, , N
those DT N
in IN N
the DT N
DHA NNP N
+ NNP N
A NNP N
group NN N
had VBD N
a DT N
slower JJR N
decline NN N
in IN N
field NN o
sensitivity NN o
and CC o
electroretinogram NN o
amplitude NN o
than IN N
those DT N
in IN N
the DT N
control NN N
+ VBZ N
A NNP N
group NN N
over IN N
the DT N
first JJ N
2 CD N
years NNS N
( ( N
P NNP N
=.01 NNP N
and CC N
P NNP N
=.03 NNP N
, , N
respectively RB N
) ) N
; : N
these DT N
differences NNS N
were VBD N
not RB N
observed VBN N
in IN N
years NNS N
3 CD N
and CC N
4 CD N
of IN N
follow-up JJ N
or CC N
among IN N
patients NNS N
taking VBG N
vitamin NN N
A NNP N
prior RB N
to TO N
entry NN N
. . N

In IN N
this DT N
study NN N
we PRP N
examined VBD N
the DT N
social JJ N
behaviors NNS N
of IN N
4- JJ N
to TO N
12-year-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
; : p
N NNP p
= NNP p
24 CD p
) ) p
during IN p
three CD p
tradic JJ p
interactions NNS p
with IN p
an DT p
adult NN i
confederate NN i
and CC i
an DT i
interaction NN i
partner NN i
, , i
where WRB i
the DT i
interaction NN i
partner NN i
varied VBD i
randomly RB i
among IN i
( ( i
1 CD i
) ) i
another DT i
adult NN i
human NN i
, , i
( ( i
2 CD i
) ) i
a DT i
touchscreen JJ i
computer NN i
game NN i
, , i
and CC i
( ( i
3 CD i
) ) i
a DT i
social JJ i
dinosaur NN i
robot NN i
. . i

Regardless RB N
of IN N
the DT N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
the DT N
total JJ N
yield NN N
of IN N
CD34 NNP N
( ( N
+ NNP N
) ) N
cells NNS N
from IN N
apheresis NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
plerixafor NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
significantly RB N
more JJR N
patients NNS N
in IN N
the DT N
plerixafor NN N
group NN N
collected VBD N
the DT N
minimum NN N
( ( N
? . N
? . N
10 CD N
( ( N
6 CD N
) ) N
cells/kg NN N
) ) N
and CC N
optimum JJ N
( ( N
? . N
? . N
10 CD N
( ( N
6 CD N
) ) N
cells/kg NN N
) ) N
stem NN N
cell NN N
yields NNS N
on IN N
each DT N
day NN N
of IN N
apheresis NN N
. . N

Methods NNS N
Patients NNS N
randomized VBD N
to TO N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ i
acid NN i
5 CD i
mg NN i
or CC i
risedronate NN i
( ( i
5 CD i
mg/day NN i
) ) i
and CC i
stratified VBN i
based VBN i
on IN i
glucocorticoids NNS i
duration NN i
[ FW i
treatment NN i
( ( i
> JJ i
3 CD i
months NNS i
) ) i
and CC i
prevention NN i
( ( i
? . i
3 CD i
months NNS i
) ) i
subpopulations NNS i
] VBP i
were VBD i
subgrouped VBN i
by IN p
age NN p
; : p
gender NN p
; : p
menopausal NN p
status NN p
in IN p
women NNS p
; : p
dose VB p
and CC p
duration NN p
of IN p
prednisone NN p
during IN p
the DT p
trial NN p
; : p
and CC p
baseline VB p
serum JJ p
25-OH JJ p
vitamin NN p
D NNP p
, , p
LS NNP p
BMD NNP p
T-score NNP p
, , p
creatinine JJ p
clearance NN p
, , p
and CC p
concomitant JJ p
medication NN p
use NN p
. . p

HRs NNP o
( ( N
three-class JJ N
vs NN N
combined VBN N
two-class NN N
) ) N
for IN N
AIDS NNP N
or CC N
death NN N
were VBD N
similar JJ N
for IN N
participants NNS N
with IN N
baseline NN N
CD4 NNP N
cell NN N
counts NNS N
of IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
or CC N
less JJR N
and CC N
of IN N
more JJR N
than IN N
200 CD N
cells NNS N
per IN N
mm3 NN N
( ( N
p=0.38 NN N
for IN N
interaction NN N
) ) N
, , N
and CC N
for IN N
participants NNS N
with IN N
baseline NN N
HIV NNP N
RNA NNP N
concentrations NNS N
less JJR N
than IN N
100 CD N
000 CD N
copies NNS N
per IN N
mL NN N
and CC N
100,000 CD N
copies NNS N
per IN N
mL NN N
or CC N
more JJR N
( ( N
p=0.26 NN N
for IN N
interaction NN N
) ) N
. . N

United NNP p
States NNPS p
children NNS p
two CD p
months NNS p
of IN p
age NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
that WDT N
received VBD N
either RB N
the DT N
commercially RB i
available JJ i
oral JJ i
trivalent NN i
poliovirus NN i
vaccine NN i
( ( i
OPV NNP i
) ) i
or CC i
an DT i
injectable JJ i
( ( i
inactivated VBN i
) ) i
trivalent NN i
poliovirus NN i
vaccine NN i
( ( i
IPV NNP i
) ) i
with IN N
a DT N
confirmed JJ N
minimum JJ N
D-antigen NNP N
content NN N
of IN N
27 CD N
, , N
3.5 CD N
, , N
and CC N
29 CD N
units NNS N
for IN N
poliovirus NN N
types NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
. . N

METHODS NNP N
We PRP N
prospectively RB N
evaluated VBD N
the DT N
association NN N
between IN N
baseline NN p
BMI NNP p
and CC p
the DT p
risk NN p
of IN p
incident JJ p
distal JJ p
adenoma NN p
( ( p
1,213 CD p
cases NNS p
) ) p
, , p
recurrent JJ p
adenoma NN p
( ( p
752 CD p
cases NNS p
) ) p
, , p
and CC p
incident JJ p
colorectal NN p
cancer NN p
( ( p
966 CD p
cases NNS p
) ) p
among IN p
men NNS p
and CC p
women NNS p
, , p
ages VBZ p
55 CD p
to TO p
74 CD p
years NNS p
, , p
randomly RB p
assigned VBN p
to TO p
receive VB p
flexible JJ i
sigmoidoscopy NN i
screening NN i
as IN p
part NN p
of IN p
the DT p
Prostate NNP p
, , p
Lung NNP p
, , p
Colorectal NNP p
, , p
and CC p
Ovarian JJ p
Cancer NNP p
Screening NNP p
Trial NNP p
. . p

No DT N
significant JJ N
differences NNS N
in IN N
FEV NNP o
( ( o
1 CD o
) ) o
values NNS o
were VBD N
observed VBN N
between IN N
group NN N
A NNP N
( ( N
P=0.704 NNP N
) ) N
or CC N
group NN N
B NNP N
( ( N
P=0.270 NNP N
) ) N
at IN N
baseline NN N
, , N
or CC N
at IN N
5 CD N
( ( N
Group NNP N
A NNP N
: : N
P=0.340 NNP N
; : N
Group NNP N
B NNP N
: : N
P=0.559 NN N
) ) N
and CC N
15 CD N
min NN N
( ( N
Group NNP N
A NNP N
: : N
P=0.526 NNP N
; : N
Group NNP N
B NNP N
: : N
P=0.818 NNP N
) ) N
post NN N
dose NN N
. . N

49 CD p
patients NNS p
( ( p
22 CD p
women NNS p
, , p
27 CD p
men NNS p
, , p
mean JJ p
age NN p
43.7 CD p
[ JJ p
21-65 JJ p
] NNP p
years NNS p
) ) p
with IN p
Hodgkin NNP p
's POS p
disease NN p
were VBD p
examined VBN p
by IN p
Doppler NNP p
echocardiography NN p
a DT p
median NN p
of IN p
5.37 CD p
( ( p
2-10 JJ p
) ) p
years NNS p
after IN p
the DT p
end NN p
of IN p
chemotherapy NN p
( ( p
given VBN p
according VBG p
to TO p
the DT p
COPP/ABVD NNP p
scheme NN p
, , p
with IN p
or CC p
without IN p
mediastinal JJ p
irradiation NN p
) ) p
for IN p
possible JJ p
chronic JJ p
changes NNS p
in IN p
myocardium NN p
, , p
pericardium NN p
or CC p
cardiac JJ p
valves NNS p
, , p
as RB p
well RB p
as IN p
for IN p
any DT p
haemodynamic JJ p
sequelae NN p
. . p

METHODS NNP N
The DT N
relationship NN N
between IN N
ACE NNP N
genotype NN N
and CC N
the DT N
response NN N
to TO N
11weeks CD N
of IN N
resistance NN i
exercise NN i
training NN i
was VBD N
determined VBN N
in IN N
37 CD p
CHF JJ p
patients NNS p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
Functional NNP p
Class=2.3 NNP p
; : p
left VBD p
ventricular JJ p
ejection NN p
fraction NN p
28 CD p
% NN p
; : p
age NN p
64 CD p
; : p
32:5 CD p
male NN p
: : p
female NN p
) ) p
who WP p
were VBD p
randomised VBN p
to TO p
either DT p
resistance NN i
exercise NN i
( ( i
n=19 JJ i
) ) i
or CC i
inactive JJ i
control NN i
group NN p
( ( p
n=18 RB p
) ) p
. . p

METHODS NNP N
Sixty-eight NNP p
consecutively RB p
recruited VBD p
, , p
premenopausal NN p
, , p
omnivorous JJ p
women NNS p
of IN p
all DT p
races NNS p
and CC p
ethnicities NNS p
between IN p
the DT p
ages NNS p
of IN p
25 CD p
years NNS p
and CC p
55 CD p
years NNS p
were VBD p
admitted VBN p
to TO p
the DT p
study NN p
and CC p
randomized VBN p
to TO p
an DT p
experimental JJ p
group NN p
supplemented VBD p
with IN p
soy NN i
( ( i
40 CD i
mg NN i
genistein NNS i
per IN i
day NN i
) ) i
or CC i
to TO i
a DT i
control NN i
group NN i
that WDT i
consumed VBD i
a DT i
placebo NN i
for IN N
a DT N
12-week JJ N
period NN N
. . N

Minimal JJ o
treatment-related JJ o
adverse JJ o
events NNS o
were VBD N
seen VBN N
at IN N
doses NNS N
up RB N
to TO N
8 CD N
mg. NNS N
Serum NNP N
interferon NN N
( ( N
IFN NNP N
) ) N
- : N
was VBD N
only RB N
detected VBN N
in IN N
subjects NNS N
who WP N
received VBD N
8 CD N
or CC N
12 CD N
mg NN N
doses NNS N
, , N
and CC N
the DT N
adverse JJ o
event NN o
profile NN o
at IN N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
was VBD N
generally RB N
consistent JJ N
with IN N
that DT N
associated VBN N
with IN N
IFN- NNP N
exposure NN N
( ( N
flu-like JJ N
symptoms NNS N
) ) N
, , N
consistent JJ N
with IN N
the DT N
mechanism NN N
of IN N
TLR7 NNP N
agonism NN N
. . N

Interestingly RB N
however RB N
, , N
when WRB N
segregated VBN N
on IN N
the DT N
Choi NNP N
criteria NNS N
, , N
cytotoxic NN N
drugs NNS N
alone RB N
showed VBD N
a DT N
non-significant JJ N
trend NN N
in IN N
improved JJ N
survival NN o
( ( N
74 CD N
% NN N
versus IN N
55 CD N
% NN N
, , N
p RB N
0.32 CD N
) ) N
as RB N
well RB N
as IN N
event-free JJ o
survival NN o
( ( N
44 CD N
% NN N
versus IN N
40 CD N
% NN N
, , N
p RB N
0.42 CD N
) ) N
for IN N
the DT N
germinal JJ N
centre NN N
as IN N
opposed VBN N
to TO N
the DT N
activated VBN N
B-cell NNP N
subtype NN N
. . N

In IN N
contrast NN N
, , N
GH-secretagogues NNP o
elevated VBD o
leptin NN o
levels NNS o
within IN N
12 CD N
h. JJ N
Infusion NNP N
of IN N
GHRP-2 NNP N
alone RB N
induced VBD N
a DT N
maximal JJ N
leptin JJ N
increase NN N
of IN N
+87 NNP N
% NN N
after IN N
24 CD N
h NN N
, , N
whereas WP N
GHRH NNP N
+ VBD N
GHRP-2 NNP N
elevated VBD N
leptin NN N
by IN N
up IN N
to TO N
+157 VB N
% NN N
after IN N
24 CD N
h. VBD N
The DT N
increase NN N
in IN N
leptin NN N
within IN N
12 CD N
h NN N
was VBD N
related VBN N
( ( N
R2 NNP N
= NNP N
0.58 CD N
) ) N
to TO N
the DT N
substantial JJ N
rise NN N
in IN N
insulin NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
24-week JJ N
randomized JJ N
trial NN N
compared VBN N
parent NN i
training NN i
( ( p
n JJ p
= NNP p
89 CD p
) ) p
to TO p
parent VB p
education NN p
( ( p
n JJ p
= NNP p
91 CD p
) ) p
at IN p
6 CD p
centers NNS p
( ( p
Emory NNP p
University NNP p
, , p
Indiana NNP p
University NNP p
, , p
Ohio NNP p
State NNP p
University NNP p
, , p
University NNP p
of IN p
Pittsburgh NNP p
, , p
University NNP p
of IN p
Rochester NNP p
, , p
Yale NNP p
University NNP p
) ) p
. . p

OBJECTIVE NN N
To TO N
compare VB N
efficacy NN o
among IN N
1578 CD p
patients NNS p
with IN p
osteoarthritis JJ p
randomized VBN p
to TO p
take VB p
acetaminophen NN i
4000 CD N
mg NN N
( ( N
n=269 JJ N
) ) N
, , N
celecoxib $ i
200 CD N
mg NN N
( ( N
n=523 JJ N
) ) N
, , N
rofecoxib VBZ N
12.5 CD N
mg NN N
( ( N
n=259 JJ N
) ) N
, , N
or CC N
rofecoxib VB N
25 CD N
mg NN N
( ( N
n=527 JJ N
) ) N
in IN N
a DT N
double JJ N
blind NN N
trial NN N
[ NNP N
Vioxx NNP i
, , i
Acetaminophen NNP i
, , i
Celecoxib NNP i
Trial NNP i
( ( i
VACT2 NNP i
) ) i
] NN i
. . i

The DT N
most RBS N
reliable JJ N
combination NN N
of IN N
predictive JJ N
factors NNS N
was VBD N
a DT N
negative JJ N
anti-human JJ o
immunodeficiency NN o
virus NN o
antibody NN o
status NN o
, , o
with IN o
either DT o
a DT o
positive JJ o
history NN o
of IN o
acute JJ o
icteric JJ o
hepatitis NN o
and CC o
AST NNP o
greater JJR o
than IN N
45 CD N
IU NNP N
per IN N
liter NN N
or CC N
no DT N
history NN N
of IN N
acute JJ N
icteric JJ N
hepatitis NN N
and CC N
AST NNP N
greater JJR N
than IN N
85 CD N
IU NNP N
per IN N
liter NN N
, , N
which WDT N
predicted VBD N
response NN N
in IN N
77 CD N
% NN N
with IN N
a DT N
specificity NN N
of IN N
79 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

METHODS NNP N
Heparin NNP N
in IN N
Acute NNP N
Embolic NNP N
Stroke NNP N
Trial NNP N
( ( N
HAEST NNP N
) ) N
was VBD N
a DT N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
and CC N
double-dummy JJ N
trial NN N
on IN N
the DT N
effect NN N
of IN N
low-molecular-weight JJ i
heparin NN i
( ( i
LMWH NNP i
, , i
dalteparin VBZ i
100 CD i
IU/kg NNP i
subcutaneously RB i
twice RB i
a DT i
day NN i
) ) i
or CC i
aspirin NN i
( ( N
160 CD N
mg NN N
every DT N
day NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
449 CD p
patients NNS p
with IN p
acute JJ p
ischaemic JJ p
stroke NN p
and CC p
atrial JJ p
fibrillation NN p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
observer-blinded JJ N
fashion NN N
, , N
40 CD p
ASA NNP p
1 CD p
paediatric JJ p
patients NNS p
undergoing VBG p
subumbilical JJ p
surgery NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
caudal JJ i
injection NN i
of IN i
either DT i
plain NN i
ropivacaine VBP i
0.2 CD i
% NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.2 NNP i
) ) i
or CC i
a DT i
mixture NN i
of IN i
ropivacaine JJ i
0.1 CD N
% NN N
with IN N
clonidine JJ i
2 CD i
microg/kg NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.1C NNP i
) ) i
. . i

Ten CD p
male JJ p
subjects NNS p
with IN p
untreated JJ p
type NN p
2 CD p
diabetes NNS p
were VBD N
given VBN N
, , N
in IN N
random JJ i
sequence NN i
, , i
50 CD i
g NN i
protein NN i
in IN i
the DT i
form NN i
of IN i
very RB i
lean JJ i
beef NN i
or CC i
only RB i
water NN i
at IN i
0800 CD i
h NN i
and CC i
studied VBN i
over IN i
the DT i
subsequent JJ i
8 CD i
h. NN i
Protein NNP i
ingestion NN i
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
circulating VBG o
insulin NN o
, , o
C-peptide NNP o
, , o
glucagon NN o
, , o
alpha NN o
amino NN o
and CC o
urea JJ o
nitrogen NN o
, , o
and CC o
triglycerides NNS o
; : o
a DT o
decrease NN o
in IN o
nonesterified JJ o
fatty JJ o
acids NNS o
; : o
and CC o
a DT o
modest JJ o
increase NN o
in IN o
respiratory JJ o
quotient NN o
. . o

One CD p
hundred CD p
and CC p
eleven RB p
previously RB p
untreated JJ p
patients NNS p
with IN p
extensive JJ p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
with IN N
the DT N
aim NN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
tolerance NN o
of IN o
high-dose JJ i
epirubicin NN i
( ( N
120 CD N
mg/m2 NN N
) ) N
in IN N
combination NN N
with IN N
either DT N
cyclophosphamide NN i
( ( N
800 CD N
mg/m2 NN N
; : N
arm CC N
1 CD N
) ) N
or CC N
cisplatin NN i
( ( N
60 CD N
mg/m2 NN N
; : N
arm CC N
2 CD N
) ) N
. . N

Although IN N
the DT N
intensive JJ i
insulin NN i
therapy NN i
group NN N
had VBD N
more RBR N
glucose JJ o
measurements NNS o
performed VBN N
than IN N
the DT N
control NN N
group NN N
, , N
a DT N
similar JJ N
proportion NN N
of IN N
values NNS N
were VBD N
within IN N
the DT N
target NN N
range NN N
( ( N
682 CD N
[ RB N
42.4 CD N
% NN N
] NN N
of IN N
1607 CD N
values NNS N
in IN N
the DT N
5- JJ N
to TO N
7-mmol/L JJ N
range NN N
; : N
250 CD N
[ $ N
38.7 CD N
% NN N
] NN N
of IN N
660 CD N
values NNS N
in IN N
the DT N
8- JJ N
to TO N
10-mmol/L JJ N
range NN N
, , N
P NNP N
= NNP N
.35 NNP N
) ) N
. . N

METHODS NNP N
Twenty NNP p
consecutive JJ p
patients NNS p
who WP p
underwent VBP p
sigmoidectomy NN p
for IN p
sigmoid JJ p
colon NN p
cancer NN p
were VBD N
prospectively RB N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
the DT N
ligatures NNS i
group NN i
, , i
in IN i
which WDT i
bowel NN i
ligatures NNS i
were VBD i
placed VBN i
, , i
3 CD i
, , i
5 CD i
, , i
10 CD i
cm NN i
from IN i
the DT i
tumor NN i
proximally RB i
and CC i
distally RB i
before IN i
dissection NN i
; : i
and CC i
the DT i
no DT i
ligatures NNS i
group NN i
, , i
in IN i
which WDT i
the DT i
corresponding NN i
sites NNS i
were VBD i
ligated VBN i
only RB i
immediately RB i
before IN i
taking VBG i
the DT i
specimen NNS i
out RP i
. . i

Continuous JJ i
chemotherapy NN i
in IN N
responsive JJ p
metastatic JJ p
breast NN p
cancer NN p
: : p
a DT N
role NN N
for IN N
tumour NN N
markers NNS N
? . N
A DT N
biochemical JJ N
response NN N
index NN N
comprising VBG N
ESR NNP N
, , N
CEA NNP N
and CC N
CA NNP N
15.3 CD N
was VBD N
evaluated VBN N
in IN N
67 CD p
patients NNS p
with IN p
systemic JJ p
breast NN p
cancer NN p
treated VBN p
by IN p
chemotherapy NN p
; : p
55 CD p
were VBD p
assessable JJ p
by IN p
UICC NNP p
criteria NNS p
and CC p
the DT p
response NN p
index NN p
( ( p
96 CD p
% NN p
of IN p
all DT p
UICC NNP p
assessable JJ p
patients NNS p
) ) p
. . p

This DT N
prospective JJ N
, , N
6-week JJ N
, , N
multicenter NN N
, , N
double-blind NN N
study NN N
examined VBD N
the DT N
benefits NNS N
of IN N
initiating VBG N
treatment NN N
with IN N
combination NN i
valsartan/hydrochlorothiazide NN i
( ( i
HCTZ NNP i
) ) i
compared VBN N
with IN N
initial JJ N
valsartan NNS N
monotherapy NN N
for IN N
648 CD p
patients NNS p
with IN p
stage-1 JJ p
or CC p
stage-2 JJ p
hypertension NN p
( ( p
age=52.6+/-10 JJ p
years NNS p
; : p
54 CD p
% NN p
male NN p
; : p
baseline VB p
blood NN p
pressure NN p
( ( p
BP NNP p
) ) p
=161/98 VBP p
mm JJ p
Hg NNP p
, , p
32 CD p
% NN p
stage NN p
1 CD p
) ) p
. . p

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
short-term JJ N
benefit NN N
of IN N
adding VBG N
60 CD N
mg NN N
of IN N
trimetazidine NN i
to TO N
the DT N
daily JJ N
therapeutic JJ N
regimen NNS N
of IN N
29 CD p
male JJ p
patients NNS p
with IN p
coronary JJ p
insufficiency NN p
who WP p
had VBD p
persistent JJ p
ST NNP p
depression NN p
on IN p
exercise NN p
tolerance NN p
test NN p
( ( p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
1 CD p
mm NN p
) ) p
, , p
despite IN p
treatment NN p
with IN p
nifedipine JJ i
40 CD N
mg JJ N
per IN N
day NN N
. . N

In IN N
this DT N
randomized VBN N
, , N
blinded VBD N
, , N
multicenter FW N
comparison NN N
study NN N
, , N
377 CD p
infants NNS p
and CC p
children NNS p
with IN p
acute NN p
otitis NN p
media NNS p
( ( p
AOM NNP p
) ) p
received VBD p
a DT p
10-day JJ p
course NN p
of IN p
an DT p
oral JJ p
suspension NN p
of IN p
one CD p
of IN p
the DT p
following NN p
: : p
cefuroxime NN i
axetil NN i
( ( i
CAE NNP i
) ) i
, , i
30 CD i
mg/kg/day NN i
; : i
cefaclor NN i
( ( i
CEC NNP i
) ) i
, , i
40 CD i
mg/kg/day NN i
; : i
or CC i
amoxicillin-clavulanate JJ i
potassium NN i
( ( i
AMX-CL NNP i
) ) i
, , i
40 CD i
mg/kg/day NN i
. . i

Male JJ p
well-informed JJ p
patients NNS p
with IN p
primary JJ p
monolateral JJ p
inguinal JJ p
hernia NN p
( ( p
ASA NNP p
I-II NNP p
) ) p
were VBD N
divided VBN N
into IN N
2 CD N
groups NNS N
and CC N
consecutively RB N
treated VBD N
; : N
group NN N
A DT N
was VBD N
treated VBN N
with IN N
laparoscopic JJ i
transabdominal JJ i
preperitoneal NN i
approach NN i
( ( i
TAPP NNP i
) ) i
( ( p
median JJ p
age NN p
47+/-7 JJ p
years NNS p
, , p
57 CD p
patients NNS p
) ) p
, , p
group NN p
B NNP p
with IN p
open JJ i
mesh NN i
herniorrhaphy NN i
( ( p
45+/-6 JJ p
years NNS p
, , p
64 CD p
patients NNS p
) ) p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Stable JJ p
patients NNS p
who WP p
had VBD p
anuria NNS p
and CC p
were VBD p
on IN p
low-flux JJ p
polysulfone NN p
membrane NN p
were VBD N
randomly RB N
allocated VBN N
either RB N
to TO N
HD NNP N
with IN N
high-flux JJ i
polyamide NN i
membrane NN i
( ( N
group NN N
A NNP N
; : N
22 CD N
patients NNS N
) ) N
or CC N
to TO N
HD NNP N
with IN N
low-flux JJ i
polyamide NN i
membrane NN i
( ( N
group NN N
B NNP N
; : N
24 CD N
patients NNS N
) ) N
for IN N
24 CD N
weeks NNS N
, , N
then RB N
they PRP N
were VBD N
started VBN N
on IN N
24 CD N
weeks NNS N
of IN N
the DT N
alternative JJ N
HD NNP N
treatment NN N
. . N

Patients NNS N
received VBD N
a DT N
5 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
bolus NN N
of IN N
magnesium NN i
sulphate NN i
followed VBN i
by IN i
a DT i
500 CD i
mg NN i
h NN i
( ( i
-1 NNP i
) ) i
infusion NN i
or CC i
saline NN i
in IN N
the DT N
same JJ N
volumes NNS N
for IN N
24 CD N
h. JJ N
Time NNP N
to TO N
first VB N
pain NN N
, , N
analgesic JJ N
request NN N
, , N
return NN N
of IN N
motor NN o
function NN o
, , o
visual JJ o
analogue NN o
pain NN o
and CC o
sedation NN o
scores NNS o
were VBD N
evaluated VBN N
every DT N
4 CD N
h NN N
during IN N
the DT N
24 CD N
h JJ N
postoperative JJ N
period NN N
. . N

Significant JJ N
improvements NNS N
in IN N
patients NNS o
' POS o
global JJ o
function NN o
were VBD N
seen VBN N
versus NN N
placebo NN i
at IN N
week NN N
24 CD N
( ( N
observed JJ N
cases NNS N
) ) N
, , N
on IN N
the DT N
Clinician NNP o
's POS o
Interview-Based JJ o
Impression NN o
of IN o
Change-Plus NNP o
version NN o
only RB N
for IN N
patients NNS N
on IN N
donepezil JJ N
5 CD N
mg/d NN N
( ( N
P=0.014 NNP N
) ) N
, , N
and CC N
on IN N
the DT N
Sum NNP o
of IN o
the DT o
Boxes NNP o
of IN o
the DT o
Clinical NNP o
Dementia NNP o
Rating NNP o
only RB N
for IN N
patients NNS N
on IN N
10 CD N
mg/d NN N
( ( N
P=0.007 NNP N
) ) N
. . N

Participants NNS N
were VBD N
randomly RB N
allocated VBN N
at IN N
the DT N
cluster NN i
level NN i
to TO i
10 CD i
weeks NNS i
of IN i
: : i
( ( i
1 CD i
) ) i
workplace NN i
physical JJ i
exercise NN i
( ( i
WORK NNP i
) ) i
performed VBD i
in IN i
groups NNS i
during IN i
working VBG i
hours NNS i
for IN i
5 CD i
minutes NNS i
per IN i
week NN i
and CC i
up RB i
to TO i
five CD i
group-based JJ i
coaching NN i
sessions NNS i
on IN i
motivation NN i
for IN i
regular JJ i
physical JJ i
exercise NN i
, , i
or CC i
( ( i
2 CD i
) ) i
home-based JJ i
physical JJ i
exercise NN i
( ( i
HOME NNP i
) ) i
performed VBD i
during IN i
leisure NN i
time NN i
for IN i
5 CD i
minutes NNS i
per IN i
week NN i
. . i

Using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
design NN N
, , N
motor NN N
thresholds NNS N
, , N
recruitment NN N
curves NNS N
, , N
cortical JJ N
stimulation-induced JJ N
silent JJ N
period NN N
( ( N
CSP NNP N
) ) N
, , N
short JJ i
intracortical JJ i
inhibition NN i
( ( i
ICI NNP i
) ) i
, , i
intracortical JJ i
facilitation NN i
( ( i
ICF NNP i
) ) i
, , N
and CC N
late JJ N
inhibition NN N
( ( N
L-ICI NNP N
) ) N
in IN N
14 CD p
healthy JJ p
subjects NNS p
were VBD N
investigated VBN N
after IN N
oral JJ N
doses NNS N
of IN N
50 CD N
and CC N
100 CD N
mg NNS N
amantadine VBP i
with IN i
single JJ i
and CC i
paired JJ i
pulse NN i
TMS NNP i
paradigms NN i
. . i

RESULTS NNP N
Only RB N
topical JJ N
bupivacaine NN i
was VBD N
found VBN N
to TO N
decrease VB N
postoperative JJ o
pain NN o
scores NNS o
significantly RB N
over IN N
those DT N
with IN N
placebo NN N
, , N
at IN N
30 CD N
minutes NNS N
postoperatively RB N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
4 CD N
, , N
P NNP N
= NNP N
.002 NNP N
) ) N
and CC N
at IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
3 CD N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Post NNP N
hoc NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rizatriptan JJ i
versus NN i
placebo NN i
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
had VBD N
pain NN o
relief NN o
when WRB N
their PRP$ N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
on IN N
weekends NNS N
( ( N
65 CD N
% NN N
versus IN N
36 CD N
% NN N
, , N
P=.046 NNP N
) ) N
compared VBN N
with IN N
weekdays NNS N
( ( N
66 CD N
% NN N
versus IN N
61 CD N
% NN N
, , N
P=.365 NNP N
) ) N
, , N
and CC N
the DT N
weekend NN o
placebo NN o
response NN o
rate NN o
was VBD N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
adults NNS N
. . N

Treatment NN N
with IN N
ranitidine NN i
, , N
but CC N
not RB N
placebo VB i
, , N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
CD4+ NNP o
lymphocytes NNS o
( ( N
33 CD N
% NN N
to TO N
49 CD N
% NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
CD8+ NNP o
lymphocytes NNS o
( ( N
41 CD N
% NN N
to TO N
27 CD N
% NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
occurrence NN o
of IN o
reported VBN o
oral JJ o
irritation NN o
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
108 CD p
iron-deficient JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
Group NNP i
C NNP i
( ( i
control NN i
) ) i
or CC i
Group NNP i
IE NNP i
( ( i
200 CD i
mg NN i
of IN i
iron NN i
sucrose NN i
intravenously RB i
over IN i
1 CD i
hr NNS i
and CC i
3000 CD i
IU NNP i
of IN i
rHuEPO- JJ i
subcutaneously NN i
during IN N
the DT N
operation NN N
and CC N
during IN N
the DT N
postoperative JJ N
period NN N
if IN N
the DT N
hemoglobin NN N
[ NNP N
Hb NNP N
] NNP N
level NN N
was VBD N
70-80 JJ N
g/L NN N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
relative VBP N
to TO N
the DT N
control NN N
group NN N
, , N
were VBD N
able JJ N
to TO N
reduce VB N
the DT N
use NN N
of IN N
antihypertensive JJ N
medications NNS N
( ( N
31 CD N
vs. FW N
8 CD N
% NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
fewer JJR N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
additional JJ N
medications NNS N
or CC N
increases NNS N
in IN N
dosage NN N
relative NN N
to TO N
the DT N
controls NNS N
( ( N
11 CD N
vs. FW N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
142 CD p
patients NNS p
with IN p
symptomatic JJ p
heart NN p
failure NN p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
III NNP p
and CC p
IV NNP p
) ) p
were VBD N
randomized VBN N
to TO N
double-blind VB N
, , N
short-term JJ i
treatment NN i
with IN i
conivaptan NN i
, , i
a DT i
dual JJ i
V NNP i
( ( i
1a CD i
) ) i
/V NN i
( ( i
2 CD i
) ) i
vasopressin NN i
receptor NN i
antagonist NN i
, , i
at IN i
a DT i
single JJ i
intravenous JJ i
dose NN i
( ( i
10 CD i
, , i
20 CD i
, , i
or CC i
40 CD i
mg NN i
) ) i
or CC i
placebo NN i
. . i

Eyes NNS N
treated VBN N
with IN N
latanoprost NN N
, , N
stored VBD N
both DT N
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C NNP N
, , N
achieved VBD N
statistically RB N
significantly RB N
lower JJR N
mean NN o
IOPs NNP o
than IN N
untreated JJ N
eyes NNS N
at IN N
all DT N
time NN N
points NNS N
, , N
except IN N
at IN N
21 CD N
hours NNS N
treated VBN N
by IN N
the DT N
drug NN N
stored VBD N
at IN N
30 CD N
degrees NNS N
C. NNP N
We PRP N
subtracted VBD N
the DT N
IOP NNP N
of IN N
eyes NNS N
receiving VBG N
latanoprost NN N
from IN N
the DT N
IOP NNP N
of IN N
untreated JJ N
eyes NNS N
for IN N
each DT N
time NN N
point NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
the DT N
eye NN N
drops NNS N
( ( N
delta JJ N
IOP NNP N
) ) N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
of IN N
15 CD p
aspirin-naive JJ p
patients NNS p
( ( p
mean JJ p
age NN p
48.8 CD p
? . p
10.2 CD p
years NNS p
) ) p
with IN p
the DT p
metabolic JJ p
syndrome NN p
, , p
statin NN i
monotherapy NN i
( ( i
simvastatin JJ i
40 CD i
mg JJ i
daily RB i
) ) i
was VBD i
compared VBN i
to TO i
combination VB i
therapy NN i
( ( i
simvastatin JJ i
40 CD i
mg NN i
and CC i
ezetimibe $ i
10 CD i
mg JJ i
daily RB i
) ) i
on IN N
biomarkers NNS N
of IN N
inflammation NN N
and CC N
platelet NN N
activity NN N
. . N

METHODS NNP N
In IN N
this DT N
post-hoc JJ N
analysis NN N
of IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
multi-center JJ N
therapeutic JJ N
equivalence NN N
trial NN N
, , N
76 CD p
patients NNS p
undergoing JJ p
elective JJ p
on-pump JJ p
cardiac NN p
surgery NN p
received VBD p
perioperative JJ i
volume NN i
replacement NN i
using VBG i
either CC i
10 CD i
% NN i
HES NNP i
130/0.4 CD i
( ( i
N.=37 NNP i
) ) i
or CC i
10 CD i
% NN i
HES NNP i
200/0.5 CD i
( ( i
N.=39 NNP i
) ) i
up RB i
to TO i
a DT i
maximum JJ i
dose NN i
of IN i
20 CD i
mL JJ i
kg-1 NN i
. . i

To TO N
determine VB N
if IN N
muscle NN N
atrophy NN N
could MD N
be VB N
minimized VBN N
with IN N
exercise NN i
therapy NN i
, , N
30 CD p
patients NNS p
undergoing JJ p
marrow JJ p
transplantation NN p
for IN p
acute NN p
leukemia NN p
completed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
receive VB N
: : N
( ( i
1 CD i
) ) i
no DT i
therapy NN i
( ( i
controls NNS i
) ) i
, , i
( ( i
2 CD i
) ) i
physical JJ i
therapy NN i
thrice NN i
weekly RB i
( ( i
PT3 NNP i
) ) i
, , i
or CC i
( ( i
3 CD i
) ) i
physical JJ i
therapy NN i
five CD i
times NNS i
weekly JJ i
( ( i
PT5 NNP i
) ) i
. . i

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
4-week JJ N
cycle NN N
of IN N
subcutaneous JJ i
low JJ i
doses NNS i
IL-2 NNP i
+ NNP i
IFN NNP i
in IN N
months NNS N
1 CD N
, , N
3 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
every DT N
3 CD N
months NNS N
until IN N
the DT N
first JJ N
documented JJ N
disease NN N
progression NN N
( ( N
arm NN N
A NNP N
, , N
suspension NN N
) ) N
, , N
or CC N
the DT N
same JJ N
regimen NNS N
, , N
with IN N
chronic JJ N
maintenance NN N
of IN N
immunotherapy NN N
, , N
regardless RB N
of IN N
tumour JJ N
response NN N
, , N
until IN N
death NN o
or CC o
intolerable JJ o
toxicity NN o
( ( N
arm NN N
B NNP N
, , N
maintenance NN N
) ) N
. . N

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN N
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN o
was VBD N
not RB N
significantly RB N
increased VBN N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

METHODS NNP N
The DT N
study NN N
included VBD N
42 CD p
patients NNS p
( ( p
29 CD p
women NNS p
and CC p
13 CD p
men NNS p
; : p
mean JJ p
age NN p
53.2+/-14.2 JJ p
years NNS p
; : p
body NN p
surface JJ p
area NN p
1.76+/-0.14 JJ p
m2 NN p
) ) p
with IN p
SH NNP p
, , p
as IN p
judged VBN p
by IN p
elevated JJ p
serum NN p
TSH NNP p
levels NNS p
( ( p
> $ p
3.6 CD p
mIU/l NN p
; : p
range NN p
, , p
3.8-12.0 JJ p
) ) p
and CC p
normal JJ p
free JJ p
thyroid NN p
hormones NNS p
( ( p
FT4 NNP p
and CC p
FT3 NNP p
) ) p
and CC p
30 CD p
euthyroid JJ p
volunteer NN p
. . p

METHODS NNP N
A NNP N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ i
study NN N
was VBD N
performed VBN N
in IN N
40 CD p
healthy JJ p
Chinese JJ p
subjects NNS p
( ( p
4 CD p
groups NNS p
of IN p
10 CD p
subjects NNS p
each DT p
, , p
placebo VBZ p
4:1 CD p
ratio NN p
) ) p
who WP p
received VBD p
infusions NNS p
of IN p
uricase NN p
( ( p
single JJ p
doses NNS p
of IN p
0.1 CD p
, , p
0.2 CD p
, , p
and CC p
0.3 CD p
mg/kg NN p
; : p
multiple JJ p
doses NNS p
of IN p
0.2 CD p
mg NN p
( ( p
-1 NN p
) ) p
? . p
( ( p
-1 NN p
) ) p
for IN p
7 CD p
d NN p
) ) p
. . p

At IN N
1 CD N
year NN N
, , N
no DT N
differences NNS N
in IN N
the DT N
resolution NN o
of IN o
symptoms NNS o
were VBD N
observed VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
and CC N
over IN N
2 CD N
years NNS N
, , N
the DT N
overall JJ o
incidence NN o
of IN o
complications NNS o
was VBD N
the DT N
same JJ N
, , N
specifically RB N
fecaloma JJ N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
in IN N
the DT N
MM NNP N
group NN N
and CC N
external JJ o
hemorrhoidal NN o
thrombosis NN o
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
in IN N
the DT N
SH NNP N
group NN N
. . N

METHODS NNP N
Out-patients NNS p
scheduled VBN p
for IN p
endoscopic NN p
ultrasonography NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
oral JJ N
pre-medication NN N
with IN N
the DT N
anti-foam JJ i
agent NN i
, , i
dimethylpolysiloxane NN i
, , i
alone RB i
( ( N
treatment NN N
A NNP N
; : N
n JJ N
= NNP N
29 CD N
) ) N
, , N
with IN N
dimethylpolysiloxane JJ i
plus CC i
sodium JJ i
bicarbonate NN i
( ( i
treatment NN i
B NNP i
; : i
n CC i
= VB i
29 CD i
) ) i
or CC i
with IN i
dimethylpolysiloxane NN i
, , i
sodium NN i
bicarbonate NN i
and CC i
pronase NN i
( ( N
treatment NN N
C NNP N
; : N
n CC N
= VB N
29 CD N
) ) N
. . N

The DT N
percentages NNS o
of IN o
patients NNS o
who WP o
achieved VBD o
meaningful JJ o
pain NN o
relief NN o
within IN N
the DT N
first JJ N
hour NN N
after IN N
treatment NN N
were VBD N
77.6 CD N
% NN N
and CC N
83.7 CD N
% NN N
for IN N
ibuprofen JJ i
arginate NN i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
61.0 CD N
% NN N
and CC N
63.0 CD N
% NN N
for IN N
ibuprofen JJ i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
39.8 CD N
% NN N
for IN N
placebo NN i
. . i

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Forty NNP p
patients NNS p
who WP p
had VBD p
diabetes NNS p
with IN p
nephropathy JJ p
and CC p
arteriosclerosis NN p
obliterans NNS p
and CC p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN p
II NNP p
receptor NN p
blocker NN p
( ( p
n JJ p
= NNP p
40 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
sarpogrelate VB i
( ( N
300 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
or CC N
aspirin JJ i
group NN N
( ( N
100 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
amprenavir NN o
plasma NN o
concentrations NNS o
were VBD N
decreased VBN N
by IN N
saquinavir JJ N
soft JJ N
gel NN N
capsule NN N
( ( N
by IN N
32 CD N
% NN N
for IN N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
at IN N
steady JJ N
state NN N
[ NNS N
AUC NNP N
( ( N
ss NN N
) ) N
] NN N
and CC N
37 CD N
% NN N
for IN N
peak NN N
plasma NN N
concentration NN N
at IN N
steady JJ N
state NN N
[ NNS N
C NNP N
( ( N
max NN N
, , N
ss NN N
) ) N
] NN N
) ) N
and CC N
increased VBN N
by IN N
indinavir NN N
( ( N
33 CD N
% NN N
for IN N
AUC NNP N
( ( N
ss NN N
) ) N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
multicenter NN p
study NN p
patients NNS p
with IN p
symptoms NNS p
of IN p
acute JJ p
UC NNP p
and CC p
a DT p
baseline NN p
Modified NNP p
Mayo NNP p
Disease NNP p
Activity NNP p
Index NNP p
( ( p
MMDAI NNP p
) ) p
score NN p
between IN p
6 CD p
and CC p
10 CD p
, , p
inclusive JJ p
, , p
with IN p
a DT p
subscale JJ p
rating NN p
of IN p
> NNP p
or CC p
=2 NN p
for IN p
both DT p
rectal JJ p
bleeding NN p
and CC p
mucosal JJ p
appearance NN p
were VBD N
randomized VBN N
to TO N
receive VB N
3.3 CD N
g NN N
of IN N
balsalazide NN i
or CC i
placebo NN i
tablets NNS i
twice RB i
daily RB i
for IN i
8 CD i
weeks NNS i
. . i

Patients NNS p
who WP p
qualified VBD p
for IN p
the DT p
prospective JJ p
, , p
randomized VBN p
, , p
double-masked JJ p
, , p
placebo-controlled JJ i
trial NN N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
single JJ N
dose NN N
of IN N
oral JJ i
clindamycin NN i
administered VBN i
preoperatively RB i
( ( i
single-dose JJ i
group NN i
) ) i
; : i
( ( i
2 CD i
) ) i
clindamycin NN i
administered VBD i
preoperatively RB i
with IN i
continued JJ i
therapy NN i
for IN i
5 CD i
days NNS i
( ( i
5-day JJ i
group NN i
) ) i
; : i
and CC i
( ( i
3 CD i
) ) i
a DT i
placebo NN i
group NN N
. . N

Although IN N
the DT N
incidence NN o
of IN o
HCMV NNP o
infection NN o
was VBD N
comparable JJ N
in IN N
DNAemia NNP N
and CC N
antigenemia NN N
arms NNS N
( ( N
34 CD N
% NN N
vs JJ N
42 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
.259 NNP N
) ) N
, , N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP N
arm NN N
( ( N
18 CD N
% NN N
vs JJ N
31 CD N
% NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
insulin NN i
, , i
amino JJ i
acid NN i
( ( i
AA NNP i
) ) i
, , i
and CC i
branched-chain JJ i
ketoacid NN i
( ( i
KA NNP i
) ) i
availability NN i
on IN N
leucine JJ N
kinetics NNS N
in IN N
eight CD p
healthy JJ p
volunteers NNS p
( ( p
age NN p
= VBZ p
22 CD p
+/- JJ p
2 CD p
y NN p
, , p
body NN p
mass NN p
index NN p
= VBD p
24 CD p
+/- JJ p
1 CD p
kg NN p
) ) p
by IN p
using VBG p
the DT p
euglycemic JJ i
insulin NN i
clamp NN i
and CC N
[ JJ N
1-14C JJ N
] NNP N
leucine NN N
turnover NN N
techniques NNS N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
106 CD p
patients NNS p
without IN p
underlying VBG p
liver NN p
disease NN p
and CC p
submitted VBN p
to TO p
liver VB p
resection NN p
using VBG p
INT NNP p
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP i
( ( i
10 CD i
minutes NNS i
of IN i
inflow JJ i
occlusion NN i
followed VBN i
by IN i
10 CD i
minutes NNS i
of IN i
reperfusion NN i
before IN i
liver JJ i
transection NN i
) ) i
, , i
APC NNP i
( ( i
sevoflurane JJ i
administration NN i
for IN i
20 CD i
minutes NNS i
before IN i
liver JJ i
transection NN i
) ) i
, , i
and CC i
INT NNP i
( ( i
no DT i
preconditioning NN i
) ) i
. . i

The DT N
enhanced JJ N
label NN N
includes VBZ N
a DT N
universal JJ N
medication NN N
schedule NN N
( ( N
UMS NNP N
) ) N
that WDT N
standardizes VBZ N
the DT N
directions NNS N
for IN N
use NN N
incorporating VBG N
1 CD N
) ) N
standard NN N
time NN N
periods NNS N
for IN N
administration NN N
( ( N
morning NN N
, , N
noon NN N
, , N
evening NN N
, , N
and CC N
bedtime NN N
) ) N
, , N
2 CD N
) ) N
numeric JJ N
vs. FW N
alpha NN N
characters NNS N
, , N
3 CD N
) ) N
'carriage NN N
returns NNS N
' POS N
to TO N
separate VB N
daily JJ N
dose NN N
and CC N
4 CD N
) ) N
a DT N
graphic JJ N
aid NN N
to TO N
visually RB N
depict VB N
dose NN N
and CC N
frequency NN N
. . N

The DT N
parents NNS p
of IN p
consecutive JJ p
children NNS p
with IN p
autism NN p
( ( p
2 CD p
( ( p
1/2 CD p
) ) p
-5 CD p
years NNS p
old JJ p
) ) p
from IN p
the DT p
autism NN p
assessment NN p
services NNS p
for IN p
the DT p
intervention NN p
regions NNS p
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
20-week JJ i
manual-based JJ i
parent NN i
education NN i
and CC i
behavior JJ i
management NN i
intervention NN i
( ( i
n JJ i
= NNP i
35 CD i
) ) i
or CC i
a DT i
manual-based JJ i
parent NN i
education NN i
and CC i
counseling VBG i
intervention NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

METHODS NNP N
Fifty-six JJ p
patients NNS p
with IN p
unstable JJ p
angina NN p
, , p
mean JJ p
age NN p
of IN p
55.4 CD p
+/- JJ p
8.5 CD p
, , p
41 CD p
men NNS p
and CC p
15 CD p
women NNS p
, , p
were VBD p
evaluated VBN p
in IN p
a DT p
randomized JJ p
, , p
double-blind JJ p
study NN p
of IN p
two CD p
groups NNS p
of IN p
patients NNS p
treated VBN p
with IN p
diltiazem NN i
or CC i
propranolol NN i
at IN N
total JJ N
daily JJ N
doses NNS N
of IN N
180 CD N
mg NNS N
and CC N
120 CD N
mg NN N
respectively RB N
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
. . N

METHOD NNP N
Data NNP p
were VBD p
collected VBN p
over IN p
a DT p
23-week JJ p
period NN p
, , p
from IN p
4:00 CD p
PM NNP p
to TO p
midnight VB p
, , p
and CC p
resulted VBD p
in IN p
446 CD p
patients NNS p
being VBG p
recruited VBN p
into IN p
the DT p
study NN p
( ( p
90 CD p
% NN p
of IN p
those DT p
who WP p
screened VBD p
positive JJ p
) ) p
and CC p
randomized VBN p
to TO p
three CD p
conditions NNS p
following VBG p
a DT p
two-stage JJ p
process NN p
: : p
screened VBN p
only RB p
( ( p
n JJ p
= NNP p
147 CD p
) ) p
, , p
assessed VBN p
( ( p
n JJ p
= NNP p
152 CD p
) ) p
, , p
and CC p
received VBN p
intervention NN p
( ( p
n JJ p
= NNP p
147 CD p
) ) p
. . p

The DT N
cumulative JJ o
HBsAg NNP o
reverse NN o
seroconversion NN o
rates NNS o
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
since IN N
chemotherapy NN N
were VBD N
0 CD N
% NN N
, , N
6.4 CD N
% NN N
, , N
and CC N
16.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
respectively RB N
, , N
which WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.032 NNP N
) ) N
. . N

During IN N
orthopaedic JJ N
surgery NN N
of IN N
the DT N
limb NN N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
controlled VBD N
study NN N
on IN N
three CD p
parallel JJ p
groups NNS p
in IN p
30 CD p
patients NNS p
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ N
and CC N
pharmacodynamic JJ N
effect NN N
of IN N
infiltration NN N
of IN N
the DT N
iliac JJ N
crest NN N
bone NN N
graft NN N
harvest NN N
site NN N
with IN N
20 CD N
ml NNS N
of IN N
bupivacaine NN i
( ( N
100 CD N
mg NN N
) ) N
, , N
ropivacaine NN i
( ( i
150 CD i
mg NN i
) ) i
or CC i
saline JJ i
as IN i
control NN i
group NN i
( ( N
n JJ N
= NN N
10 CD N
in IN N
each DT N
group NN N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
parallel-group NN p
study NN p
, , p
patients NNS p
naive VBP p
to TO p
emetogenic VB p
chemotherapy NN p
( ( p
N NNP p
= NNP p
1,085 CD p
) ) p
who WP p
were VBD p
scheduled VBN p
to TO p
receive VB p
cyclophosphamide- NN i
( ( p
500 CD p
to TO p
1,200 CD p
mg/m2 NN p
) ) p
or CC p
carboplatin NN p
( ( p
> CD p
or CC p
= VB p
300 CD p
mg/m2 NN p
) ) p
based VBN p
chemotherapy NN i
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
granisetron NN i
( ( i
n JJ i
= NNP i
542 CD i
) ) i
or CC i
I.V NNP i
. . i

After IN N
the DT N
first JJ N
4 CD N
weeks NNS N
all DT N
subjects NNS N
were VBD N
changed VBN N
from IN N
CC NNP N
to TO N
sevelamer VB N
3.0 CD N
g/day NN N
for IN N
another DT N
4 CD N
weeks NNS N
, , N
then RB N
allocated VBD N
randomly RB N
to TO N
three CD N
groups NNS N
for IN N
the DT N
final JJ N
4 CD N
weeks NNS N
: : N
group NN N
A NNP N
, , N
sevelamer NN i
6.0 CD i
g/day NN i
; : i
group NN i
B NNP i
, , i
sevelamer VBD i
3.0 CD i
g/day NN i
and CC i
CC NNP i
3.0 CD i
g/day NN i
; : i
group NN i
C NNP i
, , i
CC NNP i
3.0 CD i
g/day NN i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
Forty-five JJ p
HF NNP p
patients NNS p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II-III NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB i
or CC i
sildenafil VB i
( ( N
50 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
) ) N
for IN N
1 CD N
year NN N
, , N
with IN N
assessment NN N
( ( N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
) ) N
of IN N
LV NNP o
ejection NN o
fraction NN o
, , o
diastolic JJ o
function NN o
, , o
geometry NN o
, , o
cardiopulmonary JJ o
exercise NN o
performance NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

This DT N
study NN N
compared VBN N
oral JJ N
mucositis NN o
pain NN o
levels NNS o
in IN N
4 CD p
groups NNS p
of IN p
cancer NN p
patients NNS p
receiving VBG p
bone NN p
marrow NN p
transplants NNS p
( ( p
BMT NNP p
) ) p
: : p
( ( p
1 CD p
) ) p
treatment NN i
as IN i
usual JJ i
control NN i
, , i
( ( i
2 CD i
) ) i
therapist NN i
support NN i
, , i
( ( i
3 CD i
) ) i
relaxation NN i
and CC i
imagery NN i
training NN i
, , i
and CC i
( ( i
4 CD i
) ) i
training NN i
in IN i
a DT i
package NN i
of IN i
cognitive-behavioral JJ i
coping NN i
skills NNS i
which WDT i
included VBD i
relaxation NN i
and CC i
imagery NN i
. . i

Randomization NN N
was VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
CNS NNP o
leukemia NN o
occurred VBD N
at IN N
initial JJ N
diagnosis NN N
of IN N
acute JJ N
lymphocytic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
( ( N
Stratum NNP N
I PRP N
, , N
15 CD N
patients NNS N
) ) N
, , N
during IN N
first JJ N
bone NN N
marrow NN N
( ( N
BM NNP N
) ) N
remission NN N
( ( N
Stratum NNP N
II NNP N
, , N
49 CD N
patients NNS N
) ) N
, , N
simultaneous JJ N
with IN N
first JJ N
BM NNP N
relapse NN N
( ( N
Stratum NNP N
III NNP N
, , N
12 CD N
patients NNS N
) ) N
, , N
or CC N
during IN N
second JJ N
BM NNP N
remission NN N
( ( N
Stratum NNP N
IV NNP N
, , N
11 CD N
patients NNS N
) ) N
. . N

At IN N
week NN N
8 CD N
compared VBN N
with IN N
week NN N
4 CD N
, , N
the DT N
concentration NN o
of IN o
P NNP o
increased VBD N
from IN N
5.7+/-1.4 JJ N
to TO N
6.4+/-1.7 JJ N
mg/dL NN N
in IN N
group NN N
A NNP N
, , N
and CC N
decreased VBD N
significantly RB N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
, , N
and CC N
in IN N
group NN N
B NNP N
compared VBN N
with IN N
groups NNS N
A NNP N
and CC N
C NNP N
; : N
groups NNS N
A DT N
and CC N
C NNP N
had VBD N
similar JJ N
concentrations NNS N
at IN N
week NN N
8 CD N
. . N

The DT N
modified VBN N
scale NN N
( ( N
CYBOCS-PDD NNP N
) ) N
, , N
which WDT N
contains VBZ N
only RB N
the DT N
five CD N
Compulsion NNP N
severity NN N
items NNS N
( ( N
range VB N
0-20 NN N
) ) N
, , N
was VBD N
administered VBN N
to TO N
172 CD p
medication-free JJ p
children NNS p
( ( p
mean JJ p
8.2 CD p
+/- JJ p
2.6 CD p
years NNS p
) ) p
with IN p
PDD NNP p
( ( p
autistic JJ p
disorder NN p
, , p
n JJ p
= VBP p
152 CD p
; : p
Asperger NNP p
's POS p
disorder NN p
, , p
n JJ p
= VBP p
6 CD p
; : p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , p
n JJ p
= NNP p
14 CD p
) ) p
participating NN p
in IN p
RUPP NNP p
clinical JJ p
trials NNS p
. . p

To TO N
investigate VB N
the DT N
clinical JJ N
effects NNS N
of IN N
a DT N
novel JJ i
PD NNP i
fluid NN i
buffered VBD i
with IN i
34 CD i
mM NNS i
pure JJ i
bicarbonate NN i
at IN i
neutral JJ i
pH NN i
, , N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
crossover JJ N
comparison NN N
with IN N
conventional JJ i
, , i
acidic JJ i
, , i
35 CD i
mM NN i
lactate NN i
PD NNP i
fluid NN i
was VBD N
performed VBN N
for IN N
two CD N
consecutive JJ N
12-wk JJ N
periods NNS N
with IN N
28 CD p
children NNS p
( ( p
age NN p
, , p
6 CD p
mo NN p
to TO p
15 CD p
yr NN p
) ) p
undergoing NN p
automated VBN i
PD NNP i
( ( i
APD NNP i
) ) i
. . i

The DT N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
in IN N
the DT N
non-deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
14 CD N
% NN N
, , N
and CC N
the DT N
incidence NN o
of IN o
postoperative JJ o
pulmonary JJ o
complications NNS o
in IN N
the DT N
deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
17 CD N
% NN N
, , N
( ( N
absolute JJ N
risk NN N
reduction NN N
-3 NNP N
% NN N
, , N
95 CD N
% NN N
C1 NNP N
-22 NNP N
to TO N
19 CD N
% NN N
) ) N
. . N

Group NNP N
I PRP N
patients NNS N
received VBD N
lumbar JJ i
interlaminar JJ i
epidural JJ i
injections NNS i
of IN i
local JJ i
anesthetic JJ i
( ( i
lidocaine JJ i
0.5 CD N
% NN N
) ) N
6 CD N
mL NN N
, , N
whereas WP N
Group NNP N
II NNP N
received VBD N
lumbar JJ i
interlaminar JJ i
epidural JJ i
injections NNS i
with IN i
local JJ i
anesthetic NN i
( ( i
lidocaine JJ i
0.5 CD i
% NN i
) ) i
5 CD i
mL NN i
mixed JJ i
with IN i
1 CD i
mL NNS i
of IN i
steroids NNS i
and CC i
6 CD i
mg NN i
of IN i
betamethasone NN i
. . i

STUDY NNP N
DESIGN NNP N
A NNP N
total NN N
of IN N
78 CD p
boys NNS p
age NN p
13-15 CD p
years NNS p
with IN p
a DT p
mean JJ p
body NN p
fat JJ p
percentage NN p
of IN p
30 CD p
% NN p
+/-9 JJ p
% NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
consume VB N
fish JJ N
oil NN N
( ( N
providing VBG N
1.5 CD N
g NN N
of IN N
n-3 JJ i
long-chain NN i
polyunsaturated VBD i
fatty JJ i
acid/day NN i
) ) i
or CC i
vegetable JJ i
oil NN i
( ( i
control NN i
) ) i
for IN N
16 CD N
weeks NNS N
. . N

Didanosine NNP i
( ( N
125 CD N
to TO N
200 CD N
mg NNS N
given VBN N
as IN N
buffered JJ N
tablets NNS N
) ) N
and CC N
delavirdine JJ i
mesylate NN i
( ( N
400 CD N
mg NN N
) ) N
pharmacokinetics NNS N
were VBD N
evaluated VBN N
when WRB N
each DT N
drug NN N
was VBD N
given VBN N
alone RB N
( ( N
treatments NNS N
A DT N
and CC N
B NNP N
, , N
respectively RB N
) ) N
, , N
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
given VBN N
concurrently RB N
( ( N
treatment NN N
C NNP N
) ) N
, , N
and CC N
when WRB N
didanosine NN i
was VBD N
given VBN N
1 CD N
h NN N
after IN N
delavirdine NN N
( ( N
treatment NN N
D NNP N
) ) N
. . N

Each DT N
month NN N
for IN N
6 CD N
months NNS N
, , N
subjects VBZ N
received VBN N
either RB N
3 CD N
consecutive JJ N
weeks NNS N
of IN N
the DT N
OC NNP i
( ( N
i.e NN N
, , N
tablets NNS N
containing VBG N
a DT N
fixed VBN N
dose NN N
of IN N
ethinyl JJ i
estradiol NN i
[ VBD i
0.035 CD i
mg NN i
] NN i
and CC i
increasing VBG i
doses NNS i
of IN i
norgestimate JJ i
[ NNS i
0.180 CD i
mg NNS i
, , i
0.215 CD i
mg NN i
, , i
0.250 CD i
mg NN i
] NN i
) ) i
followed VBN i
by IN i
7 CD i
days NNS i
of IN i
inactive JJ i
drug NN i
or CC i
placebo NN i
( ( i
color-matched JJ i
tablets NNS i
) ) i
. . i

The DT N
mean JJ o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
RPE NNP o
, , o
number NN o
of IN o
steps NNS o
( ( N
determined VBN N
by IN N
step NN N
counter NN N
) ) N
, , N
and CC N
blood NN o
lactate NN o
concentrations NNS o
were VBD N
determined VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
15 CD N
minutes NNS N
during IN N
the DT N
recovery NN N
from IN N
the DT N
exercise NN i
, , i
with IN i
and CC i
without IN i
motivational JJ i
music NN i
( ( N
2 CD N
separate JJ N
sessions NNS N
, , N
at IN N
random JJ N
order NN N
) ) N
. . N

During IN p
2 CD p
years NNS p
and CC p
7 CD p
months NNS p
from IN p
June NNP p
, , p
1985 CD p
to TO p
December NNP p
, , p
1987 CD p
, , p
a DT p
randomized JJ p
multi-center JJ p
trial NN p
of IN p
PVB NNP i
, , i
VAB-6 NNP i
, , i
BVP NNP i
regimen NNS i
( ( i
group NN i
A DT i
) ) i
without IN i
etoposide JJ i
versus NN i
PEB NNP i
chemotherapy NN i
( ( i
bleomycin NN i
, , i
etoposide RB i
and CC i
cisplatinum NN i
) ) i
( ( N
group NN N
B NNP N
) ) N
was VBD N
given VBN N
to TO N
patients NNS N
with IN N
disseminated JJ N
testicular JJ N
tumors NNS N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
this DT N
multisite NN N
study NN N
, , N
171 CD p
children NNS p
with IN p
standard-risk JJ p
ALL NNP p
, , p
age NN p
1 CD p
to TO p
9.99 CD p
years NNS p
at IN p
diagnosis NN p
, , p
previously RB p
randomly RB p
assigned VBN p
to TO p
IT NNP i
methotrexate NNP i
( ( i
n JJ i
= NNP i
82 CD i
) ) i
or CC i
to TO i
triple VB i
IT NNP i
therapy NN i
( ( p
n JJ p
= NNP p
89 CD p
) ) p
on IN p
CCG NNP p
1952 CD p
, , p
underwent JJ p
neurocognitive JJ p
evaluation NN p
by IN p
a DT p
licensed JJ p
psychologist NN p
at IN p
a DT p
mean NN p
of IN p
5.9 CD p
years NNS p
after IN p
random JJ p
assignment NN p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
Twenty NNP p
ulcerative JJ p
colitis NN p
patients NNS p
with IN p
poor JJ p
pouch JJ p
function NN p
( ( p
score NN p
> VBZ p
4 CD p
on IN p
a DT p
12-point JJ p
score NN p
) ) p
were VBD N
recruited VBN N
for IN N
inclusion NN N
to TO N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
crossover NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
ursodeoxycholic JJ i
acid NN i
( ( N
10 CD N
mg/kg NNS N
per IN N
day NN N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
1 CD N
month NN N
) ) N
. . N

The DT N
mean JJ N
treatment NN N
duration NN N
was VBD N
10 CD N
and CC N
14 CD N
weeks NNS N
, , N
median JJ o
time NN o
to TO o
PSA NNP o
progression NN o
was VBD N
27.2 CD N
and CC N
30.8 CD N
weeks NNS N
, , N
median JJ o
survival NN o
time NN o
was VBD N
44 CD N
and CC N
50.9 CD N
weeks NNS N
, , N
and CC N
PSA NNP o
response NN o
rate NN o
was VBD N
only RB N
24.6 CD N
and CC N
28.9 CD N
% NN N
in IN N
the DT N
EMP/VBL NNP N
and CC N
EMP NNP N
arms NNS N
, , N
respectively RB N
. . N

The DT N
subjects NNS N
were VBD N
asked VBN N
to TO N
perform VB N
the DT N
following JJ N
tasks NNS N
, , N
with IN N
the DT N
affected JJ N
hand NN N
for IN N
30 CD N
seconds NNS N
: : N
( ( N
1 CD N
) ) N
transfer NN N
pegs NN N
from IN N
a DT N
saucer NN N
to TO N
a DT N
pegboard NN N
; : N
( ( N
2 CD N
) ) N
grasp NN N
, , N
carry NN N
, , N
and CC N
release VB N
a DT N
hard JJ N
rubber NN N
ball NN N
; : N
and CC N
( ( N
3 CD N
) ) N
eating NN N
, , N
using VBG N
a DT N
spoon NN N
to TO N
remove VB N
the DT N
jelly NN N
from IN N
the DT N
plate NN N
, , N
bring VBG N
it PRP N
towards IN N
the DT N
mouth NN N
, , N
and CC N
then RB N
place VB N
it PRP N
on IN N
another DT N
plate NN N
. . N

METHOD NNP N
Adults NNP p
aged VBD p
18-75 CD p
years NNS p
with IN p
MDD NNP p
( ( p
DSM-IV-TR NNP p
) ) p
and CC p
Montgomery-Asberg NNP p
Depression NNP p
Rating NNP p
Scale NNP p
( ( p
MADRS NNP p
) ) p
total NN p
score NN p
? . p
26 CD p
were VBD p
randomized VBN p
( ( p
1:1:1 CD p
) ) p
to TO p
receive VB p
vortioxetine NN i
10 CD i
mg NN i
or CC i
15 CD i
mg NN i
or CC i
placebo NN i
once RB N
daily JJ N
, , N
with IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
being VBG N
change NN N
from IN N
baseline NN N
at IN N
week NN N
8 CD N
in IN N
MADRS NNP N
analyzed VBN N
by IN N
mixed JJ N
model NN N
for IN N
repeated JJ N
measures NNS N
. . N

Overall JJ o
significant JJ o
improvement NN o
was VBD N
achieved VBN N
for IN N
65.7 CD N
? . N
37.3 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
and CC N
68.9 CD N
? . N
37.7 CD N
weeks NNS N
in IN N
Group NNP N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
when WRB N
all DT N
participants NNS N
were VBD N
considered VBN N
; : N
whereas NNS N
, , N
this DT N
was VBD N
77 CD N
? . N
27.8 CD N
weeks NNS N
and CC N
77.9 CD N
? . N
30.2 CD N
weeks NNS N
when WRB N
they PRP N
were VBD N
separated VBN N
into IN N
successful JJ N
categories NNS N
. . N

METHODS NNP N
This DT N
12-month JJ N
, , N
open JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
in IN N
15 CD p
centers NNS p
in IN p
France NNP p
and CC p
1 CD p
center NN p
in IN p
Belgium NNP p
; : p
309 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
receive VB p
either DT p
induction NN i
therapy NN i
with IN i
ATG NNP i
( ( p
n=151 NN p
) ) p
followed VBN p
by IN p
initiation NN p
of IN p
tacrolimus NN i
on IN i
day NN i
9 CD i
or CC i
immediate JJ i
tacrolimus-based JJ i
triple NN i
therapy NN i
( ( p
n=158 JJ p
) ) p
. . p

We PRP N
performed VBD N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
of IN N
rituximab NN i
( ( i
375 CD i
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
given VBN i
either CC i
concurrently RB i
before IN i
each DT i
infusional JJ i
etoposide NN i
, , i
vincristine NN i
, , i
doxorubicin NN i
, , i
cyclophosphamide NN i
, , i
and CC i
prednisone NN i
( ( i
EPOCH NNP i
) ) i
chemotherapy NN i
cycle NN N
or CC N
sequentially RB N
( ( N
weekly JJ N
for IN N
6 CD N
weeks NNS N
) ) N
after IN N
completion NN N
of IN N
all DT N
chemotherapy NN N
in IN N
HIV-associated NNP N
NHL NNP N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
among IN N
the DT N
three CD N
treatment NN N
groups NNS N
with IN N
respect NN N
to TO N
clinical JJ N
outcome NN N
; : N
more JJR N
patients NNS N
in IN N
the DT N
CAE NNP i
group NN N
( ( N
62 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CEC NNP i
group NN N
( ( N
46 CD N
% NN N
) ) N
or CC N
the DT N
AMX-CL JJ N
group NN N
( ( N
52 CD N
% NN N
) ) N
had VBD N
complete JJ o
resolution NN o
of IN o
signs NNS o
and CC o
symptoms NNS o
of IN o
AOM NNP o
( ( o
including VBG o
effusion NN o
) ) o
. . o

At IN N
week NN N
8 CD N
Ca NNP N
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
occurred VBD N
in IN N
groups NNS N
B NNP N
and CC N
C. NNP N
Side-effects NNP o
with IN o
sevelamer JJ o
administration NN o
occurred VBD N
in IN N
34 CD N
of IN N
the DT N
86 CD N
patients NNS N
and CC N
24 CD N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
, , N
with IN N
a DT N
high JJ N
frequency NN N
in IN N
group NN N
A NNP N
( ( N
13/29 CD N
; : N
44.8 CD N
% NN N
) ) N
. . N

Twenty-six JJ p
hemiplegic JJ p
subjects NNS p
with IN p
chronic JJ p
stroke NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
20-session JJ i
wrist NN i
training NN i
with IN i
an DT i
electromyography NN i
( ( i
EMG NNP i
) ) i
-driven RB i
NMES NNP i
robot NN i
( ( i
NMES NNP i
robot NNP i
group NN i
, , i
n RB i
= VBZ i
11 CD i
) ) i
and CC i
with IN i
an DT i
EMG-driven JJ i
robot NN i
( ( i
robot JJ i
group NN N
, , N
n RB N
= VBZ N
15 CD N
) ) N
, , N
completed VBD N
within IN N
7 CD N
consecutive JJ N
weeks NNS N
. . N

CLASSIFICATION NN N
OF NNP N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
III NNP N
evidence NN N
that WDT N
CBT NNP i
in IN N
addition NN N
to TO N
SMC NNP N
, , N
as IN N
compared VBN N
to TO N
SMC NNP N
alone RB N
, , N
significantly RB N
reduces VBZ N
seizure NN o
frequency NN o
in IN N
patients NNS N
with IN N
PNES NNP N
( ( N
change NN N
in IN N
median JJ N
monthly JJ N
seizure NN N
frequency NN N
: : N
baseline NN N
to TO N
6 CD N
months NNS N
follow-up RB N
, , N
CBT NNP N
group NN N
, , N
12 CD N
to TO N
1.5 CD N
; : N
SMC NNP N
alone RB N
group NN N
, , N
8 CD N
to TO N
5 CD N
) ) N
. . N

DESIGN NNP N
Subjects VBZ p
with IN p
type NN p
2 CD p
diabetes NNS p
( ( p
n JJ p
= NNP p
62 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
approximately RB N
10 CD N
% NN N
of IN N
energy NN i
from IN i
low-fiber JJ i
breakfast NN i
cereal NN i
( ( i
LF NNP i
diet NN i
) ) i
, , i
high-fiber JJ i
breakfast NN i
cereal NN i
( ( i
HF NNP i
diet NN i
) ) i
, , i
or CC i
monounsaturated VBN i
fatty JJ i
acids NNS i
( ( i
MUFA NNP i
diet NN i
) ) i
for IN N
6 CD N
mo NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
clinical JJ N
trial NN N
for IN N
one CD N
year NN N
in IN N
southern JJ p
India NNP p
involving VBG p
15,419 CD p
preschool-age JJ p
children NNS p
who WP p
received VBD p
either CC p
8.7 CD i
mumol NN i
( ( i
8333 CD i
IU NNP i
) ) i
of IN i
vitamin NN i
A NNP i
and CC i
46 CD i
mumol NN i
( ( i
20 CD i
mg NN i
) ) i
of IN i
vitamin NN i
E NNP i
( ( i
the DT i
treated VBN i
group NN i
) ) i
or CC i
vitamin JJ i
E NNP i
alone RB i
( ( N
the DT N
control NN N
group NN N
) ) N
. . N

PARTICIPANTS NNP N
Twenty NNP p
eyes NNS p
of IN p
20 CD p
consecutive JJ p
patients NNS p
( ( p
spherical JJ p
equivalent NN p
[ NNP p
SE NNP p
] NNP p
, , p
-2.01+/-1.36 NNP p
diopters NNS p
[ NNP p
D NNP p
] NNP p
) ) p
treated VBD p
with IN p
wavefront-guided JJ i
Zyoptix NNP i
Ablation NNP i
Refinement NNP i
software NN i
( ( i
ZAR NNP i
) ) i
LASIK NNP i
and CC p
20 CD p
eyes NNS p
of IN p
20 CD p
consecutive JJ p
patients NNS p
( ( p
SE NNP p
, , p
-1.81+/-1.21 NNP p
D NNP p
) ) p
treated VBD p
with IN p
standard JJ i
Planoscan NNP i
LASIK NNP i
, , p
both DT p
for IN p
residual JJ p
refractive JJ p
error NN p
enhancement NN p
. . p

METHODS NNP N
This DT N
post NN N
hoc NN N
exploratory NN N
analysis NN N
evaluated VBD N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
treated VBN p
with IN p
IPE NNP i
4 CD i
grams/day NN i
, , i
IPE NNP i
2 CD i
grams/day NN i
, , i
or CC i
placebo NN i
in IN p
phase NN p
3 CD p
, , p
randomized VBN p
, , p
placebo-controlled JJ p
studies NNS p
entitled VBN p
: : p
MARINE NNP p
[ NNP p
triglyceride NN p
( ( p
TG NNP p
) ) p
levels NNS p
? . p
and CC p
? . p
mg/dL NN p
] NN p
and CC p
ANCHOR NNP p
[ NNP p
TG NNP p
levels NNS p
? . p
and CC p
< $ p
500 CD p
mg/dL NN p
, , p
despite IN p
low-density JJ p
lipoprotein NN p
cholesterol NN p
( ( p
LDL-C NNP p
) ) p
control NN p
with IN p
stable JJ p
statin NN p
therapy NN p
] NN p
. . p

Women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
1 CD N
) ) N
control NN i
: : i
continue NN i
established VBD i
dietary JJ i
intake NN i
; : i
2 CD i
) ) i
medium NN i
dairy NN i
: : i
substitute NN i
dairy NN i
products NNS i
to TO i
achieve VB i
intake NN i
of IN i
calcium NN i
of IN i
approximately RB i
1000-1100 JJ i
mg/d NN i
and CC i
maintain VB i
isocaloric JJ i
intake NN i
; : i
3 CD i
) ) i
high JJ i
dairy NN i
: : i
substitute NN i
dairy NN i
products NNS i
to TO i
achieve VB i
intake NN i
of IN i
calcium NN i
of IN i
1300-1400 JJ i
mg/d NN i
and CC i
maintain VB i
isocaloric JJ i
intake NN i
. . i

Protocol $ p
1 CD p
: : p
96 CD p
bovine NN p
incisors NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
, , N
and CC N
enamel JJ i
surfaces NNS i
were VBD i
bonded VBN i
in IN i
accordance NN i
with IN i
the DT i
following JJ i
treatments NNS i
: : i
( ( i
1E CD i
) ) i
ozone NN i
+ NN i
Clearfil NNP i
Protect NNP i
Bond NNP i
; : i
( ( i
2E CD i
) ) i
Clearfil NNP i
Protect NNP i
Bond NNP i
( ( i
control NN i
) ) i
; : i
( ( i
3E CD i
) ) i
ozone NN i
+ JJ i
Xeno NNP i
III NNP i
; : i
( ( i
4E CD i
) ) i
Xeno NN i
III NNP i
( ( i
control NN i
) ) i
. . i

Myocardial JJ o
ultrastructure NN o
on IN o
septal JJ o
biopsies NNS o
, , N
obtained VBD N
within IN N
5 CD N
min NN N
from IN N
weaning VBG N
from IN N
extracorporeal JJ N
circulation NN N
, , N
showed VBD N
better JJR N
preservation NN o
scores NNS o
for IN N
all DT N
considered VBN N
parameters NNS N
( ( N
nucleus NN N
, , N
sarcoplasmic JJ N
reticulum NN N
, , N
mitochondria NN N
and CC N
cellular JJ N
oedema NN N
) ) N
in IN N
the DT N
treated JJ N
subjects NNS N
, , N
although IN N
the DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
only RB N
for IN N
nuclei NN N
. . N

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
high-density NN o
lipoprotein NN o
cholesterol/total JJ o
cholesterol NN o
ratio NN o
was VBD N
observed VBN N
in IN N
the DT N
ethinyl JJ i
E2-desogestrel NNP i
group NN N
, , N
and CC N
no DT N
persistent JJ N
changes NNS N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
could MD N
be VB N
demonstrated VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

For IN N
example NN N
, , N
approximately RB N
20 CD N
% NN N
of IN N
patients NNS N
might MD N
be VB N
expected VBN N
to TO N
have VB N
a DT N
chance NN N
increase NN N
or CC N
decrease NN N
in IN N
symptom NN o
score NN o
by IN N
at IN N
least JJS N
4.9 CD N
points NNS N
, , N
in IN N
peak JJ o
urine JJ o
flow NN o
rate NN o
by IN N
at IN N
least JJS N
4.1 CD N
ml NN N
. . N

We PRP N
assigned VBD N
a DT N
total NN N
of IN N
578 CD p
adult NN p
ambulatory NN p
surgery NN p
patients NNS p
to TO N
either VB N
a DT N
control NN i
group NN i
that WDT i
was VBD i
given VBN i
two CD i
folded JJ i
, , i
warmed JJ i
cotton NN i
blankets NNS i
or CC i
a DT i
treatment NN i
group NN i
that WDT i
was VBD i
given VBN i
a DT i
warmed NN i
, , i
unfolded JJ i
cotton NN i
sheet NN i
and CC i
cotton NN i
blanket NN i
. . i

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
between IN N
prehydration NN N
with IN N
3 CD N
% NN N
hypertonic JJ i
saline NN i
and CC N
with IN N
isotonic JJ i
lactated VBN i
Ringer NNP i
's POS i
solution NN i
on IN N
the DT N
hemodynamic JJ o
changes NNS o
and CC o
serum NN o
electrolyte NN o
concentrations NNS o
in IN N
patients NNS p
undergoing JJ p
spinal JJ p
anesthesia NN p
. . p

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ o
DPP-4 JJ o
inhibition NN o
at IN o
steady-state NN o
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
? . N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

CONCLUSION NNP N
The DT N
suppression NN N
of IN N
the DT N
RAS NNP N
by IN N
the DT N
blockade NN N
of IN N
angiotensin NN N
II NNP N
type NN N
1 CD N
( ( N
AT NNP N
( ( N
1 CD N
) ) N
) ) N
receptors NNS N
may MD N
demonstrate VB N
remodeling VBG N
effects NNS N
on IN N
the DT N
ubiquitous JJ N
small JJ N
resistance NN N
vessels NNS N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
the DT N
myocardium NN N
and CC N
renal JJ N
glomeruli NN N
, , N
thus RB N
affording VBG N
more JJR N
complete JJ N
end-organ JJ N
protection NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
angiotensin NN i
converting VBG i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
on IN N
cough NN N
responses NNS N
to TO N
bradykinin VB N
( ( N
BK NNP N
) ) N
, , N
substance NN N
P NNP N
( ( N
SP NNP N
) ) N
and CC N
citric JJ N
acid NN N
in IN N
a DT N
double JJ N
blind NN N
, , N
random NN N
study NN N
on IN N
10 CD p
hypertensive JJ p
patients NNS p
receiving VBG p
ACE NNP p
inhibitors NNS p
. . p

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN o
in IN o
plasma NN o
transferrin NN o
levels NNS o
and CC N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN N
in IN N
plasma JJ o
superoxide JJ o
dismutase NN o
levels NNS o
between IN N
the DT N
2 CD N
groups NNS N
. . N

Forty-four JJ p
patients NNS p
underwent JJ i
CRT NNP i
device NN i
implantation NN i
using VBG i
Overlay NNP i
Ref NNP i
to TO i
guide VB i
target NN i
vein JJ i
selection NN i
and CC i
advance VB i
a DT i
specifically RB i
designed VBN i
pacing VBG i
lead NN i
into IN i
the DT i
target NN i
vein NN i
( ( i
Overlay NNP i
Ref NNP i
group NN i
) ) i
; : i
44 CD i
patients NNS i
were VBD i
conventionally RB i
implanted VBN i
( ( i
control VB i
group NN i
) ) i
. . i

Each DT N
specimen NN N
was VBD N
embedded VBN N
in IN N
a DT N
self-cured JJ i
acrylic JJ i
resin NN i
block NN i
from IN N
2.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
margins NNS N
of IN N
a DT N
cast JJ i
Ni-Cr JJ i
alloy NN i
crown NN i
, , N
then RB N
loaded VBD N
at IN N
150 CD N
degrees NNS N
from IN N
the DT N
long JJ N
axis NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
at IN N
a DT N
crosshead JJ N
speed NN N
of IN N
1.0 CD N
mm/minute NN N
until IN N
fracture NN N
. . N

Most JJS N
responses NNS N
returned VBN N
to TO N
the DT N
baseline NN N
values NNS N
within IN N
24 CD N
h. NN N
Plasma NNP N
bupivacaine NN N
concentrations NNS N
remained VBD N
within IN N
safe JJ N
limits NNS N
during IN N
the DT N
study NN N
, , N
but CC N
systemic JJ o
concentrations NNS o
increased VBD N
in IN N
some DT N
of IN N
the DT N
patients NNS N
during IN N
postoperative JJ N
infusion NN N
with IN N
0.125 CD N
% NN N
bupivacaine NN i
. . i

This DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
water NN i
extracts NNS i
of IN i
Graptopetalum NNP i
paraguayense NN i
( ( i
WGP NNP i
, , i
4 CD i
g/d NN i
) ) i
on IN N
blood NN o
pressure NN o
, , o
blood NN o
glucose JJ o
level NN o
, , o
and CC o
lipid JJ o
profiles NNS o
in IN N
subjects NNS p
with IN p
metabolic JJ p
syndrome NN p
( ( p
MS NNP p
) ) p
. . p

During IN N
the DT N
first JJ N
and CC N
second JJ N
months NNS N
of IN N
the DT N
washout NN N
, , N
slight JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
changes NNS N
of IN N
various JJ N
fatty JJ N
acids NNS N
among IN N
different JJ N
phospholipid JJ N
fractions NNS N
, , N
but CC N
after IN N
3 CD N
mo NN N
of IN N
washout NN N
, , N
only RB N
minor JJ N
alterations NNS N
were VBD N
still RB N
detectable JJ N
with IN N
respect NN N
to TO N
pretreatment VB N
values NNS N
. . N

The DT N
effects NNS N
of IN N
consuming VBG N
a DT N
liquid JJ N
formula NN N
containing VBG N
either CC N
fish JJ i
oil NN i
enriched VBN i
in IN i
omega-3 JJ i
fatty JJ i
acids NNS i
or CC i
vegetable JJ i
oil NN i
enriched VBN N
in IN N
oleic JJ N
acid NN N
was VBD N
evaluated VBN N
in IN N
20 CD p
male JJ p
subjects NNS p
randomly RB p
allocated VBN p
into IN p
two CD p
groups NNS p
over IN p
a DT p
42-d JJ p
period NN p
. . p

A DT p
total NN p
of IN p
1,480 CD p
pigs NNS p
were VBD N
used VBN N
in IN N
3 CD N
experiments NNS N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
corn NN i
distillers NNS i
dried VBD i
grains NNS i
with IN i
solubles NNS i
( ( i
DDGS NNP i
) ) i
varying VBG N
in IN N
oil NN N
content NN N
on IN N
growth NN N
performance NN N
, , N
carcass NN N
traits NNS N
, , N
and CC N
nutrient JJ N
digestibility NN N
in IN N
finishing VBG p
pigs NNS p
. . p

We PRP N
conclude VBP N
that IN N
intramuscular JJ N
administration NN N
of IN N
the DT N
fixed JJ N
combination NN N
of IN N
troxerutin $ i
150 CD N
mg NN N
and CC N
carbazochrome VB i
1.5 CD N
mg NN N
is VBZ N
effective JJ N
, , N
well RB N
tolerated VBN N
and CC N
superior JJ N
to TO N
placebo VB i
in IN N
improving VBG N
hemorrhoidal NN o
and CC o
post-surgical JJ o
symptoms NNS o
during IN N
the DT N
five CD N
days NNS N
following VBG N
surgery NN N
. . N

CONTEXT NN N
We PRP N
have VBP N
recently RB N
demonstrated VBN N
short-term JJ N
( ( N
6-month JJ N
) ) N
efficacy NN N
and CC N
safety NN N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS p
with IN p
central JJ p
precocious JJ p
puberty NN p
( ( p
CPP NNP p
) ) p
. . p

Theophylline NNP i
concentrations NNS i
in IN N
saliva NN N
have VBP N
been VBN N
compared VBN N
with IN N
those DT N
in IN N
serum NN N
in IN N
13 CD p
asthmatic JJ p
patients NNS p
after IN N
single JJ N
and CC N
multiple JJ N
oral JJ N
dosage NN N
of IN N
a DT N
microcrystalline JJ i
theophylline NN i
tablet NN i
( ( i
Nuelin NNP i
) ) i
and CC i
a DT i
sustained-release JJ i
preparation NN i
( ( i
Nuelin NNP i
Retard NNP i
) ) i
. . i

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
in IN N
infarct JJ o
size NN o
estimated VBN o
by IN o
measurement NN o
of IN o
serum JJ o
CK-MB NNP o
, , o
planimetry NN o
of IN o
infarct JJ o
area NN o
on IN o
technetium NN o
pyrophosphate NN o
myocardial JJ o
scintigrams NNS o
or CC o
R-wave JJ o
measurements NNS o
in IN N
patients NNS p
with IN p
transmural JJ p
anterior NNS p
and CC p
inferior JJ p
infarcts NNS p
. . p

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
satisfaction NN o
rate NN o
, , o
efficacy NN o
, , o
and CC o
complication NN o
rate NN o
of IN N
carbon NN i
dioxide NN i
( ( i
CO NNP i
( ( i
2 CD i
) ) i
) ) i
versus NN i
normal JJ i
saline NN i
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
outpatient JJ p
diagnostic JJ p
vaginoscopic NN p
hysteroscopy NN p
in IN p
infertile JJ p
patients NNS p
. . p

The DT N
Phase NNP N
1 CD N
single JJ N
round NN N
of IN N
DMSA NNP N
led VBD N
to TO N
a DT N
dramatic JJ N
normalization NN N
of IN N
RBC NNP o
glutathione NN o
in IN N
almost RB N
all DT N
cases NNS N
, , N
and CC N
greatly RB N
improved VBN N
abnormal JJ o
platelet NN o
counts NNS o
, , N
suggesting VBG N
a DT N
significant JJ N
decrease NN N
in IN N
inflammation NN N
. . N

DISCUSSION NNP N
The DT N
finding NN N
of IN N
high JJ N
vitamin NN N
B NNP N
( ( N
6 CD N
) ) N
levels NNS N
is VBZ N
consistent JJ N
with IN N
recent JJ N
reports NNS N
of IN N
low JJ N
levels NNS N
of IN N
pyridoxal-5-phosphate NN N
and CC N
low JJ N
activity NN N
of IN N
pyridoxal NN N
kinase NN N
( ( N
i.e JJ N
, , N
pyridoxal NN N
is VBZ N
only RB N
poorly RB N
converted VBN N
to TO N
pyridoxal-5-phosphate NN N
, , N
the DT N
enzymatically RB N
active JJ N
form NN N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN N
or CC N
zeaxanthin NN i
enriched VBN i
egg NN i
yolks NNS i
as RB i
well RB i
as IN i
an DT i
egg NN i
yolk-based JJ i
beverage NN i
show NN N
increases VBZ N
in IN N
serum NN o
lutein NN o
and CC o
zeaxanthin NN o
levels NNS o
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

Both DT N
carbapenems NNS N
revealed VBD N
high JJ N
SBAs NNP o
against IN o
clinically RB o
important JJ o
pathogens NNS o
at IN N
1 CD N
h NN N
; : N
meropenem NN N
had VBD N
a DT N
higher JJR N
SBA NNP o
against IN N
E. NNP N
cloacae NN N
and CC N
P. NNP N
mirabilis NN N
, , N
and CC N
the DT N
SBA NNP o
of IN N
imipenem NN N
against IN N
S. NNP N
aureus NN N
was VBD N
greater JJR N
than IN N
the DT N
SBA NNP N
of IN N
meropenem NN N
. . N

Thereby RB N
, , N
GH NNP i
shows VBZ N
a DT N
triphasic JJ N
action NN N
on IN N
BMD NNP o
: : o
an DT N
initial JJ N
decrease NN N
in IN N
BMD NNP o
during IN N
the DT N
1st CD N
year NN N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
increase NN N
in IN N
BMD NNP o
with IN N
buildup NN N
of IN N
a DT N
stable JJ N
plateau NN N
after IN N
60 CD N
months NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
blood NN o
biochemistry NN o
and CC o
hematological JJ o
parameters NNS o
were VBD N
not RB N
different JJ N
among IN N
treatments NNS N
except IN N
concentration NN o
of IN o
plasma JJ o
urea JJ o
N NNP o
, , o
plasma NN o
glucose NN o
, , o
and CC o
total JJ o
blood NN o
protein NN o
were VBD N
improved VBN N
especially RB N
with IN N
U-cas JJ N
supplementation NN N
at IN N
180 CD N
g/kg NN N
DM NNP N
in IN N
FB NNP N
. . N

The DT N
blood NN o
sugar NN o
profile NN o
and CC o
insulin NN o
consumption NN o
over IN N
a DT N
24 CD N
hour NN N
period NN N
was VBD N
not RB N
affected VBN N
by IN N
either DT N
penbutolol NN i
or CC i
placebo NN i
, , N
nor CC N
could MD N
any DT N
changes NNS N
be VB N
measured VBN N
in IN N
these DT N
parameters NNS N
when WRB N
measured VBN N
after IN N
food NN N
intake NN N
. . N

Sequential JJ i
methotrexate NN i
( ( N
Mtx NNP N
) ) N
absorption NN N
studies NNS N
were VBD N
undertaken VBN N
in IN N
127 CD p
children NNS p
undergoing JJ p
treatment NN p
for IN p
childhood NN p
non-T JJ p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
( ( p
ALL NNP p
) ) p
to TO N
determine VB N
whether IN N
serum JJ N
drug NN N
concentration NN N
, , N
clearance NN N
and CC N
dosage NN N
affect JJ N
event NN N
free JJ N
survival NN N
( ( N
EFS NNP N
) ) N
. . N

A DT N
Phase NNP N
II NNP N
clinical JJ N
study NN N
that WDT N
was VBD N
not RB N
completed VBN N
documented VBD N
that IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
PPS NNP i
administered VBD N
for IN N
8 CD N
weeks NNS N
lowered VBD N
plasma JJ N
levels NNS N
of IN N
sVCAM-1 NN i
and CC N
tended VBD N
to TO N
improve VB N
microvascular JJ o
blood NN o
flow NN o
in IN N
patients NNS p
with IN p
SCD NNP p
. . p

In IN N
61 CD N
acceptable JJ N
patients NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
response NN o
rate NN o
, , o
time NN o
to TO o
progression NN o
, , o
duration NN o
of IN o
the DT o
response NN o
, , o
and CC o
survival JJ o
rate NN o
. . o

In IN N
the DT N
BL NNP N
, , N
NO2 NNP N
exposure NN N
caused VBD N
increases NNS N
in IN N
polymorphonuclear JJ o
neutrophils NNS o
( ( o
PMNs NNP o
) ) o
, , o
interleukin JJ o
6 CD o
( ( o
IL-6 NNP o
) ) o
, , o
IL-8 NNP o
, , o
alpha1-antitrypsin NN o
, , o
and CC o
tissue NN o
plasminogen NN o
activator NN o
, , o
and CC o
decreases NNS o
in IN o
epithelial JJ o
cells NNS o
. . o

The DT N
physostigmine NN N
patch NN N
application NN N
in IN N
doses NNS N
of IN N
30 CD N
mg NNS N
and CC N
60 CD N
mg NNS N
apparently RB N
did VBD N
not RB N
lead VB N
to TO N
physostigmine VB o
plasma JJ o
concentrations NNS o
that WDT N
were VBD N
sufficient JJ N
to TO N
compensate VB N
for IN N
cholinergic JJ N
deficiencies NNS N
in IN N
affected JJ N
brain NN N
areas NNS N
and CC N
produce VB N
clinical JJ N
benefits NNS N
. . N

CONCLUSIONS NNP N
Clinical NNP N
efficacy NN N
of IN N
T NNP N
replacement NN N
therapy NN N
in IN N
hypogonadal JJ p
men NNS p
with IN p
MS NNP p
is VBZ N
reached VBN N
when WRB N
its PRP$ N
plasmatic JJ N
levels NNS N
approach VBP N
into IN N
the DT N
medium-high JJ N
range NN N
of IN N
normality NN N
( ( N
> JJ N
5 CD N
ng/ml NN N
) ) N
, , N
although IN N
subjective JJ N
threshold JJ N
values NNS N
may MD N
be VB N
different JJ N
. . N

More RBR N
proven JJ o
systemic JJ o
fungal JJ o
infections NNS o
occurred VBD N
in IN N
flu NN N
( ( N
Aspergillus NNP N
four CD N
, , N
Candida NNP N
tropicalis VBZ N
one CD N
, , N
C. NNP N
krusei NNP N
one NN N
) ) N
than IN N
itra NN N
( ( N
C. NNP N
albicans VBZ N
one CD N
) ) N
and CC N
more JJR N
of IN N
these DT N
were VBD N
fatal JJ N
( ( N
four CD N
versus NN N
nil NN N
) ) N
. . N

On IN N
the DT N
day NN N
of IN N
the DT N
O NNP N
( ( N
3 CD N
) ) N
exposure NN N
, , N
supplemented VBN N
subjects NNS N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
increased VBN N
levels NNS o
of IN o
plasma NN o
ascorbate NN o
, , o
tocopherols NNS o
, , o
and CC o
carotenoids NNS o
as IN N
compared VBN N
with IN N
those DT N
of IN N
the DT N
placebo NN N
group NN N
. . N

RESULTS NNP N
Although IN N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
found VBN N
in IN N
both DT N
the DT N
maxillary NN o
and CC o
mandibular JJ o
arches NNS o
after IN N
phase NN N
1 CD N
, , N
these DT N
differences NNS N
were VBD N
no RB N
longer RBR N
evident JJ N
by IN N
the DT N
end NN N
of IN N
full JJ N
orthodontic JJ N
treatment NN N
or CC N
after IN N
posttreatment JJ N
retention NN N
. . N

It PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
a DT N
single JJ N
nucleotide NN N
polymorphism NN N
( ( N
SNP NNP N
) ) N
in IN N
exon $ N
12 CD N
of IN N
HIF-1alpha NNP N
gene NN N
is VBZ N
present JJ N
in IN N
renal JJ p
cell NN p
carcinoma NN p
and CC p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
patients NNS p
. . p

Intensive JJ N
treatment NN N
should MD N
be VB N
started VBN N
as RB N
soon RB N
as IN N
is VBZ N
safely RB N
possible JJ N
after IN N
the DT N
onset NN N
of IN N
type NN N
1 CD N
diabetes NNS N
mellitus NN N
and CC N
maintained VBD N
thereafter RB N
, , N
aiming VBG N
for IN N
a DT N
practicable JJ N
target NN N
HbA NNP N
( ( N
1c CD N
) ) N
level NN N
of IN N
7.0 CD N
% NN N
or CC N
less JJR N
. . N

The DT N
fixed JJ N
combination NN N
between IN N
troxerutin $ i
150 CD N
mg NN N
and CC N
carbazochrome VB i
1.5 CD N
mg NN N
( ( N
Fleboside NNP N
ampoules NNS N
) ) N
was VBD N
previously RB N
shown VBN N
to TO N
have VB N
a DT N
good JJ N
efficacy NN o
and CC o
safety NN o
profile NN o
in IN N
non-surgical JJ p
patients NNS p
with IN p
acute JJ p
uncomplicated JJ p
hemorrhoids NNS p
. . p

However RB N
, , N
in IN N
5 CD N
subjects NNS N
with IN N
acute JJ N
increases NNS N
in IN N
serum JJ o
creatinine NN o
levels NNS o
, , o
serum NN o
creatine NN o
kinase NN o
levels NNS o
were VBD N
significantly RB N
elevated VBN N
as RB N
well RB N
, , N
suggesting VBG N
that IN N
myocyte JJ N
toxicity NN N
may MD N
have VB N
been VBN N
responsible JJ N
. . N

METHODS NNP N
Plasma NNP o
concentrations NNS o
of IN o
vWf NN o
and CC o
sP-sel NN o
were VBD N
measured VBN N
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
in IN N
1321 CD p
participants NNS p
in IN p
the DT p
SPAF NNP p
III NNP p
study NN p
and CC N
related VBN N
to TO N
the DT N
presence NN N
and CC N
onset NN N
of IN N
clinical JJ N
CHF NNP N
, , N
as RB N
well RB N
as IN N
echocardiographic JJ N
findings NNS N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
included VBD N
target NN o
vessel NN o
failure NN o
( ( o
TVF NNP o
; : o
including VBG o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
target VB o
vessel JJ o
revascularization NN o
) ) o
and CC o
Academic NNP o
Research NNP o
Consortium-defined NNP o
definite/probable JJ o
stent NN o
thrombosis NN o
( ( o
ST NNP o
) ) o
within IN N
12 CD N
months NNS N
. . N

All DT N
adverse JJ o
events NNS o
resolved VBD N
within IN N
72 CD N
h. JJ N
Induction NNP N
of IN N
chemokines/cytokines NNS o
and CC o
IFN-stimulated JJ o
genes NNS o
were VBD N
seen VBN N
at IN N
GS-9620 NNP N
doses NNS N
? . N
2 CD N
mg NN N
, , N
well RB N
below IN N
doses NNS N
that WDT N
induced VBD N
serum JJ N
IFN- NNP N
or CC N
led VBN N
to TO N
clinical JJ N
adverse JJ N
events NNS N
. . N

The DT N
odds NNS N
ratio NN N
in IN N
the DT N
control NN N
group NN N
for IN N
the DT N
rate NN o
of IN o
morbidity NN o
( ( o
cerebral JJ o
infarction NN o
and CC o
reversible JJ o
ischemic JJ o
neurological JJ o
deficits NNS o
) ) o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
following VBG N
the DT N
operation NN N
was VBD N
3.2 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

Mean JJ N
changes NNS N
in IN N
log NN o
serum JJ o
level NN o
of IN o
PSA NNP o
, , o
testosterone NN o
, , o
dihydrotestosterone NN o
, , o
luteinizing VBG o
hormone NN o
and CC o
sex NN o
hormone NN o
binding VBG o
globulin NN o
over IN N
21 CD N
weeks NNS N
between IN N
the DT N
verum NN N
and CC N
the DT N
placebo NN N
group NN N
were VBD N
compared VBN N
by IN N
analysis NN N
of IN N
covariance NN N
. . N

Protein NNP o
breakdown NN o
, , o
protein JJ o
oxidation NN o
, , o
protein JJ o
balance NN o
, , o
and CC o
glucose JJ o
production NN o
were VBD N
assessed VBN N
by IN N
stable JJ N
isotope NN N
tracer NN N
kinetics NNS N
using VBG N
l- JJ N
[ JJ N
1- JJ N
( ( N
13 CD N
) ) N
C NNP N
] NNP N
leucine NN N
and CC N
[ JJ N
6,6- JJ N
( ( N
2 CD N
) ) N
H2 NNP N
] NNP N
glucose NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
death NN o
at IN o
30 CD o
days NNS o
, , o
interleukin-6 JJ o
levels NNS o
, , o
inotropic NN o
score NN o
, , o
fluid NN o
balance NN o
, , o
serum JJ o
creatinine NN o
, , o
and CC o
intensive JJ o
care NN o
unit NN o
and CC o
hospital NN o
stay NN o
. . o

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ o
burst NN o
time NN o
with IN o
time NN o
to TO o
peak VB o
plasma JJ o
level NN o
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN N
level NN N
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

Plasma NNP o
P-selectin NNP o
antigen NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
( ( o
tPA NN o
) ) o
antigen NN o
and CC o
activity NN o
, , o
and CC o
plasminogen NN o
activator NN o
inhibitor-1 JJ o
( ( o
PAI-1 NNP o
) ) o
activity NN o
were VBD N
determined VBN N
in IN N
60 CD p
acute JJ p
atherosclerotic JJ p
stroke NN p
patients NNS p
and CC p
matched VBN p
control NN p
subjects NNS p
. . p

There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
eradication NN o
of IN o
both DT o
therapies NNS o
in IN N
both DT N
the DT N
antrum NN N
and CC N
gastric JJ N
body NN N
samples NNS N
( ( N
over IN N
80 CD N
% NN N
eradication NN N
) ) N
, , N
allowing VBG N
the DT N
results NNS N
to TO N
be VB N
classified VBN N
as IN N
satisfactory NN N
. . N

The DT N
effect NN N
of IN N
zidovudine NN i
and CC i
didanosine NN i
on IN N
the DT N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
concentrations NNS N
of IN N
neopterin NN N
was VBD N
studied VBN N
in IN N
12 CD p
patients NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
type-1 NN p
( ( p
HIV-1 NNP p
) ) p
infection NN p
3-12 JJ p
months NNS p
after IN p
initiation NN p
of IN p
antiretroviral JJ p
therapy NN p
. . p

The DT N
treatment NN N
group NN N
also RB N
showed VBD N
in IN N
vivo JJ o
T-cell NNP o
activation NN o
with IN N
an DT N
initial JJ N
lymphopenia NN N
followed VBN N
by IN N
a DT N
rebound NN o
lymphocytosis NN o
and CC o
upregulation NN o
of IN o
the DT o
subset NN o
markers NNS o
CD25 NNP o
( ( o
interleukin JJ o
2 CD o
receptor NN o
) ) o
and CC o
CD45RO NNP o
( ( o
T-memory NNP o
cells NNS o
) ) o
. . o

OBJECTIVE IN N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
there EX N
is VBZ N
a DT N
threshold JJ N
beyond IN N
which WDT N
increasing VBG N
doses NNS N
of IN N
vitamin NN N
D NNP N
, , N
or CC N
concentrations NNS N
of IN N
serum JJ N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
, , N
no RB N
longer RBR N
increase VB N
calcium NN o
absorption NN o
. . o

Compared VBN N
to TO N
baseline VB N
, , N
ABCA1 NNP o
and CC o
3-hydroxy-3-methyl-glutaryl NNP o
( ( o
HMG NNP o
) ) o
-CoA VBP o
reductase NN o
mRNA JJ o
expression NN o
increased VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
EGG NNP i
group NN N
only RB N
, , N
whereas NNS N
changes NNS N
in IN N
PBMC NNP o
total JJ o
cholesterol NN o
positively RB N
correlated VBN N
with IN N
changes NNS N
in IN N
lipid JJ N
raft NN N
content NN N
. . N

After IN N
a DT N
total NN N
of IN N
15,000 CD N
protein NNS N
nitrogen JJ N
units NNS N
( ( N
PNU NNP N
) ) N
had VBD N
been VBN N
given VBN N
, , N
blocking VBG o
antibody NN o
activity NN o
in IN N
the DT N
monomer NN N
group NN N
rose VBD N
from IN N
a DT N
mean NN N
of IN N
170 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
a DT N
mean NN N
of IN N
2,813 CD N
. . N

Bepotastine NNP i
besilate NN i
ophthalmic JJ i
solution NN i
( ( i
BBOS NNP i
) ) i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ i
histamine NN i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
new JJ i
, , i
purified JJ i
, , i
heat-treated JJ i
equine NN i
rabies NNS i
immunoglobulin VBP i
( ( i
PHT-Erig NNP i
) ) i
, , i
F NNP i
( ( i
ab IN i
' POS i
) ) i
2 CD i
preparation NN i
, , N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP p
and CC p
in IN p
the DT p
Philippines-two JJ p
countries NNS p
where WRB p
rabies NNS p
is VBZ p
endemic JJ p
. . p

Women NNS N
in IN N
the DT N
intervention NN N
arm NN N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
take VB o
their PRP$ o
infant NN o
to TO o
the DT o
clinic NN o
within IN o
the DT o
first JJ o
week NN o
of IN o
life NN o
( ( N
risk NN N
ratio VBP N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.04-1.18 JJ N
) ) N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
with IN N
placebo NN i
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
total JJ o
heart NN o
rate NN o
variability NN o
, , o
parasympathetically RB o
governed VBN o
high JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
or CC o
sympathetically RB o
influenced JJ o
low JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
. . o

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
current JJ N
Recommended NNP N
Dietary NNP N
Allowance NNP N
for IN N
vitamin NN i
B6 NNP i
during IN N
pregnancy NN N
( ( N
2.5 CD N
mg NN N
) ) N
is VBZ N
too RB N
low JJ N
and CC N
that DT N
supplementation NN N
of IN N
this DT N
vitamin NN N
in IN N
an DT N
amount NN N
more JJR N
than IN N
4 CD N
mg JJ N
daily JJ N
is VBZ N
recommended VBN N
. . N

RESULTS NNS N
When WRB N
including VBG N
all DT N
follow-up JJ N
variables NNS N
, , N
there EX N
were VBD N
three CD p
groups NNS p
: : p
( ( p
1 CD p
) ) p
Thirty-seven CD p
children NNS p
with IN p
male JJ p
predominance NN p
, , p
familial JJ p
history NN p
of IN p
epilepsy NN p
, , p
simple JJ p
febrile JJ p
convulsions NNS p
, , p
massive JJ p
myoclonus NN p
, , p
tonic-clonic JJ p
fits NNS p
. . p

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
on IN N
the DT N
serological JJ N
response NN N
at IN N
influenza JJ N
vaccination NN N
was VBD N
studied VBN N
in IN N
117 CD p
patients NNS p
who WP p
had VBD p
undergone JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
SCT NNP p
) ) p
. . p

The DT N
mean JJ o
change NN o
from IN o
baseline NN o
in IN o
instantaneous JJ o
and CC o
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ o
severity NN o
of IN o
instantaneous JJ o
and CC o
reflective JJ o
itching NN o
. . o

Complication NN o
rates NNS o
, , o
mortality NN o
, , o
and CC o
hospital JJ o
length NN o
of IN o
stay NN o
were VBD N
similar JJ N
between IN N
the DT N
2 CD N
groups NNS N
; : N
however RB N
, , N
administration NN N
of IN N
dopexamine NN i
was VBD N
associated VBN N
with IN N
earlier JJR o
return NN o
of IN o
tolerating VBG o
an DT o
enteral JJ o
diet NN o
. . o

METHODS NNP N
Thirty NNP p
eyes NNS p
of IN p
30 CD p
consecutive JJ p
patients NNS p
with IN p
cystoid JJ p
macular JJ p
edema NN p
secondary JJ p
to TO p
nonischemic JJ p
branch NN p
retinal JJ p
vein NN p
occlusion NN p
were VBD N
assigned VBN N
to TO N
either DT N
GLP NNP i
group NN i
or CC i
to TO i
intravitreal VB i
bevacizumab NN i
( ( i
IB NNP i
) ) i
group NN i
. . i

CONCLUSION NNP N
The DT N
results NNS N
of IN N
this DT N
nested JJ N
case-control NN N
study NN N
confirm VBP N
that IN N
finasteride NN i
blocks VBZ N
the DT N
conversion NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone VB N
( ( N
DHT NNP N
) ) N
and CC N
of IN N
androstenedione NN N
to TO N
5 CD N
, , N
which WDT N
also RB N
leads VBZ N
to TO N
the DT N
reduction NN N
of IN N
DHT NNP N
formation NN N
. . N

ASA NNP i
caused VBD N
a DT N
significant JJ N
reduction NN N
of IN N
B-TG NNP o
plasma NN o
levels NNS o
in IN N
TIA NNP N
patients NNS N
2 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
at IN N
the DT N
7th CD N
and CC N
14th CD N
day NN N
of IN N
treatment NN N
. . N

INTRODUCTION NNP N
The DT N
potential JJ N
effect NN N
of IN N
strontium NN i
( ( i
Sr NNP i
) ) i
on IN N
bone NN N
apatite JJ N
crystals NNS N
was VBD N
investigated VBN N
in IN N
paired JJ p
biopsies NNS p
of IN p
osteoporotic JJ p
women NNS p
treated VBN p
with IN p
either DT p
strontium NN i
ranelate NN i
( ( i
SrRan NNP i
) ) i
or CC i
a DT i
placebo NN i
for IN p
36 CD p
months NNS p
. . p

Although IN N
no DT N
statistical JJ N
difference NN N
in IN N
mortality NN o
rate NN o
was VBD N
appreciated VBN N
among IN N
the DT N
3 CD N
fluid NN N
resuscitation NN N
groups NNS N
, , N
a DT N
trend NN N
of IN N
decreased JJ N
mortality NN o
rate NN o
was VBD N
observed VBN N
in IN N
the DT N
HBOCS NNP N
group NN N
. . N

Serum NNP o
antibody NN o
responses NNS o
to TO N
three CD N
Haemophilus NNP i
influenzae NN i
type NN i
b NN i
( ( i
Hib NNP i
) ) i
capsular VBD i
polysaccharide-protein JJ i
conjugate NN i
vaccine NN i
( ( i
PRP-OMP NNP i
, , i
PRP-T NNP i
, , i
and CC i
HbOC NNP i
) ) i
were VBD N
evaluated VBN N
in IN N
174 CD p
Philippine JJ p
infants NNS p
after IN p
a DT p
primary JJ p
vaccination NN p
series NN p
. . p

CONCLUSIONS IN N
It PRP N
can MD N
be VB N
suggested VBN N
that IN N
0.6 CD N
and CC N
0.8 CD N
ml NN N
of IN N
4 CD N
% NN N
Ar NNP N
+ NNP N
1:100,000 CD N
Ep NNP N
, , N
delivered VBN N
by IN N
CCLADS NNP N
, , N
offer VBP N
high JJ N
success NN N
rate NN N
and CC N
effective JJ N
clinical JJ N
parameters NNS N
of IN N
ISA NNP N
as IN N
a DT N
primary JJ N
anesthesia NN N
. . N

CONCLUSION NNP N
GnRH NNP i
agonist NN i
and CC i
norethindrone JJ i
acetate NN i
alone RB i
or CC i
combined VBN i
with IN i
low-dose JJ i
conjugated JJ i
equine NN i
estrogens NNS i
administered VBN N
to TO N
symptomatic JJ p
endometriosis NN p
patients NNS p
for IN N
12 CD N
months NNS N
provides VBZ N
extended JJ o
pain NN o
relief NN o
and CC o
bone JJ o
mineral JJ o
density NN o
preservation NN o
after IN N
completion NN N
of IN N
therapy NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
perioperative JJ o
blood NN o
loss NN o
, , o
the DT o
amount NN o
of IN o
morphine NN o
used VBN o
, , o
or CC o
FFD NNP o
in IN o
the DT o
early JJ o
postoperative JJ o
period NN o
or CC o
in IN o
ROM NNP o
and CC o
FFD NNP o
at IN o
6 CD o
weeks NNS o
postoperatively RB o
. . o

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
hemostasis NN N
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD N
hemostasis NN N
until IN N
surgical JJ N
closure NN N
was VBD N
88.2 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
and CC N
89.6 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
these DT N
same JJ N
cardiac NN i
contractility NN i
modulating NN i
( ( i
CCM NNP i
) ) i
electrical JJ i
signals NNS i
on IN N
myocardial JJ o
oxygen NN o
consumption NN o
( ( o
MVO NNP o
( ( o
2 CD o
) ) o
) ) o
in IN N
both DT N
patients NNS p
and CC p
dogs NNS p
with IN p
chronic JJ p
HF NNP p
. . p

OBJECTIVE NN N
To TO N
find VB N
the DT N
optimal JJ N
dose NN N
of IN N
a DT N
new JJ N
hypoallergenic JJ N
folding NN N
variant NN N
of IN N
recombinant JJ i
Bet NNP i
v NN i
1 CD i
( ( i
rBet JJ i
v IN i
1-FV JJ i
) ) i
as IN N
SIT NNP N
for IN N
patients NNS p
with IN p
birch NN p
pollen NN p
allergy NN p
. . p

Although IN N
at IN N
the DT N
4-week JJ N
follow-up NN N
the DT N
intervention NN N
group NN N
indicated VBD N
that IN N
they PRP N
were VBD N
very RB N
likely JJ N
to TO N
have VB N
an DT N
annual JJ o
clinical JJ o
breast NN o
examination NN o
more RBR N
frequently RB N
than IN N
controls NNS N
, , N
no DT N
differences NNS N
were VBD N
detected VBN N
at IN N
6 CD N
months NNS N
. . N

In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB i
depolymerized VBN i
low JJ i
molecular JJ i
weight NN i
heparin NN i
( ( i
LMW-heparin NNP i
; : i
Logiparin NNP i
) ) i
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
letrozole NN i
in IN N
HER2+ NNP N
breast NN N
cancer NN N
was VBD N
confirmed VBN N
by IN N
fluorescent NN N
in IN N
situ JJ N
hybridization NN N
analysis NN N
and CC N
was VBD N
found VBN N
to TO N
be VB N
comparable JJ N
to TO N
that DT N
of IN N
HER2- NNP N
cases NNS N
( ( N
ORR NNP N
71 CD N
% NN N
in IN N
both DT N
subsets NNS N
) ) N
. . N

PATIENTS NNP N
Seventy-two JJ p
children NNS p
( ( p
mean JJ p
age NN p
, , p
8.5 CD p
? . p
1.6 CD p
y NN p
; : p
65 CD p
females NNS p
) ) p
with IN p
CPP NNP p
completed VBD p
and CC p
showed VBD p
maintenance NN p
of IN p
LH NNP p
suppression NN p
after IN p
a DT p
6-month JJ p
lead-in NN p
study NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
ROAM NNP o
, , o
gait NN o
, , o
pain NN o
, , o
perimeter NN o
of IN o
right NN o
and CC o
left VBD o
lower JJR o
limb NN o
, , o
and CC o
quality NN o
of IN o
life NN o
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
48 CD N
hours NNS N
posttreatment NN N
. . N

Three CD N
patients NNS N
experienced VBD N
ocular JJ o
adverse JJ o
events NNS o
considered VBN N
possibly RB N
related VBN N
to TO N
study VB N
drug NN N
: : N
Conjunctival NNP o
edema NN o
and CC o
reduced JJ o
visual JJ o
acuity NN o
were VBD N
reported VBN N
in IN N
1 CD N
SCJ NNP N
patient JJ N
each DT N
and CC N
iritis NN N
was VBD N
reported VBN N
in IN N
1 CD N
IVT NNP N
patient NN N
. . N

In IN N
both DT N
duodenal JJ N
ulcer NN N
treatment NN N
groups NNS N
, , N
and CC N
with IN N
both DT N
drugs NNS N
, , N
healing NN N
was VBD N
negatively RB N
influenced VBN N
by IN N
ulcer JJ o
size NN o
, , o
ulcer JJ o
number NN o
, , o
smoking VBG o
habits NNS o
and CC o
a DT o
disease NN o
duration NN o
of IN o
5 CD o
years NNS o
or CC o
more JJR o
. . o

Plasma NNP o
level NN o
variations NNS o
of IN o
TAM NNP o
, , o
N-desmethyl NNP o
TAM NNP o
and CC o
MPA NNP o
were VBD N
checked VBN N
at IN N
various JJ N
intervals NNS N
on IN N
3 CD N
patients NNS N
of IN N
group NN N
B NNP N
, , N
and CC N
confirmed VBD N
that IN N
our PRP$ N
schedule NN N
is VBZ N
able JJ N
to TO N
produce VB N
a DT N
drug NN N
wash-out NN N
period NN N
for IN N
tumor NN N
cells NNS N
. . N

Also RB N
, , N
the DT N
mean JJ o
time NN o
to TO o
peak VB o
plasma JJ o
level NN o
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

Ten CD N
out IN N
of IN N
18 CD N
patients NNS N
responded VBD N
to TO N
fluvoxamine VB i
treatment NN N
; : N
allele CC N
type JJ N
analysis NN N
revealed VBD N
that IN N
clinical JJ o
global JJ o
effectiveness NN o
was VBD N
noted VBN N
significantly RB N
more RBR N
in IN N
the DT N
l NN N
allele NN N
than IN N
in IN N
the DT N
s NN N
allele NN N
. . N

They PRP N
prepared VBD N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
, , N
placed VBD N
resin NN N
restorations NNS N
and CC N
evaluated JJ N
subjects NNS N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
30 CD N
days NNS N
and CC N
six CD N
months NNS N
postoperatively RB N
for IN N
pulp NN o
vitality NN o
, , o
recurrent NN o
caries NNS o
, , o
pain NN o
and CC o
discomfort NN o
, , o
and CC o
restoration NN o
retention NN o
. . o

RESULTS JJ N
Caregivers NNS N
in IN N
the DT N
IOL NNP i
group NN N
reported VBD N
higher JJR N
levels NNS o
of IN o
stress NN o
than IN N
those DT N
in IN N
the DT N
CL NNP N
group NN N
3 CD N
months NNS N
after IN N
surgery NN N
, , N
but CC N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
in IN N
stress NN o
scores NNS o
at IN N
the DT N
post-VA JJ N
assessment NN N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Mental NNP o
Development NNP o
Index NNP o
( ( o
MDI NNP o
) ) o
of IN N
the DT N
Bayley NNP N
Scales NNP N
of IN N
Infant NNP N
Development NNP N
, , N
2nd CD N
edition NN N
, , N
assessed VBN N
at IN N
36 CD N
months NNS N
by IN N
evaluators NNS N
unaware JJ N
of IN N
treatment NN N
group NN N
and CC N
resuscitation NN N
history NN N
. . N

Operating NN o
and CC o
anesthesia NN o
times NNS o
, , o
postoperative JJ o
pain NN o
, , o
complications NNS o
, , o
hospital NN o
stay NN o
, , o
functional JJ o
index NN o
( ( o
1 CD o
week NN o
postoperatively RB o
) ) o
, , o
sick JJ o
leave VBP o
, , o
and CC o
time NN o
to TO o
full JJ o
recovery NN o
were VBD N
documented VBN N
. . N

Effects NNS N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
aspirin NN i
( ( i
600 CD i
mg NN i
) ) i
on IN i
bradykinin-stimulated JJ i
prostaglandin NN i
( ( i
PG NNP i
) ) i
and CC N
on IN N
thromboxane NN N
( ( N
TX NNP N
) ) N
biosynthesis NN N
were VBD N
determined VBN N
in IN N
nine CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

A DT N
graph NN N
was VBD N
used VBN N
to TO N
demonstrate VB N
the DT N
treatment NN N
effect NN N
( ( N
the DT N
estimated VBN N
difference NN N
of IN N
kg/cow/day NN N
of IN N
milk NN N
yield NN N
between IN N
the DT N
treated VBN N
and CC N
placebo JJ N
cows NNS N
) ) N
, , N
with IN N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
as IN N
the DT N
ODR NNP N
values NNS N
increase NN N
. . N

Arch NNP N
dimensions NNS N
were VBD N
followed VBN N
; : N
maxillary JJ N
and CC N
mandibular JJ N
alginate NN N
impressions NNS N
were VBD N
taken VBN N
at IN N
baseline NN N
, , N
end NN N
of IN N
early JJ N
Class NNP N
II NNP N
treatment NN N
or CC N
observation NN N
, , N
beginning VBG N
of IN N
fixed JJ N
appliance NN i
treatment NN N
, , N
end NN N
of IN N
orthodontic JJ N
treatment NN N
, , N
and CC N
approximately RB N
3 CD N
years NNS N
posttreatment NN N
. . N

Normothermic JJ N
patients NNS N
were VBD N
warmed VBN N
to TO N
36.5-37.0 JJ N
degrees NNS N
C NNP N
after IN N
an DT N
initial JJ N
temperature NN N
decrease NN N
, , N
and CC N
hypothermic JJ N
patients NNS N
were VBD N
cooled VBN N
to TO N
35 CD N
degrees NNS N
C. NNP N
In IN N
the DT N
hypothermic JJ N
group NN N
temperatures NNS N
were VBD N
allowed VBN N
to TO N
drift VB N
to TO N
34.5 CD N
degrees NNS N
C NNP N
before IN N
rewarming VBG N
was VBD N
initiated VBN N
. . N

We PRP N
used VBD N
continuous JJ N
intraluminal JJ N
esophageal NN N
and CC N
tracheal JJ N
pH NN N
monitoring NN N
probes NNS N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
ranitidine NN i
on IN N
the DT N
incidence NN N
of IN N
GER NNP N
and CC N
tracheal JJ N
aspiration NN N
in IN N
80 CD p
adult NN p
patients NNS p
undergoing VBG p
thoracotomy NN p
. . p

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Every NNP N
6 CD N
months NNS N
, , N
a DT N
structured JJ N
questionnaire NN N
was VBD N
administered VBN N
to TO N
elicit VB N
reports NNS N
of IN N
any DT N
bruising NN o
and/or NN o
skin NN o
rashes NNS o
, , o
slow JJ o
healing NN o
of IN o
cuts NNS o
or CC o
sores NNS o
, , o
or CC o
other JJ o
skin JJ o
changes NNS o
. . o

CONCLUSIONS NNP N
Similar NNP N
decreases NNS N
in IN N
BMD NNP o
over IN N
96 CD N
weeks NNS N
occurred VBD N
in IN N
ART-naive JJ N
subjects NNS N
receiving VBG N
either CC N
EFV-based JJ N
regimen NNS N
or CC N
LPV/r-based JJ N
regimen NNS N
, , N
which WDT N
was VBD N
not RB N
altered VBN N
by IN N
simplification NN N
to TO N
LPV/r NNP N
monotherapy NN N
and CC N
was VBD N
unrelated VBN N
to TO N
markers NNS N
of IN N
tumor NN N
necrosis JJ N
factor-alpha JJ N
activity NN N
. . N

Comparison NNP N
of IN N
the DT N
two CD N
groups NNS N
made VBN N
use NN N
of IN N
the DT N
Wilcoxon NNP N
test NN N
for IN N
the DT N
continuous JJ N
variables NNS N
and CC N
the DT N
Fisher NNP N
's POS N
exact JJ N
test NN N
for IN N
the DT N
comparison NN N
of IN N
frequencies NNS N
, , N
at IN N
significance NN N
value NN N
of IN N
5 CD N
% NN N
. . N

A DT N
sixty-day JJ N
feeding NN N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
dietary JJ i
pyridoxine NN i
( ( i
PN NNP i
) ) i
on IN N
hemato-immunological JJ N
parameters NNS N
in IN N
Labeo NNP N
rohita VBP N
fingerlings NNS N
exposed VBN N
to TO N
an DT N
elevated JJ N
temperature NN N
( ( N
ET NNP N
) ) N
of IN N
33 CD N
? . N
. . N

To TO N
minimize VB N
the DT N
consequence NN N
of IN N
haemorrhage NN N
, , N
we PRP N
performed VBD N
every DT N
rigid JJ i
bronchoscopy NN i
, , i
placing VBG i
a DT i
non NN i
inflated VBN i
Fogarty NNP i
balloon NN i
and CC i
a DT i
rigid JJ i
aspirator NN i
( ( i
diameter JJ i
4 CD i
mm NN i
) ) i
in IN i
lobar NN i
bronchus NN i
near IN i
the DT i
biopsy NN i
segment NN i
. . i

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-nine NNP p
patients NNS p
( ( p
72 CD p
jaws NNS p
) ) p
with IN p
edentulous JJ p
maxillas NNS p
and/ VBP p
or CC p
mandibles NNS p
, , p
were VBD p
consecutively RB p
recruited VBN p
and CC p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
the DT p
treatment NN p
groups NNS p
. . p

METHODS NNP N
Packed NNP i
red JJ i
cells NNS i
without IN i
buffy NN i
coat NN i
( ( i
PC NNP i
group NN i
) ) i
were VBD i
compared VBN i
with IN i
filtered JJ i
, , i
leucoreduced VBD i
, , i
red JJ i
cells NNS i
( ( i
LD NNP i
group NN i
) ) i
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
697 CD p
patients NNS p
with IN p
colorectal JJ p
carcinoma NN p
. . p

RESULTS JJ N
Persons NNS N
with IN N
one CD N
or CC N
two CD N
long JJ N
( ( N
l NN N
) ) N
5HTTLPR CD N
alleles NNS N
had VBD N
CSF NNP N
levels NNS N
of IN N
the DT N
major JJ N
serotonin NN N
metabolite NN N
, , N
5HIAA CD N
, , N
that WDT N
were VBD N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
of IN N
persons NNS N
with IN N
the DT N
s/s NN N
5HTTLPR CD N
genotype NN N
. . N

Our PRP$ N
findings NNS N
indicate VBP N
that IN N
DHA NNP N
is VBZ N
quantitatively RB N
superior JJ N
to TO N
EPA NNP N
in IN N
view NN N
of IN N
the DT N
EPA+DHA NNP N
tissue NN N
incorporation NN N
and CC N
also RB N
that IN N
4 CD N
g/d NN N
ALA NNP N
is VBZ N
not RB N
sufficient JJ N
to TO N
increase VB N
the DT N
omega-3 JJ N
index NN N
over IN N
a DT N
6-wk JJ N
period NN N
. . N

Efficacy NN o
was VBD N
assessed VBN N
by IN N
facial JJ o
acne JJ o
lesion NN o
counts NNS o
, , o
an DT o
investigator NN o
's POS o
global JJ o
assessment NN o
, , o
a DT o
subject NN o
's POS o
self-assessment NN o
, , o
and CC o
an DT o
analysis NN o
of IN o
within-cycle JJ o
variation NN o
( ( o
cycle NN o
6 CD o
) ) o
in IN o
lesion NN o
counts NNS o
. . o

Treadmill NNP i
exercise NN i
testing VBG i
with IN N
measurement NN N
of IN N
expired NNP o
gas NN o
exchange NN o
and CC o
respiratory NN o
flow NN o
was VBD N
performed VBN N
before IN N
ablation NN N
and CC N
4 CD N
weeks NNS N
after IN N
pacemaker NN N
implantation NN N
, , N
with IN N
the DT N
pacemaker NN N
programmed VBD N
to TO N
both DT N
the DT N
fixed-rate JJ N
VVI NNP N
and CC N
rate-modulating JJ N
minute NN N
ventilation NN N
VVIR NNP N
pacing VBG N
modes NNS N
in IN N
random JJ N
sequence NN N
. . N

METHODS NNP N
Seventy-two NNP p
OSM NNP p
patients NNS p
were VBD N
assigned VBN N
to TO N
2 CD N
groups NNS N
by IN N
a DT N
randomizing JJ N
digital NN N
table NN N
, , N
the DT N
treated VBN N
group NN N
and CC N
the DT N
control NN N
group NN N
, , N
they PRP N
were VBD N
treated VBN N
respectively RB N
by IN N
ZJC1 NNP i
and CC i
Wuzi NNP i
Yanzong NNP i
Pill NNP i
( ( i
WYP NNP i
) ) i
. . i

NCX-4016 JJ o
inhibited JJ o
AA-induced JJ o
platelet NN o
aggregation NN o
as RB N
well RB N
as IN N
serum NN N
TXB NNP N
( ( N
2 CD N
) ) N
and CC N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
generation NN N
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN i
( ( N
not RB N
significant JJ N
vs. FW N
aspirin NN N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
1 CD N
hour NN N
of IN N
SHS NNP N
exposure NN N
at IN N
bar/restaurant NN N
levels NNS N
is VBZ N
accompanied VBN N
by IN N
significant JJ N
decrements NNS N
on IN N
lung NN N
function NN N
and CC N
marked JJ N
increases NNS N
in IN N
inflammatory JJ N
cytokines NNS N
, , N
particularly RB N
in IN N
men NNS N
. . N

Among IN N
patients NNS N
who WP N
achieved VBD N
50 CD N
% NN N
improvement NN N
in IN N
disease NN o
activity NN o
according VBG o
to TO o
the DT o
American NNP o
College NNP o
of IN o
Rheumatology NNP o
criteria NNS o
, , N
only RB N
? . N
% NN N
required VBD N
a DT N
reduction NN N
in IN N
acute-phase JJ o
reactant NN o
values NNS o
in IN N
order NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
. . N

Urinary JJ o
excretion NN o
of IN o
phenylethylamine NN o
increased VBN N
proportionately RB N
with IN N
doses NNS N
up RB N
to TO N
24 CD N
mg. NN N
No NNP N
changes NNS N
in IN N
urinary JJ o
elimination NN o
of IN o
catecholamines NNS o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
or CC o
ECG NNP o
were VBD N
observed VBN N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP o
infection NN o
rate NN o
, , o
duration NN o
of IN o
ICU NNP o
stay NN o
, , o
in-hospital JJ o
mortality NN o
rate NN o
and CC o
neurologic JJ o
outcome NN o
at IN o
6 CD o
months NNS o
follow-up RB o
. . o

) ) N
CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
the DT N
prophylactic JJ N
intravenous JJ N
administration NN N
of IN N
10 CD N
mg NNS N
dexamethasone VBP N
immediately RB N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
PONV NNP N
in IN N
the DT N
general JJ p
surgical JJ p
adult NN p
patient JJ p
population NN p
. . p

In IN N
comparison NN N
between IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
Bifidobacterium NNP N
was VBD N
detected VBN N
significantly RB N
earlier RBR N
in IN N
group NN N
A NNP N
, , N
and CC N
the DT N
number NN N
of IN N
Enterobacteriaceae NNP N
present NN N
in IN N
the DT N
infants NNS N
at IN N
2 CD N
weeks NNS N
after IN N
birth NN N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
. . N

Thus RB N
, , N
50 CD N
mg NN N
of IN N
oral JJ N
SDZ NNP N
ENS-163 NNP N
has VBZ N
cholinomimetic JJ o
activity NN o
in IN N
normal JJ p
men NNS p
, , N
but CC N
this DT N
dose NN N
is VBZ N
insufficient JJ N
to TO N
reverse VB N
the DT N
muscarinic JJ N
effects NNS N
of IN N
0.4 CD N
mg NN N
of IN N
intravenous JJ N
scopolamine NN i
. . i

The DT N
levels NNS o
of IN o
serum NN o
MDA NNP o
and CC o
SOD NNP o
activity NN o
were VBD o
assayed VBN o
by IN o
chemical NN o
colorimetry NN o
, , o
and CC o
other JJ o
indices NNS o
, , o
including VBG o
blood NN o
pressure NN o
, , o
lipids NNS o
and CC o
hepatic/renal JJ o
function NN o
, , N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

METHODS NNP N
The DT N
effects NNS N
of IN N
oral JJ N
administration NN N
of IN N
Bifidobacterium NNP i
breve NN i
( ( i
B. NNP i
breve VBP i
) ) i
supplements NNS i
were VBD N
studied VBN N
in IN N
a DT N
controlled JJ p
trial NN p
with IN p
low JJ p
birth NN p
weight NN p
infants NNS p
( ( p
average JJ p
birth NN p
weight NN p
1489 CD p
g NN p
) ) p
. . p

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
hydrocodone/acetaminophen NN i
( ( N
Vicodin NNP N
[ VBZ N
5/500 CD N
] NN N
) ) N
provides VBZ N
more RBR N
efficacious JJ o
analgesia NN o
than IN N
codeine/acetaminophen NN i
( ( N
Tylenol NNP N
# # N
3 CD N
[ $ N
30/300 CD N
] NN N
) ) N
in IN N
patients NNS p
discharged VBN p
from IN p
the DT p
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
. . p

The DT N
provocative JJ N
concentration NN N
of IN N
AMP NNP N
producing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP N
( ( N
PC20 NNP N
) ) N
was VBD N
measured VBN N
after IN N
each DT N
washout NN N
at IN N
baseline NN N
and CC N
at IN N
4-6 JJ N
h NN N
following VBG N
the DT N
first JJ N
and CC N
last JJ N
doses NNS N
of IN N
each DT N
randomized VBN N
treatment NN N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
incidence NN o
of IN o
catheter-related JJ o
bloodstream NN o
infections NNS o
( ( o
CRBSIs NNP o
) ) o
, , o
thrombosis NN o
, , o
and CC o
2 CD o
indicators NNS o
of IN o
rheologic JJ o
function NN o
: : o
mean JJ o
effective JJ o
blood NN o
flow NN o
rate NN o
and CC o
urokinase NN o
use NN o
. . o

The DT N
first JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
incremental JJ N
doses NNS N
of IN N
GH NNP i
( ( N
0.5 CD N
, , N
1.0 CD N
, , N
2.0 CD N
IU/day NNP N
for IN N
1 CD N
wk NNS N
each DT N
) ) N
on IN N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
levels NNS N
during IN N
each DT N
estrogen NN N
treatment NN N
phase NN N
. . N

Pregabalin NNP i
( ( i
PRE NNP i
) ) i
acts VBZ N
as IN N
a DT N
presynaptic JJ N
inhibitor NN N
of IN N
the DT N
release NN N
of IN N
excessive JJ N
levels NNS N
of IN N
excitatory NN N
neurotransmitters NNS N
by IN N
selectively RB N
binding VBG N
to TO N
the DT N
alpha NN N
( ( N
2 CD N
) ) N
-delta NN N
subunit NN N
of IN N
voltage-gated JJ N
calcium NN N
channels NNS N
. . N

We PRP N
found VBD N
that IN N
early JJ N
treatment NN N
was VBD N
important JJ N
, , N
since IN N
the DT N
effect NN N
on IN N
duration NN o
of IN o
whoops NNS o
was VBD N
most RBS N
pronounced JJ N
when WRB N
disease NN N
duration NN N
before IN N
treatment NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
7 CD N
days NNS N
. . N

Adjuvant NNP i
immunochemotherapy NN i
using VBG i
the DT i
antitumour JJ i
polysaccharide NN i
sizofiran NN i
( ( i
SPG NNP i
) ) i
, , N
an DT N
extract NN N
from IN N
the DT N
culture NN N
broth NN N
of IN N
Schizophyllum NNP N
commune NN N
Fries NNS N
, , N
was VBD N
prescribed VBN N
randomly RB N
for IN N
386 CD p
Japanese JJ p
patients NNS p
with IN p
resectable JJ p
gastric JJ p
cancer NN p
. . p

The DT N
discomfort NN o
score NN o
correlated VBD N
well RB N
with IN N
the DT N
pain NN o
relief NN o
scoring VBG o
without IN N
any DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
except IN N
in IN N
the DT N
last JJ N
visit NN N
( ( N
at IN N
3 CD N
month NN N
) ) N
. . N

The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS N
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN o
, , o
hepatomegaly NN o
, , o
and CC o
subjective JJ o
symptoms NNS o
of IN o
morbidity NN o
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
. . N

MAIN NNP o
OUTCOMES NNP o
AND NNP o
MEASURES NNP o
A NNP o
positive JJ o
response NN o
was VBD o
defined VBN o
as IN o
having VBG o
a DT o
score NN o
of IN o
at IN o
least JJS o
much JJ o
improved VBN o
on IN o
the DT o
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
at IN N
week NN N
12 CD N
. . N

METHODS NNP N
AND CC N
FINDINGS NNP N
We PRP N
identified VBD N
57,857 CD p
middle JJ p
and CC p
high JJ p
school NN p
students NNS p
( ( p
13-18 CD p
year NN p
olds NNS p
) ) p
from IN p
a DT p
Korean NNP p
nationally RB p
representative JJ p
survey NN p
, , p
which WDT p
was VBD p
surveyed VBN p
in IN p
2009 CD p
. . p

At IN N
30 CD N
min NN N
after IN N
stretching VBG i
, , N
significant JJ N
recovery NN o
in IN o
concentric JJ o
moment NN o
and CC o
muscle NN o
activity NN o
was VBD N
detected VBN N
at IN N
dorsiflexed JJ N
joint JJ N
angles NNS N
, , N
while IN N
Achilles NNP o
tendon CC o
stiffness NN o
and CC o
passive JJ o
joint JJ o
moment NN o
remained VBD N
significantly RB N
reduced VBN N
. . N

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
acceptability NN o
of IN N
6 CD i
% NN i
cellulose JJ i
sulfate NN i
( ( i
CS NNP i
) ) i
gel NN i
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN N
sexually RB N
abstinent JJ N
and CC N
active JJ N
HIV-infected JJ p
women NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
whether IN N
uterine JJ N
shrinkage NN N
induced VBN N
by IN N
gonadotropin-releasing VBG i
hormone NN i
( ( i
GnRH NNP i
) ) i
agonists VBZ i
in IN N
women NNS p
with IN p
a DT p
large JJ p
uterus NN p
( ( p
> JJ p
14 CD p
wks NNS p
) ) p
may MD p
facilitate VB p
total JJ p
laparoscopic JJ p
hysterectomy NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
incidences NNS o
of IN o
nausea NN o
, , o
retching VBG o
or CC o
vomiting VBG o
in IN N
the DT N
first JJ N
48 CD N
h NN N
after IN N
surgery NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
emergence NN N
agitation NN N
in IN N
the DT N
post-anaesthetic JJ N
care NN N
unit NN N
. . N

Performance NN o
on IN o
the DT o
BBT NNP o
and CC o
the DT o
10 CD o
MWT NNP o
( ( o
velocity NN o
and CC o
stride JJ o
length NN o
in IN o
self-paced JJ o
task NN o
and CC o
velocity NN o
in IN o
as-quickly-as-possible JJ o
task NN o
) ) o
were VBD N
improved VBN N
after IN N
MT NNP N
+ NNP N
MG NNP N
compared VBN N
with IN N
MT NNP N
. . N

In IN N
this DT N
study NN N
, , N
87 CD p
volunteers NNS p
who WP p
wanted VBD p
to TO p
quit VB p
cigarette NN p
smoking NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
experimental JJ N
hypnosis NN N
group NN N
, , N
the DT N
comparison NN N
relaxation NN N
group NN N
, , N
and CC N
the DT N
waiting VBG i
list NN i
control NN i
group NN i
. . i

Fifty-six JJ p
patients NNS p
with IN p
90 CD p
double JJ p
lumen NNS p
VACs NNP p
were VBD N
randomly RB N
chosen VBN N
, , N
and CC N
received VBD N
either DT N
1- JJ N
or CC N
2-week JJ N
catheterizations NNS N
from IN N
operators NNS N
experienced VBN N
in IN N
the DT N
placement NN N
of IN N
such JJ N
catheters NNS N
at IN N
three CD N
sites NNS N
such JJ N
as IN N
the DT N
internal JJ N
jugular NN N
, , N
subclavian JJ N
, , N
or CC N
femoral JJ N
vein NN N
. . N

No DT N
routine JJ N
laboratory NN N
or CC N
physical JJ N
findings NNS N
reliably RB N
predicted VBD N
the DT N
development NN N
of IN N
the DT N
fat JJ o
embolism NN o
syndrome NN o
except IN o
petechial JJ o
rash NN o
, , N
which WDT N
occurred VBD N
only RB N
in IN N
5 CD N
placebo-treated JJ N
patients NNS N
who WP N
developed VBD N
the DT N
syndrome NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
formulations NNS i
( ( N
11.25 CD N
and CC N
30 CD N
mg NN N
) ) N
effectively RB N
suppressed VBD N
the DT N
GnRH NNP N
axis NN N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
positively RB N
impact VB N
patient JJ N
convenience NN N
and CC N
compliance NN N
. . N

The DT N
mixed-effects NNS N
model NN N
analyses VBZ N
showed VBD N
significant JJ N
treatment NN N
differences NNS N
in IN N
change NN N
from IN N
baseline NN N
to TO N
week NN N
61 CD N
with IN N
enzalutamide JJ i
compared VBN N
with IN N
placebo NN i
for IN N
most JJS N
FACT-P JJ N
endpoints NNS N
and CC N
EQ-5D NNP o
visual JJ o
analogue NN o
scale NN o
. . o

In IN N
a DT N
first JJ N
study NN N
, , N
the DT N
extent NN N
of IN N
absorption NN N
was VBD N
similar JJ N
for IN N
a DT N
syrup NN N
, , N
for IN N
Theo-dur NNP N
, , N
and CC N
for IN N
the DT N
experimental JJ N
formulation NN N
of IN N
theophylline NN i
with IN i
70 CD i
% NN i
drum-dried JJ i
corn NN i
starch NN i
as IN N
the DT N
sustained-release JJ N
agent NN N
( ( N
DDCS-70 NNP N
) ) N
. . N

CONCLUSIONS NNP o
Ankle NNP o
dorsiflexion NN o
during IN o
gait NN o
, , o
walking VBG o
parameters NNS o
, , o
peripheral JJ o
edema NN o
, , o
venous JJ o
pain NN o
, , o
and CC o
quality NN o
of IN o
life NN o
remain VBP o
improved VBN o
in IN N
patients NNS N
with IN N
CVI NNP N
at IN N
1 CD N
month NN N
after IN N
mixed JJ N
KT-compression NNP N
therapy NN N
. . N

Arterial JJ N
thrombus NN N
formation NN N
was VBD N
induced VBN N
ex JJ N
vivo NN N
by IN N
exposing VBG N
a DT N
collagen-coated JJ N
surface NN N
in IN N
a DT N
parallel-plate JJ N
perfusion NN N
chamber NN N
to TO N
native JJ N
blood NN N
for IN N
3 CD N
min NN N
( ( N
arterial JJ N
wall NN N
shear NN N
rate NN N
2600 CD N
s NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

After IN N
a DT N
submaximal JJ i
exercise NN i
load NN i
on IN i
the DT i
bicycle NN i
ergometer NN i
( ( N
1 CD N
watt NN N
per IN N
kg NN N
body NN N
weight VBD N
) ) N
following VBG N
an DT N
evening JJ N
meal NN N
, , N
no DT N
difference NN N
could MD N
be VB N
observed VBN N
between IN N
penbutolol NN i
and CC i
placebo NN i
in IN N
the DT N
above-mentioned JJ N
parameters NNS N
. . N

Complement JJ o
activation NN o
was VBD N
present JJ N
in IN N
all DT N
patients NNS N
studied VBN N
who WP N
had VBD N
the DT N
syndrome NN N
( ( N
5 CD N
of IN N
27 CD N
) ) N
but CC N
also RB N
in IN N
many JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
our PRP$ N
diagnostic JJ N
criteria NNS N
, , N
suggesting VBG N
a DT N
multifactorial JJ N
cause NN N
. . N

CONCLUSIONS VB N
The DT N
CE-MARC NNP N
2 CD N
trial NN N
will MD N
provide VB N
comparative JJ N
efficacy NN N
and CC N
safety NN N
evidence NN N
for IN N
3 CD N
different JJ N
strategies NNS N
of IN N
investigating VBG N
patients NNS p
with IN p
suspected JJ p
CHD NNP p
, , N
with IN N
the DT N
intension NN N
of IN N
reducing VBG N
unnecessary JJ N
invasive JJ N
angiography NN N
rates NNS N
. . N

This DT N
clinical JJ N
trial NN N
is VBZ N
the DT N
largest JJS N
ever RB N
conducted VBN N
in IN N
the DT N
setting NN N
of IN N
FAP NNP N
and CC N
found VBD N
a DT N
trend NN N
of IN N
reduced JJ N
polyp NN N
load NN N
( ( N
number NN N
and CC N
size NN N
) ) N
with IN N
600 CD N
mg NNS N
of IN N
aspirin JJ i
daily JJ N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
AM NNP o
pre-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
and CC o
secondary JJ o
endpoints NNS o
included VBD o
other JJ o
measures NNS o
of IN o
lung NN o
function NN o
, , o
rescue NN o
albuterol NN o
use NN o
, , o
health NN o
status NN o
and CC o
exacerbations NNS o
. . o

This DT N
study NN N
showed VBD N
that IN N
the DT N
two CD N
combinations NNS N
of IN N
0.5 CD N
% NN N
timolol JJ i
maleate NN i
and CC N
2 CD N
% NN N
pilocarpine NN i
HCl NNP i
compared VBN N
in IN N
this DT N
study NN N
were VBD N
equally RB N
effective JJ N
in IN N
reducing VBG N
intraocular JJ o
pressure NN o
. . o

The DT N
urogenital JJ o
and CC o
sexuality NN o
score NN o
, , N
along IN N
with IN N
the DT N
vaginal JJ N
health NN N
index NN N
and CC N
the DT N
vaginal JJ N
maturation NN N
index NN N
( ( N
VMI NNP N
) ) N
, , N
was VBD N
calculated VBN N
at IN N
the DT N
beginning NN N
of IN N
therapy NN N
and CC N
12 CD N
weeks NNS N
later RB N
. . N

Early JJ N
intensification NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
bone NN o
marrow NN o
relapses NNS o
and CC N
a DT N
reduction NN N
in IN N
the DT N
odds NNS N
of IN N
death NN N
of IN N
0.63 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
0.46-0.87 JJ N
) ) N
. . N

METHODS NNP N
Data NNP N
are VBP N
obtained VBN N
from IN N
in-person JJ N
, , N
structured JJ N
, , N
closed-end JJ N
interviews NNS N
with IN N
the DT N
caretakers NNS p
of IN p
children NNS p
aged VBN p
4-12 CD p
years NNS p
with IN p
persistent JJ p
asthma NN p
living NN p
in IN p
households NNS p
with IN p
incomes NNS p
less JJR p
than IN p
200 CD p
% NN p
of IN p
poverty NN p
. . p

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN o
passage NN o
, , o
1- JJ o
or CC o
5-minute JJ o
Apgar NNP o
scores NNS o
< VBP o
7 CD o
, , o
neonatal JJ o
resuscitations NNS o
, , o
or CC o
admissions NNS o
to TO o
the DT o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

Moreover RB N
, , N
pruritus NN o
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN N
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS N
of IN N
the DT N
betamethasone NN i
group NN N
. . N

PURPOSE NNP N
We PRP N
determined VBD N
whether IN N
the DT N
decrease NN N
in IN N
serum NN o
PSA NNP o
seen VBN N
with IN N
5alpha-reductase JJ N
inhibitors NNS N
affects VBZ N
the DT N
clinical JJ N
usefulness NN N
of IN N
PSA NNP i
for IN N
prostate NN N
cancer NN N
screening VBG N
using VBG N
data NNS N
from IN N
2 CD p
dutasteride JJ p
benign JJ p
prostatic JJ p
hyperplasia NN p
studies NNS p
. . p

METHODS NNP N
ACS NNP p
patients NNS p
undergoing VBG p
cardiac JJ p
catheterization NN p
with IN p
> NNP p
or=1 VBP p
nonobstructive JJ p
native JJ p
coronary JJ p
artery NN p
atheroma NN p
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP i
selective NN i
delipidated VBD i
or CC i
control VB i
plasma JJ i
apheresis/reinfusions NNS i
. . i

( ( N
2 CD N
) ) N
In IN N
addition NN N
, , N
the DT N
effect NN N
of IN N
killing VBG N
technique NN N
on IN N
apparent JJ N
ileal NN N
protein NN N
digestibility NN N
values NNS N
obtained VBN N
by IN N
a DT N
slaughter NN N
method NN N
and CC N
effect NN N
of IN N
rapeseed NN N
feeding VBG N
on IN N
size NN N
of IN N
specific JJ N
organs NNS N
were VBD N
studied VBN N
. . N

Patients NNS p
( ( p
n JJ p
= NNP p
113 CD p
) ) p
with IN p
stage NN p
3-4 JJ p
CKD NNP p
and CC p
evidence NN p
of IN p
CAC NNP p
on IN p
a DT p
phosphorus-restricted JJ p
diet NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
calcium NN i
carbonate NN i
or CC i
sevelamer NN i
added VBN i
to TO i
their PRP$ i
phosphorus-restricted JJ i
diet NN i
. . i

A DT N
follow-up JJ N
procedure NN N
requiring VBG N
all DT N
subjects NNS N
to TO N
choose VB N
between IN N
the DT N
color NN N
prompt NN N
and CC N
the DT N
position NN N
cue NN N
revealed VBD N
that IN N
11 CD N
of IN N
20 CD N
subjects NNS N
consistently RB N
chose VBD N
the DT N
color NN N
cue NN N
, , N
even RB N
though IN N
it PRP N
resulted VBD N
in IN N
improper JJ N
lacing NN N
. . N

In IN N
group NN N
A NNP N
, , N
the DT N
CT NNP N
scan NN N
was VBD N
performed VBN N
with IN N
conventional JJ i
bowel NN i
preparation NN i
( ( N
a DT N
full JJ N
cathartic NN N
dose NN N
and CC N
oral JJ N
contrast NN N
medium NN N
to TO N
tag VB N
any DT N
residue NN N
in IN N
the DT N
3 CD N
days NNS N
preceding VBG N
the DT N
study NN N
) ) N
. . N

Similarly RB N
, , N
in IN N
a DT N
fifth NN N
subject NN N
, , N
who WP N
was VBD N
not RB N
restudied VBN N
until IN N
6 CD N
months NNS N
of IN N
androgen NN N
therapy NN N
were VBD N
completed VBN N
, , N
an DT N
increase NN N
in IN N
RBC NNP o
mass NN o
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
erythron NNP o
iron NN o
turnover NN o
. . o

Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
vegetarianism NN N
on IN N
skeletal JJ N
muscle NN o
total JJ o
creatine NN o
( ( o
TCr NNP o
) ) o
content NN o
and CC o
creatine NN o
transporter NN o
( ( o
CreaT NNP o
) ) o
gene NN o
expression NN o
, , N
prior RB N
to TO N
and CC N
during IN N
5 CD N
d NN N
of IN N
Cr NNP i
supplementation NN i
( ( i
CrS NNP i
) ) i
. . i

However RB N
, , N
in IN N
the DT N
second JJ N
week NN N
pain NN o
scores NNS o
increased VBD N
more RBR N
in IN N
the DT N
potassium NN i
titanyl NN i
phosphate VBP i
laser NN i
group NN N
than IN N
in IN N
the DT N
bipolar JJ N
radiofrequency NN N
group NN N
( ( N
means VBZ N
8.5 CD N
and CC N
6 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
assessed VBN N
by IN N
vasodilator-stimulated JJ o
phosphoprotein NN o
phosphorylation NN o
assay NN o
, , o
light JJ o
transmittance NN o
aggregometry NN o
, , o
VerifyNow NNP o
P2Y12 NNP o
assay NN o
( ( o
Accumetric NNP o
, , o
Inc. NNP o
, , o
San NNP o
Diego NNP o
, , o
California NNP o
) ) o
, , o
and CC o
multiple JJ o
electrode NN o
aggregometry NN o
at IN N
baseline NN N
and CC N
14 CD N
days NNS N
. . N

A DT N
second JJ N
trial NN N
( ( N
Study NNP N
2 CD N
) ) N
simulated VBD N
post-exposure JJ N
rabies NNS N
prophylaxis VBN N
by IN N
using VBG N
a DT N
reference NN N
cell NN N
culture NN N
vaccine NN N
, , N
the DT N
purified JJ i
Vero-cell NNP i
rabies NNS i
vaccine NN i
( ( i
PVRV NNP i
) ) i
, , N
administered VBN N
in IN N
association NN N
with IN N
either DT N
Erig NNP i
PMC NNP i
or CC i
PHT-Erig NNP i
. . i

No DT N
differences NNS N
between IN N
diets NNS N
were VBD N
found VBN N
for IN N
cortisol NN N
, , N
corticosteroid-binding JJ N
globulin NN N
, , N
and CC N
catecholamine JJ N
concentrations NNS N
in IN N
plasma NN N
and CC N
for IN N
GR NNP N
binding NN N
in IN N
hippocampus NN N
and CC N
hypothalamus NN N
in IN N
piglets NNS N
at IN N
PND NNP N
1 CD N
and CC N
27 CD N
. . N

BACKGROUND IN N
A NNP N
previous JJ N
study NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
high-normal JJ p
body NN p
lead NN p
burdens VBZ p
showed VBD p
that IN p
EDTA NNP i
chelation NN i
therapy NN i
for IN p
3 CD p
months NNS p
slows VBZ p
progressive JJ p
diabetic JJ p
nephropathy NN p
during IN p
a DT p
12-month JJ p
follow-up NN p
. . p

Significant JJ N
shorter JJR N
procedure NN N
and CC N
fluoroscopy NN N
times NNS N
compared VBN N
with IN N
a DT N
primary JJ N
4:1 CD N
ablation NN N
mode NN N
during IN N
repeat NN N
PVI NNP N
are VBP N
mainly RB N
attributed VBN N
to TO N
a DT N
lower JJR N
incidence NN N
of IN N
acutely RB N
reconnected VBN N
PVs NNP N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

During IN N
each DT N
treatment NN N
period NN N
, , N
subjects VBZ N
received VBN N
a DT N
single JJ N
dose NN N
of IN N
either CC N
donepezil JJ i
HCl NNP i
( ( i
5 CD i
mg NN i
) ) i
, , i
digoxin NN i
( ( i
0.25 CD i
mg NN i
) ) i
, , i
or CC i
a DT i
combination NN i
of IN i
both DT i
drugs NNS i
. . i

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS o
of IN o
increase NN o
in IN o
retinal JJ o
area NN o
involved VBN o
by IN o
CMV NNP o
, , o
visual JJ o
field NN o
loss NN o
, , o
or CC o
visual JJ o
acuity NN o
outcomes NNS o
. . o

AIM NNP N
Present NNP N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
glycemic JJ N
control NN N
and CC N
maternal-fetal JJ N
outcome NN N
in IN N
pregnant JJ p
type NN p
1 CD p
diabetic JJ p
patient NN p
treated VBN p
with IN p
continuous JJ i
subcutaneous JJ i
insulin NN i
infusion NN i
( ( i
CSII NNP i
) ) i
or CC i
multiple JJ i
daily JJ i
injections NNS i
of IN i
insulin NN i
( ( i
MDI NNP i
) ) i
. . i

One CD N
patient NN N
in IN N
the DT N
amlodipine JJ i
camsylate NN i
group NN N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
at IN N
week NN N
0 CD N
of IN N
treatment NN N
( ( N
this DT N
patient NN N
did VBD N
not RB N
use VB N
any DT N
study NN N
medication NN N
) ) N
and CC N
was VBD N
excluded VBN N
from IN N
the DT N
modified VBN N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
. . N

The DT N
low JJ N
value NN N
( ( N
2.8 CD N
U/L NNP N
) ) N
of IN N
drug NN N
concentration NN N
that WDT N
achieved VBD N
50 CD N
% NN N
of IN N
maximum JJ N
effect NN N
( ( N
EC50 NNP N
) ) N
indicated VBD N
that IN N
low JJ N
plasma NN N
uricase NN N
concentrations NNS N
were VBD N
sufficient JJ N
to TO N
produce VB N
pharmacological JJ N
effects NNS N
. . N

Change NN N
in IN N
serum NN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ N
weight NN N
gain NN N
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN N
dose NN N
. . N

Prolactin NN o
levels NNS o
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
alpha JJ i
dihidroergocriptine NN i
with IN N
an DT N
important JJ N
difference NN N
between IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
6 CD N
months NNS N
study JJ N
period NN N
. . N

This DT N
was VBD N
done VBN N
, , N
prospectively RB N
, , N
to TO N
determine VB N
doses NNS N
of IN N
these DT N
agents NNS N
that WDT N
would MD N
increase VB N
or CC N
decrease VB N
plasma JJ o
norepinephrine NN o
levels NNS o
by IN N
> NNP N
/= NNP N
30 CD N
% NN N
. . N

With IN N
the DT N
exception NN N
of IN N
BI NNP N
at IN N
23 CD N
weeks NNS N
post-SRP JJ N
, , N
all DT N
reductions NNS N
cited VBN N
above IN N
for IN N
the DT N
test NN N
group NN N
were VBD N
statistically RB N
significantly RB N
different JJ N
from IN N
the DT N
control NN N
group NN N
for IN N
both DT N
PPD NNP N
and CC N
BI NNP N
for IN N
all DT N
comparisons NNS N
. . N

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD p
healthy JJ p
children NNS p
of IN p
2-5 JJ p
months NNS p
old JJ p
in IN p
Jiangsu NNP p
province NN i
were VBD i
administered VBN i
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
and CC i
control NN i
vaccines NNS i
. . i

Pre-operatively RB i
, , N
and CC N
2 CD N
h NN N
after IN N
commencing VBG N
their PRP$ N
post-operative JJ N
feeds NNS N
, , N
rates NNS N
of IN N
whole-body NN N
protein NN N
synthesis NN N
and CC N
breakdown NN N
were VBD N
measured VBN N
over IN N
a DT N
9-h JJ N
period NN N
following VBG N
intravenous JJ N
injection NN N
of IN N
a DT N
single JJ N
tracer NN N
dose NN N
of IN N
15N-glycine JJ i
by IN i
the DT i
ammonia NN i
and CC i
urea JJ i
end-product NN i
methods NNS i
. . i

The DT N
naproxen JJ o
concentration NN o
2 CD N
h NN N
after IN N
ingestion NN N
and CC N
the DT N
Cmax NNP N
were VBD N
higher JJR N
on IN N
the DT N
second JJ N
occasion NN N
, , N
regardless RB N
of IN N
preparation NN N
, , N
suggesting VBG N
that IN N
the DT N
subjects NNS N
were VBD N
clinically RB N
different JJ N
on IN N
the DT N
two CD N
occasions NNS N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
5 CD N
% NN N
lidocaine NN i
( ( i
ELA-Max NNP i
) ) i
cream NN i
applied VBN i
after IN i
erbium NN i
: : i
yttrium-aluminum-garnet NN i
( ( i
Er NNP i
: : i
YAG NN i
) ) i
laser JJR i
ablation NN i
of IN N
the DT N
stratum NN N
corneum NN N
. . N

PURPOSE NN N
This DT N
study NN N
examined VBD N
whether IN N
safe JJ o
and CC o
effective JJ o
mydriasis NN o
can MD N
be VB N
achieved VBN N
in IN N
premature NN p
infants NNS p
with IN p
heavily RB p
pigmented VBN p
irides NNS p
using VBG p
combination NN p
cyclopentolate VB p
0.2 CD p
% NN p
and CC p
phenylephrine VB p
1 CD p
% NN p
eyedrops NNS p
. . p

Patients NNS N
on IN N
acetazolamide NN i
showed VBD N
a DT N
slightly RB N
better RBR N
improvement NN N
of IN N
angiographic JJ o
signs NNS o
( ( N
at IN N
least JJS N
by IN N
one CD N
grade NN N
improvement NN N
) ) N
over IN N
that DT N
of IN N
placebo NN i
( ( N
12 CD N
vs NN N
five CD N
eyes NNS N
) ) N
. . N

CONCLUSIONS NNP N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
unlike IN N
cAMP-dependent JJ N
positive JJ N
inotropic NN N
drugs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
during IN N
CCM NNP i
therapy NN i
is VBZ N
elicited VBN N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
. . o

CONCLUSION NNP N
Mizolastine NNP i
( ( N
10 CD N
mg NNS N
daily RB N
) ) N
is VBZ N
confirmed VBN N
as IN N
an DT N
effective JJ N
and CC N
well RB N
tolerated JJ N
agent NN N
, , N
comparable JJ N
to TO N
loratadine VB i
and CC N
superior VB N
to TO N
placebo VB i
, , N
for IN N
the DT N
management NN N
of IN N
CIU NNP N
. . N

Intervention NN N
was VBD N
based VBN N
on IN N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
oral JJ i
steroid NN i
, , i
with IN i
or CC i
without IN i
vitamin JJ i
D NNP i
( ( N
3 CD N
) ) N
, , N
or CC N
placebo VBZ i
only RB N
on IN N
the DT N
day NN N
of IN N
the DT N
build-up JJ N
phase NN N
of IN N
SIT NNP N
. . N

This DT N
study NN N
compared VBN N
live JJ N
ratings NNS N
with IN N
ratings NNS N
of IN N
videotapes NNS i
and CC N
compared VBN N
response NN N
to TO N
clomipramine VB i
with IN N
response NN N
to TO N
haloperidol VB i
in IN N
8 CD p
subjects NNS p
, , p
mean JJ p
age NN p
5.62 CD p
years NNS p
, , p
who WP p
met VBD p
criteria NNS p
for IN p
autism NN p
. . p

In IN N
IC NNP N
, , N
LF NNP o
and CC o
HF NNP o
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

TSAb NNP N
determined VBD N
again RB N
during IN N
follow-up NN N
was VBD N
negative JJ N
in IN N
each DT N
of IN N
the DT N
18 CD p
patients NNS p
in IN p
remission NN p
, , p
and CC p
positive JJ p
in IN p
8/10 CD p
patients NNS p
at IN p
the DT p
time NN p
of IN p
relapse NN p
, , p
whatever WDT p
its PRP$ p
level NN p
at IN p
the DT p
end NN p
of IN p
the DT p
drug NN p
course NN p
. . p

The DT N
visual JJ o
analog NN o
scale NN o
score NN o
for IN o
pain NN o
on IN o
postoperative JJ o
day NN o
1 CD o
and CC o
the DT o
requirement NN o
for IN o
tramadol NN o
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
in IN N
group NN N
II NNP N
( ( N
P=.004 NNP N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
percentage NN o
of IN o
attacks NNS o
in IN o
which WDT o
headache NN o
improved VBD o
from IN o
severe JJ o
or CC o
moderate JJ o
before IN N
treatment NN N
to TO N
mild VB N
or CC N
absent VB N
at IN N
1 CD N
hour NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

A DT N
statistically RB N
significant JJ N
linear JJ N
trend NN N
of IN N
an DT N
increase NN N
in IN N
calcium JJ o
absorption NN o
adjusted VBN N
for IN N
age NN N
and CC N
body NN N
mass NN N
index NN N
with IN N
increasing VBG N
vitamin NN N
D NNP N
dose NN N
or CC N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
concentration NN N
was VBD N
observed VBN N
. . N

BACKGROUND NNP N
Three NNP N
methods NNS N
of IN N
treating VBG N
chalazia NN N
were VBD N
compared VBN N
: : N
intralesional JJ i
triamcinolone NN i
acetonide NN i
injections NNS N
( ( N
0.2 CD N
mL NN N
of IN N
10 CD N
mg/mL NN N
) ) N
, , N
incision NN i
and CC i
curettage NN i
and CC N
advice NN N
regarding VBG N
the DT N
application NN N
of IN N
hot JJ N
compresses NNS N
to TO N
the DT N
affected JJ N
eyelid NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
mean JJ o
change NN o
in IN o
Facial NNP o
Pain NNP o
Scale NNP o
scores VBZ o
between IN N
the DT N
control NN N
and CC N
the DT N
intervention NN N
groups NNS N
in IN N
children NNS N
< VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

We PRP N
randomly RB N
recruited VBD N
304 CD p
women NNS p
from IN p
the DT p
Samliem NNP p
inner-city NN p
community NN p
, , p
Khon NNP p
Kaen NNP p
, , p
Northeast NNP p
Thailand NNP p
, , p
and CC p
assigned VBD p
participants NNS p
to TO p
either VB p
the DT p
intervention NN p
or CC p
control VB p
zone NN p
. . p

METHODS NNP N
In IN N
this DT N
preliminary JJ N
study NN N
, , N
33 CD p
adults NNS p
and CC p
30 CD p
children NNS p
( ( p
aged VBN p
8-11 CD p
years NNS p
) ) p
with IN p
no DT p
known JJ p
history NN p
of IN p
listening VBG p
difficulties NNS p
were VBD p
tested VBN p
. . p

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB o
completed VBN o
CARS NNP o
score NN o
and CC o
blood NN o
samples NNS o
for IN o
TARC NNP o
serum NN o
level NN o
were VBD N
taken VBN N
before RB N
and CC N
after IN N
milk NN N
consumption NN N
of IN N
500 CD N
ml NNS N
per IN N
day NN N
in IN N
children NNS N
's POS N
regular JJ N
daily JJ N
diet NN N
. . N

The DT N
assay NN N
reproducibility NN N
was VBD N
shown VBN N
by IN N
reanalysis NN N
of IN N
200 CD N
study NN N
samples NNS N
and CC N
the DT N
% NN N
change NN N
in IN N
the DT N
concentration NN o
of IN o
repeat NN o
values NNS o
from IN N
the DT N
original JJ N
values NNS N
was VBD N
within IN N
? . N
% NN N
. . N

Fifteen NNP N
minutes NNS N
later RB N
( ( N
before IN N
IoA NNP N
) ) N
, , N
each DT N
dog NN N
received VBD N
treatment NN i
IV NNP i
with IN i
propofol NN i
, , i
K-P NNP i
, , i
or CC i
K-D. NNP i
Cardiorespiratory NNP o
and CC o
arterial JJ o
blood NN o
gas NN o
variables NNS o
were VBD N
assessed VBN N
before RB N
, , N
immediately RB N
after IN N
, , N
and CC N
5 CD N
minutes NNS N
after IN N
IoA NNP N
. . N

Plasma NNP o
concentrations NNS o
of IN o
6-oxo-PGF1 JJ o
alpha NN o
and CC o
13,14-dihydro-15-oxo-PGF2 JJ o
alpha NN o
were VBD N
measured VBN N
in IN N
samples NNS N
obtained VBN N
during IN N
repeated JJ N
10 CD N
min NN N
intravenous JJ N
infusions NNS N
of IN N
bradykinin NN N
before IN N
and CC N
up RB N
to TO N
6 CD N
h NN N
after IN N
the DT N
dose NN N
of IN N
aspirin NN i
. . i

CONCLUSION NN N
This DT N
trial NN N
found VBD N
that IN N
taking VBG N
20 CD N
mg NN N
pravastatin NN i
for IN N
2 CD N
years NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
kidney NN o
function NN o
or CC o
urinary JJ o
protein NN o
excretion NN o
in IN N
patients NNS p
with IN p
ADPKD NNP p
. . p

Modeling NN N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ p
patients NNS p
receiving VBG p
5 CD p
mg JJ p
linagliptin NN i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ o
events NNS o
( ( N
all DT N
with IN N
incidence NN N
of IN N
5 CD N
% NN N
or CC N
less JJR N
) ) N
among IN N
patients NNS N
receiving VBG N
rizatriptan NNS i
were VBD N
dry JJ o
mouth NN o
, , o
dizziness NN o
, , o
asthenia/fatigue NN o
, , o
nausea NN o
, , o
and CC o
somnolence NN o
. . o

Twenty-four JJ p
children NNS p
meeting VBG p
ICD-10 NNP p
criteria NNS p
for IN p
childhood NN p
autism NN p
( ( p
mean JJ p
age NN p
= VBD p
23 CD p
months NNS p
) ) p
were VBD N
identified VBN N
using VBG N
the DT N
CHAT NNP i
screen NN i
and CC i
randomised VBD i
to TO i
the DT i
parent NN i
training VBG i
group NN i
or CC i
to TO i
local JJ i
services NNS i
only RB i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Change NNP N
in IN N
pain NN o
VAS NNP o
scores VBZ o
during IN N
5 CD N
years NNS N
after IN N
the DT N
operation NN N
and CC N
rates NNS N
of IN N
pregnancy NN N
, , N
repeat NN N
surgery NN N
, , N
and CC N
use NN N
of IN N
hormone NN N
therapy NN N
were VBD N
evaluated VBN N
. . N

Plasma NNP o
Abeta NNP o
concentrations NNS o
decreased VBD N
in IN N
a DT N
dose-dependent JJ N
manner NN N
over IN N
a DT N
6-hour JJ N
interval NN N
following VBG N
drug NN N
administration NN N
, , N
with IN N
a DT N
maximum JJ N
decrease NN N
of IN N
approximately RB N
40 CD N
% NN N
relative JJ N
to TO N
baseline VB N
. . N

The DT N
H-AT NNP N
for IN N
4 CD N
weeks NNS N
up-regulated JJ o
co-stimulatory JJ o
molecule NN o
CD28 NNP o
expression NN o
and CC o
was VBD o
accompanied VBN o
by IN o
depressed JJ o
KLRG1 NNP o
level NN o
on IN o
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
, , o
or CC o
CD8 NNP o
( ( o
bright VBN o
) ) o
lymphocytes VBZ o
at IN o
rest NN o
or CC o
following VBG o
exercise NN o
. . o

METHODS NNP N
Sixty NNP p
children NNS p
of IN p
autism NN p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
electroacupuncture NN i
( ( i
EA NNP i
) ) i
plus CC i
behavior JJ i
therapy NN i
group NN i
and CC i
a DT i
behavior JJ i
therapy NN i
group NN N
, , N
30 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

METHODS NNP N
Patients NNS p
above IN p
18 CD p
years NNS p
with IN p
a DT p
rectal JJ p
cancer NN p
, , p
able JJ p
to TO p
give VB p
informed JJ p
consent NN p
, , p
and CC p
scheduled VBD p
for IN p
an DT p
anterior JJ p
resection NN p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
. . p

Best-corrected JJ o
visual JJ o
acuity NN o
( ( o
Early JJ o
Treatment NNP o
Diabetic NNP o
Retinopathy NNP o
Study NNP o
chart NN o
) ) o
, , o
intraocular JJ o
pressure NN o
measurement NN o
, , o
biomicroscopy NN o
, , o
funduscopy NN o
, , o
digital JJ o
fluorescein NN o
, , o
and CC o
indocyanine NN o
green JJ o
angiography NN o
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

The DT N
effects NNS N
of IN N
dietary JJ i
supplementation NN i
with IN i
coconut JJ i
oil NN i
on IN N
the DT N
biochemical JJ N
and CC N
anthropometric JJ N
profiles NNS N
of IN N
women NNS p
presenting VBG p
waist JJ p
circumferences NNS p
( ( p
WC NNP p
) ) p
> VBD p
88 CD p
cm NN p
( ( p
abdominal JJ p
obesity NN p
) ) p
were VBD N
investigated VBN N
. . N

We PRP N
found VBD N
that IN N
reducing VBG N
the DT N
number NN o
of IN o
adjudicators NNS o
from IN N
five CD N
to TO N
two CD N
or CC N
three CD N
would MD N
probably RB N
have VB N
changed VBN N
the DT N
consensus NN N
outcome NN N
in IN N
less JJR N
than IN N
10 CD N
% NN N
of IN N
cases NNS N
. . N

RESULTS NNP N
Study NNP p
participants NNS p
( ( p
N=170 NNP p
) ) p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
28.4 CD p
years NNS p
( ( p
SD=9.6 NNP p
; : p
range VB p
18-60 JJ p
) ) p
and CC p
formed VBD p
a DT p
racially RB p
diverse JJ p
group NN p
. . p

Exercise NN o
time NN o
to TO o
onset VB o
of IN o
angina NN o
, , o
total JJ o
exercise NN o
duration NN o
and CC o
time NN o
to TO o
1 CD o
mm NNS o
ST NNP o
segment NN o
depression NN o
were VBD N
all DT N
significantly RB N
increased VBN N
after IN N
initial JJ N
application NN N
during IN N
the DT N
continuous JJ N
and CC N
intermittent JJ N
treatment NN N
periods NNS N
. . N

A DT N
total NN N
of IN N
45 CD p
children NNS p
diagnosed VBN p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
ages VBZ p
7-14 CD p
were VBD N
randomly RB N
assigned VBN N
to TO N
standard VB N
, , N
directive JJ N
, , N
or CC N
control VB i
story NN i
conditions NNS i
. . i

Fifty-nine NNP p
episodes NNS p
of IN p
atrial JJ p
flutter NN p
in IN p
54 CD p
patients NNS p
who WP p
failed VBD p
to TO p
terminate VB p
with IN p
an DT p
intravenous JJ p
infusion NN p
of IN p
ibutilide NN i
, , i
procainamide NN i
, , i
or CC i
placebo VB i
alone JJ p
underwent JJ p
attempts NNS p
at IN p
pacing VBG p
termination NN p
using VBG p
a DT p
standard JJ p
protocol NN p
of IN p
burst JJ p
atrial JJ p
overdrive JJ p
pacing NN p
. . p

The DT N
effect NN N
lasted VBD N
for IN N
the DT N
entire JJ N
period NN N
of IN N
drug NN N
administration NN N
and CC N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
a DT N
normal JJ o
platelet NN o
aggregation NN o
was VBD N
maintained VBN N
until IN N
the DT N
fourth JJ N
day NN N
after IN N
discontinuation NN N
of IN N
the DT N
drug NN N
. . N

Tibial NNP i
bone NN i
marrow NN i
aspirates VBZ i
demonstrated VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
bone NN o
marrow NN o
neutrophil JJ o
storage NN o
pool NN o
( ( N
BM NNP N
NSP NNP N
) ) N
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

Local JJ i
anesthetic JJ i
solutions NNS i
used VBN N
were VBD N
0.5 CD N
per IN N
cent NN N
bupivacaine NN N
HCl NNP N
, , N
2 CD N
per IN N
cent NN N
lidocaine NN N
HCl NNP N
, , N
and CC N
lidocaine-bupivacaine JJ N
mixtures NNS N
in IN N
the DT N
ratios NNS N
of IN N
1:3 CD N
, , N
1:1 CD N
or CC N
3:1 CD N
by IN N
volume NN N
. . N

AIM IN N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN i
on IN N
insulin NN N
requirements NNS N
and CC N
glycaemic JJ N
control NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
receiving VBG p
exogenous JJ p
insulin NN p
due JJ p
to TO p
secondary JJ p
failure NN p
of IN p
maximum NN p
dose JJ p
sulphonylurea JJ p
therapy NN p
. . p

CONCLUSION NNP N
Ten CD N
percent NN N
HES NNP N
130/0.4 CD N
was VBD N
equally RB N
effective JJ N
and CC N
safe JJ o
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
for IN N
volume NN N
therapy NN N
in IN N
patients NNS p
undergoing VBG p
cardiovascular JJ p
surgery NN p
. . p

INTERVENTION NN N
Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
topical JJ i
gauze NN i
sponges NNS i
soaked VBN i
in IN i
either DT i
1:500 CD i
RA NNP i
or CC i
0.9 CD i
% NN i
sodium NN i
chloride NN i
( ( i
physiological JJ i
saline NN i
) ) i
for IN N
3 CD N
min NN N
after IN N
adenoidectomy NN N
. . N

Three CD N
of IN N
five CD N
participants NNS N
acquired VBD N
word NN N
production NN N
within IN N
the DT N
DTT NNP N
framework NN N
and CC N
achieved VBD N
milestones NNS o
of IN o
early JJ o
functional JJ o
spoken NN o
language NN o
use NN o
( ( N
Tager-Flusberg NNP N
et FW N
al NN N
, , N
J NNP N
Speech NNP N
Lang NNP N
Hear NNP N
Res NNP N
52:643-652 CD N
, , N
2009 CD N
) ) N
. . N

A DT p
sample NN p
of IN p
301 CD p
volunteer NN p
subjects NNS p
recruited VBN p
from IN p
the DT p
waiting VBG p
list NN p
for IN p
treatment NN p
in IN p
the DT p
Beth NNP p
Israel NNP p
methadone NN i
program NN i
were VBD i
randomly RB i
assigned VBN i
to TO i
immediate VB i
entry NN i
into IN i
the DT i
interim JJ i
clinic NN i
or CC i
a DT i
control NN i
group NN i
. . i

RESULTS VB N
The DT N
five-year JJ o
survival NN o
rate NN o
is VBZ N
98.3 CD N
% NN N
for IN N
the DT N
IMZ NNP N
group NN N
, , N
98.3 CD N
% NN N
for IN N
the DT N
Br NNP N
group NN N
and CC N
100 CD N
% NN N
for IN N
the DT N
ITI NNP N
group NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
target VB o
vessel JJ o
revascularization NN o
( ( o
TVR NNP o
) ) o
was VBD N
analyzed VBN N
as IN N
time-to-first JJ N
event NN N
within IN N
9 CD N
months NNS N
of IN N
the DT N
index NN N
PCI NNP N
. . N

The DT N
63 CD p
hypertensive JJ p
women NNS p
had VBD N
a DT N
high JJ N
incidence NN N
of IN N
diabetes NNS o
mellitus NNS o
diagnosed VBD N
during IN N
pregnancy NN N
( ( N
49.2 CD N
% NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
authors NNS N
' POS N
general JJ N
obstetric JJ N
population NN N
( ( N
8.1 CD N
% NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Timing NNP o
of IN o
referrals NNS o
and CC o
discharge NN o
planning NN o
; : o
total JJ o
length NN o
of IN o
stay NN o
; : o
and CC o
complication NN o
and CC o
readmission NN o
rates NNS o
within IN o
28 CD o
days NNS o
of IN o
discharge NN o
. . o

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP o
score NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP N
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP N
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Thus RB N
, , N
we PRP N
hypothesized VBD N
that IN N
compared VBN N
to TO N
high JJ N
dialysate NN N
sodium NN N
, , N
low JJ N
dialysate NN N
sodium NN N
concentration NN N
would MD N
lower VB N
endothelin VB N
1 CD N
levels NNS N
, , N
increase NN N
NO NNP N
release NN N
, , N
and CC N
reduce VB N
BP NNP o
. . o

Grade $ o
4 CD o
neutropenia NN o
was VBD N
significantly RB N
associated VBN N
with IN N
a DT N
PS NNP N
> NNP N
or=1 NN N
, , N
whereas JJ N
risk NN o
of IN o
grade NN o
> NNP o
or=3 NN o
diarrhea NN o
was VBD N
directly RB N
related VBN N
to TO N
age NN N
and CC N
previous JJ N
weight NN N
loss NN N
. . N

METHODS NNP N
A DT N
three-day JJ N
treatment NN N
period NN N
and CC N
14-day JJ N
follow-up JJ N
period NN N
was VBD N
performed VBN N
in IN N
any DT p
subject JJ p
weighting NN p
more JJR p
than IN p
10 CD p
kg NNS p
, , p
presenting VBG p
with IN p
a DT p
malaria NN p
paroxysm NN p
confirmed VBN p
by IN p
parasitaemia NN p
> NN p
or CC p
= $ p
1,000/microl CD p
, , p
after IN p
informed JJ p
consent NN p
. . p

Plaques NNS N
were VBD N
subjected VBN N
to TO N
the DT N
analysis NN N
of IN N
CD3 NNP o
, , o
CD68 NNP o
, , o
soluble JJ o
intercellular JJ o
adhesion NN o
molecule NN o
1 CD o
( ( o
ICAM-1 NNP o
) ) o
, , o
matrix JJ o
metalloprotease-9 NN o
( ( o
MMP-9 NNP o
) ) o
, , o
CD40L NNP o
, , o
tenascin-C NN o
, , o
and CC o
collagen NN o
content NN o
lipid JJ o
content NN o
by IN N
immunohistochemistry NN N
or CC N
polarized VBN N
light JJ N
analysis NN N
. . N

In IN N
a DT N
population NN p
setting NN p
of IN p
people NNS p
undergoing VBG p
assisted JJ p
reproduction NN p
, , p
44 CD p
individuals NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
receiving VBG i
standard JJ i
one-on-one JJ i
genetic JJ i
counseling NN i
or CC i
education NN i
by IN i
the DT i
IC NNP i
program NN i
. . i

CONCLUSION NNP N
CM NNP i
administered VBD N
for IN N
2 CD N
wk NNS N
significantly RB N
improved VBN N
clinical JJ o
measurements NNS o
of IN o
autism NN o
severity NN o
and CC o
decreased VBD o
serum JJR o
level NN o
of IN o
TARC NNP o
in IN N
autistic JJ p
children NNS p
, , N
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
. . N

In IN N
our PRP$ N
study NN N
of IN N
borderline JJ N
hypertension NN N
in IN N
Tecumseh NNP N
, , N
white-coat JJ N
hypertension NN N
is VBZ N
present JJ N
in IN N
7.1 CD N
% NN N
of IN N
the DT N
whole JJ N
population NN N
and CC N
in IN N
58 CD N
% NN N
of IN N
all DT N
subjects NNS N
with IN N
elevated JJ N
blood NN N
pressures NNS N
in IN N
the DT N
clinic NN N
. . N

Aspirin NNP i
infusion NN N
reduced VBD N
urinary JJ o
excretion NN o
of IN N
both DT N
metabolites NNS N
greater JJR N
than IN N
90 CD N
% NN N
, , N
but CC N
excretion NN o
of IN o
2,3-dinor-6-oxo-PGF1 JJ o
alpha NN o
recovered VBD o
more RBR N
rapidly RB N
than IN N
did VBD N
that IN N
of IN N
2,3-dinor-TXB2 JJ N
. . N

CONCLUSIONS NNP N
Tapered NNP N
, , N
roughened-surface JJ N
implants NNS N
immediately RB N
restored VBN N
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN N
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN N
. . N

; : i
nitrendipine NN i
, , N
20 CD N
mg NN N
once RB N
daily JJ N
; : N
or CC N
placebo VB i
on IN N
blood NN o
glucose NN o
and CC o
plasma JJ o
insulin NN o
and CC o
C-peptide JJ o
response NN o
to TO N
an DT N
intravenous JJ N
glucose NN N
load NN N
in IN N
mildly RB p
or CC p
transiently RB p
hypertensive JJ p
nondiabetic JJ p
obese JJ p
patients NNS p
. . p

METHODS NNP N
Forty NNP p
below-knee NN p
amputees NNS p
( ( p
after IN p
war NN p
wounding NN p
) ) p
, , p
average JJ p
age NN p
35.6 CD p
+/- JJ p
10.6 CD p
years NNS p
, , p
that WDT p
were VBD p
included VBN p
in IN p
primary JJ p
rehabilitation NN p
program NN p
with IN p
prosthetics NNS p
, , p
were VBD p
examined VBN p
. . p

CONCLUSION NNP N
Five NNP N
weeks NNS N
of IN N
5 CD N
% NN N
imiquimod JJ N
cream NN N
once RB N
daily JJ N
with IN N
a DT N
1-week JJ N
interval NN N
was VBD N
more RBR N
effective JJ N
but CC N
as RB N
well RB N
tolerated VBN o
as IN N
the DT N
8-week JJ N
alternate NN N
week NN N
regimen NNS N
for IN N
sBCC NN N
. . N

Untreated VBN N
controls NNS N
at IN N
the DT N
2 CD N
intervals NNS N
showed VBD N
a DT N
mean JJ N
decrease NN N
in IN N
sensitivity NN N
to TO N
cold VB N
of IN N
3.6 CD N
degrees NNS N
C NNP N
and CC N
4.1 CD N
degrees NNS N
C. NNP N
Statistical NNP N
analysis NN N
showed VBD N
type NN N
of IN N
composite JJ N
cement NN N
to TO N
be VB N
a DT N
significant JJ N
factor NN N
. . N

Pain NN o
scores NNS o
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

MEASUREMENTS NNP N
Distance NNP o
walked VBD o
in IN o
6 CD o
minutes NNS o
and CC o
sum NN o
of IN o
the DT o
function NN o
, , o
pain NN o
, , o
and CC o
stiffness JJ o
subscores NNS o
of IN o
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
. . o

Eleven NNP N
( ( N
19 CD N
% NN N
) ) N
women NNS N
experienced VBD N
intermenstrual JJ o
bleeding NN o
judged VBD o
to TO N
be VB N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
use NN N
( ( N
four CD N
in IN N
the DT N
CS NNP N
and CC N
seven CD N
in IN N
the DT N
placebo NN i
gel NN i
group NN N
) ) N
. . N

In IN N
both DT N
groups NNS N
plasma VBP o
levels NNS o
of IN o
triglycerides NNS o
, , o
very RB o
low-density JJ o
lipoprotein NN o
cholesterol NN o
, , o
and CC o
high-density NN o
lipoprotein NN o
cholesterol NN o
increased VBD N
significantly RB N
after IN N
3 CD N
months NNS N
. . N

During IN N
aspirin JJ N
intake NN N
, , N
these DT N
results NNS N
varied VBD N
considerably RB N
from IN N
day NN N
to TO N
day NN N
in IN N
nine CD N
out IN N
of IN N
20 CD N
men NNS N
, , N
resulting VBG N
in IN N
an DT N
overlap NN N
between IN N
the DT N
reference NN N
ranges VBZ N
at IN N
baseline NN N
and CC N
during IN N
therapy NN N
. . N

For IN N
the DT N
same JJ N
total JJ N
daily JJ N
dose NN N
of IN N
60 CD N
mg NN N
, , N
both DT N
bleeding VBG o
frequency NN o
and CC o
trough JJ o
edoxaban NN o
concentrations NNS o
were VBD N
higher JJR N
in IN N
the DT N
30-mg JJ N
bid NN N
group NN N
than IN N
in IN N
the DT N
60-mg JJ N
qd NN N
group NN N
. . N

3 CD N
Isoprenaline NNP N
dose-response JJ N
curves NNS N
for IN N
decreases NNS N
in IN N
diastolic JJ N
blood NN N
pressure NN N
also RB N
showed VBD N
shifts NNS N
to TO N
the DT N
right NN N
after IN N
oral JJ N
prizidilol NN N
, , N
providing VBG N
evidence NN N
of IN N
beta-adrenoceptor NN N
antagonism NN N
by IN N
this DT N
drug NN N
in IN N
peripheral JJ N
resistance NN N
vessels NNS N
. . N

Health-related JJ o
QoL NNP o
was VBD N
assessed VBN N
at IN N
entry NN N
and CC N
after IN N
every DT N
cycle NN N
by IN N
the DT N
EORTC-QLQ-C30 NNP o
and CC o
LC13 NNP o
questionnaires NNS o
, , o
toxicity NN o
by IN N
the DT N
NCI-NCCN NNP i
CTC NNP i
vs NN N
2 CD N
, , N
and CC N
intent-to-treat JJ N
objective JJ N
response NN N
by IN N
the DT N
Recist NNP N
criteria NNS N
. . N

However RB N
, , N
significant JJ N
synergistic JJ N
effect NN N
of IN N
CoQ NNP i
( ( N
10 CD N
) ) N
with IN N
ET NNP i
was VBD N
observed VBN N
only RB N
for IN N
peak NN N
SWTI NNP N
suggesting VBG N
that IN N
ET NNP N
amplifies VBZ N
the DT N
already RB N
described JJ N
effect NN N
of IN N
CoQ NNP i
( ( N
10 CD N
) ) N
on IN N
contractility NN N
of IN N
dysfunctional JJ N
myocardium NN N
. . N

CONCLUSIONS NNP N
The DT N
combination NN N
of IN N
clonidine NN i
( ( N
2 CD N
microg/kg NN N
) ) N
and CC N
ropivacaine VB i
0.1 CD N
% NN N
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
quality NN o
of IN o
postoperative JJ o
analgesia NN o
compared VBN N
to TO N
plain VB N
0.2 CD N
% NN N
ropivacaine NN i
. . i

In IN p
648 CD p
normal JJ p
karyotype NN p
( ( p
NK NNP p
) ) p
AML NNP p
patients NNS p
, , N
we PRP N
found VBD N
a DT N
significant JJ N
independent JJ N
effect NN N
of IN N
the DT N
quantitative JJ N
FLT3ITD NNP N
mRNA NN N
level NN N
-- : N
measured VBN N
as IN N
( ( N
FLT3ITD/wtFLT3 NNP N
) ) N
/ NN N
( ( N
FLT3ITD/wtFLT3+1 NNP N
) ) N
-- : N
on IN N
outcome NN N
. . N

These DT N
two CD N
groups NNS N
were VBD N
given VBN N
either RB N
intravenous JJ i
dezocine NN i
0.1 CD i
mg/kg NN i
or CC i
a DT i
matching JJ i
placebo NN i
( ( i
equal JJ i
volume NN i
of IN i
0.9 CD i
% NN i
saline NN i
) ) i
10 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD p
patients NNS p
with IN p
alopecia JJ p
areata NNS p
to TO p
whom WP p
either DT p
DNCB NNP i
or CC i
croton VB i
oil NN i
was VBD N
applied VBN N
topically RB N
. . N

In IN N
Group NNP N
B NNP N
( ( N
November NNP N
2007-October JJ N
2008 CD N
) ) N
, , N
we PRP N
calculated VBD N
the DT N
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
under IN o
this DT o
TM-PD NNP o
criteria NNS o
, , N
which WDT N
was VBD N
compared VBN N
with IN N
the DT N
TTP NNP N
under IN N
the DT N
RECIST NNP N
criteria NNS N
. . N

Hypotension NN o
and CC o
associated VBN o
symptoms NNS o
resolved VBD N
within IN N
30 CD N
minutes NNS N
after IN N
discontinuation NN N
of IN N
esmolol JJ N
infusion NN N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
the DT N
short JJ N
duration NN N
of IN N
action NN N
of IN N
esmolol NN N
( ( N
elimination JJ N
half-life NN N
of IN N
9.2 CD N
minutes NNS N
) ) N
. . N

Sixteen JJ p
young JJ p
subjects NNS p
( ( p
age NN p
range NN p
, , p
19-27 JJ p
years NNS p
) ) p
and CC p
24 CD p
elderly JJ p
subjects NNS p
( ( p
age NN p
range NN p
, , p
60-86 JJ p
years NNS p
) ) p
participated VBD p
. . p

Paracetamol NNP i
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ i
alone RB i
or CC i
with IN i
( ( i
300 CD i
mg NN i
) ) i
ferrous JJ i
sulphate NN i
by IN N
ten JJ p
healthy JJ p
male NN p
volunteers NNS p
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP o
, , o
safety NN o
, , o
predictability NN o
, , o
stability NN o
, , o
HOAs NNP o
, , o
and CC o
CS NNP o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
enhancement NN N
at IN N
6 CD N
months NNS N
' POS N
follow-up NN N
. . N

In IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

Nineteen JJ p
patients NNS p
with IN p
limited JJ p
disease NN p
( ( p
ID NNP p
and CC p
IID NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
3-week JJ N
chemotherapy NN i
regimen NNS i
associated VBN i
with IN i
whole JJ i
abdominal JJ i
radiotherapy NN i
or CC i
chemotherapy NN i
for IN p
3 CD p
years NNS p
. . p

CONCLUSION NNP N
The DT N
single JJ N
combination NN N
eyedrop NN N
of IN N
cyclopentolate JJ i
0.2 CD N
% NN N
and CC N
phenylephrine VB i
1 CD N
% NN N
is VBZ N
as IN N
effective JJ o
and CC o
safe JJ o
a DT o
mydriatic JJ o
for IN N
infants NNS N
with IN N
dark JJ N
irides NNS N
as IN N
both DT N
tropicamide IN i
0.5 CD N
% NN N
and CC N
phenylephrine VB N
2.5 CD N
% NN N
. . N

Similar JJ N
decreases NNS N
in IN N
blood NN o
pressure NN o
were VBD N
seen VBN N
24 CD N
h NN N
after IN N
the DT N
last JJ N
dose NN N
of IN N
perindopril NN i
or CC i
hydrochlorothiazide NN i
( ( N
11/7 CD N
mm NN N
Hg NNP N
supine NN N
) ) N
given VBN N
alone RB N
at IN N
these DT N
doses NNS N
. . N

Salmeterol NNP i
, , N
however RB N
, , N
showed VBD N
a DT N
flatter JJ o
dose-response JJ o
curve NN o
, , N
and CC N
a DT N
significantly RB N
weaker JJR N
maximal JJ o
protective JJ o
effect NN o
( ( N
2.8 CD N
doubling VBG N
doses NNS N
after IN N
250 CD N
micrograms NNS N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
investigate VB N
whether IN N
pre-operative JJ i
chemotherapy NN i
leads VBZ N
to TO N
a DT N
15 CD N
% NN N
higher JJR N
curative JJ o
resectability NN o
rate NN o
in IN N
patients NNS p
with IN p
operable JJ p
gastric JJ p
cancer NN p
. . p

Interestingly RB N
, , N
letrozole NN N
was VBD N
effective JJ N
even RB N
in IN N
marginally RB N
ER+ NNP N
tumors NNS N
and CC N
, , N
unlike IN N
tamoxifen NN N
, , N
consistently RB N
reduced VBD N
the DT N
expression NN o
from IN o
estrogen-regulated JJ o
genes NNS o
( ( N
progesterone NN N
receptor NN N
and CC N
trefoil NN N
factor NN N
1 CD N
) ) N
. . N

Patients NNS p
were VBD p
divided VBN p
into IN p
four CD p
groups NNS p
( ( p
20 CD p
patients NNS p
for IN p
each DT p
) ) p
: : p
dexmedetomidine NN i
and CC i
topical JJ i
anesthesia NN i
, , i
dexmedetomidine NN i
and CC i
peribulbar NN i
anesthesia NN i
, , i
midazolam+fentanyl NN i
and CC i
topical JJ i
anesthesia NN i
, , i
and CC i
midazolam+fentanyl NN i
and CC i
peribulbar NN i
anesthesia NN i
. . i

More RBR N
importantly RB N
, , N
whereas IN N
most JJS N
smoke-induced JJ N
effects NNS N
on IN N
lung NN N
function NN N
appear VBP N
to TO N
recede VB N
within IN N
60 CD N
minutes NNS N
, , N
inflammatory JJ N
cytokines NNS N
remain VBP N
elevated JJ N
for IN N
at IN N
least JJS N
3 CD N
hours NNS N
after IN N
exposure NN N
to TO N
SHS NNP N
. . N

METHODS NNP N
Sixty NNP p
patients NNS p
aged VBD p
18 CD p
years NNS p
or CC p
older JJR p
with IN p
unresectable JJ p
upper JJ p
abdominal JJ p
cancers NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
USCPN NNP i
. . i

Fourteen JJ p
animals NNS p
were VBD p
inoculated VBN p
with IN p
virulent JJ p
canine NN p
parvovirus NN p
; : p
10 CD p
animals NNS p
that WDT p
developed VBD p
clinical JJ p
signs NNS p
thereby RB p
meeting VBG p
the DT p
inclusion NN p
criteria NNS p
were VBD p
admitted VBN p
to TO p
the DT p
treatment NN p
phase NN p
in IN p
two CD p
randomly RB p
selected VBN p
groups NNS p
( ( p
placebo NN i
and CC i
IFN NNP i
) ) i
of IN i
equal JJ i
size NN i
. . i

PATIENTS NNS N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
extensive JJ p
SCLC NNP p
with IN p
a DT p
Karnofsky NNP p
performance NN p
score NN p
( ( p
KPS NNP p
) ) p
> VBD p
or CC p
= $ p
50 CD p
and CC p
adequate JJ p
renal JJ p
function NN p
and CC p
bone NN p
marrow NN p
reserve NN p
were VBD p
eligible JJ p
. . p

Furthermore RB N
, , N
less JJR N
than IN N
10 CD N
% NN N
of IN N
a DT N
bupropion NN i
dose NN N
is VBZ N
excreted VBN N
as IN N
urinary JJ N
bupropion NN N
and CC N
its PRP$ N
characterized JJ N
metabolites NNS N
hydroxybupropion NN N
, , N
threohydrobupropion NN N
, , N
and CC N
erythrohydrobupropion NN N
, , N
suggesting VBG N
that IN N
alternative JJ N
metabolic JJ N
pathways NNS N
may MD N
exist VB N
. . N

RESULTS NN N
Of IN N
the DT N
160 CD N
subjects NNS N
in IN N
whom WP N
efficacy NN N
could MD N
be VB N
evaluated VBN N
, , N
the DT N
OC NNP N
group NN N
showed VBD N
a DT N
statistically RB N
significantly RB N
greater JJR N
improvement NN N
than IN N
the DT N
placebo NN i
group NN N
for IN N
all DT N
primary JJ N
efficacy NN N
measures NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD p
patients NNS p
with IN p
osteoarthritis NN p
who WP p
underwent VBD p
computer-navigated JJ p
total JJ p
knee NN p
arthroplasty NN p
for IN p
one CD p
knee NN p
and CC p
conventional JJ p
total JJ p
knee NN p
arthroplasty NN p
for IN p
the DT p
other JJ p
. . p

More JJR N
than IN N
4 CD N
mg NN N
of IN N
pyridoxine JJ N
supplementation NN N
daily RB N
was VBD N
required VBN N
for IN N
most JJS N
pregnancies NNS N
to TO N
maintain VB N
maternal JJ o
plasma NN o
PLP NNP o
levels NNS o
within IN N
the DT N
range NN N
observed VBD N
during IN N
the DT N
first JJ N
trimester NN N
and CC N
in IN N
the DT N
nonpregnant JJ N
state NN N
. . N

A DT N
significant JJ N
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
improvement NN N
in IN N
the DT N
nasal JJ o
index NN o
occurred VBD N
as RB N
early RB N
as IN N
12 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
triamcinolone NN N
acetonide RB N
aqueous JJ N
nasal NN N
spray NN N
. . N

RESULTS NNP N
All NNP N
these DT N
parameters NNS N
, , N
reflecting VBG N
crystal NN N
and CC N
unit NN N
cell NN N
characteristics NNS N
, , N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
Sr NNP N
and CC N
were VBD N
similar JJ N
in IN N
SrRan NNP N
and CC N
placebo NN N
groups NNS N
after IN N
36 CD N
months NNS N
of IN N
treatment NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
accuracy NN N
and CC N
clinical JJ N
value NN N
of IN N
combining VBG N
64 CD i
multi-slice JJ i
spiral JJ i
computer NN i
tomography NN i
( ( i
MSCT NNP i
) ) i
and CC i
serum $ i
amyloid VB i
A NNP i
protein NN i
( ( i
SAA NNP i
) ) i
in IN N
the DT N
preoperative JJ N
staging NN N
of IN N
rectal JJ p
cancer NN p
. . p

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ p
female NN p
patients NNS p
and CC p
twenty-five JJ p
male NN p
patients NNS p
with IN p
a DT p
combined JJ p
average JJ p
age NN p
of IN p
fifty JJ p
years NNS p
and CC p
an DT p
average JJ p
body NN p
mass NN p
index NN p
of IN p
30.9 CD p
. . p

Two CD p
high JJ p
prevalence NN p
HIV/AIDS NNP p
villages NNS p
in IN p
rural JJ p
Andhra NNP p
Pradesh NNP p
, , p
which WDT p
were VBD p
demographically RB p
alike JJ p
and CC p
served VBN p
by IN p
distinct JJ p
Public NNP p
Health NNP p
Centers NNP p
, , p
were VBD p
selected VBN p
randomly RB p
from IN p
a DT p
total NN p
of IN p
16 CD p
villages NNS p
. . p

Anti-tetanus NNP i
GMTs NNP i
in IN N
placebo NN i
and CC i
chloroquine NN i
groups NNS N
declined VBD N
over IN N
14 CD N
months NNS N
to TO N
levels NNS N
comparable JJ N
to TO N
those DT N
of IN N
unvaccinated JJ N
controls NNS N
, , N
but CC N
levels NNS N
in IN N
the DT N
primaquine NN N
group NN N
remained VBD N
significantly RB N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

CONCLUSIONS NNS N
Compared VBN N
with IN N
TAH NNP i
, , i
LAVH NNP i
has VBZ N
advantages NNS N
in IN N
removing VBG N
uteri JJ N
weighing VBG N
< NN N
or CC N
= $ N
500 CD N
g NN N
, , N
with IN N
comparable JJ N
operating NN N
time NN N
, , N
less JJR N
post-operative JJ o
pain NN o
and CC o
shorter JJR o
recovery NN o
. . o

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60 CD N
% NN N
of IN N
maximal JJ o
static JJ o
inspiratory NN o
mouth NN o
pressure NN o
( ( o
PI NNP o
, , o
mmax NN o
) ) o
at IN o
functional JJ o
residual JJ o
capacity NN o
, , N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
overall JJ o
survival NN o
and CC o
progression-free JJ o
survival NN o
both DT N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
patients NNS N
with IN N
PD-L1 NNP N
expression NN N
on IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
. . N

This DT N
trial NN N
also RB N
tested VBD N
the DT N
hypothesis NN N
that WDT N
neoadjuvant JJ i
and CC i
concurrent JJ i
hormonal JJ i
therapy NN i
( ( i
NCHT NNP i
) ) i
improves VBZ N
PFS NNP N
compared VBN N
with IN N
adjuvant JJ N
hormonal JJ N
therapy NN N
( ( N
AHT NNP N
) ) N
by IN N
10 CD N
% NN N
. . N

Toxicity NN o
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
arms NNS N
, , N
although IN N
patients NNS N
with IN N
a DT N
baseline NN N
CD4 NNP N
count NN N
less JJR N
than IN N
50/microL CD N
had VBD N
a DT N
high JJ N
infectious JJ o
death NN o
rate NN o
in IN N
the DT N
concurrent NN N
arm NN N
. . N

Both DT o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
were VBD N
significantly RB N
lower JJR N
after IN N
administration NN N
of IN N
captopril JJ i
25 CD N
mg NN N
, , N
whereas WP N
blood NN o
pressure NN o
was VBD N
unaffected VBN N
by IN N
enalapril NNS i
compared VBN N
with IN N
placebo NN i
. . i

The DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS o
of IN o
BMS-181101 NNP o
, , N
a DT N
new JJ N
anti-depressant JJ N
under IN N
development NN N
, , N
was VBD N
investigated VBN N
in IN N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
at IN p
steady JJ p
state NN p
. . p

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo JJ N
( ( N
b NN N
, , N
f NN N
) ) N
pyrazino- NN i
( ( N
1,2-d CD N
) ) N
- : N
( ( N
1,4 CD N
) ) N
-oxazepine NN i
hydrogen NN i
maleate NN i
( ( N
Org NNP N
GC NNP N
94 CD N
) ) N
is VBZ N
an DT N
oral JJ N
antamine NN N
preparation NN N
with IN N
anti-serotoninergic JJ N
and CC N
anti-histaminic JJ N
effects NNS N
. . N

BACKGROUND IN N
There EX N
are VBP N
few JJ N
large JJ N
case NN N
series NN N
describing VBG N
the DT N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
genotypes VBZ N
found VBN N
in IN N
women NNS p
diagnosed VBN p
with IN p
rigorously RB p
reviewed VBN p
cervical JJ p
intraepithelial JJ p
neoplasia NN p
grade VBD p
3 CD p
( ( p
CIN3 NNP p
) ) p
, , p
cervical JJ p
precancer NN p
. . p

The DT N
infusion NN N
was VBD N
started VBN N
with IN N
an DT N
initial JJ N
dose NN N
given VBN N
over IN N
10 CD N
min NNS N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
; : N
at IN N
induction NN N
the DT N
maintenance NN N
rate NN N
was VBD N
begun VBN N
and CC N
continued VBN N
until IN N
closure NN N
of IN N
the DT N
abdominal JJ N
fascia NN N
. . N

This DT N
study NN N
identified VBD N
subtypes NNS N
of IN N
aggression NN N
in IN N
a DT N
sample NN N
of IN N
206 CD p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
who WP p
participated VBD p
in IN p
2 CD p
risperidone NN p
trials NNS p
. . p

In IN N
addition NN N
, , N
the DT N
effectiveness NN N
of IN N
a DT N
2-g JJ N
single JJ N
dose NN N
of IN N
metronidazole NN i
was VBD N
compared VBN N
with IN N
a DT N
seven-day JJ N
course NN N
of IN N
500 CD N
mg NN N
of IN N
metronidazole JJ i
twice NN N
a DT N
day NN N
in IN N
patients NNS p
with IN p
bacterial JJ p
vaginosis NN p
. . p

However RB N
, , N
several JJ N
laboratories NNS N
have VBP N
reported VBN N
that IN N
protein JJ N
ingestion NN N
does VBZ N
not RB N
result VB N
in IN N
an DT N
increase NN N
in IN N
the DT N
circulating NN N
glucose JJ N
concentration NN N
in IN N
people NNS p
with IN p
or CC p
without IN p
type JJ p
2 CD p
diabetes NNS p
. . p

OBJECTIVE NN N
To TO N
assess VB N
long-term JJ N
( ( N
36-month JJ N
) ) N
hypothalamic-pituitary-gonadal JJ N
axis JJ N
suppression NN N
and CC N
safety NN N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS p
with IN p
CPP NNP p
. . p

Slide NNP N
positivity NN N
rate NN N
( ( N
SPR NNP N
) ) N
and CC N
malaria $ N
incidence NN N
per IN N
1000 CD N
population NN N
( ( N
PI NNP N
) ) N
were VBD N
compared VBN N
between IN N
the DT N
three CD N
study NN N
arms NNS N
to TO N
assess VB N
the DT N
impact NN N
of IN N
use NN N
of IN N
Interceptor NNP i
nets NNS i
. . i

RESULTS NNP N
Fracture NNP o
union NN o
was VBD N
achieved VBN N
in IN N
all DT N
patients NNS N
in IN N
the DT N
operative JJ N
group NN N
, , N
whereas IN N
nonunion NN o
was VBD N
observed VBN N
in IN N
3 CD N
of IN N
30 CD N
patients NNS N
of IN N
the DT N
nonoperative JJ N
group NN N
. . N

A DT N
significant JJ N
survival JJ o
benefit NN o
was VBD N
identified VBN N
at IN N
study NN N
completion NN N
in IN N
the DT N
pre-defined JJ p
sub-group NN p
of IN p
123 CD p
patients NNS p
who WP p
had VBD p
received VBN p
prior RB p
chemotherapy NN i
( ( N
P=0.045 NNP N
, , N
hazard NN N
ratio=1.53 NN N
( ( N
1.00-2.34 JJ N
) ) N
) ) N
. . N

PURPOSE NNP N
In IN N
a DT N
register NN N
study NN N
, , N
the DT N
risk NN N
of IN N
anastomotic JJ o
leakage NN o
correlated VBD N
to TO N
the DT N
choice NN N
of IN N
circular JJ i
stapling VBG i
device NN i
with IN N
a DT N
4 CD N
% NN N
difference NN N
between IN N
the DT N
two CD N
brands NNS N
used VBN N
. . N

In IN N
the DT N
second JJ N
study NN N
473 CD p
patients NNS p
with IN p
suspected JJ p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
oxprenolol NN i
, , i
disopyramide JJ i
phosphate NN i
, , i
or CC i
placebo NN i
. . i

Patients NNS N
received VBD N
treatment NN N
during IN N
interventional JJ N
visits NNS N
: : N
one CD N
SC NNP i
and CC i
one CD i
ID NNP i
basal/bolus CC i
infusion NN i
of IN i
insulin JJ i
aspart NN i
( ( i
NovoRapid NNP i
U-100 NNP i
) ) i
administered VBD N
over IN N
3 CD N
days NNS N
in IN N
a DT N
randomized JJ N
order NN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS N
showed VBD N
a DT N
rapid JJ N
increase NN N
of IN N
intragastric JJ o
pH NN o
with IN o
a DT o
mean JJ o
intragastric JJ o
pH NN o
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

In IN N
both DT N
groups NNS N
, , N
minute JJ o
ventilation NN o
( ( o
VE NNP o
) ) o
and CC o
f $ o
progressively RB o
decreased VBN o
as IN o
resistance NN o
was VBD N
increased VBN N
by IN N
decreasing VBG N
the DT N
aperture NN N
size NN N
from IN N
15 CD N
to TO N
16 CD N
mm NNS N
. . N

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
proparacaine NN i
eye NN i
drops NNS i
( ( N
0.5 CD N
% NN N
) ) N
, , N
we PRP N
compared VBN N
the DT N
Premature NNP o
Infant NNP o
Pain NNP o
Profile NNP o
( ( o
PIPP NNP o
) ) o
scores VBZ o
in IN N
40 CD p
preterm JJ p
infants NNS p
undergoing VBG p
ROP NNP p
screening NN p
. . p

METHODS NNP N
After IN p
refraining VBG p
from IN p
all DT p
oral JJ p
hygiene NN p
procedures NNS p
for IN p
23-25 JJ p
hours NNS p
, , p
subjects NNS p
received VBD N
an DT N
oral JJ N
tissue NN N
examination NN N
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
number NN o
of IN o
total JJ o
bleeding VBG o
episodes NNS o
in IN N
the DT N
intent-to-treat JJ N
population NN N
, , N
was VBD N
analyzed VBN N
after IN N
the DT N
last JJ N
patient NN N
had VBD N
completed VBN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Prophylaxis NN N
with IN N
Calcium NNP i
entry NN i
blocker NN i
Flunarizine NNP i
( ( i
Sibelium NNP i
) ) i
or CC i
Thromboxane VB i
A DT i
inhibitor NN i
Acetylsalicylic NNP i
acid NN i
( ( i
ASS NNP i
) ) i
was VBD N
carried VBN N
out RP N
in IN N
a DT N
double JJ N
blind NN N
design NN N
for IN N
3 CD N
months NNS N
. . N

These DT N
dogs NNS N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
that WDT N
were VBD N
treated VBN N
for IN N
84 CD N
days NNS N
with IN N
either DT N
the DT N
test NN N
product NN N
, , N
imidapril NN i
, , i
or CC i
the DT i
positive JJ i
control NN i
, , i
benazepril NN i
, , i
and CC i
followed VBD i
up RP i
in IN i
parallel NN i
over IN i
this DT i
period NN i
. . i

Clindamycin NNP i
applied VBD N
in IN N
a DT N
single JJ N
preoperative NN N
dose NN N
of IN N
600 CD N
mg NN N
with IN N
or CC N
without IN N
subsequent JJ N
5-day JJ N
therapy NN N
does VBZ N
not RB N
demonstrate VB N
efficacy NN o
in IN o
prophylaxis NN o
for IN o
postoperative JJ o
inflammatory NN o
complications NNS o
after IN p
third JJ p
molar JJ p
surgery NN p
. . p

Documented VBN o
histologic JJ o
conversion NN o
was VBD N
often RB N
associated VBN N
with IN N
a DT N
more RBR N
aggressive JJ o
clinical JJ o
behavior NN o
of IN o
the DT o
lymphoma NN o
, , o
and CC o
the DT o
median JJ o
survival NN o
after IN N
conversion NN N
was VBD N
less JJR N
than IN N
1 CD N
yr NN N
. . N

Patients NNS N
were VBD N
monitored VBN N
daily RB N
for IN N
recurrence NN o
of IN o
pain NN o
, , o
need VBP o
to TO o
stop VB o
feeding NN o
, , o
post-refeeding JJ o
LOH NNP o
( ( N
primary JJ N
end NN N
point NN N
) ) N
, , N
and CC N
for IN N
28 CD N
days NNS N
post-refeeding JJ N
to TO N
capture VB N
re-admission NN o
rates NNS o
. . o

The DT N
eprinomectin NN N
protocol NN N
employed VBN N
in IN N
Study NNP N
2 CD N
, , N
consisting VBG N
of IN N
four CD N
weekly JJ N
topical JJ N
administrations NNS N
at IN N
the DT N
dose JJ N
rate NN N
of IN N
500mug/kg CD N
of IN N
body NN N
weight NN N
, , N
proved VBD N
highly RB N
effective JJ N
at IN N
reducing VBG N
the DT N
Chorioptes NNPS N
mite JJ N
burden NN N
in IN N
alpacas NN p
. . p

Grade $ o
4 CD o
neutropaenia NN o
, , o
grade VBD o
3/4 CD o
anaemia NN o
, , o
febrile JJ o
neutropaenia NN o
, , o
and CC o
diarrhoea NNS o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
oxygen JJ o
saturation NN o
, , o
respiratory NN o
rate NN o
, , o
RDAI NNP o
measurement NN o
twice RB o
daily RB o
for IN o
the DT o
first JJ o
4 CD o
days NNS o
, , o
and CC o
the DT o
length NN o
of IN o
hospitalization NN o
. . o

Fifty NNP p
women NNS p
with IN p
uterine JJ p
myoma NN p
, , p
who WP p
met VBD p
the DT p
criteria NNS p
of IN p
the DT p
study NN p
thoroughly RB p
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP i
or CC i
Cabergoline NNP i
. . i

Fifty-four JJ p
patients NNS p
treated VBN p
with IN p
daunorubicin NN i
, , i
cytosine JJ i
arabinoside NN i
and CC i
thioquanine NN i
for IN p
acute JJ p
myeloid NN p
leukemia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ i
lithium NN i
carbonate NN i
1200 CD i
mg JJ i
daily JJ i
or CC i
no DT i
lithium NN i
. . i

A DT N
total NN N
of IN N
110 CD p
patients NNS p
undergoing JJ p
elective JJ p
abdominal JJ p
hysterectomy NN p
were VBD p
anesthetized VBN p
in IN p
random JJ p
order NN p
with IN p
either DT p
isoflurane NN i
in IN i
nitrous JJ i
oxide NN i
and CC i
oxygen NN i
or CC i
isoflurane NN i
in IN i
air NN i
and CC i
oxygen NN i
. . i

METHODS NNP N
We PRP N
recruited VBD N
three CD N
family NN p
members NNS p
per IN p
family NN p
for IN p
assessment NN p
- : p
the DT p
melanoma NN p
case NN p
, , p
a DT p
first-degree JJ p
relative NN p
( ( p
FDR NNP p
) ) p
, , p
and CC p
a DT p
relative NN p
who WP p
is VBZ p
a DT p
parent NN p
of IN p
a DT p
child JJ p
age NN p
18 CD p
or CC p
younger JJR p
. . p

In IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
, , N
time NN o
to TO o
recurrence VB o
in IN N
the DT N
2 CD N
treatment NN N
groups NNS N
was VBD N
compared VBN N
with IN N
the DT N
log-rank JJ N
test NN N
in IN N
the DT N
subgroup NN N
of IN N
patients NNS p
with IN p
structural JJ p
heart NN p
disease NN p
. . p

Blood NN o
samples NNS o
were VBD N
collected VBN N
up RB N
to TO N
24 CD N
h NN N
after IN N
administration NN N
of IN N
the DT N
first JJ N
dose NN N
, , N
and CC N
the DT N
concentration NN N
of IN N
AmB NNP N
in IN N
plasma NN N
was VBD N
analyzed VBN N
by IN N
a DT N
high-performance NN N
liquid NN N
chromatography NN N
assay NN N
. . N

Each DT N
patient NN N
also RB N
received VBD N
ibuprofen NNS i
; : i
acetaminophen VBZ i
with IN N
codeine NN i
( ( N
30 CD N
mg NN N
) ) N
; : N
and CC N
a DT N
7-day JJ N
diary NN N
to TO N
record NN N
pain NN o
, , o
percussion NN o
pain NN o
, , o
and CC o
number NN o
and CC o
type NN o
of IN o
pain NN o
medication NN o
taken VBN o
. . o

Hierarchical JJ N
linear NN N
modeling NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
ethnic JJ N
match NN N
on IN N
drinking NN o
outcomes NNS o
including VBG o
volume NN o
per IN o
week NN o
, , o
maximum JJ o
amount NN o
, , o
and CC o
frequency NN o
of IN o
5 CD o
or CC o
more JJR o
drinks NNS o
per IN o
occasion NN o
. . o

Combination NNP o
therapy NN o
cleared VBD o
all DT o
AK NNP o
lesions NNS o
only RB N
after IN N
the DT N
first JJ N
course NN N
, , N
while IN N
PDT NNP N
and CC N
imiquimod JJ N
therapy NN N
cleared VBD N
41.7 CD N
% NN N
and CC N
66.7 CD N
% NN N
of IN N
AK NNP N
lesions NNS N
after IN N
the DT N
first JJ N
course NN N
, , N
respectively RB N
. . N

Although IN N
LGG NNP N
is VBZ N
a DT N
relatively RB N
poor JJ N
colonizer NN N
in IN N
infants NNS N
, , N
especially RB N
those DT N
infants NNS N
weighing VBG N
less JJR N
than IN N
1500 CD N
g NN N
at IN N
birth NN N
, , N
it PRP N
does VBZ N
appear VB N
to TO N
affect VB N
neonatal JJ o
intestinal JJ o
colonization NN o
patterns NNS o
. . o

The DT N
IFRS NNP N
is VBZ N
designed VBN N
to TO N
release VB N
a DT N
daily JJ N
dose NN N
of IN N
0.12mg CD N
of IN N
sodium NN N
fluoride NN N
, , N
which WDT N
can MD N
be VB N
evenly RB N
distributed VBN N
throughout IN N
the DT N
oral JJ N
cavity NN N
for IN N
a DT N
single JJ N
application NN N
of IN N
4 CD N
months NNS N
. . N

This DT N
study NN N
examined VBD N
whether IN N
cognitive JJ N
gains NNS N
among IN N
192 CD p
students NNS p
from IN p
47 CD p
kindergarten-through-second-grade JJ p
autism NN p
support NN p
classrooms NNS p
participating VBG p
in IN p
a DT p
year-long JJ p
behavioral JJ p
intervention NN p
study NN p
were VBD p
associated VBN p
with IN p
gains NNS p
in IN p
social JJ p
functioning NN p
. . p

At IN N
follow-up JJ N
, , N
39 CD N
% NN N
of IN N
conservative JJ N
management NN N
patients NNS N
requested VBD N
surgery NN N
, , N
and CC N
interference NN o
of IN o
symptoms NNS o
with IN o
life NN o
and CC o
an DT o
unsuccessful JJ o
outcome NN o
were VBD N
more JJR N
commonly RB N
reported VBN N
in IN N
this DT N
arm NN N
. . N

CONCLUSIONS NNP N
Simple NNP i
knee NNP i
flexion NN i
and CC i
extension NN i
exercises NNS i
( ( i
WB NNP i
and CC i
NWB NNP i
) ) i
performed VBD N
over IN N
8 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
the DT N
WOMAC NNP o
function NN o
scale NN o
and CC o
knee NN o
strength NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

After IN N
at IN N
least JJS N
14 CD N
days NNS N
, , N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
olopatadine NN i
in IN N
one CD N
eye NN N
and CC N
placebo NN i
in IN N
the DT N
contralateral JJ N
eye NN N
, , N
or CC N
ketorolac NN N
in IN N
one CD N
eye NN N
and CC N
placebo NN N
in IN N
the DT N
contralateral JJ N
eye NN N
. . N

RESULTS NNP N
Bleeding NNP o
of IN o
the DT o
gums NNS o
on IN o
probing VBG o
( ( o
BOP NNP o
) ) o
and CC o
pocket NN o
depth NN o
( ( o
PD NNP o
) ) o
improved VBD N
at IN N
the DT N
treatment NN N
site NN N
and CC N
were VBD N
maintained VBN N
for IN N
13 CD N
weeks NNS N
after IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
high JJ N
intakes NNS N
of IN N
iTFA NN i
and CC i
CLA NNP i
did VBD N
not RB N
substantially RB N
affect JJ N
plasma NN o
concentrations NNS o
of IN o
inflammatory JJ o
markers NNS o
, , N
but CC N
they PRP N
increased VBD N
the DT N
urine JJ o
8-iso-PGF JJ o
( ( o
2 CD o
) ) o
concentration NN o
. . o

After IN N
5 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
the DT N
cumulative JJ o
incidence NN o
of IN o
IBR NNP o
was VBD N
2.5 CD N
% NN N
in IN N
the DT N
surgery-only JJ N
arm NN N
and CC N
0.7 CD N
% NN N
in IN N
the DT N
surgery NN N
plus CC N
RT NNP N
arm NN N
. . N

Lethality NNP o
was VBD N
56 CD N
% NN N
in IN N
the DT N
sepsis NN N
group NN N
; : N
in IN N
the DT N
therapy NN N
group NN N
lethality NN N
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS N
with IN N
plasmapheresis NN N
, , N
even RB N
though IN N
in IN N
this DT N
population NN N
the DT N
organic JJ o
failure NN o
rate NN o
was VBD N
higher JJR N
. . N

Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
. . N

Analysis NN N
comparing VBG N
change NN N
between IN N
baseline NN N
and CC N
week NN N
8 CD N
of IN N
treatment NN N
for IN N
L-carnitine NNP i
and CC N
the DT N
placebo NN i
showed VBD N
that IN N
both DT N
parents/caregivers NNS N
and CC N
medical JJ N
follow-up NN N
detected JJ N
improvements NNS N
in IN N
the DT N
subjects NNS N
' POS N
well-being NN N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN i
suffered VBD N
mild JJ o
adverse JJ o
effects NNS o
( ( o
nausea NN o
, , o
vomiting VBG o
, , o
headache NN o
, , o
hypotension NN o
and CC o
rash NN o
) ) o
. . o

METHODS NNP N
On IN N
four CD N
separate JJ N
occasions NNS N
, , N
12 CD p
male JJ p
team-sport NN p
players NNS p
performed VBD N
a DT N
standardized JJ N
warm-up NN N
, , N
followed VBN N
by IN N
a DT N
test NN N
of IN N
either DT N
RSA NNP i
or CC i
CODS NNP i
( ( N
on IN N
two CD N
occasions NNS N
each DT N
) ) N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

Extrinsic JJ N
tooth DT N
stain NN N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
and CC N
14 CD N
days NNS N
using VBG N
a DT N
Modified NNP i
Lobene NNP i
Stain NNP i
Index NNP i
( ( i
MLSI NNP i
) ) i
with IN N
Lobene NNP N
inclusion NN N
criteria NNS N
of IN N
? . N
1.5 CD N
. . N

In IN N
conclusion NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
from IN N
baseline NN N
in IN N
the DT N
coronary JJ o
plaque NN o
volume NN o
in IN N
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris NN p
who WP p
received VBD p
olmesartan PRP i
or CC i
valsartan VB i
for IN N
6 CD N
months NNS N
. . N

Although IN N
the DT N
mean JJ o
hemoglobin NN o
concentration NN o
was VBD N
higher RBR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
after IN N
6 CD N
days NNS N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
until IN N
9.5 CD N
days NNS N
of IN N
ICU NNP N
care NN N
. . N

Measured NNP N
serum NN o
propofol NN o
concentrations NNS o
in IN N
equilibrium NN N
with IN N
the DT N
effect-site NN N
at IN N
which WDT N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
did VBD N
not RB N
respond VB N
to TO N
verbal VB N
commands NNS N
( ( N
EC50 NNP N
for IN N
loss NN N
of IN N
consciousness NN N
) ) N
were VBD N
determined VBN N
by IN N
logistic JJ N
regression NN N
. . N

Stepwise NN N
linear JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
loss NN N
of IN N
periprosthetic JJ o
BMD NNP o
in IN N
the DT N
proximal JJ N
high-pressure NN N
region NN N
after IN N
2 CD N
years NNS N
increased VBD N
with IN N
higher RBR N
postoperative JJ o
BMD NNP o
and CC N
when WRB N
the DT N
uncemented JJ N
design NN N
had VBD N
been VBN N
used VBN N
. . N

The DT N
authors NNS N
hypothesized VBD N
that IN N
the DT N
Dietary NNP N
Approaches NNP N
to TO N
Stop VB i
Hypertension NNP i
( ( i
DASH NNP i
) ) i
diet NN i
and CC i
reduced JJ i
sodium NN i
intake NN i
would MD N
control VB N
stage NN N
1 CD N
hypertension NN N
and CC N
reduce VB N
high-normal JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
to TO N
optimal JJ N
levels NNS N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ N
tissue NN N
concentrations NNS N
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP p
. . p

The DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
skin NN i
anesthetic JJ i
before IN i
( ( i
99m CD i
) ) i
Tc-SC CD i
injections NNS i
, , N
whereas IN N
the DT N
experimental JJ N
group NN N
first JJ N
underwent JJ N
skin NN i
anesthesia NN i
with IN i
an DT i
injection NN i
of IN i
2 CD i
% NN i
sodium JJ i
bicarbonate-buffered JJ i
lidocaine NN i
. . i

The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ N
and CC N
intermittent JJ N
insulin NN N
delivery NN N
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD p
normal JJ p
men NNS p
and CC p
nine CD p
insulin-dependent NN p
( ( p
type JJ p
1 CD p
) ) p
diabetic JJ p
patients NNS p
. . p

When WRB N
comparing VBG N
olanzapine NN i
with IN N
haloperidol NN i
, , N
cost NN o
savings NNS o
are VBP N
seen VBN N
throughout IN N
the DT N
treatment NN N
period NN N
( ( N
1 CD N
year NN N
) ) N
, , N
with IN N
physical JJ N
functioning VBG N
most JJS N
highly RB N
affected VBN N
over IN N
time NN N
. . N

The DT N
study NN N
included VBD N
only RB N
ACB NNP N
's POS N
with IN N
intraoperative JJ N
blood NN N
flow NN N
rates NNS N
< VBP N
or CC N
= VBP N
40 CD N
ml/min NN N
as IN N
it PRP N
is VBZ N
just RB N
these DT N
ACB NNP N
's POS N
which WDT N
are VBP N
at IN N
the DT N
highest JJS N
risk NN N
of IN N
early JJ N
and CC N
late JJ N
occlusions NNS N
. . N

BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ i
flour NN i
and CC i
select JJ i
cereal NN i
grain NN i
products NNS i
was VBD i
implemented VBN i
in IN i
Canada NNP i
with IN i
the DT i
intention NN i
to TO i
increase VB i
dietary JJ i
folate JJ i
intakes NNS i
of IN N
reproducing VBG p
women NNS p
. . p

METHODS NNP N
Following NNP N
assessment NN N
, , N
individual JJ N
profiles NNS N
were VBD N
developed VBN N
and CC N
each DT N
week NN N
teachers NNS N
and CC N
parents NNS N
were VBD N
given VBN N
guidelines NNS N
for IN N
working VBG N
with IN N
the DT N
children NNS N
and CC N
each DT N
child NN N
had VBD N
three CD N
to TO N
four CD N
sessions NNS N
a DT N
week NN N
lasting VBG N
approximately RB N
for IN N
20 CD N
minutes NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
mean JJ o
hemoglobin NN o
concentration NN o
declined VBD N
most JJS N
rapidly RB N
in IN N
the DT N
first JJ N
24 CD N
hrs NN N
of IN N
ICU NNP N
care NN N
and CC N
, , N
thereafter RB N
, , N
declined VBD N
more RBR N
slowly RB N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
efficacy NN o
and CC o
tolerability NN o
were VBD N
comparable JJ N
between IN N
C/A NNP N
and CC N
H/A NNP N
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT N
patients NNS N
with IN N
moderate JJ N
or CC N
severe JJ N
, , N
chronic JJ N
, , N
cancer-related JJ N
pain NN N
. . N

Gentamicin NNP i
4 CD N
mg/kg NN N
every DT N
day NN N
( ( N
OD NNP N
) ) N
or CC N
gentamicin $ N
1.33 CD N
mg/kg NN N
three CD N
times NNS N
daily RB N
( ( N
MD NNP N
) ) N
( ( N
with IN N
dose-reduction NN N
in IN N
case NN N
of IN N
renal JJ N
dysfunction NN N
) ) N
were VBD N
given VBN N
intravenously RB N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
median JJ o
progression-free NN o
or CC o
overall JJ o
survival NN o
times NNS o
for IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
study NN N
included VBD N
60 CD p
patients NNS p
with IN p
A NNP p
degree NN p
of IN p
ERD NNP p
, , p
consistently RB p
received VBN p
in-patient JJ p
treatment NN p
in IN p
the DT p
Municipal NNP p
KGVV NNP p
, , p
mean JJ p
age NN p
79.0 CD p
+/- JJ p
6.8 CD p
years NNS p
. . p

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN i
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
was VBD N
well RB N
tolerated VBN o
and CC o
improved VBN o
blood NN o
glucose NN o
control NN o
. . o

Over IN N
a DT N
24-month JJ N
observation NN N
period NN N
the DT N
immunized JJ N
group NN N
always RB N
had VBD N
higher JJR N
levels NNS o
of IN o
peripheral JJ o
leukocytes NNS o
and CC o
peripheral JJ o
lymphocytes NNS o
; : o
this DT N
difference NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
21 CD N
months NNS N
. . N

In IN N
conclusion NN N
, , N
supplementation NN N
of IN N
aPLA2 NN i
improved VBN i
FE NNP i
of IN N
growing VBG p
beef NN p
calves NNS p
when WRB N
fed VBN N
LC NNP N
diets NNS N
in IN N
Phase NNP N
1 CD N
and CC N
addition NN N
of IN N
aPLA2 NN i
had VBD N
no DT N
effect NN N
on IN N
fermentation NN N
parameters NNS N
of IN N
LC NNP N
and CC N
HC NNP N
substrates NNS N
. . N

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ o
vegetable JJ o
intake NN o
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

All DT N
of IN N
these DT N
changes NNS N
in IN N
flow NN N
were VBD N
statistically RB N
more JJR N
common JJ N
for IN N
the DT N
circumflex JJ N
coronary JJ N
artery NN N
and CC N
early JJ N
treatment NN N
( ( N
less JJR N
than IN N
4 CD N
h NN N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
anistreplase NN N
or CC N
streptokinase NN i
. . i

DESIGN NNP N
Reanalysis NNP N
of IN N
the DT N
baseline NN N
prediction NN N
model NN N
for IN N
the DT N
development NN N
of IN N
POAG NNP N
from IN N
the DT N
Ocular NNP N
Hypertension NNP N
Treatment NNP N
Study NNP N
( ( N
OHTS NNP N
) ) N
substituting VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
using VBG N
5 CD N
different JJ N
correction NN N
formulae NN N
for IN N
unadjusted JJ N
IOP NNP N
. . N

The DT N
dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN N
infusion NN N
was VBD N
studied VBN N
in IN N
20 CD p
adult NN p
surgical JJ p
patients NNS p
during IN p
propofol-nitrous JJ i
oxide NN i
and CC i
isoflurane NN i
( ( i
1 CD i
MAC NNP i
) ) i
-nitrous JJ i
oxide JJ i
anaesthesia NN i
. . i

INTERPRETATION NNP N
In IN N
patients NNS p
undergoing VBG p
elective JJ p
hip-replacement JJ p
surgery NN p
, , N
2.5 CD N
mg NN N
fondaparinux NN N
once RB N
daily RB N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ N
than IN N
30 CD N
mg JJ N
enoxaparin JJ i
twice RB N
daily RB N
in IN N
reducing VBG N
risk NN o
of IN o
venous JJ o
thromboembolism NN o
. . o

The DT N
primary JJ N
outcome NN N
was VBD N
objective JJ o
cure NN o
rate NN o
of IN o
the DT o
anterior JJ o
compartment NN o
( ( o
point NN o
Ba NNP o
) ) o
assessed VBD N
at IN N
the DT N
12-month JJ N
follow-up JJ N
visit NN N
, , N
with IN N
stages NNS N
0 CD N
and CC N
I PRP N
defined VBD N
as IN N
anatomical JJ N
success NN N
. . N

UNLABELLED NN N
In IN N
paired JJ p
biopsies NNS p
of IN p
osteoporotic JJ p
women NNS p
treated VBN p
with IN p
either DT p
strontium NN i
ranelate NN i
or CC i
a DT i
placebo NN i
for IN N
36 CD N
months NNS N
, , N
characteristics NNS N
of IN N
bone NN N
apatite JJ N
crystals NNS N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
strontium NN i
. . i

High JJ N
Zn NNP N
intakes NNS N
resulted VBD N
in IN N
a DT N
reduced JJ N
gene NN o
expression NN o
of IN N
? . N
3 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
expression NN o
of IN o
TFF3 NNP o
. . o

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
high- JJ N
compared VBN N
to TO N
low-dose JJ N
atorvastatin NN i
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
eGFR NN N
at IN N
1 CD N
year NN N
, , N
which WDT N
was VBD N
related VBN N
to TO N
a DT N
decrease NN N
in IN N
subsequent JJ N
HF NNP N
hospitalization NN N
. . N

In IN N
group NN N
I PRP N
, , N
thrombolysis NN o
was VBD o
successful JJ o
in IN N
all DT N
patients NNS N
, , N
without IN N
complications NNS N
, , N
within IN N
6-72 JJ N
h. NN N
In IN N
group NN N
II NNP N
, , N
heparin NN N
treatment NN N
was VBD N
successful JJ N
in IN N
six CD N
patients NNS N
in IN N
3-32 JJ N
days NNS N
. . N

METHODS NNP N
20 CD p
patients NNS p
with IN p
facet-joint JJ p
pain NN p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB i
blindly RB i
( ( i
B NNP i
group NN i
) ) i
or CC i
guided VBN i
by IN i
ultrasound NN i
( ( i
US NNP i
group NN i
) ) i
respectively RB i
. . i

RESULTS NNP N
Of IN N
all PDT N
the DT N
subjects NNS N
assessed VBN N
, , N
FA-specific NNP o
IgE NNP o
was VBD N
detected VBN N
in IN N
only RB N
two CD N
asthmatics NNS N
, , N
and CC N
their PRP$ N
IgE NNP N
levels NNS N
of IN N
FA NNP N
were VBD N
low JJ N
( ( N
0.42 CD N
and CC N
0.46 CD N
UA/ml NNP N
) ) N
. . N

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN i
group NN N
demonstrated VBD N
significant JJ N
improvements NNS N
in IN N
MG NNP o
plugging NN o
, , o
MG NNP o
secretions NNS o
, , o
and CC o
eyelid JJ o
redness NN o
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

PURPOSE VB N
A DT N
let-7 JJ N
microRNA-complementary JJ N
site NN N
( ( N
LCS6 NNP N
) ) N
polymorphism NN N
in IN N
the DT N
3 CD N
' POS N
untranslated JJ N
region NN N
of IN N
the DT N
KRAS NNP N
gene NN N
has VBZ N
been VBN N
shown VBN N
to TO N
disrupt VB N
let-7 JJ N
binding NN N
and CC N
upregulate JJ N
KRAS NNP N
expression NN N
. . N

In IN N
subjects NNS N
so RB N
selected VBN N
, , N
the DT N
estimated JJ N
duration NN N
of IN N
MEE NNP N
ranged VBD N
from IN N
none NN N
to TO N
65.6 CD N
% NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
and CC N
44.8 CD N
% NN N
of IN N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
. . N

After IN N
hospital JJ N
discharge NN N
, , N
usual JJ N
care NN N
patients NNS N
received VBD N
no DT N
further JJ N
nutrition NN N
support NN N
, , N
whereas RB N
extended VBN N
care NN N
patients NNS N
received VBD N
telephone NN i
dietary JJ i
counselling NN i
from IN i
the DT i
same JJ i
dietitian NN i
for IN i
up IN i
to TO i
100 CD i
days NNS i
post-transplantation NN i
. . i

METHODS NNP N
Fifty-six NNP p
male NN p
patients NNS p
( ( p
mean JJ p
age NN p
71.2 CD p
+/- JJ p
8.2 CD p
years NNS p
) ) p
scheduled VBD p
for IN p
TURP NNP p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

In IN N
surveys NNS N
carried VBD N
out RP N
after IN N
three CD N
years NNS N
of IN N
initial JJ N
distribution NN N
, , N
78.7 CD N
% NN N
( ( N
737/936 CD N
) ) N
nets NNS N
were VBD N
still RB N
in IN N
possession NN N
with IN N
the DT N
households NNS N
, , N
of IN N
which WDT N
68 CD N
% NN N
were VBD N
used VBN N
every DT N
night NN N
. . N

Treatment NNP N
consisted VBD N
of IN N
approximately RB N
3,800 CD N
total JJ N
shock NN N
waves NNS N
( ( N
+/-10 JJ N
) ) N
reaching VBG N
an DT N
approximated JJ i
total NN i
energy NN i
delivery NN i
of IN i
1,300 CD i
mJ/mm NN i
( ( i
2 CD i
) ) i
( ( i
ED+ NNP i
) ) i
in IN N
a DT N
single JJ N
session NN N
versus IN N
placebo NN i
treatment NN i
. . i

CONCLUSION NN N
In IN N
IRS-IV NNP o
, , o
response NN o
rate NN o
to TO o
induction NN o
therapy NN o
was VBD N
77 CD N
% NN N
in IN N
group NN N
III NNP N
patients NNS N
, , N
was VBD N
independent JJ N
of IN N
histology NN N
, , N
and CC N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP o
overall JJ o
. . o

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
HbA1c NNP o
was VBD N
observed VBN N
in IN N
the DT N
nateglinide JJ N
group NN N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
of IN N
HbA1c NNP o
was VBD N
observed VBN N
in IN N
the DT N
untreated JJ N
group NN N
. . N

Immunohistochemical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
anti JJ N
HMGB1 NNP N
antibodies NNS N
and CC N
the DT N
expression NN N
of IN N
HMGB1 NNP N
protein NN N
in IN N
the DT N
spinal JJ N
cord NN N
was VBD N
determined VBN N
by IN N
western JJ N
blot NN N
analysis NN N
after IN N
intrathecal JJ N
delivery NN N
( ( N
n JJ N
= RB N
8 CD N
each DT N
) ) N
. . N

RESULTS VB N
The DT N
MCIC NNP N
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
. . N

Marginal JJ N
adaptation NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
computer-assisted JJ N
quantitative JJ N
marginal JJ N
analysis NN N
in IN N
a DT N
scanning NN N
electron NN N
microscope NN N
( ( N
SEM NNP N
) ) N
on IN N
epoxy JJ N
replicas NN N
before IN N
, , N
after IN N
thermal JJ N
and CC N
mechanical JJ N
stressing NN N
and CC N
after IN N
1 CD N
year NN N
of IN N
water NN N
storage NN N
. . N

Reported VBN N
frequency NN o
of IN o
GI NNP o
abnormalities NNS o
, , o
including VBG o
abnormal JJ o
stool NN o
consistency NN o
( ( o
e.g JJ o
, , o
bulky NN o
or CC o
loose JJ o
) ) o
, , N
was VBD N
increased VBN N
( ( N
54 CD N
% NN N
) ) N
. . N

The DT N
outcome NN N
variables NNS N
were VBD N
total JJ o
scores NNS o
on IN o
the DT o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
CARS NNP o
) ) o
and CC o
the DT o
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
( ( o
CGAS NNP o
) ) o
after IN N
6 CD N
months NNS N
. . N

The DT N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
the DT N
difference NN N
in IN N
the DT N
percentage NN o
variation NN o
of IN o
MAP NNP o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
( ( N
-3.1 JJ N
, , N
+3.7 NNP N
) ) N
. . N

On IN N
PND NNP N
81 CD N
, , N
an DT N
increased VBN N
adrenal JJ o
medulla NN o
area NN o
was VBD N
observed VBN N
in IN N
LP NNP N
offspring VBG N
compared VBN N
with IN N
the DT N
AP NNP N
offspring NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
12 CD N
months NNS N
of IN N
GH NNP i
treatment NN N
, , N
the DT N
individual JJ o
changes NNS o
in IN o
BF NNP o
ranged VBD N
from IN N
-12.5 NN N
to TO N
4.3 CD N
kg NNS N
and CC N
from IN N
-4.5 NNP N
to TO N
10.1 CD N
kg NNS N
in IN N
LBM NNP N
. . N

After IN N
screening VBG N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
, , N
for IN i
a DT i
period NN i
of IN i
4 CD i
weeks NNS i
, , i
either CC i
a DT i
cocoa NN i
husk NN i
supplement NN i
or CC i
placebo NN i
plus CC i
standardized JJ i
toilet NN i
training NN i
procedures NNS i
. . i

Classical JJ N
90 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
90CI CD N
) ) N
were VBD N
calculated VBN N
for IN N
the DT N
overall JJ N
sample NN N
, , N
and CC N
for IN N
males NNS N
and CC N
females NNS N
separately RB N
, , N
and CC N
gender NN N
effects NNS N
were VBD N
investigated VBN N
using VBG N
an DT N
appropriate JJ N
model NN N
. . N

Also RB N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
wound NN o
healing VBG o
score RB o
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
( ( N
P=0.003 NNP N
) ) N
. . N

The DT N
influence NN N
of IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
and CC N
tumor NN N
differentiation NN N
on IN N
the DT N
response NN N
to TO N
accelerated VBN i
radiotherapy NN i
of IN p
squamous JJ p
cell NN p
carcinomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
in IN p
the DT p
randomized JJ p
DAHANCA NNP p
6 CD p
and CC p
7 CD p
study NN p
. . p

Skill NNP o
performance NN o
and CC o
retention NN o
were VBD N
shown VBN N
to TO N
be VB N
high JJ N
following VBG N
either CC N
training VBG N
method NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
performance NN N
of IN N
either DT N
group NN N
( ( N
chi JJ N
2 CD N
) ) N
. . N

In IN N
contrast NN N
to TO N
the DT N
hypothesis NN N
to TO N
be VB N
tested VBN N
, , N
the DT N
efficacy NN N
of IN N
physostigmine NN N
was VBD N
not RB N
superior JJ N
to TO N
that DT N
of IN N
placebo NN i
after IN N
a DT N
treatment NN N
period NN N
of IN N
24 CD N
weeks NNS N
. . N

METHODS NNP N
101 CD p
hemodialysis NN p
patients NNS p
were VBD p
randomized VBN p
for IN p
each DT p
phosphate NN p
binder NN p
and CC p
submitted VBN p
to TO p
multislice VB p
coronary JJ p
tomographies NNS p
and CC p
bone NN p
biopsies NNS p
at IN p
entry NN p
and CC p
12 CD p
months NNS p
. . p

On IN N
the DT N
basis NN N
of IN N
this DT N
reduced JJ N
nephrotoxicity NN o
, , o
a DT o
incremental JJ o
cost NN o
of IN N
$ $ N
435 CD N
per IN N
case NN N
of IN N
nephrotoxicity NN o
prevented VBN N
was VBD N
found VBN N
for IN N
vancomycin NN N
serum NN N
concentration NN N
monitoring NN N
. . N

RESULTS NN N
We PRP N
found VBD N
significant JJ N
differences NNS N
in IN N
answers NNS o
to TO o
the DT o
asthma JJ o
questions NNS o
, , N
by IN N
40 CD N
% NN N
improvement NN N
, , N
but CC N
no DT N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Recurrences NNS o
of IN o
arrhythmia NN o
, , o
deaths NNS o
, , o
and CC o
adverse JJ o
drug NN o
effects NNS o
during IN N
long-term JJ N
follow-up NNS N
were VBD N
recorded VBN N
for IN N
the DT N
296 CD N
patients NNS N
in IN N
whom WP N
an DT N
antiarrhythmic JJ N
drug NN N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ N
. . N

A DT N
second JJ N
dose NN N
of IN N
fenoterol NN N
and CC N
of IN N
the DT N
combination NN N
regimen NNS N
resulted VBD N
in IN N
a DT N
further JJ N
significant JJ N
increase NN N
in IN N
FEV1 NNP o
after IN N
120 CD N
min NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
telephone NN i
appointments NNS i
offered VBD N
bygeneral JJ N
practice NN N
receptionists NNS N
increase VBP N
the DT N
uptake NN o
of IN o
irfluenza JJ o
immunisation NN o
among IN N
the DT N
registered JJ p
population NN p
aged VBD p
over IN p
65 CD p
years NNS p
in IN p
east JJ p
London NNP p
practices NNS p
. . p

CI-AKI NNP N
was VBD N
defined VBN N
as IN N
a DT N
relative JJ N
increase NN N
in IN N
serum JJ o
creatinine NN o
of IN o
? . o
% NN o
, , o
or CC o
an DT o
absolute JJ o
increase NN o
of IN o
? . o
mg/dL NN o
, , o
occurring VBG o
within IN o
48 CD o
hours NNS o
after IN N
contrast NN N
administration NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
virtual JJ i
reality NN i
distraction NN i
intervention NN i
on IN N
chemotherapy-related JJ o
symptom NN o
distress NN o
levels NNS o
in IN N
16 CD p
women NNS p
aged VBD p
50 CD p
and CC p
older JJR p
. . p

Patients NNS N
received VBD N
hydrocortisone RB i
0.1 CD i
% NN i
solution NN i
, , i
ASA NNP i
1 CD i
% NN i
solution NN i
, , i
piroxicam VB i
0.5 CD i
% NN i
solution NN i
or CC i
placebo NN i
as IN N
eye NN N
drops NNS N
, , N
all DT N
one CD N
drop NN N
in IN N
each DT N
eye NN N
q.i.d NN N
. . N

Fourty-four JJ p
DES-exposed JJ p
offspring NN p
had VBD p
their PRP$ p
vaginal JJ p
adenosis NN p
treated VBN p
with IN p
the DT p
carbon NN i
dioxide NN i
laser NN i
( ( N
group NN N
I PRP N
) ) N
, , N
and CC N
the DT N
remaining VBG N
35 CD N
DES-exposed JJ N
offspring NN N
( ( N
group NN N
II NNP N
) ) N
did VBD N
not RB N
receive VB N
any DT N
specific JJ N
treatment NN N
for IN N
this DT N
condition NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Women NNP p
with IN p
invasive JJ p
breast NN p
cancer NN p
were VBD p
eligible JJ p
if IN p
there EX p
were VBD p
one CD p
to TO p
three CD p
positive JJ p
lymph NN p
nodes NNS p
or CC p
if IN p
the DT p
node-negative JJ p
tumor NN p
was VBD p
greater JJR p
than IN p
1 CD p
cm NN p
. . p

No DT N
significant JJ N
differences NNS N
in IN N
bronchodilator NN o
efficacy NN o
between IN N
the DT N
patients NNS N
continuing VBG N
to TO N
receive VB N
CFC NNP N
albuterol NN N
and CC N
those DT N
switched VBN N
to TO N
HFA NNP N
albuterol NN N
were VBD N
found VBN N
in IN N
the DT N
12 CD N
weeks NNS N
after IN N
the DT N
switch NN N
. . N

Maximal JJ o
heart NN o
rate NN o
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

Thirty NN p
patients NNS p
undergoing VBG p
elective JJ p
cholecystectomy NN p
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
an DT N
infusion NN N
of IN N
morphine NN i
or CC i
an DT i
infusion NN i
of IN i
placebo NN i
( ( i
control VB i
group NN i
) ) i
for IN i
24 CD i
hours NNS i
. . i

A DT N
simple JJ N
meal NN N
plan NN N
of IN N
'eating VBG N
vegetables NNS N
before IN N
carbohydrate NN N
' '' N
was VBD N
more RBR N
effective JJ N
for IN N
achieving VBG N
glycemic JJ N
control NN N
than IN N
an DT N
exchange-based JJ N
meal NN N
plan NN N
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

CONCLUSIONS NNP N
The DT N
continuous JJ N
oral JJ N
administration NN N
of IN N
UFT NNP N
for IN N
7 CD N
days NNS N
preoperatively RB N
resulted VBD N
in IN N
enhanced JJ o
apoptosis NN o
and CC N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
the DT N
AI NNP N
and CC N
5-FU JJ N
concentrations NNS N
in IN N
lung NN N
adenocarcinoma NN N
. . N

Amplitude NNP o
changes NNS o
as RB N
well RB N
as IN N
areas NNS N
under IN N
the DT N
curve NN N
( ( N
AUCs NNP N
) ) N
over IN N
150 CD N
min NNS N
were VBD N
compared VBN N
for IN N
the DT N
four CD N
treatments NNS N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP N
( ( N
significance NN N
0.05 CD N
) ) N
. . N

Community-dwelling JJ p
frail NN p
elderly JJ p
subjects NNS p
, , p
aged VBD p
65 CD p
years NNS p
and CC p
older JJR p
, , p
with IN p
dyspnoea NN p
, , p
participating VBG p
in IN p
a DT p
screening NN p
study NN p
on IN p
COPD NNP p
and CC p
heart NN p
failure NN p
were VBD p
included VBN p
. . p

The DT N
primary JJ N
analysis NN N
examined VBD N
the DT N
agreement NN N
rate NN N
between IN N
CTP NNP N
and CC N
SPECT NNP N
for IN N
detecting VBG N
or CC N
excluding VBG N
reversible JJ N
ischemia NN N
in IN N
? . N
2 CD N
myocardial JJ N
segments NNS N
as IN N
assessed VBN N
by IN N
independent JJ N
, , N
blinded VBD N
readers NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
any DT N
other JJ N
response NN N
biomarker NN N
between IN N
the DT N
two CD N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
, , N
nor CC N
was VBD N
any DT N
biomarker NN N
able JJ N
to TO N
predict VB N
recurrence NN o
risk NN o
. . o

Often RB N
the DT N
X-ray JJ N
photograph NN N
leads VBZ N
to TO N
the DT N
diagnosis NN N
in IN N
the DT N
second JJ N
stage NN N
( ( N
ARCO NNP N
1992 CD N
) ) N
or CC N
in IN N
the DT N
third JJ N
stage NN N
, , N
when WRB N
the DT N
femoral JJ N
head NN N
has VBZ N
begun VBN N
to TO N
collapse NN N
. . N

Fifty NNP i
endoscopic NN i
resections NNS i
were VBD N
performed VBN N
with IN N
a DT N
suck-and-ligate JJ i
device NN i
without IN i
prior JJ i
submucosa NN i
injection NN i
and CC i
50 CD i
with IN i
the DT i
cap NN i
technique NN i
with IN i
prior JJ i
submucosa JJ i
injection NN i
of IN i
a DT i
dilute JJ i
saline JJ i
solution NN i
of IN i
epinephrine NN i
. . i

While IN N
the DT N
patient NN N
in IN N
the DT N
observation NN N
group NN N
were VBD N
treated VBN N
by IN N
the DT N
routine JJ N
treatment NN N
and CC N
acupuncture NN i
treatment NN N
48 CD N
h NN N
( ( N
-1 NNP N
) ) N
week NN N
after IN N
operation NN N
in IN N
different JJ N
stages NNS N
with IN N
different JJ N
acupoints NNS N
selected VBN N
when WRB N
the DT N
situation NN N
was VBD N
stable JJ N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ o
level NN o
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN o
effects NNS o
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

When WRB N
the DT N
dose NN N
of IN N
HBsAg NNP N
was VBD N
diminished VBN N
from IN N
3 CD N
micrograms NNS N
to TO N
1.5 CD N
, , N
0.6 CD N
, , N
and CC N
0.25 CD N
microgram NN N
, , N
no DT N
decrease NN N
of IN N
the DT N
anti-HBs JJ o
response NN o
was VBD N
observed VBN N
. . N

The DT N
WAIS-III NNP N
General NNP N
Ability NNP N
Index NNP N
( ( N
GAI NNP N
; : N
Tulsky NNP N
, , N
Saklofske NNP N
, , N
Wilkins NNP N
, , N
& CC N
Weiss NNP N
, , N
2001 CD N
) ) N
is VBZ N
a DT N
recently RB N
developed VBN N
, , N
6-subtest JJ o
measure NN o
of IN o
global JJ o
intellectual JJ o
functioning NN o
. . o

The DT p
subjects NNS p
, , p
131 CD p
children NNS p
aged VBN p
0.6-12 CD p
years NNS p
who WP p
lived VBD p
in IN p
an DT p
endemic JJ p
area NN p
of IN p
Nigeria NNP p
, , N
were VBD N
randomly RB N
allotted VBN N
to TO N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
responders NNS N
had VBD N
not RB N
reached VBN N
the DT N
median JJ o
survival NN o
yet RB o
, , N
the DT N
patients NNS N
with IN N
SD NNP N
had VBD N
a DT N
median JJ N
survival NN N
of IN N
14.7 CD N
months NNS N
and CC N
the DT N
PD NNP N
9.5 CD N
months NNS N
. . N

Acute NNP N
stress NN N
consisted VBD N
of IN N
losing VBG N
against IN N
a DT N
competitor NN N
of IN N
the DT N
opposite JJ N
sex NN N
on IN N
the DT N
criterion NN N
motor NN N
task NN N
while IN N
receiving VBG N
unpleasant JJ N
information NN N
about IN N
their PRP$ N
performance NN N
over IN N
30 CD N
preintervention NN N
and CC N
30 CD N
postintervention NN N
trials NNS N
. . N

The DT N
enteral JJ i
formula NN i
diet NN i
was VBD i
energy NN i
dense NN i
, , i
containing VBG i
40 CD i
mmol NN i
Na/day NNP i
, , i
whole JJ i
protein NN i
plus CC i
branched-chain JJ i
amino NN i
acids NNS i
, , i
medium- JJ i
and CC i
long-chain JJ i
triglycerides NNS i
, , i
and CC i
maltodextrin NN i
. . i

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
8 CD N
weeks NNS N
of IN N
assisted JJ i
exercise NN i
on IN N
bone NN o
strength NN o
and CC o
metabolism NN o
in IN N
VLBW NNP p
premature NN p
infants NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
One NNP p
hundred VBD p
and CC p
six CD p
consecutive JJ p
patients NNS p
with IN p
ureteric JJ p
calculi NNS p
at IN p
different JJ p
levels NNS p
were VBD p
treated VBN p
by IN p
ESWL NNP i
using VBG i
Siemens NNP i
Lithostar NNP i
2 CD i
machine NN i
. . i

These DT N
principles NNS N
make VBP N
it PRP N
possible JJ N
to TO N
reduce VB N
the DT N
need NN N
for IN N
primary JJ N
colostomy NN N
to TO N
approximately RB N
50 CD N
per IN N
cent NN N
in IN N
a DT N
large JJ N
ongoing VBG N
group NN N
of IN N
patients NNS N
with IN N
colonic JJ N
injury NN N
. . N

After IN N
a DT N
follow-up JJ N
period NN N
of IN N
approximately RB N
4 CD N
months NNS N
, , N
both DT N
groups NNS N
had VBD N
similar JJ N
event NN o
rates NNS o
and CC o
comparable JJ o
hemodynamic JJ o
parameters NNS o
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

Short-term JJ i
aerobic JJ i
exercise NN i
training NN i
in IN N
obese JJ p
humans NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus JJ p
improves VBZ N
whole-body JJ N
insulin NN N
sensitivity NN N
through IN N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
hepatic JJ N
insulin NN N
sensitivity NN N
. . N

Exercise NN o
stimulates VBZ o
release NN o
of IN o
renin NN o
; : o
this DT o
action NN o
was VBD N
greater JJR N
with IN N
captopril JJ i
administration NN N
( ( N
treatment NN N
effect NN N
: : N
p NN N
< VBZ N
10 CD N
( ( N
-4 NN N
) ) N
, , N
indicating VBG N
blockade NN N
of IN N
the DT N
RAS NNP N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
Group NNP N
II NNP N
patients NNS N
received VBD N
dopexamine JJ i
infusion NN N
, , N
at IN N
a DT N
dose NN N
of IN N
1 CD N
microgram/kg/m NN N
, , N
and CC N
at IN N
a DT N
dose NN N
of IN N
0.5 CD N
micrograms/kg/m NN N
from IN N
declamping VBG N
to TO N
the DT N
end NN N
of IN N
the DT N
surgery NN N
. . N

METHODS NNP N
Patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
were VBD p
tested VBN p
for IN p
CYP2C19 NNP p
genotype NN p
as IN p
poor JJ p
metabolizers NNS p
( ( p
PMs NNP p
) ) p
or CC p
extensive JJ p
metabolizers NNS p
( ( p
EMs NNP p
, , p
homozygous JJ p
EM NNP p
or CC p
heterozygous JJ p
EM NNP p
) ) p
and CC p
given VBN p
rabeprazole NN i
for IN N
7 CD N
days NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
clinical JJ o
cure NN o
and CC o
complete JJ o
( ( o
clinical JJ o
plus CC o
mycological JJ o
) ) o
cure NN o
of IN o
the DT o
target NN o
toenail NN o
and CC o
complete JJ o
cure NN o
of IN o
all DT o
10 CD o
toenails NNS o
. . o

In IN N
conclusion NN N
, , N
olanzapine JJ N
LAI NNP N
and CC N
oral JJ N
olanzapine NN i
were VBD N
similarly RB N
effective JJ o
and CC o
well RB o
tolerated VBN o
for IN N
up RB N
to TO N
2 CD N
years NNS N
of IN N
treatment NN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN o
zeaxanthin NN o
concentration NN o
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN i
enriched VBN i
eggs NNS i
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

BACKGROUND NNP N
Triple NNP N
therapy NN N
regimens VBZ N
including VBG N
two CD N
antibiotics NNS N
plus CC N
acid JJ N
suppression NN N
have VBP N
become VBN N
the DT N
new JJ N
standard NN N
therapy NN N
in IN N
Helicobacter NNP N
pylori FW N
eradication NN N
because IN N
of IN N
success NN N
rates NNS N
of IN N
about RB N
90 CD N
% NN N
. . N

In IN N
the DT N
NR NNP N
group NN N
, , N
patients NNS N
were VBD N
postoperatively RB N
educated VBN N
in IN N
the DT N
possibility NN N
of IN N
mandibular JJ o
fracture NN o
and CC N
were VBD N
given VBN N
an DT N
emphasis NN N
on IN N
the DT N
necessity NN N
of IN N
limiting VBG N
mastication NN N
to TO N
a DT N
soft JJ N
diet NN N
for IN N
4 CD N
weeks NNS N
. . N

METHOD NNP N
Fifty NNP p
patients NNS p
with IN p
blepharitis NN p
, , p
conjuctivitis NN p
, , p
or CC p
blepharoconjunctivitis NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN p
with IN p
0.3 CD p
% NN p
ofloxacin JJ p
eyedrops NNS p
, , p
BID NNP p
or CC p
QID NNP i
, , N
for IN N
10 CD N
days NNS N
. . N

When WRB N
contour NN N
spacing NN N
was VBD N
beyond IN N
a DT N
critical JJ N
range NN N
( ( N
about IN N
2 CD N
degrees NNS N
) ) N
, , N
however RB N
, , N
the DT N
detectability NN N
dropped VBD N
to TO N
chance NN N
levels NNS N
, , N
regardless RB N
of IN N
the DT N
number NN N
of IN N
colinear JJ N
lines NNS N
. . N

Risperidone NN i
was VBD N
associated VBN N
with IN N
increased VBN N
appetite NN o
and CC o
a DT o
mild JJ o
weight NN o
gain NN o
, , o
mild JJ o
sedation NN o
in IN N
20 CD N
% NN N
, , N
and CC N
transient NN N
dyskinesias NN N
in IN N
three CD N
children NNS N
. . N

Sputum NNP o
cells NNS o
and CC o
supernatant JJ o
levels NNS o
of IN o
ECP NNP o
, , o
sICAM NN o
, , o
IL-5 NNP o
and CC o
IL-10 NNP o
, , o
and CC o
plasma NN o
levels NNS o
of IN o
IL-5 NNP o
and CC o
ECP NNP o
, , N
were VBD N
measured VBN N
before IN N
and CC N
24 CD N
h NN N
after IN N
nasal JJ N
allergen NN N
challenge NN N
. . N

Irregular JJ o
uterine NN o
bleeding NN o
was VBD N
almost RB N
entirely RB N
confined VBN N
to TO N
the DT N
earlier JJR N
phase NN N
of IN N
the DT N
study NN N
and CC N
was VBD N
substantially RB N
less JJR N
with IN N
the DT N
formulation NN N
containing VBG N
1 CD N
mg JJ N
norethisterone NN i
acetate NN i
. . i

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
intravesical JJ N
THP NNP N
instillation NN N
prior RB N
to TO N
TUR NNP N
would MD N
be VB N
effective JJ N
for IN N
patients NNS N
with IN N
single JJ N
, , N
low JJ N
grade NN o
lesions NNS o
larger JJR o
than IN o
1 CD o
cm NN o
of IN o
superficial JJ o
bladder NN o
cancer NN o
. . o

The DT N
relation NN N
of IN N
pacing VBG N
rate NN N
to TO N
physiologic VB N
variables NNS N
of IN N
metabolic JJ N
demand NN N
was VBD N
examined VBN N
in IN N
10 CD p
consecutive JJ p
patients NNS p
with IN p
a DT p
minute NN p
ventilation-sensing NN p
, , p
rate-modulating JJ p
ventricular JJ p
pacemaker NN p
implanted VBN p
for IN p
complete JJ p
heart NN p
block NN p
. . p

Application NN N
of IN N
either DT N
cream NN N
produced VBD N
a DT N
very RB N
slight JJ N
increase NN N
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.5 CD N
log NN N
cycle NN N
) ) N
in IN N
the DT N
skin NN o
flora NN o
during IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
we PRP N
will MD N
for IN N
the DT N
first JJ N
time NN N
assess VB N
the DT N
effect NN N
of IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
infusion NN N
of IN N
autologous JJ N
BMCs NNP N
following VBG N
AMI NNP N
on IN N
cardiac JJ N
function NN N
. . N

The DT N
selective JJ N
5-hydroxytryptamine JJ N
type NN N
4 CD N
receptor NN N
partial JJ N
agonist NN N
tegaserod NN N
is VBZ N
a DT N
novel JJ N
promotile NN N
agent NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
functional JJ N
motility NN N
disorders NNS N
such JJ N
as IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
. . N

We PRP N
compared VBN N
iron NNS N
intake NN N
and CC N
iron NN N
nutritional JJ N
status NN N
of IN N
two CD p
groups NNS p
of IN p
healthy JJ p
term NN p
infants NNS p
who WP p
received VBD p
meat-containing JJ i
baby NN i
foods NNS i
fortified VBN i
with IN i
ferrous JJ i
sulphate NN i
( ( p
2 CD p
mg NN p
Fe/100 NNP p
g NN p
) ) p
. . p

It PRP N
can MD N
be VB N
concluded VBN N
that IN N
10 CD N
weeks NNS N
of IN N
step NN N
aerobics NNS N
was VBD N
not RB N
effective JJ N
in IN N
improving VBG N
all DT N
of IN N
the DT N
measured VBN N
anaerobic JJ o
indices NNS o
in IN N
men NNS p
and CC p
women NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ o
maintenance NN o
, , o
peri-implant JJ o
mucosal NN o
response NN o
, , o
and CC o
papilla NN o
index NN o
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
. . N

Furthermore RB N
, , N
cross-validated JJ N
discriminant NN N
analysis NN N
, , N
using VBG N
four CD N
physiologically RB N
and CC N
three CD N
psychophysically RB N
derived JJ N
parameters NNS N
, , N
correctly RB N
classified VBD N
83 CD N
% NN N
of IN N
individuals NNS N
who WP N
scored VBD N
either CC N
high JJ N
or CC N
low JJ N
on IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
. . N

Mean JJ N
differences NNS N
in IN N
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
- : o
and CC o
low-density JJ o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
-cholesterol NN o
levels NNS o
at IN N
cycle NN N
7 CD N
compared VBN N
to TO N
baseline VB N
were VBD N
assessed VBN N
. . N

A DT N
randomised JJ N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
tracheal NN i
tube NN i
rotation NN i
on IN N
the DT N
passage NN N
of IN N
a DT N
tube NN N
over IN N
a DT N
gum-elastic JJ N
bougie NN N
into IN N
the DT N
trachea NN N
in IN N
100 CD p
patients NNS p
. . p

Areas NNP N
of IN N
secondary JJ N
hyperalgesia NN N
, , N
heat NN N
pain NN N
detection NN N
thresholds NNS N
, , N
and CC N
painfulness NN N
of IN N
stimulation NN N
with IN N
45 CD N
degrees NNS N
C NNP N
for IN N
1 CD N
min NNS N
( ( N
long JJ N
thermal JJ N
stimulation NN N
) ) N
were VBD N
quantified VBN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG o
no DT o
drug NN o
effects NNS o
. . o

If IN N
N-acetylcysteine NNP i
is VBZ N
needed VBN N
because IN N
of IN N
a DT N
toxic JJ N
serum NN N
acetaminophen NN N
level NN N
, , N
bioavailability NN N
can MD N
be VB N
ensured VBN N
by IN N
increasing VBG N
the DT N
N-acetylcysteine JJ N
loading NN N
dose NN N
from IN N
140 CD N
mg/kg NNS N
to TO N
235 CD N
mg/kg NNS N
. . N

A DT N
correlation NN N
of IN N
the DT N
angiographic JJ N
evolution NN N
of IN N
coronary JJ N
stenoses NNS N
( ( N
stenosis NN N
diameter NN N
> NN N
or CC N
= VB N
20 CD N
% NN N
) ) N
with IN N
morphological JJ N
stenosis NN N
parameters NNS N
at IN N
baseline NN N
could MD N
help VB N
to TO N
identify VB N
the DT N
risk NN N
of IN N
progressive JJ N
stenoses NNS N
. . N

Twenty NNP p
children NNS p
with IN p
autism NN p
( ( p
mean JJ p
age NN p
, , p
5 CD p
years NNS p
) ) p
were VBD p
recruited VBN p
for IN p
the DT p
study NN p
from IN p
a DT p
school NN p
for IN p
children NNS p
with IN p
autism NN p
. . p

Wound IN o
infection NN o
rate NN o
was VBD N
25 CD N
% NN N
in IN N
the DT N
erythromycin NN i
group NN N
, , N
and CC N
organisms NNS N
recovered VBN N
from IN N
the DT N
wound NN N
in IN N
all DT N
cases NNS N
were VBD N
fecal JJ N
in IN N
nature NN N
. . N

4 CD N
In IN N
comparison NN N
to TO N
metoprolol VB i
, , i
pindolol VB i
produced VBN N
less JJR N
reduction NN N
in IN N
resting VBG o
heart NN o
rate NN o
, , o
cardiac JJ o
index NN o
and CC o
ejection NN o
velocity NN o
reflecting VBG N
the DT N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
of IN N
the DT N
drug NN N
. . N

After IN N
lymph JJ N
node JJ N
excision NN N
, , N
patients NNS N
without IN N
any DT N
detectable JJ N
metastases NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
TIL NNP i
plus CC i
interleukin-2 JJ i
( ( i
IL-2 NNP i
) ) i
for IN N
2 CD N
months NNS N
, , N
or CC N
IL-2 NNP i
only RB i
. . i

In IN N
Study NNP N
3 CD N
( ( N
a DT N
daily RB N
event NN N
sampling VBG N
study NN N
) ) N
, , N
the DT N
authors NNS N
showed VBD N
that IN N
the DT N
congruence NN o
effect NN o
was VBD N
explained VBN N
by IN N
the DT N
importance NN N
of IN N
parental JJ N
approval NN N
. . N

In IN N
eight CD N
out IN N
of IN N
15 CD p
healthy JJ p
patients NNS p
undergoing VBG p
body NN p
surface NN p
surgery NN p
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ i
infusion NN i
on IN i
a DT i
conventional JJ i
thiopentone NN i
, , i
nitrous JJ i
oxide NN i
, , i
oxygen NN i
and CC i
halothane NN i
anaesthetic NN i
was VBD i
studied VBN i
. . i

METHODS NNP N
626 CD p
patients NNS p
with IN p
reflux JJ p
esophagitis NN p
were VBD N
enrolled VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
( ( N
classical JJ N
healing NN N
concept NN N
or CC N
the DT N
complete JJ N
remission NN N
concept NN N
) ) N
to TO N
investigate VB N
differences NNS N
in IN N
treatment NN N
intensity NN N
. . N

Later RB N
, , N
60 CD p
older JJR p
adults NNS p
( ( p
mean VB p
? . p
SD NNP p
age NN p
: : p
68.7 CD p
? . p
6.1 CD p
years NNS p
) ) p
were VBD N
recruited VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
PM NNP N
or CC N
SM NNP N
group NN N
. . N

Vascular JJ o
assessments NNS o
( ( o
including VBG o
measures NNS o
of IN o
endothelial JJ o
damage NN o
, , o
activation NN o
, , o
dysfunction NN o
and CC o
oxidative JJ o
stress NN o
) ) o
and CC o
HbA1c NNP o
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
repeated VBD N
after IN N
12 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

The DT N
study NN N
will MD N
compare VB N
12-week JJ N
remission NN o
rates NNS o
and CC N
, , N
among IN N
those DT N
who WP N
have VBP N
at IN N
least JJS N
a DT N
partial JJ N
response NN N
, , N
relapse NN o
rates NNS o
for IN N
up IN N
to TO N
6 CD N
months NNS N
of IN N
additional JJ N
treatment NN N
. . N

Toxicity NN o
was VBD N
unexpectedly RB N
high JJ N
in IN N
both DT N
treatment NN N
arms NNS N
and CC N
led VBD N
to TO N
treatment NN N
withdrawal NN N
or CC N
refusal NN N
in IN N
49 CD N
% NN N
of IN N
all DT N
patients NNS N
, , N
predominantly RB N
already RB N
during IN N
the DT N
first JJ N
treatment NN N
cycle NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
difference NN N
in IN N
the DT N
change NN N
in IN N
the DT N
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
from IN N
baseline NN N
to TO N
week NN N
10 CD N
between IN N
the DT N
two CD N
groups NNS N
. . N

Men NNS p
aged VBN p
? . p
years NNS p
who WP p
were VBD p
not RB p
receiving VBG p
lipid JJ p
lowering NN p
or CC p
anti-hypertensive JJ p
medication NN p
and CC p
not RB p
at IN p
high JJ p
cardiovascular JJ p
risk NN p
were VBD p
recruited VBN p
from IN p
10 CD p
general JJ p
practices NNS p
in IN p
the DT p
East NNP p
of IN p
England NNP p
. . p

Rilpivirine NNP i
and CC i
its PRP$ i
deuterated JJ i
analogue NN i
, , i
rilpivirine-d6 NN i
, , N
used VBD N
as IN N
an DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
were VBD N
quantitatively RB N
extracted VBN N
by IN N
liquid-liquid JJ N
extraction NN N
with IN N
methyl-tert-butyl JJ N
ether NN N
and CC N
diethyl NN N
ether RB N
solvent JJ N
mixture NN N
from IN N
50 CD N
? . N
plasma NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
in IN N
the DT N
esthetic JJ N
zones NNS N
performed VBN N
on IN N
implants NNS N
placed VBN N
immediately RB N
after IN N
tooth JJ N
extraction NN N
or CC N
8 CD N
weeks NNS N
later RB N
( ( N
immediate JJ N
replacement NN N
vs. FW N
immediate JJ N
restoration NN N
) ) N
. . N

Increased VBN N
platelet NN o
5-HT JJ o
levels NNS o
were VBD N
found VBN N
in IN N
40 CD N
% NN N
of IN N
the DT N
autistic JJ N
population NN N
, , N
suggesting VBG N
that IN N
hyperserotonaemia NN N
may MD N
be VB N
a DT N
pathologic JJ N
factor NN N
in IN N
infantile JJ p
autism NN p
. . p

Serum NNP o
norfloxacin NN o
's POS o
highest JJS o
concentrations NNS o
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS N
and CC N
nitric JJ N
oxide NN N
. . N

No DT N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
anesthetic JJ N
techniques NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN o
, , o
vomiting VBG o
, , N
or CC N
both DT N
during IN N
the DT N
first JJ N
24 CD N
hr NN N
after IN N
operation NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
controls NNS N
, , N
patients NNS N
who WP N
viewed VBD N
either DT N
of IN N
the DT N
videotapes NNS N
before IN N
hospital NN N
release NN N
reported VBD N
higher JJR N
self-efficacy NN N
for IN N
adhering VBG N
to TO N
the DT N
recommended VBN N
low-fat NN N
diet JJ N
both DT N
at IN N
discharge NN N
and CC N
1 CD N
month NN N
after IN N
surgery NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
data NNS N
on IN N
the DT N
efficacy NN N
of IN N
nitrofurantoin NN i
for IN N
the DT N
treatment NN N
of IN N
acute NN N
uncomplicated JJ N
cystitis NN N
in IN N
regimens NNS N
shorter JJR N
than IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
After IN N
569 CD p
patients NNS p
had VBD p
undergone JJ p
randomization NN p
, , p
enrollment NN p
was VBD p
stopped VBN p
because IN p
of IN p
concerns NNS p
about IN p
the DT p
safety NN p
of IN p
the DT p
patients NNS p
who WP p
had VBD p
been VBN p
assigned VBN p
to TO p
receive VB p
warfarin NN i
. . i

METHODS NNP N
Nine NNP p
patients NNS p
underwent JJ p
NCE NNP i
4D CD i
MRA NNP i
for IN N
the DT N
evaluation NN N
of IN N
DAVF NNP i
in IN N
the DT N
transverse NN N
sinus NN N
at IN N
3 CD N
T. NNP N
One CD N
patient NN N
was VBD N
examined VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
once RB N
after IN N
the DT N
interventional JJ N
treatment NN N
. . N

Rapid JJ N
efficacy NN N
of IN N
the DT N
highly RB i
selective JJ i
alpha1A-adrenoceptor NN i
antagonist NN i
silodosin NN i
in IN N
men NNS p
with IN p
signs NNS p
and CC p
symptoms NNS p
of IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
: : p
pooled JJ N
results NNS N
of IN N
2 CD N
phase NN N
3 CD N
studies NNS N
. . N

CONCLUSIONS NNP N
Co-administration NN N
of IN N
single JJ N
doses NNS N
of IN N
donepezil NN i
HCl NNP i
( ( N
5 CD N
mg NN N
) ) N
and CC N
digoxin NN i
( ( N
0.25 CD N
mg NN N
) ) N
produced VBD N
no DT N
changes NNS N
in IN N
the DT N
pharmacokinetic JJ o
profile NN o
of IN o
either DT o
drug NN o
. . o

Furthermore RB N
, , N
2.8 CD N
mg NN N
BM NNP N
of IN N
PSE NNP N
taken VBN N
90 CD N
min NN N
before IN N
exercise NN N
, , N
with IN N
or CC N
without IN N
food NN N
, , N
resulted VBD N
in IN N
urinary JJ N
PSE NNP N
concentrations NNS N
exceeding VBG N
the DT N
present JJ N
WADA NNP N
threshold NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Ninety-nine NNP p
eligible JJ p
patients NNS p
with IN p
T2 NNP p
to TO p
T4b NNP p
transitional JJ p
cell NN p
bladder NN p
cancer NN p
participated VBD p
, , p
64 CD p
% NN p
with IN p
cT3b NN p
or CC p
cT4 NN p
. . p

The DT N
absolute JJ o
bioavailability NN o
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN i
. . i

Analysis NN N
of IN N
CD19+ NNP N
blood NN N
cells NNS N
in IN N
relationship NN N
to TO N
circulating VBG N
clonal JJ N
cells NNS N
was VBD N
done VBN N
in IN N
13 CD p
myeloma NN p
patients NNS p
using VBG p
a DT p
clonotypic NN i
, , N
quantitative JJ N
allele-specific JJ N
oligonucleotide-polymerase NN N
chain NN N
reaction NN N
( ( N
PCR NNP N
) ) N
assay VBP N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Sample NNP N
size NN N
was VBD N
calculated VBN N
to TO N
achieve VB N
90 CD N
% NN N
power NN N
at IN N
an DT N
alpha NN N
of IN N
0.025 CD N
to TO N
detect VB N
a DT N
non-inferiority JJ N
margin NN N
of IN N
? . N
cm NN N
on IN N
the DT N
VAS NNP N
, , N
using VBG N
a DT N
one-sided JJ N
, , N
two-sample JJ N
t-test NN N
. . N

INTERVENTIONS NNP N
Four CD N
counseling NN i
sessions NNS i
over IN i
7 CD i
weeks NNS i
with IN i
a DT i
message NN i
of IN i
sit NN i
less CC i
and CC i
move VB i
more JJR i
( ( i
intervention NN i
group NN i
) ) i
or CC i
calcium NN i
for IN i
bone NN i
health NN i
( ( i
attention-matched JJ i
control NN i
group NN i
) ) i
. . i

16 CD p
patients NNS p
with IN p
relapsing VBG p
non-Hodgkin NN p
's POS p
malignant JJ p
lymphomas NN p
considered VBN p
as IN p
clinical JJ p
stage NN p
I PRP p
or CC p
II NNP p
were VBD p
treated VBN p
by IN p
an DT p
association NN p
of IN p
chemo NN i
+ NNP i
radiotherapy NN i
and CC i
thereafter RB i
by IN i
maintenance NN i
BCG NNP i
therapy NN i
. . i

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
esomeprazole NN i
in IN N
patients NNS p
with IN p
frequent JJ p
heartburn NN p
for IN p
> NN p
or CC p
= $ p
6 CD p
months NNS p
and CC p
no DT p
evidence NN p
of IN p
erosive JJ p
oesophagitis NN p
on IN p
endoscopy NN p
. . p

PATIENT NNP p
( ( p
S NNP p
) ) p
Infertile NNP p
couples NNS p
( ( p
n=52 NN p
) ) p
with IN p
a DT p
female JJ p
partner NN p
less JJR p
than IN p
42 CD p
years NNS p
old JJ p
with IN p
eight CD p
or CC p
more JJR p
mature JJ p
oocytes VBZ p
retrieved VBN p
. . p

The DT N
secondary JJ N
outcomes NNS N
are VBP N
an DT N
additional JJ N
measure NN N
of IN N
pain NN o
relief NN o
, , o
maternal JJ o
sedation NN o
, , o
nausea NN o
and CC o
vomiting NN o
, , o
maternal JJ o
oxygen NN o
saturation NN o
, , o
satisfaction NN o
with IN o
analgesia NN o
, , o
whether IN o
method NN o
of IN o
analgesia NN o
would MD o
be VB o
used VBN o
again RB o
, , o
use NN o
of IN o
Entonox NNP o
, , o
umbilical JJ o
arterial NN o
and CC o
venous JJ o
pH NN o
, , o
fetal JJ o
heart NN o
rate NN o
, , o
meconium NN o
staining NN o
, , o
time NN o
from IN o
delivery NN o
to TO o
first JJ o
breath NN o
, , o
Apgar NNP o
scores VBZ o
at IN o
5 CD o
mins NNS o
, , o
naloxone JJ o
requirement NN o
, , o
transfer NN o
to TO o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
, , o
neonatal JJ o
haemoglobin NN o
oxygen NN o
saturation NN o
at IN o
30 CD o
, , o
60 CD o
, , o
90 CD o
, , o
and CC o
120 CD o
mins NNS o
after IN o
delivery NN o
, , o
and CC o
neonatal JJ o
sedation NN o
and CC o
feeding VBG o
behaviour NN o
during IN o
first JJ o
2 CD o
hours NNS o
. . o

METHODOLOGY NN N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD p
patients NNS p
who WP p
had VBD p
anterior CC p
or CC p
premolar JJ p
teeth NNS p
with IN p
irreversible JJ p
pulpitis NN p
without IN p
any DT p
signs NNS p
and CC p
symptoms NNS p
of IN p
acute NN p
or CC p
chronic JJ p
apical JJ p
periodontitis NN p
and CC p
moderate VB p
to TO p
severe VB p
pain NN p
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN N
group NN N
receiving VBG N
a DT N
placebo NN i
medication NN i
, , N
and CC N
three CD N
experimental JJ N
groups NNS N
receiving VBG N
a DT N
single JJ N
dose NN N
of IN N
either DT N
Tramadol NNP i
( ( N
100 CD N
mg NN N
) ) N
, , N
Novafen NNP i
( ( N
325 CD N
mg NN N
of IN N
paracetamol NN i
, , i
200 CD i
mg NN i
ibuprofen NN i
and CC i
40 CD i
mg NNS i
caffeine VBP i
anhydrous JJ i
) ) i
or CC i
Naproxen NNP i
( ( N
500 CD N
mg NN N
) ) N
immediately RB N
after IN N
the DT N
first JJ N
appointment NN N
where WRB N
the DT N
pulp NN N
was VBD N
removed VBN N
, , N
and CC N
the DT N
canals NNS N
were VBD N
fully RB N
prepared VBN N
. . N

( ( N
15/11 CD N
mmHg NN N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
hypotensive JJ o
peak NN o
after IN N
20 CD N
min NN N
( ( N
57/38 CD N
mmHg NN N
, , N
p NN N
greater JJR N
than IN N
0.001 CD N
) ) N
; : N
2 CD N
) ) N
no DT N
significant JJ N
differences NNS N
for IN N
hypotensive JJ o
effectiveness NN o
between IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
with IN N
SLC NNP N
having VBG N
a DT N
mildly RB N
delayed JJ N
onset NN N
of IN N
action NN N
when WRB N
compared VBN N
to TO N
SLN NNP N
; : N
3 CD N
) ) N
antihypertensive JJ o
effect NN o
lasting VBG N
for IN N
about IN N
6 CD N
hours NNS N
in IN N
patients NNS N
treated VBN N
with IN N
SLC NNP N
and CC N
blood NN N
pressure NN N
progressively RB N
raising VBG N
after IN N
4 CD N
hours NNS N
in IN N
patients NNS N
who WP N
received VBD N
SLN NNP N
; : N
4 CD N
) ) N
a DT N
significant JJ N
correlation NN N
between IN N
blood NN o
pressure NN o
reduction NN o
and CC o
blood NN o
pressure NN o
before IN N
drug NN N
administration NN N
in IN N
both DT N
groups NNS N
; : N
a DT N
significant JJ N
correlation NN N
between IN N
pretreatment NN N
PRA NNP o
and CC o
antihypertensive JJ o
effect NN o
in IN N
the DT N
SLC NNP N
group NN N
. . N

Sixteen JJ p
strength-trained JJ p
men NNS p
were VBD N
tested VBN N
for IN N
1RM CD N
leg NN N
press NN N
after IN N
4 CD N
GWU NNP N
conditions NNS N
after IN N
specific JJ N
warm-up NN N
: : N
short JJ N
duration NN N
and CC N
low JJ N
intensity NN N
( ( N
SDLI NNP N
; : N
i.e NN N
, , N
5 CD N
minutes NNS N
at IN N
40 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
long JJ N
duration NN N
and CC N
low JJ N
intensity NN N
( ( N
LDLI NNP N
; : N
i.e NN N
, , N
15 CD N
minutes NNS N
at IN N
40 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
short JJ N
duration NN N
and CC N
moderate JJ N
intensity NN N
( ( N
SDMI NNP N
; : N
i.e NN N
, , N
5 CD N
minutes NNS N
at IN N
70 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
long JJ N
duration NN N
and CC N
moderate JJ N
intensity NN N
( ( N
LDMI NNP N
; : N
i.e NN N
, , N
15 CD N
minutes NNS N
at IN N
70 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
and CC N
the DT N
control NN N
( ( N
CTRL NNP N
) ) N
no-GWU JJ N
condition NN N
. . N

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
phase VB N
III NNP N
clinical JJ N
trial NN N
was VBD N
carried VBN N
out RP N
in IN N
two CD N
parallel JJ N
groups NNS N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
ebrotidine NN i
( ( i
N- JJ i
[ NN i
( ( i
E NNP i
) ) i
- : i
[ JJ i
[ JJ i
2- JJ i
[ NN i
[ NNP i
[ NNP i
2- JJ i
[ NNP i
( ( i
diaminomethylene NN i
) ) i
amino NN i
] JJ i
-4-thiazolyl NNP i
] NNP i
methyl NN i
] NNP i
thio NN i
] NNP i
ethyl VBZ i
] NNP i
amino NN i
] NNP i
methylene NN i
] NNP i
-4-bromo-benzenesulfonamide NNP i
, , i
CAS NNP i
100981-43-9 CD N
, , N
FI-3542 NNP N
) ) N
400 CD N
mg NN N
and CC N
ranitidine VB i
300 CD N
mg NN N
given VBN N
in IN N
single JJ N
evening NN N
dose NN N
, , N
combined VBN N
with IN N
amoxicillin JJ N
750 CD N
mg NN N
and CC N
metronidazole $ i
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
14 CD N
days NNS N
, , N
in IN N
the DT N
eradication NN N
of IN N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS p
with IN p
duodenal JJ p
ulcer NN p
. . p

METHODS NNP N
We PRP N
randomly RB N
assigned VBD N
2079 CD p
men NNS p
and CC p
women NNS p
who WP p
were VBD p
35 CD p
years NNS p
of IN p
age NN p
or CC p
older JJR p
and CC p
who WP p
had VBD p
had VBN p
one CD p
or CC p
more JJR p
histologically RB p
confirmed VBN p
colorectal JJ p
adenomas NN p
removed VBD p
within IN p
six CD p
months NNS p
before IN p
randomization NN p
to TO p
one CD p
of IN p
two CD p
groups NNS p
: : p
an DT p
intervention NN i
group NN i
given VBN i
intensive JJ i
counseling NN i
and CC i
assigned VBD i
to TO i
follow VB i
a DT i
diet NN i
that WDT i
was VBD i
low JJ i
in IN i
fat NN i
( ( i
20 CD i
percent NN i
of IN i
total JJ i
calories NNS i
) ) i
and CC i
high JJ i
in IN i
fiber NN i
( ( i
18 CD i
g NN i
of IN i
dietary JJ i
fiber NN i
per IN i
1000 CD i
kcal NN i
) ) i
and CC i
fruits NNS i
and CC i
vegetables NNS i
( ( i
3.5 CD i
servings NNS i
per IN i
1000 CD i
kcal NN i
) ) i
, , i
and CC i
a DT i
control NN i
group NN i
given VBN i
a DT i
standard JJ i
brochure NN i
on IN i
healthy JJ i
eating NN i
and CC i
assigned VBD i
to TO i
follow VB i
their PRP$ i
usual JJ i
diet NN i
. . i

The DT N
experimental JJ N
group NN N
also RB N
showed VBD N
significant JJ o
pre-/posttreatment JJ o
improvements NNS o
in IN o
both DT o
lower JJR o
limbs NN o
in IN o
gait JJ o
dorsiflexion NN o
ROAM NNP o
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.02-2.49 JJ N
) ) N
, , N
cadence NN o
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.45-1.47 NNP N
) ) N
, , N
stride JJ o
length NN o
( ( N
95 CD N
% NN N
CI NNP N
, , N
21.48-10.83 JJ N
) ) N
, , N
step JJ N
length NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.68-6.61 JJ N
) ) N
, , N
stance NN N
phase NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
61-107 JJ N
) ) N
, , N
and CC N
foot NN o
( ( N
95 CD N
% NN N
CI NNP N
, , N
.56-.92 NNP N
) ) N
and CC N
malleolus $ N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.15-1.63 JJ N
) ) N
circumference NN N
. . N

MAIN NNP N
RESULTS NNP N
The DT N
12 CD N
patients NNS N
treated VBN N
with IN N
GM-CSF NNP i
, , N
when WRB N
compared VBN N
with IN N
placebo NN i
recipients NNS N
, , N
had VBD N
shorter JJR N
periods NNS N
of IN N
neutropenia NN o
( ( o
median JJ o
duration NN o
of IN o
an DT o
absolute JJ o
neutrophil NN o
count NN o
of IN N
less JJR N
than IN N
1000 CD N
cells/mm3 NN N
, , N
16 CD N
days NNS N
compared VBN N
with IN N
27 CD N
days NNS N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
shorter JJR N
periods NNS N
of IN N
platelet-transfusion NN o
dependency NN o
( ( o
median JJ o
duration NN o
, , N
13.5 CD N
days NNS N
compared VBN N
with IN N
21 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
shorter JJR N
hospitalizations NNS o
( ( o
median JJ o
hospital NN o
stay NN o
, , N
32 CD N
days NNS N
compared VBN N
with IN N
40.5 CD N
days NNS N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ i
group NN i
leisure NN i
programme NN i
intended VBN i
to TO i
facilitate VB i
interaction NN i
with IN i
media NNS i
, , i
engagement NN i
in IN i
exercise NN i
, , i
playing VBG i
games NNS i
and CC i
doing VBG i
crafts NNS i
, , i
attending VBG i
events NNS i
, , i
and CC i
participating VBG i
in IN i
other JJ i
recreation NN i
activities NNS i
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD p
participants NNS p
( ( p
22 CD p
male NN p
, , p
15 CD p
female NN p
) ) p
, , p
ages VBZ p
17-39 JJ p
( ( p
M NNP p
= NNP p
31.49 CD p
) ) p
years NNS p
at IN p
the DT p
beginning NN p
of IN p
the DT p
programme NN p
) ) p
diagnosed VBD p
with IN p
an DT p
ASD NNP p
and CC p
a DT p
group NN p
of IN p
34 CD p
adults NNS p
with IN p
ASD NNP p
as IN p
control NN p
group NN p
( ( p
waiting VBG p
list NN p
) ) p
( ( p
19 CD p
male NN p
, , p
15 CD p
female NN p
) ) p
, , p
ages VBZ p
24-38 JJ p
( ( p
M NNP p
= VBZ p
30 CD p
at IN p
programme JJ p
initiation NN p
) ) p
years NNS p
. . p

During IN N
a DT N
recent JJ N
9-month JJ N
period NN N
, , N
170 CD p
consecutive JJ p
patients NNS p
( ( p
114 CD p
men NNS p
and CC p
56 CD p
women NNS p
; : p
age NN p
range NN p
, , p
40-85 JJ p
years NNS p
; : p
mean VB p
, , p
67.7 CD p
years NNS p
) ) p
with IN p
suspected VBN p
chronic JJ p
liver NN p
diseases NNS p
were VBD N
randomized VBN N
into IN N
three CD N
CT NNP i
groups NNS i
according VBG i
to TO i
the DT i
following JJ i
iodine-load NN i
and CC i
tube-voltage NN i
protocols NNS i
: : i
600 CD i
milligram NN i
per IN i
kilogram NN i
body NN i
weight NN i
( ( i
mg/kg NN i
) ) i
iodine NN i
load NN i
and CC i
120 CD i
peak NN i
kilovolt NN i
( ( i
kVp NN i
) ) i
tube NN i
voltage NN i
setting VBG i
( ( i
600-120 JJ i
group NN i
) ) i
, , i
500 CD i
mg/kg NN i
and CC i
80 CD i
kVp NN i
( ( i
500-80 JJ i
group NN i
) ) i
, , i
and CC i
400mg/kg CD i
and CC i
80 CD i
kVp NN i
( ( i
400-80 JJ i
group NN i
) ) i
. . i

METHODS NN N
Patients NNS p
( ( p
n=603 JJ p
; : p
mean JJ p
age NN p
, , p
73.9 CD p
years NNS p
; : p
55.2 CD p
% NN p
men NNS p
) ) p
with IN p
probable JJ p
( ( p
70.5 CD p
% NN p
) ) p
or CC p
possible JJ p
( ( p
29.5 CD p
% NN p
) ) p
VaD NNP p
, , p
according VBG p
to TO p
criteria NNS p
of IN p
the DT p
National NNP p
Institute NNP p
of IN p
Neurological NNP p
Disorders NNP p
and CC p
Stroke NNP p
( ( p
NINDS NNP p
) ) p
and CC p
the DT p
Association NNP p
Internationale NNP p
pour VBP p
la NN p
Recherche NNP p
et CC p
l'Enseignement JJ p
en NN p
Neurosciences NNP p
( ( p
AIREN NNP p
) ) p
, , N
were VBD N
randomized VBN N
to TO N
24 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
donepezil JJ i
5 CD N
mg/d NN N
( ( N
n=198 JJ N
) ) N
, , N
donepezil $ i
10 CD N
mg/d NN N
( ( N
5 CD N
mg/d NN N
for IN N
first JJ N
28 CD N
days NNS N
; : N
n=206 CC N
) ) N
, , N
or CC N
placebo NN i
( ( N
n=199 JJ N
) ) N
. . N

RESULTS VB N
The DT N
increase NN N
in IN N
the DT N
proportion NN o
of IN o
total JJ o
urinary JJ o
arsenic NN o
excreted VBD o
as IN N
DMA NNP N
in IN N
the DT N
folic JJ N
acid NN N
group NN N
( ( N
72 CD N
% NN N
before IN N
and CC N
79 CD N
% NN N
after IN N
supplementation NN N
) ) N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
as IN N
was VBD N
the DT N
reduction NN N
in IN N
the DT N
proportions NNS N
of IN N
total JJ o
urinary JJ o
arsenic NN o
excreted VBD o
as IN N
MMA NNP N
( ( N
13 CD N
% NN N
and CC N
10 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
as IN N
InAs NNP N
( ( N
15 CD N
% NN N
and CC N
11 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

After IN N
PBSCT NNP i
, , N
the DT N
time NN N
to TO N
achieve VB N
an DT N
absolute JJ o
neutrophil NN o
count NN o
( ( N
ANC NNP N
) ) N
of IN N
> $ N
0.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
median JJ N
, , N
11 CD N
v NN N
12 CD N
days NNS N
; : N
the DT N
log-rank JJ N
test NN N
, , N
P NNP N
=.046 NNP N
) ) N
, , N
although IN N
the DT N
last JJ N
day NN N
of IN N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
transfusion NN N
( ( N
day NN N
11 CD N
v NN N
day NN N
10 CD N
) ) N
and CC N
the DT N
duration NN N
of IN N
febrile JJ N
days NNS N
( ( N
> JJ N
38 CD N
degrees NNS N
C NNP N
) ) N
after IN N
PBSCT NNP i
( ( N
4 CD N
v RB N
4 CD N
days NNS N
) ) N
were VBD N
identical JJ N
in IN N
both DT N
groups NNS N
. . N

Among IN N
155 CD N
randomized JJ N
patients NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
grade NN o
3 CD o
and CC o
4 CD o
oral JJ o
mucositis NN o
( ( N
primary JJ N
study NN N
endpoint NN N
) ) N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
( ( N
three CD N
in IN N
palifermin NN N
arm NN N
( ( N
4 CD N
% NN N
) ) N
, , N
8 CD N
in IN N
placebo NN N
arm NN N
( ( N
10 CD N
% NN N
; : N
P NNP N
= NNP N
0 CD N
) ) N
; : N
however RB N
, , N
when WRB N
considering VBG N
the DT N
severity NN N
of IN N
oral JJ N
mucositis NN N
( ( N
World NNP N
Health NNP N
Organization NNP N
grade VBD N
0-4 NNP N
) ) N
, , N
there EX N
was VBD N
evidence NN N
of IN N
reduced JJ o
rates NNS o
of IN o
higher JJR o
grades NNS o
of IN o
oral JJ o
mucositis NN o
in IN N
the DT N
palifermin NN N
arm NN N
( ( N
P NNP N
= NNP N
0 CD N
, , N
test NN N
for IN N
trend NN N
) ) N
. . N

METHODS NNP N
409 CD p
patients NNS p
with IN p
malignant JJ p
pleural JJ p
mesothelioma NN p
, , p
from IN p
76 CD p
centres NNS p
in IN p
the DT p
UK NNP p
and CC p
two CD p
in IN p
Australia NNP p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
ASC NNP i
alone RB i
( ( i
treatment NN i
could MD i
include VB i
steroids NNS i
, , i
analgesic JJ i
drugs NNS i
, , i
bronchodilators NNS i
, , i
palliative JJ i
radiotherapy NN i
[ NNP i
n=136 RB i
] NNP i
) ) i
; : i
to TO i
ASC NNP i
plus CC i
MVP NNP i
( ( i
four CD i
cycles NNS i
of IN i
mitomycin NN i
6 CD i
mg/m2 NN i
, , i
vinblastine VBP i
6 CD i
mg/m2 NN i
, , i
and CC i
cisplatin VBZ i
50 CD i
mg/m2 NN i
every DT i
3 CD i
weeks NNS i
[ JJ i
n=137 RB i
] NNP i
) ) i
; : i
or CC i
to TO i
ASC NNP i
plus CC i
vinorelbine NN i
( ( i
one CD i
injection NN i
of IN i
vinorelbine NN i
30 CD N
mg/m2 NN N
every DT N
week NN N
for IN N
12 CD N
weeks NNS N
[ JJ N
n=136 RB N
] NN N
) ) N
. . N

METHODS NN N
Patients NNS p
( ( p
men NNS p
? . p
45 CD p
years NNS p
; : p
women NNS p
? . p
50 CD p
years NNS p
) ) p
with IN p
known VBN p
or CC p
suspected VBN p
coronary JJ p
artery NN p
disease NN p
( ( p
n JJ p
= NNP p
124 CD p
) ) p
were VBD p
randomized VBN p
to TO p
1 CD p
of IN p
2 CD p
diagnostic JJ p
sequences NNS p
: : p
rest NN i
and CC i
regadenoson NN i
SPECT NNP i
on IN i
day NN i
1 CD i
, , i
then RB i
regadenoson NN i
CTP NNP i
and CC i
rest VB i
CTP NNP i
( ( i
and CC i
coronary JJ i
CT NNP i
angiography NN i
[ NNP i
CTA NNP i
] NNP i
) ) i
( ( i
CTA NNP i
; : i
same JJ i
acquisition NN i
) ) i
on IN i
day NN i
2 CD i
or CC i
regadenoson VB i
CTP NNP i
and CC i
rest VB i
CTP NNP i
( ( i
and CC i
CTA NNP i
) ) i
on IN N
Day NNP N
1 CD N
, , N
then RB N
rest NN N
and CC N
regadenoson NN i
SPECT NNP i
on IN N
day NN N
2 CD N
. . N

Each DT N
year NN N
, , N
cows NNS N
were VBD N
blocked VBN N
by IN N
age NN i
and CC i
BCS NNP i
and CC i
assigned VBD i
randomly RB i
to TO i
one CD i
of IN i
three CD i
treatments NNS i
: : i
PRE NNP i
( ( i
n JJ i
= NNP i
115 CD i
) ) i
cows NNS i
received VBD i
1.14 CD i
kg/d NNS i
( ( i
DM NNP i
basis NN i
) ) i
of IN i
whole JJ i
corn NN i
germ NN i
for IN i
approximately RB i
45 CD i
d NN i
before IN i
calving VBG i
; : i
POST NNP i
( ( i
n JJ i
= NNP i
109 CD i
) ) i
cows NNS i
were VBD i
fed VBN i
1.14 CD i
kg/d NNS i
of IN i
whole JJ i
corn NN i
germ NN i
for IN i
approximately RB i
45 CD i
d NN i
after IN i
calving VBG i
; : i
and CC i
control VB i
cows NNS i
( ( i
n JJ i
= NNP i
118 CD i
) ) i
were VBD i
fed VBN i
similar JJ i
energy NN i
and CC i
protein NN i
from IN i
dry-rolled JJ i
corn NN i
( ( i
1.82 CD i
kg NN i
of IN i
DM/d NNP i
) ) i
for IN i
45 CD i
d NN i
before IN i
and CC i
after IN i
calving VBG i
. . i

All DT N
six CD N
criterion NN N
measures NNS N
were VBD N
characterized VBN N
by IN N
significant JJ N
changes NNS N
over IN N
time NN N
for IN N
the DT N
entire JJ N
group NN N
( ( N
n JJ N
= VBZ N
45 CD N
; : N
time NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
, , N
as IN N
follows VBZ N
: : N
pain NN o
and CC o
medication NN o
intake NN o
were VBD N
similar JJ N
on IN N
days NNS N
1 CD N
and CC N
2 CD N
, , N
but CC N
were VBD N
significantly RB N
less JJR N
on IN N
day NN N
3 CD N
, , N
and CC N
pulmonary JJ o
functions NNS o
were VBD N
significantly RB N
lower JJR N
than IN N
preoperatively RB N
on IN N
day NN N
1 CD N
, , N
decreased VBD N
further RBR N
on IN N
day NN N
2 CD N
, , N
and CC N
despite IN N
an DT N
improvement NN N
on IN N
day NN N
3 CD N
, , N
remained VBD N
significantly RB N
lower JJR N
than IN N
preoperative JJ N
values NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
from IN N
radial JJ N
artery NN N
and CC N
S-G NNP N
catheter NN N
for IN N
blood NN N
gas NN N
analysis NN N
at IN N
following VBG N
intervals NNS N
: : N
during IN N
spontaneous JJ N
breathing VBG N
when WRB N
the DT N
patient NN N
was VBD N
awake JJ N
( ( N
T0 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
tracheal JJ N
indubation NN N
( ( N
T1 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
patient NN N
was VBD N
placed VBN N
in IN N
lateral JJ N
position NN N
( ( N
T2 NNP N
) ) N
and CC N
15 CD N
min NN N
after IN N
it PRP N
( ( N
T3 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
ribs NN N
was VBD N
braced VBN N
( ( N
T4 NNP N
) ) N
, , N
30 CD N
, , N
60 CD N
, , N
120 CD N
min NN N
during IN N
the DT N
course NN N
of IN N
OLV NNP i
( ( N
T5 NNP N
, , N
T6 NNP N
, , N
T7 NNP N
) ) N
, , N
the DT N
two CD N
lungs NNS N
were VBD N
ventilated VBN N
again RB N
for IN N
30 CD N
min NN N
( ( N
T8 NNP N
) ) N
and CC N
Qs/Qt NNP N
was VBD N
calculated VBN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
seven CD p
consecutive JJ p
coronary JJ p
artery NN p
bypass NN p
patients NNS p
( ( p
mean JJ p
age NN p
62 CD p
+/- JJ p
11 CD p
years NNS p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
sotalol NN i
alone RB i
( ( N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
5 CD N
days NNS N
starting VBG N
from IN N
the DT N
morning NN N
of IN N
the DT N
first JJ N
postoperative JJ N
day NN N
) ) N
( ( N
group NN N
S NNP N
) ) N
, , N
magnesium NN N
alone RB N
( ( N
1.5 CD N
g NNS N
daily RB N
for IN N
6 CD N
days NNS N
starting VBG N
in IN N
the DT N
operating NN N
room NN N
just RB N
before IN N
cardiopulmonary JJ N
bypass NN N
) ) N
( ( N
group NN N
M NNP N
) ) N
, , N
both DT N
pharmacologic JJ N
agents NNS N
at IN N
the DT N
same JJ N
dosages NNS N
( ( N
group NN N
S+M NNP i
) ) i
, , i
or CC i
no DT i
antiarrhythmic JJ i
agents NNS i
( ( i
group NN i
CTR NNP i
) ) i
. . i

Subjects NNS p
due JJ p
for IN p
CRC NNP p
screening VBG p
were VBD N
randomized VBN N
within IN N
each DT N
practice NN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
usual JJ i
care NN i
; : i
( ( i
2 CD i
) ) i
physician JJ i
chart NN i
reminder NN i
; : i
( ( i
3 CD i
) ) i
physician JJ i
chart NN i
reminder NN i
, , i
mailed VBN i
education NN i
, , i
CRC NNP i
reminder NN i
magnet NN i
, , i
and CC i
fecal JJ i
immunochemical JJ i
test NN i
( ( i
FIT NNP i
) ) i
( ( i
mailed JJ i
education/FIT NN i
) ) i
; : i
or CC i
( ( i
4 CD i
) ) i
all PDT i
the DT i
preceding VBG i
plus CC i
a DT i
structured JJ i
telephone NN i
call NN i
to TO i
the DT i
patient NN i
from IN i
project JJ i
staff NN i
to TO i
provide VB i
education NN i
, , i
assess JJ i
interest NN i
in IN i
screening VBG i
, , i
explain VB i
the DT i
screening NN i
tests NNS i
, , i
and CC i
address JJ i
barriers NNS i
( ( i
mailed VBN i
education/FIT RB i
plus CC i
phone NN i
call NN i
) ) i
. . i

METHODS NNP N
Patients NNS p
with IN p
unresectable JJ p
and/or JJ p
recurrent NN p
advanced VBD p
gastric JJ p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
: : N
S-1 NNP i
( ( i
40 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
twice RB i
daily RB i
) ) i
on IN i
days NNS i
1-14 JJ i
plus JJ i
paclitaxel NN i
( ( i
60 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
) ) i
on IN i
days NNS i
1 CD i
, , i
8 CD i
, , i
and CC i
15 CD i
of IN i
a DT i
4-week JJ i
cycle NN i
( ( i
S-1+paclitaxel NNP i
) ) i
or CC i
S-1 NNP i
( ( i
40 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
twice RB i
daily RB i
) ) i
on IN i
days NNS i
1-21 JJ i
plus JJ i
cisplatin NN i
( ( i
60 CD i
mg NN i
m NN i
( ( i
-2 NNP i
) ) i
) ) i
on IN i
day NN i
8 CD i
of IN i
a DT i
5-week JJ i
cycle NN i
( ( i
S-1+cisplatin NNP i
) ) i
. . i

In IN N
the DT N
placebo NN i
, , i
vitamin FW i
A NNP i
, , i
and CC i
beta NN i
carotene NN i
groups NNS N
the DT N
rates NNS o
of IN o
stillbirth NN o
and CC o
infant JJ o
mortality NN o
were VBD N
47.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
44.3-51.5 JJ N
) ) N
, , N
45.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
42.1-49.2 JJ N
) ) N
, , N
and CC N
51.8 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
48.0-55.6 JJ N
) ) N
per IN N
1000 CD N
births NNS N
and CC N
68.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
63.7-72.5 NNP N
) ) N
, , N
65.0 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
60.7-69.4 NNP N
) ) N
, , N
and CC N
69.8 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
65.4-72.3 JJ N
) ) N
per IN N
1000 CD N
live JJ N
births NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD i
programs NNS i
: : i
group NN i
1 CD i
-- : i
a DT i
full-time JJ i
, , i
intensive JJ i
3-week JJ i
multidisciplinary JJ i
program NN i
, , i
including VBG i
active JJ i
physical JJ i
and CC i
ergonomic JJ i
training NN i
and CC i
psychological JJ i
pain NN i
management NN i
, , i
followed VBN i
by IN i
1 CD i
day NN i
weekly VB i
for IN i
the DT i
subsequent JJ i
3 CD i
weeks NNS i
; : i
group NN i
2 CD i
-- : i
active JJ i
physical JJ i
training NN i
, , i
twice RB i
a DT i
week NN i
for IN i
6 CD i
weeks NNS i
, , i
for IN i
a DT i
total NN i
of IN i
24h CD i
; : i
group NN i
3 CD i
-- : i
psychological JJ i
pain NN i
management NN i
combined VBN i
with IN i
active JJ i
physical JJ i
training NN i
, , i
twice RB i
a DT i
week NN i
for IN i
6 CD i
weeks NNS i
, , i
also RB i
for IN i
a DT i
total NN i
of IN i
24h CD i
. . i

METHODS NNP N
Twenty NNP p
male NN p
, , p
white JJ p
patients NNS p
( ( p
27 CD p
+/- JJ p
1 CD p
years NNS p
) ) p
with IN p
mild JJ p
essential JJ p
hypertension NN p
( ( p
143 CD p
+/- JJ p
11/95 CD p
+/- JJ p
6 CD p
mm NN p
Hg NNP p
) ) p
were VBD N
included VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
fourfold JJ N
cross-over NN N
study NN N
with IN N
placebo NN i
, , i
enalapril NN i
( ( i
20 CD i
mg/day NN i
) ) i
, , i
eprosartan FW i
( ( i
600 CD i
mg/day NN i
) ) i
, , i
or CC i
combination NN i
of IN i
both DT i
drugs NNS i
( ( i
10 CD i
and CC i
300 CD i
mg/day NN i
, , i
respectively RB i
) ) i
each DT i
over IN i
a DT i
one CD i
week NN i
period NN i
followed VBN i
by IN i
a DT i
two-week JJ i
washout NN i
phase NN i
. . i

Cox NNP N
regression NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
treatment NN N
and CC N
gender NN N
regarding VBG N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
( ( N
P NNP N
= NNP N
0 CD N
) ) N
and CC N
RFS NNP N
( ( N
P NNP N
= NNP N
0 CD N
) ) N
, , N
with IN N
a DT N
lower JJR N
hazard NN N
in IN N
females NNS N
than IN N
males NNS N
in IN N
the DT N
OG NNP N
[ NNP N
OS NNP N
: : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
= VBZ N
0 CD N
; : N
RFS NNP N
: : N
HR NNP N
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0 CD N
] NNP N
, , N
and CC N
no DT N
significant JJ N
differences NNS N
between IN N
males NNS N
and CC N
females NNS N
in IN N
the DT N
TG NNP N
. . N

METHODS NN N
From IN p
1991 CD p
to TO p
1995 CD p
, , p
89 CD p
patients NNS p
with IN p
T3b NNP p
, , p
T4 NNP p
or CC p
metastatic JJ p
urothelial JJ p
carcinoma NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
methotrexate NN i
, , i
epirubicin NN i
and CC i
cisplatin NN i
chemotherapy NN i
group NN i
( ( i
arm JJ i
1 CD i
: : i
S-MEC JJ i
therapy NN i
; : i
n CC i
= VB i
29 CD i
) ) i
, , i
a DT i
dose-intensified JJ i
MEC NNP i
therapy NN i
combined VBN i
with IN i
G-CSF NNP i
group NN i
( ( i
arm JJ i
2 CD i
: : i
I-MEC JJ i
therapy NN i
; : i
n CC i
= VB i
30 CD i
) ) i
or CC i
a DT i
methotrexate NN i
, , i
vinblastine NN i
, , i
doxorubicin NN i
and CC i
cisplatin NN i
chemotherapy NN i
( ( i
arm JJ i
3 CD i
: : i
M-VAC JJ i
therapy NN i
; : i
n CC N
= VB N
30 CD N
) ) N
. . N

After IN N
visit NN N
1 CD N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
group NN N
A NNP N
, , N
control NN i
( ( i
usual JJ i
care NN i
) ) i
; : i
( ( i
2 CD i
) ) i
group NN i
B NNP i
, , i
treatment NN i
( ( i
video JJ i
peer NN i
modeling NN i
that WDT i
involved VBD i
watching VBG i
a DT i
DVD NNP i
recording NN i
of IN i
a DT i
typically RB i
developing VBG i
child NN i
undergoing VBG i
a DT i
dental JJ i
visit NN i
) ) i
; : i
( ( i
3 CD i
) ) i
group NN i
C NNP i
, , i
treatment NN i
( ( i
video JJ i
goggles NNS i
that WDT i
involved VBD i
watching VBG i
a DT i
favorite JJ i
movie NN i
during IN i
the DT i
dental JJ i
visit NN i
using VBG i
sunglass-style JJ i
video NN i
eyewear NN i
) ) i
; : i
and CC i
( ( i
4 CD i
) ) i
group NN i
D NNP i
, , i
treatment NN i
( ( i
video JJ i
peer NN i
modeling VBG i
plus CC i
video JJ i
goggles NNS i
) ) i
. . i

RESULTS NNP N
Three NNP N
variables NNS N
qualified VBD N
, , N
all DT N
of IN N
them PRP N
represented VBN N
in IN N
3 CD N
follow-ups NNS N
: : N
Low NNP o
total JJ o
prior RB o
sick-listing NN o
( ( N
including VBG N
all DT N
diagnoses NNS N
) ) N
was VBD N
the DT N
strongest JJS N
predictor NN N
in IN N
2 CD N
follow-ups NNS N
, , N
18 CD N
and CC N
24 CD N
months NNS N
, , N
OR NNP N
4.8 CD N
[ JJ N
1.9-12.3 JJ N
] NN N
and CC N
3.8 CD N
[ JJ N
1.6-8.7 JJ N
] NN N
respectively RB N
, , N
High NNP N
self NN N
prediction NN N
( ( N
the DT N
patients NNS N
' POS N
own JJ N
belief NN N
in IN N
return-to-work NN N
) ) N
was VBD N
the DT N
strongest JJS N
at IN N
12 CD N
months NNS N
, , N
OR NNP N
5.2 CD N
[ JJ N
1.5-17.5 JJ N
] NN N
and CC N
Young NNP N
age NN N
( ( N
max JJ N
44 CD N
years NNS N
) ) N
the DT N
second JJ N
strongest NN N
at IN N
18 CD N
months NNS N
, , N
OR NNP N
3.5 CD N
[ JJ N
1.3-9.1 JJ N
] NN N
. . N

The DT N
meals NNS N
contained VBD N
either CC N
oat JJ i
powder NN i
( ( N
62 CD N
g NN N
, , N
of IN N
which WDT N
2.7 CD N
soluble JJ N
fibre NN N
) ) N
, , N
rye NN i
bran NN i
( ( N
31 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
sugar JJ i
beet NN i
fibre NN i
( ( N
19 CD N
g NN N
, , N
of IN N
which WDT N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
( ( N
74 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD i
g NN i
soluble JJ i
fibre NN i
from IN i
each DT i
source NN i
, , i
giving VBG i
5 CD i
g NN i
soluble JJ i
fibre NN i
) ) i
or CC i
no DT i
added JJ i
fibre NN i
( ( i
control NN i
) ) i
and CC N
were VBD N
all DT N
adjusted VBN N
to TO N
contain VB N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
available JJ N
carbohydrates NNS N
. . N

The DT N
pre-pPCI JJ o
ST-segment JJ o
resolution NN o
( ( N
55+/-21.4 CD N
% NN N
vs JJ N
42.4+/-18.2 CD N
% NN N
, , N
p=0.005 NN N
) ) N
, , N
TIMI NNP o
flow NN o
grade VBD o
3 CD o
( ( N
29 CD N
% NN N
vs JJ N
7 CD N
% NN N
, , N
p=0.042 NN N
) ) N
, , N
corrected VBN o
TIMI NNP o
frame NN o
count NN o
( ( N
58.4+/-32.7 JJ N
vs NN N
78.9+/-28.4 JJ N
frame NN N
, , N
p=0.018 NN N
) ) N
% NN N
diameter JJ o
stenosis NN o
( ( N
76.3 CD N
/63.5-100/ JJ N
vs NN N
100 CD N
/73.5-100/ NN N
; : N
median JJ N
/interquartile NN N
range/ NN N
, , N
p=0.023 NN N
) ) N
, , N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
1 CD N
vs NN N
Group NNP N
2 CD N
. . N

Three CD p
hundred VBD p
eighty-four JJ p
patients NNS p
with IN p
stage NN p
III NNP p
( ( p
6 CD p
% NN p
) ) p
and CC p
IV NNP p
( ( p
94 CD p
% NN p
) ) p
oropharyngeal NN p
( ( p
59.4 CD p
% NN p
) ) p
, , p
hypopharyngeal NN p
( ( p
32.3 CD p
% NN p
) ) p
, , p
and CC p
oral JJ p
cavity NN p
( ( p
8.3 CD p
% NN p
) ) p
cancer NN p
were VBD i
randomly RB i
assigned VBN i
to TO i
30 CD i
Gy/2 NNP i
Gy NNP i
daily RB i
followed VBN i
by IN i
twice-daily JJ i
1.4 CD i
Gy NNP i
to TO i
a DT i
total NN i
of IN i
70.6 CD i
Gy NNP i
concurrently RB i
with IN i
mitomycin JJ i
C/5-FU NNP i
( ( i
C-HART NNP i
) ) i
or CC i
16 CD i
Gy/2 NNP i
Gy NNP i
daily RB i
followed VBN i
by IN i
twice-daily JJ i
1.4 CD i
Gy NNP i
to TO i
a DT i
total JJ i
dose NN i
of IN i
77.6 CD i
Gy NNP i
alone RB i
( ( i
HART NNP i
) ) i
. . i

RESULTS NNP N
Program NNP N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
sexual JJ N
partner NN N
notification NN N
at IN N
1 CD N
month NN N
( ( N
86 CD N
% NN N
control NN N
, , N
92 CD N
% NN N
intervention NN N
; : N
adjusted VBN N
odds NNS N
ratio VBP N
[ JJ N
AOR NNP N
] NNP N
= NNP N
1.8 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.02 CD N
, , N
3.0 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
no DT N
unprotected JJ o
sexual JJ o
intercourse NN o
at IN N
6 CD N
months NNS N
( ( N
38 CD N
% NN N
control NN N
, , N
48 CD N
% NN N
intervention NN N
; : N
AOR NNP N
= VBZ N
1.5 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.1 CD N
, , N
2.1 CD N
) ) N
. . N

Nine NNP p
healthy JJ p
volunteers NNS p
( ( p
age NN p
, , p
23.4 CD p
+/- JJ p
0.2 CD p
years NNS p
; : p
body NN p
mas VBZ p
index NN p
[ NNP p
BMI NNP p
] NNP p
, , p
23.5 CD p
+/- JJ p
1.6 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
were VBD N
fed VBN N
, , N
in IN N
random JJ N
order NN N
, , N
with IN N
a DT N
high-fat JJ i
diet NN i
( ( i
HFD NNP i
) ) i
( ( i
65 CD i
% NN i
of IN i
energy NN i
content NN i
fat NN i
, , i
15 CD i
% NN i
protein NN i
, , i
20 CD i
% NN i
carbohydrate NN i
) ) i
or CC i
a DT i
high-carbohydrate JJ i
diet NN i
( ( i
HCD NNP i
) ) i
( ( i
70 CD i
% NN i
carbohydrate NN i
, , i
15 CD i
% NN i
protein NN i
, , i
15 CD i
% NN i
fat NN i
) ) i
for IN i
5 CD i
days NNS i
, , i
with IN i
a DT i
washout JJ i
period NN i
of IN i
10 CD i
days NNS i
between IN i
the DT i
diets NNS i
. . i

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ i
( ( i
n JJ i
= NNP i
156 CD i
) ) i
or CC i
2-tablet JJ i
( ( i
n JJ i
= NNP i
153 CD i
) ) i
dose NN i
of IN i
combination NN i
hydrocodone NN i
7.5 CD i
mg NN i
and CC i
ibuprofen $ i
200 CD i
mg NN i
( ( i
HI1 NNP i
and CC i
HI2 NNP i
, , i
respectively RB i
) ) i
or CC i
a DT i
2-tablet JJ i
dose NN i
of IN i
combination NN i
codeine NN i
30 CD i
mg NN i
and CC i
acetaminophen $ i
300 CD i
mg NN i
( ( i
CA NNP i
, , i
n RB i
= VBZ i
160 CD i
) ) i
, , i
the DT i
active JJ i
comparator NN i
, , i
every DT i
6 CD i
to TO i
8 CD i
hours NNS i
as IN i
needed VBN i
for IN i
pain NN i
. . i

Recovery NN N
from IN N
incontinence NN N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
were VBD N
observed VBN N
in IN N
22 CD N
( ( N
27.8 CD N
% NN N
) ) N
, , N
42 CD N
( ( N
53.2 CD N
% NN N
) ) N
, , N
and CC N
57 CD N
( ( N
72.2 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
, , N
treated VBD N
with IN N
, , N
and CC N
23 CD N
( ( N
29.1 CD N
% NN N
) ) N
, , N
47 CD N
( ( N
59.5 CD N
% NN N
) ) N
, , N
and CC N
59 CD N
( ( N
74.7 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
, , N
treated VBD N
without IN N
the DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
, , N
with IN N
no DT N
significant JJ N
difference NN N
in IN N
time NN N
to TO N
recovery NN N
from IN N
incontinence NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
neutrophil JJ o
nadir NN o
was VBD N
similar JJ N
with IN N
and CC N
without IN N
priming VBG N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
490 CD N
+/- JJ N
310/microL CD N
v JJ N
550 CD N
+/- JJ N
350/microL CD N
, , N
respectively RB N
; : N
P NNP N
=.2 NNP N
) ) N
; : N
however RB N
, , N
on IN N
day NN N
16 CD N
the DT N
mean NN o
neutrophil NN o
count NN o
was VBD N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1030 CD N
+/- JJ N
580/microL CD N
v JJ N
690 CD N
+/- JJ N
370/microL CD N
, , N
P NNP N
=.004 NNP N
) ) N
, , N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
a DT N
neutrophil JJ N
count NN N
less JJR N
than IN N
500/microL CD N
was VBD N
lower JJR N
after IN N
priming VBG N
than IN N
before IN N
( ( N
six CD N
of IN N
35 CD N
or CC N
17 CD N
. . N

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
and CC N
crossover JJ N
design NN N
, , N
nine CD p
female NN p
and CC p
three CD p
male NN p
healthy JJ p
subjects NNS p
( ( p
age NN p
34 CD p
( ( p
sd VB p
11 CD p
) ) p
years NNS p
, , p
BMI NNP p
24.5 CD p
( ( p
sd VB p
2.5 CD p
) ) p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
with IN p
a DT p
preference NN p
for IN p
a DT p
high-fat JJ i
diet NN i
ingested VBN i
ENT NNP i
( ( p
3 CD p
x RB p
15 CD p
mg/d NN p
) ) p
or CC p
placebo NN i
( ( i
PLA NNP i
) ) i
while IN N
consuming VBG N
a DT N
high-fat JJ i
diet JJ i
ad NN i
libitum NN i
for IN i
4 CD i
d. NNS i
Eight JJ i
subjects NNS i
ended VBD i
each DT i
intervention NN i
with IN i
a DT i
36 CD i
h NN i
stay NN i
in IN i
the DT i
respiration NN i
chamber NN i
, , i
continuing VBG i
the DT i
diet JJ i
and CC i
treatment NN i
. . i

Forty-one CD p
children NNS p
and CC p
youths NNS p
between IN p
5 CD p
months NNS p
and CC p
21 CD p
years NNS p
with IN p
prior JJ p
NRTI NNP i
and CC i
no DT i
prior JJ i
NNRTI NNP i
or CC i
protease VB i
inhibitor NN i
experience NN i
received VBD i
either CC i
nelfinavir JJ i
( ( i
NFV NNP i
) ) i
30 CD i
mg/kg JJ i
twice RB i
daily RB i
( ( i
bid NN i
) ) i
, , i
ritonavir FW i
( ( i
RTV NNP i
) ) i
400 CD i
mg/m JJ i
bid NN i
and CC i
buffered VBN i
didanosine NN i
( ( i
ddI NN i
) ) i
240 CD i
mg/m JJ i
daily JJ i
( ( i
arm IN i
A NNP i
) ) i
or CC i
NFV NNP i
50-55 JJ i
mg/kg NN i
bid NN i
, , i
nevirapine NN i
( ( i
NVP NNP i
) ) i
120 CD i
mg/m JJ i
bid NN i
and CC i
stavudine NN i
( ( i
d4T NN i
) ) i
1 CD N
mg/kg JJ N
bid NN N
( ( N
arm NN N
B NNP N
) ) N
. . N

For IN N
FPV NNP N
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS N
for IN N
plasma NN N
APV NNP N
AUC NNP N
( ( N
0-tau JJ N
) ) N
, , N
C NNP N
( ( N
max NN N
) ) N
, , N
and CC N
C NNP N
( ( N
tau NN N
) ) N
were VBD N
26 CD N
, , N
48 CD N
, , N
and CC N
32 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS N
for IN N
plasma NN N
RTV NNP N
AUC NNP N
( ( N
0-tau JJ N
) ) N
, , N
C NNP N
( ( N
max NN N
) ) N
, , N
and CC N
C NNP N
( ( N
tau NN N
) ) N
increased VBD N
4.15-fold JJ N
, , N
4.17-fold JJ N
, , N
and CC N
3.99-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
to TO N
those DT N
for IN N
FPV NNP N
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
. . N

Male JJ p
Sprague-Dawley NNP p
rats NNS p
( ( p
n JJ p
= $ p
6 CD p
per IN p
group NN p
) ) p
were VBD p
housed VBN p
in IN p
photobiologic JJ i
light-exposure JJ i
chambers NNS i
configured VBD i
to TO i
create VB i
1 CD i
) ) i
a DT i
12:12-h JJ i
light NN i
: : i
dark JJ i
cycle NN i
without IN i
dark-phase JJ i
light JJ i
contamination NN i
( ( i
control JJ i
condition NN i
; : i
123 CD N
? . N
( ( N
2 CD N
) ) N
, , N
lights NNS N
on IN N
at IN N
0600 CD N
) ) N
, , N
2 CD N
) ) N
experimental NN N
exposure NN N
to TO N
a DT N
low JJ N
level NN N
of IN N
light NN N
during IN N
the DT N
12-h JJ N
dark NN N
phase NN N
( ( N
with IN N
0.02 CD N
, , N
0.05 CD N
, , N
0.06 CD N
, , N
or CC N
0.08 CD N
? . N
( ( N
2 CD N
) ) N
light NN i
at IN i
night NN i
) ) i
, , i
or CC i
3 CD i
) ) i
constant JJ i
bright JJ i
light NN i
( ( N
123 CD N
? . N
( ( N
2 CD N
) ) N
) ) N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
GH NNP N
treatment NN N
efficacy NN N
in IN N
short JJ N
SGA NNP N
children NNS N
when WRB N
treatment NN N
was VBD N
started VBN N
during IN N
adolescence NN N
; : N
to TO N
assess VB N
whether IN N
GH NNP N
2 CD N
mg/m NN N
( ( N
2 CD N
) ) N
? . N
d NN N
during IN N
puberty JJ N
improves NNS N
adult VBP N
height NN N
( ( N
AH NNP N
) ) N
compared VBN N
with IN N
1 CD N
mg/m NNS N
( ( N
2 CD N
) ) N
? . N
d NN N
; : N
and CC N
to TO N
assess VB N
whether IN N
an DT N
additional JJ N
2-yr JJ N
postponement NN N
of IN N
puberty NN N
by IN N
GnRH NNP i
analog NN i
( ( i
GnRHa NNP i
) ) i
improves VBZ N
AH NNP N
in IN N
children NNS p
who WP p
are VBP p
short JJ p
at IN p
the DT p
start NN p
of IN p
puberty NN p
( ( p
< JJ p
140 CD p
cm NN p
) ) p
, , p
with IN p
a DT p
poor JJ p
AH NNP p
expectation NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP N
in IN N
the DT N
clinical JJ o
symptom NN o
score NN o
( ( o
consisting VBG o
of IN o
the DT o
subscores NNS o
redness NN o
, , o
swelling VBG o
, , o
pain NN o
, , o
and CC o
secretion NN o
) ) o
and CC o
of IN o
the DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
rating NN o
for IN o
pain NN o
from IN N
Visit NNP N
1 CD N
( ( N
Day NNP N
1 CD N
) ) N
to TO N
Visit VB N
2 CD N
( ( N
Day NNP N
4 CD N
+/- JJ N
1 CD N
) ) N
, , N
patient NN N
's POS N
assessment NN N
of IN N
efficacy NN N
at IN N
Visit NNP N
3 CD N
( ( N
Day NNP N
10 CD N
+/- JJ N
2 CD N
) ) N
, , N
and CC N
the DT N
frequency NN o
and CC o
type NN o
of IN o
adverse JJ o
events NNS o
. . o

METHODS NNP N
Applied NNP N
with IN N
open-labeled JJ N
, , N
randomized VBN N
, , N
and CC N
clinical JJ N
trial NN N
design NN N
, , N
136 CD p
postmenopausal JJ p
women NNS p
were VBD N
assigned VBN N
into IN N
four CD N
groups NNS N
: : N
group NN N
A DT N
: : N
estradiol NN i
valerate NN i
( ( i
E2 NNP i
V NNP i
) ) i
1 CD i
mg/d NN i
+ NNP i
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
2 CD i
mg/d NN i
; : i
group NN i
B NNP i
: : i
conjugated JJ i
equine NN i
estrogen NN i
0.45 CD i
mg/d NN i
+ NNP i
MPA NNP i
2 CD i
mg/d NN i
; : i
group NN i
C NNP i
: : i
tibolone NN i
1.25 CD i
mg/d NN i
; : i
group NN i
D NNP i
: : i
a DT i
Chinese JJ i
formulated VBN i
herbs JJ i
product NN i
( ( i
Kuntai NNP i
) ) i
4 CD i
# # i
tid NN i
. . i

In IN N
this DT N
randomised VBN N
controlled VBD N
pilot JJ N
trial NN N
we PRP N
compared VBN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
a DT N
24 CD N
week NN N
with IN N
that DT N
of IN N
a DT N
48 CD N
week NN N
course NN N
of IN N
combination NN i
therapy NN i
with IN i
interferon NN i
alpha NN i
and CC i
ribavirin NN i
in IN i
interferon NN i
monotherapy NN i
relapsers NNS i
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
METHODS NNP N
Interferon NNP p
alpha NN p
monotherapy NN p
relapsers NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
were VBD N
randomised VBN N
to TO N
receive VB N
interferon NN i
alpha NN i
2b CD i
( ( i
3 CD i
x RB i
3 CD i
MIU NNP i
sc JJ i
weekly RB i
) ) i
and CC i
oral JJ i
ribavirin NN i
( ( N
1000/1200 CD N
mg NNS N
po JJ N
daily RB N
) ) N
for IN N
either DT N
24 CD N
weeks NNS N
or CC N
48 CD N
weeks NNS N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP i
significantly RB N
decreased VBD N
postprandial JJ o
glucose JJ o
area NN o
under IN o
the DT o
curve NN o
AUC NNP o
( ( N
0-2 JJ N
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN i
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

METHOD NNP N
Ten CD p
patients NNS p
with IN p
chronic JJ p
stroke NN p
( ( p
7 CD p
males NNS p
; : p
mean JJ p
age NN p
, , p
61.4+/-3.02 JJ p
years NNS p
; : p
age NN p
range NN p
, , p
48 CD p
to TO p
79 CD p
years NNS p
; : p
mean JJ p
time NN p
since IN p
stroke NN p
, , p
28.5 CD p
months NNS p
; : p
range NN p
, , p
13 CD p
to TO p
42 CD p
months NNS p
) ) p
exhibiting VBG p
stable JJ p
, , N
affected JJ N
arm NN N
motor NN N
deficits NNS N
were VBD N
administered VBN N
mCIT NN N
, , N
consisting VBG N
of IN N
: : N
( ( N
1 CD N
) ) N
structured VBD N
therapy NN N
emphasizing VBG N
affected JJ N
arm NN N
use NN N
in IN N
functional JJ N
activities NNS N
3 CD N
days/week NN N
for IN N
10 CD N
weeks NNS N
; : N
and CC N
( ( N
2 CD N
) ) N
less RBR N
affected JJ N
arm NN N
restraint NN N
5 CD N
days/week NN N
for IN N
5 CD N
hours NNS N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
comprised VBD N
120 CD p
patients NNS p
who WP p
had VBD p
ST-elevation NNP p
myocardial JJ p
infarction NN p
that WDT p
was VBD p
treated VBN p
within IN p
12 CD p
hours NNS p
from IN p
symptom JJ p
onset VBN p
with IN p
a DT p
high JJ i
dose NN i
of IN i
GIK NNP i
( ( i
25 CD i
% NN i
glucose NN i
, , i
50 CD i
IU NNP i
of IN i
soluble JJ i
insulin NN i
per IN i
liter NN i
, , i
and CC i
80 CD i
mmol NN i
of IN i
potassium NN i
chloride NN i
per IN i
liter NN i
at IN i
1 CD i
ml/kg/hour NN i
over IN i
24 CD i
hours NNS i
) ) i
as IN i
adjunct NN i
to TO i
thrombolytic JJ i
therapy NN i
( ( i
1.5 CD i
MU NNP i
of IN i
streptokinase/30 NN i
to TO i
60 CD i
minutes NNS i
; : i
GIK NNP i
group NN i
) ) i
or CC i
thrombolytic JJ i
therapy NN i
alone RB i
( ( i
control VB i
group NN i
) ) i
. . i

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ i
blockers NNS i
and CC i
high-dose JJ i
fentanyl NN i
( ( p
50 CD p
micrograms.kg-1 NN p
) ) p
, , p
40 CD p
patients NNS p
with IN p
aortic JJ p
valve NNS p
stenosis NN p
( ( p
AS IN p
) ) p
and CC p
20 CD p
patients NNS p
with IN p
aortic JJ p
insufficiency NN p
( ( p
AI NNP p
) ) p
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following NN N
: : N
( ( N
1 CD N
) ) N
pancuronium NN i
0.12 CD N
mg.kg-1 NN N
, , N
( ( N
2 CD N
) ) N
vecuronium NN N
0.12 CD N
mg.kg-1 NN N
, , N
( ( N
3 CD N
) ) N
atracurium NN i
0.4 CD i
mg.kg-1 NN i
, , i
or CC i
( ( i
4 CD i
) ) i
pancuronium-metocurine NN i
mixture NN i
( ( N
0.4 CD N
mg NN N
+ VBD N
1.6 CD N
mg/ml NN N
) ) N
: : N
1 CD N
ml/10 NNS N
kg NN N
) ) N
. . N

One CD p
hundred CD p
nineteen JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
( ( p
96 CD p
completing VBG p
six CD p
months NNS p
and CC p
92 CD p
a DT p
one CD p
year NN p
study NN p
period NN p
) ) p
were VBD p
randomized VBN p
into IN p
four CD p
parallel NN p
groups NNS p
and CC p
treated VBN p
with IN p
one CD i
of IN i
four CD i
programs NNS i
: : i
200 CD i
mg NN i
of IN i
metoprolol JJ i
plus CC i
placebo NN i
; : i
200 CD i
mg NN i
of IN i
metoprolol NN i
plus CC i
25 CD i
mg NN i
of IN i
hydrochlorothiazide NN i
; : i
200 CD i
mg NN i
of IN i
metoprolol NN i
plus CC i
50 CD i
mg NN i
hydrochlorothiazide NN i
, , i
or CC i
; : i
200 CD i
mg NN i
metoprolol NN i
plus CC i
50 CD i
mg NN i
of IN i
hydralazine NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Forty-eight NNP p
osteoporotic JJ p
patients NNS p
with IN p
prostate JJ p
cancer NN p
, , p
treated VBN p
with IN p
3-month JJ p
depot NN p
triptorelina NN p
, , p
were VBD p
enrolled VBN p
and CC p
randomly RB p
assigned VBN p
to TO p
two CD p
different JJ p
treatment NN p
groups NNS p
: : p
group NN p
A NNP p
( ( p
n JJ p
= NNP p
24 CD p
) ) p
was VBD p
treated VBN p
with IN p
a DT p
daily JJ i
calcium NN i
and CC i
cholecalciferol NN i
supplement NN i
( ( i
500 CD i
mg NN i
of IN i
elemental JJ i
calcium NN i
and CC i
400 CD i
IU NNP i
cholecalciferol NN i
) ) i
, , i
and CC i
group NN i
B NNP i
( ( i
n JJ i
= NNP i
24 CD i
) ) i
received VBN i
in IN i
addition NN i
to TO i
the DT i
same JJ i
daily JJ i
calcium NN i
and CC i
cholecalciferol NN i
supplement NN i
, , i
25 CD i
mg NN i
of IN i
neridronate JJ i
given VBN i
intramuscularly RB i
every DT i
month NN i
. . i

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
phase JJ N
3 CD N
, , N
randomised VBD N
controlled VBN N
trial NN N
conducted VBN N
in IN N
101 CD p
centres NNS p
in IN p
19 CD p
countries NNS p
, , p
we PRP p
enrolled VBD p
patients NNS p
aged VBN p
18 CD p
years NNS p
or CC p
older JJR p
with IN p
histologically RB p
or CC p
cytologically RB p
confirmed VBN p
HNSCC NNP p
that WDT p
was VBD p
recurrent NN p
, , p
metastatic JJ p
, , p
or CC p
both DT p
who WP p
had VBD p
progressed VBN p
on IN p
or CC p
after IN p
first-line JJ p
platinum-based JJ p
therapy NN p
, , p
were VBD p
not RB p
amenable JJ p
for IN p
salvage NN p
surgery NN p
or CC p
radiotherapy NN p
, , p
and CC p
who WP p
had VBD p
an DT p
Eastern JJ p
Cooperative NNP p
Oncology NNP p
Group NNP p
( ( p
ECOG NNP p
) ) p
performance NN p
status NN p
of IN p
0 CD p
or CC p
1 CD p
. . p

After IN N
premedication NN N
with IN N
0.1 CD N
mg/kg NNS N
acepromazine VBP i
intramuscularly RB N
and CC N
0.6 CD N
mg/kg NNS N
xylazine JJ i
intravenously RB N
, , N
anaesthesia NN N
was VBD N
induced VBN N
either RB N
with IN N
2 CD N
g NNS N
thiopentone NN i
in IN N
500 CD N
ml NN N
of IN N
a DT N
10 CD N
per IN N
cent NN N
guaifenesin NN i
solution NN N
, , N
given VBN N
intravenously RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
ml/kg NNS N
( ( N
group NN N
TG NNP N
) ) N
, , N
or CC N
with IN N
100 CD N
mg/kg NNS N
guaifenesin NN i
and CC N
2.2 CD N
mg/kg NN N
ketamine NN i
given VBN N
intravenously RB N
( ( N
group NN N
KG NNP N
) ) N
, , N
or CC N
with IN N
0.06 CD N
mg/kg NNS N
midazolam NN i
, , N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN i
given VBN N
intravenously RB N
( ( N
group NN N
KM NNP N
) ) N
. . N

RESULTS JJ N
Patients NNS N
with IN N
statin NN N
withdrawal NN N
showed VBD N
a DT N
higher JJR N
frequency NN o
of IN o
mRS NN o
score NN o
> VBD N
2 CD N
at IN N
the DT N
end NN N
of IN N
follow-up NN N
( ( N
60.0 CD N
% NN N
vs JJ N
39.0 CD N
% NN N
; : N
p CC N
= VB N
0.043 CD N
) ) N
, , N
END NNP N
( ( N
65.2 CD N
% NN N
vs JJ N
20.9 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
, , N
and CC N
greater JJR N
infarct NN o
volume NN o
( ( N
74 CD N
[ RB N
45 CD N
, , N
126 CD N
] NN N
vs NN N
26 CD N
[ NN N
12 CD N
, , N
70 CD N
] JJ N
mL NN N
; : N
p CC N
= VB N
0.002 CD N
) ) N
compared VBN N
with IN N
the DT N
non-statin-withdrawal JJ N
group NN N
. . N

In IN N
the DT N
risperidone NN i
group NN N
, , N
12 CD N
of IN N
19 CD N
children NNS N
showed VBD N
improvement NN N
in IN N
the DT N
total JJ o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
score NN o
and CC N
17 CD N
of IN N
19 CD N
children NNS N
in IN N
the DT N
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
score NN o
compared VBN N
with IN N
0 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
score NN N
and CC N
2 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Children NNP N
's POS N
Global NNP o
Assessment NNP o
Scale NNP o
score NN o
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
and CC N
P NNP N
= NNP N
.035 NNP N
, , N
respectively RB N
) ) N
. . N

RESULTS NNP N
Uveitis NNP o
recurrence NN o
was VBD N
reduced VBN N
in IN N
implanted JJ N
eyes NNS N
from IN N
62 CD N
% NN N
( ( N
during IN N
the DT N
1-year JJ N
preimplantation NN N
period NN N
) ) N
to TO N
4 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
during IN N
the DT N
1- JJ N
, , N
2- JJ N
, , N
and CC N
3-year JJ N
postimplantation NN N
periods NNS N
, , N
respectively RB N
, , N
for IN N
the DT N
0.59-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
from IN N
58 CD N
% NN N
to TO N
7 CD N
% NN N
, , N
17 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
2.1-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
European NNP N
and CC N
Australian NNP N
Stroke NNP N
Prevention NNP N
in IN N
Reversible NNP N
Ischaemia NNP N
Trial NNP N
( ( N
ESPRIT NNP N
) ) N
is VBZ N
a DT N
randomised JJ N
clinical JJ N
trial NN N
in IN N
which WDT N
patients NNS p
with IN p
cerebral JJ p
ischaemia NN p
of IN p
arterial JJ p
origin NN p
will MD N
be VB N
randomised VBN N
between IN N
oral JJ N
anticoagulation NN N
( ( N
international JJ N
normalized VBN N
ratio NN N
( ( N
INR NNP N
) ) N
: : N
2.0-3.0 JJ N
) ) N
, , N
the DT N
combination NN N
of IN N
acetylsalicylic JJ i
acid NN i
( ( N
in IN N
any DT N
dose NN N
between IN N
30 CD N
and CC N
325 CD N
mg NNS N
per IN N
day NN N
) ) N
plus CC N
dipyridamole JJ i
( ( N
400 CD N
mg NNS N
daily RB N
) ) N
and CC N
acetylsalicylic JJ i
acid NN i
only RB N
( ( N
in IN N
any DT N
dose NN N
between IN N
30 CD N
and CC N
325 CD N
mg NNS N
per IN N
day NN N
) ) N
. . N

Large JJ p
bleeding VBG p
gastric JJ p
varices NNS p
in IN p
20 CD p
heparinized JJ p
dogs NNS p
were VBD N
randomized VBN N
to TO N
endoscopic VB i
injection NN i
treatment NN i
with IN i
one CD i
of IN i
the DT i
following JJ i
agents NNS i
: : i
cyanoacrylate NN i
; : i
a DT i
1:1:1 CD i
mixture NN i
of IN i
sodium NN i
tetradecyl NN i
sulfate VBP i
3 CD i
% NN i
, , i
ethanol RB i
98 CD i
% NN i
, , i
and CC i
normal JJ i
saline JJ i
solution NN i
; : i
ethanolamine VB i
oleate VBP i
5 CD i
% NN i
; : i
sodium NN i
morrhuate VBP i
5 CD i
% NN i
; : i
sodium NN i
tetradecyl NN i
sulfate VBP i
1.5 CD i
% NN i
; : i
polidocanol CC i
1 CD i
% NN i
; : i
normal JJ i
saline JJ i
solution NN i
with IN i
epinephrine JJ i
1:10,000 CD i
; : i
or CC i
normal JJ i
saline JJ i
solution NN i
( ( i
control NN i
) ) i
. . i

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
9-month JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
losartan NN i
( ( N
25 CD N
mg NN N
; : N
n CC N
= VB N
18 CD N
) ) N
versus NN N
enalapril NN i
( ( N
10 CD N
mg NN N
; : N
n CC N
= VB N
18 CD N
) ) N
versus IN N
the DT N
combination NN N
of IN N
losartan NN i
( ( N
25 CD N
mg NN N
) ) N
and CC N
enalapril $ i
( ( N
10 CD N
mg NN N
) ) N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
on IN N
proteinuria NN N
, , N
kidney NN N
function NN N
and CC N
metabolic JJ N
profile NN N
in IN N
54 CD p
patients NNS p
with IN p
biopsy-proven JJ p
chronic JJ p
glomerulonephritis NN p
, , p
hypertension NN p
and CC p
normal JJ p
or CC p
slightly RB p
impaired JJ p
kidney NN p
function NN p
. . p

Compared VBN N
with IN N
placebo NN i
, , i
conivaptan NN i
at IN N
20 CD N
and CC N
40 CD N
mg NN N
significantly RB N
reduced VBD N
pulmonary JJ o
capillary JJ o
wedge NN o
pressure NN o
( ( N
-2.6+/-0.7 UH N
, , N
-5.4+/-0.7 NNP N
, , N
and CC N
-4.6+/-0.7 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN N
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
right JJ o
atrial JJ o
pressure NN o
( ( N
-2.0+/-0.4 UH N
, , N
-3.7+/-0.4 NNP N
, , N
and CC N
-3.5+/-0.4 NNP N
mm VBP N
Hg NNP N
for IN N
placebo NN i
and CC N
20 CD N
and CC N
40 CD N
mg NN N
groups NNS N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
3- JJ N
to TO N
6-hour JJ N
interval NN N
after IN N
intravenous JJ N
administration NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
Randomized NNP N
controlled VBD N
multicenter RBR N
Trial NNP N
of IN N
Intensified NNP i
vs FW i
Standard NNP i
Medical NNP i
Therapy NNP i
in IN N
Elderly JJ p
Patients NNS p
With IN p
Congestive NNP p
Heart NNP p
Failure NNP p
( ( p
TIME-CHF NNP p
) ) p
of IN p
499 CD p
patients NNS p
aged VBN p
60 CD p
years NNS p
or CC p
older JJR p
with IN p
systolic JJ p
heart NN p
failure NN p
( ( p
ejection NN p
fraction NN p
< NN p
or CC p
= VB p
45 CD p
% NN p
) ) p
, , p
New NNP p
York NNP p
Heart NNP p
Association NNP p
( ( p
NYHA NNP p
) ) p
class NN p
of IN p
II NNP p
or CC p
greater JJR p
, , p
prior JJ p
hospitalization NN p
for IN p
heart NN p
failure NN p
within IN p
1 CD p
year NN p
, , p
and CC p
N-terminal JJ p
BNP NNP p
level NN p
of IN p
2 CD p
or CC p
more JJR p
times NNS p
the DT p
upper JJ p
limit NN p
of IN p
normal JJ p
. . p

METHODS NNP N
Diagnosed VBD p
hypertensive JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
RCT NNP N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
: : N
( ( i
1 CD i
) ) i
the DT i
intervention NN i
condition NN i
-- : i
Web-based JJ i
hypertension NN i
feedback NN i
, , i
based VBN i
on IN i
the DT i
individual JJ i
patient NN i
's POS i
self-report NN i
of IN i
health NN i
variables NNS i
and CC i
previous JJ i
BP NNP i
measurements NNS i
, , i
to TO i
prompt VB i
them PRP i
to TO i
ask VB i
questions NNS i
during IN i
their PRP$ i
next JJ i
physician NN i
's POS i
visit NN i
about IN i
hypertension NN i
care NN i
( ( i
2 CD i
) ) i
the DT i
control NN i
condition NN i
-- : i
Web-based JJ i
preventive JJ i
health NN i
feedback NN i
, , i
based VBN i
on IN i
the DT i
individual NN i
's POS i
self-report NN i
of IN i
receiving VBG i
preventive JJ i
care NN i
( ( i
e.g UH i
, , i
pap JJ i
testing VBG i
) ) i
, , i
to TO i
prompt VB i
them PRP i
to TO i
ask VB i
questions NNS i
during IN i
their PRP$ i
next JJ i
physician NN i
's POS i
visit NN i
about IN i
preventive JJ i
care NN i
. . i

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ o
blood NN o
saturation NN o
levels NNS o
and CC o
decreased VBD o
blood NN o
pressure NN o
, , o
pulse NN o
and CC o
respiration NN o
? . o
( ( o
2 CD o
) ) o
What WP o
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ p
patients NNS p
with IN p
unilateral JJ p
lung NN p
pathology NN p
were VBD p
positioned VBN i
on IN i
their PRP$ i
sides NNS i
with IN i
the DT i
unaffected JJ i
lung NN i
down RP i
, , i
on IN i
their PRP$ i
sides NNS i
with IN i
the DT i
affected JJ i
lung NN i
down RB i
, , i
and CC i
also RB i
in IN i
semi-Fowler NN i
's POS i
position NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Peak NNP o
E NNP o
( ( o
2 CD o
) ) o
levels NNS o
, , o
days NNS o
of IN o
stimulation NN o
with IN o
rFSH NN o
, , o
total JJ o
rFSH NN o
dosage NN o
, , o
total JJ o
number NN o
of IN o
oocytes NNS o
retrieved VBN o
, , o
M2 NNP o
oocytes VBZ o
retrieved VBN o
, , o
total JJ o
number NN o
of IN o
embryos NN o
, , o
number NN o
of IN o
embryos NN o
transferred VBN o
, , o
number NN o
of IN o
Grade-1 NNP o
embryos NN o
transferred VBD o
, , o
clinical JJ o
pregnancy NN o
rate NN o
( ( o
positive JJ o
fetal JJ o
cardiac JJ o
activity NN o
) ) o
, , o
and CC o
cancellation NN o
rates NNS o
of IN o
stimulation NN o
and CC o
embryo NN o
transfer NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
shortened JJ N
postpartum NN N
course NN N
of IN N
magnesium NN i
sulphate NN i
is VBZ N
as RB N
effective JJ N
as IN N
the DT N
standard JJ N
Pritchard NNP N
regimen NN N
in IN N
controlling VBG N
fits NNS N
in IN N
eclampsia NN p
Between NNP p
January NNP p
and CC p
June NNP p
2011 CD p
, , p
98 CD p
eclamptic JJ p
mothers NNS p
presenting VBG p
at IN p
the DT p
labour JJ p
ward NN p
of IN p
the DT p
University NNP p
of IN p
Maiduguri NNP p
Teaching NNP p
Hospital NNP p
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
the DT N
standard JJ i
Pritchard NNP i
regimen NN i
of IN i
magnesium NN i
sulphate NN i
or CC i
a DT i
shortened JJ i
postpartum NN i
course NN i
in IN i
which WDT i
only RB i
two CD i
doses NNS i
of IN i
intramuscular JJ i
magnesium NN i
sulphate NN i
is VBZ N
given VBN N
four CD N
hours NNS N
apart RB N
. . N

This DT N
hypothesis NN N
has VBZ N
now RB N
received VBN N
strong JJ N
support NN N
and CC N
is VBZ N
currently RB N
based VBN N
on IN N
three CD N
types NNS N
of IN N
arguments NNS N
: : N
( ( N
1 CD N
) ) N
similarity NN N
between IN N
autistic JJ N
symptomatology NN N
and CC N
abnormal JJ N
behaviors NNS N
induced VBD N
in IN N
young JJ N
animals NNS N
by IN N
injections NNS N
of IN N
exogenous JJ N
opioids NNS N
, , N
such JJ N
as IN N
increasing VBG N
social JJ N
aloofness NN N
and CC N
decreasing VBG N
social JJ N
vocalization NN N
; : N
( ( N
2 CD N
) ) N
direct JJ N
biochemical JJ N
evidence NN N
of IN N
abnormalities NNS N
of IN N
peripheral JJ N
endogenous JJ N
opioids NNS N
being VBG N
reported VBN N
in IN N
autism NN N
and CC N
( ( N
3 CD N
) ) N
therapeutic JJ N
effects NNS N
of IN N
the DT N
long JJ N
lasting NN N
opioid JJ N
receptor NN N
blocking VBG N
agent NN N
naltrexone NN N
in IN N
autism NN N
. . N

The DT N
participants NNS N
consisted VBD N
of IN N
60 CD p
unfit JJ p
male NN p
university NN p
undergraduate JJ p
students NNS p
with IN p
no DT i
previous JJ i
training NN i
in IN i
stress JJ i
management NN i
who WP i
were VBD i
randomly RB i
and CC i
evenly RB i
assigned VBD i
to TO i
engage VB i
in IN i
one CD i
of IN i
four CD i
treatments NNS i
over IN i
10 CD i
weeks NNS i
: : i
( ( i
a DT i
) ) i
moderate NN i
aerobic JJ i
exercise NN i
, , i
( ( i
b NN i
) ) i
progressive NN i
relaxation NN i
, , i
( ( i
c NN i
) ) i
a DT i
placebo NN i
group NN i
that WDT i
engaged VBD i
in IN i
group NN i
discussion NN i
but CC i
did VBD i
experience VB i
acute NN i
stress NN i
, , i
and CC i
( ( i
d NN i
) ) i
a DT i
nonintervention NN i
control NN i
group NN i
that WDT i
did VBD i
not RB i
experience VB i
stress NN i
while IN i
performing VBG i
the DT i
motor NN i
task NN i
. . i

METHOD NNP N
This DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , p
relapse-prevention JJ p
trial NN p
enrolled VBD p
patients NNS p
( ( p
6-17 CD p
years NNS p
) ) p
who WP p
met VBD p
the DT p
current JJ p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
( ( p
DMS-IV-TR NNP p
) ) p
criteria NN p
for IN p
autistic JJ p
disorder NN p
and CC p
who WP p
also RB p
had VBD p
serious JJ p
behavioral JJ p
problems NNS p
( ( p
ie VB p
, , p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
behavioral JJ p
problems NNS p
) ) p
between IN p
March NNP p
2011 CD p
and CC p
June NNP p
2012 CD p
. . p

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
number NN o
of IN o
painful JJ o
joints NNS o
and CC o
swollen JJ o
joints NNS o
, , o
joint JJ o
pain NN o
and CC o
joint JJ o
swelling NN o
indices NNS o
, , o
left VBD o
and CC o
right JJ o
grip NN o
strength NN o
, , o
investigator NN o
global JJ o
assessment NN o
, , o
and CC o
patient JJ o
global JJ o
assessment NN o
returned VBD N
to TO N
baseline VB N
for IN N
the DT N
amiprilose JJ N
group NN N
and CC N
showed VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
differences NNS N
from IN N
the DT N
placebo NN N
group NN N
within IN N
4 CD N
to TO N
6 CD N
weeks NNS N
. . N

FINDINGS NNP N
( ( N
1 CD N
) ) N
The DT N
a DT N
priori JJ N
matching NN N
hypothesis NN N
that IN N
TSF NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
MET NNP N
for IN N
clients NNS o
with IN o
networks NNS o
supportive NN o
of IN o
drinking NN o
was VBD N
supported VBN N
at IN N
the DT N
3 CD N
year NN N
follow-up NN N
; : N
( ( N
2 CD N
) ) N
AA NNP N
involvement NN N
was VBD N
a DT N
partial JJ N
mediator NN N
of IN N
this DT N
effect NN N
; : N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
assigned VBN N
to TO N
TSF VB N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
involved VBN N
in IN N
AA NNP o
; : o
AA NNP o
involvement NN o
was VBD N
associated VBN N
with IN N
better JJR N
3-year JJ N
drinking NN N
outcomes NNS N
for IN N
such JJ N
clients NNS N
. . N

RESULTS NNP N
sCD44v6 NN N
was VBD N
significantly RB N
positive JJ N
correlated VBN N
with IN N
the DT N
degree NN o
of IN o
cancer NN o
cell NN o
differentiation NN o
, , o
infiltration NN o
and CC o
lymph NN o
node JJ o
metastasis NN o
; : o
( ( o
2 CD o
) ) o
Level NN o
of IN o
sCD44v6 NN o
was VBD N
the DT N
highest JJS N
in IN N
patients NNS N
of IN N
blood NN N
stasis NN N
type NN N
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
patients NNS N
of IN N
Pi-deficiency NNP N
type NN N
or CC N
of IN N
damp-heat JJ N
type NN N
, , N
the DT N
difference NN N
was VBD N
significant JJ N
; : N
( ( N
3 CD N
) ) N
After IN N
ending VBG N
treatment NN N
, , N
level NN o
of IN o
sCD44v6 NN o
in IN N
the DT N
trial NN N
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

To TO p
be VB p
eligible JJ p
for IN p
inclusion NN p
, , p
women NNS p
had VBD p
to TO p
be VB p
( ( p
i NN p
) ) p
under IN p
26 CD p
years NNS p
old JJ p
, , p
( ( p
ii NN p
) ) p
less JJR p
that IN p
27 CD p
weeks NNS p
pregnant JJ p
, , p
( ( p
iii NN p
) ) p
sufficiently RB p
fluent VBN p
in IN p
French JJ p
to TO p
give VB p
truly NN p
informed JJ p
consent NN p
to TO p
participate VB p
in IN p
the DT p
study NN p
and CC p
benefit NN p
from IN p
the DT p
intervention NN p
and CC p
( ( p
iv NN p
) ) p
presenting VBG p
with IN p
one CD p
or CC p
more JJR p
of IN p
the DT p
following JJ p
social JJ p
vulnerability NN p
factors NNS p
: : p
low JJ p
income NN p
, , p
low JJ p
educational JJ p
level NN p
, , p
and/or RB p
intending VBG p
to TO p
bring VB p
up RP p
the DT p
child NN p
without IN p
the DT p
child NN p
's POS p
father NN p
. . p

RESULTS VB N
The DT N
fundamental JJ N
conclusions NNS N
of IN N
the DT N
primary JJ N
analysis NN N
were VBD N
confirmed VBN N
in IN N
that DT N
there EX N
was VBD N
no DT N
survival JJ o
benefit NN o
overall JJ o
for IN N
patients NNS N
with IN N
1 CD N
to TO N
3 CD N
metastases NNS N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
benefit NN N
for IN N
the DT N
subset NN N
of IN N
patients NNS N
with IN N
GPA NNP N
3.5 CD N
to TO N
4.0 CD N
( ( N
median JJ N
survival NN o
time NN o
[ NNP o
MST NNP o
] NNP o
for IN o
WBRT NNP o
+ NNP o
SRS NNP o
vs FW N
WBRT NNP N
alone RB N
was VBD N
21.0 CD N
versus NN N
10.3 CD N
months NNS N
, , N
P=.05 NNP N
) ) N
regardless NN N
of IN N
the DT N
number NN N
of IN N
metastases NNS N
. . N

Four CD N
different JJ N
methods-microscopy NN N
of IN N
Gram NNP o
stained VBD o
mucosal JJ o
smear NN o
, , o
specific JJ o
culture NN o
, , o
biopsy NN o
urease JJ o
test NN o
, , o
histology NN o
of IN o
H NNP o
& CC o
E NNP o
staining-were JJ o
taken VBN o
for IN N
identifying VBG N
colonization NN N
of IN N
H. NNP N
pylori NN N
before IN N
treatment NN N
, , N
and CC N
for IN N
finding VBG N
the DT N
eradication NN N
of IN N
H. NNP N
pylori FW N
4 CD N
weeks NNS N
after IN N
completion NN N
of IN N
therapy NN N
in IN N
each DT N
treatment NN N
group NN N
( ( N
cometidine NN i
, , i
omeprazole NN i
, , i
colloidal JJ i
bismuth NN i
subcitrate NN i
( ( i
CBS NNP i
) ) i
, , i
CBS NNP i
and CC i
metronidazole JJ i
double JJ i
therapy NN i
, , i
CBS NNP i
, , i
metronidazole NN i
and CC i
amoxicillin JJ i
triple JJ i
therapy NN i
) ) i
. . N

The DT N
factorial JJ N
analysis NN N
showed VBD N
that IN N
both DT N
1000 CD N
mg NN N
acetaminophen NN i
and CC N
60 CD N
mg NN N
codeine NN i
made VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
contribution NN N
to TO N
the DT N
analgesic JJ N
effectiveness NN N
of IN N
the DT N
combination NN N
on IN N
all DT N
measures NNS N
of IN N
efficacy NN o
( ( o
sum NN o
of IN o
pain NN o
intensity NN o
differences NNS o
, , o
largest JJS o
pain NN o
intensity NN o
difference NN o
, , o
total JJ o
pain NN o
relief NN o
, , o
largest JJS o
pain NN o
relief NN o
, , o
and CC o
time NN o
to TO o
remedication NN o
) ) o
. . o

PARTICIPANTS NNS N
Two CD p
hundred VBD p
thirty-eight JJ p
elderly JJ p
men NNS p
and CC p
women NNS p
aged VBD p
60 CD p
to TO p
80 CD p
at IN p
high JJ p
risk NN p
for IN p
cardiovascular JJ p
disease NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
interventional JJ N
groups NNS N
: : N
a DT N
recommended JJ i
low-fat JJ i
diet NN i
( ( i
control VB i
diet JJ i
group NN i
) ) i
, , i
a DT i
Mediterranean NNP i
diet NN i
supplemented VBD i
with IN i
virgin JJ i
olive JJ i
oil NN i
, , i
or CC i
a DT i
Mediterranean NNP i
diet NN i
supplemented VBD i
with IN i
mixed JJ i
nuts NNS i
. . i

MATERIAL NNP N
AND NNP N
METHODS NNP N
Using NNP N
impressions NNS N
made VBD N
from IN N
a DT N
stainless JJ N
steel NN N
complete-crown JJ N
master NN N
die NN N
, , N
9 CD p
stone NN p
cast NN p
replicas NN p
were VBD p
fabricated VBN p
, , p
numbered VBN p
, , p
and CC p
distributed VBD p
into IN p
8 CD p
ceramic JJ p
ZrO NNP p
( ( p
2 CD p
) ) p
CAD/CAM NNP p
system NN p
groups NNS p
( ( p
Lava NNP p
Frame NNP p
0.3 CD p
and CC p
0.5 CD p
, , p
IPS NNP p
e.max VBZ p
ZirCAD NNP p
, , p
VITA NNP p
YZ NNP p
, , p
Procera NNP p
AllZircon NNP p
, , p
Digizon NNP p
, , p
DC NNP p
Zircon NNP p
, , p
and CC p
Cercon NNP p
Base NNP p
) ) p
and CC p
to TO p
a DT p
lithium NN p
disilicate JJ p
glass-ceramic JJ p
control NN p
group NN p
( ( p
IPS NNP p
e.max RB p
Press NNP p
) ) p
using VBG p
a DT p
simple JJ p
computer-generated JJ p
randomization NN p
method NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
indices NNS o
were VBD N
evaluated VBN N
at IN N
the DT N
baseline NN N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
, , N
including VBG N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
, , o
condition NN o
assessment NN o
, , o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
, , o
disease NN o
activity NN o
index NN o
28 CD o
( ( o
DAS28 NNP o
) ) o
, , o
laboratory JJ o
parameters NNS o
of IN o
erythrocyte JJ o
sedimentation NN o
rate NN o
( ( o
ESR NNP o
) ) o
and CC o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
safety NN o
indicators NNS o
, , o
and CC o
Chinese NNP o
medical JJ o
syndrome NN o
integrals NNS o
. . o

PURPOSE VB N
The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
the DT N
following JJ N
: : N
1 CD N
) ) N
to TO N
examine VB N
patterns NNS N
of IN N
adherence NN i
to TO i
a DT i
brisk JJ i
walking VBG i
program NN i
in IN N
women NNS p
receiving VBG p
adjuvant JJ p
chemotherapy NN p
or CC p
radiation NN p
therapy NN p
for IN p
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
using VBG N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
experimental JJ N
design NN N
; : N
2 CD N
) ) N
to TO N
examine VB N
the DT N
influence NN N
of IN N
disease NN N
symptoms NNS N
and CC N
treatment NN N
side NN N
effects NNS N
on IN N
exercise NN N
levels NNS N
; : N
and CC N
3 CD N
) ) N
to TO N
suggest VB N
methods NNS N
that WDT N
may MD N
improve VB N
future NN N
clinical JJ N
trials NNS N
of IN N
moderate-intensity NN N
exercise NN N
in IN N
similar JJ N
populations NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Roland NNP o
adaptation NN o
of IN o
the DT o
Sickness NNP o
Impact NNP o
Profile NNP o
, , o
visual JJ o
analogue NN o
pain NN o
scale NN o
, , o
health NN o
status NN o
scale NN o
, , o
EuroQol NNP o
, , o
use NN o
of IN o
primary JJ o
and CC o
secondary JJ o
care NN o
services NNS o
, , o
and CC o
physical JJ o
and CC o
complementary JJ o
therapies NNS o
, , o
sickness JJ o
absence NN o
, , o
medication NN o
use NN o
, , o
patient JJ o
satisfaction NN o
, , o
reassurance NN o
and CC o
belief NN o
in IN o
value NN o
of IN N
radiography NN N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
post-randomisation NN N
. . N

To TO N
characterize VB N
the DT N
time NN N
course NN N
of IN N
plasma NN N
and CC N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
changes NNS N
after IN N
n-3 JJ N
polyunsaturated JJ i
fatty JJ i
acid NN i
( ( i
PUFA NNP i
) ) i
supplementation NN N
, , N
20 CD p
healthy JJ p
male NN p
volunteers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
four CD i
1-g JJ i
capsules NNS i
of IN i
n-3 JJ i
PUFA NNP i
ethyl NN i
esters NNS i
or CC i
four CD i
1-g JJ i
capsules NNS i
of IN i
olive JJ i
oil NN i
( ( i
as IN i
placebo NN i
) ) i
for IN i
a DT i
period NN i
of IN i
4 CD i
mo NN i
, , i
followed VBN i
by IN i
a DT i
3-mo JJ i
washout NN i
period NN i
. . i

OBJECTIVE IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP N
formulations NNS N
( ( N
one CD N
reconstituted VBN N
with IN N
5 CD N
mL NNS N
of IN N
sterile JJ i
water NN i
, , i
the DT i
other JJ i
reconstituted VBD i
with IN i
4 CD i
mL NNS i
sodium JJ i
chloride RB i
0.9 CD i
% NN i
USP NNP i
) ) i
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ i
, , i
full-length JJ i
FVIII NNP i
preparation NN i
( ( i
Hemofil NNP i
M NNP i
) ) i
in IN N
patients NNS p
with IN p
haemophilia PDT p
A DT p
to TO p
determine VB p
bioequivalence NN p
. . p

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multi-centre JJ N
randomised JJ N
2 CD N
x JJ N
2 CD N
factorial JJ N
design NN N
study NN N
evaluating VBG N
two CD N
independent JJ N
variables NNS N
of IN N
VP NNP N
design NN N
, , N
branching NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
, , N
and CC N
structured VBD N
clinical JJ N
reasoning NN N
feedback NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
.The NN N
study NN N
will MD N
be VB N
carried VBN N
out RP N
in IN N
medical JJ p
student NN p
volunteers NNS p
in IN p
one CD p
year NN p
group NN p
from IN p
three CD p
university NN p
medical JJ p
schools NNS p
in IN p
the DT p
United NNP p
Kingdom NNP p
, , p
Warwick NNP p
, , p
Keele NNP p
and CC p
Birmingham NNP p
. . p

Magnetic JJ N
resonance NN N
spectroscopy NN N
was VBD N
used VBN N
as IN N
a DT N
means NN N
of IN N
predicting VBG N
the DT N
probability NN N
of IN N
developing VBG N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
in IN N
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
secondary JJ p
to TO p
chronic VB p
hepatitis NN p
B.This NNP p
study NN p
included VBD p
20 CD p
healthy JJ p
volunteers NNS p
, , p
20 CD p
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
secondary JJ p
to TO p
chronic VB p
hepatitis NN p
B NNP p
( ( p
cirrhosis NN p
group NN p
) ) p
, , p
and CC p
20 CD p
patients NNS p
with IN p
small JJ p
HCC NNP p
secondary JJ p
to TO p
cirrhosis VB p
liver RB p
parenchyma NN p
( ( p
HCC NNP p
group NN p
) ) p
. . p

OBJECTIVES NN N
To TO N
( ( N
1 CD N
) ) N
determine VB N
the DT N
efficacy NN N
of IN N
venlafaxine NN i
XR NN i
for IN N
the DT N
treatment NN N
of IN N
pain NN N
( ( N
secondary JJ N
aim NN N
) ) N
in IN N
individuals NNS p
with IN p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
enrolled VBD p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
( ( p
RCT NNP p
) ) p
on IN p
the DT p
efficacy NN p
of IN p
venlafaxine NN i
XR NN i
for IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
( ( p
primary JJ p
aim NN p
) ) p
; : p
and CC p
( ( p
2 CD p
) ) p
test NN N
the DT N
hypothesis NN N
that WDT N
venlafaxine NN i
XR NNP i
would MD N
be VB N
effective JJ N
for IN N
both DT N
neuropathic JJ N
and CC N
nociceptive JJ N
pain NN N
. . N

Data NNS N
from IN N
2 CD N
separate JJ N
multicenter NN N
, , N
double-blind JJ N
clinical JJ N
studies NNS N
following VBG N
the DT N
same JJ N
protocol NN N
, , N
except IN N
for IN N
the DT N
selection NN N
of IN N
doses NNS N
, , N
were VBD N
pooled VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
fixed JJ N
doses NNS N
of IN N
a DT N
new JJ N
sustained-release NN N
( ( N
SR NNP N
) ) N
formulation NN N
of IN N
nifedipine JJ i
compared VBN N
with IN N
placebo NN i
in IN N
388 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
uncomplicated JJ p
essential JJ p
hypertension NN p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
age NN o
, , o
peak JJ o
serum NN o
E NNP o
( ( o
2 CD o
) ) o
concentration NN o
, , o
days NNS o
of IN o
stimulation NN o
with IN o
rFSH NN o
, , o
total JJ o
number NN o
of IN o
M2 NNP o
oocytes VBZ o
retrieved VBN o
, , o
number NN o
of IN o
embryos NN o
transferred VBN o
, , o
clinical JJ o
pregnancy NN o
rates NNS o
, , o
and CC o
cancellation NN o
rates NNS o
of IN o
stimulation NN o
and CC o
embryo NN o
transfer NN o
between IN N
the DT N
three CD N
groups NNS N
except IN N
for IN N
total JJ N
rFSH JJ N
dosage NN N
. . N

Three CD p
groups NNS p
of IN p
unimpaired JJ p
participants NNS p
trained VBN p
with IN p
the DT p
target NN p
arm JJ p
movement NN p
broken VBD p
down RB p
in IN p
three CD p
ways NNS p
: : p
1 CD p
) ) p
elbow NN i
flexion/extension NN i
and CC i
the DT i
unified JJ i
shoulder NN i
motion NN i
independently RB i
( ( i
anatomical JJ i
decomposition NN i
) ) i
, , i
2 CD i
) ) i
three CD i
component JJ i
shoulder NN i
motions NNS i
in IN i
Euler NNP i
coordinates NNS i
and CC i
elbow JJ i
flexion/extension NN i
( ( i
Euler NNP i
decomposition NN i
) ) i
, , i
or CC i
3 CD i
) ) i
the DT i
motion NN i
of IN i
the DT i
tip NN i
of IN i
the DT i
elbow NN i
and CC i
motion NN i
of IN i
the DT i
hand NN i
with IN i
respect NN i
to TO i
the DT i
elbow NN i
, , i
independently RB i
( ( i
visual JJ i
decomposition NN i
) ) i
. . i

METHODS NNP N
AND CC N
FINDINGS NNP N
During IN N
18 CD N
y NNS N
of IN N
follow-up NN N
of IN N
14,916 CD p
men NNS p
initially RB p
free JJ p
of IN p
diagnosed JJ p
cancer NN p
, , p
we PRP p
identified VBD p
1,066 CD p
men NNS p
with IN p
incident JJ p
prostate NN p
cancer NN p
( ( p
including VBG p
496 CD p
with IN p
aggressive JJ p
disease NN p
, , p
defined VBD p
as IN p
stage NN p
C NNP p
or CC p
D NNP p
, , p
Gleason NNP p
7-10 CD p
, , p
metastatic JJ p
, , p
and CC p
fatal JJ p
prostate NN p
cancer NN p
) ) p
and CC p
1,618 CD p
cancer-free JJ p
, , p
age- JJ p
and CC p
smoking-matched JJ p
control NN p
participants NNS p
in IN p
the DT p
Physicians NNPS p
' POS p
Health NNP p
Study NNP p
. . p

PURPOSE NN N
This DT N
randomized VBN N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD i
communication NN i
interventions NNS i
( ( i
Responsive JJ i
Education NN i
and CC i
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
[ NNP i
RPMT NNP i
] NNP i
and CC i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
) ) i
on IN N
spoken JJ N
communication NN N
in IN N
36 CD p
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
measure VB N
the DT N
degree NN o
of IN o
anesthesia NN o
following VBG N
the DT N
administration NN N
of IN N
3.6 CD N
ml NN N
of IN N
2 CD N
% NN N
lidocaine JJ i
solutions NNS N
with IN N
either DT N
1:50,000 CD N
, , N
1:80,000 CD N
, , N
or CC N
1:100,000 CD N
for IN N
inferior JJ N
alveolar JJ N
nerve NN N
block NN N
and CC N
to TO N
compare VB N
the DT N
results NNS N
with IN N
those DT N
obtained VBN N
following VBG N
the DT N
administration NN N
of IN N
1.8 CD N
ml NN N
of IN N
the DT N
same JJ N
solutions NNS N
( ( N
1 CD N
) ) N
. . N

Most JJS N
cases NNS N
initially RB N
experienced VBD N
bleeding NN o
in IN N
the DT N
first JJ N
3 CD N
months NNS N
but CC N
such JJ N
initiation NN N
was VBD N
a DT N
bit NN N
later RB N
in IN N
group NN N
C. NNP N
Endometrium NNP o
, , N
as IN N
detected VBN N
by IN N
B-mode NNP N
ultrasound NN N
, , N
increased VBD N
approximately RB N
1 CD N
mm NNS N
in IN N
HT NNP N
groups NNS N
, , N
while IN N
it PRP N
was VBD N
a DT N
bit NN N
thicker NN N
in IN N
group NN N
C. NNP N
Long NNP N
periods NNS N
in IN N
reproductive JJ N
age NN N
and CC N
short JJ N
time NN N
since IN N
menopause NN N
were VBD N
high JJ N
risk NN N
factors NNS N
for IN N
irregular JJ o
bleeding NN o
. . o

The DT N
effects NNS N
on IN N
behavior NN N
of IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
sulforaphane NN i
( ( N
50-150 JJ N
? . N
) ) N
for IN N
18 CD N
wk NN N
, , N
followed VBN N
by IN N
4 CD N
wk NNS N
without IN N
treatment NN N
, , N
were VBD N
quantified VBN N
by IN N
three CD N
widely RB N
accepted VBD N
behavioral JJ N
measures NNS N
completed VBN N
by IN N
parents/caregivers NNS N
and CC N
physicians NNS N
: : N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
and CC o
Clinical NNP o
Global NNP o
Impression NNP o
Improvement NNP o
Scale NNP o
( ( o
CGI-I NNP o
) ) o
. . o

CONCLUSIONS NNP N
This DT N
secondary JJ N
analysis NN N
of IN N
predominantly RB N
lung JJ N
cancer NN N
patients NNS N
, , N
consistent JJ N
with IN N
the DT N
original JJ N
analysis NN N
, , N
shows VBZ N
no DT N
survival JJ o
advantage NN o
for IN N
the DT N
group NN N
overall JJ N
when WRB N
treated VBN N
with IN N
WBRT NNP N
and CC N
SRS NNP N
; : N
however RB N
, , N
in IN N
patients NNS N
with IN N
high JJ N
GPA NNP N
( ( N
3.5-4 JJ N
) ) N
, , N
there EX N
is VBZ N
a DT N
survival JJ o
advantage NN o
regardless NN N
of IN N
whether IN N
they PRP N
have VBP N
1 CD N
, , N
2 CD N
, , N
or CC N
3 CD N
BM NNP N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effect NN N
of IN N
granisetron NN N
injection NN N
at IN N
a DT N
dose NN N
of IN N
40 CD N
microg/kg NNS N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
nausea/vomiting VBG N
induced VBN N
by IN N
multidrug NN i
combined VBN i
cancer NN i
chemotherapy NN i
excluding VBG i
cisplatin NN i
in IN N
patients NNS p
with IN p
tumors NNS p
of IN p
hematopoietic JJ p
organs NNS p
was VBD N
evaluated VBN N
by IN N
comparing VBG N
a DT N
30-min JJ N
infusion NN N
and CC N
a DT N
slow JJ N
intravenous JJ N
injection NN N
given VBN N
over IN N
30 CD N
s. JJ N
METHODS NNP N
A DT N
two-group JJ N
random-allocation NN N
comparative NN N
study NN N
was VBD N
performed VBN N
with IN N
the DT N
cooperation NN N
of IN N
multiple JJ N
institutions NNS N
using VBG N
a DT N
central JJ N
registration NN N
system NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
( ( N
1 CD N
) ) N
to TO N
assess VB N
baseline JJ N
echocardiographic JJ N
predictors NNS N
of IN N
clinical JJ N
outcome NN N
, , N
( ( N
2 CD N
) ) N
to TO N
investigate VB N
changes NNS N
in IN N
echocardiographic JJ N
parameters NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
to TO N
compare VB N
these DT N
echocardiographic JJ N
changes NNS N
with IN N
changes NNS N
in IN N
plasma NN o
levels NNS o
of IN o
b-type JJ o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
in IN N
a DT N
population NN p
of IN p
children NNS p
with IN p
systemic JJ p
ventricular JJ p
dysfunction NN p
and CC p
symptomatic JJ p
heart NN p
failure NN p
treated VBN p
with IN p
carvedilol NN i
or CC i
placebo NN i
. . i

Whereas NNP N
standard JJ N
laboratory NN N
tests NNS N
of IN N
coagulation NN N
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
von FW o
Willebrand NNP o
factor NN o
activity NN o
on IN N
the DT N
first JJ N
postoperative JJ N
morning NN N
tended VBD N
to TO N
be VB N
higher JJR N
following VBG N
treatment NN N
with IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
P=0.025 NNP N
) ) N
with IN N
this DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
only RB N
in IN N
the DT N
per-protocol JJ N
analysis NN N
( ( N
P=0.02 NNP N
) ) N
. . N

In IN N
order NN N
to TO N
assess VB N
if IN N
the DT N
use NN N
of IN N
the DT N
laryngeal JJ N
mask NN N
airway NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
gastric JJ N
regurgitation NN N
during IN N
mechanical JJ N
ventilation NN N
, , N
we PRP N
studied VBD N
50 CD p
patients NNS p
allocated VBD p
randomly RB p
to TO p
undergo VB p
anaesthesia NN p
with IN p
either DT p
artificial JJ i
ventilation NN i
with IN i
isoflurane NN i
and CC i
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
and CC i
atracurium NN i
( ( i
group NN i
A NNP i
) ) i
or CC i
spontaneous JJ i
ventilation NN i
with IN i
isoflurane NN i
and CC i
nitrous JJ i
oxide NN i
in IN i
oxygen NN i
( ( i
group NN i
B NNP i
) ) i
. . i

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
protocols NNS N
with IN N
the DT N
aim NN N
of IN N
remineralising VBG N
the DT N
lesions NNS N
: : N
A DT N
) ) N
daily RB N
topical JJ i
applications NNS i
of IN i
a DT i
dental JJ i
cream NN i
containing VBG i
CPP-ACP NNP i
( ( i
Topacal NNP i
) ) i
for IN N
3 CD N
months NNS N
followed VBN N
by IN N
a DT N
3-month JJ N
period NN N
of IN N
daily JJ N
toothbrushing VBG N
with IN N
fluoridated JJ N
dentifrice NN N
, , N
or CC N
B NNP N
) ) N
daily RB N
0.05 CD N
% NN N
sodium NN i
fluoride NN i
mouthwash NN i
combined VBN i
with IN i
fluoridated JJ i
dentifrice NN i
for IN N
6 CD N
months NNS N
. . N

Before IN N
catheter NN N
insertion NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
( ( N
1:1:1:1 CD N
) ) N
patients NNS N
via IN N
a DT N
secure JJ N
web-based JJ N
random-number JJ N
generator NN N
( ( N
permuted JJ N
blocks NNS N
of IN N
eight CD N
, , N
stratified VBN N
by IN N
centre NN N
) ) N
to TO N
have VB N
all DT N
intravascular JJ N
catheters NNS N
prepared VBD N
with IN N
2 CD N
% NN N
chlorhexidine-70 JJ i
% NN i
isopropyl NN i
alcohol NN i
( ( i
chlorhexidine-alcohol NN i
) ) i
or CC i
5 CD i
% NN i
povidone JJ i
iodine-69 JJ i
% NN i
ethanol NN i
( ( i
povidone JJ i
iodine-alcohol NN i
) ) i
, , N
with IN N
or CC N
without IN N
scrubbing VBG N
of IN N
the DT N
skin NN N
with IN N
detergent NN N
before IN N
antiseptic JJ N
application NN N
. . N

Follicle NNP o
stimulating VBG o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
luteinizing VBG o
hormone NN o
( ( o
LH NNP o
) ) o
levels NNS o
, , o
number NN o
of IN o
follicles NNS o
, , o
number NN o
of IN o
follicles NNS o
> VBP o
18 CD o
mm NN o
, , o
relative JJ o
frequency NN o
of IN o
mature NN o
oocytes NNS o
, , o
number NN o
and CC o
days NNS o
of IN o
gonadotropin JJ o
injections NNS o
, , o
day NN o
of IN o
human JJ o
chorionic JJ o
gonadotropin NN o
( ( o
HCG NNP o
) ) o
administration NN o
, , o
estradiol JJ o
level NN o
and CC o
abortion NN o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Double-pulse JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
dpTMS NN i
) ) i
was VBD N
used VBN N
to TO N
examine VB N
inhibition NN N
by IN N
means NNS N
of IN N
short-interval JJ N
intracortical JJ N
inhibition NN N
( ( N
SICI NNP N
) ) N
of IN N
the DT N
contralateral JJ N
primary JJ N
motor NN N
cortex NN N
in IN N
a DT N
sample NN N
of IN N
64 CD p
healthy JJ p
right-handed JJ p
human JJ p
subjects NNS p
covering VBG p
a DT p
wide JJ p
range NN p
of IN p
the DT p
adult NN p
lifespan NN p
( ( p
age NN p
range NN p
20-88 CD p
years NNS p
, , p
mean VB p
47.6 CD p
? . p
20.7 CD p
, , p
34 CD p
female NN p
) ) p
. . p

Evaluations NNS N
were VBD N
carried VBN N
out RP N
before IN N
and CC N
12 CD N
weeks NNS N
after IN N
treatment NN N
with IN N
either DT N
100 CD N
mg NNS N
denbufylline JJ i
BID NNP N
or CC N
placebo NN N
and CC N
included VBD N
EEG NNP o
mapping NN o
, , o
the DT o
Sandoz NNP o
Clinical NNP o
Assessment NNP o
Geriatric NNP o
( ( o
SCAG NNP o
) ) o
score/factors NNS o
, , o
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
, , o
the DT o
Digit NNP o
Symbol NNP o
Substitution NNP o
Test NNP o
( ( o
DSST NNP o
) ) o
, , o
the DT o
Trail-Making JJ o
Test NNP o
( ( o
TMT NNP o
) ) o
and CC o
the DT o
Digit NNP o
Span NNP o
Test NNP o
( ( o
DS NNP o
) ) o
. . o

In IN N
a DT N
2 CD N
? . N
2 CD N
factorial JJ N
design NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
four CD N
study NN N
arms NNS N
: : N
aspirin NN i
plus CC i
RS NNP i
placebo NN i
; : i
RS NNP i
plus CC i
aspirin JJ i
placebo NN i
; : i
aspirin CC i
plus CC i
RS NNP i
; : i
RS NNP i
placebo NN i
plus CC i
aspirin JJ i
placebo NN i
; : i
they PRP N
were VBD N
followed VBN N
with IN N
standard JJ N
annual JJ N
clinical JJ N
examinations NNS N
including VBG N
endoscopy NN N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
in IN N
which WDT N
women NNS p
with IN p
advanced JJ p
anterior JJ p
vaginal NN p
wall NN p
prolapse NN p
, , p
at IN p
least JJS p
stage NN p
II NNP p
with IN p
Ba NNP p
? . p
+1 NN p
cm NN p
according VBG p
to TO p
the DT p
Pelvic NNP p
Organ NNP p
Prolapse NNP p
Quantification NNP p
( ( p
POP-Q NNP p
) ) p
classification NN p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
either DT N
anterior JJ i
colporrhaphy NN i
( ( i
n JJ i
= NNP i
39 CD i
) ) i
or CC i
repair NN i
using VBG i
trocar-guided JJ i
transvaginal JJ i
mesh NN i
( ( N
n JJ N
= NNP N
40 CD N
) ) N
. . N

ETAC NNP i
( ( N
Early JJ N
Treatment NN N
of IN N
the DT N
Atopic NNP p
Child NNP p
) ) p
, , p
a DT p
multi-centre JJ p
predominantly RB p
European JJ p
study NN p
to TO N
investigate VB N
the DT N
potential NN N
for IN N
cetirizine NN i
to TO N
prevent VB N
the DT N
development NN N
of IN N
asthma NN N
in IN N
infants NNS p
with IN p
atopic NN p
dermatitis NN p
has VBZ p
completed VBN p
enrollment NN p
: : p
817 CD p
children NNS p
have VBP N
been VBN N
randomised VBN N
to TO N
18 CD N
months NNS N
' POS N
treatment NN N
with IN N
either DT N
active JJ N
or CC N
placebo NN i
and CC N
a DT N
subsequent JJ N
18 CD N
months NNS N
of IN N
post-treatment JJ N
follow-up NN N
. . N

Our PRP$ N
preliminary JJ N
studies NNS N
of IN N
the DT N
efficacy NN N
of IN N
lithium NN i
carbonate NN i
therapy NN i
for IN N
alcoholism NN N
under IN N
double-blind NN N
, , N
placebo-controlled JJ i
conditions NNS N
demonstrated VBD N
that IN N
alcoholics NNS p
who WP p
took VBD p
their PRP$ p
assigned JJ p
medication NN i
( ( i
lithium NN i
or CC i
placebo NN i
) ) i
for IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
discharge NN N
from IN N
an DT N
inpatient JJ N
rehabilitation NN N
program NN N
were VBD N
more RBR N
likely JJ N
to TO N
abstain VB N
from IN N
any DT N
alcohol NN N
use NN N
for IN N
18 CD N
months NNS N
following VBG N
discharge NN N
than IN N
were VBD N
alcoholics NNS N
who WP N
took VBD N
their PRP$ N
medication NN N
erratically RB N
or CC N
not RB N
at IN N
all DT N
. . N

Pyrimethamine NNP i
, , N
25 CD N
mg NN N
thrice NN N
weekly RB N
, , N
was VBD N
evaluated VBN N
as IN N
primary JJ N
prophylaxis NN N
for IN N
toxoplasmic JJ N
encephalitis NN N
( ( N
TE NNP N
) ) N
in IN N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
in IN N
patients NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
disease NN p
, , p
absolute JJ p
CD4 NNP p
lymphocyte NN p
count NN p
of IN p
< $ p
200/microL CD p
( ( p
or CC p
prior RB p
AIDS-defining NNP p
opportunistic JJ p
infection NN p
) ) p
, , p
and CC p
the DT p
presence NN p
of IN p
serum NN p
IgG NNP p
to TO p
Toxoplasma NNP p
gondii NN p
. . p

METHODS NNP N
A NNP p
total NN p
of IN p
27 CD p
infants NNS p
, , p
mean JJ p
age NN p
4.6 CD p
months NNS p
, , p
who WP p
manifested VBD p
atopic JJ p
eczema NN p
during IN p
exclusive JJ p
breast-feeding NN p
and CC p
who WP p
have VBP p
had VBN p
no DT p
exposure NN p
to TO p
any DT p
infant NN p
or CC p
substitute NN p
formula NN p
were VBD p
weaned VBN p
to TO p
probiotic-supplemented JJ i
, , i
Bifidobacterium NNP i
lactis VBZ i
Bb-12 NNP i
or CC i
Lactobacillus NNP i
strain VBP i
GG NNP i
( ( i
ATCC NNP i
53103 CD i
) ) i
, , i
extensively RB i
hydrolysed VBD i
whey JJ i
formulas NNS i
or CC i
to TO i
the DT i
same JJ i
formula NN i
without IN i
probiotics NNS i
. . i

Investigators NNS N
of IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
entered VBD N
73 CD p
children NNS p
with IN p
previously RB p
untreated VBN p
localized JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
on IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
systemic JJ i
treatment NN i
with IN i
either DT i
a DT i
four-drug JJ i
program NN i
( ( i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
methotrexate NN i
, , i
prednisone NN i
[ NNP i
COMP NNP i
] NNP i
) ) i
or CC i
a DT i
10-drug JJ i
( ( i
LSA2-L2 NNP i
modified VBN i
) ) i
program NN i
of IN i
18 CD i
months NNS i
duration NN i
. . i

There EX N
was VBD N
also RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatments NNS N
in IN N
the DT N
number NN o
of IN o
participants NNS o
whose WP$ o
changes NNS o
in IN o
Visual NNP o
Analog NNP o
Scale NNP o
scores VBZ o
met VBD N
the DT N
study NN N
definition NN N
of IN N
success NN N
at IN N
both DT N
6 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
posttreatment NN N
; : N
and CC N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
posttreatment NN N
in IN N
the DT N
Roles NNP N
and CC N
Maudsley NNP N
Score NNP N
. . N

Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD p
rural JJ p
breast NN p
cancer NN p
survivors NNS p
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ o
QOL NNP o
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ o
QOL NNP o
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
. . N

Data NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
among IN N
22 CD p
premenopausal JJ p
women NNS p
, , p
age NN p
32.6 CD p
( ( p
range JJ p
20-45 CD p
years NNS p
) ) p
, , N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
two CD N
treatments NNS N
with IN N
continuous JJ N
progestogens NNS N
for IN N
contraception NN N
were VBD N
analyzed VBN N
; : N
depot-medroxyprogesterone JJ i
acetate NN i
( ( i
DMPA NNP i
) ) i
or CC i
continuous JJ i
levonorgestrel NN i
treatment NN i
with IN i
subdermal JJ i
implants NNS i
( ( i
Norplant NNP i
) ) i
, , N
respectively RB N
. . N

We PRP N
examined VBD N
how WRB N
plasma JJ i
Lp NNP i
[ VBZ N
a DT N
] NN N
in IN N
healthy JJ p
young JJ p
men NNS p
was VBD p
affected VBN p
by IN p
fats NNS p
high JJ p
in IN p
stearic JJ p
( ( p
C18 NNP p
) ) p
, , p
palmitic JJ p
( ( p
C16 NNP p
) ) p
, , p
and CC p
lauric+myristic JJ i
( ( i
C12+ NNP i
C14 NNP i
) ) i
acid NN i
( ( N
experiment JJ N
I PRP N
, , N
15 CD N
subjects NNS N
) ) N
, , N
and CC N
by IN N
fats NNS i
high JJ i
in IN i
myristic JJ i
( ( i
C14 NNP i
) ) i
and CC i
palmitic JJ i
( ( i
C16 NNP i
) ) i
acid NN i
( ( N
experiment JJ N
II NNP N
, , N
12 CD N
subjects NNS N
) ) N
. . N

A DT N
clinical JJ N
comparison NN N
of IN N
an DT N
emulsion NN N
containing VBG N
a DT N
new JJ N
pilocarpine NN i
polymer NN i
( ( i
Polym NNP i
) ) i
compound NN N
to TO N
that DT N
of IN N
a DT N
traditional JJ i
pilocarpine NN i
salt NN i
solution NN i
( ( i
Plc NNP i
) ) i
on IN N
the DT N
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
has VBZ N
been VBN N
performed VBN N
in IN N
40 CD p
open-angle JJ p
patients NNS p
treated VBN p
with IN p
the DT p
long JJ p
acting JJ p
pilocarpine-complex NN p
for IN p
120 CD p
days NNS p
. . p

METHODS NNP N
We PRP N
tested VBD N
two CD N
doses NNS N
of IN N
the DT N
CRF NNP i
( ( i
1 CD i
) ) i
antagonist NN i
R317573 NNP i
for IN N
effects NNS N
on IN N
regional JJ i
cerebral JJ i
glucose NN i
metabolism NN i
( ( i
rCMglu NN i
) ) i
using VBG i
[ NNP i
( ( i
18 CD i
) ) i
F NNP i
] JJ i
fluoro-2-deoxy-D NN i
: : i
-glucose NN i
( ( i
FDG NNP i
) ) i
positron NN i
emission NN i
tomography NN i
( ( i
PET NNP i
) ) i
following VBG N
single-dose JJ N
challenges NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
cross-over JJ N
design NN N
, , N
in IN N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

METHODS NNP N
We PRP N
assessed VBD N
caffeine JJ N
responses NNS N
and CC N
levels NNS N
of IN N
saliva JJ N
concentration NN N
of IN N
caffeine NN N
in IN N
52 CD p
subjects NNS p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
one CD p
of IN p
two CD p
drug NN p
administration NN p
instructions NNS p
: : p
( ( p
a DT p
) ) p
placebo-informed JJ p
instructions NNS p
( ( p
i.e NN p
, , p
individuals NNS p
informed VBD p
of IN p
the DT p
placebo NN i
) ) i
analogous JJ N
to TO N
those DT N
used VBN N
in IN N
double-blind JJ N
studies NNS N
and CC N
( ( N
b NN N
) ) N
placebo-uninformed JJ N
instructions NNS N
( ( N
i.e NN N
, , N
individuals NNS N
informed VBD N
they PRP N
are VBP N
taking VBG N
an DT N
active JJ N
stimulant NN N
) ) N
. . N

INTERVENTION NN N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
( ( N
1 CD N
) ) N
an DT N
experimental JJ N
group NN N
to TO N
receive VB N
a DT N
mixed JJ i
KT-compression NNP i
treatment NN i
following VBG i
KT NNP i
recommendations NNS i
for IN i
gastrocnemius JJ i
muscle NN i
enhancement NN i
and CC i
functional JJ i
correction NN i
of IN i
the DT i
ankle NN i
, , i
and CC i
adding VBG i
2 CD i
tapes NNS i
to TO i
simulate VB i
traditional JJ i
compression NN i
bandages NNS i
( ( N
no DT N
KT NNP N
guidelines NNS N
) ) N
; : N
or CC N
( ( N
2 CD N
) ) N
a DT N
placebo NN i
control NN i
group NN i
for IN i
sham NN i
KT NNP i
. . i

An DT N
intent-to-treat JJ N
comparison NN N
of IN N
the DT N
numbers NNS N
of IN N
courses NNS N
affected VBN N
by IN N
acute JJ o
toxicity NN o
( ( o
fever NN o
, , o
rigors NNS o
) ) o
and CC o
chronic JJ o
toxicity NN o
( ( o
nephrotoxicity NN o
) ) o
also RB N
indicated VBD N
that IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
AmB NNP N
infused VBD N
in IN N
dextrose NN N
( ( N
78 CD N
courses NNS N
) ) N
and CC N
AmB NNP N
infused VBD N
in IN N
lipid JJ N
emulsion NN N
( ( N
84 CD N
courses NNS N
) ) N
. . N

METHOD NNP N
the DT N
research NN N
sample NN N
consisted VBD N
of IN N
11 CD p
mothers NNS p
of IN p
children NNS p
diagnosed VBN p
, , p
according VBG p
to TO p
the DT p
criteria NNS p
established VBN p
by IN p
the DT p
DSM NNP p
IVtr NNP p
( ( p
APA NNP p
, , p
2002 CD p
) ) p
, , p
with IN p
autism NN p
( ( p
six CD p
) ) p
and CC p
with IN p
Asperger NNP p
Syndrome NNP p
( ( p
five CD p
) ) p
and CC p
who WP p
were VBD p
seen VBN p
at IN p
the DT p
Investigation NNP p
Laboratory NNP p
of IN p
Global NNP p
Developmental NNP p
Disorders NNP p
of IN p
the DT p
Federal NNP p
University NNP p
of IN p
S NNP p
Paulo NNP p
. . p

It PRP N
was VBD N
designed VBN N
as IN N
an DT N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
comparative JJ N
study NN N
involving VBG N
104-week JJ i
oral JJ i
treatment NN i
with IN i
1 CD i
of IN i
the DT i
3 CD i
drugs NNS i
( ( i
aripiprazole NN i
, , i
blonanserin NN i
, , i
and CC i
paliperidone NN i
) ) i
in IN N
patients NNS p
with IN p
schizophrenia NN p
aged VBN p
20 CD p
years NNS p
or CC p
over IN p
who WP p
required VBD p
antipsychotic JJ p
medication NN p
or CC p
switching NN p
of IN p
the DT p
current JJ p
medication NN p
to TO p
others NNS p
for IN p
reasons NNS p
such JJ p
as IN p
lack NN p
of IN p
efficacy NN p
and CC p
intolerability NN p
. . p

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
, , N
the DT N
immune JJ o
success NN o
rates NNS o
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
90 CD p
patients NNS p
( ( p
96 CD p
hips NNS p
) ) p
scheduled VBN p
for IN p
THA NNP i
were VBD N
stratified VBN N
in IN N
three CD N
groups NNS N
according VBG N
to TO N
the DT N
method NN N
of IN N
fixation NN i
of IN i
the DT i
acetabular JJ i
component NN i
: : i
acrylic JJ i
bone NN i
cement NN i
with IN i
fluoride NN i
( ( i
Cemex-F NNP i
) ) i
, , i
porous-coated JJ i
press-fit JJ i
cup NN i
with IN i
ceramic JJ i
coating NN i
( ( i
Trilogy NNP i
, , i
uncemented VBD i
) ) i
and CC i
acrylic JJ i
cement NN i
with IN i
gentamicin NN i
( ( i
Palacos NNP i
) ) i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP p
patients NNS p
with IN p
single JJ p
HCC NNP p
? . p
4 CD p
cm NN p
in IN p
diameter NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
treatments NNS p
: : p
15 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
PLA NNP i
, , i
using VBG i
a DT i
multifibre NN i
system NN i
connected VBN i
to TO i
a DT i
neodymium JJ i
yttrium-aluminium-garnet NN i
laser NN i
source NN i
; : i
15 CD i
patients NNS i
were VBD i
treated VBN i
with IN i
RFA NNP i
, , i
using VBG i
an DT i
expandable JJ i
needle JJ i
electrode NN i
. . i

Analysis NN N
of IN N
variance NN N
failed VBD N
to TO N
demonstrate VB N
an DT N
effect NN N
of IN N
either DT N
intervention NN N
on IN N
the DT N
median JJ N
change NN N
in IN N
standardized JJ N
amount NN N
of IN N
benzodiazepines NNS N
prescribed VBN N
per IN N
physician NN N
, , N
with IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
controls NNS N
yielding VBG N
values NNS N
of IN N
-278 NN N
( ( N
range NN N
: : N
-4,137 NN N
, , N
2,844 CD N
) ) N
, , N
-330 NNP N
( ( N
-1,531 NNP N
, , N
1,358 CD N
) ) N
, , N
and CC N
-541 NNP N
( ( N
range NN N
: : N
-3,716 NN N
, , N
2,185 CD N
) ) N
, , N
respectively RB N
. . N

No DT o
systemic JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
, , N
but CC N
severe JJ o
skin NN o
reactions NNS o
occurred VBD N
more RBR N
frequently RB N
in IN N
those DT N
assigned VBN N
to TO N
chlorhexidine-alcohol NN i
( ( N
27 CD N
[ RB N
3 CD N
% NN N
] JJ N
patients NNS N
vs JJ N
seven CD N
[ $ N
1 CD N
% NN N
] NN N
with IN N
povidone JJ N
iodine-alcohol NN N
; : N
p=0 CC N
) ) N
and CC N
led VBN N
to TO N
chlorhexidine VB i
discontinuation NN N
in IN N
two CD N
patients NNS N
. . N

Temporal JJ o
changes NNS o
in IN o
plasma NN o
renin NN o
, , o
angiotensin-II JJ o
, , o
aldosterone NN o
, , o
epinephrine NN o
, , o
norepinephrine JJ o
, , o
B-type JJ o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
, , N
and CC N
N-terminal JJ N
atrial JJ N
natriuretic JJ N
peptide NN N
( ( N
NT-ANP NNP N
) ) N
in IN N
768 CD N
treated JJ N
patients NNS N
with IN N
heart NN N
failure NN N
measured VBN N
at IN N
baseline NN N
and CC N
17 CD N
and CC N
43 CD N
weeks NNS N
after IN N
randomization NN N
were VBD N
examined VBN N
for IN N
their PRP$ N
relations NNS N
with IN N
concurrent NN N
changes NNS N
in IN N
the DT N
EF NNP N
, , N
cardiac JJ N
volumes NNS N
, , N
and CC N
risk NN N
for IN N
subsequent JJ N
adverse JJ N
clinical JJ N
outcomes NNS N
. . N

Extending VBG N
the DT N
surveillance NN N
to TO N
8 CD N
years NNS N
also RB N
tended VBD N
to TO N
increase VB N
the DT N
risk NN N
more RBR N
in IN N
the DT N
group NN N
being VBG N
examined VBN N
every DT N
4 CD N
years NNS N
, , N
but CC N
reduction NN N
of IN N
the DT N
number NN N
of IN N
surveillance NN N
examinations NNS N
by IN N
more JJR N
than IN N
50 CD N
% NN N
and CC N
a DT N
probable JJ N
reduction NN N
of IN N
complications NNS N
from IN N
surveillance NN N
examinations NNS N
themselves PRP N
may MD N
justify VB N
a DT N
recommendation NN N
for IN N
the DT N
longest JJS N
interval NN N
. . N

In IN N
the DT N
first JJ N
study NN N
388 CD p
patients NNS p
with IN p
suspected JJ p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
propranolol NN i
, , i
atenolol NN i
, , i
or CC i
placebo NN i
, , N
and CC N
when WRB N
analysed VBN N
on IN N
an DT N
initial JJ N
intention NN N
to TO N
treat VB N
basis NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
three CD N
groups NNS N
in IN N
respect NN N
of IN N
the DT N
mortality NN N
at IN N
one CD N
year NN N
. . N

With IN N
every DT N
one CD N
point NN N
increase NN N
in IN N
PSQI NNP o
scores NNS o
across IN o
time NN o
, , o
a DT o
woman NN o
's POS o
risk NN o
for IN o
recurrence NN o
increased VBN N
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN N
PSQI NNP o
scores NNS o
and CC o
IL-6 NNP o
concentrations NNS o
in IN N
early JJ N
postpartum NN N
( ( N
? . N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
. . N

BACKGROUND NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
diabetes NN i
specific JJ i
formula NN i
( ( i
Diason NNP i
low JJ i
energy NN i
: : i
313.8 CD i
kJ/100 NNS i
ml NN i
) ) i
, , i
compared VBN i
with IN i
a DT i
standard JJ i
formula NN i
, , N
on IN N
insulin NN o
sensitivity NN o
, , o
serum JJ o
C NNP o
peptide NN o
, , o
serum JJ o
lipids NNS o
and CC o
free JJ o
fatty NN o
acid NN o
( ( o
FFA NNP o
) ) o
in IN N
type NN p
2 CD p
diabetics NNS p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN o
and CC o
plaque NN o
removal NN o
efficacy NN o
of IN N
two CD i
oscillating/rotating/pulsating VBG i
toothbrushes NNS i
( ( i
Oral-B NNP i
ProfessionalCare NNP i
7000 CD i
[ NNP i
PC NN i
7000 CD i
] NN i
and CC i
Oral-B JJ i
3D CD i
Excel NNP i
[ VBD i
3DE CD i
] NN i
) ) i
and CC i
a DT i
high-frequency NN i
toothbrush NN i
( ( i
Sonicare NNP i
Advance NNP i
, , i
Philips NNP i
Oral NNP i
Healthcare NNP i
; : i
SA NNP i
) ) i
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

From IN N
a DT N
previously RB N
reported VBN N
5-year JJ N
screening VBG N
programme NN N
of IN N
6,956 CD p
47-49-year-old JJ p
Malm NNP p
males NNS p
, , p
a DT p
series NN p
of IN p
41 CD p
subjects NNS p
with IN p
early-stage JJ p
Type NNP p
2 CD p
( ( p
non-insulin-dependent JJ p
) ) p
diabetes VBZ p
mellitus JJ p
and CC p
181 CD p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
were VBD N
selected VBN N
for IN N
prospective JJ N
study NN N
and CC N
to TO N
test VB N
the DT N
feasibility NN N
aspect NN N
of IN N
long-term JJ N
intervention NN N
with IN N
an DT N
emphasis NN N
on IN N
life-style JJ i
changes NNS i
. . i

Increases NNS N
in IN N
PSA NNP o
from IN o
baseline NN o
and CC o
the DT o
maximum JJ o
increase NN o
from IN o
nadir JJ o
to TO N
month NN N
24 CD N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
and CC N
analyzed VBN N
by IN N
prostate NN N
cancer NN N
status NN N
, , N
as IN N
determined VBN N
by IN N
PSA NNP N
driven JJ N
biopsy NN N
and CC N
an DT N
advised JJ N
cutoff NN N
of IN N
more JJR N
than IN N
4 CD N
ng/ml NNS N
after IN N
doubling VBG N
to TO N
correct VB N
for IN N
dutasteride JJ N
treatment NN N
with IN N
sensitivity NN N
and CC N
specificity NN N
calculated VBN N
for IN N
each DT N
. . N

One CD p
thousand CD p
one CD p
hundred CD p
and CC p
twenty-two JJ p
patients NNS p
( ( p
533 CD p
males NNS p
and CC p
589 CD p
females NNS p
; : p
mean JJ p
age NN p
62.2 CD p
+/- JJ p
11.4 CD p
yrs NN p
) ) p
were VBD p
enrolled VBN p
in IN p
a DT p
multicentre NN p
controlled VBN p
study NN p
, , N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
enoxaparin NN i
in IN N
comparison NN N
to TO N
calcium VB i
heparin NN i
in IN N
the DT N
prevention NN N
of IN N
deep JJ p
venous JJ p
thrombosis NN p
( ( p
DVT NNP p
) ) p
following VBG p
general JJ p
surgery NN p
. . p

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
diagnostic JJ N
performance NN N
of IN N
three CD N
methods NNS N
commonly RB N
used VBD N
for IN N
GDM NNP i
screening NN i
: : i
fasting NN i
plasma NN i
glucose NN i
( ( i
FPG NNP i
) ) i
, , i
two-step JJ i
50 CD i
g NN i
glucose JJ i
challenge NN i
test NN i
( ( i
GCT NNP i
) ) i
, , i
and CC i
75 CD i
g NN i
glucose JJ i
tolerance NN i
test NN i
( ( i
GTT NNP i
) ) i
in IN N
a DT N
randomized JJ N
study NN N
design NN N
to TO N
predict VB N
GDM NNP N
in IN N
the DT N
first JJ N
trimester NN N
and CC N
determine VB N
the DT N
best JJS N
approach NN N
in IN N
predicting VBG N
GDM NNP N
. . N

Seventy-three JJ p
patients NNS p
undergoing VBG p
elective JJ p
perianal JJ p
surgery NN p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
control NN i
group NN i
, , i
a DT i
group NN i
who WP i
received VBD i
a DT i
caudal JJ i
injection NN i
of IN i
20 CD i
ml NNS i
bupivacaine VBP i
0.5 CD i
% NN i
plain NN i
and CC N
a DT N
group NN N
who WP N
received VBD N
diamorphine JJ i
2.5 CD i
mg NN i
in IN i
10 CD i
ml NNS i
normal JJ i
saline NN i
by IN i
caudal JJ i
injection NN i
; : i
a DT i
comparison NN i
was VBD i
then RB i
made VBN i
of IN i
postoperative JJ i
analgesia NN i
requirements NNS i
. . i

In IN N
our PRP$ N
study NN N
, , N
vWF NN o
and CC o
factor NN o
VIII NNP o
: : o
C NNP o
levels NNS o
increased VBN N
while IN N
the DT N
bleeding NN o
time NN o
decreased VBN N
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
, , N
although IN N
vWF NN o
and CC o
factor NN o
VIII NNP o
: : o
C NN o
levels NNS o
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS N
at IN N
90 CD N
min NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

The DT N
interventions NNS N
provided VBD N
identical JJ N
intensity NN N
( ( N
10 CD N
hours NNS N
per IN N
week NN N
in IN N
classroom NN N
) ) N
, , N
student-to-teacher JJ N
ratio NN N
, , N
schedule NN N
, , N
home-based JJ N
parent NN N
training NN N
( ( N
1.5 CD N
hours NNS N
per IN N
month NN N
) ) N
, , N
parent JJ N
education NN N
( ( N
38 CD N
hours NNS N
) ) N
, , N
and CC N
instructional JJ N
strategies NNS N
, , N
except IN N
the DT N
Interpersonal NNP N
Synchrony NNP N
condition NN N
provided VBD N
a DT N
supplementary JJ N
curriculum NN N
targeting VBG N
socially RB N
engaged VBN N
imitation NN N
, , N
joint JJ N
attention NN N
, , N
and CC N
affect JJ N
sharing NN N
; : N
measures NNS N
of IN N
these DT N
were VBD N
primary JJ N
outcomes NNS N
. . N

Furthermore RB N
, , N
after IN N
6 CD N
months NNS N
of IN N
enrichment JJ N
therapy NN N
, , N
21 CD N
% NN N
of IN N
the DT N
children NNS N
who WP N
initially RB N
had VBD N
been VBN N
given VBN N
an DT N
autism NN N
classification NN N
, , N
using VBG N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
improved VBN N
to TO N
the DT N
point NN N
that IN N
, , N
although IN N
they PRP N
remained VBD N
on IN N
the DT N
autism NN N
spectrum NN N
, , N
they PRP N
no RB N
longer RBR N
met VBD N
the DT N
criteria NNS N
for IN N
classic JJ N
autism NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
622 CD p
men NNS p
and CC p
women NNS p
with IN p
radiological JJ p
evidence NN p
of IN p
primary JJ p
knee NN p
OA NNP p
and CC p
mild VB p
to TO p
severe VB p
symptoms NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
a DT N
topical JJ i
diclofenac NN i
solution NN i
plus CC i
placebo JJ i
oral JJ i
capsules NNS i
, , i
or CC i
placebo VB i
topical JJ i
solution NN i
plus CC i
oral JJ i
diclofenac NN i
( ( i
50 CD i
mg NN i
) ) i
capsules NNS i
. . i

In IN N
addition NN N
, , N
systemic JJ N
exposure NN N
of IN N
risperidone NN i
active JJ N
moiety NN N
( ( N
risperidone JJ N
plus CC N
9-hydroxyrisperidone CD N
) ) N
, , N
the DT N
most RBS N
clinically RB N
relevant JJ N
component NN N
of IN N
risperidone NN i
treatment NN N
, , N
was VBD N
not RB N
affected VBN N
by IN N
galantamine JJ N
coadministration NN N
, , N
while IN N
systemic JJ o
exposure NN o
was VBD N
increased VBN N
by IN N
approximately RB N
10 CD N
% NN N
for IN N
risperidone NN i
and CC N
decreased VBN N
by IN N
about IN N
10 CD N
% NN N
for IN N
9-hydroxyrisperidone CD N
( ( N
active JJ N
metabolite NN N
of IN N
risperidone NN i
) ) i
. . i

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
, , N
50 CD p
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
and CC p
dilated VBD p
left JJ p
atrium NN p
, , p
submitted VBN p
to TO p
surgical JJ p
mitral JJ p
repair NN p
, , N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP i
I PRP i
contained VBD i
25 CD i
patients NNS i
with IN i
left JJ i
auricular JJ i
reduction NN i
and CC i
mitral JJ i
surgery NN i
, , i
and CC i
Group NNP i
II NNP i
contained VBD i
25 CD i
patients NNS i
with IN i
isolated JJ i
valve NN i
surgery NN i
. . i

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
threefold VBN N
: : N
( ( N
1 CD N
) ) N
Assess IN N
the DT N
pressure NN N
loss NN N
of IN N
two CD N
types NNS N
of IN N
pressure NN i
garments NNS i
that WDT N
are VBP N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
hypertrophic JJ N
scars NNS N
after IN N
burn JJ N
injury NN N
, , N
( ( N
2 CD N
) ) N
investigate VB N
the DT N
influence NN N
of IN N
two CD N
different JJ N
levels NNS N
of IN N
compression NN N
on IN N
erythema NN o
and CC o
thickness NN o
of IN o
burn NN o
scars NNS o
and CC N
( ( N
3 CD N
) ) N
examine VBP N
the DT N
association NN N
between IN N
erythema NN o
and CC o
thickness NN o
. . o

Two CD p
hundred VBD p
one CD p
male NN p
and CC p
female JJ p
subjects NNS p
, , p
aged VBD p
20 CD p
to TO p
70 CD p
years NNS p
, , p
with IN p
elevated VBN p
low-density NN p
lipoprotein NN p
cholesterol NN p
values NNS p
( ( p
in IN p
the DT p
75th CD p
to TO p
95th CD p
percentiles NNS p
) ) p
, , N
participated VBN N
in IN N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind NN N
study NN N
using VBG N
a DT N
new JJ N
form NN N
of IN N
niacin NN i
( ( i
Enduracin NNP i
) ) i
, , N
which WDT N
employs VBZ N
a DT N
wax-matrix JJ N
vehicle NN N
for IN N
sustained JJ N
release NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ N
measures NNS N
and CC N
socio-demographic JJ N
questionnaires NNS N
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
a DT N
group NN N
which WDT N
was VBD N
treated VBN N
topically RB N
with IN N
Contractubex NNP i
gel NN i
( ( i
Merz NNP i
+ NNP i
Co. NNP i
, , i
D-Frankfurt/Main NNP i
) ) i
, , i
containing VBG i
10 CD i
% NN i
onion NN i
extract NN i
, , i
50/U CD i
of IN i
sodium NN i
heparin NN i
per IN i
one CD i
g NN i
of IN i
gel NN i
and CC i
1 CD i
% NN i
allantoin NN i
, , i
or CC i
to TO i
a DT i
group NN i
receiving VBG i
no DT i
treatment NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
242 CD p
patients NNS p
with IN p
type JJ p
III NNP p
prostatitis NN p
diagnosed VBN p
by IN p
the DT p
NIH NNP p
criteria NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
experimental JJ N
and CC N
a DT N
control NN i
group NN i
of IN i
equal JJ i
number NN i
, , i
the DT i
former JJ i
treated VBN i
with IN i
Compound NNP i
Xuanju NNP i
Capsule NNP i
+ NNP i
Tamsulosin NNP i
Hydrochloride NNP i
, , i
and CC i
the DT i
latter NN i
with IN i
Quinolinone NNP i
antibiotics NNS i
+ VBP i
Tamsulosin NNP i
and CC i
Hydrochloride NNP i
, , i
both DT i
for IN i
6 CD i
months NNS i
. . i

RESULTS VB N
The DT N
eradication NN o
rate NN o
of IN N
the DT N
cimetidine NN i
group NN N
the DT N
omeprazole NN i
group NN N
, , N
and CC N
the DT N
CBS NNP i
group NN N
were VBD N
0 CD N
% NN N
, , N
7.7 CD N
% NN N
, , N
0 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
that IN N
of IN N
the DT N
double JJ N
therapy NN N
group NN N
and CC N
the DT N
triple JJ N
therapy NN N
group NN N
were VBD N
44.4 CD N
% NN N
and CC N
89.3 CD N
% NN N
, , N
respectively RB N
. . N

Differences NNS N
from IN N
placebo NN i
in IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
were VBD N
not RB N
statistically RB N
significant JJ N
for IN N
vortioxetine NN i
10 CD N
mg NN N
or CC N
vortioxetine NN N
15 CD N
mg. NN N
Nausea NNP o
, , o
headache NN o
, , o
dry JJ o
mouth NN o
, , o
constipation NN o
, , o
diarrhea NN o
, , o
vomiting VBG o
, , o
dizziness NN o
, , o
and CC o
flatulence NN o
were VBD N
reported VBN N
in IN N
? . N
5 CD N
% NN N
of IN N
subjects NNS N
receiving VBG N
vortioxetine NN N
. . N

Calves NNS p
were VBD p
fed VBN p
a DT p
low-concentrate NN p
( ( p
LC NNP p
) ) p
growing VBG N
diet JJ N
, , N
blocked VBN N
by IN N
weight NN N
and CC N
sex NN N
, , N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
pens NNS N
to TO N
receive VB N
either RB N
no DT i
additional JJ i
supplement NN i
( ( i
CON NNP i
; : i
n CC i
= VB i
35 CD i
) ) i
or CC i
receive VB i
a DT i
supplement NN i
of IN i
anti-phospholipase JJ i
A2 NNP i
antibody NN i
( ( i
aPLA2 NN i
) ) i
at IN N
an DT N
inclusion NN N
rate NN N
of IN N
0.6 CD N
% NN N
of IN N
the DT N
diet JJ i
DM NNP i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

METHODS NN N
Patients NNS p
( ( p
n=766 JJ p
) ) p
, , p
aged VBD p
18 CD p
to TO p
65 CD p
years NNS p
inclusive JJ p
, , p
with IN p
current JJ p
manic NN p
or CC p
mixed JJ p
episodes NNS p
were VBD p
initially RB p
randomized VBN p
( ( p
4:1 CD p
) ) p
to TO p
flexibly-dosed JJ i
paliperidone NN i
ER NNP i
( ( N
3-12 JJ N
mg/day NN N
) ) N
or CC N
olanzapine JJ i
( ( N
5-20 JJ N
mg/day NN N
; : N
3-week JJ N
acute NN N
treatment NN N
phase NN N
) ) N
; : N
responders NNS N
continued VBD N
the DT N
same JJ N
treatment NN N
( ( N
12-week JJ N
continuation NN N
phase NN N
) ) N
. . N

The DT N
results NNS N
showed VBD N
that IN N
adherence NN o
measures NNS o
varied VBN N
with IN N
lowest JJS N
adherence NN N
from IN N
two CD N
items NNS N
of IN N
self-report NN o
related VBN o
to TO o
forgetfulness VB o
( ( N
46 CD N
and CC N
55 CD N
% NN N
) ) N
and CC N
stringent JJ o
electronic JJ o
monitoring NN o
with IN o
the DT o
MEMS NNP o
( ( N
58 CD N
% NN N
) ) N
to TO N
percentages NNS N
in IN N
the DT N
80-90 JJ N
range NN N
for IN N
other JJ N
self-report JJ o
items NNS o
and CC o
the DT o
general JJ o
adherence NN o
scale NN o
. . o

DESIGN NN N
In IN N
this DT N
double-blind NN N
, , N
prospective JJ N
study NN N
, , N
postmenopausal JJ p
women NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
four CD p
treatment NN p
groups NNS p
: : p
hysterectomized VBN p
women NNS p
were VBD N
assigned VBN N
to TO N
either DT N
1 CD N
) ) N
micronized VBN i
E2 NNP i
( ( i
0.5 CD i
mg NN i
) ) i
or CC i
2 CD i
) ) i
micronized VBN i
E2 NNP i
( ( i
0.5 CD i
mg NN i
) ) i
+ VBZ i
micronized VBN i
T NNP i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

We PRP N
now RB N
report VBP N
the DT N
outcomes NNS N
of IN N
a DT N
similar JJ N
randomized NN N
controlled VBD N
trial NN N
in IN N
which WDT N
children NNS p
with IN p
autism NN p
, , p
3 CD p
to TO p
6 CD p
years NNS p
old JJ p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
that WDT N
received VBD N
either DT N
daily JJ i
sensorimotor NN i
enrichment NN i
, , N
administered VBN N
by IN N
their PRP$ N
parents NNS N
, , N
along IN N
with IN N
standard JJ N
care NN N
, , N
or CC N
they PRP N
received VBD N
standard JJ i
care NN i
alone RB i
. . i

This DT N
report NN N
examines VBZ N
associations NNS N
of IN N
stages NNS N
of IN N
change NN N
with IN N
diet JJ N
prospectively RB N
and CC N
addresses VBZ N
whether IN N
( ( N
1 CD N
) ) N
baseline NN N
stage NN N
of IN N
change NN N
predicts NNS N
participation NN N
, , N
( ( N
2 CD N
) ) N
forward NN N
changes NNS N
in IN N
stage NN N
movement NN N
were VBD N
greater JJR N
in IN N
treatment NN N
work NN N
sites NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
change NN N
in IN N
stage NN N
was VBD N
associated VBN N
with IN N
adoption NN N
of IN N
healthful JJ N
diets NNS N
, , N
using VBG N
data NNS N
from IN N
a DT N
cohort NN N
of IN N
11,237 CD p
employees NNS p
. . p

At IN N
1 CD N
year NN N
there RB N
was VBD N
a DT N
7 CD N
% NN N
absolute NN N
and CC N
a DT N
24 CD N
% NN N
relative JJ N
risk NN o
reduction NN o
of IN o
death NN o
and CC o
dependency NN o
in IN N
the DT N
coiling VBG N
group NN N
compared VBN N
with IN N
the DT N
clipping VBG N
group NN N
, , N
but CC N
the DT N
medium-term JJ N
results NNS N
showed VBD N
the DT N
increased VBN N
need NN o
for IN o
re-treatment NN o
of IN o
the DT o
target NN o
aneurysm NN o
in IN N
the DT N
patients NNS N
given VBN N
coiling VBG N
. . N

BACKGROUND NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
Interceptor NNP N
, , N
long-lasting JJ N
polyester NN N
net NN N
, , N
75 CD N
denier NN N
and CC N
bursting VBG N
strength NN N
of IN N
minimum JJ N
250 CD N
kPa NN N
coated VBN N
with IN N
alpha-cypermethrin JJ N
@ NNS N
200 CD N
mg/m NN N
was VBD N
evaluated VBN N
for IN N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
the DT N
mosquito NN N
density NN N
, , N
blood NN N
feeding NN N
inhibition NN N
and CC N
malaria NN N
incidence NN N
in IN N
a DT N
tribal NN N
dominated VBN N
malaria NNS N
endemic JJ N
area NN N
in IN N
Chhattisgarh NNP N
state NN N
, , N
central JJ N
India NNP N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
mite JJ o
counts NNS o
on IN N
day NN N
7 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
within IN N
treatment NN N
Groups NNP N
A NNP N
and CC N
B NNP N
of IN N
Study NNP N
1 CD N
, , N
but CC N
mite JJ o
counts NNS o
increased VBD N
again RB N
on IN N
day NN N
14 CD N
and CC N
remained VBD N
high JJ N
for IN N
the DT N
duration NN N
of IN N
the DT N
trial NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

In IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
50 CD N
consecutive JJ N
eyes NNS N
, , N
we PRP N
compared VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
draining VBG i
subretinal JJ i
fluid NN i
transchoroidally RB i
in IN N
primary JJ N
scleral JJ N
buckling NN N
for IN N
rhegmatogenous JJ o
retinal JJ o
detachment NN o
using VBG N
a DT N
needle JJ N
, , N
with IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
same JJ N
procedure NN N
using VBG N
an DT N
angulated VBN N
endolaser NN N
probe NN N
set VBN N
at IN N
1 CD N
W NNP N
for IN N
0.2 CD N
seconds NNS N
, , N
using VBG N
an DT N
average NN N
of IN N
2.4 CD N
laser NN N
burns NNS N
. . N

METHODS NNP N
Simplified NNP o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
SDAI NNP o
) ) o
scores VBZ o
, , o
Clinical JJ o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
CDAI NNP o
) ) o
scores VBZ o
, , N
and CC N
the DT N
Disease NNP o
Activity NNP o
Score NNP o
in IN N
28 CD N
joints NNS N
( ( N
DAS28 NNP N
) ) N
were VBD N
calculated VBN N
using VBG N
data NNS N
from IN N
tocilizumab JJ N
trials NNS N
in IN N
patients NNS N
with IN N
RA NNP N
in IN N
whom WP N
disease NN N
had VBD N
remained VBN N
active JJ N
despite IN N
treatment NN N
with IN N
disease-modifying JJ N
antirheumatic JJ N
drugs NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Bronchoalveolar NNP N
lavage NN N
( ( N
BAL NNP N
) ) N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
study NN N
days NNS N
4 CD N
and CC N
7 CD N
to TO N
obtain VB N
BAL NNP N
fluid NN N
( ( N
BALF NNP N
) ) N
for IN N
measurement NN N
of IN N
total JJ o
protein NN o
, , o
ceruloplasmin NN o
, , o
and CC o
transferrin NN o
, , o
total JJ o
neutrophil NN o
count NN o
, , o
IL-8 NNP o
, , o
IL-6 NNP o
, , o
tumor NN o
necrosis NN o
factor-alpha NN o
, , o
and CC o
leukotriene JJ o
B4 NNP o
. . o

OBJECTIVES IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
blood NN N
pressure NN N
and CC N
associated JJ N
neural JJ N
tonicity NN N
in IN N
ambient JJ N
ischemia NN N
of IN N
a DT N
group NN N
of IN N
hypertensive JJ p
patients NNS p
with IN p
stable JJ p
angina NN p
, , p
and CC p
2 CD p
) ) p
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
immediate JJ N
release NN N
nifedipine JJ i
therapy NN i
in IN N
controlling VBG N
the DT N
total JJ N
ischemic JJ N
burden NN N
in IN N
both DT N
office-measured JJ N
and CC N
ambulatory JJ N
blood NN N
pressure NN N
. . N

The DT p
Medical NNP p
Research NNP p
Council NNP p
( ( p
MRC NNP p
) ) p
United NNP p
Kingdom NNP p
trial NN p
for IN p
childhood NN p
acute NN p
lymphoblastic JJ p
leukaemia NN p
( ( p
UKALL NNP p
X NNP p
) ) p
randomised VBD p
patients NNS p
aged VBN p
0-14 CD p
years NNS p
inclusive JJ p
with IN p
an DT p
initial JJ p
white JJ p
blood NN p
count NN p
of IN p
less JJR p
than IN p
100 CD p
x JJ p
10 CD p
( ( p
9 CD p
) ) p
/l NN p
to TO p
receive VB p
an DT p
early JJ p
intensification NN p
block NN p
, , N
a DT N
late JJ N
intensification NN N
block NN N
, , N
both DT N
, , N
or CC N
neither DT N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
, , N
comprising VBG N
11 CD p
patients NNS p
with IN p
at IN p
least JJS p
two CD p
screw JJ p
type NN p
implants NNS p
with IN p
bleeding VBG p
on IN p
probing VBG p
( ( p
BOP NNP p
) ) p
, , p
probing VBG p
pocket NN p
depth NN p
( ( p
PPD NNP p
) ) p
> VBD p
or CC p
=5 JJ p
mm NN p
, , p
and CC p
at IN p
least JJS p
1.5 CD p
mm JJ p
radiographic JJ p
bone NN p
loss NN p
and CC p
exposed VBN p
implant JJ p
threads NNS p
, , N
was VBD N
carried VBN N
out RP N
as IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

When WRB N
meloxicam NN N
and CC N
Glu-Ch NNP N
were VBD N
discontinued VBN N
and CC N
the DT N
placebo NN i
commenced VBD N
, , N
a DT N
significant JJ N
proportion NN N
of IN N
the DT N
meloxicam NN i
group NN N
showed VBD N
worsening NN o
of IN o
all PDT o
the DT o
owner-assessed JJ o
scores NNS o
between IN N
day NN N
70 CD N
and CC N
day NN N
98 CD N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
( ( N
mobility NN N
p=0.01 NN N
; : N
activity NN N
p=0.02 NN N
; : N
temperament JJ N
p=0.04 NN N
; : N
lifestyle CC N
p=0.01 NN N
) ) N
. . N

METHODS NNP N
Sixty-four JJ p
adults NNS p
from IN p
the DT p
original JJ p
91 CD p
participants NNS p
experiencing VBG p
heightened VBN p
anxiety NN p
or CC p
stress JJ p
2-3 JJ p
months NNS p
following VBG p
the DT p
22nd CD p
February NNP p
2011 CD p
earthquake NN p
and CC p
who WP p
had VBD p
been VBN p
randomized VBN p
to TO p
receive VB p
three CD p
different JJ p
doses NNS p
of IN p
micronutrients NNS p
completed VBN p
on-line JJ p
questionnaires NNS p
assessing VBG p
mood NN p
, , p
anxiety NN p
, , p
stress NN p
, , p
and CC p
symptoms NNS p
associated VBN p
with IN p
post-traumatic JJ p
stress NN p
disorder NN p
1 CD p
year NN p
after IN p
completing VBG p
the DT p
initial JJ p
study NN p
. . p

A DT N
randomized JJ N
double JJ N
blind NN N
placebo NN i
controlled VBD N
trial NN N
to TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN o
combined-herbs JJ o
( ( o
SH NNP o
) ) o
given VBN N
with IN N
zidovudine NN i
( ( i
ZDV NNP i
) ) i
and CC i
zalcitabine NN i
( ( i
ddC NN i
) ) i
for IN N
the DT N
treatment NN N
of IN N
HIV NNP p
infection NN p
in IN p
Thai NNP p
adults NNS p
was VBD p
conducted VBN p
in IN p
3 CD p
hospitals NNS p
in IN p
northern JJ p
Thailand NNP p
during IN p
2002 CD p
to TO p
2003 CD p
. . p

DESIGN NNP N
Twenty-four CD p
BMT NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
standard JJ i
PN NNP i
containing VBG i
conventional JJ i
amounts NNS i
of IN i
dextrose NN i
, , i
amino JJ i
acids NNS i
, , i
micronutrients NNS i
, , i
and CC i
lipid JJ i
( ( i
120 CD i
kJ/d NN i
) ) i
or CC i
a DT i
solution NN i
containing VBG i
only JJ i
micronutrients NNS i
( ( i
identical JJ i
to TO i
those DT i
in IN i
standard JJ i
PN NNP i
) ) i
and CC N
a DT N
small JJ N
amount NN N
of IN N
lipid JJ N
( ( N
12 CD N
kJ/d NN N
) ) N
. . N

We PRP N
compared VBN N
the DT N
onset NN N
of IN N
neuromuscular JJ N
block NN N
with IN N
succinylcholine NN i
( ( N
1 CD N
mg RB N
kg-1 NN N
) ) N
and CC N
two CD N
doses NNS N
of IN N
rocuronium NN i
( ( N
0.6 CD N
and CC N
0.9 CD N
mg JJ N
kg-1 NN N
) ) N
at IN N
the DT N
adductor NN N
pollicis NN N
muscle NN N
using VBG N
electromyography NN N
( ( N
EMG NNP N
) ) N
and CC N
acceleromyography NN N
( ( N
AMG NNP N
) ) N
, , N
and CC N
at IN N
the DT N
adductor NN N
laryngeal NN N
muscles NNS N
with IN N
a DT N
new JJ N
electromyographic JJ N
method NN N
using VBG N
a DT N
disposable JJ N
surface NN N
electrode NN N
attached VBN N
to TO N
the DT N
cuff NN N
of IN N
a DT N
tracheal JJ N
tube NN N
. . N

The DT N
secondary JJ N
events NNS N
during IN N
the DT N
first JJ N
14 CD N
days NNS N
also RB N
revealed VBD N
no DT N
benefit NN N
of IN N
dalteparin NN i
compared VBN N
with IN N
aspirin NN i
: : i
symptomatic JJ o
cerebral JJ o
haemorrhage NN o
6/224 CD N
versus NN N
4/225 CD N
; : N
symptomatic JJ o
and CC o
asymptomatic JJ o
cerebral JJ o
haemorrhage NN o
26/224 CD N
versus NN N
32/225 CD N
; : N
progression NN o
of IN o
symptoms NNS o
within IN N
the DT N
first JJ N
48 CD N
hours NNS N
24/224 CD N
versus NN N
17/225 CD N
; : N
and CC N
death NN N
21/224 CD N
versus NN N
16/225 CD N
. . N

RESULT NNP N
Compared NNP N
with IN N
the DT N
placebo NN i
group NN N
, , N
the DT N
scores NNS N
for IN N
hot JJ o
flashes NNS o
and CC o
excessive JJ o
sweating NN o
were VBD N
significantly RB N
reduced VBN N
after IN N
3 CD N
months NNS N
, , N
and CC N
the DT N
scores NNS N
for IN N
weakness NN o
, , o
palpitations NNS o
, , o
limb NN o
paresthesia NN o
, , o
and CC o
total JJ o
symptoms NNS o
after IN N
6 CD N
months NNS N
, , N
in IN N
the DT N
EP NNP N
group NN N
only RB N
. . N

The DT N
secondary JJ N
outcomes NNS N
were VBD N
a DT N
hemoglobin JJ o
drop NN o
of IN o
30 CD o
mg/L NN o
or CC o
greater JJR o
, , o
the DT o
use NN o
of IN o
additional JJ o
oxytocin NN o
, , o
an DT o
estimated VBN o
blood NN o
loss NN o
greater JJR N
than IN N
1000 CD N
mL NN N
, , N
manual JJ N
removal NN N
of IN N
the DT N
placenta NN N
, , N
a DT N
blood NN o
transfusion NN o
, , o
and CC o
shivering VBG o
and CC o
fever NN o
( ( N
> JJ N
or=38 NN N
degrees NNS N
C NNP N
) ) N
as IN N
adverse JJ o
effects NNS o
of IN N
misoprostol NN i
. . i

The DT N
authors NNS N
herein VBP N
present JJ N
their PRP$ N
personal JJ N
series NN N
on IN N
the DT N
clinical JJ N
evaluation NN N
of IN N
the DT N
analgesic JJ o
efficacy NN o
of IN N
2 CD N
opiodes NNS i
, , i
peridural JJ i
morphine NN i
hydrochloride NN i
( ( N
0.5 CD N
mg/kg NN N
) ) N
administered VBD N
to TO N
group NN N
A NNP N
patients NNS N
, , N
and CC N
sublingual JJ N
buprenorphine NN i
( ( N
0.4 CD N
mg NN N
) ) N
administered VBD N
to TO N
group NN N
B NNP N
patients NNS N
in IN N
the DT N
management NN N
of IN N
post-operative JJ p
pain NN p
in IN p
major JJ p
abdominal JJ p
surgery NN p
. . p

We PRP N
compared VBN N
the DT N
test NN N
performances NNS N
of IN N
high-risk JJ N
HPV NNP N
testing NN N
( ( N
Hybrid JJ N
Capture NNP N
2 CD N
) ) N
using VBG N
self-collected JJ i
and CC i
clinician-collected JJ i
samples NNS i
as RB N
well RB N
as IN N
cervical JJ N
cytology NN N
for IN N
identifying VBG N
cervical JJ p
intraepithelial JJ p
neoplasia NN p
grades NNS p
2 CD p
or CC p
3 CD p
or CC p
invasive JJ p
cervical JJ p
cancer NN p
( ( p
CIN2+ NNP p
) ) p
among IN p
women NNS p
who WP p
did VBD p
( ( p
n=812 NN p
) ) p
and CC p
did VBD p
not RB p
( ( p
n=1858 JJ p
) ) p
undergo VBP p
cryotherapy NN p
in IN p
a DT p
South JJ p
African JJ p
screen-and-treat JJ p
trial NN p
. . p

METHODS NNP N
In IN p
a DT p
population-based JJ p
screening NN p
program NN p
in IN p
Sweden NNP p
, , p
12,527 CD p
women NNS p
32 CD p
to TO p
38 CD p
years NNS p
of IN p
age NN p
were VBD N
randomly RB N
assigned VBN N
at IN N
a DT N
1:1 CD N
ratio NN N
to TO N
have VB N
an DT N
HPV NNP i
test NN i
plus CC i
a DT i
Papanicolaou NNP i
( ( i
Pap NNP i
) ) i
test NN i
( ( i
intervention NN i
group NN i
) ) i
or CC i
a DT i
Pap JJ i
test NN i
alone RB i
( ( i
control VB i
group NN i
) ) i
. . i

To TO N
identify VB N
the DT N
risk NN N
factors NNS N
for IN N
the DT N
development NN N
of IN N
postoperative JJ N
septic JJ N
complications NNS N
in IN N
patients NNS p
with IN p
intestinal JJ p
perforation NN p
after IN p
abdominal JJ p
trauma NN p
, , N
and CC N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
single-drug JJ N
and CC N
dual-drug JJ N
prophylactic JJ N
antibiotic JJ N
therapy NN N
, , N
we PRP N
studied VBD N
145 CD p
patients NNS p
who WP p
presented VBD p
with IN p
abdominal JJ p
trauma NN p
and CC p
intestinal JJ p
perforation NN p
at IN p
two CD p
hospitals NNS p
between IN p
July NNP p
1979 CD p
and CC p
June NNP p
1982 CD p
. . p

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
CsA NNP N
for IN N
the DT N
first JJ N
10 CD N
days NNS N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
Evr NNP N
in IN N
combination NN N
with IN N
CsA NNP i
up RB i
to TO i
day NN i
30 CD i
, , i
then RB i
either DT i
continued VBN i
on IN i
Evr NNP i
monotherapy NN i
( ( i
Evr NNP i
group NN i
) ) i
or CC i
maintained VBN i
on IN i
CsA NNP i
with/without NN i
mycophenolate NN i
mofetil NN i
( ( i
CsA NNP i
group NN i
) ) i
in IN i
case NN i
of IN i
chronic JJ i
kidney NN i
disease NN i
( ( i
CKD NNP i
) ) i
. . i

The DT N
main JJ N
problem NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
difficulty NN N
in IN N
recruiting VBG N
an DT N
adequate JJ N
number NN N
of IN N
patients NNS N
and CC N
following VBG N
them PRP N
for IN N
a DT N
sufficient JJ N
period NN N
of IN N
time NN N
: : N
general JJ N
conditions NNS N
rapidly RB N
deteriorated VBD N
in IN N
many JJ N
patients NNS N
, , N
and CC N
approximately RB N
25 CD N
% NN N
of IN N
the DT N
66 CD N
enrolled NNS N
were VBD N
not RB N
considered VBN N
evaluable JJ N
; : N
few JJ N
patients NNS N
survived VBD N
for IN N
the DT N
length NN N
of IN N
the DT N
study NN N
, , N
one CD N
year NN N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
triple JJ i
combination NN i
cream NN i
with IN i
fluocinolone NN i
acetonide RB i
0.01 CD N
% NN N
, , N
hydroquinone CD N
4 CD N
% NN N
and CC N
tretinoin VB N
0.05 CD N
% NN N
as IN N
adjuvant NN N
to TO N
cryotherapy VB i
in IN N
the DT N
treatment NN N
of IN N
solar JJ N
lentigines NNS N
in IN N
hands NNS N
dorsum JJ N
, , N
and CC N
in IN N
the DT N
prevention NN N
of IN N
post-inflammatory JJ o
hyperpigmentation NN o
after IN N
cryotherapy NN i
. . i

Primary JJ N
endpoints NNS N
were VBD N
a DT N
composite NN o
of IN o
an DT o
AIDS-defining JJ o
event NN o
, , o
death NN o
, , o
or CC o
CD4 NNP o
cell VBP o
count NN o
decline NN o
to TO o
less JJR o
than IN o
200 CD o
cells NNS o
per IN o
mm3 NN o
for IN o
the DT o
PI NNP o
versus NN o
NNRTI NNP o
comparison NN o
, , o
and CC o
average JJ o
change NN o
in IN o
CD4 NNP o
cell NN o
count NN o
at IN N
or CC N
after IN N
32 CD N
months NNS N
for IN N
the DT N
three-class JJ N
versus NN N
combined VBD N
two-class JJ N
comparison NN N
. . N

OBJECTIVE NNP N
As IN N
part NN N
of IN N
a DT N
prospective JJ N
study NN N
of IN N
possible JJ N
effects NNS N
of IN N
early-life JJ i
otitis NN i
media NNS i
on IN N
speech NN N
, , N
language NN N
, , N
cognitive JJ N
, , N
and CC N
psychosocial JJ N
development NN N
, , N
we PRP N
tested VBD N
relationships NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
duration NN N
of IN N
middle JJ o
ear JJ o
effusion NN o
( ( o
MEE NNP o
) ) o
in IN o
their PRP$ o
first JJ o
3 CD o
years NNS o
of IN o
life NN o
and CC o
their PRP$ o
scores NNS o
on IN o
measures NNS o
of IN o
language NN o
, , o
speech NN o
sound NN o
production NN o
, , N
and CC N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

AIMS NNP N
( ( N
1 CD N
) ) N
To TO N
examine VB N
the DT N
matching JJ N
hypothesis NN N
that WDT N
Twelve NNP N
Step NNP i
Facilitation NNP i
Therapy NNP i
( ( i
TSF NNP i
) ) i
is VBZ N
more RBR N
effective JJ N
than IN N
Motivational NNP N
Enhancement NNP N
Therapy NNP N
( ( N
MET NNP N
) ) N
for IN N
alcohol-dependent JJ N
clients NNS N
with IN N
networks NNS N
highly RB N
supportive JJ N
of IN N
drinking VBG N
3 CD N
years NNS N
following VBG N
treatment NN N
; : N
( ( N
2 CD N
) ) N
to TO N
test VB N
a DT N
causal NN N
chain NN N
providing VBG N
the DT N
rationale NN N
for IN N
this DT N
effect NN N
. . N

This DT N
phase NN N
2 CD N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
evaluated VBD N
an DT N
IFN- JJ i
and CC i
RBV-free JJ i
regimen NNS i
of IN i
once-daily JJ i
ombitasvir NN i
( ( i
ABT-267 NNP i
) ) i
, , i
an DT i
NS5A NNP i
inhibitor NN i
, , i
plus CC i
paritaprevir NN i
( ( i
ABT-450 NNP i
) ) i
, , N
an DT N
NS3/4A NNP i
protease NN i
inhibitor NN i
dosed VBD i
with IN i
ritonavir NN i
( ( i
paritaprevir/ritonavir NN i
) ) i
, , N
in IN N
pegylated JJ p
IFN/RBV NNP p
treatment-experienced JJ p
Japanese JJ p
patients NNS p
with IN p
hepatitis NN p
C NNP p
virus NN p
subtype NN p
1b CD p
or CC p
genotype VB p
2 CD p
infection NN p
. . p

Diclofenac NNP i
reduced VBD N
the DT N
anti-aggregatory JJ o
action NN o
of IN o
aspirin NN o
in IN N
the DT N
first JJ N
two CD N
days NNS N
, , N
since IN N
the DT N
CT NNP N
did VBD N
not RB N
rise VB N
significantly RB N
( ( N
109+/-19 JJ N
s NN N
, , N
148+/-56 JJ N
s NN N
, , N
and CC N
168+/-66 JJ N
s NN N
at IN N
0 CD N
h NN N
, , N
24 CD N
h NN N
, , N
48 CD N
h NN N
, , N
respectively RB N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
a DT N
1-month JJ N
washout NN N
placebo NN N
period NN N
, , N
using VBG N
a DT N
double-blind JJ N
crossover NN N
design NN N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
nifedipine VB i
( ( N
20 CD N
mg NN N
twice RB N
a DT N
day NN N
) ) N
, , N
chlorthalidone NN i
( ( N
25 CD N
mg NN N
once RB N
a DT N
day NN N
) ) N
, , N
the DT N
two CD N
drugs NNS N
combined VBN N
at IN N
the DT N
same JJ N
doses NNS N
and CC N
the DT N
corresponding JJ N
placebo NN i
. . i

PATIENTS NNS N
AND CC N
METHODS NNP N
Eight NNP p
cirrhotics NNS p
( ( p
Child NNP p
's POS p
B NNP p
or CC p
C NNP p
) ) p
without IN p
transjugular JJ i
intrahepatic JJ i
portosystemic JJ i
shunts NNS i
( ( i
TIPS NNP i
) ) i
and CC i
seven CD i
with IN i
TIPS NNP i
underwent JJ i
two CD i
oral JJ i
glutamine NN i
( ( i
20 CD i
g NN i
) ) i
challenges VBZ i
, , i
receiving VBG i
LOLA NNP i
( ( i
5 CD i
g RB i
intravenously RB i
) ) i
on IN i
one CD i
occasion NN i
and CC i
placebo NN i
on IN N
the DT N
other JJ N
in IN N
random JJ N
order NN N
. . N

When WRB N
prevaccination NN N
IgG NNP N
levels NNS N
( ( N
mean VB N
+ RB N
3 CD N
standard JJ N
deviations NNS N
) ) N
were VBD N
used VBN N
to TO N
determine VB N
a DT N
negative JJ N
cut-off NN N
, , N
a DT N
low JJ N
percentage NN N
( ( N
< JJ N
38 CD N
% NN N
) ) N
of IN N
vaccinees NNS N
converted VBN N
to TO N
responder VB N
status NN N
for IN N
either DT N
anti-mycobacterial JJ N
or CC N
anti-leishmanial JJ N
responses NNS N
, , N
and CC N
those DT N
who WP N
did VBD N
would MD N
be VB N
classified VBN N
as IN N
'low-responder NN N
' '' N
status NN N
compared VBN N
with IN N
titres NNS N
observed VBN N
in IN N
severe JJ N
forms NNS N
of IN N
disease NN N
. . N

However RB N
, , N
nicotinic JJ i
acid NN i
therapy NN i
resulted VBD N
in IN N
the DT N
deterioration NN o
of IN o
glycemic JJ o
control NN o
, , N
as IN N
evidenced VBN N
by IN N
a DT N
16 CD N
% NN N
increase NN N
in IN N
mean JJ o
plasma NN o
glucose JJ o
concentrations NNS o
, , N
a DT N
21 CD N
% NN N
increase NN N
in IN N
glycosylated JJ o
hemoglobin NN o
levels NNS o
, , N
and CC N
the DT N
induction NN N
of IN N
marked JJ N
glycosuria NN N
in IN N
some DT N
patients NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
consistent JJ N
tendency NN N
for IN N
RSA NNP N
times NNS N
to TO N
be VB N
slower JJR N
after IN N
the DT N
static JJ i
stretching NN i
intervention NN i
, , N
which WDT N
was VBD N
supported VBN N
by IN N
statistical JJ N
significance NN N
for IN N
three CD N
performance NN N
variables NNS N
( ( N
MST NNP N
0-5 NNP N
m NN N
set NN N
2 CD N
, , N
MST NNP N
0-20 NNP N
m NN N
set NN N
2 CD N
, , N
and CC N
TST NNP N
set VBD N
2 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
age-standardized JJ o
prevalences NNS o
of IN o
metabolic JJ o
syndrome NN o
were VBD N
16.2 CD N
% NN N
, , N
32.2 CD N
% NN N
, , N
and CC N
28.3 CD N
% NN N
in IN N
men NNS N
and CC N
26.8 CD N
% NN N
, , N
37.2 CD N
% NN N
, , N
and CC N
34.6 CD N
% NN N
in IN N
women NNS N
, , N
according VBG N
to TO N
the DT N
definitions NNS N
of IN N
the DT N
NCEP NNP N
2004 CD N
, , N
NCEP NNP N
2005 CD N
, , N
and CC N
IDF NNP N
, , N
respectively RB N
. . N

METHODS NNP N
49 CD p
Malnourished NNP p
( ( p
weight JJ p
loss NN p
> VBZ p
10 CD p
% NN p
) ) p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
who WP p
were VBD p
included VBN p
in IN p
a DT p
nutrition NN p
intervention NN p
trial NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
no DT i
preoperative JJ i
and CC i
standard JJ i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
I PRP i
) ) i
, , i
standard JJ i
preoperative NN i
and CC i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
II NNP i
) ) i
or CC i
arginine-supplemented JJ i
preoperative NN i
and CC i
postoperative JJ i
tube-feeding NN i
( ( i
group NN i
III NNP i
) ) i
. . i

At IN N
a DT N
cut-off NN N
of IN N
26 CD N
, , N
the DT N
AQ-J NNP N
had VBD N
satisfactory JJ N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
negative JJ N
predictive JJ N
value NN N
, , N
but CC N
it PRP N
had VBD N
low JJ N
positive JJ N
predictive NN N
value NN N
( ( N
0.24 CD N
) ) N
possibly RB N
due JJ N
to TO N
the DT N
facts NNS N
that IN N
the DT N
25 CD N
mild JJ N
HPDD NNP N
patients NNS N
scored VBD N
lower JJR N
and CC N
the DT N
controls NNS N
scored VBD N
higher JJR N
on IN N
the DT N
AQ-J NNP N
than IN N
British NNP N
counterparts NNS N
on IN N
the DT N
AQ NNP N
. . N

INTERVENTIONS NNP N
After IN N
a DT N
6-hr-period JJ i
of IN i
protective JJ i
conventional JJ i
mechanical JJ i
ventilation NN i
, , i
patients NNS i
were VBD i
submitted VBN i
to TO i
three CD i
1-hr JJ i
periods NNS i
of IN i
high-frequency NN i
oscillatory NN i
ventilation NN i
( ( i
+5 JJ i
, , i
+10 NNP i
, , i
+15 NNP i
) ) i
in IN i
a DT i
randomized JJ i
order NN i
, , i
with IN i
a DT i
mean JJ i
airway NN i
pressure NN i
level NN i
determined VBN i
by IN i
adding VBG i
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
cm NNS i
H2O NNP i
to TO i
the DT i
mean JJ i
airway NN i
pressure NN i
recorded VBN i
during IN i
conventional JJ i
mechanical JJ i
ventilation NN i
. . i

STUDY NNP N
DESIGN NNP N
Fifty-five JJ p
children NNS p
with IN p
cancer NN p
and CC p
eight CD p
children NNS p
given VBN p
total JJ p
parenteral JJ p
nutrition NN p
by IN p
the DT p
surgery NN p
or CC p
nutrition NN p
support NN p
services NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
heparin NN i
CVC NNP i
flush JJ i
solution NN i
( ( i
n JJ i
= NNP i
31 CD i
) ) i
or CC i
a DT i
heparin-vancomycin JJ i
CVC NNP i
flush NN i
solution NN i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

The DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
of IN N
a DT N
fixed VBN N
dose JJ N
combination NN N
tablet NN N
of IN N
lamivudine NN i
( ( i
CAS NNP i
134678-17-4 CD i
) ) i
and CC i
stavudine NN i
( ( i
CAS NNP i
3056-17-5 CD i
) ) i
with IN N
the DT N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ i
tablet NN i
and CC i
stavudine NN i
capsule NN i
in IN N
24 CD p
healthy JJ p
volunteers NNS p
under IN p
fasting VBG p
conditions NNS p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
, , N
a DT N
total NN N
of IN N
56,294 CD p
men NNS p
aged VBN p
55-74 CD p
years NNS p
were VBD p
screened VBN p
with IN p
serum NN p
prostate NN p
specific JJ p
antigen NN p
( ( p
PSA NNP p
) ) p
in IN p
five CD p
countries NNS p
of IN p
the DT p
European NNP p
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP i
Cancer NNP i
( ( i
ERSPC NNP i
) ) i
with IN N
an DT N
overall JJ N
detection NN N
rate NN N
( ( N
prevalence NN N
) ) N
of IN N
2.8 CD N
% NN N
( ( N
1972 CD N
prostate NN N
cancers NNS N
) ) N
. . N

The DT N
overall JJ N
results NNS N
show VBP N
that IN N
of IN N
the DT N
four CD N
possible JJ N
treatment NN N
randomizations NNS N
, , N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
is VBZ N
inferior JJ N
in IN N
terms NNS N
of IN N
overall JJ o
survival NN o
( ( N
30 CD N
weeks NNS N
median JJ N
survival NN N
) ) N
to TO N
the DT N
other JJ N
three CD N
treatment NN N
options NNS N
( ( N
39 CD N
weeks NNS N
median JJ N
survival NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
experience NN N
leading VBG N
to TO N
withdrawal VB N
was VBD N
rash NN N
, , N
with IN N
approximately RB N
double JJ N
the DT N
proportion NN N
of IN N
reports NNS N
occurring VBG N
in IN N
patients NNS N
on IN N
CBZ NNP i
600 CD N
( ( N
5.1 CD N
% NN N
) ) N
compared VBN N
with IN N
lamotrigine NN i
( ( N
1.7 CD N
% NN N
on IN N
LTG NNP i
100 CD N
and CC N
2.7 CD N
% NN N
on IN N
LTG NNP i
200 CD N
) ) N
. . N

RESULTS NNP N
Both NNP N
treatments NNS N
resulted VBD N
in IN N
significant JJ N
and CC N
progressive JJ o
improvement NN o
in IN o
overall JJ o
mental JJ o
health NN o
at IN N
follow-up NN N
( ( N
F NNP N
= NNP N
2 CD N
, , N
97 CD N
, , N
p FW N
=.007 NN N
) ) N
and CC N
mental JJ o
health NN o
significantly RB N
improved VBN N
over RP N
time NN N
in IN N
the DT N
54 CD N
% NN N
of IN N
principal JJ N
caregivers NNS N
who WP N
had VBD N
the DT N
highest JJS N
levels NNS N
of IN N
mental JJ N
health NN N
problems NNS N
. . N

METHODS NNP N
Ninety NNP p
participants NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
80 CD p
men/10 NN p
women NNS p
, , p
mean JJ p
age NN p
57 CD p
? . p
8 CD p
years NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD i
exercise NN i
modes NNS i
: : i
group NN i
exercise NN i
( ( i
GE NNP i
) ) i
, , i
treadmill JJ i
exercise NN i
( ( i
TE NNP i
) ) i
, , i
or CC i
home-based JJ i
exercise NN i
( ( i
HE NNP i
) ) i
. . i

RESULTS NNP N
After IN N
6 CD N
and CC N
12 CD N
months NNS N
, , N
whereas JJ N
patients NNS N
treated VBD N
only RB N
with IN N
calcium NN N
and CC N
cholecalciferol NN N
( ( N
group NN N
A NNP N
) ) N
showed VBD N
a DT N
marked JJ N
bone NN o
loss NN o
, , N
with IN N
increased JJ N
levels NNS o
of IN o
DPD NNP o
and CC o
BALP NNP o
compared VBN N
with IN N
baseline NN N
values NNS N
, , N
patients NNS N
treated VBD N
also RB N
with IN N
neridronate NN N
( ( N
group NN N
B NNP N
) ) N
had VBD N
substantially RB N
unchanged JJ N
levels NNS N
of IN N
these DT N
markers NNS N
. . N

We PRP p
enrolled VBD p
1,164 CD p
patients NNS p
stratified VBN p
by IN p
ethnicity NN p
and CC p
language NN p
( ( p
49.3 CD p
% NN p
non-Hispanic JJ p
, , p
27.2 CD p
% NN p
Hispanic/English NNP p
, , p
23.4 CD p
% NN p
Hispanic/Spanish NNP p
) ) p
from IN p
26 CD p
offices NNS p
around IN p
5 CD p
centers NNS p
( ( p
Sacramento NNP p
, , p
California NNP p
; : p
Rochester NNP p
and CC p
the DT p
Bronx NNP p
, , p
New NNP p
York NNP p
; : p
Denver NNP p
, , p
Colorado NNP p
; : p
and CC p
San NNP p
Antonio NNP p
, , p
Texas NNP p
) ) p
. . p

The DT N
results NNS N
of IN N
a DT N
multicenter NN N
, , N
randomized VBN N
trial NN N
on IN N
the DT N
effect NN N
of IN N
intravenous JJ N
administration NN N
of IN N
gamma JJ i
globulin NN i
( ( i
IVGG NNP i
) ) i
plus CC i
aspirin JJ i
versus NN i
aspirin NN i
alone RB i
upon IN N
coronary JJ N
aneurysm NN N
formation NN N
show VBP N
a DT N
decrease NN N
in IN N
coronary JJ o
aneurysm NN o
formation NN o
from IN N
the DT N
usual JJ N
20 CD N
% NN N
-30 NN N
% NN N
to TO N
3 CD N
% NN N
. . N

Thirty-two JJ p
patients NNS p
awaiting VBG p
a DT p
total JJ p
hip NN p
arthroplasty NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
, , N
( ( N
A DT N
) ) N
, , N
to TO N
have VB N
six CD N
sessions NNS N
of IN N
acupuncture NN i
each DT i
lasting VBG i
up RP i
to TO i
25 CD i
minutes NNS i
, , i
or CC i
the DT i
control NN i
group NN i
, , i
( ( i
B NNP i
) ) i
, , i
to TO i
be VB i
given VBN i
advice NN i
and CC i
exercises NNS i
for IN i
their PRP$ i
hip NN i
over IN i
a DT i
six CD i
week NN i
period NN i
. . i

In IN N
a DT N
randomized JJ N
crossover NN N
design NN N
controlled VBD N
feeding NN N
study NN N
, , N
each DT N
participant NN N
( ( N
a DT N
total NN N
of IN N
23 CD N
; : N
5-12 JJ N
per IN N
group NN N
) ) N
consumed VBD N
the DT N
experimental JJ i
diet NN i
( ( i
1.5 CD i
cups NNS i
of IN i
cooked JJ i
dry JJ i
beans NNS i
) ) i
and CC i
a DT i
control NN i
diet NN i
( ( i
isocaloric JJ i
average JJ i
American JJ i
diet NN i
) ) i
for IN i
4 CD i
weeks NNS i
with IN i
a DT i
3-week JJ i
washout NN i
period NN i
between IN i
diets NNS i
. . i

RESULTS VB N
The DT N
mean JJ o
FVIIa NNP o
activity NN o
was VBD N
measurable JJ N
for IN N
up IN N
to TO N
at IN N
least JJS N
72 CD N
h NN N
after IN N
dosing VBG N
, , N
and CC N
the DT N
overall JJ o
mean NN o
t NN o
( ( o
1/2 CD o
) ) o
for IN o
FVIIa NNP o
activity NN o
was VBD N
15 CD N
h. PDT N
The DT N
pharmacokinetics NNS N
of IN N
N7-GP NNP i
appeared VBD N
to TO N
be VB N
dose-proportional JJ N
in IN N
the DT N
dose JJ N
range NN N
investigated VBN N
. . N

Individuals NNS p
with IN p
high JJ p
levels NNS p
of IN p
BP NNP p
features NNS p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
and CC p
controls NNS p
with IN p
low JJ p
levels NNS p
of IN p
BP NNP p
features NNS p
( ( p
n JJ p
= NNP p
44 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
condition NN N
involving VBG N
negative JJ N
evaluation NN N
based VBN N
on IN N
writing NN N
( ( N
negative JJ N
evaluation/academic NN N
) ) N
, , N
or CC N
a DT N
condition NN N
involving VBG N
negative JJ N
evaluation NN N
based VBN N
on IN N
personal JJ N
characteristics NNS N
as RB N
well RB N
as IN N
social JJ o
rejection NN o
( ( o
negative JJ o
evaluation/social JJ o
rejection NN o
) ) o
. . o

To TO N
address VB N
the DT N
need NN N
for IN N
improved JJ N
educational JJ N
outcomes NNS N
, , N
a DT N
previously RB N
tested VBN N
consultation NN N
intervention NN N
called VBD N
the DT N
Collaborative NNP N
Model NNP N
for IN N
Promoting VBG N
Competence NNP N
and CC N
Success NNP N
( ( N
COMPASS NNP N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2010 CD N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2012 CD N
) ) N
was VBD N
evaluated VBN N
in IN N
a DT N
2nd CD N
randomized VBN N
controlled VBN N
trial NN N
, , N
with IN N
the DT N
addition NN N
of IN N
a DT N
web-based JJ N
group NN N
. . N

When WRB N
comparing VBG N
the DT N
efficacy NN N
of IN N
the DT N
three CD N
randomized VBN N
therapeutic JJ N
regimens NNS N
while IN N
on IN N
the DT N
Na+ NNP N
supplement NN N
, , N
the DT N
valsartan NN N
160 CD N
mg/HCTZ NN N
12.5 CD N
mg NN N
was VBD N
the DT N
most RBS N
effective JJ N
therapy NN N
with IN N
an DT N
incremental JJ N
reduction NN N
in IN N
blood NN o
pressure NN o
of IN N
-10.5/-6.9 NNP N
mm FW N
Hg NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
to TO N
valsartan VB N
160 CD N
mg/day JJ N
alone RB N
. . N

RESULTS JJ N
Devices NNPS N
were VBD N
used VBN N
in IN N
138/150 CD N
allocated JJ N
to TO N
AS NNP N
and CC N
124/150 CD N
allocated VBN N
to TO N
SC NNP N
patients NNS N
( ( N
92 CD N
% NN N
vs. FW N
83 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
Patients NNS N
with IN N
MC NNP N
experienced VBD N
more JJR N
pain NN o
during IN N
sheath NN N
removal NN N
than IN N
patients NNS N
receiving VBG N
a DT N
device NN N
, , N
and CC N
rated VBD N
their PRP$ N
period NN N
of IN N
bed NN N
rest NN N
as IN N
less RBR N
comfortable JJ N
. . N

This DT N
sample NN N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
2-year JJ o
mortality NN o
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
. . N

PARTICIPANTS NNS N
Participants NNS p
( ( p
N=20 NNP p
) ) p
who WP p
were VBD p
community-living JJ p
older JJR p
adults NNS p
at IN p
least JJS p
65 CD p
years NNS p
old JJ p
( ( p
mean JJ p
age NN p
, , p
70y CD p
) ) p
, , p
50 CD p
% NN p
women NNS p
, , p
and CC p
who WP p
had VBD p
no DT p
experience NN p
of IN p
using VBG p
a DT p
wheelchair NN p
were VBD p
randomly RB p
allocated VBN p
to TO p
an DT p
intervention NN p
( ( p
n=10 JJ p
) ) p
or CC p
control NN p
( ( p
n=10 JJ p
) ) p
group NN p
. . p

Fifty-one CD p
pairs NNS p
of IN p
premenarcheal JJ p
female NN p
twins NNS p
( ( p
27 CD p
monozygotic NN p
and CC p
24 CD p
dizygotic JJ p
; : p
mean JJ p
+/- JJ p
sd NN p
age NN p
, , p
10.3 CD p
+/- JJ p
1.5 CD p
yr NN p
) ) p
participated VBD p
in IN N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ i
trial NN i
with IN i
one CD i
twin NN i
of IN i
each DT i
pair NN i
receiving VBG i
a DT i
1200-mg JJ i
calcium NN i
carbonate NN i
( ( i
Caltrate NNP i
) ) i
supplement NN i
. . i

During IN N
the DT N
1-hour JJ N
study NN N
period NN N
, , N
the DT N
incidence NN o
of IN o
central JJ o
nervous JJ o
system NN o
side NN o
effects NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN i
group NN N
, , N
hypotension NN o
occurred VBD N
in IN N
11 CD N
patients NNS N
, , N
nine CD N
of IN N
whom WP N
had VBD N
received VBN N
lidocaine NN i
, , N
and CC N
four CD N
patients NNS N
died VBD N
from IN N
asystole NN N
, , N
three CD N
of IN N
whom WP N
had VBD N
had VBN N
lidocaine NN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Participants NNP p
, , p
2862 CD p
eligible JJ p
overweight NN p
and CC p
obese JJ p
( ( p
BMI NNP p
= VBZ p
27 CD p
to TO p
40 CD p
kg/m2 NNS p
) ) p
members NNS p
from IN p
four CD p
regions NNS p
of IN p
Kaiser NNP p
Permanente NNP p
's POS p
integrated JJ p
health NN p
care NN p
delivery NN p
system NN p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
tailored VBN i
expert NN i
system NN i
or CC i
information-only JJ i
Web-based JJ i
weight NN i
management NN i
materials NNS i
. . i

Comparison NNP N
of IN N
ketazolam NNP i
given VBN N
once-a-day JJ N
with IN N
diazepam NN i
given VBN N
three CD N
times NNS N
a DT N
day NN N
and CC N
placebo VB i
given VBN N
either DT N
once RB N
or CC N
3 CD N
times NNS N
a DT N
day NN N
in IN N
101 CD N
anxious JJ N
outpatients NNS N
showed VBD N
ketazolam NNS N
to TO N
be VB N
significantly RB N
better JJR N
than IN N
placebo NN i
in IN N
alleviating VBG N
the DT N
symptoms NNS N
of IN N
anxiety NN N
and CC N
, , N
on IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
better JJR N
than IN N
diazepam NN i
as IN N
well RB N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
motivational JJ i
Strengths NNP i
Model NNP i
bridging VBG i
case NN i
management NN i
intervention NN i
( ( i
BCM NNP i
) ) i
beginning VBG N
approximately RB N
3 CD N
months NNS N
prior RB N
to TO N
and CC N
continuing VBG N
6 CD N
months NNS N
after IN N
release NN N
versus IN N
a DT N
standard NN i
of IN i
care NN i
prison-administered JJ i
discharge NN i
planning VBG i
program NN i
( ( i
SOC NNP i
) ) i
for IN N
HIV-infected JJ p
state NN p
prison NN p
inmates NNS p
. . p

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
toxicity NN o
of IN N
1 CD N
mg NN N
of IN N
amphotericin NN i
B NNP i
( ( i
AmB NNP i
) ) i
per IN N
kg NN N
of IN N
body NN N
weight JJ N
per IN N
day NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
AmB NNP i
infused VBD N
in IN N
lipid JJ N
emulsion NN N
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
. . p

Tacrolimus NNP i
ointment VBD i
0.03 CD N
% NN N
is VBZ N
approved VBN N
for IN N
moderate JJ p
to TO p
severe VB p
atopic NN p
dermatitis NN p
in IN p
the DT p
patient JJ p
population NN p
between IN p
two CD p
to TO p
seventeen VB p
years NNS p
of IN p
age NN p
and CC p
Tacrolimus NNP p
0.1 CD p
% NN p
ointment NN p
for IN p
moderate JJ p
to TO p
severe VB p
atopic NN p
dermatitis NN p
in IN p
patients NNS p
18 CD p
years NNS p
of IN p
age NN p
and CC p
older JJR p
. . p

METHODS NNP N
Sixty-eight JJ p
patients NNS p
with IN p
peripheral JJ p
obstructive JJ p
arterial JJ p
disease NN p
and CC p
intermittent JJ p
claudication NN p
( ( p
Fontaine NNP p
stage NN p
II NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
into IN N
the DT N
treadmill NN i
training NN i
( ( N
repetitive JJ N
intervals NNS N
to TO N
onset VB N
of IN N
claudication NN N
pain NN N
, , N
three CD N
times NNS N
a DT N
week NN N
) ) N
or CC N
a DT N
control NN i
group NN i
( ( i
no DT i
change NN i
in IN i
physical JJ i
activity NN i
) ) i
over IN N
3 CD N
months NNS N
. . N

RESULTS JJ N
Pre-medication NN N
with IN N
pronase NN N
( ( N
treatment NN N
C NNP N
) ) N
significantly RB N
reduced VBN N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT N
visibility NN o
score NN o
( ( N
score RB N
4 CD N
, , N
46 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
obtained VBN N
for IN N
pre-medication NN N
without IN N
pronase NN N
( ( N
10 CD N
% NN N
for IN N
both DT N
treatments NNS N
A DT N
and CC N
B NNP N
) ) N
. . N

METHODS NNP N
We PRP N
assessed VBD N
status NN N
of IN N
BRAF NNP i
c.1799T NN i
> VBZ i
A NNP i
( ( i
p.V600E NN i
) ) i
mutation NN i
and CC i
MSI NNP i
in IN N
506 CD p
stage NN p
III NNP p
colon NN p
cancer NN p
patients NNS p
enrolled VBN p
in IN p
a DT p
randomized JJ p
adjuvant NN i
chemotherapy NN i
trial NN i
[ NNP i
5-fluorouracil CD i
and CC i
leucovorin NN i
( ( i
FU/LV NNP i
) ) i
vs. FW i
irinotecan JJ i
( ( i
CPT11 NNP i
) ) i
, , i
FU NNP i
and CC i
LV NNP i
( ( i
IFL NNP i
) ) i
; : i
CALGB $ N
89803 CD N
] NN N
. . N

METHODS NNP N
Patients NNS p
with IN p
stable JJ p
CHF NNP p
( ( p
NYHA NNP p
II/III NNP p
; : p
59 CD p
( ( p
11 CD p
) ) p
years NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
training NN N
group NN N
( ( N
n=18 JJ N
; : N
3-month JJ i
aerobic JJ i
program NN i
above IN i
standard JJ i
treatment NN i
) ) i
or CC i
control VB i
group NN i
( ( i
n=16 RB i
; : i
standard JJ i
treatment NN i
without IN i
special JJ i
advice NN i
for IN i
exercise NN i
) ) i
. . i

METHODS/DESIGN NNP N
Seventy NNP p
patients NNS p
, , p
aged VBD p
18 CD p
to TO p
45 CD p
years NNS p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
BPD NNP p
, , p
showing VBG p
a DT p
chronic JJ p
pattern NN p
of IN p
parasuicidal JJ p
gestures NNS p
and/or IN p
reporting VBG p
high JJ p
degrees NNS p
of IN p
severity NN p
of IN p
other JJ p
borderline NN p
symptoms NNS p
, , N
are VBP N
randomly RB N
allocated VBN N
to TO N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
diclofenac-K NN i
( ( N
12.5 CD N
mg NN N
) ) N
tablets VBZ N
vs JJ N
paracetamol NN i
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
pain NN p
within IN p
8 CD p
hours NNS p
of IN p
extraction NN p
of IN p
impacted JJ p
third JJ p
molars NNS p
. . p

OBJECTIVES IN N
The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dose-dependent JJ N
anesthetic JJ N
efficacy NN N
of IN N
the DT N
intraseptal JJ i
anesthesia NN i
( ( i
ISA NNP i
) ) i
and CC i
periodontal JJ i
ligament NN i
anesthesia NN i
( ( i
PLA NNP i
) ) i
obtained VBD N
with IN N
different JJ N
volumes NNS N
of IN N
4 CD N
% NN N
articaine NN i
and CC i
1:100,000 CD i
epinephrine NN i
( ( N
Ar NNP N
+ NNP N
Ep NNP N
) ) N
in IN N
human JJ p
mandibular JJ p
premolars NNS p
, , N
using VBG N
a DT N
computer-controlled JJ N
local JJ N
anesthetic JJ N
delivery NN N
system NN N
( ( N
CCLADS NNP N
) ) N
. . N

METHODS NNP N
Seventeen NNP p
sedentary JJ p
adults NNS p
aged VBN p
> JJ p
or=55 CD p
years NNS p
with IN p
insomnia NN p
( ( p
mean JJ p
age NN p
61.6 CD p
[ NN p
SD NNP p
] NNP p
years NNS p
; : p
16 CD p
female NN p
) ) p
participated VBD p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
comparing VBG p
16 CD i
weeks NNS i
of IN i
aerobic JJ i
physical JJ i
activity NN i
plus CC i
sleep JJ i
hygiene NN i
to TO i
non-physical JJ i
activity NN i
plus CC i
sleep JJ i
hygiene NN i
. . i

METHODS NNP N
Sixty-four NNP p
male NN p
patients NNS p
, , p
mean JJ p
age NN p
55.6 CD p
? . p
6.0 CD p
years NNS p
, , N
were VBD N
randomized VBN N
either RB N
to TO N
six CD i
weeks NNS i
of IN i
aerobic JJ i
training NN i
, , p
three CD p
times NNS p
a DT p
week NN p
, , p
at IN p
60-80 CD p
% NN p
of IN p
maximal JJ p
heart NN p
rate NN p
( ( p
training VBG p
group NN p
, , p
Ex NNP p
, , p
n JJ p
= NNP p
32 CD p
) ) p
or CC p
to TO p
a DT p
control NN p
group NN p
( ( p
n JJ p
= NNP p
32 CD p
) ) p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
60 CD p
patients NNS p
were VBD p
allocated VBN p
from IN p
September NNP p
2011 CD p
until IN p
March NNP p
2013 CD p
into IN p
one CD p
of IN p
the DT p
two CD p
groups NNS p
: : p
resistance NN i
training NN i
( ( i
group NN i
A NNP i
) ) i
or CC i
passive JJ i
physical JJ i
therapy NN i
( ( N
group NN N
B NNP N
) ) N
with IN N
thirty NN N
patients NNS N
in IN N
each DT N
group NN N
during IN N
RT NNP N
. . N

A DT N
prospective JJ N
study NN N
over IN N
15 CD N
months NNS N
in IN N
100 CD p
elderly JJ p
patients NNS p
with IN p
signs NNS p
of IN p
cerebro-vascular JJ p
impairment NN p
demonstrated VBN p
by IN p
psychometric JJ p
testing VBG p
that IN p
Hydergine NNP i
( ( N
an DT N
ergot NN N
alkaloid JJ N
preparation NN N
: : N
4.5 CD N
mg NNS N
daily RB N
) ) N
compensated VBD N
the DT N
signs NNS N
of IN N
dementia NN N
, , N
present NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
in IN N
some DT N
patients NNS N
actually RB N
brought VBD N
about IN N
a DT N
significant JJ N
improvement NN N
in IN N
mental JJ o
activity NN o
. . o

Among IN N
the DT N
children NNS N
in IN N
the DT N
secretin NN i
group NN N
, , N
the DT N
mean JJ o
total NN o
score NN o
on IN N
the DT N
Autism NNP N
Behavior NNP N
Checklist NNP N
at IN N
base NN N
line NN N
was VBD N
59.0 CD N
( ( N
range NN N
of IN N
possible JJ N
values NNS N
, , N
0 CD N
to TO N
158 CD N
, , N
with IN N
a DT N
larger JJR N
value NN N
corresponding VBG N
to TO N
greater JJR N
impairment NN N
) ) N
, , N
and CC N
among IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
it PRP N
was VBD N
63.2 CD N
. . N

The DT N
occlusion NN N
was VBD N
released VBN N
after IN N
2 CD N
min NN N
and CC N
one-fourth NN N
of IN N
the DT N
total JJ N
propofol NN N
dose NN N
was VBD N
injected VBN N
into IN N
the DT N
vein NN N
over IN N
a DT N
period NN N
of IN N
5 CD N
s. NN N
During IN N
the DT N
injection NN N
of IN N
both DT N
pretreatment JJ N
solution NN N
and CC N
propofol NN N
, , N
patients NNS N
' POS N
pain NN N
was VBD N
assessed VBN N
and CC N
recorded VBN N
as IN N
0-3 NN N
, , N
corresponding VBG N
to TO N
no DT N
, , N
mild RB N
, , N
moderate JJ N
or CC N
severe JJ N
pain NN N
, , N
respectively RB N
. . N

Twenty-four JJ N
vs JJ N
forty-eight JJ N
weeks NNS N
of IN N
re-therapy NN i
with IN i
interferon NN i
alpha NN i
2b CD i
and CC i
ribavirin VB i
in IN N
interferon NN N
alpha NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
BACKGROUND/AIM NNP N
Roughly NNP N
50 CD N
% NN N
of IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
, , p
who WP p
relapsed VBD p
after IN p
a DT p
previous JJ p
monotherapy NN p
with IN p
interferon NN i
alpha NN i
, , N
will MD N
respond VB N
in IN N
a DT N
sustained JJ N
fashion NN N
to TO N
24 CD N
weeks NNS N
of IN N
re-therapy NN i
with IN i
the DT i
combination NN i
of IN i
interferon NN i
alpha NN i
plus CC i
ribavirin NN i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN o
between IN N
randomized VBN N
allocations NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.6 CD N
) ) N
CONCLUSION NNP N
Routine NNP N
administration NN N
of IN N
perindopril-indapamide JJ i
lowers NNS N
blood NN N
pressure NN N
safely RB N
and CC N
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
of IN p
at IN p
least JJS p
75 CD p
years NNS p
with IN p
type NN p
2 CD p
diabetes NNS p
. . p

METHODS NNP N
A NNP N
randomised VBD N
, , N
multi-centre JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
study NN N
was VBD N
carried VBN N
out RP N
at IN N
19 CD p
centres NNS p
in IN p
France NNP p
, , p
Germany NNP p
and CC p
the DT p
Netherlands NNP p
in IN p
patients NNS p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
acute JJ p
ischaemic JJ p
stroke NN p
, , p
and CC p
onset NN p
of IN p
symptoms NNS p
within IN p
12 CD p
hours NNS p
before IN p
start NN p
of IN p
study JJ p
drug NN p
administration NN p
. . p

DESIGN NNP N
AND CC N
METHODS NNP N
Cases NNP p
who WP p
had VBD p
a DT p
first JJ p
venous JJ p
thrombosis NN p
( ( p
n=515 JJ p
) ) p
and CC p
matched VBN p
controls NNS p
( ( p
n=1,505 NN p
) ) p
were VBD p
identified VBN p
from IN p
a DT p
population-based JJ p
, , p
nested JJ p
, , p
case-cohort JJ p
study NN p
( ( p
the DT p
HUNT NNP p
2 CD p
study NN p
) ) p
comprising VBG p
71 CD p
% NN p
( ( p
n=66,140 JJ p
) ) p
of IN p
the DT p
adult NN p
residents NNS p
of IN p
Nord-Tr NNP p
County NNP p
in IN p
Norway NNP p
. . p

METHODS NNP N
Patients NNS p
with IN p
severe JJ p
OSA NNP p
currently RB p
using VBG p
CPAP NNP i
at IN i
? . i
h/night NN i
with IN i
a DT i
nasal JJ i
mask NN i
were VBD i
examined VBN i
( ( i
including VBG i
Mallampati NNP i
scale NN i
, , i
incisal NN i
relationship NN i
, , i
and CC i
mandibular JJ i
protrusion NN i
) ) i
and CC i
then RB i
randomized VBN i
to TO i
receive VB i
auto-positive JJ i
airway NN i
pressure NN i
( ( i
PAP NNP i
) ) i
or CC i
fixed VBN i
CPAP NNP i
at IN i
a DT i
manually RB i
titrated JJ i
pressure NN i
for IN N
1 CD N
week NN N
each DT N
at IN N
home NN N
, , N
with IN N
immediate JJ N
crossover NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Among IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
Treatment NNP p
of IN p
Preserved NNP p
Cardiac NNP p
Function NNP p
Heart NNP p
Failure NNP p
With IN p
an DT p
Aldosterone NNP p
Antagonist NNP p
Trial NNP p
( ( p
TOPCAT NNP p
) ) p
, , p
3400 CD p
patients NNS p
completed VBD p
the DT p
Kansas NNP p
City NNP p
Cardiomyopathy NNP p
Questionnaire NNP p
, , p
3395 CD p
patients NNS p
completed VBN p
European JJ p
QOL NNP p
5D CD p
Visual NNP p
Analog NNP p
Scale NNP p
, , p
and CC p
1431 CD p
patients NNS p
in IN p
United NNP p
States NNPS p
and CC p
Canada NNP p
completed VBD p
the DT p
Patient NNP p
Health NNP p
Questionnaire-9 NNP p
. . p

Thirty NNP p
healthy JJ p
volunteers NNS p
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP i
suppositories NNS i
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP i
ointment NN i
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN i
suppositories NNS i
and CC i
ointment NN i
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

We PRP N
conducted VBD N
a DT N
placebo-controlled JJ i
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
palifermin NN i
( ( N
keratinocyte JJ N
growth NN N
factor NN N
) ) N
, , N
given VBN N
at IN N
60 CD N
? . N
per IN N
daily JJ N
IV NNP N
for IN N
3 CD N
d NN N
before IN N
and CC N
after IN N
chemotherapy NN N
, , N
for IN N
mucosal NN N
protection NN N
in IN N
adult NN p
patients NNS p
with IN p
previously RB p
untreated VBN p
AML NNP p
receiving VBG p
induction NN p
therapy NN p
with IN p
idarubicin NN i
, , i
high-dose JJ i
cytarabine NN i
and CC i
etoposide NN i
. . i

CONCLUSIONS NNP N
Caudal NNP i
neostigmine NN i
( ( N
2 CD N
, , N
3 CD N
and CC N
4 CD N
microg.kg NN N
( ( N
-1 NNP N
) ) N
) ) N
with IN N
bupivacaine NN i
produces VBZ N
a DT N
dose-independent JJ o
analgesic JJ o
effect NN o
( ( N
approximately RB N
16-17 JJ N
hr NN N
) ) N
in IN N
children NNS N
as IN N
compared VBN N
to TO N
those DT N
receiving VBG N
caudal JJ i
bupivacaine NN i
alone RB N
( ( N
approximately RB N
five CD N
hours NNS N
) ) N
and CC N
a DT N
reduction NN N
in IN N
postoperative JJ N
rescue NN N
analgesic JJ N
consumption NN N
without IN N
increasing VBG N
the DT N
incidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

One CD p
hundred VBD p
seventy-seven JJ p
women NNS p
aged VBD p
41 CD p
+/- JJ p
8 CD p
( ( p
mean JJ p
+/- NNP p
SD NNP p
) ) p
years NNS p
, , p
referred VBD p
for IN p
evaluation NN p
of IN p
excessive JJ p
uterine JJ p
bleeding NN p
, , N
were VBD N
enrolled VBN N
in IN N
an DT N
open-label JJ N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
local JJ i
anesthesia NN i
before IN i
hysteroscopy NN i
in IN p
an DT p
outpatient JJ p
population NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
studied VBD N
23 CD p
patients NNS p
in IN p
NYHA NNP p
class NN p
II NNP p
and CC p
III NNP p
( ( p
20 CD p
men NNS p
, , p
three CD p
women NNS p
, , p
mean JJ p
age NN p
59+/-9 CD p
years NNS p
) ) p
with IN p
stable JJ p
CHF NNP p
secondary JJ p
to TO p
ischaemic VB p
heart NN p
disease NN p
[ NNP p
ejection NN p
fraction NN p
37+/-7 CD p
% NN p
] NN p
, , N
using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
design NN N
. . N

In IN N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
, , N
young JJ p
men NNS p
( ( p
aged VBN p
13-27 NNS p
) ) p
with IN p
moderate JJ p
to TO p
severe VB p
ASD NNP p
received VBD N
the DT N
phytochemical JJ i
sulforaphane NN i
( ( i
n JJ i
= NNP i
29 CD i
) ) i
-- : i
derived VBN i
from IN i
broccoli NN i
sprout NN i
extracts NNS i
-- : i
or CC i
indistinguishable JJ i
placebo NN i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
antiplatelet NN o
activity NN o
of IN o
ASA NNP o
, , o
as IN o
assessed VBN o
by IN o
ARU NNP o
ratio NN o
relative NN o
to TO o
baseline VB o
in IN o
the DT o
VerifyNow NNP o
ASA NNP o
assay VBP o
; : o
suppression NN o
of IN o
serum NN o
thromboxane NN o
B NNP o
( ( N
2 CD N
) ) N
( ( N
TXB NNP N
( ( N
2 CD N
) ) N
) ) N
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

Two CD N
sprays NNS N
of IN N
IB NNP i
at IN N
a DT N
dose NN N
of IN N
42 CD N
micrograms/spray NN N
( ( N
0.06 CD N
% NN N
) ) N
, , N
or CC N
saline NN i
, , N
were VBD N
administered VBN N
intranasally RB N
twice JJ N
daily RB N
for IN N
two CD N
weeks NNS N
, , N
after IN N
which WDT N
time NN N
the DT N
participants NNS N
were VBD N
given VBN N
another DT N
nasal NN N
spray NN N
( ( N
either CC N
IB NNP i
or CC i
saline NN i
) ) i
for IN N
the DT N
crossover NN N
portion NN N
of IN N
the DT N
study NN N
. . N

A DT N
stratified JJ N
random JJ N
sample NN N
of IN N
450 CD p
parents NNS p
were VBD N
randomized VBN N
into IN N
three CD N
incentive JJ N
groups NNS N
: : N
( ( N
a DT N
) ) N
no DT N
incentive NN N
; : N
( ( N
b NN N
) ) N
a DT N
promised JJ N
incentive NN N
of IN N
one CD N
lottery NN N
ticket NN N
to TO N
be VB N
received VBN N
upon IN i
reply NN i
; : i
( ( i
c NN i
) ) i
a DT i
promised JJ i
incentive NN i
of IN i
one CD i
lottery NN i
ticket NN i
to TO i
be VB i
received VBN i
upon IN i
reply NN i
and CC i
an DT i
additional JJ i
lottery NN i
ticket NN i
upon IN i
reply NN i
within IN i
1 CD i
week NN i
. . i

The DT N
effects NNS N
of IN N
three CD N
different JJ N
regimens NNS N
of IN N
inhaled JJ i
bronchodilators NNS i
on IN N
spirometry NN o
and CC o
respiratory JJ o
impedance NN o
as IN N
measured VBN N
with IN N
the DT N
technique NN N
of IN N
forced JJ N
oscillations NNS N
were VBD N
compared VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
in IN N
22 CD p
patients NNS p
with IN p
stable JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
FEV1 NNP p
less JJR p
than IN p
70 CD p
percent NN p
predicted VBN p
) ) p
. . p

The DT N
main JJ N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
( ( N
1 CD N
) ) N
compare VBP N
the DT N
plasma NN i
propranolol NN i
concentrations NNS i
( ( i
Cp-prop NNP i
) ) i
following VBG i
sublingual JJ i
administration NN i
of IN i
a DT i
specially RB i
buffered VBN i
formulation NN i
( ( i
Promptol NNP i
) ) i
to TO i
that DT i
following VBG i
oral JJ i
administration NN i
of IN i
Inderal NNP i
( ( i
? . i
) ) i
and CC i
( ( i
2 CD i
) ) i
evaluate VB i
the DT i
utility NN i
of IN i
a DT i
special JJ i
pharmacokinetic JJ i
model NN i
in IN i
describing VBG i
the DT i
Cp-prop NNP i
following VBG i
sublingual JJ i
administration NN i
. . i

A DT N
2 CD N
x NN N
6 CD N
( ( N
treatment NN N
x NNS N
game NN N
day NN N
) ) N
analysis NN N
of IN N
variance NN N
indicated VBD N
that IN N
the DT N
group NN N
practicing VBG N
with IN N
lighter JJR i
balls NNS i
had VBD N
significantly RB N
more RBR N
correct JJ o
sets NNS o
and CC o
a DT o
higher JJR o
average JJ o
daily JJ o
success NN o
rate NN o
for IN N
the DT N
set NN N
and CC N
underhand JJ N
serve NN N
on IN N
game NN N
days NNS N
than IN N
the DT N
group NN N
using VBG N
a DT N
regulation NN N
ball NN N
. . N

The DT N
effect NN N
of IN N
guar NN i
( ( N
15.6 CD N
g/day NN N
) ) N
, , N
a DT N
dietary JJ i
fibre NN i
, , i
and CC i
simultaneous JJ i
administration NN i
of IN i
bezafibrate NN i
( ( N
600 CD N
mg/day NN N
) ) N
during IN N
dietetic JJ N
treatment NN N
on IN N
the DT N
plasma NN N
lipoproteins NNS N
and CC N
apolipoproteins NNS N
was VBD N
investigated VBN N
in IN N
12 CD p
patients NNS p
with IN p
familial JJ p
hypercholesterolemia NN p
( ( p
corresponding VBG p
to TO p
the DT p
HLP NNP p
type NN p
IIa NNP p
pattern NN p
) ) p
. . p

INTERVENTIONS JJ N
Patients NNS N
were VBD N
premedicated VBN i
with IN i
oral JJ i
temazepam NN i
20 CD i
mg. NN i
Anesthesia NNP i
was VBD i
induced VBN i
with IN i
either DT i
eltanolone NN i
0.58 CD i
mg/kg NN i
or CC i
propofol VB i
1.7 CD i
mg/kg NN i
, , i
neuromuscular JJ i
blockade NN i
was VBD i
achieved VBN i
with IN i
vecuronium NN i
0.1 CD i
mg/kg NN i
, , i
and CC i
anesthesia NN i
was VBD i
maintained VBN i
with IN i
enflurane JJ i
0.5 CD i
% NN i
to TO i
1.0 CD i
% NN i
in IN i
nitrous JJ i
oxide NN i
( ( N
67 CD N
% NN N
) ) N
. . N

Using VBG N
logistic JJ N
regression NN N
, , N
we PRP N
estimated VBD N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
to TO N
prospectively RB N
evaluate VB N
the DT N
association NN N
between IN N
lignan NN N
and CC N
proanthocyanidin JJ N
intake NN N
, , N
estimated VBN N
from IN N
databases NNS N
linked VBN N
to TO N
a DT N
food NN N
frequency NN N
questionnaire NN N
, , N
and CC N
adenoma JJ o
recurrence NN o
in IN N
1,859 CD N
participants NNS N
of IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

METHODS NNP N
Pregnant NNP p
women NNS p
with IN p
WHO NNP p
stage VBP p
1 CD p
, , p
2 CD p
, , p
or CC p
3 CD p
HIV-1 JJ p
infection NN p
who WP p
had VBD p
CD4 NNP p
cell NN p
counts NNS p
of IN p
200-500 JJ p
cells NNS p
per IN p
? . p
were VBD p
enrolled VBN p
at IN p
five CD p
study NN p
sites NNS p
in IN p
Burkina NNP p
Faso NNP p
, , p
Kenya NNP p
, , p
and CC p
South NNP p
Africa NNP p
to TO p
start VB p
study VB p
treatment NN p
at IN p
28-36 JJ p
weeks NNS p
' POS p
gestation NN p
. . p

In IN N
addition NN N
, , N
because IN N
the DT N
duration NN N
of IN N
stimulation NN N
does VBZ N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
the DT N
usage NN N
of IN N
300 CD N
IU NNP N
rFSH NN N
in IN N
microdose JJ N
cycles NNS N
results NNS N
in IN N
less JJR N
total JJ N
amount NN N
of IN N
rFSH NN N
consumed VBN N
in IN N
a DT N
cycle NN N
compared VBN N
with IN N
higher JJR N
dosages NNS N
, , N
and CC N
this DT N
would MD N
obviously RB N
cost VB N
less JJR N
money NN N
to TO N
the DT N
patients NNS N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC N
ibuprofen $ i
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC N
acetaminophen $ i
300 CD N
mg NN N
. . N

The DT N
median JJ o
number NN o
of IN o
total JJ o
bleeding NN o
episodes NNS o
and CC o
total JJ o
bleeding NN o
episodes NNS o
per IN o
year NN o
were VBD N
significantly RB N
lower JJR N
with IN N
prophylaxis NN N
than IN N
with IN N
on-demand JJ N
treatment NN N
( ( N
total JJ N
, , N
0 CD N
vs. FW N
54.5 CD N
; : N
total JJ N
per IN N
year NN N
, , N
0 CD N
vs. FW N
27.9 CD N
; : N
both DT N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
cisapride NN i
, , N
10 CD N
mg NN N
three CD N
times NNS N
daily RB N
, , N
in IN N
improving VBG N
gastric JJ o
emptying NN o
, , o
reducing VBG o
distress NN o
during IN o
meals NNS o
, , o
and CC o
facilitating VBG o
weight JJ o
gain NN o
in IN N
anorexia JJ p
nervosa NN p
, , N
we PRP N
conducted VBD N
an DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
on IN N
29 CD p
inpatients NNS p
. . p

When WRB N
entered VBN N
together RB N
into IN N
a DT N
regression NN N
analysis NN N
, , N
metrics NNS N
that IN N
represented VBD N
( ( N
a DT N
) ) N
the DT N
number NN o
of IN o
parent NN o
utterances NNS o
following VBG o
into IN o
the DT o
child NN o
's POS o
focus NN o
of IN o
attention NN o
and CC o
( ( o
b NN o
) ) o
the DT o
number NN o
of IN o
parent NN o
utterances NNS o
responding VBG o
to TO o
child VB o
verbal JJ o
communication NN o
acts NNS o
both DT N
accounted VBD N
for IN N
unique JJ N
variance NN N
in IN N
predicting VBG N
change NN N
in IN N
spoken JJ N
vocabulary NN N
from IN N
Time NNP N
1 CD N
to TO N
Time NNP N
2 CD N
. . N

OBJECTIVE NN N
This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
a DT N
12-week JJ N
, , N
low-intensity JJ i
( ( i
1-hour/wk CD i
of IN i
therapist JJ i
contact NN i
) ) i
, , i
parent-delivered JJ i
intervention NN i
for IN N
toddlers NNS p
at IN p
risk NN p
for IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
aged VBD p
14 CD p
to TO p
24 CD p
months NNS p
and CC p
their PRP$ p
families NNS p
. . p

At IN N
the DT N
point NN N
of IN N
protocol-defined JJ N
study NN N
completion NN N
( ( N
85 CD N
% NN N
mortality NN N
in IN N
the DT N
placebo NN N
arm NN N
) ) N
there EX N
was VBD N
a DT N
modest JJ N
difference NN N
in IN N
survival NN o
in IN N
the DT N
intention-to-treat JJ N
population NN N
in IN N
favour NN N
of IN N
marimastat NN i
( ( N
P=0.07 NNP N
log-rank JJ N
test NN N
, , N
hazard NN N
ratio=1.23 NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.98-1.55 NNP N
) ) N
) ) N
. . N

RESULTS NNP N
Among IN N
423 CD p
participants NNS p
with IN p
1 CD p
study NN p
eye NN p
, , N
the DT N
correct JJ o
assignment NN o
was VBD N
stated VBN N
by IN N
9.9 CD N
% NN N
of IN N
the DT N
sham NN N
plus CC N
prompt JJ N
laser NN N
group NN N
, , N
88.0 CD N
% NN N
of IN N
the DT N
ranibizumab NN i
plus CC i
prompt JJ i
laser NN i
group NN N
, , N
89.6 CD N
% NN N
of IN N
the DT N
unmasked JJ N
ranibizumab NN i
plus CC i
deferred JJ i
laser NN i
group NN N
, , N
and CC N
44.0 CD N
% NN N
of IN N
the DT N
triamcinolone NN N
plus CC N
prompt JJ N
laser NN N
group NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
observation NN N
period NN N
, , N
the DT N
clinical JJ o
course NN o
of IN o
scar NN o
development NN o
was VBD N
rated VBN N
as IN N
very RB N
good JJ N
or CC N
good JJ N
in IN N
more JJR N
than IN N
90 CD N
% NN N
of IN N
the DT N
treated JJ N
patients NNS N
, , N
good JJ N
in IN N
less JJR N
than IN N
40 CD N
% NN N
and CC N
moderate JJ N
or CC N
bad JJ N
in IN N
more JJR N
than IN N
60 CD N
% NN N
of IN N
the DT N
untreated JJ N
cases NNS N
. . N

METHODS NNP N
Sixteen NNP p
overweight MD p
to TO p
obese VB p
adults NNS p
( ( p
BMI NNP p
30.6 CD p
? . p
0.8 CD p
; : p
67.2 CD p
? . p
4.0 CD p
years NNS p
of IN p
age NN p
) ) p
with IN p
either DT p
impaired JJ p
fasting NN p
glucose NN p
, , p
or CC p
impaired VBD p
glucose JJ p
tolerance NN p
completed VBD p
one CD p
of IN p
two CD p
lifestyle JJ p
interventions NNS p
: : p
DIWL NNP p
( ( p
n JJ p
= NNP p
8 CD p
) ) p
or CC p
EX NNP p
( ( p
n JJ p
= NNP p
8 CD p
) ) p
. . p

Orally RB N
administered VBN N
furosemide NN i
, , N
at IN N
doses NNS N
commonly RB N
used VBN N
in IN N
the DT N
clinic NN N
( ( N
40 CD N
mg NN N
) ) N
, , N
significantly RB N
reduced VBN N
spinal JJ o
inhibitory JJ o
interneuronal JJ o
activity NN o
for IN N
at IN N
least JJS N
70 CD N
min NN N
from IN N
intake NN N
compared VBN N
to TO N
control VB N
experiments NNS N
in IN N
the DT N
same JJ N
subjects NNS N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
. . N

One CD N
half NN N
of IN N
the DT N
home NN N
studies NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
performed VBN N
with IN N
a DT N
sleep JJ N
technician NN N
's POS N
set VBN N
up IN N
of IN N
the DT N
equipment NN N
in IN N
the DT N
patient NN N
's POS N
home NN N
( ( N
group NN N
1 CD N
) ) N
, , N
and CC N
the DT N
other JJ N
half NN N
with IN N
the DT N
patient NN N
's POS N
own JJ N
setup NN N
of IN N
the DT N
sleep-recording JJ N
device NN N
( ( N
group NN N
2 CD N
) ) N
, , N
after IN N
an DT N
instruction NN N
period NN N
in IN N
the DT N
hospital NN N
. . N

Patients NNS N
with IN N
a DT N
stable JJ N
response NN N
( ( N
? . N
25 CD N
% NN N
decrease NN N
in IN N
Aberrant NNP o
Behavior NNP o
Checklist-irritability NNP o
subscale NN o
score NN o
and CC N
a DT N
rating NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
) ) N
for IN N
12 CD N
consecutive JJ N
weeks NNS N
were VBD N
randomized VBN N
into IN N
phase NN N
2 CD N
to TO N
continue VB N
aripiprazole NN N
or CC N
switch VB N
to TO N
placebo VB i
. . i

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT p
hypersensitive JJ p
root NN p
surfaces NNS p
of IN p
selected VBN p
teeth NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD i
of IN i
3 CD i
treatments NNS i
: : i
coating NN i
with IN i
a DT i
self-etching JJ i
adhesive NN i
( ( i
Linkmax NNP i
) ) i
and CC i
its PRP$ i
respective JJ i
cement NN i
, , i
coating VBG i
with IN i
a DT i
conventionally RB i
etched VBN i
adhesive NN i
( ( i
RelyX NNP i
ARC NNP i
) ) i
and CC i
its PRP$ i
cement NN i
, , i
or CC i
no DT i
treatment NN i
( ( i
negative JJ i
control NN i
) ) i
. . i

PATIENTS NNS N
AND CC N
METHODS NNP N
20 CD p
adult NN p
patients NNS p
with IN p
GHD NNP p
( ( p
eleven JJ p
male NN p
, , p
nine CD p
female NN p
, , p
mean JJ p
age NN p
42.5 CD p
years NNS p
) ) p
were VBD p
included VBN p
in IN p
the DT p
study NN p
and CC p
randomized VBN p
to TO p
either DT p
GH NNP i
or CC i
placebo NN i
in IN N
a DT N
dose NN N
of IN N
0.25 CD N
U/kg NNP N
body NN N
weight/week NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
examine VB N
the DT N
feasibility NN N
and CC N
treatment NN N
efficacy NN N
of IN N
a DT N
Korean JJ i
version NN i
of IN i
PEERS NNP i
( ( i
? . i
) ) i
for IN N
enhancing VBG N
social JJ N
skills NNS N
through IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
.The VBP N
English JJ N
version NN N
of IN N
the DT N
PEERS NNP i
( ( i
? . i
) ) i
Treatment NN i
Manual NNP i
( ( i
Laugeson NNP i
& CC p
Frankel NNP p
, , p
2010 CD p
) ) p
was VBD p
translated VBN p
into IN p
Korean NNP p
and CC p
reviewed VBN p
by IN p
21 CD p
child JJ p
mental JJ p
health NN p
professionals NNS p
. . p

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
danazol NN i
and CC i
triptorelin NN i
( ( N
Decapeptyl NNP N
CR NNP N
, , N
Ferring NNP N
, , N
Kiel NNP N
, , N
Germany NNP N
) ) N
in IN N
the DT N
management NN N
of IN N
moderate JJ N
and CC N
severe JJ N
endometriosis NN N
in IN N
terms NNS N
of IN N
symptom NN o
control NN o
and CC o
revised VBN o
American JJ o
Fertility NNP o
Society NNP o
( ( o
AFS NNP o
) ) o
score NN o
reduction NN o
, , N
and CC N
to TO N
evaluate VB N
the DT N
hormonal JJ N
profile NN N
of IN N
patients NNS N
treated VBN N
with IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

Postoperative JJ o
visual JJ o
analog NN o
pain NN o
scale NN o
( ( o
VAS NNP o
) ) o
scores VBZ o
at IN N
8 CD N
and CC N
24 CD N
hours NNS N
and CC N
14 CD N
days NNS N
after IN N
surgery NN N
, , N
in-hospital JJ o
analgesic JJ o
use NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
success NN o
rate NN o
, , o
blood NN o
transfusion NN o
rate NN o
, , o
and CC o
postoperative JJ o
complications NNS o
were VBD N
compared VBN N
for IN N
the DT N
two CD N
groups NNS N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
with IN N
placebo NN i
study NN N
, , N
27 CD p
women NNS p
with IN p
climacteric JJ p
symptoms NNS p
and CC p
atrophic JJ p
vaginitis NN p
were VBD N
treated VBN N
for IN N
4 CD N
months NNS N
with IN N
HT NNP i
plus CC i
vaginal JJ i
estriol NN i
0.5 CD i
mg/day NN i
( ( i
group NN i
E NNP i
) ) i
or CC i
placebo NN i
( ( N
group NN N
P NNP N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
10 CD p
healthy JJ p
subjects NNS p
received VBN N
, , N
on IN N
each DT N
of IN N
5 CD N
dosing VBG N
occasions NNS N
, , N
MTX NNP i
alone RB i
as IN i
tablets NNS i
or CC i
intravenous JJ i
solution NN i
, , i
HCQ NNP i
alone RB i
as IN i
a DT i
tablet NN i
or CC i
oral JJ i
solution NN i
, , i
or CC i
a DT i
coadministered JJ i
dose NN i
of IN i
MTX NNP i
tablets NNS i
with IN i
an DT i
HCQ NNP i
tablet NN i
. . i

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
compare VB N
injection NN N
pain NN N
and CC N
postinjection NN N
pain NN N
of IN N
2 CD N
% NN N
lidocaine NN i
with IN N
1:100,000 CD N
epinephrine NN i
and CC i
3 CD i
% NN i
mepivacaine NN i
using VBG i
the DT i
computer-assisted JJ i
Wand NNP i
Plus NNP i
injection NN i
system NN i
to TO i
administer VB i
the DT i
palatal-anterior JJ i
superior JJ i
alveolar NN i
( ( i
P-ASA NNP i
) ) i
injection NN i
. . i

This DT N
prospective JJ N
study NN N
assesses VBZ N
the DT N
effect NN N
of IN N
2.5 CD N
, , N
4 CD i
, , i
and CC i
10 CD i
mg NN i
of IN i
pyridoxine JJ i
supplementation NN i
during IN i
pregnancy NN i
on IN i
maternal JJ o
and CC o
fetal JJ o
plasma NN o
levels NNS o
of IN o
pyridoxal NN o
5'-phosphate JJ o
( ( o
PLP NNP o
) ) o
and CC N
on IN N
the DT N
degree NN o
of IN o
coenzyme NN o
saturation NN o
( ( o
activation JJ o
factor NN o
) ) o
of IN o
aspartate NN o
aminotransferase NN o
and CC o
alanine JJ o
aminotransferase NN o
( ( o
alphaEGOT JJ o
and CC o
alphaEGPT NN o
) ) o
in IN o
maternal JJ o
erythrocytes NNS o
. . o

Before IN N
the DT N
ISDN NNP i
treatment NN i
, , i
GTN NNP i
reduced VBD N
exercise NN N
PAWP NNP N
to TO N
13.9 CD N
+/- JJ N
5.27 CD N
mmHg NN N
and CC N
MAP NNP N
to TO N
119 CD N
+/- JJ N
11.2 CD N
mmHg NN N
, , N
whereas NNS N
after IN N
4 CD N
weeks NNS N
ISDN NNP N
treatment NN N
, , N
the DT N
addition NN N
of IN N
GTN NNP i
did VBD N
not RB N
reduce VB N
exercise NN o
PAWP NNP o
and CC o
MAP NNP o
to TO N
the DT N
same JJ N
low JJ N
levels NNS N
. . N

This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
intervention NN N
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP i
Cancer NNP i
Education NNP i
Intervention NNP i
( ( i
BCEI NNP i
) ) i
on IN N
overall JJ o
QOL NNP o
. . o

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
overall JJ o
recurrent JJ o
thromboembolic JJ o
events NNS o
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP i
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN i
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
. . N

Do VB N
colonic JJ N
short-chain NN N
fatty JJ N
acids NNS N
contribute NN N
to TO N
the DT N
long-term JJ N
adaptation NN N
of IN N
blood NN N
lipids NNS N
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
consuming VBG p
a DT p
high-fiber JJ p
diet NN p
? . N
BACKGROUND NNP N
We PRP N
recently RB N
obtained VBD N
evidence NN N
of IN N
long-term JJ N
adaptation NN N
of IN N
blood NN N
lipids NNS N
to TO N
changes NNS N
in IN N
intakes NNS N
of IN N
carbohydrate NN i
and CC i
fiber NN i
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

At IN N
the DT N
end NN N
of IN N
the DT N
3 CD N
wk NN N
, , N
we PRP N
measured VBD N
plasma JJ o
inflammatory JJ o
markers NNS o
IL-6 NNP o
, , o
C-reactive NNP o
protein NN o
, , o
tumor NN o
necrosis NN o
factor NN o
receptors NNS o
I PRP o
and CC o
II NNP o
( ( o
TNF-RI NNP o
and CC o
-RII NNP o
) ) o
, , o
monocyte JJ o
chemotactic JJ o
protein-1 NN o
and CC o
E-selectin NNP o
, , o
and CC o
urinary JJ o
8-iso-PGF NN o
( ( o
2 CD o
) ) o
, , o
a DT o
marker NN o
of IN o
lipid JJ o
peroxidation NN o
. . o

After IN N
a DT N
1-week JJ N
, , N
single-blind JJ i
placebo NN i
run-in NN N
, , N
patients NNS N
received VBD N
a DT N
single JJ N
daily JJ N
dose NN N
of IN N
amantadine NN i
( ( N
2.5 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
placebo NN i
for IN N
the DT N
next JJ N
week NN N
, , N
and CC N
then RB N
bid VB N
dosing VBG N
( ( N
5.0 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
. . N

This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
with IN N
blinded JJ N
assessment NN N
of IN N
endpoints NNS N
to TO N
compare VB N
the DT N
2-year JJ N
effect NN N
of IN N
strict JJ N
treatment NN N
to TO N
maintain VB N
systolic JJ o
blood NN o
pressure NN o
below IN N
140 CD N
mmHg NN N
with IN N
that DT N
of IN N
mild JJ N
treatment NN N
to TO N
maintain VB N
systolic JJ N
blood NN N
pressure NN N
below IN N
160 CD N
but CC N
at IN N
or CC N
above IN N
140 CD N
mmHg NN N
in IN N
elderly JJ p
hypertensive JJ p
patients NNS p
. . p

In IN N
the DT N
clinical JJ N
trial NN N
, , N
the DT N
rate NN o
of IN o
ulcer NN o
healing VBG o
within IN N
8 CD N
weeks NNS N
was VBD N
77.9 CD N
% NN N
( ( N
67/86 CD N
) ) N
in IN N
patients NNS N
receiving VBG N
6 CD N
micrograms NNS N
EGF NNP N
intravenously RB N
twice RB N
a DT N
week NN N
, , N
being VBG N
significantly RB N
greater JJR N
than IN N
51.7 CD N
% NN N
( ( N
45/87 CD N
) ) N
in IN N
those DT N
given VBN N
CH NNP N
. . N

In IN N
the DT N
6- JJ N
to TO N
< VB N
16-week JJ N
cohort NN N
, , N
more JJR N
influenza JJ N
vaccine NN N
, , N
recipients NNS N
experienced VBD N
irritability NN N
( ( N
66.7 CD N
% NN N
vs JJ N
35.7 CD N
% NN N
) ) N
and CC N
runny JJ o
nose NN o
or CC o
nasal JJ o
congestion NN o
( ( N
63.3 CD N
% NN N
vs JJ N
33.3 CD N
% NN N
) ) N
after IN N
dose JJ N
1 CD N
but CC N
not RB N
dose JJ N
2 CD N
. . N

RESULTS NNP N
While IN N
12-month JJ N
self-reported JJ o
abstinence NN o
was VBD N
consistent JJ N
with IN N
other JJ N
published VBN N
studies NNS N
of IN N
smoking VBG i
cessation NN i
( ( N
22 CD N
% NN N
and CC N
26 CD N
% NN N
point NN N
prevalence NN N
abstinence NN N
for IN N
Proactive NNP N
and CC N
Reactive NNP N
conditions NNS N
, , N
respectively RB N
) ) N
, , N
48 CD N
% NN N
of IN N
participants NNS N
who WP N
were VBD N
tested VBN N
for IN N
cotinine NN N
failed VBD N
biochemical JJ N
verification NN N
, , N
indicating VBG N
a DT N
considerable JJ N
falsification NN N
of IN N
self-reported JJ N
cessation NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
simvastatin NN i
( ( i
MK NNP i
733 CD i
) ) i
, , i
a DT i
new JJ i
competitive JJ i
inhibitor NN i
of IN i
HMG NNP i
CoA NNP i
reductase NN i
, , i
alone RB i
and CC i
in IN i
combination NN i
with IN i
a DT i
bile JJ i
acid NN i
sequestrant NN i
, , i
cholestyramine NN i
, , N
on IN N
serum NN N
levels NNS N
of IN N
lipoproteins NNS N
and CC N
apoproteins NNS N
A1 NNP N
and CC N
B NNP N
, , N
in IN N
24 CD p
patients NNS p
with IN p
familial JJ p
hypercholesterolemia NN p
. . p

AIM NNP N
To TO N
determine VB N
the DT N
proportion NN N
of IN N
patients NNS N
achieving VBG N
tacrolimus JJ o
whole-blood JJ o
concentrations NNS o
of IN N
? . N
ng/mL NN N
within IN N
3 CD N
days NNS N
of IN N
kidney NN N
transplantation NN N
, , N
after IN N
randomization NN N
either RB N
to TO N
standard VB N
dosing VBG N
( ( N
control VB N
group NN N
) ) N
or CC N
post-transplantation NN i
dosing NN i
guided VBN i
by IN N
a DT N
2-hour JJ N
( ( N
C NNP N
( ( N
2 CD N
) ) N
) ) N
level NN N
following VBG N
a DT N
preoperative JJ N
tacrolimus NN i
dose NN N
( ( N
T2 NNP N
group NN N
) ) N
. . N

CONCLUSIONS NNP N
Tapentadol NNP i
PR NNP i
500 CD N
mg NN N
is VBZ N
associated VBN N
with IN N
comparable JJ N
improvements NNS N
in IN N
pain NN o
intensity NN o
and CC o
quality-of-life JJ o
measures NNS o
to TO N
tapentadol VB N
PR NNP N
300 CD N
mg/pregabalin NN N
300 CD N
mg NN N
, , N
with IN N
improved JJ N
central JJ o
nervous JJ o
system NN o
tolerability NN o
, , N
suggesting VBG N
that IN N
tapentadol NN i
PR NNP i
monotherapy NN i
may MD N
offer VB N
a DT N
favorable JJ N
treatment NN N
option NN N
for IN N
severe JJ p
low JJ p
back RB p
pain NN p
with IN p
a DT p
neuropathic JJ p
component NN p
. . p

After IN N
a DT N
pseudo-randomization NN i
, , i
usual JJ i
pain NN i
management NN i
( ( N
n JJ N
= NNP N
132 CD N
) ) N
was VBD N
compared VBN N
to TO N
a DT N
multifactorial JJ N
strategy NN N
( ( N
n JJ N
= NNP N
107 CD N
) ) N
associating VBG N
preliminary JJ N
application NN N
of IN N
an DT N
anesthesic JJ i
patch NN i
, , i
preferential JJ i
use NN i
of IN i
specified JJ i
vaccines NNS i
, , i
child JJ i
education NN i
by IN i
the DT i
parents NNS i
and CC i
the DT i
doctor NN i
, , i
parental JJ i
accompaniment NN i
and CC i
child JJ i
distraction NN i
with IN i
soap NN i
bubbles NNS i
during IN i
the DT i
procedure NN i
. . i

CRP NNP o
, , o
IL-6 NNP o
, , o
IL-8 NNP o
, , o
HIF-1 NNP o
( ( o
ELISA NNP o
) ) o
, , o
CD11 NNP o
and CC o
CD18 NNP o
expression NN o
( ( o
flow JJ o
cytometry NN o
) ) o
, , o
and CC o
haemoxygenase NN o
( ( o
HO-1 NNP o
) ) o
promoter NN o
polymorphisms NN o
( ( o
PCR/electrophoresis NNP o
) ) o
were VBD N
measured VBN N
before IN N
anaesthetic JJ N
induction NN N
, , N
4 CD N
hours NNS N
post-CPB JJ N
, , N
and CC N
24 CD N
hours NNS N
later RB N
. . N

METHODS NNP N
Pronuclear-stage NNP p
human JJ p
embryos NN p
were VBD N
randomly RB N
divided VBN N
and CC N
cultured VBN N
in IN N
human JJ i
tubal JJ i
fluid NN i
medium NN i
( ( i
HTF NNP i
) ) i
supplemented VBD i
with IN i
either DT i
HSA NNP i
( ( i
5 CD i
mg/mL NN i
) ) i
or CC i
Plasmatein NNP i
( ( i
10 CD i
% NN i
, , i
v/v NN i
; : i
5 CD i
mg/ml NN i
) ) i
as IN i
a DT i
means NN i
of IN i
indirectly RB i
assessing VBG i
the DT i
effect NN i
alpha- JJ i
and CC i
beta-globulins NNS i
have VBP i
on IN i
embryonic JJ i
development NN i
. . i

Twenty-nine JJ p
patients NNS p
were VBD p
treated VBN p
with IN p
laparoscopic NN i
assisted VBN i
vaginal JJ i
hysterectomy NN i
( ( i
LAVH NNP i
) ) i
and CC i
bilateral JJ i
salpingo-oophrectomy NN i
( ( i
BSO NNP i
) ) i
plus CC i
minus CC i
laparoscopic JJ i
pelvic JJ i
lymphadenectomy NN i
( ( i
LPLA NNP i
) ) i
, , p
while IN p
32 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
the DT p
traditional JJ i
laparotomy NN i
and CC i
underwent JJ i
total JJ i
abdominal JJ i
hysterectomy NN i
( ( i
TAH NNP i
) ) i
and CC i
BSO NNP i
plus CC i
minus CC i
pelvic JJ i
lymphadenectomy NN i
( ( i
PLA NNP i
) ) i
. . i

METHODS NNP N
Children NNP p
with IN p
core NN p
autism NN p
( ( p
aged VBN p
2 CD p
years NNS p
to TO p
4 CD p
years NNS p
and CC p
11 CD p
months NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
in IN p
a DT p
one-to-one JJ p
ratio NN p
to TO p
a DT p
parent-mediated JJ i
communication-focused JJ i
( ( i
Preschool NNP i
Autism NNP i
Communication NNP i
Trial NNP i
[ NNP i
PACT NNP i
] NNP i
) ) i
intervention NN i
or CC i
treatment NN i
as IN i
usual JJ i
at IN i
three CD i
specialist NN i
centres NNS i
in IN i
the DT i
UK NNP i
. . i

Among IN N
women NNS N
treated VBN N
with IN N
goserelin NN N
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
the DT N
proportion NN o
of IN o
menstruating VBG o
women NNS o
, , N
1 CD N
year NN N
after IN N
completed VBN N
treatment NN N
compared VBN N
to TO N
at IN N
24 CD N
months NNS N
of IN N
treatment NN N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
in IN N
contrast NN N
to TO N
all DT N
other JJ N
treatment NN N
groups NNS N
, , N
who WP N
were VBD N
unchanged JJ N
or CC N
more RBR N
often RB N
amenorrheic JJ N
. . N

Pooled VBN N
analysis NN N
of IN N
VACT1/VACT2 NNP N
demonstrated VBD N
greater JJR N
PGART NNP N
( ( N
p=0.023 NN N
) ) N
with IN N
rofecoxib NN N
25 CD N
mg NN N
( ( N
56.1 CD N
% NN N
) ) N
than IN N
celecoxib NN i
( ( N
49.8 CD N
% NN N
) ) N
at IN N
6 CD N
weeks NNS N
and CC N
greater JJR N
response NN N
to TO N
all DT N
other JJ N
PGART NNP N
and CC N
WOMAC NNP N
endpoints NNS N
, , N
and CC N
confirmed VBD N
superiority NN N
of IN N
COX-2 NNP N
inhibitors NNS N
to TO N
acetaminophen VB i
. . i

METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
with IN N
21 CD p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
diagnoses NNS p
, , N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
, , N
who WP N
received VBD N
the DT N
same JJ N
short-term JJ i
intervention NN i
types NNS i
( ( i
6 CD i
weeks NNS i
with IN i
the DT i
mother NN i
and CC i
6 CD i
weeks NNS i
with IN i
the DT i
support NN i
of IN i
an DT i
educational JJ i
software NN i
program NN i
) ) i
. . i

Fifty-two JJ p
patients NNS p
with IN p
severe JJ p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
from IN p
four CD p
Australian JJ p
centres NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
cyclosporin NN i
A NNP i
( ( i
CSA NNP i
) ) i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
azathioprine NN i
( ( i
AZA NNP i
) ) i
( ( N
n JJ N
= NNP N
27 CD N
) ) N
for IN N
six CD N
months NNS N
. . N

Evaluation NN N
of IN N
different JJ N
inhaled JJ i
combination NN i
therapies NNS i
( ( i
EDICT NNP i
) ) i
: : i
a DT N
randomised JJ N
, , N
double-blind JJ N
comparison NN N
of IN N
Seretide NNP i
( ( i
50/250 CD i
microg NN i
bd NN i
Diskus NNP i
vs. FW i
formoterol NN i
( ( N
12 CD N
microg RB N
bd NN N
) ) N
and CC N
budesonide NN i
( ( N
800 CD N
microg RB N
bd NN N
) ) N
given VBN N
concurrently RB N
( ( N
both DT N
via IN N
Turbuhaler NNP N
) ) N
in IN N
patients NNS p
with IN p
moderate-to-severe JJ p
asthma NN p
. . p

CONCLUSION NN N
In IN N
atrial JJ p
fibrillation NN p
patients NNS p
with IN p
dilated JJ p
left JJ p
atrium NN p
and CC p
hypertension NN p
or CC p
failed VBD p
prior RB p
atrial JJ p
fibrillation NN p
CA NNP i
, , i
SA NNP i
is VBZ N
superior JJ N
to TO N
CA NNP N
in IN N
achieving VBG N
freedom NN N
from IN N
left VBN N
atrial JJ N
arrhythmias NNS N
after IN N
12 CD N
months NNS N
of IN N
follow-up NN N
, , N
although IN N
the DT N
procedural JJ N
adverse JJ N
event NN N
rate NN N
is VBZ N
significantly RB N
higher JJR N
for IN N
SA NNP N
than IN N
for IN N
CA NNP N
. . N

Analysing VBG N
response NN N
to TO N
FUFA NNP N
and CC N
FOLFIRI NNP N
in IN N
the DT N
per NN N
protocol NN N
set VBN N
( ( N
n=119 NN N
) ) N
after IN N
un-blinding JJ N
TS NNP N
in IN N
the DT N
data NN N
base NN N
revealed VBD N
a DT N
trend NN N
to TO N
better JJR N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
( ( N
9/19 CD N
, , N
47 CD N
% NN N
) ) N
in IN N
TS NNP N
high JJ N
compared VBN N
to TO N
FUFA NNP N
( ( N
5/23 CD N
, , N
22 CD N
% NN N
, , N
p=0.077 NN N
) ) N
. . N

RESULTS JJ N
Participants NNS N
failing VBG N
to TO N
achieve VB N
a DT N
? . N
% NN N
weight JJ o
loss NN o
at IN N
Month NNP N
1 CD N
were VBD N
5.6 CD N
( ( N
95 CD N
% NN N
CI:4.5 NNP N
, , N
7.0 CD N
) ) N
times NNS N
more RBR N
likely JJ N
to TO N
also RB N
not RB N
achieve VB N
a DT N
? . N
% NN N
weight JJ o
loss NN o
at IN N
Year NNP N
1 CD N
, , N
compared VBN N
to TO N
those DT N
losing VBG N
? . N
% NN N
initially RB N
. . N

In IN N
order NN N
to TO N
establish VB N
a DT N
set NN N
of IN N
predictive JJ N
equations NNS N
for IN N
the DT N
gas NN o
exchange NN o
, , o
ventilatory NN o
and CC o
cardiovascular JJ o
responses NNS o
to TO N
maximum VB N
ramp-incremental JJ N
cycle NN N
ergometry NN N
, , N
this DT N
study NN N
prospectively RB N
evaluated VBD N
120 CD p
sedentary JJ p
individuals NNS p
( ( p
60 CD p
males NNS p
, , p
60 CD p
females NNS p
, , p
aged VBD p
20-80 CD p
) ) p
, , p
randomly-selected JJ p
from IN p
> JJ p
8,000 CD p
subjects NNS p
. . p

In IN N
a DT N
1-year JJ N
cessation NN N
trial NN N
of IN N
smokers NNS N
with IN N
COPD NNP N
, , N
continuous JJ N
abstinence NN N
compared VBN N
with IN N
continuous JJ N
smoking VBG N
significantly RB N
improved VBN N
post-bronchodilator NN N
FEV NNP N
( ( N
1 CD N
) ) N
at IN N
Week $ N
12 CD N
( ( N
although IN N
the DT N
difference NN N
narrowed VBD N
subsequently RB N
) ) N
and CC N
CCQ NNP o
Total NNP o
Scores NNP o
at IN N
Week NNP N
12 CD N
, , N
with IN N
sustained JJ N
improvement NN N
thereafter RB N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Sixteen NNP p
patients NNS p
who WP p
had VBD p
chronic JJ p
mitral JJ p
regurgitation NN p
due JJ p
to TO p
myxomatous JJ p
degeneration NN p
were VBD p
randomized VBN p
to TO p
preservation NN i
( ( i
Pres NNP i
group NN i
, , i
n RB i
= VBZ i
8 CD i
) ) i
or CC i
no DT i
preservation NN i
( ( i
No NNP i
Pres NNP i
group NN i
, , i
n RB i
= VBZ i
8 CD i
) ) i
of IN i
the DT i
chordae NN i
tendineae NN i
and CC i
papillary JJ i
muscles NNS i
during IN i
mitral JJ i
valve FW i
replacement NN i
. . i

The DT N
most RBS N
noteworthy JJ N
group NN N
difference NN N
was VBD N
observed VBN N
for IN N
cerebrovascular JJ N
end NN N
points NNS N
( ( N
strokes NNS N
and CC N
transient JJ N
ischemic JJ N
attacks NNS N
) ) N
, , N
with IN N
an DT N
incidence NN N
of IN N
8.2 CD N
% NN N
( ( N
9 CD N
patients NNS N
) ) N
in IN N
the DT N
drug NN N
treatment NN N
group NN N
and CC N
19.0 CD N
% NN N
( ( N
23 CD N
patients NNS N
) ) N
in IN N
the DT N
placebo NN i
group NN N
. . N

METHODS NNP N
Three CD p
hundred VBD p
fifty JJ p
patients NNS p
who WP p
had VBD p
reoperation NN p
with IN p
CABG NNP p
only RB p
( ( p
58 CD p
% NN p
) ) p
, , p
or CC p
with IN p
valve JJ p
operations NNS p
( ( p
42 CD p
% NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
a DT N
heparin-coated JJ i
( ( i
Duraflo NNP i
II NNP i
; : i
study VB i
group NN i
) ) i
or CC i
uncoated JJ i
( ( i
control VB i
group NN i
) ) i
circuit NN i
. . i

Bilastine NNP i
was VBD N
characterized VBN N
by IN N
two-compartmental JJ N
kinetics NNS N
with IN N
a DT N
rapid-absorption NN N
phase NN N
( ( N
first-order JJ N
absorption NN N
rate NN N
constant JJ N
= NN N
1.50 CD N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
plasma JJ o
peak NN o
concentrations NNS o
were VBD N
observed VBN N
at IN N
1 CD N
hour NN N
following VBG N
administration NN N
and CC N
the DT N
maximal JJ N
response NN N
was VBD N
observed VBN N
at IN N
approximately RB N
4 CD N
hours NNS N
or CC N
later RB N
. . N

A DT N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
clinical JJ i
hypnosis NN i
versus NN i
cognitive JJ i
behavioral NN i
( ( i
CB NNP i
) ) i
coping VBG i
skills NNS i
training VBG i
in IN N
alleviating VBG N
the DT N
pain NN N
and CC N
distress NN N
of IN N
30 CD p
pediatric JJ p
cancer NN p
patients NNS p
( ( p
age NN p
5 CD p
to TO p
15 CD p
years NNS p
) ) p
undergoing VBG p
bone NN p
marrow NN p
aspirations NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
intervention NN N
study NN N
in IN N
which WDT N
37 CD p
healthy JJ p
, , p
sedentary JJ p
men NNS p
and CC p
women NNS p
( ( p
52+/-2 JJ p
years NNS p
) ) p
performed VBD p
13 CD p
weeks NNS p
of IN p
ST NNP p
( ( p
n=13 NN p
) ) p
, , p
ST+aerobic NNP i
exercise NN i
( ( p
n=12 JJ p
) ) p
or CC p
stretching VBG i
exercises NNS i
as IN N
a DT N
control NN N
group NN N
( ( N
n=12 RB N
) ) N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
conatumumab NN i
( ( N
an DT N
agonistic JJ N
monoclonal NN N
antibody NN N
against IN N
human JJ N
death NN N
receptor NN N
5 CD N
) ) N
and CC N
ganitumab NN N
( ( N
a DT N
monoclonal NN N
antibody NN N
against IN N
the DT N
type NN N
1 CD N
insulin-like JJ N
growth NN N
factor NN N
receptor NN N
) ) N
combined VBN N
with IN N
standard JJ i
FOLFIRI NNP i
chemotherapy NN i
as IN N
a DT N
second-line JJ N
treatment NN N
in IN N
patients NNS N
with IN N
mutant JJ N
KRAS NNP N
mCRC NN N
. . N

PURPOSE NN N
This DT N
study NN N
was VBD N
undertaken VBN N
with IN N
the DT N
null JJ N
hypothesis NN N
that IN N
in IN N
patients NNS p
, , p
fully RB p
denate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
, , p
mastication NN p
does VBZ p
not RB p
affect VB p
late JJ p
mandibular JJ p
fracture NN p
after IN p
surgical JJ p
removal NN p
of IN p
impacted JJ p
third JJ p
molars NNS p
( ( p
M3s NNP p
) ) p
associated VBN p
with IN p
no DT p
gross JJ p
pathology NN p
. . p

We PRP N
used VBD N
logistic JJ N
regression NN N
models NNS N
to TO N
assess VB N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
inadequate JJ N
FSG NNP N
( ( N
defined VBN N
as IN N
a DT N
study NN N
in IN N
which WDT N
the DT N
depth NN N
of IN N
insertion NN N
of IN N
FSG NNP N
was VBD N
< JJ N
50 CD N
cm NN N
or CC N
visual JJ N
inspection NN N
was VBD N
limited VBN N
to TO N
< VB N
90 CD N
% NN N
of IN N
the DT N
mucosal JJ N
surface NN N
but CC N
without IN N
detection NN N
of IN N
a DT N
polyp NN N
or CC N
mass NN N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
completely RB p
resected VBN p
( ( p
stage NN p
IB NNP p
, , p
II NNP p
, , p
or CC p
IIIA NNP p
) ) p
NSCLC NNP p
stratified VBN p
by IN p
stage NN p
, , p
histology NN p
, , p
sex NN p
, , p
postoperative JJ p
radiotherapy NN p
, , p
and CC p
chemotherapy NN p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
gefitinib NN i
250 CD i
mg NN i
per IN i
day NN i
or CC i
placebo NN i
for IN N
2 CD N
years NNS N
. . N

Patients NNS p
were VBD p
randomized VBN p
to TO p
three CD p
treatment NN p
groups NNS p
: : p
SCHEDULE VB p
A NNP p
( ( p
control NN p
) ) p
: : p
conventional JJ p
one CD p
treatment NN p
per IN p
day NN p
regimen NNS p
totalling VBG p
3,760 CD p
rads NNS p
in IN p
22-23 JJ p
days NNS p
; : p
SCHEDULE NNP p
B NNP p
: : p
2 CD p
sessions NNS p
per IN p
day NN p
totalling VBG p
3,440 CD p
rads NNS p
in IN p
10-11 JJ p
days NNS p
; : p
and CC p
SCHEDULE NNP p
C NNP p
: : p
2 CD p
sessions NNS p
per IN p
day NN p
totalling VBG p
3,568 CD p
rads NNS p
in IN p
10-11 JJ p
days NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
variations NNS N
in IN N
implant JJ o
indications NNS o
and CC o
baseline VB o
antiarrhythmic JJ o
drug NN o
use NN o
over IN N
the DT N
3-year JJ N
enrollment NN N
period NN N
, , N
although IN N
an DT N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
dual-chamber JJ o
ICDs NNP o
implanted VBD o
occurred VBD N
, , N
with IN N
the DT N
majority NN N
( ( N
65 CD N
% NN N
) ) N
of IN N
implanted JJ N
ICDs NNP N
being VBG N
dual-chamber JJ N
devices NNS N
by IN N
the DT N
end NN N
of IN N
the DT N
enrollment JJ N
period NN N
. . N

The DT N
diabetic JJ N
patients NNS N
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT N
saline NN N
or CC N
a DT N
smaller JJR N
amount NN N
of IN N
insulin NN N
delivered VBN N
continuously RB N
( ( N
0.15 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC N
in IN N
a DT N
pulsatile JJ N
manner NN N
( ( N
0.97 CD N
mU RB N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused VBN N
) ) N
. . N

AIMS NNP N
To TO N
evaluate VB N
whether IN N
a DT N
combination NN N
of IN N
locally RB N
administered VBN N
morphine NN i
( ( N
1 CD N
mg NN N
) ) N
and CC N
lidocaine NN i
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
analgesic JJ N
approach NN N
is VBZ N
safe JJ N
, , N
and CC N
whether IN N
it PRP N
improves VBZ N
pain JJ o
control NN o
during IN p
the DT p
first JJ p
24 CD p
hours NNS p
after IN p
odontogenic JJ p
maxillary JJ p
cyst NN p
removal NN p
under IN p
general JJ p
anesthesia NN p
compared VBN p
to TO p
local JJ i
lidocaine NN i
alone RB i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
71 CD p
patients NNS p
with IN p
confirmed VBN p
severe JJ p
acute NN p
pancreatitis NN p
from IN p
March NNP p
2009 CD p
to TO p
September NNP p
2011 CD p
in IN p
the DT p
Department NNP p
of IN p
Critical NNP p
Care NNP p
Medicine NNP p
of IN p
Huizhou NNP p
Municipal NNP p
Central NNP p
Hospital NNP p
, , p
Guangdong NNP p
, , p
China NNP p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
. . p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
40 CD N
mg NN N
of IN N
the DT N
beta-blocker NN i
penbutolol NN i
( ( i
Betapressin NNP i
TM NNP i
; : i
Hoechst NNP i
Ltd. NNP i
, , i
Frankfurt/Main NNP i
) ) i
in IN N
comparison NN N
to TO N
placebo VB i
on IN N
the DT N
insulin NN N
consumption NN N
on IN N
the DT N
blood NN N
sugar NN N
profile NN N
in IN N
twelve JJ p
insulin-dependent JJ p
diabetes NNS p
( ( p
IDDM NNP p
) ) p
patients NNS p
. . p

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ i
study NN N
in IN N
25 CD p
healthy JJ p
postmenopausal NN p
women NNS p
( ( p
52.5 CD p
+/- JJ p
2.8 CD p
years NNS p
) ) p
, , N
we PRP N
therefore VBP N
examined VBD N
the DT N
short-term JJ N
effect NN N
of IN N
unopposed JJ i
estrogen NN i
on IN N
the DT N
fasting NN N
and CC N
fat-load-stimulated JJ N
plasma NN N
levels NNS N
of IN N
total JJ i
factor NN i
VII NNP i
versus NN i
active JJ i
factor NN i
VII NNP i
. . i

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
topical JJ i
racemic JJ i
adrenaline NN i
( ( i
RA NNP i
) ) i
( ( i
Micronefrin NNP i
; : i
Bird NNP N
Products NNPS N
, , N
Palm NNP N
Springs NNP N
, , N
CA NNP N
, , N
USA NNP N
) ) N
in IN N
the DT N
control NN N
of IN N
intraoperative JJ N
bleeding NN N
and CC N
the DT N
prevention NN N
of IN N
postoperative JJ p
bleeding NN p
, , p
laryngeal JJ p
spasm NN p
and CC p
postoperative JJ p
pain NN p
in IN p
adenoidectomy NN p
among IN p
children NNS p
< VBP p
6 CD p
years NNS p
of IN p
age NN p
. . p

We PRP N
present VBP N
the DT N
results NNS N
of IN N
two CD N
blind NNS N
randomized JJ N
trials NNS N
comparing VBG N
both DT N
guanethidine JJ i
3 CD i
per IN i
cent NN i
and CC i
adrenaline VB i
0.5 CD i
per IN i
cent NN i
( ( i
Ganda NNP i
3.0/0.5 CD i
) ) i
and CC i
guanethidine $ i
1 CD i
per IN i
cent NN i
and CC i
adrenaline VB i
0.2 CD N
per IN N
cent NN N
( ( N
Ganda NNP N
1.0/0.2 CD N
) ) N
in IN N
single JJ N
drop NN N
form NN N
with IN N
Timolol NNP i
( ( i
Timoptol NNP i
) ) i
0.25 CD N
per IN N
cent NN N
. . N

The DT N
efficacy NN N
of IN N
eprinomectin JJ i
versus NN i
ivermectin NN i
( ( N
Study NNP N
1 CD N
: : N
a DT N
single-centre JJ N
, , N
randomised JJ N
, , N
treatment-controlled JJ N
, , N
blinded VBD N
field NN N
trial NN N
) ) N
, , N
and CC N
the DT N
field NN N
efficacy NN N
of IN N
eprinomectin NN i
( ( N
Study NNP N
2 CD N
: : N
a DT N
single-centre JJ N
, , N
open JJ N
, , N
un-controlled JJ N
field NN N
trial NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
chorioptic JJ N
infestation NN N
in IN N
naturally RB p
infested VBN p
alpacas NN p
were VBD N
assessed VBN N
in IN N
two CD N
studies NNS N
. . N

METHOD NNP N
Eighty-nine NNP p
suppressed VBD p
patients NNS p
> CD p
or CC p
=18 CD p
years NNS p
old JJ p
with IN p
CD4 NNP p
counts VBZ p
> JJ p
50 CD p
cells/mm NN p
( ( p
3 CD p
) ) p
were VBD p
enrolled VBN p
in IN p
this DT p
phase NN p
II NNP p
, , p
open-label NN p
, , p
multicenter NN p
, , N
randomized VBN N
, , N
stratified VBN N
( ( N
by IN N
pretrial JJ i
protease NN i
inhibitor NN i
[ NNP i
PI NNP i
] NNP i
) ) i
, , i
parallel-group JJ i
clinical JJ i
trial NN i
. . i

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
665 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
colorectal JJ p
adenomas NN p
to TO N
three CD N
treatment NN N
groups NNS N
, , N
in IN N
a DT N
parallel JJ N
design NN N
: : N
calcium NN i
gluconolactate NN i
and CC i
carbonate NN i
( ( i
2 CD i
g NN i
elemental JJ i
calcium NN i
daily RB i
) ) i
, , i
fibre JJ i
( ( i
3.5 CD i
g NN i
ispaghula NN i
husk NN i
) ) i
, , i
or CC i
placebo NN i
. . i

METHODS NNP N
In IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
we PRP N
randomized VBD N
1223 CD p
mothers NNS p
with IN p
infants NNS p
at IN p
high JJ p
risk NN p
for IN p
allergy NN p
to TO p
receive VB p
a DT p
probiotic JJ i
mixture NN i
( ( i
2 CD i
lactobacilli NN i
, , i
bifidobacteria NN i
, , i
and CC i
propionibacteria NN i
) ) i
or CC i
placebo NN i
during IN p
the DT p
last JJ p
month NN p
of IN p
pregnancy NN p
and CC p
their PRP$ p
infants NNS p
to TO p
receive VB p
it PRP p
from IN p
birth NN p
until IN p
age NN p
6 CD p
months NNS p
. . p

No DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
numbers NNS o
of IN o
CD19+ NNP o
B NNP o
cells NNS o
( ( N
range NN N
, , N
5 CD N
% NN N
to TO N
51 CD N
% NN N
) ) N
and CC N
PCR NNP N
estimates NNS N
of IN N
the DT N
number NN o
of IN o
clonal JJ o
cells NNS o
in IN N
the DT N
peripheral JJ N
blood NN N
( ( N
range NN N
, , N
.009 CD N
% NN N
to TO N
3.6 CD N
% NN N
) ) N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN o
of IN o
chronic JJ o
lung NN o
disease NN o
( ( N
28 CD N
day NN N
and CC N
36 CD N
week NN N
definitions NNS N
) ) N
, , N
death NN o
, , o
pneumothorax NN o
, , o
intraventricular JJ o
haemorrhage NN o
, , o
number NN o
of IN o
ventilator NN o
days NNS o
, , o
or CC o
length NN o
of IN o
oxygen NN o
dependency NN o
between IN N
groups NNS N
. . N

METHODS NNP N
Three CD p
hundred VBD p
and CC p
seventy JJ p
nine CD p
women NNS p
( ( p
260 CD p
with IN p
a DT p
family NN p
history NN p
of IN p
breast NN p
cancer NN p
; : p
119 CD p
with IN p
breast NN p
cancer NN p
) ) p
from IN p
The DT p
Royal NNP p
Marsden NNP p
NHS NNP p
Foundation NNP p
Trust NNP p
were VBD N
randomised VBN N
to TO N
receive VB i
or CC i
not RB i
receive JJ i
written VBN i
educational JJ i
information NN i
on IN i
cancer NN i
genetics NNS i
. . i

METHODS NNP N
Sixty-five JJ p
day-only JJ p
patients NNS p
with IN p
renal JJ p
impairment NN p
( ( p
mean JJ p
serum NN p
creatinine NN p
concentration NN p
0.16+/-0.03 NNP p
mmol/l NN p
) ) p
due JJ p
to TO p
undergo JJ p
coronary JJ p
or CC p
peripheral JJ p
angiography NN p
and/or NN p
stenting VBG p
were VBD N
randomly RB N
assigned VBN N
to TO N
IV NNP i
NAC NNP i
300 CD i
or CC i
600 CD i
mg NNS i
immediately RB i
before IN i
and CC i
after IN i
the DT i
procedure NN i
or CC i
IV NNP i
fluid VBP i
alone RB i
. . i

In IN N
a DT N
placebo-controlled JJ i
, , N
randomised JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
the DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN N
of IN N
patient-administered JJ i
1 CD i
% NN i
fusidic JJ i
acid RB i
viscous JJ i
eye NN i
drops NNS i
in IN N
clearing VBG N
the DT N
commonest JJS N
organisms JJ N
causing VBG N
pseudophakic NN N
endophthalmitis NN N
( ( N
Staphylococcus NNP N
epidermidis RB N
and CC N
aureus RB N
) ) N
from IN N
the DT N
lids NNS N
and CC N
conjunctivae NN N
of IN N
79 CD p
patients NNS p
before IN p
cataract JJ p
surgery NN p
. . p

The DT N
most RBS N
frequently RB N
reported VBD N
post-vaccination NN o
symptoms NNS o
were VBD o
irritability NN o
in IN N
the DT N
DTPa-IPV-Hib NNP N
plus CC N
separate JJ N
HBV NNP N
group NN N
( ( N
49 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
and CC N
fever NN N
, , N
defined VBD N
as IN N
axillary JJ N
temperature NN N
> NN N
or CC N
=37.5 NN N
degrees NNS N
C NNP N
, , N
in IN N
the DT N
DTPa NNP i
HBV- NNP i
IPV-Hib NNP i
group NN N
( ( N
50 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
. . N

Immediately RB p
after IN p
the DT p
CETs NNP p
horses NNS p
were VBD p
allowed VBN p
water NN i
ad NN i
libitum NN i
and CC N
either DT N
: : N
1 CD N
) ) N
8 CD N
L NNP N
of IN N
a DT N
hypertonic JJ i
NaAcetate/acetic NNP i
acid NN i
solution NN i
via IN i
nasogastric JJ i
tube NN i
followed VBN i
by IN i
a DT i
typical JJ i
hay/grain NN i
meal NN i
( ( i
NAA NNP i
trial NN i
) ) i
; : i
or CC i
2 CD i
) ) i
a DT i
hay/grain JJ i
meal NN i
alone RB i
( ( i
Control NNP i
trial NN i
) ) i
. . i

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
and CC N
outcome NN N
of IN N
the DT N
step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB i
A NNP i
( ( i
CSA NNP i
) ) i
or CC i
methotrexate NN i
( ( i
MTX NNP i
) ) i
as IN N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
treatment NN N
with IN N
these DT N
2 CD N
agents NNS N
in IN N
combination NN p
in IN p
early JJ p
, , p
nonerosive JJ p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

Within IN N
48 CD N
hours NNS N
of IN N
administration NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
circulating VBG o
absolute JJ o
neutrophil NN o
count NN o
( ( o
ANC NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
, , N
which WDT N
continued VBD N
for IN N
at IN N
least JJS N
24 CD N
hours NNS N
after IN N
discontinuation NN N
of IN N
rhuGM-CSF NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Five NNP p
hundred VBD p
sixty NN p
patients NNS p
, , p
fully RB p
dentate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
who WP p
had VBD p
no DT p
gross JJ p
pathology NN p
associated VBN p
with IN p
their PRP$ p
impacted VBN p
lower JJR p
M3s NNP p
, , p
were VBD p
recruited VBN p
in IN p
this DT p
study NN p
. . p

Time NN o
to TO o
prostate-specific JJ o
antigen NN o
progression NN o
was VBD N
4.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.1 CD N
to TO N
6.9 CD N
months NNS N
) ) N
on IN N
the DT N
ixabepilone-alone JJ i
arm NN N
and CC N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
4.5 CD N
to TO N
6.8 CD N
months NNS N
) ) N
on IN N
the DT N
combination NN N
arm NN N
. . N

We PRP N
analyzed VBD N
thresholds NNS N
for IN N
contact NN N
detection NN N
, , N
two-point JJ N
discrimination NN N
, , N
and CC N
two-point JJ N
perception NN N
, , N
obtained VBN N
during IN N
the DT N
clinical JJ N
trial NN N
before IN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
, , N
to TO N
assess VB N
tactile JJ N
detection NN N
and CC N
discriminative JJ N
sensitivities NNS N
, , N
and CC N
subjective JJ N
interpretation NN N
of IN N
tactile JJ N
stimulation NN N
, , N
respectively RB N
. . N

Two CD p
hundred VBD p
patients NNS p
with IN p
similar JJ p
demographics NNS p
undergoing JJ p
elective JJ p
LC NNP p
were VBD p
randomized VBN p
to TO p
one CD p
of IN p
four CD p
groups NNS p
of IN p
50 CD p
patients NNS p
each DT p
, , p
including VBG p
Group NNP p
A NNP p
placebo NN i
control NN i
, , i
Group NNP i
B NNP i
with IN i
isotonic JJ i
saline NN i
irrigation NN i
, , i
Group NNP i
C NNP i
with IN i
bupivacaine JJ i
irrigation NN i
, , i
and CC i
Group NNP i
D NNP i
with IN i
lignocaine JJ i
irrigation NN i
. . i

BACKGROUND NNP N
Previous NNP N
analyses NNS N
of IN N
the DT N
International NNP N
Subarachnoid NNP N
Aneurysm NNP N
Trial NNP N
( ( N
ISAT NNP N
) ) N
cohort NN N
have VBP N
reported VBN N
on IN N
the DT N
risks NNS o
of IN o
recurrent NN o
subarachnoid JJ o
haemorrhage NN o
and CC o
death NN o
or CC o
dependency NN o
for IN N
a DT N
minimum NN N
of IN N
5 CD N
years NNS N
and CC N
up RB N
to TO N
a DT N
maximum NN N
of IN N
14 CD N
years NNS N
after IN N
treatment NN N
of IN N
a DT N
ruptured JJ N
intracranial JJ N
aneurysm NN N
with IN N
either DT N
neurosurgical JJ N
clipping NN N
or CC N
endovascular JJ N
coiling NN N
. . N

Efficacy NN o
measurements NNS o
were VBD N
comparable JJ N
between IN N
the DT N
three CD N
treatment NN N
groups NNS N
, , N
although IN N
the DT N
higher JJR N
lamotrigine NN i
dose NN N
was VBD N
possibly RB N
most RBS N
effective JJ N
, , N
with IN N
60.4 CD N
% NN N
completing VBG N
seizure NN N
free JJ N
compared VBN N
with IN N
51.3 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
54.7 CD N
% NN N
( ( N
CBZ NNP N
600 CD N
) ) N
. . N

RESULTS VB N
The DT N
rates NNS o
of IN o
retinitis NN o
progression NN o
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ N
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ o
times NNS o
to TO o
progression NN o
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

Burn NNP o
depth NN o
, , o
measured VBN o
by IN o
laser NN o
Doppler NNP o
imaging NN o
( ( o
LDI NNP o
) ) o
and CC o
histologically RB o
, , o
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
and CC o
plasma JJ o
cytokine NN o
inflammatory NN o
markers NNS o
were VBD N
assessed VBN N
at IN N
24 CD N
h NN N
( ( N
pre JJ N
HBOT NNP N
) ) N
and CC N
48 CD N
h NN N
( ( N
post VB N
HBOT NNP N
) ) N
post NN N
burn NN N
, , N
as IN N
were VBD N
immunohistochemistry NN N
and CC N
microbiology NN N
of IN N
burns NNS N
tissue NN N
samples NNS N
at IN N
48 CD N
h NN N
post NN N
burn NN N
. . N

Cholesterol NN o
levels NNS o
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN N
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Two CD p
hundred VBD p
three CD p
patients NNS p
( ( p
median JJ p
age NN p
26 CD p
years NNS p
; : p
range VB p
18-45 JJ p
) ) p
with IN p
untreated JJ p
multiple NNS p
and CC p
widespread JJ p
anogenital JJ p
condyloma NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
study NN N
arms NNS N
in IN N
order NN N
to TO N
compare VB N
the DT N
efficacy NN o
, , o
toxicity NN o
, , o
and CC o
tolerability NN o
of IN N
recombinant JJ i
interferon NN i
alpha-2b NN i
with IN i
those DT i
of IN i
diathermocoagulation NN i
. . i

A DT N
greater JJR N
reduction NN N
in IN N
the DT N
duration NN o
of IN o
air NN o
leaks NNS o
was VBD N
observed VBN N
before IN N
postoperative JJ N
day NN N
4 CD N
in IN N
group NN N
1 CD N
, , N
and CC N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
having VBG N
a DT N
pleural JJ N
tent NN N
procedure NN N
was VBD N
the DT N
most RBS N
significant JJ N
predictive JJ N
factor NN N
of IN N
air NN o
leaks NNS o
that WDT N
persisted VBD N
for IN N
less JJR N
than IN N
4 CD N
days NNS N
. . N

SRP NNP i
was VBD N
performed VBN N
three CD N
weeks NNS N
after IN N
baseline NN N
, , N
and CC N
clinical JJ N
assessments NNS N
, , N
i.e NN N
, , N
pocket NN o
probing VBG o
depth NN o
( ( o
PPD NNP o
) ) o
and CC o
bleeding VBG o
index NN o
( ( o
BI NNP o
) ) o
, , N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
13 CD N
, , N
and CC N
26 CD N
weeks NNS N
of IN N
peroxide JJ N
gel NN N
applications NNS N
. . N

Complications NNS o
such JJ o
as IN o
cardiac JJ o
tamponade NN o
and CC o
mitral JJ o
regurgitation NN o
( ( o
requiring VBG o
or CC o
not RB o
requiring VBG o
mitral JJ o
valve FW o
replacement NN o
) ) o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
3 CD N
complications NNS N
in IN N
the DT N
IBMC NNP i
group NN N
, , N
compared VBN N
with IN N
4 CD N
complications NNS N
in IN N
the DT N
PMMC NNP i
group NN N
( ( N
P NNP N
=.29 NNP N
) ) N
. . N

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ o
response NN o
rate NN o
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS N
who WP N
achieve VBP N
a DT N
decrease NN N
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ N
insulin NN N
dose NN N
at IN N
6 CD N
months NNS N
. . N

A DT N
total NN N
of IN N
452 CD p
consecutive JJ p
patients NNS p
( ( p
240 CD p
with IN p
kidney NN p
disease NN p
and CC p
212 CD p
without IN p
kidney NN p
disease NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
diagnostic JJ i
strategy NN i
with IN i
( ( i
BNP NNP i
group NN i
) ) i
or CC i
without IN i
( ( i
control NN i
group NN i
) ) i
the DT i
use NN i
of IN i
BNP NNP i
levels NNS i
provided VBN i
by IN i
a DT i
rapid JJ i
bedside NN i
assay NN i
. . i

METHODS NNP N
The DT N
effects NNS N
of IN N
captopril NN i
( ( N
12.5 CD N
mg NN N
and CC N
25 CD N
mg NN N
) ) N
and CC N
enalapril $ i
( ( N
5 CD N
mg NN N
and CC N
10 CD N
mg NN N
) ) N
administered VBD N
during IN N
7-day JJ N
periods NNS N
on IN N
electroencephalogram NN o
( ( o
EEG NNP o
) ) o
, , o
cognitive JJ o
functions NNS o
, , o
and CC o
subjective JJ o
assessments NNS o
were VBD N
investigated VBN N
in IN N
healthy JJ p
males NNS p
. . p

Fourteen JJ p
subjects NNS p
( ( p
three CD p
females NNS p
and CC p
11 CD p
males NNS p
) ) p
, , p
who WP p
met VBD p
the DT p
criteria NNS p
for IN p
pathological JJ p
gambling NN p
in IN p
accordance NN p
with IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
IV NNP p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
a DT p
Treatment NNP p
Group NNP p
( ( p
n=7 RB p
) ) p
or CC p
a DT p
waiting JJ p
list NN p
Control NNP p
Group NNP p
( ( p
n=7 RB p
) ) p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
156 CD p
patients NNS p
with IN p
stage NN p
III NNP p
or CC p
IV NNP p
gastric JJ p
cancer NN p
who WP p
had VBD p
undergone JJ p
curative JJ p
resection NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
treatment NN N
groups NNS N
: : N
BCG NNP i
+ NNP i
FAM NNP i
( ( i
immunochemotherapy NN i
) ) i
, , i
FAM NNP i
( ( i
chemotherapy NN i
) ) i
, , i
and CC i
control NN i
( ( i
surgery NN i
only RB i
) ) i
. . i

Analyses NNS N
were VBD N
conducted VBN N
on IN N
eligible JJ N
participants NNS N
( ( N
n=77 NN N
) ) N
for IN N
the DT N
stabilization NN N
( ( N
maximum JJ N
18 CD N
weeks NNS N
) ) N
and CC N
maintenance NN N
phases NNS N
( ( N
up RB N
to TO N
Week NNP N
104 CD N
) ) N
on IN N
primary JJ N
outcome JJ N
measures NNS N
of IN N
time NN o
to TO o
stabilization NN o
and CC o
relapse NN o
, , o
change NN o
in IN o
symptoms NNS o
and CC o
safety NN o
, , N
and CC N
comparisons NNS N
made VBN N
across IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
, , p
fully RB p
dentate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
who WP p
have VBP p
no DT p
jawbone NN p
atrophy NN p
and CC p
no DT p
systemic JJ p
problems NNS p
that WDT p
may MD p
impair VB p
bone NN p
strength NN p
, , p
mastication NN p
seems VBZ p
not RB p
to TO p
affect VB p
late JJ p
mandibular JJ p
fracture NN p
after IN p
surgical JJ p
removal NN p
of IN p
impacted JJ p
M3s NNP p
associated VBN p
with IN p
no DT p
gross JJ p
pathology NN p
. . p

The DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
showed VBD N
that IN N
the DT N
QTcI NNP N
slope NN N
for IN N
vilazodone NN i
was VBD N
not RB N
different JJ N
from IN N
0.0 CD N
and CC N
that IN N
the DT N
predicted JJ N
increase NN N
from IN N
baseline NN N
in IN N
the DT N
QTc NNP o
at IN o
Cmax NNP o
for IN N
the DT N
highest JJS N
therapeutic JJ N
dose NN N
( ( N
156 CD N
ng/ml RB N
after IN N
40 CD N
mg/day NN N
) ) N
was VBD N
< JJ N
1 CD N
ms NN N
. . N

Feeding VBG N
a DT N
LS NNP i
or CC i
a DT i
HS NNP i
diet NN i
for IN N
30 CD N
d NN N
before IN N
breeding NN N
may MD N
be VB N
inadequate JJ N
to TO N
stimulate VB N
puberty NN N
in IN N
beef NN N
heifers NNS N
, , N
but CC N
feeding VBG N
a DT N
diet JJ N
with IN N
a DT N
greater JJR N
amount NN N
of IN N
starch NN N
for IN N
60 CD N
d NN N
before IN N
breeding NN N
may MD N
increase VB N
the DT N
incidence NN o
of IN o
puberty NN o
during IN N
breeding NN N
of IN N
heifers NNS N
that WDT N
have VBP N
inadequate JJ N
yearling NN N
weight NN N
. . N

Therefore RB N
, , N
we PRP N
set VBP N
out RP N
to TO N
determine VB N
1 CD N
) ) N
the DT N
contribution NN N
of IN N
prostacyclin NN N
to TO N
the DT N
bradykinin-mediated JJ N
vasodepressor NN N
effects NNS N
of IN N
ACE NNP N
inhibitors NNS N
, , N
2 CD N
) ) N
whether IN N
ACE NNP N
inhibitors NNS N
alter VBP N
the DT N
effect NN N
of IN N
bradykinin NN N
on IN N
prostacyclin NN N
, , N
and CC N
3 CD N
) ) N
whether IN N
the DT N
effects NNS N
of IN N
ACE NNP N
inhibitors NNS N
on IN N
bradykinin NN N
and CC N
prostaglandins NNS N
are VBP N
class NN N
effects NNS N
or CC N
dependent NN N
on IN N
ACE NNP N
inhibitor NN N
structure NN N
. . N

Evaluation NN N
of IN N
serum NN o
androgen NN o
levels NNS o
, , o
grading NN o
of IN o
acne NN o
and CC o
hirsutism NN o
( ( N
respectively RB N
with IN N
Pillsbury NNP N
and CC N
Ferriman-Gallwey NNP N
score NN N
) ) N
and CC N
non-invasive JJ N
assessment NN N
of IN N
skin JJ N
hydration NN N
, , N
transepidermal JJ o
water NN o
loss NN o
( ( o
TEWL NNP o
) ) o
and CC o
skin JJ o
homogeneity NN o
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
( ( N
end NN N
of IN N
treatment NN N
) ) N
. . N

METHODS NNP N
In IN N
an DT N
open-labelled JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
with IN N
16 CD p
non-asthmatic JJ p
SAR NNP p
patients NNS p
( ( p
median JJ p
age NN p
25 CD p
years NNS p
, , p
56 CD p
% NN p
males NNS p
) ) p
, , N
the DT N
effect NN N
of IN N
a DT N
single JJ i
nasal NN i
allergen NN i
challenge NN i
performed VBD N
out IN N
of IN N
season NN N
on IN N
induced JJ N
sputum NN N
inflammatory NN N
parameters NNS N
was VBD N
evaluated VBN N
. . N

Fifty-two JJ p
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
on IN p
cardiopulmonary JJ p
bypass NN p
were VBD N
divided VBN N
randomly RB N
into IN N
3 CD N
groups NNS N
: : N
the DT N
first JJ N
group NN N
received VBD N
100 CD i
microg NNS i
x JJ i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
propofol NN i
, , N
the DT N
other JJ N
groups NNS N
received VBD N
one CD N
minimum NN N
alveolar JJ N
concentration NN N
of IN N
sevoflurane NN i
or CC i
isoflurane NN i
for IN N
anesthesia JJ N
maintenance NN N
. . N

In IN N
this DT N
double-blind NN N
, , N
three-arm NN N
study NN N
, , N
105 CD p
patients NNS p
diagnosed VBN p
with IN p
acute JJ p
abacterial JJ p
otitis NN p
externa NN p
were VBD N
included VBN N
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
glycerol NN i
eardrops VBZ i
, , i
glycerol NN i
eardrops NNS i
with IN i
0.5 CD i
% NN i
lidocaine NN i
, , i
or CC i
glycerol NN i
eardrops NNS i
with IN i
2 CD i
% NN i
lidocaine NN i
for IN N
seven CD N
days NNS N
. . N

Outcome NN N
measurements NNS N
included VBD N
Composite NNP o
Spasticity NNP o
Scale NNP o
, , o
peak NN o
torques NNS o
generated VBD o
during IN o
maximum JJ o
isometric JJ o
voluntary JJ o
contraction NN o
of IN o
ankle JJ o
dorsiflexors NNS o
and CC o
plantarflexors NNS o
, , o
and CC o
gait VBP o
velocity NN o
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
and CC N
4 CD N
weeks NNS N
after IN N
treatment NN N
ended VBD N
. . N

In IN N
a DT N
Cox NNP N
model NN N
, , N
the DT N
presence NN N
of IN N
tense NN N
ascites NNS N
( ( N
relative JJ N
risk NN N
3.4 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
CI NNP N
2.5-5.9 CD N
) ) N
and CC N
a DT N
prior JJ N
history NN N
of IN N
hemorrhage NN N
( ( N
relative JJ N
risk NN N
4.4 CD N
, , N
95 CD N
% NN N
CI NNP N
2.6-7.5 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
variceal JJ N
hemorrhage NN N
. . N

fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ i
radiation NN i
therapy NN i
( ( i
HFX NNP i
RT NNP i
) ) i
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP N
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN i
( ( i
CDDP NNP i
) ) i
for IN N
head NN p
and CC p
neck NN p
cancer NN p
. . p

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ p
infants NNS p
of IN p
longer JJR p
Kangaroo NNP i
Care NNP i
( ( i
30 CD i
minutes NNS i
, , i
KC30 NNP i
) ) i
and CC i
shorter JJR i
KC NNP i
( ( p
15 CD p
minutes NNS p
, , p
KC15 NNP p
) ) p
before IN p
and CC p
throughout IN p
heel NN p
stick NNS p
compared VBN p
with IN p
incubator NN i
care NN i
( ( i
IC NNP i
) ) i
. . i

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
trial NN N
of IN N
20 CD p
healthy JJ p
women NNS p
( ( p
mean JJ p
age NN p
45 CD p
( ( p
SD NNP p
8 CD p
) ) p
yr NN p
) ) p
who WP p
were VBD p
to TO p
undergo VB p
uterine JJ p
surgery NN p
through IN p
a DT p
low JJ p
transverse NN p
incision NN p
. . p

To TO N
compare VB N
the DT N
short-term JJ N
effects NNS N
of IN N
metformin NN i
( ( i
M NNP i
) ) i
, , i
naltrexone RB i
( ( i
N NNP i
) ) i
, , i
and CC i
a DT i
combination NN i
of IN i
OC NNP i
and CC i
prednisolone NN i
( ( i
OC/Pr NNP i
) ) i
on IN N
the DT N
metabolic JJ N
state NN N
and CC N
the DT N
ovarian JJ N
function NN N
of IN N
PCOS NNP p
women NNS p
, , p
we PRP p
randomized VBD p
29 CD p
women NNS p
to TO p
a DT p
3-month JJ p
course NN p
of IN p
therapy NN p
. . p

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
184 CD p
healthy JJ p
post-menopausal JJ p
women NNS p
randomized VBD p
to TO p
6 CD p
cycles NNS p
of IN p
either DT p
estradiol NN i
( ( i
2mg CD i
) ) i
+trimegestone NN i
( ( i
0.5mg CD i
) ) i
( ( i
T-group NNP i
) ) i
or CC i
estradiol NN i
( ( i
2mg CD i
) ) i
+dydrogesterone NN i
( ( i
10mg CD i
) ) i
( ( i
DYDR NNP i
group NN i
) ) i
. . i

LAVH NNP i
, , N
when WRB N
compared VBN N
with IN N
TAH NNP N
in IN N
the DT N
two CD N
weight NN N
subgroups NNS N
, , N
required VBD N
a DT N
significantly RB N
longer RBR N
operating VBG o
time NN o
only RB N
in IN N
Group NNP N
2 CD N
, , N
significantly RB N
reduced VBN N
analgesics NNS N
administration NN N
only RB N
in IN N
Group NNP N
1 CD N
, , N
and CC N
significantly RB N
reduced VBN N
hospital NN o
stay NN o
in IN N
both DT N
groups NNS N
. . N

Eligible JJ p
subjects NNS p
in IN p
a DT p
multicenter NN p
, , p
double-masked JJ p
, , p
randomized VBN p
, , p
parallel-group JJ p
, , p
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP i
1.5 CD i
% NN i
or CC i
placebo NN i
eyedrops NNS N
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

RESULTS NNP N
Acceptability NNP o
of IN o
study NN o
participation NN o
is VBZ N
high JJ N
with IN N
86 CD N
% NN N
of IN N
those DT N
referred VBN N
who WP N
met VBD N
eligibility NN N
criteria NNS N
and CC N
85 CD N
% NN N
of IN N
those DT N
who WP N
were VBD N
able JJ N
to TO N
receive VB N
injections NNS N
prior RB N
to TO N
release VB N
accepted JJ N
injections NNS N
, , N
yet RB N
important JJ N
implementation NN N
issues NNS N
are VBP N
identified VBN N
and CC N
addressed VBN N
during IN N
the DT N
study NN N
and CC N
are VBP N
discussed VBN N
in IN N
this DT N
paper NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
all DT N
, , N
202 CD p
consecutive JJ p
patients NNS p
from IN p
the DT p
hospital NN p
waiting VBG p
list NN p
were VBD N
randomized VBN N
to TO N
undergo VB N
TURP NNP N
using VBG N
either CC N
a DT N
bipolar JJ i
system NN i
( ( i
Surgmaster NNP i
TURis NNP i
, , i
Olympus NNP i
, , i
Tokyo NNP i
, , i
Japan NNP i
) ) i
or CC i
a DT i
monopolar JJ i
system NN i
( ( i
24 CD i
F NNP i
, , i
Storz NNP i
, , i
T NNP i
, , i
Germany NNP i
) ) i
. . i

77 CD p
were VBD p
assigned VBN p
to TO p
PACT NNP p
( ( p
London NNP p
[ NNP p
n=26 MD p
] VB p
, , p
Manchester NNP p
[ NNP p
n=26 MD p
] VB p
, , p
and CC p
Newcastle NNP p
[ NNP p
n=25 FW p
] NNP p
) ) p
; : p
and CC p
75 CD p
to TO p
treatment NN p
as IN p
usual JJ p
( ( p
London NNP p
[ NNP p
n=26 MD p
] VB p
, , p
Manchester NNP p
[ NNP p
n=26 MD p
] VB p
, , p
and CC p
Newcastle NNP p
[ NNP p
n=23 FW p
] NNP p
) ) p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
parallel-group NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
equivalence NN N
trial NN N
of IN N
infants NNS p
aged VBN p
6 CD p
weeks NNS p
to TO p
12 CD p
months NNS p
of IN p
age NN p
with IN p
physician-diagnosed JJ p
bronchiolitis NN p
newly RB p
admitted VBN p
into IN p
eight CD p
paediatric JJ p
hospital NN p
units NNS p
in IN p
the DT p
UK NNP p
( ( p
the DT p
Bronchiolitis NNP p
of IN p
Infancy NNP p
Discharge NNP p
Study NNP p
[ NNP p
BIDS NNP p
] NNP p
) ) p
. . p

Improvements NNS N
were VBD N
sustained VBN N
at IN N
week NN N
24 CD N
for IN N
the DT N
ACR20 NNP o
, , o
ACR50 NNP o
, , o
and CC o
ACR70 NNP o
responses NNS o
, , o
scores NNS o
for IN o
the DT o
Health NNP o
Assessment NNP o
Questionnaire NNP o
disability NN o
index NN o
, , o
the DT o
3-variable JJ o
Disease NNP o
Activity NNP o
Score NNP o
in IN o
28 CD o
joints NNS o
using VBG o
the DT o
C-reactive JJ o
protein NN o
level NN o
( ( o
DAS28-CRP NNP o
) ) o
, , o
and CC o
a DT o
3-variable JJ o
DAS28-CRP NNP o
of IN o
< NNP o
2.6 CD o
. . o

At IN N
the DT N
end NN N
of IN N
each DT N
study NN N
week NN N
, , N
the DT N
authors NNS N
assessed VBD N
diastolic JJ o
function NN o
( ( o
myocardial JJ o
relaxation NN o
velocities NNS o
[ VBP o
E NNP o
' POS o
] NN o
using VBG o
tissue NN o
Doppler NNP o
imaging NN o
) ) o
and CC o
RBF NNP o
( ( o
para-aminohippurate JJ o
clearance NN o
) ) o
at IN N
baseline NN N
and CC N
after IN N
infusion NN N
of IN N
Ang NNP N
II NNP N
( ( N
3 CD N
ng/kg/min RB N
x JJ N
45 CD N
min NN N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
m-chlorophenylpiperazine NN i
( ( i
m-CPP JJ i
) ) i
on IN N
repetitive JJ N
behaviours NNS N
and CC N
prolactin JJ N
response NN N
in IN N
11 CD p
adults NNS p
with IN p
autism NN p
or CC p
Aspergers NNS p
disorder VBP p
and CC p
8 CD p
age- JJ p
and CC p
gender-matched JJ p
healthy JJ p
controls NNS p
via IN N
randomized VBN N
double-blind NN N
, , N
m-CPP JJ i
and CC i
placebo JJ i
challenges NNS N
. . N

The DT N
intervention NN N
will MD N
be VB N
conducted VBN N
by IN N
specially RB i
trained JJ i
oncology NN i
nurses NNS i
and CC i
includes VBZ i
components NNS i
of IN i
patient JJ i
education NN i
, , i
skills NNS i
training NN i
and CC i
counseling NN i
to TO i
improve VB i
self PRP i
care VB i
regarding VBG i
pain JJ i
management NN i
beginning VBG i
with IN i
admission NN i
followed VBN i
by IN i
booster NN i
session NN i
every DT i
3rd CD i
day NN i
and CC i
one CD i
follow VBP i
up RP i
telephone NN i
counseling NN i
within IN i
2 CD i
to TO i
3 CD i
days NNS i
after IN i
discharge NN i
. . i

151 CD p
patients NNS p
with IN p
locally RB p
advanced JJ p
prostatic JJ p
cancer NN p
( ( p
T3-4 NNP p
M0 NNP p
) ) p
, , p
representing VBG p
38 CD p
% NN p
of IN p
the DT p
404 CD p
cancer NN p
patients NNS p
in IN p
a DT p
Finnish JJ p
multicenter NN p
study NN p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
orchiectomy NN i
, , i
estrogens VBZ i
or CC i
radiotherapy NN i
. . i

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
in IN N
an DT N
academic JJ N
medical JJ N
center-based JJ N
infectious JJ N
disease NN N
clinic NN N
, , N
11 CD p
clinically RB p
stable JJ p
, , p
HIV-infected JJ p
adults NNS p
had VBD p
been VBN p
treated VBN p
with IN p
highly RB p
active JJ p
, , p
antiretroviral JJ p
therapy NN p
and CC p
had VBD p
HIV NNP p
plasma NN p
RNA NNP p
levels NNS p
of IN p
less JJR p
than IN p
10 CD p
000 CD p
copies/mL NN p
. . p

This DT N
randomized VBN N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD i
communication NN i
interventions NNS i
( ( i
Responsive JJ i
Education NN i
and CC i
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
[ NNP i
RPMT NNP i
] NNP i
and CC i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
) ) i
in IN N
36 CD p
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Twenty NNP p
ASA NNP p
physical JJ p
status NN p
I PRP p
patients NNS p
undergoing VBG p
gynecological JJ p
laparoscopy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
SSA NNP N
with IN N
lidocaine JJ i
10 CD i
mg NN i
+ NNP i
sufentanil VBD i
10 CD i
microg NN i
or CC i
general JJ i
anesthesia NN i
with IN i
DES NNP i
and CC N
N NNP N
( ( N
2 CD N
) ) N
O. NNP N
Intraoperative NNP N
conditions NNS N
, , N
recovery NN o
times NNS o
, , o
postanesthesia JJ o
recovery NN o
scores NNS o
, , N
and CC N
postoperative JJ N
outcomes NNS N
were VBD N
recorded VBN N
. . N

Olanzapine-treated JJ i
patients NNS N
also RB N
experienced VBD N
longer JJR N
time NN o
to TO o
depressive VB o
symptomatic JJ o
relapse NN o
( ( N
85 CD N
versus NN N
22 CD N
days NNS N
, , N
p=0.001 NN N
) ) N
and CC N
manic JJ o
symptomatic JJ o
relapse NN o
( ( N
too RB N
few JJ N
relapses NNS N
to TO N
calculate VB N
versus NN N
42 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
than IN N
did VBD N
placebo-treated JJ N
patients NNS N
. . N

Adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
occurring VBG N
more RBR N
frequently RB N
with IN N
sitaxsentan NN i
( ( N
50 CD N
or CC N
100 CD N
mg NN N
) ) N
included VBD N
headache NN o
, , o
peripheral JJ o
edema NN o
, , o
dizziness NN o
, , o
nausea NN o
, , o
extremity NN o
pain NN o
, , o
and CC o
fatigue NN o
; : o
most JJS o
AEs NNP o
were VBD N
of IN N
mild NN N
or CC N
moderate JJ N
severity NN N
. . N

A DT N
protocol-planned JJ N
exploratory NN N
analysis NN N
stratified VBD N
patients NNS N
according VBG N
to TO N
baseline NN N
activity NN N
; : N
this DT N
analysis NN N
showed VBD N
that IN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
in IN N
the DT N
valacyclovir NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
developed VBD N
fewer JJR N
new JJ o
active JJ o
lesions NNS o
per IN o
scan JJ o
than IN N
did VBD N
those DT N
in IN N
the DT N
placebo NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Totally NNP p
25 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
differentiated JJ p
thyroid JJ p
carcinoma NN p
on IN p
long-term JJ p
TSH-suppressive JJ i
levothyroxine NN i
( ( p
l-T JJ p
( ( p
4 CD p
) ) p
) ) p
substitution NN p
were VBD N
randomized VBN N
to TO N
persistent JJ i
TSH-suppressive JJ i
l-T NN i
( ( i
4 CD i
) ) i
substitution NN i
( ( i
low-TSH JJ i
group NN i
) ) i
or CC i
restoration NN i
of IN i
euthyroidism NN i
. . i

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
338 CD p
patients NNS p
aged VBN p
60 CD p
years NNS p
or CC p
older JJR p
who WP p
had VBD p
aneurysms NNS p
of IN p
at IN p
least JJS p
5.5 CD p
cm NN p
in IN p
diameter NN p
and CC p
who WP p
had VBD p
been VBN p
referred VBN p
to TO p
one CD p
of IN p
31 CD p
hospitals NNS p
in IN p
the DT p
UK NNP p
. . p

METHODS NNP N
In IN N
this DT N
52-week JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
, , N
male NN p
and CC p
female JJ p
patients NNS p
( ( p
aged VBN p
at IN p
least JJS p
40 CD p
years NNS p
) ) p
with IN p
symptomatic JJ p
primary JJ p
OA NNP p
of IN p
the DT p
hip NN p
, , p
knee NN p
, , p
hand NN p
or CC p
spine NN p
were VBD p
randomised VBN p
( ( p
1:2:1 CD p
) ) p
to TO p
lumiracoxib VB i
100 CD i
mg NN i
o.d NN i
. . i

Heart NNP i
failure NN i
therapy NN i
guided VBN i
by IN i
N-terminal NNP i
BNP NNP i
improved VBD N
outcomes NNS N
in IN N
patients NNS p
aged VBD p
60 CD p
to TO p
75 CD p
years NNS p
but CC p
not RB p
in IN p
those DT p
aged VBN p
75 CD p
years NNS p
or CC p
older JJR p
( ( N
P NNP N
< NNP N
.02 NNP N
for IN N
interaction NN N
) ) N
CONCLUSION NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
did VBD N
not RB N
improve VB N
overall JJ o
clinical JJ o
outcomes NNS o
or CC o
quality NN o
of IN o
life NN o
compared VBN N
with IN N
symptom-guided JJ N
treatment NN N
. . N

Rectal JJ o
pain NN o
thresholds NNS o
and CC o
smooth JJ o
muscle NN o
tone NN o
were VBD N
measured VBN N
with IN N
a DT N
barostat NN N
before IN N
and CC N
after IN N
treatment NN N
in IN N
18 CD N
patients NNS N
( ( N
study VB N
I PRP N
) ) N
, , N
and CC N
treatment NN N
changes NNS N
in IN N
heart NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
skin JJ o
conductance NN o
, , o
finger NN o
temperature NN o
, , o
and CC o
forehead JJ o
electromyographic JJ o
activity NN o
were VBD N
assessed VBN N
in IN N
24 CD N
patients NNS N
( ( N
study VB N
II NNP N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
bupivacaine NN i
group NN N
compared VBN N
with IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
at IN N
the DT N
intervals NNS N
of IN N
6 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
hours NNS N
postbanding VBG N
there EX N
was VBD N
no DT N
sustained JJ N
reduction NN N
in IN N
the DT N
severity NN o
of IN o
pain NN o
and CC o
no DT o
reduction NN o
in IN o
analgesic JJ o
requirements NNS o
or CC o
limitation NN o
of IN o
normal JJ o
activities NNS o
. . o

DISCUSSION NNP N
The DT N
RCT NNP N
design NN N
, , N
combined VBN N
with IN N
access NN N
to TO N
clinical JJ N
records NNS N
at IN N
all DT N
provincial JJ N
abortion NN N
clinics NNS N
, , N
and CC N
to TO N
information NN N
in IN N
provincial JJ N
single-payer NN N
linked VBD N
administrative JJ N
health NN N
databases NNS N
, , N
birth NN N
registry NN N
, , N
and CC N
hospital NN N
records NNS N
, , N
offers VBZ N
a DT N
unique JJ N
opportunity NN N
to TO N
determine VB N
if IN N
a DT N
novel NN N
IUD NNP N
has VBZ N
a DT N
comparable JJ N
expulsion NN N
rate NN N
to TO N
that DT N
of IN N
the DT N
current JJ N
standard NN N
IUD NNP N
in IN N
Canada NNP N
, , N
in IN N
addition NN N
to TO N
the DT N
first JJ N
opportunity NN N
to TO N
determine VB N
pregnancy NN N
rate NN N
and CC N
method NN N
satisfaction NN N
at IN N
1 CD N
year NN N
post-abortion NN N
for IN N
women NNS N
choosing VBG N
a DT N
range NN N
of IN N
post-abortion NN N
contraceptive NN N
options NNS N
. . N

OBJECTIVES IN N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
document NN N
the DT N
efficacy NN N
of IN N
a DT N
device NN N
intended VBN N
to TO N
conserve VB N
blood NN N
in IN N
critically RB p
ill JJ p
patients NNS p
; : p
b NN N
) ) N
determine VBZ N
the DT N
effect NN N
of IN N
this DT N
blood NN N
conservation NN N
on IN N
hemoglobin JJ N
concentration NN N
and CC N
the DT N
need NN N
for IN N
blood NN N
transfusions NNS N
; : N
c NNS N
) ) N
determine VBP N
if IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
interference NN N
with IN N
arterial JJ N
pressure NN N
waveforms NNS N
; : N
d NN N
) ) N
determine NN N
if IN N
use NN N
of IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
a DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
accidental JJ N
needle JJ N
punctures NNS N
suffered VBN N
by IN N
healthcare JJ N
workers NNS N
. . N

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS p
with IN p
low-functioning JJ p
autism NN p
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
; : i
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
fever NN N
is VBZ N
associated VBN N
with IN N
worsened JJ N
outcome NN N
in IN N
surgical JJ p
subarachnoid JJ p
hemorrhage NN p
patients NNS p
, , N
although IN N
, , N
because IN N
the DT N
association NN N
between IN N
fever NN N
and CC N
the DT N
primary JJ N
outcome NN N
measure NN N
for IN N
the DT N
trial NN N
is VBZ N
dependent JJ N
on IN N
the DT N
covariates NNS N
used VBN N
in IN N
the DT N
analysis NN N
( ( N
particularly RB N
operative JJ N
events NNS N
and CC N
delayed VBN N
ischemic JJ N
neurological JJ N
deficits NNS N
) ) N
, , N
we PRP N
can MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
fever NN N
is VBZ N
a DT N
marker NN N
for IN N
other JJ N
events NNS N
. . N

This DT N
study NN N
demonstrates VBZ N
for IN N
the DT N
first JJ N
time NN N
that IN N
the DT N
efficiency NN N
of IN N
TIL NNP i
in IN N
stage NN N
III NNP N
melanoma NN N
( ( N
AJCC NNP N
) ) N
is VBZ N
directly RB N
related VBN N
to TO N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
, , N
indicating VBG N
that IN N
tumor NN N
burden NN N
might MD N
be VB N
a DT N
crucial JJ N
factor NN N
in IN N
the DT N
efficacy NN N
and/or NN N
in IN N
vitro JJ N
expansion NN N
of IN N
T NNP N
cells NNS N
specific JJ N
for IN N
autologous JJ N
tumor NN N
antigen NN N
, , N
a DT N
finding NN N
which WDT N
could MD N
be VB N
of IN N
value NN N
in IN N
future JJ N
vaccine NN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
melanoma NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
Considering NNP N
that IN N
lymph VBD N
node DT N
status NN N
is VBZ N
a DT N
key JJ N
factor NN N
in IN N
colorectal JJ N
cancer NN N
staging NN N
, , N
and CC N
the DT N
main JJ N
determinant NN N
for IN N
adjuvant JJ N
therapy NN N
of IN N
colorectal JJ N
cancer NN N
being VBG N
this DT N
therapy NN N
, , N
responsible JJ N
for IN N
a DT N
significant JJ N
increase NN N
in IN N
colorectal JJ o
cancer NN o
patients NNS o
survival JJ o
, , N
the DT N
staging VBG N
methods NNS N
should MD N
be VB N
the DT N
most RBS N
accurate JJ N
possible JJ N
in IN N
order NN N
to TO N
offer VB N
this DT N
individuals NNS N
the DT N
opportunity NN N
to TO N
be VB N
adequate JJ N
treated VBN N
in IN N
order NN N
to TO N
achieve VB N
the DT N
best JJS N
survival NN N
possible JJ N
. . N

Side NN o
effects NNS o
, , N
such JJ N
as IN N
hypotension NN o
and CC o
emesis NN o
were VBD N
negligible JJ N
, , N
severe JJ o
bradycardia NN o
and CC o
urinary JJ o
retention NN o
did VBD N
not RB N
occur VB N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
reported VBD N
transient JJ o
neurological JJ o
symptoms NNS o
over IN N
24 CD N
h. NNS N
In IN N
conclusion NN N
, , N
plain VBP N
mepivacaine NN i
in IN N
a DT N
60- JJ N
or CC N
80-mg JJ N
dose NN N
is VBZ N
a DT N
suitable JJ N
local JJ N
anesthetic JJ N
choice NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
with IN N
respect NN N
to TO N
anesthetic JJ N
, , N
as RB N
well RB N
as IN N
recovery NN N
profiles NNS N
. . N

Two CD N
serious JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
; : N
one CD N
drug-related JJ o
hypotensive JJ o
infusion NN o
reaction NN o
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
30.0 CD N
mg/kg JJ N
MEDI-545 NNP N
dose NN N
group NN N
, , N
causing VBG N
discontinuation NN N
of IN N
study JJ N
drug NN N
in IN N
that DT N
subject NN N
and CC N
study NN N
dismissal NN N
of IN N
the DT N
other JJ N
subjects NNS N
in IN N
the DT N
same JJ N
cohort NN N
; : N
and CC N
a DT N
myocardial JJ o
infarction NN o
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
10 CD N
mg/kg JJ N
MEDI-545 NNP N
dose NN N
group NN N
, , N
which WDT N
was VBD N
considered VBN N
to TO N
be VB N
unrelated JJ N
to TO N
treatment NN N
. . N

Stimulating VBG N
the DT N
GH/IGF-I NNP N
axis NN N
with IN N
GH-secretagogues NNP N
increased VBD N
leptin NN N
levels NNS N
within IN N
12 CD N
h. NN N
Because IN N
leptin NN N
may MD N
stimulate VB N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
and CC N
because IN N
GH NNP N
, , N
IGF-I NNP N
, , N
and CC N
insulin NN N
have VBP N
a DT N
protein-sparing JJ N
effect NN N
, , N
GH-secretagogue NNP N
administration NN N
may MD N
be VB N
expected VBN N
to TO N
result VB N
in IN N
increased JJ N
utilization NN N
of IN N
fat NN N
as IN N
preferential JJ N
substrate NN N
and CC N
to TO N
restore VB N
protein JJ N
content NN N
in IN N
vital JJ N
tissues NNS N
and CC N
, , N
consequently RB N
, , N
has VBZ N
potential JJ N
as IN N
a DT N
strategy NN N
to TO N
reverse VB N
the DT N
paradoxical JJ N
metabolic JJ N
condition NN N
of IN N
protracted JJ N
critical JJ N
illness NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ o
scores NNS o
of IN o
stress NN o
levels NNS o
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN o
of IN o
life NN o
that WDT o
were VBD o
measured VBN o
( ( o
satisfaction NN o
, , o
independence NN o
, , o
competence NN o
and CC o
social JJ o
interaction NN o
) ) o
as RB N
well RB N
as IN N
the DT N
total JJ o
score NN o
for IN o
quality NN o
of IN o
life NN o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
a DT N
subset NN N
of IN N
acute JJ p
respiratory NN p
distress JJ p
syndrome JJ p
patients NNS p
from IN N
this DT N
trial NN N
, , N
we PRP N
performed VBD N
a DT N
preliminary JJ N
examination NN N
of IN N
the DT N
potential JJ N
mechanisms NN N
underlying VBG N
these DT N
clinical JJ N
improvements NNS N
by IN N
retrospectively RB N
testing VBG N
the DT N
hypothesis NN N
that IN N
enteral JJ N
feeding VBG N
with IN N
EPA+GLA NNP i
could MD N
reduce VB N
alveolar-capillary JJ o
membrane NN o
protein NN o
permeability NN o
and CC o
the DT o
production NN o
of IN o
interleukin NN o
( ( o
IL NNP o
) ) o
-8 NN o
, , o
IL-6 NNP o
, , o
tumor NN o
necrosis NN o
factor-alpha NN o
, , o
and CC o
leukotriene JJ o
B4 NNP o
that WDT N
are VBP N
responsible JJ N
, , N
in IN N
part NN N
, , N
for IN N
pulmonary JJ N
inflammation NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
in IN N
the DT N
presence NN N
of IN N
overt JJ N
emotional JJ N
disturbance NN N
, , N
of IN N
new JJ o
psychological JJ o
or CC o
psychophysiological JJ o
symptoms NNS o
preceding VBG o
the DT o
rash NN o
by IN N
up IN N
to TO N
a DT N
year NN N
, , N
and CC N
of IN N
high JJ N
motivation NN N
for IN N
it PRP N
, , N
brief JJ N
psychiatric JJ N
treatment NN N
improves VBZ N
the DT N
outcome NN N
in IN N
eczema NN o
( ( N
the DT N
proportion NN N
clear JJ N
at IN N
18 CD N
months NNS N
was VBD N
about IN N
doubled VBN N
) ) N
, , N
whereas NNS N
in IN N
their PRP$ N
absence NN N
such JJ N
treatment NN N
may MD N
worsen VB N
it PRP N
, , N
especially RB N
in IN N
the DT N
short JJ N
term NN N
. . N

Though IN N
the DT N
response NN o
rate NN o
for IN N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
slightly RB N
higher JJR N
than IN N
for IN N
the DT N
systemic JJ N
arm NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
, , N
and CC N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
nausea NN o
, , o
vomiting VBG o
, , o
diarrhea NN o
, , o
in IN o
addition NN o
to TO o
complications NNS o
of IN o
femoral-arterial JJ o
thrombosis NN o
, , o
bleeding NN o
, , o
and CC o
infection NN o
at IN o
the DT o
catheter NN o
site NN o
not RB N
seen VBN N
in IN N
patients NNS N
treated VBN N
by IN N
systemic JJ N
chemotherapy NN N
. . N

METHODS/DESIGN NNP N
Consenting NNP p
women NNS p
choosing VBG p
to TO p
use VB p
an DT p
IUD NNP p
after IN p
an DT p
abortion NN p
for IN p
a DT p
pregnancy NN p
of IN p
less JJR p
than IN p
12 CD p
weeks NNS p
of IN p
gestation NN p
will MD N
be VB N
randomized VBN N
to TO N
device-type JJ N
groups NNS N
to TO N
receive VB N
immediate JJ i
post-abortion JJ i
placement NN i
of IN i
either CC i
a DT i
Flexi-T380 NNP i
( ( i
+ NNP i
) ) i
IUD NNP i
, , N
a DT N
device NN N
for IN N
which WDT N
no DT N
current JJ N
evidence NN N
on IN N
expulsion NN N
or CC N
effectiveness NN N
rates NNS N
is VBZ N
available JJ N
, , N
or CC N
the DT N
Nova-T200 JJ N
IUD NNP N
, , N
the DT N
only RB N
other JJ N
brand NN N
of IN N
copper NN N
IUD NNP N
available JJ N
in IN N
Canada NNP N
at IN N
the DT N
time NN N
of IN N
study NN N
initiation NN N
. . N

Ninety-eight JJ p
undergraduate JJ p
students NNS p
were VBD N
given VBN N
transparent JJ N
boxes NNS N
of IN N
chocolate NN N
Hershey NNP N
's POS N
Kisses NNP N
and CC N
instructed VBN N
to TO N
keep VB N
the DT N
chocolates NNS N
with IN N
them PRP N
, , N
but CC N
not RB N
to TO N
eat VB N
them PRP N
, , N
for IN N
48 CD N
h. NN N
Before IN N
receiving VBG N
the DT N
Kisses NNP N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
( ( N
a DT N
) ) i
no DT i
intervention NN i
, , i
( ( i
b NN i
) ) i
instruction NN i
in IN i
control-based JJ i
coping VBG i
strategies NNS i
such JJ i
as IN i
distraction NN i
and CC i
cognitive JJ i
restructuring NN i
, , i
or CC i
( ( i
c NN i
) ) i
instruction NN i
in IN i
acceptance-based JJ i
strategies NNS i
such JJ N
as IN N
experiential JJ N
acceptance NN N
and CC N
defusion NN N
techniques NNS N
. . N

Since IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
AD NNP i
patients NNS N
and CC N
age-matched JJ N
controls NNS N
with IN N
regard NN N
to TO N
the DT N
fraction NN N
of IN N
CD45RA+ NNP N
or CC N
CD45RO+ NNP N
CD4+ NNP N
T NNP N
cells NNS N
nor CC N
the DT N
ability NN N
of IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
to TO N
produce VB N
IL-2 NNP N
or CC N
IL-4 NNP N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
the DT N
difference NN N
in IN N
DEX NNP N
sensitivity NN N
is VBZ N
due JJ N
to TO N
a DT N
changed VBN N
lymphokine NN N
profile NN N
or CC N
a DT N
changed JJ N
composition NN N
of IN N
the DT N
CD4+ NNP N
T NNP N
cell NN N
population NN N
. . N

It PRP N
was VBD N
established VBN N
that IN N
CHF NNP N
patients NNS N
with IN N
progression NN N
of IN N
the DT N
disease NN N
had VBD N
worsening NN N
of IN N
their PRP$ N
clinical JJ N
condition NN N
together RB N
with IN N
an DT N
increase NN N
of IN N
oxidative JJ o
stress NN o
which WDT N
was VBD N
characterized VBN N
through IN N
decrease NN N
of IN N
NO NNP o
metabolites NNS o
, , o
NADPH NNP o
-- : o
diaphorase NN o
( ( o
eNOS NN o
) ) o
, , o
increase NN o
of IN o
nitrite JJ o
reductase NN o
( ( o
iNOS NN o
) ) o
and CC o
peroxinitrite JJ o
( ( o
ONOO NNP o
) ) o
, , o
correlative JJ o
increase NN o
the DT o
level NN o
of IN o
brain NN o
natriuretic JJ o
peptide NN o
in IN o
blood NN o
plazma NN o
. . o

We PRP N
found VBD N
significant JJ N
differences NNS N
between IN N
before IN N
and CC N
after IN N
the DT N
therapy NN N
in IN N
the DT N
length NN N
of IN N
the DT N
gait NN N
cycle NN N
that WDT N
became VBD N
more RBR N
stable JJ N
in IN N
the DT N
sagital JJ N
plane NN N
and CC N
concluded VBD N
that IN N
our PRP$ N
results NNS N
proved VBD N
that IN N
horse NN N
therapy NN N
may MD N
be VB N
successfully RB N
used VBN N
as IN N
an DT N
additional JJ N
therapy NN N
for IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
it PRP N
may MD N
be VB N
a DT N
form NN N
of IN N
rehabilitation NN N
in IN N
cases NNS N
when WRB N
other JJ N
therapies NNS N
are VBP N
not RB N
successful JJ N
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
performance NN N
of IN N
three CD i
staging VBG i
systems NNS i
[ NNP i
Okuda NNP i
, , i
Cancer NNP i
of IN i
the DT i
Liver NNP i
Italian JJ i
Program NNP i
( ( i
CLIP NNP i
) ) i
and CC i
Barcelona NNP i
Clinic NNP i
Liver NNP i
Cancer NNP i
group NN i
( ( i
BCLC NNP i
) ) i
] NN i
, , N
for IN N
predicting VBG N
survival NN N
in IN N
patients NNS p
with IN p
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
and CC N
to TO N
explore VB N
how WRB N
to TO N
improve VB N
prognostic JJ N
classification NN N
among IN N
French JJ p
patients NNS p
with IN p
HCC NNP p
whose WP$ p
main JJ p
etiology NN p
is VBZ p
alcoholic JJ p
cirrhosis NN p
. . p

This DT N
double-blind JJ N
and CC N
placebo-controlled JJ i
clinical JJ N
trial NN N
in IN N
autistic JJ p
children NNS p
had VBD N
three CD N
objectives NNS N
: : N
( ( N
a DT N
) ) N
to TO N
replicate VB N
earlier JJR N
findings NNS N
that IN N
haloperidol JJ i
administration NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
of IN N
behavioral JJ N
symptoms NNS N
; : N
( ( N
b NN N
) ) N
to TO N
further JJ N
assess NN N
its PRP$ N
safety NN N
when WRB N
given VBN N
on IN N
a DT N
short-term JJ N
basis NN N
; : N
and CC N
( ( N
c NN N
) ) N
to TO N
assess VB N
whether IN N
it PRP N
has VBZ N
an DT N
effect NN N
on IN N
discrimination NN N
learning NN N
. . N

RESULTS NNP N
Latent NNP N
variable JJ N
structural JJ N
equation NN N
modeling VBG N
indicated VBD N
that IN N
: : N
1 CD N
) ) N
the DT N
intervention NN N
had VBD N
direct JJ N
, , N
positive JJ N
effects NNS N
on IN N
physical JJ N
activity NN N
and CC N
factors NNS N
influencing VBG N
enjoyment NN N
of IN N
PE NNP N
, , N
which WDT N
subsequently RB N
explained VBD N
the DT N
effects NNS N
of IN N
increased JJ N
physical JJ N
activity NN N
enjoyment NN N
and CC N
self-efficacy NN N
on IN N
increased JJ N
physical JJ N
activity NN N
; : N
and CC N
2 CD N
) ) N
an DT N
additional JJ N
, , N
indirect JJ N
effect NN N
of IN N
physical JJ N
activity NN N
enjoyment NN N
on IN N
physical JJ N
activity NN N
operated VBN N
by IN N
an DT N
influence NN N
on IN N
self-efficacy NN N
. . N

Comparison NNP N
of IN N
quality NN o
of IN o
life NN o
, , o
work NN o
productivity NN o
and CC o
medical JJ o
resource NN o
utilization NN o
of IN N
peginterferon NN i
alpha NN i
2a CD i
vs IN N
the DT N
combination NN N
of IN N
interferon NN i
alpha NN i
2b CD i
plus CC i
ribavirin VB i
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
work NN o
productivity NN o
, , o
and CC o
medical JJ o
resource NN o
utilization NN o
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

CONCLUSIONS NNP N
Including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
did VBD N
not RB N
appear VB N
to TO N
have VB N
a DT N
detrimental JJ N
effect NN N
on IN N
patient JJ N
recruitment NN N
or CC N
the DT N
completion NN N
of IN N
this DT N
trial NN N
in IN N
the DT N
short-term JJ N
; : N
overall JJ N
, , N
conservative JJ N
management NN N
was VBD N
successfully RB N
completed VBN N
by IN N
the DT N
majority NN N
of IN N
patients NNS N
during IN N
the DT N
trial NN N
period NN N
, , N
suggesting VBG N
that IN N
researchers NNS N
need VBP N
not RB N
avoid VB N
including VBG N
a DT N
no-intervention JJ N
arm NN N
in IN N
surgical JJ N
trials NNS N
as RB N
long RB N
as IN N
they PRP N
take VBP N
care NN N
with IN N
its PRP$ N
presentation NN N
. . N

OBJECTIVE NN N
To TO N
describe VB N
the DT N
process NN N
and CC N
results NNS N
of IN N
diet JJ N
standardization NN N
, , N
diet JJ N
validation NN N
, , N
and CC N
monitoring NN N
of IN N
diet JJ N
composition NN N
, , N
which WDT N
were VBD N
key JJ N
components NNS N
of IN N
protocol JJ N
1 CD N
of IN N
Dietary NNP N
Effects NNPS N
on IN N
Lipoproteins NNS N
and CC N
Thrombogenic NNP N
Activity NNP N
( ( N
DELTA-1 NNP N
) ) N
, , N
the DT N
initial JJ N
protocol NN N
in IN N
a DT N
program NN N
of IN N
multicenter NN N
human JJ N
feeding NN N
studies NNS N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amount NN N
and CC N
type NN N
of IN N
fat NN N
on IN N
lipoproteins NNS N
and CC N
hemostasis NN N
parameters NNS N
in IN N
various JJ N
demographic JJ N
groups NNS N
. . N

Outcome NNP N
measures NNS N
included VBD N
improvements NNS o
in IN o
severity NN o
and CC o
behavioral JJ o
features NNS o
of IN o
autistic JJ o
disorder NN o
( ( o
stereotypies NNS o
, , o
lethargy NN o
, , o
irritability NN o
, , o
hyperactivity NN o
, , o
emotional JJ o
reciprocity NN o
, , o
sharing VBG o
pleasures NNS o
) ) o
and CC o
improvements NNS o
in IN o
language NN o
and CC o
communication NN o
, , o
socialization NN o
, , o
and CC o
daily RB o
living VBG o
skills NNS o
noted VBD N
after IN N
12 CD N
weeks NNS N
( ( N
the DT N
end NN N
of IN N
a DT N
4-week JJ N
maintenance NN N
phase NN N
) ) N
. . N

The DT N
current JJ N
study NN N
asked VBD N
: : N
does VBZ N
regular JJ N
antacid NN i
therapy NN i
have VBP N
a DT N
favorable JJ N
influence NN N
on IN N
the DT N
natural JJ o
history NN o
of IN o
symptomatic JJ o
reflux NN o
esophagitis NN o
, , N
ie NN N
, , N
does VBZ N
therapy VB N
heal NN N
or CC N
otherwise RB N
change NN N
esophagitis NN N
so IN N
that DT N
painful JJ N
episodes NNS N
are VBP N
either RB N
less RBR N
frequent JJ N
, , N
less RBR N
severe JJ N
, , N
or CC N
both DT N
? . N
We PRP N
found VBD N
that IN N
the DT N
natural JJ N
history NN N
of IN N
symptomatic JJ N
reflux NN N
esophagitis NN N
was VBD N
to TO N
improve VB N
with IN N
either DT N
antacid NN i
or CC i
placebo NN i
. . i

This DT N
prospective JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
individualized JJ N
, , N
comprehensive JJ N
, , N
home-based JJ i
cardiac JJ i
rehabilitation NN i
program NN i
combining NN i
exercise NN i
training NN i
with IN i
risk NN i
factor NN i
modification NN i
and CC i
psychosocial JJ i
counseling NN i
on IN N
risk NN o
factors NNS o
, , o
psychological JJ o
well-being NN o
, , o
functional JJ o
capacity NN o
, , o
and CC o
work NN o
resumption NN o
in IN N
99 CD p
post-percutaneous JJ p
coronary JJ p
interventions NNS p
( ( p
PCI NNP p
) ) p
patients NNS p
randomized VBN p
to TO p
control VB i
( ( i
standard JJ i
care NN i
plus CC i
telephone NN i
follow-up NN i
, , i
n=49 NN i
) ) i
or CC i
intervention NN i
( ( i
individualized VBN i
, , i
comprehensive JJ i
, , i
home-based JJ i
cardiac JJ i
rehabilitation NN i
, , i
n=50 NN i
) ) i
groups NNS i
. . i

The DT N
AV NNP N
Node NNP N
Ablation NNP N
with IN N
CLS NNP N
and CC N
CRT NNP N
Pacing NNP N
Therapies NNP N
for IN N
Treatment NNP N
of IN N
AF NNP N
trial NN N
( ( N
AVAIL NNP N
CLS/CRT NNP N
) ) N
was VBD N
designed VBN N
to TO N
demonstrate VB N
superiority NN N
of IN N
BiV NNP N
pacing VBG N
in IN N
patients NNS N
with IN N
AF NNP N
after IN N
AV NNP N
node JJ N
ablation NN N
, , N
to TO N
evaluate VB N
its PRP$ N
effects NNS N
on IN N
cardiac JJ N
structure NN N
and CC N
function NN N
, , N
and CC N
to TO N
investigate VB N
additional JJ N
benefits NNS N
of IN N
Closed JJ N
Loop NNP N
Stimulation NNP N
( ( N
CLS NNP N
) ) N
( ( N
BIOTRONIK NNP N
, , N
Berlin NNP N
, , N
Germany NNP N
) ) N
. . N

As IN N
secondary JJ N
objectives NNS N
we PRP N
examine VBP N
five CD N
year NN o
survival NN o
rates NNS o
( ( o
OS NNP o
and CC o
DFS NNP o
) ) o
, , o
blood NN o
loss NN o
, , o
duration NN o
of IN o
operation NN o
, , o
requirement NN o
of IN o
blood NN o
transfusions NNS o
, , o
morbidity NN o
rate NN o
, , o
prognostic JJ o
relevance NN o
of IN o
tumor NN o
cell NN o
detection NN o
in IN o
blood NN o
and CC o
bone NN o
marrow NN o
and CC o
the DT o
comparison NN o
of IN o
tumor NN o
cell NN o
detection NN o
by IN N
different JJ N
detection NN N
methods NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
retrospective JJ N
study NN N
is VBZ N
to TO N
contribute VB N
to TO N
the DT N
existing VBG N
knowledge NN N
of IN N
the DT N
comparative JJ N
studies NNS N
of IN N
the DT N
volatile JJ N
anesthetic JJ N
agents NNS N
such JJ N
as IN N
isoflurane NN i
, , i
sevoflurane NN i
and CC i
desflurane NN i
by IN N
evaluating VBG N
the DT N
maintenance NN N
and CC N
emergence NN N
characteristics NNS N
after IN N
volatile JJ N
anesthetics-induced JJ i
preconditioning NN i
with IN i
isoflurane NN i
, , i
sevoflurane NN i
or CC i
desflurane NN i
for IN N
inpatient JJ p
ischemia/reperfusion NN p
cerebral JJ p
injury NN p
during IN p
cerebral JJ p
or CC p
neural JJ p
surgeries NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
LDL NNP N
from IN N
the DT N
beta-carotene NN N
and CC N
placebo NN N
groups NNS N
, , N
as IN N
assessed VBN N
by IN N
measuring VBG N
the DT N
lag NN o
time NN o
for IN o
formation NN o
of IN o
conjugated JJ o
dienes NNS o
; : o
the DT o
rate NN o
of IN o
formation NN o
and CC o
the DT o
amount NN o
of IN o
conjugated VBN o
dienes NNS o
formed VBN o
; : o
the DT o
amount NN o
of IN o
lipid JJ o
peroxides NNS o
generated VBD o
; : o
and CC o
the DT o
relative JJ o
electrophoretic JJ o
mobility NN o
, , N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
this DT N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
the DT N
drug NN N
for IN N
the DT N
purpose NN N
of IN N
relief NN o
Remaxol NNP o
hepatic JJ o
dysfunction NN o
and CC o
prevention NN o
of IN o
drug NN o
liver NN o
toxicity NN o
in IN N
conditions NNS N
ofperitonitis VBP N
, , N
after IN N
48 CD N
hours NNS N
of IN N
operation NN N
, , N
provides VBZ N
a DT N
positive JJ N
dynamics NNS N
and CC N
stabilization NN N
ofparameters NNS N
of IN N
central JJ N
hemodynamics NNS N
, , N
contributing VBG N
to TO N
the DT N
abolition NN N
of IN N
vasopressor NN N
support NN N
, , N
and CC N
contributes VBZ N
to TO N
the DT N
effective JJ N
utilization NN N
of IN N
oxygen NN N
, , N
while IN N
providing VBG N
antioxidant JJ N
effect NN N
. . N

Even RB N
under IN N
temperate NN N
conditions NNS N
( ( N
T NNP N
( ( N
a DT N
) ) N
< $ N
28 CD N
) ) N
, , N
shearing VBG N
significantly RB N
reduced VBN N
core NN o
body NN o
temperature NN o
, , o
water NN o
intake NN o
, , o
and CC o
respiratory NN o
rate NN o
in IN N
German JJ N
Blackhead NNP N
mutton NN N
sheep NN N
, , N
thus RB N
indicating VBG N
heat NN N
stress NN N
in IN N
fleeced JJ N
animals NNS N
, , N
which WDT N
should MD N
be VB N
considered VBN N
when WRB N
determining VBG N
the DT N
optimal JJ N
shearing NN N
time NN N
in IN N
sheep NN N
as RB N
well RB N
as IN N
when WRB N
estimating VBG N
water NN N
requirements NNS N
. . N

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS N
for IN N
the DT N
PlayWisely NNP N
measure NN N
on IN N
the DT N
Yellow NNP N
Sets NNPS N
that WDT N
examine VBP N
recognition NN N
; : N
Purple NNP N
Sets VBZ N
that IN N
examine NN N
brain NN N
region NN N
agility NN N
and CC N
early JJ N
memory NN N
skills NNS N
; : N
Blue NNP N
Sets NNPS N
that WDT N
examine VBP N
phonemic JJ o
awareness NN o
and CC o
recognition NN o
; : o
and CC N
for IN N
the DT N
Total NNP N
Sets NNP N
, , N
with IN N
a DT N
similar JJ N
trend NN N
toward IN N
improvement NN N
in IN N
the DT N
Green JJ N
Sets NNS N
that WDT N
examine VBP N
perception NN N
and CC N
Red NNP N
Sets NNP N
that IN N
examine JJ N
attention NN N
. . N

A DT N
significant JJ N
difference NN N
of IN N
average JJ o
values NNS o
of IN o
CRP NNP o
between IN N
the DT N
3rd CD N
and CC N
21st CD N
day NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
was VBD N
established VBN N
, , N
as RB N
well RB N
as IN N
the DT N
similarity NN N
in IN N
average JJ N
values NNS N
of IN N
CRP NNP N
, , N
which WDT N
points VBZ N
to TO N
the DT N
fact NN N
that IN N
the DT N
mechanical JJ N
effect NN N
of IN N
through IN N
drainage NN N
is VBZ N
dominant JJ N
, , N
speaking VBG N
about IN N
rinsing VBG N
focus NN N
of IN N
infection NN N
and CC N
eliminating VBG N
necrotic JJ N
tissues NNS N
and CC N
small JJ N
sequesters NNS N
. . N

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
no DT N
overall JJ N
effect NN N
on IN N
self-reported JJ o
recovery NN o
or CC o
administrative JJ o
measures NNS o
or CC o
lost VBN o
work NN o
time NN o
between IN N
the DT N
study NN N
groups NNS N
, , N
a DT N
back JJ N
support NN N
plus CC N
health NN N
education NN N
may MD N
have VB N
some DT N
value NN N
in IN N
preventing VBG N
recurrent JJ N
WR-LBD NNP N
in IN N
industrial JJ N
workers NNS N
who WP N
work VBP N
in IN N
psychosocial JJ N
environments NNS N
and CC N
perform VB N
manual JJ N
material NN N
handling VBG N
tasks NNS N
similar JJ N
to TO N
those DT N
found VBN N
in IN N
parts NNS N
distribution NN N
centers NNS N
. . N

However RB N
, , N
the DT N
percent NN N
of IN N
variance NN N
in IN N
these DT N
scores NNS N
explained VBN N
by IN N
time NN N
with IN N
MEE NNP N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
beyond IN N
that DT N
explained VBN N
by IN N
sociodemographic JJ N
variables NNS N
ranged VBD N
only RB N
from IN N
1.2 CD N
% NN N
to TO N
2.9 CD N
% NN N
, , N
and CC N
the DT N
negative JJ N
correlations NNS N
were VBD N
concentrated VBN N
in IN N
the DT N
subgroup NN N
of IN N
children NNS N
whose WP$ N
families NNS N
had VBD N
private JJ N
health NN N
insurance NN N
( ( N
rather RB N
than IN N
Medicaid NNP N
) ) N
. . N

Findings NNS N
suggest VBP N
that IN N
some DT N
aspect NN N
of IN N
both DT N
auditory JJ N
training NN N
and CC N
listening VBG N
to TO N
selected VBN N
unmodified JJ N
music NN N
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
children NNS p
with IN p
autism NN p
and CC p
sound JJ p
sensitivity NN p
, , N
and CC N
indicate VBP N
a DT N
need NN N
for IN N
further JJ N
research NN N
into IN N
the DT N
effects NNS N
that WDT N
led VBD N
to TO N
these DT N
changes NNS N
and CC N
the DT N
mechanisms NNS N
involved VBN N
in IN N
the DT N
sensory JJ N
abnormalities NNS N
commonly RB N
associated VBN N
with IN N
autism NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
rates NNS o
of IN o
in IN o
vitro JJ o
oocyte JJ o
maturation NN o
, , o
fertilization NN o
and CC o
cleavage NN o
, , o
as RB o
well RB o
as IN o
implantation NN o
rate NN o
and CC o
pregnancy NN o
rate NN o
, , N
could MD N
be VB N
improved VBN N
by IN N
low-dose JJ N
priming NN N
with IN N
FSH NNP i
in IN N
vivo NN N
before IN N
retrieval NN N
of IN N
immature NN N
oocytes NNS N
in IN N
patients NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

CONCLUSIONS NNP N
Despite IN N
increases NNS N
having VBG N
been VBN N
found VBN N
in IN N
straylight JJ o
values NNS o
with IN N
tinted VBN N
contact NN N
lenses NNS N
, , N
those DT N
changes NNS N
are VBP N
not RB N
likely JJ N
to TO N
induce VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
visual JJ N
function NN N
under IN N
photopic NN N
conditions NNS N
, , N
even RB N
for IN N
the DT N
grey-green JJ N
CL NNP N
, , N
which WDT N
seems VBZ N
to TO N
increase VB N
straylight JJ o
values NNS o
more RBR N
significantly RB N
than IN N
the DT N
amber JJ N
CL NNP N
. . N

Most JJS N
importantly RB N
, , N
the DT N
experiments NNS N
clarified VBD N
apparently RB N
contradictory JJ N
results NNS N
of IN N
previous JJ N
studies NNS N
by IN N
indicating VBG N
that IN N
concreteness NN o
effects NNS o
generally RB N
do VBP N
not RB N
occur VB N
in IN N
memory NN N
for IN N
prose NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
between-subjects NNS N
, , N
and CC N
that IN N
their PRP$ N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
of IN N
presentation NN N
. . N

Although IN N
dissecting VBG N
the DT N
ureter NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
operation NN N
did VBD N
not RB N
produce VB N
a DT N
significant JJ N
discrepancy NN N
in IN N
operation NN o
time NN o
, , o
blood NN o
loss NN o
, , o
hospitalization NN o
day NN o
and CC o
ureter JJ o
injury NN o
when WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
the DT N
uterine JJ N
arteries NNS N
, , N
however RB N
, , N
may MD N
be VB N
confidently RB N
desiccated VBN N
once RB N
the DT N
path NN N
of IN N
the DT N
ureter NN N
near IN N
the DT N
uterosacral JJ N
ligament NN N
is VBZ N
identified VBN N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
a DT N
new JJ i
combined VBN i
hormonal JJ i
contraceptive JJ i
vaginal JJ i
ring NN i
( ( i
CVR NNP i
) ) i
delivering VBG i
the DT i
nonandrogenic JJ i
progestin NN i
Nestorone NNP i
( ( i
NES NNP i
) ) i
and CC i
ethinyl JJ i
estradiol NN i
( ( i
EE NNP i
) ) i
on IN N
several JJ N
key JJ N
estrogen-sensitive JJ N
hepatic JJ N
proteins NNS N
that WDT N
may MD N
be VB N
markers NNS N
for IN N
the DT N
risk NN N
of IN N
arterial JJ N
or CC N
venous JJ N
disease NN N
events NNS N
and CC N
on IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
. . o

The DT N
present JJ N
randomized VBN N
placebo NN i
( ( i
PLC NNP i
) ) i
-controlled VBD i
within-subject JJ i
pharmaco-functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
( ( i
fMRI NN i
) ) i
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
single JJ N
intranasal NN N
dose NN N
of IN N
synthetic JJ i
OXT NNP i
( ( N
24 CD N
IU NNP N
) ) N
would MD N
facilitate VB N
both DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
interpersonal VB N
touch NN N
in IN N
a DT N
context- NN N
( ( N
female JJ N
vs NN N
male NN N
touch NN N
) ) N
and CC N
trait- JJ N
( ( N
autistic JJ N
trait NN N
load NN N
) ) N
specific JJ N
manner NN N
. . N

Venous JJ o
pressures NNS o
moved VBD o
parallel RB o
to TO o
ascitic JJ o
fluid NN o
pressures NNS o
, , o
and CC o
glomerular JJ o
filtration NN o
rate NN o
, , o
renal JJ o
plasma NN o
flow NN o
, , o
and CC o
urine JJ o
flow NN o
all DT N
improved VBD N
sharply RB N
; : N
then RB N
, , N
as IN N
ascitic JJ N
fluid NN N
continued VBD N
to TO N
form VB N
, , N
reducing VBG N
vascular JJ o
volume NN o
, , o
urine JJ o
flow NN o
, , o
glomerular JJ o
filtration NN o
rate NN o
, , o
and CC o
renal JJ o
plasma NN o
flow NN o
all DT N
decreased VBD N
slowly RB N
. . N

Recovery NN o
after IN N
a DT N
predetermined JJ N
AMP NNP N
PC20 NNP N
challenge NN N
was VBD N
measured VBN N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
along IN N
with IN N
exhaled JJ o
nitric JJ o
oxide NN o
levels NNS o
, , o
plasma NN o
eosinophil NN o
cationic JJ o
protein NN o
levels NNS o
, , o
peripheral JJ o
eosinophil NN o
counts NNS o
, , o
pulmonary JJ o
function NN o
, , o
diary JJ o
card NN o
outcomes NNS o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( N
all DT N
secondary JJ N
outcomes NNS N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
mental VB o
or CC o
physical JJ o
health NN o
, , o
low JJ o
back RB o
pain NN o
, , o
back RB o
pain NN o
disability NN o
, , o
neurogenic JJ o
symptoms NNS o
, , o
lost VBN o
work NN o
time NN o
, , o
likelihood NN o
of IN o
recurrence NN o
of IN o
an DT o
episode NN o
of IN o
a DT o
back JJ o
disorder NN o
, , o
or CC o
other JJ o
administrative JJ o
measures NNS o
of IN o
healthcare JJ o
utilization NN o
or CC o
lost VBN o
work NN o
time NN o
. . o

Although IN N
AmB NNP i
in IN N
lipid JJ N
emulsion NN N
is VBZ N
apparently RB N
cleared VBN N
faster RBR N
and CC N
distributes VBZ N
more RBR N
widely RB N
than IN N
AmB NNP N
in IN N
dextrose NN N
, , N
this DT N
study NN N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
advantage NN N
with IN N
respect NN N
to TO N
safety NN o
and CC o
tolerance NN o
in IN N
the DT N
administration NN N
of IN N
AmB NNP i
in IN N
lipid JJ N
emulsion NN N
compared VBN N
to TO N
its PRP$ N
administration NN N
in IN N
dextrose NN N
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
. . p

These DT N
PSL-LBNP JJ N
exposures NNS N
were VBD N
conducted VBN N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
and CC N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h. NN N
While IN N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
either CC N
the DT N
response NN o
pattern NN o
or CC o
magnitude NN o
of IN o
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
to TO N
the DT N
differing NN N
protocols NNS N
, , N
the DT N
cumulative JJ N
stress NN N
index NN N
and CC N
the DT N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
varied VBD N
proportionally RB N
with IN N
the DT N
length NN N
of IN N
the DT N
stage NN N
durations NNS N
. . N

The DT N
results NNS N
demonstrate VBP N
the DT N
clinical JJ o
efficacy NN o
of IN o
anti-inflammatory JJ o
drugs NNS o
in IN N
the DT N
treatment NN N
of IN N
pollen-induced JJ p
allergic JJ p
conjunctivitis NN p
; : p
they PRP N
also RB N
suggest VBP N
the DT N
use NN N
of IN N
NSAIDs NNP i
in IN N
long-term JJ N
treatment NN N
, , N
as IN N
their PRP$ N
efficacy NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
closely RB N
comparable JJ N
to TO N
that DT N
of IN N
steroids NNS N
, , N
while IN N
avoiding VBG N
the DT N
well-known JJ N
side-effects NNS N
of IN N
the DT N
latter NN N
in IN N
prolonged JJ N
treatment NN N
. . N

To TO N
avoid VB N
this DT N
complication NN N
, , N
it PRP N
is VBZ N
necessary JJ N
to TO N
better RBR N
understand VB N
the DT N
depth NN N
of IN N
the DT N
wound NN N
produced VBN N
by IN N
different JJ N
strengths NNS N
and CC N
combinations NNS N
of IN N
peeling VBG N
agents NNS N
applied VBN N
to TO N
living VBG N
eyelid JJ N
tissue NN N
and CC N
, , N
more RBR N
important JJ N
, , N
to TO N
determine VB N
the DT N
concentrations NNS N
of IN N
TCA NNP N
that WDT N
are VBP N
likely JJ N
to TO N
lead VB N
to TO N
cicatricial JJ N
ectropion NN N
when WRB N
applied VBN N
in IN N
a DT N
consistent JJ N
fashion NN N
. . N

This DT N
controlled VBD N
clinical JJ N
trial NN N
tested VBD N
virtual JJ i
reality NN i
exposure NN i
( ( i
VRE NNP i
) ) i
therapy NN i
for IN N
the DT N
fear NN p
of IN p
flying VBG p
( ( p
FOF NNP p
) ) p
, , N
a DT N
relatively RB N
new JJ N
and CC N
innovative JJ N
way NN N
to TO N
do VB N
exposure NN N
therapy NN N
, , N
and CC N
compared VBN N
it PRP N
to TO N
standard VB i
( ( i
in IN i
vivo NN i
) ) i
exposure NN i
therapy NN i
( ( i
SE NNP i
) ) i
and CC N
a DT N
wait JJ N
list NN N
( ( N
WL NNP N
) ) N
control NN N
with IN N
a DT N
6- JJ N
and CC N
12-month JJ N
follow-up NN N
. . N

BACKGROUND NNP N
Despite IN N
it PRP N
is VBZ N
accepted VBN N
that IN N
acne NN N
is VBZ N
mostly RB N
caused VBN N
by IN N
an DT N
hyper-responsiveness NN N
of IN N
the DT N
pilo-sebaceous JJ N
unit NN N
to TO N
normal JJ N
circulating VBG N
androgen NN N
hormones NNS N
, , N
in IN N
a DT N
few JJ N
patients NNS N
, , N
especially RB N
women NNS N
, , N
acneic JJ N
lesions NNS N
can MD N
be VB N
associated VBN N
with IN N
increased JJ N
serum NN N
androgen NN N
levels NNS N
( ( N
hyperandrogenism NN N
) ) N
, , N
of IN N
which WDT N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
. . N

However RB N
, , N
the DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
regarding VBG N
time NN o
from IN o
balloon NN o
insertion NN o
to TO o
active JJ o
labor NN o
, , o
time NN o
from IN o
balloon NN o
expulsion NN o
to TO o
delivery NN o
, , o
cervical JJ o
ripening NN o
, , o
cesarean JJ o
section NN o
, , o
instrumental JJ o
delivery NN o
, , o
pain NN o
score NN o
, , o
need VBP o
for IN o
analgesia NN o
, , o
hospital NN o
stay NN o
and CC o
maternal JJ o
satisfaction NN o
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
response NN N
to TO N
improved VBN N
blood NN o
folate NN o
concentrations NNS o
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ i
acid NN i
supplement NN i
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS p
with IN p
high JJ p
blood NN p
folate NN p
values NNS p
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
. . N

By IN N
comparison NN N
of IN N
3-month JJ N
changes NNS N
between IN N
randomized VBN N
subgroups NNS N
, , N
the DT N
addition NN N
of IN N
low-dose JJ N
flutamide NN N
was VBD N
found VBN N
to TO N
have VB N
consistently RB N
( ( N
more RBR N
) ) N
normalizing VBG N
effects NNS N
on IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
, , o
IL-6 NNP o
, , o
and CC o
adiponectin NN o
, , o
lean JJ o
body NN o
mass NN o
, , o
total JJ o
and CC o
abdominal JJ o
fat JJ o
mass NN o
, , o
and CC o
arterial JJ o
flow NN o
in IN o
the DT o
ovaries NNS o
. . o

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
study NN N
arms NNS N
at IN N
3 CD N
months NNS N
in IN N
number NN o
of IN o
male JJ o
partners NNS o
, , o
number NN o
of IN o
unprotected JJ o
anal JJ o
intercourse NN o
partners NNS o
, , o
proportion NN o
reporting NN o
unprotected JJ o
sex NN o
, , o
number NN o
of IN o
acts NNS o
protected VBN o
by IN o
condoms NNS o
, , o
self-efficacy NN o
, , o
condom NN o
attitudes NNS o
, , o
condom NN o
intentions NNS o
, , o
social JJ o
isolation NN o
and CC o
psychological JJ o
distress NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incremental JJ o
cost-effectiveness JJ o
ratios NNS o
( ( N
ICERs NNP N
) ) N
of IN N
two CD i
brief JJ i
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
-based VBD i
interventions NNS i
and CC i
a DT i
pharmacological JJ i
treatment NN i
, , i
compared VBN i
with IN i
usual JJ i
care NN i
, , i
initiated VBN i
in IN i
the DT i
emergency NN i
department NN i
( ( i
ED NNP i
) ) i
for IN N
individuals NNS p
with IN p
panic JJ p
disorder NN p
( ( p
PD NNP p
) ) p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
noncardiac JJ p
chest NN p
pain NN p
. . p

ORG-2766 NNP N
( ( N
a DT N
) ) N
increased VBD N
the DT N
occipital JJ o
P3 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
visual JJ o
targets NNS o
, , o
( ( o
b NN o
) ) o
decreased VBD o
the DT o
occipital JJ o
P3 NNP o
component NN o
of IN o
the DT o
ERP NNP o
to TO o
auditory JJ o
targets NNS o
, , o
( ( o
c NN o
) ) o
did VBD o
not RB o
affect VB o
visual JJ o
and CC o
auditory JJ o
parietal JJ o
target NN o
P3 NNP o
components NNS o
, , o
and CC o
( ( o
d NN o
) ) o
also RB o
did VBD o
not RB o
affect VB o
the DT o
A/Pcz/300 NNP o
to TO o
auditory VB o
novel JJ o
stimuli NNS o
. . o

The DT N
Stroke NNP N
Team NNP N
Remote NNP N
Evaluation NNP N
Using VBG N
a DT N
Digital NNP N
Observation NNP N
Camera NNP N
( ( N
STRokE NNP N
DOC NNP N
) ) N
trial NN N
reported VBD N
more RBR N
accurate JJ N
decision NN N
making NN N
for IN N
telemedicine JJ i
consultations NNS N
compared VBN N
with IN N
telephone-only JJ i
and CC N
that IN N
the DT N
California-based JJ N
research NN N
network NN N
facilitated VBD N
a DT N
high JJ o
rate NN o
of IN o
thrombolysis NN o
use NN o
, , o
improved VBN o
data NNS o
collection NN o
, , o
low JJ o
risk NN o
of IN o
complications NNS o
, , o
low JJ o
technical JJ o
complications NNS o
, , o
and CC o
favorable JJ o
assessment NN o
times NNS o
. . o

Denbufylline NNP i
induced VBD N
a DT N
statistically RB N
significant JJ N
and CC N
clinically RB N
relevant JJ N
improvement NN N
in IN N
both DT N
SDAT NNP N
and CC N
MID NNP N
patients NNS N
, , N
whereas NNS N
after IN N
placebo NN i
this DT N
was VBD N
not RB N
the DT N
case NN N
in IN N
CGI NNP N
, , N
the DT N
TMT NNP N
, , N
and CC N
the DT N
DS NNP N
, , N
with IN N
interdrug JJ N
differences NNS N
being VBG N
significant JJ N
in IN N
all DT N
primary JJ N
target NN N
variables NNS N
such JJ N
as IN N
the DT N
CGI NNP o
, , o
MMS NNP o
, , o
SCAG NNP o
, , o
and CC o
DSST NNP o
. . o

CONCLUSIONS NNP N
Although IN N
the DT N
main JJ N
findings NNS N
were VBD N
similar JJ N
to TO N
those DT N
from IN N
other JJ N
brief-intervention NN N
studies NNS N
in IN N
Western JJ N
cultures NNS N
, , N
findings NNS N
here RB N
also RB N
suggest VBP N
that IN N
intervention NN N
may MD N
have VB N
differential JJ N
benefits NNS N
for IN N
specific JJ N
subgroups NNS N
of IN N
patients NNS N
in IN N
the DT N
ED NNP N
, , N
an DT N
area NN N
of IN N
research NN N
that WDT N
may MD N
warrant VB N
additional JJ N
study NN N
of IN N
brief JJ N
intervention NN N
in IN N
the DT N
ED NNP N
setting NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
controlled VBN N
trial NN N
involving VBG N
98 CD p
children NNS p
and CC p
families NNS p
was VBD N
carried VBN N
out RP N
in IN N
three CD N
different JJ N
sites NNS N
investigating VBG N
the DT N
efficacy NN N
of IN N
a DT N
parent NN N
delivery NN N
of IN N
the DT N
Early JJ i
Start NNP i
Denver NNP i
model NN i
( ( i
P-ESDM NNP i
) ) i
, , i
which WDT i
fosters VBZ i
parental JJ i
use NN i
of IN i
a DT i
child-centered JJ i
responsive JJ i
interaction NN i
style NN i
that WDT i
embeds VBZ i
many JJ i
teaching VBG i
opportunities NNS i
into IN i
play NN i
, , i
compared VBN i
to TO i
community NN i
treatment NN i
as IN i
usual JJ i
. . i

Several JJ N
racial JJ N
and CC N
ethnic JJ N
group NN N
differences NNS N
existed VBD N
in IN N
physical JJ o
and CC o
emotional JJ o
health NN o
, , N
as RB N
well RB N
as IN N
in IN N
total JJ o
frustration NN o
with IN o
caregiving NN o
, , o
emotional JJ o
burden NN o
, , o
and CC o
CG-rated JJ o
bother NN o
with IN o
CR NNP o
's POS o
activities NNS o
of IN o
daily JJ o
living NN o
and CC o
instrumental JJ o
activities NNS o
of IN o
daily JJ o
living NN o
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
, , N
although IN N
differences NNS N
between IN N
baseline NN N
and CC N
posttest NN N
did VBD N
not RB N
vary JJ N
according VBG N
to TO N
race NN N
. . N

The DT N
aim NN N
of IN N
the DT N
Finnish NNP N
Diabetes NNP N
Prevention NNP N
Study NNP N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
an DT N
intensive JJ i
diet-exercise NN i
programme NN i
in IN N
preventing VBG N
or CC N
delaying VBG N
type JJ N
2 CD N
diabetes NNS N
in IN N
individuals NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
( ( p
IGT NNP p
) ) p
and CC N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
programme NN i
on IN N
the DT N
risk NN N
factors NNS N
of IN N
atherosclerotic JJ N
vascular NN N
diseases NNS N
and CC N
the DT N
incidence NN N
of IN N
cardiovascular JJ o
events NNS o
. . o

As IN N
this DT N
project NN N
is VBZ N
much RB N
longer JJR N
term NN N
than IN N
previous JJ N
investigations NNS N
in IN N
the DT N
area NN N
of IN N
exercise NN N
and CC N
cancer NN N
, , N
we PRP N
will MD N
gain VB N
knowledge NN N
as IN N
to TO N
the DT N
continuing VBG N
effects NNS N
of IN N
exercise NN N
in IN N
this DT N
patient JJ N
population NN N
specifically RB N
targeting VBG N
bone NN o
density NN o
, , o
cardiovascular JJ o
function NN o
, , o
lean JJ o
and CC o
fat JJ o
mass NN o
, , o
physical JJ o
function NN o
and CC o
falls VBZ o
risk NN o
as IN N
primary JJ N
study NN N
endpoints NNS N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
S-form NNP N
type NN N
is VBZ N
associated VBN N
with IN N
previously-identified JJ N
adverse JJ N
risk NN N
WBC NNP N
parameters NNS N
but CC N
that IN N
the DT N
identification NN N
of IN N
the DT N
S-form NNP N
or CC N
L-form NNP N
type NN N
of IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
, , N
per IN N
se FW N
, , N
does VBZ N
not RB N
predict VB N
clinical JJ N
outcome NN N
or CC N
add VB N
to TO N
the DT N
value NN N
of IN N
an DT N
increased VBN N
WBC NNP o
count NN o
as IN N
a DT N
negative JJ N
prognostic JJ N
indicator NN N
in IN N
APL NNP p
patients NNS p
. . p

However RB N
, , N
during IN N
the DT N
whole JJ N
12-month JJ N
training NN N
period NN N
, , N
both DT N
dynamic JJ o
and CC o
isometric JJ o
back NN o
extension NN o
and CC o
flexion NN o
strength NN o
, , N
as RB N
well RB N
as IN N
mobility NN N
of IN N
the DT N
spine NN N
and CC N
repetitive JJ N
squat-test JJ N
results NNS N
, , N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
physical JJ N
function NN N
parameters NNS N
between IN N
the DT N
STG NNP N
and CC N
CG NNP N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
an DT N
IVF NNP i
protein NN i
supplement NN i
prepared VBN N
from IN N
human JJ N
serum NN N
albumin NN N
( ( N
HSA NNP N
) ) N
and CC N
human JJ N
globulins NNS N
would MD N
retain VB N
performance NN N
characteristics NNS N
equivalent JJ N
to TO N
those DT N
reported VBN N
for IN N
the DT N
commercial JJ N
plasma NN N
expanders NNS N
, , N
Plasmatein NNP N
( ( N
Alpha NNP N
Therapeutics NNP N
, , N
Los NNP N
Angeles NNP N
, , N
California NNP N
) ) N
and CC N
Plasmanate NNP N
( ( N
Cutter NNP N
Biological NNP N
, , N
Miles NNP N
Inc. NNP N
, , N
Elkhart NNP N
, , N
Indiana NNP N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
initial JJ N
cortical JJ N
response NN N
to TO N
the DT N
magnocellular JJ N
afferents NNS N
is VBZ N
weaker JJR N
at IN N
low JJ N
contrast NN N
in IN N
the DT N
high JJ N
autistic JJ N
tendency NN N
group NN N
and CC N
that IN N
a DT N
second-order JJ N
response NN N
, , N
reflecting VBG N
magnocellular JJ N
activity NN N
, , N
demonstrated VBD N
a DT N
delay NN N
for IN N
high JJ N
versus NN N
low JJ N
scorers NNS N
when WRB N
the DT N
parvocellular JJ N
pathway NN N
was VBD N
also RB N
active JJ N
in IN N
response NN N
to TO N
a DT N
high JJ N
contrast NN N
stimulus NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
compared VBN N
the DT N
effect NN N
of IN N
epidural JJ i
analgesia NN i
and CC i
IV NNP i
morphine VBP i
patient-controlled JJ i
analgesia NN i
( ( i
PCA NNP i
) ) i
on IN N
pain NN o
relief NN o
, , o
duration NN o
of IN o
hospitalization NN o
, , o
oral JJ o
nutrition NN o
, , o
ambulation NN o
, , o
and CC o
side NN o
effects NNS o
in IN N
patients NNS p
undergoing VBG p
a DT p
major JJ p
surgical JJ p
procedure NN p
( ( p
i.e JJ p
, , p
unilateral JJ p
mastectomy NN p
with IN p
immediate JJ p
transverse NN p
rectus NN p
abdominis VBP p
musculocutaneous JJ p
flap JJ p
reconstruction NN p
) ) p
. . p

The DT N
results NNS N
provide VBP N
evidence NN N
that IN N
the DT N
two CD N
tumor NN N
markers NNS N
are VBP N
not RB N
directly RB N
linked VBN N
and CC N
that IN N
DCP NNP N
levels NNS N
may MD N
not RB N
reflect VB N
HCC NNP N
cell NN N
growth NN N
, , N
as IN N
DCP NNP N
levels NNS N
were VBD N
decreased VBN N
in IN N
patients NNS N
without IN N
AFP NNP N
change NN N
, , N
and CC N
were VBD N
suppressed VBN N
in IN N
vitro NN N
at IN N
1 CD N
% NN N
of IN N
the DT N
vitamin NN N
K1 NNP N
concentration NN N
needed VBD N
to TO N
inhibit VB N
AFP NNP N
. . N

CONCLUSION NNP N
The DT N
level NN o
of IN o
absence NN o
of IN o
cold JJ o
sensation NN o
, , o
level NN o
of IN o
pinprick JJ o
analgesia NN o
, , o
and CC o
time NN o
to TO o
achieve VB o
sensory JJ o
block NN o
to TO o
T4 NNP o
level NN o
were VBD N
statistically RB N
higher JJR N
in IN N
patients NNS N
receiving VBG N
hyperbaric JJ N
bupivacaine NN i
than IN N
in IN N
patients NNS N
receiving VBG N
plain JJ i
bupivacaine NN i
and CC i
plain NN i
levobupivacaine NN i
, , N
while IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
regarding VBG N
effective JJ o
surgical JJ o
anesthesia NN o
, , o
postoperative JJ o
analgesia NN o
, , o
and CC o
side JJ o
effects NNS o
. . o

The DT N
secondary JJ N
outcome NN N
measures NNS N
are VBP N
the DT N
Center NNP o
for IN o
Epidemiological NNP o
Studies NNPS o
Depression NNP o
Scale NNP o
, , o
the DT o
World NNP o
Health NNP o
Organization NNP o
Quality NNP o
of IN o
Life NNP o
Scale NNP o
26-item JJ o
version NN o
, , o
the DT o
Global NNP o
Assessment NNP o
of IN o
Functioning NNP o
, , o
State-trait NNP o
Anxiety NNP o
Inventory NNP o
, , o
Social NNP o
Phobia NNP o
and CC o
Anxiety NNP o
Inventory NNP o
, , o
and CC o
Liebowitz NNP o
Social NNP o
Anxiety NNP o
Scale NNP o
. . o

CONCLUSIONS NNP N
For IN N
a DT N
longer RBR N
follow-up JJ N
period NN N
than IN N
in IN N
previous JJ N
studies NNS N
, , N
this DT N
heart NN N
failure NN N
disease JJ N
management NN N
program NN N
model NN N
of IN N
patients NNS N
under IN N
the DT N
supervision NN N
of IN N
a DT N
cardiologist NN N
is VBZ N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
unplanned JJ o
hospitalization NN o
, , o
a DT o
reduction NN o
of IN o
total JJ o
hospital NN o
days NNS o
, , o
and CC o
a DT o
reduced JJ o
need NN o
for IN o
emergency NN o
care NN o
, , N
as RB N
well RB N
as IN N
improved VBN N
quality NN o
of IN o
life NN o
, , N
despite IN N
modest JJ N
program NN N
adherence NN N
over IN N
time NN N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes NNS N
: : N
the DT N
NPI-Q NNP o
sum NN o
score NN o
as RB N
well RB N
as IN N
the DT N
subscales NNS o
NPI-Q NNP o
agitation NN o
and CC o
NPI-Q JJ o
psychosis NN o
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control NN N
, , N
the DT N
QUALID NNP o
score NN o
was VBD N
in IN N
favour NN N
of IN N
DCM NNP N
versus NN N
control NN N
and CC N
the DT N
CSDD NNP o
score NN o
was VBD N
in IN N
favour NN N
of IN N
VPM NNP N
versus NN N
control NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
Neurologic NNP i
Music NNP i
Therapy NNP i
( ( i
NMT NNP i
) ) i
sensory-motor NN i
rehabilitation NN i
technique NN i
, , i
Therapeutic NNP i
Instrumental NNP i
Music NNP i
Performance NNP i
( ( i
TIMP NNP i
) ) i
as IN N
compared VBN N
to TO N
Traditional NNP i
Occupational NNP i
Therapy NNP i
( ( i
TOT NNP i
) ) i
, , N
on IN N
endurance NN o
, , o
self-perceived JJ o
fatigue NN o
, , o
and CC o
self-perceived JJ o
exertion NN o
of IN N
35 CD p
hospitalized JJ p
patients NNS p
in IN p
physical JJ p
rehabilitation NN p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
methylphenidate NN i
( ( i
MPH NNP i
) ) i
to TO N
treat VB N
attention-deficit/hyperactivity JJ p
disorder NN p
( ( p
ADHD NNP p
) ) p
symptoms NNS p
in IN p
an DT p
understudied JJ p
population NN p
of IN p
preschoolers NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
or CC p
intellectual JJ p
disability NN p
( ( p
ID NNP p
) ) p
. . p

GOALS NNP N
To TO N
measure VB N
visit-to-visit JJ N
intraindividual JJ N
variations NNS N
of IN N
both DT N
clinic JJ N
and CC N
24-h JJ N
mean NN N
BP NNP N
in IN N
the DT N
hypertensive JJ p
patients NNS p
of IN p
the DT p
European NNP p
Lacidipine NNP p
Study NNP p
on IN p
Atherosclerosis NNP p
( ( p
ELSA NNP p
) ) p
trial NN p
treated VBD p
for IN p
4 CD p
years NNS p
with IN p
either DT p
atenolol NN i
or CC i
lacidipine NN i
, , i
and CC i
to TO i
check VB i
whether IN i
interindividual JJ i
clinic NN i
and CC i
24-h JJ i
BP NNP i
variabilities NNS i
during IN i
treatment NN i
can MD i
really RB i
be VB i
considered VBN i
a DT i
surrogate NN i
of IN i
intraindividual JJ i
variabilities NNS i
in IN i
exploring VBG i
differences NNS i
between IN i
? . i
and CC i
calcium JJ i
antagonist NN i
treatments NNS i
. . i

Split-course JJ i
radiation NN i
therapy NN i
is VBZ N
superior JJ N
to TO N
continuous JJ N
radiation NN N
therapy NN N
because IN N
it PRP N
is VBZ N
better RBR N
tolerated VBN o
by IN N
the DT N
patient NN N
and CC N
because IN N
re-examination NN N
of IN N
the DT N
patient NN N
prior RB N
to TO N
the DT N
second JJ N
half NN N
of IN N
split-course JJ N
therapy NN N
permits VBZ N
the DT N
detection NN N
of IN N
new JJ N
metastatic JJ N
disease NN N
that WDT N
has VBZ N
become VBN N
manifest JJS N
during IN N
the DT N
rest NN N
period NN N
and CC N
spares VBZ N
the DT N
patient NN N
the DT N
futile JJ N
second JJ N
half NN N
of IN N
radiation NN N
therapy NN N
. . N

CONCLUSION NNP N
Although IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
consider VB N
all DT N
factors NNS N
which WDT N
can MD N
have VB N
an DT N
influence NN N
on IN N
SSI NNP N
and CC N
use VB N
all PDT N
the DT N
means NNS N
shown VBN N
to TO N
be VB N
effective JJ N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
SSI NNP N
, , N
there EX N
is VBZ N
a DT N
rationale NN N
for IN N
using VBG N
ORC NNP N
to TO N
prevent VB N
this DT N
kind NN N
of IN N
infection NN N
, , N
especially RB N
in IN N
patients NNS N
who WP N
undergo VBP N
dirty JJ N
surgery NN N
. . N

DESIGN NNP N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ N
adherence NN N
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

The DT N
absence NN N
of IN N
suppression NN N
of IN N
reflexive JJ N
sympathetic JJ N
responses NNS N
contrasts NNS N
with IN N
the DT N
effects NNS N
of IN N
rilmenidine NN i
in IN N
experimental JJ N
animals NNS N
, , N
and CC N
emphasises VBZ N
the DT N
previously RB N
demonstrated VBN N
unique JJ N
importance NN N
in IN N
humans NNS N
of IN N
suprabulbar NN N
noradrenergic JJ N
neuronal JJ N
projections NNS N
from IN N
the DT N
brainstem NN N
, , N
which WDT N
are VBP N
inhibited VBN N
by IN N
imidazoline JJ N
binding NN N
agents NNS N
, , N
in IN N
regulating VBG N
tonic JJ N
sympathetic JJ N
activity NN N
in IN N
essential JJ N
hypertension NN N
. . N

Accordingly RB N
, , N
it PRP N
would MD N
be VB N
anticipated VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
would MD N
significantly RB N
alter VB N
the DT N
autonomic JJ N
imbalance NN N
characteristic NN N
of IN N
patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
and CC N
that IN N
this DT N
influence NN N
over IN N
neural JJ N
mechanisms NNS N
of IN N
cardiovascular JJ N
control NN N
may MD N
significantly RB N
contribute VB N
to TO N
the DT N
hemodynamic JJ N
benefit NN N
and CC N
improved VBN N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
therapy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Amount NNP o
of IN o
intraoperative JJ o
bleeding NN o
( ( o
surgeons NNS o
' POS o
subjective JJ o
estimate NN o
) ) o
, , o
need VBP o
for IN o
additional JJ o
packings NNS o
, , o
need VBP o
for IN o
electrocautery NN o
, , o
laryngeal JJ o
spasm NN o
, , o
postoperative JJ o
bleeding NN o
and CC o
pain NN o
, , o
duration NN o
of IN o
procedure NN o
and CC o
duration NN o
of IN o
patients NNS o
' POS o
stay NN o
in IN o
the DT o
operation NN o
room NN o
( ( o
OR NNP o
) ) o
. . o

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
functional JJ N
endoscopic NN N
sinus NN N
surgery NN N
, , N
combined VBN N
with IN N
appropriate JJ N
postoperative JJ N
care NN N
, , N
is VBZ N
effective JJ N
at IN N
maintaining VBG N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
overall JJ N
general JJ N
health NN N
status NN N
of IN N
patients NNS N
for IN N
at IN N
least JJS N
3 CD N
years NNS N
after IN N
surgical JJ N
intervention NN N
and CC N
that IN N
the DT N
overall JJ N
scores NNS N
return VBP N
to TO N
a DT N
range NN N
of IN N
normative JJ N
values NNS N
for IN N
the DT N
general JJ N
population NN N
. . N

Polygraphic JJ o
recordings NNS o
included VBD o
sleep JJ o
state NN o
( ( o
active JJ o
and CC o
quiet JJ o
sleep NN o
by IN o
electroencephalogram NN o
, , o
eye NN o
movements NNS o
, , o
breathing NN o
, , o
and CC o
behavior NN o
) ) o
, , o
cardiorespiratory JJ o
measurements NNS o
( ( o
nasal JJ o
airflow NN o
, , o
chest VBP o
wall NN o
movements NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
oxygen PRP o
saturation NN o
) ) o
, , o
swallowing VBG o
, , o
and CC o
esophageal JJ o
activity NN o
( ( o
solid JJ o
state NN o
pressure NN o
catheter NN o
) ) o
. . o

The DT N
comparison NN N
involved VBD N
randomly RB N
assigning VBG N
150 CD p
outpatients NNS p
with IN p
major JJ p
depression NN p
to TO p
a DT p
treatment NN i
focused VBN i
exclusively RB i
on IN i
the DT i
behavioral JJ i
activation NN i
( ( i
BA NNP i
) ) i
component NN i
of IN i
CT NNP i
, , i
a DT i
treatment NN i
that WDT i
included VBD i
both DT i
BA NNP i
and CC i
the DT i
teaching NN i
of IN i
skills NNS i
to TO i
modify VB i
automatic JJ i
thoughts NNS i
( ( i
AT NNP i
) ) i
, , i
but CC i
excluding VBG i
the DT i
components NNS i
of IN i
CT NNP i
focused VBD i
on IN i
core NN i
schema NN i
, , i
or CC i
the DT i
full JJ i
CT NNP i
treatment NN i
. . i

Although IN N
the DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
considered VBN N
the DT N
gold JJ N
standard NN N
in IN N
research NN N
for IN N
determining VBG N
the DT N
efficacy NN N
of IN N
health NN N
education NN N
interventions NNS N
, , N
such JJ N
trials NNS N
may MD N
be VB N
vulnerable JJ N
to TO N
preference VB N
effects NNS N
; : N
that DT N
is VBZ N
, , N
differential JJ N
outcomes NNS N
depending VBG N
on IN N
whether IN N
an DT N
individual NN N
is VBZ N
randomized VBN N
to TO N
his PRP$ N
or CC N
her PRP$ N
preferred JJ N
treatment NN N
. . N

PURPOSE NN N
To TO N
prospectively RB N
assess VB N
the DT N
effect NN N
of IN N
reduced JJ N
iodine JJ N
load NN N
to TO N
contrast VB N
enhancement NN N
, , N
image NN N
quality NN N
, , N
and CC N
detectability NN N
of IN N
hepatocellular JJ N
carcinomas NN N
( ( N
HCCs NNP N
) ) N
in IN N
hepatic JJ i
CT NNP i
with IN i
a DT i
combination NN i
of IN i
80 CD i
kVp NNS i
tube JJ i
voltage NN i
setting NN i
and CC i
adaptive JJ i
statistical JJ i
iterative JJ i
reconstruction NN i
( ( i
ASIR NNP i
) ) i
technique NN i
in IN N
patients NNS p
with IN p
chronic JJ p
liver NN p
disease NN p
. . p

RESULTS JJ N
Women NNP N
in IN N
the DT N
pilot NN N
group NN N
had VBD N
significantly RB N
more RBR N
continuity NN N
of IN N
care NN N
throughout IN N
each DT N
of IN N
the DT N
three CD N
periods NNS N
, , N
were VBD N
generally RB N
more RBR N
satisfied JJ N
with IN N
their PRP$ N
care NN N
, , N
felt VBD N
that IN N
they PRP N
had VBD N
more JJR N
choice NN N
over IN N
a DT N
variety NN N
of IN N
aspects NNS N
of IN N
care NN N
and CC N
experienced VBD N
no DT N
compromise NN N
in IN N
clinical JJ N
outcomes NNS N
( ( N
P NNP N
= VBZ N
0.05 CD N
or CC N
less JJR N
in IN N
each DT N
case NN N
) ) N
. . N

OBJECTIVE IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
first RB N
to TO N
analyze VB N
neurocognitive JJ N
outcomes NNS N
of IN N
patients NNS p
after IN p
open-chamber JJ p
cardiac JJ p
surgery NN p
to TO N
determine VB N
whether IN N
carbon NN i
dioxide NN i
pericardial JJ i
insufflation NN i
reduces NNS N
incidence NN N
of IN N
neurocognitive JJ N
decline NN N
( ( N
primary JJ N
end NN N
point NN N
) ) N
as IN N
measured VBN N
6 CD N
weeks NNS N
postoperatively RB N
and CC N
second JJ N
to TO N
assess VB N
the DT N
utility NN N
of IN N
carbon NN N
dioxide NN N
insufflation NN N
in IN N
cardiac JJ N
chamber NN N
deairing NN N
as IN N
assessed VBN N
by IN N
transesophageal JJ N
echocardiography NN N
. . N

Baseline NNP o
NE NNP o
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
NE NNP N
AUC0-90 NNP N
in IN N
all DT N
three CD N
groups NNS N
, , N
suggesting VBG N
that IN N
, , N
although IN N
the DT N
NE NNP N
system NN N
may MD N
be VB N
dysregulated VBN N
in IN N
the DT N
MDE NNP N
and CC N
MDE NNP N
+ NNP N
P NNP N
patients NNS N
, , N
the DT N
NE NNP N
system NN N
still RB N
appears VBZ N
to TO N
respond VB N
somewhat RB N
predictably RB N
following VBG N
a DT N
challenge NN N
, , N
even RB N
though IN N
the DT N
actual JJ N
magnitude NN N
of IN N
response NN N
may MD N
vary VB N
. . N

Yet RB N
, , N
sleep VBP N
withdrawal NN N
even RB N
if IN N
only RB N
partial JJ N
, , N
has VBZ N
a DT N
negative JJ N
influence NN N
on IN N
performance NN N
, , N
particularly RB N
when WRB N
the DT N
type NN N
of IN N
exercise NN N
requires VBZ N
good JJ N
psychomotor NN N
performance NN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
intake NN N
of IN N
a DT N
hypnotic JJ N
drug NN N
would MD N
have VB N
negative JJ N
effects NNS N
on IN N
physical JJ N
performance NN N
capacity NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
overall JJ o
mood NN o
profiles NNS o
were VBD N
similar JJ N
for IN N
the DT N
users NNS N
of IN N
any DT N
of IN N
the DT N
standard JJ N
malaria NN N
chemoprophylaxis NN N
regimens NNS N
, , N
we PRP N
found VBD N
that IN N
women NNS N
using VBG N
mefloquine NN N
showed VBD N
more JJR N
fatigue NN o
and CC o
confusion NN o
than IN N
men NNS N
and CC N
that IN N
younger JJR N
persons NNS N
aged VBD N
less JJR N
than IN N
34 CD N
years NNS N
, , N
regardless RB N
of IN N
chemoprophylaxis NN N
used VBN N
, , N
reported VBD N
more JJR N
tension NN o
and CC o
fatigue NN o
than IN N
their PRP$ N
older JJR N
counterparts NNS N
. . N

The DT N
emerging VBG N
concept NN N
of IN N
opioid JJ N
peptides NNS N
as IN N
a DT N
new JJ N
class NN N
of IN N
chemical JJ N
messengers NNS N
of IN N
the DT N
neuroimmune JJ N
axis NN N
and CC N
the DT N
presence NN N
of IN N
a DT N
number NN N
of IN N
immunological JJ N
abnormalities NNS N
in IN N
infantile JJ N
autism NN N
prompted VBD N
us PRP N
to TO N
correlate VB N
biological JJ N
( ( N
hormonal JJ N
and CC N
immunological JJ N
) ) N
determinations NNS N
and CC N
behavioural JJ N
performances NNS N
during IN N
treatment NN N
with IN N
the DT N
potent NN N
opiate JJ N
antagonist NN N
, , N
naltrexone NN i
( ( i
NAL NNP i
) ) i
. . i

The DT N
results NNS N
of IN N
that DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
suggest VBP N
that IN N
fluoxetine NN i
was VBD N
effective JJ N
in IN N
decreasing VBG N
but CC N
not RB N
eliminating VBG N
both CC N
the DT N
depressive NN o
symptoms NNS o
( ( o
including VBG o
suicidal JJ o
ideations NNS o
) ) o
and CC o
the DT o
level NN o
of IN o
alcohol JJ o
consumption NN o
among IN N
a DT N
study NN N
group NN N
of IN N
subjects NNS N
with IN N
comorbid NN N
major JJ N
depressive JJ N
disorder NN N
and CC N
alcohol NN N
dependence NN N
, , N
many JJ N
of IN N
whom WP N
displayed VBD N
suicidal JJ N
ideations NNS N
. . N

The DT N
seven-day JJ N
course NN N
of IN N
metronidazole NN N
was VBD N
superior JJ N
to TO N
the DT N
single-dose JJ N
regimen NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
clue JJ N
cells NNS N
and CC N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
positive JJ N
sniff NN N
test NN N
at IN N
the DT N
first JJ N
follow-up JJ N
visit NN N
; : N
however RB N
, , N
differences NNS N
in IN N
the DT N
initial JJ o
cure NN o
rate NN o
assessed VBN o
by IN o
clinical JJ o
criteria NNS o
and CC o
Gram-stained JJ o
smear JJ o
criteria NNS o
were VBD N
not RB N
statistically RB N
significant JJ N
between IN N
the DT N
two CD N
patient NN N
treatment NN N
regimens NNS N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
ratings NNS o
of IN o
pain NN o
and CC o
sleep JJ o
quality NN o
as RB o
well RB o
as IN o
the DT o
ability NN o
to TO o
perform VB o
daily JJ o
activities NNS o
( ( o
Ambulatory NNP o
Post NNP o
Acute NNP o
Care NNP o
Daily NNP o
Activities NNP o
Short NNP o
Form NNP o
) ) o
, , o
quality NN o
of IN o
life NN o
( ( o
Functional NNP o
Assessment NNP o
of IN o
Cancer NNP o
Therapy-General NNP o
) ) o
, , o
and CC o
fatigue NN o
( ( o
Functional NNP o
Assessment NNP o
of IN o
Cancer NNP o
Therapy-Fatigue NNP o
) ) o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
combining VBG i
electrically RB i
induced JJ i
sensory NN i
inputs NNS i
through IN i
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
with IN i
task-related JJ i
training NN i
( ( i
TRT NNP i
) ) i
in IN N
a DT N
home-based JJ N
program NN N
would MD N
augment VB N
voluntary JJ N
motor NN N
output NN N
in IN N
chronic JJ p
stroke NN p
survivors NNS p
better RBR N
than IN N
either DT N
treatment NN N
alone RB N
or CC N
no DT N
treatment NN N
. . N

One CD N
randomly NN N
assigned VBN N
group NN N
of IN N
10 CD p
autistic JJ p
subjects NNS p
first RB i
learned VBD i
to TO i
lace VB i
shoes NNS i
whose WP$ i
laces NNS i
and CC i
eyelets NNS i
were VBD i
color-coded JJ i
red JJ i
and CC i
white JJ i
, , i
and CC i
then RB i
encountered VBD i
the DT i
no DT i
extra JJ i
prompt JJ i
condition NN i
in IN i
which WDT i
color NN i
codes NNS i
could MD i
no RB i
longer RB i
be VB i
depended VBN i
upon IN i
to TO i
solve VB i
the DT i
position NN i
discriminations NNS i
required VBN i
to TO i
lace VB i
properly RB i
. . i

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Outcomes NNP N
included VBD N
death NN o
within IN o
60 CD o
days NNS o
( ( o
primary JJ o
outcome NN o
) ) o
, , o
survival JJ o
, , o
cardiovascular JJ o
events NNS o
, , o
performance NN o
status NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
symptoms NNS o
, , o
number NN o
of IN o
nonstatin JJ o
medications NNS o
, , o
and CC o
cost NN o
savings NNS o
. . o

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
the DT N
Play NNP N
and CC N
Language NNP N
for IN N
Autistic NNP p
Youngsters NNP p
( ( i
PLAY NNP i
) ) i
Project NNP i
Home NNP i
Consultation NNP i
model NN i
, , N
in IN N
combination NN N
with IN N
usual JJ i
community NN i
services NNS i
( ( i
CS NNP i
) ) i
, , N
to TO N
improve VB N
parent-child JJ N
interaction NN N
, , N
child NN N
development NN N
, , N
and CC N
autism NN N
symptomatology NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
compared VBN N
with IN N
CS NNP i
only RB N
. . N

CONCLUSIONS NNP N
In IN N
asymptomatic JJ N
patients NNS N
, , N
the DT N
use NN N
of IN N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
residue NN N
from IN N
images NNS N
in IN N
conjunction NN N
with IN N
reduced JJ N
bowel NN N
preparation NN N
does VBZ N
not RB N
reduce VB N
examination NN o
quality NN o
or CC o
diagnostic JJ o
performance NN o
when WRB N
compared VBN N
with IN N
the DT N
conventional JJ N
CT NNP N
colonography NN N
technique NN N
and CC N
is VBZ N
more RBR N
acceptable JJ N
to TO N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
rated VBD N
periventricular JJ N
and CC N
subcortical JJ N
signal NN N
hyperintensities NNS N
on IN N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
MRI NNP i
) ) i
scans VBZ i
in IN N
elderly JJ p
patients NNS p
with IN p
depression NN p
and CC p
in IN p
normal JJ p
subjects NNS p
with IN p
similar JJ p
demographic JJ p
features NNS p
to TO N
examine VB N
whether IN N
such JJ N
changes NNS N
discriminate VBP N
patients NNS N
with IN N
depression NN N
from IN N
normal JJ N
subjects NNS N
and CC N
whether IN N
they PRP N
are VBP N
associated VBN N
with IN N
any DT N
clinical JJ N
variables NNS N
. . N

INTRODUCTION NNP N
Exercise NNP N
can MD N
increase VB N
bone NN o
strength NN o
, , N
but CC N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
fracture NN N
risk NN N
, , N
exercise NN N
must MD N
be VB N
feasible JJ N
enough JJ N
to TO N
be VB N
adopted VBN N
into IN N
daily JJ N
life NN N
and CC N
influence NN N
potentially RB N
vulnerable JJ N
skeletal JJ N
sites NNS N
such JJ N
as IN N
the DT N
superolateral JJ N
cortex NN N
of IN N
the DT N
femoral JJ N
neck NN N
, , N
where WRB N
thinning NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
fracture NN N
risk NN N
. . N

CONCLUSIONS NNP N
This DT N
preliminary JJ N
investigation NN N
showing VBG N
a DT N
decrease NN N
in IN N
BALF NNP o
levels NNS o
of IN o
IL-8 NNP o
and CC o
leukotriene JJ o
B4 NNP o
and CC N
the DT N
associated JJ N
reduction NN N
of IN N
BALF NNP N
neutrophils NNS N
and CC N
alveolar JJ N
membrane NN N
protein NN N
permeability NN N
in IN N
acute JJ N
respiratory NN N
distress JJ N
syndrome JJ N
patients NNS N
fed VBP N
EPA+GLA NNP N
support NN N
, , N
in IN N
part NN N
, , N
the DT N
potential JJ N
mechanisms NN N
underlying VBG N
the DT N
previously RB N
described VBN N
clinical JJ N
improvements NNS N
with IN N
this DT N
diet NN N
. . N

Such JJ N
augmentation NN N
of IN N
vagal JJ N
tone NN N
is VBZ N
known VBN N
to TO N
be VB N
protective JJ N
against IN N
malignant JJ N
ventricular JJ N
arrhythmias NNS N
in IN N
patients NNS p
with IN p
ischemic JJ p
heart NN p
disease NN p
and CC N
therefore NN N
may MD N
have VB N
similar JJ N
benefit NN N
in IN N
the DT N
setting NN N
of IN N
ventricular JJ N
failure NN N
, , N
thus RB N
contributing VBG N
to TO N
the DT N
improved JJ N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
therapy NN i
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

The DT N
limit NN N
to TO N
exercise VB N
tolerance NN N
in IN N
humans NNS N
: : N
mind NN N
over IN N
muscle NN N
? . N
In IN N
exercise NN N
physiology NN N
, , N
it PRP N
has VBZ N
been VBN N
traditionally RB N
assumed VBN N
that IN N
high-intensity NN i
aerobic JJ i
exercise NN i
stops NNS i
at IN N
the DT N
point NN N
commonly RB N
called VBD N
exhaustion NN N
because IN N
fatigued VBN N
subjects NNS N
are VBP N
no RB N
longer RBR N
able JJ N
to TO N
generate VB N
the DT N
power NN o
output NN o
required VBN N
by IN N
the DT N
task NN N
despite IN N
their PRP$ N
maximal JJ N
voluntary JJ N
effort NN N
. . N

In IN N
addition NN N
, , N
sera NN N
were VBD N
collected VBN N
from IN N
a DT N
randomized JJ N
sample NN N
of IN N
subjects NNS N
in IN N
each DT N
vaccine NN N
group NN N
at IN N
approximately RB N
3-month JJ N
intervals NNS N
from IN N
which WDT N
antibody NN N
kinetic JJ N
curves NNS N
were VBD N
constructed VBN N
, , N
which WDT N
allowed VBD N
us PRP N
to TO N
estimate VB N
specific JJ N
antibody NN N
values NNS N
to TO N
pertussis VB N
toxin NN N
( ( N
PT NNP N
) ) N
, , N
filamentous JJ N
hemagglutinin NN N
( ( N
FHA NNP N
) ) N
, , N
pertactin JJ N
and CC N
fimbriae-2 JJ N
at IN N
the DT N
time NN N
of IN N
exposure NN N
in IN N
the DT N
household NN N
setting NN N
. . N

BACKGROUND NNP N
Androgen NNP i
deprivation NN i
therapy NN i
( ( i
ADT NNP i
) ) i
is VBZ N
accompanied VBN N
by IN N
a DT N
number NN N
of IN N
adverse JJ N
side NN N
effects NNS N
including VBG N
reduced VBD N
bone JJ o
mass NN o
and CC o
increased VBD o
risk NN o
for IN o
fracture NN o
, , o
reduced VBN o
lean JJ o
mass NN o
and CC o
muscle NN o
strength NN o
, , o
mood NN o
disturbance NN o
and CC o
increased VBD o
fat JJ o
mass NN o
compromising VBG o
physical JJ o
functioning NN o
, , o
independence NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

RESULTS NN N
We PRP N
found VBD N
weak JJ N
to TO N
moderate VB N
, , N
statistically RB N
significant JJ N
negative JJ N
correlations NNS N
between IN N
children NNS o
's POS o
cumulative JJ o
durations NNS o
of IN o
MEE NNP o
in IN o
their PRP$ o
first JJ o
year NN o
of IN o
life NN o
or CC N
in IN N
age NN N
periods NNS N
that WDT N
included VBD N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
, , N
and CC N
their PRP$ N
scores NNS N
on IN N
formal JJ N
tests NNS N
of IN N
receptive JJ o
vocabulary NN o
and CC o
verbal JJ o
aspects NNS o
of IN o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

As IN N
nimodipine NN i
might MD N
have VB N
anticraving VBG N
and CC N
mood-stabilizing JJ N
properties NNS N
and CC N
cardio- NN N
and CC N
neuroprotective JJ N
properties NNS N
in IN N
the DT N
face NN N
of IN N
cocaine NN N
intoxication NN N
and CC N
might MD N
possibly RB N
even RB N
reverse VB N
some DT N
cocaine-induced JJ N
brain NN N
deficits NNS N
, , N
further JJ N
investigation NN N
of IN N
the DT N
role NN N
of IN N
nimodipine NN i
( ( N
and CC N
other JJ N
VSCCBs NNP N
) ) N
in IN N
cocaine NN N
addiction NN N
appears VBZ N
an DT N
attractive JJ N
avenue NN N
of IN N
future JJ N
medication NN N
development NN N
. . N

Results NNS N
revealed VBD N
, , N
in IN N
comparison NN N
to TO N
the DT N
waitlist NN N
group NN N
, , N
that IN N
the DT N
experimental JJ N
treatment NN N
group NN N
significantly RB N
improved VBN N
their PRP$ N
knowledge NN o
of IN o
PEERS NNP o
concepts NNS o
and CC o
friendship NN o
skills NNS o
, , o
increased VBN o
in IN o
their PRP$ o
amount NN o
of IN o
get-togethers NNS o
, , o
and CC o
decreased VBN o
in IN o
their PRP$ o
levels NNS o
of IN o
social JJ o
anxiety NN o
, , o
core NN o
autistic NN o
symptoms NNS o
, , o
and CC o
problem NN o
behaviors NNS o
from IN o
pre-to JJ o
post-PEERS NNS o
. . o

These DT N
findings NNS N
suggest VBP N
that IN N
increases NNS N
in IN N
RBC NNP o
mass NN o
during IN N
nandrolone JJ N
decanoate NN N
therapy NN N
result NN N
from IN N
two CD N
mechanisms NNS N
: : N
increased VBN N
erythropoiesis NN N
( ( N
shown VBN N
by IN N
simultaneous JJ N
increases NNS N
in IN N
RBC NNP o
mass NN o
and CC o
erythron NN o
iron NN o
turnover NN o
) ) o
and CC o
increased JJ o
RBC NNP o
survival NN o
( ( N
indirectly RB N
shown VBN N
by IN N
increases NNS N
in IN N
RBC NNP N
mass NN N
without IN N
increases NNS N
in IN N
erythron NN N
iron NN N
turnover NN N
) ) N
. . N

Main NNP N
end NN N
points NNS N
of IN N
the DT N
study NN N
included VBD N
the DT N
3-month JJ o
dichotomized JJ o
Glasgow NNP o
Outcome NNP o
Score NNP o
( ( o
GOS NNP o
) ) o
, , o
development NN o
of IN o
delayed JJ o
ischemic JJ o
neurological JJ o
deficit NN o
( ( o
DIND NNP o
) ) o
, , o
occurrence NN o
of IN o
Transcranial NNP o
Doppler NNP o
( ( o
TCD NNP o
) ) o
vasospasm NN o
, , o
and CC o
length NN o
of IN o
stay NN o
in IN o
the DT o
ICU NNP o
and CC o
hospital NN o
. . o

The DT N
AQ-J NNP N
and CC N
two CD N
short JJ N
forms NNS N
are VBP N
useful JJ N
not RB N
to TO N
predict VB N
but CC N
to TO N
rule VB N
out RP N
mild NN N
HPDD NNP N
, , N
the DT N
most RBS N
difficult JJ N
part NN N
of IN N
HPDD NNP N
to TO N
be VB N
distinguished VBN N
from IN N
non-PDD JJ N
conditions NNS N
, , N
in IN N
persons NNS N
scoring VBG N
under IN N
the DT N
cut-offs NNS N
and CC N
to TO N
consider VB N
professionals NNS N
' POS N
examination NN N
of IN N
HPDD NNP N
in IN N
persons NNS N
scoring VBG N
over IN N
them PRP N
, , N
because IN N
their PRP$ N
negative JJ N
predictive JJ N
values NNS N
were VBD N
satisfactory JJ N
. . N

METHODS NNP N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
timely JJ N
patient JJ N
feedback NN N
in IN N
the DT N
form NN N
of IN N
a DT N
letter NN N
providing VBG N
recent JJ N
patient-specific JJ N
symptoms NNS N
, , N
medication NN N
, , N
and CC N
health NN N
service NN N
use NN N
combined VBN N
with IN N
guideline-based JJ i
recommendations NNS i
for IN N
changes NNS N
in IN N
therapy NN N
on IN N
improving VBG N
the DT N
quality NN N
of IN N
asthma NN p
care NN p
by IN p
inner-city NN p
primary NN p
care NN p
providers NNS p
and CC p
on IN p
resultant JJ p
asthma JJ p
morbidity NN p
. . p

RESULTS NNP N
Several NNP N
key JJ N
elements NNS N
emerge VBP N
as RB N
critical JJ N
to TO N
the DT N
ultimate JJ N
success NN N
of IN N
a DT N
clinical JJ N
trial NN N
, , N
including VBG N
the DT N
probability NN N
of IN N
receiving VBG N
placebo NN N
, , N
study NN N
duration NN N
, , N
dosing VBG N
schedule NN N
, , N
visit NN N
frequency NN N
, , N
the DT N
use NN N
of IN N
blinded JJ N
lead-in JJ N
phases NNS N
, , N
the DT N
use NN N
of IN N
centralized JJ N
raters NNS N
, , N
illness JJ N
severity NN N
and CC N
duration NN N
, , N
and CC N
comorbid NN N
anxiety NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
aimed VBN N
to TO N
( ( N
1 CD N
) ) N
investigate NN N
whether IN N
provision NN N
of IN N
a DT N
home-based JJ i
program NN i
in IN N
addition NN N
to TO N
a DT N
center-based JJ i
program NN i
improves VBZ N
development NN N
in IN N
young JJ p
children NNS p
with IN p
disabilities NNS p
and CC p
coping VBG p
abilities NNS p
of IN p
their PRP$ p
families NNS p
and CC p
( ( p
2 CD p
) ) p
describe VB p
the DT p
characteristics NNS p
of IN p
children NNS p
and CC p
families NNS p
who WP p
benefit VBP p
most RBS p
from IN p
the DT p
intervention NN p
. . p

Two CD N
studies NNS N
utilizing VBG N
1,862 CD p
yearling VBG p
heifers NNS p
were VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
fenbendazole JJ i
oral JJ i
drench NN i
in IN i
addition NN i
to TO i
an DT i
ivermectin JJ i
pour-on NN i
( ( i
SG+IVPO NNP i
) ) i
, , N
compared VBN N
with IN N
an DT N
ivermectin JJ i
pour-on NN i
( ( i
IVPO NNP i
) ) i
or CC i
a DT i
doramectin NN i
injectable JJ i
( ( i
DMX NNP i
) ) i
alone RB i
, , N
on IN N
parasite JJ o
burden NN o
, , o
feedlot NN o
performance NN o
, , o
and CC o
carcass NN o
merit NN o
of IN o
feedlot NN o
cattle NNS o
. . o

CONCLUSION VB N
A DT N
Mediterranean NNP N
dietary JJ N
pattern NN N
associated VBN N
with IN N
a DT N
high JJ N
dietary JJ N
acid NN N
load NN N
derived VBN N
from IN N
consumption NN N
of IN N
mixed JJ N
nuts NNS N
does VBZ N
not RB N
seem VB N
to TO N
have VB N
a DT N
much RB N
greater JJR N
effect NN N
on IN N
bone NN N
metabolism NN N
biomarkers NNS N
, , N
with IN N
the DT N
exception NN N
of IN N
PTH NNP N
levels NNS N
, , N
than IN N
a DT N
Mediterranean NNP N
diet NN N
without IN N
mixed JJ N
nuts NNS N
or CC N
a DT N
control NN N
diet NN N
in IN N
elderly JJ p
subjects NNS p
. . p

Similarly RB N
, , N
nonsignificant JJ N
changes NNS N
were VBD N
detected VBN N
for IN N
the DT N
fibrinolytic JJ o
parameters NNS o
tissue VBP o
plasminogen JJ o
activator NN o
activity NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
antigen NN o
, , o
and CC o
global JJ o
fibrinolytic JJ o
activity NN o
, , o
but CC o
plasminogen NN o
activator NN o
inhibitor NN o
type VBD o
1 CD o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
due JJ N
to TO N
a DT N
questionable JJ N
increase NN N
in IN N
the DT N
levels NNS N
in IN N
the DT N
control NN N
group NN N
. . N

OBJECTIVE NNP N
Although IN N
metformin NNP i
( ( i
MET NNP i
) ) i
is VBZ N
an DT N
insulin JJ N
sensitizer NN N
currently RB N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
the DT N
treatment NN N
of IN N
some DT N
of IN N
the DT N
complications NNS N
of IN N
childhood NN p
obesity NN p
besides IN p
type JJ p
2 CD p
diabetes NNS p
mellitus NN p
, , N
few JJ N
studies NNS N
have VBP N
comprehensively RB N
examined VBN N
its PRP$ N
metabolic NN N
and CC N
clinical JJ N
effects NNS N
in IN N
obese JJ p
children NNS p
with IN p
normal JJ p
glucose JJ p
tolerance NN p
( ( p
NGT NNP p
) ) p
. . p

The DT N
benefit NN N
of IN N
low-dose JJ N
dopamine NN i
during IN i
vigorous JJ i
diuresis NN i
for IN N
congestive JJ p
heart NN p
failure NN p
associated VBN p
with IN p
renal JJ p
insufficiency NN p
: : p
does VBZ N
it PRP N
protect VB N
renal JJ N
function NN N
? . N
BACKGROUND NNP N
Low-dose NNP N
dopamine NN i
, , N
a DT N
renal JJ i
vasodilator NN i
, , N
has VBZ N
been VBN N
used VBN N
empirically RB N
to TO N
improve VB N
renal JJ N
function NN N
or CC N
outcome NN N
in IN N
critically RB p
ill JJ p
patients NNS p
with IN p
oliguria NNS p
or CC p
acute JJ p
renal JJ p
failure NN p
. . p

Results NNS N
suggested VBD N
that IN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
depended VBD N
on IN N
baseline NN N
PFS NNP N
levels NNS N
, , N
such JJ N
that IN N
acceptance-based JJ N
strategies NNS N
were VBD N
associated VBN N
with IN N
better JJR N
outcomes NNS N
( ( N
cravings NNS N
, , N
consumption NN N
) ) N
among IN N
those DT N
reporting VBG N
the DT N
highest JJS N
susceptibility NN N
to TO N
the DT N
presence NN N
of IN N
food NN N
, , N
but CC N
greater JJR N
cravings NNS N
among IN N
those DT N
who WP N
scored VBD N
lowest JJS N
on IN N
the DT N
PFS NNP N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
role NN N
that WDT N
treatment NN N
response NN N
plays VBZ N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
an DT N
antidepressant JJ N
among IN N
people NNS p
with IN p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
diagnosed VBD p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
in IN p
explaining VBG p
quality NN p
of IN p
life NN p
( ( p
QOL NNP p
) ) p
, , N
assessed VBD N
both DT N
globally RB N
as IN N
life NN N
satisfaction NN N
and CC N
in IN N
terms NNS N
of IN N
physical JJ N
and CC N
mental JJ N
health-related JJ N
QOL NNP N
. . N

OBJECTIVES NNP N
To TO N
test VB N
the DT N
hypotheses NNS N
that WDT N
: : N
( ( N
1 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ p
care NN p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
is VBZ N
not RB N
associated VBN N
with IN N
improved JJ N
patient NN N
outcomes NNS N
, , N
including VBG N
pain NN o
, , o
disability NN o
, , o
health NN o
status NN o
, , o
sickness NN o
absence NN o
, , o
reassurance NN o
, , o
and CC o
patient JJ o
satisfaction NN o
or CC o
belief NN o
in IN N
the DT N
value NN N
of IN N
radiography NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Swallowing NNP o
function NN o
was VBD o
evaluated VBN o
by IN o
the DT o
water NN o
swallow JJ o
test NN o
and CC o
Standardized NNP o
Swallowing NNP o
Assessment NNP o
, , o
oral JJ o
intake NN o
was VBD o
evaluated VBN o
by IN o
the DT o
Functional NNP o
Oral NNP o
Intake NNP o
Scale NNP o
, , o
quality NN o
of IN o
life NN o
was VBD o
evaluated VBN o
by IN o
the DT o
Swallowing-Related JJ o
Quality NN o
of IN o
Life NNP o
( ( o
SWAL-QOL NNP o
) ) o
Scale NNP o
, , o
and CC o
cognition NN o
was VBD N
evaluated VBN N
by IN N
the DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
( ( N
MMSE NNP N
) ) N
. . N

Comparisons NNS N
were VBD N
also RB N
made VBN N
for IN N
self-reported JJ N
breast NN N
symptoms NNS N
occurring VBG N
during IN N
the DT N
study NN N
period NN N
and CC N
for IN N
changes NNS N
in IN N
serum NN N
values NNS N
of IN N
antinuclear JJ N
antibodies NNS N
, , N
rheumatoid JJ N
factor NN N
, , N
and CC N
cardiolipin NN N
antibodies NNS N
immunoglobulin VBP N
G NNP N
and CC N
immunoglobulin NN N
M. NNP N
The DT N
majority NN N
of IN N
the DT N
women NNS N
with IN N
implant JJ N
rupture NN N
had VBD N
no DT N
visible JJ N
magnetic JJ N
resonance NN N
imaging NN N
changes NNS N
of IN N
their PRP$ N
ruptured JJ N
implants NNS N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP i
Care NNP i
Mapping NNP i
( ( i
DCM NNP i
) ) i
or CC i
the DT i
VIPS NNP i
practice NN i
model NN i
( ( i
VPM NNP i
) ) i
is VBZ N
more RBR N
effective JJ N
than IN N
education NN N
of IN N
the DT N
nursing NN N
home NN N
staff NN N
about IN N
dementia NN N
( ( N
control VB N
group NN N
) ) N
in IN N
reducing VBG N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ p
home NN p
patients NNS p
. . p

The DT N
mean JJ o
duration NN o
for IN o
obtaining VBG o
good JJ o
contractions NNS o
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
in IN N
both CC N
the DT N
first JJ N
and CC N
second JJ N
day NN N
of IN N
induction NN N
The DT N
mean JJ N
interval NN N
between IN N
the DT N
beginning NN N
of IN N
induction NN N
until IN N
the DT N
beginning NN N
of IN N
active JJ N
phase NN N
at IN N
the DT N
first JJ N
day NN N
of IN N
induction NN N
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
four CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
( ( i
ESM NNP i
) ) i
: : i
animated VBN i
video NN i
, , i
video NN i
of IN i
self NN i
, , i
video NN i
of IN i
a DT i
familiar JJ i
person NN i
engaged VBD i
with IN i
an DT i
immersive JJ i
virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
game NN i
, , i
and CC i
immersion NN i
of IN i
self NN i
in IN i
the DT i
VR NNP i
game NN i
. . i

Fifty-nine NNP p
junior JJ p
high JJ p
school NN p
students NNS p
who WP p
volunteered VBD p
to TO p
participate VB p
in IN p
treatment NN p
for IN p
interpersonal JJ p
anxiety NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
rational-emotive JJ i
therapy NN i
without IN i
imagery NN i
( ( i
RET NNP i
) ) i
, , i
rational-emotive JJ i
therapy NN i
with IN i
imagery NN i
( ( i
REI NNP i
) ) i
, , i
relationship-oriented JJ i
counseling NN i
( ( i
ROC NNP i
) ) i
, , i
and CC i
waiting-list JJ i
control NN i
( ( i
WLC NNP i
) ) i
groups NNS N
. . N

Because IN N
persons NNS N
whose WP$ N
urine JJ N
contains NNS N
low JJ N
proportions NNS N
of IN N
DMA NNP N
and CC N
high JJ N
proportions NNS N
of IN N
MMA NNP N
and CC N
InAs NNP N
have VBP N
been VBN N
reported VBN N
to TO N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
skin NN N
and CC N
bladder NN N
cancers NNS N
and CC N
peripheral JJ N
vascular JJ N
disease NN N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
folic JJ N
acid DT N
supplementation NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
arsenic-related JJ N
health NN N
outcomes NNS N
. . N

RESULTS NN N
We PRP N
found VBD N
that IN N
sevoflurane NN i
, , N
when WRB N
compared VBN N
with IN N
isoflurane NN i
and CC i
desflurane NN i
, , N
provided VBN N
anesthesia NN N
with IN N
similar JJ N
hemodynamic JJ N
stability NN N
but CC N
allowed VBN N
for IN N
a DT N
smoother NN N
, , N
more RBR N
rapid JJ N
emergence NN N
and CC N
better JJR N
quality NN o
of IN o
induction NN o
and CC o
recovery NN o
to TO N
surgical JJ N
patients NNS N
under IN N
clinical JJ N
conditions NNS N
, , N
particularly RB N
to TO N
those DT N
who WP N
were VBD N
experiencing VBG N
substantial JJ N
cerebral JJ N
vasodilation NN N
. . N

METHODS NNP N
This DT N
investigation NN N
assesses VBZ N
the DT N
validity NN N
of IN N
the DT N
Lactate NNP i
Minimum NNP i
Test NNP i
( ( i
LMT NNP i
) ) i
, , N
which WDT N
consists VBZ N
of IN N
inducing VBG N
lactic JJ N
acidosis NN N
through IN N
a DT N
VO2peak NNP N
test NN N
, , N
followed VBN N
by IN N
an DT N
eight-minute JJ N
walking NN N
recovery NN N
and CC N
an DT N
incremental JJ N
exercise NN N
test NN N
, , N
to TO N
determine VB N
if IN N
the DT N
running VBG N
velocity NN N
associated VBN N
with IN N
the DT N
minimum JJ N
lactate NN N
value NN N
predicts VBZ N
the DT N
MLSS NNP o
velocity NN o
. . o

BACKGROUND NNP N
Silent NNP N
myocardial JJ N
ischemia NN N
is VBZ N
an DT N
adverse JJ N
prognostic JJ N
marker NN N
in IN N
patients NNS p
with IN p
coronary JJ p
disease NN p
; : p
however RB N
, , N
controlled VBN N
data NNS N
on IN N
the DT N
effect NN N
of IN N
treatment NN N
are VBP N
sparse JJ N
and CC N
contradictory NN N
, , N
and CC N
the DT N
relations NNS N
among IN N
the DT N
occurrence NN N
of IN N
ST NNP o
segment NN o
depression NN o
, , o
drug NN o
efficacy NN o
, , o
and CC o
heart NN o
rate NN o
are VBP N
unclear JJ N
. . N

With IN N
the DT N
use NN N
of IN N
effectiveness NN N
measures NNS N
that WDT N
favored VBD N
clozapine NN i
( ( N
extrapyramidal JJ N
side NN N
effects NNS N
, , N
disruptiveness NN N
) ) N
, , N
bootstrap NN N
techniques NNS N
indicated VBD N
that IN N
, , N
even RB N
when WRB N
a DT N
payer NN N
is VBZ N
unwilling JJ N
to TO N
incur VB N
any DT N
additional JJ N
cost NN N
for IN N
gains NNS N
in IN N
effectiveness NN N
, , N
the DT N
probability NN N
that IN N
clozapine NN i
is VBZ N
more RBR N
cost-effective JJ N
than IN N
usual JJ N
care NN N
is VBZ N
at IN N
least JJS N
0.80 CD N
. . N

OBJECTIVE NN N
To TO N
examine VB N
the DT N
bioavailability NN N
of IN N
methotrexate NN i
( ( i
MTX NNP i
) ) i
in IN N
the DT N
presence NN N
of IN N
hydroxychloroquine NN i
( ( i
HCQ NNP i
) ) i
, , N
and CC N
vice NN N
versa NN N
, , N
to TO N
determine VB N
a DT N
possible JJ N
pharmacokinetic JJ N
explanation NN N
for IN N
the DT N
observation NN N
that IN N
combination NN N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
with IN N
MTX NNP i
and CC i
HCQ NNP i
has VBZ N
been VBN N
shown VBN N
, , N
clinically RB N
, , N
to TO N
be VB N
more RBR N
potent JJ N
than IN N
MTX NNP i
used VBD N
alone RB N
. . N

OBJECTIVE NN N
To TO N
elucidate VB N
the DT N
effect NN N
on IN N
blood NN o
pressure NN o
and CC o
blood NN o
lipids NNS o
of IN N
an DT N
angiotensin NN i
converting VBG i
enzyme JJ i
inhibitor NN i
( ( i
captopril NN i
) ) i
, , N
and CC N
a DT N
beta-receptor NN i
blocking NN i
agent NN i
( ( i
atenolol NN i
) ) i
, , i
given VBN i
alone RB i
or CC i
in IN i
combination NN i
with IN i
a DT i
cholesterol NN i
reducing VBG i
drug NN i
, , i
the DT i
beta-hydroxy-methylglutaryl-coenzyme NN i
A DT i
reductase NN i
inhibitor NN i
pravastatin NN i
, , N
in IN N
patients NNS N
who WP N
were VBD N
also RB N
encouraged VBN N
to TO N
improve VB N
their PRP$ N
lifestyle NN N
. . N

The DT N
study NN N
was VBD N
a DT N
blinded JJ N
, , N
exploratory JJ N
evaluation NN N
of IN N
the DT N
PlayWisely NNP i
program NN i
on IN N
autism NN p
symptoms NNS p
and CC p
essential JJ p
learning NN p
foundation NN p
skills NNS p
( ( p
attention NN p
, , p
recognition NN p
, , p
and CC p
memory NN p
skills NNS p
) ) p
in IN p
children NNS p
with IN p
a DT p
diagnosis NN p
of IN p
autism NN p
, , p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
, , p
pervasive JJ p
developmental NN p
disorder NN p
- : p
not RB p
otherwise RB p
specified VBN p
( ( p
PDD-NOS NNP p
) ) p
, , p
and CC p
Asperger NNP p
syndrome VBP p
( ( p
AS IN p
) ) p
. . p

Onset NNP N
of IN N
action NN N
was VBD N
determined VBN N
to TO N
have VB N
taken VBN N
place NN N
the DT N
first JJ N
time NN N
that IN N
the DT N
effects NNS N
of IN N
ciclesonide NN i
, , N
as IN N
reflected VBN N
in IN N
the DT N
total JJ o
nasal JJ o
symptom NN o
score NN o
, , N
were VBD N
significantly RB N
greater JJR N
than IN N
those DT N
of IN N
placebo NN i
at IN N
a DT N
particular JJ N
hourly JJ N
assessment NN N
, , N
provided VBD N
that IN N
the DT N
subsequent JJ N
hourly NN N
assessment NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
. . N

CONCLUSIONS NNP N
- : N
RECOMMENDATIONS NN N
FOR IN N
FURTHER JJ N
RESEARCH NN N
: : N
Further JJ N
work NN N
is VBZ N
required VBN N
to TO N
develop VB N
and CC N
test VB N
an DT N
educational JJ N
package NN N
that WDT N
educates VBZ N
patients NNS N
and CC N
GPs NNP N
about IN N
the DT N
utility NN N
of IN N
radiography NN N
and CC N
provides VBZ N
strategies NNS N
for IN N
identifying VBG N
and CC N
meeting VBG N
the DT N
information NN N
needs NNS N
of IN N
patients NNS p
, , p
and CC p
the DT p
needs NNS p
of IN p
patients NNS p
and CC p
GPs NNP p
to TO p
be VB p
reassured VBN p
about IN p
missing VBG p
serious JJ p
disease NN p
. . p

The DT N
impact NN N
of IN N
the DT N
intervention NN N
was VBD N
assessed VBN N
against IN N
patient JJ N
outcomes NNS N
: : N
routinely RB N
available JJ N
asthma JJ N
outcome NN N
measures NNS N
( ( N
beta2-agonist JJ N
prescription NN N
rate NN N
and CC N
number NN N
of IN N
oral JJ N
steroid NN N
courses NNS N
) ) N
for IN N
asthma NN p
patients NNS p
identified VBN N
as IN N
being VBG N
poorly-controlled JJ N
from IN N
practice NN N
records NNS N
; : N
and CC N
questionnaire VB N
data NNS N
- : N
Mini NNP N
Asthma NNP N
Quality NNP N
of IN N
Life NNP i
Questionnaire NNP i
( ( i
AQLQ NNP i
) ) i
and CC N
the DT N
Asthma NNP N
Control NNP i
Questionnaire NNP i
( ( i
ACQ NNP i
) ) i
- : N
from IN N
a DT N
subset NN N
of IN N
consenting VBG p
patients NNS p
. . p

Participants NNS p
had VBD p
autistic JJ p
spectrum NN p
disorders NNS p
, , p
Asperger NNP p
disorder NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
of IN p
at IN p
least JJS p
moderate JJ p
on IN p
the DT p
Clinical NNP p
Global NNP p
Impressions NNP p
, , p
Severity NNP p
of IN p
Illness NNP p
Scale NNP p
; : p
and CC p
scored VBD p
at IN p
least JJS p
moderate JJ p
on IN p
compulsive JJ p
behaviors NNS p
measured VBN p
with IN p
the DT p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive NNP p
Compulsive NNP p
Scales NNP p
modified VBD p
for IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

CONCLUSION NN N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP o
CNS NNP o
disease NN o
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB N
worse JJR N
outcome JJ N
independent JJ N
of IN N
initial JJ o
bone NN o
marrow NN o
status NN o
and CC o
LDH NNP o
level NN o
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION NNP N
One-year-long NNP N
complementary JJ N
feeding NN N
with IN N
FS NNP i
does VBZ N
not RB N
have VB N
a DT N
significantly RB N
larger JJR N
effect NN N
than IN N
LP NNP N
on IN N
mean JJ o
weight NN o
gain NN o
in IN N
all DT N
infants NNS N
, , N
but CC N
it PRP N
is VBZ N
likely JJ N
to TO N
boost VB N
linear JJ N
growth NN N
in IN N
the DT N
most RBS N
disadvantaged JJ N
individuals NNS N
and CC N
, , N
hence RB N
, , N
decrease VB N
the DT N
incidence NN o
of IN o
severe JJ o
stunting NN o
. . o

Although IN N
anxiety NN o
sensitivity NN o
( ( N
AS NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN N
symptoms NNS N
and CC N
panic NN N
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN N
psychopathology NN N
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
accuracy NN N
of IN N
non-rigid JJ N
nine-parameter JJ N
image NN N
registrations NNS N
based VBN N
on IN N
153Gd CD N
transmission NN N
computed VBN N
tomography NN N
( ( N
TCT NNP N
) ) N
images VBZ N
as IN N
compared VBN N
with IN N
those DT N
based VBN N
on IN N
99mTc-ethyl JJ i
cysteinate NN i
dimer NN i
( ( i
ECD NNP i
) ) i
images NNS N
and CC N
to TO N
assess VB N
whether IN N
normalised JJ N
mutual JJ N
information NN N
( ( N
NMI NNP N
) ) N
or CC N
count NN N
difference NN N
( ( N
CD NN N
) ) N
should MD N
be VB N
used VBN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
protection NN N
from IN N
bronchoconstriction NN N
afforded VBN N
by IN N
the DT N
calcium NN N
channel NN N
blockers NNS N
depends VBZ N
on IN N
the DT N
choice NN N
of IN N
agent NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
bronchoconstricting NN N
stimulus NN N
, , N
and CC N
they PRP N
raise VBP N
the DT N
possibility NN N
that IN N
the DT N
contribution NN N
of IN N
transmembrane NN N
calcium NN N
ion NN N
influx NN N
to TO N
the DT N
pathogenesis NN N
of IN N
bronchoconstriction NN N
may MD N
vary VB N
according VBG N
to TO N
stimulus JJ N
intensity NN N
. . N

BACKGROUND NNP N
Amantadine NNP i
hydrochloride NN i
and CC i
pemoline NN i
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ p
sclerosis NN p
( ( p
MS NNP p
) ) p
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
MS NNP p
. . p

We PRP N
registered VBD N
a DT N
significant JJ N
improvement NN N
of IN N
tactile JJ o
roughness NN o
and CC o
fine JJ o
lines NNS o
in IN N
the DT N
half JJ N
side NN N
of IN N
the DT N
face NN N
treated VBD N
with IN N
BAs NNP N
; : N
noninvasive JJ N
instrumental JJ N
diagnostic JJ N
investigations NNS N
showed VBD N
an DT N
improvement NN N
of IN N
elasticity NN N
, , N
a DT N
decrease NN N
of IN N
sebum JJ N
excretion NN N
, , N
and CC N
a DT N
change NN N
of IN N
echographic JJ N
parameters NNS N
suggesting VBG N
a DT N
reshaping NN N
of IN N
dermal JJ N
tissue NN N
. . N

AIMS IN N
It PRP N
is VBZ N
necessary JJ N
to TO N
clarify VB N
if IN N
the DT N
presence NN N
of IN N
a DT N
prominent JJ N
R NNP N
wave NN N
in IN N
V1 NNP N
, , N
in IN N
post-myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
patients NNS p
, , p
is VBZ p
due JJ p
to TO p
the DT p
involvement NN p
of IN p
the DT p
posterior NN i
wall NN i
( ( i
currently RB i
inferobasal VBP i
segment NN i
) ) i
or CC i
the DT i
lateral JJ i
wall NN i
( ( N
as IN N
has VBZ N
been VBN N
demonstrated VBN N
recently RB N
by IN N
electrocardiographic JJ N
contrast-enhanced JJ N
cardiac JJ N
magnetic JJ N
resonance NN N
[ VBD N
ECG-CE-CMR NNP N
] NNP N
correlations NNS N
studies NNS N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
an DT N
alternative JJ N
drug NN N
product NN N
by IN N
using VBG N
a DT N
different JJ N
salt NN N
of IN N
perindopril NN i
and CC N
to TO N
evaluate VB N
the DT N
bioequivalence NN N
between IN N
PE NNP N
, , N
not RB N
still RB N
licensed VBN N
, , N
and CC N
perindopril JJ i
arginine NN i
( ( i
PA NNP i
) ) i
, , i
licensed VBD i
in IN N
many JJ N
countries NNS N
, , N
and CC N
to TO N
prepare VB N
PE NNP N
tablets NNS N
by IN N
using VBG N
direct JJ N
compression NN N
method NN N
. . N

For IN N
examination NN N
of IN N
whether IN N
this DT N
is VBZ N
based VBN N
on IN N
the DT N
same JJ N
mechanisms NN N
as IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
or CC N
thiazolidinedione NN N
, , N
effects NNS N
of IN N
sarpogrelate NN i
on IN N
atherosclerotic JJ N
inflammatory NN N
molecules NNS N
and CC N
their PRP$ N
relations NNS N
to TO N
albuminuria NNS N
in IN N
patients NNS N
who WP N
had VBD N
diabetes NNS N
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
and CC N
with IN N
or CC N
without IN N
thiazolidinedione NN i
were VBD N
examined VBN N
. . N

A DT N
falls VBZ N
calendar NN N
will MD N
be VB N
kept VBN N
by IN N
each DT N
participant NN N
for IN N
12 CD N
months NNS N
after IN N
outpatient JJ N
therapy.Consistent NN N
with IN N
the DT N
recommendations NNS N
of IN N
the DT N
Prevention NNP N
of IN N
Falls NNP N
Network NNP N
Europe NNP N
group NN N
, , N
three CD N
falls NNS N
variables NNS N
will MD N
be VB N
used VBN N
as IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
: : N
the DT N
number NN o
of IN o
fallers NNS o
, , o
the DT o
number NN o
of IN o
multiple JJ o
fallers NNS o
and CC o
the DT o
falls JJ o
rate NN o
. . o

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
, , N
collateral JJ N
damage NN N
, , N
and CC N
convenience NN N
of IN N
panretinal JJ i
photocoagulation NN i
for IN N
proliferative JJ p
diabetic JJ p
retinopathy NN p
or CC p
severe JJ p
nonproliferative JJ p
diabetic JJ p
retinopathy NN p
using VBG N
a DT N
532-nm JJ i
solid-state NN i
green JJ i
laser NN i
( ( i
GLX NNP i
) ) i
versus VBP N
a DT N
multispot NN i
532-nm JJ i
pattern JJ i
scan JJ i
laser NN i
( ( i
PASCAL NNP i
) ) i
. . i

INTRODUCTION NN N
This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
non-contrast-enhanced JJ i
4D CD i
magnetic JJ i
resonance NN i
angiography NN i
( ( i
NCE NNP i
4D CD i
MRA NNP i
) ) i
with IN i
signal JJ i
targeting VBG i
with IN i
alternative JJ i
radiofrequency NN i
( ( i
STAR NNP i
) ) i
spin NN i
labeling NN i
and CC i
variable JJ i
flip NN i
angle NN i
( ( i
VFA NNP i
) ) i
sampling NN i
in IN N
the DT N
assessment NN N
of IN N
dural JJ N
arteriovenous JJ N
fistula NN N
( ( N
DAVF NNP N
) ) N
in IN N
the DT N
transverse NN N
sinus NN N
. . N

BACKGROUND NNP N
Previous NNP N
interventions NNS N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS p
with IN p
high JJ p
risk NN p
for IN p
disease NN p
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

However RB N
, , N
DG NNP N
and CC N
FD NNP N
manifested VBD N
with IN N
different JJ N
impacts NNS N
on IN N
weights NNS o
of IN o
egg NN o
and CC o
egg NN o
albumen NNS o
, , o
proteolytic JJ o
activity NN o
of IN o
jejunal JJ o
digesta NN o
, , o
plasma JJ o
TRAP NNP o
activity NN o
, , o
ileal JJ o
total JJ o
AA NNP o
digestibility NN o
, , o
and CC o
several JJ o
intestinal JJ o
genes NNS o
and CC o
hepatic JJ o
proteins NNS o
. . o

To TO N
test VB N
the DT N
reliability NN N
and CC N
durability NN N
of IN N
positive JJ N
treatment NN N
effects NNS N
obtained VBN N
in IN N
a DT N
type NN N
A DT N
intervention NN N
project NN N
for IN N
healthy JJ p
managers NNS p
, , N
the DT N
analysis NN N
was VBD N
extended VBN N
to TO N
data NNS N
available JJ N
from IN N
a DT N
third JJ N
treatment NN N
group NN N
( ( N
a DT N
special JJ N
behavior JJ N
therapy NN N
group NN N
for IN N
participants NNS N
eliminated VBN N
from IN N
the DT N
main JJ N
sample NN N
because IN N
of IN N
manifestations NNS N
of IN N
clinical JJ N
CHD NNP N
) ) N
and CC N
to TO N
measures NNS N
obtained VBN N
6 CD N
months NNS N
following VBG N
the DT N
end NN N
of IN N
treatment NN N
. . N

A DT N
strong JJ N
priming NN N
effect NN N
was VBD N
found VBN N
, , N
robust VBZ N
over IN N
participants NNS N
and CC N
over IN N
items NNS N
; : N
participants NNS N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
relevant JJ N
to TO N
the DT N
inference NN o
evoked VBN o
by IN N
the DT N
vignette NN N
faster RBR N
than IN N
they PRP N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
irrelevant JJ N
, , N
and CC N
no DT N
interaction NN N
with IN N
group NN N
membership NN N
or CC N
type NN N
of IN N
knowledge NN N
was VBD N
found VBN N
. . N

Specifically RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
attitude JJ N
certainty NN N
can MD N
be VB N
conceptualized VBN N
, , N
and CC N
empirically RB N
separated VBN N
, , N
in IN N
terms NNS N
of IN N
attitude NN N
clarity NN N
( ( N
the DT N
subjective NN N
sense NN N
that WDT N
one CD N
knows VBZ N
what WP N
one CD N
's POS N
attitude NN N
is VBZ N
) ) N
and CC N
attitude JJ N
correctness NN N
( ( N
the DT N
subjective NN N
sense NN N
that IN N
one CD N
's POS N
attitude NN N
is VBZ N
correct JJ N
or CC N
valid JJ N
) ) N
. . N

The DT N
results NNS N
of IN N
our PRP$ N
manikin NN N
study NN N
suggest VBP N
that IN N
for IN N
personnel NNS N
not RB N
experienced VBN N
in IN N
tracheal JJ o
intubation NN o
, , N
the DT N
LTS-D NNP N
offers VBZ N
a DT N
good JJ N
alternative NN N
to TO N
ET NNP N
and CC N
BMV NNP N
to TO N
manage VB N
the DT N
airway NN N
during IN N
resuscitation NN N
, , N
and CC N
to TO N
avoid VB N
the DT N
failure NN N
to TO N
achieve VB N
tracheal JJ N
intubation NN N
with IN N
the DT N
ET NNP N
, , N
and CC N
the DT N
failure NN N
to TO N
achieve VB N
adequate JJ N
ventilation NN N
with IN N
the DT N
BMV NNP N
. . N

Thus RB N
, , N
RLAI NNP i
offers VBZ N
no DT N
advantage NN N
to TO N
patients NNS N
in IN N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
, , N
but CC N
is VBZ N
likely JJ N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
for IN N
those DT N
who WP N
may MD N
have VB N
problems NNS N
with IN N
adherence NN N
and CC N
may MD N
either RB N
choose VB N
to TO N
take VB N
it PRP N
or CC N
be VB N
prescribed VBN N
under IN N
conditions NNS N
of IN N
external JJ N
control NN N
such JJ N
as IN N
community NN N
treatment NN N
orders NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
, , N
in IN N
low-income JJ p
minority NN p
children NNS p
, , N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
among IN N
the DT N
frequency NN o
of IN o
RTEC NNP o
consumption NN o
and CC o
nutrient JJ o
intakes NNS o
measured VBN N
at IN N
baseline NN N
, , N
and CC N
whether IN N
there EX N
is VBZ N
a DT N
relationship NN N
between IN N
the DT N
frequency NN o
of IN o
RTEC NNP o
and CC o
BMI NNP o
controlling VBG o
for IN o
age NN o
, , o
sex NN o
, , o
ethnicity NN o
, , o
and CC o
energy NN o
intake NN o
. . o

Although IN N
SADQ NNP o
scores NNS o
and CC o
Rand NNP o
definite VBP o
alcoholism NN o
were VBD N
in IN N
general JJ N
agreement NN N
, , N
there EX N
were VBD N
a DT N
number NN N
of IN N
borderline JJ N
instances NNS N
and CC N
cases NNS N
of IN N
disagreement NN N
, , N
and CC N
neither DT N
was VBD N
in IN N
good JJ N
agreement NN N
with IN N
estimates NNS N
of IN N
problem NN N
duration NN N
, , N
nor CC N
with IN N
reports NNS N
of IN N
recent JJ N
or CC N
earlier RBR N
attainment NN N
of IN N
abstinence NN o
or CC o
control NN o
. . o

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
a DT N
12-week JJ N
supervised JJ N
low-intensity NN i
resistance NN i
training NN i
program NN i
associated VBN N
with IN N
partial JJ o
blood NN o
flow NN o
restriction NN N
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
muscle NN N
strength NN N
and CC N
function NN N
as RB N
well RB N
as IN N
muscle NN N
mass NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
PM NNP p
and CC p
DM NNP p
. . p

8-oxo-dG NN N
is VBZ N
significantly RB N
higher JJR N
( ( N
up IN N
to TO N
about IN N
threefold NN N
) ) N
in IN N
lymphocyte NN N
DNA NN N
from IN N
men NNS N
in IN N
Ireland NNP N
and CC N
the DT N
U.K. NNP N
Oxidative NNP o
DNA NNP o
damage NN o
is VBZ N
not RB N
significantly RB N
affected VBN N
by IN N
carotenoid JJ N
supplementation NN N
; : N
nor CC N
is VBZ N
there EX N
any DT N
association NN N
with IN N
mean JJ N
baseline NN N
levels NNS N
of IN N
antioxidants NNS N
, , N
which WDT N
are VBP N
generally RB N
similar JJ N
in IN N
the DT N
five CD N
countries NNS N
. . N

Inflammatory JJ o
reactions NNS o
, , o
based VBN o
on IN o
interleukin-6 JJ o
and CC o
C-reactive JJ o
protein NN o
levels NNS o
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ N
immunity NN N
( ( N
CD3+ NNP N
and CC N
CD4+ NNP N
counts NNS N
, , N
and CC N
the DT N
CD4+/CD8+ NNP N
ratio NN N
) ) N
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

In IN N
a DT N
prospective JJ N
controlled VBN N
study NN N
, , N
involving VBG N
42 CD p
patients NNS p
subdivided VBD p
into IN p
four CD p
groups NNS p
namely RB p
, , i
higher JJR i
or CC i
lower JJR i
insufflation NN i
pressures NNS i
, , i
chemically RB i
inert JJ i
insufflation NN i
gas NN i
and CC i
control NN i
groups NNS i
; : i
the DT i
use NN i
of IN i
analgetics NNS i
, , i
lung NN o
function NN o
, , o
operation NN o
duration NN o
, , o
amount NN o
of IN o
insufflated JJ o
gas NN o
, , o
intraperitoneal JJ o
pH-values NNS o
and CC o
post-operative JJ o
complications NNS o
in IN N
the DT N
various JJ N
subgroups NNS N
were VBD N
compared VBN N
to TO N
each DT N
other JJ N
with IN N
regard NN N
to TO N
post-operative JJ N
pain NN N
perception NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
low JJ i
molecular JJ i
weight NN i
heparin NN i
( ( i
LMWH NNP i
) ) i
combined VBD N
with IN N
graduated JJ i
compression NN i
stockings NNS i
( ( i
GCS NNP i
) ) i
with IN i
GCS NNP i
alone RB i
as IN N
prophylactic JJ N
measures NNS N
for IN N
venous JJ N
thromboembolism NN N
( ( N
VTE NNP N
) ) N
in IN N
post-operative JJ p
patients NNS p
with IN p
gynecologic JJ p
cancer NN p
. . p

CONCLUSIONS NNP N
Two CD N
cycles NNS N
of IN N
regional JJ N
2-min JJ N
IP NNP N
in IN N
the DT N
LAD NNP N
, , N
followed VBN N
by IN N
3 CD N
min NN N
of IN N
reperfusion NN N
, , N
proved VBD N
to TO N
be VB N
applicable JJ N
and CC N
safe JJ N
in IN N
patients NNS p
undergoing VBG p
off-pump JJ p
myocardial JJ p
revascularization NN p
, , N
it PRP N
tended VBD N
to TO N
decrease VB N
the DT N
immediate JJ o
myocardial JJ o
enzyme NN o
release NN o
, , N
it PRP N
prohibited VBD N
the DT N
postoperative JJ N
increase NN N
in IN N
HR NNP N
, , N
and CC N
it PRP N
enhanced VBD N
the DT N
recovery NN o
of IN o
SVI NNP o
. . o

In IN N
the DT N
walk-to-reach NN N
task NN N
, , N
they PRP N
used VBD N
monocular JJ N
and/or NN N
binocular NN N
? . N
information NN N
to TO N
guide VB N
the DT N
head NN N
and CC N
then RB N
switched VBD N
to TO N
using VBG N
relative JJ N
disparity NN N
? . N
to TO N
guide VB N
the DT N
hand NN N
to TO N
final JJ N
target NN N
acquisition NN N
, , N
switching VBG N
when WRB N
the DT N
hand NN N
centric NN N
? . N
became VBD N
less JJR N
than IN N
the DT N
head NN N
centric NN N
? . N
Dynamical JJ N
models NNS N
of IN N
the DT N
information NN N
and CC N
control NN N
strategies NNS N
were VBD N
used VBN N
to TO N
perform VB N
simulations NNS N
that WDT N
were VBD N
found VBN N
to TO N
fit VB N
the DT N
data NN N
well RB N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN N
early JJ i
EN NNP i
with IN i
addition NN i
of IN i
probiotics NNS i
( ( i
bifidobacterium NN i
) ) i
resulted VBD N
in IN N
significant JJ N
lowering NN N
of IN N
the DT N
level NN o
of IN o
pro-inflammatory JJ o
cytokines NNS o
, , o
earlier JJR o
restoration NN o
of IN o
gastrointestinal JJ o
function NN o
, , o
decrease NN o
of IN o
complications NNS o
such JJ o
as IN o
infection NN o
, , o
and CC o
shortening NN o
of IN o
hospital JJ o
day NN o
in IN N
patients NNS N
with IN N
SAP NNP N
. . N

Due JJ N
to TO N
the DT N
richness NN N
of IN N
the DT N
neural JJ N
pathways NNS N
in IN N
the DT N
auditory NN N
system NN N
and CC N
the DT N
redundancy NN N
of IN N
acoustic JJ N
information NN N
in IN N
spoken JJ N
language NN N
, , N
a DT N
normal JJ N
listener NN N
is VBZ N
able JJ N
to TO N
recognize VB N
speech NN N
even RB N
when WRB N
parts NNS N
of IN N
the DT N
signal NN N
are VBP N
missing VBG N
, , N
whereas IN N
this DT N
ability NN N
is VBZ N
often RB N
impaired VBN N
in IN N
listeners NNS N
with IN N
APD NNP N
. . N

For IN N
both DT N
modes NNS N
of IN N
NPPV NNP N
, , N
a DT N
full JJ N
face NN N
mask NN N
and CC N
an DT N
artificial JJ N
leak NN N
in IN N
the DT N
ventilatory NN N
circuit NN N
were VBD N
used VBN N
at IN N
three CD N
different JJ N
settings NNS N
, , N
and CC N
applied VBD N
during IN N
daytime JJ i
NPPV NNP i
, , i
either RB i
without IN i
leakage NN i
( ( i
setting VBG i
I PRP i
) ) i
, , i
with IN i
leakage NN i
during IN i
inspiration NN i
only RB i
( ( i
setting VBG i
II NNP i
) ) i
, , i
and CC i
with IN i
leakage NN i
during IN i
inspiration NN i
and CC i
expiration NN i
( ( i
setting VBG i
III NNP i
) ) i
. . i

In IN N
each DT N
subject NN N
, , N
positron NN o
emission NN o
tomographic JJ o
images NNS o
of IN o
regional JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose JJ o
with IN o
[ JJ o
18F CD o
] NNS o
fluorodeoxyglucose JJ o
were VBD N
obtained VBN N
in IN N
two CD N
conditions NNS N
in IN N
the DT N
morning NN N
on IN N
different JJ N
days NNS N
: : N
about IN N
3min CD i
after IN i
approximately RB i
1-2mg JJ i
of IN i
nasal JJ i
nicotine JJ i
spray NN i
and CC i
after IN i
an DT i
equivalent JJ i
volume NN i
of IN i
an DT i
active JJ i
placebo NN i
spray NN i
of IN i
oleoresin NN i
of IN i
pepper NN i
in IN N
a DT N
random NN N
counterbalanced VBD N
design NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
icosapent JJ i
ethyl NN i
( ( i
eicosapentaenoic JJ i
acid NN i
ethyl NN i
ester NN i
, , i
IPE NNP i
) ) i
on IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
( ( N
hsCRP NN N
) ) N
and CC N
lipid JJ N
parameters NNS N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
, , p
with IN p
and CC p
without IN p
stable JJ p
statin NN p
therapy NN p
. . p

In IN N
a DT N
survival JJ N
analysis NN N
of IN N
treatment NN N
compliance NN N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
groups NNS N
T NNP N
and CC N
C. NNP N
At IN N
the DT N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
myofascial JJ o
pain NN o
, , N
as IN N
measured VBN N
on IN N
a DT N
visual JJ o
analog NN o
scale NN o
, , N
was VBD N
found VBN N
in IN N
all DT N
three CD N
groups NNS N
. . N

Because IN N
two-thirds NNS N
of IN N
patients NNS p
with IN p
Major JJ p
Depressive NNP p
Disorder NNP p
do VBP N
not RB N
achieve VB N
remission NN N
with IN N
their PRP$ N
first JJ N
antidepressant NN N
, , N
we PRP N
designed VBD N
a DT N
trial NN N
of IN N
three CD N
next-step JJ i
strategies NNS i
: : i
switching NN i
to TO i
another DT i
antidepressant NN i
( ( i
bupropion-SR JJ i
) ) i
or CC i
augmenting VBG i
the DT i
current JJ i
antidepressant NN i
with IN i
either DT i
another DT i
antidepressant NN i
( ( i
bupropion-SR JJ i
) ) i
or CC i
with IN i
an DT i
atypical JJ i
antipsychotic NN i
( ( i
aripiprazole JJ i
) ) i
. . i

Adverse JJ N
effects NNS N
within IN N
2 CD N
weeks NNS N
after IN N
TAI NNP N
were VBD N
evaluated VBN N
by IN N
subjective JJ o
signs NNS o
and CC o
symptoms NNS o
such JJ o
as IN o
fever NN o
( ( o
maximum JJ o
body NN o
temperature NN o
) ) o
and CC o
the DT o
frequency NN o
of IN o
shaking VBG o
chills NNS o
and CC o
abdominal JJ o
pain NN o
, , o
and CC o
by IN o
biochemical JJ o
parameters NNS o
such JJ o
as IN o
albumin NN o
, , o
prothrombin JJ o
time NN o
, , o
and CC o
aspartate NN o
and CC o
alanine NN o
aminotransferases NNS o
. . o

Despite IN N
excellent JJ N
adherence NN N
to TO N
treatment NN N
protocols NNS N
by IN N
the DT N
therapists NNS N
, , N
a DT N
clear JJ N
bias NN N
favoring VBG N
CT NNP N
, , N
and CC N
the DT N
competent JJ N
performance NN N
of IN N
CT NNP N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
complete JJ N
treatment NN N
produced VBD N
better JJR N
outcomes NNS N
, , N
at IN N
either CC N
the DT N
termination NN N
of IN N
acute JJ N
treatment NN N
or CC N
the DT N
6-month JJ N
follow-up NN N
, , N
than IN N
either DT N
component JJ N
treatment NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
number NN o
of IN o
deaths NNS o
, , o
attendance NN o
at IN o
hospital JJ o
outpatient NN o
clinics NNS o
and CC o
general JJ o
practice NN o
and CC o
proportion NN o
of IN o
days NNS o
in IN o
hospital NN o
over IN o
the DT o
follow-up JJ o
period NN o
, , o
together RB o
with IN o
patients NNS o
' POS o
general JJ o
well-being NN o
, , o
satisfaction NN o
with IN o
the DT o
service NN o
and CC o
knowledge NN o
of IN o
and CC o
adherence NN o
to TO o
prescribed VB o
medication NN o
. . o

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
resistance NN i
training NN i
versus IN i
passive JJ i
physical JJ i
therapy NN i
on IN N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
, , o
fatigue NN o
, , o
and CC o
emotional JJ o
distress NN o
outcomes NNS o
during IN N
radiation NN N
therapy NN N
in IN N
patients NNS p
with IN p
spinal JJ p
bone NN p
metastases NNS p
under IN p
radiotherapy NN p
( ( p
RT NNP p
) ) p
. . p

The DT N
frequency NN o
of IN o
perceived JJ o
adverse JJ o
events NNS o
and CC o
near JJ o
misses NNS o
was VBD N
also RB N
lower JJR N
in IN N
the DT N
BL NNP N
than IN N
in IN N
the DT N
non-BL JJ N
periods NNS N
, , N
but CC N
not RB N
significantly RB N
so RB N
, , N
possibly RB N
indicating VBG N
that IN N
the DT N
one-month JJ N
observation NN N
period NN N
was VBD N
too RB N
short JJ N
to TO N
achieve VB N
any DT N
significant JJ N
success NN N
. . N

CONCLUSIONS NNP N
The DT N
addition NN N
of IN N
magnesium NN N
to TO N
levobupivacaine VB i
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN o
of IN o
postoperative JJ o
analgesia NN o
and CC o
increases VBZ o
patient JJ o
satisfaction NN o
; : o
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

However RB N
, , N
when WRB N
the DT N
data NNS N
were VBD N
analyzed VBN N
without IN N
regard NN N
for IN N
their PRP$ N
dependence NN N
on IN N
time NN N
, , N
they PRP N
demonstrated VBD N
a DT N
negative JJ N
, , N
linear JJ N
correlation NN N
between IN N
alphaEGOT NN o
and CC o
log NN o
plasma NN o
PLP NNP o
and CC o
between IN o
alphaEGPT NN o
and CC o
log NN o
plasma NN o
PLP NNP o
for IN N
the DT N
group NN N
on IN N
2.5 CD N
mg NN N
of IN N
pyridoxine NN N
and CC N
for IN N
all PDT N
the DT N
subjects NNS N
combined VBN N
. . N

UNLABELLED NNP N
Coronary NNP N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
is VBZ N
the DT N
leading VBG N
cause NN N
of IN N
morbidity NN N
and CC N
mortality NN N
across IN N
the DT N
entire JJ N
world NN N
, , N
in IN N
which WDT N
reversion NN N
of IN N
angina NN N
or CC N
improvement NN N
of IN N
ECG NNP N
remains VBZ N
an DT N
unrealistic JJ N
therapeutic JJ N
option NN N
for IN N
most JJS N
patients NNS N
, , N
suggesting VBG N
that IN N
microvascular JJ N
dysfunction NN N
or CC N
impaired JJ N
oxygen NN N
delivery NN N
might MD N
be VB N
critical JJ N
factors NNS N
in IN N
CHD NNP N
. . N

Cleveland NNP o
constipation NN o
score NN o
( ( o
CCS NNP o
) ) o
, , o
numerical JJ o
rating NN o
scale NN o
( ( o
NRS NNP o
) ) o
of IN o
pain NN o
and CC o
Chinese JJ o
version NN o
of IN o
European JJ o
Organisation NNP o
for IN o
Research NNP o
and CC o
Treatment NNP o
of IN o
Cancer NNP o
, , o
Quality NNP o
of IN o
Life NNP o
Questionnaire-C30 NNP o
V3.0 NNP o
( ( o
EORTC NNP o
QLQ-C30 NNP o
V3.0 NNP o
) ) o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
, , o
pain NN o
controlled VBD o
and CC o
QOL NNP o
status NN o
. . o

The DT N
antiischemic JJ N
effects NNS N
were VBD N
documented VBN N
by IN N
relief NN o
of IN o
symptoms NNS o
, , o
reduction NN o
of IN o
ST-depression NNP o
, , o
improvement NN o
of IN o
impaired JJ o
myocardial JJ o
wall NN o
motion NN o
, , o
decrease NN o
to TO o
normalization NN o
of IN o
pathologically RB o
elevated VBN o
filling JJ o
pressure NN o
, , o
amelioration NN o
of IN o
coronary JJ o
blood NN o
flow NN o
as IN N
evidenced VBN N
by IN N
myocard NN N
scintigraphy NN N
and CC N
washout NN N
time NN N
of IN N
an DT N
intracoronarily JJ N
injected VBN N
echo-contrast JJ N
medium NN N
. . N

RESULTS NNP N
Fluvoxamine NNP i
and CC i
clomipramine VB i
both DT N
resulted VBN N
in IN N
marked JJ N
improvements NNS N
; : N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
them PRP N
on IN N
the DT N
17-item JJ o
HAMD NNP o
total NN o
score NN o
, , o
the DT o
clinical JJ o
global JJ o
impression NN o
severity NN o
of IN o
illness NN o
or CC o
global JJ o
improvement NN o
items NNS o
or CC o
the DT o
Montgomery-Asberg JJ o
depression NN o
rating NN o
scale NN o
, , N
at IN N
any DT N
visit NN N
. . N

Results NNS N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
eye-hand JJ o
performances NNS o
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Although IN N
the DT N
results NNS N
presented VBD N
within IN N
do VBP N
not RB N
include VB N
factors NNS N
of IN N
study NN N
and CC N
study-by-treatment JJ N
interaction NN N
, , N
analyses NNS N
were VBD N
performed VBN N
to TO N
confirm VB N
that IN N
the DT N
results NNS N
were VBD N
consistent JJ N
across IN N
the DT N
2 CD N
identical JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
studies NNS N
and CC N
within IN N
each DT N
treatment NN N
group NN N
across IN N
studies NNS N
to TO N
justify VB N
pooling VBG N
the DT N
data NN N
from IN N
both DT N
studies NNS N
. . N

When WRB N
the DT N
pattern NN N
of IN N
cognitive JJ N
change NN N
over IN N
time NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
compared VBN N
using VBG N
sophisticated JJ N
modeling NN N
techniques NNS N
, , N
the DT N
two CD N
groups NNS N
were VBD N
again RB N
comparable JJ N
, , N
except IN N
for IN N
results NNS N
on IN N
the DT N
test NN N
of IN N
verbal JJ o
fluency NN o
, , N
in IN N
which WDT N
the DT N
off-pump NN N
group NN N
showed VBD N
more RBR N
rapid JJ o
postsurgical JJ o
cognitive NN o
gains NNS o
than IN N
the DT N
on-pump JJ N
group NN N
. . N

Why WRB N
does VBZ N
lag NN N
affect VB N
the DT N
durability NN N
of IN N
memory-based JJ N
automaticity NN N
: : N
loss NN N
of IN N
memory NN N
strength NN N
or CC N
interference NN N
? . N
In IN N
Rickard NNP N
, , N
Lau NNP N
, , N
and CC N
Pashler NNP N
's POS N
( ( N
2008 CD N
) ) N
investigation NN N
of IN N
the DT N
lag NN N
effect NN N
on IN N
memory-based JJ o
automaticity NN o
, , N
response NN N
times NNS N
were VBD N
faster RBR N
and CC N
proportion NN N
of IN N
trials NNS N
retrieved VBN N
was VBD N
higher JJR N
at IN N
the DT N
end NN N
of IN N
practice NN N
for IN N
short JJ N
lag NN N
items NNS N
than IN N
for IN N
long JJ N
lag NN N
items NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
an DT N
applied JJ i
behaviour NN i
analysis NN i
( ( i
ABA NNP i
) ) i
-based VBD i
intervention NN i
conducted VBN i
by IN i
a DT i
robot NN i
compared VBN i
to TO i
an DT i
ABA-based JJ i
intervention NN i
conducted VBN i
by IN i
a DT i
human JJ i
trainer NN i
in IN i
promoting VBG i
self-initiated JJ i
questions NNS i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

The DT N
absence NN o
of IN o
activity NN o
significantly RB N
correlated VBN N
with IN N
temporal JJ N
complexity NN N
during IN N
continue JJ N
suggests NNS N
that IN N
, , N
once RB N
an DT N
overlearned VBN N
timed JJ N
movement NN N
sequence NN N
has VBZ N
been VBN N
selected VBN N
and CC N
initiated VBN N
, , N
there EX N
is VBZ N
no DT N
further JJ N
adjustment NN N
of IN N
the DT N
timing NN N
control NN N
processes VBZ N
related VBN N
to TO N
its PRP$ N
continued JJ N
production NN N
in IN N
absence NN N
of IN N
external JJ N
cues NNS N
. . N

Concerning VBG N
spectral JJ N
analysis NN N
, , N
temazepam NN i
induces NNS N
a DT N
light JJ N
increase NN N
of IN N
the DT N
relative JJ N
power NN N
of IN N
the DT N
slowest JJS N
frequencies NNS N
, , N
paralleled VBN N
by IN N
an DT N
increase NN N
of IN N
the DT N
fast JJ N
bands NNS N
, , N
while IN N
major JJ N
effects NNS N
are VBP N
found VBN N
on IN N
the DT N
characteristic JJ N
periodicity NN N
of IN N
delta NN N
activities NNS N
, , N
which WDT N
appear VBP N
disrupted VBN N
by IN N
the DT N
drug NN N
. . N

Based VBN N
on IN N
these DT N
experiments NNS N
, , N
nomograms NNS N
were VBD N
constructed VBN N
from IN N
which WDT N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
Ringer NNP i
's POS i
solution NN i
and CC N
the DT N
infusion NN N
time NN N
required VBN N
to TO N
obtain VB N
a DT N
defined JJ N
plasma NN N
dilution NN N
in IN N
both DT N
males NNS N
and CC N
females NNS N
can MD N
be VB N
estimated VBN N
together RB N
with IN N
the DT N
infusion NN N
rate NN N
needed VBN N
to TO N
maintain VB N
the DT N
dilution NN N
at IN N
the DT N
level NN N
reached VBD N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
28-day JJ o
mortality NN o
, , o
hospital JJ o
mortality NN o
, , o
or CC o
length NN o
of IN o
hospital NN o
stay NN o
, , o
but CC o
ICU NNP o
mortality NN o
and CC o
the DT o
length NN o
of IN o
ICU NNP o
stay NN o
in IN N
the DT N
HA NNP N
group NN N
were VBD N
markedly RB N
reduced VBN N
. . N

Does NNP N
aerobic VB i
training VBG i
lead NN N
to TO N
a DT N
more RBR N
active JJ o
lifestyle NN o
and CC o
improved JJ o
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
? . p
BACKGROUND NNP p
Due NNP p
to TO p
dyspnea VB p
and CC p
fatigue VB p
, , p
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
are VBP N
often RB N
restricted VBN N
in IN N
the DT N
performance NN N
of IN N
everyday JJ N
activities NNS N
, , N
which WDT N
gradually RB N
may MD N
lead VB N
to TO N
hypoactivity NN N
. . N

RESULTS VB N
The DT N
results NNS N
indicated VBD N
that IN N
the DT N
distorting NN N
goggles NNS N
degraded VBD N
throwing VBG N
at IN N
the DT N
beginning NN N
of IN N
training NN N
, , N
visual JJ N
feedback NN N
improved VBD N
throwing VBG N
during IN N
training NN N
, , N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
persisted VBN N
into IN N
the DT N
throwing VBG N
posttest NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
did VBD N
not RB N
transfer VB N
to TO N
the DT N
verbal JJ N
metric JJ N
estimation NN N
posttest NN N
. . N

The DT N
processing NN N
of IN N
time-dependent JJ N
features NNS N
of IN N
movement NN N
has VBZ N
a DT N
crucial JJ N
role NN N
in IN N
predicting VBG N
whether IN N
the DT N
outcome NN N
of IN N
a DT N
complex JJ N
motor NN N
sequence NN N
, , N
such JJ N
as IN N
handwriting NN N
or CC N
playing VBG N
a DT N
musical JJ N
passage NN N
, , N
will MD N
be VB N
consistent JJ N
with IN N
its PRP$ N
ultimate JJ N
goal NN N
, , N
or CC N
results NNS N
instead RB N
in IN N
an DT N
execution NN N
error NN N
. . N

The DT N
following VBG N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
intervention NN N
: : N
strength NN N
by IN N
one CD N
repetition NN N
maximum NN N
, , N
physical JJ N
activity NN N
by IN N
the DT N
7-d JJ N
accelerometry NN N
and CC N
the DT N
3-d JJ o
physical JJ o
activity NN o
recall NN o
, , o
dietary JJ o
intake NN o
by IN o
3-d JJ o
records NNS o
, , o
body NN o
composition NN o
by IN o
dual-energy JJ o
x-ray JJ o
absorptiometry NN o
( ( o
DEXA NNP o
) ) o
, , o
glucose/insulin JJ o
indices NNS o
by IN o
oral JJ o
glucose JJ o
tolerance NN o
test NN o
, , o
and CC o
intravenous JJ o
glucose JJ o
tolerance NN o
test NN o
with IN N
minimal JJ N
modeling NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
either RB N
that DT N
persistent JJ N
early-life JJ N
MEE NNP N
actually RB N
causes VBZ N
later RB N
small JJ N
, , N
circumscribed JJ N
impairments NNS N
of IN N
receptive JJ o
language NN o
and CC o
verbal JJ o
aspects NNS o
of IN o
cognition NN o
in IN p
certain JJ p
groups NNS p
of IN p
children NNS p
or CC p
that DT p
unidentified JJ p
, , p
confounding VBG p
factors NNS p
predispose JJ p
children NNS p
both DT p
to TO p
early-life NN p
otitis NN p
media NNS p
and CC p
to TO p
certain JJ p
types NNS p
of IN p
developmental JJ p
impairment NN p
. . p

The DT N
ESDM NNP N
group NN N
and CC N
typical JJ N
children NNS N
showed VBD N
a DT N
shorter NN N
Nc NNP o
latency NN o
and CC o
increased VBD o
cortical JJ o
activation NN o
( ( o
decreased VBN o
? . o
power NN o
and CC o
increased VBD o
? . o
power NN o
) ) o
when WRB o
viewing VBG o
faces VBZ o
, , N
whereas IN N
the DT N
community NN N
intervention NN N
group NN N
showed VBD N
the DT N
opposite JJ N
pattern NN N
( ( N
shorter JJ N
latency NN o
event-related JJ o
potential JJ o
[ NN o
ERP NNP o
] NNP o
and CC o
greater JJR o
cortical JJ o
activation NN o
when WRB o
viewing VBG o
objects NNS o
) ) o
. . o

SWAL-QOL JJ o
Scale NNP o
scores NNS o
increased VBD N
more RBR N
significantly RB N
in IN N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
groups NNS N
than IN N
in IN N
the DT N
traditional JJ N
swallowing NN N
therapy NN N
group NN N
, , N
and CC N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
groups NNS N
showed VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
P=.04 NNP N
) ) N
. . N

Lumbar NNP o
spine NN o
BMD NNP o
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
, , N
and CC N
trabecular JJ N
bone NN N
mineral JJ N
density NN N
at IN N
the DT N
distal JJ N
radius NN N
, , N
cortical JJ N
bone NN N
density NN N
, , N
and CC N
relative JJ N
cortical JJ N
volume NN N
at IN N
the DT N
radial JJ N
diaphysis NN N
by IN N
peripheral JJ N
computed VBN N
tomography NN N
before IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
4th CD N
, , N
8th CD N
, , N
and CC N
12th CD N
month NN N
. . N

Although IN N
propranolol NN i
can MD N
be VB N
administered VBN N
safely RB N
to TO N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
who WP N
are VBP N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
simple JJ N
clinical JJ N
criteria NNS N
, , N
there EX N
is VBZ N
no DT N
evidence NN N
of IN N
reduction NN N
of IN N
infarct NN o
size NN o
when WRB N
beta NN N
blockade NN N
is VBZ N
begun VBN N
8.5 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
symptoms NNS N
. . N

This DT N
study NN N
, , N
the DT N
first JJ N
performed VBN N
in IN N
an DT N
unselected JJ N
, , N
unscreened JJ N
population NN N
, , N
shows VBZ N
that IN N
serum NN o
PSA NNP o
is VBZ N
the DT N
most RBS N
sensitive JJ N
technique NN N
to TO N
identify VB N
men NNS N
at IN N
high JJ N
risk NN N
of IN N
having VBG N
prostate NN N
cancer NN N
and CC N
that IN N
12 CD N
% NN N
more JJR N
cancers NNS N
can MD N
be VB N
found VBN N
at IN N
first JJ N
visit NN N
by IN N
doing VBG N
DRE NNP i
in IN N
addition NN N
to TO N
PSA NNP N
. . N

A DT N
few JJ N
studies NNS N
have VBP N
been VBN N
conducted VBN N
that IN N
evaluate VBP N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
; : N
however RB N
, , N
none NN N
of IN N
these DT N
studies NNS N
have VBP N
combined VBN N
objective JJ N
measures NNS N
with IN N
rating NN N
scales NNS N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
across IN N
home NN N
and CC N
clinical JJ N
settings NNS N
. . N

AIMS IN N
The DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS N
and CC N
teachers NNS N
, , N
with IN N
guidance NN N
, , N
can MD N
assist VB N
in IN N
the DT N
management NN N
of IN N
children NNS p
with IN p
DCD NNP p
; : p
whether IN N
children NNS p
with IN p
DCD NNP p
are VBP N
helped VBN N
in IN N
this DT N
way NN N
and CC N
how WRB N
this DT N
may MD N
contribute VB N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
condition NN N
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
short-term JJ o
efficacy NN o
and CC o
safety NN o
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
who WP p
were VBD p
manifesting VBG p
behaviors NNS p
such JJ p
as IN p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
. . p

The DT N
secondary JJ N
outcome NN N
measures NNS N
included VBD N
psychological JJ o
stress NN o
, , o
anxiety NN o
, , o
irritation NN o
, , o
headache-related JJ o
disability NN o
and CC o
the DT o
frequency NN o
( ( o
number NN o
of IN o
days NNS o
per IN o
month NN o
) ) o
of IN o
migraine NN o
attack NN o
and CC o
of IN o
headache NN o
of IN o
at IN o
least JJS o
moderate JJ o
intensity NN o
( ( o
pain NN o
rating NN o
? . o
) ) o
. . o

Factors NNS N
associated VBN N
with IN N
better JJR N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
and CC N
European NNP N
QOL NNP N
5D CD N
Visual NNP N
Analog NNP N
Scale NNP N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
were VBD N
American JJ N
region NN N
, , N
older JJR N
age NN N
, , N
no DT N
history NN N
of IN N
angina JJ N
pectoris NN N
or CC N
asthma NN N
, , N
no DT N
use NN N
of IN N
hypoglycemic JJ N
agent NN N
, , N
more JJR N
activity NN N
level NN N
, , N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
. . N

Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
and CC o
the DT o
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
GARS NNP o
) ) o
were VBD o
used VBN o
to TO o
assess VB o
core NN o
autism NN o
behaviours NNS o
, , o
Vineland NNP o
Adaptive NNP o
Behaviour NNP o
Scales NNP o
( ( o
VABS NNP o
) ) o
to TO o
ascertain VB o
developmental JJ o
level NN o
, , o
and CC o
Attention-Deficit NNP o
Hyperactivity NNP o
Disorder NNP o
- : o
IV NNP o
scale NN o
( ( o
ADHD-IV NNP o
) ) o
to TO o
determine VB o
inattention NN o
and CC o
hyperactivity NN o
. . o

CONCLUSIONS NNP N
In IN N
the DT N
very RB N
high-risk JJ N
population NN N
studied VBN N
, , N
effective JJ N
anti-H. JJ N
pylori NN N
treatment NN N
and CC N
dietary JJ N
supplementation NN N
with IN N
antioxidant JJ N
micronutrients NNS N
may MD N
interfere VB N
with IN N
the DT N
precancerous JJ N
process NN N
, , N
mostly RB N
by IN N
increasing VBG N
the DT N
rate NN N
of IN N
regression NN N
of IN N
cancer NN N
precursor NN N
lesions NNS N
, , N
and CC N
may MD N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
prevent VB N
gastric JJ N
carcinoma NN N
. . N

Considering VBG o
growth NN o
over IN N
all DT N
3 CD N
measurement NN N
periods NNS N
, , N
an DT N
exploratory NN N
analysis NN N
showed VBD N
that IN N
growth NN o
rate NN o
of IN o
the DT o
number NN o
of IN o
different JJ o
nonimitative JJ o
words NNS o
was VBD N
faster RBR N
in IN N
the DT N
PECS NNP i
group NN N
than IN N
in IN N
the DT N
RPMT NNP i
group NN N
for IN N
children NNS p
who WP p
began VBD p
treatment NN p
with IN p
relatively RB p
high JJ p
object JJ p
exploration NN p
. . p

CONCLUSION NNP N
Medication-assisted NNP i
therapies NNS i
for IN N
prevention NN N
of IN N
relapse NN N
to TO N
alcohol VB N
use NN N
for IN N
CJS NNP N
populations NNS N
transitioning VBG N
to TO N
the DT N
community NN N
, , N
especially RB N
for IN N
HIV-infected JJ N
patients NNS N
, , N
are VBP N
urgently RB N
needed VBN N
in IN N
order NN N
to TO N
reduce VB N
alcohol NN o
relapse NN o
after IN N
release NN N
and CC N
improve VB N
HIV NNP N
treatment NN N
outcomes NNS N
and CC N
contribute NN N
to TO N
improved VBN N
individual JJ N
and CC N
public JJ N
health NN N
. . N

CONCLUSIONS NNP N
Since IN N
this DT N
analysis NN N
of IN N
reliability NN N
, , N
validity NN N
, , N
and CC N
responsiveness NN N
to TO N
change VB N
did VBD N
not RB N
clearly RB N
favour VBP N
one CD N
instrument NN N
above IN N
the DT N
other JJ N
, , N
the DT N
choice NN N
between IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
can MD N
be VB N
based VBN N
on IN N
other JJ N
considerations NNS N
such JJ N
as IN N
the DT N
required JJ N
sample NN N
size NN N
or CC N
the DT N
availability NN N
of IN N
reference NN N
values NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
conjugated JJ i
linoleic JJ i
acid NN i
( ( i
CLA NNP i
) ) i
supplementation NN N
and CC N
endurance NN N
exercise NN N
training-induced JJ N
changes NNS N
on IN N
post-heparin JJ o
lipoprotein NN o
lipase NN o
( ( o
PH-LPL NNP o
) ) o
and CC o
butyrylcholinesterase NN o
( ( o
BChE NNP o
) ) o
activities NNS o
along IN N
with IN N
leptin NN N
, , N
insulin NN N
and CC N
lipid JJ N
levels NNS N
in IN N
plasma NN N
by IN N
a DT N
randomized JJ N
double JJ N
blind NN N
experiment NN N
. . N

The DT N
study NN N
will MD N
investigate VB N
the DT N
effects NNS N
on IN N
falls NNS o
, , o
mobility NN o
and CC o
quality NN o
of IN o
life NN o
of IN o
( ( o
i NN o
) ) o
movement NN o
strategy NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
, , i
( ( i
ii NN i
) ) i
progressive NN i
resistance NN i
strength NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
, , i
( ( i
iii NN i
) ) i
a DT i
generic JJ i
life-skills JJ i
social JJ i
program NN i
( ( i
control VB i
group NN i
) ) i
. . i

Furthermore RB N
, , N
TCM NNP o
, , o
histological JJ o
grading NN o
of IN o
myeloma NN o
cells NNS o
, , o
degree NN o
of IN o
bone NN o
marrow NN o
infiltration NN o
, , o
haemoglobin NN o
, , o
platelet NN o
counts NNS o
, , o
calcium NN o
, , o
creatinine NN o
, , o
albumin NN o
, , o
beta NN o
2M CD o
, , o
and CC o
Bence NNP o
Jones NNP o
proteinuria NNS o
correlated VBD N
to TO N
both DT N
OAS NNP N
and CC N
TRS NNP N
. . N

Additionally RB N
, , N
dose-dependent JJ N
reductions NNS N
in IN N
the DT N
indices NNS o
of IN o
platelet NN o
activation NN o
and CC o
endothelial JJ o
dysfunction NN o
were VBD N
observed VBN N
in IN N
patients NNS N
administered VBN N
high JJ N
dose JJ N
treatments NNS N
of IN N
eprosartan NN i
and CC i
enalapril NN i
, , N
and CC N
the DT N
beneficial JJ N
effects NNS N
of IN N
these DT N
agents NNS N
were VBD N
not RB N
correlated VBN N
with IN N
the DT N
reduction NN N
of IN N
blood NN o
pressure NN o
using VBG N
both DT N
agents NNS N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
observed JJ N
cost NN o
and CC o
QALY NNP o
measures NNS o
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
, , N
although IN N
a DT N
tendency NN N
was VBD N
noted VBN N
for IN N
psychosocial JJ N
care NN N
leading VBG N
to TO N
cost NN N
increases NNS N
with IN N
informal JJ N
care NN N
that WDT N
was VBD N
not RB N
outweighed VBN N
by IN N
the DT N
tendency NN N
for IN N
cost NN N
savings NNS N
with IN N
formal JJ N
care NN N
. . N

Repeated-measures JJ N
multivariate NN N
analysis NN N
of IN N
variance NN N
performed VBN N
on IN N
normalized JJ N
relative JJ N
area NN N
values NNS N
revealed VBD N
that IN N
ethanol NN i
had VBD N
significant JJ N
effects NNS N
on IN N
EEG NNP o
activity NN o
at IN N
anterior JJ N
sites NNS N
: : N
frontal NN N
( ( N
F3 NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
C4 NNP N
) ) N
that WDT N
presented VBD N
as IN N
increased JJ N
activity NN N
in IN N
the DT N
slow JJ N
alpha NN N
frequency NN N
band NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Pain NNP o
on IN o
the DT o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
, , o
the DT o
Oswestry NNP o
and CC o
the DT o
Million NNP o
disability NN o
indexes NNS o
, , o
isometric JJ o
and CC o
dynamic JJ o
trunk NN o
muscle NN o
strength NN o
, , o
mobility NN o
in IN o
the DT o
lumbar NN o
spine NN o
, , o
and CC o
straight-leg JJ o
raising NN o
were VBD N
measured VBN N
. . N

The DT N
active JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
controls NNS N
on IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
-- : o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
total NN o
score NN o
, , o
particularly RB o
in IN o
reciprocal JJ o
social JJ o
interaction NN o
-- : o
and CC o
on IN o
secondary JJ o
measures NNS o
of IN o
expressive JJ o
language NN o
, , o
communicative JJ o
initiation NN o
and CC o
parent-child JJ o
interaction NN o
. . o

The DT N
Stages NNP N
to TO N
Healthy NNP N
Eating NNP N
Patterns NNP N
Study NNP N
( ( N
STEPs NNP N
) ) N
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN i
, , i
tailored VBN i
, , i
iterative JJ i
dietary JJ i
feedback NN i
delivered VBN i
by IN i
mail NN i
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

DISCUSSION NN N
If IN N
ROMEO NNP N
confirms VBZ N
that IN N
group NN N
care NN N
can MD N
be VB N
successfully RB N
implemented VBN N
in IN N
different JJ N
clinics NNS N
, , N
a DT N
novel JJ N
clinico-pedagogic JJ N
tool NN N
will MD N
have VB N
been VBN N
acquired VBN N
to TO N
support VB N
patient-centred JJ N
education NN N
, , N
improve VB N
lifestyle NN N
and CC N
outcomes NNS N
, , N
support NN N
team NN N
work NN N
, , N
enhance NN N
providers NNS N
' POS N
attitudes NNS N
and CC N
competencies NNS N
and CC N
ameliorate VB N
diabetes NNS N
care JJ N
organization NN N
. . N

The DT N
physical JJ i
activity NN i
intervention NN i
will MD i
consist VB i
of IN i
a DT i
number NN i
of IN i
strategies NNS i
including VBG i
: : i
delivering NN i
structured VBD i
fundamental JJ i
movement NN i
skill NN i
activities NNS i
, , i
increasing VBG i
physical JJ i
activity NN i
opportunities NNS i
, , i
increasing VBG i
staff NN i
role NN i
modelling NN i
, , i
providing VBG i
children NNS i
with IN i
a DT i
physical JJ i
activity NN i
promoting VBG i
indoor NN i
and CC i
outdoor JJ i
environment NN i
and CC i
limiting VBG i
children NNS i
's POS i
small JJ i
screen JJ i
recreation NN i
and CC i
sedentary JJ i
behaviours NNS i
. . i

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
quantitative JJ o
sensory NN o
tests NNS o
using VBG N
the DT N
CASE NNP N
IV NNP N
System NNP N
, , N
the DT N
Neuropathy NNP o
Symptom NNP o
and CC o
Change NNP o
questionnaire NN o
, , N
the DT N
Patient NNP N
Benefit NNP N
Questionnaire NNP N
( ( N
PBQ NNP N
) ) N
, , N
and CC N
a DT N
global JJ N
symptom NN N
assessment NN N
, , N
as RB N
well RB N
as IN N
nerve NN N
conduction NN N
studies NNS N
and CC N
occurrence NN N
of IN N
new JJ o
plantar JJ o
foot NN o
ulcers NNS o
. . o

Improvements NNS o
in IN o
mood NN o
were VBD N
associated VBN N
with IN N
modest JJ N
gains NNS N
in IN N
verbal JJ o
memory NN o
and CC o
executive NN o
functioning NN o
over IN N
the DT N
10-week JJ N
treatment NN N
period NN N
and CC N
accounted VBD N
for IN N
greater JJR N
variance NN N
in IN N
neuropsychological JJ N
outcomes NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
than IN N
other JJ N
known JJ N
correlates NNS N
of IN N
cognitive JJ N
functioning NN N
in IN N
PD NNP N
, , N
such JJ N
as IN N
disease NN N
severity NN N
, , N
age NN N
, , N
and CC N
education NN N
. . N

Both DT N
groups NNS N
showed VBD N
habituation NN o
in IN o
heart NN o
rate NN o
from IN N
the DT N
first JJ N
to TO N
the DT N
second JJ N
presentation NN N
, , N
and CC N
both DT N
groups NNS N
reported VBD N
perception NN o
of IN o
a DT o
higher JJR o
heart NN o
rate NN o
, , N
but CC N
only RB N
social JJ N
phobics NNS N
reported VBD N
significantly RB N
more JJR N
anxiety NN o
and CC o
were VBD o
more JJR o
worried JJ o
about IN o
their PRP$ o
heart NN o
rates NNS o
in IN N
the DT N
public NN N
than IN N
in IN N
the DT N
private JJ N
condition NN N
. . N

Use NNP N
of IN N
activated JJ N
charcoal NN N
in IN N
a DT N
simulated JJ p
poisoning NN p
with IN p
acetaminophen NN p
: : p
a DT N
new JJ N
loading NN N
dose NN N
for IN N
N-acetylcysteine NNP N
? . N
STUDY NNP N
OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
ability NN N
of IN N
a DT N
supranormal JJ N
dose NN N
of IN N
N-acetylcysteine NNP i
to TO N
overcome VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
N-acetylcysteine NNP N
bioavailability NN N
and CC N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
activated JJ N
charcoal NN N
on IN N
serum NN N
acetaminophen NN N
levels NNS N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
333 CD p
seronegative JJ p
African JJ p
American JJ p
female JJ p
drug NN p
users NNS p
( ( p
aged VBN p
18-59 CD p
years NNS p
) ) p
participating VBG p
in IN p
an DT p
HIV NNP p
intervention NN p
and CC p
with IN p
higher JJR p
levels NNS p
of IN p
emotional JJ o
distress NN o
, , o
specifically RB o
symptoms NNS o
of IN o
depression NN o
and CC o
anxiety NN o
, , o
reduced VBD o
HIV NNP o
risk NN o
behaviors NNS o
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
those DT N
with IN N
lower JJR N
levels NNS N
of IN N
emotional JJ N
distress NN N
. . N

Acupuncture NN i
is VBZ N
becoming VBG N
a DT N
common JJ N
technique NN N
within IN N
the DT N
physiotherapy NN N
profession NN N
as IN N
a DT N
treatment NN N
modality NN N
for IN N
pain NN N
relief NN N
; : N
however RB N
, , N
few JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN N
, , N
particularly RB N
in IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
hip NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ N
efficacy NN N
of IN N
the DT N
clinical JJ N
neurosensory JJ N
test NN N
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
gold JJ N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
rate NN o
of IN o
major JJ o
adverse JJ o
cardiac NN o
events NNS o
( ( o
MACEs NNP o
) ) o
at IN o
1 CD o
month NN o
, , o
defined VBD o
as IN o
a DT o
composite NN o
of IN o
cardiac JJ o
death NN o
, , o
reinfarction NN o
, , o
serious JJ o
arrhythmias NN o
( ( o
ventricular JJ o
fibrillation NN o
and/or IN o
tachycardia NN o
) ) o
, , o
and CC o
severe JJ o
heart NN o
failure NN o
. . o

The DT N
use NN N
of IN N
thrombolytic JJ i
agents NNS i
in IN N
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
early JJ N
and CC N
long-term JJ N
mortality NN N
by IN N
about IN N
20 CD N
% NN N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
since IN N
time NN N
is VBZ N
an DT N
important JJ N
factor NN N
, , N
pre-hospital JJ N
treatment NN N
would MD N
give VB N
better JJR N
results NNS N
. . N

Here RB N
, , N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
peripheral JJ o
FMRP NNP o
level NN o
, , o
visual JJ o
perception NN o
( ( o
contrast JJ o
sensitivity NN o
, , o
perceptual JJ o
integration NN o
, , o
motion/form VB o
perception NN o
) ) o
, , o
and CC o
neuropsychological JJ o
functions NNS o
in IN o
schizophrenia NN o
as IN o
measured VBN o
with IN o
the DT o
Repeatable JJ o
Battery NN o
for IN o
the DT o
Assessment NNP o
of IN o
Neuropsychological NNP o
Status NNP o
( ( o
RBANS NNP o
) ) o
. . o

The DT N
goal NN N
was VBD N
to TO N
assess VB N
if IN N
a DT N
16-wk JJ i
nutrition NN i
plus CC i
CAST NNP i
pilot NN N
study NN N
had VBD N
stronger JJR N
effects NNS N
on IN N
reducing VBG N
adiposity NN o
and CC N
on IN N
improving VBG N
glucose/insulin NN o
indices NNS o
compared VBN N
with IN N
control NN N
( ( N
C NNP N
) ) N
, , N
nutrition NN N
only RB N
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
nutrition NN N
plus CC N
strength NN N
training NN N
( ( N
N NNP N
+ NNP N
ST NNP N
) ) N
groups NNS N
. . N

PURPOSE NN N
To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
ifosfamide NN i
to TO i
cisplatin VB i
plus JJ i
etoposide JJ i
improves VBZ N
the DT N
response NN o
rate NN o
, , o
time NN o
to TO o
disease VB o
progression NN o
, , o
or CC o
overall JJ o
survival NN o
in IN N
previously RB p
untreated JJ p
patients NNS p
with IN p
extensive-stage JJ p
small-cell JJ p
carcinoma NN p
of IN p
the DT p
lung NN p
( ( p
SCLC NNP p
) ) p
. . p

This DT N
randomized VBD N
clinical JJ N
trial NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
a DT N
verbally-based JJ i
intervention NN i
, , i
Pivotal NNP i
Response NNP i
Training NNP i
( ( i
PRT NNP i
) ) i
to TO i
a DT i
pictorially-based JJ i
behavioral JJ i
intervention NN i
, , i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
on IN i
the DT i
acquisition NN i
of IN i
spoken JJ i
language NN i
by IN i
young JJ i
( ( i
2-4 JJ i
years NNS i
) ) i
, , i
nonverbal JJ i
or CC i
minimally RB i
verbal JJ i
( ( p
? . p
words NNS p
) ) p
children NNS p
with IN p
autism NN p
. . p

Outcome NN N
measures NNS N
were VBD N
the DT N
Dutch JJ o
version NN o
of IN o
the DT o
McGill NNP o
Pain NNP o
Questionnaire NNP o
( ( o
MPQ-DLV NNP o
) ) o
, , o
the DT o
Health-related JJ o
quality NN o
of IN o
life NN o
instrument NN o
( ( o
HRQOL NNP o
) ) o
, , o
visual JJ o
analogue NN o
scales NNS o
( ( o
VAS NNP o
) ) o
, , o
the DT o
duration NN o
of IN o
the DT o
procedure NN o
, , o
and CC o
the DT o
analgesic JJ o
doses NNS o
taken VBN o
each DT o
day NN o
. . o

The DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
( ( o
rise NN o
in IN o
serum JJ o
creatinine NN o
and CC o
fall NN o
in IN o
serum JJ o
potassium NN o
, , o
loss NN o
of IN o
appetite NN o
and CC o
shivering NN o
, , o
rigor NN o
and CC o
fever NN o
during IN o
infusion NN o
indicative NN o
of IN o
renal JJ o
, , o
GIT NNP o
and CC o
infusion NN o
related JJ o
toxicities NNS o
respectively RB o
) ) o
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all PDT N
the DT N
four CD N
study NN N
parameters NNS N
, , N
which WDT N
correlated VBD N
well RB N
with IN N
the DT N
improvement NN N
in IN N
symptoms NNS o
of IN o
urogenital JJ o
atrophy NN o
and CC o
sexual JJ o
dysfunction NN o
in IN N
both CC N
the DT N
study NN N
groups NNS N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
computer NN i
software NN i
( ( i
i.e NN i
, , i
Mind NNP i
Reading NNP i
) ) i
and CC i
in IN i
vivo JJ i
rehearsal NN i
treatment NN i
on IN N
the DT N
emotion NN o
decoding NN o
and CC o
encoding VBG o
skills NNS o
, , o
autism NN o
symptoms NNS o
, , o
and CC o
social JJ o
skills NNS o
of IN N
43 CD p
children NNS p
, , p
ages VBZ p
7-12 CD p
years NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorder NN p
( ( p
HFASD NNP p
) ) p
. . p

RESULTS NNP N
Comparing VBG N
the DT N
tooth JJ N
widths NNS N
of IN N
patients NNS p
with IN p
unilateral JJ p
canine NN p
displacement NN p
with IN N
the DT N
corresponding JJ N
contralateral JJ N
quadrants NNS N
, , N
we PRP N
noted VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
, , N
namely RB N
that IN N
the DT N
central JJ o
and CC o
lateral JJ o
incisors NNS o
and CC o
the DT o
canines NNS o
of IN o
the DT o
affected JJ o
side NN o
were VBD N
narrower JJR N
than IN N
those DT N
of IN N
the DT N
non-affected JJ N
side NN N
in IN N
the DT N
same JJ N
patient NN N
. . N

Results NNS N
of IN N
the DT N
therapeutic JJ N
effects NNS N
will MD N
not RB N
be VB N
available JJ N
for IN N
some DT N
time NN N
, , N
but CC N
the DT N
study NN N
has VBZ N
provided VBN N
an DT N
opportunity NN N
to TO N
investigate VB N
influences NNS N
on IN N
sensitization NN N
to TO N
allergens NNS N
in IN N
a DT p
large JJ p
cohort NN p
of IN p
1-2 JJ p
years NNS p
olds VBZ p
with IN p
already RB p
established VBN p
atopic NN p
dermatitis NN p
, , p
resident NN p
in IN p
different JJ p
countries NNS p
and CC p
in IN p
different JJ p
environments NNS p
. . p

The DT N
examination NN N
and CC N
treatment NN N
of IN N
64 CD p
patients NNS p
have VBP N
shown VBN N
that IN N
inclusion NN N
of IN N
complex JJ N
antioxidant NN N
cytoflavin NN N
in IN N
intensive JJ N
therapy NN N
at IN N
the DT N
postoperative JJ N
period NN N
of IN N
diffuse NN N
peritonitis NN N
allows VBZ N
the DT N
hypoxia NN o
degree NN o
to TO N
be VB N
decreased VBN N
that IN N
in IN N
its PRP$ N
turn NN N
results NNS N
in IN N
quicker JJ N
recovery NN o
of IN o
the DT o
antioxidant JJ o
system NN o
and CC o
decreased JJ o
activity NN o
of IN o
peroxidation NN o
and CC o
endotoxicosis NN o
level NN o
. . o

We PRP N
further RB N
sought VBD N
to TO N
determine VB N
whether IN N
egg NN i
yolk NNS i
intake VBP i
affects NNS N
peripheral JJ o
blood NN o
mononuclear NN o
cell NN o
( ( o
PBMC NNP o
) ) o
inflammation NN o
and CC N
cholesterol NN N
homeostasis NN N
in IN N
MetS NNP N
, , N
as IN N
HDL NNP N
and CC N
its PRP$ N
associated JJ N
lipid JJ N
transporter NN N
ATP-binding NNP N
cassette NN N
transporter NN N
A1 NNP N
( ( N
ABCA1 NNP N
) ) N
reduce VB N
the DT N
inflammatory JJ N
potential NN N
of IN N
leukocytes NNS N
through IN N
modulation NN N
of IN N
cellular JJ N
cholesterol NN N
content NN N
and CC N
distribution NN N
. . N

There EX N
was VBD N
wide JJ N
individual JJ N
variation NN N
in IN N
the DT N
ratio NN N
of IN N
serum NN N
to TO N
saliva VB N
concentrations NNS N
indicating VBG N
that IN N
, , N
even RB N
when WRB N
individual JJ N
serum NN N
to TO N
saliva VB N
ratios NNS N
have VBP N
been VBN N
established VBN N
, , N
the DT N
use NN N
of IN N
saliva JJ N
theophylline NN N
measurements NNS N
alone RB N
is VBZ N
unreliable JJ N
for IN N
the DT N
routine JJ N
monitoring NN N
of IN N
theophylline JJ N
therapy NN N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN i
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ i
solution NN i
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

Intervals NNS o
between IN o
calving VBG o
and CC o
first JJ o
oestrus NN o
, , o
first JJ o
insemination NN o
and CC o
conception NN o
, , o
the DT o
time NN o
of IN o
first JJ o
emergence NN o
of IN o
a DT o
dominant JJ o
follicle NN o
, , o
milk NN o
progesterone NN o
concentration NN o
, , o
and CC o
the DT o
diameter NN o
of IN o
the DT o
corpus NN o
luteum NN o
( ( o
CL NNP o
) ) o
in IN o
the DT o
first JJ o
luteal JJ o
phase NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
nutritional JJ i
supplement NN i
containing VBG i
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
C NNP i
and CC i
coenzyme JJ i
Q10 NNP i
on IN N
changes NNS N
in IN N
serum NN o
levels NNS o
of IN o
PSA NNP o
in IN N
patients NNS p
with IN p
hormonally RB p
untreated JJ p
carcinoma NN p
of IN p
the DT p
prostate NN p
and CC p
rising VBG p
serum NN p
PSA NNP p
levels NNS p
. . p

Although IN N
this DT N
test NN N
can MD N
evaluate VB N
their PRP$ N
physical JJ N
function NN N
using VBG N
movements NNS N
similar JJ N
to TO N
daily JJ N
activities NNS N
as IN N
compared VBN N
to TO N
MSL NNP i
, , N
it PRP N
has VBZ N
not RB N
been VBN N
clarified VBN N
whether IN N
it PRP N
can MD N
adequately RB N
evaluate VB N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
abilities NNS N
of IN N
the DT N
elderly JJ N
, , N
as IN N
they PRP N
decrease VBP N
with IN N
age NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
manualized JJ i
12-week JJ i
supportive-expressive JJ i
group NN i
therapy NN i
program NN i
among IN N
primary JJ p
breast NN p
cancer NN p
patients NNS p
treated VBN p
in IN p
community NN p
settings NNS p
, , p
to TO p
determine VB p
whether IN p
highly RB p
distressed JJ p
patients NNS p
were VBD N
most RBS N
likely JJ N
to TO N
benefit VB N
and CC N
whether IN N
therapist NN N
's POS N
training NN N
or CC N
experience NN N
was VBD N
related VBN N
to TO N
outcome VB N
. . N

Outcome NN N
parameters NNS N
such JJ N
as IN N
glycemic JJ o
control NN o
( ( o
HbA1c NNP o
) ) o
, , o
hypoglycemic JJ o
events NNS o
, , o
time NN o
and CC o
mode NN o
of IN o
delivery NN o
and CC o
labor NN o
results NNS o
( ( o
abortion NN o
, , o
premature NN o
labor NN o
, , o
perinatal JJ o
mortality NN o
, , o
neonatal JJ o
weight NN o
, , o
Apgar NNP o
score NN o
, , o
neonatal JJ o
hypoglycaemia NN o
, , o
presence NN o
of IN o
congenital JJ o
abnormalities NNS o
) ) o
were VBD N
analyzed VBN N
. . N

The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
no DT N
difference NN N
over IN N
the DT N
intervention NN N
year NN N
in IN N
the DT N
number NN N
of IN N
symptom JJ N
days NNS N
, , N
yet RB N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
fewer JJR N
days NNS N
of IN N
limited JJ N
activity NN N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
emergency NN o
department NN o
visits NNS o
by IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
controls NNS N
. . N

RESULTS NNP N
Adjusting NNP N
for IN N
ethnicity/language NN N
, , N
study NN N
center NN N
, , N
and CC N
the DT N
previsit NN N
value NN N
of IN N
the DT N
dependent NN N
variable NN N
, , N
compared VBN N
with IN N
control NN N
patients NNS N
, , N
the DT N
IMCP NNP i
led VBD N
to TO N
significantly RB N
greater JJR N
colorectal JJ o
cancer NN o
screening VBG o
knowledge NN o
, , o
self-efficacy NN o
, , o
readiness NN o
, , o
test NN o
preference NN o
specificity NN o
, , o
discussion NN o
, , o
and CC o
recommendation NN o
. . o

A DT N
communication-based JJ i
intervention NN i
for IN N
nonverbal JJ p
children NNS p
with IN p
autism NN p
: : p
what WP N
changes NNS N
? . N
Who WP N
benefits NNS N
? . N
OBJECTIVE IN N
This DT N
article NN N
examines VBZ N
the DT N
form NN N
and CC N
function NN N
of IN N
spontaneous JJ N
communication NN N
and CC N
outcome NN N
predictors NNS N
in IN N
nonverbal JJ p
children NNS p
with IN p
autism NN p
following VBG p
classroom-based JJ i
intervention NN i
( ( i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
training NN i
) ) i
. . i

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
oxytocin NN i
enhances VBZ N
the DT N
ability NN o
to TO o
understand VB o
others NNS o
' POS o
social JJ o
emotions NNS o
that WDT N
have VBP N
also RB N
required VBN N
second-order NN N
false JJ N
belief NN N
rather RB N
than IN N
first-order JJ N
false JJ N
beliefs NNS N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
in IN N
autism NN N
spectrum NN N
disorder NN N
at IN N
both DT N
the DT N
behaviour NN N
and CC N
neural JJ N
levels NNS N
. . N

These DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT N
conventional JJ i
group NN i
, , i
in IN i
which WDT i
capillary JJ i
measurement NN i
and CC i
recording NN i
as RB i
well RB i
as IN i
insulin NN i
adjustment NN i
were VBD i
made VBN i
every DT i
4h CD i
, , i
and CC i
an DT i
intervention NN i
group NN i
, , i
in IN i
which WDT i
measurement NN i
and CC i
recording NN i
as RB i
well RB i
as IN i
insulin NN i
adjustment NN i
were VBD i
made VBN i
every DT i
hour NN i
with IN i
a DT i
subcutaneous JJ i
continuous JJ i
monitoring NN i
system NN i
. . i

BACKGROUND IN N
The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
program NN N
of IN N
cooperation NN N
between IN N
physician NN N
and CC N
pharmacist NN N
to TO N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
by IN N
promoting VBG N
better JJR N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
control NN N
, , N
appropriate JJ N
changes NNS N
in IN N
antihypertensive JJ N
medications NNS N
, , N
and CC N
beneficial JJ N
changes NNS N
in IN N
lifestyle NN N
. . N

BACKGROUND NN N
It PRP N
has VBZ N
been VBN N
postulated VBN N
from IN N
virologic JJ N
studies NNS N
that WDT N
herpesvirus VBP N
infection NN N
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
progression NN N
of IN N
MS. NNP N
METHODS NNP N
Patients NNPS p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
if IN p
they PRP p
had VBD p
had VBN p
two CD p
or CC p
more JJR p
MS JJ p
relapses NNS p
in IN p
the DT p
2-year JJ p
period NN p
before IN p
enrollment NN p
. . p

This DT N
study NN N
investigated VBD N
the DT N
utility NN N
and CC N
validity NN N
of IN N
clinician-rated JJ N
global JJ N
functioning NN N
using VBG N
the DT N
Developmental NNP N
Disability-Child NNP N
Global NNP N
Assessment NNP N
Scale NNP N
in IN N
a DT N
sample NN p
of IN p
higher JJR p
functioning NN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
comorbid NN p
anxiety NN p
disorders NNS p
enrolled VBD p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
. . p

OBJECTIVES NNP N
In IN N
comparison NN N
with IN N
usual JJ i
care NN i
( ( i
UC NNP i
) ) i
, , N
to TO N
assess VB N
the DT N
impact NN N
of IN N
GP-led NNP i
telephone NN i
triage NN i
( ( i
GPT NNP i
) ) i
and CC i
nurse-led JJ i
computer-supported JJ i
telephone NN i
triage NN i
( ( i
NT NNP i
) ) i
on IN N
primary JJ N
care NN N
workload NN N
and CC N
cost NN N
, , N
patient JJ N
experience NN N
of IN N
care NN N
, , N
and CC N
patient JJ N
safety NN N
and CC N
health NN N
status NN N
for IN N
patients NNS p
requesting VBG p
same-day JJ p
consultations NNS p
in IN p
general JJ p
practice NN p
. . p

Dietary NNP i
sulforaphane NN i
, , N
of IN N
recognized VBN N
low JJ N
toxicity NN N
, , N
was VBD N
selected VBN N
for IN N
its PRP$ N
capacity NN N
to TO N
reverse VB N
abnormalities NNS N
that WDT N
have VBP N
been VBN N
associated VBN N
with IN N
ASD NNP N
, , N
including VBG N
oxidative JJ o
stress NN o
and CC o
lower JJR o
antioxidant NN o
capacity NN o
, , o
depressed VBD o
glutathione NN o
synthesis NN o
, , o
reduced VBN o
mitochondrial JJ o
function NN o
and CC o
oxidative JJ o
phosphorylation NN o
, , o
increased VBD o
lipid JJ o
peroxidation NN o
, , o
and CC o
neuroinflammmation NN o
. . o

Analyses NNS N
reveal VBP N
that IN N
olanzapine NN N
shows VBZ N
a DT N
greater JJR N
clinical JJ o
cost NN o
effectiveness NN o
, , N
as RB N
well RB N
as IN N
a DT N
greater JJR N
functional JJ o
cost NN o
effectiveness NN o
, , N
than IN N
haloperidol NN i
, , N
and CC N
that IN N
functional JJ N
outcomes NNS N
, , N
in IN N
particular JJ N
, , N
show VBP N
promise NN N
as IN N
important JJ N
measures NNS N
of IN N
effectiveness NN N
. . N

By IN N
exploiting VBG N
the DT N
long JJ N
integration NN o
time NN o
of IN o
noisy JJ o
motion NN o
stimuli NN o
, , N
and CC N
by IN N
forcing VBG N
human JJ N
observers NNS N
to TO N
make VB N
difficult JJ N
speeded VBN N
decisions NNS N
-- : N
sometimes RB N
a DT N
blind JJ N
guess NN N
-- : N
about IN N
stimulus JJ N
direction NN N
, , N
we PRP N
traced VBD N
the DT N
temporal JJ N
buildup NN N
of IN N
motion NN N
discrimination NN N
capability NN N
and CC N
perceptual JJ N
awareness NN N
, , N
as IN N
assessed VBN N
trial NN N
by IN N
trial NN N
through IN N
direct JJ N
rating NN N
. . N

CONCLUSIONS NNP N
Although IN N
this DT N
multicenter NN N
RCT NNP N
was VBD N
conducted VBN N
in IN N
a DT N
strict JJ N
setting NN N
, , N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ N
PD NNP N
did VBD N
not RB N
benefit VB N
long-term JJ N
survival NN N
in IN N
patients NNS p
with IN p
resectable JJ p
pancreatic JJ p
head NN p
cancer NN p
and CC N
led VBD N
to TO N
levels NNS N
of IN N
morbidity NN o
, , o
mortality NN o
and CC o
quality NN o
of IN o
life NN o
comparable JJ N
to TO N
those DT N
found VBN N
after IN N
standard JJ N
lymphadenectomy NN N
. . N

Further JJ N
analysis NN N
( ( N
Manetl-Naenszel NNP N
test NN N
) ) N
showed VBD N
the DT N
over-all JJ N
difference NN N
in IN N
outcome NN N
to TO N
be VB N
significant JJ N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
, , N
but CC N
the DT N
general JJ N
applicability NN N
of IN N
this DT N
result NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
rather RB N
low JJ N
incidence NN N
of IN N
gram-negative JJ N
bacterial JJ N
infections NNS N
in IN N
this DT N
study NN N
. . N

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN o
ratio NN o
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN N
II NNP N
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS N
IX NNP N
and CC N
X NNP N
showed VBD N
little JJ N
response NN N
. . N

Since IN N
GABAA-mediated NNP N
intracortical JJ N
inhibition NN N
has VBZ N
been VBN N
shown VBN N
to TO N
underlie VB N
plastic NN N
changes NNS N
throughout IN N
the DT N
lifespan NN N
from IN N
development NN N
to TO N
aging VBG N
, , N
here RB N
, , N
the DT N
aging VBG N
motor NN N
system NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
analyze VB N
the DT N
interdependence NN N
of IN N
plastic JJ N
alterations NNS N
within IN N
the DT N
inhibitory JJ N
motorcortical JJ N
network NN N
and CC N
level NN N
of IN N
behavioral JJ N
performance NN N
. . N

BACKGROUND NNP N
Although IN N
some DT N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
pharmacist JJ N
intervention NN N
can MD N
improve VB N
drug NN N
therapy NN N
among IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
( ( p
CVD NNP p
) ) p
, , N
more JJR N
evidence NN N
derived VBN N
from IN N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCTs NNP N
) ) N
is VBZ N
needed VBN N
, , N
including VBG N
assessment NN N
of IN N
the DT N
effect NN N
of IN N
community NN N
pharmacist NN N
interventions NNS N
in IN N
patients NNS p
with IN p
CVD NNP p
. . p

Given VBN N
preclinical JJ N
studies NNS N
revealing VBG N
the DT N
role NN N
of IN N
the DT N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
human JJ p
appetite NN p
and CC p
the DT p
potential NN p
of IN p
antipsychotic JJ p
medications NNS p
to TO N
interfere VB N
with IN N
this DT N
system NN N
, , N
we PRP N
hypothesized VBD N
that IN N
opioid JJ N
antagonists NNS N
may MD N
be VB N
beneficial JJ N
in IN N
arresting VBG N
antipsychotic-associated JJ N
weight NN N
gain NN N
and CC N
promoting VBG N
further JJ N
weight JJ N
loss NN N
in IN N
women NNS p
with IN p
schizophrenia NN p
. . p

HDPM NNP i
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN N
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN i
oxide NN i
was VBD N
ineffective JJ N
in IN N
ameliorating VBG o
autistic JJ o
behaviors NNS o
as IN N
assessed VBN N
by IN N
the DT N
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
, , o
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
Scale NNP o
, , o
and CC o
the DT o
NIMH NNP o
Global NNP o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
. . o

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
bowel NN N
preparation NN N
protocols NNS N
based VBN N
on IN N
a DT N
low JJ i
residue JJ i
diet NN i
and CC i
4L CD i
polyethylene NN i
glycol NN i
( ( i
PEG NNP i
) ) i
solution NN i
, , i
and CC i
to TO i
compare VB i
these DT i
new JJ i
options NNS i
with IN i
the DT i
traditional JJ i
liquid NN i
diet NN i
and CC i
the DT i
PEG NNP i
4L CD i
lavage NN i
. . i

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
The DT N
aim NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
fatty JJ i
fish NN i
and CC i
lean JJ i
( ( i
white JJ i
) ) i
fish NN i
on IN N
fatty JJ N
acid JJ N
composition NN N
of IN N
serum NN N
lipids NNS N
and CC N
cardiovascular JJ N
risk NN N
factors NNS N
in IN N
subjects NNS p
with IN p
CHD NNP p
using VBG p
multiple JJ p
drugs NNS p
for IN p
this DT p
condition NN p
. . p

Endpoint NN N
analysis NN N
revealed VBD N
no DT N
significant JJ N
differences NNS N
across IN N
treatment NN N
groups NNS N
on IN N
a DT N
modified JJ o
global JJ o
improvement NN o
scale NN o
( ( o
validated VBN o
in IN o
irritable JJ o
bowel NN o
syndrome JJ o
studies NNS o
) ) o
, , o
number NN o
of IN o
daily JJ o
bowel NN o
movements NNS o
, , o
days NNS o
of IN o
constipation NN o
, , o
or CC o
severity NN o
of IN o
problem NN o
behaviors NNS o
. . o

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ i
oxygen NN i
therapy NN i
plus CC i
standard NN i
wound NN i
care NN i
compared VBN N
with IN N
standard NN N
wound NN N
care NN N
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ N
amputation NN N
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
and CC p
chronic JJ p
ulcers NNS p
of IN p
the DT p
lower JJR p
limb NN p
. . p

To TO N
investigate VB N
whether IN N
sensorimotor NN N
control NN N
of IN N
the DT N
hand NN N
could MD N
be VB N
an DT N
outcome NN N
indicator NN N
after IN N
carpal JJ N
tunnel NN N
release NN N
( ( N
CTR NNP N
) ) N
, , N
this DT N
work NN N
examined VBD N
changes NNS N
in IN N
the DT N
results NNS N
of IN N
patients NNS N
' POS N
manual JJ N
tactile NN o
test NN o
( ( o
MTT NNP o
) ) o
, , o
pinch-holding-up JJ o
activity NN o
( ( o
PHUA NNP o
) ) o
, , o
two-point JJ o
discrimination NN o
( ( o
2PD CD o
) ) o
and CC o
Semmes-Weinstein JJ o
monofilament NN o
( ( o
SWM NNP o
) ) o
tests NNS o
. . o

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
by IN N
using VBG N
urn JJ N
design NN N
method NN N
either DT N
to TO N
receive VB N
the DT N
usual JJ i
care NN i
that WDT i
followed VBD i
in IN i
the DT i
clinics NNS i
( ( i
control NN i
) ) i
or CC i
the DT i
usual JJ i
care NN i
procedure NN i
plus CC i
extra JJ i
counselling NN i
sessions NNS i
through IN i
phone NN i
calls NNS i
during IN i
the DT i
first JJ i
month NN i
of IN i
quit NN i
attempt NN i
( ( i
intervention NN i
) ) i
. . i

While IN N
there EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
in IN N
sex NN o
, , o
age NN o
, , o
intellectual JJ o
disability NN o
, , o
language NN o
level NN o
, , o
or CC o
baseline VB o
ADHD NNP o
symptoms NNS o
, , o
autistic JJ o
symptoms NNS o
tended VBD N
to TO N
be VB N
more RBR N
prevalent JJ N
in IN N
the DT N
IED NNP N
group NN N
( ( N
according VBG N
to TO N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule-2 NNP N
criteria NNS N
) ) N
. . N

After IN N
discharge NN N
, , N
study NN N
controls NNS N
received VBD N
usual JJ i
care NN i
( ( i
sporadic JJ i
rehabilitation NN i
) ) i
, , N
whereas JJ N
intervention NN N
patients NNS N
received VBD N
a DT N
combination NN N
of IN N
in-home JJ i
cognitive NN i
, , i
physical JJ i
, , i
and CC i
functional JJ i
rehabilitation NN i
over IN i
a DT i
3-month JJ i
period NN i
via IN i
a DT i
social JJ i
worker NN i
or CC i
master NN i
's POS i
level NN i
psychology NN i
technician JJ i
utilizing JJ i
telemedicine NN i
to TO N
allow VB N
specialized JJ N
multidisciplinary JJ N
treatment NN N
. . N

Nevertheless RB N
, , N
DBT NNP i
showed VBD N
significant JJ N
benefits NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
of IN N
improved JJ N
disability NN o
and CC o
quality NN o
of IN o
life NN o
scores NNS o
, , N
a DT N
clinically RB N
useful JJ N
result NN N
that WDT N
is VBZ N
also RB N
in IN N
keeping VBG N
with IN N
the DT N
theoretical JJ N
constructs NNS N
of IN N
the DT N
benefits NNS N
of IN N
DBT NNP N
. . N

OBJECTIVE IN N
This DT N
exploratory NN N
study NN N
focuses VBZ N
on IN N
the DT N
mental JJ i
health NN i
( ( i
MH NNP i
) ) i
and CC i
caregiving VBG i
experience NN p
of IN p
carers NNS p
of IN p
adolescents NNS p
with IN p
Bulimia NNP p
Nervosa NNP p
( ( p
BN NNP p
) ) p
/Eating VBG p
Disorder NNP p
not RB p
otherwise RB p
specified VBN p
( ( p
EDNOS NNP p
) ) p
, , N
aiming VBG N
to TO N
determine VB N
: : N
levels NNS N
of IN N
MH NNP N
problems NNS N
in IN N
carers NNS N
and CC N
if IN N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
predicts NNS N
carer VBP N
MH NNP N
status NN N
and CC N
which WDT N
factors NNS N
predict VBP N
a DT N
negative JJ N
experience NN N
of IN N
caregiving NN N
. . N

If IN N
people NNS N
are VBP N
indeed RB N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
these DT N
kinds NNS N
of IN N
outcomes NNS N
, , N
then RB N
lowering VBG N
behavioral JJ N
inhibition NN N
by IN N
reminding VBG N
people NNS N
of IN N
having VBG N
acted VBN N
in IN N
the DT N
past NN N
without IN N
inhibitions NNS N
( ( N
in IN N
a DT N
manner NN N
that WDT N
is VBZ N
unrelated JJ N
to TO N
the DT N
outcomes NNS N
participants NNS N
subsequently RB N
receive VBP N
) ) N
should MD N
affect VB N
reactions NNS N
to TO N
the DT N
outcomes NNS N
. . N

The DT N
primary JJ N
outcome NN N
, , N
knowledge NN o
of IN o
benefits NNS o
and CC o
harms NNS o
of IN o
screening NN o
, , o
and CC o
secondary JJ o
outcomes NNS o
, , o
informed VBN o
choice NN o
( ( o
composite JJ o
of IN o
knowledge NN o
, , o
values NNS o
and CC o
intention NN o
) ) o
, , o
anxiety NN o
and CC o
acceptability NN o
of IN o
the DT o
DA NNP o
were VBD o
measured VBN o
using VBG o
online JJ o
questionnaires NNS o
. . o

Investigators NNS N
examined VBD N
the DT N
6-month JJ N
impact NN N
of IN N
three CD N
cognitive-behavioral JJ i
HIV NNP i
risk-reduction NN i
programs NNS i
on IN N
behavioral JJ o
factors NNS o
( ( o
substance NN o
use NN o
and CC o
sexual JJ o
risk NN o
behaviors NNS o
) ) o
and CC o
cognitive JJ o
and CC o
psychological JJ o
resources NNS o
of IN N
325 CD p
women NNS p
who WP p
resided VBD p
in IN p
emergency NN p
or CC p
sober-living NN p
shelters NNS p
and CC p
their PRP$ p
308 CD p
intimate JJ p
sexual JJ p
partners NNS p
. . p

An DT N
alternative JJ N
stepwise NN N
model NN N
selection NN N
process NN N
including VBG N
all DT N
fever-related JJ N
measures NNS N
from IN N
the DT N
preoperative NN N
and CC N
intraoperative JJ N
period NN N
( ( N
e.g JJ N
, , N
hydrocephalus JJ N
, , N
duration NN N
of IN N
surgery NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
) ) N
resulted VBD N
in IN N
the DT N
loss NN N
of IN N
significance NN N
for IN N
dichotomized JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
, , N
but CC N
significant JJ N
associations NNS N
between IN N
fever NN N
and CC N
several JJ N
other JJ N
outcome JJ N
measures NNS N
remained VBD N
. . N

DISCUSSION NN N
This DT N
study NN N
has VBZ N
the DT N
potential NN N
to TO N
determine VB N
whether IN N
outpatient JJ i
movement NN i
strategy NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
or CC i
progressive JJ i
resistance NN i
strength NN i
training NN i
combined VBN i
with IN i
falls NNS i
prevention JJ i
education NN i
are VBP N
effective JJ N
for IN N
reducing VBG N
falls NNS o
and CC o
improving VBG o
mobility NN o
and CC o
life NN o
quality NN o
in IN N
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
who WP p
live VBP p
at IN p
home NN p
. . p

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
the DT N
Dader NNP N
Method NNP N
for IN N
pharmaceutical JJ N
care NN N
on IN N
achieving VBG N
therapeutic JJ N
goals NNS N
for IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
and CC o
both DT o
BP NNP o
and CC o
TC NNP o
( ( o
BP/TC NNP o
) ) o
in IN N
patients NNS p
with IN p
CVD NNP p
and/or VBP p
high JJ p
or CC p
intermediate JJ p
cardiovascular NN p
( ( p
CV NNP p
) ) p
risk NN p
attending VBG p
community NN p
pharmacies NNS p
in IN p
Spain NNP p
. . p

CONCLUSIONS NN N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

CONCLUSION NNP N
Orally NNP N
administered VBD N
misoprostol NN i
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ o
blood NN o
loss NN o
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN o
effects NNS o
. . o

OBJECTIVE IN N
The DT N
authors NNS N
designed VBD N
a DT N
small JJ N
semi-randomized JJ N
clinical JJ N
trial NN N
to TO N
explore VB N
whether IN N
long-lasting JJ N
clinically RB N
important JJ N
gains NNS N
can MD N
be VB N
achieved VBN N
by IN N
adding VBG N
theta JJ i
burst JJ i
stimulation NN i
( ( i
TBS NNP i
) ) i
, , i
a DT i
form NN i
of IN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
TMS NNP i
) ) i
, , N
to TO N
a DT N
rehabilitation NN N
program NN N
for IN N
the DT N
hand NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
behavioral JJ i
plus CC i
nutrition JJ i
education NN i
intervention NN i
, , N
Be NNP N
In IN N
CHARGE NNP N
! . N
, , N
compared VBN N
with IN N
that DT N
of IN N
a DT N
nutrition NN i
education NN i
intervention NN i
alone RB i
on IN N
caloric JJ N
intake NN N
and CC N
weight JJ N
gain NN N
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
and CC p
pancreatic JJ p
insufficiency NN p
. . p

Although IN N
various JJ N
pharmaceutical JJ N
agents NNS N
are VBP N
available JJ N
for IN N
the DT N
treatment NN N
of IN N
obsessive-compulsive JJ N
disorder NN N
, , N
psychiatrists NNS N
often RB N
find VBP N
that IN N
many JJ N
patients NNS N
can MD N
not RB N
tolerate VB N
the DT N
side NN N
effects NNS N
of IN N
these DT N
medications NNS N
, , N
the DT N
patients NNS N
do VBP N
not RB N
respond VB N
properly RB N
to TO N
the DT N
treatment NN N
, , N
or CC N
the DT N
medications NNS N
lose VBP N
their PRP$ N
effectiveness NN N
after IN N
a DT N
period NN N
of IN N
treatment NN N
. . N

On IN N
the DT N
contrary JJ N
, , N
naltrexone RB i
increased VBD N
the DT N
incidence NN N
of IN N
stereotypic JJ N
behavior NN N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
and CC o
the DT o
care NN o
staff NN o
evaluated VBD N
the DT N
effect NN N
of IN N
the DT N
50-mg/d JJ N
treatment NN N
as IN N
being VBG N
significantly RB N
worse JJR N
than IN N
that DT N
of IN N
the DT N
placebo NN i
treatment NN N
as IN N
measured VBN N
by IN N
the DT N
Clinical NNP o
Global NNP o
Impression NNP o
Scale NNP o
. . o

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
having VBG N
studied VBN N
the DT N
particular JJ N
mechanism NN N
of IN N
action NN N
of IN N
propionyl-L-carnitine NN N
the DT N
authors NNS N
conclude VBP N
that IN N
it PRP N
represents VBZ N
a DT N
drug NN N
of IN N
undoubted JJ N
therapeutic JJ N
interest NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
, , N
in IN N
whom WP N
it PRP N
could MD N
be VB N
efficaciously RB N
administered VBN N
along IN N
with IN N
a DT N
standard JJ N
pharmacological JJ N
therapy NN N
. . N

The DT N
achievement NN N
of IN N
learning VBG N
objectives NNS N
was VBD N
predicted VBN N
by IN N
caregiver NN N
factors NNS N
, , N
such JJ N
as IN N
education NN N
, , N
presence NN N
of IN N
father NN N
or CC N
surrogate VB N
father NN N
in IN N
the DT N
household NN N
, , N
and CC N
safety NN N
of IN N
the DT N
neighborhood NN N
, , N
but CC N
not RB N
by IN N
child JJ N
factors NNS N
, , N
such JJ N
as IN N
age NN N
or CC N
severity NN N
of IN N
asthma NN N
as IN N
implied VBN N
by IN N
the DT N
prescribed JJ N
asthma JJ N
medication NN N
regimen NNS N
. . N

Recently RB N
, , N
a DT N
new JJ N
form NN N
of IN N
treatment NN N
based VBN N
on IN N
porphobilinogen NN i
deaminase NN i
enzyme JJ i
replacement NN i
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
an DT N
acute JJ N
intermittent NN N
porphyria NN N
mouse NN N
model NN N
which WDT N
, , N
during IN N
phenobarbital JJ N
( ( N
phenobarbitone NN N
) ) N
induction NN N
of IN N
haem JJ N
biosynthesis NN N
, , N
mimics VBZ N
the DT N
biochemical JJ N
pattern NN N
of IN N
acute JJ N
porphyric JJ N
attacks NNS N
. . N

Taken VBN N
together RB N
, , N
this DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
that IN N
the DT N
perceived VBN N
hedonic JJ N
value NN N
of IN N
human JJ N
heterosexual JJ N
interpersonal JJ N
touch NN N
is VBZ N
facilitated VBN N
by IN N
OXT NNP N
in IN N
men NNS N
, , N
but CC N
that IN N
its PRP$ N
behavioral JJ N
and CC N
neural JJ N
effects NNS N
in IN N
this DT N
context NN N
are VBP N
blunted VBN N
in IN N
individuals NNS p
with IN p
autistic JJ p
traits NNS p
. . p

In IN N
the DT N
placebo NN N
group NN N
, , N
a DT N
significant JJ N
deterioration NN N
of IN N
the DT N
indices NNS N
, , N
with IN N
the DT N
exception NN N
of IN N
Valsalva NNP N
ratio NN N
, , N
was VBD N
recorded VBN N
, , N
while IN N
tolrestat NN N
induced VBD N
a DT N
significant JJ N
beneficial JJ N
change NN N
in IN N
the DT N
values NNS N
of IN N
most JJS N
standard JJ N
cardiovascular JJ N
reflex NN N
tests NNS N
, , N
in IN N
comparison NN N
to TO N
baseline VB N
and CC N
placebo VB N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
fibromyalgia JJ o
severity NN o
, , o
pain NN o
interference NN o
, , o
sleep JJ o
quality NN o
, , o
pain VBP o
coping VBG o
strategies NNS o
, , o
depression NN o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
, , o
patient JJ o
global JJ o
impression NN o
of IN o
change NN o
( ( o
PGIC NNP o
) ) o
, , o
and CC o
perceived VBD o
pain NN o
relief NN o
. . o

This DT N
study NN N
evaluates VBZ N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
package NN N
including VBG N
a DT N
discrete JJ N
trial NN N
program NN i
( ( i
Rapid NNP i
Motor NNP i
Imitation NNP i
Antecedent NNP i
Training NNP i
( ( i
Tsiouri NNP i
and CC i
Greer NNP i
, , i
J NNP i
Behav NNP i
Educat NNP i
12:185-206 CD i
, , i
2003 CD i
) ) i
combined VBN i
with IN i
parent NN i
education NN i
for IN N
eliciting VBG N
first JJ N
words NNS N
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
had VBD p
little JJ p
or CC p
no DT p
spoken JJ p
language NN p
. . p

BACKGROUND NNP N
Coronary NNP i
artery NN i
bypass NN i
graft NN i
( ( i
CABG NNP i
) ) i
surgery NN i
is VBZ N
effective JJ N
in IN N
relieving VBG N
angina NN N
and CC N
improving VBG N
survival NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
obstructive JJ p
coronary JJ p
artery NN p
disease NN p
; : p
however RB N
, , N
recurrent JJ N
angina NN N
, , N
myocardial JJ N
infarction NN N
, , N
neurological JJ N
injury NN N
, , N
and CC N
death NN N
can MD N
occur VB N
in IN N
the DT N
perioperative NN N
and CC N
postoperative JJ N
period NN N
. . N

Secondary JJ N
analyses NNS N
revealed VBD N
that IN N
the DT N
WSTP NNP i
had VBD N
greater JJR N
effects NNS N
on IN N
confidence NN o
in IN o
areas NNS o
related VBN o
to TO o
maneuvering VBG o
around IN o
the DT o
physical JJ o
environment NN o
, , o
knowledge NN o
and CC o
problem NN o
solving NN o
, , o
advocacy NN o
, , o
and CC o
managing VBG o
emotions NNS o
than IN o
in IN o
areas NNS o
related VBN o
to TO o
performing VBG o
activities NNS o
and CC o
behaving VBG o
in IN o
social JJ o
situations NNS o
. . o

Six CD N
of IN N
the DT N
seven CD N
secondary JJ N
efficacy NN o
measures NNS o
( ( o
total JJ o
comedones NNS o
, , o
open JJ o
comedones NNS o
, , o
closed VBD o
comedones NNS o
, , o
papules NNS o
, , o
pustules NNS o
, , o
and CC o
the DT o
subject NN o
's POS o
self-assessment NN o
of IN o
study NN o
treatment NN o
) ) o
were VBD N
also RB N
significantly RB N
more RBR N
favorable JJ N
in IN N
the DT N
OC NNP N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
most RBS N
salient JJ N
feature NN N
in IN N
the DT N
verum NN N
group NN N
was VBD N
a DT N
drastic JJ N
increase NN N
in IN N
the DT N
absolute JJ o
number NN o
of IN o
immunocompetent JJ o
cells NNS o
, , N
with IN N
an DT N
especially RB N
pronounced JJ N
effect NN N
on IN N
T NNP o
lymphocytes NNS o
, , N
predominantly RB N
of IN N
the DT N
helper/inducer NN N
type NN N
, , N
but CC N
also RB N
on IN N
cytotoxic NN o
and CC o
natural JJ o
killer NN o
cells NNS o
. . o

Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ o
leakage NN o
, , o
local JJ o
and CC o
systemic JJ o
inflammation NN o
, , o
( ( o
aspiration NN o
) ) o
pneumonia NN o
, , o
surgical JJ o
complications NNS o
classified VBD o
according VBG o
to TO o
Clavien-Dindo NNP o
, , o
quality NN o
of IN o
life NN o
, , o
gut FW o
barrier JJR o
integrity NN o
and CC o
time NN o
until IN o
functional JJ o
recovery NN o
. . o

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
: : p
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN N
observation NN N
treatment NN N
( ( N
AOT NNP N
) ) N
may MD N
also RB N
improve VB N
motor NN o
recovery NN o
in IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
, , N
in IN N
addition NN N
to TO N
conventional JJ i
physiotherapy NN i
. . i

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP N
analogue NN N
to TO N
females NNS N
with IN N
myomas NN N
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN o
genes NNS o
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN o
and CC o
leptin NN o
levels NNS o
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
dialysis NN i
with IN N
polyamide JJ N
membranes NNS N
with IN N
different JJ N
flux NN N
characteristics NNS N
did VBD N
not RB N
modify VB N
the DT N
inflammatory NN o
indices NNS o
and CC o
lipid JJ o
profile NN o
in IN N
stable JJ N
HD NNP N
patients NNS N
; : N
however RB N
, , N
a DT N
seemingly RB N
beneficial JJ o
effect NN o
on IN o
aortic JJ o
stiffness NN o
was VBD N
noted VBN N
for IN N
patients NNS N
who WP N
were VBD N
maintained VBN N
on IN N
high-flux JJ N
polyamide NN N
membrane NN N
. . N

In IN N
the DT N
current JJ N
article NN N
, , N
we PRP N
address VBP N
the DT N
existing VBG N
assumption NN N
in IN N
the DT N
literature NN N
on IN N
cognitive JJ N
behavioral JJ N
treatment NN N
of IN N
PTSD NNP N
that IN N
patients NNS N
with IN N
severe JJ N
negative JJ N
trauma-related JJ N
cognitions NNS N
would MD N
benefit VB N
more RBR N
from IN N
a DT N
treatment NN N
package NN N
that WDT N
includes VBZ N
exposure NN N
and CC N
cognitive JJ N
techniques NNS N
compared VBN N
with IN N
a DT N
treatment NN N
that WDT N
includes VBZ N
exposure NN N
only RB N
. . N

INTRODUCTION NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
low-intensity JJ i
resistance NN i
training NN i
program NN i
combined VBN i
with IN i
partial JJ i
blow NN i
flow NN i
restriction NN i
( ( i
BFR NNP i
training NN i
) ) i
in IN N
a DT N
cohort NN N
of IN N
patients NNS p
with IN p
polymyositis NN p
( ( p
PM NNP p
) ) p
and CC p
dermatomyositis NN p
( ( p
DM NNP p
) ) p
. . p

Changes NNS N
in IN N
motor NN N
cortex NN N
excitability NN N
associated VBN N
with IN N
temporal JJ i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
tinnitus NN p
: : p
hints NNS N
for IN N
cross-modal JJ N
plasticity NN N
? . N
BACKGROUND NNP N
Motor NNP N
cortex VBP N
excitability NN N
was VBD N
found VBN N
to TO N
be VB N
changed VBN N
after IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
of IN N
the DT N
temporal JJ N
cortex NN N
highlighting VBG N
the DT N
occurrence NN N
of IN N
cross-modal JJ N
plasticity NN N
in IN N
non-invasive JJ N
brain NN N
stimulation NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
Cavitron NNP i
ultrasonic JJ i
surgical JJ i
aspirator NN i
( ( i
CUSA NNP i
) ) i
with IN i
bipolar JJ i
cautery NN i
( ( i
BP NNP i
) ) i
to TO i
CUSA NNP i
with IN i
a DT i
radiofrequency NN i
coagulator NN i
[ NN i
TissueLink NNP i
( ( i
TL NNP i
) ) i
] VBP i
in IN N
terms NNS N
of IN N
efficacy NN N
and CC N
safety NN N
for IN N
hepatic JJ N
transection NN N
in IN N
living VBG p
donor NN p
liver JJ p
transplantation NN p
. . p

The DT N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
Asha-Life NNP i
intervention NN i
engaging VBG N
with IN N
an DT N
HIV-trained JJ N
village NN N
woman NN N
, , N
Asha NNP i
( ( i
Accredited NNP i
Social NNP i
Health NNP i
Activist NNP i
) ) i
, , N
to TO N
participate VB N
in IN N
the DT N
care NN N
of IN N
women NNS N
living VBG N
with IN N
AIDS NNP N
( ( N
WLA NNP N
) ) N
, , N
along IN N
with IN N
other JJ N
health NN N
care NN N
providers NNS N
compared VBN N
to TO N
a DT N
Usual NNP N
Care NNP N
group NN N
. . N

The DT N
overall JJ N
main JJ N
reason NN N
for IN N
sunbathing NN N
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

To TO N
test VB N
elements NNS N
of IN N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
measured VBN N
blood NN N
levels NNS N
of IN N
dietary JJ N
antioxidants NNS N
, , N
and CC N
8-oxodeoxyguanosine JJ N
( ( N
8-oxo-dG JJ N
) ) N
concentrations NNS N
in IN N
lymphocyte NN N
DNA NN N
, , N
in IN N
healthy JJ p
men NNS p
and CC p
women NNS p
from IN p
five CD p
European JJ p
countries NNS p
: : p
France NNP p
, , p
Ireland NNP p
, , p
The DT p
Netherlands NNP p
, , p
Spain NNP p
, , p
and CC p
the DT p
U.K NNP p
. . p

Unlike IN N
other JJ N
sedatives NNS N
and CC N
anesthetics NNS N
, , N
the DT N
concentration-dependence NN N
of IN N
clonidine NN N
demonstrates VBZ N
a DT N
ceiling NN N
beyond IN N
which WDT N
the DT N
administration NN N
of IN N
an DT N
additional JJ N
drug NN N
fails NNS N
to TO N
enhance VB N
the DT N
effect NN N
, , N
suggesting VBG N
that IN N
the DT N
thermoregulatory JJ N
effect NN N
of IN N
clonidine NN N
may MD N
be VB N
limited VBN N
, , N
even RB N
at IN N
high JJ N
plasma NN N
concentrations NNS N
. . N

INTERPRETATION NNP N
AND NNP N
CONCLUSIONS NNP N
Increasing VBG N
the DT N
dose NN N
of IN N
G-CSF NNP i
does VBZ N
not RB N
appear VB N
to TO N
reduce VB N
early JJ N
deaths NNS N
, , N
does VBZ N
not RB N
improve VB N
peripheral JJ o
blood NN o
counts NNS o
nor CC o
survival NN o
, , N
and CC N
may MD N
reduce VB N
the DT N
response NN o
rate NN o
in IN N
patients NNS p
with IN p
SAA NNP p
receiving VBG p
ALG NNP p
and CC p
CyA NNP p
. . p

Only RB N
14 CD N
% NN N
of IN N
youth NN p
with IN p
ASD NNP p
had VBD N
a DT N
discussion NN N
with IN N
their PRP$ N
pediatrician JJ N
about IN N
transitioning VBG N
to TO N
an DT N
adult NN N
provider NN N
, , N
less JJR N
than IN N
a DT N
quarter NN N
had VBD N
a DT N
discussion NN N
about IN N
health NN o
insurance NN o
retention NN o
, , N
and CC N
just RB N
under IN N
half NN N
discussed VBN N
adult NN N
health NN N
care NN N
needs NNS N
or CC N
were VBD N
encouraged VBN N
to TO N
take VB N
on IN N
appropriate JJ N
responsibility NN N
. . N

The DT N
present JJ N
study NN N
aims NNS N
to TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
traditional JJ i
Chinese JJ i
Chan-based JJ i
mind-body NN i
exercise NN i
, , i
Nei NNP i
Yang NNP i
Gong NNP i
, , i
with IN i
that DT i
of IN i
the DT i
conventional JJ i
Progressive NNP i
Muscle NNP i
Relaxation NNP i
( ( i
PMR NNP i
) ) i
technique NN i
in IN N
enhancing VBG N
the DT N
self-control NN N
of IN N
children NNS p
with IN p
ASD NNP p
. . p

In IN N
terms NNS N
of IN N
advancement NN N
of IN N
prostate NN N
cancer NN N
care NN N
, , N
we PRP N
expect VBP N
dissemination NN N
of IN N
the DT N
knowledge NN N
gained VBN N
from IN N
this DT N
project NN N
to TO N
reduce VB N
fracture NN o
risk NN o
, , o
improve VB o
physical JJ o
and CC o
functional JJ o
ability NN o
, , o
quality NN o
of IN o
life NN o
and CC o
ultimately RB o
survival JJ o
rate NN o
in IN N
this DT N
population NN N
. . N

A DT N
cross-over JJ N
design NN N
was VBD N
used VBN N
to TO N
answer VB N
the DT N
following JJ N
research NN N
questions NNS N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
virtual JJ i
reality NN i
an DT i
effective JJ i
distraction NN i
intervention NN i
for IN N
reducing VBG N
chemotherapy-related JJ o
symptom NN o
distress NN o
levels NNS o
in IN N
older JJR p
women NNS p
with IN p
breast NN p
cancer NN p
? . N
( ( N
2 CD N
) ) N
Does NNP N
virtual JJ N
reality NN N
have VBP N
a DT N
lasting JJ N
effect NN N
? . N
Chemotherapy NN N
treatments NNS N
are VBP N
intensive JJ N
and CC N
difficult JJ N
to TO N
endure VB N
. . N

IMPORTANCE IN N
The DT N
prevalence NN N
of IN N
psychological JJ i
distress NN i
among IN N
mothers NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
suggests VBZ p
a DT p
need NN p
for IN p
interventions NNS p
that WDT p
address VBP p
parental JJ p
mental JJ p
health NN p
during IN p
the DT p
critical JJ p
period NN p
after IN p
the DT p
child NN p
's POS p
autism NN p
diagnosis NN p
when WRB p
parents NNS p
are VBP p
learning VBG p
to TO p
navigate VB p
the DT p
complex JJ p
system NN p
of IN p
autism NN p
services NNS p
. . p

The DT N
main JJ N
intervention NN N
strategies NNS N
were VBD N
: : N
information NN N
about IN N
the DT N
risk NN i
factor NN i
concept NN i
to TO i
participant VB i
and CC i
spouse VB i
( ( i
in IN i
groups NNS i
) ) i
individual VBP i
diet JJ i
and CC i
anti-smoking JJ i
counselling NN i
after IN N
finishing VBG N
an DT N
extensive JJ N
clinical JJ N
and CC N
electrocardiographic JJ N
examination NN N
, , N
including VBG N
exercise-ECG JJ N
basis NN N
and CC N
background NN N
for IN N
the DT N
counselling NN i
strategy NN i
: : i
the DT N
total JJ N
situation NN N
of IN N
the DT N
participant NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
an DT N
alteration NN N
of IN N
the DT N
writing VBG N
movement NN N
representation NN N
at IN N
a DT N
central JJ N
level NN N
and CC N
are VBP N
consistent JJ N
with IN N
the DT N
view NN N
that IN N
dystonia NN N
is VBZ N
not RB N
a DT N
purely RB N
motor NN N
disorder NN N
, , N
but CC N
it PRP N
also RB N
involves VBZ N
non-motor NN N
( ( N
sensory JJ N
, , N
cognitive JJ N
) ) N
aspects NNS N
related VBN N
to TO N
movement NN N
processing NN N
and CC N
planning NN N
. . N

The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
plasma-derived JJ i
heat-inactivated JJ i
hepatitis NN i
B NNP i
vaccine NN i
( ( i
CLB NNP i
) ) i
were VBD N
evaluated VBN N
in IN N
471 CD p
healthy JJ p
human JJ p
volunteers NNS p
, , p
who WP p
, , p
both DT p
in IN p
their PRP$ p
occupations NNS p
and CC p
in IN p
their PRP$ p
private JJ p
lives NNS p
, , p
had VBD p
been VBN p
at IN p
minimal JJ p
risk NN p
of IN p
being VBG p
infected VBN p
with IN p
hepatitis NN p
B NNP p
virus NN p
. . p

CONCLUSIONS NNP N
Seeking NNP N
evidence NN N
for IN N
a DT N
possibly RB N
effective JJ N
adjunct NN N
to TO N
traditional JJ N
behavioral JJ N
approaches NNS N
for IN N
treatment NN N
of IN N
MA NNP N
dependence NN N
, , N
this DT N
study NN N
is VBZ N
assessing VBG N
the DT N
ability NN N
of IN N
an DT N
8-week JJ N
aerobic NN N
and CC N
resistance NN N
exercise NN N
protocol NN N
to TO N
reduce VB N
relapse NN N
to TO N
MA NNP N
use NN N
during IN N
a DT N
12-week JJ N
follow-up JJ N
period NN N
after IN N
discharge NN N
from IN N
residential-based JJ N
treatment NN N
. . N

OBJECTIVE NN N
To TO N
explore VB N
the DT N
association NN N
of IN N
a DT N
functional JJ N
germline NN N
variant NN N
in IN N
the DT N
3'-UTR CD N
of IN N
KRAS NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
, , N
as RB N
well RB N
as IN N
the DT N
association NN N
of IN N
microRNA NN N
( ( N
miRNA NN N
) ) N
signatures NNS N
and CC N
the DT N
KRAS-variant NNP N
with IN N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
outcomes NNS N
in IN N
two CD N
prospective JJ N
RTOG NNP N
endometrial JJ N
cancer NN N
trials NNS N
. . N

DISCUSSION NN N
Because IN N
this DT N
study NN N
is VBZ N
expected VBN N
to TO N
yield VB N
evidence NN N
regarding VBG N
the DT N
selection NN N
of IN N
antipsychotics NNS N
for IN N
facilitating VBG N
the DT N
recovery NN N
of IN N
social JJ N
activity NN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
, , p
it PRP p
is VBZ p
considered VBN p
highly RB p
valuable JJ p
to TO p
perform VB p
this DT p
effectiveness NN p
study NN p
under IN p
ordinary JJ p
healthcare NN p
setting VBG p
in IN p
Japan NNP p
. . p

AIMS NNP N
To TO N
assess VB N
if IN N
raising VBG N
concentrations NNS N
of IN N
crude NN i
protein NN i
( ( i
CP NNP i
) ) i
in IN N
pasture NN N
in IN N
spring NN N
by IN N
the DT N
frequent JJ N
application NN N
of IN N
urea JJ i
fertiliser NN i
would MD N
affect VB N
ovarian JJ o
follicular JJ o
dynamics NNS o
, , o
luteal JJ o
function NN o
, , o
onset NN o
of IN o
oestrus NN o
and CC o
reproductive JJ o
performance NN o
of IN N
dairy NN p
cows NNS p
under IN p
farming VBG p
conditions NNS p
in IN p
New NNP p
Zealand NNP p
. . p

The DT N
current JJ N
study NN N
examined VBD N
the DT N
relationship NN N
between IN N
multisensory JJ i
temporal JJ i
processing NN i
( ( N
assessed JJ N
via IN N
a DT N
simultaneity NN N
judgment NN N
task NN N
wherein NN N
participants NNS N
were VBD N
to TO N
report VB N
whether IN N
a DT N
visual JJ o
stimulus NN o
and CC o
an DT o
auditory JJ o
stimulus NN o
occurred VBD N
at IN N
the DT N
same JJ N
time NN N
or CC N
at IN N
different JJ N
times NNS N
) ) N
and CC N
self-reported JJ N
symptoms NNS N
of IN N
autism NN N
( ( N
assessed JJ N
via IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
questionnaire NN N
) ) N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
short-term JJ N
effect NN N
of IN N
a DT N
mixed JJ i
Kinesio NNP i
taping NN i
( ( i
KT NNP i
) ) i
model NN i
on IN N
range NN N
of IN N
ankle JJ N
motion NN N
( ( N
ROAM NNP N
) ) N
, , N
gait NN N
, , N
pain NN N
, , N
perimeter NN N
of IN N
lower JJR N
limbs NN N
, , N
and CC N
quality NN N
of IN N
life NN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
chronic JJ p
venous JJ p
insufficiency NN p
( ( p
CVI NNP p
) ) p
. . p

To TO N
further RBR N
unravel VB N
this DT N
paradoxical JJ N
metabolic JJ N
condition NN N
, , N
and CC N
in IN N
search NN N
of IN N
potential JJ N
therapeutic JJ N
strategies NNS N
, , N
we PRP N
measured VBD N
serum JJ N
concentrations NNS N
of IN N
leptin NN N
; : N
studied VBD N
the DT N
relationship NN N
with IN N
body NN N
mass NN N
index NN N
, , N
insulin NN N
, , N
cortisol NN N
, , N
thyroid JJ N
hormones NNS N
, , N
and CC N
somatomedins NNS N
; : N
and CC N
documented VBD N
the DT N
effects NNS N
of IN N
hypothalamic JJ N
releasing NN N
factors NNS N
, , N
in IN N
particular JJ N
, , N
GH-secretagogues NNP N
and CC N
TRH NNP N
. . N

Secondary JJ N
measures NNS N
included VBD N
time NN o
spent VBN o
sitting VBG o
( ( o
including VBG o
in IN o
prolonged JJ o
bouts NNS o
? . o
) ) o
, , o
standing VBG o
, , o
and CC o
stepping VBG o
as IN N
measured VBN N
by IN N
the DT N
thigh-worn JJ N
inclinometer NN N
( ( N
7d CD N
, , N
24h/d CD N
protocol NN N
) ) N
and CC N
time NN N
spent VBN N
in IN N
physical JJ N
activity NN N
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
as IN N
measured VBN N
by IN N
a DT N
triaxial JJ i
accelerometer NN i
. . i

CONCLUSION NNP N
Data NNP N
obtained VBD N
from IN N
gas NN N
exchange NN N
analysis NN N
are VBP N
more RBR N
sensitive JJ N
and CC N
potentially RB N
more RBR N
useful JJ N
in IN N
the DT N
detection NN N
of IN N
short-term JJ N
changes NNS N
in IN N
exercise NN N
capacity NN N
than IN N
data NNS N
obtained VBN N
from IN N
either CC N
exercise JJ N
time NN N
or CC N
peak JJ N
work NN N
rate NN N
, , N
indexes NNS N
that WDT N
are VBP N
commonly RB N
used VBN N
to TO N
assess VB N
drug NN N
therapy NN N
. . N

PURPOSE VB N
The DT N
study NN N
evaluated VBD N
whether IN N
targeted VBN N
changes NNS N
in IN N
factors NNS N
influencing VBG N
enjoyment NN N
of IN N
physical JJ N
education NN N
( ( N
PE NNP N
) ) N
, , N
physical JJ N
activity NN N
enjoyment NN N
, , N
and CC N
self-efficacy NN N
beliefs NNS N
about IN N
participating VBG N
in IN N
physical JJ N
activity NN N
mediated VBD N
the DT N
effect NN N
of IN N
the DT N
Lifestyle NNP i
Education NNP i
for IN i
Activity NNP i
Program NNP i
( ( i
LEAP NNP i
) ) i
intervention NN i
on IN N
participation NN N
in IN N
physical JJ N
activity NN N
. . N

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ i
cognitive-behavioural JJ i
stress NN i
management NN i
( ( i
CBSM NNP i
) ) i
intervention NN i
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN N
control NN N
condition NN N
on IN N
measures NNS N
of IN N
mood NN i
, , i
coping VBG i
and CC i
social JJ i
support NN i
in IN N
mildly RB p
symptomatic JJ p
HIV-positive JJ p
homosexual JJ p
and CC p
bisexual JJ p
men NNS p
. . p

The DT N
mean JJ o
values NNS o
of IN o
compound NN o
muscle NN o
action NN o
potential JJ o
M-wave NNP o
amplitudes NNS o
in IN N
the DT N
adjacent JJ N
muscles NNS N
( ( N
abductor NN N
digiti NN N
quinti NN N
and CC N
abductor NN N
hallucis NN N
) ) N
were VBD N
above IN N
the DT N
predefined JJ N
threshold NN N
of IN N
effect NN N
, , N
indicating VBG N
that IN N
there EX N
was VBD N
no DT N
relevant JJ N
diffusion-induced JJ N
reduction NN N
of IN N
muscle NN N
activity NN N
. . N

Guidelines NNS N
on IN N
the DT N
management NN N
of IN N
low JJ N
back RB N
pain NN N
in IN N
primary JJ N
care NN N
should MD N
be VB N
consistent JJ N
about IN N
not RB N
recommending VBG N
lumbar NN N
spine NN N
radiography NN N
in IN N
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
in IN p
the DT p
absence NN p
of IN p
red JJ p
flags NNS p
for IN p
serious JJ p
spinal JJ p
pathology NN p
, , N
even RB N
if IN N
the DT N
pain NN N
has VBZ N
persisted VBN N
for IN N
at IN N
least JJS N
6 CD N
weeks NNS N
. . N

BACKGROUND NNP N
Although IN N
psychosocial JJ i
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
mortality NN N
after IN N
myocardial JJ N
infarction NN N
, , N
it PRP N
is VBZ N
unknown JJ N
whether IN N
the DT N
benefits NNS N
of IN N
psychosocial JJ i
therapy NN i
on IN N
mortality NN N
reduction NN N
extend VBP N
to TO N
out-of-hospital JJ N
sudden JJ N
cardiac NN N
arrest NN N
, , N
a DT N
main JJ N
cause NN N
of IN N
cardiovascular JJ N
mortality NN N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
correlations NNS N
in IN N
the DT N
study NN N
population NN N
as IN N
a DT N
whole NN N
or CC N
in IN N
any DT N
subgroup NN N
between IN N
time NN o
with IN o
MEE NNP o
during IN o
antecedent JJ o
periods NNS o
and CC o
children NNS o
's POS o
scores NNS o
on IN o
measures NNS o
of IN o
spontaneous JJ o
expressive JJ o
language NN o
, , o
speech NN o
sound NN o
production NN o
, , o
or CC o
other JJ o
measured JJ o
aspects NNS o
of IN o
cognition NN o
. . o

AIMS NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
human JJ i
synthetic JJ i
secretin NN i
( ( i
HSS NNP i
) ) i
on IN N
behaviour NN N
and CC N
communication NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
using VBG N
an DT N
objective JJ N
measure NN N
of IN N
communication NN N
and CC N
social JJ N
reciprocity NN N
and CC N
standardised VBD N
rating NN N
scales NNS N
. . N

Poorer NNP o
PFS NNP o
and CC o
OS NNP o
were VBD N
observed VBN N
in IN N
CC NNP N
compared VBN N
to TO N
other JJ N
types NNS N
, , N
but CC N
a DT N
lack NN N
of IN N
benefit NN N
from IN N
chemotherapy NN N
was VBD N
not RB N
shown VBN N
, , N
and CC N
as IN N
this DT N
histology NN N
represents VBZ N
such PDT N
a DT N
small JJ N
fraction NN N
, , N
it PRP N
does VBZ N
not RB N
seem VB N
feasible JJ N
to TO N
have VB N
separate JJ N
chemotherapy NN N
trials NNS N
for IN N
CC NNP N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ i
insulin NN i
therapy NN i
and CC i
conventional JJ i
glucose NN i
control NN i
protocol NN i
during IN p
staying VBG p
in IN p
neurological JJ p
intensive JJ p
care NN p
unit NN p
( ( p
NICU NNP p
) ) p
on IN p
infection NN p
rate NN p
, , p
days NNS p
in IN p
NICU NNP p
, , p
in-hospital JJ p
mortality NN p
and CC p
long-term JJ p
neurological JJ p
outcome NN p
in IN p
severe JJ p
traumatic JJ p
brain NN p
injury NN p
( ( p
TBI NNP p
) ) p
patients NNS p
. . p

In IN N
an DT N
attempt NN N
to TO N
delineate VB N
the DT N
effect NN N
of IN N
membrane NN N
permeability NN N
, , N
we PRP N
performed VBD N
a DT N
randomized VBN N
, , N
crossover NN N
study NN N
to TO N
compare VB N
the DT N
inflammatory JJ o
biomarkers NNS o
, , o
lipid JJ o
profile NN o
, , o
and CC o
aortic JJ o
pulse NN o
wave NN o
velocity NN o
( ( o
PWV NNP o
) ) o
of IN N
two CD N
dialyzers NNS N
that WDT N
are VBP N
composed VBN N
of IN N
identical JJ N
membranes NNS N
but CC N
with IN N
different JJ N
flux NN N
characteristics NNS N
. . N

Although IN N
88 CD N
percent NN N
of IN N
doughnuts NNS N
obtained VBN N
in IN N
the DT N
stapled JJ N
group NN N
contained VBD N
some DT N
smooth JJ N
muscle NN N
fibers NNS N
, , N
no DT N
association NN N
was VBD N
found VBN N
between IN N
smooth JJ o
muscle NN o
incorporation NN o
and CC o
postoperative JJ o
continence NN o
function NN o
, , N
and CC N
as IN N
a DT N
whole JJ N
the DT N
continence NN N
outcomes NNS N
of IN N
the DT N
stapled VBN N
group NN N
were VBD N
similar JJ N
to TO N
those DT N
after IN N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
. . N

KEY NNP N
POINTS NNP N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
accurately RB N
differentiate VB N
nonsolid JJ N
from IN N
part-solid JJ N
pulmonary JJ N
nodules NNS N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
manual JJ N
measurements NNS N
? . N
Semiautomatic JJ N
segmentation NN N
may MD N
aid VB N
management NN N
of IN N
subsolid JJ N
nodules NNS N
following VBG N
Fleischner NNP N
Society NNP N
recommendations NNS N
? . N
Performance NN N
for IN N
the DT N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
depends VBZ N
on IN N
the DT N
chosen VBN N
attenuation NN N
thresholds NNS N
. . N

This DT N
randomized VBD N
controlled VBN N
study NN N
( ( N
N NNP p
= NNP p
49 CD p
) ) p
indicates VBZ p
that IN p
providing VBG p
children NNS p
with IN p
low-functioning JJ p
autism NN p
( ( p
LFA NNP p
) ) p
and CC p
high JJ p
functioning NN p
autism NN p
( ( p
HFA NNP p
) ) p
opportunities VBZ N
to TO N
practice NN N
attending VBG N
to TO N
eye NN N
gaze NN N
, , N
discriminating VBG N
facial JJ N
expressions NNS N
and CC N
recognizing VBG N
faces VBZ N
and CC N
emotions NNS N
in IN N
FaceSay NNP N
's POS N
structured JJ N
environment NN N
with IN N
interactive JJ N
, , N
realistic JJ N
avatar NN N
assistants NNS N
improved VBD N
their PRP$ N
social JJ N
skills NNS N
abilities NNS N
. . N

Main NNP N
outcome NN N
measures NNS N
included VBD N
visual JJ o
acuity NN o
, , o
estimated VBN o
red JJ o
reflex NN o
, , o
postsurgical JJ o
inflammatory NN o
reaction NN o
, , o
corneal JJ o
clarity NN o
, , o
posterior JJ o
synechias NN o
, , o
iris JJ o
capture NN o
, , o
IOL NNP o
position NN o
, , o
capsulectomy JJ o
size NN o
, , o
glaucoma NN o
, , o
cystoid JJ o
macular NN o
edema NN o
, , o
retinal JJ o
tear NN o
, , o
and CC o
postoperative JJ o
refraction NN o
. . o

The DT N
results NNS N
show VBP N
that IN N
the DT N
benefits NNS N
of IN N
nasal JJ i
oxytocin NN i
for IN N
young JJ p
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
may MD N
be VB N
more JJR N
circumscribed JJ N
than IN N
suggested VBN N
by IN N
previous JJ N
studies NNS N
, , N
and CC N
suggest JJS N
caution NN N
in IN N
recommending VBG N
it PRP N
as IN N
an DT N
intervention NN N
that WDT N
is VBZ N
broadly RB N
effective JJ N
. . N

DISCUSSION NNP N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Future JJ N
investigations NNS N
with IN N
a DT N
larger JJR N
sample JJ N
size NN N
should MD N
be VB N
conducted VBN N
to TO N
build VB N
on IN N
this DT N
pilot JJ N
feasibility NN N
program NN N
and CC N
to TO N
confirm VB N
these DT N
results NNS N
, , N
as RB N
well RB N
as IN N
to TO N
elucidate VB N
the DT N
elements NNS N
of IN N
rehabilitation NN N
contributing VBG N
most JJS N
to TO N
improved VBN N
outcomes NNS N
. . N

A DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ o
language NN o
and CC o
secondary JJ o
outcome NN o
measures NNS o
of IN o
narrative JJ o
, , o
parent-reported JJ o
pragmatic JJ o
functioning NN o
and CC o
social JJ o
communication NN o
, , o
blind-rated JJ o
perceptions NNS o
of IN o
conversational JJ o
competence NN o
and CC o
teacher-reported JJ o
ratings NNS o
of IN o
classroom NN o
learning VBG o
skills NNS o
were VBD N
taken VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

The DT N
similar JJ N
effect NN N
of IN N
these DT N
drugs NNS N
on IN N
the DT N
reactance NN N
can MD N
be VB N
explained VBN N
by IN N
an DT N
increase NN N
in IN N
the DT N
capacitance NN N
of IN N
the DT N
respiratory NN N
system NN N
, , N
and CC N
in IN N
combination NN N
with IN N
a DT N
decrease NN N
in IN N
frequency NN o
dependence NN o
of IN o
resistance NN o
, , N
by IN N
assuming VBG N
a DT N
decrease NN N
in IN N
peripheral JJ o
airway NN o
resistance NN o
. . o

In IN N
order NN N
to TO N
question VB N
the DT N
value NN N
of IN N
both DT N
glycol JJ N
metabolites NNS N
as IN N
peripheral JJ N
indices NNS N
of IN N
central JJ N
noradrenergic JJ N
activity NN N
, , N
a DT N
comparative JJ N
study NN N
of IN N
plasma NN N
DOPEG NNP N
and CC N
MOPEG NNP N
( ( N
measured VBN N
by IN N
HPLC NNP N
) ) N
related VBD N
to TO N
depression NN N
, , N
sex NN N
, , N
age NN N
and CC N
diagnostic JJ N
categories NNS N
( ( N
DSM-III NNP N
) ) N
was VBD N
carried VBN N
out RP N
on IN N
depressed JJ p
and CC p
control JJ p
subjects NNS p
. . p

While IN N
the DT N
employment NN N
of IN N
questionnaires NNS N
disclosed VBN N
that IN N
autistic JJ N
children NNS N
had VBD N
an DT N
earlier JJR N
morning NN o
awakening NN o
time NN o
and CC o
multiple NN o
and CC o
early JJ o
night NN o
arousals NNS o
, , o
actigraphic JJ o
monitoring NN o
showed VBD N
that IN N
with IN N
the DT N
exception NN N
of IN N
an DT N
earlier JJR N
morning NN o
arousal NN o
time NN o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
, , N
sleep JJ o
patterns NNS o
of IN N
autistic JJ N
children NNS N
were VBD N
similar JJ N
to TO N
that DT N
of IN N
normal JJ N
children NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Operative NNP o
parameters NNS o
( ( o
operative JJ o
time NN o
, , o
fluid JJ o
absorption NN o
, , o
complications NNS o
, , o
need VBP o
for IN o
second JJ o
intervention NN o
) ) o
and CC o
reproductive JJ o
outcome NN o
parameters NNS o
( ( o
pregnancy NN o
, , o
abortion NN o
, , o
term NN o
and CC o
preterm JJ o
delivery NN o
, , o
modality NN o
of IN o
delivery NN o
, , o
cervical JJ o
cerclage NN o
) ) o
were VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
showed VBD N
improvements NNS N
in IN N
affective JJ N
speech NN N
comprehension NN N
from IN N
pre- JJ N
to TO N
post-infusion NN N
; : N
however RB N
, , N
whereas NNS N
those DT N
who WP N
received VBD N
placebo NN N
first RB N
tended VBD N
to TO N
revert VB N
to TO N
baseline VB N
after IN N
a DT N
delay NN N
, , N
those DT N
who WP N
received VBD N
oxytocin PRP N
first RB N
retained VBD N
the DT N
ability NN N
to TO N
accurately RB N
assign VB N
emotional JJ N
significance NN N
to TO N
speech VB N
intonation NN N
on IN N
the DT N
speech NN N
comprehension NN N
task NN N
. . N

Current JJ N
therapy NN N
with IN N
beta NN N
adrenergic JJ N
antagonists NNS N
is VBZ N
designed VBN N
to TO N
moderate VB N
the DT N
up-regulation NN N
of IN N
norepinephrine NN N
and CC N
sympathetic JJ N
effects NNS N
; : N
however RB N
, , N
to TO N
date NN N
, , N
there EX N
are VBP N
no DT N
therapies NNS N
that WDT N
specifically RB N
address VBP N
the DT N
withdrawal NN N
of IN N
parasympathetic JJ N
influences NNS N
on IN N
cardiac JJ N
function NN N
and CC N
structure NN N
. . N

Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
motivational JJ i
music NN i
( ( i
music NN i
that WDT N
stimulates VBZ N
or CC N
inspires VBZ N
physical JJ N
activity NN N
) ) N
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
, , N
on IN N
activity NN o
pattern NN o
, , o
rate NN o
of IN o
perceived VBN o
exertion NN o
( ( o
RPE NNP o
) ) o
, , o
and CC o
blood NN o
lactate NN o
concentration NN o
. . o

CONCLUSIONS NNP N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ N
effects NNS N
of IN N
remifentanil NN i
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN o
effects NNS o
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

BACKGROUND NNP N
In IN N
a DT N
large JJ N
cluster NN N
randomized VBD N
control JJ N
trial NN N
of IN N
insecticide-treated JJ i
bed NN i
nets NNS i
( ( i
ITN NNP i
) ) i
in IN N
Western JJ p
Myanmar NNP p
the DT N
malaria NN N
protective JJ N
effect NN N
of IN N
ITN NNP i
was VBD N
found VBN N
to TO N
be VB N
highly RB N
variable JJ N
and CC N
, , N
in IN N
aggregate NN N
, , N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
agreement NN N
with IN N
findings NNS N
in IN N
animal JJ N
studies NNS N
, , N
our PRP$ N
results NNS N
suggest VBP N
that IN N
microalbuminuria NN i
is VBZ N
to TO N
a DT N
large JJ N
extent NN N
pressure-dependent NN N
, , N
probably RB N
because IN N
of IN N
glomerular JJ N
hypertension NN N
, , N
and CC N
that DT N
autoregulation NN N
of IN N
glomerular JJ N
filtration NN N
rate NN N
is VBZ N
normal JJ N
in IN N
most JJS N
patients NNS p
with IN p
incipient JJ p
diabetic JJ p
nephropathy NN p
. . p

AIM IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
oxidized JJ i
regenerated VBN i
cellulose NN i
( ( i
ORC NNP i
) ) i
, , N
applied VBN N
to TO N
dirty VB N
surgical JJ N
wounds NNS N
, , N
is VBZ N
able JJ N
to TO N
reduce VB N
the DT N
microbial JJ N
load NN N
and CC N
, , N
consequently RB N
, , N
the DT N
infection NN o
rate NN o
as IN N
compared VBN N
to TO N
conventional JJ N
local JJ N
wound NN N
treatment NN N
. . N

PURPOSE NN N
To TO N
date NN N
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
synergistic JJ N
effects NNS N
of IN N
a DT N
nutrition NN i
and CC i
combination NN i
of IN i
aerobic JJ i
and CC i
strength NN i
training NN i
( ( i
CAST NNP i
) ) i
on IN N
both DT N
adiposity NN o
and CC o
metabolic JJ o
parameters NNS o
in IN N
overweight JJ p
Latina NNP p
adolescent NN p
females NNS p
. . p

In IN N
a DT N
30-day JJ N
study NN N
, , N
we PRP N
compared VBN N
the DT N
abilities NNS N
of IN N
four CD N
different JJ N
treatments NNS i
( ( i
lithium JJ i
plus CC i
early JJ i
morning NN i
sleep NN i
deprivation NN i
, , i
lithium NN i
plus CC i
a DT i
control NN i
sleep JJ i
deprivation NN i
procedure NN i
, , i
and CC i
desipramine NN i
with IN i
either DT i
of IN i
the DT i
two CD i
sleep JJ i
manipulations NNS i
) ) i
to TO i
induce VB i
a DT i
rapid JJ i
( ( i
next-day JJ i
) ) i
and CC i
sustained VBN i
antidepressant JJ i
response NN i
in IN N
16 CD p
depressed JJ p
patients NNS p
. . p

Relative JJ N
change NN N
in IN N
serum NN o
retinol NN o
concentration NN o
was VBD N
significantly RB N
higher JJR N
among IN N
the DT N
Experimental NNP N
group NN N
, , N
with IN N
one-third NN N
of IN N
total JJ N
vitamin FW N
A DT N
intake NN N
coming VBG N
from IN N
vitamin JJ N
A-fortified JJ N
cooking NN N
oil NN N
intake NN N
, , N
than IN N
in IN N
the DT N
Control NNP N
groups NNS N
, , N
with IN N
more JJR N
than IN N
half NN N
of IN N
intake NN N
from IN N
other JJ N
vitamin JJ N
A-rich JJ N
foods NNS N
. . N

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
pressure NN N
garments NNS N
that WDT N
deliver VBP N
a DT N
pressure NN N
of IN N
at IN N
least JJS N
15 CD N
mmHg JJ N
pressure NN N
tend VBP N
to TO N
accelerate VB N
scar NN N
maturation NN N
and CC N
that IN N
measurements NNS N
of IN N
the DT N
pattern NN N
of IN N
change NN N
of IN N
the DT N
erythema NN N
can MD N
be VB N
used VBN N
to TO N
predict VB N
changes NNS N
in IN N
scar NN N
thickness NN N
and CC N
vice NN N
versa NN N
. . N

It PRP N
was VBD N
therefore RB N
concluded VBD N
that IN N
, , N
although IN N
patients NNS p
with IN p
LV NNP p
hypertrophy NN p
and CC p
non-Q-wave JJ p
AMI NNP p
have VBP N
smaller JJR N
enzymatic JJ N
infarcts NNS N
and CC N
the DT N
same JJ N
short-term JJ N
prognosis NN N
as IN N
do JJ N
patients NNS N
without IN N
LV NNP o
hypertrophy NN o
, , o
their PRP$ o
reinfarction NN o
and CC o
mortality NN o
rates NNS o
are VBP N
significantly RB N
increased VBN N
during IN N
the DT N
first JJ N
year NN N
of IN N
follow-up NN N
. . N

Patients NNS p
selected VBN p
for IN p
moderately RB p
progressive JJ p
IgA NNP p
nephropathy JJ p
benefit NN N
from IN N
treatment NN N
with IN N
prednisolone NN i
and CC i
cytotoxic NN i
agents NNS i
; : i
results NNS N
are VBP N
consistent JJ N
with IN N
modulation NN N
of IN N
systemic JJ N
immune JJ N
response NN N
or CC N
nephritic JJ N
injury NN N
, , N
thus RB N
explaining VBG N
improved VBN N
outcome NN N
, , N
and CC N
indicate VBP N
that IN N
this DT N
therapy NN N
has VBZ N
an DT N
acceptably RB N
low JJ N
risk NN N
of IN N
side NN N
effects NNS N
. . N

Some DT N
children NNS N
appeared VBD N
to TO N
respond VB N
positively RB N
to TO N
the DT N
dimethylglycine NN N
, , N
and CC N
there RB N
was VBD N
a DT N
smaller JJR N
proportion NN N
of IN N
negative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine NN N
group NN N
, , N
but CC N
the DT N
quantitative JJ N
changes NNS N
in IN N
the DT N
dimethylglycine JJ o
behavioral JJ o
assessments NNS o
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
what WP N
was VBD N
observed VBN N
among IN N
children NNS N
who WP N
received VBD N
placebo NN i
. . i

RESULTS RB N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
the DT N
parameters NNS N
measured VBD N
with IN N
one CD N
exception NN N
; : N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
discomfort NN o
levels NNS o
for IN N
the DT N
laser NN N
system NN N
at IN N
the DT N
time NN N
of IN N
cavity NN N
preparation NN N
for IN N
subjects NNS N
who WP N
declined VBD N
to TO N
receive VB N
local JJ N
anesthetic NN N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
the DT N
composite NN o
of IN o
all-cause JJ o
mortality NN o
, , o
non JJ o
fatal JJ o
myocardial JJ o
infarction NN o
( ( o
including VBG o
silent JJ o
myocardial JJ o
infarction NN o
) ) o
, , o
stroke VBD o
, , o
acute JJ o
coronary JJ o
syndrome NN o
, , o
endovascular JJ o
or CC o
surgical JJ o
intervention NN o
in IN o
the DT o
coronary NN o
or CC o
leg NN o
arteries NNS o
, , o
and CC o
amputation NN o
above IN o
the DT o
ankle NN o
. . o

We PRP N
observed VBD N
significant JJ N
improvements NNS N
in IN N
hyperandrogenemia NN o
and CC o
ovulation NN o
rates NNS o
in IN N
PCOS NNP N
women NNS N
of IN N
all DT N
three CD N
groups NNS N
, , N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
the DT N
metabolic JJ N
state NN N
, , N
suggesting VBG N
that IN N
insulin NN N
resistance NN N
in IN N
PCOS NNP N
patients NNS N
is VBZ N
only RB N
one CD N
of IN N
several JJ N
factors NNS N
leading VBG N
to TO N
hyperandrogenemic VB N
ovarian JJ N
failure NN N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitor NN i
enalapril NN i
and CC i
diuretic JJ i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
the DT o
central JJ o
blood NN o
pressure NN o
in IN N
Chinese JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Citalopram NNP i
use NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
adverse JJ o
events NNS o
, , o
particularly RB o
increased VBD o
energy NN o
level NN o
, , o
impulsiveness NN o
, , o
decreased VBN o
concentration NN o
, , o
hyperactivity NN o
, , o
stereotypy NN o
, , o
diarrhea NN o
, , o
insomnia NN o
, , o
and CC o
dry JJ o
skin NN o
or CC o
pruritus NN o
. . o

OBJECTIVE IN N
The DT N
current JJ N
study NN N
's POS N
primary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
feasibility NN o
and CC o
acceptability NN o
for IN o
use NN o
by IN p
older JJR p
adults NNS p
of IN p
the DT p
Internet NNP i
Mindfulness NNP i
Meditation NNP i
Intervention NNP i
( ( i
IMMI NNP i
) ) i
, , N
a DT N
program NN N
that WDT N
had VBD N
been VBN N
developed VBN N
by IN N
the DT N
research NN N
team NN N
, , N
as RB N
well RB N
as IN N
of IN N
an DT N
Internet-based JJ i
health-and-wellness JJ i
education NN i
program NN i
, , i
the DT i
control NN i
. . i

PURPOSE NNP N
While IN N
the DT N
benefits NNS N
of IN N
planned JJ i
replacement NN i
of IN i
soft JJ i
contact NN i
lenses NNS i
have VBP N
been VBN N
investigated VBN N
, , N
the DT N
question NN N
of IN N
whether IN N
there EX N
are VBP N
any DT N
clinical JJ N
benefits NNS N
to TO N
planned VBN i
replacement NN i
of IN i
rigid JJ i
gas NN i
permeable NN i
( ( i
RGP NNP i
) ) i
lenses VBZ i
does VBZ N
not RB N
appear VB N
to TO N
have VB N
been VBN N
addressed VBN N
experimentally RB N
. . N

OBJECTIVE NN N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
there EX N
would MD N
be VB N
better RB N
clinical JJ N
outcomes NNS N
following VBG N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
acute JJ p
lung NN p
injury NN p
( ( p
ALI NNP p
) ) p
using VBG N
noninvasive JJ N
positive-pressure JJ i
mechanical JJ i
ventilation NN i
( ( i
NIPPV NNP i
) ) i
delivered VBD i
via IN i
a DT i
complex JJ i
critical JJ i
care NN i
ventilator NN i
compared VBN i
with IN i
a DT i
conventional JJ i
mini-ventilator NN i
. . i

PARTICIPANTS VB N
The DT N
study NN p
enrolled VBD p
male NN p
and CC p
female JJ p
outpatients NNS p
aged VBN p
5-12 CD p
years NNS p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
based VBN p
on IN p
the DT p
DSM-IV-TR NNP p
criteria NNS p
and CC p
a DT p
score NN p
of IN p
? . p
on IN p
the DT p
Aberrant NNP p
Behavior NNP p
Checklist-Community NNP p
( ( p
ABC-C NNP p
) ) p
irritability NN p
subscale NN p
who WP p
had VBD p
discontinued VBN p
other JJ p
medications NNS p
because IN p
of IN p
a DT p
lack NN p
of IN p
efficacy NN p
. . p

Our PRP$ N
findings NNS N
demonstrate VBP N
that IN N
in IN N
patients NNS N
with IN N
multiple JJ N
myeloma NNS N
who WP N
might MD N
be VB N
predicted VBN N
to TO N
fail VB N
mobilization NN N
based VBN N
on IN N
low JJ N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
the DT N
addition NN N
of IN N
plerixafor NN N
to TO N
G-CSF NNP N
allows NNS N
for IN N
collection NN N
of IN N
the DT N
minimal JJ N
and CC N
optimal JJ N
cell NN N
doses NNS N
in IN N
a DT N
greater JJR N
proportion NN N
of IN N
patients NNS N
compared VBN N
with IN N
G-CSF NNP N
alone RB N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
is VBZ N
to TO N
evaluate VB N
the DT N
treatment NN N
of IN N
depressive JJ N
disorder NN N
in IN N
primary JJ N
care NN N
in IN N
the DT N
Netherlands NNP N
by IN N
means NNS N
of IN N
an DT N
adapted JJ i
collaborative NN i
care NN i
framework NN i
, , i
including VBG i
contracting NN i
and CC i
adherence-improving JJ i
strategies NNS i
, , i
combined VBN i
with IN i
Problem NNP i
Solving NNP i
Treatment NNP i
and CC i
antidepressant JJ i
medication NN i
according VBG i
to TO i
a DT i
treatment NN i
algorithm NN i
. . i

The DT N
two CD N
lower JJR N
doses NNS N
of IN N
lornoxicam NN i
and CC i
aspirin VB i
all DT N
showed VBD N
apparent JJ N
degrees NNS N
of IN N
efficacy NN o
intermediate NN o
between IN N
that DT N
of IN N
placebo NN i
and CC i
lornoxicam $ i
8 CD N
mg NN N
, , N
although IN N
the DT N
trial NN N
proved VBD N
to TO N
have VB N
inadequate JJ N
power NN N
to TO N
show VB N
significant JJ N
differences NNS N
between IN N
these DT N
three CD N
treatments NNS N
. . N

BACKGROUND NNP N
In IN N
cemented JJ N
THA NNP N
, , N
aseptic JJ N
loosening NN N
of IN N
the DT N
cup NN N
is VBZ N
more RBR N
common JJ N
than IN N
loosening NN N
of IN N
the DT N
stem NN N
, , N
while IN N
periprosthetic JJ N
osteolysis NN N
of IN N
the DT N
socket NN N
resulting VBG N
in IN N
difficult JJ N
reconstruction NN N
problems NNS N
has VBZ N
emerged VBN N
as IN N
the DT N
most RBS N
significant JJ N
problem NN N
with IN N
cementless JJ N
cup NN N
fixation NN N
. . N

All DT N
measures NNS N
of IN N
outcome NN N
were VBD N
worse JJR N
in IN N
patients NNS N
who WP N
developed VBD N
fever NN N
, , N
even RB N
in IN N
those DT N
without IN N
infections NNS N
or CC N
who WP N
were VBD N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grade VBD N
I. NNP N
Logistic NNP N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
adjust VB N
for IN N
differences NNS N
in IN N
preoperative JJ N
factors NNS N
( ( N
e.g NN N
, , N
age NN N
, , N
Fisher NNP N
grade NN N
, , N
initial JJ N
neurological JJ N
status NN N
) ) N
. . N

Phentolamine NN i
was VBD N
given VBN N
first RB N
to TO N
isolate VB N
the DT N
contribution NN N
of IN N
nitric JJ N
oxide NN N
to TO N
postexercise VB N
hypotension NN N
by IN N
preventing VBG N
reflex JJ N
changes NNS N
in IN N
sympathetic JJ N
tone NN N
that WDT N
result NN N
from IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
and CC N
to TO N
control VB N
for IN N
alterations NNS N
in IN N
resting VBG N
sympathetic JJ N
activity NN N
after IN N
exercise NN N
. . N

Chemoimmunotherapy NN i
with IN i
levamisole JJ i
or CC i
levamisole-BCG JJ i
offers NNS N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
CR NNP o
rates NNS o
, , o
CR NNP o
duration NN o
, , o
or CC o
survival NN o
compared VBN N
to TO N
CHOP NNP i
chemotherapy NN i
alone RB N
, , N
and CC N
levamisole NN i
may MD N
have VB N
had VBD N
an DT N
adverse JJ N
impact NN N
on IN N
outcome NN N
in IN N
certain JJ N
subtypes NNS N
of IN N
ML NNP N
. . N

OBJECTIVE IN N
The DT N
objectives NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
in IN N
treating VBG N
basal NN N
cell NN N
carcinoma NN N
preceding VBG N
excision NN N
by IN N
Mohs NNP i
micrographic JJ i
surgery NN i
and CC N
to TO N
determine VB N
if IN N
reflectance-mode JJ i
confocal JJ i
microscopy NN i
is VBZ N
useful JJ N
to TO N
establish VB N
the DT N
need NN N
for IN N
surgical JJ N
intervention NN N
after IN N
imiquimod JJ N
treatment NN N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Largely NNP N
because IN N
the DT N
program NN N
increased VBD N
consumers NNS o
' POS o
ability NN o
to TO o
get VB o
the DT o
authorized JJ o
amount NN o
of IN o
paid VBN o
care NN o
, , o
expenditures VBZ o
for IN o
personal JJ o
care/waiver NN o
services NNS o
were VBD N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
in IN N
each DT N
state NN N
and CC N
age NN N
group NN N
, , N
except IN N
among IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
. . N

Results NNS N
of IN N
both DT N
inquiries NNS N
indicate VBP N
that IN N
although IN N
treatment NN N
with IN N
secretin NN i
was VBD N
reported VBN N
to TO N
cause VB N
transient JJ N
changes NNS N
in IN N
speech NN o
and CC o
behavior NN o
in IN N
some DT N
children NNS N
, , N
overall JJ N
it PRP N
produced VBD N
few JJ N
clinically RB N
meaningful JJ N
changes NNS N
when WRB N
compared VBN N
to TO N
children NNS N
given VBN N
placebo JJ i
injections NNS N
. . N

CONCLUSION NNP N
The DT N
presently RB N
studied VBN N
diphtheria NN i
, , i
tetanus NN i
, , i
acellular JJ i
pertussis-H. NN i
influenzae NN i
b NN i
vaccine NN i
conjugated VBN i
to TO i
tetanus VB i
toxoid JJ i
combination NN i
was VBD i
at IN i
least JJS i
as RB i
immunogenic JJ i
as IN i
the DT i
diphtheria NN i
, , i
tetanus NN i
, , i
whole JJ i
cell NN i
pertussis-H. JJ i
influenzae NN i
b NN i
vaccine NN i
conjugated VBN i
to TO i
tetanus VB i
toxoid JJ i
combination NN i
, , N
with IN N
a DT N
significantly RB N
better JJR N
safety NN o
profile NN o
. . o

Primary JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
OPSCC NNP N
at IN N
most JJS N
centers NNS N
, , N
and CC N
over IN N
the DT N
last JJ N
decade NN N
, , N
the DT N
addition NN N
of IN N
concurrent NN N
chemotherapy NN N
has VBZ N
led VBN N
to TO N
a DT N
significant JJ N
improvement NN N
in IN N
survival NN N
, , N
but CC N
at IN N
the DT N
cost NN N
of IN N
increased VBN N
acute NN N
and CC N
late JJ N
toxicity NN N
. . N

Any DT N
subsequent JJ N
trials NNS N
of IN N
the DT N
HART NNP i
regimen NNS N
must MD N
address VB N
the DT N
issues NNS N
that WDT N
led VBD N
to TO N
early JJ N
closure NN N
, , N
including VBG N
slow JJ o
accrual NN o
, , o
logistics NNS o
of IN o
HART NNP o
, , o
mucosal NN o
toxicity NN o
, , N
and CC N
the DT N
fact NN N
that IN N
concurrent JJ N
chemoradiotherapy NN N
now RB N
seems VBZ N
more RBR N
effective JJ N
than IN N
sequential JJ N
treatment NN N
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

When WRB N
designing VBG N
a DT N
clinical JJ N
trial NN N
, , N
selecting VBG N
volunteers NNS N
, , N
or CC N
judging VBG N
the DT N
tolerance NN N
of IN N
a DT N
new JJ N
drug NN N
, , N
the DT N
rise NN N
in IN N
TSB NNP N
caused VBN N
by IN N
fasting VBG N
must MD N
therefore RB N
be VB N
taken VBN N
into IN N
account NN N
, , N
particularly RB N
in IN N
trials NNS N
where WRB N
volunteers NNS N
or CC N
patients NNS N
fast JJ N
before IN N
entering VBG N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
In IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
, , N
changes NNS N
in IN N
serum NN o
SCFAs NNP o
in IN o
response NN o
to TO o
changes NNS o
in IN o
carbohydrate NN o
and CC o
fiber NN o
intakes NNS o
took VBD N
many JJ N
months NNS N
to TO N
occur VB N
, , N
and CC N
the DT N
changes NNS N
in IN N
serum NN N
acetate NN N
were VBD N
significantly RB N
related VBN N
to TO N
the DT N
long-term JJ o
adaptive JJ o
changes NNS o
in IN o
blood NN o
lipids NNS o
. . o

INTRODUCTION NN N
In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
short-term JJ N
finasteride JJ i
treatment NN N
on IN N
microvessel NN N
density NN N
( ( N
MVD NNP N
) ) N
which WDT N
is VBZ N
an DT N
indicator NN N
of IN N
prostatic JJ N
angiogenesis NN N
in IN N
patients NNS p
with IN p
hematuria NNS p
secondary JJ p
to TO p
benign VB p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
. . p

We PRP N
provide VBP N
evidence NN N
that IN N
low-dose JJ N
CY NNP N
not RB N
only RB N
depletes VBZ N
patients NNS N
' POS N
Treg NNP N
cells NNS N
and CC N
enhances NNS N
function NN o
of IN o
HPV-specific NNP o
T NNP o
cells NNS o
and CC o
NK NNP o
cells NNS o
in IN N
the DT N
periphery NN N
, , N
but CC N
also RB N
ameliorates VBZ N
the DT N
immune JJ N
milieu NN N
of IN N
the DT N
lesion NN N
site NN N
, , N
leading VBG N
to TO N
the DT N
elimination NN N
of IN N
remnant JJ N
viruses NNS N
. . N

This DT N
difference NN N
between IN N
the DT N
tinted JJ N
CL NNP N
could MD N
suggest VB N
a DT N
wavelength JJ N
dependence NN N
of IN N
straylight NN N
values NNS N
, , N
although IN N
this DT N
should MD N
be VB N
investigated VBN N
further JJ N
by IN N
controlling VBG N
for IN N
pupil NN N
size NN N
and CC N
subjects NNS N
' POS N
pigmentation NN N
, , N
as RB N
well RB N
as IN N
by IN N
using VBG N
neutral JJ N
density NN N
filters NNS N
. . N

BACKGROUND NNP N
Since IN N
laparoscopic NN i
adrenalectomy NN i
( ( i
LA NNP i
) ) i
has VBZ N
been VBN N
adopted VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
treatment NN N
of IN N
adrenal JJ N
diseases NNS N
, , N
the DT N
development NN N
of IN N
technology NN N
for IN N
vascular JJ N
control NN N
and CC N
dissection NN N
manoeuvres NNS N
, , N
amongst VBZ N
other JJ N
things NNS N
, , N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
its PRP$ N
further JJ N
improvement NN N
. . N

Other JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
LAIV-induced NNP N
immunity NN N
is VBZ N
also RB N
partially RB N
explained VBN N
by IN N
T-cell NNP N
immunity NN N
, , N
serum NN N
antibody NN N
responses NNS N
, , N
and CC N
innate JJ N
immunity NN N
, , N
consistent JJ N
with IN N
the DT N
multi-faceted JJ N
nature NN N
of IN N
immunity NN N
induced VBN N
by IN N
wild-type JJ N
influenza JJ N
infection NN N
and CC N
other JJ N
live JJ N
virus NN N
vaccines NNS N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
none NN N
of IN N
the DT N
three CD N
beta-blockers NNS N
tested VBN N
nor CC N
disopyramide JJ i
phosphate NN i
is VBZ N
likely JJ N
to TO N
reduce VB N
the DT N
mortality NN o
from IN o
acute JJ o
myocardial JJ o
infarction NN o
when WRB N
given VBN N
prophylactically RB N
, , N
although IN N
disopyramide JJ i
phosphate NN i
does VBZ N
reduce VB N
the DT N
incidence NN o
of IN o
'serious JJ o
' POS o
ventriicular JJ o
arrhythmias NNS o
. . o

We PRP N
examined VBD N
the DT N
associations NNS N
of IN N
prediagnostic JJ o
plasma NN o
levels NNS o
of IN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
and CC o
1,25 CD o
( ( o
OH NNP o
) ) o
2D CD o
, , o
individually RB o
and CC o
jointly RB o
, , o
with IN o
total JJ o
and CC o
aggressive JJ o
disease NN o
, , N
and CC N
explored VBD N
whether IN N
relations NNS N
between IN N
vitamin NN N
D NNP N
metabolites NNS N
and CC N
prostate NN N
cancer NN N
were VBD N
modified VBN N
by IN N
the DT N
functional JJ N
VDR NNP N
FokI NNP N
polymorphism NN N
, , N
using VBG N
conditional JJ N
logistic JJ N
regression NN N
. . N

Therefore RB N
, , N
a DT N
multicenter NN N
RCT NNP N
was VBD N
proposed VBN N
in IN N
1998 CD N
to TO N
evaluate VB N
the DT N
primary JJ N
end NN N
point NN N
of IN N
long-term JJ o
survival NN o
and CC N
the DT N
secondary JJ N
end NN N
points NNS N
of IN N
morbidity NN o
, , o
mortality NN o
and CC o
quality NN o
of IN o
life NN o
of IN N
patients NNS N
undergoing VBG N
standard JJ N
versus NN N
extended VBD N
lymphadenectomy NN N
in IN N
radical JJ N
PD NNP N
for IN N
pancreatic JJ p
cancer NN p
. . p

CONCLUSION NN N
In IN N
this DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
the DT N
addition NN N
of IN N
a DT N
direct JJ i
nitric JJ i
oxide NN i
donor NN i
to TO i
nitroglycerin VB i
in IN N
an DT N
antispastic JJ N
cocktail NN N
did VBD N
not RB N
reduce VB N
the DT N
risk NN o
of IN o
spasm NN o
, , N
and CC N
the DT N
use NN N
of IN N
nitroglycerin NN i
was VBD N
found VBN N
to TO N
be VB N
as RB N
effective JJ N
as IN N
nitroprusside RB N
. . N

MEASUREMENTS NNS N
At IN N
the DT N
time NN N
of IN N
enrolment NN N
into IN N
a DT N
wider NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
hip NN p
protectors NNS p
on IN p
hip NN p
fractures NNS p
, , p
participants NNS p
recruited VBD N
at IN N
home NN N
completed VBD N
an DT N
assessment NN N
of IN N
fear NN N
of IN N
falling VBG o
and CC o
falls VBZ o
efficacy NN o
as IN N
measured VBN N
by IN N
the DT N
Falls NNP o
Efficacy NNP o
Scale NNP o
and CC o
the DT o
Modified NNP o
Falls NNP o
Efficacy NNP o
Scale NNP o
. . o

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN N
disease NN N
extent NN N
, , N
maintenance NN N
therapy NN N
, , N
Karnofsky NNP N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
, , N
and CC N
absolute JJ N
dose-intensity NN N
( ( N
ADI NNP N
) ) N
of IN N
anthracycline NN i
given VBN N
during IN N
induction NN N
, , N
limited JJ N
disease NN N
( ( N
LD NNP N
) ) N
and CC N
maintenance NN N
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN N
. . N

RESULTS NNP N
PRIMARY NNP N
MEASUREMENTS NNP N
3-monthly JJ o
HbA1c NNP o
, , o
fasting VBG o
blood NN o
glucose NN o
, , o
body NN o
weight VBD o
, , o
waist-hip JJ o
ratio NN o
, , o
yearly RB o
blood NN o
lipids NNS o
, , o
and CC o
bi-yearly JJ o
assessment NN o
of IN o
knowledge NN o
of IN o
diabetes NNS o
, , o
health NN o
behaviours NNS o
and CC o
quality NN o
of IN o
life NN o
. . o

Although IN N
Canada411 NNP N
could MD N
find VB N
significantly RB N
more RBR N
subjects NNS N
than IN N
InfoSpace NNP N
, , N
the DT N
number NN o
of IN o
potential JJ o
matches NNS o
returned VBN N
by IN N
Canada411 NNP N
was VBD N
also RB N
higher JJR N
, , N
which WDT N
meant VBD N
that IN N
a DT N
longer RBR N
list NN N
of IN N
potential JJ N
matches NNS N
had VBD N
to TO N
be VB N
examined VBN N
before IN N
a DT N
true JJ N
match NN N
could MD N
be VB N
found VBN N
. . N

Feeding VBG N
problems NNS N
represent VBP N
a DT N
frequent NN N
concern NN N
reported VBN N
by IN N
caregivers NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
, , N
and CC N
growing VBG N
evidence NN N
suggests VBZ N
atypical JJ N
patterns NNS N
of IN N
intake NN N
may MD N
place VB N
this DT N
population NN N
at IN N
risk NN N
of IN N
nutritional JJ N
and/or NN N
related JJ N
medical JJ N
issues NNS N
, , N
including VBG N
chronic JJ p
vitamin NN p
and CC p
mineral JJ p
deficiencies NNS p
, , p
poor JJ p
bone NN p
growth NN p
, , p
and CC p
obesity NN p
. . p

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS N
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN N
of IN N
anuria NNS N
and CC N
a DT N
significantly RB N
faster RBR N
recovery NN o
from IN o
hypertension NN o
in IN N
the DT N
treated JJ N
group NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
were VBD N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
for IN o
pain NN o
at IN o
rest NN o
and CC o
on IN o
movement NN o
( ( o
dynamic JJ o
) ) o
, , o
heart NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
pruritus NN o
, , o
itching NN o
, , o
nausea NN o
, , o
vomiting VBG o
and CC o
sedation NN o
. . o

Hence RB N
, , N
although IN N
there EX N
was VBD N
evidence NN N
for IN N
a DT N
background NN N
endemic JJ N
response NN N
to TO N
both DT N
leishmanial JJ N
and CC N
mycobacterial JJ N
antigens NNS N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
vaccination NN N
per IN N
se NN N
led VBD N
to TO N
a DT N
potentially RB N
disease JJ N
exacerbatory JJ N
level NN N
of IN N
TH2-associated NNP N
antibody NN N
response NN N
especially RB N
with IN N
respect NN N
to TO N
the DT N
anti-leishmanial JJ N
response NN N
. . N

Moreover RB N
, , N
the DT N
technic NN N
of IN N
exteriorization NN i
is VBZ N
a DT N
safe JJ N
adjunct NN N
to TO N
management NN N
and CC N
is VBZ N
recommended VBN N
in IN N
any DT p
patient NN p
with IN p
a DT p
colonic JJ p
injury NN p
above IN p
18 CD p
cm NN p
in IN N
which WDT N
one CD N
suture NN N
line NN N
is VBZ N
required VBN N
and CC N
in IN N
which WDT N
the DT N
additional JJ N
operating NN N
time NN N
of IN N
twenty NN N
minutes NNS N
will MD N
not RB N
compromise VB N
the DT N
management NN N
of IN N
secondary JJ N
injuries NNS N
. . N

RESULTS NNP N
Total NNP o
knee NN o
scores NNS o
, , o
knee NN o
function NN o
scores NNS o
, , o
pain NN o
scores NNS o
, , o
WOMAC NNP o
scores VBZ o
, , o
knee VB o
motion NN o
, , o
and CC o
activity NN o
scores NNS o
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

RESULTS JJ N
Patients NNS p
with IN p
a DT p
short JJ p
duration NN p
of IN p
untreated JJ p
negative JJ p
symptoms NNS p
( ( p
DUNS NNP p
) ) p
or CC p
a DT p
short JJ p
duration NN p
of IN p
untreated JJ p
positive JJ p
symptoms NNS p
( ( p
DUPS NNP p
) ) p
outperformed VBD p
patients NNS p
with IN p
a DT p
long JJ p
duration NN p
of IN p
untreated JJ p
symptoms NNS p
on IN p
memory NN o
tasks NNS o
and CC o
a DT o
pre-attentional JJ o
visual JJ o
task NN o
but CC o
not RB o
on IN o
measures NNS o
of IN o
verbal JJ o
fluency NN o
, , o
attention NN o
, , o
reaction NN o
time NN o
, , o
visual JJ o
processing NN o
and CC o
executive NN o
functions NNS o
. . o

Furthermore RB N
, , N
young JJ N
children NNS N
only RB N
succeeded VBD N
on IN N
TOM NNP N
items NNS N
that WDT N
tap VBP N
the DT N
basic JJ N
domains NNS N
of IN N
theory NN N
of IN N
mind NN N
( ( N
e.g JJ N
, , N
emotion JJ N
recognition NN N
) ) N
, , N
whereas JJ N
older JJR N
children NNS N
also RB N
passed VBD N
items NNS N
that WDT N
measure VBP N
the DT N
more JJR N
mature JJ o
areas NNS o
of IN o
theory NN o
of IN o
mind NN o
( ( o
e.g JJ o
, , o
understanding NN o
of IN o
humor NN o
, , o
understanding VBG o
of IN o
second-order JJ o
beliefs NNS o
) ) o
. . o

Secondary JJ N
endpoints NNS N
include VBP N
all-cause JJ o
mortality NN o
, , o
development NN o
of IN o
renal JJ o
and CC o
visual JJ o
impairment NN o
, , o
peripheral JJ o
neuropathy NN o
, , o
health NN o
service NN o
costs NNS o
, , o
self-reported JJ o
quality NN o
of IN o
life NN o
, , o
functional JJ o
status NN o
and CC o
health NN o
utility NN o
. . o

CONCLUSION NNP N
Despite IN N
the DT N
fact NN N
that IN N
the DT N
combination NN N
of IN N
anxiolytics NNS N
and CC N
analgesics NNS N
as IN N
compared VBN N
with IN N
analgesics NNS N
alone RB N
reduced VBN N
anxiety NN N
and CC N
the DT N
requirement NN N
of IN N
Morphine NNP N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
acute JJ N
coronary JJ N
syndrome NN N
, , N
this DT N
strategy NN N
did VBD N
not RB N
reduce VB N
patients NNS N
' POS N
estimation NN N
of IN N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ o
version NN o
of IN o
the DT o
Neuropsychiatric NNP o
Inventory NNP o
Questionnaire NNP o
( ( o
NPI-Q NNP o
) ) o
, , o
the DT o
Cornell NNP o
Scale NNP o
for IN o
Depression NNP o
in IN o
Dementia NNP o
( ( o
CSDD NNP o
) ) o
and CC o
the DT o
Quality NN o
of IN o
Life NNP o
in IN o
Late-Stage NNP o
Dementia NNP o
( ( o
QUALID NNP o
) ) o
scale NN o
. . o

However RB N
, , N
a DT N
uniform JJ N
PB NNP N
CD34 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
that WDT N
predicts VBZ N
mobilization NN N
failure NN N
has VBZ N
not RB N
been VBN N
defined VBN N
, , N
resulting VBG N
in IN N
the DT N
development NN N
of IN N
institute-specific JJ N
algorithms NN N
for IN N
mobilization NN N
, , N
particularly RB N
regarding VBG N
the DT N
decision NN N
of IN N
when WRB N
to TO N
use VB N
the DT N
novel JJ N
stem NN N
cell NN N
mobilization NN N
agent NN N
plerixafor NN N
. . N

We PRP N
present VBP N
an DT N
economic JJ N
evaluation NN N
using VBG N
data NNS N
from IN N
the DT N
Distal NNP N
Radius NNP N
Acute NNP N
Fracture NNP N
Fixation NNP N
Trial NNP N
( ( N
DRAFFT NNP N
) ) N
to TO N
compare VB N
the DT N
relative JJ N
cost NN N
effectiveness NN N
of IN N
percutaneous JJ i
Kirschner NNP i
wire NN i
( ( i
K-wire NNP i
) ) i
fixation NN i
and CC i
volar JJ i
locking-plate JJ i
fixation NN i
for IN N
patients NNS p
with IN p
dorsally-displaced JJ p
fractures NNS p
of IN p
the DT p
distal JJ p
radius NN p
. . p

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
baseline NN N
characteristics NNS N
of IN N
participants NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
as IN N
it PRP N
relates VBZ N
to TO N
impaired JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
and CC N
depression NN N
, , N
identify JJ N
predictors NNS N
of IN N
poor JJ N
QOL NNP N
and CC N
depression NN N
, , N
and CC N
determine VB N
the DT N
correlation NN N
between IN N
QOL NNP N
and CC N
depression NN N
. . N

Since IN N
the DT N
long-term JJ N
prognosis NN N
for IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
remains VBZ N
very RB N
poor JJ N
and CC N
the DT N
incidence NN N
of IN N
arrhythmic JJ N
death NN N
is VBZ N
high JJ N
, , N
every DT N
new JJ N
drug NN N
to TO N
be VB N
employed VBN N
against IN N
this DT N
disease NN N
should MD N
be VB N
thoroughly RB N
tested VBN N
in IN N
order NN N
to TO N
rule VB N
out RP N
any DT N
possible JJ N
arrhythmogenic JJ N
action NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
other JJ o
behavioural JJ o
or CC o
psychological JJ o
measures NNS o
, , N
although IN N
at IN N
the DT N
4-week JJ N
follow-up JJ N
the DT N
control NN N
group NN N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
, , N
relative VBP N
to TO N
other JJ N
women NNS N
their PRP$ N
age NN N
, , N
as IN N
a DT N
lot NN N
lower JJR N
than IN N
did VBD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
intravaginal JJ i
electrical JJ i
stimulation NN i
( ( i
ES NNP i
) ) i
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ p
women NNS p
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ p
women NNS p
. . p

Secondary JJ N
outcome NN N
variables NNS N
included VBD N
OA NNP o
pain NN o
in IN o
the DT o
target NN o
joint NN o
, , o
patient NN o
's POS o
and CC o
physician NN o
's POS o
global JJ o
assessments NNS o
of IN o
disease NN o
activity NN o
, , o
Short NNP o
Arthritis NNP o
assessment JJ o
Scale NNP o
( ( o
SAS NNP o
) ) o
total NN o
score NN o
, , o
rescue NN o
medication NN o
use NN o
, , o
and CC o
safety NN o
and CC o
tolerability NN o
. . o

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
an DT N
educational JJ i
intervention NN i
for IN N
health NN N
care NN N
providers NNS N
would MD N
result VB N
in IN N
improved JJ N
documentation NN N
of IN N
cases NNS p
of IN p
possible JJ p
physical JJ p
child NN p
abuse NN p
in IN p
children NNS p
< VBP p
36 CD p
months NNS p
old JJ p
treated VBN p
in IN p
the DT p
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
setting NN p
. . p

Therefore RB N
, , N
we PRP N
concluded VBD N
that IN N
the DT N
ipsilateral JJ N
arm NN N
swing NN N
may MD N
partially RB N
affect VB N
the DT N
depression NN o
of IN o
the DT o
soleus JJ o
H-reflex NNP o
during IN N
the DT N
arm NN N
swing NN N
phase NN N
of IN N
walking VBG N
but CC N
is VBZ N
not RB N
responsible JJ N
for IN N
depression NN N
of IN N
the DT N
soleus NN N
H-reflex NNP N
throughout IN N
the DT N
entire JJ N
walking NN N
cycle NN N
. . N

The DT N
acceptability NN o
curve NN o
showed VBD N
that IN N
, , N
even RB N
in IN N
the DT N
case NN N
of IN N
a DT N
maximum JJ o
threshold JJ o
value NN o
of IN o
? . o
per IN o
QALY NNP o
gained VBD o
, , N
the DT N
probability NN N
of IN N
AS NNP N
being VBG N
more RBR N
cost-effective JJ o
than IN N
regular JJ N
cardiac JJ N
surgery NN N
did VBD N
not RB N
reach VB N
beyond IN N
50 CD N
% NN N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
the DT N
5-year JJ N
follow-up JJ N
data NNS N
, , N
there EX N
is VBZ N
strong JJ N
evidence NN N
that IN N
surgical JJ N
manipulation NN N
of IN N
one CD N
or CC N
more JJR N
migraine JJ N
trigger NN N
sites NNS N
can MD N
successfully RB N
eliminate VB N
or CC N
reduce VB N
the DT N
frequency NN o
, , o
duration NN o
, , o
and CC o
intensity NN o
of IN o
migraine NN o
headache NN o
in IN N
a DT N
lasting JJ N
manner NN N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
the DT N
joint JJ N
effect NN N
of IN N
the DT N
methylenetetrahydrofolate NN i
reductase NN i
( ( i
MTHFR NNP i
) ) i
C677T NNP i
and CC i
A1298C NNP i
, , i
methionine NN i
synthase NN i
( ( i
MTR NNP i
) ) i
A2756G NNP i
, , i
and CC i
methionine JJ i
synthase NN i
reductase NN i
( ( i
MTRR NNP i
) ) i
A66G NNP i
polymorphisms NN i
on IN N
folate JJ p
deficiency NN p
in IN p
a DT p
Chinese JJ p
hypertensive JJ p
population NN p
. . p

Using VBG N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
, , N
we PRP N
examined VBD N
whether IN N
oxytocin NN i
would MD N
enhance VB N
emotion NN o
recognition NN o
from IN N
facial JJ N
sections NNS N
of IN N
the DT N
eye NN N
vs VBZ N
the DT N
mouth JJ N
region NN N
and CC N
modulate JJ N
regional JJ N
activity NN N
in IN N
brain NN N
areas NNS N
associated VBN N
with IN N
face NN N
perception NN N
in IN N
both DT N
adults NNS N
with IN N
AS NNP N
, , N
and CC N
a DT N
neurotypical JJ N
control NN N
group NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
clomipramine NN i
hydrochloride NN i
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
with IN N
unique JJ N
anti-obsessional JJ N
properties NNS N
, , N
is VBZ N
differentially RB N
effective JJ N
for IN N
obsessive-compulsive JJ N
and CC N
stereotyped VBD N
motor NN N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
compared VBN N
with IN N
placebo NN i
and CC N
with IN N
the DT N
noradrenergic JJ i
tricyclic JJ i
antidepressant NN i
agent NN i
, , i
desipramine JJ i
hydrochloride NN i
. . i

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN o
relief NN o
scores NNS o
, , o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
, , o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
, , o
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
therapy NN o
due JJ o
to TO o
an DT o
unsatisfactory JJ o
analgesic JJ o
response NN o
, , o
and CC o
global JJ o
assessment NN o
scores NNS o
. . o

OBJECTIVE IN N
We PRP N
collected VBD N
preliminary JJ N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN i
to TO N
improve VB N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
in IN N
a DT N
sample NN N
of IN N
persons NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
and CC p
acquired VBD p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
. . p

Repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
is VBZ N
a DT N
safe JJ N
and CC N
efficacious JJ N
technique NN N
when WRB N
targeting VBG N
specific JJ N
areas NNS N
of IN N
cortical JJ N
dysfunction NN N
in IN N
major JJ N
depressive JJ N
disorder NN N
, , N
and CC N
a DT N
similar JJ N
approach NN N
could MD N
yield VB N
therapeutic JJ N
benefits NNS N
in IN N
ASD NNP N
, , N
if IN N
applied VBN N
to TO N
relevant VB N
cortical JJ N
regions NNS N
. . N

CONCLUSIONS VB N
This DT N
4-site JJ N
PEP NNP N
regimen NNS N
proved VBD N
as RB N
immunogenic JJ N
as IN N
current JJ N
regimens NNS N
, , N
and CC N
has VBZ N
the DT N
advantages NNS N
of IN N
requiring VBG N
fewer JJR N
clinic JJ N
visits NNS N
, , N
being VBG N
more RBR N
practicable JJ N
, , N
and CC N
having VBG N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
, , N
especially RB N
in IN N
inexperienced JJ N
hands NNS N
, , N
than IN N
the DT N
2-site JJ N
regimen NNS N
. . N

CONCLUSION NNP N
Imiquimod NNP N
5 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
external JJ N
genital NN N
and CC N
perianal JJ N
warts NNS N
and CC N
provides VBZ N
a DT N
significant JJ N
benefit NN N
in IN N
comparison NN N
with IN N
vehicle NN N
cream NN N
, , N
independent JJ N
of IN N
gender NN N
, , N
initial JJ N
wart NN N
size NN N
, , N
duration NN N
of IN N
current JJ N
outbreak NN N
of IN N
warts NNS N
, , N
previous JJ N
wart NN N
treatment NN N
, , N
or CC N
tobacco NN N
use NN N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
( ( i
QTLM NNP i
) ) i
computer NN i
game NN i
on IN N
dietary JJ o
behaviors NNS o
, , o
physical JJ o
activity NN o
behaviors NNS o
, , o
and CC o
psychosocial JJ o
factors NNS o
among IN N
ethnically RB p
diverse JJ p
children NNS p
in IN p
Texas NNP p
. . p

In IN N
the DT N
entire JJ N
study NN N
sample NN N
, , N
correlations NNS N
between IN N
SSQ NNP o
patient JJ o
ratings NNS o
and CC o
QLQ-C30 JJ o
change NN o
scores NNS o
were VBD N
lower JJR N
than IN N
previously RB N
reported VBN N
, , N
ranging VBG N
between IN N
0.15 CD N
and CC N
0.24 CD N
for IN N
the DT N
four CD N
different JJ N
domains NNS N
, , N
but CC N
were VBD N
higher JJR N
when WRB N
QOL NNP N
scores VBZ N
producing VBG N
ceiling NN N
effects NNS N
were VBD N
omitted VBN N
. . N

Hence RB N
the DT N
current JJ N
trial NN N
was VBD N
conducted VBN N
with IN N
the DT N
objective NN N
to TO N
show VB N
the DT N
therapeutic JJ N
equivalence NN N
of IN N
two CD N
treatments NNS N
( ( N
placebo NN i
and CC i
amoxycillin NN i
) ) i
for IN N
children NNS p
presenting VBG p
with IN p
non-severe JJ p
pneumonia NN p
with IN p
wheeze NN p
, , p
who WP p
have VBP p
persistent VBN p
fast RB p
breathing NN p
after IN p
nebulisation NN p
with IN p
salbutamol NN p
, , p
and CC p
have VBP p
normal JJ p
chest NN p
radiograph NN p
. . p

The DT N
recommendation NN N
for IN N
practice NN N
in IN N
settings NNS N
that WDT N
are VBP N
similar JJ N
to TO N
the DT N
Danish JJ N
setting NN N
is VBZ N
to TO N
provide VB N
follow-up JJ N
with IN N
referral JJ N
to TO N
available JJ N
local JJ N
support NN N
programmes NNS N
when WRB N
needed VBN N
, , N
and CC N
to TO N
restrict VB N
large JJ N
multifaceted VBN N
intervention NN N
programmes NNS N
to TO N
patients NNS p
and CC p
caregivers NNS p
with IN p
special JJ p
needs NNS N
until IN N
further JJ N
evidence NN N
for IN N
cost-effectiveness JJ N
emerges NNS N
. . N

The DT N
Self-Care JJ i
Rehabilitation NNP i
in IN N
Pediatric NNP p
Asthma NNP p
( ( p
SCRPA NNP p
) ) p
project NN p
was VBD p
designed VBN p
to TO p
ascertain VB p
the DT p
level NN p
to TO p
which WDT p
children NNS p
with IN p
asthma NN p
are VBP p
able JJ p
to TO p
acquire VB p
the DT p
asthma NN p
knowledge NN p
and CC p
skills NNS p
presented VBN p
in IN p
a DT p
self-management JJ p
training NN p
program NN p
conducted VBN p
by IN p
the DT p
American NNP p
Lung NNP p
Association NNP p
of IN p
Utah NNP p
and CC p
the DT p
effect NN p
of IN p
such JJ p
training NN p
on IN p
the DT p
asthma JJ p
experience NN p
. . p

CONCLUSIONS NNP N
Differences NNS N
in IN N
outcomes NNS N
between IN N
medical JJ N
and CC N
chiropractic JJ N
care NN N
without IN N
physical JJ N
therapy NN N
or CC N
modalities NNS N
are VBP N
not RB N
clinically RB N
meaningful JJ N
, , N
although IN N
chiropractic JJ i
may MD N
result VB N
in IN N
a DT N
greater JJR N
likelihood NN N
of IN N
perceived JJ N
improvement NN N
, , N
perhaps RB N
reflecting VBG N
satisfaction NN N
or CC N
lack NN N
of IN N
blinding NN N
. . N

RESULTS NNP N
TB1 NNP N
( ( N
containing VBG N
ginseng NN N
leaf NN N
, , N
cistanche NN N
, , N
fleeceflower JJR N
root NN N
, , N
immature NN N
bitter JJ N
orange NN N
, , N
rhubarb NN N
, , N
etc FW N
) ) N
could MD N
improve VB N
various JJ N
symptoms NNS N
of IN N
aging VBG N
, , N
and CC N
had VBD N
the DT N
effect NN N
in IN N
regulating VBG o
immune NN o
and CC o
endocrinal JJ o
function NN o
, , o
scavenging VBG o
free JJ o
radicals NNS o
and CC o
adjusting VBG o
coli JJ o
flora NNS o
. . o

The DT N
RESCUEicp NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
Surgery NNP N
with IN N
Craniectomy NNP N
for IN N
Uncontrollable JJ N
Elevation NN N
of IN N
intracranial JJ N
pressure NN N
) ) N
study NN N
has VBZ N
been VBN N
established VBN N
to TO N
determine VB N
whether IN N
decompressive JJ i
craniectomy NN i
has VBZ N
a DT N
role NN N
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
traumatic JJ p
brain NN p
injury NN p
and CC p
raised VBD p
intracranial JJ p
pressure NN p
that WDT p
does VBZ p
not RB p
respond VB p
to TO p
initial JJ p
treatment NN p
measures NNS p
. . p

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
iron NN p
deficiency NN p
anemia NN p
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
, , N
rapid JJ N
IV NNP N
administration NN N
of IN N
large JJ N
doses NNS N
of IN N
a DT N
new JJ N
iron NN N
agent NN N
, , N
ferric JJ N
carboxymaltose NN N
, , N
is VBZ N
more RBR N
effective JJ N
than IN N
oral JJ N
iron NN i
therapy NN i
in IN N
correcting VBG N
anemia NN N
, , N
replenishing VBG N
iron NN N
stores NNS N
, , N
and CC N
improving VBG N
quality NN o
of IN o
life NN o
. . o

Asthma JJ o
medications NNS o
were VBD N
stepped VBN N
up RP N
when WRB N
indicated VBN N
after IN N
46.0 CD N
% NN N
of IN N
these DT N
visits NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
35.6 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
when WRB N
asthma NN N
symptoms NNS N
warranted VBD N
a DT N
step NN N
up RB N
in IN N
therapy NN N
, , N
medication NN N
changes NNS N
occurred VBD N
earlier RBR N
among IN N
the DT N
intervention NN N
children NNS N
. . N

Although IN N
TOISD NNP N
might MD N
not RB N
be VB N
necessarily RB N
on IN N
surgical JJ N
incisional JJ N
site NN N
not RB N
infested VBN N
with IN N
bacteria NNS N
for IN N
the DT N
initial JJ N
post-operation NN N
days NNS N
, , N
it PRP N
is VBZ N
helpful JJ N
in IN N
preventing VBG N
further JJ N
transcription NN N
and CC N
division NN N
for IN N
opportunistic JJ N
bacteria NNS N
, , N
thus RB N
might MD N
reduce VB N
the DT N
risk NN N
of IN N
superficial JJ N
incisional JJ N
SSI NNP N
. . N

The DT N
level NN o
of IN o
an DT o
absence NN o
of IN o
cold JJ o
sensation NN o
, , o
the DT o
level NN o
of IN o
pinprick JJ o
analgesia NN o
, , o
and CC o
time NN o
to TO o
achieve VB o
sensory JJ o
block NN o
to TO o
T4 NNP o
level NN o
of IN o
Group NNP o
H NNP o
was VBD N
significantly RB N
higher JJR N
than IN N
Group NNP N
B NNP N
and CC N
Group NNP N
L. NNP N
The DT N
degree NN o
of IN o
motor NN o
block NN o
was VBD N
comparable JJ N
in IN N
all DT N
groups NNS N
. . N

To TO N
determine VB N
the DT N
effects NNS N
of IN N
dietary JJ i
glycemic JJ i
load NN i
( ( i
GL NNP i
) ) i
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
during IN N
weight JJ o
loss NN o
, , o
body NN o
weight NN o
and CC o
eating VBG o
behavior JJ o
self-efficacy NN o
were VBD N
measured VBN N
every DT N
six CD N
months NNS N
in IN N
overweight JJ p
adults NNS p
participating VBG p
in IN p
a DT p
12-mo JJ p
randomized JJ p
trial NN p
testing VBG i
energy-restricted JJ i
diets NNS i
differing VBG i
in IN i
GL NNP i
. . i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ i
II-receptor NNP i
blockers NNS i
( ( i
ARB NNP i
) ) i
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ i
calcium NN i
channel NN i
blockers NNS i
( ( i
CCB NNP i
) ) i
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ p
AF NNP p
with IN p
hypertension NN p
. . p

CONCLUSIONS NNP N
With IN N
regard NN N
to TO N
gait VB o
kinematics NNS o
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
( ( N
three CD N
months NNS N
) ) N
, , N
the DT N
present JJ N
study NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
for IN N
patients NNS N
who WP N
underwent VBD N
a DT N
total JJ N
hip NN N
arthroplasty NN N
through IN N
a DT N
minimally RB N
invasive JJ N
Watson-Jones NNS N
approach NN N
in IN N
comparison NN N
with IN N
those DT N
who WP N
were VBD N
managed VBN N
with IN N
a DT N
standard JJ i
transgluteal NN i
approach NN i
. . i

This DT N
study NN N
suggests VBZ N
that IN N
, , N
in IN N
this DT N
clinical JJ N
setting NN N
, , N
the DT N
addition NN N
of IN N
deep JJ N
breathing NN N
and CC N
coughing NN N
exercises NNS N
to TO N
a DT N
physiotherapist-directed JJ N
program NN N
of IN N
early JJ N
mobilisation NN N
does VBZ N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
significant JJ N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
high JJ p
risk NN p
open JJ p
abdominal JJ p
surgery NN p
subjects NNS p
. . p

This DT N
lack NN N
of IN N
interest NN N
is VBZ N
regretful JJ N
particularly RB N
considering VBG N
the DT N
fact NN N
that IN N
anesthetics NNS N
during IN N
neurosurgery NN N
are VBP N
an DT N
issue NN N
of IN N
extreme JJ N
sensitivity NN N
and CC N
subtlety NN N
, , N
where WRB N
the DT N
cerebral JJ N
oxygenation NN N
process NN N
plays VBZ N
a DT N
significant JJ N
role NN N
in IN N
the DT N
neuroprotective JJ N
mechanisms NN N
. . N

BACKGROUND NNP N
Unstuck NNP i
and CC i
On IN i
Target NNP i
( ( i
UOT NNP i
) ) i
is VBZ N
an DT N
executive JJ N
function NN N
( ( N
EF NNP N
) ) N
intervention NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
targeting VBG N
insistence NN N
on IN N
sameness NN N
, , N
flexibility NN N
, , N
goal-setting NN N
, , N
and CC N
planning VBG N
through IN N
a DT N
cognitive-behavioral JJ N
program NN N
of IN N
self-regulatory JJ N
scripts NNS N
, , N
guided/faded VBD N
practice NN N
, , N
and CC N
visual/verbal JJ N
cueing NN N
. . N

CONCLUSIONS JJ N
Patients NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
, , p
who WP p
were VBD p
younger JJR p
had VBD p
higher JJR p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
or CC p
comorbid NN p
angina NNS p
pectoris NN p
, , p
had VBD p
lower JJR p
activity NN p
levels NNS p
, , p
lived VBD p
in IN p
Eastern NNP p
Europe NNP p
or CC p
were VBD p
taking VBG p
hypoglycemic JJ p
agents NNS p
, , p
were VBD p
more RBR p
likely JJ p
to TO p
have VB p
impaired VBN p
QOL NNP p
and CC p
depression NN p
. . p

There EX N
was VBD N
no DT N
relationship NN N
between IN N
plasma NN o
levels NNS o
and CC o
age NN o
, , o
level NN o
of IN o
intellectual JJ o
functioning NN o
, , o
scores NNS o
on IN o
the DT o
14 CD o
selected VBD o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
items NNS o
, , o
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Global NNP o
Clinical NNP o
Consensus NNP o
, , o
and CC o
the DT o
CPRS NNP o
hyperactivity NN o
factor NN o
. . o

Quantitative JJ N
measures NNS N
of IN N
pain NN o
intensity NN o
, , o
situational JJ o
anxiety NN o
, , o
and CC o
pain NN o
distress NN o
( ( N
as IN N
perceived VBN N
by IN N
the DT N
parent NN N
) ) N
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
7-point JJ o
Facial NNP o
Pain NNP o
Scale NNP o
, , o
State NNP o
Trait NNP o
Anxiety NNP o
Inventory NNP o
for IN N
Children NNP N
, , N
and CC N
a DT N
visual JJ N
analog NN N
scale NN N
, , N
respectively RB N
, , N
before IN N
and CC N
after IN N
laceration NN N
repair NN N
. . N

The DT N
present JJ N
study NN N
sets VBZ N
out RP N
to TO N
test VB N
the DT N
effects NNS N
of IN N
testosterone NN i
administration NN N
in IN N
healthy JJ p
female NN p
volunteers NNS p
using VBG N
an DT N
objective JJ N
implicit JJ N
measure NN N
of IN N
social JJ N
motivational JJ N
behavior NN N
: : N
the DT N
social JJ N
Approach-Avoidance NNP N
Task NNP N
, , N
a DT N
reaction NN N
time NN N
task NN N
requiring VBG N
participants NNS N
to TO N
approach VB N
or CC N
avoid VB N
visually RB N
presented VBN N
emotional JJ N
( ( N
happy JJ N
, , N
angry JJ N
, , N
and CC N
neutral JJ N
) ) N
faces VBZ N
. . N

Therefore RB N
, , N
the DT N
bleeding VBG o
complications NNS o
of IN N
intermittent JJ N
heparin NN i
therapy NN i
could MD N
have VB N
been VBN N
due JJ N
to TO N
the DT N
higher JJR N
dose NN N
, , N
and CC N
the DT N
recurrences NNS N
associated VBN N
with IN N
continuous JJ N
heparin NNS N
therapy NN N
may MD N
have VB N
resulted VBN N
from IN N
lower JJR N
doses NNS N
rather RB N
than IN N
from IN N
differences NNS N
in IN N
the DT N
method NN N
of IN N
administration NN N
. . N

METHODS NNP N
To TO N
enter VB N
the DT N
study NN N
, , N
children NNS p
with IN p
sickle NN p
cell NN p
anemia NN p
and CC p
no DT p
history NN p
of IN p
stroke NN p
had VBD p
to TO p
have VB p
undergone JJ p
two CD p
transcranial JJ p
Doppler NNP p
studies NNS p
that WDT p
showed VBD p
that IN p
the DT p
time-averaged JJ p
mean JJ p
blood-flow JJ p
velocity NN p
in IN p
the DT p
internal JJ p
carotid NN p
or CC p
middle JJ p
cerebral JJ p
artery NN p
was VBD p
200 CD p
cm JJ p
per IN p
second NN p
or CC p
higher JJR p
. . p

Clinical JJ o
assessment NN o
was VBD o
based VBN o
on IN o
House-Brackmann NNP o
scale NN o
( ( o
H-B NNP o
) ) o
, , o
neurophysiological JJ o
diagnostics NNS o
included VBD o
facial JJ o
electroneurography NN o
[ NNP o
ENG NNP o
, , o
compound NN o
muscle NN o
action NN o
potential NN o
( ( o
CMAP NNP o
) ) o
] NN o
, , o
mimetic JJ o
muscle NN o
electromyography NN o
( ( o
EMG NNP o
) ) o
and CC o
blink-reflex JJ o
examinations NNS o
( ( o
BR NNP o
) ) o
. . o

BACKGROUND IN N
The DT N
primary JJ N
aim NN N
and CC N
central JJ N
hypothesis NN N
of IN N
the DT N
study NN N
are VBP N
that IN N
a DT N
designated VBN N
syncope NN N
unit NN N
in IN N
the DT N
emergency NN N
department NN N
improves VBZ N
diagnostic JJ N
yield NN N
and CC N
reduces NNS N
hospital JJ N
admission NN N
for IN N
patients NNS p
with IN p
syncope NN p
who WP p
are VBP p
at IN p
intermediate JJ p
risk NN p
for IN p
an DT p
adverse JJ p
cardiovascular JJ p
outcome NN p
. . p

CONCLUSION NN N
It PRP N
is VBZ N
possible JJ N
to TO N
test VB N
the DT N
effects NNS N
of IN N
LKM NNP N
with IN N
tactile JJ N
and CC N
non-tactile JJ N
blinding NN N
strategies NNS N
; : N
even RB N
with IN N
blinding VBG N
in IN N
this DT N
small JJ N
preliminary JJ N
study NN N
, , N
subjects NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
well-being NN N
which WDT N
were VBD N
reflected VBN N
in IN N
objective JJ N
physiologic JJ N
measures NNS N
of IN N
autonomic JJ N
activity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
establish VB N
a DT N
model NN N
for IN N
randomized VBN N
controlled JJ N
trial NN N
research NN N
, , N
identify VB N
appropriate JJ N
outcome NN N
measures NNS N
, , N
and CC N
address VB N
the DT N
effectiveness NN N
of IN N
sensory JJ i
integration NN i
( ( i
SI NNP i
) ) i
interventions NNS i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Secondary JJ N
outcomes NNS N
included VBD N
resolution NN o
of IN o
sleep JJ o
disturbances NNS o
, , o
sleep VBP o
quality NN o
measured VBN o
by IN o
the DT o
Pittsburgh NNP o
Sleep NNP o
Quality NNP o
Index NNP o
( ( o
PSQI NNP o
) ) o
questionnaire NN o
, , o
and CC o
work NN o
productivity NN o
measured VBN o
by IN o
the DT o
Work NNP o
Productivity NNP o
and CC o
Activity NNP o
Impairment NNP o
Questionnaire NNP o
. . o

Patient-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
of IN N
midazolam NN i
at IN N
3-minute JJ N
intervals NNS N
provides VBZ N
comparable JJ N
conditions NNS N
to TO N
that DT N
of IN N
doctor-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
at IN N
1-minute JJ N
intervals NNS N
, , N
except IN N
for IN N
the DT N
longer JJR N
duration NN N
taken VBN N
for IN N
the DT N
patients NNS N
to TO N
achieve VB N
satisfactory JJ N
sedation NN N
prior RB N
to TO N
surgery NN N
. . N

DISCUSSION NN N
If IN N
the DT N
trial NN N
demonstrates VBZ N
that IN N
diamorphine NN i
provides VBZ N
better RBR N
analgesia NN N
with IN N
fewer JJR N
side NN N
effects NNS N
in IN N
mother NN p
and CC p
neonate NN p
this DT N
could MD N
lead VB N
to TO N
a DT N
change NN N
in IN N
national JJ N
practice NN N
and CC N
result NN N
in IN N
diamorphine NN i
becoming VBG N
the DT N
preferred JJ N
intramuscular JJ N
opioid NN N
for IN N
analgesia NN N
in IN N
labour NN N
. . N

Inclusion NN p
criteria NNS p
were VBD p
as IN p
follows VBZ p
: : p
patients NNS p
with IN p
permanent JJ p
molars NNS p
presenting VBG p
deep JJ p
caries NNS p
lesions NNS p
( ( p
lesion NN p
affecting VBG p
? . p
1/2 CD p
of IN p
the DT p
dentin NN p
on IN p
radiographic JJ p
examination NN p
) ) p
, , p
positive JJ p
response NN p
to TO p
a DT p
cold JJ p
test NN p
, , p
absence NN p
of IN p
spontaneous JJ p
pain NN p
, , p
negative JJ p
sensitivity NN p
to TO p
percussion NN p
, , p
and CC p
absence NN p
of IN p
periapical JJ p
lesions NNS p
( ( p
radiographic JJ p
examination NN p
) ) p
. . p

In IN N
conclusion NN N
, , N
our PRP$ N
findings NNS N
revealed VBD N
the DT N
feasibility NN N
of IN N
including VBG N
greater JJR N
levels NNS N
of IN N
microalgal JJ i
biomass NN i
as IN N
a DT N
source NN N
of IN N
feed NN N
protein NN N
for IN N
laying VBG p
hens NNS p
and CC N
a DT N
novel JJ N
potential NN N
of IN N
the DT N
biomass NN N
in IN N
improving VBG N
dietary JJ N
protein NN N
digestion NN N
and CC N
body NN N
protein VBP N
metabolism NN N
than IN N
previously RB N
perceived VBN N
. . N

This DT N
indicated VBD N
the DT N
beneficial JJ N
effect NN N
on IN N
ulcers NNS N
of IN N
oral JJ N
administration NN N
of IN N
EGF NNP N
with IN N
agents NNS N
allowing VBG N
it PRP N
to TO N
remain VB N
at IN N
high JJ N
levels NNS N
in IN N
the DT N
stomach NN N
, , N
whereas IN N
most JJS N
reports NNS N
suggested VBD N
less RBR N
effect NN N
of IN N
oral JJ N
EGF NNP N
on IN N
healing NN o
of IN o
gastroduodenal JJ o
ulcers NNS o
. . o

These DT N
results NNS N
provide VBP N
insight RB N
into IN N
the DT N
nature NN N
of IN N
multisensory NN N
processing NN N
while IN N
also RB N
revealing VBG N
a DT N
continuum NN N
over IN N
which WDT N
perceptual JJ N
abilities NNS N
correlate VBP N
with IN N
symptoms NNS N
of IN N
autism NN N
and CC N
that IN N
this DT N
continuum NN N
is VBZ N
not RB N
just RB N
specific JJ N
to TO N
clinical JJ N
populations NNS N
but CC N
is VBZ N
present JJ N
within IN N
the DT N
general JJ N
population NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
empirical JJ N
treatment NN N
with IN N
antifungal JJ N
drugs NNS N
in IN N
the DT N
26 CD N
weeks NNS N
after IN N
enrolment NN N
( ( N
for IN N
the DT N
biomarker-based JJ N
diagnostic JJ N
strategy NN N
, , N
a DT N
single JJ N
postive JJ N
galactomannan NN N
or CC N
PCR NNP N
result NN N
was VBD N
deemed VBN N
insufficient JJ N
to TO N
confirm VB N
invasive JJ N
aspergillosis NN N
, , N
so RB N
treatment NN N
in IN N
this DT N
context NN N
was VBD N
classified VBN N
as IN N
empirical JJ N
) ) N
. . N

A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ N
screening NN N
for IN N
endometrial JJ N
cancer NN N
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN N
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
relative JJ N
efficacy NN N
and CC N
technical JJ N
ease NN N
of IN N
use NN N
of IN N
eight CD N
different JJ N
agents NNS N
for IN N
endoscopic JJ N
hemostasis NN N
and CC N
obliteration NN N
of IN N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
a DT N
canine NN N
model NN N
, , N
as IN N
no DT N
comparative JJ N
data NNS N
are VBP N
available JJ N
on IN N
gastric JJ N
variceal NN N
sclerotherapy NN N
. . N

The DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
statins NNS i
on IN N
the DT N
levels NNS N
of IN N
haemostatic JJ N
variables NNS N
reflecting VBG N
procoagulant NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
, , N
with IN N
the DT N
hypothesis NN N
that WDT N
statins VBZ N
might MD N
beneficially RB N
modify VB N
these DT N
levels NNS N
. . N

The DT N
task NN N
was VBD N
optimized VBN N
for IN N
investigation NN N
of IN N
the DT N
abilities NNS N
to TO N
infer VB N
another DT N
person NN N
's POS N
social JJ N
emotions NNS N
and CC N
beliefs NNS N
distinctively RB N
so RB N
as IN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
oxytocin VBZ i
improves VBZ N
deficit NN N
in IN N
inferring VBG N
others NNS N
' POS N
social JJ N
emotions NNS N
rather RB N
than IN N
beliefs NNS N
, , N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
. . N

This DT N
study NN N
clearly RB N
shows VBZ N
that IN N
a DT N
pretreatment NN N
with IN N
a DT N
conventional JJ N
dose NN N
of IN N
formoterol NN i
, , i
salmeterol NN i
, , i
or CC i
oxitropium JJ i
bromide NN i
does VBZ N
not RB N
preclude VB N
the DT N
possibility NN N
of IN N
inducing VBG N
a DT N
further JJ N
bronchodilation NN N
with IN N
salbutamol NN i
in IN N
patients NNS p
suffering VBG p
from IN p
partially RB p
reversible JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

KEY NNP N
FINDINGS NNP N
Examination NNP N
of IN N
the DT N
erythema JJ o
time NN o
course NN o
by IN N
a DT N
sensitive JJ N
spectrophotometric JJ N
reflectance NN N
method NN N
showed VBD N
a DT N
significant JJ N
increase NN N
of IN N
skin JJ o
reactions NNS o
in IN N
the DT N
non-treated JJ N
group NN N
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
and CC N
maximal JJ N
alterations NNS N
between IN N
the DT N
fourth JJ N
and CC N
sixth JJ N
week NN N
. . N

Additional JJ N
investigations NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
potential NN N
for IN N
interactions NNS N
in IN N
elderly JJ N
patients NNS N
with IN N
dementia NNS N
who WP N
may MD N
eliminate VB N
risperidone NN N
and CC N
donepezil VB N
more JJR N
slowly RB N
and CC N
thus RB N
be VB N
more RBR N
vulnerable JJ N
to TO N
clinical JJ N
drug NN N
interactions NNS N
than IN N
the DT N
young JJ p
healthy JJ p
subjects NNS p
examined VBN N
in IN N
this DT N
study NN N
. . N

The DT N
oil NN N
supplementation NN N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ o
filtration NN o
rate NN o
, , o
effective JJ o
renal JJ o
plasma NN o
flow NN o
, , o
filtration NN o
fraction NN o
or CC o
blood NN o
pressure NN o
, , N
which WDT N
does VBZ N
not RB N
exclude VB N
effects NNS N
of IN N
the DT N
cyclosporin-induced JJ i
rigidified JJ i
erythrocytes NNS N
in IN N
the DT N
acute JJ p
phase NN p
of IN p
renal JJ p
transplantation NN p
. . p

We PRP N
conclude VBP N
that IN N
smoking VBG N
adversely RB N
affects VBZ N
duodenal JJ N
ulcer NN N
healing NN N
by IN N
cimetidine NN i
and CC N
hastens VBZ N
subsequent JJ N
relapse NN N
, , N
and CC N
that IN N
sucralfate NN N
overcomes VBZ N
the DT N
adverse JJ N
effect NN N
of IN N
smoking VBG N
on IN N
healing NN N
as IN N
encountered VBN N
with IN N
cimetidine NN i
, , N
and CC N
results NNS N
in IN N
a DT N
subsequent JJ N
remission NN N
period NN N
double JJ N
that IN N
of IN N
cimetidine NN i
. . i

Parameters NNS N
assessed VBD N
included JJ N
severity NN o
of IN o
SDB NNP o
( ( o
polysomnography NN o
) ) o
, , o
subjective JJ o
and CC o
objective JJ o
loudness NN o
of IN o
snoring VBG o
( ( o
visual JJ o
analog NN o
scale NN o
and CC o
SNAP NNP o
recording NN o
) ) o
, , o
sleepiness NN o
( ( o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
) ) o
, , o
and CC o
anatomic JJ o
changes NNS o
( ( o
upper JJ o
airway RB o
endoscopy NN o
) ) o
, , N
as RB N
well RB N
as IN N
demographic JJ N
factors NNS N
. . N

Retrospective JJ N
subset NN N
analyses NNS N
showed VBD N
that IN N
, , N
irrespective NN N
of IN N
the DT N
cutoff NN N
used VBD N
or CC N
the DT N
treatment NN N
arm NN N
, , N
MET NNP N
expression NN N
did VBD N
not RB N
show VB N
prognostic JJ N
significance NN N
, , N
in IN N
terms NNS N
of IN N
objective JJ o
response NN o
rate NN o
, , o
progression-free JJ o
survival NN o
, , o
or CC o
overall JJ o
survival NN o
. . o

Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN i
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN o
cancer NN o
mortality NN o
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR o
detection NN o
and CC o
( ( o
b NN o
) ) o
incidence NN o
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN N
due JJ N
to TO N
aspirin-induced JJ o
gastrointestinal JJ o
bleeding NN o
. . o

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
visual JJ i
laser NN i
ablation NN i
treatment NN i
with IN i
neodymium-doped JJ i
yttrium NN i
aluminum NN i
garnet NN i
( ( i
Nd NNP i
: : i
YAG NN i
) ) i
laser NN i
in IN N
male JJ p
patients NNS p
with IN p
urethral JJ p
strictures NNS p
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS N
treated VBN N
with IN N
Sachse NNP i
's POS i
optical JJ i
urethrotomy NN i
. . i

CONCLUSIONS NNP N
Erythromycin NNP i
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
, , N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
acute JJ N
bronchitis NN N
, , N
regardless RB N
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
nebivolol NN i
on IN N
the DT N
metabolic JJ N
state NN N
of IN N
oxidative JJ N
stress NN N
, , N
and CC N
antioxidant JJ N
status NN N
markers NNS N
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome-X NN p
( ( p
CSX NNP p
) ) p
, , N
additionally RB N
, , N
to TO N
compare VB N
with IN N
the DT N
effect NN N
of IN N
metoprolol NN i
treatment NN i
. . i

Research NN N
suggests VBZ N
that IN N
programs NNS N
delivered VBN N
in IN N
collaboration NN N
with IN N
schools NNS N
are VBP N
particularly RB N
effective JJ N
when WRB N
they PRP N
target VBP N
social JJ N
and CC N
emotional JJ N
skill NN N
building NN N
, , N
utilize VB N
an DT N
interactive JJ N
instructional JJ N
style NN N
, , N
provide VB N
opportunities NNS N
for IN N
youth NN N
participation NN N
and CC N
self-direction NN N
, , N
and CC N
include VBP N
explicit JJ N
attempts NNS N
to TO N
enhance VB N
youth RB N
social JJ N
competence NN N
. . N

Prolonged NNP N
critical JJ N
illness NN N
is VBZ N
characterized VBN N
by IN N
feeding-resistant JJ N
wasting NN N
of IN N
protein NN N
, , N
whereas JJ N
reesterification NN N
, , N
instead RB N
of IN N
oxidation NN N
of IN N
fatty JJ N
acids NNS N
, , N
allows VBZ N
fat JJ N
stores NNS N
to TO N
accrue NNS N
and CC N
associate NN N
with IN N
a DT N
low-activity JJ N
status NN N
of IN N
the DT N
somatotropic NN N
and CC N
thyrotropic NN N
axis NN N
, , N
which WDT N
seems VBZ N
to TO N
be VB N
partly RB N
of IN N
hypothalamic JJ N
origin NN N
. . N

Atropine NNP i
and CC i
glycopyrrolate NN i
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
heart NN o
rate NN o
with IN N
a DT N
simultaneous JJ N
decrease NN N
in IN N
pressure NN o
rate NN o
quotient NN o
( ( o
PRQ NNP o
) ) o
, , N
while IN N
scopolamine NN i
caused VBD N
a DT N
significant JJ N
decrease NN N
in IN N
heart NN o
rate NN o
with IN N
a DT N
simultaneous JJ N
increase NN N
in IN N
PRQ NNP o
. . o

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ i
treatment NN i
in IN N
patients NNS p
with IN p
acute JJ p
bronchitis NN p
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS N
will MD N
respond VB N
to TO N
therapy VB N
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP o
Clinically NNP o
Important NNP o
Change NNP o
( ( o
MCIC NNP o
) ) o
of IN o
the DT o
pain NN o
intensity NN o
numerical JJ o
rating NN o
scale NN o
( ( o
PI-NRS NNP o
) ) o
, , o
the DT o
Quebec NNP o
Back NNP o
Pain NNP o
Disability NNP o
Scale NNP o
( ( o
QBPDS NNP o
) ) o
, , o
and CC o
the DT o
Euroqol NNP o
( ( o
EQ NNP o
) ) o
in IN N
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
. . p

Primary JJ N
efficacy NN N
was VBD N
based VBN N
on IN N
data NNS N
kept VBN N
by IN N
primary JJ N
caregivers NNS N
, , N
including VBG N
a DT N
daily JJ o
diary NN o
; : o
daily JJ o
visual JJ o
analogue NN o
scales NNS o
of IN o
affection NN o
, , o
reciting VBG o
, , o
or CC o
aspects NNS o
of IN o
social JJ o
interaction NN o
; : o
Aberrant NNP o
Behavior NNP o
Checklists NNP o
( ( o
ABC NNP o
, , o
Aman NNP o
) ) o
; : o
and CC o
Clinical NNP o
Global NNP o
Improvement NNP o
scales NNS o
. . o

Compared VBN N
with IN N
placebo NN i
, , N
treatment NN N
with IN N
enzyme NN N
was VBD N
not RB N
associated VBN N
with IN N
clinically RB N
significant JJ N
improvement NN N
in IN N
behaviour NN o
, , o
food NN o
variety NN o
, , o
gastrointestinal JJ o
symptoms NNS o
, , o
sleep JJ o
quality NN o
, , o
engagement NN o
with IN o
therapist NN o
, , o
or CC o
the DT o
Language NNP o
Development NNP o
Survey NNP o
Vocabulary NNP o
or CC o
Sentence NNP o
Complexity NNP o
Scores NNP o
. . o

Results NNS N
from IN N
the DT N
Nutritional NNP N
Prevention NNP N
of IN N
Cancer NNP N
Trial NNP N
conducted VBD N
among IN N
individuals NNS p
at IN p
high JJ p
risk NN p
of IN p
nonmelanoma JJ p
skin NN p
cancer NN p
continue VBP N
to TO N
demonstrate VB N
that IN N
selenium NN i
supplementation NN i
is VBZ N
ineffective JJ N
at IN N
preventing VBG N
basal NN N
cell NN N
carcinoma NN N
and CC N
that IN N
it PRP N
increases VBZ N
the DT N
risk NN N
of IN N
squamous JJ p
cell NN p
carcinoma NN p
and CC p
total JJ p
nonmelanoma NN p
skin NN p
cancer NN p
. . p

Virtual JJ i
reality NN i
colonoscopy NN i
simulation NN i
: : i
a DT N
compulsory NN N
practice NN N
for IN N
the DT N
future JJ N
colonoscopist NN N
? . N
BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIM NNP N
As IN N
for IN N
any DT N
manual JJ N
procedure NN N
, , N
the DT N
learning NN N
curves NNS N
for IN N
medical JJ N
interventions NNS N
can MD N
have VB N
undesirable JJ N
phases NNS N
, , N
occurring VBG N
mostly RB N
in IN N
the DT N
early JJ N
experience NN N
of IN N
applying VBG N
a DT N
technique NN N
. . N

In IN N
view NN N
of IN N
the DT N
correlation NN N
between IN N
angiographic JJ N
progression NN N
and CC N
subsequent JJ N
clinical JJ N
events NNS N
as IN N
demonstrated VBN N
in IN N
several JJ N
large JJ N
trials NNS N
, , N
it PRP N
is VBZ N
not RB N
unrealistic JJ N
to TO N
also RB N
anticipate VB N
in IN N
this DT N
population NN N
, , N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
events NNS N
with IN N
longer JJR N
follow-up NN N
. . N

In IN N
this DT N
comparative NN N
controlled VBD N
trial NN N
, , N
the DT N
ADPT NNP i
vaccines NNS i
were VBD N
more JJR N
immunogenic JJ o
, , N
with IN N
less JJR N
local JJ o
and CC o
systemic JJ o
reactions NNS o
, , N
than IN N
the DT N
WCDPT NNP i
vaccine NN i
but CC N
there EX N
was VBD N
a DT N
considerable JJ N
drop NN N
in IN N
antibody NN o
titres NNS o
in IN N
all PDT N
the DT N
vaccine NN N
groups NNS N
12 CD N
months NNS N
after IN N
primary JJ N
vaccination NN N
. . N

The DT N
intraoral JJ i
fluoride-releasing NN i
system NN i
( ( i
IFRS NNP i
) ) i
containing VBG i
a DT i
sodium NN i
fluoride NN i
core NN i
is VBZ N
a DT N
newly RB N
developed VBN N
, , N
sustained-release JJ N
, , N
passive JJ N
drug NN N
delivery NN N
system NN N
that WDT N
does VBZ N
not RB N
require VB N
patient JJ N
involvement NN N
except IN N
for IN N
periodic JJ N
replacement NN N
, , N
thus RB N
reducing VBG N
the DT N
effect NN N
of IN N
patient NN N
compliance NN N
on IN N
its PRP$ N
effectiveness NN N
in IN N
dental JJ N
caries NNS N
prevention NN N
. . N

Supplementary NNP N
motor NN N
area NN N
involvement NN N
also RB N
relied VBD N
on IN N
the DT N
predictability NN N
( ( N
in IN N
controls NNS N
) ) N
or CC N
presence NN N
( ( N
in IN N
Parkinson NNP N
's POS N
disease NN N
) ) N
of IN N
timing VBG N
cues NNS N
and CC N
not RB N
spatial JJ N
cues NNS N
, , N
indicating VBG N
a DT N
role NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
and CC N
basal NN N
ganglia NNS N
in IN N
the DT N
temporal JJ N
organizations NNS N
of IN N
sequential JJ N
movement NN N
rather RB N
than IN N
the DT N
programming NN N
of IN N
specific JJ N
movements NNS N
. . N

The DT N
use NN N
of IN N
the DT N
IHC NNP N
based VBN N
TMA NNP N
methodology NN N
has VBZ N
shown VBN N
to TO N
be VB N
a DT N
simple JJ o
, , o
cost NN o
effective JJ o
and CC o
a DT o
robust JJ o
alternative NN o
to TO o
gene NN o
expression NN o
profiling VBG o
( ( o
GEP NNP o
) ) o
which WDT N
is VBZ N
currently RB N
regarded VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
classification NN N
in IN N
lymphomas NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
rates NNS o
for IN o
successful JJ o
first-time JJ o
intubation NN o
in IN N
those DT N
patients NNS N
with IN N
tube JJ N
orientation NN N
of IN N
-90 NN N
degrees NNS N
( ( N
with IN N
the DT N
bevel NN N
facing VBG N
posteriorly RB N
) ) N
as IN N
compared VBN N
with IN N
a DT N
tube JJ N
orientation NN N
of IN N
0 CD N
degrees NNS N
( ( N
the DT N
normal JJ N
orientation NN N
with IN N
the DT N
bevel NN N
facing NN N
left VBD N
) ) N
. . N

The DT N
presence NN N
of IN N
metabolic JJ N
syndrome NN N
and CC N
changes NNS N
in IN N
the DT N
mean NN o
of IN o
physiological JJ o
parameters NNS o
such JJ o
as IN o
Hba1c NNP o
, , o
P-glucose NNP o
, , o
P-insulin NNP o
, , o
lipids NNS o
, , o
blood NN o
pressure NN o
, , o
physical JJ o
working NN o
capacity NN o
, , o
body NN o
mass NN o
index NN o
, , o
Heart NNP o
Score NNP o
were VBD o
investigated VBN o
and CC o
participants NNS o
' POS o
satisfaction NN o
assessed VBD o
. . o

With IN N
respect NN N
to TO N
total JJ o
, , o
partial JJ o
colon NN o
, , o
and CC o
rectum VB o
transit NN o
time NN o
, , N
there EX N
seemed VBN N
to TO N
be VB N
a DT N
trend NN N
, , N
although IN N
statistically RB N
nonsignificant JJ N
, , N
toward IN N
faster JJR N
transit NN o
times NNS o
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

However RB N
, , N
the DT N
age NN N
of IN N
the DT N
subjects NNS N
was VBD N
found VBN N
to TO N
be VB N
an DT N
intervening VBG N
variable NN N
: : N
The DT N
older JJR N
subjects NNS N
of IN N
both DT N
groups NNS N
demonstrated VBD N
a DT N
gradual JJ N
but CC N
not RB N
significant JJ N
decline NN N
in IN N
hypertonus NN N
, , N
whereas IN N
the DT N
younger JJR N
adults NNS N
demonstrated VBD N
a DT N
significant JJ N
decline NN N
in IN N
hypertonus NN N
over IN N
a DT N
6-week JJ N
period NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
usual JJ i
care NN i
plus CC i
written VBN i
education NN i
, , i
pharmaceutical JJ i
care NN i
focused VBN i
on IN i
patient JJ i
evaluation NN i
and CC i
follow-up NN i
in IN i
collaboration NN i
with IN i
physicians NNS i
improved VBN N
the DT N
achievement NN N
of IN N
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
treatment NN o
goals NNS o
in IN N
patients NNS p
with IN p
CVD NNP p
and/or VBP p
high JJ p
or CC p
intermediate JJ p
CV NNP p
risk NN p
attending VBG p
community NN p
pharmacies NNS p
in IN p
Spain NNP p
. . p

Wound IN o
infection NN o
scores NNS o
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
placebo NN i
group NN N
, , N
but CC N
the DT N
differences NNS N
in IN N
the DT N
values NNS o
of IN o
infection NN o
scores NNS o
between IN N
both DT N
the DT N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
during IN N
the DT N
7-day JJ N
post-PEG JJ N
follow-up NN N
. . N

RESULTS NNP N
Children NNP N
with IN N
FASD NNP N
were VBD N
more RBR N
variable JJ N
in IN N
saccade JJ o
endpoint NN o
accuracy NN o
, , N
which WDT N
was VBD N
reflected VBN N
by IN N
statistically RB N
significant JJ N
increases NNS N
in IN N
the DT N
error NN o
of IN o
the DT o
initial JJ o
saccade NN o
endpoint NN o
and CC o
the DT o
frequency NN o
of IN o
additional JJ o
, , o
corrective JJ o
saccades NNS o
required VBN o
to TO o
achieve VB o
final JJ o
fixation NN o
. . o

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
large JJ N
amounts NNS N
of IN N
urea JJ i
fertiliser NN i
during IN N
spring NN N
and CC N
the DT N
consequent NN N
increases NNS N
in IN N
concentrations NNS N
of IN N
CP NNP N
in IN N
pasture NN N
and CC N
urea NN N
in IN N
serum NN N
did VBD N
not RB N
negatively RB N
affect JJ N
any DT N
of IN N
the DT N
parameters NNS N
of IN N
reproductive JJ N
performance NN N
of IN N
pasture-fed JJ p
dairy NN p
cows NNS p
that WDT N
were VBD N
assessed VBN N
in IN N
this DT N
study NN N
. . N

CONCLUSION NNP N
Data NNP N
from IN N
this DT N
large JJ N
prospective JJ N
study NN N
suggest VBP N
that IN N
obesity NN N
is VBZ N
important JJ N
throughout IN N
the DT N
natural JJ N
history NN N
of IN N
colorectal JJ N
cancer NN N
, , N
at IN N
least JJS N
in IN N
men NNS N
, , N
and CC N
colorectal JJ N
cancer NN N
prevention NN N
efforts NNS N
should MD N
encourage VB N
the DT N
achievement NN N
and CC N
maintenance NN N
of IN N
a DT N
healthy JJ N
body NN N
weight NN N
in IN N
addition NN N
to TO N
regular JJ N
screenings NNS N
. . N

In IN N
addition NN N
, , N
tumor NN N
miRNA NN N
expression NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
patient JJ N
age NN N
, , N
lymphovascular JJ N
invasion NN N
and CC N
the DT N
KRAS-variant NNP N
, , N
supporting VBG N
the DT N
hypothesis NN N
that WDT N
altered VBD N
tumor NN N
biology NN N
can MD N
be VB N
measured VBN N
by IN N
miRNA JJ N
expression NN N
, , N
and CC N
that IN N
the DT N
KRAS-variant NNP N
likely JJ N
impacts NNS N
endometrial JJ N
tumor NN N
biology NN N
. . N

CONCLUSIONS NNP N
The DT N
findings NNS N
show VBP N
that IN N
fluoxetine NN N
normalises NNS N
frontal JJ N
lobe NN N
dysfunctions NNS N
in IN N
both DT N
disorders NNS N
via IN N
inverse JJ N
effects NNS N
, , N
downregulating VBG N
abnormally RB N
increased VBN N
frontal JJ N
activation NN N
in IN N
ASD NNP N
and CC N
upregulating VBG N
abnormally RB N
decreased VBN N
frontal JJ N
activation NN N
in IN N
ADHD NNP N
, , N
potentially RB N
reflecting VBG N
inverse JJ N
baseline NN N
serotonin NN N
levels NNS N
in IN N
both DT N
disorders NNS N
. . N

PURPOSE VB N
The DT N
authors NNS N
assessed VBD N
the DT N
quality NN o
, , o
diagnostic JJ o
accuracy NN o
and CC o
patient JJ o
acceptability NN o
of IN N
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
colonography NN i
performed VBD N
using VBG N
a DT N
simplified JJ N
bowel NN N
preparation NN N
and CC N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
stool NN N
and CC N
fluid NN N
data NNS N
from IN N
images NNS N
compared VBN N
with IN N
the DT N
examination NN N
obtained VBN N
with IN N
conventional JJ N
preparation NN N
. . N

Outcomes RB N
evaluated VBN N
over RP N
a DT N
12-month JJ N
period NN N
included VBD N
: : N
self-reported JJ o
measures NNS o
of IN o
back RB o
pain NN o
, , o
back RB o
pain NN o
disability NN o
level NN o
, , o
physical JJ o
health NN o
, , o
mental JJ o
health NN o
, , o
and CC o
administrative JJ o
measures NNS o
of IN o
recurrence NN o
, , o
lost VBN o
work NN o
time NN o
, , o
and CC o
medical JJ o
care NN o
utilization NN o
. . o

CONCLUSIONS NNP N
The DT N
regular JJ N
provision NN N
of IN N
a DT N
supplement NN N
of IN N
vitamin NN N
A NNP N
to TO N
children NNS N
, , N
at IN N
a DT N
level NN N
potentially RB N
obtainable JJ N
from IN N
foods NNS N
, , N
in IN N
an DT N
area NN N
where WRB N
vitamin NN N
A DT N
deficiency NN N
and CC N
under-nutrition NN N
are VBP N
documented VBN N
public JJ N
health NN N
problems NNS N
contributed VBD N
substantially RB N
to TO N
children NNS N
's POS N
survival NN N
; : N
mortality NN N
was VBD N
reduced VBN N
on IN N
average NN N
by IN N
54 CD N
percent NN N
. . N

These DT N
results NNS N
question VBP N
the DT N
notion NN N
that IN N
training VBG N
loads NNS N
that WDT N
induce VBP N
greater JJR N
than IN N
10 CD N
% NN N
reduction NN N
in IN N
sprint NN o
velocity NN o
would MD N
negatively RB N
affect VB N
sprint NN o
performance NN o
and CC N
point NN N
out RP N
the DT N
potential JJ N
benefit NN N
of IN N
using VBG N
a DT N
heavier JJR N
load NN N
for IN N
weighted JJ i
sled VBD i
towing NN i
. . i

However RB N
, , N
to TO N
the DT N
authors NNS N
' POS N
knowledge NN N
, , N
no DT N
researchers NNS N
yet RB N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
100 CD N
percent NN N
NovaMin NNP N
powder NN N
with IN N
NovaMin-containing NNP N
toothpaste NN N
in IN N
reducing VBG N
dentin JJ N
hypersensitivity NN N
compared VBN N
with IN N
the DT N
effectiveness NN N
of IN N
NovaMin-containing NNP N
toothpaste NN N
only RB N
and CC N
a DT N
desensitizing NN N
toothpaste NN N
containing VBG N
potassium NN N
nitrate NN N
as IN N
a DT N
control NN N
. . N

Some DT N
of IN N
the DT N
most RBS N
important JJ N
items NNS N
: : N
personality NN N
, , N
motivation NN N
, , N
diet JJ N
history NN N
, , N
bodyweight NN N
, , N
blood NN N
lipids NNS N
and CC N
blood NN N
sugar NN N
anti-smoking JJ N
advice NN N
given VBN N
individually RB N
to TO N
all DT N
smokers NNS N
in IN N
the DT N
intervention NN N
group NN N
advice NN N
that IN N
smoking VBG N
cessation NN N
was VBD N
expected VBN N
to TO N
be VB N
of IN N
special JJ N
importance NN N
for IN N
those DT N
with IN N
elevated JJ N
blood NN N
lipids NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
significant JJ N
differences NNS N
in IN N
improvements NNS N
between IN N
lamotrigine NN i
or CC i
placebo NN i
groups NNS N
on IN N
the DT N
Autism NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
scales NNS o
, , o
the DT o
PL-ADOS NNP o
, , o
or CC o
the DT o
CARS NNPS o
. . o

The DT N
results NNS N
show VBP N
that IN N
postprandial JJ o
levels NNS o
of IN o
both DT o
intact JJ o
neurotensin NN o
and CC N
NH2-terminal JJ N
immunoreactivity NN N
are VBP N
related VBN N
to TO N
the DT N
length NN N
of IN N
the DT N
functioning NN N
ileum NN N
and CC N
that IN N
even RB N
a DT N
difference NN N
in IN N
length NN N
of IN N
25 CD N
cm NN N
is VBZ N
reflected VBN N
in IN N
the DT N
circulating NN N
levels NNS N
of IN N
neurotensin NN N
. . N

Subjects NNS p
with IN p
white-coat JJ p
hypertension NN p
in IN N
Tecumseh NNP N
appear VBP N
to TO N
be VB N
at IN N
an DT N
increased VBN N
risk NN N
for IN N
coronary JJ N
heart NN N
disease NN N
: : N
they PRP N
show VBP N
repeated VBN N
elevated JJ N
clinic NN N
readings NNS N
throughout IN N
their PRP$ N
life NN N
time NN N
, , N
their PRP$ N
parents NNS N
have VBP N
higher JJR N
blood NN o
pressure NN o
, , o
their PRP$ o
high-density NN o
lipoprotein NN o
is VBZ o
decreased VBN o
and CC o
insulin NN o
, , o
cholesterol NN o
and CC o
triglycerides NNS o
are VBP N
elevated VBN N
. . N

This DT N
is VBZ N
possibly RB N
due JJ N
to TO N
the DT N
fact NN N
that IN N
either DT N
subacromial JJ N
tissue NN N
, , N
despite IN N
of IN N
chronic JJ N
inflammation NN N
, , N
does VBZ N
not RB N
show VB N
the DT N
same JJ N
reagibility NN N
as IN N
synovia NN N
or CC N
it PRP N
is VBZ N
a DT N
problem NN N
of IN N
the DT N
nearly RB N
complete JJ N
resection NN N
of IN N
the DT N
subacromial JJ N
bursa NN N
. . N

PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS p
with IN p
disseminated JJ p
small JJ p
noncleaved-cell JJ p
lymphoma NN p
and CC p
B-cell NNP p
leukemia NN p
who WP p
were VBD p
treated VBN p
in IN p
four CD p
successive JJ p
Children NNP p
's POS p
Cancer NNP p
Group NNP p
trials NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
adverse JJ o
mood NN o
effects NNS o
of IN N
two CD N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
during IN N
postmenopausal NN p
hormone CD p
replacement NN p
therapy NN p
( ( p
HRT NNP p
) ) p
in IN p
women NNS p
with IN p
and CC p
without IN p
a DT p
history NN p
of IN p
premenstrual JJ p
syndrome NN p
( ( p
PMS NNP p
) ) p
. . p

Results NNS N
identified VBD N
significant JJ N
positive JJ N
changes NNS N
in IN N
Goal NNP o
Attainment NNP o
Scaling NNP o
scores NNS o
for IN N
both DT N
groups NNS N
; : N
more RBR N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
, , N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
autistic JJ o
mannerisms NNS o
occurred VBD N
in IN N
the DT N
SI NNP N
group NN N
. . N

In IN N
the DT N
healthy JJ N
subjects NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
duration NN o
of IN o
action NN o
with IN N
the DT N
different JJ N
doses NNS N
but CC N
in IN N
duodenal JJ N
ulcer NN N
patients NNS N
a DT N
tenfold JJ N
increase NN N
of IN N
the DT N
antacid NN N
dose NN N
resulted VBD N
in IN N
a DT N
doubling NN N
of IN N
the DT N
duration NN o
of IN o
action NN o
. . o

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
social JJ o
network NN o
salience NN o
, , o
number NN o
of IN o
friendship JJ o
nominations NNS o
, , o
teacher JJ o
report NN o
of IN o
social JJ o
skills NNS o
in IN o
the DT o
classroom NN o
, , o
and CC o
decreased JJ o
isolation NN o
on IN N
the DT N
playground NN N
for IN N
children NNS N
who WP N
received VBD N
PEER NNP i
interventions NNS i
. . i

METHODS NNP N
Outcomes NNP N
7.5 CD N
months NNS N
after IN N
randomisation NN N
were VBD N
acceptability NN o
of IN o
randomisation NN o
, , o
overall JJ o
acceptability NN o
of IN o
and CC o
satisfaction NN o
with IN o
conservative JJ o
management NN o
, , o
impact NN o
on IN o
quality NN o
of IN o
life NN o
, , o
perceived VBD o
need NN o
for IN o
further JJ o
treatment NN o
and CC o
treatment NN o
failure NN o
( ( o
defined VBD o
a DT o
priori NN o
) ) o
. . o

RESULTS NN N
In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
brachial JJ o
systolic JJ o
blood NN o
pressure NN o
was VBD N
successfully RB N
reduced VBN N
, , N
but CC N
the DT N
central JJ o
PP NNP o
increased VBD N
significantly RB N
, , N
whereas IN N
the DT N
other JJ N
blood NN o
pressure NN o
parameters NNS o
did VBD N
not RB N
change NN N
from IN N
the DT N
baseline NN N
. . N

BACKGROUND NNP N
Maximum NNP N
lactate NN N
steady JJ N
state NN N
( ( N
MLSS NNP N
) ) N
is VBZ N
defined VBN N
as IN N
the DT N
highest JJS N
steady JJ N
state NN N
exercise NN N
level NN N
one CD N
can MD N
maintain VB N
while IN N
also RB N
maintaining VBG N
an DT N
equilibrium NN N
between IN N
the DT N
elimination NN N
of IN N
blood NN N
lactate NN N
and CC N
the DT N
diffusion NN N
of IN N
lactate NN N
into IN N
the DT N
blood NN N
. . N

While IN N
the DT N
study NN N
did VBD N
not RB N
yield VB N
definitive JJ N
data NNS N
about IN N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
ESM NNP i
alternatives NNS N
, , N
it PRP N
does VBZ N
provide VB N
a DT N
foundation NN N
for IN N
future JJ N
research NN N
, , N
including VBG N
guidance NN N
related VBN N
to TO N
participant JJ N
profiles NNS N
, , N
stimulus NN N
characteristics NNS N
, , N
and CC N
data NNS N
coding NN N
challenges NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
a DT N
dietary JJ i
supplement NN i
of IN i
soy NN i
protein NN i
, , i
isoflavones NNS i
, , i
and CC i
cotyledon VB i
fiber NN i
( ( i
Abalon NNP i
) ) i
affects VBZ N
cardiovascular JJ o
risk NN o
markers NNS o
, , o
blood NN o
glucose NN o
, , o
and CC o
insulin NN o
levels NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ o
sexual JJ o
behavior NN o
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
. . N

RESULTS VB N
The DT N
postoperative JJ o
hidden JJ o
blood NN o
loss NN o
, , o
knee NN o
swelling NN o
, , o
and CC o
scope NN o
of IN o
ecchymosis NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
flexion NN N
group NN N
than IN N
in IN N
the DT N
extension NN N
group NN N
, , N
and CC N
ROM NNP o
and CC o
straight-leg JJ o
raising VBG o
action NN o
were VBD N
significantly RB N
higher JJR N
during IN N
the DT N
early JJ N
period NN N
after IN N
operation NN N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
single- JJ i
and CC i
multi-dose JJ i
( ( i
5-day JJ i
) ) i
clindamycin NN i
therapy NN i
for IN N
the DT N
prevention NN N
of IN N
inflammatory JJ N
complications NNS N
in IN N
patients NNS p
undergoing VBG p
lower JJR p
third JJ p
molar JJ p
surgical JJ p
extraction NN p
with IN p
bone NN p
removal NN p
. . p

In IN N
this DT N
work NN N
, , N
we PRP N
use VBP N
genome-wide JJ N
data NNS N
on IN N
SNPs NNP N
and CC N
array-based JJ N
expression NN N
measures NNS N
from IN N
mononuclear JJ N
cells NNS N
obtained VBN N
from IN N
a DT N
population-based JJ p
cohort NN p
of IN p
1,799 CD p
Bangladeshi NNP p
individuals NNS p
to TO N
characterize VB N
cis- JJ N
and CC N
trans-eQTLs JJ N
and CC N
determine VB N
if IN N
observed VBN N
trans-eQTL JJ N
associations NNS N
are VBP N
mediated VBN N
by IN N
expression NN N
of IN N
transcripts NNS N
in IN N
cis NN N
with IN N
the DT N
SNPs NNP N
showing VBG N
trans-association NN N
, , N
using VBG N
Sobel NNP N
tests NNS N
of IN N
mediation NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
mainly RB p
pulmonary JJ p
acute NN p
respiratory NN p
distress NN p
syndrome NN p
, , N
using VBG N
high JJ N
mean JJ N
airway NN N
pressure NN N
under IN N
high-frequency NN N
oscillatory JJ N
ventilation NN N
can MD N
worsen VB N
right JJ N
ventricular NN N
function NN N
when WRB N
compared VBN N
with IN N
protective JJ N
conventional JJ N
mechanical JJ N
ventilation NN N
, , N
notably RB N
in IN N
patients NNS N
in IN N
whom WP N
high-frequency NN N
oscillatory NN N
ventilation NN N
produced VBD N
less JJR N
alveolar JJ N
recruitment NN N
of IN N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lungs NNS N
. . N

OBJECTIVE IN N
The DT N
goal NN N
of IN N
this DT N
study NN N
has VBZ N
been VBN N
to TO N
determine VB N
whether IN N
hyaluronic JJ i
acid NN i
( ( i
HA NNP i
) ) i
or CC i
exercise NN i
therapy NN i
can MD N
improve VB N
functional JJ N
parameters NNS N
in IN N
patients NNS p
with IN p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
ankle NN p
. . p

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN o
response NN o
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
an DT N
internet NN N
accessed VBD N
training VBG N
program NN N
that WDT N
included VBD N
Theory NNP N
of IN N
Mind-based JJ i
guidance NN i
, , i
video NN i
models NNS i
, , i
visual JJ i
supports NNS i
, , i
and CC i
virtual JJ i
reality NN i
practice NN i
sessions NNS i
in IN N
teaching VBG N
appropriate JJ N
job NN N
interview NN N
skills NNS N
to TO N
individuals NNS p
with IN p
high JJ p
functioning VBG p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

PURPOSE NN N
To TO N
compare VB N
multi-detector JJ i
row NN i
computed VBN i
tomographic JJ i
( ( i
CT NNP i
) ) i
angiography NN i
and CC i
digital JJ i
subtraction NN i
angiography NN i
( ( i
DSA NNP i
) ) i
prior RB N
to TO N
revascularization NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
arterial JJ p
disease NN p
for IN N
the DT N
purpose NN N
of IN N
assessing VBG N
recommendations NNS N
for IN N
additional JJ N
imaging NN N
and CC N
physician JJ N
confidence NN N
ratings NNS N
for IN N
chosen NN N
therapy NN N
. . N

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
who WP N
had VBD N
more JJR N
than IN N
one CD N
active JJ N
MRI-evident JJ N
lesion NN N
during IN N
4 CD N
weeks NNS N
, , N
valacyclovir FW N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
reduced JJ N
number NN o
of IN o
new JJ o
active JJ o
MRI-evident JJ o
lesions NNS o
and CC N
with IN N
an DT N
increase NN N
in IN N
the DT N
number NN o
of IN o
scans NNS o
free JJ o
of IN o
new JJ o
active JJ o
lesions NNS o
. . o

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implications NNS N
for IN N
the DT N
need NN N
for IN N
more RBR N
effective JJ N
treatments NNS N
in IN N
general JJ N
, , N
and CC N
the DT N
role NN N
of IN N
individual JJ N
differences NNS N
in IN N
the DT N
likelihood NN N
of IN N
returning VBG o
to TO o
smoking VBG o
following VBG N
treatment NN N
for IN N
quitting VBG N
. . N

BACKGROUND NNP N
Atypical NNP N
antipsychotic JJ N
agents NNS N
, , N
which WDT N
block VBP N
postsynaptic JJ N
dopamine NN N
and CC N
serotonin NN N
receptors NNS N
, , N
have VBP N
advantages NNS N
over IN N
traditional JJ N
antipsychotic JJ N
medications NNS N
in IN N
the DT N
treatment NN N
of IN N
adults NNS N
with IN N
schizophrenia NN N
and CC N
may MD N
be VB N
beneficial JJ N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
who WP p
have VBP p
serious JJ p
behavioral JJ p
disturbances NNS p
. . p

CONCLUSION NNP N
The DT N
use NN N
of IN N
materials NNS N
that WDT N
include VBP N
both DT N
fluoride JJ i
and CC i
chlorhexidine NN i
as IN N
routine JJ N
treatment NN N
of IN N
children NNS p
with IN p
disability NN p
may MD N
increase VB N
the DT N
success NN N
of IN N
restorations NNS N
by IN N
improving VBG N
oral JJ N
hygiene NN N
, , N
reduce VB N
the DT N
need NN N
for IN N
future JJ N
restorative JJ N
treatments NNS N
and CC N
thus RB N
the DT N
need NN N
for IN N
general JJ N
anaesthesia NN N
. . N

Results NNS N
largely RB N
supported VBD N
the DT N
study NN N
hypotheses NNS N
such JJ N
that IN N
( ( N
a DT N
) ) N
NTX NNP i
significantly RB N
blunted VBD N
cue-induced JJ N
craving NN N
for IN N
MA NNP N
and CC N
( ( N
b NN N
) ) N
attenuated VBD N
several JJ N
of IN N
the DT N
hedonic JJ N
subjective JJ N
effects NNS N
of IN N
MA NNP N
, , N
including VBG N
craving NN N
, , N
during IN N
controlled VBN N
MA NNP N
administration NN N
and CC N
as IN N
compared VBN N
with IN N
placebo NN i
. . i

IMPLICATIONS NNP N
This DT N
study NN N
demonstrates VBZ N
that IN N
when WRB N
fentanyl NN N
is VBZ N
added VBN N
to TO N
a DT N
local JJ N
anesthetic NN N
, , N
lidocaine NN i
, , N
with IN N
spinal JJ N
anesthesia NN N
for IN N
egg NN N
retrieval NN N
procedures NNS N
, , N
patients NNS N
are VBP N
more RBR N
comfortable JJ N
during IN N
the DT N
procedure NN N
compared VBN N
with IN N
those DT N
who WP N
receive VBP N
lidocaine NN i
alone RB N
. . N

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ i
music NN i
therapy NN i
and CC i
play NN i
sessions NNS i
with IN i
toys NNS i
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

After IN N
two CD N
sessions NNS N
of IN N
treatment NN N
and CC N
after IN N
three CD N
months NNS N
follow-up RB N
, , N
CTTH NNP N
score NN N
( ( N
including VBG N
the DT N
score NN N
of IN N
headache NN o
attack NN o
frequency NN o
and CC o
the DT o
score NN o
of IN o
headache NN o
severity NN o
) ) o
was VBD N
observed VBN N
and CC N
compared VBN N
before IN N
and CC N
after IN N
treatment NN N
separately RB N
. . N

CONCLUSIONS VB N
The DT N
two CD N
doses NNS N
of IN N
leuprolide JJ i
acetate JJ N
3-month JJ N
depot NN N
were VBD N
associated VBN N
with IN N
an DT N
acceptable JJ N
safety NN N
profile NN N
and CC N
provided VBD N
maintenance NN N
of IN N
LH NNP N
suppression NN N
in IN N
the DT N
majority NN N
of IN N
children NNS p
with IN p
CPP NNP p
during IN p
the DT p
36 CD p
months NNS p
of IN p
the DT p
study NN p
or CC p
until IN p
readiness NN p
for IN p
puberty NN p
. . p

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
the DT N
absence NN N
of IN N
a DT N
customised JJ N
immobilisation NN N
device NN N
, , N
to TO N
cover VB N
95 CD N
% NN N
of IN N
errors NNS N
, , N
margins NNS N
of IN N
0.6 CD N
cm NN N
for IN N
RL NNP N
and CC N
SI NNP N
directions NNS N
and CC N
0.9 CD N
cm NN N
for IN N
AP NNP N
direction NN N
should MD N
be VB N
allowed VBN N
between IN N
the DT N
planning NN N
and CC N
clinical JJ N
target NN N
volumes NNS N
. . N

By IN N
the DT N
evaluation NN N
of IN N
the DT N
individual JJ N
data NN N
, , N
it PRP N
became VBD N
apparent JJ N
that IN N
, , N
the DT N
pains NNS o
increase NN o
with IN o
increasing VBG o
gas NN o
consumption NN o
, , N
a DT N
fact NN N
which WDT N
led VBD N
to TO N
assumption NN N
that IN N
the DT N
pains NNS N
are VBP N
caused VBN N
by IN N
a DT N
physical JJ N
effect NN N
such JJ N
as IN N
the DT N
cooling NN N
of IN N
the DT N
peritoneum NN N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
variants NNS N
in IN N
presumed JJ N
nutrient-sensitive JJ N
genes NNS N
involved VBN N
in IN N
lipid JJ N
metabolism NN N
modified VBD N
lipid JJ N
profile NN N
after IN N
weight JJ N
loss NN N
and CC N
in IN N
response NN N
to TO N
a DT N
given VBN N
diet JJ N
, , N
among IN N
overweight JJ p
European JJ p
adults NNS p
participating VBG p
in IN p
the DT p
Diet NNP p
Obesity NNP p
and CC p
Genes NNP p
study NN p
. . p

The DT N
step NN N
aerobics NNS N
group NN N
showed VBD N
significant JJ N
improvement NN N
only RB N
in IN N
mean JJ o
power NN o
relative NN o
to TO o
body NN o
weight JJ o
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
women NNS N
showed VBD N
significant JJ N
improvement NN N
only RB N
in IN N
anaerobic JJ o
power NN o
of IN o
vertical JJ o
jump NN o
when WRB N
compared VBN N
with IN N
men NNS N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
lumbar NN i
interlaminar JJ i
epidural JJ i
injections NNS i
with IN i
or CC i
without IN i
steroids NNS i
in IN N
providing VBG N
effective JJ N
and CC N
long-lasting JJ N
pain NN o
relief NN o
with IN N
improvement NN N
in IN N
functional JJ N
status NN N
for IN N
the DT N
management NN N
of IN N
chronic NN p
low JJ p
back RB p
and CC p
lower JJR p
extremity NN p
pain NN p
related VBN p
to TO p
lumbar VB p
central JJ p
spinal JJ p
stenosis NN p
. . p

Is VBZ N
individual JJ N
peer NN N
support NN N
a DT N
promising NN N
intervention NN N
for IN N
persons NNS N
with IN N
heart NN N
failure NN N
? . N
Peer NNP N
support NN N
has VBZ N
been VBN N
used VBN N
effectively RB N
in IN N
a DT N
variety NN N
of IN N
patient JJ N
populations NNS N
, , N
but CC N
its PRP$ N
effectiveness NN N
in IN N
improving VBG N
outcomes NNS N
in IN N
persons NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

Immediate NNP N
or CC N
early JJ N
use NN N
of IN N
proliferation NN N
signal NN N
inhibitor NN N
( ( N
PSI NNP N
) ) N
/mammalian JJ N
target NN N
of IN N
rapamycin NN N
( ( N
mTOR NN N
) ) N
inhibitor NN N
therapy NN N
can MD N
avoid VB N
high JJ N
exposure NN N
to TO N
calcineurin VB N
inhibitors NNS N
but CC N
concerns NNS N
exist VBP N
relating VBG N
to TO N
the DT N
risk NN N
of IN N
delayed JJ o
graft NN o
function NN o
( ( o
DGF NNP o
) ) o
and CC o
impaired JJ o
wound NN o
healing VBG o
with IN N
the DT N
mTOR NN N
sirolimus NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
one CD p
nicotine NN p
transdermal NN p
system NN p
( ( p
Nicoderm NNP p
, , p
Marion NNP p
Merrell NNP p
Dow NNP p
Inc NNP p
, , p
Kansas NNP p
City NNP p
, , p
Mo NNP p
, , p
and CC p
ALZA NNP p
Corporation NNP p
, , p
Palo NNP p
Alto NNP p
, , p
Calif NNP p
) ) p
in IN p
a DT p
population NN p
who WP p
were VBD p
allowed VBN p
to TO p
continue VB p
smoking NN p
. . p

CONCLUSIONS NNP N
This DT N
study NN N
confirms VBZ N
the DT N
findings NNS N
in IN N
a DT N
previous JJ N
open JJ N
label NN N
trial NN N
that IN N
administration NN N
of IN N
VLP NNP i
immunotherapy NN i
may MD N
assist VB N
in IN N
clearance NN N
of IN N
recurrent JJ N
genital JJ N
warts NNS N
in IN N
patients NNS p
for IN p
whom WP p
destructive JJ p
therapy NN p
is VBZ p
unsuccessful JJ p
and CC p
that DT p
unsuccessful JJ p
destructive JJ p
therapy NN p
is VBZ N
more RBR N
common JJ N
with IN N
increasing VBG N
prior JJ N
disease NN N
duration NN N
. . N

This DT N
pilot NN N
study NN N
revealed VBD N
that IN N
the DT N
IFRS NNP N
was VBD N
well-tolerated JJ N
and CC N
safe JJ N
in IN N
this DT N
study NN N
population NN N
associated VBN N
with IN N
minimal JJ N
complications NNS N
during IN N
the DT N
duration NN N
of IN N
this DT N
study NN N
and CC N
was VBD N
comparable JJ N
in IN N
efficacy NN N
to TO N
a DT N
SnF NNP N
( ( N
2 CD N
) ) N
gel NN N
in IN N
preventing VBG N
caries NNS N
development NN N
. . N

However RB N
the DT N
mutagenic JJ N
studies NNS N
of IN N
several JJ N
biological JJ N
systems NNS N
indicate VBP N
that IN N
it PRP N
has VBZ N
a DT N
mutagenic JJ N
effect NN N
, , N
but CC N
the DT N
mutagenic JJ o
and CC o
carcinogenic JJ o
effects NNS o
on IN N
humans NNS N
and CC N
animals NNS N
remain VBP N
questionable JJ N
, , N
because IN N
FZ NNP N
has VBZ N
been VBN N
biotransformed VBN N
into IN N
other JJ N
metabolites NNS N
. . N

Though IN N
propofol NN i
seemed VBD N
to TO N
be VB N
better JJR N
for IN N
effectiveness NN o
and CC o
safety NN o
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
for IN N
all DT N
three CD N
primary JJ N
end NN N
points NNS N
and CC N
the DT N
safety NN o
parameters NNS o
( ( o
hypotension NN o
, , o
hypoxia NN o
, , o
bradycardia NN o
) ) o
. . o

CONCLUSION NNP N
The DT N
absence NN N
of IN N
an DT N
association NN N
between IN N
allostatic JJ N
load NN N
and CC N
SRH NNP N
in IN N
diabetic JJ N
individuals NNS N
contrasts NNS N
with IN N
previous JJ N
findings NNS N
in IN N
non-diabetic JJ N
women NNS N
, , N
and CC N
shows VBZ N
that IN N
it PRP N
is VBZ N
hazardous JJ N
to TO N
apply VB N
findings NNS N
in IN N
one CD N
population NN N
to TO N
another DT N
, , N
especially RB N
diabetic JJ N
and CC N
non-diabetic JJ N
populations NNS N
. . N

Data NNS p
from IN p
460 CD p
patients NNS p
were VBD p
available JJ p
for IN p
analysis NN p
, , p
which WDT p
includes VBZ p
both CC p
a DT p
National NNP p
Health NNP p
Service NNP p
cost NN p
perspective NN p
including VBG p
costs NNS o
of IN o
surgery NN o
, , o
implants NNS o
and CC o
healthcare NN o
resource NN o
use NN o
over IN N
a DT N
12-month JJ N
period NN N
after IN N
surgery NN N
, , N
and CC N
a DT N
societal JJ N
perspective NN N
, , N
which WDT N
includes VBZ N
the DT N
cost NN o
of IN o
time NN o
off IN o
work NN o
and CC o
the DT o
need NN o
for IN o
additional JJ o
private JJ o
care NN o
. . o

The DT N
quality NN o
of IN o
pain NN o
control NN o
, , o
the DT o
amount NN o
and CC o
character NN o
of IN o
the DT o
drain NN o
fluid NN o
, , o
incidence NN o
of IN o
nausea NN o
and CC o
vomiting NN o
, , o
length NN o
of IN o
stay NN o
in IN o
the DT o
postoperative JJ o
care NN o
unit NN o
, , o
and CC o
amount NN o
of IN o
morphine NN o
used VBN o
for IN o
treatment NN o
of IN o
break-through JJ o
pain NN o
were VBD N
recorded VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
whey-predominant JJ i
, , i
50 CD i
% NN i
medium NN i
chain NN i
triglyceride IN i
formula NN i
with IN i
relatively RB i
high JJ i
concentrations NNS i
of IN i
zinc NN i
and CC i
copper NN i
would MD N
promote VB N
the DT N
achievement NN N
of IN N
the DT N
in IN N
utero JJ o
accretion NN o
rate NN o
for IN o
zinc NN o
and CC o
copper NN o
in IN N
the DT N
preterm NN p
infant NN p
. . p

We PRP N
investigated VBD N
the DT N
benefit NN N
of IN N
adding VBG N
all-trans JJ i
retinoic NN i
acid NN i
( ( i
ATRA NNP i
) ) i
to TO i
chemotherapy VB i
for IN N
younger JJR p
patients NNS p
with IN p
nonacute JJ p
promyelocytic JJ p
acute NN p
myeloid NN p
leukemia NN p
and CC p
high-risk JJ p
myelodysplastic JJ p
syndrome NN p
, , N
and CC N
considered VBD N
interactions NNS N
between IN N
treatment NN N
and CC N
molecular JJ N
markers NNS N
. . N

BACKGROUND NNP N
While IN N
low JJ N
back RB N
pain NN N
is VBZ N
the DT N
number NN N
one CD N
cause NN N
of IN N
disability NN N
in IN N
the DT N
United NNP p
States NNPS p
, , p
lumbar VBP p
spinal JJ p
stenosis NN p
along IN p
with IN p
intervertebral JJ p
disc NN p
herniation NN p
and CC p
degenerative JJ p
spondylolisthesis NN p
is VBZ N
one CD N
of IN N
the DT N
3 CD N
most JJS N
common JJ N
diagnosis NN N
of IN N
low JJ N
back RB N
and CC N
leg NN N
pain NN N
for IN N
which WDT N
surgery NN N
is VBZ N
performed VBN N
. . N

Additionally RB N
, , N
efforts NNS N
will MD N
be VB N
made VBN N
to TO N
define VB N
whether IN N
noninvasive JJ N
hemodynamic JJ N
parameters NNS N
, , N
retinal JJ N
vessel FW N
measurement NN N
changes NNS N
, , N
or CC N
biologic JJ N
markers NNS N
may MD N
predict VB N
and CC N
track VB N
the DT N
underlying VBG N
vascular JJ N
morphologic NN N
and CC N
physiologic JJ N
changes NNS N
induced VBN N
by IN N
either DT N
regimen NNS N
during IN N
the DT N
12-month JJ N
treatment NN N
period NN N
. . N

One CD N
strategy NN N
to TO N
minimize VB N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
per IN N
true JJ N
match NN N
is VBZ N
to TO N
first JJ N
search NN N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
then RB N
by IN N
Canada411 NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
and CC N
finally RB N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
initial JJ N
. . N

The DT N
current JJ N
intervention NN N
, , N
unlike IN N
many JJ N
others NNS N
for IN N
the DT N
same JJ N
or CC N
similar JJ N
difficulties NNS N
proposed VBN N
in IN N
the DT N
past NN N
, , N
was VBD N
successful JJ N
without IN N
requiring VBG N
extensive JJ N
time NN N
, , N
training NN N
, , N
or CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
providers NNS N
and CC N
parents NNS N
or CC N
their PRP$ N
children NNS N
, , N
nor CC N
did VBD N
it PRP N
require VB N
large-scale JJ N
institutional JJ N
changes NNS N
. . N

It PRP N
is VBZ N
hoped VBN N
that IN N
, , N
if IN N
this DT N
inhibition NN N
can MD N
be VB N
mitigated VBN N
, , N
it PRP N
will MD N
be VB N
possible JJ N
to TO N
assist VB N
the DT N
compromised VBN N
immune NN N
system NN N
and CC N
maintain VB N
a DT N
certain JJ N
level NN N
of IN N
immune JJ N
performance NN N
which WDT N
will MD N
prevent VB N
recurrence NN N
and CC N
improve VB N
survival NN o
rate NN o
. . o

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
relative JJ N
efficacy NN N
of IN N
the DT N
sublingual JJ N
administration NN N
of IN N
micronized JJ i
estradiol NN i
( ( i
E2 NNP i
) ) i
, , i
progesterone NN i
( ( i
P4 NNP i
) ) i
, , i
and CC i
testosterone NN i
( ( i
T NNP i
) ) i
on IN N
bone NN N
mineral JJ N
density NN N
and CC N
biochemical JJ N
markers NNS N
of IN N
bone NN N
metabolism NN N
. . N

Although IN N
maternal JJ N
attachment NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
infant JJ N
attachment JJ N
security NN N
and CC N
other JJ N
developmental JJ N
outcomes NNS N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
formation NN N
of IN N
maternal JJ N
attachment NN N
in IN N
the DT N
first JJ N
few JJ N
months NNS N
of IN N
the DT N
infant NN N
's POS N
life NN N
, , N
particularly RB N
among IN N
ethnic JJ p
minority NN p
mothers NNS p
. . p

Results NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
anti-migraine JJ N
efficacy NN N
is VBZ N
not RB N
mediated VBN N
solely RB N
through IN N
the DT N
5-HT JJ N
( ( N
1D CD N
) ) N
receptor NN N
subtype NN N
, , N
although IN N
this DT N
receptor NN N
may MD N
contribute VB N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
to TO N
the DT N
adverse JJ N
cardiovascular JJ N
effects NNS N
observed VBN N
with IN N
5-HT JJ N
agonist JJ N
medications NNS N
. . N

It PRP N
is VBZ N
widely RB N
held VBN N
that IN N
first-order JJ N
modulations NNS N
are VBP N
represented VBN N
by IN N
the DT N
firing VBG N
rates NNS N
of IN N
simple JJ N
and CC N
complex JJ N
cells NNS N
( ( N
first-order JJ N
neurons NNS N
) ) N
in IN N
primary JJ N
visual JJ N
cortex NN N
( ( N
V1 NNP N
) ) N
that IN N
, , N
likewise RB N
, , N
have VBP N
spatially RB N
localized VBN N
receptive JJ N
fields NNS N
that WDT N
are VBP N
selective JJ N
for IN N
orientation- JJ N
and CC N
SF NNP N
. . N

Prediction NN N
linear JJ N
equations NNS N
for IN N
the DT N
main JJ N
variables NNS N
of IN N
clinical JJ N
interest NN N
were VBD N
established VBN N
by IN N
backward NN N
stepwise NN N
regression NN N
analysis NN N
including VBG N
: : N
sex NN N
, , N
age NN N
, , N
knee NN N
extensor NN N
peak NN N
torque NN N
, , N
bone-free JJ N
lean JJ N
leg NN N
mass NN N
, , N
total JJ N
and CC N
lean JJ N
body NN N
mass NN N
, , N
height NN N
, , N
and CC N
physical JJ N
activity NN N
scores NNS N
. . N

Despite IN N
a DT N
relative JJ N
lack NN N
of IN N
published VBN N
data NNS N
antazoline NN N
has VBZ N
been VBN N
marketed VBN N
in IN N
Poland NNP N
and CC N
widely RB N
used VBN N
in IN N
cardiology NN N
wards NNS N
and CC N
emergency NN N
rooms NNS N
for IN N
many JJ N
years NNS N
due JJ N
to TO N
its PRP$ N
efficacy NN N
, , N
safety NN N
and CC N
rapid JJ N
onset NN N
of IN N
action NN N
within IN N
minutes NNS N
of IN N
administration NN N
. . N

Even RB N
though IN N
the DT N
number NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
is VBZ N
small JJ N
, , N
because IN N
this DT N
study NN N
did VBD N
not RB N
show VB N
an DT N
effect NN N
in IN N
the DT N
intent-to-treat JJ N
group NN N
, , N
rheopheresis NN N
should MD N
not RB N
be VB N
performed VBN N
for IN N
AMD NNP N
outside NN N
of IN N
an DT N
approved JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

A DT N
modified JJ N
World NNP N
Health NNP N
Organization NNP N
14-day JJ N
in IN N
vivo JJ N
drug NN N
efficacy NN N
test NN N
for IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NN N
in IN N
areas NNS N
with IN N
intense JJ N
malaria NNS N
transmission NN N
was VBD N
adapted VBN N
to TO N
reflect VB N
the DT N
clinical JJ N
and CC N
epidemiologic JJ N
features NNS N
of IN N
a DT N
low-intensity JJ N
malaria NN N
transmission NN N
area NN N
in IN N
the DT N
Pacific NNP N
Coast NNP N
Region NNP N
of IN N
Colombia NNP N
. . N

AIM IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
explore VB N
the DT N
result NN N
of IN N
pretreatment NN N
and CC N
concomitant NN N
use NN N
of IN N
metformin NN i
with IN i
clomiphene JJ i
citrate NN i
( ( i
CC NNP i
) ) i
and CC i
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

The DT N
beneficial JJ N
effects NNS N
of IN N
buspirone NN i
in IN N
helping VBG N
this DT N
patient NN N
with IN N
autism NN N
in IN N
his PRP$ N
natural JJ N
daily JJ N
settings NNS N
suggest VBP N
that IN N
buspirone NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
neuroleptic JJ N
agents NNS N
in IN N
the DT N
medical JJ N
therapy NN N
of IN N
autism NN N
; : N
further JJ N
study NN N
in IN N
other JJ N
patients NNS N
is VBZ N
needed VBN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN i
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ o
PAF/PAFL NNP o
recurrence NN o
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN i
in IN N
patients NNS p
with IN p
PAF/PAFL NNP p
. . p

Patients NNS N
completed VBD N
self-rating JJ N
scales NNS N
on IN N
pain NN o
, , o
global JJ o
health NN o
, , o
mood NN o
, , o
quality NN o
of IN o
life NN o
, , o
coping VBG o
style NN o
, , o
health NN o
locus NN o
of IN o
control NN o
, , o
multidimensional JJ o
well-being NN o
, , o
spirituality NN o
, , o
sense NN o
of IN o
coherence NN o
, , o
positive JJ o
states NNS o
of IN o
mind NN o
, , o
and CC o
social JJ o
desirability NN o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that DT N
supplementation NN N
of IN N
a DT N
combination NN N
of IN N
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
C NNP i
and CC i
coenzyme-Q10 NN i
does VBZ N
not RB N
affect VB N
serum JJ o
level NN o
of IN o
PSA NNP o
or CC o
hormone NN o
levels NNS o
in IN N
patients NNS p
with IN p
hormonally RB p
untreated JJ p
carcinoma NN p
of IN p
the DT p
prostate NN p
. . p

CONCLUSIONS VB N
A DT N
20-week JJ i
parent NN i
education NN i
and CC i
skills NNS i
training VBG i
program NN i
for IN N
parents NNS p
of IN p
young JJ p
children NNS p
newly RB p
diagnosed VBN p
with IN p
autism NN p
provides VBZ N
significant JJ N
improvements NNS N
in IN N
parental JJ o
mental JJ o
health NN o
and CC N
adjustment NN N
, , N
justifying VBG N
its PRP$ N
addition NN N
to TO N
early JJ N
intervention NN N
programs NNS N
at IN N
least JJS N
for IN N
parents NNS p
with IN p
mental JJ p
health NN p
problems NNS p
. . p

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
a DT N
large JJ N
proportion NN N
of IN N
the DT N
US NNP N
men NNS N
had VBD N
suboptimal JJ N
vitamin NN N
D NNP N
status NN N
( ( N
especially RB N
during IN N
the DT N
winter/spring NN N
season NN N
) ) N
, , N
and CC N
both DT N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
preventing VBG N
prostate NN N
cancer NN N
progression NN N
. . N

RESULTS NN N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO N
PPMD NNP o
recurrence NN o
, , o
poor JJ o
sleep JJ o
quality NN o
, , N
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN N
PPMD NNP o
recurrence NN o
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
pilot NN N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
developmentally RB N
modified VBN N
CBT NNP N
for IN N
young JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
to TO N
teach VB N
emotion NN N
regulation NN N
strategies NNS N
for IN N
reducing VBG N
anger NN N
and CC N
anxiety NN N
, , N
commonly RB N
noted VBD N
problems NNS N
in IN N
this DT N
population NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
are VBP N
relapse-free JJ o
survival NN o
, , o
proportion NN o
of IN o
laparoscopy-assisted JJ o
distal JJ o
gastrectomy NN o
completion NN o
, , o
proportion NN o
of IN o
conversion NN o
to TO o
open VB o
surgery NN o
, , o
adverse JJ o
events NNS o
, , o
short-term JJ o
clinical JJ o
outcomes NNS o
, , o
postoperative JJ o
quality NN o
of IN o
life NN o
. . o

Thus RB N
the DT N
potassium-retaining JJ i
diuretic JJ i
amiloride NN i
, , N
like IN N
the DT N
aldosterone NN i
antagonist NN i
spironolactone NN i
, , N
markedly RB N
reduces VBZ N
both CC N
the DT N
ulcer-healing JJ N
and CC N
the DT N
metabolic JJ N
side-effects NNS N
of IN N
carbenoxolone NN i
sodium NN i
, , N
and CC N
should MD N
not RB N
be VB N
used VBN N
together RB N
with IN N
it PRP N
in IN N
the DT N
treatment NN N
of IN N
peptic JJ N
ulcer NN N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
ability NN N
of IN N
novices NNS N
to TO N
learn VB N
selected VBN N
aspects NNS N
of IN N
Advanced NNP N
Cardiac NNP N
Life NNP N
Support NNP N
( ( N
ACLS NNP N
) ) N
in IN N
training NN N
conditions NNS N
that WDT N
did VBD N
not RB N
incorporate VB N
simulation NN N
compared VBN N
to TO N
those DT N
that WDT N
contained VBD N
low- JJ N
and CC N
high-fidelity JJ N
simulation NN N
activities NNS N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
extended-release JJ i
niacin NN i
( ( i
niacin JJ i
ER NNP i
) ) i
either CC i
alone RB i
or CC i
in IN i
combination NN i
with IN i
atorvastatin NN i
for IN N
the DT N
lipid JJ N
profile NN N
modification NN N
in IN N
the DT N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
and CC p
its PRP$ p
equivalents NNS p
. . p

The DT N
impact NN N
on IN N
outcome NN N
of IN N
the DT N
addition NN N
of IN N
all-trans NNS i
retinoic JJ i
acid NN i
to TO N
intensive JJ N
chemotherapy NN N
in IN N
younger JJR p
patients NNS p
with IN p
nonacute JJ p
promyelocytic JJ p
acute NN p
myeloid NN p
leukemia NN p
: : p
overall JJ N
results NNS N
and CC N
results NNS N
in IN N
genotypic JJ N
subgroups NNS N
defined VBN N
by IN N
mutations NNS N
in IN N
NPM1 NNP N
, , N
FLT3 NNP N
, , N
and CC N
CEBPA NNP i
. . i

The DT N
broad-spectrum JJ N
effectiveness NN N
of IN N
a DT N
combination NN N
of IN N
a DT N
fenbendazole JJ N
oral JJ N
drench NN N
and CC N
an DT N
ivermectin JJ i
pour-on NN N
reduced VBD N
parasite JJ o
burden NN o
and CC o
increased VBD o
feed NN o
intake NN o
, , o
ADG NNP o
, , o
and CC o
carcass NN o
weight NN o
in IN N
feedlot NN p
heifers NNS p
compared VBN N
with IN N
treatment NN N
with IN N
an DT N
endectocide JJ N
alone NN N
. . N

This DT N
study NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
in IN N
the DT N
primary JJ o
efficacy NN o
outcome NN o
of IN o
pain NN o
during IN o
the DT o
first JJ o
few JJ o
minutes NNS o
of IN o
walking VBG o
measured VBN o
by IN o
a DT o
visual JJ o
analog NN o
scale NN o
. . o

Thus RB N
, , N
in IN N
patients NNS p
undergoing VBG p
coronary JJ i
artery NN i
bypass NN i
grafting NN i
, , i
dietary JJ i
supplementation NN i
with IN i
n-3 JJ i
fatty JJ i
acids NNS i
reduced VBD N
the DT N
incidence NN N
of IN N
vein NN N
graft NN N
occlusion NN N
, , N
and CC N
an DT N
inverse JJ N
relation NN N
between IN N
relative JJ N
change NN N
in IN N
serum JJ o
phospholipid JJ o
n-3 JJ o
fatty JJ o
acids NNS o
and CC o
vein NN o
graft NN o
occlusions NNS o
was VBD N
observed VBN N
. . N

RESULTS JJ N
Placebo-corrected JJ N
time-matched JJ N
analysis NN N
of IN N
the DT N
QTcI NNP N
duration NN N
for IN N
the DT N
vilazodone NN i
treatment NN N
effect NN N
indicated VBD N
that IN N
no DT N
vilazodone NN i
dose NN N
had VBD N
an DT N
upper JJ N
bound NN N
that IN N
approached VBD N
or CC N
exceeded VBD N
10 CD N
ms NN N
, , N
demonstrating VBG N
no DT N
signal NN N
for IN N
a DT N
significant JJ N
vilazodone NN N
effect NN N
on IN N
cardiac JJ N
repolarization NN N
. . N

It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
RTD NNP N
may MD N
prevent VB N
the DT N
rapid JJ N
development NN N
of IN N
collateral JJ N
circulation NN N
and CC N
increase VB N
the DT N
production NN N
of IN N
oxygen-derived JJ N
free JJ N
radicals NNS N
, , N
which WDT N
may MD N
be VB N
the DT N
responsible JJ N
factors NNS N
for IN N
the DT N
ischemic JJ N
treatment NN N
of IN N
hepatic JJ N
tumours NNS N
. . N

While IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
, , N
overall JJ N
, , N
sibenadet JJ N
therapy NN N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
lack NN N
of IN N
sustained JJ N
benefit NN N
reported VBD N
in IN N
large-scale JJ N
clinical JJ N
efficacy NN N
studies NNS N
means VBZ N
that IN N
sibenadet NN N
development NN N
will MD N
not RB N
be VB N
continued VBN N
. . N

The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN N
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP N
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
messiness NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
. . N

Six CD N
months NNS N
after IN N
treatment NN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
showed VBD N
good JJ N
maintenance NN N
of IN N
treatment NN N
effects NNS N
, , N
but CC N
the DT N
differences NNS N
between IN N
groups NNS N
had VBD N
become VBN N
somewhat RB N
sharper JJ N
, , N
with IN N
the DT N
special JJ N
behavior JJ N
therapy NN N
group NN N
faring VBG N
best JJS N
, , N
the DT N
regular JJ N
behavior NN N
therapy NN N
group NN N
intermediate NN N
, , N
and CC N
the DT N
psychotherapy NN N
group NN N
worst JJS N
. . N

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP N
analogue NN N
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN o
volume NN o
, , o
changes NNS o
expression NN o
of IN o
leptin NN o
genes NNS o
and CC o
gene NN o
coding VBG o
leptin JJ o
receptor NN o
isoforms NNS o
in IN o
uterine JJ o
myomas NN o
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
and CC N
adherence NN N
to TO N
an DT N
active JJ i
video NN i
game NN i
promotion NN i
intervention NN i
on IN N
anthropometrics NNS N
, , N
sedentary JJ N
screen NN N
time NN N
and CC N
consumption NN N
of IN N
sugar-sweetened JJ N
beverages NNS N
and CC N
snacks NNS N
among IN N
non-active JJ p
video NN p
gaming VBG p
adolescents NNS p
who WP p
primarily RB p
were VBD p
of IN p
healthy JJ p
weight NN p
. . p

Since IN N
FGF23 NNP N
shares NNS N
structural JJ N
features NNS N
with IN N
FGF19 NNP N
subfamily RB N
members NNS N
that IN N
exert JJ N
hormonal JJ N
control NN N
of IN N
fat JJ N
mass NN N
, , N
we PRP N
hypothesized VBD N
that DT N
high JJ N
circulating NN N
FGF23 NNP N
concentrations NNS N
would MD N
be VB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
a DT N
uremic JJ N
lipid NN N
profile NN N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

The DT N
drug NN N
tested VBD N
may MD N
be VB N
very RB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
type NN N
IV NNP N
hyperlipoproteinemia NN N
, , N
especially RB N
in IN N
those DT N
forms NNS N
in IN N
which WDT N
an DT N
increase NN N
in IN N
thromboembolic JJ N
risk NN N
is VBZ N
suspected VBN N
, , N
either RB N
associated VBN N
with IN N
, , N
or CC N
secondary JJ N
to TO N
, , N
the DT N
actual JJ N
atherosclerotic JJ N
disease NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
study NN N
was VBD N
small JJ N
owing NN N
to TO N
recruitment VB N
difficulties NNS N
, , N
it PRP N
still RB N
provides VBZ N
evidence NN N
of IN N
effectiveness NN N
of IN N
melatonin NN i
in IN N
children NNS p
with IN p
sleep JJ p
difficulties NNS p
and CC p
ASD NNP p
, , N
which WDT N
we PRP N
predict VBP N
a DT N
larger JJR N
study NN N
would MD N
confirm VB N
. . N

OBJECTIVE NN N
To TO N
describe VB N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
six CD N
different JJ N
dosing VBG N
regimens NNS N
for IN N
epoetin NN i
alfa NN i
, , N
and CC N
whether IN N
more JJR N
rapid JJ N
and CC N
robust JJ N
reticulocytosis NN N
can MD N
be VB N
elicited VBN N
with IN N
more RBR N
frequent JJ N
administration NN N
of IN N
epoetin JJ i
alfa NN i
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
. . p

Our PRP$ N
data NNS N
support NN N
historical JJ N
data NNS N
indicating VBG N
that IN N
agglutinating VBG N
antibodies NNS N
are VBP N
associated VBN N
with IN N
protection NN N
and CC N
also RB N
recent JJ N
serologic JJ N
correlates NNS N
data NNS N
and CC N
clinical JJ N
efficacy NN N
data NNS N
which WDT N
indicate VBP N
that IN N
multicomponent NN N
vaccines NNS N
containing VBG N
pertactin NN i
and CC i
fimbriae NN i
have VBP N
better JJR N
efficacy NN N
than IN N
PT NNP N
or CC N
PT/FHA NNP N
vaccines NNS N
. . N

For IN N
this DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
usual JJ N
care NN N
group NN N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
improvement NN N
in IN N
the DT N
level NN o
of IN o
advice NN o
recorded VBN N
as IN N
having VBG N
been VBN N
given VBN N
on IN N
drug NN o
compliance NN o
, , o
adverse JJ o
drug NN o
effects NNS o
, , o
driving VBG o
, , o
alcohol NN o
intake NN o
, , o
and CC o
self PRP o
help VBP o
groups NNS o
. . o

The DT N
authors NNS N
undertook VBP N
this DT N
study NN N
to TO N
further RBR N
evaluate VB N
the DT N
level NN N
of IN N
adenosine JJ i
deaminase NN i
( ( i
ADA NNP i
) ) i
in IN N
patients NNS p
with IN p
chronic JJ p
schizophrenia NN p
treated VBN p
with IN p
monotherapy NN p
of IN p
haloperidol NN i
, , i
risperidone NN i
or CC i
clozapine NN i
and CC N
correlation NN N
between IN N
the DT N
ADA NNP N
level NN N
with IN N
response NN N
to TO N
treatment NN N
. . N

BACKGROUND NNP N
Concomitant NNP N
administration NN N
of IN N
erlotinib NN i
with IN i
standard JJ i
chemotherapy NN i
does VBZ N
not RB N
appear VB N
to TO N
improve VB N
survival NN o
among IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
, , N
but CC N
preliminary JJ N
studies NNS N
suggest VBP N
that IN N
sequential JJ N
administration NN N
might MD N
be VB N
effective JJ N
. . N

Although IN N
difficulty NN N
in IN N
understanding VBG N
of IN N
others NNS N
' POS N
social JJ N
emotions NNS N
and CC N
beliefs NNS N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
also RB N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
potential JJ N
effect NN N
of IN N
oxytocin NN i
on IN N
this DT N
difficulty NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
incidence NN o
of IN o
metaphase NN o
II NNP o
stage NN o
oocytes NNS o
with IN o
numeric JJ o
chromosomal JJ o
abnormalities NNS o
, , N
using VBG N
full JJ N
( ( N
spectral JJ N
karyotyping NN N
) ) N
or CC N
partial JJ N
( ( N
fluorescent JJ N
in IN N
situ JJ N
hybridization NN N
with IN N
seven CD N
probes NNS N
) ) N
karyotyping VBG N
or CC N
Giemsa NNP N
count NN N
. . N

Compared VBN N
to TO N
ten VB N
IQ- NNP N
and CC N
age-matched JJ N
healthy JJ N
controls NNS N
, , N
eight CD N
participants NNS N
with IN N
autism NN N
showed VBD N
less JJR N
fixation JJ o
specificity NN o
to TO N
the DT N
eyes NNS N
and CC N
mouth NN N
, , N
a DT N
greater JJR N
tendency NN N
to TO N
saccade VB N
away RB N
from IN N
the DT N
eyes NNS N
when WRB N
information NN N
was VBD N
present JJ N
in IN N
those DT N
regions NNS N
, , N
and CC N
abnormal JJ o
directionality NN o
of IN o
saccades NNS o
. . o

Because IN N
most JJS N
NSAIDs NNP N
are VBP N
weak JJ N
acids NNS N
( ( N
pKa IN N
3-5 NNP N
) ) N
and CC N
become VBN N
concentrated JJ N
in IN N
acidic JJ N
tissues NNS N
, , N
such JJ N
as IN N
injured JJ N
and CC N
inflamed JJ N
tissues NNS N
, , N
we PRP N
hypothesized VBD N
that IN N
local JJ N
administration NN N
may MD N
enhance VB N
its PRP$ N
analgesic JJ N
efficacy NN N
while IN N
lowering VBG N
the DT N
potential NN N
for IN N
systemic JJ N
complications NNS N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
in IN N
a DT N
manikin JJ N
model NN N
whether IN N
using VBG N
the DT N
single-use JJ N
laryngeal NN N
tube NN N
with IN N
suction NN i
option NN i
( ( i
LTS-D NNP i
) ) i
instead RB i
of IN i
endotracheal JJ i
intubation NN i
( ( i
ET NNP i
) ) i
and CC i
bag-mask-valve JJ i
ventilation NN i
( ( i
BMV NNP i
) ) i
for IN i
emergency NN i
airway NN i
management NN i
could MD i
reduce VB i
the DT i
no-flow JJ i
time NN i
( ( i
NFT NNP i
) ) i
. . i

Secondary JJ N
outcomes NNS N
included VBD N
quantification NN o
of IN o
other JJ o
vaginal JJ o
compartments NNS o
( ( o
POP-Q NNP o
points NNS o
) ) o
, , o
comparison NN o
of IN o
quality NN o
of IN o
life NN o
by IN o
the DT o
prolapse NN o
quality NN o
of IN o
life NN o
( ( o
P-QOL NNP o
) ) o
questionnaire NN o
, , o
and CC o
complication NN o
rate NN o
between IN N
the DT N
groups NNS N
after IN N
1 CD N
year NN N
. . N

When WRB N
the DT N
results NNS N
obtained VBD N
with IN N
a DT N
particularly RB N
promising JJ N
new JJ N
drug NN N
or CC N
procedure NN N
are VBP N
presented VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
study NN N
( ( N
within IN N
1-2 CD N
years NNS N
) ) N
, , N
the DT N
investigators NNS N
should MD N
strongly RB N
consider VB N
a DT N
repeat NN N
evaluation NN N
after IN N
an DT N
additional JJ N
3-5 CD N
years NNS N
of IN N
follow-up NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
either CC N
the DT N
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
responses VBZ o
to TO o
the DT o
PSL-LBNP NNP o
or CC o
the DT o
tolerance NN o
indices NNS o
( ( o
cumulative JJ o
stress NN o
index NN o
; : o
maximum JJ o
negative JJ o
pressure NN o
tolerated VBN o
; : o
and CC o
duration NN o
of IN o
negative JJ o
pressure NN o
exposure NN o
) ) o
. . o

METHOD NN N
To TO N
make VB N
further JJ N
advances NNS N
in IN N
untangling VBG N
this DT N
chicken-and-egg JJ N
question NN N
, , N
we PRP N
employed VBD N
autoregressive JJ N
cross-lagged JJ N
modeling NN N
over IN N
4 CD N
time NN N
points NNS N
in IN N
a DT N
sample NN N
of IN N
149 CD p
depressive JJ p
patients NNS p
receiving VBG p
supportive-expressive JJ i
psychotherapy NN i
or CC i
clinical JJ i
management NN i
combined VBN i
with IN i
pharmacotherapy NN i
or CC i
clinical JJ i
management NN i
combined VBN i
with IN i
placebo NN i
. . i

OBJECTIVE NN N
To TO N
assess VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS p
of IN p
children NNS p
with IN p
autism NN p
compared VBN p
with IN p
parents NNS p
of IN p
children NNS p
with IN p
asthma NN p
or CC p
other JJ p
special JJ p
health NN p
care NN p
needs VBZ p
report NN p
receiving VBG p
primary JJ p
care NN p
for IN p
their PRP$ p
child NN p
consistent NN p
with IN p
the DT p
American JJ p
Academy NNP p
of IN p
Pediatrics NNP p
medical JJ p
home NN p
model NN p
. . p

Antipyrine NNP o
clearance NN o
and CC o
response NN o
to TO N
interferon VB N
treatment NN N
in IN N
patients NNS p
with IN p
chronic JJ p
active JJ p
hepatitis NN p
C. NNP p
To TO N
determine VB N
whether IN N
hepatic JJ N
metabolic JJ N
function NN N
affects VBZ N
the DT N
response NN N
to TO N
interferon VB N
treatment NN N
, , N
we PRP N
measured VBD N
antipyrine JJ i
clearance NN i
( ( i
APC NNP i
) ) i
in IN N
85 CD p
patients NNS p
with IN p
chronic JJ p
active JJ p
hepatitis NN p
C NNP p
and CC N
compared VBN N
the DT N
results NNS N
with IN N
treatment NN N
outcome NN N
. . N

This DT N
report NN N
specifically RB N
addresses VBZ N
the DT N
issues NNS N
of IN N
safety NN N
in IN N
patients NNS p
with IN p
squamous JJ p
cell NN p
tumors NNS p
, , p
effect NN p
of IN p
treatment NN p
in IN p
elderly JJ p
patients NNS p
, , p
and CC p
uncertainties NNS p
regarding VBG p
effects NNS p
in IN p
patients NNS p
with IN p
tumors NNS p
harboring VBG p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
or CC p
anaplastic JJ p
lymphoma NN p
kinase NN p
genomic JJ p
tumor NN p
aberrations NNS p
. . p

In IN N
response NN N
to TO N
the DT N
therapist NN o
's POS o
interpersonal JJ o
demands NNS o
, , o
'compliant NNP o
( ( o
positive JJ o
) ) o
responses NNS o
' POS o
were VBD N
observed VBN N
more RBR N
in IN N
music NN N
therapy NN N
than IN N
in IN N
toy JJ N
play NN N
sessions NNS N
, , N
and CC N
'no POS N
responses NNS N
' POS N
were VBD N
twice RB N
as RB N
frequent JJ N
in IN N
toy JJ N
play NN N
sessions NNS N
as IN N
in IN N
music NN N
therapy NN N
. . N

OBJECTIVE IN N
We PRP N
investigated VBD N
the DT N
changes NNS N
in IN N
the DT N
temporomandibular JJ N
joint NN N
( ( N
TMJ NNP N
) ) N
after IN N
bilateral JJ N
sagittal JJ N
split NN N
osteotomy NN N
of IN N
the DT N
mandible JJ N
for IN N
orthognathic JJ N
surgery NN N
and CC N
the DT N
influence NN N
of IN N
positioning NN N
of IN N
the DT N
condylar JJ N
process NN N
in IN N
the DT N
centre NN N
of IN N
the DT N
articular JJ N
fossa NN N
before IN N
and CC N
during IN N
the DT N
operation NN N
for IN N
preventing VBG N
changes NNS N
in IN N
the DT N
TMJ NNP N
postoperatively RB N
. . N

This DT N
pilot NN N
study NN N
shows VBZ N
for IN N
the DT N
first JJ N
time NN N
in IN N
human JJ p
volunteers NNS p
that WDT N
naloxone RB i
does VBZ N
not RB N
inhibit VB N
paracetamol JJ N
antinociception NN N
, , N
suggesting VBG N
no DT N
significant JJ N
implication NN N
of IN N
the DT N
opioid NN N
system NN N
in IN N
paracetamol JJ N
mechanism NN N
of IN N
action NN N
: : N
this DT N
needs VBZ N
be VB N
confirmed VBN N
on IN N
a DT N
larger JJR N
number NN N
of IN N
subjects NNS N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
RTD NNP N
is VBZ N
superior JJ N
to TO N
HAL NNP N
in IN N
terms NNS N
of IN N
the DT N
objective JJ N
response NN N
to TO N
the DT N
therapy NN N
, , N
reduction NN N
of IN N
tumor NN o
size NN o
, , o
patient NN o
's POS o
symptom JJ o
relief NN o
, , o
liver CC o
function NN o
and CC o
AFP NNP o
changes NNS o
and CC o
patient NN o
's POS o
survival NN o
. . o

Thus RB N
, , N
folate JJ N
deficiency NN N
may MD N
amplify VB N
the DT N
effect NN N
of IN N
other JJ N
risk NN N
factors NNS N
such JJ N
as IN N
elevated JJ N
homocysteine NN N
levels NNS N
or CC N
variant JJ N
MTHFR NNP N
genotype NN N
, , N
as RB N
well RB N
as IN N
influencing VBG N
the DT N
ability NN N
of IN N
antioxidant JJ N
supplementation NN N
to TO N
protect VB N
against IN N
genetic JJ N
damage NN N
. . N

CONCLUSION NN N
This DT N
study NN N
, , N
based VBN N
on IN N
a DT N
limited JJ N
number NN N
of IN N
patients NNS N
, , N
indicates VBZ N
that IN N
adjuvant JJ i
immunochemotherapy NN i
( ( i
BCG NNP i
+ NNP i
FAM NNP i
) ) i
may MD N
prolong VB N
the DT N
survival NN N
of IN N
gastric JJ p
cancer NN p
patients NNS p
after IN p
curative JJ p
gastrectomy NN p
; : p
in IN p
particular JJ p
, , p
in IN p
patients NNS p
with IN p
pT2/T3 JJ p
tumors NNS p
and CC p
intestinal-type JJ p
primary JJ p
tumors NNS p
. . p

CONCLUSION NN N
This DT N
analysis NN N
demonstrates VBZ N
that IN N
the DT N
previously RB N
reported VBN N
benefit NN N
in IN N
survival NN N
is VBZ N
maintained VBN N
at IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
and CC N
firmly RB N
establishes VBZ N
the DT N
role NN N
of IN N
RT NNP N
in IN N
the DT N
treatment NN N
of IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

If IN N
prognostic JJ N
factors NNS N
have VBP N
to TO N
be VB N
taken VBN N
into IN N
account NN N
, , N
the DT N
Cox NNP N
model NN N
provides VBZ N
tests NNS N
of IN N
Ho NNP N
, , N
and CC N
a DT N
useful JJ N
confidence NN N
interval NN N
for IN N
the DT N
adjusted JJ N
relative JJ N
derived VBN N
from IN N
the DT N
regression NN N
parameter NN N
for IN N
the DT N
treatment NN N
indicator NN N
. . N

We PRP N
included VBD N
patients NNS p
admitted VBN p
to TO p
the DT p
unit NN p
during IN p
the DT p
study NN p
with IN p
a DT p
Mini-Mental JJ p
State NNP p
Examination NNP p
( ( p
MMSE NNP p
) ) p
score NN p
of IN p
more JJR p
than IN p
23/30 CD p
to TO p
receive VB p
individualised JJ i
education NN i
that WDT N
was VBD N
based VBN N
on IN N
principles NNS N
of IN N
changes NNS N
in IN N
health NN N
behaviour NN N
from IN N
a DT N
trained JJ N
health NN N
professional NN N
, , N
in IN N
addition NN N
to TO N
usual JJ N
care NN N
. . N

Individual-ESI NNP i
also RB N
showed VBD N
differential JJ N
efficacy NN N
on IN N
a DT N
parent NN N
report NN N
measure NN N
of IN N
communication NN o
, , o
daily JJ o
living NN o
, , o
and CC o
social JJ o
skills NNS o
, , N
as IN N
they PRP N
showed VBD N
improvement NN N
or CC N
stability NN N
, , N
whereas IN N
group-ESI NN N
led VBD N
to TO N
worsening VBG N
or CC N
no DT N
significant JJ N
change NN N
on IN N
these DT N
skills NNS N
. . N

Despite IN N
numerous JJ N
publications NNS N
and CC N
clinical JJ N
trials NNS N
, , N
the DT N
results NNS N
of IN N
treatment NN N
of IN N
recalcitrant JJ N
chronic JJ N
plantar NN N
fasciitis NN N
with IN N
extracorporeal JJ i
shockwave JJ i
therapy NN i
( ( i
ESWT NNP i
) ) i
still RB N
remain VBP N
equivocal JJ N
as IN N
to TO N
whether IN N
or CC N
not RB N
this DT N
treatment NN N
provides VBZ N
relief NN N
from IN N
the DT N
pain NN N
associated VBN N
with IN N
this DT N
condition NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
fatigue JJ o
( ( o
measured VBN o
by IN o
Chalder NNP o
fatigue NN o
questionnaire NN o
score NN o
) ) o
and CC o
physical JJ o
function NN o
( ( N
measured VBN N
by IN N
short JJ N
form-36 JJ N
subscale NN N
score NN N
) ) N
up IN N
to TO N
52 CD N
weeks NNS N
after IN N
randomisation NN N
, , N
and CC N
safety NN N
was VBD N
assessed VBN N
primarily RB N
by IN N
recording VBG N
all DT N
serious JJ N
adverse JJ N
events NNS N
, , N
including VBG N
serious JJ N
adverse JJ N
reactions NNS N
to TO N
trial NN N
treatments NNS N
. . N

RATIONALE VB N
The DT N
response NN N
characteristics NNS N
of IN N
the DT N
6 CD N
minute NN N
walk NN N
test NN N
( ( N
6MWT CD N
) ) N
in IN N
studies NNS N
of IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
( ( N
IPF NNP N
) ) N
are VBP N
only RB N
poorly RB N
understood JJ N
, , N
and CC N
the DT N
change NN N
in IN N
walk NN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
minimum JJ N
important JJ N
difference NN N
( ( N
MID NNP N
) ) N
over IN N
time NN N
is VBZ N
unknown JJ N
. . N

Randomization NN N
was VBD N
unbalanced JJ N
1:2 CD N
in IN N
favor NN N
of IN N
the DT N
combination NN N
therapy NN N
, , N
since IN N
study NN N
conditions NNS N
were VBD N
identical JJ N
to TO N
the DT N
previous JJ N
CML-study NNP N
I PRP N
and CC N
it PRP N
had VBD N
been VBN N
planned VBN N
in IN N
advance NN N
to TO N
add VB N
the DT N
HU NNP N
patients NNS N
of IN N
study NN N
I PRP N
( ( N
n=194 RB N
) ) N
to TO N
the DT N
HU NNP N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN o
populations NNS o
for IN o
any DT o
demographic JJ o
or CC o
clinical JJ o
characteristic NN o
( ( o
e.g JJ o
, , o
visual JJ o
acuity NN o
, , o
intraocular JJ o
pressure NN o
[ NNP o
IOP NNP o
] NNP o
, , o
initial JJ o
hyphema NN o
size NN o
) ) o
measured VBN N
in IN N
the DT N
study NN N
. . N

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
, , o
the DT o
overall JJ o
assessment NN o
of IN o
efficacy NN o
and CC o
the DT o
Zung NNP o
Self-rating NNP o
Scale NNP o
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
discrete JJ N
symptoms NNS N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
, , N
as RB N
well RB N
as IN N
other JJ N
symptoms NNS N
captured VBN N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
. . o

BACKGROUND NNP N
Limited NNP N
data NN N
suggest NN N
that IN N
low JJ N
levels NNS N
of IN N
serum JJ N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
and CC N
high JJ N
levels NNS N
of IN N
triglyceride-rich JJ N
lipoproteins NNS N
may MD N
be VB N
associated VBN N
with IN N
more RBR N
rapid JJ N
rates NNS N
of IN N
kidney NN N
function NN N
loss NN N
in IN N
individuals NNS p
with IN p
chronic JJ p
renal JJ p
insufficiency NN p
( ( p
CRI NNP p
) ) p
. . p

CONCLUSIONS NNP N
These DT N
results NNS N
should MD N
encourage VB N
health NN N
professionals NNS N
to TO N
educate VB N
pregnant JJ p
women NNS p
regarding VBG N
the DT N
harms NNS N
of IN N
SHS NNP N
while IN N
both DT N
empowering VBG N
and CC N
equipping VBG N
them PRP N
with IN N
the DT N
tools NNS N
to TO N
confront VB N
their PRP$ N
family NN N
members NNS N
and CC N
effectively RB N
reduce VB N
their PRP$ N
SHS NNP N
exposure NN N
while IN N
promoting VBG N
smoke-free JJ N
social JJ N
norms NNS N
. . N

Activity NN N
in IN N
parts NNS N
of IN N
the DT N
human JJ N
motor NN N
system NN N
has VBZ N
been VBN N
shown VBN N
to TO N
correlate VB N
with IN N
the DT N
complexity NN N
of IN N
performed JJ N
motor NN N
sequences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
limbs NNS N
moved VBN N
, , N
number NN o
of IN o
movements NNS o
, , o
and CC o
number NN o
of IN o
trajectories NNS o
. . o

The DT N
primary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behaviour NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
and CC N
the DT N
secondary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
relating VBG o
to TO o
people NNS o
and CC o
verbal JJ o
communication NN o
) ) o
. . o

AIM NNP N
A NNP N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
investigate VB N
people NNS N
's POS N
interest NN N
in IN N
participating VBG N
in IN N
health NN N
checks NNS N
and CC N
in IN N
discussions NNS N
about IN N
health NN N
with IN N
their PRP$ N
own JJ N
general JJ N
practitioner NN N
, , N
participants NNS N
' POS N
health NN N
status NN N
, , N
the DT N
proportion NN N
who WP N
received VBD N
health NN N
advice NN N
following VBG N
health NN N
checks NNS N
, , N
and CC N
the DT N
lifestyle JJ N
goals NNS N
they PRP N
set VBP N
following VBG N
discussion NN N
with IN N
their PRP$ N
general JJ N
practitioner NN N
. . N

Topical JJ i
diclofenac NN i
diethylamine NN i
( ( i
DDEA NNP i
) ) i
1.16 CD N
% NN N
gel NN N
is VBZ N
clinically RB N
proven VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
acute NN N
and CC N
chronic JJ N
musculoskeletal NN N
conditions NNS N
, , N
but CC N
until IN N
now RB N
no DT N
clinical JJ N
data NNS N
existed VBD N
for IN N
its PRP$ N
use NN N
in IN N
acute JJ N
NP NNP N
. . N

Participants NNS p
had VBD p
autistic JJ p
disorder NN p
, , p
Asperger NNP p
syndrome NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
that WDT p
were VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
the DT p
Clinical JJ p
Global NNP p
Impression-Severity NNP p
scale NN p
; : p
and CC N
scored VBD N
moderate JJ N
or CC N
more JJR N
than IN N
moderate VB N
on IN N
compulsive JJ N
behaviors NNS N
measured VBN N
with IN N
the DT N
modified JJ N
Children NNP N
's POS N
Yale-Brown JJ N
Obsessive-Compulsive JJ N
Scale NNP N
. . N

After IN N
excavation NN N
, , N
the DT N
cavities NNS N
were VBD N
analyzed VBN N
using VBG N
: : N
( ( N
a DT N
) ) N
the DT N
tactile NN N
method NN N
, , N
( ( N
b NN N
) ) N
caries-detection NN N
dye NN N
to TO N
stain VB N
demineralized JJ N
dentin NN N
, , N
as IN N
proposed VBN N
by IN N
Smales NNP N
& CC N
Fang NNP N
, , N
and CC N
( ( N
c NN N
) ) N
Demineralized NNP N
Tissue NNP N
Removal NNP N
index NN N
, , N
as IN N
proposed VBN N
in IN N
this DT N
study NN N
. . N

Smith NNP p
( ( p
1993 CD p
) ) p
obtained VBD p
event-related JJ p
brain NN p
potentials NNS p
( ( p
ERPs NNP p
) ) p
from IN p
subjects NNS p
performing VBG p
a DT p
recognition NN i
memory NN i
task NN i
using VBG i
remember NN i
( ( p
R NNP p
) ) p
and CC p
know $ p
( ( p
K NNP p
) ) p
judgments NNS p
, , N
and CC N
reported VBD N
observing VBG N
in IN N
the DT N
ERP NNP N
a DT N
neurophysiological JJ N
manifestation NN N
of IN N
recollective JJ N
experience NN N
as IN N
a DT N
difference NN N
between IN N
the DT N
positive JJ N
waveforms NNS N
elicited VBN N
by IN N
stimuli NNS N
that WDT N
yielded VBD N
R NNP N
and CC N
K NNP N
judgments NNS N
. . N

In IN N
conclusion NN N
, , N
low-dose JJ N
flutamide NN N
is VBZ N
herewith JJ N
identified VBN N
as IN N
a DT N
pivotal JJ N
component NN N
within IN N
a DT N
first JJ N
contraceptive JJ N
combination NN N
therapy NN N
that WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
attenuate VB N
the DT N
hypoadiponectinemia NN o
, , o
ovarian JJ o
vascular NN o
hyperresistance NN o
, , o
lean JJ o
mass NN o
deficit NN o
, , o
and CC o
central JJ o
adiposity NN o
of IN N
young JJ N
women NNS N
with IN N
polycystic JJ N
ovary JJ N
syndrome NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
gather VB N
data NNS N
on IN N
the DT N
safety NN N
of IN N
lasalocid NN i
when WRB N
fed NN N
to TO N
Chinese JJ p
ring-necked JJ p
pheasants NNS p
at IN N
one CD N
, , N
two CD N
, , N
and CC N
three CD N
times NNS N
the DT N
recommended JJ N
high JJ N
dose NN N
of IN N
lasalocid NN i
used VBN N
for IN N
prevention NN N
of IN N
coccidiosis NN N
in IN N
other JJ N
poultry NN N
at IN N
three CD N
times NNS N
the DT N
normal JJ N
treatment NN N
period NN N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
preSMA NN i
and CC N
rostral JJ N
dorsal NN N
PMC NNP N
activities NNS N
during IN N
initiate NN N
may MD N
be VB N
associated VBN N
with IN N
selection NN N
of IN N
timing VBG N
parameters NNS N
, , N
while IN N
activation NN N
in IN N
centromedial JJ N
prefrontal JJ N
cortex NN N
during IN N
both DT N
initiate JJ N
and CC N
synchronise NN N
may MD N
be VB N
associated VBN N
with IN N
temporal JJ N
error NN N
monitoring NN N
or CC N
correction NN N
. . N

CONCLUSION NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN N
, , N
local JJ N
administration NN N
of IN N
1 CD N
mg NN N
of IN N
morphine NN i
prior RB N
to TO N
the DT N
surgical JJ N
removal NN N
of IN N
an DT N
odontogenic JJ N
maxillary JJ N
cyst NN N
was VBD N
safe JJ N
, , N
but CC N
it PRP N
did VBD N
not RB N
prove VB N
to TO N
be VB N
very RB N
effective JJ N
as IN N
an DT N
add-on JJ N
therapy NN N
for IN N
postoperative JJ N
pain NN N
control NN N
. . N

The DT N
end NN N
points NNS N
were VBD N
toxicity NN o
and CC o
PSA NNP o
response NN o
in IN N
both DT N
groups NNS N
, , N
with IN N
the DT N
option NN N
to TO N
continue VB N
the DT N
trial NN N
as IN N
a DT N
Phase NNP N
III NNP N
study NN N
with IN N
time NN N
to TO N
progression NN N
and CC N
survival NN N
as IN N
end NN N
points NNS N
, , N
if IN N
sufficient JJ N
responses NNS N
were VBD N
observed VBN N
. . N

For IN N
HLA-DR NNP o
expression NN o
, , o
IL-6 NNP o
, , o
and CC o
CRP NNP o
levels NNS o
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
tested VBD N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome VBP p
whether IN p
allopurinol NNS i
through IN N
decreasing VBG N
oxidative JJ o
stress NN o
improves VBZ o
endothelial JJ o
function NN o
, , o
and CC o
ameliorates VBZ o
inflammatory JJ o
state NN o
represented VBN o
by IN o
markers NNS o
of IN o
myeloperoxidase NN o
, , o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
and CC o
fibrinogen NN o
. . o

The DT N
retentive JJ N
effect NN N
of IN N
labetalol NN i
on IN N
sodium NN N
was VBD N
directly RB N
related VBN N
to TO N
the DT N
decrease NN N
of IN N
blood NN o
pressure NN o
, , N
and CC N
the DT N
successive JJ N
sodium NN N
escape NN N
might MD N
be VB N
explained VBN N
either RB N
by IN N
the DT N
observed JJ N
increase NN N
of IN N
plasma JJ o
volume NN o
( ( N
indirectly RB N
measured VBN N
by IN N
packed JJ N
cell NN N
volume NN N
) ) N
or CC N
by IN N
aldosterone JJ N
inhibition NN N
. . N

Group NNP N
A NNP N
was VBD N
expected VBN N
to TO N
give VB N
more JJR N
correct JJ o
answers NNS o
to TO o
questions NNS o
about IN N
the DT N
common JJ N
facts NNS N
than IN N
Group NNP N
B NNP N
, , N
when WRB N
tested VBN N
postoperatively RB N
, , N
and CC N
Group NNP N
B NNP N
to TO N
attribute VB N
more JJR N
fame NN N
to TO N
presented VBN N
names NNS N
than IN N
Group NNP N
A NNP N
( ( N
famous JJ N
names RB N
test NN N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
nonstructured JJ N
recovery NN N
from IN N
intense JJ N
exercise NN N
leads VBZ N
to TO N
increased VBN N
activity NN N
, , N
faster JJR N
lactate JJ N
clearance NN N
, , N
and CC N
reduced VBD N
RPE NNP N
and CC N
therefore RB N
may MD N
be VB N
used VBN N
by IN N
athletes NNS N
in IN N
their PRP$ N
effort NN N
to TO N
enhance VB N
recovery NN N
. . N

In IN N
Parkinson NNP N
's POS N
disease NN N
, , N
however RB N
, , N
the DT N
supplementary JJ N
motor NN N
area NN N
was VBD N
only RB N
involved VBN N
in IN N
movements NNS N
which WDT N
must MD N
be VB N
internally RB N
determined VBN N
( ( N
non-cued JJ N
movements NNS N
, , N
but CC N
not RB N
externally RB N
cued VBN N
movements NNS N
) ) N
; : N
therefore RB N
impaired VBD N
internal JJ N
control NN N
mechanisms NNS N
, , N
operating VBG N
via IN N
the DT N
supplementary JJ N
motor NN N
area NN N
, , N
are VBP N
bypassed VBN N
when WRB N
external JJ N
cues NNS N
are VBP N
given VBN N
. . N

DISCUSSION NNP N
Along NNP N
with IN N
a DT N
technique NN N
to TO N
improve VB N
health NN o
workers NNS o
performance NN o
on IN N
the DT N
protocol NN N
, , N
the DT N
study NN N
will MD N
generate VB N
evidence NN N
on IN N
the DT N
research NN N
gap NN N
on IN N
the DT N
effectiveness NN N
of IN N
the DT N
simplified JJ N
neonatal JJ N
resuscitation NN N
protocol NN N
on IN N
intrapartum NN o
outcome NN o
and CC o
early JJ o
neonatal JJ o
survival NN o
. . o

Analysis NN N
of IN N
variance NN N
and CC N
post-hoc JJ N
analyses NNS N
suggest VBP N
that IN N
subjects NNS N
who WP N
first RB N
learned VBN N
under IN N
the DT N
color-coded JJ N
, , N
extra JJ N
prompt JJ N
condition NN N
encountered VBD N
significant JJ N
difficulty NN N
in IN N
transferring VBG N
their PRP$ N
newly RB N
acquired VBN N
skill NN N
to TO N
the DT N
naturalistic JJ N
, , N
non-color-coded JJ N
condition NN N
, , N
whereas JJ N
subjects NNS N
who WP N
learned VBD N
initially RB N
without IN N
the DT N
extra JJ N
prompts NNS N
had VBD N
little JJ N
difficulty NN N
with IN N
the DT N
subsequent JJ N
color-coded JJ N
condition NN N
. . N

Alfentanil NNP i
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ o
effects NNS o
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN N
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

Though IN N
in IN N
the DT N
stent JJ N
group NN N
event-free JJ o
survival NN o
was VBD o
lower JJR o
and CC o
target VB o
lesion JJ o
revascularization NN o
rate NN o
was VBD N
higher JJR N
, , N
retroinfusion-supported JJ i
stent NN i
implantation NN i
was VBD N
associated VBN N
with IN N
substantially RB N
lower JJR N
costs NNS N
and CC N
might MD N
be VB N
considered VBN N
as IN N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
selected VBN N
group NN N
of IN N
high-risk JJ N
patients NNS N
. . N

Before IN N
the DT N
intervention NN N
, , N
strenuous JJ N
exercise NN N
up RB N
to TO N
exhaustion NN N
increased VBD N
the DT N
mobilization NN o
of IN o
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
, , o
or CC o
CD8 NNP o
( ( o
bright VBN o
) ) o
lymphocytes VBZ o
expressing VBG o
activated VBN o
( ( o
CD11a NNP o
) ) o
or CC o
senescent NN o
( ( o
KLRG1 NNP o
) ) o
molecules VBZ o
into IN o
the DT o
peripheral JJ o
blood NN o
compartment NN o
. . o

CONCLUSIONS NNP N
Higher NNP N
rates NNS N
of IN N
primary JJ N
and CC N
repeat JJ N
amputation NN N
for IN N
African JJ N
American JJ N
patients NNS N
at IN N
study NN N
hospitals NNS N
, , N
which WDT N
all DT N
have VBP N
significant JJ N
vascular JJ N
surgery NN N
capacity NN N
and CC N
an DT N
aggressive JJ N
policy NN N
of IN N
limb NN N
salvage NN N
, , N
suggest VBP N
that IN N
these DT N
rates NNS N
may MD N
be VB N
even RB N
higher JJR N
at IN N
less JJR N
well RB N
equipped JJ N
institutions NNS N
. . N

We PRP N
conclude VBP N
that IN N
, , N
whilst VB N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
obtain VB N
reasonable JJ N
point NN N
estimates NNS N
of IN N
total JJ o
hip NN o
BMD NNP o
from IN N
other JJ N
measures NNS N
in IN N
the DT N
hip NN N
, , N
these DT N
estimates NNS N
are VBP N
too RB N
imprecise JJ N
to TO N
allow VB N
conclusions NNS N
about IN N
change NN N
in IN N
BMD NNP N
to TO N
be VB N
made VBN N
. . N

CONCLUSIONS NNP N
Disaster NNP p
survivors NNS p
improve VBP N
psychologically RB N
over IN N
time NN N
regardless NN N
of IN N
receiving VBG N
intervention NN N
; : N
however RB N
, , N
those DT N
taking VBG N
micronutrients NNS N
during IN N
the DT N
acute JJ N
phase NN N
following VBG N
a DT N
disaster NN N
show NN N
better RBR N
outcomes RB N
, , N
identifying VBG N
micronutrients NNS N
as IN N
a DT N
viable JJ N
treatment NN N
for IN N
acute JJ N
stress NN N
following VBG N
a DT N
natural JJ N
disaster NN N
with IN N
maintenance NN N
of IN N
benefits NNS N
1 CD N
year NN N
later RB N
. . N

Factors NNS N
associated VBN N
with IN N
depression NN N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
included VBD N
younger JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
comorbid NN N
angina NN N
, , N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
, , N
use NN N
of IN N
a DT N
hypoglycemic JJ N
agent NN N
, , N
lower JJR N
activity NN N
level NN N
, , N
higher JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
use NN N
. . N

These DT N
results NNS N
support VBP N
parental JJ N
responsiveness NN N
as IN N
an DT N
important JJ N
intervention NN N
target NN N
given VBN N
its PRP$ N
general JJ N
association NN N
with IN N
child NN N
outcomes NNS N
in IN N
the DT N
extant JJ N
literature NN N
; : N
however RB N
, , N
additional JJ N
supports NNS N
are VBP N
likely JJ N
needed VBN N
to TO N
fully RB N
maintain VB N
the DT N
treatment NN N
effect NN N
and CC N
to TO N
affect VB N
child NN N
outcomes NNS N
. . N

CONCLUSIONS NN N
In IN N
this DT N
group NN N
of IN N
patients NNS N
we PRP N
were VBD N
able JJ N
to TO N
show VB N
that DT N
guided VBD i
isometric JJ i
resistance NN i
training NN i
of IN i
the DT i
paravertebral JJ i
muscles NNS i
can MD N
improve VB N
functional JJ o
capacity NN o
, , o
reduce VB o
fatigue NN o
and CC N
thereby NN N
enhance NN N
QoL NNP N
over IN N
a DT N
6-months JJ N
period NN N
in IN N
patients NNS p
with IN p
stable JJ p
spinal JJ p
metastases NNS p
. . p

OBJECTIVE NN N
To TO N
examine VB N
the DT N
safety NN o
and CC o
tolerability NN o
of IN N
a DT N
single JJ i
intra-articular JJ i
injection NN i
of IN i
rAAV2-TNFR NN i
: : i
Fc NNP N
, , N
an DT N
adenoassociated JJ i
virus NN i
serotype NN i
2 CD i
vector NN i
containing VBG i
the DT i
cDNA NN i
for IN p
the DT p
human JJ p
tumour JJ p
necrosis NN p
factor-immunoglobulin JJ p
Fc NNP p
fusion NN p
gene NN p
( ( p
tgAAC94 NN p
) ) p
, , p
in IN p
subjects NNS p
with IN p
inflammatory JJ p
arthritis NN p
. . p

However RB N
, , N
the DT N
decreased JJ N
5 CD N
alpha-reduction NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone NN N
is VBZ N
the DT N
only RB N
impaired JJ N
steroid JJ N
conversion NN N
to TO N
have VB N
clinical JJ N
consequences NNS N
, , N
e.g NN N
, , N
ambiguous JJ N
genitalia NN N
, , N
impaired JJ N
prostate NN N
differentiation NN N
and CC N
development NN N
, , N
and CC N
decreased VBD N
facial JJ o
and CC o
body JJ o
hair NN o
. . o

Although IN N
some DT N
authors NNS N
have VBP N
postulated VBN N
decreased JJ N
requirements NNS N
for IN N
ABT NNP N
by IN N
using VBG N
autologous JJ N
retransfusion NN N
devices NNS N
, , N
other JJ N
trials NNS N
, , N
mostly RB N
evaluating VBG N
retransfusion NN N
devices NNS N
for IN N
unwashed JJ N
shed VBN N
blood NN N
( ( N
USB NNP N
) ) N
, , N
verified VBD N
a DT N
small JJ N
or CC N
no DT N
benefit NN N
in IN N
reducing VBG N
the DT N
need NN N
for IN N
postoperative JJ N
ABT NNP N
. . N

OBJECTIVES IN N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP N
risk NN N
stratification NN N
scheme NN N
to TO N
a DT N
MONICA NNP N
sample NN N
of IN N
6000 CD p
subjects NNS p
from IN p
a DT p
geographically RB p
defined VBN p
population NN p
in IN p
northern JJ p
Sweden NNP p
, , p
regarding VBG p
indications NNS p
for IN p
treatment NN p
, , p
target VB p
blood NN p
pressure NN p
and CC p
risk NN p
distribution NN p
. . p

Clinical JJ N
evaluation NN N
of IN N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
a DT N
transdermal JJ i
nicotine NN i
system NN i
( ( i
Nicoderm NNP i
) ) i
BACKGROUND NNP N
Transdermal NNP i
nicotine NN i
therapy NN i
has VBZ N
shown VBN N
promise NN N
as IN N
a DT N
smoking NN N
cessation NN N
aid NN N
, , N
but CC N
questions NNS N
about IN N
its PRP$ N
contact NN N
sensitization NN N
potential NN N
and CC N
long-term JJ N
topical JJ N
safety NN N
have VBP N
been VBN N
raised VBN N
. . N

RESULTS NNP N
Principal NNP N
components NNS N
analysis NN N
identified VBD N
three CD N
primary JJ N
dietary JJ N
patterns NNS N
among IN N
rural JJ N
dwellers NNS N
( ( N
high JJ N
sweets NNS N
and CC N
starches NNS N
, , N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
, , N
and CC N
mixed JJ N
) ) N
and CC N
three CD N
among IN N
urban JJ i
dwellers NNS i
( ( i
high JJ i
fruits NNS i
and CC i
vegetables NNS i
, , i
high JJ i
meat NN i
and CC i
refined VBD i
grains NNS i
, , i
and CC i
high JJ i
sugar-sweetened JJ i
beverages NNS i
) ) i
. . i

The DT N
children NNS N
on IN N
both DT N
regimens NNS N
were VBD N
comparable JJ N
for IN N
sex NN N
, , N
race NN N
, , N
age NN N
at IN N
initial JJ N
ALL NNP N
diagnosis NN N
, , N
time NN N
from IN N
ALL NNP N
diagnosis NN N
to TO N
first JJ N
episode NN N
of IN N
CNS NNP N
leukemia NN N
, , N
systemic JJ N
therapy NN N
both DT N
before IN N
and CC N
after IN N
CNS NNP N
relapse NN N
, , N
and CC N
number NN N
of IN N
blasts NNS N
in IN N
the DT N
spinal JJ p
fluid NN p
at IN p
diagnosis NN p
of IN p
CNS NNP p
leukemia NN p
. . p

Class NN N
V NNP N
preparations NNS N
in IN N
extracted JJ p
upper JJ p
premolars NNS p
were VBD p
used VBN p
and CC p
ten JJ p
restorations NNS p
were VBD p
used VBN p
for IN p
each DT p
of IN p
the DT p
following JJ p
groups NNS p
: : p
( ( i
i NN i
) ) i
two CD i
layers NNS i
of IN i
copal JJ i
varnish JJ i
and CC i
amalgam NN i
; : i
( ( i
ii NN i
) ) i
conventional JJ i
glass-ionomer JJ i
and CC i
amalgam NN i
; : i
( ( i
iii NN i
) ) i
light-cured JJ i
glass-ionomer NN i
and CC i
amalgam NN i
; : i
( ( i
iv NN i
) ) i
bonding NN i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
; : i
( ( i
v NN i
) ) i
conventional JJ i
glass-ionomer JJ i
, , i
bonding JJ i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
; : i
( ( i
vi NN i
) ) i
light-cured JJ i
glass-ionomer NN i
, , i
extended VBD i
0.3 CD i
mm NN i
short NN i
of IN i
the DT i
enamel JJ i
margin NN i
bonding VBG i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
; : i
and CC i
( ( i
vii NN i
) ) i
light-cured JJ i
glass-ionomer NN i
, , i
extended VBD i
1 CD i
mm NN i
short NN i
of IN i
the DT i
enamel NN i
margin NN i
, , i
bonding VBG i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
. . i

Residual JJ o
urine NN o
volume NN o
was VBD N
significantly RB N
decreased VBN N
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
after IN N
instillation NN N
of IN N
saline NN N
into IN N
the DT N
bladder NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
The DT N
maximum NN o
and CC o
average JJ o
flow JJ o
rates NNS o
were VBD N
significantly RB N
increased VBN N
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
Average NNP o
flow JJ o
rate NN o
showed VBD N
significant JJ N
differences NNS N
between IN N
groups NNS N
M NNP N
or CC N
H NNP N
versus NN N
group NN N
P. NNP N
Neither NNP N
orthostatic JJ o
hypotension NN o
nor CC N
a DT N
decrease NN N
in IN N
blood NN o
pressure NN o
was VBD N
noted VBN N
. . N

Results NNS N
for IN N
treatment NN N
outcome NN N
suggest VBP N
that IN N
the DT N
TG NNP N
showed VBD N
significant JJ N
improvement NN N
in IN N
communication NN o
and CC o
social JJ o
interaction NN o
domain NN o
scores NNS o
on IN o
the DT o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
, , o
interpersonal JJ o
relationship NN o
and CC o
play/leisure NN o
time NN o
on IN o
the DT o
subdomain NN o
scores NNS o
of IN o
the DT o
Korean JJ o
version NN o
of IN o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scale NNP o
( ( o
p NN o
's POS o
< NNP o
0.01 CD o
) ) o
, , o
social JJ o
skills NNS o
knowledge VBP o
total JJ o
scores NNS o
on IN o
the DT o
Test NNP o
of IN o
Adolescent NNP o
Social NNP o
Skills NNP o
Knowledge-Revised JJ o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
decreased VBD N
depressive JJ o
symptoms NNS o
on IN o
the DT o
Child NNP o
Depression NNP o
Inventory NNP o
following VBG N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
was VBD N
86.7 CD N
% NN N
in IN N
the DT N
EA NNP N
plus CC N
behavior JJ N
therapy NN N
group NN N
which WDT N
was VBD N
better JJR N
than IN N
56.7 CD N
% NN N
of IN N
the DT N
behavior JJ N
therapy NN N
group NN N
, , N
and CC N
had VBD N
significant JJ N
enhancement NN N
in IN N
sensation NN o
, , o
association NN o
, , o
body NN o
, , o
and CC o
ability NN o
of IN o
self-care NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
was VBD N
better JJR N
than IN N
the DT N
behavior JJ N
therapy NN N
group NN N
in IN N
sensation NN o
, , o
body NN o
and CC o
self-care JJ o
factors NNS o
, , N
with IN N
no DT N
significantly RB N
improvement NN N
in IN N
the DT N
scores NNS o
of IN o
PPVT NNP o
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
new JJ o
or CC o
recurrent JJ o
carious JJ o
lesions NNS o
in IN N
the DT N
group NN N
treated VBD N
with IN N
the DT N
fluoride NN N
gel NN N
was VBD N
slightly RB N
lower JJR N
than IN N
in IN N
the DT N
IFRS NNP N
group NN N
, , N
based VBN N
on IN N
carious JJ N
lesions NNS N
at IN N
the DT N
baseline NN N
examination NN N
( ( N
Poisson NNP N
mean VBP N
number NN N
of IN N
new JJ N
or CC N
recurrent JJ N
carious JJ N
lesions NNS N
for IN N
the DT N
control NN N
group=0.55 NN N
per IN N
year NN N
vs. FW N
0.83 CD N
per IN N
year NN N
for IN N
the DT N
study NN N
group NN N
, , N
p=0.705 NN N
; : N
odds NNS o
ratio NN o
of IN o
the DT o
occurrence NN o
of IN o
any DT o
new JJ o
or CC o
recurrent JJ o
caries NNS o
during IN N
follow-up JJ N
for IN N
control NN N
group NN N
vs. FW N
the DT N
study NN N
group=0.80 NN N
; : N
p=0.781 NN N
) ) N
. . N

Systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
, , o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
, , o
fasting VBG o
glucose NN o
( ( o
FG NNP o
) ) o
, , o
lipid JJ o
profiles NNS o
( ( o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
triglyceride RB o
( ( o
TG NNP o
) ) o
, , o
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
and CC o
high JJ o
density NN o
lipoprotein NN o
( ( o
HDL-C NNP o
) ) o
) ) o
, , o
and CC o
antioxidant JJ o
enzymes NNS o
activities NNS o
( ( o
catalase NN o
( ( o
CAT NNP o
) ) o
, , o
superoxide JJ o
dismutase NN o
( ( o
SOD NNP o
) ) o
, , o
and CC o
glutathione NN o
peroxidase NN o
( ( o
GPx NNP o
) ) o
) ) o
were VBD N
measured VBN N
. . N

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
CARS NNP o
) ) o
, , o
hand NN o
muscle NN o
testing NN o
, , o
and CC o
modified VBD o
clinical JJ o
global JJ o
impression NN o
( ( o
CGI NNP o
) ) o
forms VBZ o
; : o
parent NN o
completed VBD o
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
( ( o
ATEC NNP o
) ) o
, , o
treatment NN o
adherence NN o
measurement NN o
( ( o
TAM NNP o
) ) o
, , o
frequency NN o
and CC o
intensity NN o
of IN o
side JJ o
effect NN o
rating NN o
( ( o
FISER NNP o
) ) o
/global VBD o
rating NN o
of IN o
side JJ o
effect NN o
burden NN o
( ( o
GRSEB NNP o
) ) o
/patient VBD o
report NN o
of IN o
incidence NN o
of IN o
side NN o
effects NNS o
( ( o
PRISE NNP o
) ) o
forms NNS o
; : o
and CC o
lab VB o
testing NN o
. . o

As IN N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
angiotensin JJ N
II NNP N
alone RB N
, , N
indomethacin JJ N
pre-treatment NN N
followed VBN N
by IN N
angiotensin NN N
II NNP N
infusion NN N
led VBD N
to TO N
much RB N
greater JJR N
falls NNS o
in IN o
absolute JJ o
rate NN o
of IN o
sodium NN o
excretion NN o
, , o
fractional JJ o
sodium NN o
excretion NN o
, , o
urine JJ o
flow NN o
rate NN o
and CC o
effective JJ o
renal JJ o
plasma NN o
flow NN o
( ( N
all DT N
P NNP N
< NNP N
0.0001 CD N
vs NN N
placebo NN N
) ) N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
glomerular JJ o
filtration NN o
rate NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
not RB N
observed VBN N
with IN N
angiotensin JJ N
II NNP N
alone RB N
. . N

Men NN p
and CC p
women NNS p
, , p
22-36 JJ p
years NNS p
old JJ p
, , N
performed VBD N
a DT N
synchronization-continuation NN i
task NN i
with IN i
intertap JJ i
intervals NNS i
( ( i
ITI NNP i
) ) i
from IN N
0.4 CD N
s NNS N
to TO N
2.2 CD N
s. NNS N
ISIP NNP N
variability NN N
was VBD N
partitioned VBN N
into IN N
components NNS N
attributable JJ N
to TO N
drift VB N
and CC N
1st-order JJ N
serial JJ N
correlation NN N
, , N
and CC N
the DT N
results NNS N
indicate VBP N
that IN N
( ( N
a DT N
) ) N
drift NN N
contributes VBZ N
substantially RB N
to TO N
the DT N
dispersion NN N
for IN N
longer JJR N
ITIs NNP N
, , N
( ( N
b NN N
) ) N
drift NN N
and CC N
1st-order JJ N
correlation NN N
are VBP N
different JJ N
functions NNS N
of IN N
the DT N
ITI NNP N
, , N
and CC N
( ( N
c NN N
) ) N
drift NN N
exhibits VBZ N
break VBP N
close JJ N
to TO N
1.0 CD N
s NNS N
and CC N
1.4 CD N
s NN N
ITI NNP N
. . N

In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
change NN N
in IN N
the DT N
B-type NNP o
natriuretic JJ o
peptide NN o
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
brachial JJ o
PP NNP o
( ( N
r VB N
= RB N
0.18 CD N
) ) N
, , N
central JJ o
systolic JJ o
blood NN o
pressure NN o
( ( N
r JJ N
= NNP N
0.18 CD N
) ) N
, , N
central JJ N
PP NNP N
( ( N
r VB N
= RB N
0.26 CD N
) ) N
, , N
and CC N
PP NNP N
amplification NN N
( ( N
r JJ N
= NNP N
-0.22 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
the DT N
confounding NN N
factors NNS N
. . N

RESULTS NN N
After IN N
controlling VBG N
for IN N
body NN N
weight NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
effect NN N
of IN N
time NN o
on IN o
fasting VBG o
serum NN o
glucose NN o
( ( N
P NNP N
= NNP N
0.0177 CD N
) ) N
and CC N
total JJ o
cholesterol NN o
( ( N
P NNP N
= NNP N
0.0386 CD N
) ) N
concentrations NNS N
, , N
and CC N
on IN N
diastolic JJ o
blood NN o
pressure NN o
( ( N
P NNP N
= NNP N
0.0413 CD N
) ) N
, , N
with IN N
reductions NNS N
in IN N
these DT N
variables NNS N
occurring VBG N
over IN N
time NN N
; : N
there EX N
was VBD N
no DT N
time-by-diet JJ N
interaction NN N
for IN N
any DT N
of IN N
the DT N
parameters NNS N
studied VBD N
. . N

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
the DT N
score NN o
of IN o
the DT o
'Issues NNS o
on IN o
treatment NN o
compliance NN o
' POS o
factor NN o
and CC o
the DT o
score NN o
of IN o
the DT o
'Autistic JJ o
life NN o
' POS o
factor NN o
, , o
which WDT o
are VBP o
subscales NNS o
of IN o
the DT o
Discharge NNP o
Difficulty NNP o
Scale NNP o
, , N
for IN N
the DT N
DPP NNP i
group NN N
, , N
on IN N
two-way JJ N
ANOVA NNP N
( ( N
'Issues NNS N
on IN N
treatment NN N
compliance NN N
' '' N
: : N
F NNP N
= VBZ N
3.818 CD N
, , N
P NNP N
< NNP N
0.10 CD N
; : N
'Autistic JJ N
life NN N
' POS N
: : N
F NNP N
= VBZ N
4.155 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
These DT N
factors NNS N
affected VBD N
discharge NN N
outcome NN N
. . N

Based VBN N
on IN N
the DT N
analysis NN N
of IN N
covariance NN N
models NNS N
adjusted VBN N
for IN N
the DT N
baseline NN N
rating NN N
scores NNS N
, , N
parents NNS N
( ( N
but CC N
not RB N
teachers NNS N
) ) N
provided VBD N
a DT N
higher JJR N
average JJ o
rating NN o
of IN o
social JJ o
skills NNS o
on IN o
the DT o
BASC NNP o
for IN N
the DT N
children NNS N
in IN N
the DT N
placebo NN N
group NN N
compared VBN N
to TO N
the DT N
DHA NNP N
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
teachers NNS N
( ( N
but CC N
not RB N
parents NNS N
) ) N
provided VBD N
a DT N
higher JJR N
average JJ o
rating NN o
of IN o
functional JJ o
communication NN o
on IN o
the DT o
BASC NNP o
for IN N
the DT N
children NNS N
in IN N
the DT N
DHA NNP N
group NN N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
progression-free JJ o
survival NN o
was VBD N
10.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
6.2 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
placebo NN i
( ( N
hazard JJ N
ratio NN N
for IN N
disease NN N
progression NN N
, , N
0.54 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
the DT N
corresponding JJ o
rates NNS o
of IN o
response NN o
were VBD N
44.8 CD N
percent NN N
and CC N
34.8 CD N
percent NN N
( ( N
P=0.004 NNP N
) ) N
. . N

Because IN N
the DT N
aim NN N
of IN N
prostate NN N
cancer NN N
detection NN N
is VBZ N
to TO N
find VB N
cancers NNS N
at IN N
an DT N
early JJ N
, , N
potentially RB N
curable JJ N
stage NN N
, , N
it PRP N
is VBZ N
of IN N
major JJ N
interest NN N
that IN N
71.8 CD N
% NN N
of IN N
evaluable JJ N
cancers NNS N
were VBD N
clinical JJ N
stage NN N
B NNP N
; : N
8.4 CD N
% NN N
and CC N
10.7 CD N
% NN N
were VBD N
stages NNS N
C1 NNP N
and CC N
C2 NNP N
, , N
respectively RB N
; : N
only RB N
9.2 CD N
% NN N
were VBD N
stage JJ N
D NNP N
( ( N
metastatic JJ N
) ) N
at IN N
first JJ N
visit NN N
while IN N
none NN N
was VBD N
at IN N
stage NN N
D NNP N
at IN N
follow-up JJ N
visits NNS N
. . N

Factors NNS N
associated VBN N
with IN N
exclusive JJ N
breastfeeding NN N
included VBD N
maternal JJ o
work NN o
( ( N
OR=3.92 NNP N
; : N
p-value JJ N
< NNP N
0.001 CD N
) ) N
, , N
planned VBN o
pregnancy NN o
( ( N
OR=2.42 NNP N
, , N
p-value=0.010 NN N
) ) N
, , N
intention NN o
to TO o
breastfeed VB o
( ( N
OR=3.28 NNP N
; : N
p-value=0.043 NN N
) ) N
, , N
source NN o
of IN o
maternal JJ o
emotional JJ o
support NN o
( ( N
OR=1.87 NNP N
, , N
p-value=0.039 NN N
) ) N
and CC N
the DT N
use NN N
the DT N
postpartum NN N
support NN N
video NN N
, , N
the DT N
hotline NN N
service NN N
or CC N
both DT N
( ( N
OR=2.55 NNP N
, , N
p-value=0.044 NN N
; : N
OR=3.87 NNP N
, , N
p-value=0.004 NN N
and CC N
OR=4.13 NNP N
, , N
p-value=0.003 NN N
) ) N
. . N

For IN N
patients NNS N
who WP N
achieved VBD N
a DT N
stable JJ o
PT NNP o
ratio NN o
( ( N
defined VBN N
as IN N
a DT N
PT NNP N
ratio NN N
between IN N
1.3 CD N
and CC N
2.5 CD N
that WDT N
varied VBN N
by IN N
less JJR N
than IN N
0.05 CD N
on IN N
two CD N
consecutive JJ N
days NNS N
or CC N
by IN N
less JJR N
than IN N
0.1 CD N
on IN N
three CD N
consecutive JJ N
days NNS N
without IN N
a DT N
dosage NN N
change NN N
) ) N
before IN N
discharge NN N
, , N
the DT N
number NN N
of IN N
days NNS N
( ( N
time NN N
to TO N
stabilization NN N
) ) N
from IN N
administration NN N
of IN N
the DT N
first JJ N
warfarin NN N
dose NN N
to TO N
achievement NN N
of IN N
the DT N
warfarin NN N
dosage NN N
that WDT N
produced VBD N
a DT N
stable JJ N
PT NNP N
ratio NN N
( ( N
stabilization JJ N
dosage NN N
) ) N
was VBD N
compared VBN N
. . N

Wind-up JJ N
to TO N
the DT N
2 CD N
Hz NNP o
train NN o
increased VBD o
in IN o
the DT o
UO NNP o
( ( o
wind-up JJ o
ratio NN o
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ N
central JJ N
neuronal JJ N
excitability NN N
. . N

Blood NNP o
pressure NN o
in IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
trial NN N
was VBD N
equally RB N
and CC N
significantly RB N
reduced VBN N
; : N
systolic JJ o
pressure NN o
22.2 CD o
mmHg NN o
and CC o
diastolic JJ o
pressure NN o
15.5 CD N
mmHg NN N
in IN N
the DT N
supine JJ N
position NN N
, , N
and CC N
24.4 CD N
mmHg NN N
and CC N
18.4 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
standing VBG N
position NN N
in IN N
those DT N
on IN N
nicardipine NN N
, , N
and CC N
by IN N
23.7 CD N
and CC N
16.2 CD N
mmHg NN N
and CC N
28.0 CD N
and CC N
19.2 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
propranolol NN i
group NN N
. . N

Although IN N
6-thioguanine JJ i
conferred VBD N
a DT N
significantly RB N
lower JJR N
risk NN o
of IN o
isolated JJ o
CNS NNP o
relapse NN o
than IN N
did VBD N
6-mercaptopurine JJ i
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
0.30-0.92 CD N
, , N
p=0.02 NN N
) ) N
, , N
the DT N
benefit NN N
was VBD N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN o
of IN o
death NN o
in IN o
remission NN o
( ( N
2.22 CD N
, , N
1.20-4.14 CD N
, , N
p=0.01 NN N
) ) N
, , N
mainly RB N
due JJ N
to TO N
infections NNS N
during IN N
continuing VBG N
therapy NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
blood NN o
transfusion NN o
( ( N
1.0 CD N
% NN N
in IN N
the DT N
cangrelor NN N
group NN N
and CC N
0.6 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
P=0.13 NNP N
) ) N
, , N
though IN o
major JJ o
bleeding VBG o
on IN o
one CD o
scale NN o
was VBD N
increased VBN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
from IN N
3.5 CD N
% NN N
to TO N
5.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
because IN N
of IN N
more JJR N
groin JJ N
hematomas NN N
. . N

Heart NNP o
rate NN o
, , o
core NN o
temperature NN o
, , o
maximal JJ o
voluntary JJ o
isometric JJ o
contraction NN o
, , o
passive JJ o
hip NN o
flexion NN o
, , o
passive JJ o
hamstring NN o
stiffness NN o
( ( o
PHS NNP o
) ) o
, , o
plasma JJ o
creatine JJ o
kinase NN o
activity NN o
, , o
and CC o
myoglobin NNS o
were VBD N
recorded VBN N
at IN N
prestretching NN N
, , N
at IN N
poststretching NN N
, , N
and CC N
every DT N
day NN N
after IN N
the DT N
eccentric JJ N
exercises NNS N
for IN N
5 CD N
d. NN N
RESULTS NNP N
After IN N
stretching VBG i
, , N
the DT N
change NN N
in IN N
hip NN o
flexion NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
SAS NNP N
( ( N
5 CD N
) ) N
and CC N
DAS NNP N
( ( N
10.8 CD N
) ) N
groups NNS N
than IN N
in IN N
the DT N
CON NNP i
( ( N
-4.1 NNP N
) ) N
group NN N
. . N

RESULTS VB N
The DT N
mean JJ o
area NN o
under IN o
the DT o
curve NN o
of IN o
improvement NN o
for IN o
scaling/hypertrophy NN o
, , o
pain NN o
, , o
itching NN o
and CC o
global JJ o
patient NN o
assessment NN o
was VBD N
significantly RB N
better JJR N
for IN N
the DT N
actively RB N
treated JJ N
patients NNS N
as IN N
compared VBN N
with IN N
placebo NN i
( ( N
scaling/hypertrophy NN N
, , N
P NNP N
= NNP N
0.0262 CD N
; : N
pain NN N
, , N
P NNP N
= NNP N
0.0238 CD N
; : N
itching NN N
, , N
P NNP N
= NNP N
0.0135 CD N
; : N
global JJ N
patient NN N
assessment NN N
, , N
P NNP N
= NNP N
0.045 CD N
) ) N
. . N

However RB N
, , N
the DT N
mean JJ o
6-month JJ o
change NN o
in IN o
central JJ o
macular JJ o
thickness NN o
( ( o
CMT NNP o
) ) o
in IN N
the DT N
combination NN N
group NN N
was VBD N
-124 VBN N
? . N
( ( N
-29.7 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
while IN N
in IN N
the DT N
ranibizumab-only JJ N
group NN N
, , N
the DT N
change NN N
was VBD N
-86.9 VBN N
? . N
( ( N
-19.5 CD N
% NN N
; : N
p=0.001 CC N
) ) N
; : N
thus RB N
, , N
the DT N
combination NN N
treatment NN N
resulted VBD N
in IN N
a DT N
greater JJR N
reduction NN N
( ( N
p=0.003 NN N
) ) N
. . N

RESULTS NNP N
Immediately NNP N
after IN N
placement NN N
, , N
the DT N
self-etching JJ N
adhesive NN N
and CC N
its PRP$ N
respective JJ N
cement NN N
resulted VBD N
in IN N
more RBR N
suppression NN o
of IN o
cold JJ o
sensitivity NN o
than IN N
no DT N
treatment NN N
( ( N
control NN N
) ) N
; : N
with IN N
Linkmax NNP N
treatment NN N
, , N
the DT N
temperature NN N
at IN N
which WDT N
teeth EX N
responded VBD N
was VBD N
reduced VBN N
by IN N
8.4 CD N
degrees NNS N
C. NNP N
The DT N
conventionally RB N
etched VBN N
adhesive JJ N
and CC N
its PRP$ N
cement NN N
reduced VBD N
the DT N
temperature NN N
at IN N
which WDT N
teeth NN N
responded VBD N
by IN N
9.4 CD N
degrees NNS N
C. NNP N
After IN N
1 CD N
week NN N
, , N
these DT N
temperature NN N
reductions NNS N
were VBD N
7.0 CD N
degrees NNS N
C NNP N
and CC N
4.3 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

After IN N
treatment NN N
, , N
the DT N
Chinese JJ o
medicine JJ o
syndrome NN o
scores NNS o
, , o
urinary JJ o
protein NN o
and CC o
urinary JJ o
red-cell NN o
count NN o
reduced VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
showed VBD N
significant JJ N
difference NN N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
while IN N
the DT N
endogenous JJ o
creatinine NN o
clearance NN o
was VBD N
changed VBN N
insignificantly RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
adverse JJ o
experiences NNS o
, , N
except IN N
that DT N
weight NN o
gain NN o
, , o
fluid JJ o
retention NN o
, , o
and CC o
dyspnea NN o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ i
HCL NNP i
, , N
whereas JJ N
nausea NN o
and CC o
vomiting NN o
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN i
acetate NN i
. . i

METHODS NNP N
Sixty NNP p
qualifying VBG p
subjects NNS p
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
Regimen NNP N
One NNP N
, , N
a DT N
whitening NN i
dentifrice NN i
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
toothpaste NN N
] NN N
and CC N
powered VBD N
toothbrush NN N
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
Extra NNP N
Whitening NNP N
Spinbrush NNP N
) ) N
; : N
Regimen NNP N
Two CD N
, , N
the DT N
dentifrice NN N
and CC N
powered VBD N
toothbrush NN N
with IN N
the DT N
addition NN N
of IN N
a DT N
whitening JJ N
booster NN N
; : N
or CC N
Regimen NNP N
Three NNP N
, , N
a DT N
negative JJ N
control NN N
( ( N
Colgate NNP N
Cavity NNP N
Protection NNP N
toothpaste NN N
and CC N
an DT N
ADA NNP N
standard NN N
manual JJ N
brush NN N
) ) N
. . N

The DT N
mean NN o
maximal JJ o
temperature NN o
elevation NN o
induced VBN N
by IN N
interferon NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
from IN N
102.1 CD N
to TO N
100.7 CD N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
by IN N
indomethacin NN i
, , N
but CC N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
interferon-related JJ o
fatigue NN o
, , o
reduction NN o
in IN o
performance NN o
status NN o
, , o
headache NN o
, , o
depression NN o
, , o
confusion NN o
, , o
elevations NNS o
in IN o
liver JJ o
function NN o
tests NNS o
, , o
and CC o
myelosuppression NN o
were VBD N
no DT N
different JJ N
in IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

With IN N
or CC N
without IN N
HBO NNP N
pre-treatment NN N
, , N
the DT N
rats NNS N
were VBD N
further RB N
divided VBN N
into IN N
the DT N
following JJ N
subgroups NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
: : N
( ( N
i NN N
) ) N
LPS NNP i
injection NN i
, , i
( ( i
ii NN i
) ) i
normal JJ i
saline NN i
( ( i
N/S NNP i
) ) i
injection NN i
, , i
( ( i
iii NN i
) ) i
hemin NN i
( ( i
a DT i
HO-1 NNP i
inducer NN i
) ) i
plus CC i
LPS NNP i
, , i
( ( i
iv NN i
) ) i
hemin NN i
alone RB i
, , i
( ( i
v NN i
) ) i
tin NN i
protoporphyrin NN i
( ( i
SnPP NNP i
; : i
a DT i
HO-1 NNP i
inhibitor NN i
) ) i
plus CC i
LPS NNP i
, , i
and CC i
( ( i
vi NN i
) ) i
SnPP NNP i
alone RB i
. . i

In IN N
experimental JJ N
study NN N
, , N
monoaminic JJ N
transmitters NNS N
activated VBN N
in IN N
hypothalamus NN N
; : N
weight NN o
of IN o
pituitary JJ o
, , o
adrenal JJ o
and CC o
thymus NN o
decreased VBN o
; : o
number NN o
of IN o
CRH NNP o
positive JJ o
neurons NNS o
in IN o
hypothalamic JJ o
paraventricular JJ o
nucleus NN o
, , o
CRH NNP o
positive JJ o
neurofibrilin NN o
median JJ o
eminence NN o
and CC o
anterior JJ o
pituitary JJ o
ACTH NNP o
positive JJ o
secretory NN o
cells NNS o
decreased VBD o
; : o
adrenal JJ o
fasciculate NN o
zone NN o
and CC o
thymus NN o
cortex NN o
atrophies NNS o
; : o
NK NNP o
cell VBP o
cytotoxicity NN o
and CC o
the DT o
level NN o
of IN o
IL-2 NNP o
and CC o
gamma-IFN NN o
which WDT N
were VBD N
produced VBN N
by IN N
lymphocytes NNS N
reduced VBN N
in IN N
CORT-rats NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS JJ N
Students NNS p
in IN p
PA NNP p
schools NNS p
, , N
compared VBN N
with IN N
those DT N
in IN N
control NN N
schools NNS N
, , N
had VBD N
more RBR N
favorable JJ N
change NN N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
in IN N
positive JJ N
affect NN N
( ( N
standardized JJ N
mean NN N
difference NN N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
.17 NNP N
) ) N
and CC N
life NN o
satisfaction NN o
( ( N
ES NNP N
= NNP N
.13 NNP N
) ) N
as RB N
well RB N
as IN N
significantly RB N
lower JJR N
depression NN N
( ( N
ES NNP N
= NNP N
-.14 NNP N
) ) N
and CC N
anxiety NN o
( ( N
ES NNP N
= NNP N
-.26 NNP N
) ) N
at IN N
study JJ N
end NN N
point NN N
. . N

At IN N
T3 NNP N
, , N
T4 NNP o
and CC o
T5 NNP o
, , o
OI NNP o
and CC o
Cstat NNP o
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
Raw NNP o
and CC o
P NNP o
( ( o
A- NNP o
) ) o
O2 NNP o
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Both DT N
groups NNS N
performed VBD N
treadmill JJ N
test NN N
to TO N
assess VB N
pain-free JJ o
walking NN o
time NN o
( ( o
PFWT NNP o
) ) o
and CC o
maximal JJ o
walking NN o
time NN o
( ( o
MWT NNP o
) ) o
and CC o
had VBD o
blood NN o
analyses NNS o
[ VBP o
for IN o
haematocrit NN o
, , o
fibrinogen NN o
, , o
triglycerides NNS o
, , o
and CC o
cholesterol NN o
: : o
total JJ o
, , o
high-density JJ o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
and CC o
low-density JJ o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
] VBD o
done VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
and CC N
12 CD N
weeks NNS N
of IN N
the DT N
study NN N
. . N

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN o
during IN N
the DT N
procedure NN N
than IN N
the DT N
injection NN N
sclerotherapy NN N
( ( N
IS NNP N
) ) N
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN o
per IN o
rectum NN o
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB N
satisfied VBN N
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

Vascular JJ o
function NN o
was VBD o
assessed VBN o
by IN o
brachial JJ o
dilation NN o
as RB N
well RB N
as IN N
by IN N
plasma NN N
samples NNS N
analysed VBN N
for IN N
hs-CRP NN N
( ( N
high-sensitivity JJ N
C-reactive NNP N
protein NN N
) ) N
, , N
IL-6 NNP o
( ( o
interleukin-6 NN o
) ) o
, , o
IL-8 NNP o
, , o
ICAM-1 NNP o
( ( o
intercellular JJ o
adhesion NN o
molecule-1 NN o
) ) o
, , o
vWF FW o
( ( o
von FW o
Willebrand NNP o
factor NN o
) ) o
, , o
MCP-1 NNP o
( ( o
monocyte JJ o
chemoattractant NN o
protein-1 NN o
) ) o
, , o
PAI-1 NNP o
( ( o
plasminogen JJ o
activator NN o
inhibitor-1 NN o
) ) o
and CC o
fibrinogen NN o
. . o

On IN N
comparing VBG N
bone NN o
gainers NNS o
with IN o
increase NN o
of IN o
lumbar JJ o
spine NN o
BMD NNP o
by IN N
2 CD N
% NN N
or CC N
more JJR N
with IN N
bone NN N
losers NNS N
with IN N
a DT N
decrease NN N
by IN N
2 CD N
% NN N
or CC N
more JJR N
, , N
only RB N
urine JJ o
Ca/Cr NNP o
was VBD N
significantly RB N
different JJ N
, , N
lower RBR N
in IN N
the DT N
former JJ N
than IN N
in IN N
the DT N
latter NN N
, , N
despite IN N
the DT N
general JJ N
tendency NN N
for IN N
bone NN N
resorption NN N
markers NNS N
to TO N
decrease VB N
in IN N
bone NN N
gainers NNS N
and CC N
to TO N
increase VB N
in IN N
bone JJ N
losers NNS N
. . N

The DT N
best JJS N
treatment NN N
modalities NNS N
, , N
irrespective NN N
of IN N
the DT N
kind NN N
of IN N
lesion NN N
, , N
were VBD N
found VBN N
to TO N
be VB N
the DT N
combination NN N
of IN N
5-FU JJ i
plus JJ i
IFN NNP i
alpha-2a NN i
( ( N
high JJ N
dose NN N
) ) N
( ( N
98.27 CD N
% NN N
) ) N
, , N
the DT N
combination NN N
of IN N
CO2 NNP i
laser NN i
vaporization NN i
plus CC i
5-FU JJ i
plus JJ i
IFN NNP i
alpha-2a NN i
( ( N
high JJ N
dose NN N
) ) N
( ( N
93.93 CD N
% NN N
) ) N
and CC N
the DT N
combination NN N
of IN N
CO2 NNP i
laser NN i
vaporization NN i
plus CC i
5-FU JJ i
( ( N
87.23 CD N
% NN N
) ) N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Compared NNP N
with IN N
group NN N
I PRP N
, , N
the DT N
rate NN o
of IN o
premature NN o
LH NNP o
surge NN o
was VBD N
statistically RB N
significantly RB N
lower JJR N
for IN N
group NN N
II NNP N
( ( N
43.4 CD N
% NN N
[ CC N
13/30 CD N
] NN N
vs. FW N
19.4 CD N
% NN N
[ CC N
6/31 CD N
] NN N
) ) N
, , N
but CC N
the DT N
amount NN N
of IN N
gonadotropins NNS N
used VBN N
was VBD N
statistically RB N
significantly RB N
higher JJR N
( ( N
817.5 CD N
+/- JJ N
28.5 CD N
vs. FW N
907.5 CD N
+/- JJ N
27.3 CD N
IU NNP N
) ) N
. . N

Time NNP o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
was VBD N
slightly RB N
longer JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemohormonal JJ i
therapy NN i
compared VBN N
with IN N
chemotherapy NN N
alone RB N
patients NNS N
( ( N
13.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.087 NNP N
) ) N
, , N
and CC N
TTF NNP o
was VBD N
significantly RB N
longer RBR N
in IN N
ER-positive JJ N
compared VBN N
with IN N
ER-negative JJ N
patients NNS N
( ( N
17.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.048 NNP N
) ) N
. . N

OBJECTIVE NN N
To TO N
examine VB N
further RB N
the DT N
relations NNS N
of IN N
plasma NN o
von NN o
Willebrand NNP o
factor NN o
( ( o
vWf NN o
, , o
an DT o
index NN o
of IN o
endothelial JJ o
damage NN o
and CC o
dysfunction NN o
) ) o
and CC o
soluble JJ o
P-selectin NNP o
( ( o
sP-sel NN o
, , o
an DT o
index NN o
of IN o
platelet NN o
activation NN o
) ) o
concentrations NNS o
to TO o
the DT o
presence NN o
and CC o
onset NN o
of IN o
clinical JJ o
congestive JJ o
heart NN o
failure NN o
( ( o
CHF NNP o
) ) o
and CC o
the DT o
degree NN o
of IN o
left NN o
ventricular NN o
( ( o
LV NNP o
) ) o
dysfunction NN o
in IN N
patients NNS p
taking VBG p
part NN p
in IN p
the DT p
SPAF NNP p
( ( p
stroke JJ p
prevention NN p
in IN p
atrial JJ p
fibrillation NN p
) ) p
study NN p
. . p

The DT N
conclusion NN N
is VBZ N
that IN N
children NNS p
with IN p
isolated JJ p
CNS NNP p
leukemia NN p
can MD N
achieve VB N
prolonged JJ N
survival NN N
with IN N
aggressive JJ N
therapy NN N
, , N
and CC N
that IN N
CSpRT NNP i
is VBZ N
possibly RB N
less RBR N
toxic JJ o
and CC N
more RBR N
likely JJ N
than IN N
is VBZ N
CRT NNP N
+ NNP N
ITC NNP N
to TO N
prevent VB N
subsequent JJ N
BM NNP N
and CC N
testicular JJ o
relapse NN o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
not RB N
subsequent JJ N
CNS NNP o
relapse NN o
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
. . N

RESULTS NNP N
Intention-to-treat NNP N
analysis NN N
revealed VBD N
significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
respective JJ N
eradication NN o
rates NNS o
of IN o
the DT o
LOAD NNP o
therapies NNS o
( ( N
88.9 CD N
% NN N
( ( N
80/90 CD N
) ) N
LOAD-10 NNP N
, , N
90 CD N
% NN N
( ( N
81/90 CD N
) ) N
LOAD-7 NNP N
, , N
89.4 CD N
% NN N
( ( N
161/180 CD N
) ) N
for IN N
combined VBN N
LOAD NNP N
) ) N
compared VBN N
with IN N
those DT N
receiving VBG N
LAC NNP N
, , N
73.3 CD N
% NN N
( ( N
66/90 CD N
) ) N
. . N

RESULTS VB N
The DT N
three CD N
methods NNS N
of IN N
evaluation NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
Groups NNP N
A NNP N
vs. NN N
B NNP N
, , N
and CC N
C NNP N
vs. FW N
D NNP N
, , N
while IN N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
Groups NNP N
A NNP N
vs. FW N
C NNP N
, , N
A NNP N
vs. NN N
D NNP N
, , N
B NNP N
vs. FW N
C NNP N
and CC N
B NNP N
vs. FW N
D. NNP N
Based VBD N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
the DT N
size NN N
of IN N
occlusal JJ N
access NN N
significantly RB N
affected VBD N
the DT N
efficacy NN N
of IN N
demineralized JJ N
tissue NN N
removal NN N
. . N

RESULTS NN N
In IN N
the DT N
ER+ NNP N
( ( N
Estrogen NNP N
Receptor NNP N
? . N
positive JJ N
) ) N
subgroup NN N
of IN N
the DT N
randomised JJ N
cohort NN N
, , N
YAP1 NNP o
expression NN o
was VBD N
inversely RB N
correlated VBN N
to TO N
histological JJ o
grade NN o
and CC o
proliferation NN o
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
p VB N
= JJ N
0.016 CD N
, , N
respectively RB N
) ) N
whereas NNS N
in IN N
the DT N
ER- NNP o
( ( o
Estrogen NNP o
Receptor NNP o
? . o
negative JJ o
) ) o
subgroup NN o
YAP1 NNP o
expression NN o
correlated VBD N
positively RB N
to TO N
proliferation NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
. . N

Overall JJ o
survival NN o
was VBD N
greater JJR N
with IN N
the DT N
implantable JJ N
defibrillator NN N
, , N
with IN N
unadjusted JJ N
estimates NNS N
of IN N
89.3 CD N
percent NN N
, , N
as IN N
compared VBN N
with IN N
82.3 CD N
percent NN N
in IN N
the DT N
antiarrhythmic-drug JJ N
group NN N
at IN N
one CD N
year NN N
, , N
81.6 CD N
percent NN N
versus NN N
74.7 CD N
percent NN N
at IN N
two CD N
years NNS N
, , N
and CC N
75.4 CD N
percent NN N
versus NN N
64.1 CD N
percent NN N
at IN N
three CD N
years NNS N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Although IN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
leptin NN o
levels NNS o
did VBD N
not RB N
change VB N
in IN N
Ex NNP N
patients NNS N
( ( N
6.7 CD N
? . N
3.2 CD N
vs NN N
6.9 CD N
? . N
3.6 CD N
ng/mL NN N
, , N
NS NNP N
) ) N
, , N
they PRP N
did VBD N
increase VB N
significantly RB N
in IN N
the DT N
control NN N
group NN N
( ( N
8.0 CD N
? . N
4.0 CD N
vs NN N
9.3 CD N
? . N
5.2 CD N
ng/mL NN N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
. . N

Results NNS N
obtained VBD N
from IN N
the DT N
average JJ o
intensity NN o
scores NNS o
of IN N
the DT N
three CD N
determinations NNS N
indicated VBD N
that IN N
Synemol NNP N
cream NN N
( ( N
0.025 CD N
% NN N
) ) N
is VBZ N
actually RB N
a DT N
more RBR N
active JJ N
compound NN N
than IN N
are VBP N
Diprosone NNP N
cream NN N
( ( N
0.05 CD N
% NN N
) ) N
, , N
Aristocort-A NNP i
cream NN i
( ( N
0.5 CD N
% NN N
) ) N
, , N
and CC N
Valisone NNP i
cream NN i
( ( N
0.1 CD N
% NN N
) ) N
, , N
and CC N
that IN N
its PRP$ N
activity NN N
is VBZ N
longer RBR N
acting VBG N
. . N

Expression NN o
of IN o
VEGF NNP o
and CC o
VEGFR-2 NNP o
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
with IN N
a DT N
high JJ N
degree NN N
of IN N
microvessel NN o
density NN o
compared VBN N
to TO N
those DT N
with IN N
a DT N
low JJ N
degree NN N
( ( N
VEGF NNP N
: : N
P NNP N
=0.024 NNP N
; : N
VEGFR-2 JJ N
: : N
P NNP N
=0.040 NNP N
) ) N
and CC N
correlated VBN N
well RB N
with IN N
bone NN o
marrow NN o
microvessel NN o
density NN o
( ( N
r NN N
( ( N
s PRP N
) ) N
=0.566 NN N
and CC N
0.609 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
for IN N
patients NNS N
with IN N
gram-positive JJ o
bacteremia NN o
and CC N
for IN N
all DT N
other JJ N
patients NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
by IN N
treatment NN N
regimens NNS N
in IN N
the DT N
proportion NN N
of IN N
febrile JJ N
patients NNS N
on IN N
each DT N
trial NN N
day NN N
( ( N
P NNP N
= NNP N
.85 NNP N
, , N
P NNP N
= NNP N
.82 NNP N
, , N
respectively RB N
) ) N
or CC N
in IN N
the DT N
duration NN o
of IN o
fever NN o
( ( N
P NNP N
= NNP N
.22 NNP N
, , N
P NNP N
= NNP N
.93 NNP N
, , N
respectively RB N
) ) N
. . N

Moreover RB N
, , N
the DT N
percentage NN N
of IN N
patients NNS N
without IN N
induration NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
and CC N
a DT N
statistically RB N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
size NN o
of IN o
the DT o
lesional JJ o
area NN o
was VBD N
also RB N
seen VBN N
in IN N
the DT N
overall JJ N
analysis NN N
of IN N
the DT N
R-salbutamol-treated JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.0197 CD N
) ) N
. . N

When WRB N
the DT N
children NNS N
with IN N
complete JJ N
resolution NN N
of IN N
their PRP$ N
liver NN N
enlargement NN N
were VBD N
considered VBN N
separately RB N
, , N
t NN N
( ( N
1/2hp CD N
) ) N
( ( N
P=0.0008 NNP N
) ) N
but CC N
not RB N
AUC NNP N
( ( N
hp NN N
) ) N
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
lower JJR N
, , N
and CC N
AUC NNP o
( ( o
hpFr196 NN o
) ) o
( ( N
P=0.01 NNP N
) ) N
and CC N
CL NNP o
( ( o
Bhl NNP o
) ) o
( ( N
P=0.002 NNP N
) ) N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
CQCP NNP N
group NN N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

During IN N
the DT N
last JJ N
weeks NNS N
of IN N
the DT N
pretreatment NN N
and CC N
third JJ N
treatment NN N
cycles NNS N
, , N
blood NN N
samples NNS N
were VBD N
obtained VBN N
for IN N
determinations NNS N
of IN N
plasma JJ o
concentrations NNS o
of IN o
angiotensinogen NN o
, , o
an DT o
estrogen-sensitive JJ o
hepatic JJ o
protein NN o
, , o
and CC o
serum JJ o
concentrations NNS o
of IN o
sex NN o
hormone-binding JJ o
globulin NN o
( ( o
SHBG NNP o
) ) o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
high-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
HDL-C NNP o
) ) o
, , o
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
triglycerides NNS o
( ( o
TG NNP o
) ) o
and CC o
estrogen- JJ o
and CC o
androgen-sensitive JJ o
proteins NNS o
. . o

In IN N
the DT N
presence NN N
of IN N
leakage NN N
( ( N
settings NNS N
II NNP N
and CC N
III NNP N
) ) N
, , N
the DT N
attempt NN N
to TO N
compensate VB N
for IN N
leak NN N
was VBD N
only RB N
evident JJ N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
since IN N
inspiratory NN N
volumes NNS N
delivered VBN N
by IN N
the DT N
ventilator NN N
increased VBD N
from IN N
726+/-129 NNP N
( ( N
setting VBG N
I PRP N
) ) N
to TO N
1104+/-164 JJ N
( ( N
setting VBG N
II NNP N
) ) N
, , N
and CC N
to TO N
1257+/-166 JJ N
( ( N
setting VBG N
III NNP N
) ) N
ml NN N
during IN N
pressure-limited JJ N
NPPV NNP N
, , N
respectively RB N
( ( N
all DT N
p VBP N
< $ N
0.001 CD N
) ) N
; : N
however RB N
, , N
they PRP N
remained VBD N
stable JJ N
during IN N
volume-limited JJ N
NPPV NNP N
. . N

Compared VBN N
with IN N
tPA NN N
, , N
however RB N
, , N
primary JJ N
PTCA NNP N
resulted VBD N
in IN N
a DT N
markedly RB N
lower JJR N
rate NN o
of IN o
recurrent NN o
myocardial JJ o
ischemia NN o
( ( N
9.7 CD N
% NN N
vs JJ N
27.8 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
fewer JJR N
unscheduled JJ o
catheterization NN o
and CC o
revascularization NN o
procedures NNS o
, , N
and CC N
a DT N
shorter JJR N
hospital NN o
stay NN o
( ( N
7.0 CD N
vs RB N
8.6 CD N
days NNS N
, , N
p VBP N
= RB N
0.01 CD N
) ) N
in IN N
nonanterior JJ N
wall NN N
AMI NNP N
. . N

RESULTS NNP N
Constitutive NNP o
proteins VBZ o
such JJ o
as IN o
albumin NN o
, , o
prealbumin NN o
, , o
and CC o
retinol-binding JJ o
protein NN o
levels NNS o
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
acute JJ o
phase NN o
proteins NNS o
such JJ o
as IN o
alpha JJ o
1-acid JJ o
glycoprotein NN o
, , o
C3 NNP o
complement NN o
, , o
alpha JJ o
2-macroglobulin JJ o
, , o
and CC o
fibrinogen NN o
levels NNS o
significantly RB N
decreased VBN N
in IN N
the DT N
oxandrolone NN N
group NN N
compared VBN N
with IN N
placebo NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Mean NNP o
peak NN o
FEV1 NNP o
change NN o
( ( N
primary JJ N
endpoint NN N
) ) N
was VBD N
maximum JJ N
with IN N
the DT N
administration NN N
of IN N
the DT N
combination NN N
of IN N
ipratropium NN i
and CC i
formoterol NN i
( ( N
335.2 CD N
ml NN N
, , N
SE NNP N
24.6 CD N
) ) N
, , N
and CC N
it PRP N
differed VBD N
significantly RB N
from IN N
the DT N
observed JJ N
peak NN o
changes NNS o
following VBG N
single JJ N
administration NN N
of IN N
the DT N
two CD N
tested VBD N
doses NNS N
of IN N
ipratropium NN i
( ( N
p JJ N
< NN N
0.05 CD N
and CC N
p VB N
< JJ N
0.05 CD N
respectively RB N
) ) N
. . N

For IN N
respective JJ N
comparisons NNS N
of IN N
ALLO NNP N
and CC N
AUTO NNP N
transplants NNS N
in IN N
the DT N
GLN NNP N
and CC N
GLY NNP N
hematologic VBP N
groups NNS N
and CC N
AUTO NNP N
in IN N
the DT N
solid JJ N
tumor NN N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
hospital NN o
stay NN o
, , o
duration NN o
of IN o
stay NN o
after IN o
BMT NNP o
, , o
TPN NNP o
days NNS o
, , o
neutrophil JJ o
recovery NN o
> NN o
500/mm3 CD o
, , o
incidence NN o
of IN o
positive JJ o
blood NN o
cultures NNS o
, , o
sepsis NN o
, , o
mucositis NN o
, , o
and CC o
diarrhea NN o
. . o

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
levels NNS o
of IN o
metals NNS o
in IN o
blood NN o
( ( o
zinc NN o
( ( o
Zn NNP o
) ) o
, , o
copper NN o
( ( o
Cu NNP o
) ) o
, , o
aluminium NN o
( ( o
Al NNP o
) ) o
, , o
lead JJ o
( ( o
Pb NNP o
) ) o
and CC o
mercury NN o
( ( o
Hg NNP o
) ) o
) ) o
, , N
as RB N
well RB N
as IN N
the DT N
specific JJ N
porphyrin NN N
levels NNS N
in IN N
the DT N
urine NN N
of IN N
patients NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
compared VBN p
with IN p
patients NNS p
with IN p
other JJ p
neurological JJ p
disorders NNS p
. . p

RESULTS VB N
The DT N
mean JJ o
total JJ o
ATEC NNP o
scores NNS o
by IN N
both DT N
parents NNS N
and CC N
clinicians NNS N
were VBD N
significantly RB N
improved VBN N
after IN N
intervention NN N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
compared VBN N
to TO N
the DT N
score NN N
before IN N
intervention NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
in IN N
both DT N
groups NNS N
by IN N
parents NNS N
, , N
P NNP N
= VBZ N
0.015 CD N
in IN N
HBOT NNP N
group NN N
and CC N
P NNP N
= NNP N
0.004 CD N
in IN N
sham NN N
group NN N
by IN N
clinician NN N
) ) N
. . N

Although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
incidence NN o
of IN o
de FW o
novo FW o
adnexal JJ o
adhesions NNS o
, , N
the DT N
lowest JJS N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
, , N
with IN N
4/32 CD N
patients NNS N
( ( N
12.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/29 CD N
patients NNS N
( ( N
6.8 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
5/30 CD N
patients NNS N
( ( N
16.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

RESULTS NNP N
After IN N
1 CD N
cycle NN N
, , N
BMI NNP o
, , o
total JJ o
T NNP o
level NN o
, , o
and CC o
percentage NN o
of IN o
participants NNS o
with IN o
insulin NN o
resistance NN o
were VBD N
significantly RB N
decreased VBN N
in IN N
the DT N
metformin NN i
group NN N
, , N
without IN N
any DT N
significant JJ N
decrease NN N
in IN N
LH NNP o
, , o
FSH NNP o
, , o
and CC o
DHEAS NNP o
levels NNS o
; : o
and CC N
in IN N
the DT N
second JJ N
cycle NN N
, , N
CC NNP N
treatment NN N
resulted VBD N
in IN N
a DT N
higher JJR N
ovulation NN o
rate NN o
and CC o
a DT o
thicker NN o
endometrium NN o
in IN N
the DT N
metformin NN N
group NN N
. . N

Core NN o
temperature NN o
decreased VBN N
in IN N
all PDT N
the DT N
three CD N
groups NNS N
30 CD N
minutes NNS N
after IN N
general JJ N
anesthesia NN N
induction NN N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
; : N
afterwards NNS N
, , N
it PRP N
progressively RB N
decreased VBD N
in IN N
the DT N
control NN N
and CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
, , N
with IN N
a DT N
reduction NN N
from IN N
baseline NN N
values NNS N
measured VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
of IN N
2.0 CD N
degrees NNS N
C NNP N
and CC N
1.6 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

We PRP N
found VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
duration NN o
of IN o
sensory JJ o
blockade NN o
( ( N
120.92 CD N
+/- JJ N
36.21 CD N
min NN N
with IN N
prilocaine NN i
and CC N
145.83 CD N
+/- JJ N
35.81 CD N
min NN N
with IN N
mepivacaine NN i
) ) i
and CC N
in IN N
motor NN o
blockade NN o
( ( N
106.29 CD N
+/- JJ N
38.16 CD N
min NN N
with IN N
prilocaine NN i
and CC N
133.16 CD N
+/- JJ N
42.21 CD N
min NN N
with IN N
mepivacaine NN N
) ) N
. . N

RESULTS NNP N
For IN N
pramipexole JJ N
recipients NNS N
, , N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
PLM NNP o
per IN o
hour NN o
in IN o
bed NN o
asleep NN o
or CC o
awake NN o
( ( o
the DT o
PLM NNP o
index NN o
, , o
or CC o
PLMI NNP o
) ) o
, , N
decreased VBN N
by IN N
a DT N
median NN N
of IN N
-26.55 NN N
to TO N
-52.70 VB N
depending VBG N
on IN N
dosage NN N
group NN N
, , N
vs. FW N
-3.00 NN N
for IN N
placebo NN i
( ( N
p JJ N
< VBP N
0.01 CD N
or CC N
0.001 CD N
for IN N
each DT N
group NN N
vs. FW N
placebo NN N
; : N
Wilcoxon-Mann-Whitney NNP N
test NN N
) ) N
. . N

As IN N
compared VBN N
with IN N
placebo NN i
, , i
the DT i
S. NNP i
boulardii NN i
group NN N
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
blood NN o
and CC o
tissue NN o
levels NNS o
of IN o
proinflammatory NN o
cytokines NNS o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
and CC o
tumor JJ o
necrosis NN o
factor- NN o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
and CC o
an DT o
increase NN o
in IN o
anti-inflammatory JJ o
IL-10 JJ o
levels NNS o
, , N
as RB N
well RB N
as IN N
an DT N
increase NN N
in IN N
the DT N
tissue NN N
IL-10/IL-12 NNP N
ratio NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
years NNS N
1 CD N
and CC N
2 CD N
, , N
the DT N
mean JJ o
postvaccination NN o
strain-specific NN o
to TO o
total JJ o
IgA NNP o
ratio NN o
was VBD N
3.1-fold JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2.0-fold JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
higher JJR N
among IN N
LAIV JJ N
recipients NNS N
with IN N
no DT N
evidence NN N
of IN N
culture-confirmed JJ N
influenza NN N
illness NN N
compared VBN N
with IN N
LAIV NNP i
recipients NNS N
who WP N
developed VBD N
culture-confirmed JJ N
influenza NN N
illness NN N
; : N
a DT N
similar JJ N
and CC N
consistent JJ N
trend NN N
was VBD N
observed VBN N
for IN N
each DT N
individual NN N
study NN N
and CC N
type/subtype NN N
. . N

Since IN N
the DT N
90 CD N
% NN N
CI NNP N
for IN N
Cmax NNP o
and CC o
AUCs NNP o
ratios NNS o
were VBD N
all DT N
within IN N
the DT N
80-125 JJ N
% NN N
bioequivalence NN N
limit NN N
proposed VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
cyproheptadine JJ i
test NN i
formulation NN i
( ( i
Cobactin NNP i
) ) i
is VBZ N
bioequivalent JJ N
to TO N
the DT N
Cobavital NNP N
formulation NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
the DT N
extent NN N
of IN N
absorption NN N
of IN N
cyproheptadine NN i
. . i

Twenty NNP p
adults NNS p
, , p
critically RB p
ill VB p
for IN p
several JJ p
weeks NNS p
and CC p
supported VBD p
with IN p
normocaloric JJ p
, , p
continuously RB p
administered VBN p
parenteral JJ p
and/or JJ p
enteral JJ p
feeding NN p
, , p
were VBD p
studied VBN p
for IN p
45 CD p
h. NN p
They PRP p
had VBD p
been VBN p
randomized VBN p
to TO p
receive VB i
one CD i
of IN i
three CD i
combinations NNS i
of IN i
peptide JJ i
infusions NNS i
, , i
in IN i
random JJ i
order NN i
: : i
TRH NN i
( ( i
one CD i
day NN i
) ) i
and CC i
placebo NN i
( ( i
other JJ i
day NN i
) ) i
; : i
TRH NNP i
+ NNP i
GH-releasing NNP i
peptide NN i
( ( i
GHRP NNP i
) ) i
-2 NN i
and CC i
GHRP-2 NNP i
; : i
TRH NNP i
+ NNP i
GHRH NNP i
+ NNP i
GHRP-2 NNP i
and CC i
GHRH NNP i
+ NNP i
GHRP-2 NNP i
. . i

Significant JJ N
improvement NN N
was VBD N
recorded VBN N
for IN N
all DT N
symptoms NNS N
at IN N
days NNS N
10 CD N
and CC N
28 CD N
in IN N
all DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
levosulpiride NN i
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
superior NN N
to TO N
domperidone VB i
, , i
metoclopramide NN i
and CC i
placebo VB i
both DT N
in IN N
the DT N
overall JJ N
clinical JJ N
improvement NN N
scale NN N
as RB N
well RB N
as IN N
in IN N
a DT N
subgroup NN N
of IN N
symptoms NNS o
( ( o
postprandial JJ o
bloating NN o
, , o
epigastric JJ o
pain NN o
, , o
heartburn NN o
) ) o
. . o

The DT N
heavy JJ N
group NN N
significantly RB N
improved VBN N
both DT N
the DT N
5- JJ o
and CC o
10-m JJ o
sprint NN o
time NN o
by IN N
5.7 CD N
? . N
5.7 CD N
and CC N
5.0 CD N
? . N
3.5 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
only RB N
10-m JJ o
sprint NN o
time NN o
was VBD N
improved VBN N
significantly RB N
by IN N
3.0 CD N
? . N
3.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
light JJ N
group NN N
. . N

Tissue NNP o
plasminogen NN o
activator NN o
antigen NN o
concentration NN o
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN i
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN o
activator NN o
inhibitor NN o
1 CD o
. . o

The DT N
WCGF NNP i
diets NNS i
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
the DT N
concentration NN o
of IN o
milk NN o
fat NN o
( ( N
3.94 CD N
, , N
3.74 CD N
, , N
and CC N
4.15 CD N
+/- JJ N
0.08 CD N
% NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
) ) N
, , N
but CC N
because IN N
total JJ o
milk NN o
yield NN o
was VBD N
increased VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
total JJ o
milk NN o
fat JJ o
yield NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
positive JJ o
response NN o
on IN o
the DT o
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Improvement NNP o
subscale NN o
between IN N
the DT N
citalopram-treated JJ N
group NN N
( ( N
32.9 CD N
% NN N
) ) N
and CC N
the DT N
placebo NN i
group NN N
( ( N
34.2 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
, , N
0.96 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.61-1.51 JJ N
; : N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

RESULTS NN N
After IN N
induction NN N
of IN N
anesthesia NN N
, , N
the DT N
decrease NN N
in IN N
pupil JJ o
size NN o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.112 CD N
) ) N
, , N
but CC N
for IN N
the DT N
next JJ N
two CD N
stages NNS N
, , N
it PRP N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
diclofenac NN i
group NN N
( ( N
P NNP N
= NNP N
0.012 CD N
and CC N
P NNP N
= NNP N
0.003 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ o
rate NN o
of IN o
exacerbations NNS o
( ( o
mild NN o
, , o
moderate JJ o
or CC o
severe JJ o
) ) o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Salm/FP NNP i
group NN N
( ( N
0.472 CD N
) ) N
compared VBN N
with IN N
the DT N
Form+Bud NNP N
group NN N
( ( N
0.735 CD N
) ) N
( ( N
ratio JJ N
= VBZ N
0.64 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
despite IN N
the DT N
three-fold JJ N
lower JJR N
microgram NN N
inhaled VBN N
corticosteroid NN N
dose NN N
in IN N
the DT N
Salm/FP NNP N
group NN N
. . N

Safety NNP N
analyses NNS N
of IN N
patients NNS N
applying VBG N
topical JJ i
diclofenac NN i
solution NN N
revealed VBD N
some DT N
minor JJ o
skin NN o
irritation NN o
at IN N
the DT N
application NN N
site NN N
-- : N
mostly RB N
skin JJ N
dryness NN N
in IN N
83/311 CD N
( ( N
27 CD N
% NN N
) ) N
patients NNS N
-- : N
but CC N
a DT N
significantly RB N
reduced VBN N
incidence NN o
, , o
relative JJ o
to TO o
oral JJ o
diclofenac NN o
, , o
of IN o
total JJ o
and CC o
severe JJ o
gastrointestinal NN o
( ( o
GI NNP o
) ) o
adverse JJ o
events NNS o
, , o
including VBG o
dyspepsia NN o
, , o
abdominal JJ o
pain NN o
, , o
diarrhea NN o
, , o
and CC o
nausea NN o
. . o

The DT N
overall JJ o
incidence NN o
of IN o
adverse JJ o
events NNS o
and CC o
subsequent JJ o
downtime NN o
was VBD N
increased VBN N
for IN N
Er NN N
: : N
YAG NNP N
( ( N
1/10 CD N
patients NNS N
experienced JJ N
hyperpigmentation NN o
, , o
3/10 CD o
exfoliation NN o
, , o
1/10 CD o
blistering NN o
, , o
and CC o
5/10 CD o
discomfort NN o
) ) o
compared VBN N
to TO N
IPL NNP N
( ( N
1/10 CD N
exfoliation NN N
and CC N
1/10 CD N
discomfort NN N
) ) N
, , N
although IN N
no DT N
permanent JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
treatment NN N
arm NN N
. . N

Following VBG N
endodontic JJ N
treatment NN N
, , N
the DT N
teeth NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
: : N
cast VBN i
Ni-Cr JJ i
alloy NN i
dowel-core NN i
with IN i
no DT i
ferrule NN i
( ( i
Group NNP i
A1 NNP i
) ) i
, , i
cast VBD i
Ni-Cr JJ i
alloy NN i
dowel-core NN i
with IN i
2.0 CD i
mm NNS i
ferrule NN i
( ( i
Group NNP i
A2 NNP i
) ) i
, , i
prefabricated VBN i
carbon NN i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
with IN i
no DT i
ferrule NN i
( ( i
Group NNP i
B1 NNP i
) ) i
and CC i
carbon JJ i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
with IN i
2.0 CD i
mm NNS i
ferrule NN i
( ( i
Group NNP i
B2 NNP i
) ) i
. . i

At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
there EX N
were VBD N
no DT N
statistically RB N
or CC N
clinically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
for IN N
the DT N
Western NNP o
Ontario NNP o
Shoulder NNP o
Instability NNP o
Index NNP o
( ( o
P NNP o
= NNP o
.71 NNP o
) ) o
, , o
American NNP o
Shoulder NNP o
and CC o
Elbow NNP o
Surgeons NNP o
score NN o
( ( o
P NNP o
= NNP o
.43 NNP o
) ) o
, , o
Constant JJ o
score NN o
( ( o
P NNP o
= NNP o
.43 NNP o
) ) o
, , o
and CC o
active JJ o
range NN o
of IN o
motion NN o
. . o

One CD p
hundred VBD p
sixty-three JJ p
colon NN p
cancer NN p
patients NNS p
underwent VBD p
the DT p
traditional JJ i
protocol NN i
and CC i
open JJ i
operation NN i
( ( i
traditional JJ i
open JJ i
group NN p
, , p
n=42 RB p
) ) p
, , p
the DT p
traditional JJ i
protocol NN i
and CC i
laparoscopic NN i
operation NN i
( ( i
traditional JJ i
laparoscopic NN i
group NN i
, , i
n=40 RB i
) ) i
, , i
the DT i
FT NNP i
protocol NN i
and CC i
open JJ i
operation NN i
( ( i
FT NNP i
open JJ i
group NN i
, , i
n=41 RB i
) ) i
, , i
or CC i
the DT i
FT NNP i
protocol NN i
and CC i
laparoscopic NN i
operation NN i
( ( i
FT NNP i
laparoscopic NN i
group NN N
, , N
n=40 RB N
) ) N
. . N

Rowers NNS N
in IN N
the DT N
Fe NNP N
group NN N
had VBD N
slower JJR o
lactate JJ o
response NN o
during IN N
the DT N
first JJ N
half NN N
of IN N
the DT N
time NN N
trial NN N
and CC N
after IN N
5 CD N
min NN N
of IN N
recovery NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
showed VBD N
greater JJR N
improvements NNS N
in IN N
energy NN o
expenditure NN o
( ( N
P NNP N
= VBZ N
0.01 CD N
for IN N
group-by JJ N
time NN N
) ) N
and CC N
energetic JJ N
EF NNP N
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
= VBZ N
0.03 CD N
for IN N
group-by JJ N
time NN N
) ) N
. . N

CONCLUSION NN N
When WRB N
compared VBN N
with IN N
SRP NNP i
alone RB N
, , N
clinical JJ N
improvements NNS N
in IN N
PPD NNP N
( ( N
e.g NN N
, , N
-1.0 NNP N
mm NN N
for IN N
pockets NNS N
> VBP N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
were VBD N
maintained VBN N
for IN N
up IN N
to TO N
six CD N
months NNS N
after IN N
SRP NNP i
with IN N
adjunctive JJ N
use NN N
of IN N
1.7 CD N
% NN N
hydrogen NN N
peroxide NN N
gel NN N
, , N
locally RB N
administered VBN N
using VBG N
prescription NN N
customized VBD N
trays NNS N
in IN N
the DT N
treatment NN N
of IN N
subjects NNS p
with IN p
moderate JJ p
to TO p
advanced JJ p
periodontitis NN p
. . p

Mutans NNS o
streptococci VBP o
( ( o
MS NNP o
) ) o
and CC o
lactobacilli $ o
( ( o
LB NNP o
) ) o
levels NNS o
, , o
visible JJ o
plaque NN o
index NN o
( ( o
VPI NNP o
) ) o
and CC o
gingival JJ o
bleeding NN o
index NN o
( ( o
GBI NNP o
) ) o
were VBD N
evaluated VBN N
at IN N
four CD N
stages NNS N
: : N
T0 NNP N
, , N
before IN N
general JJ N
anaesthesia NN N
; : N
T1 NNP N
, , N
one CD N
month NN N
after IN N
treatment NN N
; : N
T2 NNP N
, , N
six CD N
months NNS N
after IN N
treatment NN N
; : N
T3 NNP N
, , N
twelve JJ N
months NNS N
after IN N
treatment NN N
. . N

Stress NNP o
incontinence NN o
was VBD N
greater JJR N
among IN N
primiparous JJ N
women NNS N
in IN N
the DT N
VB NNP N
group NN N
( ( N
VB NNP N
34.5 CD N
% NN N
vs. FW N
CS NNP N
12.8 CD N
% NN N
) ) N
regardless NN N
of IN N
prior JJ N
UI NNP N
history NN N
, , N
but CC N
the DT N
proportion NN N
of IN N
women NNS N
whose WP$ N
UI NNP N
was VBD N
severe JJ N
enough RB N
to TO N
wear VB N
a DT N
pad NN N
was VBD N
similar JJ N
in IN N
primiparous JJ N
women NNS N
( ( N
VB NNP N
16.0 CD N
% NN N
, , N
CS NNP N
15.4 CD N
% NN N
) ) N
and CC N
multiparous JJ N
women NNS N
( ( N
VB NNP N
23.8 CD N
% NN N
, , N
CS NNP N
25.0 CD N
% NN N
) ) N
. . N

Larger NNP N
decreases VBZ N
in IN N
body NN o
weight NN o
, , o
body NN o
mass NN o
index NN o
, , o
waist NN o
circumference NN o
, , o
body NN o
fat NN o
, , o
total JJ o
fat JJ o
area NN o
and CC o
subcutaneous JJ o
fat JJ o
area NN o
in IN o
the DT o
abdomen NNS o
and CC o
serum NN o
triglycerides NNS o
, , o
low-density NN o
lipoprotein NN o
cholesterol NN o
, , o
apolipoprotein NN o
B NNP o
, , o
C2 NNP o
, , o
C3 NNP o
and CC o
E NNP o
were VBD N
observed VBN N
in IN N
male JJ N
subjects NNS N
in IN N
the DT N
MLCT NNP i
group NN N
than IN N
those DT N
in IN N
the DT N
LCT NNP i
group NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
relationship NN N
between IN N
failure NN o
of IN o
the DT o
fixation NN o
and CC o
varus NN o
reduction NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
as RB N
well RB N
as IN N
screw/neck NN o
angle NN o
deviation NN o
more JJR N
than IN N
20 CD N
degrees NNS N
in IN N
the DT N
lateral JJ N
projection NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
or CC N
if IN N
the DT N
implant NN N
was VBD N
in IN N
a DT N
superior JJ N
or CC N
posterior JJ N
position NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

METHODS NNP N
Sixty-six JJ p
patients NNS p
with IN p
gastric JJ p
carcinoma NN p
scheduled VBN p
for IN p
gastrectomy NN p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
, , N
namely RB N
group NN N
P NNP N
( ( N
n=22 NN N
) ) N
, , N
group NN N
E NNP N
( ( N
n=22 NN N
) ) N
and CC N
group NN N
V NNP N
( ( N
n=22 NN N
) ) N
, , N
to TO N
receive VB N
preemptive JJ i
epidural JJ i
analgesia NN i
combined VBN i
with IN i
postoperative JJ i
epidural JJ i
analgesia NN i
, , i
exclusive JJ i
postoperative JJ i
epidural JJ i
analgesia NN i
, , i
and CC i
exclusive JJ i
postoperative NN i
intravenous JJ i
analgesia NN i
, , i
respectively RB i
. . i

At IN N
3-month JJ N
follow-up NN N
, , N
intervention NN N
group NN N
patients NNS N
demonstrated VBD N
significantly RB N
improved VBN N
cognitive JJ o
executive NN o
functioning NN o
on IN N
the DT N
widely RB N
used VBN N
and CC N
well-normed JJ N
Tower NNP N
test NN N
( ( N
for IN N
planning NN N
and CC N
strategic JJ N
thinking NN N
) ) N
vs. NN N
controls NNS N
( ( N
median JJ N
[ NN N
interquartile NN N
range NN N
] NNP N
, , N
13.0 CD N
[ JJ N
11.5-14.0 JJ N
] NNP N
vs. FW N
7.5 CD N
[ JJ N
4.0-8.5 JJ N
] NN N
; : N
adjusted VBN N
p NN N
< NNP N
.01 NNP N
) ) N
. . N

RESULTS NNP N
MDI NNP o
was VBD N
higher RBR N
in IN N
the DT N
EDI NNP N
( ( N
102.6 CD N
? . N
9.8 CD N
) ) N
compared VBN N
with IN N
the DT N
control NN N
resuscitated VBD N
children NNS N
( ( N
98.0 CD N
? . N
14.6 CD N
, , N
1-sided JJ N
P NNP N
= NNP N
.0202 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
nonresuscitated JJ N
children NNS N
( ( N
100.1 CD N
? . N
10.7 CD N
vs NN N
97.7 CD N
? . N
10.4 CD N
, , N
P NNP N
= NNP N
.1392 NNP N
) ) N
. . N

Intervention NNP N
group NN N
patients NNS N
also RB N
reported VBD N
better JJR N
performance NN N
( ( N
i.e NN N
, , N
lower JJR N
score NN N
) ) N
on IN N
one CD N
of IN N
the DT N
most RBS N
frequently RB N
used JJ N
measures NNS N
of IN N
functional JJ o
status NN o
( ( o
Functional NNP o
Activities NNP o
Questionnaire NNP o
at IN N
3 CD N
months NNS N
vs. FW N
controls NNS N
, , N
1.0 CD N
[ NN N
0.0 CD N
-3.0 NN N
] NNP N
vs VBZ N
8.0 CD N
[ JJ N
6.0-11.8 JJ N
] NN N
, , N
adjusted VBN N
p NN N
= NNP N
.04 NNP N
) ) N
. . N

The DT N
corresponding JJ N
reductions NNS N
in IN N
mortality NN o
( ( N
with IN N
95 CD N
percent NN N
confidence NN N
limits NNS N
) ) N
with IN N
the DT N
implantable JJ N
defibrillator NN N
were VBD N
39+/-20 JJ N
percent NN N
, , N
27+/-21 JJ N
percent NN N
, , N
and CC N
31+/-21 JJ N
percent NN N
CONCLUSIONS NNP N
Among IN N
survivors NNS N
of IN N
ventricular JJ N
fibrillation NN N
or CC N
sustained VBN N
ventricular JJ N
tachycardia NN N
causing VBG N
severe JJ N
symptoms NNS N
, , N
the DT N
implantable JJ N
cardioverter-defibrillator NN N
is VBZ N
superior JJ N
to TO N
antiarrhythmic VB N
drugs NNS N
for IN N
increasing VBG N
overall JJ o
survival NN o
. . o

Mean JJ o
muscle NN o
volume NN o
of IN o
the DT o
thigh NN o
, , o
estimated VBN o
by IN o
computerised JJ o
tomography NN o
, , N
increased VBD N
significantly RB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
initial JJ N
placebo NN N
period NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
a DT N
slight JJ N
decrease NN N
was VBD N
recorded VBN N
in IN N
adipose JJ o
tissue NN o
volume NN o
of IN o
the DT o
thigh NN o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
and CC N
subscapular JJ o
skinfold NN o
thickness NN o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Using VBG N
one CD N
definition NN N
, , N
the DT N
prevalence NN N
of IN N
low JJ N
RF NNP N
profile NN N
increased VBD N
from IN N
3.8 CD N
% NN N
( ( N
3.1-4.5 JJ N
) ) N
in IN N
1984-1986 JJ N
to TO N
6.7 CD N
% NN N
( ( N
6.1-7.3 JJ N
) ) N
in IN N
2003-2006 JJ N
; : N
using VBG N
another DT N
definition NN N
, , N
the DT N
results NNS N
were VBD N
5.9 CD N
% NN N
( ( N
5.1-6.8 JJ N
) ) N
and CC N
9.7 CD N
% NN N
( ( N
9.0-10.5 CD N
) ) N
, , N
respectively RB N
. . N

RESULTS NNP N
Intervention NNP N
patients NNS N
reported VBD N
using VBG N
more JJR N
skills NNS N
than IN N
controls NNS N
in IN N
five CD N
of IN N
six CD N
skill JJ N
areas NNS N
, , N
including VBG N
identification NN o
of IN o
problems/concerns NNS o
, , o
information NN o
exchange NN o
, , o
treatment NN o
adherence NN o
, , o
shared VBN o
decision-making NN o
and CC o
interpersonal JJ o
rapport NN o
( ( N
all DT N
p NN N
< NNP N
.05 NNP N
) ) N
; : N
post VBN N
intervention NN N
, , N
physicians NNS N
reported VBD N
using VBG N
more JJR N
skills NNS N
in IN N
the DT N
same JJ N
5 CD N
areas NNS N
( ( N
all DT N
p NN N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
effects NNS N
of IN N
captopril NN i
( ( N
C NNP N
) ) N
( ( N
50 CD N
mg NN N
, , N
three CD N
times NNS N
daily RB N
for IN N
3 CD N
days NNS N
) ) N
on IN N
arterial JJ N
pressure NN N
( ( N
AP NNP N
) ) N
, , N
O2 NNP N
consumption NN N
( ( N
VO2 NNP N
) ) N
, , N
variations NNS N
in IN N
auricular JJ i
natriuretic JJ i
factor NN i
( ( i
ANF NNP i
) ) i
, , N
renin NN N
, , N
angiotensin NN N
II NNP N
( ( N
AII NNP N
) ) N
plasma NN N
levels NNS N
, , N
as RB N
well RB N
as IN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
GFR NNP N
) ) N
and CC N
microalbuminuria $ N
( ( N
MA NNP N
) ) N
were VBD N
evaluated VBN N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ o
myocardial JJ o
infarctions NNS o
with IN N
ZES NNP N
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS o
of IN o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
target NN o
vessel NN o
revascularization NN o
, , o
or CC o
stent JJ o
thrombosis NN o
. . o

Fewer NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
major JJ o
infectious JJ o
events NNS o
( ( o
infectious JJ o
death NN o
or CC o
delay NN o
in IN o
treatment NN o
of IN o
underlying JJ o
disease NN o
due JJ o
to TO o
infection NN o
) ) o
were VBD N
observed VBN N
during IN N
piperacillin/ JJ N
tazobactam JJ N
treatment NN N
( ( N
2.6 CD N
% NN N
) ) N
than IN N
with IN N
the DT N
ceftazidime NN i
regimen NNS N
( ( N
11.3 CD N
% NN N
) ) N
, , N
despite IN N
a DT N
lower JJR N
frequency NN N
of IN N
glycopeptide JJ N
addition NN N
when WRB N
piperacillin/tazobactam NN N
was VBD N
used VBN N
( ( N
54.4 CD N
% NN N
versus IN N
77.4 CD N
% NN N
) ) N
according VBG N
to TO N
the DT N
rules NNS N
adopted VBN N
. . N

The DT N
incidence NN o
of IN o
mucositis NN o
requiring VBG o
morphine NN o
sulfate NN o
( ( o
MSO4 NNP o
) ) o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
42.9 CD N
% NN N
) ) N
, , N
with IN N
the DT N
mean JJ N
number NN N
of IN N
days NNS N
with IN N
MSO4 NNP N
being VBG N
7.8 CD N
( ( N
SD NNP N
= NNP N
3.4 CD N
) ) N
in IN N
the DT N
PTX NNP i
group NN N
versus VBD N
8.2 CD N
( ( N
SD NNP N
= NNP N
3.4 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
NS NNP N
) ) N
. . N

However RB N
, , N
results NNS N
from IN N
the DT N
Conners NNP o
' POS o
Parent NNP o
Questionnaire NNP o
revealed VBD N
an DT N
improvement NN N
only RB N
for IN N
anxiety NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
massage NN N
group NN N
, , N
whereas IN N
when WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
conduct NN o
problem NN o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
anxiety NN o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
was VBD N
found VBN N
. . N

Compared VBN N
to TO N
the DT N
Placebo NNP i
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
and CC N
fish JJ N
oil NN N
containing VBG N
Gamma-linolenic JJ N
acid NN N
( ( N
GLA NNP N
) ) N
, , N
Eicosapentaenoic NNP N
acid NN N
( ( N
EPA NNP N
) ) N
, , N
and CC N
Docosahexaenoic NNP i
acid NN i
( ( i
DHA NNP i
) ) i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
edema NN o
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

Fasting VBG o
blood NN o
samples NNS o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
12-month JJ N
treatment NN N
for IN N
determinations NNS N
of IN N
fibrinogen NN o
, , o
prothrombin JJ o
fragment NN o
1+2 CD o
( ( o
F1+2 NNP o
) ) o
, , o
plasma JJ o
D-dimer NNP o
, , o
soluble JJ o
tissue NN o
factor NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
( ( o
tPA NN o
) ) o
antigen NN o
, , o
tPA NN o
activity NN o
, , o
plasminogen NN o
activator NN o
inhibitor JJ o
type-1 JJ o
activity NN o
( ( o
PAI-1 NNP o
activity NN o
) ) o
and CC o
serum JJ o
D-dimer NNP o
as IN o
a DT o
global JJ o
test NN o
of IN o
fibrinolytic JJ o
activity NN o
. . o

( ( N
2 CD N
) ) N
The DT N
rate NN N
of IN N
achieving VBG N
the DT N
LDL-C JJ N
goal NN N
of IN N
The DT N
National NNP N
Cholesterol NNP N
Education NNP N
Program NNP N
( ( N
NCEP NNP N
) ) N
in IN N
Adult NNP N
Treatment NNP N
Panel NNP N
III NNP N
( ( N
ATP NNP N
III NNP N
) ) N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
was VBD N
73.5 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
atorvastatin NN i
and CC N
niacin JJ N
groups NNS N
( ( N
47.7 CD N
% NN N
and CC N
42.1 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
oral JJ N
hygiene NN N
instructions NNS N
and CC N
ultrasonic JJ N
supragingival NN N
instrumentation NN N
, , N
the DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
for IN N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
CIC NNP i
, , i
scaled VBD i
with IN i
Gracey NNP i
curettes NNS i
; : i
CIUS NNP i
, , i
scaled VBD i
with IN i
ultrasonic JJ i
device NN i
; : i
CDC NNP i
, , i
calculus JJ i
deattachment NN i
with IN i
Gracey NNP i
curettes NNS i
and CC i
brushing VBG i
with IN i
saline JJ i
solution NN i
; : i
and CC i
CDUS NNP i
, , i
calculus JJ i
deattachment NN i
with IN i
ultrasonic JJ i
device NN i
and CC i
brushing VBG i
with IN i
saline JJ i
solution NN i
. . i

Radial JJ o
trabecular NN o
bone NN o
density NN o
showed VBD N
a DT N
significantly RB N
higher JJR N
rate NN o
of IN o
increase NN o
in IN N
group NN N
I PRP N
( ( N
ipriflavone VB N
group NN N
) ) N
than IN N
in IN N
group NN N
II NNP N
( ( N
elcatonin JJ N
group NN N
) ) N
at IN N
the DT N
4th CD N
month NN N
, , N
whereas JJ N
lumbar NN o
spine NN o
BMD NNP o
showed VBD N
more RBR N
pronounced JJ N
increase NN N
in IN N
the DT N
elcatonin NN i
group NN N
than IN N
in IN N
the DT N
ipriflavone NN i
group NN N
throughout IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS o
of IN o
PAI NNP o
activity NN o
in IN N
the DT N
imidapril NN N
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

Therefore RB N
, , N
a DT N
combined JJ N
parameter NN N
was VBD N
constructed VBN N
showing VBG N
a DT N
more RBR N
prominent JJ N
separation NN N
of IN N
response NN N
: : N
tumors NNS N
with IN N
high JJ N
EGFr NNP N
and CC N
well/moderate JJ N
differentiation NN N
did VBD N
benefit VB N
from IN N
moderate JJ N
acceleration NN N
of IN N
treatment NN N
regarding VBG N
locoregional JJ N
control NN N
, , N
HR NNP N
0.54 CD N
( ( N
0.37-0.78 NN N
) ) N
, , N
whereas NNS N
such JJ N
an DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
tumors NNS N
with IN N
low JJ N
EGFr NNP N
and/or NN N
poor JJ N
differentiation NN N
, , N
HR NNP N
0.8 CD N
( ( N
0.51-1.25 NN N
) ) N
. . N

Incidence NN o
of IN o
the DT o
primary JJ o
endpoint NN o
( ( o
biopsy-proven JJ o
acute NN o
rejection NN o
, , o
BPAR NNP o
; : o
graft NN o
loss NN o
, , o
death NN o
, , o
DGF NNP o
, , o
wound VBD o
healing VBG o
complications NNS o
related VBN o
to TO o
transplant VB o
surgery NN o
or CC o
loss NN o
to TO o
follow-up NN o
) ) o
was VBD N
64.6 CD N
% NN N
and CC N
66.2 CD N
% NN N
in IN N
the DT N
IE NNP N
and CC N
DE NNP N
groups NNS N
, , N
respectively RB N
, , N
at IN N
month NN N
12 CD N
( ( N
P NNP N
= NNP N
0.860 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
angle NN N
between IN N
the DT N
radiographic JJ N
image NN N
of IN N
the DT N
bar NN N
and CC N
the DT N
axial JJ N
inclination NN N
of IN N
the DT N
upper JJ N
first JJ N
premolar NN N
and CC N
molar JJ o
teeth NN o
was VBD p
( ( p
5.34 CD p
and CC p
2.73 CD p
degrees NNS p
for IN p
the DT p
right JJ p
premolars NNS p
, , p
5.17 CD p
and CC p
2.28 CD p
degrees NNS p
for IN p
the DT p
left NN p
premolars VBZ p
, , p
11.83 CD p
and CC p
3.73 CD p
degrees NNS p
for IN p
the DT p
right JJ p
molars NNS p
, , p
and CC p
9.75 CD p
and CC p
5.64 CD p
degrees NNS p
for IN p
the DT p
left JJ p
molars NNS p
in IN p
the DT p
banded JJ p
and CC p
bonded VBD p
groups NNS p
, , p
respectively RB p
. . p

Formulations NNS i
of IN i
Aloe NNP i
vera NN i
, , i
Chamomilla NNP i
recutita NN i
, , i
Hamamelis NNP i
virginiana NN i
, , i
Melissa NNP i
officinalis NN i
, , i
Mentha NNP i
arvensis NN i
, , i
Melaleuca NNP i
alternifolia NN i
, , i
Coriandrum NNP i
sativum NN i
as RB i
well RB i
as IN i
1 CD i
% NN i
hydrocortisone NN i
acetate NN i
and CC i
0.1 CD i
% NN i
betamethasone NN i
valerate NN i
as IN i
positive JJ i
controls NNS i
and CC i
unguentum JJ i
leniens NNS i
as IN N
vehicle NN N
control NN N
were VBD N
applied VBN N
under IN N
occlusion NN N
on IN N
the DT N
irradiated JJ N
areas NNS N
and CC N
on IN N
non-irradiated JJ N
area NN N
on IN N
the DT N
contralateral JJ N
side NN N
. . N

Subjects NNS N
received VBD N
either RB N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
( ( i
Crest NNP i
Whitestrips NNP i
) ) i
and CC i
an DT i
anticavity NN i
toothpaste NN i
( ( i
Crest NNP i
Cavity NNP i
Protection NNP i
) ) i
, , i
placebo JJ i
strips NNS i
and CC i
a DT i
sodium NN i
fluoride NN i
( ( i
NaF NNP i
) ) i
whitening VBG i
dentifrice NN i
( ( i
Mentadent NNP i
Whitening NNP i
Toothpaste NNP i
) ) i
or CC i
placebo VBN i
strips NNS i
and CC i
a DT i
sodium NN i
monofluorophosphate NN i
( ( i
MFP NNP i
) ) i
whitening VBG i
dentifrice NN i
( ( i
Rembrandt NNP i
Low NNP i
Abrasion NNP i
Whitening NNP i
Toothpaste NNP i
) ) i
. . i

RESULTS NN N
In IN N
the DT N
portal JJ N
venous JJ N
phase NN N
, , N
correlation NN o
coefficients NNS o
for IN o
the DT o
correlation NN o
of IN o
change NN o
in IN o
CT NNP o
number NN o
per IN o
gram NN o
of IN o
iodine NN o
with IN o
TBW NNP o
for IN N
the DT N
aorta NN N
and CC N
liver NN N
were VBD N
-0.71 NNP N
and CC N
-0.79 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
TBW NNP N
group NN N
; : N
-0.80 CC N
and CC N
-0.86 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
LBW NNP N
group NN N
; : N
and CC N
-0.68 VB N
and CC N
-0.66 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
BV NNP N
group NN N
. . N

The DT N
immunological JJ o
response NN o
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN o
counts NNS o
, , o
HLA-DR NNP o
expression NN o
on IN o
monocytes NNS o
, , o
the DT o
acute-phase JJ o
response NN o
by IN o
means NNS o
of IN o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
interleukin-6 JJ o
( ( o
IL-6 NNP o
) ) o
, , o
and CC o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
, , o
and CC o
the DT o
stress NN o
response NN o
was VBD o
measured VBN o
by IN o
cortisol NN o
, , o
growth NN o
hormone NN o
, , o
and CC o
prolactin NN o
. . o

At IN N
the DT N
3-month JJ N
follow-up JJ N
assessment NN N
, , N
PSE NNP N
mothers NNS N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
those DT N
serving VBG N
as RB N
controls NNS N
to TO N
have VB N
clinically RB N
significant JJ N
parental JJ o
stress NN o
( ( N
3.8 CD N
% NN N
vs JJ N
29.3 CD N
% NN N
; : N
adjusted VBN N
relative JJ N
risk NN N
[ NNP N
aRR NN N
] NNP N
, , N
0.17 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.04 CD N
to TO N
0.65 CD N
) ) N
. . N

Irritability NNP o
subscale NN o
score NN o
significantly RB N
decreased VBD N
during IN N
this DT N
trial NN N
in IN N
both DT N
groups NNS N
( ( N
buspirone NN i
group NN N
: : N
declined VBD N
from IN N
25.7 CD N
[ NNS N
SD NNP N
5.7 CD N
] NN N
to TO N
16.3 CD N
[ NNS N
SD NNP N
8.5 CD N
] NNP N
; : N
placebo CC i
group NN N
: : N
declined VBD N
from IN N
24.7 CD N
[ NNS N
SD NNP N
7.6 CD N
] NN N
to TO N
18.2 CD N
[ NNS N
SD NNP N
7.7 CD N
] NN N
) ) N
. . N

Among IN N
group NN N
A NNP N
patients NNS N
, , N
the DT N
adverse JJ o
events NNS o
risk NN o
was VBD N
greater JJR N
in IN N
those DT N
randomised VBN N
to TO N
stenting VBG N
( ( N
odds JJ N
ratios NNS N
6.603 CD N
v NN N
1.197 CD N
, , N
p NN N
= NNP N
0.046 CD N
) ) N
, , N
whereas IN N
there EX N
was VBD N
no DT N
difference NN N
in IN N
risk NN N
if IN N
the DT N
group NN N
was VBD N
analysed VBN N
according VBG N
to TO N
whether IN N
the DT N
CFVR NNP N
was VBD N
< JJ N
2.5 CD N
or CC N
> VB N
/= CD N
2.5 CD N
after IN N
balloon NN i
angioplasty NN i
. . i

Using VBG N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
( ( N
CDC NNP N
) ) N
standardized VBD N
scores NNS N
, , N
both DT N
weight NN o
and CC o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
increased VBD N
with IN N
risperidone NN N
during IN N
the DT N
acute JJ N
trial NN N
( ( N
0.5 CD N
and CC N
0.6 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
risperidone NN N
; : N
0.0 CD N
and CC N
0.1 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
placebo NN N
) ) N
and CC N
into IN N
open-label JJ N
extension NN N
( ( N
0.19 CD N
and CC N
0.16 CD N
SDs NNP N
, , N
respectively RB N
) ) N
, , N
although IN N
the DT N
amount NN N
of IN N
gain NN N
decelerated VBN N
with IN N
time NN N
. . N

Eradication NN o
or CC o
presumed VBN o
eradication NN o
was VBD N
detected VBN N
for IN N
97.3 CD N
% NN N
and CC N
96.3 CD N
% NN N
of IN N
S. NNP N
pneumoniae NN N
, , N
85.0 CD N
% NN N
and CC N
90.5 CD N
% NN N
of IN N
H. NNP N
influenzae NN N
, , N
88.9 CD N
% NN N
and CC N
90.9 CD N
% NN N
of IN N
S. NNP N
aureus NN N
and CC N
100.0 CD N
% NN N
and CC N
83.3 CD N
% NN N
of IN N
M. NNP N
catarrhalis NN N
in IN N
faropenem JJ i
daloxate NN i
and CC i
cefuroxime NN i
axetil NN i
recipients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Clinical JJ o
Global NNP o
Impressions NNP o
Improvement NNP o
and CC o
Severity NNP o
Scales NNP o
( ( o
CGI-I NNP o
and CC o
CGI-S NNP o
) ) o
; : o
secondary JJ N
outcomes NNS N
were VBD N
the DT N
Preschool NNP o
Language NNP o
Scale-4 NNP o
( ( o
PLS-4 NNP o
) ) o
, , o
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
and CC o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scales NNP o
( ( o
Vineland NNP o
) ) o
. . o

Fenofibrate NNP i
caused VBD N
a DT N
significant JJ N
decrease NN N
in IN N
serum JJ o
triglyceride JJ o
concentration NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
plasma NN o
malondialdehyde NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
an DT N
increase NN N
in IN N
plasma JJ o
PAI-1 NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
P-selectin NNP o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
concentrations NNS o
. . o

RESULTS NNP N
After IN N
12 CD N
months NNS N
, , N
bone JJ o
mineral JJ o
density NN o
increased VBN N
by IN N
1.2 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
1.3 CD N
% NN N
at IN N
the DT N
hip NN N
in IN N
women NNS N
on IN N
risedronate NN N
vs. FW N
significant JJ N
decreases NNS N
for IN N
women NNS N
in IN N
the DT N
placebo NN i
group NN N
of IN N
0.9 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
0.8 CD N
% NN N
at IN N
the DT N
hip NN N
( ( N
P NNP N
< NNP N
0.01 CD N
, , N
difference NN N
between IN N
groups NNS N
) ) N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ o
in IN o
plaque NN o
removal NN o
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN N
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

Moreover RB N
, , N
MIP NNP N
and CC N
MEP NNP N
significantly RB N
improved VBD N
only RB N
after IN N
magnesium NN N
administration NN N
( ( N
change NN N
in IN N
MIP NNP N
: : N
11 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.5 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
change NN N
in IN N
MEP NNP N
: : N
11.9 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.8 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

On IN N
multivariate JJ N
analysis NN N
of IN N
the DT N
added JJ N
diagnostic JJ N
role NN N
of IN N
RapSP-LS NNP i
or CC i
RapLSI NNP i
on IN N
top NN N
of IN N
clinical JJ N
, , N
electrocardiographic JJ N
, , N
and CC N
conventional JJ N
echocardiographic JJ N
parameters NNS N
, , N
addition NN N
of IN N
RapLSI NNP i
produced VBD N
only RB N
borderline JJ N
increase NN N
in IN N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
multivariate NN N
model NN N
( ( N
P=0.05 NNP N
) ) N
, , N
whereas JJ N
addition NN N
of IN N
RapSP-LS NNP i
significantly RB N
increased VBD N
it PRP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
odds NNS N
ratio NN N
associated VBN N
with IN N
the DT N
fibre NN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
in IN N
participants NNS N
with IN N
baseline NN N
dietary JJ N
calcium NN N
intake NN N
above IN N
the DT N
median JJ N
than IN N
in IN N
those DT N
with IN N
intake JJ N
below IN N
the DT N
median NN N
( ( N
interaction JJ N
test NN N
, , N
p=0.028 NN N
) ) N
INTERPRETATION NNP N
Supplementation NNP N
with IN N
fibre NN N
as IN N
ispaghula JJ N
husk NN N
may MD N
have VB N
adverse JJ N
effects NNS N
on IN N
colorectal JJ o
adenoma NN o
recurrence NN o
, , N
especially RB N
in IN N
patients NNS N
with IN N
high JJ N
dietary JJ N
calcium NN N
intake NN N
. . N

RESULTS VB N
The DT N
physical JJ N
activity NN N
group NN N
improved VBD N
in IN N
sleep JJ o
quality NN o
on IN o
the DT o
global JJ o
PSQI NNP o
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
, , N
sleep JJ o
latency NN o
( ( N
p=.049 NN N
) ) N
, , N
sleep JJ o
duration NN o
( ( N
p=.04 NN N
) ) N
, , N
daytime JJ o
dysfunction NN o
( ( N
p=.027 NN N
) ) N
, , N
and CC N
sleep JJ o
efficiency NN o
( ( N
p=.036 NN N
) ) N
PSQI NNP N
sub-scores NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
obtained VBN N
with IN N
regard NN N
to TO N
examination NN o
quality NN o
( ( N
180 CD N
vs. FW N
165 CD N
segments NNS N
free JJ N
from IN N
stools NNS N
and CC N
fluid NN N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
and CC N
overall JJ o
diagnostic JJ o
accuracy NN o
( ( N
16/17 CD N
colonic JJ N
polyps NNS N
detected VBN N
in IN N
group NN N
A NNP N
and CC N
12/13 CD N
in IN N
group NN N
B NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
. . N

RESULTS JJ N
Analysis NNP N
of IN N
grip NN N
strength NN N
data NNS N
revealed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
strength NN o
within IN N
the DT N
treatment NN N
group NN N
after IN N
the DT N
first JJ N
intervention NN N
( ( N
6.95 CD N
% NN N
right NN N
, , N
12.61 CD N
% NN N
left NN N
) ) N
as IN N
compared VBN N
with IN N
the DT N
second JJ N
( ( N
11.53 CD N
% NN N
right NN N
, , N
17.02 CD N
% NN N
left NN N
) ) N
and CC N
the DT N
third JJ N
interventions NNS N
( ( N
10.53 CD N
% NN N
right NN N
, , N
16.81 CD N
% NN N
left VBD N
) ) N
. . N

As IN N
compared VBN N
with IN N
placebo NN i
, , i
angiotensin NN i
II NNP i
infusion NN i
alone RB i
caused VBD N
significant JJ N
reductions NNS N
in IN N
absolute JJ o
rate NN o
of IN o
sodium NN o
excretion NN o
, , o
fractional JJ o
sodium NN o
excretion NN o
, , o
urine JJ o
flow NN o
rate NN o
and CC o
effective JJ o
renal JJ o
plasma NN o
flow NN o
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
vs NN N
placebo NN N
) ) N
but CC N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ o
filtration NN o
rate NN o
. . o

Bradykinin-induced JJ o
release NN o
of IN o
active JJ o
t-PA NN o
was VBD N
more RBR N
than IN N
doubled VBD N
during IN N
treatment NN N
with IN N
quinapril NN i
in IN N
comparison NN N
to TO N
placebo VB i
or CC N
losartan VB i
( ( N
two-way JJ N
ANOVA NNP N
: : N
p NN N
< VBZ N
0.003 CD N
for IN N
treatment NN N
group NN N
, , N
p VBP N
< $ N
0.001 CD N
for IN N
t-PA JJ N
response NN N
and CC N
p NN N
= NNP N
ns NN N
for IN N
interaction NN N
) ) N
, , N
whereas IN N
the DT N
substance NN N
P NNP N
response NN N
was VBD N
unaffected VBN N
. . N

In IN N
the DT N
forced-air JJ N
group NN N
, , N
after IN N
the DT N
initial JJ N
significant JJ N
decrease NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
baseline NN N
) ) N
, , N
core JJ o
temperature NN o
progressively RB N
increased VBD N
to TO N
35.8 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C NNP N
, , N
which WDT N
was VBD N
similar JJ N
to TO N
preoperative VB N
values NNS N
and CC N
significantly RB N
higher JJR N
than IN N
either CC N
the DT N
control NN N
or CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
changes NNS N
in IN N
bone NN N
density NN N
were VBD N
consistent JJ N
with IN N
the DT N
changes NNS N
in IN N
biochemical JJ N
indices NNS N
for IN N
bone NN N
metabolism NN N
; : N
DMPA NNP N
users NNS N
showed VBD N
signs NNS N
of IN N
increased VBN N
bone NN N
turnover NN N
and CC N
users NNS N
of IN N
levonorgestrel NN N
showed VBD N
increased JJ N
bone NN N
formation NN N
with IN N
increased JJ N
levels NNS N
of IN N
both DT N
alkaline JJ o
phosphatase NN o
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
osteocalcin $ N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
. . N

FDRs NNS o
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB N
if IN N
they PRP N
were VBD N
female JJ N
( ( N
OR=1.77 NNP N
; : N
CI=1.1-.85 NNP N
) ) N
and CC N
parents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB N
if IN N
the DT N
case NN N
had VBD N
been VBN N
diagnosed VBN N
more RBR N
recently RB N
( ( N
OR=3.3 NNP N
; : N
CI=1.9-5.93 NNP N
) ) N
, , N
if IN N
the DT N
parent NN N
was VBD N
partnered VBN N
( ( N
OR=4.37 NNP N
; : N
CI=1.86-10.26 NNP N
) ) N
, , N
and CC N
if IN N
the DT N
parent NN N
lived VBD N
in IN N
the DT N
same JJ N
city NN N
as IN N
the DT N
case NN N
( ( N
OR=2.88 NNP N
; : N
CI=1.08-7.68 NNP N
) ) N
. . N

The DT N
average NN N
of IN N
the DT N
maximum JJ o
pressure NN o
rises VBZ o
above IN N
the DT N
preoperative JJ N
level NN N
over IN N
the DT N
24 CD N
hour NN N
period NN N
was VBD N
greatest JJS N
for IN N
the DT N
group NN N
receiving VBG N
acetazolamide IN i
only RB N
at IN N
8.9 CD N
mm NN N
Hg NNP N
; : N
for IN N
the DT N
acetylcholine NN i
group NN N
the DT N
average NN N
maximum JJ N
rise NN N
was VBD N
6.3 CD N
mm JJ N
Hg NNP N
; : N
while IN N
the DT N
combined JJ N
treatment NN N
group NN N
showed VBD N
a DT N
decrease NN N
of IN N
0.7 CD N
mm NN N
Hg NNP N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN o
rate NN o
and CC o
mean VB o
arterial JJ o
pressure NN o
, , o
oxygen NN o
saturation NN o
, , o
visual JJ o
analogue NN o
score NN o
( ( o
VAS NNP o
) ) o
, , o
verbal JJ o
rating NN o
scale NN o
( ( o
VRS NNP o
) ) o
, , o
rescue NN o
analgesic JJ o
requirements NNS o
, , o
total JJ o
opioid JJ o
consumption NN o
, , o
side NN o
effects NNS o
and CC o
time NN o
to TO o
first JJ o
mobilisation NN o
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS VB N
The DT N
density NN o
, , o
motility NN o
and CC o
morphology NN o
of IN o
sperm NN o
were VBD N
improved VBN N
and CC N
sperm JJ o
deformity NN o
rate NN o
was VBD N
significantly RB N
decreased VBN N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
the DT N
effects NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
better JJR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Among IN N
participants NNS N
not RB N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
or CC N
modalities NNS N
, , N
the DT N
estimated JJ N
improvements NNS N
in IN N
pain NN o
and CC o
disability NN o
and CC o
18-month JJ o
risk NN o
of IN o
complete JJ o
remission NN o
were VBD N
a DT N
little JJ N
greater JJR N
in IN N
the DT N
chiropractic JJ i
group NN N
than IN N
in IN N
the DT N
medical JJ N
group NN N
( ( N
adjusted VBN N
RR NNP N
of IN N
remission NN N
= NNP N
1.29 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-2.07 NN N
) ) N
. . N

The DT N
combination NN N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN N
to TO N
outperform VB N
other JJ N
active JJ N
treatment NN N
groups NNS N
, , N
with IN N
fewer JJR N
dropouts NNS N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
treatment NN N
responders NNS N
achieving VBG N
clinically RB N
significant JJ N
changes NNS N
( ( N
63.38 CD N
% NN N
normative JJ N
sleep JJ o
efficiency NN o
criterion NN N
of IN N
> $ N
85 CD N
% NN N
and CC N
84.62 CD N
% NN N
, , N
sleep JJ o
onset NN o
latency NN o
< VBD N
30 CD N
min NN N
) ) N
. . N

The DT N
levels NNS o
of IN o
P-selectin NNP o
, , o
tPA NN o
antigen NN o
, , o
and CC o
PAI-1 JJ o
activity NN o
were VBD N
all DT N
significantly RB N
higher JJR N
in IN N
stroke NN N
patients NNS N
compared VBN N
with IN N
controls NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
; : N
the DT N
level NN o
of IN o
tPA JJ o
activity NN o
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS N
than IN N
that DT N
in IN N
controls NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
. . N

The DT N
actuarial JJ N
probability NN N
of IN N
a DT N
recurrence NN o
of IN o
arrhythmia NN o
after IN N
a DT N
prediction NN N
of IN N
drug NN N
efficacy NN N
by IN N
either DT N
strategy NN N
was VBD N
significantly RB N
lower JJR N
for IN N
patients NNS N
treated VBN N
with IN N
sotalol NN i
than IN N
for IN N
patients NNS N
treated VBN N
with IN N
the DT N
other JJ N
drugs NNS N
( ( N
risk NN N
ratio NN N
, , N
0.43 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.29 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
primary JJ N
safety NN N
end NN N
point NN N
of IN N
significant JJ N
adverse JJ o
events NNS o
during IN N
the DT N
12-month JJ N
follow-up NN N
was VBD N
significantly RB N
higher JJR N
for IN N
SA NNP i
than IN N
for IN N
CA NNP i
( ( N
n=21 JJ N
[ RB N
34.4 CD N
% NN N
] JJ N
versus NN N
n=10 NN N
[ VBD N
15.9 CD N
% NN N
] NN N
; : N
P=0.027 NNP N
) ) N
, , N
driven VBN N
mainly RB N
by IN N
procedural JJ N
complications NNS N
such JJ N
as IN N
pneumothorax NN N
, , N
major JJ N
bleeding NN N
, , N
and CC N
the DT N
need NN N
for IN N
pacemaker NN N
. . N

These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ o
parameters NNS o
, , o
homocysteine NN o
, , o
and CC o
multiple JJ o
cardiac JJ o
risk NN o
factors NNS o
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
. . N

RESULTS NNP N
CTTH NNP o
score NN o
was VBD N
all DT N
reduced VBN N
after IN N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
score NN N
in IN N
the DT N
sticking VBG N
needling VBG N
group NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
acupuncture NN N
group NN N
( ( N
2.38 CD N
+/- JJ N
1.22 CD N
vs JJ N
4.16 CD N
+/- JJ N
2.54 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

METHODS NNP N
Thirteen NNP p
emmetropic JJ p
subjects NNS p
were VBD N
randomly RB N
fitted VBN N
with IN N
two CD i
different JJ i
tinted VBN i
Nike NNP i
Maxsight NNP i
( ( i
Bausch NNP i
& CC i
Lomb NNP i
, , i
Rochester NNP i
, , i
NY NNP i
, , i
USA NNP i
) ) i
CL NNP i
in IN i
one CD i
eye NN i
, , i
while IN i
the DT i
contralateral JJ i
eye NN i
was VBD i
fitted VBN i
with IN i
a DT i
clear JJ i
lens NNS i
made VBN i
of IN i
the DT i
same JJ i
material NN i
( ( i
Optima NNP i
38 CD i
, , i
Bausch NNP i
& CC i
Lomb NNP i
) ) i
. . i

Median JJ o
total JJ o
sleep JJ o
time NN o
increased VBN N
by IN N
25.75-66.75min JJ N
, , N
vs. FW N
25.50 CD N
( ( N
p NN N
< VBZ N
0.05 CD N
for IN N
0.50mg/d CD N
) ) N
, , N
and CC N
median JJ o
time NN o
in IN o
stages NNS o
2-4/rapid JJ o
eye NN o
movement NN o
( ( o
REM NNP o
) ) o
sleep NN o
increased VBN N
by IN N
37.00-68.00min JJ N
, , N
vs. FW N
26.75 CD N
( ( N
p NN N
< VBZ N
0.05 CD N
for IN N
0.50mg/d CD N
) ) N
. . N

RESULTS NNP N
Ovulation NNP o
( ( N
89.09 CD N
% NN N
) ) N
and CC N
pregnancy NN N
( ( N
54.55 CD N
% NN N
) ) N
rates NNS N
were VBD N
higher JJR N
in IN N
group NN N
B. NNP N
Ovulation NNP N
( ( N
74.55 CD N
% NN N
) ) N
and CC N
pregnancy NN N
( ( N
29.09 CD N
% NN N
) ) N
rates NNS N
were VBD N
also RB N
satisfactory JJ N
in IN N
group NN N
C NNP N
but CC N
a DT N
dose NN N
of IN N
rFSH JJ o
requirement NN o
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

However RB N
, , N
subjects NNS N
in IN N
the DT N
mCIT+mental JJ N
practice NN N
group NN N
exhibited VBD N
significantly RB N
larger JJR N
changes NNS N
on IN N
both DT N
movement NN N
measures NNS N
after IN N
intervention NN N
: : N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
, , N
+15.4-point JJ N
change NN N
versus IN N
+8.4-point JJ N
change NN N
for IN N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
Fugl-Meyer NNP N
, , N
+7.8-point JJ N
change NN N
versus IN N
+4.1-point JJ N
change NN N
for IN N
the DT N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P=0.01 NNP N
) ) N
. . N

By IN N
week NN N
12 CD N
post-release NN N
, , N
88.4 CD N
% NN N
of IN N
the DT N
BCM NNP N
arm NN N
and CC N
78.3 CD N
% NN N
of IN N
the DT N
SOC NNP N
arm NN N
had VBD N
at IN N
attended VBN N
at IN N
least JJS N
one CD N
medical JJ N
appointment NN N
( ( N
P NNP N
= NNP N
0.2 CD N
) ) N
, , N
increasing VBG N
in IN N
both DT N
arms NNS N
at IN N
week NN N
24-90.7 CD N
% NN N
with IN N
BCM NNP N
and CC N
89.1 CD N
% NN N
with IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
. . N

RESULTS NNP N
Dapsone NNP N
gel-treated JJ N
patients NNS N
achieved VBN N
superior JJ N
results NNS N
in IN N
terms NNS N
of IN N
the DT N
investigator NN o
's POS o
global JJ o
acne NN o
assessment NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
the DT N
mean JJ o
percentage NN o
reduction NN o
in IN o
inflammatory NN o
, , o
noninflammatory NN o
, , o
and CC o
total JJ o
lesion NN o
counts NNS o
( ( N
all DT N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
week NN N
12 CD N
. . N

beta-Carotene NN i
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
total JJ o
WBC NNP o
count NN o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
% NN N
change NN N
in IN N
CD4 NNP o
count NN o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
% NN N
change NN N
in IN N
CD4/CD8 NNP o
ratios NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
compared VBN N
to TO N
placebo VB i
. . i

When WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
time NN o
to TO o
analgesic VB o
need NN o
was VBD o
increased VBN o
and CC o
total JJ o
analgesic JJ o
consumption NN o
was VBD N
reduced VBN N
in IN N
the DT N
magnesium NN N
group NN N
( ( N
meperidine JJ N
consumption NN N
60.0 CD N
+/- JJ N
73.1 CD N
mg NNS N
control NN N
group NN N
, , N
31.8 CD N
+/- JJ N
30.7 CD N
mg JJ N
magnesium NN N
group NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Loads NNS N
ranged VBD N
in IN N
magnitude NN N
from IN N
imperceptible JJ N
( ( N
R0/E0 NNP N
) ) N
through IN N
just RB N
perceptible JJ N
( ( N
R1/E1 NNP N
) ) N
to TO N
large JJ N
( ( N
R2/E2 NNP N
) ) N
and CC N
resulted VBN N
in IN N
respiratory NN o
pattern NN o
responses NNS o
that WDT N
were VBD N
due JJ N
to TO N
reflex JJ N
responses NNS N
alone RB N
( ( N
R0/E0 NNP N
) ) N
or CC N
to TO N
a DT N
combination NN N
of IN N
reflex JJ N
responses NNS N
and CC N
behavioral JJ N
reactions NNS N
to TO N
the DT N
perception NN N
of IN N
impeded JJ N
breathing NN N
( ( N
R1/E1 NNP N
and CC N
R2/E2 NNP N
) ) N
. . N

The DT N
median JJ o
effect NN o
size NN o
in IN N
this DT N
trial NN N
was VBD N
-0.015 NNP N
( ( N
seizure JJ o
rate NN o
increased VBN N
by IN N
1.5 CD N
% NN N
in IN N
the DT N
phenytoin NN N
group NN N
) ) N
, , N
95 CD N
% NN N
probability NN N
interval NN N
-0.127 NN N
to TO N
0.091 CD N
( ( N
12.7 CD N
% NN N
higher JJR N
rate NN N
of IN N
posttraumatic JJ o
seizures NNS o
to TO N
a DT N
9.1 CD N
% NN N
lower JJR N
rate NN N
of IN N
posttraumatic JJ o
seizures NNS o
with IN o
phenytoin NN o
) ) o
. . o

There EX N
was VBD N
significantly RB N
more JJR N
intracardiac JJ o
gas NN o
noted VBD N
on IN N
intraoperative JJ N
transesophageal NN N
echocardiography NN N
in IN N
all DT N
cardiac JJ N
chambers NNS N
( ( N
left JJ N
atrium NN N
, , N
left VBD N
ventricle NN N
, , N
and CC N
aorta NN N
) ) N
at IN N
all DT N
measured VBN N
times NNS N
( ( N
after IN N
crossclamp NN N
removal NN N
, , N
during IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
and CC N
at IN N
declaration NN N
of IN N
adequate JJ N
deairing NN N
by IN N
the DT N
anesthetist NN N
) ) N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
carbon NN N
dioxide NN N
group NN N
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
. . N

Immediately RB N
before IN N
and CC N
after IN N
the DT N
five CD N
treatment NN N
sessions NNS N
and CC N
7 CD N
days NNS N
after IN N
treatment NN N
ended VBN N
, , N
both DT N
patient NN N
and CC N
physician NN N
measured VBD N
the DT N
degree NN o
of IN o
pain NN o
using VBG o
a DT o
categoric JJ o
scale NN o
( ( o
no DT o
pain NN o
, , o
slight JJ o
pain NN o
, , o
intermediate JJ o
pain NN o
, , o
strong JJ o
pain NN o
, , o
and CC o
very RB o
strong JJ o
pain NN o
) ) o
and CC o
evaluated VBN o
pain NN o
intensity NN o
using VBG o
the DT o
Scott NNP o
and CC o
Huskisson NNP o
Visual NNP o
Analogue NNP o
Scale NNP o
( ( o
VAS NNP o
) ) o
. . o

There EX N
were VBD N
also RB N
differences NNS N
in IN N
Cho/Lip NNP N
between IN N
the DT N
control NN N
and CC N
cirrhosis NN N
groups NNS N
, , N
the DT N
control NN N
and CC N
HCC NNP N
groups NNS N
, , N
and CC N
the DT N
cirrhosis NN N
and CC N
HCC NNP N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
.H-MRS NN N
followed VBN N
by IN N
the DT N
analysis NN N
with IN N
LCModel NNP N
can MD N
be VB N
used VBN N
to TO N
measure VB N
changes NNS N
in IN N
hepatic JJ o
metabolite NN o
levels NNS o
in IN N
patients NNS N
with IN N
liver JJ N
cirrhosis NN N
secondary JJ N
to TO N
chronic VB N
hepatitis NN N
B NNP N
and CC N
HCC NNP N
. . N

METHODS NNP N
Drawing VBG p
from IN p
South NNP p
Texas NNP p
cancer NN p
registries NNS p
, , p
444 CD p
Hispanic JJ p
men NNS p
and CC p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
experimental JJ N
conditions NNS N
: : N
standard JJ i
direct-mailed JJ i
procedures NNS i
( ( i
X1 NNP i
) ) i
, , i
X1 NNP i
plus CC i
culturally RB i
tailored JJ i
materials NNS i
( ( i
X2 NNP i
) ) i
, , i
and CC i
X2 NNP i
plus CC i
interpersonal JJ i
phone NN i
contact NN i
( ( i
X3 NNP i
) ) i
. . i

RESULTS VB N
The DT N
median JJ o
duration NN o
of IN o
survival NN o
was VBD N
20.3 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
15.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
placebo NN i
, , N
corresponding VBG N
to TO N
a DT N
hazard NN N
ratio NN N
for IN N
death NN N
of IN N
0.66 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Measurements NNS N
were VBD N
made VBN N
of IN N
oxygen NN o
consumption NN o
( ( o
VO2 NNP o
) ) o
, , o
carbon NN o
dioxide NN o
production NN o
( ( o
VCO2 NNP o
) ) o
, , o
minute JJ o
ventilation NN o
( ( o
VE NNP o
) ) o
, , o
tidal JJ o
volume NN o
( ( o
VT NNP o
) ) o
, , o
respiratory JJ o
frequency NN o
( ( o
fR NN o
) ) o
, , o
inspiratory JJ o
and CC o
expiratory JJ o
time NN o
( ( o
TI NNP o
, , o
TE NNP o
) ) o
and CC o
mean JJ o
inspiratory NN o
flow NN o
( ( o
VT/TI NNP o
) ) o
using VBG o
a DT o
non-invasive JJ o
canopy-computer-spirometer NN o
system NN o
. . o

OBJECTIVE NN N
To TO N
evaluate VB N
two CD N
solutions NNS i
, , i
lactated VBD i
Ringer NNP i
's POS i
( ( i
LR NNP i
) ) i
and CC i
a DT i
balanced JJ i
salt NN i
solution NN i
( ( i
BSS NNP i
Plus NNP N
, , N
Alcon NNP N
Laboratories NNPS N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
, , N
compared VBN N
with IN N
normal JJ i
saline JJ i
solution NN i
( ( i
NSS NNP i
) ) i
, , N
for IN N
ocular JJ N
irrigation NN N
in IN N
healthy JJ p
adult NN p
volunteers NNS p
with IN p
and CC p
without IN p
the DT p
Morgan NNP p
therapeutic JJ p
lens NNS p
( ( p
MTL NNP p
) ) p
. . p

The DT N
average JJ o
interval NN o
from IN o
start NN o
of IN o
induction NN o
to TO o
vaginal JJ o
delivery NN o
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN i
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN i
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
. . N

RESULTS NNP N
Both NNP N
the DT N
beverage NN o
aroma NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
and CC N
beverage JJ o
temperature NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
had VBD N
significant JJ N
and CC N
positive JJ N
effects NNS N
on IN N
performance NN N
, , N
which WDT N
was VBD N
considerably RB N
better RBR N
with IN N
ice-slush JJ N
than IN N
with IN N
a DT N
neutral JJ N
temperature NN N
beverage NN N
, , N
whatever WDT N
the DT N
aroma NN N
( ( N
P NNP N
< NNP N
0.002 CD N
) ) N
, , N
and CC N
with IN N
menthol JJ N
vs JJ N
non-menthol NN N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
number NN o
of IN o
episodes NNS o
of IN o
angina NN o
was VBD N
decreased VBN N
by IN N
D NNP N
and CC N
unchanged JJ N
by IN N
P NNP N
, , N
while IN N
eight CD N
out IN N
of IN N
the DT N
11 CD N
failures NNS N
with IN N
P NNP N
were VBD N
immediate JJ N
successes NNS N
when WRB N
treatment NN N
was VBD N
replaced VBN N
with IN N
D. NNP N
These DT N
results NNS N
suggest VBP N
that IN N
D NNP N
is VBZ N
preferable JJ N
to TO N
P VB N
for IN N
management NN N
of IN N
unstable JJ N
angina NNS N
in IN N
patients NNS p
with IN p
angina NN p
which WDT p
is VBZ p
exclusively RB p
spontaneous JJ p
. . p

Circulating VBG N
25-hydroxyvitamin JJ N
D3 NNP N
( ( N
25 CD N
[ NNP N
OH NNP N
] NNP N
D NNP N
) ) N
, , N
the DT N
most RBS N
commonly RB N
used JJ N
index NN N
of IN N
vitamin NN N
D NNP N
status NN N
, , N
is VBZ N
converted VBN N
to TO N
the DT N
active JJ N
hormone NN N
1,25 CD N
dihydroxyvitamin NN N
D3 NNP N
( ( N
1,25 CD N
[ NNP N
OH NNP N
] NNP N
2D CD N
) ) N
, , N
which WDT N
, , N
operating VBG N
through IN N
the DT N
vitamin NN N
D NNP N
receptor NN N
( ( N
VDR NNP N
) ) N
, , N
inhibits VBZ N
in IN N
vitro NN N
cell NN N
proliferation NN N
, , N
induces NNS N
differentiation NN N
and CC N
apoptosis NN N
, , N
and CC N
may MD N
protect VB N
against IN N
prostate JJ N
cancer NN N
. . N

When WRB N
the DT N
safety NN N
practices NNS N
involved VBN N
little JJ N
time NN N
or CC N
expense NN N
( ( N
eg UH N
, , N
putting VBG N
away RB N
sharp JJ N
objects NNS N
) ) N
, , N
the DT N
educational JJ N
book NN N
group NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
these DT N
behaviors NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
40 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.19 CD N
) ) N
or CC N
noneducational JJ N
book NN N
group NN N
( ( N
27 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.13 CD N
) ) N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
decreased VBN N
activated VBN o
CECs NNP o
after IN o
therapy NN o
and CC o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
r JJ N
= NN N
0.322 CD N
, , N
P NNP N
= NNP N
0.012 CD N
) ) N
; : N
a DT N
negative JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
amount NN N
of IN N
survivin NN N
mRNA NN N
in IN N
serum JJ o
post-therapy NN o
and CC o
TTP NNP o
( ( N
r NN N
= NNP N
-0.291 NNP N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

Naftidrofuryl NNP i
significantly RB N
improved VBD N
the DT N
physiological JJ o
function NN o
of IN o
the DT o
liver NN o
cells NNS o
as IN N
reflected VBN N
by IN N
indocyanine NN o
green NN o
( ( o
ICG NNP o
) ) o
clearance NN o
by IN N
the DT N
liver NN N
( ( N
t JJ N
= VBZ N
2.61 CD N
; : N
p NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.02 CD N
) ) N
and CC N
also RB N
caused VBD N
a DT N
larger JJR N
fall NN N
in IN N
raised VBN N
serum NN o
levels NNS o
of IN o
gamma NN o
glutamyl NN o
transpeptidase NN o
( ( o
GGT NNP o
) ) o
than IN N
did VBD N
the DT N
placebo NN N
injections NNS N
. . N

Hip NNP p
protector NN p
users NNS p
had VBD N
greater JJR N
improvement NN N
in IN N
falls VBZ o
self-efficacy NN o
at IN N
follow-up JJ N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP o
Efficacy NNP o
Scale NNP o
( ( N
t JJ N
= NN N
2.44 CD N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
the DT N
Modified NNP o
Falls NNP o
Efficacy NNP o
Scale NNP o
( ( N
t JJ N
= NN N
2.08 CD N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

RESULTS VB N
The DT N
oat NN N
cereal NN N
group NN N
experienced VBD N
a DT N
7.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
SBP NNP o
( ( N
P NNP N
& CC N
lt.01 NN N
) ) N
and CC N
a DT N
5.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
DBP NNP o
( ( N
P NNP N
& CC N
lt.02 NN N
) ) N
, , N
while IN N
there EX N
was VBD N
virtually RB N
no DT N
change NN N
in IN N
either DT N
SBP NNP o
or CC o
DBP NNP o
in IN N
the DT N
control NN N
group NN N
. . N

Thus RB N
, , N
three CD N
groups NNS N
were VBD N
formed VBN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
according VBG N
to TO N
the DT N
adhesive JJ N
system NN N
employed VBN N
: : N
All-Bond JJ i
2 CD i
( ( i
TE3 NNP i
) ) i
+ VBP i
resin JJ i
cement NN i
post NN i
( ( i
rcp NN i
) ) i
+ VBZ i
Duo-link NNP i
( ( i
Dl NNP i
) ) i
; : i
One-Step JJ i
Plus NNP i
( ( i
TE2 NNP i
) ) i
+ VBP i
rcp JJ i
+ NNP i
Dl NNP i
; : i
Tyrian/One-Step JJ i
Plus NNP i
( ( i
SE NNP i
) ) i
+ VBP i
rcp JJ i
+ NNP i
Dl NNP i
. . i

METHODS NNP N
Four CD N
devices NNS N
were VBD N
compared VBN N
in IN N
a DT N
simulated JJ i
resuscitation NN i
scenario NN i
: : i
ILMA NNP i
( ( i
Intavent NNP i
Direct NNP i
Ltd NNP i
, , i
Buckinghamshire NNP i
, , i
United NNP i
Kingdom NNP i
) ) i
, , i
Cobra NNP i
PLA NNP i
( ( i
Engineered NNP i
Medical NNP i
Systems NNP i
Inc NNP i
, , i
Indianapolis NNP i
, , i
IN NNP i
) ) i
, , i
Supraglottic JJ i
Airway NNP i
Laryngopharyngeal NNP i
Tube NNP i
( ( i
SALT NNP i
) ) i
( ( N
ECOLAB NNP N
, , N
St. NNP N
Paul NNP N
, , N
MN NNP N
) ) N
, , N
and CC N
Air-Q NNP N
( ( N
Mercury NNP N
Medical NNP N
, , N
Clearwater NNP N
, , N
FL NNP N
) ) N
. . N

In IN N
this DT N
surgical JJ N
subgroup NN N
, , N
the DT N
mean JJ o
TT-TG NNP o
distance NN o
was VBD N
22.5 CD N
mm NN N
( ( N
range NN N
, , N
19.8-25.8 JJ N
mm NN N
) ) N
by IN N
CT NNP N
and CC N
only RB N
18.7 CD N
mm NN N
( ( N
range NN N
, , N
14.4-22.8 JJ N
mm NN N
) ) N
by IN N
MRI NNP N
for IN N
a DT N
mean JJ N
difference NN N
of IN N
3.80 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Cervical JJ o
artery NN o
spasm NN o
index NN o
and CC o
atlantoaxial JJ o
displacement NN o
index NN o
had VBD N
been VBN N
significantly RB N
improved VBN N
, , N
cervical JJ o
artery NN o
spasm NN o
index NN o
was VBD N
respectively RB N
0.54 CD N
+/- JJ N
0.07 CD N
and CC N
0.52 CD N
+/- JJ N
0.13 CD N
, , N
atlantoaxial JJ o
displacement NN o
index NN o
was VBD N
respectively RB N
2.92 CD N
+/- JJ N
0.82 CD N
and CC N
4.50 CD N
+/- JJ N
1.32 CD N
between IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
. . N

Although IN N
DG NNP N
or CC N
FD NNP N
exhibited VBD N
moderate JJ N
effects NNS N
on IN N
intestinal JJ o
brush NN o
border NN o
protease NN o
activities NNS o
and CC o
mRNA NN o
levels NNS o
of IN o
duodenal JJ o
transporters NNS o
Pept1 NNP o
, , o
Lat1 NNP o
, , o
and CC o
Cat1 NNP o
, , o
both DT o
substantially RB o
enhanced VBN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
phosphorylation NN o
of IN o
hepatic JJ o
protein NN o
synthesis NN o
key JJ o
regulator NN o
S6 NNP o
ribosomal NN o
protein NN o
( ( N
S6 NNP N
) ) N
and CC N
the DT N
ratio NN N
of IN N
phospho-S6 NN N
to TO N
S6 NNP N
in IN N
the DT N
liver NN N
of IN N
hens NNS N
. . N

SCORAD NNP o
decreased VBD N
in IN N
the DT N
Bifidobacterium NNP N
lactis VBZ N
Bb-12 NNP N
group NN N
to TO N
0 CD N
( ( N
0-3.8 NN N
) ) N
, , N
and CC N
in IN N
the DT N
Lactobacillus NNP N
GG NNP N
group NN N
to TO N
1 CD N
( ( N
0.1-8.7 NN N
) ) N
, , N
vs RB N
unsupplemented JJ N
13.4 CD N
( ( N
4.5-18.2 JJ N
) ) N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
in IN N
parallel NN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
concentration NN N
of IN N
soluble JJ N
CD4 NNP N
in IN N
serum NN N
and CC N
eosinophilic JJ N
protein NN N
X NN N
in IN N
urine JJ N
. . N

The DT N
increased JJ N
number NN o
of IN o
steps NNS o
during IN o
the DT o
recovery NN o
was VBD N
accompanied VBN N
by IN N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
blood NN o
lactate NN o
concentration NN o
percentage NN o
( ( N
28.1 CD N
? . N
12.2 CD N
vs NN N
22.8 CD N
? . N
10.9 CD N
% NN N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
, , N
p VB N
? . N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
frequency NN o
of IN o
postoperative JJ o
adhesions NNS o
of IN o
the DT o
uterus NN o
was VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
, , N
with IN N
20/32 CD N
( ( N
62.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
10/29 CD N
( ( N
34.5 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
20/30 CD N
( ( N
67.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

HPLC NNP o
measurements NNS o
of IN o
eicosanoid JJ o
production NN o
in IN N
A23187-stimulated NNP N
neutrophils NNS N
revealed VBD N
a DT N
considerable JJ N
decrease NN N
in IN N
the DT N
formation NN o
of IN o
arachidonic JJ o
acid-derived JJ o
leukotriene NN o
B4 NNP o
( ( o
LTB4 NNP o
) ) o
, , N
by IN N
41 CD N
% NN N
, , N
and CC N
5-HETE JJ N
( ( N
5-hydroxyeicosatetraenoic JJ N
acid NN N
) ) N
, , N
by IN N
30 CD N
% NN N
, , N
in IN N
the DT N
fish-oil JJ N
group NN N
along IN N
with IN N
the DT N
appearance NN N
of IN N
the DT N
corresponding JJ N
EPA-derived JJ N
products NNS N
[ JJ N
LTB5 NNP N
and CC N
5-HEPE JJ N
( ( N
5-hydroxyeicosapentaenoic JJ N
acid NN N
) ) N
] NN N
. . N

RESULTS NNP N
Most JJS N
patients NNS N
in IN N
both DT N
study NN N
groups NNS N
showed VBD N
high JJ o
adherence NN o
to TO o
raloxifene VB o
at IN N
the DT N
3-month JJ N
visit NN N
: : N
56.3 CD N
% NN N
vs JJ N
62.7 CD N
% NN N
for IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
this DT N
proportion NN N
at IN N
the DT N
12-month JJ N
visit NN N
was VBD N
47.4 CD N
% NN N
( ( N
P=0.15 NNP N
) ) N
and CC N
52.5 CD N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
respectively RB N
. . N

No DT N
difference NN N
was VBD N
found VBN N
between IN N
these DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
necessary JJ N
interval NN o
for IN o
ERCP NNP o
( ( N
20.6 CD N
+/- JJ N
14.1 CD N
min NN N
versus NN N
21.4 CD N
+/- JJ N
14.7 CD N
min NN N
; : N
NS NNP N
) ) N
or CC N
the DT N
success NN o
rate NN o
for IN o
cholangiopancreatography NN o
( ( N
92.1 CD N
% NN N
versus IN N
91.7 CD N
% NN N
; : N
NS NNP N
) ) N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before NNP N
and CC N
10 CD N
minutes NNS N
after IN N
administration NN N
of IN N
each DT N
desired VBN N
end-expiratory JJ N
anesthetic JJ N
concentration NN N
, , N
the DT N
following JJ N
parameters NNS N
were VBD N
determined VBN N
: : N
hemodynamic JJ o
parameters NNS o
, , o
arterial JJ o
( ( o
SaO2 NNP o
) ) o
, , o
mixed JJ o
venous JJ o
( ( o
SvO2 NNP o
) ) o
, , o
and CC o
hepatic JJ o
venous JJ o
oxygen NN o
saturations NNS o
, , o
systemic JJ o
and CC o
splanchnic JJ o
O2 NNP o
extraction NN o
, , o
arterial JJ o
, , o
mixed JJ o
venous JJ o
, , o
and CC o
hepatic JJ o
venous JJ o
lactate NN o
concentrations NNS o
. . o

A DT N
non-significant JJ N
decrease NN N
in IN N
30-day JJ o
mortality NN o
was VBD N
observed VBN N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
( ( N
13 CD N
% NN N
: : N
P NNP N
= NNP N
0.08 CD N
) ) N
, , N
whereas IN N
the DT N
decrease NN N
in IN N
cardiac JJ o
death NN o
observed VBD N
, , N
also RB N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
, , N
was VBD N
on IN N
the DT N
borderline NN N
of IN N
significance NN N
( ( N
16 CD N
% NN N
; : N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

LCModel NNP o
software NN o
was VBD o
used VBN o
to TO o
quantify VB o
Cho NNP o
( ( o
Choline NNP o
) ) o
, , o
Lip NNP o
( ( o
lipid JJ o
) ) o
, , o
and CC o
Cho/Lip NNP o
in IN N
the DT N
3 CD N
groups NNS N
, , N
and CC N
a DT N
one-way JJ N
ANOVA NNP N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
differences NNS N
in IN N
these DT N
metabolites NNS N
between IN N
groups.Choline NN N
levels NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
control NN N
and CC N
HCC NNP N
group NN N
and CC N
between IN N
the DT N
cirrhosis NN N
group NN N
and CC N
the DT N
HCC NNP N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
correlation NN N
with IN N
the DT N
central JJ o
PP NNP o
was VBD N
stronger JJR N
than IN N
with IN N
the DT N
brachial JJ N
PP NNP N
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
or CC N
central JJ o
systolic JJ o
blood NN o
pressure NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
and CC N
these DT N
relationships NNS N
were VBD N
essentially RB N
the DT N
same JJ N
even RB N
after IN N
adjustment NN N
for IN N
the DT N
use NN N
of IN N
atenolol NN i
or CC N
the DT N
change NN N
in IN N
heart NN o
rate NN o
. . o

The DT N
addition NN N
of IN N
inflammatory JJ o
markers NNS o
improves VBZ N
the DT N
discriminatory JJ N
value NN N
of IN N
the DT N
prognostic JJ N
classification NN N
as IN N
compared VBN N
with IN N
established VBN N
factors NNS N
alone RB N
( ( N
C-statistic JJ N
0.673 CD N
vs NN N
0.654 CD N
, , N
P=0.002 NNP N
for IN N
the DT N
difference NN N
) ) N
, , N
with IN N
25.8 CD N
% NN N
( ( N
P=0.004 NNP N
) ) N
of IN N
patients NNS N
more RBR N
appropriately RB N
classified JJ N
using VBG N
the DT N
new JJ N
classification NN N
. . N

A DT N
neuropsychological JJ N
battery NN N
including VBG N
the DT N
Digit NNP o
Span NNP o
subtest JJS o
from IN o
the DT o
Wechsler NNP o
Adult NNP o
Intelligence NNP o
Scale-III NNP o
( ( o
WAIS-III NNP o
) ) o
, , o
the DT o
verbal JJ o
fluency NN o
test NN o
, , o
the DT o
Hopkins NNP o
Verbal NNP o
Learning NNP o
Test NNP o
( ( o
HVLT NNP o
) ) o
, , o
the DT o
Trail-Making JJ o
Test NNP o
( ( o
TMT NNP o
) ) o
and CC o
the DT o
Wisconsin NNP o
Card NNP o
Sorting NNP o
Test NNP o
( ( o
WCST NNP o
) ) o
was VBD N
administered VBN N
at IN N
baseline NN N
and CC N
week NN N
eight CD N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
: : N
diet NN N
, , N
based VBN N
on IN N
multiple JJ o
24-hour JJ o
recalls NNS o
( ( o
total JJ o
fat NN o
, , o
grams NNS o
of IN o
fiber NN o
, , o
servings NNS o
of IN o
fruit NN o
and CC o
vegetables NNS o
, , o
total JJ o
calories NNS o
) ) o
; : o
average JJ o
daily JJ o
energy NN o
expenditure NN o
( ( N
kcals/kg NN N
) ) N
based VBN N
on IN N
7-day JJ N
physical JJ N
activity NN N
recall VBP N
interviews NNS N
; : N
daily JJ N
minutes NNS N
of IN N
moderate-vigorous JJ N
physical JJ N
activity NN N
minutes NNS N
from IN N
accelerometery NN N
; : N
and CC N
self-reported JJ N
daily JJ N
hours NNS N
of IN N
sedentary JJ o
behavior NN o
. . o

After IN N
subjects NNS N
consumed VBD N
fish JJ N
oil NN N
, , N
supplementation NN N
with IN N
alpha-tocopheryl JJ i
acetate NN i
increased VBD N
plasma NN o
and CC o
LDL NNP o
alpha-tocopherol NN o
contents NNS o
significantly RB o
and CC o
lengthened VBD o
lag NN o
time NN o
( ( N
at IN N
even RB N
the DT N
lowest JJS N
concentration NN N
) ) N
but CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
propagation NN o
rate NN o
or CC o
maximum JJ o
production NN o
compared VBN N
with IN N
values NNS N
measured VBN N
after IN N
consumption NN N
of IN N
fish JJ N
oil NN N
alone RB N
. . N

On IN N
multivariate NN o
analysis NN o
overall JJ o
survival NN o
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
event-free JJ o
survival NN o
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
and CC N
disease-free JJ o
survival NN o
were VBD N
better JJR N
( ( N
P NNP N
=.06 NNP N
) ) N
in IN N
younger JJR N
children NNS N
due JJ N
to TO N
a DT N
lower JJR N
relapse NN o
rate NN o
( ( N
P NNP N
=.02 NNP N
) ) N
especially RB N
in IN N
the DT N
bone NN N
marrow NN N
( ( N
P NNP N
=.02 NNP N
) ) N
. . N

Over IN N
the DT N
5.4 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
simvastatin NN i
produced VBD N
changes NNS N
in IN N
total JJ o
cholesterol NN o
, , o
low JJ o
density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
cholesterol NN o
, , o
and CC o
high JJ o
density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
cholesterol NN o
of IN N
-25 NNP N
% NN N
, , N
-35 CD N
% NN N
, , N
and CC N
+8 NNP N
% NN N
, , N
respectively RB N
, , N
with IN N
minimal JJ o
adverse JJ o
effects NNS o
. . o

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS N
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN o
DBP NNP o
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN i
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP i
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

Twelve CD p
patients NNS p
( ( p
seven CD p
females NNS p
and CC p
five CD p
males NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
14.8 CD p
+/- JJ p
0.3 CD p
years NNS p
were VBD p
treated VBN p
with IN p
banded JJ p
RPE NNP p
and CC p
11 CD p
patients NNS p
( ( p
six CD p
females NNS p
and CC p
five CD p
males NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
15.1 CD p
+/- JJ p
0.7 CD p
years NNS p
with IN p
bonded JJ p
RPE NNP p
. . p

After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
2.3+/-0.6 CD N
years NNS N
, , N
the DT N
primary JJ N
endpoint NN N
( ( N
a DT N
composite NN N
of IN N
cardiovascular JJ o
mortality NN o
, , o
heart NN o
failure NN o
, , o
thrombo-embolic JJ o
complications NNS o
( ( o
TECs NNP o
) ) o
, , o
bleeding VBG o
, , o
serious JJ o
adverse JJ o
effects NNS o
of IN o
antiarrhythmic JJ o
drugs NNS o
and CC o
pacemaker NN o
implants NNS o
) ) o
was VBD N
22.4 CD N
% NN N
in IN N
the DT N
rhythm-control NN N
group NN N
vs. FW N
15.2 CD N
% NN N
in IN N
the DT N
rate-control NN N
group NN N
. . N

Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB o
higher JJR o
treatment NN o
failure NN o
rate NN o
compared VBN N
with IN N
patients NNS N
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ N
failure NN N
rate NN N
( ( N
RFR NNP N
) ) N
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin NN i
receptor NN i
blocker NN i
( ( i
ARB NNP i
) ) i
valsartan VBP i
versus IN i
the DT i
calcium NN i
channel NN i
blocker NN i
amlodipine NN i
, , N
reactive JJ N
oxygen NN N
species NNS N
( ( N
ROS NNP N
) ) N
formation NN N
by IN N
monocytes NNS N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
and CC N
left VBD N
ventricular NN N
( ( N
LV NNP N
) ) N
mass NN N
were VBD N
studied VBN N
in IN N
104 CD p
hypertensive JJ p
patients NNS p
with IN p
left JJ p
ventricular JJ p
hypertrophy NN p
( ( p
LVH NNP p
) ) p
. . p

However RB N
, , N
pain VBP o
at IN o
rest NN o
reported VBN N
by IN N
the DT N
TENS NNP i
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
reported VBN N
by IN N
the DT N
control NN N
group NN N
( ( N
treatment NN N
main JJ N
effect NN N
; : N
p CC N
< VB N
0.04 CD N
) ) N
, , N
although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
TENS NNP i
and CC i
placebo NN i
or CC N
between IN N
the DT N
placebo NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
was VBD N
higher RBR N
in IN N
the DT N
vilazodone NN i
group NN N
( ( N
57.6 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
moxifloxacin NN i
( ( N
37.0 CD N
% NN N
) ) N
and CC N
placebo NN i
( ( N
35.6 CD N
% NN N
) ) N
groups NNS N
, , N
though IN N
AEs NNP N
were VBD N
generally RB N
mild VBN N
to TO N
moderate VB N
in IN N
severity NN N
and CC N
resulted VBD N
in IN N
few JJ N
discontinuations NNS N
. . N

The DT N
five-year JJ o
survival NN o
rate NN o
was VBD N
89.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
CABG NNP N
and CC N
86.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
PTCA NNP i
( ( N
P NNP N
= NNP N
0.19 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
in IN N
survival NN N
, , N
-0.2 JJ N
percent NN N
to TO N
6.0 CD N
percent NN N
) ) N
. . N

Pulse NNP o
wave VBP o
velocity NN o
of IN o
the DT o
aorta NN o
( ( o
PWV NNP o
) ) o
, , o
brachial JJ o
artery NN o
flow NN o
mediated VBN o
dilatation NN o
( ( o
FMD NNP o
) ) o
, , o
nitroglycerin RB o
mediated VBN o
dilatation NN o
( ( o
NMD NNP o
) ) o
, , o
microvascular JJ o
endothelial JJ o
function NN o
( ( o
reactive JJ o
hyperemia NN o
index NN o
[ NNP o
RHI NNP o
] NNP o
) ) o
, , o
and CC o
circulating VBG o
biomarkers NNS o
of IN o
inflammation NN o
, , o
insulin NN o
resistance NN o
, , o
and CC o
atherosclerosis NN o
risk NN o
all DT N
were VBD N
quantified VBN N
. . N

Compared VBN N
to TO N
the DT N
placebo NN i
group NN N
, , N
the DT N
olanzapine NN i
group NN N
had VBD N
a DT N
lower JJR N
incidence NN N
of IN N
( ( N
59.2 CD N
% NN N
versus IN N
91.1 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
longer JJR N
time NN N
to TO N
( ( N
46 CD N
versus NN N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
symptomatic JJ o
relapse NN o
of IN o
any DT o
kind NN o
. . o

RESULTS VB N
The DT N
average JJ o
systolic JJ o
BP NNP o
throughout IN N
all DT N
hemodialysis NN N
treatments NNS N
in IN N
a DT N
given VBN N
week NN N
was VBD N
lower JJR N
with IN N
low JJ N
dialysate NN N
sodium NN N
concentrations NNS N
compared VBN N
with IN N
treatments NNS N
with IN N
high JJ N
dialysate NN N
sodium NN N
concentrations NNS N
( ( N
parameter NN N
estimate NN N
, , N
-9.9 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
-13.3 NNP N
to TO N
-6.4 VB N
] NNP N
mm NNP N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
positive JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP o
and CC o
left VBD o
atrial JJ o
volume NN o
( ( o
ECV NNP o
vs RB o
indexed VBD o
left JJ o
atrial JJ o
volume NN o
, , N
r NN N
= VBD N
0.65 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
negative JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP o
and CC o
diastolic JJ o
function NN o
( ( N
E NNP N
' POS N
lateral NN N
, , N
r NN N
= NNP N
-0.64 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

RESULTS NNP N
Training NNP N
did VBD N
not RB N
result VB N
in IN N
a DT N
more RBR N
active JJ o
lifestyle NN o
or CC o
improved VBN o
QoL NNP o
, , N
but CC N
improved VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
peak NN o
power NN o
( ( N
17 CD N
% NN N
) ) N
, , N
6-min JJ o
walk NN o
distance NN o
( ( N
10 CD N
% NN N
) ) N
, , N
muscle NN o
strength NN o
( ( N
13-15 CD N
% NN N
) ) N
and CC N
depression NN N
( ( N
-1.3 JJ N
unit NN N
) ) N
. . N

The DT N
information NN N
about IN N
feeding VBG N
eight CD N
diets NNS N
at IN N
two CD N
periods NNS N
[ VBP N
starter NN N
( ( N
0-21 JJ N
days NNS N
of IN N
age NN N
) ) N
and CC N
grower NN N
( ( N
22-42 JJ N
days NNS N
of IN N
age NN N
) ) N
] WDT N
were VBD N
used VBN N
to TO N
estimate VB N
AF NNP N
of IN N
broilers NNS N
by IN N
ANN-GA. NNP N
A NNP N
multilayer NN N
feed-forward JJ N
neural JJ N
network NN N
with IN N
different JJ N
structures NNS N
was VBD N
developed VBN N
using VBG N
matlab NN N
software NN N
, , N
and CC N
optimal JJ N
values NNS N
for IN N
the DT N
ANN NNP N
weights NNS N
were VBD N
obtained VBN N
using VBG N
the DT N
genetic JJ N
algorithm NN N
( ( N
GA NNP N
) ) N
. . N

Assignment NN N
to TO N
ATV/r NNP i
( ( i
vs. FW i
EFV NNP i
) ) i
resulted VBD N
in IN N
significantly RB N
greater JJR N
weight NN o
( ( N
mean JJ N
difference NN N
3.35 CD N
kg NN N
) ) N
and CC N
BMI NNP o
gain NN o
( ( N
0.88 CD N
kg/m NN N
; : N
both DT N
P=0.02 NNP N
) ) N
, , N
but CC N
not RB o
LBM NNP o
( ( N
0.67 CD N
kg NN N
; : N
P=0.15 NNP N
) ) N
, , N
whereas JJ N
ABC/3TC NNP o
and CC o
TDF/FTC NNP o
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P NNP N
) ) N
. . N

The DT N
4-year JJ o
probabilities NNS o
of IN o
transplant-related JJ o
mortality NN o
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN N
of IN N
moderate JJ N
to TO N
severe VB o
acute JJ o
graft-versus-host JJ o
disease NN o
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

Independent JJ N
samples NNS N
t-tests NNS N
revealed VBD N
no DT N
significant JJ N
differences NNS N
at IN N
baseline NN N
across IN N
the DT N
TG NNP N
and CC N
CG NNP N
conditions NNS N
with IN N
regard NN N
to TO N
age NN N
( ( N
14.04 CD N
? . N
1.64 CD N
and CC N
13.54 CD N
? . N
1.50 CD N
years NNS N
) ) N
, , N
IQ NNP N
( ( N
99.39 CD N
? . N
18.09 CD N
& CC N
100.67 CD N
? . N
16.97 CD N
) ) N
, , N
parental JJ N
education NN N
, , N
socioeconomic JJ N
status NN N
, , N
or CC N
ASD NNP N
symptoms NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
addition NN N
of IN N
ezetimibe NN i
to TO i
simvastatin VB i
over RP N
a DT N
4-week JJ N
period NN N
was VBD N
associated VBN N
with IN N
reduced JJ o
expression NN o
of IN o
CD141 NNP o
( ( N
thrombomodulin NN N
; : N
p CC N
= VB N
0.02 CD N
) ) N
, , N
platelet VBP o
endothelial JJ o
cell NN o
adhesion NN o
molecule NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
CD51/61 NNP N
( ( N
vitronectin JJ N
receptor NN N
; : N
p CC N
= VB N
0.048 CD N
) ) N
compared VBN N
to TO N
statin VB N
monotherapy NN N
. . N

The DT N
incidence NN o
of IN o
recurrent JJ o
angina NN o
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
was VBD N
also RB N
significantly RB N
reduced VBN N
in IN N
XS0601 NNP N
group NN N
( ( N
7.1 CD N
% NN N
and CC N
11.0 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
those DT N
in IN N
placebo JJ i
group NN N
( ( N
19.5 CD N
% NN N
and CC N
42.9 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
initial JJ o
RAO NNP o
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
? . N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
? . N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
the DT N
proportion NN o
of IN o
subjects NNS o
achieving VBG o
a DT o
glycated JJ o
hemoglobin NN o
A1c NNP o
value NN o
of IN o
< $ o
7 CD o
% NN o
, , o
change NN o
from IN o
baseline NN o
in IN o
fasting VBG o
plasma NN o
glucose NN o
and CC o
postprandial JJ o
glucose NN o
( ( o
as IN o
part NN o
of IN o
an DT o
oral JJ o
glucose NN o
tolerance NN o
test NN o
) ) o
, , o
body NN o
weight NN o
, , o
and CC o
blood NN o
pressure NN o
. . o

Also RB N
patients NNS N
with IN N
PPD NNP N
negative JJ N
skin NN N
reaction NN N
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
in IN N
the DT N
OK-432 NNP N
group NN N
survived VBD N
significantly RB N
longer RBR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significance NN N
between IN N
both DT N
treatment NN N
groups NNS N
in IN N
patients NNS N
with IN N
PPD NNP N
positive JJ N
skin NN N
reaction NN N
at IN N
the DT N
time NN N
of IN N
beginning VBG N
of IN N
treatment NN N
. . N

Among IN N
putative JJ N
variables NNS N
, , N
multivariate JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
only RB N
the DT N
baseline NN N
number NN o
of IN o
SBIs NNP o
( ( N
OR NNP N
= VBZ N
6.27 CD N
, , N
95 CD N
% NN N
CI NNP N
2.4-16.5 CD N
) ) N
and CC N
simvastatin JJ N
treatment NN N
( ( N
OR NNP N
= VBZ N
0.09 CD N
, , N
95 CD N
% NN N
CI NNP N
0.01-0.82 NN N
) ) N
independently RB N
predicted VBD N
the DT N
development NN N
of IN N
new JJ N
brain NN N
infarcts NNS N
. . N

RESULTS NN N
After IN N
training VBG N
with IN N
EPI-NO NNP i
we PRP N
observed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
incidence NN o
of IN o
intact JJ o
perineum NN o
( ( N
37.4 CD N
% NN N
vs JJ N
25.7 CD N
% NN N
; : N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
a DT N
tendency NN N
towards NNS N
lower JJR N
episiotomy NN o
rates NNS o
( ( N
41.9 CD N
% NN N
vs JJ N
50.5 CD N
% NN N
; : N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

The DT N
mean JJ o
volume NN o
of IN o
drainage NN o
from IN o
the DT o
breast NN o
and CC o
the DT o
total JJ o
drainage NN o
from IN o
both CC o
the DT o
breast NN o
and CC o
axilla NN o
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
EC NNP N
group NN N
compared VBN N
to TO N
UC NNP N
[ NNP N
169.3 CD N
versus NN N
58.8 CD N
mls NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
663.7 CD N
versus NN N
247.0 CD N
mls NN N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
respectively RB N
] JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Visual NNP o
field NN o
progression NN o
, , o
measured VBN o
by IN o
Humphrey NNP o
24-2 JJ o
full-threshold JJ o
testing NN o
and CC o
assessed VBN o
by IN o
the DT o
change NN o
in IN o
the DT o
mean JJ o
deviation NN o
( ( o
MD NNP o
) ) o
, , o
and CC o
an DT o
indicator NN o
of IN o
substantial JJ o
worsening NN o
of IN o
the DT o
VF NNP o
( ( o
MD NNP o
decrease NN o
of IN o
> NN o
or CC o
=3 JJ o
dB NN o
from IN o
baseline NN o
) ) o
, , N
assessed VBN N
at IN N
each DT N
follow-up JJ N
visit NN N
. . N

In IN N
contrast NN N
, , N
therapy NN N
with IN N
zofenopril NN i
was VBD N
associated VBN N
with IN N
a DT N
50 CD N
% NN N
increase NN N
in IN N
total JJ o
heart NN o
rate NN o
variability NN o
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
and CC N
a DT N
significant JJ N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
twofold NN N
increase NN N
in IN N
high JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
, , N
indicating VBG N
a DT N
significant JJ N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
. . N

Differences NNS N
in IN N
the DT N
GMC NNP o
after IN N
the DT N
primary JJ N
series NN N
of IN N
three CD N
doses NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
GMC NNP o
was VBD N
highest JJS N
for IN N
PRP-T NNP N
( ( N
6.62 CD N
micrograms/ml NN N
) ) N
, , N
followed VBN N
by IN N
HbOC NNP N
( ( N
1.9 CD N
micrograms/ml NN N
) ) N
, , N
then RB N
PRP-OMP NNP N
( ( N
1.06 CD N
micrograms/ml NN N
) ) N
, , N
and CC N
lowest JJS N
for IN N
the DT N
control NN N
group NN N
( ( N
0.11 CD N
microgram/ml NN N
) ) N
. . N

Luteinizing VBG o
hormone NN o
( ( o
LH NNP o
) ) o
, , o
follicle NN o
stimulating VBG o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
dehydroepiandrostendione JJ o
sulfate NN o
( ( o
DHEAS NNP o
) ) o
, , o
total JJ o
testosterone NN o
( ( o
T NNP o
) ) o
, , o
glucose JJ o
, , o
and CC o
insulin NN o
levels NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
first JJ N
cycle NN N
, , N
as RB N
well RB N
as IN N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
cervical JJ o
score NN o
, , o
and CC o
pregnancy NN o
rate NN o
. . o

The DT N
group NN N
treated VBD N
with IN N
GM-CSF NNP i
had VBD N
lower JJR N
total NN o
charges NNS o
after IN N
infusion NN N
of IN N
autologous JJ N
marrow NN N
than IN N
the DT N
placebo NN i
group NN N
( ( N
median JJ N
in-hospital NN N
charges NNS N
, , N
$ $ N
39,800 CD N
compared VBN N
with IN N
$ $ N
62,500 CD N
; : N
P NNP N
= NNP N
0.005 CD N
) ) N
because IN N
of IN N
lower JJR N
post-infusion NN N
charges NNS N
for IN N
room NN N
and CC N
board NN N
, , N
antibiotic JJ N
therapy NN N
, , N
transfusions NNS N
, , N
laboratory NN N
tests NNS N
, , N
and CC N
physical JJ N
therapy NN N
visits NNS N
. . N

After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN o
in IN o
H-SDSCA NNP o
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN N
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
. . N

OBJECTIVE NN N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
80-kilovoltage NN i
( ( i
kV NN i
) ) i
tube NN i
voltage NN i
coronary JJ i
computed VBD i
tomographic JJ i
angiography NN i
( ( i
CCTA NNP i
) ) i
with IN N
a DT N
reduced JJ N
amount NN N
of IN N
contrast NN N
agent NN N
on IN N
qualitative JJ N
and CC N
quantitative JJ N
image NN N
quality NN N
parameters NNS N
and CC N
on IN N
radiation NN N
dose NN N
in IN N
patients NNS p
with IN p
a DT p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
< VBD p
23.0 CD p
kg/m NN p
( ( p
2 CD p
) ) p
. . p

There EX N
was VBD N
no DT N
significant JJ N
increase NN N
in IN N
the DT N
duration NN o
of IN o
first JJ o
remission NN o
in IN N
the DT N
C+I NNP N
group NN N
( ( N
0.05 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.1 CD N
) ) N
nor CC N
in IN N
the DT N
time NN o
from IN o
first JJ o
relapse NN o
to TO o
death NN o
( ( N
0.05 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.1 CD N
) ) N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
AVM NNP o
dimensions NNS o
( ( N
79.4 CD N
% NN N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
86.9 CD N
% NN N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
and CC N
the DT N
mean JJ o
number NN o
of IN o
vessels NNS o
embolized VBN o
( ( N
2.2 CD N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
2.1 CD N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
results NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
sensory JJ o
function NN o
as IN N
detected VBN N
by IN N
the DT N
2PD CD N
and CC N
SWM NNP N
tests NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
sensorimotor JJ o
function NN o
as IN N
detected VBN N
by IN N
the DT N
MTT NNP i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
PHUA NNP i
test NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
patients NNS N
receiving VBG N
CTR NNP N
. . N

When WRB N
adjusted VBN N
for IN N
other JJ N
important JJ N
factors NNS N
, , N
complete JJ o
remission NN o
rates NNS o
were VBD N
similar JJ N
( ( N
P NNP N
=.5 NNP N
) ) N
and CC N
although IN N
there EX N
was VBD N
less RBR N
resistant JJ N
disease NN N
in IN N
younger JJR N
children NNS N
( ( N
P NNP N
=.003 NNP N
) ) N
, , N
this DT N
was VBD N
partially RB N
balanced VBN N
by IN N
a DT N
slight JJ N
increase NN N
in IN N
deaths NNS o
during IN N
induction NN N
therapy NN N
in IN N
younger JJR N
patients NNS N
( ( N
P NNP N
=.06 NNP N
) ) N
. . N

A DT N
decrease NN N
in IN N
PPD NNP N
( ( N
5.4 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
and CC N
tooth DT o
mobility NN o
( ( N
DDM-horizontal JJ N
257 CD N
microns NNS N
, , N
SD NNP N
60 CD N
microns NNS N
) ) N
and CC N
a DT N
gain NN o
of IN o
CPAL NNP o
( ( N
5.1 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
were VBD N
seen VBN N
following VBG N
the DT N
use NN N
of IN N
BRG NNP N
in IN N
presplint NN N
teeth NNS N
. . N

In IN N
the DT N
group NN N
with IN N
only RB N
one CD N
invaded VBD N
lymph NN N
node NN N
, , N
the DT N
estimated VBN N
relapse NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.0285 NN N
) ) N
and CC N
the DT N
overall JJ o
survival NN o
was VBD N
increased VBN N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.039 NN N
) ) N
in IN N
the DT N
TIL+IL-2 NNP N
arm NN N
compared VBN N
with IN N
the DT N
IL-2 NNP i
only JJ N
arm NN N
. . N

The DT N
increased VBN N
screening-coverage NN o
rate NN o
in IN N
the DT N
intervention NN N
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
zone NN N
( ( N
43.6 CD N
vs. FW N
34.9 CD N
% NN N
, , N
p=0.119 NN N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN N
in IN N
the DT N
intervention NN N
zone NN N
compared VBN N
with IN N
baseline NN N
( ( N
36.7 CD N
to TO N
43.6 CD N
% NN N
, , N
p=0.070 NN N
) ) N
. . N

In IN N
terms NNS N
of IN N
cancer NN o
deaths NNS o
, , N
only RB N
colorectal JJ N
cancer NN N
in IN N
men NNS N
shows VBZ N
a DT N
significant JJ N
positive JJ N
correlation NN N
( ( N
r JJ N
= NN N
0.91 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
stomach NN o
cancer NN o
in IN N
women NNS N
is VBZ N
negatively RB N
correlated VBN N
with IN N
DNA NNP N
oxidation NN N
( ( N
r JJ N
= NNP N
-0.92 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

A DT N
significant JJ N
ambulatory NN o
BP NNP o
reduction NN o
was VBD N
, , N
however RB N
, , N
observed VBN N
in IN N
the DT N
subjects NNS N
who WP N
received VBD N
aspirin NN i
at IN N
bedtime NN N
( ( N
decrease NN N
of IN N
6/3 CD N
mm NNS N
Hg NNP N
in IN N
the DT N
24-h JJ N
mean NN N
of IN N
systolic NN o
( ( o
SBP NNP o
) ) o
/diastolic VBP o
BP NNP o
( ( o
DBP NNP o
) ) o
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
without IN N
changes NNS N
in IN N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
from IN N
baseline NN N
. . N

Although IN N
pre-course JJ o
scores NNS o
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN N
scores NNS N
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

RESULTS NN N
After IN N
start NN N
of IN N
extracorporeal JJ N
circulation NN N
( ( N
ECC NNP N
) ) N
and CC N
aortic JJ N
crossclamping NN N
( ( N
T2 NNP N
) ) N
, , N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
drop NN N
of IN N
FCD NNP o
, , N
with IN N
a DT N
significantly RB N
higher JJR N
FCD NNP o
in IN N
the DT N
MECC NNP N
group NN N
( ( N
206.8 CD N
? . N
33.6 CD N
cm/cm NN N
in IN N
CECC NNP N
group NN N
versus VBD N
217.8 CD N
? . N
35.3 CD N
cm/cm NN N
in IN N
MECC NNP N
group NN N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

During IN N
the DT N
trials NNS N
, , N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
was VBD N
continuously RB N
monitored VBN N
, , N
whereas NNS N
core VBP o
temperature NN o
( ( o
Tco NNP o
) ) o
, , o
thermal JJ o
comfort NN o
( ( o
TC NNP o
) ) o
, , o
thermal JJ o
sensation NN o
( ( o
TS NNP o
) ) o
and CC o
rate NN o
of IN o
perceived VBN o
exertion NN o
( ( o
RPE NNP o
) ) o
were VBD N
measured VBN N
before IN N
and CC N
after IN N
warm-up JJ N
, , N
every DT N
5 CD N
km NN N
of IN N
exercise NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
exercise NN N
and CC N
after IN N
recovery NN N
. . N

In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
OS NNP N
( ( N
HR NNP N
, , N
1.125 CD N
; : N
P NNP N
= NNP N
.525 NNP N
) ) N
, , N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
( ( N
HR NNP N
, , N
1.229 CD N
; : N
P NNP N
= NNP N
.251 NNP N
) ) N
, , N
response NN N
( ( N
P NNP N
= NNP N
.607 NNP N
) ) N
, , N
and CC N
toxicity NN o
profiles NNS o
were VBD N
similar JJ N
in IN N
African JJ p
Americans NNPS p
versus NN p
whites NNS p
. . p

No DT N
differences NNS N
were VBD N
found VBN N
in IN N
thermal JJ o
sensitivity NN o
( ( N
esophagus JJ N
( ( N
p=0.67 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.17 NN N
) ) N
) ) N
, , N
sensory JJ o
response NN o
to TO N
electrical JJ N
stimulation NN N
( ( N
esophagus JJ N
( ( N
p=0.57 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.52 NN N
) ) N
) ) N
or CC N
induced VBN N
somatic JJ o
referred VBD o
pain NN o
areas NNS o
( ( N
esophagus NN N
( ( N
p=0.75 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.51 NN N
) ) N
) ) N
. . N

Two CD N
preplanned JJ N
comparisons NNS N
were VBD N
made VBN N
: : N
( ( N
a DT N
) ) N
Spinal NNP i
manipulative JJ i
therapy NN i
( ( i
SMT NNP i
) ) i
combined VBD i
with IN i
trunk NN i
strengthening VBG i
exercises NNS i
( ( i
TSE NNP i
) ) i
vs. FW i
SMT NNP i
combined VBD i
with IN i
trunk NN i
stretching VBG i
exercises NNS i
, , i
and CC i
( ( i
b NN i
) ) i
SMT NNP i
combined VBN i
with IN i
TSE NNP i
vs. FW i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
therapy NN i
combined VBN i
with IN i
TSE NNP i
. . i

Those DT p
who WP p
had VBD p
not RB p
had VBN p
hysterectomies NNS p
( ( p
n JJ p
= NNP p
16,049 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
estrogen NN i
plus CC i
progestin NN i
( ( i
n JJ i
= NNP i
8,240 CD i
) ) i
, , i
given VBN i
as IN i
0.625 CD i
mg/day NN i
conjugated VBD i
equine JJ i
estrogens NNS i
plus CC i
2.5 CD i
mg/day JJ i
medroxyprogesterone NN i
acetate NN i
, , i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
7,809 CD N
) ) N
, , N
with IN N
a DT N
mean JJ N
followup NN N
of IN N
5.6 CD N
years NNS N
. . N

After IN N
12 CD N
weeks NNS N
of IN N
care NN N
, , N
the DT N
proportion NN o
of IN o
wounds NNS o
healed VBN o
( ( N
defined VBN N
as IN N
complete JJ N
epithelialization NN N
without IN N
drainage NN N
) ) N
in IN N
the DT N
active JJ N
ultrasound NN N
therapy NN N
device NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
sham NN N
control NN N
group NN N
( ( N
40.7 CD N
% NN N
versus IN N
14.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.0366 CD N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
. . N

Significant JJ N
correlations NNS N
between IN N
changes NNS N
in IN N
serum JJ o
free-carnitine JJ o
levels NNS o
and CC o
positive JJ o
clinical JJ o
changes NNS o
were VBD N
observed VBN N
for IN N
hand NN o
muscle NN o
strength NN o
( ( N
R2=0.23 NNP N
, , N
P=0.046 NNP N
) ) N
, , N
cognitive JJ o
scores NNS o
( ( N
R2=0.27 NNP N
, , N
P=0.019 NNP N
) ) N
, , N
and CC N
CARS NNP o
scores NNS o
( ( N
R2=0.20 NNP N
, , N
P=0.047 NNP N
) ) N
. . N

Mean NNP o
( ( o
SD NNP o
) ) o
time NN o
taken VBN o
for IN o
complete JJ o
healing VBG o
with IN N
combination NN N
treatment NN N
[ VBZ N
1.9 CD N
( ( N
0.6 CD N
) ) N
weeks NNS N
] NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
with IN N
minoxidil NN i
alone RB N
( ( N
3.1 CD N
[ RB N
1.7 CD N
] JJ N
weeks NNS N
; : N
p=0.001 NN N
) ) N
or CC N
with IN N
lignocaine JJ i
alone NN N
( ( N
3.3 CD N
[ RB N
0.8 CD N
] JJ N
weeks NNS N
; : N
p=0.002 NN N
) ) N
. . N

Findings NNS N
showed VBD N
the DT N
significant JJ N
decrease NN N
in IN N
the DT N
mean JJ o
scores NNS o
of IN o
fatigue NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
significant JJ N
improvement NN N
in IN N
mean JJ o
scores NNS o
of IN o
ADL NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
QOL NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
after IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
in IN N
the DT N
case NN N
group NN N
. . N

The DT N
levels NNS o
of IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

During IN N
the DT N
placebo NN N
control NN N
period NN N
, , N
serum JJ o
IGF-I NNP o
, , o
LBM NNP o
, , o
and CC o
TBW NNP o
increased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
BF NNP o
decreased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
serum JJ o
GHBP NNP o
was VBD N
unchanged JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
GH NNP i
compared VBN N
with IN N
the DT N
patients NNS N
treated VBN N
with IN N
placebo NN i
. . i

Three-year JJ o
OS NNP o
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
( ( N
67.4 CD N
% NN N
and CC N
67.7 CD N
% NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
=1.01 VBP N
[ JJ N
0.79-1.30 JJ N
] NN N
, , N
p=0.92 NN N
) ) N
, , N
nor CC N
did VBD N
3-year JJ o
disease-free JJ o
survival NN o
, , o
response NN o
rates NNS o
, , o
toxicity NN o
, , o
or CC o
postoperative JJ o
mortality NN o
. . o

Using VBG N
the DT N
Log-rank JJ N
test NN N
, , N
patients NNS N
from IN N
arm NN N
A NNP N
achieved VBD N
a DT N
significantly RB N
longer RBR o
survival JJ o
( ( N
P=0.009 NNP N
) ) N
, , N
with IN N
the DT N
probability NN o
of IN o
survival NN o
at IN N
12 CD N
months NNS N
of IN N
0.58 CD N
for IN N
patients NNS N
in IN N
arm NN N
A NN N
and CC N
0.28 CD N
for IN N
patients NNS N
in IN N
arm NN N
B. NNP N
Grade NNP o
IV NNP o
granulocytopenia NN o
and CC o
thrombocytopenia NN o
were VBD N
more RBR N
frequent JJ N
in IN N
arm NN N
A NN N
. . N

However RB N
, , N
changes NNS N
in IN N
serum NN N
acetate NN N
from IN N
3 CD N
to TO N
6 CD N
mo NNS N
were VBD N
positively RB N
related VBN N
to TO N
changes NNS N
in IN N
the DT N
ratio NN N
of IN N
total JJ N
to TO N
HDL NNP o
cholesterol NN o
( ( N
P NNP N
= NNP N
0.041 CD N
) ) N
and CC N
in IN N
fasting NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
and CC N
postprandial JJ N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
triacylglycerols NNS N
. . N

The DT N
left NN o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
the DT N
patients NNS N
receiving VBG N
BMAC NNP N
demonstrated VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
baseline NN N
, , N
from IN N
25.1 CD N
% NN N
at IN N
screening VBG N
to TO N
31.1 CD N
% NN N
at IN N
12 CD N
months NNS N
( ( N
p=.007 NN N
) ) N
in IN N
the DT N
NIHF NNP N
group NN N
and CC N
from IN N
26.3 CD N
% NN N
to TO N
31.1 CD N
% NN N
in IN N
the DT N
IHF NNP N
group NN N
( ( N
p=.035 NN N
) ) N
. . N

Although IN N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptor NN N
II NNP N
concentrations NNS N
at IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
were VBD N
at IN N
least JJS N
marginally RB N
associated VBN N
with IN N
subsequent JJ N
changes NNS N
in IN N
BMD NNP o
( ( N
P NNP N
= NNP N
0.06 CD N
and CC N
P NNP N
= NNP N
0.028 CD N
, , N
respectively RB N
) ) N
, , N
these DT N
associations NNS N
were VBD N
no RB N
longer RBR N
significant JJ N
after IN N
adjustment NN N
for IN N
CD4 NNP N
T NNP N
cell NN N
count NN N
. . N

Children NNP N
in IN N
the DT N
omega-3 JJ i
fatty JJ i
acid NN i
group NN N
had VBD N
a DT N
greater JJR N
reduction NN N
in IN N
hyperactivity NN o
( ( N
-5.3 JJ N
points NNS N
) ) N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
-2.6 CD N
points NNS N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
1.9-point JJ N
greater JJR N
improvement NN N
in IN N
the DT N
omega-3 JJ N
group NN N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
-2.2 NNP N
to TO N
5.2 CD N
) ) N
. . N

In IN N
the DT N
two CD N
groups NNS N
significant JJ N
improvement NN N
of IN N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
, , o
ESR NNP o
, , o
CRP NNP o
, , o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
by IN o
both DT o
physicians NNS o
and CC o
patients NNS o
, , o
HAQ NNP o
, , o
DAS28 NNP o
, , o
and CC o
Chinese NNP o
medical JJ o
syndrome NN o
integrals NNS o
after IN N
treatment NN N
were VBD N
shown VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
was VBD N
3.8+/-1.4 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.006 NNP N
) ) N
and CC N
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
was VBD N
2.6+/-1.1 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
in IN N
the DT N
FO NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
inter- JJ N
or CC N
intra-group JJ N
differences NNS N
in IN N
mean JJ o
counts NNS o
were VBD N
found VBN N
; : N
however RB N
, , N
when WRB N
four-hour JJ N
and CC N
24-hour JJ N
data NNS N
for IN N
Aa NNP o
, , o
Pg NNP o
, , o
or CC o
NS NNP o
were VBD o
combined VBN o
, , o
experimental JJ o
counts NNS o
were VBD N
lower JJR N
than IN N
controls NNS N
in IN N
39/50 CD N
( ( N
78 CD N
% NN N
) ) N
of IN N
the DT N
matched VBN N
pairs NNS N
( ( N
Wilcoxon NNP N
signed-rank JJ N
test NN N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Pain NN o
scores NNS o
( ( o
rest NN o
, , o
cough NN o
, , o
and CC o
ambulation NN o
) ) o
, , o
side JJ o
effects NNS o
( ( o
nausea NN o
, , o
pruritus NN o
, , o
sedation NN o
, , o
motor NN o
block NN o
, , o
hypotension NN o
, , o
and CC o
orthostasis NN o
) ) o
, , o
and CC o
patient-controlled JJ o
epidural JJ o
analgesia NN o
consumption NN o
were VBD N
measured VBN N
for IN N
48 CD N
h. JJ N
RESULTS NNP N
All NNP N
three CD N
solutions NNS N
produced VBD N
equivalent JJ N
analgesia NN N
. . N

Again RB N
, , N
there EX N
was VBD N
no DT N
main JJ N
effect NN N
of IN N
condition NN N
on IN N
heat NN o
pain NN o
threshold NN o
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
nor CC N
on IN N
cold JJ o
pain NN o
threshold NN o
( ( N
p JJ N
= NNP N
0.65 CD N
) ) N
, , N
nor CC N
on IN N
any DT N
of IN N
the DT N
secondary JJ N
measures NNS N
( ( N
p VB N
< $ N
0.56 CD N
for IN N
all DT N
) ) N
. . N

RESULTS NNP N
Significant NNP N
differences VBZ N
and/or JJ N
trends NNS N
in IN N
favor NN N
of IN N
the DT N
EG NNP N
were VBD N
observed VBN N
regarding VBG N
the DT N
primary JJ N
endpoint NN N
endurance NN o
performance NN o
( ( N
P=0.002 NNP N
) ) N
, , N
muscular JJ N
strength NN N
( ( N
P=0.022 NNP N
) ) N
, , N
fatigue NN N
( ( N
P=0.046 NNP N
) ) N
, , N
and CC N
emotional JJ N
state NN N
( ( N
P=0.028 NNP N
) ) N
without IN N
posing VBG N
an DT N
additional JJ N
risk NN N
for IN N
the DT N
individual NN N
. . N

Monthly JJ o
pre-enalapril NNS o
and CC o
post-enalapril JJ o
neurohormone NN o
levels NNS o
( ( o
serum JJ o
ACE NNP o
activity NN o
( ( o
sACE NN o
) ) o
, , o
plasma JJ o
angiotensin NN o
II NNP o
( ( o
A-II NNP o
) ) o
, , o
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
, , o
and CC o
serum VB o
aldosterone NN o
( ( o
ALDO NNP o
) ) o
were VBD N
compared VBN N
between IN N
genotype NN N
subgroups NNS N
and CC N
between IN N
patients NNS N
who WP N
received VBD N
high- JJ N
or CC N
low-dose JJ N
enalapril NN i
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

Rates NNS o
of IN o
serious JJ o
adverse JJ o
events NNS o
( ( N
overall JJ N
rate=14.8 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
serious JJ o
infections NNS o
( ( N
overall JJ N
rate=4.2 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
cancer NN N
( ( N
overall JJ N
rate=1.0 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
and CC N
deaths NNS N
( ( N
overall JJ N
rate=0.7 NN N
events/100 IN N
patient-yrs NN N
) ) N
were VBD N
stable JJ N
each DT N
year NN N
, , N
through IN N
8 CD N
years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

Adults NNS p
with IN p
systolic JJ p
BP NNP p
120-159 JJ p
mm NN p
Hg NNP p
and CC p
diastolic JJ p
BP NNP p
80-95 JJ p
mm NN p
Hg NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
DASH NNP i
diet NN i
or CC i
a DT i
typical JJ i
American NNP i
( ( i
control NN i
) ) i
diet NN i
, , i
consuming VBG i
three CD i
different JJ i
sodium NN i
intakes NNS i
( ( i
higher=142 JJ i
mmol/d NN i
, , i
intermediate=107 NN i
mmol/d NN i
, , i
and CC i
lower=65 JJ i
mmol/d NN i
) ) i
for IN i
30 CD i
days NNS i
each DT i
. . i

RESULTS VB N
The DT N
serum NN o
levels NNS o
of IN o
TARC NNP o
decreased VBD N
significantly RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
boiled VBN N
CM NNP N
and CC N
in IN N
raw JJ N
CM NNP N
group NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
too RB N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
in IN N
placebo NN i
group NN N
. . N

In IN N
the DT N
cicloxilic JJ i
group NN N
there EX N
was VBD N
little JJ N
or CC N
no DT N
change NN N
in IN N
bile NN N
salts NNS N
and CC N
phospholipids NNS N
, , N
whereas NNS N
biliary VBP o
cholesterol NN o
concentration NN o
was VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
consequently RB N
the DT N
lithogenic JJ N
index NN N
lowered VBD N
( ( N
from IN N
1.5 CD N
to TO N
1.2 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

RESULTS NN N
At IN N
each DT N
time NN N
point NN N
, , N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
thrombus-aspiration NN N
filter NN N
device NN N
, , N
WMSI NNP o
, , o
CSI NNP o
, , o
WML NNP o
, , o
and CC o
CDL NNP o
were VBD o
significantly RB o
lower JJR o
and CC o
ejection NN o
fraction NN o
higher JJR o
( ( N
p JJ N
< $ N
0.05 CD N
vs. FW N
control NN N
patients NNS N
) ) N
, , N
whereas JJ N
LV NNP o
volumes NNS o
were VBD N
slightly RB N
but CC N
not RB N
significantly RB N
smaller JJR N
compared VBN N
with IN N
control NN N
patients NNS N
. . N

Sibenadet NNP i
therapy NN i
was VBD N
generally RB N
well RB N
tolerated VBN o
, , N
with IN N
the DT N
only JJ N
notable JJ N
differences NNS N
seen VBN N
in IN N
the DT N
incidence NN o
of IN o
tremor NN o
and CC o
taste NN o
of IN N
treatment NN N
( ( N
16.9 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
and CC N
14.5 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
in IN N
the DT N
sibenadet NN N
and CC N
placebo NN i
groups NNS N
respectively RB N
) ) N
. . N

After IN N
a DT N
mean JJ N
duration NN N
of IN N
GH NNP N
treatment NN N
of IN N
8.6 CD N
+/- JJ N
1.9 CD N
yr NN N
, , N
FH NNP N
was VBD N
reached VBN N
at IN N
a DT N
mean JJ N
age NN N
of IN N
15.8 CD N
+/- JJ N
0.9 CD N
yr. NN N
FH NNP N
, , N
expressed VBD N
in IN N
centimeters NNS N
or CC N
SD NNP N
score NN N
, , N
was VBD N
157.6 CD N
+/- JJ N
6.5 CD N
or CC N
-1.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
A NNP N
, , N
162.9 CD N
+/- JJ N
6.1 CD N
or CC N
-0.7 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
B NNP N
, , N
and CC N
163.6 CD N
+/- JJ N
6.0 CD N
or CC N
-0.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
C. NNP N
The DT N
difference NN N
in IN N
FH NNP o
in IN o
centimeters NNS o
, , o
corrected VBN o
for IN o
height NN o
SD NNP o
score NN o
and CC N
age NN N
at IN N
start NN N
of IN N
treatment NN N
, , N
was VBD N
significant JJ N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
[ NNP N
regression NN N
coefficient NN N
, , N
4.1 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.4 CD N
, , N
6.9 CD N
; : N
P NNP N
< VBD N
0.01 CD N
] NN N
, , N
and CC N
groups NNS N
A NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
5.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
2.3 CD N
, , N
7.7 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
between IN N
groups NNS N
B NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
0.9 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
, , N
3.6 CD N
) ) N
. . N

RESULTS JJ N
Results NNP N
of IN N
an DT N
intent-to-treat JJ N
analysis NN N
did VBD N
not RB N
meet VB N
the DT N
prespecified JJ N
criterion NN N
for IN N
noninferiority NN N
but CC N
did VBD N
demonstrate VB N
the DT N
superiority NN N
of IN N
continuous-dose JJ N
terbinafine NN N
for IN N
: : N
mycological JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
70.9 CD N
% NN N
[ CC N
105/148 CD N
] JJ N
vs RB N
58.7 CD N
% NN N
[ CC N
84/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
of IN N
1.21 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02-1.43 JJ N
] NN N
) ) N
; : N
clinical JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
44.6 CD N
% NN N
[ CC N
66/148 CD N
] JJ N
vs RB N
29.3 CD N
% NN N
[ CC N
42/143 CD N
] NN N
; : N
P NNP N
=.007 NNP N
, , N
RR NNP N
=1.52 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.11-2.07 JJ N
) ) N
; : N
complete JJ o
cure NN o
of IN N
the DT N
target NN N
toenail NN N
( ( N
40.5 CD N
% NN N
[ CC N
60/148 CD N
] JJ N
vs RB N
28.0 CD N
% NN N
[ CC N
40/143 CD N
] NN N
; : N
P NNP N
=.02 NNP N
, , N
RR=1.45 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.04-2.01 JJ N
) ) N
; : N
and CC N
complete JJ o
cure NN o
of IN N
all DT N
10 CD N
toenails NNS N
( ( N
25.2 CD N
% NN N
[ CC N
36/143 CD N
] JJ N
vs RB N
14.7 CD N
% NN N
[ CC N
21/143 CD N
] NN N
; : N
P NNP N
=.03 NNP N
, , N
RR NNP N
=1.71 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.79 JJ N
) ) N
. . N

RESULTS VB N
The DT N
score NN o
of IN o
symptoms NNS o
and CC o
signs NNS o
markedly RB o
decreased VBD N
after IN N
treatment NN N
, , N
in IN N
treatment NN N
group NN N
: : N
vertigo NN o
had VBD N
( ( N
2.75 CD N
+/- JJ N
1.01 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ o
pain NN o
( ( N
1.58 CD N
+/- JJ N
0.36 CD N
) ) N
, , N
headache NN o
( ( N
0.39 CD N
+/- JJ N
0.09 CD N
) ) N
, , N
nausea-vomiting JJ o
( ( N
1.58 CD N
+/- JJ N
1.30 CD N
) ) N
, , N
ear JJ o
noises NNS o
( ( N
0.48 CD N
+/- JJ N
0.32 CD N
) ) N
, , N
positive JJ o
neck NN o
rotation NN o
test NN o
( ( N
0.59 CD N
+/- JJ N
0.21 CD N
) ) N
; : N
and CC N
in IN N
control NN N
group NN N
: : N
vertigo NN o
had VBD N
( ( N
5.68 CD N
+/- JJ N
2.02 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ o
pain NN o
( ( N
3.12 CD N
+/- JJ N
1.82 CD N
) ) N
, , N
headache NN o
( ( N
1.86 CD N
+/- JJ N
0.65 CD N
) ) N
, , N
nausea-vomiting JJ o
( ( N
3.25 CD N
+/- JJ N
0.69 CD N
) ) N
, , N
ear JJ o
noises NNS o
( ( N
1.64 CD N
+/- JJ N
0.61 CD N
) ) N
, , N
positive JJ o
neck NN o
rotation NN o
test NN o
( ( N
1.79 CD N
+/- JJ N
0.67 CD N
) ) N
. . N

In IN N
a DT N
multivariate NN N
model NN N
, , N
IFN- NNP N
therapy NN N
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
favorable JJ N
RFS NNP N
( ( N
HR NNP N
0.74 CD N
; : N
95 CD N
% NN N
CI NNP N
0.55-0.99 CD N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
pre-treatment JJ N
MMP-8 NNP i
( ( N
HR NNP N
1.17 CD N
; : N
95 CD N
% NN N
CI NNP N
0.88-1.55 CD N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
, , N
gender FW N
( ( N
HR NNP N
1.16 CD N
; : N
95 CD N
% NN N
CI NNP N
0.86-1.56 CD N
; : N
P NNP N
= NNP N
0.32 CD N
) ) N
, , N
age NN N
( ( N
HR NNP N
1.00 CD N
; : N
95 CD N
% NN N
CI NNP N
1.00-1.02 CD N
; : N
P NNP N
= NNP N
0.12 CD N
) ) N
, , N
ulceration NN o
( ( N
HR NNP N
1.09 CD N
; : N
95 CD N
% NN N
CI NNP N
0.81-1.46 CD N
; : N
P NNP N
= NNP N
0.58 CD N
) ) N
, , N
and CC N
the DT N
presence NN o
of IN o
node JJ o
metastases NNS o
( ( N
HR NNP N
1.36 CD N
; : N
95 CD N
% NN N
CI NNP N
1.17-1.58 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

At IN N
15 CD N
and CC N
30-day JJ N
follow-ups NNS N
, , N
control NN N
group NN N
and CC N
nonsteroid JJ N
leads VBZ N
show VB N
a DT N
higher JJR N
threshold JJ o
value NN o
growth NN o
( ( N
in IN N
unipolar NN N
from IN N
0.16 CD N
+/- JJ N
0.11 CD N
to TO N
1.19 CD N
+/- JJ N
0.85 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.18 CD N
+/- JJ N
0.13 CD N
to TO N
1.24 CD N
+/- JJ N
0.88 CD N
microJ NN N
) ) N
than IN N
the DT N
membrane NN N
steroid NN N
leads VBZ N
( ( N
in IN N
unipolar NN N
from IN N
0.13 CD N
+/- JJ N
0.11 CD N
to TO N
0.70 CD N
+/- JJ N
0.39 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.23 CD N
+/- JJ N
0.32 CD N
to TO N
0.76 CD N
+/- JJ N
0.36 CD N
microJ NN N
) ) N
; : N
the DT N
threshold NN N
of IN N
nonsteroid JJ N
leads NNS N
decreases NNS N
after IN N
1-3 JJ N
months NNS N
and CC N
it PRP N
settles VBZ N
at IN N
the DT N
same JJ N
threshold JJ N
level NN N
of IN N
the DT N
leads NNS N
with IN N
membrane NN N
and CC N
steroid NN N
( ( N
in IN N
unipolar JJ N
0.60 CD N
+/- JJ N
0.33 CD N
microJ NN N
; : N
in IN N
bipolar JJ N
0.55 CD N
+/- JJ N
0.26 CD N
microJ NN N
) ) N
, , N
which WDT N
has VBZ N
been VBN N
stable JJ N
since IN N
the DT N
first JJ N
month NN N
. . N

During IN N
a DT N
mean JJ N
follow-up JJ N
period NN N
of IN N
1.8 CD N
years NNS N
, , N
adverse JJ o
events NNS o
in IN N
the DT N
two CD N
groups NNS N
included VBD N
death NN o
( ( N
4.3 CD N
percent NN N
in IN N
the DT N
aspirin NN i
group NN N
vs. FW N
9.7 CD N
percent NN N
in IN N
the DT N
warfarin NN i
group NN N
; : N
hazard CC N
ratio NN N
for IN N
aspirin JJ N
relative JJ N
to TO N
warfarin VB N
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.23 CD N
to TO N
0.90 CD N
; : N
P=0.02 NNP N
) ) N
, , N
major JJ o
hemorrhage NN o
( ( N
3.2 CD N
percent NN N
vs. FW N
8.3 CD N
percent NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.18 CD N
to TO N
0.84 CD N
; : N
P=0.01 NNP N
) ) N
, , N
and CC N
myocardial JJ o
infarction NN o
or CC o
sudden JJ o
death NN o
( ( N
2.9 CD N
percent NN N
vs. FW N
7.3 CD N
percent NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
, , N
0.40 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.18 CD N
to TO N
0.91 CD N
; : N
P=0.02 NNP N
) ) N
. . N

With IN N
atorvastatin NN i
, , N
the DT N
distensibility NN o
coefficient NN o
( ( o
DC NNP o
) ) o
and CC o
compliance NN o
coefficient NN o
( ( o
CC NNP o
) ) o
increased VBD N
from IN N
18.7 CD N
+/- JJ N
3.4 CD N
to TO N
21.3 CD N
+/- JJ N
2.9 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.69 CD N
+/- JJ N
0.05 CD N
to TO N
0.77 CD N
+/- JJ N
0.03 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
while IN N
they PRP N
changed VBD N
from IN N
18.3 CD N
+/- JJ N
3.6 CD N
to TO N
21.9 CD N
+/- JJ N
3.0 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.70 CD N
+/- JJ N
0.04 CD N
to TO N
0.81 CD N
+/- JJ N
0.01 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
respectively RB N
, , N
in IN N
the DT N
second JJ N
group NN N
. . N

RESULTS NNP N
Significant NNP o
time NN o
? . o
treatment NN o
interaction NN o
was VBD o
observed VBN o
for IN o
Irritability NNP o
( ( N
F NNP N
( ( N
1.658 CD N
, , N
63.021 CD N
) ) N
= NN N
13.580 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
Lethargy/Social NNP o
Withdrawal NNP o
( ( N
F NNP N
( ( N
1.948 CD N
, , N
74.032 CD N
) ) N
= NN N
16.811 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
Stereotypic NNP o
Behavior NNP o
( ( N
F NNP N
( ( N
1.742 CD N
, , N
66.198 CD N
) ) N
= NN N
12.104 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
for IN N
Hyperactivity/Noncompliance NNP i
( ( N
F NNP N
( ( N
2.564 CD N
, , N
97.424 CD N
) ) N
= NN N
1.469 CD N
, , N
P NNP N
= NNP N
0.232 CD N
) ) N
, , N
and CC N
Inappropriate NNP o
Speech NNP o
subscales NNS o
( ( N
F NNP N
( ( N
1.607 CD N
, , N
61.075 CD N
) ) N
= NN N
0.173 CD N
, , N
P NNP N
= NNP N
0.794 CD N
) ) N
. . N

PFS NNP o
was VBD N
significantly RB N
prolonged VBN N
with IN N
pazopanib NNS i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
median JJ N
, , N
PFS NNP N
9.2 CD N
v NN N
4.2 CD N
months NNS N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
the DT N
treatment-naive JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
11.1 CD N
v NN N
2.8 CD N
months NNS N
; : N
HR NNP N
, , N
0.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.60 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
and CC N
the DT N
cytokine-pretreated JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
, , N
7.4 CD N
v NN N
4.2 CD N
months NNS N
; : N
HR NNP N
, , N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.35 CD N
to TO N
0.84 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

RESULTS NNP N
After IN N
40 CD N
sessions NNS N
, , N
mean JJ o
physician JJ o
CGI NNP o
scores VBZ o
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
controls NNS N
in IN N
overall JJ N
functioning NN N
( ( N
p JJ N
= NNP N
0.0008 CD N
) ) N
, , N
receptive JJ o
language NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
social JJ o
interaction NN o
( ( N
p JJ N
= NNP N
0.0473 CD N
) ) N
, , N
and CC N
eye NN o
contact NN o
( ( N
p JJ N
= NNP N
0.0102 CD N
) ) N
; : N
9/30 CD N
children NNS N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
rated VBN N
as IN N
very RB N
much JJ N
improved VBN N
or CC N
much RB N
improved VBN N
compared VBN N
to TO N
2/26 CD N
( ( N
8 CD N
% NN N
) ) N
of IN N
controls NNS N
( ( N
p VB N
= RB N
0.0471 CD N
) ) N
; : N
24/30 CD N
( ( N
80 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
improved VBD N
compared VBN N
to TO N
10/26 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
controls NNS N
( ( N
p VB N
= RB N
0.0024 CD N
) ) N
. . N

Variables NNS N
associated VBN N
with IN N
non-adherence NN N
were VBD N
diagnosis VBN N
by IN N
screening VBG N
( ( N
OR CC N
1.88 CD N
, , N
95 CD N
% NN N
CI NNP N
1.26-2.82 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
illegal JJ o
immigration NN o
status NN o
( ( N
OR CC N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-2.15 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
unemployment NN o
( ( N
OR CC N
1.91 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28-2.85 CD N
, , N
P NNP N
= NNP N
0.0008 CD N
) ) N
, , N
illiteracy NN o
( ( N
OR CC N
1.73 CD N
, , N
95 CD N
% NN N
CI NNP N
1.04-2.88 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
lack NN o
of IN o
family NN o
support NN o
( ( N
OR NNP N
3.7 CD N
, , N
95 CD N
% NN N
CI NNP N
2.54-5.4 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
the DT N
6-month JJ N
treatment NN N
regimen NNS N
( ( N
OR NNP N
2.45 CD N
, , N
95 CD N
% NN N
CI NNP N
1.68-3.57 CD N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP o
improved VBD o
total JJ o
respiratory NN o
disturbance NN o
index NN o
( ( N
RDI NNP N
) ) N
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS N
per IN N
hour NN N
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ o
RDI NNP o
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ o
index NN o
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG o
intensity NN o
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ o
snore NN o
frequency NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
cumulative JJ N
dose NN N
of IN N
morphine NN i
administered VBN N
at IN N
each DT N
time NN N
point NN N
was VBD N
lower JJR N
in IN N
Group NNP N
P NNP N
than IN N
in IN N
Group NNP N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
at IN N
2 CD N
h NN N
( ( N
3.81 CD N
? . N
0.35 CD N
versus NN N
4.13 CD N
? . N
0.45 CD N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
16.20 CD N
? . N
1.49 CD N
versus NN N
19.60 CD N
? . N
0.35 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
26.29 CD N
? . N
2.75 CD N
versus NN N
32.49 CD N
? . N
2.42 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
41.72 CD N
? . N
2.70 CD N
versus NN N
49.97 CD N
? . N
4.53 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
60.06 CD N
? . N
4.00 CD N
versus NN N
65.68 CD N
? . N
3.23 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
estimates NNS N
( ( N
with IN N
relative JJ N
standard JJ N
errors NNS N
expressed VBD N
in IN N
percentages NNS N
in IN N
parentheses NNS N
) ) N
of IN N
the DT N
apparent JJ N
zero-order NN o
rate NN o
constant NN o
for IN o
flare NN o
or CC o
wheal NN o
spontaneous JJ o
appearance NN o
( ( N
k NN N
( ( N
in IN N
) ) N
) ) N
, , N
the DT N
first-order JJ o
rate NN o
constant NN o
for IN o
flare NN o
or CC o
wheal JJ o
disappearance NN o
( ( o
k NN o
( ( o
out IN o
) ) o
) ) o
and CC o
bilastine JJ o
IC NNP o
( ( o
50 CD o
) ) o
values NNS o
were VBD N
0.44 CD N
ng/mL/h NNS N
( ( N
14.60 CD N
% NN N
) ) N
, , N
1.09 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
15.14 CD N
% NN N
) ) N
and CC N
5.15 CD N
ng/mL NN N
( ( N
16.16 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
wheal JJ N
inhibition NN N
, , N
and CC N
11.10 CD N
ng/mL/h NN N
( ( N
8.48 CD N
% NN N
) ) N
, , N
1.03 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
8.35 CD N
% NN N
) ) N
and CC N
1.25 CD N
ng/mL NN N
( ( N
14.56 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
flare JJ N
inhibition NN N
. . N

RESULTS NN N
At IN N
the DT N
follow-up JJ N
assessment NN N
, , N
the DT N
mean NN o
score NN o
for IN o
the DT o
knowledge NN o
of IN o
helminths NNS o
, , o
calculated VBD o
as IN o
a DT o
percentage NN o
of IN o
a DT o
total NN o
of IN o
43 CD o
points NNS o
on IN o
a DT o
questionnaire NN o
, , N
was VBD N
90 CD N
% NN N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
63.3 CD N
vs. FW N
33.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
percentage NN o
of IN o
children NNS o
who WP o
washed VBD o
their PRP$ o
hands NNS o
after IN o
using VBG o
the DT o
toilet NN o
was VBD N
nearly RB N
twice RB N
as RB N
high JJ N
in IN N
the DT N
intervention NN N
group NN N
( ( N
98.9 CD N
% NN N
, , N
vs. FW N
54.2 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
incidence NN o
of IN o
infection NN o
with IN N
soil-transmitted JJ N
helminths NNS N
was VBD N
50 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
4.1 CD N
% NN N
vs. FW N
8.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

At IN N
study NN N
exit NN N
, , N
57.0 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
Papanicolaou NNP o
test NN o
in IN N
the DT N
past JJ N
24 CD N
months NNS N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
, , N
61.7 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
42.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
mammogram NN o
in IN o
the DT o
past JJ o
12 CD o
months NNS o
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
54.4 CD N
% NN N
of IN N
men NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.0 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
prostate-specific JJ o
antigen NN o
test NN o
in IN N
the DT N
past JJ N
12 CD N
months NNS N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
, , N
and CC N
43.0 CD N
% NN N
of IN N
both DT N
sexes NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
27.2 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
flexible JJ o
sigmoidoscopy NN o
or CC o
colonoscopy NN o
in IN o
the DT o
past JJ o
5 CD o
years NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

RESULTS NN N
At IN N
10 CD N
minutes NNS N
after IN N
CPR NNP N
, , N
in IN N
the DT N
low JJ o
VT NNP o
ventilation NN o
group NN o
, , o
arterial JJ o
blood NN o
pH NN o
, , o
arterial JJ o
partial JJ o
pressure NN o
of IN o
oxygen NN o
( ( o
PaO2 NNP o
) ) o
, , o
arterial JJ o
partial JJ o
pressure NN o
of IN o
carbon NN o
dioxide NN o
( ( o
PaCO2 NNP o
) ) o
, , o
HCO3 NNP o
( ( o
- : o
) ) o
, , o
arterial JJ o
oxygen NN o
saturation NN o
( ( o
SaO2 NNP o
) ) o
and CC o
blood NN o
lactic JJ o
acid NN o
were VBD N
better RB N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
conventional JJ N
VT NNP N
ventilation NN N
group NN N
( ( N
pH NN N
: : N
7.21 CD N
vs NN N
7.13 CD N
, , N
PaO2 NNP N
: : N
45.35 CD N
mm NN N
Hg NNP N
vs VBZ N
40.70 CD N
mm NN N
Hg NNP N
, , N
PaCO2 NNP N
: : N
57.10 CD N
mm NN N
Hg NNP N
vs VBZ N
61.60 CD N
mm NN N
Hg NNP N
, , N
HCO3 NNP N
( ( N
- : N
) ) N
: : N
18.50 CD N
mmol/L NN N
vs. FW N
14.75 CD N
mmol/L NN N
, , N
SaO2 NNP N
: : N
0.796 CD N
vs NN N
0.699 CD N
, , N
blood NN N
lactic JJ N
acid NN N
: : N
7.07 CD N
mmol/L NN N
vs. FW N
8.13 CD N
mmol/L NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
cotinine NN N
( ( N
serum NN N
, , N
8.9 CD N
+/- JJ N
3.2 CD N
vs. FW N
35.5 CD N
+/- JJ N
10.2 CD N
ng JJ N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-4 NNP N
( ( N
41.3 CD N
+/- JJ N
5.8 CD N
vs. FW N
44.2 CD N
+/- JJ N
4.5 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-5 NNP N
( ( N
36.1 CD N
+/- JJ N
3.2 CD N
vs. FW N
60.1 CD N
+/- JJ N
7.0 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-6 NNP o
( ( N
2.5 CD N
+/- JJ N
0.3 CD N
vs. FW N
7.6 CD N
+/- JJ N
1.4 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
IFN-gamma NNP N
( ( N
0.3 CD N
+/- JJ N
0.2 CD N
vs. FW N
0.6 CD N
+/- JJ N
0.2 CD N
IU NNP N
x NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
at IN N
3 CD N
hours NNS N
were VBD N
higher JJR N
than IN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
the DT N
systolic/diastolic JJ N
differences NNS N
between IN N
ambulatory NN N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
and CC N
home NN N
( ( N
n JJ N
= NNP N
52 CD N
) ) N
BP NNP N
groups NNS N
in IN N
home NN N
, , N
daytime JJ o
ambulatory NN o
, , o
night-time JJ o
ambulatory NN o
, , o
and CC o
24-h JJ o
ambulatory NN o
BP NNP o
changes NNS o
averaged VBD N
2.6/2.6 CD N
mm NN N
Hg NNP N
, , N
0.6/1.7 CD N
mm NN N
Hg NNP N
, , N
1.0/1.4 CD N
mm NN N
Hg NNP N
, , N
and CC N
0.6/1.5 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
( ( N
P NNP N
range VBP N
.06 NNP N
to TO N
.75 VB N
) ) N
A DT N
nonsignificant JJ N
trend NN N
to TO N
more RBR N
intensive JJ N
drug NN N
therapy NN N
in IN N
the DT N
ambulatory JJ N
BP NNP N
group NN N
and CC N
a DT N
nonsignificant JJ N
trend NN N
to TO N
larger JJR N
share NN N
of IN N
patients NNS N
reaching VBG N
( ( N
57.7 CD N
% NN N
v JJ N
43.5 CD N
% NN N
, , N
P NNP N
= NNP N
.16 NNP N
) ) N
the DT N
target NN o
pressure NN o
in IN N
the DT N
home NN N
BP NNP N
group NN N
was VBD N
observed VBN N
due JJ N
to TO N
the DT N
3.8 CD N
mm NN N
Hg NNP N
difference NN N
in IN N
ambulatory NN N
and CC N
home NN N
diastolic NN N
BP NNP N
at IN N
randomization NN N
. . N

RESULTS VB N
The DT N
following JJ N
GCV NNP N
concentrations NNS N
( ( N
mean JJ N
+/-SD NN N
) ) N
were VBD N
determined VBN N
: : N
with IN N
CrCl NNP i
of IN N
> NNP N
or CC N
=70 NNP N
ml/min NN N
, , N
the DT N
minimum JJ o
steady-state JJ o
concentration NN o
( ( o
Cmin NNP o
) ) o
and CC o
maximum JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
were VBD N
0.78+/-0.46 JJ N
microg/ml NN N
and CC N
1.42+/-0.37 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
a DT N
24-hr JJ N
area NN N
under IN N
the DT N
concentration NN o
time NN o
curve NN o
( ( N
AUC0-24 NNP N
) ) N
of IN N
24.7+/-7.8 JJ N
microg NN N
x NNP N
hr/ml NN N
; : N
with IN N
CrCl NNP N
of IN N
50-69 JJ N
ml/min NN N
, , N
the DT N
Cmin NNP o
and CC o
Cmax NNP o
were VBD N
1.93+/-0.48 JJ N
and CC N
2.57+/-0.39 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
52.1+/-10.1 JJ N
microg NN N
x NNP N
hr/ml NN N
; : N
with IN N
CrCl NNP N
of IN N
25-50 JJ N
ml/min NN N
, , N
the DT N
Cmin NNP o
and CC o
Cmax NNP o
were VBD N
0.41+/-0.27 JJ N
and CC N
1.17+/-0.32 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
14.6+/-7.4 JJ N
microg NN N
x NNP N
hr/ml NN N
. . N

Of IN N
the DT N
patients NNS N
with IN N
previous JJ N
CABG NNP N
, , N
those DT N
who WP N
had VBD N
undergone NN N
? . N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
had VBD N
significantly RB N
higher JJR N
adjusted JJ o
risks NNS o
of IN o
cardiac JJ o
death NN o
( ( N
hazard JJ N
ratio NN N
2.21 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.26 CD N
to TO N
3.76 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
myocardial JJ o
infarction NN o
( ( N
hazard JJ N
ratio NN N
2.56 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.10 CD N
to TO N
5.60 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
target NN o
lesion NN o
revascularization NN o
( ( N
hazard JJ N
ratio NN N
2.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.82 CD N
to TO N
3.81 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
definite JJ o
stent NN o
thrombosis NN o
( ( N
hazard JJ N
ratio NN N
7.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.99 CD N
to TO N
29.1 CD N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
compared VBN N
with IN N
those DT N
who WP N
underwent VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
only RB N
for IN N
the DT N
native JJ N
coronary JJ N
artery NN N
. . N

The DT N
WL+FAEE NNP i
intervention NN i
significantly RB N
reduced VBN N
body NN o
weight NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
waist JJ o
circumference NN o
( ( o
-4 CD o
% NN o
) ) o
, , o
systolic JJ o
( ( o
-8 CD o
% NN o
) ) o
and CC o
diastolic JJ o
( ( o
-5 CD o
% NN o
) ) o
blood NN o
pressures NNS o
, , o
pulse JJ o
pressure NN o
( ( o
-5 CD o
% NN o
) ) o
, , o
heart NN o
rate NN o
( ( N
-8 CD N
% NN N
) ) N
, , N
plasma JJ o
TG NNP o
concentration NN o
( ( N
-36 CD N
% NN N
) ) N
, , N
and CC N
HOMA NNP o
score NN o
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased JJ N
stroke NN o
volume NN o
( ( N
+3 CD N
% NN N
) ) N
, , N
plasma JJ o
HDL NNP o
cholesterol NN o
( ( N
+6 CD N
% NN N
) ) N
and CC N
adiponectin JJ o
concentrations NNS o
( ( N
+28 CD N
% NN N
) ) N
, , N
and CC N
C1 NNP o
( ( N
+20 NNP N
% NN N
) ) N
and CC N
C2 NNP o
( ( o
+22 NNP o
% NN o
) ) o
artery NN o
elasticity NN o
. . o

RESULTS NNP N
Capecitabine/docetaxel NNP i
resulted VBD N
in IN N
significantly RB N
superior JJ N
efficacy NN o
in IN o
time NN o
to TO o
disease VB o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
hazard JJ N
ratio NN N
, , N
0.652 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.545 CD N
to TO N
0.780 CD N
; : N
P NNP N
=.0001 NNP N
; : N
median JJ N
, , N
6.1 CD N
v NN N
4.2 CD N
months NNS N
) ) N
, , N
overall JJ o
survival NN o
( ( o
hazard JJ o
ratio NN o
, , N
0.775 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.634 CD N
to TO N
0.947 CD N
; : N
P NNP N
=.0126 NNP N
; : N
median JJ N
, , N
14.5 CD N
v NN N
11.5 CD N
months NNS N
) ) N
, , N
and CC N
objective JJ o
tumor NN o
response NN o
rate NN o
( ( N
42 CD N
% NN N
v JJ N
30 CD N
% NN N
, , N
P NNP N
=.006 NNP N
) ) N
compared VBN N
with IN N
docetaxel NN i
. . i

Ischemic NNP N
postconditioned VBD N
patients NNS N
had VBD N
a DT N
lower JJR N
peak NN o
inotropic NN o
score NN o
during IN N
the DT N
first JJ N
postoperative JJ N
24 CD N
hours NNS N
( ( N
5.6 CD N
? . N
2.2 CD N
? . N
versus NN N
8.6 CD N
? . N
3.6 CD N
? . N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
extubation JJ o
time NN o
( ( N
21.5 CD N
? . N
7.3 CD N
hours NNS N
versus IN N
30.2 CD N
? . N
12.4 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
and CC N
length NN o
of IN o
ICU NNP o
stay NN o
( ( N
43.4 CD N
? . N
12.6 CD N
hours NNS N
versus IN N
56.3 CD N
? . N
17.8 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
while IN N
they PRP N
had VBD N
a DT N
higher JJR N
cardiac JJ o
output NN o
on IN N
the DT N
first JJ N
postoperative JJ N
day NN N
( ( N
1.41 CD N
? . N
0.26 CD N
L/minute NNP N
versus NN N
1.28 CD N
? . N
0.25 CD N
L/minute NNP N
, , N
P NNP N
= NNP N
0.0255 CD N
) ) N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Compared VBN N
with IN N
Group NNP N
C NNP N
, , N
Group NNP N
P NNP N
had VBD N
significantly RB N
lower JJR N
visual JJ o
analog NN o
scale NN o
scores NNS o
at IN N
rest NN N
and CC N
with IN N
movement NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
h NN N
( ( N
4.2 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
5.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
3.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
4.5 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
3.0 CD N
, , N
P NNP N
= NNP N
0.017 CD N
and CC N
4.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
2.1 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
3.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
1.8 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
2.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

RESULTS NN N
After IN N
the DT N
intervention NN N
period NN N
, , N
the DT N
diabetes NNS N
specific JJ N
formula NN N
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
postprandial JJ o
rise NN o
in IN o
blood NN o
glucose JJ o
concentrations NNS o
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
significantly RB N
lower JJR N
peak JJ o
height NN o
of IN o
plasma NN o
glucose NN o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
significantly RB N
lower JJR N
plasma NN o
insulin NN o
concentrations NNS o
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
and CC N
a DT N
significantly RB N
lower JJR N
plasma NN o
insulin NN o
peak NN o
compared VBN N
to TO N
controls NNS N
; : N
both DT N
OGTT NNP i
and CC N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
the DT N
mean NN o
of IN o
systolic NN o
( ( N
-2.1 NNP N
vs. FW N
3.9 CD N
% NN N
mmHg NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
diastolic JJ o
( ( N
-3.8 NNP N
vs. FW N
7.5 CD N
% NN N
mmHg NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
blood NN o
pressures NNS o
, , o
HOMA-IR NNP o
index NN o
( ( N
-46.5 NNP N
vs. FW N
-5.4 NNP N
% NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
, , N
fasting VBG o
glucose NN o
( ( N
-12.3 JJ N
vs. FW N
-1.8 CD N
% NN N
mg/dL NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
triglyceride JJ o
levels NNS o
( ( N
-47.4 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
mg/dL NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
subjects NNS N
who WP N
received VBD N
MgCl2 NNP N
compared VBN N
with IN N
individuals NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Less RBR o
severe JJ o
baseline NN o
autism NN o
symptomatology NN o
( ( N
lower JJR N
Autism NNP N
Diagnosis NNP N
Observation NNP N
Schedule NNP N
[ NNP N
ADOS NNP N
] NNP N
score NN N
; : N
C. NNP N
Lord NNP N
et VBZ N
al RB N
, , N
2000 CD N
) ) N
was VBD N
associated VBN N
with IN N
greater JJR N
increase NN N
in IN N
spontaneous JJ o
speech NN o
( ( N
RR NNP N
= NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
0.98 CD N
] NN N
, , N
p NN N
= NNP N
.011 NNP N
) ) N
and CC N
less RBR N
severe JJ o
baseline NN o
expressive JJ o
language NN o
impairment NN o
( ( o
lower JJR o
ADOS NNP o
item NN o
A1 NNP o
score NN o
) ) o
, , N
with IN N
larger JJR N
increases NNS N
in IN N
spontaneous JJ o
use NN o
of IN o
speech NN o
and CC o
pictures VBZ o
together RB o
( ( N
RR NNP N
= NNP N
0.62 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.44 CD N
, , N
0.88 CD N
] NN N
, , N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

Vital NNP o
force NN o
also RB N
showed VBD N
correlations NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
lower JJR N
CGI NNP o
ratings NNS o
by IN N
the DT N
conventional JJ N
medical JJ N
provider NN N
( ( N
r VB N
=-0.32 NN N
) ) N
, , N
better RB N
selfrated VBN o
quality NN o
of IN o
life NN o
( ( N
r JJ N
= NNP N
0.33 CD N
) ) N
, , N
lesser JJR N
fatigue NN o
( ( N
r VB N
=-0.31 NN N
) ) N
, , N
better JJR o
global JJ o
health NN o
( ( N
r VB N
= RB N
0.29 CD N
) ) N
, , N
greater JJR N
sense NN o
of IN o
coherence NN o
( ( N
r JJ N
= NNP N
0.28 CD N
) ) N
, , N
powerful-others JJ o
health NN o
locus NN o
of IN o
control NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
increased VBD o
emotional JJ o
well-being NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
higher JJR o
social JJ o
desirability NN o
( ( N
r JJ N
= NNP N
0.27 CD N
) ) N
, , N
but CC N
not RB N
with IN N
age NN N
, , N
pain NN N
, , N
or CC N
illness JJ N
duration NN N
. . N

These DT N
risk NN N
reductions NNS N
, , N
achieved VBN N
at IN N
a DT N
median JJ o
HbA NNP o
( ( o
1c CD o
) ) o
level NN o
difference NN o
of IN N
9.1 CD N
% NN N
for IN N
conventional JJ N
treatment NN N
vs RB N
7.3 CD N
% NN N
for IN N
intensive JJ N
treatment NN N
have VBP N
been VBN N
maintained VBN N
through IN N
7 CD N
years NNS N
of IN N
EDIC NNP N
, , N
even RB N
though IN N
the DT N
difference NN N
in IN N
mean JJ o
HbA NNP o
( ( o
1c CD o
) ) o
levels NNS o
of IN N
the DT N
2 CD N
former JJ N
randomized VBN N
treatment NN N
groups NNS N
was VBD N
only RB N
0.4 CD N
% NN N
at IN N
1 CD N
year NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
( ( N
8.3 CD N
% NN N
in IN N
the DT N
former JJ N
conventional JJ N
treatment NN N
group NN N
vs VBD N
7.9 CD N
% NN N
in IN N
the DT N
former JJ N
intensive JJ N
treatment NN N
group NN N
) ) N
, , N
continued VBD N
to TO N
narrow VB N
, , N
and CC N
became VBD N
statistically RB N
nonsignificant JJ N
by IN N
5 CD N
years NNS N
( ( N
8.1 CD N
% NN N
vs JJ N
8.2 CD N
% NN N
, , N
P NNP N
=.09 NNP N
) ) N
. . N

Efficacy NN o
parameters NNS o
were VBD N
assessed VBN N
as IN N
follows VBZ N
: : N
at IN N
baseline NN N
( ( N
T1 NNP N
) ) N
, , N
after IN N
the DT N
first JJ N
administration NN N
( ( N
T2 NNP N
; : N
day NN N
of IN N
surgery NN N
) ) N
, , N
the DT N
second JJ N
day NN N
after IN N
the DT N
surgical JJ N
procedure NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
the DT N
fifth JJ N
day NN N
after IN N
the DT N
surgical JJ N
procedure NN N
( ( N
T4 NNP N
) ) N
; : N
hemorrhoidal PRP$ N
symptoms NNS N
based VBN N
on IN N
a DT N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
: : o
pain NN o
, , o
discharge NN o
, , o
bleeding NN o
, , o
inflammation NN o
, , o
and CC o
pruritus NN o
; : o
analgesic JJ o
intake NN o
, , o
if IN o
any DT o
; : o
time NN o
to TO o
restore VB o
a DT o
physiological JJ o
defecation NN o
; : o
edema CC o
evaluation NN o
( ( N
based VBN N
on IN N
a DT N
four-point JJ N
scale NN N
: : N
0 CD N
= JJ N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
3 CD N
= NNP N
severe RB N
) ) N
; : N
camera NN N
pictures VBZ N
taken VBN N
at IN N
T1 NNP N
and CC N
T4 NNP N
( ( N
in IN N
selected VBN N
patients NNS N
) ) N
; : N
and CC N
blood NN o
coagulation NN o
tests NNS o
. . o

Although IN N
both DT N
LOOH NNP o
and CC o
NO2- NNP o
increased VBD N
with IN N
high JJ N
altitude NN N
in IN N
lowlanders NNS N
, , N
only RB N
LOOH NNP N
correlated VBD N
with IN N
the DT N
reduction NN N
in IN N
GTN-induced NNP o
dilatation NN o
evident NN N
during IN N
acute NN N
( ( N
n JJ N
= NN N
11 CD N
, , N
r NN N
= NNP N
-0.53 NNP N
) ) N
and CC N
chronic JJ N
( ( N
n JJ N
= NN N
7 CD N
, , N
r NN N
= NNP N
-0.69 NNP N
; : N
P NNP N
? . N
0.01 CD N
) ) N
exposure NN N
to TO N
5050 CD N
m. NN N
In IN N
a DT N
follow-up JJ N
, , N
placebo-controlled JJ i
experiment NN N
( ( N
n JJ N
= $ N
11 CD N
healthy JJ N
lowlanders NNS N
) ) N
conducted VBN N
in IN N
a DT N
normobaric JJ i
hypoxic NN i
chamber NN i
( ( N
inspired JJ N
O2 NNP N
fraction NN N
( ( N
F NNP N
IO NNP N
2 CD N
) ) N
= NN N
0.11 CD N
; : N
6 CD N
h NN N
) ) N
, , N
a DT N
sustained JJ N
reduction NN N
in IN N
FMD NNP o
was VBD N
evident JJ N
within IN N
1 CD N
h NN N
of IN N
hypoxic NN N
exposure NN N
when WRB N
compared VBN N
to TO N
normoxic VB N
baseline NN N
( ( N
5.7 CD N
? . N
1.6 CD N
vs NN N
8.0 CD N
? . N
% NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
this DT N
decline NN N
in IN N
FMD NNP N
was VBD N
largely RB N
reversed VBN N
following VBG N
? . N
blockade NN N
. . N

RESULTS JJ N
Patients NNS N
with IN N
short-term JJ N
GHQ NNP N
success NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
mid-term JJ o
GHQ NNP o
success NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
marginally RB N
less RBR N
likely JJ N
to TO N
die VB N
of IN N
any DT N
causes NNS N
( ( N
p JJ N
= NNP N
.087 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
die VB o
of IN o
cardiac JJ o
causes NNS o
( ( N
p JJ N
= NNP N
.043 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
be VB N
readmitted VBN o
for IN N
any DT N
reason NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
for IN N
cardiac JJ o
reasons NNS o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
high JJ o
depression NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
anxiety NN o
( ( N
p JJ N
< NNP N
.001 NN N
) ) N
at IN N
1-year JJ N
than IN N
patients NNS N
with IN N
short-term JJ N
unsuccessful JJ N
GHQ NNP N
outcomes NNS N
. . N

However RB N
, , N
in IN N
preplanned JJ N
analyses NNS N
, , N
overall JJ o
survival NN o
was VBD N
significantly RB N
longer JJR N
for IN N
patients NNS N
with IN N
del19-positive JJ N
tumours NNS N
in IN N
the DT N
afatinib NN N
group NN N
than IN N
in IN N
the DT N
chemotherapy NN N
group NN N
in IN N
both DT N
trials NNS N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ o
overall JJ o
survival NN o
was VBD N
33.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
26.8-41.5 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
21.1 CD N
months NNS N
( ( N
16.3-30.7 JJ N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-0.79 CD N
, , N
p=0.0015 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
31.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.2-35.3 CD N
) ) N
versus NN N
18.4 CD N
months NNS N
( ( N
14.6-25.6 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
0.64 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.94 CD N
, , N
p=0.023 NN N
) ) N
. . N

RESULTS NN N
At IN N
24 CD N
months NNS N
, , N
complete JJ o
success NN o
rates NNS o
were VBD N
53.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
group NN N
and CC N
40 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.35 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
; : N
qualified VBN o
success NN o
rates NNS o
were VBD N
33.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
and CC N
26.6 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.5 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
.Mean VBP o
IOP NNP o
decreased VBD N
from IN N
25.0+/-1.9 JJ N
to TO N
17.6+/-2.2 JJ N
mmHg NN N
( ( N
-29.6 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
ELT NNP N
group NN N
and CC N
from IN N
23.9+/-0.9 JJ N
to TO N
19.1+/-1.8 JJ N
mmHg NN N
( ( N
-21 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
SLT NNP N
group NN N
. . N

Although IN N
results NNS N
through IN N
the DT N
entire JJ N
blinded VBD N
period NN N
continued VBD N
to TO N
show VB N
that IN N
selenium JJ i
supplementation NN i
was VBD N
not RB N
statistically RB N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN o
of IN o
basal NN o
cell NN o
carcinoma NN o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.09 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= VBD N
0.94 CD N
to TO N
1.26 CD N
) ) N
, , N
selenium JJ i
supplementation NN i
was VBD N
associated VBN N
with IN N
statistically RB N
significantly RB N
elevated VBN N
risk NN o
of IN o
squamous JJ o
cell NN o
carcinoma NN o
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
= VBZ N
1.03 CD N
to TO N
1.51 CD N
) ) N
and CC N
of IN N
total JJ o
nonmelanoma JJ o
skin NN o
cancer NN o
( ( N
HR NNP N
= NNP N
1.17 CD N
, , N
95 CD N
% NN N
CI NNP N
= VBZ N
1.02 CD N
to TO N
1.34 CD N
) ) N
. . N

RESULTS VB N
A NNP N
series NN N
of IN N
linear JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
age NN o
, , o
gender NN o
, , o
stroke VBD o
type NN o
( ( o
ischemic JJ o
versus NN o
hemorrhagic NN o
) ) o
, , o
interval JJ o
poststroke NN o
, , o
level NN o
of IN o
motor NN o
impairment NN o
( ( o
Fugl-Meyer NNP o
score NN o
) ) o
, , o
and CC o
walking VBG o
speed NN o
found VBD o
BMI NNP o
to TO N
be VB N
positively RB N
associated VBN N
with IN N
step NN N
width NN N
( ( N
m NN N
) ) N
( ( N
? . N
= RB N
0.364 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
positively RB N
associated VBN N
with IN N
peak JJ o
hip NN o
abduction NN o
angle NN o
of IN o
the DT o
nonparetic JJ o
limb NN o
during IN N
stance NN N
( ( N
deg NN N
) ) N
( ( N
? . N
= RB N
0.177 CD N
, , N
P NNP N
= NNP N
.040 NNP N
) ) N
, , N
negatively RB N
associated VBN N
with IN N
ankle JJ N
dorsiflexion NN N
angle NN N
at IN N
initial JJ N
contact NN N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
deg NN N
) ) N
( ( N
? . N
= NN N
-0.222 NN N
, , N
P NNP N
= NNP N
.023 NNP N
) ) N
, , N
and CC N
negatively RB N
associated VBN N
with IN N
peak NN N
ankle JJ N
power NN N
at IN N
push-off NN N
( ( N
W/kg NNP N
) ) N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
W/kg NNP N
) ) N
( ( N
? . N
= NN N
-0.142 NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

RESULTS NNP N
Group NNP N
B NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
renal JJ o
function NN o
and CC o
urinary JJ o
output NN o
: : o
serum NN o
blood NN o
urea JJ o
nitrogen RB o
48.9 CD N
+/- JJ N
10.3 CD N
to TO N
32.1 CD N
+/- JJ N
14.4 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
serum JJ N
creatinine NN N
1.97 CD N
+/- JJ N
0.24 CD N
to TO N
1.49 CD N
+/- JJ N
0.39 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
creatinine JJ N
clearance NN N
35.6 CD N
+/- JJ N
11.6 CD N
to TO N
48.8 CD N
+/- JJ N
12.3 CD N
ml/min NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
and CC N
indexed JJ o
urinary JJ o
output NN o
0.56 CD N
+/- JJ N
0.16 CD N
to TO N
2.02 CD N
+/- JJ N
0.72 CD N
ml/kg/h NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Clinical JJ o
failure NN o
was VBD N
associated VBN N
with IN N
( ( N
i NN N
) ) N
placebo NN i
treatment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.28 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01 CD N
to1.62 NN N
) ) N
, , N
( ( N
ii NN N
) ) N
excess JJ N
respiratory JJ N
rate NN N
of IN N
> $ N
10 CD N
breaths NNS N
per IN N
minute NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.51 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.19 CD N
, , N
1.92 CD N
) ) N
, , N
( ( N
iii NN N
) ) N
vomiting VBG N
at IN N
enrolment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.49 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.13 CD N
, , N
1.96 CD N
) ) N
, , N
( ( N
iv NN N
) ) N
history NN N
of IN N
use NN N
of IN N
broncho-dilators NNS N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.71 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.30 CD N
, , N
2.24 CD N
) ) N
and CC N
( ( N
v NN N
) ) N
non-adherence NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
8.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
4.36 CD N
, , N
14.92 CD N
) ) N
. . N

RESULTS NNP N
Chromium NNP N
supplementation NN N
in IN N
women NNS N
with IN N
PCOS NNP N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN N
serum JJ o
insulin NN o
levels NNS o
( ( N
-3.6 VB N
? . N
7.4 CD N
vs NN N
+3.6 NN N
? . N
6.2 CD N
? . N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
, , N
homeostasis JJ o
model NN o
of IN o
assessment-insulin JJ o
resistance NN o
( ( o
HOMA-IR NNP o
; : o
-0.8 NNP N
? . N
1.6 CD N
vs NN N
+0.9 NN N
? . N
1.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
homeostatic JJ N
model NN N
assessment-beta NN N
cell NN N
function NN N
( ( N
HOMA-B NNP N
; : N
-15.5 NNP N
? . N
32.3 CD N
vs NN N
+13.6 NN N
? . N
23.1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
quantitative JJ o
insulin NN o
sensitivity NN o
check NN o
index NN o
( ( o
QUICKI NNP o
) ) o
score NN o
( ( N
+0.02 VB N
? . N
0.03 CD N
vs NN N
-0.008 NN N
? . N
0.02 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
compared VBN N
with IN N
the DT N
placebo NN i
. . i

The DT N
significant JJ N
decrease NN N
in IN N
serum JJ o
total JJ o
and CC o
LDL-cholesterol JJ o
concentrations NNS o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
caused VBN N
by IN N
simvastatin NN i
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ o
N-acetyl-beta-glucosaminidase JJ o
activity NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
ascorbic JJ o
acid NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
plasminogen JJ o
activator NN o
inhibitor NN o
( ( o
PAI-1 NNP o
) ) o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
vonWillebrand FW o
factor NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
E-selectin NNP o
( ( o
P NNP o
< NNP o
0.01 CD o
) ) o
and CC o
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
concentrations NNS o
and CC o
with IN o
a DT o
decrease NN o
in IN o
plasma NN o
glutathione NN o
( ( o
P NNP o
< NNP o
0.01 CD o
) ) o
levels NNS o
. . o

Mean NNP o
( ( o
? . o
SEM NNP o
) ) o
number NN o
of IN o
F NNP o
& CC o
V NNP o
portions/day NN o
consumed VBN N
by IN N
the DT N
HF NNP N
and CC N
LF NNP N
groups NNS N
at IN N
baseline NN N
( ( N
3.8 CD N
? . N
0.3 CD N
and CC N
3.4 CD N
? . N
0.3 CD N
) ) N
, , N
6 CD N
weeks NNS N
( ( N
6.3 CD N
? . N
0.4 CD N
and CC N
5.8 CD N
? . N
0.3 CD N
) ) N
, , N
12 CD N
weeks NNS N
( ( N
7.0 CD N
? . N
0.3 CD N
and CC N
6.8 CD N
? . N
0.3 CD N
) ) N
and CC N
18 CD N
weeks NNS N
( ( N
7.6 CD N
? . N
0.4 CD N
and CC N
8.1 CD N
? . N
0.4 CD N
) ) N
, , N
respectively RB N
, , N
was VBD N
similar JJ N
at IN N
baseline NN N
yet RB N
higher JJR N
than IN N
the DT N
CT NNP N
group NN N
( ( N
3.9 CD N
? . N
0.3 CD N
, , N
4.3 CD N
? . N
0.3 CD N
, , N
4.6 CD N
? . N
0.4 CD N
, , N
4.5 CD N
? . N
0.3 CD N
) ) N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

In IN N
lowlanders NNS N
, , N
measurements NNS N
were VBD N
performed VBN N
at IN N
sea NN N
level NN N
( ( N
334 CD N
m NN N
) ) N
and CC N
between IN N
days NNS N
3-4 NNP N
( ( N
acute JJ N
high JJ N
altitude NN N
) ) N
and CC N
12-14 JJ N
( ( N
chronic JJ N
high JJ N
altitude NN N
) ) N
following VBG N
arrival NN N
to TO N
5050 CD N
m. NN N
Highlanders NNP N
were VBD N
assessed VBN N
once RB N
at IN N
5050 CD N
m. NN N
Compared NNP N
with IN N
sea NN N
level NN N
, , N
acute JJ N
high JJ N
altitude NN N
reduced VBD N
lowlanders NNS o
' POS o
FMD NNP o
( ( N
7.9 CD N
? . N
0.4 CD N
vs NN N
6.8 CD N
? . N
0.4 CD N
% NN N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
GTN-induced JJ o
dilatation NN o
( ( N
16.6 CD N
? . N
0.9 CD N
vs NN N
14.5 CD N
? . N
0.8 CD N
% NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
and CC N
raised VBD o
central JJ o
PWV NNP o
( ( N
6.0 CD N
? . N
0.2 CD N
vs NN N
6.6 CD N
? . N
0.3 CD N
m NN N
s NN N
( ( N
-1 NNP N
) ) N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
transportation NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
treatments NNS N
on IN N
BW NNP o
loss NN o
due JJ N
to TO N
transportation NN N
shrink VB N
( ( N
26.0 CD N
? . N
0.6 CD N
kg NN N
; : N
P NNP N
= NNP N
0.86 CD N
) ) N
, , N
BW NNP o
at IN N
d NN N
28 CD N
( ( N
339.0 CD N
? . N
4.1 CD N
kg NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
ADG NNP o
( ( N
1.28 CD N
? . N
0.03 CD N
kg/d NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
G NNP N
: : N
F NNP N
( ( N
0.164 CD N
? . N
0.004 CD N
; : N
P NNP N
= NNP N
0.83 CD N
) ) N
, , N
and CC N
concentrations NNS o
of IN o
plasma NN o
haptoglobin NN o
( ( N
0.08 CD N
? . N
0.02 CD N
mg/mL NN N
; : N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
serum NN N
TT3 NNP N
, , N
TT4 NNP N
, , N
FT3 NNP N
, , N
FT4 NNP N
and CC N
S-TSH NNP N
contents NNS N
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
TRAb NNP i
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
no DT N
significant JJ N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
decrease NN N
of IN N
TT3 NNP o
, , o
FT3 NNP o
, , o
TRAb NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
no DT N
significant JJ N
difference NN N
in IN N
decrease NN N
of IN N
TT4 NNP o
, , o
FT4 NNP o
and CC o
increase NN o
of IN o
S-TSH NNP o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Signal-to-noise JJ o
ratio NN o
( ( o
SNR NNP o
) ) o
and CC o
contrast-to-noise JJ o
ratio NN o
( ( o
CNR NNP o
) ) o
in IN o
the DT o
proximal JJ o
right JJ o
coronary NN o
artery NN o
( ( o
RCA NNP o
) ) o
and CC o
left VBD o
main JJ o
coronary JJ o
artery NN o
( ( o
LMA NNP o
) ) o
were VBD N
all DT N
lower JJR N
in IN N
80-kV CD N
than IN N
120-kV JJ N
images NNS N
( ( N
SNR NNP N
in IN N
the DT N
proximal JJ N
RCA NNP N
: : N
16.5 CD N
? . N
1.8 CD N
vs NN N
19.4 CD N
? . N
2.8 CD N
; : N
SNR NNP N
in IN N
the DT N
LMA NNP N
: : N
16.3 CD N
? . N
2.0 CD N
vs.19.6 NN N
? . N
2.7 CD N
; : N
CNR NNP N
in IN N
the DT N
proximal JJ N
RCA NNP N
: : N
19.4 CD N
? . N
2.3 CD N
vs.22.9 NN N
? . N
3.0 CD N
; : N
CNR NNP N
in IN N
the DT N
LMA NNP N
: : N
18.8 CD N
? . N
2.4 CD N
vs NN N
22.7 CD N
? . N
2.9 CD N
; : N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

In IN N
the DT N
cangrelor NN N
group NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
, , N
two CD N
prespecified VBD N
secondary JJ N
end NN N
points NNS N
were VBD N
significantly RB N
reduced VBN N
at IN N
48 CD N
hours NNS N
: : N
the DT N
rate NN o
of IN o
stent JJ o
thrombosis NN o
, , N
from IN N
0.6 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.31 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.11 CD N
to TO N
0.85 CD N
; : N
P=0.02 NNP N
) ) N
, , N
and CC N
the DT N
rate NN o
of IN o
death NN o
from IN N
any DT N
cause NN N
, , N
from IN N
0.7 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.13 CD N
to TO N
0.83 CD N
; : N
P=0.02 NNP N
) ) N
. . N

All DT N
improvements NNS N
were VBD N
equal JJ N
between IN N
groups NNS N
apart RB N
from IN N
the DT N
SF36 NNP N
domain NN N
of IN N
Bodily NNP o
Pain NNP o
, , o
where WRB o
C2 NNP o
saw VBD N
an DT N
improvement NN N
of IN N
12.8 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
4.8-20.8 JJ N
] NN N
points NNS N
over IN N
C3-4 JJ N
participants NNS N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
who WP N
also RB N
suffered VBD N
more JJR N
recurrence NN o
[ NNP o
odds NNS o
ratio NN o
( ( N
OR NNP N
) ) N
= VBZ N
2.7 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.2-6.1 JJ N
, , N
P NNP N
= VBZ N
0.022 CD N
] NN N
and CC N
required VBD N
more JJR N
secondary JJ N
procedures NNS N
( ( N
OR NNP N
= VBZ N
4.4 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.2-16.3 JJ N
, , N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Naftopidil NNP i
significantly RB N
improved VBD N
the DT N
overall JJ o
international JJ o
prostatic JJ o
symptom NN o
score NN o
; : o
from IN N
19.2 CD N
to TO N
11.7 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
19.4 CD N
to TO N
12.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
QOL NNP o
score NN o
from IN N
4.9 CD N
to TO N
3.2 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
5.0 CD N
to TO N
3.6 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
OAB NNP o
symptom VBD o
score NN o
from IN N
7.8 CD N
to TO N
5.0 CD N
in IN N
the DT N
M NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
from IN N
8.6 CD N
to TO N
5.8 CD N
3.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
use NN N
of IN N
chemotherapy NN i
after IN N
first JJ N
progression NN N
( ( N
HR NNP N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.86 CD N
; : N
p CC N
= VB N
0.008 CD N
) ) N
, , N
PS NNP N
= VBZ N
0 CD N
( ( N
HR NNP N
0.53 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.81 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
HR NNP N
0.63 CD N
; : N
95 CD N
% NN N
CI NNP N
0.41-0.98 CD N
; : N
p CC N
= VB N
0.038 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
a DT N
longer RBR N
TFPTD NNP N
; : N
treatment NN N
arm NN N
was VBD N
not RB N
significant JJ N
( ( N
HR NNP N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
0.60-1.31 CD N
; : N
p CC N
= VB N
0.54 CD N
) ) N
. . N

Statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
were VBD N
found VBN N
for IN N
cytomegalovirus NN o
( ( o
CMV NNP o
) ) o
infection NN o
( ( N
induction NN N
, , N
32.5 CD N
% NN N
vs. FW N
noninduction NN N
, , N
19.0 CD N
% NN N
, , N
P=0.009 NNP N
) ) N
, , N
leukopenia NN o
( ( N
37.3 CD N
% NN N
vs. FW N
9.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
fever RB o
( ( N
25.2 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
herpes VBZ o
simplex JJ o
( ( N
17.9 CD N
% NN N
vs. FW N
5.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
thrombocytopenia NN o
( ( N
11.3 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
, , N
P=0.007 NNP N
) ) N
. . N

Patients NNS N
of IN N
the DT N
sevelamer NN N
group NN N
with IN N
a DT N
high JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
increase NN N
in IN N
bone JJ o
resorption NN o
( ( N
eroded JJ N
surface NN N
, , N
ES/BS NNP N
= VBD N
9.0 CD N
+/- JJ N
5.9 CD N
vs. FW N
13.1 CD N
+/- JJ N
9.5 CD N
% NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
whereas JJ N
patients NNS N
of IN N
both DT N
groups NNS N
with IN N
low JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
improvement NN N
in IN N
bone NN o
formation NN o
rate NN o
( ( N
BFR/BS NNP N
= VBZ N
0.015 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.062 CD N
+/- JJ N
0.078 CD N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
calcium NN N
and CC N
0.017 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.071 CD N
+/- JJ N
0.084 CD N
microm NN N
( ( N
3 CD N
) ) N
/microm NN N
( ( N
2 CD N
) ) N
/day NN N
, , N
p NN N
= VBD N
0.010 CD N
for IN N
sevelamer NN N
) ) N
. . N

RESULTS NN N
After IN N
treatment NN N
, , N
the DT N
behavioral JJ i
plus CC i
nutrition JJ i
education NN i
intervention NN i
as IN N
compared VBN N
with IN N
the DT N
nutrition NN i
education NN i
intervention NN i
alone RB i
had VBD N
a DT N
statistically RB N
greater JJR N
average JJ o
increase NN o
on IN o
the DT o
primary JJ o
and CC o
secondary JJ o
outcomes NNS o
of IN o
caloric JJ o
intake NN o
( ( N
mean JJ N
, , N
872 CD N
vs NN N
489 CD N
cal/d NN N
, , N
respectively RB N
) ) N
, , N
percentage NN o
of IN o
the DT o
estimated VBN o
energy NN o
requirement NN o
( ( N
mean JJ N
, , N
148 CD N
% NN N
vs JJ N
127 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
weight JJ o
gain NN o
( ( N
mean JJ N
, , N
1.47 CD N
vs NN N
0.92 CD N
kg NN N
, , N
respectively RB N
) ) N
, , N
and CC N
body NN o
mass NN o
index NN o
z NN o
score NN o
( ( N
0.38 CD N
vs NN N
0.18 CD N
, , N
respectively RB N
) ) N
. . N

These DT N
markers NNS o
did VBD o
not RB o
change VB o
much RB o
at IN o
different JJ o
time NN o
points NNS o
within IN N
72 CD N
h. NN N
In IN N
stroke NN N
group NN N
, , N
P-selectin NNP o
concentration NN o
was VBD N
highly RB N
correlated VBN N
to TO N
PAI-1 NNP o
activity NN o
( ( N
r NN N
= VBZ N
0.8433 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
to TO N
tPA VB o
antigen NN o
( ( N
r JJ N
= NNP N
-0.1752 NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
tPA NN o
activity NN o
( ( N
r NN N
= VBZ N
0.2465 CD N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
further RBR N
confirmed VBN N
in IN N
the DT N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
( ( N
F NNP N
= NNP N
47.052 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Vitamin NNP i
A NNP N
compared VBN N
with IN N
either DT N
placebo NN i
or CC i
beta NN i
carotene JJ i
supplementation NN i
increased VBD N
plasma JJ o
retinol NN o
concentrations NNS o
by IN N
end NN N
of IN N
study NN N
( ( N
1.46 CD N
[ RB N
95 CD N
% NN N
CI NNP N
, , N
1.42-1.50 JJ N
] NN N
? . N
vs $ N
1.13 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
1.09-1.17 JJ N
] NN N
? . N
and CC N
1.18 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
1.14-1.22 JJ N
] NN N
? . N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
reduced VBN N
, , N
but CC N
did VBD N
not RB N
eliminate VB o
, , o
gestational JJ o
night NN o
blindness NN o
( ( N
7.1 CD N
% NN N
for IN N
vitamin NN N
A NNP N
vs RB N
9.2 CD N
% NN N
for IN N
placebo NN N
and CC N
8.9 CD N
% NN N
for IN N
beta NN N
carotene NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
for IN N
both DT N
] NNP N
) ) N
. . N

This DT N
reduction NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
total JJ o
fractional JJ o
catabolic NN o
rate NN o
of IN o
VLDL1-ApoB NNP o
( ( N
6.70 CD N
+/- JJ N
3.24 CD N
vs JJ N
4.52 CD N
+/- JJ N
2.34 CD N
pool/day NN N
, , N
p NN N
= NNP N
0.049 CD N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
8.72 CD N
+/- JJ N
3.37 CD N
vs JJ N
5.36 CD N
+/- JJ N
2.64 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
, , N
IDL-ApoB NNP N
( ( N
7.06 CD N
+/- JJ N
1.68 CD N
vs JJ N
4.21 CD N
+/- JJ N
1.51 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
and CC N
LDL-ApoB NNP N
( ( N
1.02 CD N
+/- JJ N
0.27 CD N
vs JJ N
0.59 CD N
+/- JJ N
0.13 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
tented JJ N
patients NNS N
had VBD N
statistically RB N
significant JJ N
reduction NN N
of IN N
mean JJ o
duration NN o
of IN o
air NN o
leak NN o
in IN N
days NNS N
( ( N
4.9 CD N
+/- JJ N
1.79 CD N
vs JJ N
8.2 CD N
+/- JJ N
4.2 CD N
) ) N
, , N
the DT N
number NN o
of IN o
days NNS o
of IN o
a DT o
chest NN o
tube NN o
duration NN o
( ( N
7.3 CD N
+/- JJ N
1.14 CD N
vs JJ N
12.46 CD N
+/- JJ N
3.6 CD N
) ) N
, , N
the DT N
length NN o
of IN o
postoperative JJ o
in-hospital JJ o
stay NN o
in IN N
days NNS N
( ( N
9.4 CD N
+/- JJ N
1.86 CD N
vs JJ N
13.6 CD N
+/- JJ N
2.49 CD N
) ) N
, , N
and CC N
the DT N
hospital NN o
stay NN o
cost NN o
per IN o
patient NN o
( ( N
leva NN N
, , N
3840 CD N
+/- JJ N
298 CD N
vs JJ N
5160 CD N
+/- JJ N
3890 CD N
) ) N
. . N

By IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
by IN N
treatment NN N
group NN N
for IN N
patients NNS N
with IN N
EGFR NNP N
Leu858Arg-positive JJ N
tumours NNS N
in IN N
either DT N
trial NN N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ o
overall JJ o
survival NN o
was VBD N
27.6 CD N
months NNS N
( ( N
19.8-41.7 JJ N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
40.3 CD N
months NNS N
( ( N
24.3-not JJ N
estimable NN N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
1.30 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-2.11 CD N
, , N
p=0.29 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
19.6 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
17.0-22.1 CD N
) ) N
versus NN N
24.3 CD N
months NNS N
( ( N
19.0-27.0 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
1.22 CD N
, , N
95 CD N
% NN N
CI NNP N
0.81-1.83 CD N
, , N
p=0.34 NN N
) ) N
. . N

After IN N
adjusting VBG N
for IN N
certain JJ N
baseline NN N
characteristics NNS N
, , N
diabetes NNS N
was VBD N
independently RB N
associated VBN N
with IN N
death NN N
at IN N
9 CD N
months NNS N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
1.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.31 CD N
to TO N
2.68 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
TVR NNP o
( ( N
RR NNP N
, , N
1.27 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.14 CD N
to TO N
1.42 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
composite JJ N
end NN N
point NN N
of IN N
death/myocardial JJ o
infarction/TVR NN o
( ( N
RR NNP N
, , N
1.26 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.13 CD N
to TO N
1.40 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Median JJ o
PFS NNP o
in IN N
Arms NNP N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
was VBD N
6.5 CD N
months NNS N
( ( N
HR NNP N
, , N
0.69 CD N
; : N
P NNP N
= NNP N
0.147 CD N
) ) N
, , N
4.5 CD N
months NNS N
( ( N
HR NNP N
, , N
1.01 CD N
; : N
P NNP N
= NNP N
0.998 CD N
) ) N
, , N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
; : N
median JJ o
overall JJ o
survival NN o
was VBD N
12.3 CD N
months NNS N
( ( N
HR NNP N
, , N
0.89 CD N
; : N
P NNP N
= NNP N
0.650 CD N
) ) N
, , N
12.4 CD N
months NNS N
( ( N
HR NNP N
, , N
1.27 CD N
; : N
P NNP N
= NNP N
0.357 CD N
) ) N
, , N
and CC N
12.0 CD N
months NNS N
; : N
and CC N
objective JJ o
response NN o
rate NN o
was VBD N
14 CD N
% NN N
, , N
8 CD N
% NN N
, , N
and CC N
2 CD N
% NN N
. . N

Significant JJ o
improvement NN o
in IN o
6-minute JJ o
walk NN o
test NN o
( ( N
45.8 CD N
m NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
5.2-86.4 JJ N
m NN N
; : N
p=0.031 NN N
) ) N
, , N
functional JJ o
class NN o
( ( N
-0.6+/-0.5 UH N
, , N
p=0.014 NN N
) ) N
, , N
weight JJ o
loss NN o
( ( N
-8.55 JJ N
kg NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-13.0 NN N
to TO N
-4.1 VB N
kg NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
and CC N
also RB N
significant JJ N
decreases NNS N
in IN N
total JJ o
cholesterol NN o
( ( N
p=0.017 NN N
) ) N
, , N
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( N
p=0.03 NN N
) ) N
, , N
and CC N
triglycerides NNS o
( ( N
p=0.036 NN N
) ) N
were VBD N
observed VBN N
in IN N
the DT N
orlistat NN N
group NN N
. . N

Baseline NNP N
elevated VBD N
PTX3 NNP N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
all-cause JJ N
mortality NN N
[ $ N
759 CD N
events NNS N
, , N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
for IN N
1 CD N
SD NNP N
increase NN N
1.20 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.12-1.30 CD N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
, , N
cardiovascular JJ o
mortality NN o
( ( N
587 CD N
events NNS N
, , N
HR NNP N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
1.17-1.38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
or CC o
hospitalization NN o
for IN o
worsening VBG o
HF NNP o
( ( N
720 CD N
events NNS N
, , N
HR NNP N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
1.12-1.30 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
marginally RB N
improved VBN N
discrimination NN N
. . N

Panic JJ N
management NN N
( ( N
PM NNP N
) ) N
had VBD N
an DT N
ICER NNP o
of IN N
$ $ N
124.05 CD N
, , N
per IN N
the DT N
Anxiety NN N
Disorders NNP N
Interview NNP N
Schedule NNP N
for IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
severity NN N
score NN N
change NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
$ $ N
54.63- JJ N
$ $ N
314.57 CD N
) ) N
, , N
compared VBN N
with IN N
pharmacotherapy NN i
( ( i
paroxetine NN i
) ) i
, , N
with IN N
an DT N
ICER NNP o
of IN N
$ $ N
213.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
133.51- JJ N
$ $ N
394.94 CD N
) ) N
, , N
and CC N
brief JJ N
CBT NNP N
, , N
with IN N
an DT N
ICER NNP o
of IN N
$ $ N
309.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
151.27- JJ N
$ $ N
548.28 CD N
) ) N
. . N

For IN N
depressive JJ o
symptoms NNS o
, , o
the DT o
risk NN o
reduction NN o
in IN o
clinically RB o
significant JJ o
symptoms NNS o
did VBD o
not RB o
reach VB o
statistical JJ o
significance NN o
( ( N
5.7 CD N
% NN N
vs JJ N
22.4 CD N
% NN N
; : N
aRR CC N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.10 CD N
to TO N
1.08 CD N
) ) N
; : N
however RB N
, , N
the DT N
reduction NN N
in IN N
mean JJ o
depressive NN o
symptoms NNS o
was VBD o
statistically RB o
significant JJ o
( ( o
Quick NNP o
Inventory NNP o
of IN o
Depressive NNP o
Symptomatology NNP o
score NN o
, , N
4.6 CD N
with IN N
PSE NNP N
vs FW N
6.9 CD N
with IN N
usual JJ N
care NN N
; : N
adjusted VBN N
mean NN N
difference NN N
, , N
-1.67 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-3.17 NNP N
to TO N
-0.18 VB N
) ) N
. . N

Dose-dependent JJ N
increases NNS N
in IN N
FEV1 NNP o
were VBD N
seen VBN N
( ( N
mean JJ N
values NNS N
( ( N
L NNP N
) ) N
before IN N
salbutamol NN N
and CC N
after IN N
a DT N
cumulative JJ N
dose NN N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
microg NN N
= NN N
placebo NN N
: : N
1.06 CD N
, , N
1.28 CD N
, , N
1.35 CD N
, , N
1.39 CD N
, , N
1.41 CD N
; : N
formoterol NN N
: : N
1.33 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.44 CD N
, , N
1.44 CD N
; : N
salmeterol NN i
: : i
1.30 CD N
, , N
1.33 CD N
, , N
1.36 CD N
, , N
1.39 CD N
, , N
1.42 CD N
; : N
oxitropium JJ N
bromide NN N
: : N
1.27 CD N
, , N
1.34 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.40 CD N
) ) N
. . N

WL NNP i
alone RB N
reduced VBD N
( ( N
P NNP N
< VBZ N
0.05 CD N
in IN N
all DT N
) ) N
body NN o
weight NN o
( ( N
-3 CD N
% NN N
) ) N
, , N
waist JJ o
circumference NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ o
( ( o
-3 CD o
% NN o
) ) o
and CC o
diastolic JJ o
( ( N
-3 CD N
% NN N
) ) N
blood NN o
pressures NNS o
, , o
cardiac JJ o
output NN o
( ( o
-4 CD o
% NN o
) ) o
, , o
plasma JJ o
TG NNP o
concentration NN o
( ( N
-25 CD N
% NN N
) ) N
, , N
and CC N
the DT N
homeostasis NN o
model NN o
assessment NN o
( ( o
HOMA NNP o
) ) o
score NN o
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased VBD N
plasma NN o
HDL NNP o
cholesterol NN o
( ( N
+9 CD N
% NN N
) ) N
and CC N
adiponectin NN o
( ( N
+18 CD N
% NN N
) ) N
concentrations NNS N
. . N

Numerical JJ o
analog NN o
pain NN o
score NN o
and CC o
morphine JJ o
utilization NN o
and CC o
hemodynamic JJ o
values NNS o
were VBD N
measured VBN N
for IN N
24 CD N
h. NN N
RESULTS NNP N
The DT N
patients NNS N
treated VBN N
with IN N
nicotine NN i
reported VBN N
lower JJR N
pain NN o
scores NNS o
during IN N
the DT N
first JJ N
hour NN N
after IN N
surgery NN N
( ( N
peak JJ o
numerical JJ o
analog NN o
score NN o
, , N
7.6 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
versus NN N
5.3 CD N
( ( N
SD NNP N
1.6 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
used VBN N
half PDT N
the DT N
amount NN N
of IN N
morphine NN i
as IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
( ( N
SD NNP N
6 CD N
) ) N
versus NN N
6 CD N
( ( N
SD NNP N
5 CD N
) ) N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
Spontaneous NNP o
communication NN o
using VBG o
picture NN o
cards NNS o
, , o
speech NN o
, , o
or CC o
both DT o
increased VBN o
significantly RB o
following VBG o
training NN o
( ( o
rate NN o
ratio NN o
[ NNP N
RR NNP N
] NNP N
=1.90 NNP N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.46 CD N
, , N
2.48 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
1.77 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.35 CD N
, , N
2.32 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
3.74 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
2.19 CD N
, , N
6.37 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

INTERVENTIONS NNP N
One CD N
of IN N
six CD i
dosing VBG i
epoetin NN i
alfa NN i
regimens VBZ i
for IN N
15 CD N
days NNS N
, , N
as IN N
follows VBZ N
: : N
40,000 CD N
IU NNP N
once RB N
weekly RB N
, , N
subcutaneously RB N
( ( N
group NN N
A NNP N
) ) N
or CC N
intravenously RB N
( ( N
IV NNP N
) ) N
( ( N
group NN N
B NNP N
) ) N
; : N
15,000 CD N
IU NNP N
every DT N
other JJ N
day NN N
, , N
subcutaneously RB N
( ( N
group NN N
C NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
D NNP N
) ) N
; : N
or CC N
40,000 CD N
IU NNP N
day NN N
1 CD N
and CC N
3 CD N
, , N
subcutaneously RB N
( ( N
group NN N
E NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
F NNP N
) ) N
, , N
followed VBN N
by IN N
15,000 CD N
IU NNP N
once RB N
every DT N
other JJ N
day NN N
on IN N
[ NN N
corrected VBN N
] JJ N
days NNS N
5-15 JJ N
[ NNP N
corrected VBD N
] NN N
MEASUREMENTS NNP N
Serum NNP o
erythropoietin NN o
concentration NN o
, , o
absolute JJ o
reticulocyte NN o
count NN o
, , o
and CC o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
Relative NNP N
to TO N
the DT N
group NN N
B NNP N
, , N
the DT N
group NN N
A NNP N
had VBD N
( ( N
1 CD N
) ) N
a DT N
significant JJ N
decrease NN N
of IN N
pain NN o
at IN o
rest NN o
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
following VBG N
up RP N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN o
at IN o
palpation NN o
and CC o
pain NN o
on IN o
isometric JJ o
testing VBG o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
3 CD N
) ) N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN o
during IN o
middle JJ o
finger NN o
test NN o
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
4 CD N
) ) N
a DT N
significant JJ N
decrease NN N
of IN N
pain NN o
during IN o
grip NN o
strength NN o
testing VBG o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
5 CD N
) ) N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
wrist NN o
range NN o
of IN o
motion NN o
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
( ( N
6 CD N
) ) N
an DT N
increase NN N
in IN N
grip JJ o
strength NN o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
a DT N
significant JJ N
increase NN N
in IN N
weight-test JJ N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
reperfusion NN o
arrhythmias-frequent JJ o
ventricular JJ o
premature NN o
( ( N
26.7 CD N
% NN N
vs. FW N
52.9 CD N
% NN N
) ) N
and CC N
short JJ o
array NN o
ventricular JJ o
tachycardia NN o
beat NN o
( ( N
23.3 CD N
% NN N
vs. FW N
58.8 CD N
% NN N
) ) N
as RB N
well RB N
as IN N
values NNS o
of IN o
peaks NNS o
CK NNP o
[ NNP o
( ( N
1162 CD N
? . N
548 CD N
) ) N
U/L NNP N
vs. FW N
( ( N
1732 CD N
? . N
480 CD N
) ) N
U/L NNP N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
, , N
CKMB NNP i
[ NNP N
( ( N
165 CD N
? . N
70 CD N
) ) N
U/L NNP N
vs. FW N
( ( N
280 CD N
? . N
99 CD N
) ) N
U/L NNP N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
, , N
CTFC NNP i
( ( N
22.23 CD N
? . N
3.81 CD N
vs NN N
26.97 CD N
? . N
3.42 CD N
) ) N
, , N
WMSI NNP N
( ( N
1.27 CD N
? . N
0.52 CD N
vs NN N
1.82 CD N
? . N
0.83 CD N
) ) N
, , N
and CC N
infarction NN o
areas NNS o
determined VBN o
by IN o
ECG NNP o
methods NNS N
( ( N
10.60 CD N
% NN N
? . N
4.97 CD N
% NN N
vs.14.65 NN N
% NN N
? . N
6.88 CD N
% NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
were VBD N
all DT N
significantly RB N
lower JJR N
in IN N
the DT N
postconditioning VBG N
group NN N
than IN N
in IN N
control NN N
group NN N
while IN N
LVEF NNP i
( ( N
0.55 CD N
? . N
0.08 CD N
vs NN N
0.47 CD N
? . N
0.10 CD N
) ) N
and CC N
MBG NNP o
( ( N
2.27 CD N
? . N
0.64 CD N
vs NN N
1.47 CD N
? . N
0.61 CD N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
postconditioning VBG N
group NN N
than IN N
in IN N
control NN N
group NN N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN o
relief NN o
scores NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ N
doses NNS N
of IN N
study NN N
medication NN N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ N
doses NNS N
of IN N
supplemental JJ N
analgesics NNS N
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ o
assessment NN o
scores NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

RESULTS RB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
the DT N
demographics NNS o
, , o
myocardial JJ o
enzyme NN o
release NN o
, , o
occurrence NN o
of IN o
major JJ o
arrhythmias NNS o
[ VBP o
9 CD o
( ( N
18 CD N
% NN N
) ) N
vs. FW N
12 CD N
( ( N
23.5 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.80 CD N
] NN N
, , N
heart NN o
failure NN o
[ VBZ o
18 CD N
( ( N
36 CD N
% NN N
) ) N
vs. FW N
19 CD N
( ( N
38.3 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.83 CD N
] NN N
, , N
LVEF NNP o
at IN N
first JJ N
day NN N
[ VB N
34.7 CD N
? . N
9.9 CD N
% NN N
vs. FW N
33.5 CD N
? . N
8.1 CD N
% NN N
, , N
P NNP N
= VBZ N
0.50 CD N
] NN N
or CC N
at IN N
discharge NN N
[ $ N
37.7 CD N
? . N
10 CD N
% NN N
vs. FW N
36.1 CD N
? . N
8.2 CD N
% NN N
, , N
P NNP N
= VBZ N
0.43 CD N
] NN N
, , N
and CC N
in-hospital JJ N
[ NN N
4 CD N
( ( N
8 CD N
% NN N
) ) N
vs. FW N
6 CD N
( ( N
11.8 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.74 CD N
] NN N
or CC N
6-month JJ o
mortality NN o
rates NNS o
[ VBP N
9 CD N
( ( N
18 CD N
% NN N
) ) N
vs. FW N
10 CD N
( ( N
19.6 CD N
% NN N
) ) N
, , N
P NNP N
= VBZ N
0.99 CD N
] NN N
between IN N
the DT N
CsA NNP i
vs IN N
the DT N
control NN N
group NN N
. . N

Compared VBN N
with IN N
the DT N
remaining VBG N
693 CD N
patients NNS N
, , N
subjects NNS N
with IN N
left JJ o
ventricular JJ o
thrombosis NN o
were VBD N
older JJR N
( ( N
mean NN N
( ( N
SD NNP N
) ) N
age NN N
: : N
64.6 CD N
( ( N
13.0 CD N
) ) N
v NN N
59.8 CD N
( ( N
11.7 CD N
) ) N
years NNS N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
, , N
and CC N
had VBD N
larger JJR o
infarcts NNS o
( ( N
extent NN N
of IN N
wall NN N
motion NN N
asynergy NN N
: : N
40.9 CD N
( ( N
11.5 CD N
) ) N
% NN N
v JJ N
24.9 CD N
( ( N
14 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
greater JJR N
depression NN o
of IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
at IN o
S1 NNP o
( ( N
43.3 CD N
( ( N
6.9 CD N
) ) N
% NN N
v JJ N
48.1 CD N
( ( N
6.8 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
greater JJR N
left VBD o
ventricular JJ o
volumes NNS o
at IN o
S1 NNP o
( ( N
end VB N
diastolic NN N
volume NN N
: : N
87 CD N
( ( N
22 CD N
) ) N
v NN N
78 CD N
( ( N
18 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< VBP N
0.001 CD N
; : N
end VB N
systolic JJ N
volume NN N
: : N
50 CD N
( ( N
17 CD N
) ) N
v NN N
41 CD N
( ( N
14 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Over-all NN N
, , N
empiric JJ N
antibiotic JJ N
trials NNS N
were VBD N
more RBR N
often RB N
successful JJ N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
group NN N
1 CD N
( ( N
55 CD N
of IN N
62 CD N
patients NNS N
or CC N
89 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
42 CD N
of IN N
64 CD N
patients NNS N
, , N
66 CD N
per IN N
cent NN N
) ) N
mwithin NN N
group NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
30 CD N
of IN N
32 CD N
( ( N
94 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
25 CD N
of IN N
30 CD N
( ( N
83 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
; : N
within IN N
group NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
23 CD N
of IN N
30 CD N
( ( N
77 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
19 CD N
of IN N
34 CD N
( ( N
56 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
Combined VBN N
results NNS N
in IN N
both DT N
groups NNS N
indicated VBD N
a DT N
higher JJR N
proportion NN N
of IN N
favorable JJ N
outcome NN N
in IN N
C-T/S NNP N
trials NNS N
( ( N
53 CD N
of IN N
62 CD N
, , N
85 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
C-G JJ N
trials NNS N
( ( N
44 CD N
of IN N
64 CD N
, , N
69 CD N
per IN N
cent NN N
) ) N
. . N

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN o
incidence NN o
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN i
E NNP i
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN o
deaths NNS o
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ o
cardiovascular JJ o
events NNS o
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

The DT N
plasma JJ o
IL-8 NNP o
, , o
TNF- NNP o
, , o
CRP NNP o
, , o
lipase NN o
, , o
LDH NNP o
at IN N
14 CD N
days NNS N
after IN N
intervention NN N
of IN N
nutrition NN N
in IN N
P+EN NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
PN NNP i
group NN i
and CC i
EN NNP i
group NN N
( ( N
IL-8 NNP N
: : N
21.00 CD N
? . N
7.07 CD N
? . N
vs. FW N
48.00 CD N
? . N
10.32 CD N
? . N
, , N
32.00 CD N
? . N
9.30 CD N
? . N
; : N
TNF- JJ N
: : N
44.3 CD N
? . N
10.9 CD N
ng/L JJ N
vs. FW N
132.1 CD N
? . N
34.1 CD N
ng/L NN N
, , N
67.8 CD N
? . N
22.3 CD N
ng/L NN N
; : N
CRP NNP N
: : N
35.0 CD N
? . N
12.4 CD N
mg/L NN N
vs. FW N
103.2 CD N
? . N
49.2 CD N
mg/L NN N
, , N
63.0 CD N
? . N
29.2 CD N
mg/L NN N
; : N
lipase NN N
: : N
269 CD N
? . N
79 CD N
U/L NNP N
vs. FW N
670 CD N
? . N
145 CD N
U/L NNP N
, , N
310 CD N
? . N
78 CD N
U/L NNP N
; : N
LDH NNP N
: : N
21.8 CD N
? . N
10.3 CD N
U/L NNP N
vs. FW N
78.1 CD N
? . N
37.4 CD N
U/L NNP N
, , N
37.9 CD N
? . N
25.1 CD N
U/L NNP N
, , N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
group NN N
A NNP N
, , N
endothelium NN N
dependent JJ N
[ NNP N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
vs NN N
( ( N
9 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
2.9 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
and CC N
independent JJ N
[ NNP N
( ( N
18 CD N
+/- JJ N
4 CD N
) ) N
% NN N
vs NN N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
3.4 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] JJ N
vasodilatation NN o
responses NNS o
significantly RB N
increased VBD N
after IN N
treatment NN N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
B. NNP N
Endothelium NNP N
dependent NN N
[ NNP N
( ( N
9 CD N
+/- JJ N
6 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
2.8 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
and CC N
independent JJ N
[ NNP N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
3.5 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] JJ N
vasodilatation NN o
responses NNS o
of IN N
group NN N
A NNP N
were VBD N
significantly RB N
lower JJR N
than IN N
that DT N
of IN N
group NN N
B NNP N
after IN N
treatment NN N
. . N

Allergic NNP o
mothers NNS o
had VBD o
significantly RB o
lower JJR o
amounts NNS o
of IN o
bifidobacteria NN o
in IN o
breast-milk NN o
compared VBN N
with IN N
non-allergic JJ N
mothers NNS N
[ VBP N
median JJ N
1.3 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
IQR NNP N
22.4-3.0 CD N
x NNP N
10 CD N
( ( N
3 CD N
) ) N
) ) N
vs. FW N
5.6 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
1.8 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
-1.8 NN N
x $ N
10 CD N
( ( N
4 CD N
) ) N
) ) N
, , N
respectively RB N
, , N
( ( N
P=0.004 NNP N
) ) N
] NN N
, , N
and CC N
their PRP$ N
infants NNS N
had VBD N
concurrently RB N
lower JJR N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
feces NNS N
[ VBP N
3.9 CD N
x JJ N
10 CD N
( ( N
8 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
IQR NNP N
6.5 CD N
x NN N
10 CD N
( ( N
6 CD N
) ) N
-1.5 NN N
x $ N
10 CD N
( ( N
9 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
allergic JJ N
mothers NNS N
, , N
vs. FW N
2.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
8 CD N
) ) N
-3.2 NN N
x $ N
10 CD N
( ( N
10 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
non-allergic JJ N
mothers NNS N
, , N
P=0.013 NNP N
] NNP N
. . N

One CD N
day NN N
after IN N
chemotherapy NN N
in IN N
losartan JJ N
group NN N
vs. FW N
amlodipine NN i
group NN N
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
urinary JJ o
uric JJ o
acid NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
18 CD N
mg/24 NNS N
h VBD N
vs. FW N
40 CD N
mg/24 NN N
h. NN N
Thirty NNP N
days NNS N
after IN N
chemotherapy NN N
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
azotemia NN N
of IN N
0.0 CD N
mg/dl NNS N
vs. FW N
3.8 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
serum JJ o
uric JJ o
acid NN o
of IN N
0.05 CD N
mg/dl NNS N
vs. FW N
0.49 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
urinary JJ o
uric JJ o
acid NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
23 CD N
mg/24 NNS N
h VBD N
vs. FW N
0.0 CD N
mg/24 NN N
h NN N
, , N
GFR NNP N
of IN N
2 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
vs. FW N
-8 FW N
ml/min/1.73 FW N
m NN N
( ( N
2 CD N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
systolic JJ o
BP NNP o
( ( o
SBP NNP o
) ) o
of IN N
3.6 CD N
mmHg NNS N
vs. FW N
0.8 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

From IN p
1989 CD p
to TO p
1997 CD p
, , p
68 CD p
patients NNS p
diagnosed VBN p
with IN p
previously RB p
untreated VBN p
PMBCL NNP p
, , p
aged VBD p
18-65 CD p
years NNS p
and CC p
negative JJ p
for IN p
immunodeficiency NN p
virus NN p
test NN p
, , p
were VBD p
considered VBN p
candidates NNS p
to TO p
receive VB p
either DT p
conventional JJ i
chemotherapy NN i
with IN i
CEOP-Bleo NNP i
( ( i
cyclophosphamide VB i
750 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
vincristine JJ i
1.4 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
prednisone RB i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
epirubicin $ i
70 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
and CC i
bleomycin $ i
10 CD i
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
or CC i
mega JJ i
CEOP-Bleo NNP i
( ( i
cyclophosphamide JJ i
1000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
epirubicin $ i
120 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
vincristine NN i
, , i
prednisone NN i
, , i
and CC i
bleomycin NN i
at IN i
the DT i
same JJ i
doses NNS i
) ) i
every DT i
21 CD i
days NNS i
for IN i
six CD i
cycles NNS i
, , i
followed VBN i
by IN i
radiotherapy NN i
to TO i
the DT i
mediastinum NN i
with IN i
the DT i
mantle NN i
technique NN i
( ( i
35-45 JJ i
Gy NNP i
, , i
mean VBP i
38 CD i
Gy NNP i
) ) i
. . i

OBJECTIVE NN N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
cyclooxygenase-2 JJ i
inhibitor NN i
, , i
celecoxib NN i
, , N
as IN N
adjunctive JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
METHODS NNP N
In IN N
a DT N
10-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
, , N
40 CD p
outpatient JJ p
children NNS p
with IN p
a DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
fourth JJ p
edition NN p
, , p
text JJ p
revision NN p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
celecoxib VB i
plus CC i
risperidone VB i
or CC i
placebo VB i
plus CC i
risperidone VB i
. . i

Based VBN N
on IN N
the DT N
discussions NNS N
of IN N
the DT N
Joint NNP N
Federal NNP N
Committee NNP N
( ( N
G-BA NNP N
) ) N
and CC N
the DT N
conceptual JJ N
work NN N
of IN N
the DT N
MDS NNP N
, , N
the DT N
Competence NNP N
Centre NNP N
Oncology NNP N
of IN N
the DT N
MDK NNP N
, , N
the DT N
IQWIG NNP N
and CC N
the DT N
National NNP N
Association NNP N
of IN N
Statutory NNP N
Health NNP N
Insurance NNP N
Funds NNP N
( ( N
GKV-Spitzenverband NNP N
) ) N
, , N
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
was VBD N
developed VBN N
comparing VBG N
the DT N
four CD N
treatments NNS N
actually RB N
recommended VBN N
by IN N
the DT N
German JJ N
and CC N
European JJ N
guidelines NNS N
for IN N
localised JJ N
prostate NN N
cancer NN N
( ( N
radical JJ N
prostatectomy NN N
, , N
percutaneous JJ N
radiotherapy NN N
and CC N
permanent JJ N
seed NN N
implantation NN N
and CC N
active JJ N
surveillance NN N
) ) N
allowing VBG N
a DT N
rejection NN N
of IN N
one CD N
or CC N
two CD N
treatment NN N
options NNS N
. . N

METHODS NNP N
Sixty-one CD p
patients NNS p
with IN p
depressive JJ p
disorders NNS p
who WP p
were VBD p
already RB p
in IN p
therapy NN p
in IN p
an DT p
outpatient JJ p
mental JJ p
health NN p
institution NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
eight CD N
group NN N
sessions NNS N
of IN N
COMET NNP i
in IN i
addition NN i
to TO i
their PRP$ i
regular JJ i
therapy NN i
( ( i
COMET NNP i
+ NNP i
therapy NN i
as IN i
usual JJ i
[ NNP i
TAU NNP i
] NN i
: : i
the DT i
experimental JJ i
group NN i
) ) i
or CC i
to TO i
8 CD i
weeks NNS i
of IN i
ongoing VBG i
regular JJ i
therapy NN i
( ( i
TAU NNP i
only RB i
: : i
the DT i
control NN i
group NN i
) ) i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
HD NNP p
patients NNS p
in IN p
stage NN p
I PRP p
to TO p
IIIA NNP p
with IN p
a DT p
large JJ p
mediastinal JJ p
mass NN p
, , p
E NNP p
stage NN p
, , p
or CC p
massive JJ p
spleen JJ p
involvement NN p
were VBD p
treated VBN p
with IN p
two CD i
double JJ i
cycles NNS i
of IN i
alternating VBG i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
COPP NNP i
) ) i
plus CC i
doxorubicin JJ i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
( ( i
ABVD NNP i
) ) i
followed VBN i
by IN i
EF NNP i
irradiation NN i
in IN i
two CD i
successive JJ i
trials NNS i
( ( i
HD1 NNP i
and CC i
HD5 NNP i
) ) i
. . i

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN N
of IN N
a DT N
high-dose JJ i
regimen NN i
containing VBG i
cyclophosphamide NN i
, , i
carmustine NN i
, , i
and CC i
etoposide RB i
( ( i
CBV NNP i
) ) i
followed VBN i
by IN i
autotransplantation NN i
over IN i
a DT i
consolidative JJ i
sequential JJ i
chemotherapy NN i
( ( i
ifosfamide JJ i
, , i
etoposide RB i
, , i
asparaginase NN i
, , i
and CC i
cytarabine NN i
) ) i
in IN N
patients NNS p
in IN p
first JJ p
complete JJ p
remission NN p
with IN p
intermediate- JJ p
and CC p
high-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

To TO N
determine VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
new JJ N
, , N
non-contact JJ i
, , i
kilohertz VB i
ultrasound JJ i
therapy NN i
for IN N
the DT N
healing NN N
of IN N
recalcitrant JJ o
diabetic JJ o
foot NN o
ulcers NNS o
- : N
as RB N
well RB N
as IN N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
total JJ N
closure NN N
and CC N
quantitative JJ N
bacterial JJ N
cultures NNS N
and CC N
the DT N
effect NN N
on IN N
healing NN N
of IN N
various JJ N
levels NNS N
of IN N
sharp/surgical JJ N
debridement NN N
- : N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
sham-controlled JJ N
, , N
multicenter NN N
study NN N
was VBD N
conducted VBN N
in IN N
hospital-based JJ p
and CC p
private JJ p
wound NN p
care NN p
clinics NNS p
. . p

A DT N
total NN N
of IN N
128 CD p
recipients NNS p
of IN p
first JJ p
cadaveric JJ p
renal NN p
allograft NN p
were VBD N
randomized VBN N
, , N
after IN N
an DT N
initial JJ N
induction NN N
period NN N
, , N
to TO N
receive VB N
either RB N
triple JJ i
drug NN i
therapy NN i
-- : i
i.e NN i
, , i
( ( i
low-dose JJ i
) ) i
cyclosporine NN i
, , i
azathioprine NN i
, , i
and CC i
methylprednisolone NN i
, , i
or CC i
any DT i
possible JJ i
combination NN i
of IN i
two CD i
drugs NNS i
-- : i
i.e NN i
, , i
Aza NNP i
plus CC i
CsA NNP i
, , i
Aza NNP i
plus CC i
MP NNP i
, , i
and CC i
CsA NNP i
plus CC i
MP NNP i
. . i

FUNDING NN N
Agence NNP N
nationale NN N
de IN N
recherches NNS N
sur VBP N
le JJ N
sida NN N
et NN N
les VBZ N
h JJ N
virales NNS N
, , N
Department NNP N
for IN N
International NNP N
Development NNP N
, , N
European NNP N
and CC N
Developing NNP N
Countries NNP N
Clinical NNP N
Trials NNP N
Partnership NNP N
, , N
Thrasher NNP N
Research NNP N
Fund NNP N
, , N
Belgian JJ N
Directorate NNP N
General NNP N
for IN N
International NNP N
Cooperation NNP N
, , N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
and CC N
Prevention NNP N
, , N
Eunice NNP N
Kennedy NNP N
Shriver NNP N
National NNP N
Institute NNP N
of IN N
Child NNP N
Health NNP N
and CC N
Human NNP N
Development NNP N
, , N
and CC N
UNDP/UNFPA/World NNP N
Bank/WHO NNP N
Special NNP N
Programme NNP N
of IN N
Research NNP N
, , N
Development NNP N
and CC N
Research NNP N
Training NNP N
in IN N
Human NNP N
Reproduction NNP N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
to TO N
examine VB N
whether IN N
the DT N
Chinese NNP i
medicinal JJ i
herb NN i
complex NN i
, , i
RG-CMH NNP i
, , i
which WDT i
represents VBZ i
a DT i
mixture NN i
of IN i
rose VBD i
geranium NN i
and CC i
extracts NNS i
of IN i
G. NNP i
tsugae NN i
, , i
C. NNP i
pilosula NN i
and CC i
A. NNP i
sinensis NN i
, , N
can MD N
improve VB N
the DT N
immune NN N
cell NN N
count NN N
of IN N
cancer NN p
patients NNS p
receiving VBG p
chemotherapy NN i
and/or NN i
radiotherapy NN i
to TO N
prevent VB N
leucopenia NN N
and CC N
immune JJ N
impairment NN N
that WDT N
usually RB N
occurs VBZ N
during IN N
cancer NN N
therapy NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
summarize VB N
and CC N
integrate VB N
the DT N
findings NNS N
of IN N
the DT N
Diabetes NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
( ( N
DCCT NNP N
) ) N
, , N
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
, , N
and CC N
the DT N
succeeding JJ N
observational JJ N
follow-up NN N
of IN N
the DT N
DCCT NNP N
cohort NN N
in IN N
the DT N
Epidemiology NNP N
of IN N
Diabetes NNP N
Interventions NNP N
and CC N
Complications NNP N
( ( N
EDIC NNP N
) ) N
study NN N
, , N
regarding VBG N
the DT N
effects NNS N
of IN N
intensive JJ N
treatment NN N
on IN N
the DT N
microvascular JJ N
complications NNS N
of IN N
type NN p
1 CD p
diabetes NNS p
mellitus NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
One CD p
hundred VBD p
forty-three JJ p
non-diabetic JJ p
adult NN p
RA NNP p
patients NNS p
( ( p
76.2 CD p
% NN p
female NN p
, , p
age NN p
55.2 CD p
? . p
12.1 CD p
[ JJ p
mean NN p
? . p
SD NNP p
] NNP p
) ) p
on IN p
stable JJ p
RA NNP p
standard NN p
of IN p
care NN p
treatment NN p
were VBD p
enrolled VBN p
in IN p
a DT p
randomized JJ p
, , p
double-blind JJ p
placebo NN i
controlled VBD i
crossover JJ i
trial NN i
of IN i
45 CD i
mg JJ i
daily JJ i
pioglitazone NN i
versus NN i
placebo NN i
, , i
with IN i
a DT i
3-month JJ i
duration/arm NN i
and CC i
a DT i
2-month JJ i
washout NN i
period NN i
. . i

BACKGROUND IN N
We PRP N
compared VBN N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
two CD N
combined JJ N
diphtheria-tetanus-pertussis-inactivated JJ i
poliovirus NN i
vaccines NNS i
containing VBG i
either CC i
acellular JJ i
( ( i
Pa NNP i
, , i
SmithKline NNP i
Beecham NNP i
Biologicals NNP i
) ) i
or CC i
whole JJ i
cell NN i
( ( i
Pw NNP i
, , i
Pasteur NNP i
Merieux NNP i
Connaught NNP i
) ) i
pertussis NN i
components NNS i
, , i
mixed JJ i
with IN i
a DT i
Haemophilus NNP i
influenzae NN i
type NN i
b NN i
polysaccharide NN i
polyribosylribitol IN i
phosphate-tetanus JJ i
conjugate NN i
vaccine NN i
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
in IN N
healthy JJ p
infants NNS p
. . p

PURPOSE NN N
This DT N
phase NN N
III NNP N
study NN N
compared VBN N
the DT N
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
of IN N
an DT N
oral JJ N
regimen NNS N
of IN N
dihydropyrimidine JJ i
dehydrogenase NN i
inhibitory NN i
fluoropyrimidine NN i
composed VBN N
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
tegafur NN N
and CC N
uracil NN i
in IN N
a DT N
1:4 CD N
molar JJ N
ratio NN N
( ( N
UFT NNP N
) ) N
and CC N
leucovorin $ i
( ( i
LV NNP i
) ) i
to TO i
intravenous JJ i
( ( i
IV NNP i
) ) i
fluorouracil NN i
( ( i
5-FU JJ i
) ) i
and CC N
LV NNP N
in IN N
previously RB p
untreated VBN p
metastatic JJ p
colorectal NN p
carcinoma NN p
( ( p
CRC NNP p
) ) p
patients NNS p
. . p

Patients NNS p
with IN p
untreated JJ p
stage NN p
I PRP p
MM NNP p
( ( p
defined VBN p
according VBG p
to TO p
Durie NNP p
and CC p
Salmon NNP p
) ) p
were VBD N
randomised VBN N
between IN N
being VBG N
followed VBN N
without IN N
cytostatics NNS N
until IN N
the DT N
disease NN N
progressed VBD N
and CC N
receiving VBG N
six CD N
courses NNS N
of IN N
melphalan NN i
and CC i
prednisone NN i
( ( i
MP-P NNP i
) ) i
just RB N
after IN N
diagnosis NN N
; : N
stage NN N
II NNP N
patients NNS N
were VBD N
uniformly RB N
treated VBN N
with IN N
MPH-P NNP i
and CC p
stage NN p
III NNP p
patients NNS p
were VBD N
randomised VBN N
between IN N
MPH-P NNP i
and CC i
four CD i
courses NNS i
of IN i
combination NN i
chemotherapy NN i
with IN i
Peptichemio NNP i
, , i
vincristine NN i
and CC i
prednisone NN i
( ( i
PTC-VCR-P NNP i
) ) i
. . i

METHODS NNP N
Accordingly NNP N
, , N
we PRP N
evaluated VBD N
26,466 CD N
NSTE NNP N
ACS NNP N
patients NNS N
from IN N
the DT N
Global NNP N
Use NNP N
of IN N
Strategies NNPS N
to TO N
Open VB N
Occluded NNP N
Arteries NNPS N
in IN N
Acute NNP N
Coronary NNP N
Syndromes NNP N
( ( N
GUSTO-IIb NNP N
) ) N
, , N
Platelet NNP N
Glycoprotein NNP N
IIb/IIIa NNP N
in IN N
Unstable JJ N
Angina NNP N
: : N
Receptor NNP N
Suppression NNP N
Using NNP N
Integrilin NNP N
Therapy NNP N
( ( N
PURSUIT NNP N
) ) N
, , N
and CC N
Platelet NNP N
IIb/IIIa NNP N
Antagonism NNP N
for IN N
the DT N
Reduction NNP N
of IN N
Acute NNP N
Coronary NNP N
Syndrome NNP N
Events NNP N
in IN N
a DT N
Global NNP N
Organization NNP N
Network NNP N
( ( N
PARAGON NNP N
) ) N
A NNP N
and CC N
B NNP N
trials NNS N
to TO N
ascertain VB N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
. . N

METHODS NNP N
We PRP N
investigated VBD N
in IN N
a DT N
one-year JJ N
double JJ N
blind NN N
randomized VBD N
study NN N
comparing VBG N
intramuscular JJ i
( ( i
im NN i
) ) i
gold NN i
with IN i
im JJ i
methotrexate NN i
( ( i
MTX NNP i
) ) i
, , N
whether IN N
the DT N
variation NN N
of IN N
inflammatory JJ N
activity NN N
or CC N
functional JJ N
capacity NN N
, , N
the DT N
ascending VBG N
anatomic JJ N
stage NN N
, , N
or CC N
DMARD NNP N
treatments NNS N
have VBP N
an DT N
influence NN N
on IN N
bone NN N
formation NN N
( ( N
osteocalcin NN N
) ) N
in IN N
patients NNS p
with IN p
RA NNP p
. . p

The DT N
efficacy NN o
and CC o
the DT o
tolerability NN o
of IN N
simvastatin NN i
( ( N
a DT N
inhibitor NN N
of IN N
HGM-CoA NNP i
reductase NN i
) ) i
with IN N
that DT N
of IN N
gemfibrozil NN i
( ( i
a DT i
fibric NN i
acid NN i
derivative NN i
, , N
which WDT N
can MD N
reduce VB N
the DT N
VLDL NNP N
level NN N
) ) N
were VBD N
compared VBN N
in IN N
a DT N
placebo-controlled JJ i
study NN N
in IN N
2 CD p
groups NNS p
of IN p
patients NNS p
with IN p
primary JJ p
hypercholesterolemia NN p
and CC p
mild-to-moderate JJ p
essential JJ p
hypertension NN p
treated VBN p
with IN p
hydrochlorothiazide NN i
. . i

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ o
hyperplasia NN o
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ o
restenosis NN o
in IN N
patients NNS p
with IN p
ISR NNP p
. . p

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
double-blind JJ N
study NN N
with IN N
two CD N
parallel JJ N
groups NNS N
was VBD N
to TO N
examine VB N
the DT N
safety NN o
, , o
efficacy NN o
and CC o
tolerability NN o
of IN N
two CD N
combination NN i
eye NN i
drops VBZ i
containing VBG i
0.5 CD i
% NN i
timolol NN i
and CC N
2 CD N
% NN N
pilocarpine NN i
( ( N
Fotil NNP N
, , N
Leiras NNP N
, , N
Finland NNP N
, , N
and CC N
Timpilo NNP N
, , N
MSD NNP N
, , N
USA NNP N
) ) N
in IN N
patients NNS p
with IN p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
. . p

BACKGROUND IN N
We PRP N
describe VBP N
the DT N
rationale NN N
and CC N
protocol NN N
for IN N
a DT N
randomized JJ N
noninferiority NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
to TO N
determine VB N
if IN N
the DT N
Flexi-T380 NNP i
( ( i
+ NNP i
) ) i
copper NN i
intrauterine JJ i
contraceptive JJ i
device NN i
( ( i
IUD NNP i
) ) i
is VBZ N
comparable JJ N
in IN N
terms NNS N
of IN N
effectiveness NN N
and CC N
expulsion NN N
rates NNS N
to TO N
the DT N
most RBS N
common JJ N
Canadian JJ N
IUD NNP N
currently RB N
in IN N
use NN N
, , N
NovaT-200 NNP N
, , N
when WRB N
placed VBN N
immediately RB N
after IN N
a DT N
first-trimester JJ N
abortion NN N
. . N

METHODS NNP N
One CD p
hundred VBD p
five CD p
women NNS p
undergoing VBG p
laparoscopic NN p
tubal JJ p
sterilization NN p
with IN p
silastic JJ p
bands NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
one CD N
received VBD N
intramuscular JJ i
ketorolac NN i
and CC i
topical JJ i
placebo NN i
applied VBN i
to TO i
the DT i
fallopian JJ i
tubes NN i
, , i
the DT i
second JJ i
received VBD i
intramuscular JJ i
placebo NN i
and CC i
topical JJ i
bupivacaine NN i
, , i
and CC i
the DT i
third JJ i
received VBD i
intramuscular JJ i
placebo NN i
and CC i
topical JJ i
placebo NN i
. . i

Twenty-two JJ p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
from IN p
U. NNP p
T. NNP p
M. NNP p
D. NNP p
Anderson NNP p
Cancer NNP p
Center NNP p
, , p
with IN p
radiation-induced JJ p
xerostomia NN p
, , N
were VBD N
entered VBN N
into IN N
a DT N
pilot NN N
study NN N
to TO N
contrast VB N
the DT N
daily JJ N
home NN N
use NN N
of IN N
a DT N
0.4 CD N
% NN N
stannous JJ N
fluoride-gel-containing JJ N
tray NN N
( ( N
control VB N
group NN N
) ) N
to TO N
IFRS NNP N
( ( N
study VB N
group NN N
) ) N
with IN N
respect NN N
to TO N
tolerability NN N
and CC N
adherence NN N
, , N
and CC N
to TO N
obtain VB N
information NN N
on IN N
relative JJ N
caries NNS N
preventive VBP N
efficacy NN N
. . N

In IN N
this DT N
prospective JJ N
trial NN N
, , N
a DT N
total NN N
of IN N
74 CD p
children NNS p
who WP p
were VBD p
scheduled VBN p
to TO p
undergo VB p
high-dose JJ i
chemotherapy NN i
followed VBN i
by IN i
autologous JJ i
peripheral JJ i
blood NN i
stem NN i
cell NN i
transplantation NN i
( ( i
PBSCT NNP i
) ) i
were VBD N
prospectively RB N
randomized VBN N
at IN N
diagnosis NN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
exogenous JJ i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
treatment NN i
in IN N
accelerating VBG N
hematopoietic JJ N
recovery NN N
after IN N
PBSCT NNP i
. . i

METHODS NNP N
Determining VBG N
the DT N
EFficacy NNP N
and CC N
Tolerability NNP N
of IN N
CETP NNP N
INhibition NNP N
with IN N
AnacEtrapib NNP i
( ( N
DEFINE NNP N
) ) N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
profile NN N
of IN N
anacetrapib NN i
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
or CC p
CHD NNP p
risk NN p
equivalents NNS p
( ( p
clinical JJ p
trials.gov NN p
NCT00685776 NNP p
) ) p
. . p

METHODS NNP N
An DT N
examiner-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
30 CD p
subjects NNS p
with IN p
moderate JJ p
to TO p
advanced JJ p
periodontitis NN p
who WP p
were VBD p
randomized VBN p
to TO p
SRP VB i
alone RB i
or CC i
SRP NNP i
combined VBN i
with IN i
prescription NN i
custom-tray JJ i
application NN i
( ( i
Perio NNP i
Tray NNP i
) ) i
of IN i
1.7 CD i
% NN i
hydrogen NN i
peroxide NN i
gel NN i
( ( i
Perio NNP i
Gel NNP i
) ) i
for IN N
a DT N
period NN N
of IN N
three CD N
months NNS N
, , N
then RB N
extended VBD N
to TO N
six CD N
months NNS N
. . N

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ p
heart NN p
failure NN p
: : p
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP i
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP i
A1 NNP i
Adenosine NNP i
Receptor NNP i
Antagonist NNP i
Rolofylline NNP i
for IN N
Patients NNP p
Hospitalized NNP p
With IN p
Acute NNP p
Decompensated NNP p
Heart NNP p
Failure NNP p
and CC p
Volume NN p
Overload NNP p
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

Similar JJ N
results NNS N
were VBD N
achieved VBN N
when WRB N
the DT N
patients NNS N
were VBD N
sub-divided JJ N
into IN N
subgroups NNS N
according VBG N
to TO N
sequences NNS N
of IN N
treatment NN N
( ( N
basal NN N
-- : N
-- : N
ibopamine NN N
-- : N
-- : N
placebo NN N
and CC N
basal NN N
-- : N
-- : N
placebo NN N
-- : N
-- : N
ibopamine NN N
) ) N
, , N
NYHA NNP N
class NN N
II NNP N
or CC N
III NNP N
, , N
aetiology NN o
of IN o
congestive JJ o
heart NN o
failure NN o
( ( o
dilatative JJ o
cardiomyopathy NN o
, , o
ischemic JJ o
cardiomyopathy NN o
and CC o
other JJ o
aetiologies NNS o
) ) o
, , o
associated VBN o
treatment NN o
with IN o
digitalis NN o
or CC o
diuretics NNS o
and CC o
the DT o
number NN o
and CC o
complexity NN o
of IN o
base NN o
ectopic NN o
ventricular JJ o
beats NNS o
. . o

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
phase JJ N
2 CD N
, , N
multicenter RB N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
addition NN N
of IN N
a DT N
recombinant JJ i
human JJ i
endostatin NN i
adenovirus NN i
( ( i
E10A NNP i
) ) i
to TO i
cisplatin VB i
and CC i
paclitaxel VB i
in IN N
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
or CC p
nasopharyngeal JJ p
carcinoma NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty-four NNP p
subjects NNS p
, , p
each DT p
requiring VBG p
a DT p
nonmolar JJ p
extraction NN p
and CC p
delayed JJ p
implant NN p
placement NN p
, , N
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
ridge NN i
preservation NN i
treatment NN i
with IN i
either DT i
an DT i
allograft NN i
in IN i
an DT i
experimental JJ i
putty NN i
carrier NN i
plus CC i
a DT i
calcium NN i
sulfate NN i
barrier NN i
( ( i
PUT NNP i
) ) i
or CC i
a DT i
bovine-derived JJ i
xenograft NN i
( ( i
BDX NNP i
) ) i
plus CC i
a DT i
collagen NN i
membrane NN i
. . i

BACKGROUND NNP N
In IN N
a DT N
prospective JJ N
randomized NN N
manner NN N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
; : i
CHOP NNP i
) ) i
in IN N
patients NNS p
with IN p
Stage NNP p
I PRP p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
who WP p
have VBP p
achieved VBN p
a DT p
complete JJ p
response NN p
( ( p
CR NNP p
) ) p
after IN p
radiation NN p
therapy NN p
( ( p
RT NNP p
) ) p
. . p

INTERVENTIONS NNP N
The DT N
study NN N
included VBD N
three CD N
parts NNS N
: : N
( ( N
i NN N
) ) N
a DT N
1-day JJ N
baseline NN N
survey NN N
; : N
( ( N
ii NN N
) ) N
over IN N
the DT N
following JJ N
3-month JJ N
period NN N
, , N
departments NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
all DT N
practitioners NNS i
in IN i
wards NNS i
allocated VBN i
to TO i
the DT i
intervention NN i
group NN i
were VBD i
required VBN i
to TO i
systematically RB i
use VB i
specific JJ i
anticoagulant JJ i
prescription NN i
forms NNS i
, , i
whilst NN i
doctors NNS i
in IN i
the DT i
control NN i
group NN i
continued VBD i
prescribing VBG i
according VBG i
to TO i
their PRP$ i
usual JJ i
practices NNS i
and CC i
( ( i
iii NN i
) ) i
a DT i
1-day JJ i
postintervention NN i
survey NN i
. . i

DESIGN NNP N
AND CC N
METHODS NNP N
The DT N
HERA NNP N
study NN N
( ( N
Hyperium NNP N
Effect NNP N
on IN N
the DT N
sympathetic JJ N
Reflex NNP N
activation NN N
and CC N
Adrenaline NNP N
) ) N
is VBZ N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
6-week JJ N
cross-over JJ N
trial NN N
, , N
with IN N
a DT N
1-week JJ N
placebo NN i
run-in JJ N
period NN N
, , N
two CD N
2-week JJ N
active JJ i
treatment NN i
intervals NNS i
( ( i
rilmenidine VB i
1 CD i
mg JJ i
bid NN i
, , i
placebo NN i
) ) i
and CC N
intervening VBG N
one CD N
week NN N
placebo NN N
wash-out NN N
. . N

OBJECTIVE NN N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
triphasic JJ i
combined JJ i
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
containing VBG i
ethinyl JJ i
estradiol NN i
( ( i
EE NNP i
) ) i
and CC i
norgestimate JJ i
( ( i
NGM NNP i
) ) i
and CC i
biphasic JJ i
combined VBN i
OCs NNP i
containing VBG i
EE NNP i
and CC i
desogestrel NN i
( ( i
DSG NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
acne NN p
. . p

Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN i
acetate NN i
( ( i
desmopressin NN i
) ) i
reduced VBD N
blood NN o
product NN o
requirements NNS o
in IN N
these DT N
patients NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
desmopressin NN i
( ( N
0.3 CD N
micrograms/kg NN N
, , N
i. JJ N
v. NN N
) ) N
in IN N
92 CD p
patients NNS p
with IN p
overt JJ p
bleeding NN p
and CC p
a DT p
prolonged JJ p
bleeding NN p
time NN p
. . p

IMPLICATIONS NNP N
FOR NNP N
PRACTICE NNP N
This DT N
report NN N
presents VBZ N
key JJ N
information NN N
on IN N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
approval NN N
of IN N
ramucirumab NN N
, , N
a DT N
monoclonal JJ N
antibody NN N
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor-2 NN N
, , N
given VBN N
in IN N
combination NN N
with IN N
docetaxel NN i
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
whose WP$ p
disease NN p
has VBZ p
progressed VBN p
on IN p
or CC p
after IN p
platinum-based JJ p
chemotherapy NN p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ i
, , N
multicenter JJ N
trial NN N
, , N
previously RB p
untreated JJ p
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
were VBD p
treated VBN p
with IN p
IFN-alpha NNP i
plus CC i
ribavirin JJ i
[ NN i
17 CD i
] NN i
and CC i
randomized VBN i
for IN i
treatment NN i
with IN i
amantadine NN i
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC N
placebo NN i
( ( N
n=131 JJ N
) ) N
. . N

Changes NNS N
in IN N
quality NN o
of IN o
life NN o
and CC o
sexual JJ o
health NN o
are VBP N
associated VBN N
with IN N
low-dose JJ N
peginterferon NN N
therapy NN N
and CC N
disease NN N
progression NN N
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C. NNP p
BACKGROUND NNP p
Primary NNP p
analysis NN p
of IN p
the DT p
Hepatitis NNP p
C NNP p
Antiviral NNP p
Long-Term NNP p
Treatment NNP p
against IN p
Cirrhosis NNP p
( ( p
HALT-C NNP p
) ) p
Trial NNP N
showed VBD N
long-term JJ N
peginterferon NN N
therapy NN N
did VBD N
not RB N
reduce VB N
complications NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
and CC p
advanced JJ p
fibrosis NN p
or CC p
cirrhosis NN p
. . p

Two CD N
variants NNS N
of IN N
a DT N
novel JJ i
bleomycin NN i
, , i
etoposide RB i
, , i
doxorubicin NN i
, , i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
BEACOPP NNP i
) ) i
scheme NN i
( ( i
standard JJ i
and CC i
escalated VBD i
dose NN i
) ) i
are VBP i
compared VBN i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
COPP NNP i
) ) i
/doxorubicin NN i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
( ( i
ABVD NNP i
) ) i
. . i

The DT N
purpose NN N
of IN N
the DT N
present JJ N
application NN N
was VBD N
to TO N
fulfill VB N
a DT N
postmarketing NN N
commitment NN N
to TO N
provide VB N
long-term JJ N
efficacy NN N
and CC N
safety NN N
data NNS N
on IN N
treatment NN N
with IN N
imatinib JJ o
mesylate NN o
( ( N
Gleevec NNP N
; : N
Novartis NNP N
Pharmaceuticals NNP N
, , N
East NNP N
Hanover NNP N
, , N
NJ NNP N
) ) N
in IN N
patients NNS p
with IN p
CD117 NNP p
( ( p
+ NNP p
) ) p
unresectable JJ p
and/or JJ p
metastatic JJ p
malignant JJ p
gastrointestinal JJ p
stromal NN p
tumors NNS p
( ( p
GISTs NNP p
) ) p
. . p

Treatments NNS N
included VBD N
involved JJ N
field NN N
, , N
total JJ N
lymphoid NN N
, , N
or CC N
whole JJ i
body NN i
irradiation NN i
, , i
single JJ i
alkylating VBG i
agent NN i
chemotherapy NN i
, , i
combination NN i
chemotherapy NN i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
and CC i
prednisone NN i
( ( i
CVP NNP i
) ) i
or CC i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
C-MOPP NNP i
) ) i
, , i
or CC i
various JJ i
combinations NNS i
of IN i
chemotherapy NN i
and CC i
irradiation NN i
. . i

PATIENTS NNS N
AND CC N
METHODS NNP N
The DT N
effect NN N
of IN N
institutional JJ N
experience NN N
on IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
or CC p
IV NNP p
HNC NNP p
was VBD N
investigated VBN N
within IN N
a DT N
randomized JJ N
trial NN N
of IN N
the DT N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
0129 CD N
) ) N
, , N
which WDT N
compared VBN N
cisplatin NN i
concurrent NN i
with IN i
standard JJ i
versus NN i
accelerated VBN i
fractionation NN i
radiotherapy NN i
. . i

The DT N
Southwest NNP N
Oncology NNP N
Group NNP N
in IN N
a DT N
prospective JJ N
randomized NN N
study NN N
compared VBN N
one CD N
year NN N
of IN N
adjuvant JJ i
combination NN i
chemotherapy NN i
with IN i
continuous JJ i
CMFVP NNP i
( ( i
cyclophosphamide NN i
, , i
methotrexate NN i
, , i
5-fluorouracil JJ i
, , i
vincristine NN i
, , i
and CC i
prednisone NN i
) ) i
to TO i
two CD i
years NNS i
of IN i
intermittent JJ i
L-phenylalanine JJ i
mustard NN i
( ( i
L-PAM NNP i
) ) i
in IN N
women NNS p
with IN p
operable JJ p
breast NN p
cancer NN p
with IN p
histologically RB p
positive JJ p
axillary JJ p
lymph NN p
nodes NNS p
. . p

METHODS NNP N
In IN N
the DT N
current JJ N
investigation NN N
, , N
changes NNS N
in IN N
autonomic JJ N
tone NN N
associated VBN N
with IN N
long-term JJ N
administration NN N
of IN N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
were VBD N
measured VBN N
using VBG N
spectral JJ N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
in IN N
13 CD p
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
who WP p
were VBD p
enrolled VBN p
in IN p
a DT p
double-blind JJ p
randomized JJ p
placebo-controlled JJ i
trial NN N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
zofenopril NN i
. . i

The DT N
Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP i
in IN N
Ischemic NNP p
Heart NNP p
Disease NNP p
( ( p
LIPID NNP p
) ) p
trial NN N
is VBZ N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
evaluating VBG N
the DT N
long-term JJ N
effect NN N
of IN N
pravastatin NN i
on IN N
coronary JJ N
mortality NN N
in IN N
patients NNS p
with IN p
a DT p
previous JJ p
myocardial JJ p
infarction NN p
or CC p
unstable JJ p
angina-ischemic JJ p
heart NN p
disease NN p
( ( p
IHD NNP p
) ) p
. . p

AIM NNP N
In IN N
our PRP$ N
randomized JJ N
prospective JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficiency NN N
of IN N
plasmakinetic JJ i
resection NN i
of IN i
prostate NN i
( ( i
PKRP NNP i
) ) i
by IN N
comparing VBG N
the DT N
preoperative NN N
and CC N
postoperative JJ N
results NNS N
of IN N
the DT N
transurethral JJ i
resection NN i
of IN i
prostate NN i
( ( i
TURP NNP i
) ) i
and CC i
PKRP NNP i
techniques NNS i
which WDT N
we PRP N
administered VBD N
in IN N
patients NNS p
with IN p
benign JJ p
prostate NN p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
in IN p
our PRP$ p
clinic NN p
. . p

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
sham-controlled JJ N
, , N
single-center JJ N
trial NN N
, , N
patients NNS p
scheduled VBN p
for IN p
surgical JJ p
removal NN p
of IN p
an DT p
odontogenic JJ p
maxillary JJ p
cyst NN p
under IN p
general JJ p
anesthesia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
local JJ i
injection NN i
of IN i
lidocaine JJ i
solution NN i
with IN i
either DT i
1 CD i
mg NN i
of IN i
morphine NN i
( ( i
MLA NNP i
group NN i
) ) i
or CC i
with IN i
no DT i
morphine NN i
( ( i
LA NNP i
group NN i
) ) i
. . i

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
design NN N
and CC N
rationale NN N
of IN N
a DT N
phase NN N
2 CD N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
LX4211 NNP i
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus NN p
who WP p
have VBP p
inadequate JJ p
glycemic NNS p
control NN p
on IN p
metformin NN p
monotherapy NN p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
Forty-nine NNP p
patients NNS p
( ( p
40 CD p
with IN p
abnormal JJ p
cell-mediated JJ p
immunity NN p
) ) p
participated VBD p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
high-dose JJ N
intravenously RB N
administered VBN N
immunoglobulin NN i
G. NNP i
The DT N
patients NNS N
received VBD N
three CD N
intravenous JJ N
infusions NNS N
of IN N
a DT N
placebo JJ i
solution NN i
or CC i
immunoglobulin NN i
at IN i
a DT i
dose NN i
of IN i
2 CD i
g/kg/month NN i
. . i

Therefore RB N
, , N
we PRP N
started VBD N
the DT N
randomized VBN N
EORTC/LYSA/FIL NNP N
Intergroup NNP N
H10 NNP N
trial NN N
evaluating VBG N
whether IN N
involved-node JJ i
radiotherapy NN i
( ( i
IN-RT NNP i
) ) i
could MD N
be VB N
omitted VBN N
without IN N
compromising VBG N
progression-free JJ N
survival NN N
in IN N
patients NNS p
attaining VBG p
a DT p
negative JJ p
early JJ p
PET NNP p
scan NN p
after IN p
two CD p
cycles NNS p
of IN p
ABVD NNP i
( ( i
doxorubicin NN i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
) ) i
as IN i
compared VBN i
with IN i
standard JJ i
combined-modality NN i
treatment NN i
. . i

In IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
split-face JJ N
, , N
comparative JJ N
study NN N
we PRP N
have VBP N
assessed VBN N
efficacy NN o
, , o
tolerability NN o
, , o
and CC o
safety NN o
of IN N
a DT N
base NN N
cream NN N
containing VBG N
0.5 CD N
% NN N
BAs NNP N
as IN N
compared VBN N
to TO N
the DT N
same JJ N
cream NN N
without IN N
these DT N
active JJ N
ingredients NNS N
in IN N
the DT N
treatment NN N
of IN N
clinical JJ N
manifestations NNS N
of IN N
photoaging NN p
of IN p
facial JJ p
skin NN p
. . p

METHODS NNP N
Thirty NNP p
patients NNS p
undergoing VBG p
lower JJR p
abdominal JJ p
surgery NN p
were VBD N
randomized VBN N
in IN N
a DT N
double-blinded JJ N
manner NN N
to TO N
receive VB N
one CD N
of IN N
three CD N
solutions NNS N
: : N
0.2 CD N
% NN N
ropivacaine-4 JJ i
microg NN i
fentanyl VBD i
0.1 CD i
% NN i
ropivacaine-2 JJ i
microg NN i
fentanyl NN i
, , N
or CC N
0.05 CD N
% NN N
ropivacaine-1 JJ i
microg NN i
fentanyl NN i
for IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
standardized VBN N
combined JJ N
epidural JJ N
and CC N
general JJ N
anesthesia NN N
. . N

Eighty-seven JJ p
children NNS p
with IN p
central JJ p
nervous JJ p
system NN p
( ( p
CNS NNP p
) ) p
leukemia NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
induction NN i
intrathecal JJ i
chemotherapy NN i
( ( i
ITC NNP i
) ) i
and CC i
cranial JJ i
irradiation NN i
( ( i
CRT NNP i
) ) i
plus CC i
maintenance NN i
ITC NNP i
, , i
or CC i
induction NN i
ITC NNP i
and CC i
craniospinal JJ i
irradiation NN i
( ( i
CSpRT NNP i
) ) i
with IN i
no DT i
maintenance NN i
ITC NNP i
. . i

BACKGROUND IN N
A NNP N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
toxicity NN o
and CC o
tolerance NN o
to TO N
low-dose JJ i
subcutaneous JJ i
interleukin-2 NN i
( ( i
IL-2 NNP i
) ) i
for IN N
patients NNS p
with IN p
resected JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
at IN p
high JJ p
risk NN p
for IN p
recurrent JJ p
disease NN p
( ( p
TNM NNP p
stages VBZ p
III NNP p
and CC p
IV NNP p
resected VBD p
distant JJ p
metastases NNS p
) ) p
. . p

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN o
, , o
safety NN o
, , o
and CC o
tolerability NN o
of IN N
6 CD N
dosages NNS N
of IN N
oral JJ i
tofacitinib NN i
( ( i
CP-690,550 NNP i
) ) i
with IN i
placebo NN i
for IN N
the DT N
treatment NN N
of IN N
active JJ p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
in IN p
patients NNS p
receiving VBG p
a DT p
stable JJ p
background NN p
regimen NNS p
of IN p
methotrexate NN i
( ( i
MTX NNP i
) ) i
who WP N
have VBP N
an DT N
inadequate JJ N
response NN N
to TO N
MTX NNP i
monotherapy NN i
. . i

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
secondary JJ N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
relationships NNS N
between IN N
a DT N
reduction NN N
in IN N
psychological JJ o
distress NN o
and CC o
long-term JJ o
cardiac NN o
and CC o
psychological JJ o
outcomes NNS o
in IN N
post-myocardial JJ p
infarction NN p
patients NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
of IN p
home-based JJ p
psychosocial JJ p
nursing NN p
interventions NNS p
( ( p
the DT p
Montreal NNP p
Heart NNP p
Attack NNP p
Readjustment NNP p
Trial NNP p
[ NNP p
M-HART NNP p
] NNP p
) ) p
. . p

Consolidation NNP N
consisted VBD N
of IN N
six CD N
courses NNS N
of IN N
chemotherapy NN i
; : i
the DT N
first JJ N
, , N
third JJ N
, , N
and CC N
fifth JJ N
courses NNS N
were VBD N
a DT N
combination NN N
of IN N
high-dose JJ i
cytarabine NN i
, , i
etoposide RB i
, , i
and CC i
dexamethasone NN i
( ( i
R3 NNP i
) ) i
, , i
whereas VBD i
the DT i
second JJ i
, , i
fourth JJ i
, , i
and CC i
sixth JJ i
courses NNS i
included VBD i
vincristine NN i
, , i
prednisone NN i
, , i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
( ( i
COPADM NNP i
) ) i
. . i

CONCLUSIONS NNP N
This DT N
pilot NN N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
prospectively RB N
investigate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
a DT N
combination NN N
of IN N
0.45 CD N
% NN N
ketorolac NN N
eyedrops VBZ N
three CD N
times NNS N
a DT N
day NN N
and CC N
intravitreal VB i
ranibizumab JJ i
injections NNS i
in IN N
patients NNS p
with IN p
CNV NNP p
, , N
and CC N
suggests VBZ N
that DT N
topical JJ i
ketorolac NN i
supplements VBZ i
the DT N
activity NN N
of IN N
intravitreal NN i
ranibizumab NN i
in IN N
reducing VBG N
CMT NNP N
in IN N
CNV NNP N
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
different JJ N
doses NNS N
of IN N
antithymocyte JJ i
globulin NN i
( ( i
ATG NNP i
) ) i
on IN N
the DT N
incidence NN N
of IN N
acute JJ p
GVHD NNP p
among IN p
patients NNS p
receiving VBG p
hematopoietic JJ p
SCT NNP p
without IN p
ex JJ p
vivo FW p
T-cell-depletion NN p
from IN p
haploidentical JJ p
donors NNS p
, , p
224 CD p
patients NNS p
with IN p
standard-risk JJ p
hematological JJ p
malignancy NN p
were VBD N
randomized VBN N
in IN N
this DT N
study NN N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
199 CD p
patients NNS p
with IN p
early JJ p
active JJ p
RA NNP p
were VBD N
initially RB N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
combination NN N
of IN N
methotrexate NN i
, , i
sulfasalazine NN i
, , i
and CC i
hydroxychloroquine NN i
with IN i
prednisolone NN i
( ( i
FIN-RACo NNP i
) ) i
, , i
or CC i
treatment NN i
with IN i
a DT i
single JJ i
DMARD NNP i
( ( i
initially RB i
, , i
sulfasalazine NN i
) ) i
with IN i
or CC i
without IN i
prednisolone NN i
( ( i
SINGLE NNP i
) ) i
. . i

METHODS/RESULTS NNP N
In IN N
order NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
, , N
an DT N
international JJ N
multi-center NN N
randomized VBD N
clinical JJ N
trial NN N
( ( N
INOVATE-HF NNP N
) ) N
has VBZ N
been VBN N
designed VBN N
to TO N
assess VB N
safety NN N
and CC N
efficacy NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
in IN N
symptomatic JJ p
patients NNS p
with IN p
heart NN p
failure NN p
on IN p
optimal JJ p
medical JJ p
therapy NN p
using VBG N
the DT N
CardioFit NNP N
System NNP N
( ( N
BioControl NNP N
Medical NNP N
, , N
Yehud NNP N
, , N
Israel NNP N
) ) N
. . N

METHODS NNP N
Thirty-one CD p
adults NNS p
( ( p
age NN p
[ VBZ p
mean+/-SD JJ p
] NNP p
, , p
28.1+/-7.3 JJ p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
( ( p
n=17 JJ p
) ) p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
not RB p
otherwise RB p
specified VBN p
( ( p
n=14 JJ p
) ) p
participated VBD N
in IN N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
. . i

PURPOSE VB N
This DT N
single-blinded JJ N
, , N
randomized VBN N
, , N
controlled VBN N
pilot NN N
study NN N
aimed VBN N
to TO N
investigate VB N
whether IN N
there EX N
is VBZ N
a DT N
difference NN N
between IN N
nasal NN i
and CC i
oronasal NN i
masks NNS i
in IN N
therapeutic JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
requirement NN N
, , N
residual JJ N
disease NN N
, , N
or CC N
leak VB N
when WRB N
treating VBG N
obstructive JJ N
sleep NN N
apnea NN N
( ( N
OSA NNP N
) ) N
and CC N
if IN N
differences NNS N
were VBD N
related VBN N
to TO N
measures NNS N
of IN N
upper JJ N
airway NN N
size NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
monolateral JJ p
postmastectomy NN p
lymphedema NN p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
cycles NNS N
of IN N
intermittent JJ i
pneumatic JJ i
compression NN i
( ( N
PC NNP N
group NN N
) ) N
, , N
i.e NN N
, , N
five CD N
two-hour JJ N
sessions NNS N
per IN N
week NN N
for IN N
two CD N
weeks NNS N
, , N
to TO N
be VB N
repeated VBN N
after IN N
a DT N
five-week JJ N
interval NN N
, , N
or CC N
to TO N
no DT N
treatment NN N
( ( N
control VB N
group NN N
) ) N
. . N

Eighty-eight JJ p
postmenopausal NN p
women NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
, , p
in IN p
whom WP p
estrogen NN p
receptors NNS p
( ( p
ER NNP p
) ) p
were VBD N
positive JJ N
or CC N
unknown JJ N
, , N
were VBD N
treated VBN N
on IN N
a DT N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
tamoxifen NN i
and CC N
to TO N
assess VB N
the DT N
therapeutic JJ N
advantage NN N
of IN N
sequentially RB N
adding VBG N
low-dose JJ N
cyclophosphamide-methotrexate-5-fluorouracil NN i
( ( i
CMF NNP i
) ) i
chemotherapy NN i
in IN N
tamoxifen JJ N
responders NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN i
and CC i
isoflurane NN i
via IN N
direct JJ N
arterial JJ N
blood NN N
pressure NN N
measurements NNS N
and CC N
the DT N
lithium NN N
dilution NN N
cardiac NN N
output NN N
( ( N
LDCO NNP N
) ) N
on IN N
premedicated VBN p
healthy JJ p
dogs NNS p
undergoing VBG p
elective JJ p
tibial JJ p
plateau NN p
leveling VBG p
osteotomy NN p
( ( p
TPLO NNP p
) ) p
. . p

BACKGROUND IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
the DT N
liposome-encapsulated JJ i
doxorubicin NN i
, , i
TLC NNP i
D-99 NNP i
( ( i
Myocet NNP i
, , i
Elan NNP i
Pharmaceuticals NNP i
, , i
Princeton NNP i
, , i
NJ NNP i
) ) i
, , i
and CC i
conventional JJ i
doxorubicin NN i
in IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
breast NN p
carcinoma NN p
( ( p
MBC NNP p
) ) p
. . p

BACKGROUND IN N
The DT N
VIOS NNP N
( ( N
Vascular JJ N
Improvement NN N
with IN N
Olmesartan NNP N
medoxomil NNP N
Study NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
parallel JJ N
study NN N
to TO N
determine VB N
the DT N
relative JJ N
effects NNS N
of IN N
suppressing VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
the DT N
angiotensin NN i
receptor NN i
antagonist NN i
olmesartan IN i
medoxomil NN i
versus NN N
suppressing VBG N
sympathetic JJ N
drive NN N
with IN N
the DT N
beta-adrenoceptor JJ i
antagonist NN i
atenolol NN i
on IN N
remodeling NN N
of IN N
the DT N
subcutaneous JJ N
small JJ N
resistance NN N
vessel NN N
. . N

METHODS NN N
In IN N
our PRP$ N
parallel-group NN N
randomised VBN N
trial NN N
, , N
patients NNS p
meeting NN p
Oxford NNP p
criteria NN p
for IN p
chronic JJ p
fatigue NN p
syndrome NN p
were VBD p
recruited VBN p
from IN p
six CD p
secondary-care JJ p
clinics NNS p
in IN p
the DT p
UK NNP p
and CC p
randomly RB i
allocated VBN i
by IN i
computer-generated JJ i
sequence NN i
to TO i
receive VB i
specialist NN i
medical JJ i
care NN i
( ( i
SMC NNP i
) ) i
alone RB i
or CC i
with IN i
adaptive JJ i
pacing VBG i
therapy NN i
( ( i
APT NNP i
) ) i
, , i
CBT NNP i
, , i
or CC i
GET NNP i
. . i

METHODS NNP N
Forty NNP p
outpatients NNS p
aged VBD p
4 CD p
to12 NN p
years NNS p
, , p
who WP p
were VBD p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
based VBN p
on IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
criteria NNS p
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
a DT N
two-by-two JJ N
factorial JJ N
design NN N
, , N
we PRP N
enrolled VBD p
consecutive JJ p
adults NNS p
( ( p
age NN p
? . p
years NNS p
) ) p
admitted VBD p
to TO p
one CD p
of IN p
11 CD p
French JJ p
intensive-care JJ p
units NNS p
and CC p
requiring VBG p
at IN p
least JJS p
one CD p
of IN p
central-venous JJ p
, , p
haemodialysis NN p
, , p
or CC p
arterial JJ p
catheters NNS p
. . p

This DT N
report NN N
describes VBZ N
the DT N
design NN N
, , N
recruitment NN N
, , N
enrolment NN N
and CC N
baseline JJ N
results NNS N
of IN N
the DT N
Treatment NNP N
of IN N
Lead-Exposed JJ N
Children NNP N
( ( N
TLC NNP N
) ) N
trial NN N
, , N
a DT N
randomised VBN N
, , N
multicentre FW i
, , i
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
treating VBG N
lead-exposed JJ N
children NNS N
with IN N
succimer NN N
, , N
a DT N
drug NN N
that WDT N
enhances VBZ N
urinary JJ o
excretion NN o
of IN o
lead NN o
, , o
on IN o
cognitive JJ o
, , o
behavioural JJ o
and CC o
physical JJ o
development NN o
. . o

The DT N
Nutritional NNP N
Prevention NNP N
of IN N
Cancer NNP N
Trial NNP N
was VBD N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
selenium NN i
as IN i
selenized VBN i
yeast NN i
( ( N
200 CD N
microg NNS N
daily RB N
) ) N
could MD N
prevent VB N
nonmelanoma JJ o
skin JJ o
cancer NN o
among IN N
1312 CD p
patients NNS p
from IN p
the DT p
Eastern NNP p
United NNP p
States NNPS p
who WP p
had VBD p
previously RB p
had VBN p
this DT p
disease NN p
. . p

The DT N
efficacy NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
as IN N
an DT N
adjunct NN N
to TO N
narcotic JJ N
medications NNS N
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
was VBD N
assessed VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
patients NNS p
following VBG p
coronary JJ p
artery JJ p
bypass NN p
graft NN p
( ( p
CABG NNP p
) ) p
surgery NN p
with IN p
the DT p
right NN p
or CC p
left VBD p
internal JJ p
thoracic NN p
artery NN p
( ( p
ITA NNP p
) ) p
. . p

To TO N
define VB N
the DT N
current JJ N
efficacy NN N
of IN N
Fansidar NNP i
( ( i
F. NNP i
Hoffmann-La NNP i
Roche NNP i
Ltd. NNP i
, , i
Basel NNP i
Switzerland NNP i
) ) i
( ( i
pyrimethamine NN i
and CC i
sulfadoxine NN i
) ) i
, , i
primaquine NN i
in IN N
a DT N
high JJ N
dose NN N
, , N
and CC N
artesunate NN N
for IN N
treating VBG N
acute JJ N
Plasmodium NNP N
vivax NN N
malaria NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
clinical JJ N
trial NN N
of IN N
these DT N
3 CD N
drugs NNS N
in IN N
an DT N
open-label JJ N
study NN N
. . N

This DT N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
Cappra NNP i
( ( i
? . i
) ) i
, , i
a DT i
traditional JJ i
herbal NN i
medicine NN i
which WDT N
was VBD N
used VBN N
in IN N
Thailand NNP N
for IN N
decades NNS N
, , N
for IN N
the DT N
treatment NN N
of IN N
mild NN p
and CC p
mild NN p
to TO p
moderate VB p
ED NNP p
in IN p
Thai NNP p
patients NNS p
. . p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
comparative NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
survival NN o
rate NN o
and CC N
the DT N
condition NN N
of IN N
the DT N
peri-implant JJ N
tissues NNS N
of IN N
the DT N
IMZ NNP i
implant NN i
system NN i
( ( i
two-stage JJ i
cylindertype NN i
) ) i
, , i
the DT i
Br NNP i
implant NN i
system NN i
( ( i
two-stage JJ i
screwtype NN i
) ) i
and CC i
the DT i
ITI NNP i
implant NN i
system NN i
( ( N
one-stage JJ N
screwtype NN N
) ) N
supporting VBG N
a DT N
mandibular JJ N
overdenture NN N
during IN N
a DT N
5-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
recently RB N
published VBN N
Ongoing NNP N
Telmisartan NNP i
Alone NNP i
and CC i
in IN i
Combination NNP i
With IN i
Ramipril NNP i
Global NNP i
Endpoint NNP i
Trial NNP i
( ( i
ONTARGET NNP i
) ) i
in IN N
patients NNS p
with IN p
vascular JJ p
disease NN p
or CC p
high-risk JJ p
diabetes NNS p
, , N
as IN N
the DT N
largest JJS N
published VBN N
comparative JJ N
trial NN N
of IN N
these DT N
agent NN N
classes NNS N
, , N
provides VBZ N
further JJ N
evidence NN N
concerning VBG N
the DT N
comparison NN N
between IN N
the DT N
angiotensin-receptor NN i
blockers NNS i
( ( i
ARBs NNP i
) ) i
and CC i
the DT i
angiotensin-converting JJ i
enzyme NN i
inhibitors NNS i
( ( i
ACEIs NNP i
) ) i
. . i

CONCLUSIONS NN N
It PRP N
is VBZ N
feasible JJ N
to TO N
conduct VB N
a DT N
prehospital JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
HSD NNP N
for IN N
treatment NN N
of IN N
blunt NN p
trauma NN p
patients NNS p
with IN p
head JJ p
injuries NNS p
; : p
however RB N
, , N
consent NN N
for IN N
neurofunctional JJ N
outcomes NNS N
in IN N
this DT N
cohort NN N
is VBZ N
problematic JJ N
and CC N
threatens VBZ N
the DT N
feasibility NN N
of IN N
definitive JJ N
trials NNS N
using VBG N
these DT N
potentially RB N
meaningful JJ N
end NN N
points NNS N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
examine VB N
potential JJ N
threats NNS N
to TO N
internal JJ N
and CC N
external JJ N
study NN N
validity NN N
caused VBN N
by IN N
differential JJ N
patient NN N
withdrawal NN N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
evaluating VBG N
pharmacist JJ N
management NN N
of IN N
hypertension NN N
, , N
to TO N
compare VB N
the DT N
characteristics NNS N
of IN N
patients NNS p
who WP p
withdrew VBP p
with IN p
those DT p
of IN p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
, , p
and CC p
to TO p
identify VB p
characteristics NNS p
that WDT p
predispose VBP p
patients NNS p
to TO p
withdraw VB p
from IN p
hypertension NN p
management NN p
. . p

PURPOSE NN N
To TO N
evaluate VB N
the DT N
association NN N
of IN N
efavirenz JJ i
hypersusceptibility NN i
( ( i
EFV-HS NNP i
) ) i
with IN N
clinical JJ N
outcome NN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
trial NN N
of IN N
EFV NNP i
plus CC i
indinavir NN i
( ( i
EFV+IDV NNP i
) ) i
vs. FW i
EFV+IDV NNP i
plus CC i
abacavir NN i
( ( i
ABC NNP i
) ) i
in IN N
283 CD p
nucleoside-experienced JJ p
HIV-infected JJ p
patients NNS p
. . p

MATERIALS NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
patients NNS p
with IN p
dysfunctional JJ p
, , p
stenotic JJ p
hemodialysis NN p
arteriovenous JJ p
fistulas NNS p
( ( p
AVFs NNP p
) ) p
, , p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
CBA NNP i
or CC i
HPBA NNP i
if IN N
conventional JJ N
PTA NNP N
had VBD N
suboptimal JJ N
results NNS N
( ( N
ie JJ N
, , N
residual JJ N
stenosis NN N
> VBD N
30 CD N
% NN N
) ) N
. . N

OBJECTIVE IN N
This DT N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
extrinsic JJ N
stain NN N
reduction NN N
achieved VBN N
by IN N
brushing VBG N
with IN N
a DT N
whitening NN i
dentifrice NN i
and CC N
powered VBD N
toothbrush NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
a DT N
whitening NN N
booster NN N
paste NN N
to TO N
this DT N
regimen NNS N
would MD N
enhance VB N
its PRP$ N
stain NN N
reducing VBG N
effectiveness NN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
controlled JJ p
clinical JJ p
trial NN p
at IN p
two CD p
tertiary JJ p
care NN p
centres NNS p
of IN p
patients NNS p
with IN p
SLE NNP p
according VBG p
to TO p
the DT p
ACR NNP p
criteria NNS p
, , p
with IN p
incident NN p
( ( p
no DT p
more JJR p
than IN p
15 CD p
days NNS p
) ) p
onset NN p
of IN p
severe JJ p
NP NNP p
manifestations NNS p
such JJ p
as IN p
seizures NNS p
, , p
optic JJ p
neuritis NN p
, , p
peripheral JJ p
or CC p
cranial JJ p
neuropathy NN p
, , p
coma NN p
, , p
brainstem NN p
disease NN p
, , p
or CC p
transverse JJ p
myelitis NN p
. . p

OBJECTIVES NNP N
According VBG N
to TO N
the DT N
proposed VBN N
interference NN N
of IN N
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
with IN N
pathophysiologic JJ N
processes NNS N
of IN N
autistic JJ N
disorders NNS N
( ( N
ADs NNP N
) ) N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
NAC NNP i
as IN N
an DT N
adjunct NN N
to TO N
risperidone VB i
in IN N
the DT N
treatment NN N
of IN N
ADs NNP N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
conduct VB N
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
the DT N
Early JJ i
Start NNP i
Denver NNP i
Model NNP i
( ( i
ESDM NNP i
) ) i
, , N
a DT N
comprehensive JJ i
developmental JJ i
behavioral JJ i
intervention NN i
, , N
for IN N
improving VBG N
outcomes NNS N
of IN N
toddlers NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
Eyes NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
sham NN i
injections NNS i
plus CC i
prompt JJ i
laser NN i
, , i
intravitreal JJ i
ranibizumab NN i
injections NNS i
plus CC i
prompt JJ i
laser NN i
, , i
intravitreal JJ i
ranibizumab NN i
injections NNS i
plus CC i
deferred JJ i
laser NN i
, , i
or CC i
intravitreal VB i
triamcinolone JJ i
acetonide JJ i
injections NNS i
plus CC i
prompt NN i
laser NN i
up RB N
to TO N
every DT N
16 CD N
weeks NNS N
with IN N
sham JJ N
injections NNS N
intermittently RB N
. . N

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN i
wound NN i
care NN i
with IN i
adjunctive JJ i
hyperbaric JJ i
oxygen NN i
therapy NN i
( ( i
HBOT NNP i
) ) i
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
, , N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
: : p
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
monthly JJ N
alternating VBG N
ABVD/MOPP NNP N
compared VBN N
to TO N
ABVD/OPP NNP i
regimens NNS i
in IN N
patients NNS p
with IN p
advanced JJ p
stage NN p
Hodgkin NNP p
's POS p
disease NN p
( ( p
HD NNP p
) ) p
, , p
as RB p
well RB p
as IN p
in IN p
early JJ p
stage NN p
patients NNS p
with IN p
systemic JJ p
symptoms NNS p
and/or VBP p
bulky JJ p
disease NN p
. . p

STUDY NNP N
METHODS NNP N
Women NNP p
, , p
aged VBD p
18-34 CD p
years NNS p
, , p
with IN p
no DT p
contraindications NNS p
to TO p
the DT p
use NN p
of IN p
combined JJ p
OCs NNP p
, , p
were VBD p
randomized VBN p
to TO p
three CD p
cycles NNS p
of IN p
treatment NN p
with IN p
a DT p
CVR NNP i
delivering NN i
NES/EE NNP i
( ( i
150/15 CD i
microg/day NN i
) ) i
or CC i
a DT i
combined JJ i
OC NNP i
providing VBG i
LNG NNP i
and CC i
EE NNP i
( ( i
150/30 CD i
microg NN i
per IN i
tablet NN i
) ) i
. . i

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN N
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
four CD N
or CC N
eight CD N
courses NNS N
of IN N
cytotoxic NN i
chemotherapy NN i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
and CC i
etoposide NN i
and CC i
also RB i
randomised VBD i
to TO i
receive VB i
, , i
on IN i
disease NN i
progression NN i
, , i
either CC i
second JJ i
line NN i
chemotherapy NN i
( ( i
methotrexate NN i
and CC i
doxorubicin NN i
) ) i
or CC i
symptomatic JJ i
treatment NN i
only RB i
. . i

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
split-face JJ N
randomized JJ N
prospective JJ N
open-label JJ N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
sequential JJ i
erbium NN i
: : i
yttrium-aluminum-garnet NN i
( ( i
Er NNP i
: : i
YAG NN i
) ) i
laser NN i
versus NN i
intense JJ i
pulsed VBN i
light NN i
( ( i
IPL NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
facial JJ p
photodamage NN p
. . p

Efficacy NN N
of IN N
a DT N
family NN i
practice-based JJ i
lifestyle JJ i
intervention NN i
program NN i
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS p
with IN p
high JJ p
normal JJ p
blood NN p
pressure NN p
and/or RB p
high JJ p
normal JJ p
blood NN p
glucose NN p
( ( p
SNAC NNP p
) ) p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

We PRP N
evaluated VBD N
whether IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
type NN N
is VBZ N
associated VBN N
with IN N
distinct JJ N
pretreatment JJ N
clinical JJ N
characteristics NNS N
and CC N
therapeutic JJ N
outcome NN N
in IN N
previously RB p
untreated VBN p
adult NN p
APL NNP p
patients NNS p
registered VBD p
to TO p
protocol VB p
INT NNP p
0129 CD p
by IN p
the DT p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
, , p
the DT p
Southwest NNP p
Oncology NNP p
Group NNP p
, , p
and CC p
the DT p
Cancer NNP p
and CC p
Leukemia NNP p
Group NNP p
B NNP p
. . p

UNLABELLED VBN N
BACKGROUND NNP N
AND NNP N
AIM NNP N
OF NNP N
INVESTIGATION NNP N
: : N
Intramuscular NNP N
( ( N
IM NNP N
) ) N
administration NN N
has VBZ N
been VBN N
considered VBN N
to TO N
be VB N
safer JJR N
than IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
for IN N
opioids NNS N
on IN N
wards NNS N
, , N
but CC N
a DT N
comparative JJ N
knowledge NN N
of IN N
patient JJ N
safety NN N
and CC N
analgesic JJ N
potency NN N
following VBG N
a DT N
single JJ N
dose NN N
of IN N
IV NNP N
and CC N
IM NNP N
administration NN N
is VBZ N
lacking VBG N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
adjuvant JJ i
chemotherapy NN i
employing VBG i
mitomycin JJ i
C NNP i
( ( i
MMC NNP i
) ) i
and CC i
carmofur NN i
( ( i
HCFU NNP i
) ) i
for IN N
patients NNS p
with IN p
noncuratively RB p
resected VBN p
colorectal JJ p
carcinoma NN p
, , p
a DT p
cooperative JJ p
study NN p
was VBD p
performed VBN p
by IN p
54 CD p
institutions NNS p
in IN p
the DT p
Kyushu NNP p
and CC p
Chugoku NNP p
areas NNS p
of IN p
Japan NNP p
. . p

The DT N
objective NN N
of IN N
this DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
was VBD N
to TO N
determine VB N
if IN N
topical JJ i
nasal NN i
fluticasone NN i
is VBZ N
effective JJ N
at IN N
decreasing VBG N
subjective JJ o
congestion NN o
and CC o
daytime JJ o
somnolence NN o
and CC o
improving VBG o
sleep NN o
and CC N
if IN N
this DT N
improvement NN N
correlated VBD N
with IN N
a DT N
change NN N
in IN N
overnight JJ N
sleep NN N
testing NN N
( ( N
polysomnography NN N
) ) N
. . N

OBJECTIVE NNP N
To TO N
provide VB N
an DT N
example NN N
of IN N
an DT N
occupational JJ N
therapy NN N
feasibility NN N
study NN N
and CC N
evaluate VB N
the DT N
implementation NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
and CC N
feasibility NN N
trial NN N
examining VBG N
the DT N
impact NN N
of IN N
a DT N
sensory-adapted JJ i
dental NN i
environment NN i
( ( i
SADE NNP i
) ) i
to TO N
enhance VB N
oral JJ N
care NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Here RB N
, , N
we PRP N
report VBP N
a DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
that WDT N
examined VBD N
the DT N
neural JJ N
and CC N
behavioral JJ N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ i
oxytocin NN i
on IN N
emotion NN o
recognition NN o
in IN N
individuals NNS p
with IN p
Asperger NNP p
syndrome NN p
( ( p
AS IN p
) ) p
, , p
a DT p
clinical JJ p
condition NN p
characterized VBN p
by IN p
impaired JJ p
eye NN p
gaze NN p
and CC p
facial JJ p
emotion NN p
recognition NN p
. . p

Methylphenidate NNP i
and CC N
baseball NN N
playing NN N
in IN N
ADHD NNP p
children NNS p
: : p
who WP N
's VBZ N
on IN N
first JJ N
? . N
The DT N
effects NNS N
of IN N
0.3 CD N
and CC N
0.6 CD N
mg/kg NN N
methylphenidate NN i
were VBD N
analyzed VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
cross-over JJ N
study NN N
in IN N
which WDT N
17 CD p
boys NNS p
( ( p
ages IN p
7.8-9.9 CD p
years NNS p
) ) p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
played VBD p
in IN p
baseball NN p
games NNS p
. . p

Paucity NN N
of IN N
studies NNS N
evaluating VBG N
the DT N
efficacy NN N
of IN N
single-site JJ i
vs. FW i
double-site JJ i
injections NNS i
at IN i
celiac JJ i
trunk NN i
for IN i
ultrasound-guided JJ i
celiac NN i
plexus NN i
neurolysis NN i
( ( i
USCPN NNP i
) ) i
prompted VBD N
us PRP N
to TO N
conduct VB N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-blind JJ N
clinical JJ N
trial NN N
to TO N
compare VB N
USCPN NNP i
using VBG i
bilateral JJ i
paramedian NN i
( ( i
double JJ i
needle NN i
) ) i
technique NN i
with IN i
unilateral JJ i
paramedian NN i
( ( i
single JJ i
needle NN i
) ) i
technique NN i
. . i

In IN N
this DT N
pilot NN N
randomized VBD N
clinical JJ N
trial NN N
, , N
we PRP N
challenged VBD N
the DT N
conventional JJ i
low-carbohydrate/higher-fat JJ i
( ( i
LC/CONV NNP i
) ) i
diet NN i
, , i
hypothesizing VBG i
that IN i
a DT i
higher-complex JJ i
carbohydrate/lower-fat NN i
( ( i
CHOICE NNP i
) ) i
diet NN i
would MD N
improve VB N
maternal JJ o
insulin NN o
resistance NN o
( ( o
IR NNP o
) ) o
, , o
adipose JJ o
tissue NN o
( ( o
AT NNP o
) ) o
lipolysis NN o
, , o
and CC o
infant JJ o
adiposity NN o
. . o

To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
two CD N
1-week JJ N
low-dose JJ N
triple-therapy JJ N
drug NN N
regimens NNS N
involving VBG N
antisecretory NN N
drugs NNS N
for IN N
Helicobacter NNP p
pylori JJ p
infection NN p
, , p
99 CD p
patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
were VBD N
treated VBN N
with IN N
either DT N
lansoprazole NN i
( ( i
LPZ NNP i
) ) i
or CC i
ranitidine NN i
( ( i
RNT NNP i
) ) i
used VBD N
together RB N
with IN N
clarithromycin NN i
( ( i
CAM NNP i
) ) i
and CC i
metrinidazole $ i
( ( i
MTZ NNP i
) ) i
. . i

OBJECTIVE IN N
A NNP N
randomized NN N
, , N
controlled VBD N
trial NN N
of IN N
screening NN i
, , i
brief JJ i
intervention NN i
, , i
and CC i
referral JJ i
to TO i
treatment NN i
( ( i
SBIRT NNP i
) ) i
for IN p
drinking NN p
and CC p
related JJ p
problems NNS p
among IN p
at-risk JJ p
and CC p
dependent JJ p
drinkers NNS p
was VBD p
conducted VBN p
in IN p
an DT p
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
in IN p
Sosnowiec NNP p
, , p
Poland NNP p
, , p
among IN p
patients NNS p
ages VBZ p
18 CD p
years NNS p
and CC p
older JJR p
. . p

METHODS NNP N
Twenty NNP p
randomized VBD p
patients NNS p
who WP p
underwent VBP p
a DT p
primary JJ p
total JJ p
hip NN p
replacement NN p
with IN p
use NN p
of IN p
a DT p
minimally RB i
invasive JJ i
modified VBN i
Watson-Jones JJ i
approach NN i
( ( i
minimally RB i
invasive JJ i
group NN i
) ) i
were VBD N
compared VBN N
with IN N
a DT N
group NN N
of IN N
twenty NN N
patients NNS N
who WP N
underwent VBD N
a DT N
total JJ i
hip NN i
arthroplasty NN i
with IN i
use NN i
of IN i
a DT i
standard JJ i
transgluteal NN i
Hardinge NNP i
approach NN i
( ( i
standard JJ i
group NN i
) ) i
. . i

We PRP N
designed VBD N
a DT N
randomized JJ N
trial NN N
to TO N
assess VB N
whether IN N
the DT N
early JJ N
withdrawal NN N
of IN N
cyclosporine NN i
( ( i
CsA NNP i
) ) i
followed VBN N
by IN N
the DT N
initiation NN N
of IN N
everolimus NN i
( ( i
Evr NNP i
) ) i
monotherapy NN i
in IN p
de FW p
novo FW p
liver FW p
transplantation NN p
( ( p
LT NNP p
) ) p
patients NNS p
would MD N
result VB N
in IN N
superior JJ N
renal JJ N
function NN N
compared VBN N
to TO N
a DT N
CsA-based JJ N
immunosuppression NN N
protocol NN N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
a DT N
zotarolimus-eluting JJ i
stent NN i
( ( i
ZES NNP i
; : i
Endeavor NNP i
Sprint NNP i
, , i
n=80 RB i
) ) i
to TO i
a DT i
sirolimus-eluting JJ i
stent NN i
( ( i
SES NNP i
; : i
Cypher NNP i
, , p
n=80 NN p
) ) p
in IN p
patients NNS p
with IN p
CTO NNP p
lesion NN p
with IN p
a DT p
reference NN p
vessel NN p
diameter NN p
? . p
2.5mm CD p
. . p

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
was VBD N
performed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
2-g JJ N
single JJ N
dose NN N
of IN N
metronidazole NN i
for IN N
male JJ p
partners NNS p
of IN p
women NNS p
with IN p
bacterial JJ p
vaginosis NN p
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
improving VBG N
cure NN o
rate NN o
and CC o
decreasing VBG o
recurrence NN o
rate NN o
. . o

As IN N
there EX N
is VBZ N
evidence NN N
of IN N
a DT N
possible JJ N
immunoregulatory JJ N
role NN N
for IN N
H2-histamine NNP N
receptor NN N
antagonists NNS N
, , N
we PRP N
carried VBD N
out RP N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
in IN N
vivo NN N
and CC N
in IN N
vitro JJ N
effect NN N
of IN N
cimetidine NN i
, , N
an DT N
H2-blocker NNP N
, , N
in IN N
the DT N
treatment NN N
of IN N
herpes NNS p
zoster JJ p
infection NN p
. . p

Thirty-two JJ p
adults NNS p
with IN p
acute JJ p
myeloid NN p
leukaemia NN p
( ( p
AML NNP p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
, , N
from IN N
the DT N
time NN N
of IN N
diagnosis NN N
, , N
either CC N
chemotherapy NN i
alone RB i
( ( i
C NNP i
group NN i
) ) i
or CC i
chemotherapy JJ i
plus CC i
Bacille NNP i
Calmette-Gu NNP i
vaccine NN i
( ( i
BCG NNP i
) ) i
( ( i
C+I NNP i
group NN i
) ) i
. . i

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN N
and CC N
relevance NN N
of IN N
OPN NNP N
in IN N
newly RB p
diagnosed VBN p
AML NNP p
patients NNS p
from IN p
2 CD p
large JJ p
study NN p
groups NNS p
( ( p
the DT p
German JJ p
AML NNP p
Cooperative NNP p
Group NNP p
and CC p
the DT p
Dutch-Belgian JJ p
Hematology NNP p
Oncology NNP p
Cooperative NNP p
group NN p
) ) p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
, , N
first RB N
, , N
whether IN N
intra- JJ i
or CC i
postoperative JJ i
music NN i
therapy NN i
could MD N
influence VB N
stress NN N
and CC N
immune JJ N
response NN N
during IN N
and CC N
after IN N
general JJ N
anaesthesia NN N
and CC N
second JJ N
, , N
if IN N
there EX N
was VBD N
a DT N
different JJ N
response NN N
between IN N
patients NNS N
exposed VBN N
to TO N
music NN i
intra- NN i
or CC i
postoperatively RB i
. . i

PURPOSE VB N
A NNP N
prognostic JJ N
model NN N
for IN N
5-year JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
consisting VBG N
of IN N
recursive JJ N
partitioning NN N
analysis NN N
( ( N
RPA NNP N
) ) N
and CC N
a DT N
nomogram NN N
, , N
was VBD N
developed VBN N
for IN N
patients NNS p
with IN p
early-stage JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
ES-NSCLC NNP p
) ) p
treated VBD p
with IN p
stereotactic JJ i
ablative JJ i
radiation NN i
therapy NN i
( ( i
SABR NNP i
) ) i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
homocysteine NN o
, , o
and CC o
lipids NNS o
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD p
cases NNS p
of IN p
SCD NNP p
among IN p
apparently RB p
healthy JJ p
men NNS p
enrolled VBN p
in IN p
the DT p
Physician NNP p
's POS p
Health NNP p
Study NNP p
. . p

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
combined VBN o
coronary JJ o
events NNS o
( ( o
coronary JJ o
death NN o
, , o
nonfatal JJ o
MI NNP o
, , o
percutaneous JJ o
transluminal JJ o
coronary NN o
angioplasty NN o
[ NNP o
PTCA NNP o
] NNP o
or CC o
coronary JJ o
artery NN o
bypass NN o
graft NN o
surgery NN o
[ NNP o
CABG NNP o
] NNP o
) ) o
, , o
the DT o
primary JJ o
trial NN o
end NN o
point NN o
( ( o
coronary JJ o
death NN o
or CC o
nonfatal JJ o
MI NNP o
) ) o
and CC o
stroke NN o
. . o

In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
virologic JJ N
response NN N
to TO N
retreatment VB N
with IN N
peginterferon JJ i
alfa-2a JJ i
and CC i
ribavirin NN i
( ( i
RBV NNP i
) ) i
, , N
as IN N
a DT N
function NN N
of IN N
the DT N
baseline NN N
fibrosis NN N
score NN N
( ( N
Ishak NNP N
staging VBG N
) ) N
and CC N
platelet NN N
count NN N
, , N
in IN N
1,046 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
Hepatitis NNP p
C NNP p
Antiviral NNP p
Long-term NNP p
Treatment NNP p
against IN p
Cirrhosis NNP p
( ( p
HALT-C NNP p
) ) p
Trial NNP p
. . p

In IN N
conclusion NN N
, , N
initiating VBG N
therapy NN N
with IN N
a DT N
combination NN N
of IN N
valsartan NN i
and CC i
low-dose JJ i
HCTZ NNP i
results NNS N
in IN N
early JJ N
, , N
improved JJ N
BP NNP o
efficacy NN o
with IN o
similar JJ o
tolerability NN o
as IN N
compared VBN N
with IN N
starting VBG N
treatment NN N
with IN N
a DT N
low JJ N
or CC N
higher JJR N
dose NN N
of IN N
valsartan NN i
for IN N
patients NNS p
with IN p
stage-1 JJ p
and CC p
stage-2 JJ p
hypertension NN p
. . p

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ N
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS p
aged VBN p
6-18 CD p
years NNS p
newly RB p
diagnosed VBN p
with IN p
cancer NN p
in IN p
eastern JJ p
Denmark NNP p
( ( p
n=120 NN p
) ) p
and CC p
a DT p
matched JJ p
control NN p
group NN p
in IN p
western JJ p
Denmark NNP p
( ( p
n=120 NN p
) ) p
. . p

METHODS NNP N
Using VBG N
a DT N
parallel NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
, , N
we PRP N
conducted VBD N
an DT N
interventional JJ N
study NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
supplement NN i
of IN i
cocoa NN i
husk NN i
rich JJ i
in IN i
dietary JJ i
fiber NN i
on IN N
intestinal JJ N
transit NN N
time NN N
and CC N
other JJ N
indices NNS N
of IN N
constipation NN N
in IN N
children NNS p
with IN p
constipation NN p
. . p

METHODS NNP N
The DT N
Intramuscular NNP N
Diamorphine NNP i
versus IN N
Intramuscular NNP N
Pethidine NNP i
( ( i
IDvIP NNP i
) ) i
trial NN N
is VBZ N
a DT N
randomised JJ N
double-blind NN N
two CD N
centre NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN i
and CC N
pethidine NN i
regarding VBG N
their PRP$ N
analgesic JJ N
efficacy NN N
in IN N
labour NN p
and CC p
their PRP$ p
side NN p
effects NNS p
in IN p
mother NN p
, , p
fetus NN p
and CC p
neonate NN p
. . p

METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB i
subcutaneous JJ i
enoxaparin NN i
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ i
intravenous JJ i
unfractionated JJ i
heparin NN i
( ( i
UFH NNP i
) ) i
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS N
with IN N
proximal JJ N
vein NN N
thrombosis NN N
. . N

To TO N
estimate VB N
and CC N
compare VB N
hospital NN o
costs NNS o
associated VBN N
with IN N
conventional JJ i
balloon NN i
angioplasty NN i
( ( i
percutaneous JJ i
transluminal NN i
angioplasty NN i
[ NNP i
PTA NNP i
] NNP i
) ) i
and CC i
stent JJ i
placement NN i
for IN N
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
arterial JJ p
disease NN p
, , N
the DT N
authors NNS N
performed VBD N
a DT N
prospective JJ N
economic JJ N
evaluation NN N
in IN N
conjunction NN N
with IN N
the DT N
Intracoil NNP i
Femoropopliteal NNP i
Stent NNP i
Trial NNP i
( ( i
VascuCoil NNP i
) ) i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
Two CD p
hundred VBD p
thirty-seven JJ p
consecutive JJ p
women NNS p
patients NNS p
, , p
aged VBD p
75 CD p
years NNS p
or CC p
younger JJR p
, , p
hospitalized VBN p
for IN p
acute JJ p
myocardial JJ p
infarction NN p
, , p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
, , p
or CC p
percutaneous JJ p
coronary JJ p
intervention NN p
were VBD N
randomized VBN N
to TO N
a DT N
group-based JJ i
psychosocial JJ i
intervention NN i
program NN i
or CC i
usual JJ i
care NN i
. . i

METHODS NNP N
Sixty-six NNP p
children NNS p
( ( p
mean JJ p
age NN p
7.5 CD p
y NN p
) ) p
with IN p
autistic JJ p
disorder NN p
, , p
Asperger NNP p
's POS p
disorder NN p
, , p
and CC p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , N
were VBD N
randomized VBN N
to TO N
varying VBG N
sequences NNS N
of IN N
placebo NN i
and CC i
three CD i
different JJ i
doses NNS i
of IN i
methylphenidate NN i
during IN N
a DT N
4-week JJ N
blinded NN N
, , N
crossover NN N
study NN N
. . N

Following VBG N
a DT N
starting VBG N
dose NN N
of IN N
either CC N
2.5 CD N
mg JJ N
once-daily RB N
quinapril NN i
, , i
or CC i
6.25 CD i
mg JJ i
twice-daily JJ i
captopril NN i
, , N
patients NNS N
were VBD N
reviewed VBN N
at IN N
two-weekly JJ N
intervals NNS N
, , N
and CC N
following VBG N
clinical JJ N
assessment NN N
a DT N
decision NN N
was VBD N
made VBN N
either DT N
to TO N
titrate VB N
up RP N
to TO N
the DT N
next JJ N
medication NN N
stage NN N
or CC N
to TO N
enter VB N
the DT N
patient NN N
into IN N
the DT N
16-week JJ N
maintenance NN N
phase NN N
. . N

Then RB N
, , N
to TO N
investigate VB N
potential JJ N
effects NNS N
of IN N
oxytocin NN i
on IN N
these DT N
behavioural JJ N
and CC N
neural JJ N
deficits NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
within-subject JJ N
trial NN N
for IN N
single-dose JJ N
intranasal JJ N
administration NN N
of IN N
24 CD N
IU NNP N
oxytocin NN i
in IN N
an DT N
independent JJ N
group NN N
of IN N
20 CD p
males NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVE IN N
A NNP N
randomized JJ N
phase NN N
II NNP N
trial NN N
was VBD N
conducted VBN N
to TO N
test VB N
whether IN N
the DT N
addition NN N
of IN N
gemcitabine NN i
to TO i
weekly VB i
docetaxel NN i
could MD N
improve VB N
the DT N
objective JJ o
response NN o
rate NN o
and CC o
survival NN o
outcomes NNS o
as IN N
second-line JJ N
chemotherapy NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
who WP p
have VBP p
failed VBN p
a DT p
paclitaxel-containing JJ p
regimen NN p
. . p

A DT N
European JJ N
multicenter NN N
study NN N
has VBZ N
examined VBN N
the DT N
use NN N
of IN N
dopexamine NN i
in IN N
patients NNS p
undergoing VBG p
major JJ p
abdominal JJ p
surgery NN p
, , N
showing VBG N
a DT N
trend NN N
toward IN N
improved VBN N
survival NN o
and CC o
reduced JJ o
complications NNS o
in IN N
high-risk JJ N
patients NNS N
when WRB N
receiving VBG N
low-dose JJ N
dopexamine NN i
( ( N
0.5 CD N
? . N
? . N
kg NN N
( ( N
-1 NN N
) ) N
? . N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

This DT N
pilot NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
evaluated VBD N
the DT N
feasibility NN N
and CC N
preliminary JJ N
outcomes NNS N
of IN N
the DT N
Multimodal NNP i
Anxiety NNP i
and CC i
Social NNP i
Skills NNP i
Intervention NNP i
( ( i
MASSI NNP i
) ) i
program NN i
in IN N
a DT N
sample NN N
of IN N
30 CD p
adolescents NNS p
with IN p
ASD NNP p
and CC p
anxiety NN p
symptoms NNS p
of IN p
moderate JJ p
or CC p
greater JJR p
severity NN p
. . p

In IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
randomly RB N
allocated VBN N
trial NN N
, , N
the DT N
patients NNS N
were VBD N
given VBN N
increasing VBG N
doses NNS N
of IN N
captopril NN i
at IN N
25-100 JJ N
mg NN N
twice RB N
a DT N
day NN N
or CC N
lisinopril NN i
at IN N
10-40 JJ N
mg NN N
once IN N
a DT N
day NN N
until IN N
a DT N
clinical JJ N
response NN N
was VBD N
achieved VBN N
or CC N
the DT N
highest JJS N
dose NN N
was VBD N
reached VBN N
. . N

A DT N
non-randomised JJ N
controlled JJ N
study NN N
design NN N
comprising VBG N
an DT N
intervention NN p
group NN p
( ( p
n=48 CC p
) ) p
and CC p
comparator NN p
( ( p
no DT p
intervention NN p
) ) p
group NN p
( ( p
n=28 RB p
) ) p
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
intervention NN N
on IN N
child JJ o
behaviour NN o
( ( o
Eyberg NNP o
Child NNP o
Behaviour NNP o
Inventory NNP o
; : o
parent-set JJ o
goals NNS o
) ) o
and CC o
parenting VBG o
efficacy NN o
and CC o
satisfaction NN o
( ( N
Parents NNP N
Sense NNP N
of IN N
Competence NNP N
Scale NNP N
) ) N
at IN N
post-intervention NN N
and CC N
six-month JJ N
follow-up NN N
. . N

Hyperfractionated VBN i
accelerated JJ i
radiation NN i
therapy NN i
( ( i
HART NNP i
) ) i
of IN N
70.6 CD N
Gy NNP N
with IN N
concurrent JJ N
5-FU/Mitomycin JJ N
C NNP N
is VBZ N
superior JJ N
to TO N
HART NNP i
of IN N
77.6 CD N
Gy NNP N
alone RB N
in IN N
locally RB p
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
: : p
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
COMET NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomised JJ N
trial NN N
comparing VBG N
carvedilol NN i
, , N
a DT N
comprehensive JJ N
adrenergic NN N
receptor NN N
antagonist NN N
, , N
with IN N
metoprolol NN i
, , N
a DT N
beta-1-selective JJ N
agent NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
and CC p
left VBD p
ventricular JJ p
systolic JJ p
dysfunction NN p
. . p

Relief NN o
of IN o
pain NN o
by IN N
infusion NN N
of IN N
morphine NN i
after IN N
operation NN N
: : N
does VBZ N
tolerance VB N
develop VB N
? . N
To TO N
see VB N
whether IN N
continuous JJ N
intravenous JJ N
infusion NN N
of IN N
opiates NNS N
provides VBZ N
more RBR N
effective JJ o
postoperative JJ o
relief NN o
of IN o
pain NN o
than IN N
conventional JJ N
intramuscular JJ N
injection NN N
these DT N
regimens NNS N
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
double NN N
blind IN N
trial NN N
. . N

In IN N
this DT N
extension NN N
study NN N
, , N
we PRP N
included VBD N
all DT N
patients NNS N
who WP N
had VBD N
been VBN N
assigned VBN N
everolimus RBR N
during IN N
the DT N
double-blind NN N
, , N
randomised VBD N
phase NN N
of IN N
the DT N
trial NN N
and CC N
those DT N
patients NNS N
who WP N
crossed VBD N
over IN N
from IN N
the DT N
placebo NN i
group NN N
to TO N
receive VB N
everolimus NN N
during IN N
the DT N
randomised JJ N
phase NN N
or CC N
at IN N
the DT N
start NN N
of IN N
the DT N
extension NN N
phase NN N
. . N

In IN N
order NN N
to TO N
more RBR N
precisely RB N
measure VB N
the DT N
effects NNS N
of IN N
secretin NN i
, , N
this DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
porcine NN i
secretin NN i
on IN N
12 CD p
autistic JJ p
children NNS p
through IN N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
any DT N
inconsistency NN N
with IN N
the DT N
protocol NN N
guidelines NNS N
for IN N
preoperative JJ N
radiotherapy NN i
for IN N
rectal JJ p
cancer NN p
among IN p
radiotherapy JJ p
institutions NNS p
participating VBG p
in IN p
the DT p
framework NN p
of IN p
a DT p
multicentre JJ p
phase-III JJ p
European JJ p
Organization NNP p
for IN p
Research NNP p
and CC p
Treatment NNP p
of IN p
Cancer NNP p
( ( p
EORTC NNP p
) ) p
clinical JJ p
trial NN p
. . p

This DT N
trial NN N
involved VBD N
457 CD p
patients NNS p
and CC N
sought VBD N
to TO N
assess VB N
the DT N
value NN N
of IN N
early JJ i
intensification NN i
with IN i
autologous JJ i
transplantation NN i
in IN N
patients NNS p
with IN p
poor JJ p
prognosis NN p
histologically RB p
aggressive JJ p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
showing VBG p
a DT p
response NN p
to TO p
initial JJ p
CHOP NNP i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
prednisolone NN i
) ) i
chemotherapy NN i
. . i

This DT N
approval NN N
was VBD N
based VBN N
on IN N
an DT N
improvement NN N
in IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
with IN N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
1,253 CD p
patients NNS p
with IN p
metastatic JJ p
NSCLC NNP p
previously RB p
treated VBD p
with IN p
a DT p
platinum-based JJ i
combination NN i
therapy NN i
. . i

PURPOSE NN N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
excimer FW i
laser NN i
trabeculotomy NN i
( ( i
ELT NNP i
) ) i
ab VBP i
interno JJ i
vs NN i
selective JJ i
laser NN i
trabeculoplasty NN i
( ( i
SLT NNP i
) ) i
over IN N
24 CD N
months NNS N
of IN N
follow-up NN N
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
( ( p
POAG NNP p
) ) p
refractory NN p
to TO p
medical JJ p
therapy NN p
. . p

CONCLUSIONS NNP N
AND NNP N
RELEVANCE NNP N
In IN N
this DT N
hypothesis-generating JJ N
study NN N
of IN N
patients NNS p
with IN p
advanced JJ p
uveal JJ p
melanoma NN p
, , p
selumetinib NN i
compared VBN N
with IN N
chemotherapy NN N
resulted VBN N
in IN N
a DT N
modestly RB N
improved VBN N
progression-free JJ o
survival NN o
and CC o
response NN o
rate NN o
; : o
however RB N
, , N
no DT N
improvement NN N
in IN N
overall JJ o
survival NN o
was VBD N
observed VBN N
. . N

PURPOSE NNP N
To TO N
report VB N
the DT N
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
trial NN N
comparing NN N
hyperfractionated VBD i
accelerated JJ i
chemoradiation NN i
with IN i
mitomycin JJ i
C/5-fluorouracil NNP i
( ( i
C-HART NNP i
) ) i
with IN i
hyperfractionated VBN i
accelerated JJ i
radiation NN i
therapy NN i
( ( i
HART NNP i
) ) i
alone RB N
in IN N
locally RB p
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
. . p

PURPOSE NN N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
dofequidar NN i
plus CC i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil NN i
( ( i
CAF NNP i
) ) i
therapy NN i
in IN N
comparison NN N
with IN N
CAF NNP N
alone RB N
, , N
in IN N
patients NNS p
with IN p
advanced JJ p
or CC p
recurrent JJ p
breast NN p
cancer NN p
. . p

Efficacy NN N
of IN N
dose-intensified JJ i
MEC NNP i
( ( i
methotrexate NN i
, , i
epirubicin NN i
and CC i
cisplatin NN i
) ) i
chemotherapy NN i
for IN N
advanced JJ p
urothelial JJ p
carcinoma NN p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
MEC NNP i
and CC i
M-VAC NNP i
( ( i
methotrexate NN i
, , i
vinblastine NN i
, , i
doxorubicin NN i
and CC i
cisplatin NN i
) ) i
. . i

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
study NN N
is VBZ N
described VBN N
of IN N
an DT N
assessment NN N
of IN N
the DT N
efficacy NN o
and CC o
relative JJ o
safety NN o
of IN N
the DT N
ergot NN N
alkaloid NN N
, , N
dihydroergocryptine NN i
, , N
on IN N
52 CD p
patients NNS p
with IN p
mild JJ p
organic JJ p
brain NN p
syndrome NN p
over IN p
a DT p
period NN p
of IN p
three CD p
months NNS p
using VBG p
a DT p
series NN p
of IN p
neurophysiological JJ p
tests NNS p
. . p

A DT N
total NN N
of IN N
1,615 CD p
angiographic JJ p
readings NNS p
in IN p
240 CD p
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
analyzed VBN N
from IN N
a DT N
randomized JJ N
trial NN N
of IN N
intravenous JJ i
anistreplase NN i
( ( i
Eminase NNP i
) ) i
, , i
also RB i
known VBN i
as IN i
anisoylated JJ i
plasminogen NN i
streptokinase JJ i
activator NN i
complex NN i
( ( i
APSAC NNP i
) ) i
, , i
versus FW i
intracoronary JJ i
streptokinase NN i
. . i

METHOD NNP N
Twenty-four CD p
children NNS p
with IN p
autism NN p
, , p
3.0 CD p
to TO p
8.3 CD p
years NNS p
old JJ p
( ( p
mean JJ p
5.1 CD p
) ) p
who WP p
were VBD p
living VBG p
at IN p
home NN p
and CC p
attending VBG p
appropriate JJ p
school NN p
programs NNS p
, , N
participated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
trial NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ i
open JJ i
esophagectomy NN i
[ NNP i
open JJ i
surgical JJ i
technique NN i
( ( i
OE NNP i
) ) i
] NN i
by IN N
thoracotomy NN i
and CC i
laparotomy NN i
with IN i
minimally RB i
invasive JJ i
esophagectomy NN i
[ NNP i
minimally RB i
invasive JJ i
procedure NN i
( ( i
MIE NNP i
) ) i
] NN i
by IN i
thoracoscopy NN i
and CC i
laparoscopy NN i
. . i

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
parallel JJ N
group NN N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
infants NNS p
unresponsive JJ p
to TO p
stimulation NN p
who WP p
received VBD p
bag NN p
and CC p
mask NN p
ventilation NN p
as IN p
part NN p
of IN p
their PRP$ p
resuscitation NN p
at IN p
birth NN p
and CC p
infants NNS p
who WP p
did VBD p
not RB p
require VB p
any DT p
resuscitation NN p
born VBN p
in IN p
rural JJ p
communities NNS p
in IN p
India NNP p
, , p
Pakistan NNP p
, , p
and CC p
Zambia NNP p
. . p

PURPOSE NN N
To TO N
estimate VB N
the DT N
safety NN o
, , o
activity NN o
, , o
and CC o
impact NN o
on IN o
quality NN o
of IN o
life NN o
of IN N
a DT N
combination NN N
of IN N
gemcitabine NN i
and CC i
pemetrexed NN i
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
in IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
two-stage NN N
phase NN N
II NNP N
study NN N
. . N

In IN p
the DT p
International NNP p
Breast NNP p
Cancer NNP p
Study NNP p
Group NNP p
( ( p
IBCSG NNP p
) ) p
Trials NNP p
VII NNP p
and CC p
12-93 JJ p
, , p
postmenopausal JJ p
women NNS p
with IN p
node-positive JJ p
, , p
estrogen JJ p
receptor NN p
( ( p
ER NNP p
) ) p
-positive CD p
or CC p
ER-negative JJ p
, , p
operable JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
or CC i
endocrine JJ i
therapy NN i
or CC i
combined VBN i
chemoendocrine JJ i
treatment NN i
. . i

DESIGN NNP N
Two CD p
hundred VBD p
adults NNS p
in IN p
a DT p
rural JJ p
region NN p
of IN p
Bangladesh NNP p
, , p
previously RB p
found VBN p
to TO p
have VB p
low JJ p
plasma JJ p
concentrations NNS p
of IN p
folate NN p
( ( p
< JJ p
/=9 NNP p
nmol/L NN p
) ) p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
folic JJ i
acid-supplementation NN i
trial NN N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
979 CD p
ST-segment-elevation JJ p
myocardial JJ p
infarction NN p
patients NNS p
enrolled VBN p
in IN p
the DT p
Harmonizing NNP p
Outcomes NNP p
with IN p
Revascularization NNP p
and CC p
Stents NNP p
in IN p
Acute NNP p
Myocardial NNP p
Infarction NNP p
( ( p
HORIZONS-AMI NNP p
) ) p
trial NN p
had VBD p
BNP NNP p
levels NNS p
measured VBN p
in IN p
the DT p
emergency NN p
room NN p
prior RB p
to TO p
primary JJ p
percutaneous JJ p
coronary JJ p
intervention NN p
as IN p
part NN p
of IN p
the DT p
study NN p
protocol NN p
. . p

This DT N
paper NN N
presents VBZ N
findings NNS N
from IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
electrothermal JJ i
arthroscopic NN i
capsulorrhaphy NN i
( ( i
ETAC NNP i
) ) i
compared VBN i
with IN i
open JJ i
inferior JJ i
capsular JJ i
shift NN i
( ( i
ICS NNP i
) ) i
and CC N
reviews VBZ N
the DT N
role NN N
of IN N
randomized JJ N
trials NNS N
in IN N
adopting VBG N
new JJ N
technology NN N
. . N

CONCLUSIONS NN N
In IN N
this DT N
inception NN N
cohort NN N
study NN N
of IN N
low-dose JJ N
prednisolone NN i
use NN N
during IN N
the DT N
first JJ N
2 CD N
years NNS N
of IN N
RA NNP N
disease NN N
, , N
the DT N
incidence NN o
of IN o
ischaemic JJ o
coronary JJ o
artery NN o
events NNS o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
, , N
whereas IN N
the DT N
long-term JJ o
risk NN o
of IN o
ischaemic JJ o
cerebrovascular JJ o
events NNS o
was VBD N
higher RBR N
in IN N
the DT N
prednisolone NN i
group NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
In IN N
a DT N
previous JJ N
study NN N
we PRP N
showed VBD N
that IN N
patients NNS p
with IN p
severe JJ p
aplastic JJ p
anemia NN p
( ( p
SAA NNP p
) ) p
treated VBD p
with IN p
anti-lymphocyte JJ i
globulin NN i
( ( i
ALG NNP i
) ) i
, , i
cyclosporin NN i
( ( i
CyA NNP i
) ) i
and CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
5 CD N
micro NN N
g/kg/day NN N
had VBD N
an DT N
encouraging JJ N
outcome NN N
. . N

A DT p
total NN p
of IN p
1,200 CD p
patients NNS p
will MD N
be VB N
randomized VBN N
on IN N
a DT N
2:2:1 JJ N
basis NN N
to TO N
receive VB N
3.0-T JJ i
cardiovascular JJ i
magnetic JJ i
resonance-guided JJ i
care NN i
, , i
single-photon JJ i
emission NN i
computed VBD i
tomography-guided JJ i
care NN i
( ( i
according VBG i
to TO i
American NNP i
College NNP i
of IN i
Cardiology/American NNP i
Heart NNP i
Association NNP i
appropriate-use IN i
criteria NNS i
) ) i
, , i
or CC i
National NNP i
Institute NNP i
for IN i
Health NNP i
and CC i
Care NNP i
Excellence NNP i
guidelines-based JJ i
management NN i
. . i

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
alpha-interferon JJ i
given VBN N
with IN N
or CC N
without IN N
indomethacin JJ i
to TO N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
to TO N
determine VB N
what WP N
effect NN N
, , N
if IN N
any DT N
, , N
indomethacin NN i
might MD N
have VB N
on IN N
the DT N
toxic NN N
, , N
immunomodulatory NN N
, , N
and CC N
therapeutic JJ N
properties NNS N
of IN N
interferon NN N
in IN N
this DT N
disease NN N
. . N

Results NNS N
of IN N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
amlodipine JJ i
maleate NN i
versus NN N
amlodipine NN i
besylate NN i
in IN N
Korean JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

METHODS NNP N
A NNP N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
compared VBN N
neurocognitive JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing VBG p
open-chamber JJ p
( ( p
left-sided JJ p
) ) p
cardiac NN p
surgery NN p
who WP p
were VBD p
assigned VBN p
carbon NN i
dioxide NN i
insufflation NN i
or CC i
placebo NN i
( ( p
control VB p
group NN p
) ) p
in IN p
addition NN p
to TO p
standardized VB p
mechanical JJ p
deairing VBG p
maneuvers NNS p
. . p

OBJECTIVE IN N
This DT N
5-year JJ N
observational JJ N
posthoc NN N
analysis NN N
of IN N
the DT N
REFLEX NNP N
study NN N
and CC N
its PRP$ N
open-label JJ N
extension NN N
assessed VBD N
clinical JJ N
efficacy NN N
, , N
radiographic JJ N
response NN N
, , N
and CC N
safety NN N
of IN N
rituximab NN i
( ( i
RTX NNP i
) ) i
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
who WP p
had VBD p
an DT p
inadequate JJ p
response NN p
to TO p
tumor VB i
necrosis NN i
factor NN i
( ( i
TNF NNP i
) ) i
inhibitors NNS i
. . i

The DT N
aim NN N
of IN N
this DT N
randomised VBN N
, , N
prospective JJ N
, , N
blinded VBD N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
stimulating JJ i
catheters NNS i
can MD N
decrease VB N
the DT N
minimum JJ o
effective JJ o
anaesthetic JJ o
volume NN o
in IN N
50 CD N
% NN N
of IN N
patients NNS N
during IN N
lumbar JJ N
plexus NN N
block NN N
using VBG N
mepivacaine JJ i
1.5 CD N
% NN N
compared VBN N
with IN N
standard JJ N
catheters NNS N
. . N

A DT N
unicenter NN N
, , N
single-blind NN N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
on IN N
283 CD p
patients NNS p
with IN p
active JJ p
duodenal JJ p
ulcer NN p
to TO p
compare VB p
possible JJ p
factors NNS p
that WDT p
may MD p
affect VB p
healing NN p
and CC p
relapse NN p
in IN p
patients NNS p
treated VBN p
with IN p
a DT p
potent JJ p
antisecretory NN p
agent NN p
, , p
cimetidine NN i
, , i
or CC i
a DT i
site-protective JJ i
and CC i
cytoprotective JJ i
agent NN i
, , i
sucralfate NN i
. . i

METHODS NNP N
In IN N
this DT N
parallel-design JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
54 CD p
adult NN p
volunteers NNS p
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
9.5 CD N
% NN N
hydrogen NN i
peroxide IN i
whitening VBG i
strip NN i
or CC i
placebo NN i
strip NN i
balancing NN N
for IN N
age NN N
and CC N
baseline VB N
tooth DT N
color NN N
, , N
and CC N
received VBD N
treatment NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
fifty-seven RB p
healthy JJ p
female NN p
subjects NNS p
, , p
15 CD p
to TO p
49 CD p
years NNS p
of IN p
age NN p
with IN p
moderate JJ p
acne NNS p
vulgaris NN p
, , N
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Results NNS N
of IN N
a DT N
phase NN N
III NNP N
, , N
8-week JJ N
, , N
multicenter NN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
amlodipine JJ i
camsylate NN i
versus NN N
amlodipine NN i
besylate NN i
in IN N
Korean JJ p
adults NNS p
with IN p
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

A DT N
total NN N
of IN N
4,444 CD p
patients NNS p
with IN p
angina JJ p
pectoris NN p
or CC p
previous JJ p
myocardial JJ p
infarction NN p
and CC p
serum VB p
cholesterol NN p
levels NNS p
of IN p
213-310 JJ p
mg/dl NN p
( ( p
5.5-8.0 JJ p
mmol/liter NN p
) ) p
while IN p
treated VBN p
with IN p
a DT p
lipid-lowering JJ p
diet NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB N
treatment NN N
with IN N
simvastatin NN i
or CC i
placebo NN i
. . i

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
epoetin JJ i
zeta NN i
, , N
compared VBN N
with IN N
epoetin NN i
alfa NN i
, , N
in IN N
maintaining VBG N
target NN N
haemoglobin NN N
( ( N
Hb NNP N
) ) N
concentrations NNS N
in IN N
patients NNS p
with IN p
anaemia NN p
and CC p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
maintained VBD p
on IN p
haemodialysis NN p
. . p

METHODS/DESIGN NNP N
The DT N
Staged NNP N
Nutrition NNP N
and CC N
Activity NNP N
Counseling NNP N
( ( N
SNAC NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ i
lifestyle JJ i
intervention NN i
on IN N
cardiovascular JJ N
disease NN N
risk NN N
factors NNS N
and CC N
vascular JJ N
function NN N
in IN N
patients NNS p
at IN p
risk NN p
in IN p
primary JJ p
care NN p
. . p

PURPOSE NN N
To TO N
analyze VB N
the DT N
results NNS N
of IN N
a DT N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
that WDT N
investigated VBD N
whether IN N
a DT N
hyperfractionated JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
schedule NN N
could MD N
reduce VB N
the DT N
risk NN o
of IN o
locoregional JJ o
recurrence NN o
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
breast NN p
cancer NN p
treated VBN p
with IN p
chemotherapy NN p
and CC p
mastectomy NN p
. . p

In IN N
view NN N
of IN N
the DT N
usefulness NN N
of IN N
long-term JJ i
adjuvant JJ i
chemotherapy NN i
, , p
the DT p
Cooperative NNP p
Study NNP p
Group NNP p
of IN p
Surgical NNP p
Adjuvant NNP p
Chemotherapy NNP p
for IN p
Gastric NNP p
Cancer NNP p
adopted VBD p
as IN p
the DT p
second JJ p
cooperative NN p
study NN p
a DT p
prospective JJ p
randomized VBN p
trial NN p
on IN p
three CD p
groups NNS p
; : p
MMC NNP i
alone RB i
, , i
Futraful NNP i
alone RB i
and CC i
a DT i
combination NN i
of IN i
MMC NNP i
and CC i
Futraful NNP i
. . i

BACKGROUND NNP N
Fifty NNP p
consecutive JJ p
patients NNS p
entered VBD p
the DT p
myocardial JJ p
contrast NN p
echocardiography NN p
( ( p
MCE NNP p
) ) p
substudy NN p
of IN p
the DT p
REMEDIA NNP p
( ( p
Randomized NNP p
Evaluation NNP p
of IN p
the DT p
Effect NNP p
of IN p
Mechanical NNP p
Reduction NNP p
of IN p
Distal NNP p
Embolization NNP p
by IN p
Thrombus NNP p
Aspiration NNP p
in IN p
Primary NNP p
and CC p
Rescue NNP p
Angioplasty NNP p
) ) p
trial NN p
, , N
which WDT N
defined VBD N
the DT N
role NN N
of IN N
a DT N
new JJ N
thrombus-aspirating JJ N
device NN N
in IN N
preventing VBG N
distal JJ N
microembolization NN N
after IN N
PCI NNP N
. . N

METHOD NNP N
Survivors NNS p
of IN p
out-of-hospital JJ p
ventricular JJ p
fibrillation NN p
or CC p
asystole NN p
( ( p
N NNP p
= NNP p
129 CD p
) ) p
, , p
documented VBN p
by IN p
electrocardiograms NNS p
from IN p
registries NNS p
of IN p
a DT p
citywide NN p
Medic NNP p
One NNP p
unit NN p
and CC p
two CD p
countywide NN p
emergency NN p
units NNS p
, , N
were VBD N
randomized VBN N
into IN N
a DT N
two CD N
group NN N
, , N
experimental JJ N
, , N
longitudinal JJ N
design NN N
. . N

OBJECTIVES IN N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP i
and CC i
Paclitaxel-Eluting NNP i
Stents NNP i
in IN N
Patients NNP p
with IN p
Coronary NNP p
Artery NNP p
Disease NNP p
) ) p
trial NN N
evaluated VBD N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
zotarolimus-eluting JJ i
stent NN i
( ( i
ZES NNP i
) ) i
compared VBN N
with IN N
the DT N
paclitaxel-eluting JJ i
stent NN i
( ( i
PES NNP i
) ) i
. . i

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
parallel-group JJ N
pilot NN N
study NN N
designed VBN N
to TO N
compare VB N
an DT N
oat NN i
cereal NN i
group NN i
( ( i
standardized VBN i
to TO i
5.52 CD i
g/day JJ i
beta-glucan JJ i
) ) i
to TO i
a DT i
low-fiber JJ i
cereal NN i
control NN i
group NN i
( ( i
less JJR i
than IN i
1.0 CD i
g/day JJ i
total JJ i
fiber NN i
) ) i
over IN N
6 CD N
weeks NNS N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Two CD p
hundred VBD p
eighty-eight JJ p
cancer NN p
patients NNS p
, , p
referred VBD p
to TO p
complementary JJ p
therapy NN p
services NNS p
with IN p
clinical JJ p
anxiety NN p
and/or NN p
depression NN p
, , N
were VBD N
allocated VBN N
randomly RB N
to TO N
a DT N
course NN N
of IN N
aromatherapy JJ i
massage NN i
or CC i
usual JJ i
supportive JJ i
care NN i
alone RB i
. . i

This DT N
experiment NN N
examined VBD N
the DT N
efficacy NN N
of IN N
an DT N
acustimulation NN i
wrist NN i
band NN i
for IN N
the DT N
relief NN N
of IN N
chemotherapy-induced JJ o
nausea NN o
using VBG N
a DT N
randomized JJ N
three-arm JJ N
clinical JJ N
trial NN N
( ( N
active JJ N
acustimulation NN N
, , N
sham JJ N
acustimulation NN N
, , N
and CC N
no DT N
acustimulation NN N
) ) N
in IN N
96 CD p
women NNS p
with IN p
breast NN p
cancer NN p
who WP p
experienced VBD p
nausea NN p
at IN p
their PRP$ p
first JJ p
chemotherapy NN p
treatment NN p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
post-hoc JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
two CD N
8-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
studies NNS N
evaluating VBG N
aripiprazole NN i
for IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
pediatric JJ p
subjects NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBN p
6-17 CD p
years NNS p
. . p

This DT N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
the DT N
GnRH NNP i
agonist NN i
, , i
leuprolide JJ i
acetate NN i
depot NN i
, , N
in IN N
a DT N
clearly RB p
defined VBN p
PMS NNP p
sample JJ p
versus NNS p
women NNS p
with IN p
premenstrual JJ p
symptoms NNS p
in IN p
combination NN p
with IN p
dysphoric NN p
symptoms NNS p
throughout IN p
the DT p
cycle NN p
, , p
termed VBD p
the DT p
premenstrual JJ p
exacerbation NN p
( ( p
PME NNP p
) ) p
group NN p
. . p

A DT N
recent JJ N
randomized NN N
controlled VBD N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
a DT N
dual JJ i
parent NN i
and CC i
trainer-delivered JJ i
qigong JJ i
massage NN i
intervention NN i
for IN N
young JJ p
children NNS p
with IN p
autism NN p
resulted VBN N
in IN N
improvement NN N
of IN N
measures NNS N
of IN N
autism NN N
as RB N
well RB N
as IN N
improvement NN N
of IN N
abnormal JJ o
sensory JJ o
responses NNS o
and CC o
self-regulation NN o
. . o

A DT N
controlled VBN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
ViviScal NNP i
( ( i
a DT i
new JJ i
food NN i
supplement NN i
incorporating VBG i
special JJ i
marine JJ i
extracts NNS i
and CC i
a DT i
silica JJ i
compound NN i
) ) i
with IN N
those DT N
of IN N
a DT N
fish JJ N
extract NN N
in IN N
the DT N
treatment NN N
of IN N
young JJ p
males NNS p
with IN p
hereditary JJ p
androgenic JJ p
alopecia NN p
. . p

Based VBN N
on IN N
the DT N
results NNS N
of IN N
combined JJ N
data NNS N
from IN N
three CD N
North JJ N
American JJ N
Phase NNP N
II NNP N
studies NNS N
, , N
a DT N
randomised JJ N
Phase NNP N
II NNP N
study NN N
in IN N
the DT N
same JJ N
patient JJ N
population NN N
was VBD N
performed VBN N
, , N
using VBG N
combination NN i
chemotherapy NN i
with IN i
estramustine JJ i
phosphate NN i
( ( i
EMP NNP i
) ) i
and CC i
vinblastine NN i
( ( i
VBL NNP i
) ) i
in IN N
hormone NN p
refractory NN p
prostate NN p
cancer NN p
patients NNS p
. . p

METHODS NNP N
The DT N
paroxetine NN i
352 CD N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
19-site JJ N
trial NN N
comparing VBG N
paroxetine NN i
and CC i
imipramine NN i
in IN N
117 CD p
patients NNS p
with IN p
bipolar JJ p
type NN p
I PRP p
major JJ p
depressive JJ p
episode NN p
which WDT p
was VBD p
unresponsive JJ p
to TO p
prior VB p
lithium NN i
carbonate NN i
therapy NN i
. . i

PURPOSE NN N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
supplementing VBG N
usual JJ i
supportive JJ i
care NN i
with IN i
aromatherapy JJ i
massage NN i
in IN N
the DT N
management NN N
of IN N
anxiety NN p
and CC p
depression NN p
in IN p
cancer NN p
patients NNS p
through IN p
a DT p
pragmatic JJ p
two-arm NN p
randomized VBD p
controlled JJ p
trial NN p
in IN p
four CD p
United NNP p
Kingdom NNP p
cancer NN p
centers NNS p
and CC p
a DT p
hospice NN p
. . p

BACKGROUND NNP N
Safety NNP N
and CC N
efficacy NN N
of IN N
gemcitabine JJ i
plus CC i
docetaxel JJ i
( ( i
GD NNP i
) ) i
and CC i
capecitabine JJ i
plus CC i
docetaxel JJ i
( ( i
CD NN i
) ) i
were VBD N
compared VBN N
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
, , p
where WRB p
the DT p
alternate NN i
crossover NN i
monotherapy NN i
( ( i
GD NNP i
or CC i
CD NN i
) ) i
was VBD i
predetermined VBN i
. . i

PATIENTS NNP N
Twenty NNP p
patients NNS p
admitted VBD p
with IN p
a DT p
Glasgow NNP p
Coma NNP p
Scale NNP p
score NN p
of IN p
< $ p
10 CD p
who WP p
were VBD N
enrolled VBN N
as IN N
part NN N
of IN N
a DT N
prospective JJ N
, , N
multicenter JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
multiple JJ N
risk NN N
factors NNS N
and CC N
ranitidine VB i
prophylaxis NN i
on IN N
the DT N
development NN N
of IN N
stress-related JJ N
upper JJ N
gastrointestinal NN N
bleeding NN N
. . N

Plerixafor NNP i
plus CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
versus NN i
placebo NN i
plus CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
for IN N
mobilization NN N
of IN N
CD34 NNP p
( ( p
+ NNP p
) ) p
hematopoietic JJ p
stem NN p
cells NNS p
in IN p
patients NNS p
with IN p
multiple JJ p
myeloma NNS p
and CC p
low JJ p
peripheral JJ p
blood NN p
CD34 NNP p
( ( p
+ NNP p
) ) p
cell NN p
count NN p
: : p
results NNS N
of IN N
a DT N
subset JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

This DT N
Phase NNP N
III NNP N
study NN N
( ( N
Belatacept NNP N
Evaluation NNP N
of IN N
Nephroprotection NNP N
and CC N
Efficacy NNP N
as IN N
First-line NNP N
Immunosuppression NNP N
Trial NNP N
) ) N
assessed VBD N
a DT N
more RBR N
intensive JJ N
( ( N
MI NNP N
) ) N
or CC N
less RBR N
intensive JJ N
( ( N
LI NNP N
) ) N
regimen NNS N
of IN N
belatacept JJ i
versus NN i
cyclosporine NN i
in IN N
adults NNS p
receiving VBG p
a DT p
kidney NN p
transplant NN p
from IN p
living NN p
or CC p
standard JJ p
criteria NNS p
deceased VBN p
donors NNS p
. . p

PURPOSE NN N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
recombinant JJ i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
( ( i
[ JJ i
G-CSF NNP i
] NNP i
lenogastrim NN i
) ) i
can MD N
increase VB N
the DT N
chemotherapy JJ N
dose-intensity NN N
( ( N
CDI NNP N
) ) N
delivered VBD N
during IN N
consolidation NN N
chemotherapy NN N
of IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
. . p

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ i
antidiabetic JJ i
therapy NN i
, , N
and CC N
change NN N
in IN N
A1C NNP o
and CC o
fasting VBG o
plasma NN o
glucose NN o
( ( o
FPG NNP o
) ) o
in IN N
patients NNS p
with IN p
diabetes NNS p
receiving VBG p
standard JJ p
treatment NN p
for IN p
diabetes NNS p
and CC p
randomized VBN p
to TO p
ranolazine VB i
or CC i
placebo VB i
within IN i
the DT i
MERLIN-TIMI-36 NNP i
( ( i
MERLIN NNP i
) ) i
study NN i
. . i

In IN N
a DT N
single-center JJ N
, , N
multiple-referral JJ N
source NN N
study NN N
, , N
38 CD p
patients NNS p
with IN p
progressive JJ p
IgA NNP p
nephropathy NN p
and CC p
controlled VBN p
hypertension NN p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
prednisolone NN i
and CC i
cytotoxic NN i
agents NNS i
, , N
to TO N
therapy VB N
with IN N
low-dose JJ N
cyclophosphamide NN i
then RB i
azathioprine VB i
, , N
and CC N
to TO N
control VB N
groups NNS N
. . N

Hypertension NN p
following VBG p
coronary JJ p
artery JJ p
bypass NN p
grafting NN p
is VBZ N
a DT N
common JJ N
problem NN N
that WDT N
may MD N
result VB N
in IN N
postoperative JJ N
myocardial JJ N
infraction NN N
or CC N
bleeding NN N
, , N
Hemodynamic NNP N
effects NNS N
were VBD N
compared VBN N
in IN N
45 CD p
hypertensive JJ p
coronary JJ p
bypass NN p
patients NNS p
randomized VBN N
to TO N
receive VB N
either DT N
diltiazem NN i
, , i
nitroglycerin NN i
, , i
or CC i
sodium NN i
nitroprusside RB i
. . i

SETTING NN N
Six NNP p
academic JJ p
centers NNS p
, , p
including VBG p
Mount NNP p
Sinai NNP p
School NNP p
of IN p
Medicine NNP p
, , p
North NNP p
Shore-Long NNP p
Island NNP p
Jewish NNP p
Health NNP p
System NNP p
, , p
University NNP p
of IN p
North NNP p
Carolina NNP p
at IN p
Chapel NNP p
Hill NNP p
, , p
University NNP p
of IN p
California NNP p
at IN p
Los NNP p
Angeles NNP p
, , p
Yale NNP p
University NNP p
, , p
and CC p
Dartmouth NNP p
Medical NNP p
School NNP p
. . p

METHODS NNP N
The DT N
treatment NN N
regimen NNS N
consisted VBD N
of IN N
nitrous JJ i
oxide/oxygen NN i
inhalation NN i
in IN N
conjunction NN N
with IN N
oral JJ N
administration NN N
of IN N
either DT N
diazepam NN i
0.3 CD i
mg/kg NN i
or CC i
midazolam VB i
0.5 CD N
mg/kg NN N
in IN N
a DT N
cross-over JJ N
design NN N
study NN N
of IN N
13 CD p
subjects NNS p
aged VBD p
5.8 CD p
to TO p
14.7 CD p
years NNS p
. . p

Using VBG N
an DT N
imaging NN N
genetics NNS N
approach NN N
, , N
we PRP N
studied VBD N
differential JJ N
effects NNS N
of IN N
an DT N
intranasal NN i
OT NNP i
application NN i
on IN N
neural JJ N
processing NN N
of IN N
social JJ N
stimuli NNS N
in IN N
55 CD p
healthy JJ p
young JJ p
men NNS p
depending VBG p
on IN p
their PRP$ p
CD38 NNP p
gene NN p
variant NN p
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
crossover NN N
design NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
to TO N
evaluate VB N
the DT N
cardioprotective JJ N
effects NNS N
of IN N
MC-1 NNP i
in IN N
patients NNS p
undergoing VBG p
high-risk JJ p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
: : p
MC-1 NN N
to TO N
Eliminate VB N
Necrosis NNP N
and CC N
Damage NNP N
in IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Graft NNP N
Surgery NNP N
Trial NNP N
( ( N
MEND-CABG NNP N
) ) N
II NNP N
-- : N
study NN N
design NN N
and CC N
rationale NN N
. . N

One CD p
hundred CD p
consecutive JJ p
patients NNS p
with IN p
symptomatic JJ p
gallstones NNS p
without IN p
complications NNS p
were VBD p
randomized VBN p
into IN p
groups NNS p
; : p
group NN i
T NNP i
had VBD i
two CD i
metal JJ i
clips NNS i
( ( i
titan JJ i
clip NN i
ETHICONR NNP i
) ) i
, , i
group NN i
R NNP i
( ( i
laproclipR JJ i
Davis NNP i
and CC i
Geck NNP i
) ) i
had VBD i
one CD i
absorbable JJ i
clip NN i
applied VBN i
on IN i
the DT i
cystic JJ i
duct NN i
and CC i
cystic JJ i
artery NN i
. . i

BACKGROUND IN N
The DT N
efficacy NN N
and CC N
safety NN N
of IN N
vernakalant NN N
, , N
a DT N
relatively RB N
atrial-selective JJ N
antiarrhythmic JJ N
agent NN N
, , N
in IN N
converting VBG N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
to TO N
sinus VB N
rhythm NN N
( ( N
SR NNP N
) ) N
were VBD N
evaluated VBN N
in IN N
this DT N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
patients NNS p
with IN p
AF NNP p
lasting VBG p
> RB p
3 CD p
hours NNS p
and CC p
< NNP p
or CC p
=45 JJ p
days NNS p
( ( p
RCT NNP p
no DT p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-three NNP p
edentulous JJ p
patients NNS p
who WP p
experienced VBD p
difficulties NNS p
when WRB p
using VBG p
hard JJ p
denture NN p
bases NNS p
because IN p
of IN p
changes NNS p
in IN p
denture-supporting JJ p
tissues NNS p
were VBD N
accepted VBN N
for IN N
the DT N
study NN N
and CC N
randomly RB N
received VBD N
Molloplast NNP i
B NNP i
, , i
GC NNP i
Reline NNP i
Soft NNP i
, , i
Silagum NNP i
Comfort NNP i
, , i
or CC i
Mollosil NNP i
Plus NNP i
relines NNS i
. . i

Patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
or CC p
nasopharyngeal JJ p
carcinoma NN p
not RB p
suitable JJ p
for IN p
operation NN p
or CC p
radiotherapy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
E10A NNP i
plus CC i
chemotherapy NN i
every DT i
3 CD i
weeks NNS i
for IN i
a DT i
maximum NN i
of IN i
six CD i
cycles NNS i
or CC i
to TO i
receive VB i
chemotherapy NN i
only RB i
. . i

PATIENTS NNS N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
which WDT N
S. NNP i
boulardii NN i
, , i
750 CD i
mg/day NN i
, , i
or CC i
placebo NN i
was VBD i
administered VBN i
for IN i
6 CD i
weeks NNS i
in IN i
IBS-D NNP i
patients NNS i
, , i
in IN i
addition NN i
to TO i
ispaghula VB i
husk JJ i
standard NN i
treatment NN i
. . i

Pharmacokinetics NNS o
and CC o
relative JJ o
bioavailability NN o
of IN N
the DT N
marketed JJ i
prajmalium NN i
bitartrate NN i
tablet NN i
( ( i
Neo-Gilurytmal JJ i
, , i
CAS NNP i
2589-47-1 CD N
) ) N
compared VBN N
to TO N
an DT N
oral JJ N
solution NN N
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
, , N
single-dose JJ N
two-fold JJ N
crossover NN N
study NN N
in IN N
20 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

PURPOSE NNP N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ N
aspirin NN i
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS N
from IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
aspirin NN i
and CC i
beta NN i
carotene NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN o
of IN o
attempts NNS o
at IN o
successful JJ o
identification NN o
of IN o
the DT o
spinal JJ o
space NN o
, , o
intraoperative JJ o
complications NNS o
, , o
incidence NN o
of IN o
postdural JJ o
puncture NN o
headache NN o
( ( o
PDPH NNP o
) ) o
, , o
non-postdural JJ o
puncture NN o
headache NN o
( ( o
NPDPH NNP o
) ) o
and CC o
backache NN o
. . o

The DT N
aims NNS N
of IN N
this DT N
randomised VBN N
double-blind NN N
study NN N
were VBD N
to TO N
investigate VB N
whether IN N
25 CD N
micrograms NNS N
of IN N
fentanyl NN i
administered VBN N
prophylactically RB N
by IN N
the DT N
epidural JJ N
route NN N
would MD N
influence VB N
the DT N
incidence NN N
of IN N
shivering VBG N
in IN N
parturients NNS p
who WP p
underwent VBP p
elective JJ p
Caesarean JJ p
section NN p
under IN p
epidural JJ p
analgesia NN p
and CC N
whether IN N
it PRP N
would MD N
affect VB N
the DT N
axillary JJ N
and CC N
calf JJ N
temperatures NNS N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ N
treatment NN N
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ o
velocity NN o
changes NNS o
and CC o
total JJ o
gain NN o
of IN o
height NN o
over IN N
a DT N
4-year JJ N
period NN N
. . N

We PRP N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
multicenter NN N
clinical JJ N
trial NN N
on IN N
the DT N
effects NNS N
of IN N
aspirin JJ i
plus CC i
dipyridamole JJ i
versus NN N
placebo NN i
on IN N
major JJ N
vascular JJ N
end NN N
points NNS N
in IN N
231 CD p
non-insulin-dependent JJ p
diabetic JJ p
men NNS p
with IN p
either DT p
a DT p
recent JJ p
amputation NN p
for IN p
gangrene NN p
or CC p
active JJ p
gangrene NN p
. . p

Using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
, , N
the DT N
current JJ N
study NN N
tested VBD N
the DT N
effectiveness NN N
of IN N
an DT N
evidence-based JJ i
, , i
caregiver-assisted JJ i
social JJ i
skills NNS i
intervention NN i
known VBN i
as IN i
PEERS NNP i
for IN N
Young NNP p
Adults NNP p
with IN p
high-functioning JJ p
young JJ p
adults NNS p
with IN p
ASD NNP p
( ( p
ages VBZ p
18-23 CD p
) ) p
using VBG p
self- JJ p
and CC p
caregiver-report JJ p
measures NNS p
. . p

To TO N
explore VB N
the DT N
steady-state JJ o
pharmacokinetic JJ o
profile NN o
after IN N
coadministration NN i
of IN i
galantamine NN i
and CC i
risperidone NN i
, , N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
single-center JJ N
, , N
two-way JJ N
crossover NN N
drug-drug JJ N
interaction NN N
study NN N
was VBD N
conducted VBN N
in IN N
16 CD p
healthy JJ p
elderly JJ p
subjects NNS p
, , p
ages VBZ p
60 CD p
years NNS p
and CC p
older JJR p
. . p

Long-term JJ N
follow-up NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
fludarabine-mitoxantrone NN i
, , N
compared VBN N
with IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vindesine NN i
, , i
prednisone NN i
( ( i
CHVP NNP i
) ) i
, , N
as IN N
first-line JJ N
treatment NN N
of IN N
elderly JJ p
patients NNS p
with IN p
advanced JJ p
, , p
low-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
before IN p
the DT p
era NN p
of IN p
monoclonal JJ p
antibodies NNS p
. . p

OBJECTIVE NN N
This DT N
study NN N
was VBD N
done VBN N
to TO N
compare VB N
percutaneous JJ i
laser NN i
ablation NN i
( ( i
PLA NNP i
) ) i
and CC i
radiofrequency NN i
thermoablation NN i
( ( i
RFA NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
? . p
4 CD p
cm NN p
, , p
in IN p
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
. . p

Therefore RB N
, , N
we PRP N
prospectively RB N
studied VBD N
the DT N
synthesis NN N
of IN N
IL-1 NNP i
beta NN i
by IN i
peripheral JJ i
blood NN i
mononuclear NN i
cells NNS i
( ( i
PBMC NNP i
) ) i
from IN N
42 CD p
patients NNS p
with IN p
PBC NNP p
entered VBD N
into IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBD N
trial NN N
of IN N
colchicine NN i
and CC i
methotrexate NN i
. . i

OBJECTIVE IN N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
triphasic JJ i
, , i
combination NN i
OC NNP i
( ( i
ORTHO NNP i
TRI-CYCLEN NNP i
[ NNP i
Ortho-McNeil NNP i
Pharmaceutical NNP i
, , i
Raritan NNP i
, , i
N.J. NNP i
] NNP i
, , i
norgestimate/ethinyl RB i
estradiol NN i
) ) i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ p
acne NN p
vulgaris NN p
. . p

BACKGROUND NNP N
This DT N
randomized VBN N
study NN N
compared VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fludarabine-mitoxantrone NN i
( ( i
FM NNP i
) ) i
with IN i
mini-CHVP NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vindesine NN i
, , i
prednisone NN i
) ) i
in IN N
elderly JJ p
patients NNS p
with IN p
advanced JJ p
, , p
low-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Apparently NNP p
patients NNS p
aged VBD p
16 CD p
and CC p
above IN p
who WP p
were VBD p
referred VBN p
to TO p
the DT p
Oral NNP p
Surgery NNP p
Clinic NNP p
of IN p
our PRP$ p
institution NN p
, , p
with IN p
an DT p
indication NN p
for IN p
non-surgical JJ p
extraction NN p
of IN p
pathologic JJ p
teeth NNS p
were VBD N
prospectively RB N
and CC N
uniformly RB N
randomized VBN N
into IN N
warm JJ i
saline NN i
group NN i
and CC i
control NN i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ p
Rhythm NNP p
Management NNP p
Trial NNP p
II NNP p
for IN p
Atrial NNP p
Fibrillation NNP p
( ( p
J-RHYTHM NNP p
II NNP p
study NN p
) ) p
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP i
( ( i
candesartan NN i
) ) i
and CC i
a DT i
CCB NNP i
( ( i
amlodipine NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ p
AF NNP p
associated VBN p
with IN p
hypertension NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
single-blind NN N
, , N
randomised VBN N
, , N
placebo NN i
controlled VBD N
, , N
cross-over NN N
study NN N
of IN N
the DT N
microcirculatory NN N
response NN N
to TO N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxidegenerating JJ i
gel NN i
in IN N
20 CD p
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , p
and CC p
ten RB p
healthy JJ p
volunteers NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
of IN N
risperidone NN i
as IN N
compared VBN N
with IN N
placebo NN i
for IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
in IN p
children NNS p
5 CD p
to TO p
17 CD p
years NNS p
old JJ p
. . p

A DT N
placebo-controlled JJ i
study NN N
of IN N
the DT N
effect NN N
of IN N
an DT N
Eleutherococcus NNP i
senticosus NN i
extract NN i
( ( i
Eleukokk NNP i
) ) i
on IN N
the DT N
immune NN N
system NN N
was VBD N
performed VBN N
with IN N
36 CD p
healthy JJ p
volunteers NNS p
utilising VBG p
quantitative JJ p
multi-parameter NN p
flow NN p
cytometry NN p
with IN p
monoclonal JJ p
antibodies NNS p
directed VBN p
against IN p
specific JJ p
surface NN p
markers NNS p
of IN p
human JJ p
lymphocyte JJ p
subsets NNS p
. . p

A DT N
multicenter NN N
, , N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
compared VBN N
the DT N
preventive JJ N
effect NN N
of IN N
aprindine NN i
and CC i
digoxin NN i
on IN N
the DT N
recurrence NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
with IN N
placebo NN i
, , N
and CC N
also RB N
compare VBP N
the DT N
effectiveness NN N
of IN N
these DT N
2 CD N
drugs NNS N
in IN N
the DT N
prevention NN N
of IN N
AF NNP N
. . N

PURPOSE NN N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
cutting VBG i
balloon NN i
angioplasty NN i
( ( i
CBA NNP i
) ) i
versus IN N
high-pressure NN i
balloon NN i
angioplasty NN i
( ( i
HPBA NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
hemodialysis NN p
autogenous JJ p
fistula NN p
stenoses VBZ p
resistant JJ p
to TO p
conventional JJ p
percutaneous JJ p
transluminal JJ p
angioplasty NN p
( ( p
PTA NNP p
) ) p
. . p

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN i
and CC i
ondansetron NN i
in IN N
90 CD p
patients NNS p
scheduled VBN p
for IN p
minor JJ p
gynaecological JJ p
( ( p
hysteroscopy NN p
) ) p
or CC p
urological JJ p
( ( p
ureteroscopy JJ p
) ) p
procedures NNS p
planned VBN p
to TO p
last JJ p
1-2 JJ p
h NN p
under IN p
sevoflurane NN p
anaesthesia NN p
with IN p
spontaneous JJ p
ventilation NN p
of IN p
the DT p
lungs NNS p
via IN p
a DT p
laryngeal JJ p
mask NN p
airway NN p
. . p

The DT N
Intergroup NNP N
Study NNP N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
the DT N
addition NN N
of IN N
adriamycin NN i
( ( i
ADR NNP i
) ) i
or CC i
bilateral JJ i
pulmonary JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
to TO i
vincristine VB i
, , i
dactinomycin NN i
, , i
and CC i
cyclophosphamide NN i
( ( i
VAC NNP i
therapy NN i
) ) i
would MD N
improve VB N
survival NN o
and CC o
reduce VB o
local JJ o
recurrences NNS o
and CC o
metastases NNS o
. . o

METHODS NNP N
Lymph NNP p
nodes NNS p
from IN p
patients NNS p
( ( p
n=94 NN p
) ) p
which WDT p
were VBD p
included VBN p
in IN p
a DT p
randomized JJ p
trial NN p
of IN p
lymph NN i
node NN i
sampling NN i
( ( i
LS NNP i
, , i
n=41 NN i
) ) i
versus NN i
radical JJ i
systematic JJ i
lymphadenectomy NN i
( ( i
LA NNP i
, , i
n=53 RB i
) ) i
were VBD i
screened VBN i
by IN i
immunohistochemistry NN i
for IN i
disseminated JJ i
tumor NN i
cells NNS i
using VBG i
the DT i
antibody NN i
Ber-Ep4 NNP i
. . i

METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
was VBD N
designed VBN N
to TO N
show VB N
that IN N
the DT N
use NN N
of IN N
barbed JJ i
suture NN i
in IN i
dermal JJ i
closure NN i
of IN i
the DT i
Pfannenstiel NNP i
incision NN i
during IN i
nonemergent JJ i
cesarean JJ i
delivery NN i
surgery NN i
produces VBZ i
scar JJR i
cosmesis NN i
at IN N
5 CD N
weeks NNS N
that WDT N
is VBZ N
no DT N
worse JJR N
than IN N
that DT N
observed VBD N
with IN N
conventional JJ N
closure NN N
using VBG N
3-0 JJ i
polydioxanone NN i
suture NN i
. . i

An DT N
initial JJ N
prospective NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
( ( N
Study NNP N
1 CD N
) ) N
, , N
compared VBN N
the DT N
safety NN o
and CC o
pharmacokinetics NNS o
( ( o
serum JJ o
concentrations NNS o
of IN o
rabies NNS o
antibodies NNS o
) ) o
after IN N
administration NN N
either DT N
of IN N
PHT-Erig NNP i
or CC i
of IN i
a DT i
commercially-available JJ i
, , i
equine JJ i
rabies NNS i
immune VBP i
globulin NN i
( ( i
Erig NNP i
PMC NNP i
) ) i
. . i

Effect NN N
of IN N
a DT N
nutritional JJ i
supplement NN i
containing VBG i
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
c NNS i
and CC i
coenzyme JJ i
Q10 NNP i
on IN N
serum NN o
PSA NNP o
in IN N
patients NNS p
with IN p
hormonally RB p
untreated JJ p
carcinoma NN p
of IN p
the DT p
prostate NN p
: : p
a DT N
randomised JJ N
placebo-controlled JJ i
study NN N
. . N

METHODS NNP N
One CD p
hundred CD p
and CC p
forty VB p
four CD p
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
COPD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
three CD N
months NNS N
of IN N
treatment NN N
with IN N
either DT N
salmeterol NN i
, , i
salmeterol NN i
+ NNP i
ipratropium NN i
bromide NN i
, , i
or CC i
placebo NN i
. . i

We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN i
and CC i
sirolimus NN i
( ( i
Tac/Sir NNP i
) ) i
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN i
and CC i
methotrexate NN i
( ( i
Tac/Mtx NNP i
) ) i
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
. . N

The DT N
Study NNP N
to TO N
COmpare NNP N
REstenosis NNP N
rate NN N
between IN N
QueST NNP N
and CC N
QuaDS-QP2 NNP N
( ( N
SCORE NNP N
) ) N
trial NN N
is VBZ N
a DT N
human JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
comparing VBG N
7-hexanoyltaxol JJ i
( ( i
QP2 NNP i
) ) i
-eluting VBG i
stents NNS i
( ( i
qDES NN i
) ) i
with IN i
bare NN i
metal NN i
stents NNS i
( ( i
BMS NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
de FW p
novo FW p
coronary JJ p
lesions NNS p
. . p

The DT N
primary JJ N
objective NN N
of IN N
the DT N
present JJ N
randomized JJ N
phase NN N
III NNP N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
3-yr JJ o
survival NN o
rate NN o
of IN N
patients NNS N
treated VBN N
with IN N
standard JJ i
fractionated VBN i
radiotherapy NN i
( ( i
RT NNP i
) ) i
alone RB i
or CC i
with IN i
the DT i
same JJ i
RT NNP i
concomitantly RB i
with IN i
cisplatin NN i
( ( i
DDP NNP i
) ) i
or CC i
carboplatin NN i
( ( i
Cb NNP i
) ) i
. . i

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
In IN N
this DT N
secondary JJ N
, , N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
above NN N
study NN N
, , N
octreotide-induced JJ N
changes NNS N
in IN N
liver NN o
volumes NNS o
compared VBN N
with IN N
placebo NN i
and CC N
the DT N
relationship NN N
between IN N
concomitant NN N
changes NNS N
in IN N
liver NN o
and CC o
kidney NN o
volumes NNS o
were VBD N
evaluated VBN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
3-arm JJ N
randomized VBN N
trial NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
quality-tested JJ i
aloe NN i
extract NN i
in IN N
reducing VBG N
the DT N
severity NN N
of IN N
radiation-induced JJ p
skin JJ p
injury NN p
and CC p
, , p
secondarily RB p
, , N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
moist NN N
cream NN N
versus IN N
a DT N
dry JJ N
powder NN N
skin NN N
care NN N
regimen NNS N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
immunochemotherapy NN i
with IN i
the DT i
use NN i
of IN i
BCG NNP i
( ( i
bacille IN i
Calmette-Guerin NNP i
) ) i
and CC i
FAM NNP i
( ( i
5-fluorouracil JJ i
, , i
adriamycin JJ i
, , i
mitomycin JJ i
C NNP i
) ) i
chemotherapy NN i
on IN N
the DT N
survival NN N
of IN N
patients NNS p
with IN p
locally RB p
advanced VBN p
resectable JJ p
gastric JJ p
cancer NN p
. . p

METHODS NNP N
The DT N
Atypical NNP N
Squamous NNP N
Cells NNP N
of IN N
Undetermined VBN N
Significance NNP N
( ( N
ASCUS NNP N
) ) N
and CC N
Low-Grade NNP N
Squamous NNP N
Intraepithelial NNP N
Lesion NNP N
( ( N
LSIL NNP N
) ) N
Triage NN N
Study NNP N
( ( N
ALTS NNP N
) ) N
was VBD N
a DT N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
best JJS N
management NN N
strategies NNS N
for IN N
women NNS p
with IN p
equivocal JJ p
( ( p
ASCUS NNP p
) ) p
or CC p
mildly RB p
abnormal JJ p
( ( p
LSIL NNP p
) ) p
Pap NNP p
tests NNS p
. . p

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
concurrent JJ i
capecitabine NN i
and CC i
cisplatin NN i
over IN i
concurrent JJ i
cisplatin NN i
and CC i
5-flurouracil JJ i
( ( i
5-FU JJ i
) ) i
in IN N
locally RB p
advanced JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
A NNP p
total NN p
of IN p
67 CD p
eyes NNS p
of IN p
35 CD p
Behcet NNP p
's POS p
patients NNS p
with IN p
chronic JJ p
, , p
but CC p
well-controlled JJ p
uveitis NN p
, , p
and CC p
CMO NNP p
were VBD N
randomised VBN N
into IN N
a DT N
double-masked JJ N
, , N
crossover JJ N
trial NN N
comparing VBG N
the DT N
effect NN N
of IN N
acetazolamide NN i
vs NN i
placebo NN i
. . i

Among IN N
patients NNS N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
comparing VBG N
intravenous JJ N
heparin NN i
, , i
aspirin NN i
, , N
both DT N
treatments NNS N
, , N
and CC N
neither RB N
during IN N
the DT N
acute JJ N
phase NN N
of IN N
unstable JJ N
angina NNS N
, , N
we PRP N
encountered VBD N
patients NNS p
in IN p
whom WP p
unstable JJ p
angina NN p
was VBD p
reactivated VBN p
after IN p
heparin NN p
was VBD p
discontinued VBN p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
four-arm JJ N
study NN N
with IN N
placebo JJ i
run-in JJ p
phase NN p
conducted VBN p
at IN p
travel NN p
clinics NNS p
in IN p
Switzerland NNP p
, , p
Germany NNP p
, , p
and CC p
Israel NNP p
, , p
we PRP p
compared VBN p
moods NNS p
and CC p
feelings NNS p
in IN p
chemoprophylaxis NN p
users NNS p
( ( p
n= JJ p
547 CD p
) ) p
by IN p
administering VBG i
the DT i
standardized JJ i
Profile NNP i
of IN i
Mood NNP i
States NNPS i
( ( i
POMS NNP i
) ) i
questionnaire NN i
. . i

On IN N
the DT N
other JJ N
hand NN N
, , N
when WRB N
BCG NNP i
was VBD N
given VBN N
orally RB N
in IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
with IN p
resectable JJ p
cancer NN p
of IN p
the DT p
colon NN p
and CC p
in IN p
nonrandomized JJ p
consecutive JJ p
studies NNS p
of IN p
patients NNS p
with IN p
malignant JJ p
melanoma NN p
and CC p
stage NN p
IV NNP p
carcinoma NN p
of IN p
the DT p
breast NN p
survival NN p
was VBD p
increased VBN p
. . p

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
This DT N
study NN N
has VBZ N
been VBN N
approved VBN N
by IN N
the DT N
Ethics NNP N
Review NNP N
Committee NNP N
and CC N
Clinical NNP N
Trials NNP N
Unit NNP N
at IN N
The DT N
Aga NNP N
Khan NNP N
University NNP N
with IN N
respect NN N
to TO N
scientific JJ N
content NN N
and CC N
compliance NN N
with IN N
applicable JJ N
research NN N
and CC N
human JJ N
subjects NNS N
regulations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
including VBG N
a DT N
'no CD i
active JJ i
intervention NN i
' POS i
arm NN i
( ( i
called VBN i
'conservative CD i
management NN i
' '' i
) ) i
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
comparing VBG N
treatments NNS N
( ( N
including VBG N
surgery NN N
) ) N
for IN N
men NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
related VBN p
to TO p
benign VB p
prostatic JJ p
enlargement NN p
. . p

GOALS NNP N
OF NNP N
WORK NNP N
We PRP N
set VBD N
out RP N
to TO N
assess VB N
the DT N
preference NN N
of IN N
patients NNS N
with IN N
common JJ N
cancers NNS N
involving VBG N
bone NN N
receiving VBG N
intravenous JJ N
bisphosphonate NN i
therapy NN i
for IN N
either DT N
pamidronate NN i
( ( i
P NNP i
) ) i
or CC i
zoledronic JJ i
acid NN i
( ( i
Z NNP i
) ) i
and CC N
their PRP$ N
preference NN N
for IN N
the DT N
location NN N
of IN N
the DT N
infusion NN N
( ( N
clinic JJ N
or CC N
home NN N
) ) N
. . N

We PRP N
evaluated VBD N
the DT N
LCS6 NNP o
genotype NN o
and CC o
its PRP$ o
association NN o
with IN o
KRAS NNP o
mutation NN o
status NN o
, , o
clinicopathologic NN o
features NNS o
, , o
and CC o
disease-free JJ o
survival NN o
( ( o
DFS NNP o
) ) o
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
colon NN p
cancer NN p
who WP p
enrolled VBD p
in IN p
a DT p
phase NN p
III NNP p
clinical JJ p
trial NN p
( ( p
NCCTG NNP p
N0147 NNP p
) ) p
. . p

PURPOSE/OBJECTIVES NNP N
Through IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
to TO N
compare VB N
patients NNS p
undergoing VBG p
an DT p
initial JJ p
course NN p
of IN p
chemotherapy NN i
who WP N
report VBP N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
and CC N
who WP N
are VBP N
receiving VBG N
conventional JJ i
care NN i
alone RB i
with IN i
those DT i
receiving VBG i
conventional JJ i
care NN i
plus CC i
a DT i
nursing NN i
intervention NN i
on IN N
outcomes NNS N
reported VBN N
at IN N
20 CD N
weeks NNS N
. . N

In IN N
a DT N
recent JJ N
phase NN N
I-II NNP N
trial NN N
, , N
oral JJ N
administration NN N
of IN N
pentoxifylline NN i
( ( i
PTX NNP i
) ) i
, , N
a DT N
xanthine JJ N
derivative JJ N
capable NN N
of IN N
downregulating VBG N
TNF-alpha JJ N
production NN N
in IN N
vitro NN N
, , N
was VBD N
reported VBN N
to TO N
reduce VB N
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS p
undergoing JJ p
BMT NNP p
. . p

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
PBSC NNP N
mobilization NN N
using VBG N
etoposide JJ i
and CC i
G-CSF JJ i
with IN i
or CC i
without IN i
rituximab NN i
to TO N
determine VB N
whether IN N
its PRP$ N
addition NN N
would MD N
adversely RB N
affect VB N
CD34+ NNP o
cell NN o
yield NN o
in IN N
patients NNS p
with IN p
non-Hodgkin JJ p
's POS p
lymphoma NN p
. . p

BACKGROUND IN N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
with IN p
paroxysmal JJ p
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
( ( p
PAF/PAFL NNP p
) ) p
experiencing VBG p
2 CD p
or CC p
more JJR p
episodes NNS p
of IN p
symptomatic JJ p
PAF/PAFL NNP p
during IN p
a DT p
28-day JJ p
observation NN p
period NN p
to TO p
determine VB p
the DT p
dose-response JJ p
effect NN p
and CC p
safety NN p
of IN p
flecainide NN i
. . i

In IN N
an DT N
attempt NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
lethal JJ N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
interstitial NN N
pneumonitis NN N
after IN N
allogenic JJ i
bone NN i
marrow NN i
transplantation NN i
49 CD p
patients NNS p
were VBD N
randomized VBN N
in IN N
a DT N
multicenter NN N
controlled VBN N
study NN N
to TO N
receive VB N
either DT N
CMV-hyperimmune NNP i
globulin NN i
or CC i
a DT i
control NN i
immune JJ i
globulin NN i
with IN i
low JJ i
anticytomegalovirus NN i
titer NN i
. . i

Effect NN N
of IN N
enzalutamide NN i
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
, , o
pain NN o
, , o
and CC o
skeletal-related JJ o
events NNS o
in IN N
asymptomatic JJ N
and CC N
minimally RB p
symptomatic JJ p
, , p
chemotherapy-naive JJ p
patients NNS p
with IN p
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
( ( p
PREVAIL NNP p
) ) p
: : p
results NNS N
from IN N
a DT N
randomised VBN N
, , N
phase VB N
3 CD N
trial NN N
. . N

One CD p
hundred CD p
twelve NN p
patients NNS p
who WP p
sustained VBD p
hyphema NN p
after IN p
blunt NN p
trauma NN p
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ i
acid NN i
( ( i
Amicar NNP i
) ) i
and CC i
systemic JJ i
prednisone NN i
for IN N
reducing VBG N
the DT N
rate NN o
of IN o
secondary JJ o
hemorrhage NN o
. . o

PURPOSE NN N
To TO N
evaluate VB N
the DT N
antitumor NN o
activity NN o
and CC o
safety NN o
of IN N
the DT N
epothilone NN i
B NNP i
analog NN i
, , i
ixabepilone NN i
, , i
with IN i
or CC i
without IN i
estramustine JJ i
phosphate NN i
( ( i
EMP NNP i
) ) i
, , N
in IN N
chemotherapy-naive JJ p
patients NNS p
with IN p
progressive JJ p
castrate NN p
metastatic JJ p
prostate NN p
cancer NN p
. . p

METHODS/DESIGN NNP N
The DT N
present JJ N
study NN N
involves VBZ N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
with IN N
two CD N
conditions NNS N
( ( N
experimental JJ N
versus NN N
control NN N
) ) N
, , N
in IN N
which WDT N
it PRP N
is VBZ N
investigated VBN N
whether IN N
Mindlight NNP N
is VBZ N
effective JJ N
in IN N
decreasing VBG N
( ( N
sub NN N
) ) N
clinical JJ N
anxiety NN N
symptoms NNS N
in IN N
children NNS p
with IN p
an DT p
ASD NNP p
. . p

The DT N
goal NN N
of IN N
this DT N
randomized JJ N
phase NN N
II NNP N
study NN N
is VBZ N
to TO N
compare VB N
QOL NNP o
, , o
functional JJ o
outcomes NNS o
, , o
toxicity NN o
profiles NNS o
, , o
and CC o
survival NN o
following VBG N
primary JJ i
RT NNP i
( ( i
? . i
chemotherapy NN i
) ) i
vs. FW i
TORS NNP i
( ( i
? . i
adjuvant NN i
[ NN i
chemo NN i
] NNP i
RT NNP i
) ) i
in IN N
patients NNS p
with IN p
OPSCC NNP p
. . p

OBJECTIVE NN N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
preemptive JJ i
epidural JJ i
analgesia NN i
combined VBN i
with IN i
postoperative JJ i
epidural JJ i
analgesia NN i
, , i
postoperative JJ i
epidural JJ i
analgesia NN i
alone RB i
and CC i
intravenous JJ i
analgesia NN i
for IN N
postoperative JJ N
pain NN N
relief NN N
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ o
interleukin-6 JJ o
( ( o
IL-6 NNP o
) ) o
concentration NN o
following VBG N
radical JJ N
surgery NN N
for IN N
gastric JJ p
carcinoma NN p
. . p

STUDY NNP N
DESIGN NNP N
Two CD p
hundred VBD p
patients NNS p
with IN p
indications NNS p
for IN p
induction NN p
of IN p
labor NN p
and CC p
unfavorable JJ p
cervical JJ p
examinations NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN i
( ( i
prostaglandin JJ i
E1 NNP i
) ) i
or CC N
the DT N
dinoprostone NN i
( ( i
prostaglandin JJ i
E2 NNP i
) ) i
vaginal NN i
insert NN i
. . i

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
early JJ i
intervention NN i
program NN i
Video-feedback NNP i
Intervention NNP i
to TO N
promote VB N
Positive NNP N
Parenting NNP p
adapted VBD p
to TO p
Autism NNP p
( ( p
VIPP-AUTI NNP p
) ) p
with IN p
78 CD p
primary JJ p
caregivers NNS p
and CC p
their PRP$ p
child NN p
( ( p
16-61 JJ p
months NNS p
) ) p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

OBJECTIVES IN N
The DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
imidapril NN i
were VBD N
evaluated VBN N
in IN N
dogs NNS p
that WDT p
presented VBD p
with IN p
mild NN p
to TO p
severe VB p
congestive JJ p
heart NN p
failure NN p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
stage NN p
II NNP p
to TO p
IV NNP p
) ) p
by IN N
comparing VBG N
the DT N
success NN N
rate NN N
of IN N
imidapril NN N
with IN N
a DT N
positive JJ N
control NN N
by IN N
a DT N
non-inferiority JJ N
approach NN N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
240 CD p
patients NNS p
with IN p
severe JJ p
TBI NNP p
( ( p
GCS NNP p
score RB p
3-8 JJ p
) ) p
admitted VBD p
to TO p
NICU NNP p
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ i
insulin NN i
therapy NN i
or CC i
to TO i
intensive JJ i
insulin NN i
therapy NN i
. . i

PATIENTS NNS N
AND CC N
METHODS NNP N
Following VBG N
a DT N
one- JJ N
to TO N
three-week JJ N
washout NN N
phase NN N
and CC N
a DT N
four-week JJ N
, , N
open-label JJ N
lanthanum NN i
carbonate NN i
dose-titration NN i
phase NN p
, , p
male NN p
and CC p
female JJ p
hemodialysis NN p
patients NNS p
were VBD N
randomized VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
either DT N
lanthanum NN i
carbonate NN i
or CC i
placebo NN i
for IN N
four CD N
weeks NNS N
. . N

MATERIAL/METHODS NNP N
We PRP N
performed VBD N
a DT N
post-hoc JJ N
analysis NN N
on IN N
307 CD p
kidney NN p
transplant NN p
recipients NNS p
included VBD N
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
tacrolimus/mycophenolate NN i
mofetil NN i
( ( i
Tac/MMF NNP i
) ) i
vs. FW i
cyclosporine/azathioprine NN i
( ( i
CsA/AZA NNP i
) ) i
, , i
both DT i
used VBN i
with IN i
antithymocyte JJ i
globulin NN i
induction NN i
and CC i
steroids NNS i
. . i

OBJECTIVE NN N
To TO N
follow VB N
up RP N
on IN N
a DT N
three-site JJ N
, , N
24-week JJ N
randomized JJ N
clinical JJ N
trial NN N
( ( N
N NNP N
= NNP N
124 CD N
) ) N
comparing VBG N
antipsychotic JJ i
medication NN i
alone RB i
( ( i
MED NNP i
) ) i
with IN i
antipsychotic JJ i
medication NN i
plus CC i
parent NN i
training NN i
in IN i
the DT i
behavior JJ i
management NN i
( ( p
COMB NNP p
) ) p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
severe JJ p
behavior NN p
problems NNS p
. . p

BACKGROUND NN N
From IN N
2005 CD N
to TO N
2007 CD N
the DT N
Australian JJ N
Government NNP N
funded VBD N
a DT N
multicentre NN N
, , N
clustered VBD N
randomized VBN N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
clinical JJ N
effectiveness NN N
, , N
cost-effectiveness NN N
, , N
satisfaction NN N
and CC N
safety NN N
of IN N
point NN N
of IN N
care NN N
testing VBG N
( ( N
PoCT NNP N
) ) N
in IN N
general JJ N
practice NN N
( ( N
GP NNP N
) ) N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Thirty NNP p
one CD p
colorectal NN p
cancer NN p
patients NNS p
were VBD N
prospectively RB N
studied VBN N
and CC N
sentinel JJ N
lymph NN N
node NN N
was VBD N
identified VBN N
in IN N
100 CD N
% NN N
of IN N
the DT N
cases NNS N
utilizing VBG N
either CC N
patent JJ i
blue NN i
alone RB i
, , N
or CC N
in IN N
association NN N
with IN N
radiotracer NN i
based VBN i
on IN i
technetium NN i
99m CD i
colloid JJ i
solution NN i
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

For IN N
this DT N
purpose NN N
, , N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
three-time JJ N
cross-over NN N
study NN N
using VBG N
17beta-estradiol JJ i
combined VBN i
with IN i
norethisterone JJ i
acetate NN i
for IN i
replacement NN i
therapy NN i
and CC N
as IN N
an DT N
adjunct NN N
to TO N
a DT N
naturalistic JJ i
maintenance NN i
antipsychotic JJ i
treatment NN i
was VBD N
carried VBN N
out RP N
over IN N
a DT N
period NN N
of IN N
8 CD N
months NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing JJ p
abdominal JJ p
surgery NN p
and CC p
receiving VBG p
intermittent JJ i
pneumatic JJ i
compression NN i
, , i
fondaparinux VBP i
2.5 CD N
mg NN N
reduced VBD N
the DT N
venous JJ o
thromboembolism NN o
rate NN o
by IN N
69.8 CD N
% NN N
as IN N
compared VBN N
to TO N
pneumatic JJ N
compression NN N
alone RB N
, , N
with IN N
a DT N
low JJ N
bleeding NN N
risk NN N
as IN N
compared VBN N
to TO N
placebo VB i
. . i

They PRP N
were VBD N
randomized VBN N
to TO N
be VB N
treated VBN N
with IN N
either DT N
radiotherapy NN i
alone RB i
( ( i
extended JJ i
fields NNS i
, , i
4500 CD i
cGy NN i
) ) i
or CC i
radiotherapy NN i
( ( i
the DT i
same JJ i
schedule NN i
) ) i
plus CC i
adjuvant JJ i
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
vincristine NN i
and CC i
prednisone NN i
) ) i
. . i

36 CD p
consecutive JJ p
patients NNS p
with IN p
non-metastatic JJ p
breast NN p
cancer NN p
assigned VBD p
to TO p
surgery VB p
and CC p
systemic VB p
chemotherapy NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ i
intervention NN i
( ( i
weekly JJ i
cognitive VBP i
individual JJ i
psychotherapy NN i
and CC i
bimonthly JJ i
family NN i
counselling VBG i
) ) i
or CC N
standard JJ N
follow-up NN N
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
, , N
comparing VBG N
an DT N
IMCP NNP i
tailored VBD i
to TO i
colorectal JJ i
cancer NN i
screening VBG i
self-efficacy NN i
, , i
knowledge NN i
, , i
barriers NNS i
, , i
readiness NN i
, , i
test NN i
preference NN i
, , i
and CC i
experiences NNS i
with IN i
a DT i
nontailored JJ i
informational JJ i
program NN i
, , i
both DT i
delivered VBN i
before IN i
office NN i
visits NNS i
. . i

To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
bicalutamide NN i
( ( i
Casodex NNP i
) ) i
with IN N
its PRP$ N
clinically NN N
recommended VBD N
dose NN N
, , N
the DT N
randomized VBN N
early JJ N
phase NN N
II NNP N
study NN N
was VBD N
performed VBN N
in IN N
124 CD p
patients NNS p
with IN p
prostatic JJ p
cancer NN p
( ( p
stage NN p
C NNP p
, , p
D NNP p
) ) p
. . p

METHODS NNP N
Women NNP p
in IN p
North NNP p
Bristol NNP p
, , p
UK NNP p
between IN p
8-18 JJ p
weeks NNS p
pregnant JJ p
were VBD p
recruited VBN p
through IN p
routine JJ p
contact NN p
with IN p
midwives NNS p
and CC p
randomised VBN p
to TO p
receive VB i
up RP i
to TO i
12 CD i
sessions NNS i
of IN i
individual JJ i
CBT NNP i
in IN i
addition NN i
to TO i
usual JJ i
care NN i
or CC i
to TO i
continue VB i
with IN i
usual JJ i
care NN i
only RB i
. . i

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
comparing VBG N
two CD i
versions NNS i
of IN i
the DT i
delivery NN i
of IN i
the DT i
intervention NN i
( ( i
one CD i
face-to-face NN i
home NN i
visit NN i
plus CC i
telephone NN i
calls VBZ i
versus IN i
two CD i
visits NNS i
) ) i
plus CC i
standard JJ i
care NN i
to TO i
a DT i
control NN i
group NN i
( ( i
standard JJ i
care NN i
only RB i
) ) i
across IN p
four CD p
sites NNS p
in IN p
Australia NNP p
. . p

METHODS NNP N
Postmenopausal NNP p
women NNS p
( ( p
age NN p
65 CD p
years NNS p
or CC p
older JJR p
) ) p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ i
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
, , i
or CC i
a DT i
daily JJ i
Kegel NNP i
exercise NN i
( ( i
KE NNP i
) ) i
program NN i
. . i

PURPOSE VB N
The DT N
objective NN N
of IN N
the DT N
present JJ N
pilot NN N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN N
of IN N
using VBG N
computerized JJ i
ecological JJ i
momentary JJ i
assessment NN i
( ( i
EMA NNP i
) ) i
for IN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
BF NNP N
treatment NN N
for IN N
migraine NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT N
treatment NN N
condition NN N
( ( N
n=179 JJ N
) ) N
and CC N
a DT N
control NN N
condition NN N
( ( N
n=118 JJ N
) ) N
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN i
economic JJ i
empowerment NN i
intervention NN i
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN i
of IN i
once-daily JJ i
MMX NNP i
mesalamine NN i
2.4 CD i
g/day NN i
compared VBN i
with IN i
twice-daily JJ i
delayed-release JJ i
mesalamine NN i
at IN i
a DT i
total JJ i
daily JJ i
dose NN i
of IN i
1.6 CD i
g/day NN i
in IN i
patients NNS i
with IN i
UC NNP i
in IN i
endoscopic JJ i
remission NN i
. . i

The DT N
most RBS N
convincing JJ N
neoadjuvant JJ N
trial NN N
to TO N
demonstrate VB N
the DT N
superiority NN N
of IN N
an DT N
AI NNP N
versus NN N
tamoxifen NN N
was VBD N
the DT N
P024 NNP N
study NN N
, , N
a DT N
large JJ N
multinational JJ N
double-blind JJ N
trial NN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
HR+ NNP p
breast NN p
cancer NN p
ineligible JJ p
for IN p
breast-conserving JJ p
surgery NN p
. . p

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
3-12 JJ p
year-old JJ p
children NNS p
with IN p
autism NN p
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
sensorimotor NN i
enrichment NN i
group NN N
, , N
which WDT N
received VBD N
daily RB N
olfactory/tactile JJ i
stimulation NN i
along IN i
with IN i
exercises NNS i
that WDT N
stimulated VBD N
other JJ N
paired JJ N
sensory JJ N
modalities NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
. . N

The DT N
effect NN N
of IN N
month-long JJ N
naltrexone NN i
( ( i
NTX NNP i
) ) i
treatment NN i
at IN i
a DT i
daily JJ i
oral JJ i
dose NN i
of IN i
0.5 CD i
mg/kg/day NN i
was VBD i
contrasted VBN i
with IN i
placebo NN i
( ( i
PLC NNP i
) ) i
in IN N
a DT N
double-blind NN N
study NN N
with IN N
conjoint NN N
clinical JJ N
and CC N
biochemical JJ N
evaluations NNS N
of IN N
therapeutic JJ N
effects NNS N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Following NNP N
our PRP$ N
phase NN N
II NNP N
experience NN N
, , N
a DT N
randomised JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
adding VBG N
chemotherapy NN i
to TO i
radiotherapy VB i
in IN N
patients NNS p
with IN p
unresectable JJ p
squamous JJ p
cell NN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

In IN N
a DT N
controlled VBN N
, , N
prospectively RB N
randomized VBN N
trial NN N
, , N
74 CD p
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
from IN p
colorectal JJ p
cancer NN p
were VBD N
randomized VBN N
to TO N
either DT N
intra-arterial JJ i
hepatic JJ i
artery NN i
infusion NN i
with IN i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
or CC i
systemic JJ i
chemotherapy NN i
with IN i
5-FU JJ i
. . i

One CD p
hundred CD p
thirteen JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
sodium NN i
phosphate NN i
( ( i
Fleet NNP i
Phospho-Soda NNP i
) ) i
, , i
lemon-flavored JJ i
castor NN i
oil NN i
( ( i
Purge NNP i
) ) i
, , i
or CC i
standard JJ i
polyethylene NN i
glycol-based JJ i
lavage NN i
solution NN i
( ( i
GoLYTELY NNP i
) ) i
before IN i
elective JJ i
colonoscopy NN i
. . i

We PRP N
conducted VBD N
a DT N
single JJ N
and CC N
repeat JJ N
oral JJ N
dose NN N
study NN N
of IN N
YM17E NNP i
, , i
a DT i
novel JJ i
inhibitor NN i
of IN i
acyl NN i
coenzyme NN i
A NNP N
( ( N
CoA NNP N
) ) N
: : N
cholesterol NN N
acyltransferase NN N
, , N
in IN N
healthy JJ p
male NN p
volunteers NNS p
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ N
profile NN N
, , N
tolerability NN N
and CC N
effect NN N
of IN N
the DT N
drug NN N
on IN N
serum NN o
cholesterol NN o
. . o

